<SEC-DOCUMENT>0000883984-23-000009.txt : 20230227
<SEC-HEADER>0000883984-23-000009.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227173130
ACCESSION NUMBER:		0000883984-23-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		152
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICU MEDICAL INC/DE
		CENTRAL INDEX KEY:			0000883984
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330022692
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34634
		FILM NUMBER:		23676854

	BUSINESS ADDRESS:	
		STREET 1:		951 CALLE AMANECER
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92763-6212
		BUSINESS PHONE:		949-366-2183

	MAIL ADDRESS:	
		STREET 1:		951 CALLE AMANECER
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92763-6212
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>icui-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b,d:33c36cedce9946f68c08b8ced8cb1174--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:icui="http://www.icumed.com/20221231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>icui-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y18zLTEtMS0xLTkyNzE4_6418db18-23b3-4eb2-baad-6110aec2726f">0000883984</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y180LTEtMS0xLTkyNzE4_4b3b42ce-a25a-4049-b5f2-acc85c3f99bd">ICU MEDICAL INC/DE</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y182LTEtMS0xLTkyNzE4_5eb7ac31-d5b1-4ad6-a5b1-c3994792bac4">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y183LTEtMS0xLTkyNzE4_df71bfe2-c970-49a7-b921-82920e1c483d">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y184LTEtMS0xLTkyNzE4_98f2c735-79d7-486a-829a-21a997781d15">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y185LTEtMS0xLTkyNzE4_3b7bbcc7-bbd2-4fac-85cc-3430d8a1a06d">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfMy0wLTEtMS05MjcxOA_87be4e6e-5c6b-4b54-a61e-d3584033c7ae">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfMy0wLTEtMS05MjcxOA_ed4f727a-6287-404e-b9d0-15b912195527">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_0baea7bd-78b0-43d2-bd4f-02c6f89301a8">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_1f984f27-4206-4068-beff-770acc19eaac">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_7947a7fc-e7b3-4d8a-96b0-7becbc4f0baa">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_ff39d26a-47e9-47c8-b024-f7e2b3ee2934">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_0aeb4fa6-cd6e-459f-be2f-a304576549f2">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_20ab121e-d6fa-4a69-988d-418f6ea7508d">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_436ec06d-b89d-489c-b40e-f5f35b02dc52">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_628a96ea-3825-43b0-ac31-f230969c82ef">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTI2L2ZyYWc6ODc1ZDYzYTI4NjhhNDgzY2IxOTZiMmQ5ZmU3NDMyMzIvdGFibGU6N2FkMWI4YTVjM2JmNDIzNDg1OTI2MzE5OWExZDA3ZjkvdGFibGVyYW5nZTo3YWQxYjhhNWMzYmY0MjM0ODU5MjYzMTk5YTFkMDdmOV8wLTAtMS0xLTExMDk1NQ_3cb7e75f-e2ad-4531-903e-6efe90dde60a">http://fasb.org/us-gaap/2022#InterestIncomeExpenseNet</ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTM1L2ZyYWc6MzlmNzM2ZjU1NTcxNDI3ZWEzODQzY2EyODJiZDI5MmIvdGFibGU6Y2EyMmM5MmY1M2I2NDI5MjhiNjI0ZmQ2Njk4MGQ5OTcvdGFibGVyYW5nZTpjYTIyYzkyZjUzYjY0MjkyOGI2MjRmZDY2OTgwZDk5N18wLTAtMS0xLTExMDk4MQ_c06eacfe-8478-4d76-901b-19012a422dab">http://fasb.org/us-gaap/2022#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="icui-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f3fdac040a4646ae49b87760e750b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie2e9049c6fe84be399e3b04481dcd237_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0db73ebe00014b429d98a2767a3858eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if024b016189942d089f44d314d97476f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f128dabbbb42f790c9b42b1a52d19f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98ea3f4a06d4a69b875b005c4bfdee8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a94223681d4d6f8e75c3e7b836cbec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee1b6542ad84492b4d2ec455fa9ae81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ece853202944e484c25ad349453bf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde6dfbd9e9b4a638c3f365c3f9bb4f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33927c32f4649af822a8418053d8d99_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79543f41864548a996a0edce3cc373f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1337f299defe4eaf888a017913e309b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5603cb92819e4c3ca2de991234b01760_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a7c4b10df94a5cadb8f2ccb5d91e45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68360870df24c48b23f24f3a787a64c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied10183a5d8941e6b5c8713d7c2eadd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if792565cf68b4836a7b528942b2852fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8979ceb98e47dfb43a3711dcf7912a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a5d2a2a4af46a3974d2432b63c41cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15893976f8864a729360aae7e272b56e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3688a319945e4943a3dc05ede3f036d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e7eed8de8c409a833960699b90df5c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801a4fae42184517928aa871ec10a664_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd88657bbd04d46a2104ab8bc2406fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5dce62564e466793e72557cf0c42bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca5a22717754de18e1be8d99bab4c9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9952ba8ae7440abb7a7c721d75b664_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf7a0a723cc04a34b8b697b0e8fb25cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic703ef27cbce4420b73d994faaa947af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19e854fbfba4ab0abc5e57ea4e706e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbdea58d0184ec48cf84b1a702fc5df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18d81392ae04265a3d03510728b3646_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dfd2e0db2834b9db1915caf0df77a09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7131fb5352c74f58a87b1b96952be01d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47136614a9cc4f309d163a050608f73e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e4f2ecd87ce4d80bea7d0755b982f2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f29b1e5a63a431c8553eb9154631953_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad27c484ae8448cb258c0b5ad63372b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d33b6f5efb437681ee2b0b9b8c6a33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e09627e54ce4d96a945c0e3e3954f4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3a16252c2743e49ad12be60705c508_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie803115e33c64a30a2d7ac04ce489aea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168c102715d143b4a73cd3d48cb2d99e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7994fbbb85834a97aa927e80e978ecc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96caeb3085f40b895b3276026ce87e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>icui:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie306a7088186433b94994c8694798078_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib75bb3ec5a414a9a96e90db458d22e9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7ec5e5fae0c44acbe28b5e7256bc13a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcede7ef2d55454586263cb1b17b8a37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1ce0276d2342909b3efc93b1f90403_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:MoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd24511b6794dbcafe3d83a5a8388c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:MoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7048468f159a46b288ae8a59cedfde98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980f10b9f96e4b5eb86cb041b7ed672c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a64d4f3e84f40458ca24bfae02314b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b924222777c44f6a4235eca23a1b5cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f0d2af3e944dc69bd9763b0d42c3aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90ea729e60647e7a9038b89c6e8eb51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb27ccb900a343b1ac254cb8fd9889ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6808b2296ffa42588ac59c587abb2eca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ace55fc527e48da922598ef7519c606_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc8766a58304d02b111521f7ddb4326_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5412a571299e4c32bbdeaa48ca22375a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f9efdcab0a462a9331fcb0b2523f10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace321f41b4548e6821dc5e27a26dd08_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2d38102dd74397953e5e63739100de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:FurniturefixturesandmoldsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3efe5e11e941069af3153789ec8247_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:FurniturefixturesandmoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3d6cb7b6924d47969dd4919c9df187_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07984db0625c4d03845107295d7e5a5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9543871e1aba478483a1228b53651327_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebcf08c085424ee38ab6ffd24290c1d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d433759863a438d9e188a8521981691_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e546dd32ee14e3eb76d201f21872bb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cae05c39a724907b4e3c7bec42a8d15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460a86abca634dc9802438855b8286df_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa54f208913446db511b39d4c19420d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf83aec391f64db6afb221796f3b44d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e941f5fc5947699c7c61518ca1ab67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3856be9b89747b993110c792a39aabb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46d0ee7b3624110a0d31e8dbeb2f227_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f47d5a4f3247508475ee667ae3091f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369fa34137ce41348503313048b70075_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84420d968625493db489841b6ba9cd22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib343098582894c1b8730d6b3ee859c16_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c86efa20674a879fa6ed36fec4b168_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8552f5934714f03a7223229598d0a2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be404c6e2704f988bf6f30f9911074b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df8661f299c437396b33cccb1c6eac8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63886e254baf421a9707d4d5eb8bab28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca30aa64779494ca3499ac96dcc8ff4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e43ff19422d4545a2da37ba9a92b601_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5f275b31a74d0897b0a32abeeeb534_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41f8b67700946dd803fdd98061bc244_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77c83d365be429dbcf3b8e60f6471c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057559badebc49ff81913d91205892d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2d444d9cee49b99776001b30841e74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ff0b8f85bb402b839b0f6cb69bfaa0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b990e41a8c4816ac9862a30699ee0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7bb5378ae8468895c202125d15e129_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc33001b56c64b11b1bc56c135168d51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de82ccd51af439091344dc5996e1a43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50fd4be30c6481e89383764b9f60a6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2609bce6c04e03995a81ac43177271_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70941f166b074b6aa1687d9f7338fae8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0029a1b43ec54a29b829f135a48f9cfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">icui:NonpublicCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7437d14a12be4025b5493cb7d897d472_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedical2020LimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedical2020LimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf4360bc208465f843ef61d1768b5e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1129dd1b04d7446c9d3d06c36614788e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98b9ae2742141cea974ed1a1041b446_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05325f7dac154ac19707c10ed7936bd5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c99d7dca834fc9b8ba44f702ce5c97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71cb42b4cdb34217bf31e9da4cf6cfaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4925743ff242b0b2ee65ecd693dd3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c10763b02e45ea9ffe7f02507e2e8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55936ad0651e4e25a3f22368ebb27543_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i404ace05705b44778677860b518b5b99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfdc44868074605937528148921ca05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c134c659424d68b063d67180a61ce0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a974801206342f69077c517deb2da0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31b13090f3d4d6896d08faf55e51eed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49af9a202b4c453dbe1982d3176037d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3486eaebd0f44d4582e0714314d501cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic383a5944210457b97aab0db2bac248d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75defc870864b6e98d462140afc25c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95a1fa30baf4c46a60229408037bef6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica1baa88a6474f1ca1bde91733d99703_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3ea0f082c144ce87ee7b48799015d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b1c128a1684402a9045faf165e1fc4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcdf4b4d10d049fc8afa1abd2cc0db5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002db38129f24286874e3dd53ccdaf95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8c28deaeb448d887fa9af7b3d8346a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f21e80f577f43c19fd1aa42008e7706_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e71756005b40d2933a4ea6f87d56f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df4b017e9b041fa969010720463d6c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if45f71d7222548f6aa04eb33ce7241ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5482a1d0e20f424fbf824e580d6a9199_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96a185ecb1c4a958fca6ce4a87a4b19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34be06a38704454ba49d54c4642a8be6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801bb622fa854aa8aa887087ba287be2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7155363879401cb075f883b3c05618_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib153ddca67ce46f9a87db324f5e82b2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb08893e609946fb8063faaad20c4476_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8688bac62fd54e49817ebdf4ef330a22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec83df23cc984ae1bb81bac0c2d32d43_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24294e168244b4d800b76ebe275bb94_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7b424d053745b89be43013214212ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b46600611854ead8201632b540aa737_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71707c2dff14fa99b1f7a37aa00d176_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i455063291da94c4e933985b9ba288cce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc6130bace04212a70134842313f556_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c41509b0124224b8916fec64855b95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1f7b608a83444d93727a50a57cc19c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f3edab321b4f47b9ab4112053d6a1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2003PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ced0ef8f682482e991d67cc95e1bae8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd58a5889bd341b6a832c886185b7b3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c67054a7a594d6983252a6891238d26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9241e754a3e241929d3a847fe66556ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a074cf04634fb682ff822fe3155504_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7744c2c44b6e49a192f49a29131c1146_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754c391455cd4db0bb5e009228c4ed88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie512243dc7bc4d1a8e0708ea1460f39e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MXN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c33090ddb2c4c7eb6ff7538c7bb476b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6789c74e7e04a6795307d8a02ddf4b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CZK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0541d3f55fc040d3ac00d6c25ff32778_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia728542369a84272b8c445494962161e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b3f4f1317a42f2be3e756d642c8e7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99be33b784264317acca70b9f25f1a88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184372b7fd1647f08adb94357659448d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf68976ce40345619a3f5648dcaacb18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:Srt_MultipleCurrencyAxisAxis">icui:OtherCurrenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb5e6d91a92409d9ef474923b762b07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge3MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79af1c5b1914270838bef1b8ec536a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394377fd918340248b6debe2d54beff5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3e73355e5a46779e8b500f773bcabb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099ba0834fb64e019127f5cf439531b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1f546a435746b6a9e083834063101e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia825f2d41f694d229f7aba34643141dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68398fc85c9b4c69a9d24ac18c9275b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181b26114ca442d3aaba5f83684bef22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0e5b7233314ac39c225315b21f33ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7144ed377e460497e6a92365d659ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0764c13b084d4be3bc783f9c9b3ff993_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8884b7e467144a1abd07dd5529d382c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858ccda502774a3c8bcffb5a5e2125f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9d60c60bed4ebea68c80e275f8e3d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia039837b279e455ca2dc2d46edc4b550_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820fd306ff3d43e2b341018522bb3760_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d376e7b6d2421fae5fe8fa52db03b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ec86e2578c4dc9a435e041179ae4c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc61959aa8d4d67bc160b2ede121548_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5824bf85f4040b1976e55e688d916b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i735eafbcc4e744f1a518604a58b733d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01412f1ac55c4cd89cb8ff97582fb41d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2ef219571e4d04b73e0b06787c1ad9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f036a93e924d5fa456f3b1b062e994_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d0b9ad85694f8f94491a20a88c9179_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b28be753e1e4e43a0042554fc467ca7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8aaf3d494f04e50ba69cff6e04ff60b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20054b0c9f4b47ac8c1e534ba6ea3ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08778ed5abe4561b708b5b722eeb93e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia728d4a36f3f4749a1126fa36fef1423_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836cf2e65d5e413682ba9671638f8619_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14489f445c94e4c8d8946d9f09ab71b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4670f805e84ec88fcc239984f42f1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28bced960bf4b37988c086fd5dd0698_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8dd0869a16144b0a67bc6b37b8b72bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b2cef3151a4d45a40c618a6d750d32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde680e06fbf430e8e5775077493e0c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1677095d03d54c6cad7ffddc26a40aea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120db90932414ec390afe7cf3a633cc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253805333c4f482db81b9d675244447d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d08049edd740bb914aa46bd7090759_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec03ea5060745ba8354c6aad5437d98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06fe49c746ff44d19762274cadbe0d7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7152ead34514d1f9d4453e1a803d747_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb45b8279f94588a9bb6ea15ea5b6e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c5dc156f3d4065a5ac61ee8ad07be7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e281a61518246b28c211682f9b80e67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54664f90ad4843079c7700ad05a8cd6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9694c6e8455346248c473df62e0ab068_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8ea47f15d34f9b8c4166744ab1524e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie345d2cbe6234906900704fc912fcdb4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c5dcea53454983887455c2111ad23b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fb2d02e47f4de1added70760728782_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e04f05c0ec4c2c82f5854eb7872516_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886d8381dfd34aec845daca43861614f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b89fe4e5804575a068ee1b69c7ef41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66661620e064610aa37046c932752c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignDistibutorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia073c52ce185453aad5151952a58609f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignDistibutorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic34de2470df94313bd4a853cb4b2bf53_I20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb0ac701d04472195a9beec28ba8137_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04b91b0851c487e8d69fa69f80b7e71_I20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad841eb6c614e71bdb127b3ac3d2546_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edb4cd0b8bb40dda8c7263ec544dba8_I20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdcc27cec606429689f360f5df15a62d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">icui:RevenueGrossProfitVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e89e9c91139472a80f40636d2e26639_I20191102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">icui:RevenueGrossProfitVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i941468b2385e4f209a986c7dff3b8af1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98bde5dfe72e41209cdbda2cfb7fc991_I20191102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08eae0f4c494ccd87126117aa4a660d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife89f6478b684cf2b18ee6b3e0ad8937_I20191102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae7d1235c8584e3eb8cb944747cce27f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad35dba2b3944b4fa96b9b4a1230664d_I20191102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5686278e7c91400b845a73fe1fcf028f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a9546be5e4813b1774877849c0367_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be252f91ca24066a82707f0ccc864f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689ac27a1ce141ea907010394c836e09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422117d39c024ae298b2e44b34ec42d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323ab94bdb574beaa5f3b95de704e67e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e66814fa7f4fe3ac2057be6b115992_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f770a2cbd548a0b79e3ff8f05781c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a5aa933f00841e28eb62458bbde9491_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547287843f834e908b791ca319cb5472_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30434229a1be41d2b746928edc9596bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d5d4dbdf274858bc9380796f898b48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f03abc412b44071b8f3a13dd339e879_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109a7c7dcc9143cbaa84164f7f3d1725_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i139196726adc4d44903147af425499fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42498a38a5c743788e5c175074a9c29f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8551f6edca8a4836b92c3f8ac634761f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8cb6e64c7b7454eb5293e9be41c37fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a809ee047749f983c3b7fb473a8eb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3bf5b1a2204bf9bc64adbee638216b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9659021b124e4d70badd33a6c9cda626_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f064e9a451f45aab673c4e82dcbc340_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28cf3e1c65474a53a54292b2f298eedb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7925fa17894fb08b1ed1fcb9abe902_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68c59017357e4d0eb7f04b926d3edfb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052d13e776b84488abcb5580ea31dbe2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2071503a8441eb91e6e1a18cbcc84f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f436b1a47f14d0dae8fe3ff7fc02609_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30307f3e17834aff9e9b9bfbe9740d2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0b9c47fb4a4632ae6c2ec0c8a0fe8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63099355b56b44639735fd719595c0ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49cc40992cd148db92c3dc165f590efb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34247cf421ab44c3a642063a2a64781a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d86d123e7649bc9a08ba202f8cbb1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a169b1291f4fae8f8673b8db33720e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7bcaa2cb0c40ec9f2f05572f36effb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8154538596c24715a9b857081ebbf2c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb24c12f52c4ed4bfd923928efb0545_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ea28028ba24e559823c8e265b177a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib694e789a9e14a96a033168b758bb8b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e8fec49f6742c484f4ed39291aac3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137f448db78e447e98bb2714c16ee9d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3909bff053c54be18d8308bc23b1552c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d3b6e5dace4cfcb820e268951f1c59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897c4914d2304f7eba66e3d057bfbd11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8f66bb87b841b5a46011fe3af927e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia357ea3684bd486e9a953093cc31299a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72dc2b3b6d1643f08f096152319ae32f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739de8efcf0847099e2173cceabc811e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a361b33fe1423ba9980571550cb413_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122ee70217fb4cbd8648c12f53e80c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fe6f3df45e4383a8f40e6ae0c2e20f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0627ac618c7845f1bb5092afa5095fb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd40f9b169a94661afad5c82b59ee442_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11793d1454d04740869956397beef53f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95679179f944cce9f35afb1724a6e06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c51ce9a1aa4ba2803e09d904c5763f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814802c25f134344bd1ca05e7f8d0ef7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f7481192424f469ce8b17fa4645692_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c5d747a44f4274ba30ffb47647922f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if231634d16b94cbcb21a0c638c4ef8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec9f0f2f05443f99f93d8d000ec554d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ced24d07c14cf4ab00eabf97854594_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f4092f2517f47dc82182e9da5e14d64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3aed3c3b2c4c3bb0a41361e73b80b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f16fd75aa948d082f729515410eecc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc72f3e18557464b95e8f93f95cf00e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e83c70755646978896ceeb0d4640fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3512d069dc6a415ebe18d0c8a10b509a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:Greaterthan400to100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c800885ad645afbf1ee8116a89418e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:Greaterthan400to100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcafc35b7a454888b107f59bd07d6378_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo400To100ButGreaterThan300To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3270e97d056d47e8942bc86735a9953e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo400To100ButGreaterThan300To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561277523fc640f3a0134d32b5168980_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqual300To100ButGreaterThan250to100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cba9d0dc8fe4d66bbb43d02faad4c58_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqual300To100ButGreaterThan250to100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732e1f9dac654f7d8f641f5c8da76012_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo250To100ButGreaterThan200To100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940aefe82dbf46ca9e966ea0b26dd508_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo250To100ButGreaterThan200To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c38a7e4a4342929faf1d4648044fa0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo200To100Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4c6ec34d394489821d50e1ab61b2a5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo200To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34fa01e4d2b483792e00d21e1d5819a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:GreaterThan275To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThan275To100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96000b832d5e4e13bd5d06c79eee6056_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7925517a758c4a05a8e9da61378b7c92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NonCurrentDeferredTaxAssetGrossTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NonCurrentDeferredTaxAssetGrossTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794337b645e5444f81f7183e04ce3f2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if184142ad50b45d9b675340cb944b665_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02d613a9e034e6baa9929b53040a7cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b20d6909b144f7b28ddd68e4ad46d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74afdfeacf44457849b250892ba31a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f12929d589749c8b6a43800619acc14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4edba33e66d94d07a0c91f5f1eff0b0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacef78c490d44ef6a148c9eb69aec7b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8e28b05ab3410580b2d84dbdd0ff1a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab8e7d8411f469b8720f601291c4a1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87d1ef443a94425bc7fef55aeffbb03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:MexicoPropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28ae14b327942628ff1906d2fa400b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:MexicoPropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if62f26db34af43bf98b7eb60c5ef5415_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherLATAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ccbff4571344c18aff14611e8b7d41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherLATAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5cc1fca5304ed09aeff7464d1e1b88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb2ffbc07f548e4b7b499325d1200f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeed5a4cba574b72b53f8a7432ccc8cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ItalyPropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie430db3a6d1b4b528af030bd7dd26f8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ItalyPropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858b45f5d29a4f37939d46ac810c5f30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d6d0becacb4e22863dabc259d16c28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab060b29dc6441d9456425aa02c761d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:CZK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2962b814b7d0406e9adeda9d07ebf1f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:CZK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e5eb1e1a8649b3ad0d53df35a54ddb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica41d22848d442c7a94244fcacf01646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied976c6e3e0a43d5aeb99cdfef5e2e64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636799cc86f54ffb9c9c4e4c13426aa6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ba3be1285c44ab8b8349e837ac9991_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7753094a85f4264af0e886e818d2987_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447520138d3742d59dc3a80450bc8093_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:UnitedStatespropertyandequipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706aa6c5c3ab47198dd4e501b7d0d5a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:UnitedStatespropertyandequipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa663d5f8034bcf82e68c00868a0197_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92a0b79cf4e4de386c722e094de46b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09229c1123194f28a17b163cf6604124_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1faf359ab764117901453deb57409c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da14f54cad34e0a8daba92db8c33fc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0caf14d09a404492b64fca8be909ef3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd1f43f9b9842828a851bba915574e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79dba0899e1d41e29b803de02336e957_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e9f0ccbbf147428b431dbee759a035_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a149a148884f35a6590fc0b706383d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0310811c16e34b749b6d6d1c6f540f0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88345fb489ed47658151750624bb4497_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib851d69906c841cea381d2520fe3324a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b545d554f247d7a0a02f76642e67d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3fc00bdab17483ebbb47afc85c0dab2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4fdf1f07a54b639ac859a24b648c8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ac49fefe63465a8912d34fb790031a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf00748957594ed9924d63ec3390253e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0549fbba004248979b80bb6b02218da9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322d334cb60e40d4a61f1bc09d5257bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f182769ad646e3bddd9c4239760f1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0271cf17cf0844a2a04595bf20873f7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fef45bfc2f422c819e0dbb81290ea7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205528742f3c4d1db554ed4a86cd9547_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8f43d24ee94d6093c1c5f148e1cf17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000883984</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i33c36cedce9946f68c08b8ced8cb1174_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ0_ad9c3ee5-f8a9-42d0-9742-c13a68cb0bef">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ1_543c53eb-2a30-4ec4-908a-60c06f1b8292">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8yMDc_8317e49e-608e-42cc-ab32-8e8b9708a206">December&#160;31, 2022</ix:nonNumeric> or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ2_de296777-c40c-43c9-a56e-6c95259b0c00">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM5_32831637-cd6c-476d-9ec1-14242ce4d78b">001-34634</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.908%"><tr><td style="width:1.0%"></td><td style="width:47.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6ZGM3Nzk4ZGZmYzBkNDgzMzkxMzkxYmNhNzE0MzFlZTcvdGFibGVyYW5nZTpkYzc3OThkZmZjMGQ0ODMzOTEzOTFiY2E3MTQzMWVlN18wLTAtMS0xLTkyNzE4_396592cb-de79-441f-8d2f-db4e1afe3bcc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6ZGM3Nzk4ZGZmYzBkNDgzMzkxMzkxYmNhNzE0MzFlZTcvdGFibGVyYW5nZTpkYzc3OThkZmZjMGQ0ODMzOTEzOTFiY2E3MTQzMWVlN18wLTItMS0xLTkyNzE4_2917becc-5acf-4068-b3c5-e834bebfeead">33-0022692</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:22.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8wLTAtMS0xLTkyNzE4_89a99d8e-146e-4ced-bc22-d5bbae4c7e8b">951 Calle Amanecer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTAtMS0xLTkyNzE4_d6310e9d-045a-4e7a-9951-7ed12559b7ad">San Clemente</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTItMS0xLTkyNzE4_c5f3e819-643c-4eb7-8ffa-fae63cdd140b">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTQtMS0xLTkyNzE4_7fdb546f-5302-4d26-908f-94e4c1f317ba">92673</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM2_a7979850-6d05-4838-94c9-03b7d8c04395">949</ix:nonNumeric>) <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQw_2e7ff73a-c594-420a-abeb-1874ac7fbb32">366-2183</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8xLTItMS0xLTkyNzE4_89708fbf-ffc1-4d17-9237-0b0a5061a326">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8yLTAtMS0xLTkyNzE4_7fc59886-e132-42b5-856a-a000ad87a4e6">Common stock, par value $0.10 per share</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8yLTEtMS0xLTkyNzE4_0ce85d9f-0ecc-415f-874f-68201782a443">ICUI</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Global Select Market)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section 12(g) of the Act:&#160; None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQx_2ddce5fa-43f1-40fb-97ed-522e4406b1a2">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQy_1ee15ea5-c16b-4965-8648-bd31345190ee">No</ix:nonNumeric> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM3_bf4aca89-c52a-4118-88ea-514a229d8c9e">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQz_b0599bb7-aeda-40e3-87e0-bc8a18b50116">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company.&#160; See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company," in Rule 12b-2 of the Exchange Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.322%"><tr><td style="width:1.0%"></td><td style="width:32.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV8wLTAtMS0xLTkyNzE4_c54e793b-f7ac-46b1-a9d3-c1c04f627367">Large Accelerated Filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Small reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV8yLTQtMS0xLTkyNzE4_2d294407-cd6d-4b67-bd9a-2928bddc451d">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV80LTQtMS0xLTkyNzE4_1d82b554-621f-4a28-ad97-7f2e3631da86">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM4_65314b62-1085-4829-87a9-510801b370fe">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM1_0ea9e469-55f2-44b7-a670-29a43f218880">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting stock held by non-affiliates of registrant as of June&#160;30, 2022, the last business day of registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="i08f3fdac040a4646ae49b87760e750b8_I20200630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8yOTEx_cceb2827-5856-485b-be61-cc6d8c9b226a">3,305,900,983</ix:nonFraction>.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of registrant&#8217;s common stock, $.10 par value, as of January&#160;31, 2023 was <ix:nonFraction unitRef="shares" contextRef="ie2e9049c6fe84be399e3b04481dcd237_I20230131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zMDEw_eef4ad02-7939-47c8-b8c0-d34edc4fba01">23,998,252</ix:nonFraction>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ3_e2d10b1a-774a-47e3-be0f-00b509277074" escape="true">Portions of the Proxy Statement for registrant&#8217;s 2023 Annual Meeting of Stockholders filed or to be filed pursuant to Regulation 14A within 120 days following registrant&#8217;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this Report.</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU Medical, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2022 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_1427">Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_1442">Risk Factors Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_13">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_16">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_16">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_19">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_19">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_22">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_22">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_25">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_25">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_28">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_28">38</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_34">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_34">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_34">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_37">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_37">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_37">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_40">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_40">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_40">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_43">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_43">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_46">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_46">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_49">Report</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_49">s</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_49"> of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_49">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_124">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_124">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_124">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_127">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_127">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_130">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_130">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_133">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_133">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_133">109</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_139">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_139">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_139">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_142">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_142">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_142">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_145">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_145">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_145">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_148">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_148">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_148">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_151">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_151">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_151">112</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_157">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_157">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_157">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_166">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form 10-K Summary</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_166">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_169">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i33c36cedce9946f68c08b8ced8cb1174_169">116</a></span></div></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_1427"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various portions of this Annual Report on Form&#160;10-K, including this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, and documents referenced herein, describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future. These statements about the future are &#8220;forward looking statements,&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and we may identify them by using words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "will," "continue," "could," "may," and by similar expressions and statements about aims, goals and plans. The forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable, but we do not intend the statements to be representations as to future results. They include, without limitation, statements about:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future growth; future operating results and financial condition (including, among other things, anticipated sales; accruals for restructuring charges, production costs; gross margins; litigation expense; future SG&amp;A and R&amp;D expenses; manufacturing expenses; our expectations regarding liquidity and capital resources over the next twelve months; source of funds for capital purchases and operations; future tax rates; alternative sources of capital or financing; changes in working capital items such as receivables and inventory; and income taxes);</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors affecting our operating results, such as the impact of an increase in shipping costs; loss of a strategic relationship; change in demand for our products; domestic and international sales; expansion in international markets, future increases or decreases in sales of certain products and in certain markets and distribution channels; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations; increases in systems capabilities; introduction, development and sales of new products; benefits of our products over competing systems; qualification of our new products for the expedited Section 510(k) clearance procedure; possibility of lengthier clearance process for new products; planned increases in marketing; warranty claims; rebates; product returns; bad debt expense; amortization expense; inventory requirements; lives of property, plant and equipment; manufacturing efficiencies and cost savings; unit manufacturing costs; establishment or expansion of production facilities inside or outside of the U.S.; planned new orders for semi-automated or fully automated assembly machines for new products; adequacy of production capacity; our plans to repurchase shares of our common stock; asset impairment losses; relocation of manufacturing facilities and personnel; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies; the effect of costs to customers and delivery times; business seasonality and fluctuations in quarterly results; customer ordering patterns and the effects of new accounting pronouncements; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; loss of larger distributors and the ability to locate other distributors; the outcome of our strategic initiatives; regulatory approvals and compliance; outcome of litigation; patent protection and intellectual property landscape; patent infringement claims and the impact of newly issued patents on other medical devices; competitive and market factors, including continuing development of competing products by other manufacturers; improved production processes and higher volume production; innovation requirements; consolidation of the healthcare provider market and downward pressure on selling prices; distribution or financial capabilities of competitors; healthcare reform legislation; foreign exchange risk; commodity price risk; plans to convert existing space; acquisitions of other businesses or product lines. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of acquisitions, including our recently completed acquisition of the Smiths Medical business and the integration of acquired businesses and product lines (including the Smiths Medical business).</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The forward looking statements in this report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may effect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#8220;Summary Risk Factors,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_1442"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks and uncertainties, including those described in Part I, Item 1A. "Risk Factors" in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our securities. Principal risks and uncertainties include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Damage to any of our manufacturing facilities or disruption to our supply chain network could impair our ability to produce our products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Prolonged periods of inflation, rising interest rates and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">impact of foreign currency exchange rates </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as a result of the current global macroeconomic and geopolitical conditions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have had and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">could </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the future </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have a material adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has disrupted how we, our suppliers and our customers operate and the duration, and the extent to which this will impact our business, future results of operations, liquidity and overall financial performance remains uncertain.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant sales through distributors expose us to risks that could have a material effect on our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in achieving expected operating efficiencies or expense reductions associated with  cost reduction and restructuring efforts and may experience a decline in our profitability, business disruptions or other adverse consequences to our business as a result.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development requires substantial investment that may be difficult for us to fund and may be challenging to recover through commercial product sales.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If demand for our products were to decline significantly, we might not be able to recover the cost of our expensive automated molding and assembly equipment and tooling, which could have an adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices. If we cannot reduce manufacturing costs of existing and new products to counteract such pricing pressures, our sales may not grow and our profitability may decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions at the FDA, other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved, certified, or commercialized in a timely manner, or at all, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards may adversely affect our business, operations and financial performance.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to certain fraud and abuse and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be materially and adversely affected if we fail to defend and enforce our patents or other proprietary rights, if our products are found to infringe patents or other proprietary rights owned by others or if the cost to protect our patents or other proprietary rights becomes excessive or as our patents expire.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs could have a material adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International sales pose additional risks related to competition with larger international companies and established local companies and our possibly higher cost structure.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Smiths Medical acquisition completed in January 2022 has resulted in organizational changes and significant growth to our business. If we fail to effectively manage this growth and change to our business in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The actual impact of the Smiths Medical acquisition on our financial results may be worse than the assumptions we have used.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a result of the Smiths Medical acquisition, we have used a significant portion of our cash on hand and incurred a substantial amount of debt to finance the cash consideration portion and certain other amounts paid in connection with the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part I, Item 1A of this Annual Report on Form 10-K for the detailed discussion of the above risk factors.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First person pronouns used in this Annual Report on Form 10-K, such as &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to ICU Medical, Inc. (&#8220;ICU&#8221;) and its subsidiaries unless context requires otherwise.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Background and Overview of Business</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in San Clemente, California, ICU was founded in 1984. Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. Since our inception we have grown organically and through acquisition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we acquired Pfizer Inc.&#8217;s (&#8220;Pfizer&#8221;) Hospira Infusion Systems (&#8220;HIS&#8221;) business. The HIS acquisition complemented our legacy non-dedicated infusion sets and oncology business by expanding our product portfolio to include a complete intravenous infusion therapy product-line from IV solutions to IV pumps to non-dedicated infusion sets. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we acquired Pursuit Vascular, Inc. (&#8220;Pursuit&#8221;). Pursuit was a privately-held medical device company with a primary focus on innovative catheter disinfecting products and technologies to reduce costly bloodstream infections and lower healthcare costs. Pursuit&#8217;s primary product is the ClearGuard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> HD cap, which is used for the maintenance of hemodialysis catheters. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we acquired Smiths Medical 2020 Limited (&#8220;Smiths Medical&#8221;), the holding company of Smiths Group plc&#8217;s global medical device business. The Smiths Medical acquisition complemented and broadened our preexisting product portfolio by adding syringe and ambulatory infusion devices, vascular access, and vital care products, and significantly strengthened and expanded our global market reach.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our primary product offerings are listed below. Our product offerings related to our Smiths Medical acquisition are listed separately as we integrate that business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Consumables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion therapy sets, used in hospitals and ambulatory clinics, consist of a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient&#8217;s vein, that may or may not be used with an IV pump.&#160;Closed System Transfer Devices (&#8220;CSTD&#8221;) and hazardous drug compounding systems are used to prepare and deliver hazardous IV medications such as those used in chemotherapy, which, if released, can have harmful effects to the healthcare worker and environment.&#160;Our primary products include:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Clave&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needlefree products, including the MicroClave, MicroClave Clear, and NanoClave&#8482; brand of connectors, accessories, extension and administration sets used for the administration of IV fluids and medications and the Neutron catheter patency device, used to help maintain patency of central venous catheters;</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ChemoLock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CSTD, which utilizes a proprietary needlefree connection method, is used for the preparation and administration of hazardous drugs. ChemoLock is used to limit the escape of hazardous drug or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ChemoClave</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an ISO Connection standard and universally compatible CSTD used for the preparation and administration of hazardous drugs. ChemoClave utilizes standard ISO luer locking connections, making it </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compatible with all brands of needlefree connectors and pump delivery systems. ChemoClave also is used to limit the escape of hazardous drug or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminate the risk of needlestick injury.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of hazardous drugs typically takes place in a pharmacy where drugs are removed from vials and prepared for delivery to a patient. Those prepared drugs are then transferred to a nursing unit where the chemotherapy is administered via an infusion pump set to a patient. Components of the ChemoClave and ChemoLock product lines are used both in pharmacies and on the nursing floors for the preparation and administration of hazardous drugs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Systems</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a wide range of infusion pumps, dedicated IV sets, software and professional services. Our primary Infusion System products are dedicated IV sets and the following:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infusion Pump Hardware:</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Plum 360&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plum 360&#8482; infusion pump is an ICU Medical MedNet&#8482; ready large volume infusion pump with an extensive drug library and wireless capability. Plum 360 was named the 2018, 2019, 2020 and 2022 Best in KLAS winner as top-performing IV smart pump and was the first medical device to be awarded UL Cybersecurity Assurance Program Certification. Also, in 2021, 2022 and 2023, the Plum 360 won the  award as the top-performing Smart Pump EMR-Integrated.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IV Medication Safety Software:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ICU Medical MedNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;: ICU Medical MedNet is an enterprise-class medication management platform for any sized healthcare system that can help reduce medication errors, improve quality of care, streamline workflows and maximize revenue capture. ICU Medical MedNet connects our industry-leading smart pumps to a hospital&#8217;s EHR, asset tracking systems, and alarm notification platforms with the largest array of integration partners. </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional Services: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition to the products above, our teams of clinical, information technology, and professional services experts work with customers to develop and deliver safe and efficient infusion systems, providing customized and personalized configuration, implementation, and data analytics services to complement our infusion hardware and software.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IV Solutions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide a broad portfolio of IV solutions to meet our customers&#8217; clinical needs, providing a consistent supply of IV solutions, irrigation, and nutritionals to help provide safe and effective patient care. Our primary IV Solutions products are:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IV Therapy and Diluents:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Including Sodium Chloride, Dextrose, Balanced Electrolyte Solutions, Lactated Ringer&#8217;s, Ringer&#8217;s, Mannitol, Sodium Chloride/Dextrose and Sterile Water.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Irrigation:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Including Sodium Chloride Irrigation, Sterile Water Irrigation, Physiologic Solutions, Ringer&#8217;s Irrigation, Acetic Acid Irrigation, Glycine Irrigation, Sorbitol-Mannitol Irrigation, Flexible Containers and Pour Bottle Options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Care</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Critical Care products help clinicians get accurate real-time access to patients&#8217; hemodynamic and cardiac status with an extensive portfolio of monitoring systems and advanced sensors &amp; catheters.&#160;Measurements provided by our systems help clinicians determine how well the heart is pumping blood and how efficiently oxygen from the blood is being used by the tissues. Our primary Critical Care products are:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cogent&#8482; 2-in-1 hemodynamic monitoring system;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CardioFlo&#8482; hemodynamic monitoring system;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TDQ&#8482; and OptiQ&#8482; cardiac output monitoring catheters;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TriOx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">venous oximetry catheters;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transpac&#8482; blood pressure transducers; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SafeSet&#8482; closed blood sampling and conservation system.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Systems-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a wide range of infusion pumps, disposables and safety software for use in both hospital and home settings. These products participate in adjacent categories to the legacy ICU Medical Infusion Systems product line. The primary Infusion Systems-Smiths Medical products are:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ambulatory Infusion Hardware:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">CADD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; ambulatory infusion pumps and disposables, including administration sets and medication cassette reservoirs, support a variety of IV pain management therapies across clinical care areas from hospital to outpatient treatment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Syringe Infusion Hardware:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medfusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">syringe infusion pumps are designed for the administration of fluids and medication requiring precisely controlled infusion rates from a variety of syringe sizes in acute care settings.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infusion Software:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PharmGuard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; Medication Safety Software for MedfusionTM 4000 syringe and CADD&#8482; Solis pumps allows for customized drug libraries to support the standardization of protocols for medication administration throughout the facility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vascular Access-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vascular Access-Smiths Medical products allow clinicians to safely access the patients&#8217; bloodstream to deliver fluids and medication or to obtain blood samples. Vascular Access products are often used in conjunction with Consumables and Infusion Systems devices. Our primary Vascular Access products are:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jelco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; safety and conventional peripheral IV catheters, sharps safety devices for hypodermic injection, and venipuncture blood collection and peripheral IV catheters designed to help prevent needlestick injury and to reduce the risks associated with blood exposure and contamination while reducing patients&#8217; risk of infection;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">DELTEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; implantable ports and GRIPPER&#174; non-coring needles for portal access;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Portex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; arterial blood sampling syringes, anesthesia trays and kits for pain management;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Powerwand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; midline catheters; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">MEDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> LogiCal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; Pressure Monitoring System and components.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vital Care-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a range of devices and systems to maintain patients&#8217; airways and body temperature before, during and after surgery. Our primary Vital Care products are:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; temperature management systems used in perioperative and critical care settings to help monitor and regulate patient temperature through rapid infusion, routine blood and fluid warming, irrigation warming and convective warming.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Portex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acapella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; bronchial hygiene products used to mobilize pulmonary secretions to facilitate the opening of airways in patients with chronic respiratory diseases such as chronic obstructive pulmonary disease ("COPD"), asthma and cystic fibrosis.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Portex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bivona</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; tracheostomy tubes in PVC and silicone construction that provide a secure airway for both surgical and percutaneous procedures. Our silicone tracheostomy tubes are customizable to accommodate unique patient requirements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to our reporting segment and primary product lines is set forth in Part II, Item 7. "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations" of this Annual Report on Form 10-K, and is incorporated herein by reference. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities are concentrated in the United States, Costa Rica, Mexico, and Czech Republic. See Part I, Item 2 of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on certain outside manufacturers for certain product lines in Infusion Systems and we leverage a long-term supply agreement with Pfizer (described below) to provide additional IV Solution products to us.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2017, we entered into two Manufacturing and Supply Agreements ("MSAs") with Pfizer under which, (i) Pfizer agreed to manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) we agreed to manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, with a one-time two-year option to extend. The initial supply price under each MSA is annually updated and is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. In January 2021, we amended our MSA with Pfizer whereby we agreed to manufacture and supply certain agreed upon products to Pfizer. The amendment included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes included (i) changes to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products. On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum (the "Product Addendum") to our MSA agreement whereby Pfizer agreed to manufacture and supply to us certain agreed upon products subject to certain time and pricing terms and conditions. The Product Addendum expired on November 30, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We operate regional device service centers, in a number of locations, including Salt Lake City, Utah, U.S., Sligo, Ireland; San Laurent, Quebec, Canada; Taipei, Taiwan and Rydalmere, Australia. See Part I, Item 2 of this Annual Report on Form 10-K. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Raw Materials</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We purchase many of the components and raw materials used in manufacturing our products from numerous suppliers in various countries. Certain components and raw materials are available only from a single supplier.We currently attempt to manage the risk associated with such suppliers by means of inventory management, relationship management and evaluation of alternative sources when feasible.See Item 1A. Risk Factors - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales, Marketing and Administration</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell globally through our own direct sales force and through independent distributors. We currently serve customers in over 100 countries throughout the world. The majority of our sales is denominated in United States ("U.S.") dollars and we have sales denominated in Euros, Canadian dollars,  Japanese Yen, British Pound and Australian dollars as well as other currencies. In 2022, we had worldwide net sales to Medline of 15% of consolidated net sales. In 2021 and 2020, we did not have sales over 10% to any single customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are marketed and distributed in the U.S. and internationally to medical product manufacturers, independent distributors and directly to end users.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of our products in the U.S. is supported by a network of owned and leased distribution centers, which include King of Prussia, Pennsylvania; Los Angeles, California; Dallas, Texas and Olive Branch, Mississippi. We also utilize a number of public warehouses as part of our supply chain.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, we manage distribution by utilizing international regional hubs and through independent distributors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are subject to extensive and rigorous regulation by the Food and Drug Administration ("FDA") and other federal, state and local authorities, as well as foreign regulatory authorities. The FDA regulates, among other things, the research, development, testing, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and marketing, distribution, post-approval monitoring and reporting and import and export of drug products, medical devices and combination drug/device products in the U.S. to assure the safety and effectiveness of such medical products for their intended uses and otherwise meet the applicable requirements of the Federal Food, Drug and Cosmetic Act (&#8220;FDC Act&#8221;). The Federal Trade Commission ("FTC") also regulates the advertising of our products. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training and other practices to government scrutiny. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Device Regulation in the U.S.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products are regulated by the FDA as medical devices in the U.S. Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the U.S. will require either a pre-market notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDC Act, also referred to as a 510(k) clearance, or approval from the FDA of a pre-market approval ("PMA") application. Under the FDC Act, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I devices are those that pose the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of current good manufacturing practices ("cGMPs") for medical devices known as the Quality System Regulation ("QSR"), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDA's General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed into Class III.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of most Class II devices are required to obtain from the FDA a 510(k) clearance for permission to commercially distribute the device. Class III devices require approval of a PMA application evidencing safety and effectiveness of the device.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 510(k) process, applicants must demonstrate to the FDA that the device is as safe and effective as, or substantially equivalent to, a legally marketed device, the "predicate" device. A predicate device is a legally marketed device that is not subject to pre-market approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent through the 510(k) process. Applicants must submit performance data to establish substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) pre-market notification. If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption ("IDE") regulations. If the FDA agrees that the device is substantially equivalent to a lawfully marketed predicate device, it will grant 510(k) clearance to authorize the device for commercialization. If the FDA determines that the device is "not substantially equivalent," the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification request or a PMA in the first instance, but the FDA can </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination not to seek a new 510(k) or other form of marketing authorization for the modification to the 510(k)-cleared product, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) clearance or PMA approval is obtained or a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification is granted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the PMA application process, the applicant must demonstrate to the satisfaction of the FDA that the device is safe and effective for its intended use. This approval process applies to most Class III devices, and generally requires clinical data to support the safety and effectiveness of the device, obtained in adherence with IDE requirements. Following receipt of a PMA application, the FDA determines whether the application is sufficiently complete to permit a substantive review. If FDA accepts the application for review, it has 180 days under the FDC Act to complete its review of a PMA, although in practice, the FDA's review often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel's recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers' or suppliers' facilities to ensure compliance with the QSR. The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement, or in some cases a new PMA. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is cleared or approved or otherwise authorized for marketing, numerous pervasive regulatory requirements continue to apply unless explicitly exempt. These include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment registration and device listing with the FDA;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of cleared devices;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDC Act that may present a risk to health;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with requirements governing Unique Device Identifiers on devices and also requiring the submission of certain information about each device to the FDA's Global Unique Device Identification Database;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA's recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect public health or to provide additional safety and effectiveness data for the device.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Regulation in the U.S. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our IV solutions products are regulated by the FDA as drugs. In the U.S., the FDA regulates drugs under the FDC Act, and its implementing regulations, and biologics under the FDC Act and its implementing regulations. The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA's Good Laboratory Practice requirements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an investigational new drug application ("IND"), which must become effective before clinical trials may begin;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an institutional review board ("IRB") or ethics committee at each clinical site before the trial is commenced;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended purpose;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of a New Drug Application ("NDA") or abbreviated new drug application ("ANDA") after completion of all required clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the product's continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices ("GCPs"); and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the U.S.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to beginning clinical trials of a drug product in the U.S., an IND must be submitted to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND must become effective before human clinical trials may begin. Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The NDA must include all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced and of select clinical trial sites, the FDA may issue an approval letter or a Complete Response Letter ("CRL"). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will generally describe all of the deficiencies that the FDA has identified in the NDA. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a drug is granted, such approval will be granted for particular indications and may include limitations on the indicated uses for which such drug may be marketed. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the drug&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the drug based on the results of these post-marketing studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Market Enforcement in the U.S.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw marketing authorizations for drugs or medical devices if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions. Other potential consequences include, among other things: complete withdrawal of the product from the market, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA to approve pending applications or supplements to approved applications, product seizures or detention, refusal to permit the import or export of products, consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs, the issuance of corrective information, injunctions, or the imposition of civil or criminal penalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of drugs and medical devices. A company can make only those claims relating to safety and efficacy, purity and potency that are cleared or approved by the FDA and in accordance with the provisions of the authorized label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Medical Devices in the European Union</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union ("EU") has adopted specific directives and regulations regulating the design, manufacture, clinical investigation, conformity assessment, labeling and adverse event reporting for medical devices.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until May 25, 2021, medical devices were regulated by Council Directive 93/42/EEC (the "EU Medical Devices Directive") which has been repealed and replaced by Regulation (EU) No 2017/745 (the "EU Medical Devices Regulation"). Our current certificates have been granted under the EU Medical Devices Directive whose regime is described below. However, as of May 26, 2021, some of the EU Medical Devices Regulation requirements apply in place of the corresponding requirements of the EU Medical Devices Directive with regard to registration of economic operators and of devices, post-market surveillance and vigilance requirements. Pursuing marketing of medical devices in the EU will notably require that our devices be certified under the new regime set forth in the EU Medical Devices Regulation when our current certificates expire.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU Medical Devices Directive</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EU Medical Devices Directive, all medical devices placed on the market in the EU must meet the relevant essential requirements laid down in Annex I to the EU Medical Devices Directive, including the requirement that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performance intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter as it creates a rebuttable presumption that the device satisfies that essential requirement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To demonstrate compliance with the essential requirements laid down in Annex I to the EU Medical Devices Directive, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims made about the performance and safety of the device are supported by suitable evidence. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to sterility or metrology), a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. A notified body would typically audit and examine a product's technical dossiers and the manufacturers' quality system (the notified body must presume that quality systems which implement the relevant harmonized standards &#8211; which is ISO 13485:2016 for Medical Devices Quality Management Systems &#8211; conform to these requirements). If satisfied that the relevant product conforms to the relevant essential requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the European Conformity ("CE") mark to the device, which allows the device to be placed on the market throughout the EU.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the term of the certificate of conformity, the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In particular, there will be a new audit by the notified body before it will renew the relevant certificate(s).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU Medical Devices Regulation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory landscape related to medical devices in the EU recently evolved. On April 5, 2017, the EU Medical Devices Regulation was adopted with the aim of ensuring better protection of public health and patient safety. The EU Medical Devices Regulation establishes a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. Unlike the EU Medical Devices Directive, the EU Medical Devices Regulation is directly applicable in EU member states without the need for member states to implement into national law. This aims to increase harmonization across the EU.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU Medical Devices Regulation became effective on May 26, 2021. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May 26, 2025, provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the EU Medical Devices Regulation, in particular the obligations described below.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU Medical Devices Regulation requires that before placing a device, other than a custom-made device, on the market, manufacturers (as well as other economic operators such as authorized representatives and importers) must register by submitting identification information to the electronic system (Eudamed), unless they have already registered. The information to be submitted by manufacturers (and authorized representatives) also includes the name, address and contact details of the person or persons responsible for regulatory compliance. The new Regulation also requires that before placing a device, other than a custom-made device, on the market, manufacturers must assign a unique identifier to the device and provide it along with other core data to the unique device identifier ("UDI") database. These new requirements aim at ensuring better identification and traceability of the devices. Each device &#8211; and as applicable, each package &#8211; will have a UDI composed of two parts: a device identifier ("UDI-DI") specific to a device, and a production identifier ("UDI-PI") to identify the unit producing the device. Manufacturers are also notably responsible for entering the necessary data on Eudamed, which includes the UDI database, and for keeping it up to date. The obligations for registration in Eudamed will become applicable at a later date (as Eudamed is not yet fully functional). Until Eudamed is fully functional, the corresponding provisions of the EU Medical Devices Directive continue to apply for the purpose of meeting the obligations laid down in the provisions regarding exchange of information, including, and in particular, information regarding registration of devices and economic operators.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All manufacturers placing medical devices on the market in the EU must comply with the EU medical device vigilance system which has been reinforced by the EU Medical Devices Regulation. Under this system, serious incidents and Field Safety Corrective Actions ("FSCAs") must be reported to the relevant authorities of the EU member states. These reports will have to be submitted through Eudamed &#8211; once functional &#8211; and aim to ensure that, in addition to reporting to the relevant authorities of the EU member states, other actors such as the economic operators in the supply chain will also be informed. Until Eudamed is fully functional, the corresponding provisions of the EU Medical Devices Directive continue to apply. A serious incident is defined as any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use-error due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect, which, directly or indirectly, might have led or might lead to the death of a patient or user or of other persons or to a temporary or permanent serious deterioration of a patient's, user's or other person's state of health or a serious public health threat. Manufacturers are required to take FSCAs defined as any corrective action for technical or medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasons to prevent or reduce a risk of a serious incident associated with the use of a medical device that is made available on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. For similar serious incidents that occur with the same device or device type and for which the root cause has been identified or a FSCA implemented or where the incidents are common and well documented, manufacturers may provide periodic summary reports instead of individual serious incident reports.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of medical devices is subject to some general principles set forth in EU legislation. According to the EU Medical Devices Regulation, only devices that are CE marked may be marketed and advertised in the EU in accordance with their intended purpose. Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, while not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example, requiring that advertisements are evidenced, balanced and not misleading. Specific requirements are defined at a national level. EU member states' laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national "Sunshine Acts" which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the U.S., on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, regulatory authorities have the power to carry out announced and, if necessary, unannounced inspections of companies, as well as suppliers and/or sub-contractors and, where necessary, the facilities of professional users. Failure to comply with regulatory requirements (as applicable) could require time and resources to respond to the regulatory authorities&#8217; observations and to implement corrective and preventive actions, as appropriate. Regulatory authorities have broad compliance and enforcement powers and, if such issues cannot be resolved to their satisfaction, can take a variety of actions, including untitled or warning letters, fines, consent decrees, injunctions, or civil or criminal penalties. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the European Economic Area ("EEA") which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2021, the Medicines and Healthcare Products Regulatory Agency ("MHRA") has become the sovereign regulatory authority responsible for Great Britain (i.e. England, Wales and Scotland) medical device market according to the requirements provided in the&#8239;Medical Devices Regulations 2002&#8239;(SI 2002 No 618, as amended) that sought to give effect to the three pre-existing EU directives governing active implantable medical devices, general medical devices and in vitro diagnostic medical devices whereas Northern Ireland continues to be governed by EU rules according to the Northern Ireland Protocol. Following the end of the United Kingdom's ("UK's") withdrawal from the EU ("Brexit") transitional period on January 1, 2021, new regulations require all medical devices to be registered with the MHRA before being placed on the Great Britain market. The MHRA only registers devices where the manufacturer or their UK responsible person has a registered place of business in the UK. Beginning January 1, 2022, manufacturers based outside the UK need to appoint a UK responsible person that has a registered place of business in the UK to register devices with the MHRA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2022, the MHRA published its response to a 10-week consultation on the post-Brexit regulatory framework for medical devices and diagnostics. MHRA seeks to amend the UK Medical Devices Regulations 2002 (which are based on EU legislation, primarily the EU Medical Devices Directive and the EU In Vitro Diagnostic Medical Devices Directive 98/79/EC), in particular to create a new access pathway to support innovation, create an innovative framework for regulating software and artificial intelligence as medical devices, reform IVD regulation and foster sustainability through the reuse and remanufacture of medical devices. Regulations implementing the new regime were originally scheduled to come into force in July 2023, but have recently been postponed to July 2024. Devices bearing CE marks issued by EU notified bodies under the MDR or MDD are now subject to transitional arrangements. In its consultation response, the MHRA indicated that the future UK regulations will allow devices certified under the MDR to be placed on the market in Great Britain under the CE mark until either the certificate expires or for five years after the new regulations take effect, whichever is sooner. Devices certified under the MDD could continue to be placed on the market until either the certificate expires or for three years after the new regulations take effect, whichever is sooner. Following these transitional periods, it is expected that all medical devices will require a UK Conformity Assessed ("UKCA") mark. Manufacturers may choose to use the UKCA mark on a voluntary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis until June 30, 2023.  However, UKCA marking will not be recognized in the EU. The rules for placing medical devices on the market in Northern Ireland, which is part of the UK, differ from those in the rest of the UK. Compliance with this legislation is a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trade deal between the UK and the EU generally provides for cooperation and exchange of information between the parties in the areas of product safety and compliance, including market surveillance, enforcement activities and measures, standardization-related activities, exchanges of officials, and coordinated product recalls. As such, processes for compliance and reporting should reflect requirements from regulatory authorities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Northern Ireland Protocol, Northern Ireland follows EU rules on medical devices and devices marketed in Northern Ireland require assessment according to the EU regulatory regime. Such assessment may be conducted by an EU notified body, in which case a CE mark is required before placing the device on the market in the EU or Northern Ireland. Alternatively, if a UK notified body conducts such assessment, a 'UKNI' mark is applied and the device may only be placed on the market in Northern Ireland and not the EU.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Regulation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must also comply with FDA and International Organization for Standardization ("ISO") governing medical device manufacturing practices. The FDA, state, foreign agencies and ISO require manufacturers to register and subject manufacturers to periodic FDA, state, foreign agencies and notified bodies and ISO inspections and audits of their manufacturing facilities. We are a FDA and ISO registered medical device manufacturer, and must demonstrate that we and our contract manufacturers comply with the FDA's QSR, cGMPs and similar foreign requirements. The FDA, other regulatory agencies and notified bodies outside the U.S. monitor compliance with these requirements through inspections and audits of manufacturing facilities. If an inspector observes conditions that might be violative, the manufacturer must correct those conditions or explain them satisfactorily, or face potential regulatory action that might include physical removal of the product from the marketplace.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. These laws include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any federal healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services ("CMS") information related to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments or other "transfers of value" made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician health care professionals (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), and teaching hospitals and ownership and investment interests held by the physicians described above and their immediate family members; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry's voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to track and report information related to payments and other "transfers of value" to physicians and other healthcare providers or pricing, marketing expenditures and information. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any of the laws described above include civil and criminal penalties, damages, fines, the curtailment or restructuring of an entity&#8217;s operations, the debarment, suspension or exclusion from federal and state healthcare programs and/or imprisonment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability and operations are subject to changes in legislative, regulatory and reimbursement policies and decisions as well as changes in private payer reimbursement coverage and payment decisions and policies. Our products are purchased by hospitals, physicians and other healthcare providers that typically bill various third-party payors, such as governmental programs, private insurance plans and managed care plans, for the healthcare services and products provided to their patients. The ability of our customers to obtain appropriate coverage and reimbursement for healthcare services and products from third-party payors is critical because it affects which products customer purchase and the prices they are willing to pay since our products are not separately reimbursed by any third-party payor. Third-party payors are increasingly reducing coverage and reimbursement for certain healthcare services and products and challenging prices charged for healthcare services and products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform in the U.S.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been, and we expect that there will continue to be, a number of federal and state proposals to limit payments by governmental payors for medical devices, and the procedures in which medical devices are used. For example, in March 2010, comprehensive healthcare reform legislation was enacted through the passage of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act (the "ACA"), which, among other things, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models.  </span></div><div style="padding-right:11.25pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></div><div style="padding-right:11.25pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers, which went into effect on April 1, 2013, and will stay in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals. We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or internationally, or the effect any future legislation or regulation will have on us. Such legislation and regulation of healthcare costs may, however, result in decreased lower reimbursements by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governmental and private payors to our customers, which may adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU Healthcare Reform</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                Additional healthcare reform measures in the EU may be adopted in the future as well. For instance, in December 2021, Regulation (EU) No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. This regulation which entered into force in January 2022 intends to boost cooperation among EU member states in assessing health technologies, including certain high-risk medical devices, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy and Security</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medical device companies may be subject to U.S. federal and state and foreign data privacy, security and data breach notification laws governing the collection, use, disclosure and protection of health-related and other personal information. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive.&#160;We believe our ability to effectively compete in this industry is determined by our ability to provide a wide breadth of cost-effective, high quality products.&#160;We believe the added breadth of our acquired product portfolios have increased our competitiveness as we can now provide a one-stop shop for customers and offer more flexible competitive pricing.&#160;We also believe our infusion pump product offering will enable us to achieve sales of a larger volume of higher margin infusion consumables, and we believe we have a wider customer reach through our unified distribution channels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infusion Consumables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to effectively compete in the Infusion Consumables market depends upon our ability to differentiate our products based on continued innovation, safety, quality, convenience, reliability, patent protection, ease of use and the pricing of our products, in addition to access to distribution channels.&#160;We encounter significant competition in this market both from global, large, established medical device manufacturers and from smaller companies. We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), and B. Braun Medical, Inc. ("B. Braun").&#160;Our CSTD products and systems, used for the preparation and safe handling of oncology drugs, compete with similar products from BD and EquaShield. We believe that our current CSTD product offering provides benefits over these competing systems in several areas related to safety, ease of use, quality, and cost; however, ongoing innovation will be required to remain competitive in this market space.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infusion Systems (Legacy ICU and Smiths Medical)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face strong global competitors in the Infusion Systems market. In the United States ("U.S.") our competitors include BD, Baxter, Moog Medical, Fresenius and B. Braun. Outside of the U.S., our primary competitors are BD, B. Braun, Fresenius Kabi, a division of Fresenius Group, and a large number of local market pump manufacturers.&#160;These competitors benefit from greater financial, research and development and marketing resources than we have. The smart pump market in recent years has been troubled with security concerns and product recalls. We believe our ability to effectively compete will be determined by our ability to build our brand strength using the development of technological advancements aimed at increasing the quality, reliability,  safety and security of our pumps while at the same time focusing on manufacturing efficiency and cost-effectiveness, which are operationally challenging with evolving product lines.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IV Solutions</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the IV solutions market only in the U.S. and Canada. Our primary competitors in the U.S. include Baxter and B. Braun.&#160;Demand for IV solutions is typically high and raw materials required to produce IV solutions are readily available.&#160;Our ability to compete will depend on our ability to maximize production, develop innovations in our product line, focus on cost-effectiveness and maintain the appropriate quality infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Care</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary competitor in Critical Care is Edwards Lifesciences.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vascular Access-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vascular Access product line of Smiths Medical competes primarily with BD and B. Braun as well as Angio Dynamics, Greiner Bio-One and Teleflex Incorporated. Our ability to remain competitive in this market will depend on our ability to focus on demonstrable patient outcomes by differentiating our products by improving device functionality and by providing successful customer training programs on the use and maintenance of our products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Care-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vital Care product line of Smiths Medical competes with numerous competitors due to its broad product portfolio. Those include multinational competitors such as Philips Healthcare as well as smaller more focused competitors such as Belmont and Intersurgical plc. Our ability to compete in this market will depend on our ability to continue to make technological advances to our products, thereby increasing customer efficiency, and provide product support aimed at improving clinical decision-making that ultimately enhances patient safety.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our product lines rely on patent protection. We have obtained U.S. and foreign patents relating to certain of the technologies found in our products, and are pursuing additional patent applications. There is however, no single patent or group of patents that we own that we believe is material in relation to our business as a whole. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to obtain, maintain and enforce patent protection for our products and to operate without infringing on the proprietary rights of third parties. While we have obtained certain patents and applied for additional U.S. and foreign patents covering certain of our products, there is no assurance that the scope of any patent protection will prevent competitors from introducing similar or competing devices or that any of our patents will be held valid if subsequently challenged. We can also lose patent protection through expiration. The inability to obtain effective patent protection or the loss of patent protection on a specific product line could adversely affect our ability to exclude other company from producing effective competitive products. The loss of a significant portion of our patent portfolio could have an adverse impact on our financial results. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fact that a patent is issued to us does not eliminate the possibility that patents owned by others may contain claims that are infringed by our products.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry.&#160;Litigation, which would result in substantial cost to us and diversion of our resources, may be necessary to defend us against claimed infringement of the rights of others and to determine the scope and validity of the proprietary rights of others.&#160;Adverse determinations in such litigation could subject us to significant liabilities to third parties or could require us to seek licenses from third parties and could prevent us from manufacturing, selling or using our products, any of which could have a material adverse effect on our business.&#160;In addition, we have initiated litigation, and may continue to initiate litigation in the future, to enforce our intellectual property rights against those we believe to be infringing on our patents.&#160; Such litigation could result in substantial cost and diversion of resources.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality/Quarterly Results</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is not significantly impacted by seasonal aspects.&#160;We can, however, experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which has been and may continue to be driven more by the COVID-19 pandemic surges and its impact on hospital admissions and procedure volumes along with production scheduling and customer inventory levels, as well as fluctuations due to supply constraints as a result of other macroeconomic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and global geopolitical events, such as the conflict in the Ukraine.&#160;Our expenses do not typically fluctuate in the same manner as net sales, which may result in cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in certain research and development ("R&amp;D") projects to drive future growth and to remain competitive in our product lines. Our main R&amp;D facilities are located in the U.S and India. Our R&amp;D costs primarily include personnel costs and expenses related to the development of new products. Research and development costs were $93.0 million in 2022, $47.5 million in 2021 and $42.9 million in 2020.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our employees are the foundation of our business and are key to executing our strategy globally. The knowledge, skills and abilities of our diverse workforce is paramount in upholding our mission of connecting patients and caregivers through safe, life-saving, life enhancing IV therapy products, systems, and services. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the health and well-being of our employees are cornerstones for our successful operations. Whether you are a machine operator in one of our manufacturing locations, a material handler in a distribution center, a service technician supporting our products in the field, or a clinician training customers on the use of our products in a hospital, we strive to prioritize the safety of our team members. This includes designing our work environments with a safety first mindset, providing personal protective equipment and safety training beginning day one.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain talented individuals globally begins with our commitment to offer a career that gives people a unique opportunity to work in an exhilarating, fast-paced, inspiring, and collaborative environment where what they do makes a difference. We offer competitive salaries and benefit packages to all employees as well as select participation in incentive plans based on individual and company performance.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the development of our workforce is critical for personal growth and the success of our company as well. We reinforce this with challenging, yet rewarding assignments, continued learning and training programs through our global iLearning platform, and support continued education globally through tuition reimbursement programs. Our team believes in diversity, collaboration, and removing barriers to communication&#8212;all to create an environment where innovation and creativity can flourish. This is principal for us in attracting, developing, retaining and rewarding talent on a global scale.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we believe that our leadership team, with its broad, and deep category knowledge and averaging approximately 22 years of experience in IV therapy has the necessary experience to effectively lead the execution of our strategy. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had approximately 14,500 employees located in over 35 countries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Data</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding financial data by geography is set forth in Part II, Item 8. "Financial Statements and Supplementary Data" of this Annual Report on Form 10-K in Notes 4 and 13 to the Consolidated Financial Statements, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is http://www.icumed.com.&#160;We make available our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings and amendments thereto those reports, free of charge on our website as soon as reasonably practicable after filing or furnishing them with the Securities and Exchange Commission ("SEC").&#160;We also have our code of ethics posted on our website (http://www.icumed.com).&#160;The information on our website is not incorporated into this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC on its website (http://www.sec.gov).</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating an investment in our common stock, investors should consider carefully, among other things, the following risk factors, as well as the other information contained in this Annual Report on Form 10-K and our other reports and registration statements filed with the SEC. Any of the following risks could materially and adversely affect our results of operations or financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business and Operating Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk mitigation plans employed with key suppliers of materials (such as resins) that are critical to our ability to manufacture our products, the supply of which is currently from a sole supplier, may not suffice to ensure that we are able to receive requisite materials as and when needed an in sufficient quantity. We cannot be certain that our current suppliers will continue to provide us with the quantities of materials that we require or satisfy our anticipated specifications and quality requirements on a timely basis or at all. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our products until a new source of supply, if any, could be identified and qualified. Upon identification, the qualification process of new suppliers and component materials can take a considerable amount of time. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. The price and supply of these materials may be impacted or disrupted for reasons beyond our control including supplier shutdowns, transportation delays, inflationary pricing pressures, work stoppages, labor shortages and governmental regulatory actions. We have experienced, and may continue to experience, significant challenges to our global transportation channels and other aspects of the global supply chain network, including the cost and availability of raw materials and components due to shortages and resulting cost inflation.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to impact supply channels resulting in raw material shortages and supply chain disruptions generally. Furthermore, our contract manufacturers could require us to move to another one of their production facilities. An interruption in our commercial operations could occur if we encounter delays or difficulties in securing these components, materials or services, and if we cannot then obtain an acceptable substitute. Additionally, we are subject to FDA and foreign regulations, which could further delay our ability to obtain a qualified alternative supplier. Any performance failure on the part of our suppliers could delay the development and manufacture of our products, which could have a material adverse effect on our business. Due to the highly competitive nature of the healthcare industry and the cost controls of our customers and third party payors, as well as entering into long-term fixed price contracts we may be unable to pass along cost increases for any key components or raw materials through higher prices to our customers. If the cost of key components or raw materials increases and we are unable to fully recover those increased costs through price increases or offset these increases through other cost reductions, we could experience an adverse effect on our financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Damage to any of our manufacturing facilities or disruption to our supply chain network could impair our ability to produce our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                A severe weather event, other natural or man-made disaster, or any other significant disruption, such as outbreak of disease (including the COVID-19 pandemic), the impact of war or political instability (such as the conflict in the Ukraine), work stoppages, labor shortages and similar interruptions affecting our manufacturing facilities or our suppliers and logistics partners could materially and adversely impact our business, financial condition and results of operations. The COVID-19 pandemic caused us to temporarily shut down some of our facilities. Additionally, in 2021, we experienced supply chain disruptions and general supply constraints as a result of the continued economic uncertainty and, in part, due to COVID-19 infections and quarantine protocols. In 2022, we continued to experience these supply chain disruptions, as well as an increase in raw material costs and shipping costs, as prices on several commodities, including oil and gas, increased as a result of the conflict in the Ukraine and it's impact on the global economy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a single manufacturing facility for our Clave products located in Salt Lake City, Utah. Our Salt Lake City facility also produces other components on which our manufacturing operations in Mexico and Costa Rica rely. Our IV Solutions are manufactured at our manufacturing facility in Austin, Texas and by a third party manufacturer, Pfizer, in Rocky Mount, North Carolina or our suppliers&#8217; facilities. We have also added various other manufacturing facilities with the acquisition of Smiths Medical in the U.S., Mexico, Italy and Czech Republic. If our facilities are inoperable, for even a short period of time, it could adversely affect our ability to manufacture and distribute our products in a timely or cost-effective </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manner, and our ability to make product sales. Furthermore, our facilities and the equipment we use to perform our manufacturing processes could be unavailable or costly and time-consuming to repair or replace.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Damage to any of our facilities or interruptions at our facilities due to work stoppages or labor shortages could render us unable to manufacture our products or require us to reduce the output of products at our facilities. Several of our manufacturing facilities are located near known earthquake fault zones and are vulnerable to damage from earthquakes. We carry insurance for damage to our property and disruption of our business, but this insurance may not be adequate to cover all of the risks associated with damage or disruption to our facilities and business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Prolonged periods of inflation, rising interest rates and the impact of foreign currency exchange rates as a result of the current global macroeconomic and geopolitical conditions have had and could in the future have a material adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global supply chain disruptions as a result of COVID-19 and, more recently, the war in the Ukraine has resulted in, and may continue to result in, a challenging macroeconomic environment with higher interest rates and capital costs, increased raw material costs, higher shipping costs, higher labor costs, and the negative impacts from weakening foreign exchange rates. We have experienced and may continue to experience these inflationary increases in our manufacturing costs and operating expenses, including higher materials and labor costs, as well as negative impacts on our operating results from the strengthening of the U.S. dollar relative to foreign currencies weakening exchange rates.  See the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; under the &#8220;Geographic Risks&#8221; subsection for a discussion of risks related to foreign currency exchange rates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the majority of our sales are conducted pursuant to long-term contracts. Our efforts to minimize the impact of inflation on our business through contractual protections may not prove effective, and the presence of longer pricing periods within our contracts along with sustained or higher than anticipated inflation increases the likelihood that the contract protections do not adequately mitigate the financial impact of inflation. If our contractual protections do not adequately protect us in the context of substantial cost increases and inflationary pressures, it could have a material adverse effect on our results of operations.  Prolonged inflation may also reduce or delay orders for our products and for certain products we may be unable to satisfy demand, both of which could have a material adverse impact on our sales and results of operations. The inflationary cost increases during 2022 caused by COVID -19 and the war in the Ukraine impacted our freight rates as well as, labor and materials costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic has disrupted how we, our suppliers and our customers operate and the duration, and the extent to which this will impact our business, future results of operations, liquidity and overall financial performance remains uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption. We operate globally and the COVID-19 pandemic and its adverse effects have impacted most of the locations where we, our customers and our suppliers conduct business and, as a result, we have experienced some disruption to our operations, most notably due to reduced demand for our disposable product portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have also experienced significant reductions in demand for certain products as our health care customers re-prioritized the treatment of patients, delay elective procedures and shift resources and operations to fight COVID-19 and the complications it causes. For example, during 2020, we experienced lower demand from hospital customers for our Infusion Consumables non-dedicated sets and lower demand for our Infusion Systems dedicated sets. Additionally, the COVID-19 pandemic could potentially adversely affect our distributors if they are not able to maintain their historical levels of sales.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business depends on future developments that cannot be fully predicted at this time. Accordingly, the impact of the COVID-19 pandemic on our future results of operations and overall financial performance remains uncertain and cannot as yet be quantified. Additional factors that have contributed or may contribute to the adverse impact of the COVID-19 pandemic on our business, results of operations, financial condition and liquidity include, without limitation, the following:</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lost revenue or additional costs associated with either disruptions at our production and distribution facilities or interruptions in our supply chain, including shortages of raw materials or components for our products;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labor shortages as a result of COVID-19 infections and quarantine protocols;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in demand from customers as a result of an increase in COVID-19 patient admissions in hospitals offset by the decline in non-COVID-19 patient admissions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare customers that defer the more profitable elective procedures may experience financial difficulties and may be unable to pay within payment terms for the products they purchased;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential lower demand in future periods due to over-purchasing of our products due to the COVID-19 pandemic and supply chain disruption;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced revenue due to delays in implementation of our infusion systems and oncology products at hospital locations due to restricted access;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher operating costs related to additional compensation paid to our manufacturing and distribution facility workers;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">volatility in cash flow, revenue and income due to foreign currency fluctuations and volatility;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower income due to a delay in cost savings projects as a result of the travel and social distancing requirements of COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic and related containment measures continue to adversely affect regional, national and global economic conditions and financial markets, as well as the business, results of operations, financial conditions and liquidity of us, our suppliers and our customers, it may also have the effect of heightening many of the risks described in this "Risk Factors" section and elsewhere in this Annual Report on Form 10-K for the year ended December 31, 2022, including the risks resulting from our dependency on key personnel; impairment of our supply chain or manufacturing facilities; and the impact of negative economic conditions. In addition, in light of the COVID-19 pandemic and the measures taken to limit its spread, our historical information regarding our business, results of operations, financial condition or liquidity may not be representative of the future results of operations, financial condition, liquidity or other financial or operating results of us or our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant sales through distributors expose us to risks that could have a material effect on our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, business from one distributor, Medline, accounted for 15% of our consolidated revenues. We may rely on one or more key distributors for a product, and the loss of these distributors could reduce our revenue. Additionally, distributors may face financial difficulties, including bankruptcy, which could harm our collection of accounts receivable and financial results. Failure to manage risks related to our use of distributors may reduce sales, increase expenses, and weaken our competitive position, any of which could have a material adverse effect on our results of operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be successful in achieving expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts and may experience a decline in our profitability, business disruptions or other adverse consequences to our business as a result.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;We have engaged in restructuring activities in the past and may engage in other restructuring activities in the future. For example, since the Smiths Medical acquisition, we have taken realignment and cost reduction initiatives to achieve operating efficiencies for the combined company. These types of cost reduction and restructuring activities are complex. If we do not successfully manage our current restructuring activities, or any other restructuring activities that we may take in the future, any expected efficiencies and benefits might be delayed or not fully realized, and our operations and business could be disrupted. In addition, the costs associated with implementing restructuring activities might exceed expectations, which could result in additional future charges.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement governing our Senior Secured Credit Facilities contains, among other things, certain customary restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, make certain investments, pay dividends, enter into certain transactions with affiliates, and transfer or dispose of assets as well as financial covenants. While we have not previously breached and are not currently in breach of these or any other covenants contained in our credit agreement. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to comply with these covenants may be affected by events beyond our control, including the COVID-19 pandemic, the conflict in the Ukraine, supply chain interruptions or general economic environment, including increases in inflation and interest rates. These covenants could also limit our ability to seek capital through the incurrence of new indebtedness or, if we are unable to meet our obligations, require us to repay any outstanding amounts with sources of capital we may otherwise use to fund our business. As such, these restrictive covenants contained in our Senior Secured Credit Facility may restrict our ability to pursue our business strategies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operating results may be adversely affected by unfavorable economic conditions that affect our customers&#8217; ability to buy our products and could affect our relationships with our suppliers.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions in financial markets worldwide and other worldwide macro-economic challenges have caused and may in the future cause our customers and suppliers to experience cash flow concerns. If job losses and the resulting loss of health insurance and personal savings cause individuals to forego or postpone treatment, the resulting decreased hospital use could affect the demand for our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, customers may modify, delay or cancel plans to purchase our products and suppliers may increase their prices, reduce their output or change terms of sales. Additionally, if customers&#8217; or suppliers&#8217; operating and financial performance deteriorates, or if they are unable to make scheduled payments or obtain credit, customers may not be able to pay, or may delay payment of, accounts receivable owed to us and suppliers may impose different payment terms that are less favorable to us. Any inability of current and/or potential customers to pay us for our products or any demands by suppliers for different payment terms may adversely affect our earnings and cash flow.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Other External Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consumable medical device segment of the health care industry and in particular the infusion products market is intensely competitive and continues to experience both horizontal and vertical consolidation. We believe that our ability to compete depends upon numerous factors including, among other things, continued product innovation, the quality, convenience and reliability of our products, access to distribution channels, patent protection and pricing. The ability to compete effectively depends on our ability to differentiate our products based on these factors, as well as our ability to perceive and respond to changing customer needs. We encounter significant competition in our markets both from large established medical device manufacturers and from smaller companies. Many of these companies have introduced competitive products with features not provided by the conventional products and methods they are intended to replace. Most of our current and prospective competitors have economic and other resources substantially greater than ours and are well established in the healthcare industry. Several large, established competitors offer broad product lines and have been successful in obtaining full-line contracts with a significant number of hospitals and group purchasing organizations to supply all of their infusion product requirements. Due to the highly competitive nature of the group purchasing organizations ("GPOs") or integrated delivery networks ("IDNs") contracting processes, we may not be able to obtain or maintain contract positions with major GPOs and IDNs across our products portfolio. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our products thereby affecting our profitability. While having a contract with a GPO or IDN can facilitate sales to members of that GPO or IDN, it is no assurance that the sales volume of those products will be maintained. The members of such groups may choose to purchase from our competitors due to the price or quality offered by such competitors, which could result in a decline in our sales and profitability. In addition, distributors of our products may begin to negotiate terms of sale more aggressively in an effort to increase their profitability. Failure to negotiate distribution arrangements having advantageous pricing or other terms of sale could adversely affect our results of operations and financial condition. In addition, if we fail to implement distribution arrangements successfully, it could cause us to lose market share to our competitors. Moreover, there is no assurance that our competitors will not substantially increase resources devoted to the development, manufacture and marketing of products competitive with our products. The successful implementation of such a strategy by one or more of our competitors could materially and adversely affect us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we do not successfully develop and commercialize enhanced or new products that remain competitive with new products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by rapid product development and technological advances, which places our products at risk of obsolescence. Our long-term success and profit margins depend upon the development and successful commercialization of new products, new or improved technologies and additional applications of our technology. The research and development process is time-consuming and costly, and may not result in products or applications that we can successfully commercialize.&#160; We can give no assurance that we will be able to successfully develop and commercialize enhanced or new products or that they will be accepted in the marketplace.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product development requires substantial investment that may be difficult for us to fund and may be challenging to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">recover through commercial product sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Innovations generally require a substantial investment in product development before we can determine their commercial viability, and we may not have the financial resources necessary to fund these innovations. Even if we succeed in creating new product candidates from these innovations, those innovations still may fail to result in commercially successful products. The success of new product offerings for device products depends on several factors, including our ability to anticipate and meet customers' or patients' needs, obtain timely regulatory approvals, clearances or certifications, and manufacture quality products in an economic and timely manner. Even if we are able to develop successful new products or enhancements, we may not produce sales exceeding the costs of development, and we may not avoid infringing the proprietary rights of third parties. Moreover, innovations may not be successful due to difficulties encountered in achieving positive clinical outcomes, meeting safety, efficacy or other regulatory requirements of government agencies or notified bodies, or obtaining favorable pricing on those products. Finally, innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice and uncertainty over third-party reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If demand for our products were to decline significantly, we might not be able to recover the cost of our expensive automated molding and assembly equipment and tooling, which could have an adverse effect on our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our production tooling is relatively expensive, with each "module," which consists of an automated assembly machine and the molds and molding machines that mold the components, costing several million dollars. Most of the modules are for the Clave product family. If the demand for these products changes significantly, which could happen with the loss of a customer or a change in product mix, it may be necessary for us to recognize an impairment charge for the value of the production tooling because its cost may not be recovered through production of saleable product, which could adversely affect our financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and will be ordering production molds and equipment for our new products.&#160;We expect to order semi-automated or fully automated assembly machines for certain products in 2023.&#160;If we do not achieve significant sales of these new/transitioned products, it might be necessary for us to recognize an impairment charge for the value of the production tooling because its costs may not be recovered through production of saleable product, which could adversely affect our financial condition. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices. If we cannot reduce manufacturing costs of existing and new products to counteract such pricing pressures, our sales may not grow and our profitability may decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Increasing awareness of healthcare costs, public interest in healthcare reform and continuing pressure from Medicare, Medicaid, GPOs and other payors, both domestic and international, to reduce costs in the healthcare industry, as well as increasing competition from other protective products, could make it more difficult for us to sell our products at current prices. Our products are purchased by hospitals, physicians and other healthcare providers that typically bill various third-party payors, such as governmental programs, private insurance plans and managed care plans, for the healthcare services and products provided to their patients. The ability of our customers to obtain appropriate coverage and reimbursement for healthcare services and products from third-party payors is critical because it affects which products customers purchase and the prices they are willing to pay. Because there is often no separate reimbursement for supplies used in surgical procedures, the additional cost associated with the use of our products can affect the profit margin of the hospital or surgery center where the procedure is performed. Some of our target customers may be unwilling to adopt our products in light of the additional associated cost. Further, any decline in the amount payors are willing to reimburse our customers could make it difficult for existing customers to continue using or to adopt our products and could create additional pricing pressure for us. If we are forced to lower the price we charge for our products, our gross margins will decrease, which could have a material adverse effect on our business, financial condition and results of operations and impair our ability to grow our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs. In addition, no uniform policy of coverage and reimbursement for procedures using our products exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ significantly from payor to payor. Payors continually review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and procedures. There can be no assurance that third-party payor policies will provide coverage for procedures in which our products are used. If we are not successful in reversing existing non-coverage policies, or if third-party payors that currently cover or reimburse our products and related procedures reverse or limit their coverage in the future, or if other third-party payors issue similar policies, this could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional prior authorization requirements. Third-party coverage and reimbursement for procedures using our products or any of our products in development for which we may receive regulatory approval or certification may not be available or adequate, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could have an adverse effect on our business, financial condition and results of operations and impair our ability to grow our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of further legislative or administrative reforms in the reimbursement system in the U.S. and abroad or adverse decisions relating to coverage or reimbursement could have an impact on acceptance of and demand for our products and the prices that our customers are willing to pay for them. In the event that the market will not accept current prices for our products, our sales and profits could be adversely affected. We believe that our ability to increase our market share and operate profitably in the long term may depend in part on our ability to reduce manufacturing costs on a per unit basis through high volume production using highly automated molding and assembly systems. If we are unable to reduce unit manufacturing costs, we may be unable to increase our market share for our products or may lose market share to alternative products, including competitors&#8217; products. Similarly, if we cannot reduce unit manufacturing costs of new products as production volumes increase, we may not be able to sell new products profitably or gain any meaningful market share. Any of these results would adversely affect our future results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend heavily on information technology infrastructure and systems to achieve our business objectives. Any incident that impairs or compromises this infrastructure, including security breaches, malicious attacks or more general service interruptions, could impede our ability to process orders, manufacture and ship product in a timely manner, protect sensitive data and otherwise carry on business in the normal course. Any such events could result in the loss of customers, revenue, or both, and could require us to incur significant expense to remediate, including legal claims or proceedings. Further, as cyber security related incidents continue to evolve, and regulatory focus on these issues continues to expand, additional investment in protective measures, and vulnerability remediation, may be required.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our information technology systems, which support our operations. Despite the implementation of security measures, our information technology systems, and  those of third parties on which we rely, are vulnerable to attack and damage from, among others, computer viruses, malware (e.g. ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization or similar disruptive problems. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not foreseeable or recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such event were to occur, public perception of the effectiveness of our security measures and brand could be harmed and our results of operations could be negatively affected. Data security breaches and other incidents may also result from non-technical means (e.g., actions by employees or contractors).  Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of personally identifiable information. Any compromise of our security could result in a violation of applicable security, privacy or data protection, consumer and other laws, regulatory or other governmental investigations, enforcement actions, and legal and financial exposure, including potential contractual liability. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors or other organizations with which we expect to form strategic relationships. Any such compromise could also result in damage to our reputation and a loss of confidence in our security and privacy or data protection measures. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cyber security protection costs, lost revenue, regulatory actions or litigations. Any of these effects could materially and adversely affect our business, financial condition and results of operations. Our cyber liability insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we cannot obtain additional custom tooling and equipment on a timely basis to enable us to meet demand for our products, we might be unable to increase our sales or might lose customers, in which case our sales could decline.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expanded our manufacturing capacity substantially in recent years, and we expect that continued expansion may be necessary. Molds and automated assembly machines generally have a long lead-time with vendors, often nine months or longer.  Inability to secure such tooling in a timely manner, or unexpected increases in production demands, could cause us to be unable to meet customer orders. Such inability could cause customers to seek alternatives to our products, which would adversely affect our sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost volatility or loss of supply of our raw materials could have an adverse effect on our profitability.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the materials used in our products are resins, plastics and other material that depend upon oil or natural gas as their raw material. Crude oil markets have historically been affected by political uncertainty in the Middle East and more recently, by the conflict in the Ukraine, and there is no assurance that crude oil supplies will not be interrupted in the future.&#160;New laws or regulations adopted in response to climate change could also increase energy costs as well as the costs of certain raw materials and components. Any such regulations or interruptions could have an adverse effect on our ability to produce, or the cost to produce, our products.&#160;Also, crude oil and natural gas prices have been volatile in recent years. Our suppliers have historically passed some of their cost increases on to us, and if such prices are sustained or increase further, our suppliers may pass further cost increases on to us. In addition to the effect on resin prices, transportation costs have increased because of the effect of higher crude oil prices, and we believe most of these costs have been passed on to us. Our ability to recover these increased costs may depend upon our ability to raise prices on our products.  In the past, we have rarely raised prices and it is uncertain that we would be able to raise them to recover higher prices from our suppliers. Our inability to raise prices in those circumstances, or to otherwise recover these costs, could have an adverse effect on our profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could suffer if we lose the services of key personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent upon the management and leadership of our executive team, as well as other members of our senior management team.&#160;If one or more of these individuals were unable or unwilling to continue in his or her present position, our business would be disrupted and we might not be able to find replacements on a timely basis or with the same level of skill and experience, which could have an adverse effect on our business.&#160;We do not have "key person" life insurance policies on any of our employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The price of our common stock has been and may continue to be highly volatile due to many factors.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The public equity market can be highly volatile, and we have experienced significant volatility in the price of our common stock in the past. We believe that factors such as quarter-to-quarter fluctuations in financial results, differences between stock analysts&#8217; expectations and actual quarterly and annual results, new product introductions by us or our competitors, acquisitions or divestitures, changing regulatory environments, litigation, changes in healthcare reimbursement policies, sales or the perception in the market of possible sales of common stock by insiders, market rumors, general economic trends (including macroeconomic challenges related to the COVID-19 pandemic and the conflict in the Ukraine) and substantial product orders could contribute to the volatility in the price of our common stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our common stock is held by, or included in accounts managed by, institutional investors or managers. Several of those institutions own or manage a significant percentage of our outstanding shares, with the ten largest interests accounting for approximately 65% of our outstanding shares at the end of 2022. If one or more of the institutions or if our other large stockholders should decide to reduce or eliminate their position in our common stock, it could cause a significant decrease in the price of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disruptions at the FDA, other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved, certified, or commercialized in a timely manner, or at all, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA, foreign regulatory authorities and notified bodies to review and approve or certify new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency's ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the government's ability to perform routine functions. Average review times at the FDA, other government agencies, foreign regulatory authorities and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays. Regulatory authorities and notified bodies outside the U.S. have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA, other regulatory authorities or notified bodies from conducting their regular inspections, audits, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities or notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in the EU, notified bodies must be officially designated to certify products and services in accordance with the EU Medical Devices Regulation. While several notified bodies have been designated under the EU Medical Devices Regulation the COVID-19 pandemic has significantly slowed down their designation process and the current designated notified bodies are facing a large amount of requests with the new regulation as a consequence of which review times have lengthened. This situation could impact our ability to grow our business in the EU and EEA and the ability of our notified body to timely review and process our regulatory submissions and perform its audits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal, Compliance, and Regulatory Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards may adversely affect our business, operations and financial performance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are subject to various federal, state and foreign laws that govern the collection, use, disclosure, retention and security of personal information, including patient health information. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our collaborators', service providers' and contractors' ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. In the U.S., numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws and regulations (e.g. Section 5 of the Federal Trade Commission Act (the "FTC Act")). For example, the privacy, security and breach notification rules promulgated under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, establish a set of national privacy and security standards for the protection of protected health information ("PHI") by health plans, health care clearinghouses and certain health care providers, called covered entities, and the business associates with whom such covered entities contract for services that involve creating, receiving, maintaining or transmitting PHI, as well as their covered subcontractors. HIPAA also requires covered entities to provide individuals with certain rights with respect to their PHI, and requires covered entities to enter into a written business associate contract or other arrangement with the business associate that establishes specifically what the business associate has been engaged to do and requires the business associate to comply with the requirements of HIPAA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we would be required to report the improper use or disclosure to the U.S. Department of Health and Human Services ("HHS") which would post the violation on its website, and to the media. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for failure to comply with a requirement of HIPAA vary significantly depending on the nature of violation and could include civil monetary or criminal penalties.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, California enacted the California Consumer Privacy Act of 2018 (the "CCPA"), which went into effect on January 1, 2020. The CCPA applies to certain businesses that collect personal information from California residents. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for health-related information, including PHI maintained by covered entities and business associates, the CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act ("CPRA") recently passed in California. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Connecticut, Utah and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In addition, the CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers' personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws, including the General Data Protection Regulation (the "GDPR"), which became effective in May 2018, and EU and EEA member state data protection legislation, may also apply to health-related and other personal data obtained outside of the U.S. The GDPR imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR has and will continue to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process data about them. Fines for non-compliance with the GDPR are significant-the greater of &#8364;20 million or 4% of global turnover. The GDPR provides that EU and EEA member states may impose further obligations relating to the processing of genetic, biometric or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business. Data privacy laws in the EU and the EEA are developing rapidly and, in July 2020, the Court of Justice of the EU (the "CJEU") limited how organizations could lawfully transfer personal data from the EEA to the U.S. by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses ("SCCs"). In March 2022, the US and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. While the CJEU upheld the adequacy of the SCCs, it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the SCCs cannot be complied with in the destination country and the required level of protection cannot be secured by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. The revised SCCs apply only to the transfer of personal data outside of the EEA and not the UK. The UK&#8217;s Information Commissioner&#8217;s Office has published new data transfer standard contracts for transfers from the UK under the UK GDPR. This new documentation will be mandatory for relevant data transfers from September 21, 2022; existing standard contractual clauses arrangements must be migrated to the new documentation by March 21, 2024. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. In September 2021, the UK government launched a consultation on its proposals for wide-ranging reform of UK data protection laws following Brexit and the response to this consultation was published in June 2022. There is a risk that any material changes which are made to the UK data protection regime could result in the European Commission reviewing the UK adequacy decision, and the UK losing its adequacy decision if the European Commission deems the UK to no longer provide adequate protection for personal data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to certain fraud and abuse and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims and transparency laws regarding payments and other transfers of value made to physicians and other licensed healthcare professionals. Our business practices and relationships with providers are subject to scrutiny under these laws. The healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></div><div><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual or furnishing or arranging for a good or service, for which payment may be made, in whole or in part, under federal healthcare programs, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. The U.S. government has interpreted this law broadly to apply to the marketing and sales activities of manufacturers;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. Private individuals can bring False Claims Act "qui tam" actions, on behalf of the government and such individuals, commonly known as "whistleblowers," may share in amounts paid by the entity to the government in fines or settlement. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Sunshine Act, which require certain applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program ("CHIP") to report annually to the U.S. Department of Health and Human Services' CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and chiropractors), certain other healthcare providers (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives, and teaching hospitals), and applicable manufacturers and GPOs, to report annually ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers or patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers; and state laws related to insurance fraud in the case of claims involving private insurers.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations, among other things, constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management's attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond to. If our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational harm, disgorgement and the curtailment or restructuring of our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare regulation and reform measures could adversely affect our revenue and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our profitability and operations are subject to risks relating to changes in government and private reimbursement programs and policies and changes in legal requirements in the U.S. and in the world. There have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenues and profitability in the U.S. and abroad.  Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, in 2010, the ACA was signed into law introducing comprehensive health insurance and healthcare reforms in the U.S.&#160;The ACA, among other things, provided incentives to programs that increase the federal government's comparative effectiveness research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the ACA has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while expanding individual healthcare benefits. The ultimate implementation of any healthcare reform legislation and any new laws and regulations, and its impact on us, is impossible to predict, particularly in light of the new presidential administration. Any significant reforms made to the healthcare system in the U.S., or in other jurisdictions, may have an adverse effect on our financial condition and results of operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be materially and adversely affected if we fail to defend and enforce our patents or other proprietary rights, if our products are found to infringe patents or other proprietary rights owned by others or if the cost to protect our patents or other proprietary rights becomes excessive or as our patents expire.</span></div><div><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, trademarks, copyrights, trade secrets, business methods, software and nondisclosure agreements to protect our proprietary intellectual property. Our efforts to protect our intellectual and proprietary rights may not be sufficient. Further, there is no assurance that patents pending will issue or that the protection from patents which have issued or may issue in the future will be broad enough to prevent competitors from introducing similar devices, that such patents, if challenged, will be upheld by the courts or that we will be able to prove infringement and damages in litigation.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally have multiple patents covering various features of a product, and as each patent expires, the protection afforded by that patent is no longer available to us, even though protection of features that are covered by other unexpired patents may continue to be available to us.&#160;The loss of patent protection on certain features of our products may make it possible for others to manufacture and sell products with features identical or similar to ours, which could adversely affect our business.  </span></div><div style="text-indent:38.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; If we fail to develop and successfully launch new products prior to the expiration of patents for our existing products, our sales and profits with respect to those products could decline significantly. We may not be able to develop and successfully launch more advanced replacement products before these and other patents expire.</span></div><div style="text-indent:38.25pt"><span><br/></span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to enforce and protect our intellectual property rights may be limited in certain countries outside of the U.S., which could make it easier for competitors to obtain market position in such countries by utilizing technologies that are similar to those developed by us.</span></div><div style="text-indent:38.25pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If others choose to manufacture and sell products similar to or substantially the same as our products, it could have a material adverse effect on our business through loss of unit volume or price erosion, or both, and could adversely affect our ability to secure new business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have faced patent infringement claims related to our Clave products, the CLC2000 Connector and Tego Connector. We believe these claims had no merit, and all have been settled or dismissed. We may also face claims in the future. Additionally, there has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. Patent infringement litigation, which may be necessary to enforce patents issued to us or to defend ourselves against claimed infringement of the rights of others, can be expensive and may involve a substantial commitment of our resources which may divert resources from other uses. Adverse determinations in litigation or settlements could subject us to significant liabilities to third parties, could require us to seek licenses from third parties, could prevent us from manufacturing and selling our products or could fail to prevent competitors from manufacturing products similar to ours. Any of these results could materially and adversely affect our business.</span></div><div style="text-indent:38.25pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we become aware of newly issued patents on medical devices, which we review to evaluate any infringement risk. We are aware of a number of patents for infusion connection systems that have been issued to others. While we believe these patents will not affect our ability to market our products, there is no assurance that these or other issued or pending patents might not interfere with our right or ability to manufacture and sell our products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our ability to market our products in the U.S. and other countries may be adversely affected if our products fail to comply with the applicable requirements of the FDA and regulatory agencies in other countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We and our products are subject to extensive regulation in the U.S. and elsewhere, including by the FDA and its foreign counterparts. The FDA and foreign regulatory agencies and notified bodies regulate, among other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; pre-market clearance, approval and certification; record keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the U.S., our medical device products are subject to clearance or approval by the U.S. FDA under the FDC Act. Before we can market a new medical device, or a new use of, new claim for, or significant modification to, an existing product, we must first receive either clearance under Section&#160;510(k) of the FDC Act or approval of PMA application from the FDA, unless an exemption applies. Under the 510(k) process, the manufacturer must submit to the FDA a pre-market notification, demonstrating that the device is "substantially equivalent," as defined in the FDC Act, to a legally marketed predicate device. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be "substantially equivalent," the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. If the manufacturer is unable to demonstrate substantial equivalence to FDA's satisfaction, or if there is no available predicate device, then the manufacturer may be required to seek approval through the PMA application process, which is generally more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA's satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market certain products that have received 510(k) clearance, and we may pursue 510(k) clearance for future products. However, certain of our new products may require a longer time for clearance than we have experienced in the past and there can be no assurance that a PMA application will not be required. Further, there is no assurance that other new products developed by us or any manufacturers that we might acquire will be eligible for 510(k) clearance rather than undergoing a more time consuming pre-market approval procedure or that, in any case, they will receive clearance or approval from the FDA. For example, in 2022, we acquired Smiths Medical, which has marketed its PORT-A-CATH implantable access systems pursuant to PMA approval. FDA regulatory processes are time consuming and expensive. Uncertainties as to the time required to obtain FDA clearances or approvals could adversely affect the timing and expense of new product introductions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. The FDA enforces these regulatory requirements through periodic unannounced inspections. Even after we have obtained the proper regulatory clearance or approval to market a product, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not know whether we will pass or be found compliant in any future inspections by FDA or other regulatory authorities. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities which may include any of the following sanctions:</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled letters or warning letters; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recalls, termination of distribution, administrative detention, or seizure of our products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer notifications or repair, replacement or refunds; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or refusal to grant our requests for future 510(k) clearances, PMA approvals or foreign regulatory approvals of new products, new intended uses, or modifications to existing products; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawals or suspensions of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of our products; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The FDA's and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval or certification of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development. For example, on February 23, 2022, the FDA issued a proposed rule to amend the Quality System Regulation, or QSR, which establishes current good manufacturing practice requirements for medical device manufacturers, to align more closely with the International Organization for Standardization, or ISO, standards. This proposal has</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not yet been finalized or adopted. Accordingly, it is unclear the extent to which this or any other proposals, if adopted, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise create competition that may negatively affect our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2019, the FDA issued revised final guidance describing an optional "safety and performance based" pre-market review pathway for manufacturers of "certain, well-understood device types" to demonstrate substantial equivalence under the 510(k) clearance pathway by demonstrating that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the "safety and performance based pathway" and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign counterparts in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance, approval, or certification to manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance, approval, or certification; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, the EU landscape concerning medical devices recently evolved. On May 25, 2017, the EU Medical Devices Regulation entered into force, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member state laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. Devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May 26, 2025, provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the EU Medical Devices Regulation with regard to registration of economic operators and of devices, post-market surveillance, market surveillance and vigilance requirements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the transitional provisions and in order to sell our products in EU member states, our products must comply with the general safety and performance requirements of the EU Medical Devices Regulation, which repeals and replaces EU Medical Devices Directive. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these requirements is a prerequisite to be able to affix the CE mark to our products, without which they cannot be sold or marketed in the EU. See &#8211; Government Regulation.  To demonstrate compliance with the general safety and performance requirements, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Except for low risk medical devices (Class I), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility, metrology or reuse aspects), a conformity assessment procedure requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements would also prevent us from selling our products in these three countries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules applicable in Great Britain may differ from the EEA as a result of proposals for the new regulatory landscape which will be implemented, subject to a transitional period, as a result of Brexit. Following the transitional period, compliance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the UK regulations will be a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain. See &#8220;Part 1, Item 1. Government Regulation - Regulation of Medical Devices in the European Union - Brexit.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we or our component manufacturers fail to comply with the FDA's Quality System Regulation or Good Manufacturing Practice regulations or other requirements, our manufacturing operations could be interrupted, and our product sales and operating results could suffer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and some of our component manufacturers are required to comply with regulatory requirements known as the FDA's Quality System Regulation, or QSR, a complex regulatory scheme which covers the procedures and documentation of the design, testing, production, control, quality assurance, inspection, complaint handling, recordkeeping, management review, labeling, packaging, sterilization, storage and shipping of our device products. The FDA's cGMPs apply to the manufacture of medical device components and finished medical devices. The FDA audits compliance with these regulatory requirements through periodic announced and unannounced inspections of manufacturing and other facilities. The FDA may conduct inspections or audits at any time, and we and some of our component suppliers are subject to such inspections. Although we believe our manufacturing facilities and those of our critical component suppliers are in compliance with the QSR requirements, and with applicable cGMPs for our products, we cannot provide assurance that any future inspection will not result in adverse findings. For example, on October 1, 2021, Smiths Medical received a Warning Letter from the FDA following an inspection of Smiths Medical&#8217;s Minneapolis, Minnesota Facility on March 30, 2021.  The Warning Letter cited, among other things, failures to comply with FDA's medical device reporting requirements and failures to comply with applicable portions of the QSR. There is no guarantee that we will be able to successfully resolve the issues identified in the Warning Letter or do so in a timely manner or that similar compliance issues will not be identified in a future FDA inspection.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our manufacturing facilities or those of any of our component suppliers are found to be in violation of applicable laws and regulations, or we or our suppliers have significant noncompliance issues or fail to timely and adequately respond to any adverse inspectional observations or product safety issues, or if any corrective action plan that we or our suppliers propose in response to observed deficiencies is not sufficient, the FDA or foreign regulatory authorities could take enforcement action, including any of the following sanctions:</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled letters or warning letters; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying our requests for clearance or approval or certifications of new products or modified products; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing clearances, approvals, or certifications that have already been granted; </span></div><div style="margin-bottom:1pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approval for our products; or </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any of these sanctions could adversely affect our business, financial condition and operating results.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market our products in the EU, we must conform to additional requirements and demonstrate conformance to harmonized quality standards. A notified body would typically audit and examine a product's technical dossiers and the manufacturers' quality system (the notified body must presume that quality systems which implement the relevant harmonized standards &#8211; which is ISO 13485:2016 for Medical Devices Quality Management Systems &#8211; conform to these requirements). Subject to the transitional provisions, manufacturers of medical devices must also comply with the EU Medical Devices Regulation. Compliance with these requirements assure that medical devices are both safe and effective and do not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons and meet all applicable established standards prior to being marketed in the EU. There is no assurance that we will continue to meet the requirements for distribution of our products in Europe. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the EU Medical Devices Regulation, among other things:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens the rules on placing devices on the market (e.g. reclassification of certain devices and wider scope than the EU Medical Devices Directive) and reinforces surveillance once they are available;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes explicit provisions on manufacturers' responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes explicit provisions on importers' and distributors' obligations and responsibilities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposes an obligation to identify a responsible person who is ultimately responsible for all aspects of compliance with the requirements of the new regulation;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improves the traceability of medical devices throughout the supply chain to the end-user or patient through the introduction of a unique identification number, to increase the ability of manufacturers and regulatory authorities to trace specific devices through the supply chain and to facilitate the prompt and efficient recall of medical devices that have been found to present a safety risk;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sets up a central database (Eudamed) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo a clinical evaluation consultation procedure by experts before they are placed on the market.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a result of these new requirements, we may be subject to risks associated with additional testing, modification, certification, or amendment of our existing certifications, or we may be required to modify products already installed at our customers' facilities to comply with the official interpretations of the EU Medical Devices Regulation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of our products in other countries may be subject to regulation in those countries, and there is no assurance that we will obtain necessary approvals or certifications in countries in which we want to introduce our products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products have been cleared, approved or certified by the FDA, foreign regulatory authorities and notified bodies for specific indications of use. We train our marketing personnel and direct sales force to not promote our products for uses outside of the FDA-cleared or approved indications for use, known as "off-label uses." We cannot, however, prevent a physician from using our products off-label, when in the physician's independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our products off-label. Furthermore, the use of our products for indications other than those cleared or approved by the FDA or approved by any foreign body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any foreign regulatory authorities determine that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, physicians may misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation, product liability claims or product recalls could be costly and could expose us to loss.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our products exposes us to an inherent risk of product liability. Further, the medical device industry has historically been subject to extensive litigation and we cannot offer any assurance that we will not face product liability or other lawsuits in the future. Patients, healthcare workers, healthcare providers or others who claim that our products have resulted in injury could initiate product liability litigation seeking large damage awards against us. Costs of the defense of such litigation, even if successful, could be substantial. We maintain insurance against product liability and defense costs in the amount of $40 million per occurrence. However, legal proceedings are inherently unpredictable, and the outcome can result in judgments that affect how we operate our business, or we may enter into settlements of claims for monetary damages that exceed our insurance coverage, if any is available. A successful claim against us in excess of insurance coverage could materially and adversely affect us, and result in substantial liabilities and reputational harm including product recalls or withdrawals from the market, withdrawal of clinical trial participants or clinical studies, the inability to commercialize our existing or new products, distraction of management&#8217;s attention from our primary business or decreased demand for our products or, if cleared or approved, products in development. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally offer a limited warranty for product returns which are due to defects in quality and workmanship. We attempt to estimate our potential liability for future product returns and establish reserves on our financial statements in amounts that we believe will be sufficient to address our warranty obligations; however, our actual liability for product returns may significantly exceed the amount of our reserves.  If we underestimate our potential liability for future product returns, or if unanticipated events result in returns that exceed our historical experience, our financial condition and operating results could be materially and adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and foreign regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are subject to the FDA's medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or foreign regulatory authorities could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances, approvals or certifications, seizure of our products or delay in clearance, approval, or certification of future products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. For example, on June 26, 2020, Smiths Medical ASD initiated Class 1 recalls of a Medfusion Syringe Pump. We can provide no assurance that our efforts to work with the FDA to complete the Class 1 recall, and ultimately close, this product recall will be accomplished in a timely manner, or at all. In addition, the costs associated with conducting and closing this recall, including any liabilities we may incur, could have a material adverse effect on our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depending on the corrective action we take to redress a product's deficiencies or defects, the FDA or foreign regulatory agencies may require, or we may decide, that we will need to obtain new clearances, approvals or certifications for the device before we may market or distribute the corrected device. Seeking such clearances, approvals or certifications may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA or foreign regulatory authorities warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA or foreign regulatory authorities. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA or foreign regulatory authorities. If the FDA or foreign regulatory authorities disagree with our determinations, it could require us to report those actions as recalls and we may be subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face exposure to adverse movements in foreign currency exchange rates due to our operations in foreign markets through our foreign subsidiaries and other international distributors. Our primary foreign currency exchange rate exposures are currently with the Euro, Mexican Peso, Czech Koruna, Japanese Yen, Chinese Renminbi, Australian Dollar, and the Canadian Dollar against the U.S. dollar.  Our income and expenses are based on a mix of currencies, and a decline in one currency relative to the other currencies could adversely affect our operating results. Furthermore, our operating results are reported in U.S. dollars, using the exchange rate in effect at the balance sheet date, or, for revenues and expenses, using the average monthly exchange rates during the year. Accordingly, our operating results are subject to volatility due to fluctuations in foreign currency exchange rates.  Generally, when the U.S. dollar weakens against these currencies, the dollar value of foreign-currency denominated revenue and expense increases, and when the U.S. dollar strengthens against these currencies, the dollar value of foreign-currency denominated revenue and expense decreases. We are also exposed to foreign currency risk on outstanding foreign currency denominated receivables and payables. Accordingly, changes in foreign currency exchange rates may adversely affect our results of operations. Fluctuations in currency exchange rates are caused by a number of factors that are beyond our control, including a country&#8217;s political and economic policies, inflationary conditions, disruptions in the financial markets, and global economic conditions.  During 2022, we recorded $5.8 million in foreign exchange losses due to the volatility of foreign exchange rates as a result of continued global macroeconomic challenges.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently only partially hedge against our foreign currency exchange rate risks, related to certain forecasted foreign currency-denominated revenues and expenses for Smiths Medical. We, therefore, believe our exposure to these risks may be higher than if we entered into hedging transactions, including forward exchange contracts or similar instruments that covered the whole company. If we decide in the future to enter into additional forward foreign exchange contracts to attempt to reduce the risk related to foreign currency exchange rates, these contracts may not mitigate the potential adverse impact on our financial results due to the limitations and difficulty forecasting future activity. In addition, these types of contracts may themselves cause financial harm to us and have inherent levels of counter-party risk over which we would have no control. We attempt to mitigate a portion of foreign currency exchange rate risks through foreign currency hedging. Our hedging activities, however, may not sufficiently offset the adverse financial impact caused by unfavorable movement in foreign currency exchange rates applicable to our business, and such exchange rate impacts could materially adversely affect our financial condition or results of operations. See &#8220;Item 7A. Quantitative and Qualitative Disclosures About Market Risk.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Any significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs could have a material adverse effect on our results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A significant amount of our products are manufactured outside of the U.S. The U.S. government has recently initiated substantial changes in U.S. trade policy and U.S. trade agreements, including the initiation of tariffs on certain foreign goods. In response to these tariffs, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain U.S. goods. For example, in 2018, the U.S. imposed tariffs on steel and aluminum as well as on goods imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries. Additional tariffs imposed by the U.S. on a broader range of imports, or further retaliatory trade measures taken by other countries in response, could prevent or make it difficult for us to obtain the components needed for new products which would affect our sales. Increased tariffs would require us to increase our prices which likely would decrease customer and consumer demand for our products. Additionally, we are subject to income taxes in the U.S. and numerous foreign jurisdictions. Any significant changes in current U.S. trade, tax or other policies could have a material adverse effect on our results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International sales pose additional risks related to competition with larger international companies and established local companies and our possibly higher cost structure.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have undertaken an initiative to increase our international sales, and have distribution arrangements in all the principal countries in Western Europe, the Pacific Rim, Middle East, Latin America, Canada and South Africa. We plan to sell in most other areas of the world. We export most of our products sold internationally primarily from the U.S. and Mexico and to a lesser extent Costa Rica. Our principal competitors in international markets consist of much larger companies as well as smaller companies already established in the countries into which we sell our products. Our cost structure is often higher than </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that of our competitors because of the relatively high cost of transporting product to some local markets as well as our competitors&#8217; lower local labor costs in some markets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international sales are subject to higher credit risks than sales in the U.S. Many of our distributors are small and may not be well capitalized. Payment terms are relatively long. The European hospitals tend to be significantly slower in payment which has resulted in and may continue to result in an increase to our days sales outstanding from previous years.&#160;Our prices to our international distributors, outside of Europe, for product shipped to the customers from the U.S., Costa Rica or Mexico are generally denominated in U.S. dollars, but their resale prices are set in their local currency. A decline in the value of the local currency in relation to the U.S. dollar may adversely affect their ability to profitably sell in their market the products they buy from us, and may adversely affect their ability to make payment to us for the products they purchase. Legal recourse for non-payment of indebtedness may be uncertain. These factors all contribute to a potential for credit losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are dependent on manufacturing in Mexico, and could be adversely affected by that region's increased labor costs and any economic, social or political disruptions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the material we use in manufacturing is imported into Mexico, and substantially all of the products we manufacture in Mexico are exported. Business activity in the Ensenada area has expanded significantly, providing increased employment opportunities. This could have an adverse effect on our ability to hire or retain necessary personnel and result in higher labor costs. In addition, minimum wages in regions within which we operate have increased labor costs significantly. We continue to take steps to compete for labor through attractive employment conditions and benefits, but there is no assurance that these steps will continue to be successful or that we will not continue to face increasing labor costs in the future. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Any political or economic disruption in Mexico or a change in its local economies could have an adverse effect on our operations. We depend on our ability to move goods across borders quickly, and any disruption in the free flow of goods across national borders could have an adverse effect on our business. Additionally, political and social instability resulting from violence in certain areas of Mexico has raised concerns about the safety of our personnel.&#160;These concerns may hinder our ability to send domestic personnel abroad and to hire and retain local personnel. Such concerns may require us to conduct more operations from the U.S. rather than Mexico, which may negatively impact our operations and result in higher costs and inefficiencies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act and anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business or other commercial advantage. Our policies mandate compliance with these anti-bribery laws, which often carry substantial penalties, including criminal and civil fines, potential loss of export licenses, possible suspension of the ability to do business with the federal government, denial of government reimbursement for products and exclusion from participation in government healthcare programs. We operate in jurisdictions that have experienced governmental and private sector corruption to some degree, and, in certain circumstances, strict compliance with anti-bribery laws may conflict with certain local customs and practices. We cannot assure that our internal control policies and procedures always will protect us from reckless or other inappropriate acts committed by our affiliates, employees, distributors or other agents. Violations of these laws, or allegations of such violations, could have a material adverse effect on our business, financial position and results of operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to risks associated with doing business outside of the U.S.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a global market and global operations are subject to a number of risks. Sales to customers outside of the U.S. made up approximately 36% of our revenues in 2022 and as our operations and sales located in Europe and other areas outside the U.S. increase, we may face new challenges and uncertainties, although we can give no assurance that such operations and sales will increase. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks associated with our operations outside the U.S. also include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political uncertainty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in non-U.S. government programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple non-U.S. regulatory requirements that are subject to change and that could restrict our ability to manufacture and sell our products;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different local medical practices, product preferences and product requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible failure to comply with trade protection and restriction measures and import or export licensing requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in establishing, staffing and managing non-U.S. operations; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different labor regulations or work stoppages or strikes; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political instability and actual or anticipated military or political conflicts (such as the conflict in Ukraine); </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic instability in other parts of the world and the impact on interest rates, inflation and the credit worthiness of our customers in foreign countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding judicial systems and procedures; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">minimal or diminished protection of intellectual property in some countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters or outbreak of diseases (including COVID-19);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes between countries, trade relationships and conflicts ); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of government controls.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks, individually or in the aggregate, could have an adverse effect on our results of operations and financial condition. The occurrence or allegation of these types of risks may adversely affect our business, performance, prospects, value, financial condition, and results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Strategic Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Smiths Medical acquisition completed in January 2022 has resulted in organizational changes and significant growth to our business. If we fail to effectively manage this growth and change to our business in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Smiths Medical acquisition has resulted in significant growth in our personnel and operations, adding approximately 6,700 employees to our headcount at the time of acquisition. Our total headcount as of December 31, 2022 is approximately 14,500 employees. We have incurred and will continue to incur significant expenditures and the allocation of management time to assimilate the Smiths Medical employees in a manner that preserves the key aspects of our corporate culture, including a focus on strong customer satisfaction, but there can be no assurance that we will be successful in our efforts. If we do not effectively integrate, train and manage our combined employee base and maintain strong customer relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Smiths Medical acquisition is a significant acquisition for us and the product offerings within Smiths Medical are not product offerings that we previously offered. The success of our business will depend, in part, on our ability to realize our anticipated benefits, opportunities and synergies from combining our legacy businesses and Smiths Medical. We can provide no assurance that the anticipated benefits of the Smiths Medical acquisition will be fully realized in the time frame anticipated or at all. Integrating the operations of Smiths Medical with that of our legacy business has been and will continue to be a complex, costly and time-consuming process. The integration process may disrupt the businesses and, if implemented ineffectively, would restrict the realization of the full expected benefits. The failure to meet the challenges involved in integrating the two businesses could cause an interruption of, or a loss of momentum in, the activities of the combined businesses and could adversely affect the results of operations of the combined businesses. Potential difficulties that may be encountered in the integration process include the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in preserving important strategic customer and other third-party relationships of both businesses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention to integration matters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in maintaining employee morale and retaining or attracting key employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential incompatibility of corporate cultures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs, delays and other difficulties consolidating corporate and administrative infrastructures and information systems and implementing common systems and procedures including, in particular, our internal controls over financial reporting; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating and integrating a geographically dispersed organization, including operations in jurisdictions we did not operate in prior to the Smiths Medical transaction.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any one or all of these factors may increase operating costs or lower anticipated financial performance. Achieving the anticipated benefits and the potential benefits underlying our reasons for the Smiths Medical business acquisition will depend on successful integration of the businesses. Because of the significance of the Smiths Medical business acquisition to us, our failure to successfully integrate the Smiths Medical business with that of our own could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The actual impact of the Smiths Medical acquisition on our financial results may be worse than the assumptions we have used.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain assumptions relating to the impact on our financial results of the Smiths Medical acquisition. These assumptions relate to numerous matters, including the acquisition costs, transaction and integration costs, and other financial and strategic risks of the acquisition. If one or more of these assumptions are incorrect, it could have an adverse effect on our business and operating results, and the perceived benefits from the acquisition may not be realized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to effectively manage our internal growth or growth through acquisitions of companies, assets or products, our financial performance may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expand our product offerings through acquisitions of companies or product lines. We can provide no assurance that we will be able to identify, acquire, develop or profitably manage additional companies or operations or successfully integrate such companies or operations into our existing operations without substantial costs, delays or other challenges. We recently acquired the Smiths Medical business, which includes syringe and ambulatory infusion devices, vascular access, and vital care products, but we have to make significant integration efforts to achieve the anticipated benefits. See &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Smiths Medical acquisition completed in January 2022 has resulted in organizational changes and significant growth to our business. If we fail to effectively manage this growth and change to our business in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additional production facilities outside the U.S. to reduce labor costs. We intend to continue to expand our marketing and distribution capability, which may include external expansion through acquisitions both in the U.S. and foreign markets. The expansion of our marketing, distribution and product offerings both internally and through acquisitions or by contract may place substantial burdens on our management resources and financial controls. Decentralization of assembly and manufacturing could place further burdens on management to manage those operations and maintain efficiencies and quality control.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increasing burdens on our management resources and financial controls resulting from internal growth and acquisitions could adversely affect our operating results. In addition, acquisitions may involve a number of special risks in addition to the difficulty of integrating cultures and operations and the diversion of management&#8217;s attention, including adverse short-term effects on our reported operating results, dependence on retention, hiring and training of key personnel, risks associated with unanticipated problems or legal liabilities, and amortization of acquired intangible assets, some or all of which could materially and adversely affect our operations and financial performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a result of the Smiths Medical acquisition, we have used a significant portion of our cash on hand and incurred a substantial amount of debt to finance the cash consideration portion and certain other amounts paid in connection with the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, we had $213.5 million of cash, cash equivalents and investment securities on hand, which was significantly less than the approximately $571.9 million of cash, cash equivalents and investment securities we had as of December 31, 2021, primarily as a result of the use of existing cash to partially fund the Smiths Medical acquisition. Although our management believes that we continue to have sufficient access to cash to meet our business objectives and capital needs, we do have a decreased availability of cash, cash equivalents and investment securities and we expect to have such decreased availability of cash for the foreseeable future which could constrain our ability to grow our business. Furthermore, in connection with the Smiths Medical transaction and the payment of the cash consideration, we entered into Senior Secured Credit Facilities (the "Senior Secured Credit Facilities") of $2.2 billion consisting of a term loan A facility of $850.0 million, a term loan B facility of $850.0 million and a revolving credit facility of $500.0 million.  As a result of entering into the Senior Secured Credit Facilities, we incurred additional borrowing costs. Our more leveraged financial position following the Smiths Medical transaction could make us more vulnerable to general economic downturns and industry conditions, and place us at a competitive disadvantage relative to our competitors. In the event that we do not have adequate capital to maintain or develop our business and need to seek additional financing, additional capital may not be available to us on a timely basis, on favorable terms, or at all. Moreover, our Senior Secured Credit Facilities have certain restrictions that may limit how we operate our business, including our ability to engage in certain transactions and incur additional indebtedness, and our business may be materially and adversely affected if these restrictions prevent us from implementing our business plan. See &#8220;Business and Operating Risks - The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have and may continue to acquire businesses, form strategic alliances or make investments in businesses or technologies.  Such transactions or investments could result in unforeseen operating difficulties or expenditures and require significant management resources, charges or write-downs that could adversely impact our business and operating results.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and may continue to seek to supplement our internal growth through acquisitions of complementary businesses, technologies, services, or products, as well as investments and strategic alliances. We compete for those opportunities with others including our competitors, some of which have greater financial or operational resources than we do. We may not be able to identify suitable acquisition candidates or strategic partners, we may have inadequate access to information or insufficient time to complete due diligence, and we may not be able to complete such transactions on favorable terms, if at all. Such transactions are inherently risky, and the integration of any newly-acquired business requires significant effort and management attention that otherwise would be available for ongoing development of our other businesses.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of any acquisition, investment or alliance may be affected by a number of factors, including our ability to properly assess and value the potential business opportunity or to successfully integrate any business we may acquire into our existing business. Integration of an acquired business also may disrupt our ongoing operations and require management resources that we would otherwise focus on developing our existing business. For example, we acquired the HIS business in February 2017, which includes IV pumps, solutions, and devices in order to create a leading pure-play infusion therapy company, and we acquired Smiths Medical in January 2022, which includes syringe and ambulatory infusion devices, vascular access, and vital care products. We invested significant time and resources into the HIS integration in order to achieve the anticipated benefits of the transaction, and we are doing the same with the Smiths Medical integration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any acquisition could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and cash flows. We may also experience losses related to investments in other companies, which could have an adverse effect on our results of operations and financial condition. As such, there can be no assurance that any past or future transactions or investments will be successful.</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material properties used by us in connection with our corporate administrative operations, manufacturing, distribution, research and development and service centers as of December 31, 2022, are as follows:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate Square Footage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Primary Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned/Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Clemente, California, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Headquarters and R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Clemente, California, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Headquarters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, California, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,779</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices and R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lake Forest, Illinois, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,498</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dublin, Ohio, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Houten, Netherlands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Montreal, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,414</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices/Device service center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rydalmere, NSW Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,735</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices/Device service center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chennai, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,879</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plymouth, Minnesota, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kent, United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,759</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ontario, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Offices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austin, Texas, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,602</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ensenada, Baja California, Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La Aurora, Costa Rica</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626,869</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salt Lake City, Utah, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing/Device Service Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dublin, Ohio, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gary, Indiana, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,316</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Southington, Connecticut, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tijuana, Mexico (multiple locations)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,935</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hranice, Czech Republic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,735</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latina, Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Keene, New Hampshire, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,195</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warehouse/Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oakdale, Minnesota, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,648</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warehouse/Manufacturing/Device Service Center</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Round Rock, Texas, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,960</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warehouse/Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dallas, Texas, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610,806</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution Warehouse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">King of Prussia, Pennsylvania, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,571</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution Warehouse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santa Fe Springs, California, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,794</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution Warehouse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wijchen, Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,565</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution Warehouse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olive Branch, Mississippi, U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,863</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution Warehouse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sligo, Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Device service center</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, we own and lease additional office and building space, research and development, and sales and support offices primarily in North America, Europe, South America, and Asia.  We believe our existing facilities, both owned and leased, are in good condition and suitable for the conduct of our business. </span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in Part II, Item 8. "Financial Statements and Supplementary Data" of this Annual Report on Form 10-K in Note 15. Commitments and Contingencies to the Consolidated Financial Statements, and is incorporated herein by reference.</span><span style="color:#008000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Information for Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;ICUI.&#8221; </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid dividends and do not anticipate paying dividends in the foreseeable future as the Board of Directors intends to retain future earnings for use in our business to pay down our long-term debt or to purchase our shares.&#160;Any future determination as to payment of dividends or purchase of our shares will depend upon our financial condition, results of operations and such other factors as the Board of Directors deems relevant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;31, 2023, we had 45 stockholders of record.  This does not include persons whose shares are held in nominee or &#8220;street name&#8221; accounts through brokers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities authorized for issuance under equity compensation plans are discussed in Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Repurchase of Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our stock repurchasing activity during the fourth quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>price&#160;paid<br/>per&#160;share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>purchased<br/>as&#160;part&#160;of&#160;a<br/>publicly<br/>announced<br/>program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">dollar&#160;value&#160;that</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">may&#160;yet&#160;be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">under&#160;the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/01/2022 - 10/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/01/2022 - 11/30/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/01/2022 - 12/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter 2022 total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our common stock purchase plan, which authorized the repurchase of up to $100.0 million of our common stock, was authorized by our Board of Directors and publicly announced in August 2019. This plan has no expiration date. We are not obligated to make any purchases under our stock purchase program. Subject to applicable state and federal corporate and securities laws, purchases under a stock purchase program may be made at such times and in such amounts as we deem appropriate, depending on a variety of factors, including our financial position, earnings, share price, capital requirements, other investment opportunities (including mergers and acquisitions and related financings), market conditions and other factors. Purchases made under our stock purchase program can be discontinued at any time we determine additional purchases are not warranted.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COMPARISON OF CUMULATIVE TOTAL RETURN FROM DECEMBER 31, 2017 TO DECEMBER 31, 2022 OF ICU MEDICAL, INC., NASDAQ AND NASDAQ MEDICAL SUPPLIES INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graph shows the total stockholder return on our common stock based on the market price of the common stock from December 31, 2017 to December 31, 2022 and the total returns of the NASDAQ U.S. Index and NASDAQ Medical Supplies Index for the same period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><img src="icui-20221231_g1.jpg" alt="icui-20221231_g1.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:611px"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICU Medical, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.91</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq U.S. Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Medical Supplies Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.34</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumes $100 invested on December 31, 2017 in ICU Medical Inc.&#8217;s common stock, the NASDAQ U.S. Index and the NASDAQ Medical Supplies Index and that all dividends, if any, were reinvested.</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. RESERVED</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Part I, Item 1A. &#8220;Risk Factors&#8221; or in other sections of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview and Highlights</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture, and sell infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. Our product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and nondedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. In addition, we manufacture automated pharmacy IV compounding systems with workflow technology, closed system </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfer devices for preparing and administering hazardous IV drugs and cardiac monitoring systems for critically ill patients. With the recent acquisition of Smiths Medical, our product portfolio expanded to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices and silicone and PVC tracheotomy tubes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Smiths Medical 2020 Limited  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical, the holding company of Smiths Group plc's global medical device business for a purchase price of $1.9 billion in cash, 2.5 million of fully paid and non-assessable shares of our common stock, par value $0.10 per share and a potential contingent earn-out payment of $100.0 million in cash, based on our common stock performance and other considerations. Results of operations of acquired companies are included in our consolidated financial results from the date of acquisition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To partially finance the acquisition, we entered into the Credit Agreement, dated as of January 6, 2022 (the "Credit Agreement") with Wells Fargo Bank and other financial institutions as lenders. The Credit Agreement provides for $2.2 billion of senior secured credit facilities, including a five-year term loan A facility of $850.0 million, a seven-year term loan B facility of $850.0 million and a five-year revolving credit facility of $500.0 million collectively (the "Senior Secured Credit Facilities"). See "Liquidity and Capital Resources" in the remainder of this item and Note 11 in our accompanying consolidated financial statements for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic and other Global Geopolitical Events</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations have been, and we expect will continue to be, impacted by the novel coronavirus and its variants ("COVID-19"), which has caused lower hospital admissions and medical procedure volumes and by the continuing conflict between Russia and Ukraine. These events have resulted in global economic challenges, and impacts to us and our business, such as rising inflation, especially with respect to freight costs driven by the higher fuel prices, increased cost of raw materials as well as shortages, and supply chain disruptions which have negatively impacted our gross profit margin during 2022. The rising interest rates and foreign currency impact due to the strengthening of the U.S. dollar have also impacted our results of operations during 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continually monitor the ongoing and evolving impact of the above events on our operations the overall impact remains uncertain and may not be fully reflected until future periods. The overall impact to our results of operations will depend on factors such as the duration and extent of the impact from the COVID-19 pandemic, the conflict in the Ukraine and the related global economic challenges, none of which can be fully predicted at this time. See &#8220;Part I. Item 1A. Risk Factors&#8221; for a discussion of risks and uncertainties. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present our consolidated statements of operations for each of the three years ended December 31, 2022, 2021 and 2020 in Item 8. Financial Statements and Supplementary Data. The following table shows, for each of the three most recent years, the respective percentages of items in our statements of operations in relation to total revenues:&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage&#160;of&#160;Revenues</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, strategic transaction and integration expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Benefit) provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $2.3 billion, $1.3 billion and $1.3 billion for 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the periods indicated, total revenue by product line as a percentage of total revenue:&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product&#160;line</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Consumables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems-Smiths Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Access-Smiths Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Care-Smiths Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our product distribution through a network of owned and leased distribution facilities in combination with independent distributors and third-party fulfillment and logistics providers. Our end customers, which include healthcare providers and original equipment manufacturer suppliers, may order and receive our products directly from us or through an independent full-line distributor. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. a substantial amount of our products are sold to group purchasing organization ("GPO") member hospitals.  We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships to secure long-term contracts with large healthcare providers and major buying organizations.&#160; </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality/Quarterly Results</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no significant seasonal aspects to our business.&#160; We can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which may be driven more by COVID-19 pandemic surges and its impact on hospital admissions and procedure volumes along with production scheduling and customer inventory levels, and less by seasonality.&#160;Our expenses often do not fluctuate in the same manner as net sales, which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Non-GAAP Measures</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. The presentation of revenues on a constant currency basis is a non-GAAP financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measure that excludes the impact of fluctuations in foreign currency exchange rates that occurred between the comparative periods. We provide constant currency information to enhance the visibility of underlying business trends, excluding the effects of changes in foreign currency translation rates. We believe this information is useful to investors to facilitate comparisons and better identify trends in our business. Our constant currency revenues reflect current year local currency revenues at prior year's average exchange rates. We consistently apply this approach to revenues for all currencies where the functional currency is not the U.S. dollar. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Revenues on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Consumables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Infusion Consumables revenue (in millions, except percentages):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Consumables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion Consumables revenue increased in 2022, as compared to 2021, due to increased customer demand in our global core infusion, global oncology and renal products. On a constant currency basis, Infusion Consumables revenue would have been $582.1 million, an increase of $26.9 million or 4.9% as compared to 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion Consumables revenue increased in 2021, as compared to 2020. The increase was due to lower hospital census in 2020 driven by the onset of the COVID-19 pandemic, growth in our global oncology, U.S. core infusion and renal products and the impact from foreign exchange.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a constant currency basis, Infusion Consumables revenue would have been $546.3 million, an increase of $72.6 million or 15.3%, as compared to 2020. &#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Systems</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Infusion Systems revenue (in millions, except percentages):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:24.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Infusion Systems revenue decreased in 2022, as compared to 2021, due to the impact of foreign currency. On a constant currency basis, Infusion Systems revenue would have been $363.7 million, an increase of $11.4 million or 3.2%, as compared  to 2021 driven by higher large volume pump ("LVP") dedicated set sales from the larger install base of LVPs and software sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion Systems revenue decreased in 2021, as compared to 2020. The decrease was primarily due to large volume pump sales driven by higher COVID-19-related purchases during the second and third quarters of 2020 and a decline in sales of our non-large volume pump business, which has been partially offset by higher dedicated set sales in 2021 as a result of higher hospital census and larger install base of large volume pump from new customer installations. On a constant currency basis, Infusion Systems revenue in 2021 would have been $351.4 million, a decrease of $8.3 million or 2.3%, as compared to 2020.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IV Solutions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total IV Solutions revenue (in millions, except percentages):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV Solutions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IV Solutions sales increased in 2022, as compared to 2021, primarily due to an increase in contract manufacturing sales to Pfizer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IV Solutions sales decreased in 2021, as compared to 2020, primarily due to lower contract manufacturing sales to Pfizer and lower production volumes due to supply constraints in the market. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Care</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Critical Care revenue (in millions, except percentages):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical Care revenue decreased slightly in 2022, as compared to 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical Care revenue increased for 2021, as compared to 2020 due primarily to higher U.S. hospital census as a result of the COVID-19 pandemic.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infusion Systems-Smiths Medical</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Infusion Systems-Smiths Medical revenue (in millions, except percentages):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems-Smiths Medical</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Infusion Systems-Smiths Medical revenue is a result of the acquisition of Smiths Medical. The year-to-date amount in the table above represents approximately twelve months of revenue from the closing date of the transaction to the end of the year ended December 31, 2022. Revenues in the current period is lower than historical results due to lower demand and operational challenges caused by supply chain and fulfillment constraints.</span></div><div style="margin-top:5pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vascular Access-Smiths Medical</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Vascular Access-Smiths Medical revenue (in millions, except percentages):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Access-Smiths Medical</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vascular Access-Smiths Medical revenue is a result of the acquisition of Smiths Medical. The year-to-date amount in the table above represents approximately twelve months of revenue from the closing date of the transaction to the end of the year ended December 31, 2022. Revenues in the current period is lower than historical results due to lower demand and operational challenges caused by supply chain and fulfillment constraints.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vital Care-Smiths Medical</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total Vital Care-Smiths Medical revenue (in millions, except percentages):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Care-Smiths Medical</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vital Care-Smiths Medical revenue is a result of the acquisition of Smiths Medical. The year-to-date amount in the table above represents approximately twelve months of revenue from the closing date of the transaction to the end of the current year ended December 31, 2022. Revenues in the current period is lower than historical results due to lower demand and operational challenges caused by supply chain and fulfillment constraints.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Margins</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margins were 30.6%, 37.3% and 36.3% for 2022, 2021 and 2020, respectively.&#160; </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in gross margin in 2022, as compared to 2021 was primarily driven by the acquisition of Smiths Medical, inflationary cost increases in our supply chain, and lower manufacturing absorption due to supply chain disruptions. Smiths Medical gross margins are lower than historical ICU margins for the current year primarily due to spending on quality systems and product-related remediation, the cost recognition of the purchase accounting write-up of inventory and freight costs. The inflationary cost increases during 2022 caused by COVID-19 and the war in the Ukraine notably impacted our freight rates as well as, labor and materials costs. Partially offsetting the decrease to gross margin in the current period was the impact from increased sales of higher margin consumables products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in gross margin in 2021, as compared to 2020 was primarily due to product mix and increased plant volumes, partially offset by increased costs for raw materials, direct labor and freight.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our SG&amp;A expenses (in millions, except percentages):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:23.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated SG&amp;A expenses increased in 2022, as compared to 2021. In 2022, SG&amp;A increased $296.6 million due to the impact of the Smiths Medical acquisition, which included $103.8 million of salaries and benefits, $116.8 million of depreciation and amortization expense and $19.7 million of IT and business support services. The remainder of the increase in SG&amp;A was attributable mostly due to higher selling expense due to revenue growth and the impact of inflation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated SG&amp;A expenses increased in 2021, as compared to 2020. Compensation expense increased $7.9 million, dealer fees increased $5.7 million, stock compensation increased $2.9 million, legal expenses increased $2.3 million and computer expenses increased $1.5 million. Offsetting these increases was a $2.3 million decrease in bad debt expense and $1.6 million decrease in commissions. Compensation expense increased primarily due to increased headcount and annual compensation merit increases. Dealer fees increased due to an increase in revenue from U.S. distributors in the current year. Stock compensation increased due to a change during the current year in the number of performance shares expected to vest. Legal fees increased due to additional services performed in the current year related to various legal matters. Computer expenses increased due to increased maintenance costs as well as increased hardware, software and software subscriptions based on operational needs. Bad debt expense is adjusted quarterly, if deemed necessary, based on an assessment of our accounts receivables and our expectations regarding the collectability of those accounts. Commissions decreased due to the commission plan structure in the prior year, which included certain guaranteed payments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development ("R&amp;D") Expenses</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total R&amp;D expenses (in millions, except percentages):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 over 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 over 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased in 2022, as compared to 2021, due to the acquisition of Smiths Medical. R&amp;D expenses are primarily related to headcount and employment expenses in support of ongoing R&amp;D projects</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased in 2021, as compared to 2020. Fluctuations in our R&amp;D expenses are related to headcount and employment expenses due to the timing and nature of various R&amp;D projects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses generally include compensation and benefit expenses, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs incurred on our ongoing R&amp;D projects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Strategic Transaction and Integration Expenses</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, strategic transaction and integration expenses were $71.4 million, $18.0 million and $28.4 million in 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we incurred restructuring charges of $9.7 million primarily related to severance costs. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we adjusted certain facility restructuring liabilities by $2.0 million to reflect actual amounts owed resulting in annual net restructuring credits of $(1.8) million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, restructuring charges were $7.9 million. These charges were primarily related to severance and costs related to office and other facility closures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Transaction and Integration Expenses</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we incurred $61.7 million in strategic transaction and integration expenses primarily related to our acquisition of Smiths Medical, which included legal expenses, bank fees and employee costs, and a United Kingdom stamp tax. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we incurred $19.8 million in strategic transaction and integration expenses primarily related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into the definitive agreement to acquire Smiths Medical.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we incurred $20.5 million in strategic transaction and integration expenses primarily related to the integration of HIS, which included the migration of IT systems at our Austin facility. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of contingent earn-out</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the fair value revaluation of our contingent earn-outs resulted in a decrease in value of $32.1 million. This decrease was primarily related to the fair value revaluation of our Smiths Medical contingent earn-out liability.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the second quarter of 2021, the measurement period related to the Pursuit earn-out liability ended and in October 2021 the $26.3 million earn-out was finalized and paid to Pursuit's former shareholders. There were no changes in the fair value of our earn-outs during 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the fair value revaluation of our Pursuit contingent earn-out liability resulted in an increase in value of $9.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Settlement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we did not incur any contract settlement charges. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded $0.1 million in contract settlement expense.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recorded $1.0 million in contract settlement income related to the resolution of a dispute with one of our suppliers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest (expense) income, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (expense) income, net was $(66.4) million, $1.9 million and $1.9 million in 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $70.8 million, $0.9 million and $1.8 million in 2022, 2021 and 2020, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into senior secured credit facilities that refinanced our Prior Credit Facility in full,  see "Liquidity and Capital Resources" in the remainder of this item for additional information and the estimated impact to future interest expense. In 2022, interest expense primarily includes the contractual interest incurred on borrowings under the Credit Agreement, the per annum commitment fee charged on the available amount of the revolving credit facility contained in the Credit Agreement and the amortization of debt issuance costs incurred in connection with entering into the Credit Agreement (see Note 11 Long-Term Debt in our accompanying consolidated financial statements for additional information).  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, interest expense primarily includes the per annum commitment fee charged on the unused portion of the revolver under our then five-year revolving credit facility and the amortization of financing costs that were incurred in 2017 in connection with entering into the then existing credit facility. The per annum commitment fee was based on the consolidated total leverage ratio in effect and ranged between 0.15% to 0.30% on the unused portion of the credit facility (see Note 11: Long-Term Obligations in our accompanying consolidated financial statements for additional information). </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, interest expense was primarily related to borrowings under our then existing credit facility and the amortization of financing costs. Borrowing under the credit facility bore interest, at our option, based on the Base Rate (as defined in Note 11 in our accompanying consolidated financial statements) plus applicable margin or the London Interbank Offered Rate plus applicable margin (see Note 11: Long-Term Obligations in our accompanying consolidated financial statements for additional information). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $4.4 million, $2.8 million and $3.7 million in 2022, 2021 and 2020, respectively. Interest income is primarily related to interest earned on our investment securities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (expense) income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net was $(5.1) million, $(2.0) million and $(2.6) million in 2022, 2021 and 2020, respectively.&#160;In 2022,  other expense, net was related to $5.8 million of foreign exchange losses and $2.6 million of loss from disposed assets partially offset by $3.2 million of miscellaneous income.  In 2021, other expense, net was primarily related to $1.7 million of loss from disposed assets and $1.0 million of foreign exchange losses partially offset by miscellaneous income of $0.6 million. In 2020, other expense, net was primarily related to $7.2 million of foreign exchange losses incurred as a result of the strengthening of the U.S. dollar during the first half of the year, partially offset by $2.8 million of miscellaneous income and $1.8 million of gain on disposition of assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes were accrued at an estimated annual effective tax rate of 35%, 16% and 11% in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate in 2022 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, section 162(m) excess compensation, foreign-derived intangible income ("FDII"), global intangible low-taxed income ("GILTI") and tax credits. The effective tax rate during 2022 included a tax benefit of $4.2 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The effective tax rate during 2022 also included a $0.0 million tax impact of the revaluation of contingent consideration of $6.8 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate in 2021 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, global intangible low-taxed income (&#8220;GILTI&#8221;),FDII and tax credits. The effective tax rate in 2021 included a tax benefit of $4.9 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The effective tax rate for 2021 also included U.S. federal and state return-to-provision adjustments net of related reserve changes for the year ended December 31, 2020 of $0.9 million tax provision primarily due to changes in estimates for GILTI, FDII, subpart F, and related foreign tax credits along with other prior period adjustments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate in 2020 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, GILTI, FDII and tax credits. The effective tax rate in 2020 included a tax benefit of $5.3 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The effective tax rate for 2020 also included U.S. federal and state return-to-provision adjustments net </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of related reserve changes for the year ended December 31, 2019 of $3.8 million tax benefit primarily due to changes in estimates for GILTI, FDII, and related foreign tax credits. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly evaluate our liquidity and capital resources, including our access to external capital, to ensure we can adequately meet our principal cash requirements, which include working capital requirements, planned capital investments in our business, commitments, acquisition restructuring and integration expenses, investments in quality systems and quality compliance objectives, payment of interest expense, repayment of outstanding borrowings, income tax obligations and acquisition opportunities in accordance with our growth strategy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash and cash equivalents, our short-term investment portfolio, cash flows from our operations and access to borrowing arrangements.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds generated from operations are held in cash and cash equivalents and investment securities. During 2022, our cash and cash equivalents and short-term investment securities decreased by $354.2 million from $567.2 million at December&#160;31, 2021 to $213.0 million at December&#160;31, 2022. Our short-term investment portfolio consists of investment-grade corporate and government bonds and U.S treasury securities and is primarily intended to facilitate capital preservation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Facilities and Access to Capital</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into the Credit Agreement with various lenders on January 6, 2022 in connection with the closing of the Smiths Medical acquisition. The Credit Agreement provides for a five-year term loan A facility of $850.0 million (the "Term Loan A"), a seven-year term loan B facility of $850.0 million (the "Term Loan B") and a five-year revolving credit facility of $500.0 million (the "Revolving Credit Facility") (collectively, the "Senior Secured Credit Facilities"). The proceeds from the term loans were used to finance a portion of the cash consideration for the Smiths Medical acquisition. The outstanding aggregate principal amount of the term loans is $1.7 billion as of December 31, 2022, which includes the Term Loan A that will mature in January 2027 and the Term Loan B that will mature in January 2029. The proceeds of future borrowings under the Revolving Credit Facility, which expires in January 2027, may be used as a source of liquidity to support our ongoing working capital requirements and other general corporate purposes. There are no outstanding borrowings under the Revolving Credit Facility as of December 31, 2022. As part of entering into the Senior Secured Credit Facilities, we were assigned issuer and Term Loan B credit ratings. At the date of issuance of this report, our issuer and Term Loan B credit ratings assigned and outlook were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuer/Term Loan B<br/>Credit Ratings</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Moody's</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ba3/Ba3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB/BBB-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard &amp; Poor's</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB-/BB-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stable</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains financial covenants that pertain to the Term Loan A and the Revolving Credit Facility. Specifically, we are required to maintain a Senior Secured Leverage Ratio of no more than 4.50 to 1.00 until June 30, 2024, with step-downs to 4.00 to 1.00 thereafter, and an Interest Coverage Ratio of no less than 3.00 to 1.00 (defined and discussed in greater detail in Note 11: Long-Term Debt to our accompanying consolidated financial statements). We were in compliance with these financial covenants as of December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Credit Facility</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into a five-year revolving credit facility with various lenders for $150.0 million (the "Prior Credit Facility"). The Prior Credit Facility, which was set to expire in November 2022, was terminated upon entering into the new Senior Secured Credit Facilities. There were no outstanding borrowings under the Prior Credit Facility at the time of its termination.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents along with cash flows expected to be generated from future operations, cash received from our uncommitted trade accounts receivable purchase facility (see Note 17: Subsequent Events in our accompanying consolidated financial statements for additional information) and the funds received and accessible under the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Secured Credit Facilities will provide us with sufficient liquidity to finance our cash requirements for the next twelve months. In the event that we experience downturns, cyclical fluctuations in our business that are more severe or longer than anticipated, fail to achieve anticipated revenue and expense levels, or have significant unplanned cash expenditures, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all. Our ability to generate cash flows from operations, issue debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings or other significantly unfavorable changes in economic conditions. See Part I. Item 1A. Risk Factors&#8221; for discussion of the risks and uncertainties associated with our debt financing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uses of Liquidity</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Expenditures</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures relate to the expansion and maintenance of our business. While we can provide no assurances, we estimate that our capital expenditures in 2023 will be in the range of $100 million to $120 million. We anticipate making additional investments in machinery and equipment in our manufacturing operations in Costa Rica, Europe, Mexico and the U.S. to support new and existing products and in infusion pumps that get placed with customers outside the U.S.&#160;We expect to use our cash and cash equivalents to fund our capital expenditures.&#160;Amounts of spending are estimates and actual spending may substantially differ from those amounts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical. We financed the $1.9 billion cash portion of the purchase price at closing with a combination of proceeds from the Senior Secured Credit Facilities and our cash and cash equivalents. See Note 2: Acquisitions and Note 11: Long-Term Debt in our accompanying consolidated financial statements for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal commitments at December 31, 2022 include both short and long-term future obligations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have non-cancelable operating lease agreements where we are contractually obligated for certain lease payment amounts. For more information regarding our operating lease obligations, (see Note 5: Leases in our accompanying consolidated financial statements). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt Obligations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in January 2022, we incurred borrowings under Senior Secured Credit Facilities. The principal repayment obligations and estimated interest payments on the term loans and estimated commitment fee payments on the revolver are estimated in the below table. Interest payments on the term loans were estimated using an Adjusted Term SOFR rate and an applicable margin on of 2.00% for term loan A and 2.50% for term loan B and the revolver commitment fees were estimated using a rate of 0.30%. The applicable margin rate and commitment fee rate will change from time to time in accordance with a preset pricing grid based on the leverage ratio (see Note 11: Long-Term Debt in our accompanying consolidated financial statements for pricing grids related to the Senior Secured Credit Facilities). We expect to fund these obligations with our existing cash and cash equivalents and cash generated from our future operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A Principal Payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A Interest Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B Principal Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B Interest Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Commitment Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum Purchase Obligations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum to our MSA agreement, see under Part I Item 1 Business Section above for further detail. The Product Addendum included a minimum purchase obligation of $29.6 million, which we satisfied during 2022. The Product Addendum expired on November 30, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Future Capital Investments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the January 2022 acquisition of Smiths Medical we estimate the investment needed in 2023 for restructuring and integration expenses along with spending to support quality systems and quality compliance objectives to be in the range of $75 million to $125 million, which includes acquired accrued field action liabilities. We expect to fund these obligations with our cash and cash equivalents and cash generated from our operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Historical Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operations was $(62.1) million in 2022. Net income plus adjustments for non-cash net expenses contributed $241.6 million to cash provided by operations. Net cash used in operations as a result of changes in operating assets and liabilities was $303.7 million. The changes in operating assets and liabilities included a $201.1 million increase in inventories, a $21.3 million increase in other assets, a $55.8 million decrease in accrued liabilities, $66.7 million in net changes in income taxes, including excess tax benefits and deferred income taxes and a $19.2 million increase in accounts receivable. Offsetting these amounts was a $22.9 million decrease in prepaid expenses and other current assets and a $37.5 million increase in accounts payable. The increase in inventory was primarily to build inventory safety stock levels. The increase in other assets was due to the purchase of spare parts. The primary drivers for the net decrease in accrued liabilities was primarily due to the payout of annual bonuses and decrease in deferred revenue. The net changes in income taxes was a result of recording the current deferred provision and the timing of payments. The increase in accounts receivable was primarily due to the net impact of collection efforts and the timing of revenue. The net decrease in prepaid expenses and other current assets was primarily due to a decrease in deferred costs mostly offset by capitalized debt issuance costs allocated to the revolving credit facility. The increase in accounts payable was due to the timing of payments.     </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by operations was $267.5 million in 2021. Net income plus adjustments for non-cash net expenses contributed $252.5 million to cash provided by operations. Net cash used in operations as a result of changes in operating assets and liabilities was $15.0 million. The changes in operating assets and liabilities included a $20.8 million decrease in inventories, a $13.8 million decrease in accounts receivable, a $6.3 million increase in accrued liabilities, a $2.3 million increase in accounts payable, and $0.9 million in net changes in income taxes, including excess tax benefits and deferred income taxes. Offsetting these amounts was a $21.0 million increase in other assets and a $8.0 million increase in prepaid expenses and other current assets. The decrease in inventory was primarily due to the timing of production and customer purchases. The decrease in accounts receivable is primarily due to collection efforts. The increase in accrued liabilities was primarily due to the accrual of incentive bonuses, deferred revenue collected on certain arrangements and accruals related to the Smiths Medical transaction. The increase in accounts payable was primarily due to the timing of payments. The net changes in income taxes was a result of the timing of payments. The increase in other assets was primarily due to the purchase of spare parts.  The net increase in prepaid expenses and other current assets was primarily due to an increase in deferred costs. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cash provided by operations was $222.8 million in 2020. Net income plus adjustments for non-cash net expenses contributed $239.7 million to cash provided by operations. Net cash used in operations as a result of changes in operating assets and liabilities was $17.0 million. The changes in operating assets and liabilities included a $46.4 million decrease in accounts payable, a $29.4 million decrease in accrued liabilities, $18.0 million in net changes in income taxes, including excess tax benefits and deferred income taxes, a $16.1 million increase in other assets, and a $4.3 million increase in prepaid expenses and other current assets. Offsetting these amounts was a $78.0 million decrease in accounts receivable and a $19.2 million decrease in inventories. The decrease in accounts payable was due to the payment of integration-related expenses with extended payment terms and the timing of other payments. The decrease in accrued liabilities was due to the payment of one-time accrued supply chain reorganization costs. The increase in other assets was due to the purchase of spare parts. The net changes in income taxes was a result of the timing of payments. The increase in prepaid expenses and other current assets was primarily due to an increase in deferred costs. The decrease in accounts receivable is primarily due to collection efforts. The decrease in inventory was primarily due to improved inventory management and increased demand for certain products driven by the COVID-19 pandemic at the end of the year.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in our investing cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Cash Flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,844,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,829,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in non-marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,034)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of investment securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909,468)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,687)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,139)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,818,781)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases of property, plant and equipment will vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold our Farmers Branch, Texas, U.S. distribution facility for $6.0 million.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded a $6.6 million intangible asset related to a three-year non-compete agreement with one of our international distributors, of which $2.6 million was non-cash offset with a contingent earn-out.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business acquisitions will vary from period to period based upon our current growth strategy and our ability to execute on desirable target companies. In 2022, we acquired Smiths Medical. The cash consideration for the transaction was $1.9 billion, which was financed with existing cash balances and borrowings under the Credit Agreement. Acquired cash was $78.8 million. In 2021, we acquired a small foreign infusion systems supplier for approximately $15.4 million. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we paid $3.3 million to acquire approximately a 20% non-marketable equity interest in a non-public company.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and changes in our investment strategy. Our investment policy allows for the purchase of securities with final maturities in excess of one year. If cash is not needed for known future transactions our investment strategy takes advantage of the long-term securities with higher yields. Typically, our longer term securities have maturities up to three years.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the sale of our investment securities will vary based on the maturity dates of the investments. In 2022,  proceeds from sale of investment securities includes $19.0 million received from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in our financing cash flows (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Cash Flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of lender debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of third-party debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent earn-out</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax withholding payments related to net share settlement of equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,870)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,830)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________ </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During 2022, we borrowed an aggregate of $1.7 billion under the Senior Secured Credit Facilities contained in the Credit Agreement to partially finance our acquisition of Smiths Medical (see Note 11: Long-Term Debt to our accompanying consolidated financial statements for additional information). The proceeds are net of $37.8 million in payments of lender debt issuance costs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of $22.4 million of principal payments on the Senior Secured Credit Facilities and $2.2 million in third-party debt issuance costs.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, as a result of market uncertainty caused by COVID-19, we borrowed $150.0 million under our then revolving credit facility as a precautionary measure to increase liquidity. We had fully repaid all amounts borrowed as of December 31, 2020.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the exercise of stock options will vary from period to period based on the volume of options exercised and the exercise price of the specific options exercised.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we paid $26.3 million in cash related to the settlement of the Pursuit contingent earn-out. Of the $26.3 million, the amount recorded as the acquisition date fair value, which is considered financing cash flows, was $17.3 million (see Note 8: Fair Value Measurements).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our employees surrendered 47,664 shares of our common stock from vested restricted stock awards as consideration for approximately $10.9 million in minimum statutory withholding obligations paid on their behalf. In 2021, our employees surrendered 40,350 shares of our common stock from vested restricted stock awards as consideration for approximately $8.3 million in minimum statutory withholding obligations paid on their behalf.  In 2020, our employees surrendered 67,041 shares of our common stock from vested restricted stock awards as consideration for approximately $12.9 million in minimum statutory withholding obligations paid on their behalf.    </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock purchase plan, which authorized the repurchase of up to $100.0 million of our common stock, was approved by our Board of Directors in August 2019.&#160;This plan has no expiration date. As of December 31, 2022, all of the $100.0 million available for purchase was remaining under the plan. We are limited on share purchases in accordance with the terms and conditions of our Credit Agreement (see Note 11: Long-Term Obligations in our accompanying consolidated financial statements).&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1: Basis of Presentation and Summary of Significant Accounting Policies to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form&#160;10-K.&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are summarized in Note 1 to the Consolidated Financial Statements.&#160;In preparing our consolidated financial statements in accordance with GAAP and pursuant to the rules and regulations of the SEC, we make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. We base our estimates, assumptions and judgments on historical experience and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other factors that we believe are reasonable. We evaluate our estimates, assumptions and judgments on a regular basis and apply our accounting policies on a consistent basis. We believe that the estimates, assumptions and judgments involved in the accounting for revenue recognition, accounts receivable and business combinations have the most potential impact on our consolidated financial statements. Historically, our estimates, assumptions and judgments relative to our critical accounting policies have not differed materially from actual results.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience.  Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical products are sold on a standalone basis and revenue is recognized upon the transfer of control which we deem to be at point of shipment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Deliverables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses and related software implementation services, as well as infusion consumables, IV solutions and extended warranties.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method. Revenue related to the bundled equipment, software and software implementation services is recognized upon implementation. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated at net realizable value. An allowance is provided for estimated collection losses based on an analysis of the age of the receivable, on specific past due accounts for which we consider collection to be doubtful and based on current receivables where known economic conditions specific to individual significant customers may indicate collection is doubtful. We rely on prior payment trends, financial status and other factors to estimate the cash which ultimately will be received. Such amounts cannot be known with certainty at the financial statement date. We regularly review individual past due balances for collectability. We also have credit exposure with international customers for whom normal payment terms are long in comparison to those of our other customers and with domestic distributors. If actual collection losses exceed expectations, we could be required to accrue additional bad debt expense, which could have an adverse effect on our operating results in the period in which the accrual occurs.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the acquisition method of accounting for business combinations requires the use of significant estimates, assumptions and judgments in the determination of the estimated fair value of assets acquired and liabilities assumed in order to properly allocate the purchase price at the acquisition date. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the estimates, assumptions and judgments we have made are reasonable, they are based in part on historical experience, industry data, information obtained from the management of the acquired companies and assistance from independent third-party appraisal/valuation firms, and are inherently uncertain. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of critical estimates in valuing certain of the tangible and intangible assets we have acquired, and certain liabilities assumed include but are not limited to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - we used the comparative sales method, which estimates the selling price of finished goods and work-in-progress inventory, reduced by estimated costs expected to be incurred in selling the inventory and a profit on those costs.  The fair value of inventory is recognized in our statements of operations as the inventory is sold.  Based on internal forecasts and estimates of inventory turnover, acquisition date inventory is sold and recognized in cost of goods sold over an estimated period of six months after the acquisition date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Property, Plant and Equipment - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value estimate of acquired property, plant and equipment is determined based upon the nature of the asset using either the cost approach, the sales comparison approach or the income capitalization approach.  The cost approach measures the value of an asset by estimating the cost to acquire or reproduce comparable assets. The sales comparison approach measures the value of an asset through an analysis of comparable property sales. The income approach values the asset based on its earnings potential.  The fair value of land was estimated using a sales comparison approach.  Land and building improvements were valued using the cost approach.  Personal property assets, such as, leasehold improvements, tooling, laboratory equipment, furniture and fixtures, and equipment, computer hardware, computer software, dies and molds were all valued using the cost approach.  Transportation equipment and major manufacturing and equipment were valued using the sales comparison method.  Construction-in-progress assets were valued based on the cost approach less adjustments for the nature of the assets.  The fair value of property, plant and equipment will be recognized in our statements of operations over the expected useful life of the individual depreciable assets.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Identifiable Intangible Assets - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the significant acquired identifiable intangible assets generally is determined using varying methods under the income approach. This method starts with a forecast of all of the expected future net cash flows associated with the asset and then adjusts the forecast to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Other critical estimates used to estimate the fair value are derived from royalty rates, customer retention rates and/or estimated useful lives.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Earn-out Liability - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the earn-out liabilities were valued using a Monte Carlo simulation and a probability-weighted cash flow model, as appropriate (see Note 8: Fair Value Measurements to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for details).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk    </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Smiths Medical acquisition on January 6, 2022 we entered into the Senior Secured Credit Facilities totaling approximately $2.2 billion consisting of a variable-rate term loan A facility of $850.0 million, a variable-rate term loan B facility of $850.0 million and a revolving credit facility of $500.0 million. We are exposed to changes in interest rates on all of these variable-rate debt instruments.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan A facility currently bears interest based on Adjusted Term SOFR plus an applicable margin currently 2.00% per year. The term loan B facility currently bears interest based on Adjusted Term SOFR subject to a 0.50% floor plus an initial applicable margin of 2.5%. We used a sensitivity analyses to measure our interest rate risk exposure. If the SOFR rate increases or decreases 1% from December 31, 2022, the additional annual interest expense or savings related to the term loans would be approximately $16.8 million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate and offset a portion of this interest rate risk exposure associated with these debt instruments we entered into interest rate swaps to achieve a targeted mix of fixed and variable-rate debt. The term loan A swap has an initial notional amount of $300.0 million, reducing to $150.0 million evenly on a quarterly basis excluding its final maturity on March 30, 2027 and we will pay a fixed rate of 1.32% and will receive the greater of 3-month USD SOFR or (0.15)%. The term loan B swap has an initial notional amount of $750.0 million, reducing to $46.9 million evenly on a quarterly basis excluding its final maturity on March 30, 2026 and we will pay a fixed rate of 1.17% and will receive the greater of 3-month USD SOFR or 0.35%. (see Note 7: Derivatives and Hedging Activities to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K).</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business globally in multiple currencies, some of which are considered volatile. Our international revenues and expenses and working capital positions denominated in these foreign currencies expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. As the receiver of foreign currencies we are adversely affected by the strengthening of the U.S. dollar and other currencies relative to the operating unit functional currency. Our hedging policy attempts to manage these risks to an acceptable level. We manage our foreign currency exposures on a consolidated basis to take advantage of net exposures and natural offsets, which are then further reduced by the gains and losses of our hedging instruments. Gains and losses on the hedging instruments offset gains and losses on the hedged forecasted transactions and reduce the earnings volatility related to foreign exchange, however we do not hedge our entire foreign exchange exposure and are still subject to potentially significant earnings volatility due to foreign exchange risk.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses (principally Mexican Pesos, Euros, Czech Koruna, Japanese Yen, U.S. Dollar, Canadian Dollar, Australian Dollar and Chinese Renminbi) that differ from the functional currency of the operating unit. These derivative contracts are designated and qualify as cash flow hedges (see Note 7: Derivatives and Hedging Activities to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K). We performed a sensitivity analysis to estimate changes in the fair value of our foreign exchange derivatives due to potential changes in near-term foreign exchange rates. At December 31, 2022, the effect of a hypothetical 10% weakening in the actual foreign exchange rates used for the applicable currencies would result in an estimated decrease in the fair value of these outstanding derivatives contracts by approximately $2.5 million. The sensitivity analysis recalculates the fair value of the exchange contracts outstanding at December 31, 2022 using the actual forward rates at December 31, 2022, which are then adjusted to be 10% weaker for each respective currency.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_49">Report</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_49">s</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_49"> of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_49">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_52">Consolidated Balance Sheets as of December 31, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_52">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_52"> and 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_52">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_52">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">Consolidated Statements of Operations for the Years Ended December 31, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">, 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">1</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55"> and 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">2</a>0</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_55">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">Consolidated Statements of Comprehensive </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">(Loss) </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">Income</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58"> </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">for the Years Ended December&#160;31, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">, 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">21</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58"> and 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">2</a>0</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_58">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December&#160;31, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">, 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">21</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61"> and 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">2</a>0</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_61">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">, 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">21</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64"> and 20</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">2</a>0</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_64">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_67">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_67">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_163">Schedule II-Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_163">115</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the stockholders and the Board of Directors of ICU Medical, Inc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited the accompanying consolidated balance sheets of ICU Medical, Inc. and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive (loss) income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition &#8211; Chargeback Reserve &#8212; Refer to Notes 1 and 4 to the financial statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for product sales net of a reserve for estimated chargebacks. Chargebacks are the difference between prices the Company charges distribution customers and contracted prices the Company has with the end-customer which are processed as credits to the distribution customers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks are accounted for as variable consideration when determining the transaction price for purposes of recognizing revenue. The Company estimates and reserves for chargebacks as a reduction of revenue at the time of sale to its distribution customers using information available at that time, including historical experience. Accounts receivable as of December 31, 2022 of $222 million and total revenues for the year ended December 31, 2022 of $2,280 million are recorded net of estimated chargebacks. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the subjectivity and complexity of evaluating management&#8217;s assumptions used in the determination of the chargeback reserve, including the chargeback amount related to monthly sales to distribution customers and the time to settle chargeback obligations, auditing the chargeback reserve requires a high degree of auditor judgment and an increased extent of effort. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the chargeback reserve included the following, among others: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of certain controls related to management's assessment of assumptions related to estimating the provision for chargeback reserves, the provisioning, processing, and monitoring of chargeback transactions, and the reconciliation of chargeback reserves. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested chargeback estimates for purposes of determining whether revenues recognized at the time of sale were recorded in the proper period. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the methods and assumptions used by management to estimate the chargeback reserve by:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Analyzing trends in the chargeback provision as a percent of revenues and the chargeback reserve as a percent of revenues.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Testing the underlying data, including historical sales to distribution customers, chargeback settlements with distribution customers, and inventory days on hand reported from distributors, that are utilized as the basis for the chargeback reserve, to test whether the inputs to the estimate were reasonable.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Developing an expectation of the chargeback reserve based on monthly sales to distribution customers, historical experience, and the time to settle chargeback obligations, and comparing our expectation to the amount recorded by management.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Performing retrospective reviews comparing management's estimates of expected chargeback reserves to actual amounts incurred subsequent to the dates of estimation, to assess management's ability to reasonably estimate these obligations and to identify potential bias in management's assessment of the reserve.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combination&#8212; Refer to Note 2 of the financial statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed the acquisition of Smiths Medical for $2.552 billion on January 6, 2022. The Company accounted for the acquisition under the acquisition method of accounting for business combinations. Accordingly, the purchase price was allocated to the assets acquired and liabilities assumed based on their respective fair values, including identifiable intangible assets totaling $945 million. Of the identifiable intangible assets acquired, the most significant included Customer Relationships of $510 million and Developed Technology of $400 million. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; and/or estimated useful lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the purchase price accounting allocation as a critical audit matter because of the significant estimates and assumptions management makes to determine the fair value of the identifiable intangible assets acquired. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our internal fair value specialists, when performing audit procedures to evaluate the reasonableness of management&#8217;s forecasts of future cash flows and the selection of the discount rates for the identifiable intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the business combination included the following, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over the valuation of the identifiable intangible assets, including management&#8217;s controls over forecasts of future cash flows and selection of the discount rates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We assessed the reasonableness of management&#8217;s forecasts of future cash flows by comparing the projections to historical results and growth rates observed for similar businesses and/or peer companies, and evidence obtained in other areas of the audit.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our fair value specialists, we also performed the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We evaluated the reasonableness of the valuation methodologies selected.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">We tested the source information underlying the determination of the discount rates and tested the mathematical accuracy of the calculations. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80OS9mcmFnOjMwNWY1MTlhZDJlNDRkZTNhYzQ0YmJlYTc2YWE0YmRkL3RleHRyZWdpb246MzA1ZjUxOWFkMmU0NGRlM2FjNDRiYmVhNzZhYTRiZGRfNjUxMQ_3c2ffe68-05d2-4930-9da0-ac22d917f198">DELOITTE &amp; TOUCHE LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80OS9mcmFnOjMwNWY1MTlhZDJlNDRkZTNhYzQ0YmJlYTc2YWE0YmRkL3RleHRyZWdpb246MzA1ZjUxOWFkMmU0NGRlM2FjNDRiYmVhNzZhYTRiZGRfNjUxMg_015a3f04-9acc-4d8e-91ec-53417303e038">Costa Mesa, California</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2008</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the stockholders and the Board of Directors of ICU Medical, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">We have audited the internal control over financial reporting of ICU Medical, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:111%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:111%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> issued by COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022, of the Company and our report dated February 27, 2023, expressed an unqualified opinion on those financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in &#8216;Management&#8217;s Annual Report on Internal Control over Financial Reporting&#8217;, management excluded from its assessment the internal control over financial reporting at Smiths Medical, which was acquired on January 6, 2022, and whose financial statements constitute 40% of total assets and 42% of total revenues of the consolidated financial statement amounts as of and for the year ended December 31, 2022. Accordingly, our audit did not include the internal control over financial reporting at Smiths Medical.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying &#8216;Management&#8217;s Annual Report on Internal Control over Financial Reporting&#8217;. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="padding-right:36pt"><span><br/></span></div><div style="padding-right:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">/s/ DELOITTE &amp; TOUCHE LLP</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costa Mesa, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Amounts in thousands, except par value data and treasury shares)&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNC0xLTEtMS05MjcxOA_c2b78b83-feb4-4dfb-8cf5-82acd1cd16f0">208,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNC0zLTEtMS05MjcxOA_b60286c8-9e4d-4312-aa98-a5621302eb76">552,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNS0xLTEtMS05MjcxOA_70e18950-1229-4f74-a690-0cab28a5ca27">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNS0zLTEtMS05MjcxOA_cd589bbd-7468-4002-9d55-6266a8c6c168">14,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNi0xLTEtMS05MjcxOA_bd0c6421-ee3a-44b1-8e2a-6655c841da9b">213,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNi0zLTEtMS05MjcxOA_0f9a7ee5-b5e7-40aa-b7ec-1918f243c966">567,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjVkY2I0ZDdjMTY4YjQ2ZTZhN2YyYjZkMmEzODQ3M2YyXzY3_d30f64b5-b95f-41c2-84ef-4f804ef8f58f">8,530</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjVkY2I0ZDdjMTY4YjQ2ZTZhN2YyYjZkMmEzODQ3M2YyXzc0_051fdbb1-5158-4bdd-a83f-2a281951170b">7,038</ix:nonFraction> at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0xLTEtMS05MjcxOA_77228d58-20b1-46a5-8397-e98a6002e3a1">221,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0zLTEtMS05MjcxOA_ec8c378a-ca98-4569-b7fe-b0fc07bc74c3">105,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOC0xLTEtMS05MjcxOA_d5964a34-6e81-4ac1-a305-46d5586f2c10">696,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOC0zLTEtMS05MjcxOA_42c93e37-a8d9-4f37-82d5-adcf016575b3">290,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOS0xLTEtMS05MjcxOA_ae883563-e770-42fb-a5f1-e94b3be93211">15,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOS0zLTEtMS05MjcxOA_dd3b4b97-54a8-4a40-b0c5-18275a2b865d">19,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTAtMS0xLTEtOTI3MTg_468ffd4c-4d29-4039-97e1-e9a33a6a915c">88,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTAtMy0xLTEtOTI3MTg_86020281-e5e9-4225-9bc7-9a9919d58cef">46,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL CURRENT ASSETS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTQtMS0xLTEtOTI3MTg_895802eb-4020-4798-8797-49e7527602d7">1,235,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTQtMy0xLTEtOTI3MTg_a259c734-582d-4abc-935f-1f89f94f6599">1,029,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROPERTY, PLANT AND EQUIPMENT, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTYtMS0xLTEtOTI3MTg_6aafb7f3-f46b-4914-8329-3fed5ce05749">636,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTYtMy0xLTEtOTI3MTg_c530a14a-84fc-42e5-b5d1-6a6076a99f3e">468,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING LEASE RIGHT-OF-USE ASSETS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTctMS0xLTEtOTI3MTg_c9fa2965-4d1e-417f-98de-e535e495a8f3">74,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTctMy0xLTEtOTI3MTg_79cb0c9b-4f5f-4b46-b450-49e31c00a9bf">39,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LONG-TERM INVESTMENT SECURITIES</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTgtMS0xLTEtOTI3MTg_cad77f83-54a5-407e-b891-908400c3423b">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTgtMy0xLTEtOTI3MTg_ea5967ff-e0bb-4edd-9414-5f3557b1ef9f">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOODWILL</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTktMS0xLTEtOTI3MTg_fdc18405-2b7e-4b2d-a018-4e70ba3604ad">1,449,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTktMy0xLTEtOTI3MTg_48b1a00d-5a23-488d-8520-62c188aba726">43,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTANGIBLE ASSETS, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjAtMS0xLTEtOTI3MTg_c69e5619-3902-4587-9a0f-6b7b60dba91d">982,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjAtMy0xLTEtOTI3MTg_a2909ba7-d91d-47a6-8b22-194184cec9e1">188,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFERRED INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjEtMS0xLTEtOTI3MTg_74d29916-9df2-4f6a-94ca-b9ff04893533">31,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjEtMy0xLTEtOTI3MTg_b2d18948-21b7-4779-963f-c244dacbe9c6">42,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER ASSETS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjItMS0xLTEtOTI3MTg_cd899f92-cd21-4288-9b71-7b71df385d7e">105,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjItMy0xLTEtOTI3MTg_a9e7fc9d-c87a-46c5-9898-8f297b64ccaa">63,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjMtMS0xLTEtOTI3MTg_9da084e2-9470-45fa-a497-b4c646a0fd36">4,515,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjMtMy0xLTEtOTI3MTg_0eaa3875-2024-4e38-8d68-6bd6175014c3">1,880,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjYtMS0xLTEtOTI3MTg_215cb268-dee2-4144-b48d-f3d94bf9d785">215,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjYtMy0xLTEtOTI3MTg_148a48df-1e17-4166-9ca9-ada55535da6b">81,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjctMS0xLTEtOTI3MTg_e5df3d22-56f2-419a-a67a-b98899f106c7">242,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjctMy0xLTEtOTI3MTg_113c0bd2-2797-4e7b-b20c-ca5c2ff5327c">118,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMS0xLTEtOTI5MzE_f1ab566e-61fc-4832-bab6-ab25c6ff93f7">29,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMy0xLTEtOTI5Mzg_a16e3421-eb67-44d3-8f42-345b7963cb1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMS0xLTEtOTI3MTg_4cece5fc-9ec2-4d0a-aba4-0a5788c8eb30">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMy0xLTEtOTI3MTg_09b30176-f3c2-4828-ba7e-e0e3e7a54024">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL CURRENT LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzAtMS0xLTEtOTI3MTg_cbd04090-5719-41a4-ac7a-6b1e5098a972">494,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzAtMy0xLTEtOTI3MTg_ef949798-a475-4005-ab0e-2906ed4e8c7d">200,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONTINGENT EARN-OUT LIABILITY</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzItMS0xLTEtOTI3MTg_670ee70e-4317-4dc3-911a-436908d4a37b">25,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzItMy0xLTEtOTI3MTg_30d455da-248e-4d4c-8839-53ae26abd04e">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LONG-TERM DEBT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzMtMS0xLTEtOTI3MTg_8c944757-790c-47c7-9c3d-a3b44d5aa10a">1,623,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzMtMy0xLTEtOTI3MTg_e4c087d7-4b35-4b1b-ad30-75bc599dc446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER LONG-TERM LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzQtMS0xLTEtOTI3MTg_8a4a22ff-9483-4520-a40c-84c1d789a766">114,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzQtMy0xLTEtOTI3MTg_cd16075b-a87e-40e5-80be-4327c4fb1845">41,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFERRED INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzUtMS0xLTEtOTI3MTg_4f7b7b97-2250-49cc-8260-35d750a7c1bd">126,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzUtMy0xLTEtOTI3MTg_63167ff8-ec8c-4798-a180-0373c3b323c3">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INCOME TAX LIABILITY</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzYtMS0xLTEtOTI3MTg_5544cf4b-d31a-4c31-a1fa-f6e4e9967451">41,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzYtMy0xLTEtOTI3MTg_1b31f9e2-1968-4d9e-95ff-208528f62419">18,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMMITMENTS AND CONTINGENCIES (Note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CommitmentsAndContingencies" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzctMS0xLTEtOTI3MTg_3b2006d5-e631-4f34-90ae-a4a2e90b7298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CommitmentsAndContingencies" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzctMy0xLTEtOTI3MTg_28f53e38-2b20-4449-869f-ec881aec2c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STOCKHOLDERS&#8217; EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY18zMw_61a563e7-9e6f-4ee4-b63c-dbbc418130bd"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY18zMw_f8f55c9d-37a5-4160-8917-43637a6ec07c">1.00</ix:nonFraction></ix:nonFraction> par value; Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY181OA_06e94a56-2d60-4749-9cd3-67207eec8442"><ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY181OA_15502392-8e42-4b8d-b764-5518dc2a6272">500</ix:nonFraction></ix:nonFraction> shares; Issued and outstanding&#8212; <ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY185Mw_5a6f9dc0-1854-4c78-98b0-6fd41f5f858a"><ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY185Mw_940bfab4-3f87-4223-bab1-d1757e3bc45f">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMS0xLTEtOTI3MTg_83fcb538-a9c7-4ea0-bf69-ad2a9aefdfb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMy0xLTEtOTI3MTg_9ecd4795-e2a6-4b8d-ab01-f7303fc02164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xOA_375fa254-d5f8-4a41-9502-95932a127407"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xOA_97a7541a-5eed-4485-aa0b-f39e4d81bcf1">0.10</ix:nonFraction></ix:nonFraction> par value; Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV80Mw_7399b948-6d17-473a-9e2d-2cbf4a09cc60"><ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV80Mw_7401c29d-49ce-4748-879d-48652de24b74">80,000</ix:nonFraction></ix:nonFraction> shares; Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV82MQ_4333a4df-1631-46a9-bfb2-a31a6d8ec9c7">23,995</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV82OA_1c34dd24-7bf8-46c2-a796-5b8c17e8965d">21,280</ix:nonFraction> shares at December 31, 2022 and 2021, respectively, and outstanding&#8212;<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="INF" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xMzk_920e9bcd-ecee-46ca-9902-bddcb11098d8">23,993</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xNDY_5adef0a5-bd5d-413c-9a39-d423f9ca581d">21,280</ix:nonFraction> shares at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMS0xLTEtOTI3MTg_14bdee59-ef40-4396-87ca-359cc1b52748">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMy0xLTEtOTI3MTg_fb2cdd4f-8b3c-497d-925e-f09f347bb1e3">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDEtMS0xLTEtOTI3MTg_b62b6435-4447-4b00-858c-959de463b0d5">1,331,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDEtMy0xLTEtOTI3MTg_fe123bb3-f95d-42c0-9972-93f5e0615f5d">721,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjoxYTA4MWM2NTJkM2Y0OTIxYmZlOTJjMDA5N2NiMTcyN18yOQ_7a43331f-da6e-475c-9210-346a8339ab54">1,633</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjoxYTA4MWM2NTJkM2Y0OTIxYmZlOTJjMDA5N2NiMTcyN18zNg_3df35819-3b65-4c06-92b3-172a5d049079">119</ix:nonFraction> shares, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMS0xLTEtOTI3MTg_fef73bfc-8eea-47a8-8e7e-7e537e975d04">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMy0xLTEtOTI3MTg_f61f2d2a-9840-44f0-b3fb-959f889d1b79">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDMtMS0xLTEtOTI3MTg_1583197b-7ab3-4214-abdb-a67fb4300dd3">837,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDMtMy0xLTEtOTI3MTg_03fd6892-2ecb-473e-ba7a-e27782af52f2">911,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDQtMS0xLTEtOTI3MTg_84480987-e13d-40df-baab-5afccf49efcc">80,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDQtMy0xLTEtOTI3MTg_819c5e60-4dae-47e3-a3bf-63bc5fa36827">19,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL STOCKHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDUtMS0xLTEtOTI3MTg_cedb5d74-a7c7-4ee7-9699-51d2708f3f2e">2,089,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDUtMy0xLTEtOTI3MTg_4b73972b-599e-45d0-bc54-cb38254fbb9e">1,616,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDYtMS0xLTEtOTI3MTg_2690b620-adc9-4238-b3fa-6194f1faab9f">4,515,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDYtMy0xLTEtOTI3MTg_3b47cacc-ea2e-44a5-b29e-2dc95c31f251">1,880,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL REVENUES</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC0xLTEtMS05MjcxOA_b431045a-4cd2-4aed-9687-aa21b740310d">2,279,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC0zLTEtMS05MjcxOA_01c95fd0-7778-4df7-bab2-57c27c688be6">1,316,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC01LTEtMS05MjcxOA_2f732ce4-7791-4e71-8dbf-915603968d3b">1,271,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COST OF GOODS SOLD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS0xLTEtMS05MjcxOA_33cd86ab-4675-4c64-b2b8-bbf904b11d6c">1,582,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS0zLTEtMS05MjcxOA_b0569c71-fdcf-441e-a485-d5ec61468278">824,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS01LTEtMS05MjcxOA_bbdaeceb-21d6-4212-82ec-2d5fc8782126">809,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi0xLTEtMS05MjcxOA_03cf0f58-4855-437c-a72c-237409ab9470">697,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi0zLTEtMS05MjcxOA_7ebd7de2-a507-4998-8a79-aa01031834b3">491,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi01LTEtMS05MjcxOA_c425548b-93ed-4b51-92de-ae9b1a95407b">461,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC0xLTEtMS05MjcxOA_b18355ff-fec6-4353-b71e-0ff4da2c52a0">608,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC0zLTEtMS05MjcxOA_b3101192-4061-42f3-81ba-69015c62e039">302,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC01LTEtMS05MjcxOA_c99a9f82-09ae-4f74-b3d2-f72977d9ac7d">283,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS0xLTEtMS05MjcxOA_b24d7547-983a-46e4-adf1-812eca761653">92,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS0zLTEtMS05MjcxOA_2a0ff442-e875-43b8-a7d3-995c9ae415e1">47,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS01LTEtMS05MjcxOA_00b23ebc-f7ed-47b1-baa2-0b0d162c3d3a">42,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, strategic transaction and integration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtMS0xLTEtOTI3MTg_e709b353-9c2d-470e-8903-2e070c00540a">71,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtMy0xLTEtOTI3MTg_f18638e5-019c-4800-a3a5-39a3476c7584">18,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtNS0xLTEtOTI3MTg_bed65e77-4251-43d3-aee8-6e9ca1aa41c9">28,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtMS0xLTEtOTI3MTg_a9e22fec-cda7-4f0f-a46d-31b106a8792d">32,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtMy0xLTEtOTI3MTg_3e1d3c91-aeeb-4a2c-bbd9-308d38c178da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtNS0xLTEtOTI3MTg_e32faa30-bc03-46bd-826c-6eba5d4d8f78">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:Contractsettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItMS0xLTEtOTI3MTg_6c043c64-469f-43bb-85bf-948a503023f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:Contractsettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItMy0xLTEtOTI3MTg_057323c1-8e5f-4391-b5d0-eee15473fd17">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="icui:Contractsettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItNS0xLTEtOTI3MTg_35be9190-2454-4dca-a6e2-292d08f93c09">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL OPERATING EXPENSES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtMS0xLTEtOTI3MTg_f18b0845-20b6-46d8-8502-718ac929c0fc">740,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtMy0xLTEtOTI3MTg_e96aa2e7-7610-4b00-ac80-fc6545350ecc">368,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtNS0xLTEtOTI3MTg_2e99c34a-ff01-45cc-8b30-d27a67d2d1aa">363,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(LOSS) INCOME FROM OPERATIONS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctMS0xLTEtOTI3MTg_fa204c95-5855-4352-bbcc-957c75f3dbb1">42,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctMy0xLTEtOTI3MTg_24f545b4-2bb9-44be-b0c5-3c0078a82fb0">123,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctNS0xLTEtOTI3MTg_c7736f28-8e39-4462-8e93-b1ab8e4c76f5">98,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTEREST (EXPENSE) INCOME, NET</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktMS0xLTEtOTI3MTg_49f620ff-9c92-417c-aa85-aab7ef41a4ae">66,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktMy0xLTEtOTI3MTg_07d61f04-6c00-4fe8-a1a3-da7483281aee">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktNS0xLTEtOTI3MTg_d53b91ef-7b2f-4f20-b5e6-427b94c0c332">1,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTHER EXPENSE, NET</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtMS0xLTEtOTI3MTg_ce540d90-f6d5-498b-9fdc-ce0a1f91049c">5,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtMy0xLTEtOTI3MTg_9be77489-21cd-4d95-88b9-89a85df326d0">2,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtNS0xLTEtOTI3MTg_39918b3e-614d-478e-bc37-5acbde2be73c">2,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(LOSS) INCOME BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtMS0xLTEtOTI3MTg_afc97c94-918b-48b3-ad7c-fd16d6955855">114,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtMy0xLTEtOTI3MTg_a671a7f3-275f-4017-9c45-754d7da65988">123,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtNS0xLTEtOTI3MTg_cb1c86c3-6f7e-414c-aa9b-80c901c72354">97,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BENEFIT (PROVISION) FOR INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItMS0xLTEtOTI3MTg_c1493f3a-017a-4e0f-b673-c8061e93d2e0">40,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItMy0xLTEtOTI3MTg_0ea5ee4c-20b9-4b6b-99a8-4c8c5fe75ea9">20,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItNS0xLTEtOTI3MTg_fd6b1b9f-ffbe-4ac0-bfd9-1f68182c7e97">10,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtMS0xLTEtOTI3MTg_a0dad0cd-0ff6-4f03-bac1-95f6e3a9b6f3">74,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtMy0xLTEtOTI3MTg_b49e549c-c017-407c-96c0-aec8467c16d1">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtNS0xLTEtOTI3MTg_cc035317-e07d-4b00-9f49-946c79b2a32d">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET (LOSS) INCOME PER SHARE</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtMS0xLTEtOTI3MTg_832f9d16-8e43-4ef9-bb54-028313bf0d3e">3.11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtMy0xLTEtOTI3MTg_1efb354c-29ec-41dd-b242-3dbb5bc9c12b">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtNS0xLTEtOTI3MTg_18cafea1-112f-49d1-b022-e9fb0a79fa8f">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtMS0xLTEtOTI3MTg_2eb99c72-03b3-4a90-a73f-2112da33917d">3.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtMy0xLTEtOTI3MTg_bbe62a88-46d2-489f-bc7e-79506ae8be7d">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtNS0xLTEtOTI3MTg_0656f5a2-a554-4ae6-9247-88e7d3d5585c">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WEIGHTED AVERAGE NUMBER OF SHARES</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtMS0xLTEtOTI3MTg_2b86867b-afaa-4e88-b216-d770547f244d">23,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtMy0xLTEtOTI3MTg_897e6f2d-33ee-4632-adcf-0fc9946b5c5c">21,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtNS0xLTEtOTI3MTg_bbf16e3c-3f4b-412a-8693-c0976acfc7be">20,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktMS0xLTEtOTI3MTg_adfd0e5f-a627-43ec-97c9-7d002a83a1ce">23,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktMy0xLTEtOTI3MTg_5914d297-b8ed-496c-92cd-a6cc2b964107">21,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktNS0xLTEtOTI3MTg_e6ac2651-910a-4438-b950-ab17171d7f20">21,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Amounts in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi0xLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf">74,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi0zLTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi01LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge adjustments, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzQ3_14b2faff-4bdb-4163-9c7d-f6f4f8f540ce">12,941</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzUx_d629246d-3206-49c5-915c-544a13be3da0">954</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzU4_b746e2a2-85a5-4a2c-b264-b18d925311e8">285</ix:nonFraction> for the years ended December 31, 2022, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0xLTEtMS05MjcxOA_16b6f9d8-917b-44a4-9ef8-0040eb49ee67">41,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0zLTEtMS05MjcxOA_f5daecf6-de9e-4408-b876-1df86d87dcfe">3,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC01LTEtMS05MjcxOA_467f5a20-04cb-4cdc-ab6b-8c367326ef1c">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of tax of $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_098038fc-f6fe-49e6-955d-0ff78d67a87a"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_0ad006c5-9d78-4838-90d5-5ba4741f14ea"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_ba89c985-caf2-49b5-a3d8-f37640612719">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0xLTEtMS05MjcxOA_fe1e734f-c126-4af9-8102-57594dba8b26">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0zLTEtMS05MjcxOA_9210c8c9-9632-4999-80bd-89b90c88b91e">14,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS01LTEtMS05MjcxOA_797228af-6358-4446-8e63-e7742c4953bc">12,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_1a64d531-346a-4f1f-9f91-40c5074aa190"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_41aebc5a-9643-43b6-98b4-58e13e85a2f8"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_cac3437e-0120-4db1-b86e-d65b5953a315">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0xLTEtMS05MjcxOA_87044ab5-09c3-4686-bf19-314b80164aa6">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0zLTEtMS05MjcxOA_66919ae2-8fa5-4c36-be9c-e14c24a32e6c">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi01LTEtMS05MjcxOA_1ca7a8b2-6db2-4075-a7ba-f561e472a73c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy0xLTEtMS05MjcxOA_cdbe5d5d-2a1b-40e6-a00c-4387853be82a">61,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy0zLTEtMS05MjcxOA_ffe8b398-bea5-4d32-81d1-65692d9e83a1">17,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy01LTEtMS05MjcxOA_3cbb6581-60d5-4eec-a127-ee2e1f29d4bc">13,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMPREHENSIVE (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC0xLTEtMS05MjcxOA_3396d3c0-3621-4120-a7b8-ec2cd27e8c56">135,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC0zLTEtMS05MjcxOA_704483be-aa45-443b-9418-f32c2f1e8cb2">85,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC01LTEtMS05MjcxOA_e81a48f9-dd49-4888-928f-d4e2ba42fe3c">100,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_61"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2f128dabbbb42f790c9b42b1a52d19f_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0yLTEtMS05MjcxOA_4c3b9c4e-78c7-4257-930d-96689c0a5f16">20,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98ea3f4a06d4a69b875b005c4bfdee8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy00LTEtMS05MjcxOA_2af14be3-07a5-4587-87f3-578d5beaf13f">2,074</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a94223681d4d6f8e75c3e7b836cbec_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy02LTEtMS05MjcxOA_5cf5466a-a535-4bf0-90fd-e5023e4b6330">668,947</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ee1b6542ad84492b4d2ec455fa9ae81_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy04LTEtMS05MjcxOA_1312e222-88f4-425f-8b4c-6196957998db">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ece853202944e484c25ad349453bf0_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xMC0xLTEtOTI3MTg_17a6909d-483c-4b78-83b6-bdb74f802362">721,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde6dfbd9e9b4a638c3f365c3f9bb4f0_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xMi0xLTEtOTI3MTg_f1f13b1c-8a0f-40ab-acf0-17531230d5b1">15,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xNC0xLTEtOTI3MTg_1fd3bdbc-4a36-43f9-b1ad-220c3bc96b3b">1,377,244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of restricted stock and exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS0yLTEtMS05MjcxOA_f58a97bb-421b-4cc6-93a6-2e565dd40ff2">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33927c32f4649af822a8418053d8d99_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS00LTEtMS05MjcxOA_79f82e80-8460-4eea-b4d7-42c023c4f840">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS02LTEtMS05MjcxOA_0d3e4c0a-61bd-423f-bc27-07449e4dbeee">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1337f299defe4eaf888a017913e309b5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS04LTEtMS05MjcxOA_3c4a6b47-0577-4479-9df2-7becca1a7d35">12,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS0xNC0xLTEtOTI3MTg_35a24389-4bc9-4d8e-ac57-2a6bc8eec9c3">13,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments related to net share settlement of equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi0yLTEtMS05MjcxOA_9639ff33-c64d-4bdf-95a5-c19e4134d0eb">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi02LTEtMS05MjcxOA_5efbee8a-1626-41e0-af5e-f5a0bdb97a8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1337f299defe4eaf888a017913e309b5_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi04LTEtMS05MjcxOA_594c51c2-539f-4d87-9dfa-b889df216d30">12,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi0xNC0xLTEtOTI3MTg_aa399f55-9ec7-4ce9-b68d-f0e4afaf4260">12,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOC02LTEtMS05MjcxOA_06224470-c0c5-49f5-85e8-6befb87d192a">23,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOC0xNC0xLTEtOTI3MTg_639e619a-a11a-4202-959a-a8149481b546">23,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5603cb92819e4c3ca2de991234b01760_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOS0xMi0xLTEtOTI3MTg_a4b5e841-78da-40f9-a146-2a358b85b3d3">13,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOS0xNC0xLTEtOTI3MTg_e86d334c-dbdb-4dd0-9603-0c67ac597295">13,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a7c4b10df94a5cadb8f2ccb5d91e45_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTAtMTAtMS0xLTkyNzE4_cd3f145c-86bd-4010-9890-7490bd8eaa20">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTAtMTQtMS0xLTkyNzE4_1f78ae6e-66ee-4696-9b98-8c5e3aea225a">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68360870df24c48b23f24f3a787a64c_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMi0xLTEtOTI3MTg_431beebe-aaa1-4102-89e0-577154cb3463">21,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied10183a5d8941e6b5c8713d7c2eadd8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtNC0xLTEtOTI3MTg_6c9056ee-9e2e-4e9e-ace2-7b63bf49bcf3">2,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if792565cf68b4836a7b528942b2852fe_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtNi0xLTEtOTI3MTg_b1a630a2-b71a-4266-995a-307fda4d210f">693,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff8979ceb98e47dfb43a3711dcf7912a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtOC0xLTEtOTI3MTg_174fa6f1-31dd-4846-a9ef-a88af2fc1a1a">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a5d2a2a4af46a3974d2432b63c41cf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTAtMS0xLTkyNzE4_3a756d32-8db8-4fd9-999b-5e5ca67b1594">808,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15893976f8864a729360aae7e272b56e_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTItMS0xLTkyNzE4_3b869864-968f-416e-8adb-41e32120bcf7">1,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTQtMS0xLTkyNzE4_fdc0ccf0-f675-4cad-a99b-6e293aa38ac1">1,502,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of restricted stock and exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtMi0xLTEtOTI3MTg_22c638b9-fe0d-4991-aee1-bc6738ef45f4">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e7eed8de8c409a833960699b90df5c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtNC0xLTEtOTI3MTg_d17cd20a-b710-4b0b-9eea-dca72e1bed06">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtNi0xLTEtOTI3MTg_554f3ae3-e184-4b8d-9d34-b09b41461807">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801a4fae42184517928aa871ec10a664_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtOC0xLTEtOTI3MTg_5c4f9138-e5d2-4f74-ae6f-6667490a3231">8,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtMTQtMS0xLTkyNzE4_390706dd-6167-472b-b4e4-3e35d6baa689">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments related to net share settlement of equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtMi0xLTEtOTI3MTg_d13f3ba9-f3f6-4bb9-86ca-79606f013fd3">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtNi0xLTEtOTI3MTg_067f319b-75ac-408d-b6dc-7080f02c307f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i801a4fae42184517928aa871ec10a664_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtOC0xLTEtOTI3MTg_61c8196d-33a2-4b3b-95c0-ddd25014bd18">8,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtMTQtMS0xLTkyNzE4_7a389abe-f6a3-470d-b36a-11554407d84a">8,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTYtNi0xLTEtOTI3MTg_85770381-0a55-4f62-a7c4-164d6b9bb34f">27,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTYtMTQtMS0xLTkyNzE4_bbea180b-a64b-4c67-81b8-bcf56f5f1324">27,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbd88657bbd04d46a2104ab8bc2406fa_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTctMTItMS0xLTkyNzE4_bbce13d7-07cd-48c2-8d62-89d7cbb28af9">17,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTctMTQtMS0xLTkyNzE4_dd8343c5-b7e2-4ad0-b5b0-ef36a7f19519">17,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5dce62564e466793e72557cf0c42bf_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTgtMTAtMS0xLTkyNzE4_b8ff7e3d-b5f3-4db8-9679-9325b88f4b3f">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTgtMTQtMS0xLTkyNzE4_d6fc54cd-1fed-4e36-9740-cc34d74769c4">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ca5a22717754de18e1be8d99bab4c9b_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMi0xLTEtOTI3MTg_13d058c1-a926-4f7b-80b9-bb4fd4e5168c">21,280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9952ba8ae7440abb7a7c721d75b664_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktNC0xLTEtOTI3MTg_5cd5e945-c807-433f-a1cd-96b1912f4729">2,128</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7a0a723cc04a34b8b697b0e8fb25cd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktNi0xLTEtOTI3MTg_331ab4da-0ba3-4e47-ab4a-69890562a119">721,412</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic703ef27cbce4420b73d994faaa947af_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktOC0xLTEtOTI3MTg_0aa2b934-7e07-4ec1-a0be-d34a62e6ba58">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19e854fbfba4ab0abc5e57ea4e706e8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTAtMS0xLTkyNzE4_d6a04248-f2f8-4507-9834-ce233631912a">911,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffbdea58d0184ec48cf84b1a702fc5df_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTItMS0xLTkyNzE4_4c81a45f-2b01-4fbb-9f53-01ac33ee38d5">19,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTQtMS0xLTkyNzE4_765bfd0f-d548-4a55-b9b1-c802dc9e23ca">1,616,031</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of restricted stock and exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie18d81392ae04265a3d03510728b3646_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtMi0xLTEtOTI3MTg_24aaaabd-9c5a-4ac3-8664-9799c514b0b9">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtNC0xLTEtOTI3MTg_20ff6df0-0b4a-49fd-b48b-3640e72c3e18">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtNi0xLTEtOTI3MTg_7338f110-f2ed-4cb4-8b93-cff92d24961f">1,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtOC0xLTEtOTI3MTg_a6b6c813-aec6-4b2d-bea8-c4d55fe457c0">10,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtMTQtMS0xLTkyNzE4_ccb03a2e-d9fa-411a-b1c1-74c13f94f0b6">8,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments related to net share settlement of equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie18d81392ae04265a3d03510728b3646_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItMi0xLTEtOTI3MTg_c3ec6d91-72a0-4e1e-83ab-b2449863fdde">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItNi0xLTEtOTI3MTg_3ff09843-f97d-4813-81a0-6da191b79fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItOC0xLTEtOTI3MTg_d6877973-2bac-4ed7-b018-d995c218e940">10,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItMTQtMS0xLTkyNzE4_8381cf13-ef68-429a-9ab8-ccbbe7d06d4d">10,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtMi0xLTEtOTMxOTE_68f27f47-9702-44b3-a95f-6d3c826592b3">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtNC0xLTEtOTMxOTg_be11e3cd-c082-4a63-af61-febe5a076924">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtNi0xLTEtOTMyMDU_05722b94-1258-45a5-9fb1-724f4edbf31e">575,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtMTQtMS0xLTkzMjM4_1395810e-0c8a-45fe-ac82-4246688ce484">575,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjQtNi0xLTEtOTI3MTg_a9e61fca-39c3-4cd6-88ab-fc0b9b056a93">36,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjQtMTQtMS0xLTkyNzE4_ce95c77b-7b1f-4421-a877-6f444d7c1964">36,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtNi0xLTEtOTI3MTg_8238f7b5-4f52-4f93-8c0f-5753c003d304">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dfd2e0db2834b9db1915caf0df77a09_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtMTItMS0xLTkyNzE4_f2440ff1-2741-4f55-afe2-d44ab2c18cee">61,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtMTQtMS0xLTkyNzE4_aa245ad7-adf9-4f6a-a640-0737d74d0e29">61,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7131fb5352c74f58a87b1b96952be01d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjYtMTAtMS0xLTkyNzE4_954ea2ec-7fa0-4e65-a39b-618ac64c8b52">74,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjYtMTQtMS0xLTkyNzE4_093d6da1-5304-4adb-b39f-bb0029e15b6a">74,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47136614a9cc4f309d163a050608f73e_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMi0xLTEtOTI3MTg_34f84548-baf1-4e9a-ae39-c56f1a9a8cbc">23,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e4f2ecd87ce4d80bea7d0755b982f2c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctNC0xLTEtOTI3MTg_21ceac05-063a-4e83-ac85-c8ee282b5acc">2,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f29b1e5a63a431c8553eb9154631953_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctNi0xLTEtOTI3MTg_067380c7-751b-4133-af8a-3febb50a0d38">1,331,249</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idad27c484ae8448cb258c0b5ad63372b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctOC0xLTEtOTI3MTg_a8df8638-a63c-40ee-ae3b-5f1a4c8c1f7d">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d33b6f5efb437681ee2b0b9b8c6a33_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTAtMS0xLTkyNzE4_ff974f34-cc72-45c6-8af4-8e3c60aaef5c">837,501</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e09627e54ce4d96a945c0e3e3954f4d_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTItMS0xLTkyNzE4_8d9fb2e6-1fea-49d3-8d97-3022e2304362">80,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTQtMS0xLTkyNzE4_8731fd36-b459-4df5-b9bd-26b9b12bc78f">2,089,928</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy0xLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf">74,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy0zLTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy01LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS0xLTEtMS05MjcxOA_bf9a046d-ff7f-4488-9acd-95b3204c3200">235,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS0zLTEtMS05MjcxOA_c78771cd-98d7-4d80-b43b-4a526ba9d3b8">89,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS01LTEtMS05MjcxOA_151db1c3-855b-4f58-82f6-8733300c006c">85,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncash expense for inventory step-up</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:AmortizationOfInventoryStepUp" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0xLTEtMS0xMDcyMjc_a6c3b8c3-0a68-4645-93a8-6aff6136f03a">26,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:AmortizationOfInventoryStepUp" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0zLTEtMS0xMDcyMzY_802bd53d-65b8-440d-af0f-267090412dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:AmortizationOfInventoryStepUp" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi01LTEtMS0xMDcyNDQ_84e55a18-f816-4208-8936-0de9e10e3f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0xLTEtMS05MjcxOA_b4770eb1-1d3a-4c88-b45e-affaa3cc35cc">23,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0zLTEtMS05MjcxOA_ad60229b-7902-498f-af62-c09cf437d16b">9,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi01LTEtMS05MjcxOA_b7196b5c-db53-44cd-8232-023049856993">9,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy0xLTEtMS05MjcxOA_7a72e8c1-c445-4495-b214-d369f72e44ea">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy0zLTEtMS05MjcxOA_0b36fcde-b5ee-4623-91c1-321ca3ca7653">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy01LTEtMS05MjcxOA_09dbcc0f-edc7-413a-aeb2-b9e34aaf6468">7,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for warranty and returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ProvisionForWarrantyAndReturns" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC0xLTEtMS05MjcxOA_52de0a1a-3b76-44f7-907b-1cc6efdd5df9">4,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:ProvisionForWarrantyAndReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC0zLTEtMS05MjcxOA_77122821-6648-40ab-af5e-3bdd2b603139">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="icui:ProvisionForWarrantyAndReturns" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC01LTEtMS05MjcxOA_e5f80142-9739-4e6a-b604-15fffcc91265">1,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS0xLTEtMS05MjcxOA_8275a05c-708b-4d12-b019-7a2ab894687c">36,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS0zLTEtMS05MjcxOA_7be36594-267a-40c7-bac1-7367087e2759">27,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS01LTEtMS05MjcxOA_9a9647ea-dd81-4166-804b-656bee8ed15e">23,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposal or write-off of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtMS0xLTEtOTI3MTg_3f2cee2d-104f-4305-9e3b-b8acae2c9082">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtMy0xLTEtOTI3MTg_d1d79098-1bb4-4998-9a3e-5f30ca541367">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtNS0xLTEtOTI3MTg_8e494ea0-c6b6-454e-921a-67e4cdb035d0">1,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on disposition of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtMS0xLTEtMTA1Mjg5_591ac336-16b1-4f70-8b61-e4e18f7ba717">374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtMy0xLTEtMTA1Mjk4_fb5b3172-c1bb-40fd-b8d9-7baa9511aa05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtNS0xLTEtMTA1MzA2_caa35d2c-1e8f-40d9-acf1-977d0e46c025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bond premium amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtMS0xLTEtOTI3MTg_2416d8c0-bf28-4c5a-8598-9733ec87a539">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtMy0xLTEtOTI3MTg_b09d0408-bf51-44e4-9d72-022e0df6f13d">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtNS0xLTEtOTI3MTg_1052194a-6fe4-4462-8cfc-163804cf4ad8">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issuance cost amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtMS0xLTEtOTI3MTg_a6cee758-9415-4ab9-954b-138f0ca71117">6,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtMy0xLTEtOTI3MTg_9eddc78a-e6ce-47eb-b410-3c08e7c90608">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtNS0xLTEtOTI3MTg_5d874611-e44b-4bda-a3b0-d1f8a002a546">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtMS0xLTEtOTI3MTg_085ed495-4aef-4e47-a50d-1903a3da8505">32,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtMy0xLTEtOTI3MTg_bade1224-7730-46ac-92fd-dcff103ecb8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtNS0xLTEtOTI3MTg_dee79be7-3061-4bf5-a202-b32730d32087">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product-related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctMS0xLTEtOTI3MTg_f098b2ad-aa9a-405b-bdf2-e407d71acd84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctMy0xLTEtOTI3MTg_81aab270-da7e-40d2-affe-857ddca5e737">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctNS0xLTEtOTI3MTg_91ad3d1e-3a7a-4097-9912-d3e8319f039e">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Usage of spare parts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:Sparepartsusage" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtMS0xLTEtOTI3MTg_de6ae0b0-83e0-4ed1-bd9a-fda10bae0677">11,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:Sparepartsusage" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtMy0xLTEtOTI3MTg_32b666ca-cbb9-4f84-bf3d-5158f86afc2f">13,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:Sparepartsusage" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtNS0xLTEtOTI3MTg_57c118dd-3b6c-4d49-8eb6-e4d2d622836b">11,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktMS0xLTEtOTI3MTg_fdc7d88d-f034-4ebd-acad-f0f29553b78f">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktMy0xLTEtOTI3MTg_26db62c4-830d-497f-ae6f-ada1d8be35d5">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktNS0xLTEtOTI3MTg_6008fb52-c659-432e-94a8-02f0e3f6a029">6,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of amounts acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtMS0xLTEtOTI3MTg_d799c25f-9fde-46e5-98ff-4eb57facfe4f">19,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtMy0xLTEtOTI3MTg_b34f66b6-1b53-477f-802d-feaac9e10bf1">13,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtNS0xLTEtOTI3MTg_5c8cf90e-5b72-4117-9b56-7ed758638bbf">78,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItMS0xLTEtOTI3MTg_27c7d9e6-4aa3-45f5-b2ac-b1719cc87a03">201,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItMy0xLTEtOTI3MTg_d1bbe72c-6633-4030-b085-1e6873b994ac">20,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItNS0xLTEtOTI3MTg_f6e41d10-e918-40e2-81a0-f64a8a7604ad">19,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtMS0xLTEtOTI3MTg_016bb748-3fe7-4531-9306-a434f43fc70c">22,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtMy0xLTEtOTI3MTg_c1e17ee0-7c10-4c2e-9004-4396f8a66f16">7,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtNS0xLTEtOTI3MTg_1f3ff817-5888-4c89-83dd-c33b3ed1bb21">4,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtMS0xLTEtOTI3MTg_ba2ed376-20b6-436e-972d-a68641376248">21,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtMy0xLTEtOTI3MTg_82e62fdb-7a9f-4db2-8b95-40d801ee78e1">21,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtNS0xLTEtOTI3MTg_8183dd01-a335-40fe-b9db-079bd4c43765">16,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtMS0xLTEtOTI3MTg_765ca36d-e634-4832-9912-32350904b483">37,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtMy0xLTEtOTI3MTg_20638271-75da-465c-8a69-5e83058b06aa">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtNS0xLTEtOTI3MTg_a89350cb-cbfb-484d-9ad9-250d8e138c8c">46,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtMS0xLTEtOTI3MTg_b7202e76-a8e3-48b6-99da-b352471de5c2">55,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtMy0xLTEtOTI3MTg_44273b9f-ffc3-4b06-bf2e-5d50f817378d">6,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtNS0xLTEtOTI3MTg_8ec41770-b346-42c9-af60-0b69fd783fb3">29,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes, including excess tax benefits and deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctMS0xLTEtOTI3MTg_4ef90a19-3c4f-4336-bec7-34d633e416f7">66,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctMy0xLTEtOTI3MTg_b27eb4dd-bbe6-43cb-b9b0-06b61560b561">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctNS0xLTEtOTI3MTg_07e08982-415e-4e01-9a9b-95804d42b0e9">18,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtMS0xLTEtOTI3MTg_2575f69d-3bed-4625-b2cf-d2817cb08c81">62,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtMy0xLTEtOTI3MTg_418facf1-3aed-4cd1-85cd-f8d800fd3832">267,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtNS0xLTEtOTI3MTg_5aeee896-19e7-4f78-95c4-5fde96ecd844">222,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtMS0xLTEtOTI3MTg_30fe7cc4-aff2-41b4-816d-898f95ba62ef">90,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtMy0xLTEtOTI3MTg_f6da02da-a4a0-41c3-9a5a-23775b300757">68,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtNS0xLTEtOTI3MTg_20b4cffe-6fb3-4b0c-9f5b-9fbc1f99e87e">92,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtMS0xLTEtOTI3MTg_97576681-e711-42ad-8e69-7f1bd83e4096">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtMy0xLTEtOTI3MTg_58236630-4a62-4300-90ad-3ebd8dd89ee1">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtNS0xLTEtOTI3MTg_b5188269-df6f-47df-8dbb-03e71eae4ea4">6,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtMS0xLTEtOTI3MTg_82d68b1e-7b41-48d9-9011-5caecfddba67">9,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtMy0xLTEtOTI3MTg_d77dff5a-dbb2-437f-a9f4-1eb38fd0ae23">12,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtNS0xLTEtOTI3MTg_36168faf-2fab-4e41-86f8-7bd1274759fc">8,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtMS0xLTEtOTI3MTg_89e2a82d-1dab-495b-ade8-3968523be239">1,844,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtMy0xLTEtOTI3MTg_db0cce48-e184-40ad-abfc-f9e97fd6e516">14,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtNS0xLTEtOTI3MTg_9e213e8a-3257-47f6-ad0a-aa3506b73986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in non-marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtMS0xLTEtOTI3MTg_a561926e-6966-4a71-9202-8c0445f8e4ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtMy0xLTEtOTI3MTg_d0c65606-2d82-4dcd-9144-9133a7604a52">3,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtNS0xLTEtOTI3MTg_115f5a58-b0f3-405f-bb2b-5e24d03f54c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctMS0xLTEtOTI3MTg_c4cb2606-6a50-491c-9ab1-cf831a756620">3,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctMy0xLTEtOTI3MTg_eb2684ef-923c-4b08-9a2d-865749f5a9bd">10,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctNS0xLTEtOTI3MTg_8e1840b3-1e56-4d4e-b207-dc5cabbf7aaa">32,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtMS0xLTEtOTI3MTg_a699287b-aaac-48ba-bddd-5f4a33855f58">36,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtMy0xLTEtOTI3MTg_21cd741a-42e0-40dd-92fa-8fbfef0b040f">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtNS0xLTEtOTI3MTg_480e5381-0978-4f02-8b2b-ab9f1ddcc1f1">28,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktMS0xLTEtOTI3MTg_92f3bd18-6ab2-432f-94b5-96187bcb19ae">1,909,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktMy0xLTEtOTI3MTg_d13167db-fa53-4d60-831e-327857a4b14b">90,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktNS0xLTEtOTI3MTg_176b1bdb-f341-4fef-9fdb-3ec2a95f8dc0">98,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of lender debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMS0xLTEtOTMyNzQ_23432094-5f7f-4cb7-b115-e8eaa9b40329">1,664,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMy0xLTEtOTMyODE_863361a2-7d48-403c-b44d-3fabb3632cb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtNS0xLTEtOTMyODg_178a3da0-938b-4de2-9092-1428acddb482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMS0xLTEtOTMyNzQ_815d7c34-6722-43ed-a197-748d0e662b9b">22,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMy0xLTEtOTMyODE_5982933b-6a0c-4526-9725-2b10bcc68074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItNS0xLTEtOTMyODg_e9e9ba3a-1b43-4159-bfb0-de77d95818ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of third-party debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMS0xLTEtOTMyNzQ_2a6bd159-6cf1-4f09-b818-e80b38343da0">2,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMy0xLTEtOTMyODE_a11c25e5-4c5a-4fc7-8ee5-ceaddfda6343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtNS0xLTEtOTMyODg_b80226e5-9f0b-41c0-ba03-b7cc4ba0cecd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMS0xLTEtOTI3MTg_30f195d9-7b60-4643-8ac1-c4f1d9e33825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMy0xLTEtOTI3MTg_49f2c22f-dfd0-497a-a308-8846f32d65ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtNS0xLTEtOTI3MTg_d5c0139a-eb90-4b50-996d-7460e1b37c17">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMS0xLTEtOTI3MTg_2bde277d-1fa2-44fc-8a1f-298ca65130f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMy0xLTEtOTI3MTg_46b848cb-ee7e-48d4-8525-e52a002c822f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItNS0xLTEtOTI3MTg_02a48116-1c63-4f1e-bac4-96b00deac002">150,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMS0xLTEtOTI3MTg_4dcfcbb6-505c-492a-a8e9-edc172c8c60b">8,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMy0xLTEtOTI3MTg_6de09945-2fad-466f-aa51-ab9c9bf83f4e">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtNS0xLTEtOTI3MTg_1275eb66-d8c5-41f1-89a3-f6fd308e65bc">13,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments on finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtMS0xLTEtOTI3MTg_23020ba5-d7da-4d8b-8693-f46eff944693">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtMy0xLTEtOTI3MTg_14c495eb-d49b-41da-a4f1-065aa3c68b2d">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtNS0xLTEtOTI3MTg_a363bd8b-4556-477a-ba0b-e323983ae20c">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent earn-out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtMS0xLTEtOTI3MTg_51604830-da4c-4fe0-9d00-10fa5826a24f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtMy0xLTEtOTI3MTg_bd0fed6d-b1a8-4e5d-a859-03c003fa4bd5">17,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtNS0xLTEtOTI3MTg_8e311e7b-3d6b-4971-9049-042e030d7afe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax withholding payments related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtMS0xLTEtOTI3MTg_6028cc20-88b7-40c2-a582-8f5639fcd67f">10,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtMy0xLTEtOTI3MTg_a667a22b-595b-471c-90d2-2d4ed221c48f">8,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtNS0xLTEtOTI3MTg_70e47aca-37c8-4cef-8407-1541e9ab0b9c">12,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctMS0xLTEtOTI3MTg_536b05ef-635d-40ee-911f-224b24e88d5b">1,637,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctMy0xLTEtOTI3MTg_a88e5822-9dcd-428f-9ff2-212ce52d0f7e">16,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctNS0xLTEtOTI3MTg_af6aac03-17d2-4a5d-bfb6-aa1af2446e15">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtMS0xLTEtOTI3MTg_8be2892b-bff3-44c6-a554-f98497e92416">9,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtMy0xLTEtOTI3MTg_97a19ecb-ddd3-46c4-ac40-f56fa70d8568">3,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtNS0xLTEtOTI3MTg_9097ed8b-8f62-4886-8f4d-32785867c897">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktMS0xLTEtOTI3MTg_a1f48188-86ba-44ef-b645-473f3ceab390">344,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktMy0xLTEtOTI3MTg_a5079a7e-acbb-40e5-94ed-02e4ba9b3e5a">156,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktNS0xLTEtOTI3MTg_90311d32-8307-4282-a771-ac39b8a371ec">127,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtMS0xLTEtOTI3MTg_b60286c8-9e4d-4312-aa98-a5621302eb76">552,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtMy0xLTEtOTI3MTg_5bc16c48-f04f-4aba-b63f-24add1b30045">396,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtNS0xLTEtOTI3MTg_dfc88b44-4b2d-48fb-8cf8-0c5cc08a92d2">268,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtMS0xLTEtOTI3MTg_eb5fe535-9c10-4482-8159-4599c1439178">208,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtMy0xLTEtOTI3MTg_998b24e3-124f-46f4-bd4a-291a011bced8">552,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtNS0xLTEtOTI3MTg_548ebe57-856b-46e6-b526-741874d7d147">396,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the year for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy0xLTEtMS05MjcxOA_02905293-a464-410b-82bd-7fde86c4f8c1">27,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy0zLTEtMS05MjcxOA_e48247cb-3522-4df2-b353-dc3cc3b3e53b">19,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy01LTEtMS05MjcxOA_cbf2637f-2b7f-41a5-872a-13dcf1bb363f">31,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the year for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC0xLTEtMS05MjcxOA_58e80130-c1d6-4b39-8ebb-5d7ad24fb2af">63,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC0zLTEtMS05MjcxOA_bf75fd01-4e04-4a28-bdcd-f472ccb31bac">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC01LTEtMS05MjcxOA_f0d6cc58-7373-43b6-9be6-3fe06cc10aad">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable for property, plant and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy0xLTEtMS05MjcxOA_b684a41e-5cc1-43a9-bec6-926e6c750e08">4,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy0zLTEtMS05MjcxOA_54ccc5f2-ba2b-4f41-be06-65cdf7ad5e8f">9,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy01LTEtMS05MjcxOA_a36e40e4-2abd-43c2-97a2-4a87a463eb4d">2,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-compete agreement with associated contingent earn-out liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3a16252c2743e49ad12be60705c508_D20220101-20221231" decimals="-3" name="icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC0xLTEtMS05MjcxOA_846e7f3d-55f0-4b60-98f5-7c63a47bc164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie803115e33c64a30a2d7ac04ce489aea_D20210101-20211231" decimals="-3" name="icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC0zLTEtMS05MjcxOA_d6c3393e-2ae5-435d-b04b-07c73041f8ec">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168c102715d143b4a73cd3d48cb2d99e_D20200101-20201231" decimals="-3" name="icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC01LTEtMS05MjcxOA_dd234f89-e0f3-4128-81d2-b945a46138e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Detail of assets acquired and liabilities assumed in acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="us-gaap:FairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTEtMS0xLTEtOTI3MTg_c94c49f6-a4cb-48ee-9589-068d072ad458">1,606,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231" decimals="-3" name="us-gaap:FairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTEtMy0xLTEtMTA5MTU0_6f212b0a-5e40-4004-9b09-7f83477f1be4">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="icui:NetCashPaidReceivedforcurrentandprioracquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTItMS0xLTEtOTI3MTg_c73c2dfc-8dce-48af-baf9-951b12c8fe9f">1,844,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231" decimals="-3" name="icui:NetCashPaidReceivedforcurrentandprioracquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTItMy0xLTEtMTA5MTU0_cb467643-728f-44c7-8c3f-82f58d134232">14,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMS0xLTEtMTA5MTUy_322b9afc-d0df-4214-a3a9-f66f25e74c59">575,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMy0xLTEtMTA5MTU0_644f3144-4bee-4a4f-8ac3-762631d5fba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231" decimals="-3" name="us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMS0xLTEtOTI3MTg_1a0338fc-6539-4a1b-95d7-d7358fbb73e4">55,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96caeb3085f40b895b3276026ce87e9_I20211231" decimals="-3" name="us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTQtMy0xLTEtMTA5MTU0_0b03ea4a-bf32-4425-bf83-b39264aaa6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill, acquired/adjusted during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTQtMS0xLTEtOTI3MTg_5496cb45-78e3-4475-a779-4880c9ba8492">1,462,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTUtMy0xLTEtMTA5MTU0_8d17e1c5-b476-4f86-b590-02fcc1165fcd">10,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities assumed/Adjustments to liabilities assumed</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTUtMS0xLTEtOTI3MTg_b7d2349d-4dde-4fcb-8577-de53a8f89f7c">593,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231" decimals="-3" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTYtMy0xLTEtMTA5MTU0_5803e217-5e6e-4dfa-81c2-05da0c846a4c">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_67"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MjA_0e53d93d-56f7-4191-985e-1031c1c7378e" continuedAt="idebf71367997400198d01b769258c61d" escape="true">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idebf71367997400198d01b769258c61d" continuedAt="i5941ade88ce44b55aa84f6f8ae44e9db"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1OTU_ac20e23a-9232-4832-9a66-6534506e0122" continuedAt="idbb0670bd8744283b9e814f914bb75bf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICU Medical,&#160;Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our wide-ranging product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We also manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients. Our recent acquisition of Smiths Medical broadened our product portfolio to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices, silicone and PVC tracheotomy tubes. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM0_4379c6fc-e55f-4a55-b16e-8775bc3f606a" escape="true">ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in <ix:nonFraction unitRef="segment" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgz_012f287b-005c-4b09-9488-f0427e33e10a">one</ix:nonFraction> business segment.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell the majority of our products globally through our direct sales force and through independent distributors. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All subsidiaries are wholly owned and are included in the consolidated financial statements.&#160;All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idbb0670bd8744283b9e814f914bb75bf">The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the prior year financial statements and footnotes to conform to the presentation used in the current year. In the statements of operations we reclassified interest income to interest (expense) income, net from other income (expense), net and in Note 4: Revenues, certain reclassifications were made to revenues disaggregated by geography. These reclassifications had no impact on net (loss) income, shareholder's equity or cash flows as previously reported.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical 2020 Limited ("Smiths Medical"), see Note 2: Acquisitions. Our consolidated statement of operations includes the results of operations for Smiths Medical from January 7, 2022 through December 31, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1ODQ_dd766043-e0eb-4ac7-95c3-643c606eefc4" escape="true">Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ from those estimates.</ix:nonNumeric>&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2Mzg_99243504-7d7d-46d0-ac4c-4b1d467b1fc7" escape="true">Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase.</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounts Receivable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5941ade88ce44b55aa84f6f8ae44e9db" continuedAt="id08e6cecd72c4975b1a82dfd4c56366a"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2Mzc_40077082-e571-4b0c-9ed8-05e3e3101fe4" escape="true">Accounts receivable are stated at net realizable value.&#160;An allowance is provided for estimated collection losses based on an assessment of various factors.&#160; We consider prior payment trends, the age of the accounts receivable balances, the financial status of our customers and other factors to estimate the cash which ultimately will be received.&#160; Such amounts cannot be known with certainty at the financial statement date.&#160; We regularly review individual past due balances for collectability.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MTg_3a21bded-9046-4826-8a6a-3e6914e1dc1c" escape="true">Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</ix:nonNumeric>&#160; Inventory costs include material, labor and overhead related to the manufacturing of our products.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NTE_09a6439e-25cb-4ddd-a72d-90338b46066a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMi0xLTEtMS05MjcxOA_112b3d72-e411-43ba-8d68-d13afaad395a">286,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMi0zLTEtMS05MjcxOA_9e10b229-8780-4342-99e3-e7254b997846">135,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMy0xLTEtMS05MjcxOA_ac9cb540-9d43-4d5d-a0b1-e32aa969905d">73,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMy0zLTEtMS05MjcxOA_5505ef79-6de8-4f17-b963-79146ac39336">36,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNC0xLTEtMS05MjcxOA_f8d0b7a1-d3be-48f4-9023-9b826bbd20f8">335,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNC0zLTEtMS05MjcxOA_f89d368c-756e-4e91-88e1-b40e589f9324">118,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNS0xLTEtMS05MjcxOA_ef6a0046-3407-43ac-9322-45d6e52e5540">696,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNS0zLTEtMS05MjcxOA_23887f5b-41b6-49c8-8b5f-a0341349679c">290,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Mzc_1e62a568-9371-4cd6-b279-3358b957a4ca" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie306a7088186433b94994c8694798078_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMi0xLTEtMS05MjcxOA_7040f316-7f4a-44c1-a004-436bac954fc2">414,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib75bb3ec5a414a9a96e90db458d22e9e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMi0zLTEtMS05MjcxOA_a42f8340-4055-40d0-ab70-36853c2f1796">321,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ec5e5fae0c44acbe28b5e7256bc13a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMy0xLTEtMS05MjcxOA_ad33a414-512d-4304-8759-2eda02747f8c">274,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcede7ef2d55454586263cb1b17b8a37_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMy0zLTEtMS05MjcxOA_1c2f0e1e-f69a-48f3-8453-e0b3d2e0edde">243,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1ce0276d2342909b3efc93b1f90403_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNC0xLTEtMS05MjcxOA_b8f760c4-78d7-4676-a5d1-a0716f940b83">77,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd24511b6794dbcafe3d83a5a8388c9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNC0zLTEtMS05MjcxOA_7a060cd3-ea0c-4bbe-81c4-760819ac7393">60,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7048468f159a46b288ae8a59cedfde98_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNS0xLTEtMS05MjcxOA_0288790b-e8a1-4075-a46c-ff6dea37e40e">115,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980f10b9f96e4b5eb86cb041b7ed672c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNS0zLTEtMS05MjcxOA_a18e3c55-efa1-4896-969c-d0f92647b0ec">102,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a64d4f3e84f40458ca24bfae02314b6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNi0xLTEtMS05MjcxOA_94e9a56e-ce5e-4620-a5ec-5041d2372333">29,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b924222777c44f6a4235eca23a1b5cd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNi0zLTEtMS05MjcxOA_06641b6a-023d-4f07-8700-d397a6b7020a">7,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f0d2af3e944dc69bd9763b0d42c3aa_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNy0xLTEtMS05MjcxOA_233603f3-f540-40d2-bd7e-f89c533f91bd">98,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90ea729e60647e7a9038b89c6e8eb51_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNy0zLTEtMS05MjcxOA_ca1d04cd-c549-4a9c-bacf-f558d67ad535">97,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb27ccb900a343b1ac254cb8fd9889ed_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOC0xLTEtMS05MjcxOA_20873d23-3d06-45e2-ad6f-db5142f947fb">152,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6808b2296ffa42588ac59c587abb2eca_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOC0zLTEtMS05MjcxOA_4afee7db-3a93-4ff9-82de-725fa2e1f276">72,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOS0xLTEtMS05MjcxOA_12c8b6c1-48d1-42dd-9d54-05187fb1fd40">1,162,557</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOS0zLTEtMS05MjcxOA_4873ca48-1f50-42d8-9dc6-0e01ef705c6b">905,104</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTAtMS0xLTEtOTI3MTg_4099d875-688e-4f28-8c12-a900a88c1593">526,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTAtMy0xLTEtOTI3MTg_aafc0264-270d-4021-850a-5b30d15f9c18">436,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTEtMS0xLTEtOTI3MTg_092dabf4-4db8-47ca-a063-8c6b3d3a3f48">636,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTEtMy0xLTEtOTI3MTg_81ce7e3e-0fba-4815-93dd-08a86774bbc3">468,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NDU_1e44dc8c-2c53-4dea-8ead-7eabd1dc7c06" continuedAt="i708487a037ae4d66b09d3518b6dcd1c0" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmU1N2RkZDA2YmYwMjQyMTBhY2I4OWJkZTdjMzdjOGJhXzQ_3528d871-5593-45e9-8920-76fa1cd37525">15</ix:nonNumeric> - <ix:nonNumeric contextRef="i5ace55fc527e48da922598ef7519c606_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmU1N2RkZDA2YmYwMjQyMTBhY2I4OWJkZTdjMzdjOGJhXzk_38ff8daf-17ab-4af3-9718-544e1b8ab058">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cc8766a58304d02b111521f7ddb4326_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmUxMGI1OTcyM2RlYTQ4MjdiZmVmZDNkMDJkOTE4ZWNiXzQ_79151fc4-83f1-447f-a517-dae602b01ba9">15</ix:nonNumeric> - <ix:nonNumeric contextRef="i5412a571299e4c32bbdeaa48ca22375a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmUxMGI1OTcyM2RlYTQ4MjdiZmVmZDNkMDJkOTE4ZWNiXzk_383171e1-e9ae-4329-adfc-4d9e4637e3f7">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment and molds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6f9efdcab0a462a9331fcb0b2523f10_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMi0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg2ZTc4Y2E4MjRmMDQ2NjI4OWFmNWVjZDM2ODQ4ZTdkXzQ_e076c270-1e10-4580-b0b0-6c40a07233e9">2</ix:nonNumeric> - <ix:nonNumeric contextRef="iace321f41b4548e6821dc5e27a26dd08_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMi0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg2ZTc4Y2E4MjRmMDQ2NjI4OWFmNWVjZDM2ODQ4ZTdkXzk_fc7e72af-76be-4e85-9cfb-b35fc709eae6">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc2d38102dd74397953e5e63739100de_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMy0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjdjMzRiYTUyN2UwNTQwYzg5ZDk3MWU0NzczNTJkZThjXzQ_703d47f2-2c51-4f20-8c13-b6703c099c65">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i1f3efe5e11e941069af3153789ec8247_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMy0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjdjMzRiYTUyN2UwNTQwYzg5ZDk3MWU0NzczNTJkZThjXzk_7a3790d8-d562-495c-91e7-40ead34e61e6">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d3d6cb7b6924d47969dd4919c9df187_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhOGVhMjg0YmE1NTRhYjE5OWQ4YTJiM2M3MjIyMmI4XzQ_47545695-c236-4f11-a649-74965a5fcd86">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i07984db0625c4d03845107295d7e5a5c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhOGVhMjg0YmE1NTRhYjE5OWQ4YTJiM2M3MjIyMmI4Xzk_defb04c5-1a94-4847-8568-53717fd4464f">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9543871e1aba478483a1228b53651327_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjAyMTI1MDBkYjRjZjQ2ODBiYjdhZDVjMzc0NjJhODA5XzQ_85e06cd4-1769-4edd-970b-caabbe5ca5c9">3</ix:nonNumeric> - <ix:nonNumeric contextRef="iebcf08c085424ee38ab6ffd24290c1d4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjAyMTI1MDBkYjRjZjQ2ODBiYjdhZDVjMzc0NjJhODA5Xzk_1c0b9776-1e8a-4be4-879d-f1f0a3e197c0">10</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:continuation id="i708487a037ae4d66b09d3518b6dcd1c0" continuedAt="i0565e84ab91d41ee8b495937019afd11"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred.&#160;The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="id08e6cecd72c4975b1a82dfd4c56366a" continuedAt="ib6154b46ff6d4704b708eb7672c99ba5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0565e84ab91d41ee8b495937019afd11">removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg2Mw_c9d98b98-8a3b-4e91-8c6a-0f6faa945ed9">95.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg2Nw_d589c39e-d03b-4111-899e-a1e365d7fb86">65.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg3NA_ed4596f8-59b1-4151-ae83-5b436c86a0ed">62.4</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0Nzg_4a7e015d-f8de-4a47-8b83-3159a890eb5e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We test goodwill for impairment on an annual basis in the month of November, or more frequently if an event occurs or circumstances change that would indicate that impairment may exist.&#160;In 2022, we bypassed a qualitative assessment and performed a quantitative assessment to determine whether an impairment exists. We determine the fair value of our reporting unit using the income approach and market approach to valuation, as well as other generally accepted valuation methodologies. The income approach utilizes a discounted cash flow analysis using management's assumptions. The market approach compares our reporting unit to similar companies with the assumption that companies operating in the same industry will share similar characteristics and that company values will correlate to those characteristics. If the carrying amount of the reporting unit exceeds the reporting unit&#8217;s fair value, we recognize an impairment loss equal to the difference between the carrying amount and the estimated fair value of the reporting unit. We concluded that there was no impairment of goodwill during fiscal 2022, 2021, or 2020.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NDE_66e03f2b-99ca-4390-860c-8062d7f8dc94" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of our goodwill for 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:78.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMS0yLTEtMS05MjcxOA_4414a3ca-441c-4401-96da-bb3b8c020339">31,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMy0yLTEtMS05MjcxOA_b5f847ff-1f73-4720-adf9-5ecd9cba64f3">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNC0yLTEtMS05MjcxOA_8dd6d85d-4feb-453c-ae3d-6efd24e140d4">33,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNS0yLTEtMS05MjcxOA_f6d68719-c006-4a94-a25b-b3b5a179aaf2">10,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNi0yLTEtMS05MjcxOA_3b93fc38-48ee-4d11-9dc6-09934a632cef">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNy0yLTEtMS05MjcxOA_48b1a00d-5a23-488d-8520-62c188aba726">43,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOC0yLTEtMS05MjcxOA_90276d41-decb-4119-b34c-a6f6b2f75667">1,469,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOS0yLTEtMS05NDg2NQ_b7d1e251-e698-4f5e-9a7d-af59c12b17c6">7,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMTAtMi0xLTEtMTA1MzU3_9ae5be30-3101-44df-a52b-c1b4e1cca622">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOS0yLTEtMS05MjcxOA_5748e054-1459-489b-b016-7eaa64c22a82">56,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMTAtMi0xLTEtOTI3MTg_fdc18405-2b7e-4b2d-a018-4e70ba3604ad">1,449,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, "Other" primarily relates to a $<ix:nonFraction unitRef="usd" contextRef="i7d433759863a438d9e188a8521981691_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTgzMw_bf8a78e1-05d8-47a5-9454-c6baff9bba04">1.3</ix:nonFraction>&#160;million measurement period adjustment to deferred taxes related to the 2019 acquisition of Pursuit Vascular, Inc. and foreign currency translation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2021, we acquired a small foreign infusion systems supplier, which resulted in $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjAzOQ_8b2f5fef-e1eb-4ddb-b935-c249950e3e9d">10.6</ix:nonFraction>&#160;million of goodwill.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Relates to the sale of a certain line of infusion products in China.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MTU_c9fa7637-9d41-414f-b51b-928f05170d84" continuedAt="i37e2cebbe444437aaa4194a8af4bee58" escape="true"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1OTg_a4c52ae7-c3df-4a45-a293-be595ce3f866" escape="true">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis</ix:nonNumeric>, were as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ib6154b46ff6d4704b708eb7672c99ba5" continuedAt="iee2cd50da4014be78b1645d52a322c93"><ix:continuation id="i37e2cebbe444437aaa4194a8af4bee58"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e546dd32ee14e3eb76d201f21872bb8_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi0yLTEtMS05MjcxOA_69e57b02-deeb-41dc-8d6f-d3abde2e9059">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi00LTEtMS05MjcxOA_048511bb-b855-4411-8a03-065cb401a200">29,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi02LTEtMS05MjcxOA_40ba7dbd-ee56-4ccc-9a03-b0ba525c9bc8">18,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi04LTEtMS05MjcxOA_02e7717d-7d41-43fb-853b-1a02587b3bea">11,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i460a86abca634dc9802438855b8286df_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy0yLTEtMS05MjcxOA_e8029fd2-8ea0-498e-8b8a-59bbe9e13c57">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa54f208913446db511b39d4c19420d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy00LTEtMS05MjcxOA_d3faba1f-9c8f-4d71-9ee0-4c1c0d81f35c">10,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa54f208913446db511b39d4c19420d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy02LTEtMS05MjcxOA_577907a0-df28-4715-8b7f-1ab9261a105d">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa54f208913446db511b39d4c19420d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy04LTEtMS05MjcxOA_2b2a2816-9868-4787-b5a2-595b125c072d">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf83aec391f64db6afb221796f3b44d6_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC0yLTEtMS05MjcxOA_601e24a8-3f59-4873-a860-c515dd17a7f7">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC00LTEtMS05MjcxOA_33e66d2b-8c24-4e49-9269-b981ee8e8667">546,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC02LTEtMS05MjcxOA_73dd033e-5f36-4859-8a60-f4eb1907ff03">101,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC04LTEtMS05MjcxOA_1ec0bc73-814b-4720-b17b-66b587ad2722">445,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS0yLTEtMS05MjcxOA_17d25174-c9a9-4542-9557-50970ca6cf2e">1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3856be9b89747b993110c792a39aabb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS00LTEtMS05MjcxOA_ce6a7189-9e5e-4e9b-bd78-289042a31d67">5,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3856be9b89747b993110c792a39aabb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS02LTEtMS05MjcxOA_63f57798-4506-4729-ba7d-00976e46336b">5,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3856be9b89747b993110c792a39aabb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS04LTEtMS05MjcxOA_775ee2db-27e3-4398-8acb-a0cc307d3f4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id46d0ee7b3624110a0d31e8dbeb2f227_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi0yLTEtMS05MjcxOA_64b3cd06-b10f-4ef3-9ef8-2a130197f570">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi00LTEtMS05MjcxOA_5bd71093-ba09-41b9-9cf5-1525e7fffb47">18,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi02LTEtMS05MjcxOA_af1b7b60-626b-4f53-8111-a045bbf2ac37">5,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi04LTEtMS05MjcxOA_44ce1a1c-60ea-4e08-bc60-6cd426cdd668">12,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i369fa34137ce41348503313048b70075_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy0yLTEtMS05MjcxOA_62a078fa-58ee-412e-8f4b-2c47c4c0c1bb">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84420d968625493db489841b6ba9cd22_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy00LTEtMS05MjcxOA_7bb26396-f7cb-4e86-9d25-018d7133dcce">583,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84420d968625493db489841b6ba9cd22_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy02LTEtMS05MjcxOA_1b0b404f-510c-49dc-bd03-ae29a4922fc6">108,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84420d968625493db489841b6ba9cd22_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy04LTEtMS05MjcxOA_992b68ee-709c-4a0a-bc8f-1efa72cfdca3">474,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib343098582894c1b8730d6b3ee859c16_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC0yLTEtMS05MjcxOA_64cfc698-e6ce-446f-8aeb-b4fdad32f938">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC00LTEtMS05MjcxOA_1595479c-befb-44eb-b702-9bd0018363a7">9,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC02LTEtMS05MjcxOA_57a35560-1e74-4181-a8c3-4f0d553be05b">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC04LTEtMS05MjcxOA_5326e27c-5ac1-4738-98c5-bf0188e9fcec">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS00LTEtMS05MjcxOA_b0905bae-aa26-4de3-b905-28306898d6ba">1,202,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS02LTEtMS05MjcxOA_863c2820-ca1e-414f-b21f-a059359895b9">251,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS04LTEtMS05MjcxOA_0db7b3b3-f1b5-4431-9ad5-3985e84713df">950,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8552f5934714f03a7223229598d0a2a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTEtNC0xLTEtOTI3MTg_bb79078d-ab8f-485c-a5bd-5a4a7ccf622e">31,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8552f5934714f03a7223229598d0a2a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTEtOC0xLTEtOTI3MTg_779e4c3e-bc4d-4472-9c0a-7778053b0563">31,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtNC0xLTEtOTI3MTg_e1729f53-e8da-4f08-9c96-67e80d2c1a14">1,234,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtNi0xLTEtOTI3MTg_11ff5d57-5f7d-48a8-80e8-ad5cde586a79">251,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtOC0xLTEtOTI3MTg_4906f543-30f3-45ae-8035-0d31a3d06644">982,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2be404c6e2704f988bf6f30f9911074b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi0yLTEtMS05MjcxOA_99c834bf-5a9d-417d-8957-842f5abb6f4e">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi00LTEtMS05MjcxOA_423da94f-af90-45c1-b7b8-245e2150bc03">27,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi02LTEtMS05MjcxOA_64570fba-2fb9-4107-b459-6df026c480bd">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi04LTEtMS05MjcxOA_a9174f94-9d25-435a-b917-1c60a177d4ac">10,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i63886e254baf421a9707d4d5eb8bab28_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy0yLTEtMS05MjcxOA_9268dc06-cfb7-4cc2-95b2-43cc42bbe1db">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy00LTEtMS05MjcxOA_c76a187f-d9d9-4192-90a4-d8a9e0853e39">10,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy02LTEtMS05MjcxOA_25f953ef-676b-490d-9832-b8dd79fbd1bf">6,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy04LTEtMS05MjcxOA_a3d7cf0b-cd86-4ff5-9469-ea598997c327">4,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ca30aa64779494ca3499ac96dcc8ff4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC0yLTEtMS05MjcxOA_895d5c98-1ed7-4272-b4bd-c5f09b9ed6ac">9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC00LTEtMS05MjcxOA_ce5db37b-c099-4a2d-a7cb-fb9506384734">57,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC02LTEtMS05MjcxOA_f420c2f5-4b10-47d7-b9ef-19b2ba98ce7d">33,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC04LTEtMS05MjcxOA_3711aed2-7ca0-40ce-b3cf-c4fa5881174f">24,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf5f275b31a74d0897b0a32abeeeb534_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS0yLTEtMS05MjcxOA_e6aba315-2d84-4bcc-b761-1d64655e5be4">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41f8b67700946dd803fdd98061bc244_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS00LTEtMS05MjcxOA_fd73b983-b498-4efd-a8eb-565e11fb5a06">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41f8b67700946dd803fdd98061bc244_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS02LTEtMS05MjcxOA_496a5c70-9d40-402d-92f6-f71c8413fbad">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41f8b67700946dd803fdd98061bc244_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS04LTEtMS05MjcxOA_c411a5b8-beff-452c-87eb-b417bd2709a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id77c83d365be429dbcf3b8e60f6471c1_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi0yLTEtMS05MjcxOA_45265e61-83e2-47ab-85d6-f6fd79e2f296">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057559badebc49ff81913d91205892d0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi00LTEtMS05MjcxOA_fcf4a56e-1fab-4a33-bf4c-c300ac278c28">18,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057559badebc49ff81913d91205892d0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi02LTEtMS05MjcxOA_2118abf9-2fdf-40e3-aa08-41ceeb86025f">4,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057559badebc49ff81913d91205892d0_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi04LTEtMS05MjcxOA_970f7eb7-e96a-4f5f-8422-cb6afef0f729">13,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a2d444d9cee49b99776001b30841e74_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy0yLTEtMS05MjcxOA_c468e8d8-89a5-43ce-ab6e-f7b9badfdd3f">13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy00LTEtMS05MjcxOA_0d4c5a6c-250f-4b6e-a98b-ef88da101c88">152,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy02LTEtMS05MjcxOA_92b6119f-aeef-4a27-bf32-5085f9cdd2d2">49,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy04LTEtMS05MjcxOA_d661b7df-316d-446b-881c-d0b921300b32">103,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93ff0b8f85bb402b839b0f6cb69bfaa0_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC0yLTEtMS05MjcxOA_bfd1c9a6-1ebe-42b0-bda8-6296084391bd">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC00LTEtMS05MjcxOA_3f7fcbbf-73f7-429d-b6af-c2d09e8fa337">9,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC02LTEtMS05MjcxOA_2733f712-bcfa-4a64-a247-2db213ee08d4">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC04LTEtMS05MjcxOA_82206cab-17fe-4755-8fae-a2d737a0deeb">6,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS00LTEtMS05MjcxOA_0256b2fd-d1d0-4a5e-878e-f5658df3057d">275,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS02LTEtMS05MjcxOA_c4f4fb03-81c9-43f0-bfa2-ef53f74e39f3">112,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS04LTEtMS05MjcxOA_98a6c950-3331-403a-b60f-0e63c9ee43fb">162,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTEtNC0xLTEtOTI3MTg_451dc3a6-d3e9-4e38-8615-5bb0611b0305">25,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTEtOC0xLTEtOTI3MTg_22fff3c3-03ce-485e-824c-967b67249d7d">25,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtNC0xLTEtOTI3MTg_786b50c2-34a5-4d3c-9a05-0904b5533f48">301,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtNi0xLTEtOTI3MTg_1520da28-a7b6-40b8-bc8b-26296bc45c6b">112,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtOC0xLTEtOTI3MTg_87b45d1f-9cb9-4443-8691-7e7a8bd8b22a">188,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU2OQ_ce2dc02e-5247-4011-a943-45b4698de766">139.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU3Mw_7623885c-1be3-4297-85df-db89cae5b244">23.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU4MA_7e99e475-04f4-467a-85ea-cd6555a025ad">23.2</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MzE_d0f4fd98-7feb-42de-8850-2e446f2c2b5a" continuedAt="i013d7e2f5e6c4b0a93863d5a13a80af6" escape="true">As of December 31, 2022, estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="iee2cd50da4014be78b1645d52a322c93" continuedAt="ibb0a422d3ad34fc0b6236fcad506ad14"><div style="margin-top:5pt;text-align:center"><ix:continuation id="i013d7e2f5e6c4b0a93863d5a13a80af6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:78.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMC0yLTEtMS05MjcxOA_0ae1b94d-7414-4775-97d6-39d41a15f076">130,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMS0yLTEtMS05MjcxOA_0be329be-b660-4b57-a99b-6cbf76e1a807">130,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMi0yLTEtMS05MjcxOA_074ddec1-ec35-4e4c-9cee-5307e56aa89e">123,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMy0yLTEtMS05MjcxOA_66b7d1f7-27d0-4b8f-bfda-2fc3130ba4dd">122,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNC0yLTEtMS05MjcxOA_415b7122-d4a2-4ea2-aae0-149fba27d7e6">114,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNS0yLTEtMS05MjcxOA_d442aaef-89ae-4bbf-ab38-6b69d503cc90">328,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNi0yLTEtMS05MjcxOA_f6fd1235-c3ba-4e15-abd5-7f21f775262a">950,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets that are not subject to amortization are reviewed annually for impairment or more often if there are indications of possible impairment. We perform our annual intangible assets impairment test in November of each year. We did not have any intangible asset impairments in 2022, 2021 or 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MjY_179f8f75-5013-45e6-a49b-d5c0083f3a30" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk. We did not have any long-lived asset impairments in 2022, 2021 or 2020.</span></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0OTI_a6349ff7-f8d6-4dfe-96cc-97fc3e61b095" continuedAt="ib4c5e37ff06f46eb9ac06822a2ef8a20" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition).  Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Available-for-sale Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment securities are considered available-for-sale and currently consist of short and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds. These securities are considered &#8220;investment grade&#8221; and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the carrying value is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive (loss) income. We did not have any investments in available-for-sale debt securities in unrealized loss positions as of December 31, 2022 or 2021.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib4c5e37ff06f46eb9ac06822a2ef8a20">The amortized cost of the debt securities and U.S treasury securities is adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in interest (expense) income, net in the consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2023 and 2024. All short-term investment securities are callable within one year.</ix:continuation>  </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ibb0a422d3ad34fc0b6236fcad506ad14" continuedAt="i8b5d1cfe8d3b4c498e5b093f2866f377"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Mjc_d0e64522-a39a-416d-a944-0d1d06eb80bd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi0xLTEtMS05MjcxOA_0fdb481f-5129-46bf-a0eb-9f0f04dc6b16">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7bb5378ae8468895c202125d15e129_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi0zLTEtMS05MjcxOA_59cc9226-e83f-4766-b8f3-850a10ef2108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi01LTEtMS05MjcxOA_4408b424-1c7d-4c02-9aaf-f5d50d15961a">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc33001b56c64b11b1bc56c135168d51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0xLTEtMS05NTU4NQ_a3276918-7b6c-4dba-a64b-a2f84777d231">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de82ccd51af439091344dc5996e1a43_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0zLTEtMS0xMDkxNjM_4fa67be5-65c2-4bae-a5d4-12d3366165f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50fd4be30c6481e89383764b9f60a6f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy01LTEtMS0xMDkxNjc_079a6b8c-c6f8-42e9-bf06-4a5c4aac75ff">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0xLTEtMS0xMDMyOTQ_240e55db-d89d-45b9-bd93-679b651bcd55">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2609bce6c04e03995a81ac43177271_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0zLTEtMS0xMDkxNjM_7d500db6-b4f5-4f40-a29e-81fc9c778690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC01LTEtMS0xMDkxNjc_f502ada5-56be-4b05-a531-ffcf6af4fe20">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investment securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS0xLTEtMS0xMDkxNTc_950c71c8-1f88-4076-8b19-ebf6eee2fb70">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS0zLTEtMS0xMDkxNjM_e2382b82-bf9d-4f88-9fdc-0de2acd03ffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS01LTEtMS0xMDkxNjc_5ac49916-4e38-44d7-b31a-05e735b8ad87">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0xLTEtMS05MjcxOA_f1b91036-91c6-44f2-a8a4-84de4349bd46">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7bb5378ae8468895c202125d15e129_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0zLTEtMS05MjcxOA_ea195286-b3a3-44eb-941c-450b36269c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy01LTEtMS05MjcxOA_3a7bfa60-c0aa-4d64-89f7-11840f267249">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0xLTEtMS05MjcxOA_75637cd2-dec6-405a-9aed-8428f98dc283">4,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0zLTEtMS05MjcxOA_a8120e41-436b-4d91-9680-c08c537f00f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC01LTEtMS05MjcxOA_9aa2a2da-a38f-47c7-988a-75a880f3bc0f">4,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC0xLTEtMS05MjcxOA_88492634-c21c-4bea-8ed8-7d0d8f8f8204">14,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC0zLTEtMS05MjcxOA_55480cb1-e9b9-4e08-8420-6eaf8bbce62d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC01LTEtMS05MjcxOA_8ab41293-2273-4ba9-a226-ce8ba8cd3319">14,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS0xLTEtMS05MjcxOA_4be8b15a-0623-42cc-b651-e5a30139a809">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS0zLTEtMS05MjcxOA_900052c6-f287-4e40-a8a7-0ecc55908cbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS01LTEtMS05MjcxOA_74407e3e-a2d8-44fc-ad5b-2eae42dca5a2">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtMS0xLTEtOTI3MTg_724eaa06-65e1-49b9-8359-3d5308041fb5">19,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtMy0xLTEtOTI3MTg_455a31cb-1c8b-4ef5-acef-b66c00b8034c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtNS0xLTEtOTI3MTg_c2f9d8cd-9488-4983-966c-a85fe84b972b">19,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Non-Marketable Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, we acquired approximately a <ix:nonFraction unitRef="number" contextRef="i0029a1b43ec54a29b829f135a48f9cfb_I20221231" decimals="1" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTA0MTA_bb986738-94e3-47fa-9161-a74091bbe4ad">20.0</ix:nonFraction>% non-marketable equity interest in a nonpublic company and entered into a three-year distribution agreement where we have the exclusive rights to market, sell and distribute the company's products in exchange for a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTA2NDM_20b3186e-2cee-4df3-9b2a-0d4002dbec19">3.3</ix:nonFraction>&#160;million. In addition, we were granted an exclusive license for all of the seller's intellectual property. At the expiration of the distribution agreement we have the right but not the obligation to acquire the remaining interest in the business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0ODY_4cbe23f6-2ee4-4beb-b4ad-f4b8eb8df257" escape="true">We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other expense, net in our consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on the consolidated balance sheets. We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable.</ix:nonNumeric> During 2022 and 2021, there were no indications that our non-marketable equity method investment was impaired. Our recorded share of the investee's loss was not material for the year ended December 31, 2022 and 2021. We did not receive any dividend distributions from this investment during 2022 and 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0OTc_d586a459-d9f5-4c32-8ac4-cc4d14c4f175" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-marketable equity method investment consists of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmMyYzA3N2QxODVmNDRhODk5ZWY0OTk4YzNhZDZjMDcyL3RhYmxlcmFuZ2U6YzJjMDc3ZDE4NWY0NGE4OTllZjQ5OThjM2FkNmMwNzJfMi0xLTEtMS05MjcxOA_106dde71-0153-4c3b-99db-28d9100f1503">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmMyYzA3N2QxODVmNDRhODk5ZWY0OTk4YzNhZDZjMDcyL3RhYmxlcmFuZ2U6YzJjMDc3ZDE4NWY0NGE4OTllZjQ5OThjM2FkNmMwNzJfMi0zLTEtMS05MjcxOA_e53cc4f9-841b-4662-8c1b-9de23690ebd2">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in non-marketable debt securities</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i8b5d1cfe8d3b4c498e5b093f2866f377" continuedAt="i59c6ef6aabe14d169f8fc2dc31322c1e"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter 2022, we received $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjQw_211923ba-aa51-4e9e-9d0b-50995442b60d">19.0</ix:nonFraction>&#160;million in proceeds from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NjE_da10fa7a-6754-4905-92e3-1546e5fe7274" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is &#8220;more likely than not&#8221; that all or a portion of the deferred tax assets will not be realized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NTc_59b50816-5865-4cb6-9301-aad0598fc108" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars.&#160;In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process.&#160;Translation adjustments are recorded as a component of accumulated other comprehensive loss, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows.&#160;Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our consolidated statements of operations in other expense, net, see below other expense, net table. Foreign currency transaction losses (gains), net were $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0NjQ_e5c4da5d-16bb-45c7-a847-1fb3c2d8c076">5.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0Njg_b2d7e702-dc5d-429e-b284-e19b20cff062">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0NzU_6ee250f3-76b2-4ceb-b72a-8d72c7d03816">7.2</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0NjM_43566a5d-06f5-487e-ad71-0b4c8ab95bf7" continuedAt="i9a821c484d1f44f58151547dbc6690cd" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Vascular Access and Vital Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Deliverables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i59c6ef6aabe14d169f8fc2dc31322c1e" continuedAt="if8eff76c44cd4e489647b76cd6d8c4ef"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a821c484d1f44f58151547dbc6690cd">and related software implementation services, as well as infusion consumables, IV solutions and extended warranties. Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.  Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shipping Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NzM_d8f33f3a-bef0-4c0c-87d2-bc02528fb81b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Post-retirement and Post-employment Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a Section&#160;401(k)&#160;retirement plan ("plan") for employees.&#160;Our contributions to our 401(k) plan were approximately $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgxOTE_d0a6110f-8ea1-4843-9f81-711ef8dc992b">14.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgxOTU_dd1638bf-1a7d-411d-b501-b8f7faa931b7">11.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgyMDI_8d415fa6-add9-4820-b6a9-26b2d0126962">10.7</ix:nonFraction> million in 2022, 2021 and 2020, respectively. We also have post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MjY_77bd347c-ef7d-4e78-974d-a30194d88edf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our research and development costs are expensed as incurred.  In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets.  Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM3_11ef2c13-0514-4e49-95f6-9e2672f8157e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest (expense) income, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents interest (expense) income, net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0xLTEtMS0xMDkyMDU_c7efe032-bfd6-458b-bbd4-c5583c72a923">70,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0zLTEtMS0xMDkyMDg_891b7859-6a88-4e45-9513-587d1f094c8a">858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi01LTEtMS0xMDkyMTA_d38892c8-9745-4c0e-a2f0-eba1e0a10542">1,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy0xLTEtMS0xMDkyMTM_6d7ac9fc-63f4-421c-bade-c64a98037449">4,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy0zLTEtMS0xMDkyMTU_c73d4f41-635a-4fb5-818f-c9d9e16b4df3">2,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy01LTEtMS0xMDkyMTc_1094a4bc-afd9-42d8-9d55-720f4cd7e159">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0xLTEtMS0xMDA2NzM_10e6c440-b020-4bf7-9e8f-bb5462be1a04">66,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0zLTEtMS0xMDA2NzM_1c5c4b03-e813-4023-80f6-0dee5079a3b9">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfNC01LTEtMS0xMDkyMjM_e55f2ec1-6d2c-4ea6-bf59-81b51474b533">1,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM4_f7174dc9-405f-4cb6-bd95-620e3d3b02c4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other expense, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents other income (expense), net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi0xLTEtMS0xMDkyMjk_ecadb222-370a-4ed5-8c91-cd708a7e3763">5,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi0zLTEtMS0xMDkyMzI_4c693d04-3d7b-4902-bcef-6829ab7cee33">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi01LTEtMS0xMDkyMzQ_62d23c52-4395-4334-8be7-c774dd3d4715">7,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposition of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy0xLTEtMS0xMDkyMzY_8de112b3-2696-49b0-b881-fbf99d742183">2,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy0zLTEtMS0xMDkyMzg_2571eeac-4d0b-4aef-9ad3-141c72df9f47">1,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy01LTEtMS0xMDkyNDA_8ec687d9-7abd-42ef-99c7-f15c60b93948">1,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other miscellaneous income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:MiscellaneousIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC0xLTEtMS0xMDkyNDI_740daedd-de68-43a3-ab26-9f8ba793632f">3,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:MiscellaneousIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC0zLTEtMS0xMDkyNDQ_5fc798a4-2372-42f4-a2ea-35e3d91cdbde">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:MiscellaneousIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC01LTEtMS0xMDkyNDY_3f6584d7-2f3c-4b8c-9b45-7be2fba5977f">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS0xLTEtMS0xMDkyNDg_23aa3018-abe1-4148-ad2d-34d68f67b3e6">5,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS0zLTEtMS0xMDkyNTA_7a8e6d8b-229a-48d4-8532-8c1f7ac61e7d">2,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS01LTEtMS0xMDkyNTI_0264c665-6b80-4319-8456-9a563d2c872b">2,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1ODM_180142c9-fb27-4392-a3f7-ac65e38da0d2" continuedAt="i6dc5468208cb45d78fb04f72d6c22614" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net (Loss) Income Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding plus any dilutive potential securities.&#160;Dilutive potential securities </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="if8eff76c44cd4e489647b76cd6d8c4ef" continuedAt="ibd3d07512c3e46c8957d3e298046d967"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6dc5468208cb45d78fb04f72d6c22614">include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock, are not included in the treasury stock method calculation. Restricted stock units that are anti-dilutive are not included in the treasury stock method.</ix:continuation> Due to the net loss for the year ended December 31, 2022 the inclusion of any potential securities is antidilutive, accordingly, basic and diluted net loss per share is the same for this period. There were <ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTk2NzA_0c3230d5-5b38-41d4-9fee-8be036a95772">12,354</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTk2Nzc_f91f55ec-e14a-4c8d-9cfc-5533f541eb73">12,083</ix:nonFraction> anti-dilutive shares in 2021 and 2020, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MDE_86998e38-056c-42fd-97be-77b0f6d52c5f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of net earnings per common share (&#8220;EPS&#8221;) &#8212; basic and diluted (in thousands, except per share data):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi0yLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf">74,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi00LTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi02LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6">86,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding (basic)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy0yLTEtMS05MjcxOA_2b86867b-afaa-4e88-b216-d770547f244d">23,868</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy00LTEtMS05MjcxOA_897e6f2d-33ee-4632-adcf-0fc9946b5c5c">21,206</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy02LTEtMS05MjcxOA_bbf16e3c-3f4b-412a-8693-c0976acfc7be">20,907</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC0yLTEtMS05MjcxOA_cb4e2ab5-b500-40e5-b133-3821dad10b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC00LTEtMS05MjcxOA_9a1f47f2-0b1e-41a2-93be-8953c20f54ba">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC02LTEtMS05MjcxOA_9fd20b5c-a9ac-4f2d-9b71-dbaff30ad4e1">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common and common equivalent shares outstanding&#160;(diluted)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS0yLTEtMS05MjcxOA_51ef550d-0b54-421a-8339-5f7a58e56fb4">23,868</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS00LTEtMS05MjcxOA_e00e68ea-ab61-4949-ba29-503325c893d5">21,781</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS02LTEtMS05MjcxOA_0ddf36b0-8720-4d34-8fc5-69ee8f6b376c">21,591</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi0yLTEtMS05MjcxOA_5d1e6492-4771-42a1-9128-3d41573ec206">3.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi00LTEtMS05MjcxOA_cd3d4b9f-aa86-44a8-bb3c-de0710c17c33">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi02LTEtMS05MjcxOA_464b637a-e6a0-4411-bc55-3f547694560b">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy0yLTEtMS05MjcxOA_2f5f1b43-c2cd-4fab-962d-02d40d37b308">3.11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy00LTEtMS05MjcxOA_61c360bb-4996-477a-9564-19850936d306">4.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy02LTEtMS05MjcxOA_437014e7-df90-4ae4-aed1-f0da905064e7">4.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" xsi:nil="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NTA_a6dcdbf8-7d5d-4ab5-b770-60a5a078ff6a" escape="true"></ix:nonNumeric><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Nzc_9576bedb-8a91-4bb8-a32e-b063a32731d4" continuedAt="i5c67b0aca3ae434b9ffd44a20720b69b" escape="true">Recently Issued Accounting Standards </ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd3d07512c3e46c8957d3e298046d967"><ix:continuation id="i5c67b0aca3ae434b9ffd44a20720b69b">In March 2020, the Financial Accounting Standards Board ("FASB")  issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU were effective for all entities as of March 12, 2020 through December 31, 2022. ASU No. 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap references LIBOR, these swaps were amended in early 2022 to transition to an alternative reference rate (see Note 7: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that allowed us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and allowed us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging or the optional expedient under this ASU is elected. The impact of these ASU's on our contracts has not been and is not expected to be material.</ix:continuation></ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzQyNg_560adf45-55ba-467c-83ed-01c3215f9008" continuedAt="i2fa6ecd1b581452ba2ab76c946da5c76" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2fa6ecd1b581452ba2ab76c946da5c76" continuedAt="ie771e6eafe2240ed9468ac5f6a99f91b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired <ix:nonFraction unitRef="number" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNzk_eeb6dec8-83ee-429c-aad6-3474b9d999bb">100</ix:nonFraction>% of the equity interests in Smiths Medical, the holding company of Smiths Group plc's global medical device business, from Smiths Group International Holdings Limited (&#8220;Smiths&#8221;). The acquisition of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ie771e6eafe2240ed9468ac5f6a99f91b" continuedAt="i39586d0c6f22497d870c430d38e5a7bb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smiths Medical aligns with our strategic growth plans, enabling us to broaden our product offerings to include syringe and ambulatory infusion devices, vascular access, and vital care products and to strengthen and expand our global market reach.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash consideration for the acquisition was $<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="icui:BusinessCombinationConsiderationTransferredCash" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTQy_470321a0-7b4c-449a-a4e2-12ba50fecb74">1.9</ix:nonFraction> billion, which was financed with existing cash balances and proceeds from the credit agreement entered into on January 6, 2022 (see Note 11: Long-Term Debt). We also issued share consideration to Smiths of <ix:nonFraction unitRef="shares" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5Mjkz_12715cba-4e51-4441-a253-117eb5a10fcd">2.5</ix:nonFraction>&#160;million shares of our common stock. The fair value of the common shares issued to Smiths was determined based on the opening market price of our common stock on the acquisition date. Smiths may be entitled to an additional $<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzA2_76a5f4d6-7d85-410b-9d23-0649857d44f0">100.0</ix:nonFraction>&#160;million in cash consideration contingent on our common stock achieving certain price targets for certain periods after closing in accordance with the terms of the Share Sale and Purchase Agreement (the "Purchase Agreement"). In the event that (a) on or prior to the third anniversary of closing the 30-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="INF" name="icui:MinimumStockPriceTargetForEarnOutPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzIy_86f15aaf-4be1-45c6-a6ec-92df38334d52">300.00</ix:nonFraction> per share or (b) on or prior to the fourth anniversary of closing the 45-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="INF" name="icui:MinimumStockPriceTargetForEarnOutPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzMx_b04f9442-2a46-4b69-8eca-6dd27883ac0c">300.00</ix:nonFraction> per share (each a "Price Target"), and provided Smiths beneficially owns at least <ix:nonFraction unitRef="number" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="1" name="icui:RequiredShareHoldingOfStockIssuedAtAcquisition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzU2_f5d3eb35-bda6-4486-8faf-be41e359c18b">50.0</ix:nonFraction>% of the shares of common stock issued at closing at the time the Price Target is achieved, then Smiths will be entitled to receive the additional $<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzQw_0bd34393-5b66-44ba-af9f-483686fe44c8">100.0</ix:nonFraction>&#160;million in cash consideration. The fair value of the contingent consideration was determined using an option pricing model, specifically the Monte Carlo Simulation. In the analysis, the determinants of payout are simulated in a risk neutral framework over a large number of simulation paths. The fair value of the contingent consideration is then calculated as the average present value across all simulated paths. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smiths became a related party to us when we issued <ix:nonFraction unitRef="shares" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1ODgx_13b60b7d-60e0-4033-a645-f4e707e36980">2.5</ix:nonFraction>&#160;million shares of our common stock as partial consideration for the acquisition of Smiths Medical. Additionally, we entered in to a transition services agreement ("TSA") with certain members of Smiths Group, plc. The TSA includes certain information technology, human resource and tax support services for an initial term of twelve months with the option to extend up to 24 months. During 2022, we expensed $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1ODk0_dc63351f-9d6d-4dc4-bfb4-d7ace6e98f9a">37.6</ix:nonFraction>&#160;million for services provided under the TSA. As of December 31, 2022, we have $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" sign="-" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1OTA5_35cc817f-83e3-45b9-8505-694f49527bce">5.1</ix:nonFraction>&#160;million in open payables related to the services received under the TSA.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5Mjkx_79ac9928-5094-4282-954d-9ae893424400" continuedAt="i55f008f9034443f792599703e143b729" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Final Price Allocation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i39586d0c6f22497d870c430d38e5a7bb" continuedAt="if7c4f1a597b04dc69a94f6c14e63a4a0"><ix:continuation id="i55f008f9034443f792599703e143b729"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for acquired assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMC0yLTEtMS05MjcxOA_c2967db1-c4e1-44cc-9e91-fdba602a9f21">1,922,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration payable to Smiths</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMS0yLTEtMS05MjcxOA_688c7c31-66ef-4310-9b2e-969dd908e6d0">53,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ICU Medical, Inc. common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNC0yLTEtMS05NjI4Mg_0e1d082e-1151-40c8-b1bc-66db0690adf7">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price per share (ICU's opening market price on the acquisition date)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNS0yLTEtMS05NjI4Mg_f1c7f680-d09d-4222-b8e2-6403e897f9f1">230.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ICU shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNi0yLTEtMS05NjI4Mg_17c905fe-c02b-4e6d-bb01-b95cab77a777">575,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMi0yLTEtMS05MjcxOA_76578396-f627-411f-89b1-847340d4566f">2,552,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTAtMi0xLTEtOTYyODU_03194f04-ee57-42ce-887a-aa5bdfda74b9">78,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationAcquiredReceivablesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNS0yLTEtMS05MjcxOA_a086fcb1-1f5d-4ec2-aeeb-a4c3dec6b938">106,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNi0yLTEtMS05MjcxOA_723b5f16-ac63-4eb0-a8e7-92316438a219">228,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNy0yLTEtMS05MjcxOA_094a1904-d694-4e70-8d33-c1dab91e7d96">53,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfOC0yLTEtMS05MjcxOA_0052a46e-70d7-4b1e-9fce-52ad6ff423cc">206,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTUtMi0xLTEtOTYyODU_3d93c503-78fe-41fb-be84-37f6f6f2a37c">55,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfOS0yLTEtMS05MjcxOA_f9872ce1-f01a-45f1-8575-8c461f9a59f4">945,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTgtMi0xLTEtOTYyODU_aaedb236-953e-4d3c-8567-385594b412c9">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTAtMi0xLTEtOTI3MTg_9f91bce5-de79-467a-a097-97de3d003fb7">105,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTEtMi0xLTEtOTI3MTg_59456a2e-833d-4c01-9c6b-81a2cf9c2cbb">173,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="icui:BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMjEtMi0xLTEtOTYyODU_00c83115-2998-45a4-87ae-2578c91cca55">40,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMjItMi0xLTEtOTYyODU_fddaf415-28d9-47e6-a79f-1f8d768a7575">85,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTgtMi0xLTEtOTUwNzA_84b56d8f-7da3-41ca-aac3-1614f4e7286b">187,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTItMi0xLTEtOTI3MTg_67467447-e248-4b9f-9ade-8f884f4d00b6">1,082,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill - not tax deductible</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTMtMi0xLTEtOTI3MTg_f9feecfb-31fc-4d18-8e9f-f02ef6746244">1,469,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTUtMi0xLTEtOTI3MTg_2b8e5006-36fb-480b-be13-a27524e2e41c">2,552,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets included $<ix:nonFraction unitRef="usd" contextRef="icbf4360bc208465f843ef61d1768b5e8_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM1MA_562b05de-5e7a-4056-a288-c6dd8d2bbee9">510.0</ix:nonFraction> million of customer relationships, $<ix:nonFraction unitRef="usd" contextRef="i84420d968625493db489841b6ba9cd22_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM3OA_b982391f-5088-4ae3-bde9-c29360f78021">400.0</ix:nonFraction> million of developed technology, $<ix:nonFraction unitRef="usd" contextRef="i1129dd1b04d7446c9d3d06c36614788e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4MTAx_31e21fe0-7b5f-45ee-a1cc-77e563b3a83d">30.0</ix:nonFraction>&#160;million of internally developed software, and $<ix:nonFraction unitRef="usd" contextRef="ia3856be9b89747b993110c792a39aabb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM5OQ_8d883ac0-7c88-45bf-9761-3350e60e130c">5.0</ix:nonFraction> million of trade mark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately <ix:nonNumeric contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTUzOQ_f0a10630-2fca-4782-889c-36aa1d30b675">nine years</ix:nonNumeric>, and, for each identifiable intangible asset is estimated as follows: <ix:nonNumeric contextRef="ic98b9ae2742141cea974ed1a1041b446_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTU2OA_d8c043a1-7ba6-4bc6-af87-0cc9c26faedb">eight years</ix:nonNumeric> for customer relationships, <ix:nonNumeric contextRef="i369fa34137ce41348503313048b70075_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTU5MA_cfa2ec71-7caf-4303-b6bc-086ff9164f30">ten years</ix:nonNumeric> for developed technology, <ix:nonNumeric contextRef="i05325f7dac154ac19707c10ed7936bd5_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4ODI1_6ddf1c49-949e-4880-b786-794208adab4d">five years</ix:nonNumeric> for internally developed software, and <ix:nonNumeric contextRef="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4ODI2_137b894d-9a4a-41c0-bdd1-404526cfd569">six months</ix:nonNumeric> for the trade mark.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identifiable intangible assets and other long-lived assets acquired have been valued utilizing Level 3 inputs as defined in Note 8: Fair Value Measurements. The fair value of identifiable intangible assets were generally developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and/or estimated useful lives. Certain other intangible assets were valued using a cost to replace method, estimating the labor and non-labor costs required to replace the asset under the premise that it was not part of the transaction. Property, plant and equipment was valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence which we estimate to approximate replacement cost, the work in process inventory was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="if7c4f1a597b04dc69a94f6c14e63a4a0"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Information</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smiths Medical is included in our consolidated results beginning on January 7, 2022. Total revenues and net loss attributable to Smiths Medical for the period from January 7, 2022 to December 31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzAw_53235ec6-b71c-40f0-bd30-8f3f0311933f">950.7</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzE0_72e9aac0-59e4-4cd1-b1e6-d0ae990bef9e">74.3</ix:nonFraction>)&#160;million, respectively. The net loss figure is an estimate as the results by company are less identifiable due to integration. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyNDEx_86aba4fb-8600-4c0f-9da9-291709de0e74" continuedAt="i3fee78a5cfec4e47a4995949ef22876b" escape="true">The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. </ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:continuation id="i3fee78a5cfec4e47a4995949ef22876b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Twelve months ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMi0xLTEtMS05NjQwMA_52d153f1-5280-453c-b381-846d132d29cb">2,300,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMi0zLTEtMS05NjQwMg_e81e3330-16be-414d-a95d-89e572a8e601">2,509,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMy0xLTEtMS05NjQwMA_fef4039f-c319-4514-8a2d-5b5df8476b25">70,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMy0zLTEtMS05NjQwMg_baee43c2-786b-445a-94ce-15ee7f2eb618">37,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results presented above include the impact of the following adjustments: incremental amortization expense on intangible assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ProFormaAdjustmentAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzI4_ef8bb7c1-3c4a-40b8-bf82-42a519b8d0b0">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:ProFormaAdjustmentAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1NzIx_95800ff0-588e-491f-803c-d7b7a75f52d4">24.7</ix:nonFraction>&#160;million for the twelve months ended December 31, 2022, and 2021, respectively, incremental interest expense, including amortization of debt discount and debt issuance costs, on the Credit Facilities of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ProFormaAdjustmentFinanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzQy_e948eaba-4360-4efe-9f96-c2711d3248c2">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:ProFormaAdjustmentFinanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1NzM2_2cd01b3c-c834-4207-aff6-79b6ffc38ea6">73.5</ix:nonFraction>&#160;million for the twelve months ended December 31, 2022, and 2021, respectively and a $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ProFormaAdjustmentInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzU2_c8b8433f-d4e3-4acf-8615-29ebb562bd1b">27.4</ix:nonFraction>&#160;million expense related to the increase in fair value of inventory for the twelve months ended December 31, 2021. The unaudited pro forma results include IFRS to U.S. GAAP adjustments for Smiths Medical historical results and adjustments for accounting policy alignment, which were materially similar to the Company. Any differences in accounting policies were adjusted to reflect the accounting policies of the Company in the unaudited pro forma results presented. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier and paid an initial gross cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMjc4Ng_4a7613fd-ecfe-4535-92e6-8191f9b8bcbb">15.4</ix:nonFraction>&#160;million. In addition to the initial cash consideration, total consideration for the acquisition includes an additional holdback of $<ix:nonFraction unitRef="usd" contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231" decimals="-5" name="icui:BusinessCombinationConsiderationCashHoldback" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzAyNA_34733cac-f564-4469-b33b-6f0a7109a4cf">0.5</ix:nonFraction>&#160;million, to be paid two years from the completion date of the acquisition, and also a potential earn-out payment of up to $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzE0MQ_010be1dc-f331-4319-ace0-3c2fef18c55a">2.5</ix:nonFraction>&#160;million, consisting of (i) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231" decimals="-6" name="icui:ShortTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzE4MQ_0694232b-a581-4bee-9762-48ccc05106c1">1.0</ix:nonFraction>&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231" decimals="-3" name="icui:LongTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzMyOA_5536ea34-efe8-4114-96db-3830b5636bed">1.5</ix:nonFraction>&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. The contingent earn-out based on the achievement of certain revenue targets obtained for the annual period ending December 31, 2022 was forfeited at December 31, 2022 as the minimum threshold for earning the earn-out was not met.</span></div></ix:continuation><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjk4Ng_63341a27-644f-4bef-b02d-3e0e13db6aba" continuedAt="i642928aac66b4a0c9e66956821441c2d" escape="true">RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i642928aac66b4a0c9e66956821441c2d" continuedAt="i1622fec7094243299f5bc6f91c0e1178"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, strategic transaction and integration expenses were $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTM1_dd0817cc-6986-4f13-b7c6-1f8491ff0141">71.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTQw_5264755c-a7b4-47d8-95e3-7bcfe0db351e">18.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="icui:Restructuringandstrategictransactionexpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTQ4_19373457-dcf8-4812-a227-956b0168376c">28.4</ix:nonFraction> million in 2022, 2021 and 2020, respectively.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges were $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjI4_0df602ba-02e6-4fe5-8688-8c374bf9b46e">9.7</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjMy_a16283c9-7f42-43d9-8a98-cd7e88e2b76f">1.8</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjM5_608492ad-8dd5-4c65-bb4f-20e22286ebfb">7.9</ix:nonFraction> million in 2022, 2021 and 2020, respectively, and are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we incurred restructuring charges primarily related to severance in connection with the January 6, 2022 acquisition of Smiths Medical, see Note 2: Acquisitions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we adjusted certain facility restructuring liabilities by $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-6" name="icui:RestructuringAdjustmentsSeveranceAndFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfNDc5_f83645c7-fdaa-46b6-a458-549635565ded">2.0</ix:nonFraction>&#160;million, shown in the table below under "Other adjustments," to reflect actual amounts owed which resulted in net restructuring credits of $(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfNjEz_1f838971-b720-46fc-9e4b-4b363ebb1d10">1.8</ix:nonFraction>)&#160;million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, restructuring charges were primarily related to severance and costs related to office and other facility closures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i1622fec7094243299f5bc6f91c0e1178" continuedAt="id90a851245c74fcf82daa0e6ca698c9f"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjk3OQ_e308c383-a69a-41f6-b4a3-971351acaa48" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Severance Pay and Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retention and Facility Closure Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c99d7dca834fc9b8ba44f702ce5c97_I20201231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS0yLTEtMS05MjcxOA_432a6179-0f88-4de2-ad1d-d7c700dbcac1">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71cb42b4cdb34217bf31e9da4cf6cfaa_I20201231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS02LTEtMS05MjcxOA_387c27b7-eea8-4f8f-a29c-02233da01559">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS04LTEtMS05MjcxOA_e27439cc-886d-4aa5-96a4-503f64d9ae50">3,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi0yLTEtMS05MjcxOA_0cefad4f-9412-4412-9efe-b124b78b4fb1">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi02LTEtMS05MjcxOA_56fc45c2-fd6c-46f6-aad5-da24aafb20d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi04LTEtMS05MjcxOA_cc7a1911-4671-44cf-a3d4-5149936d2f6f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy0yLTEtMS05MjcxOA_da4f7d50-3b6d-4eeb-918d-ec68e5b84532">969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy02LTEtMS05MjcxOA_d35e364b-6093-4547-b761-c23f89732747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy04LTEtMS05MjcxOA_a75be518-974a-403c-9ca9-aef9c38b49c0">969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC0yLTEtMS05MjcxOA_0afb7275-0273-4919-b5d9-52768159b4bb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC02LTEtMS05MjcxOA_601af04a-d58e-44e8-a0b7-fb6d22322ace">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC04LTEtMS05MjcxOA_69933e06-99a7-4a3f-a45a-de4d70af0f6c">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS0yLTEtMS05OTYwMA_f4dbfee9-28ac-4ca9-af36-b67fa623e6fe">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS02LTEtMS05OTYyMQ_52a63989-3b1a-49e7-ac54-0d99e03f1e39">1,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS03LTEtMS0xMDkyODI_0829365d-7b5b-4e11-befc-834597530af4">1,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4925743ff242b0b2ee65ecd693dd3f_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS0yLTEtMS05MjcxOA_b4f2f8e4-d8a5-4687-b98d-345279ebb8c7">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92c10763b02e45ea9ffe7f02507e2e8c_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS02LTEtMS05MjcxOA_7e6b4e48-b2f2-4e88-afa3-fa992b6916c3">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS04LTEtMS05MjcxOA_609254a7-11d9-4eee-b53e-f5c8d6d07d7a">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55936ad0651e4e25a3f22368ebb27543_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy0yLTEtMS0xMDkyODg_1212a7d2-5665-4e27-ae67-3db3e776724b">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404ace05705b44778677860b518b5b99_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy01LTEtMS0xMDkyOTA_c4b12b5e-89c9-421e-8516-3448201d4cf4">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy03LTEtMS0xMDkyOTI_f2452ca7-668d-4178-8224-50a29c8c943b">7,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi0yLTEtMS05MjcxOA_a492d5ac-2d09-4d46-8078-56bec5422a3c">9,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi02LTEtMS05MjcxOA_7f7b9adf-c01c-456c-ab9e-5d68bca62960">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi04LTEtMS05MjcxOA_02b93277-e0af-4ba2-a949-9314920d4038">9,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy0yLTEtMS05MjcxOA_873b107a-3b6e-4070-a416-e7038a91e0d3">11,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231" decimals="INF" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy02LTEtMS05MjcxOA_e9ac8564-6ee6-4e44-a374-2f52e3aa5721">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy04LTEtMS05MjcxOA_229aca5c-494d-44d6-881a-4a375b6fd136">11,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC0yLTEtMS05MjcxOA_9e66f78d-fef1-4bae-b06e-e6bce64db774">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC02LTEtMS05MjcxOA_68795c52-033d-465d-8b09-efaf1e67203f">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC04LTEtMS05MjcxOA_3989c974-3507-440a-b49e-bb3ec01a74a1">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS0yLTEtMS05MjcxOA_48e0eac7-6d83-4ae5-b751-7abf99f8add4">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS02LTEtMS05MjcxOA_0f756256-44f2-4e87-acff-26e0a7c48b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS04LTEtMS05MjcxOA_ed43a592-fa8d-428e-ba53-c5983f52f106">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55936ad0651e4e25a3f22368ebb27543_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtMi0xLTEtOTI3MTg_f141babf-5240-40c3-b901-4abd81961fd8">4,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404ace05705b44778677860b518b5b99_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtNi0xLTEtOTI3MTg_b6aa3a15-54cb-490f-9b8f-a930045aaefa">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtOC0xLTEtOTI3MTg_f291549e-1de4-4dbf-b409-3df726fcaf8e">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Transaction and Integration Expenses</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id90a851245c74fcf82daa0e6ca698c9f">We incurred $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="icui:StrategicTransactionandIntegration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgxMA_b2d59d89-d010-4088-80b7-2cf1410dcf9f">61.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="icui:StrategicTransactionandIntegration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgxNA_8b179daf-4f8c-4e88-b028-fb871d1cacb1">19.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="icui:StrategicTransactionandIntegration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgyMQ_4dc2a204-89b3-479a-89be-eefbd7517800">20.5</ix:nonFraction> million in strategic transaction and integration expenses in 2022, 2021 and 2020, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2022 were primarily related to transaction and integration expenses associated with our acquisition of Smiths Medical on January 6, 2022 (see Note 2: Acquisitions) which primarily included legal expenses, bank fees, employee costs and a United Kingdom stamp tax. The strategic transaction and integration expenses during 2021 were related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into a definitive agreement to acquire Smiths Medical. The integration expenses during 2020 were related to the integration of HIS and included expenses for the migration of IT systems at our Austin facility.</ix:continuation> </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4:  <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTI5NA_90c0746a-951d-4020-a2e9-03446934b988" continuedAt="i107e43a738f54219b5b28fb69c2f6975" escape="true">REVENUE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i107e43a738f54219b5b28fb69c2f6975" continuedAt="i5c42cdd03bf74398b19058f3caf03cec"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisition of Smiths Medical our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and  renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to both our distribution and end customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5c42cdd03bf74398b19058f3caf03cec" continuedAt="i5d195a2f43424289b5f672c125f20da4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts in order to determine the transaction price, we use information available at the time, including our historical experience.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Performance Obligations</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into arrangements which include multiple performance obligations, (see Note 1: Basis of Presentation and Summary of Significant Accounting Policies). </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant judgments related to these arrangements include: </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying the various performance obligations of these arrangements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue disaggregated</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTI5Nw_09cb95bb-168e-4156-8f8f-9788d3120c6d" continuedAt="ia18efaa7be2f448ebf638e695949546d" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product line</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Consumables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0xLTEtMS05MjcxOA_8b2359fb-2b8b-494e-bbed-92ff7a3cf310">566,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0zLTEtMS05MjcxOA_09843070-cd39-4a2b-9c6c-6d56f8db74f4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy01LTEtMS05MjcxOA_123c814f-0a7f-47fe-9458-582dd6258060">555,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy03LTEtMS05MjcxOA_7f9e4032-0795-4a55-98dc-f07ccfe6afce">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy05LTEtMS05MjcxOA_5b47a815-19a6-449b-8fb0-796ca9cf22d6">473,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0xMS0xLTEtOTI3MTg_01a86b8f-b4a7-4a5f-a9c5-cc4831a58d66">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0xLTEtMS05MjcxOA_f537f2c1-f4e2-4fe0-a98c-380a22e760ef">351,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0zLTEtMS05MjcxOA_7ec0a5d1-0bdb-47dd-ba05-e1951bc92863">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC01LTEtMS05MjcxOA_6afc87e5-a86f-40e5-a4d2-c0173c125768">352,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC03LTEtMS05MjcxOA_43864408-80d4-4658-8ed1-909cfd771e6f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC05LTEtMS05MjcxOA_c6d5e84c-e4c4-4001-88b8-d6d6fa6c6105">359,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0xMS0xLTEtOTI3MTg_8ca25d8f-dc61-44db-aec3-0e0f94b0de4a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV Solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c134c659424d68b063d67180a61ce0_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0xLTEtMS05MjcxOA_f4310667-2d03-4eb1-9ca3-9543dee0404e">363,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7c134c659424d68b063d67180a61ce0_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0zLTEtMS05MjcxOA_39f0a0ee-0e7e-4ca9-bdf6-87a6aab83d7b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS01LTEtMS05MjcxOA_167d1577-972b-4e95-977f-e735b44355ab">359,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS03LTEtMS05MjcxOA_3712d31e-ae09-4519-9976-2beb2a94ada6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS05LTEtMS05MjcxOA_aeccf982-a1b8-4e71-9358-f722e47f33c6">388,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0xMS0xLTEtOTI3MTg_384661ec-d1d5-44a8-8de7-db8ab29b4d2e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0xLTEtMS05MjcxOA_efd52dcf-1b84-4a85-bbf5-87f5a508dd99">47,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0zLTEtMS05MjcxOA_ec07693c-82dd-427f-bb1f-0c97d8dde3cd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a974801206342f69077c517deb2da0b_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi01LTEtMS05MjcxOA_2be68399-f5aa-490c-a748-ae1657127bec">49,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a974801206342f69077c517deb2da0b_D20210101-20211231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi03LTEtMS05MjcxOA_3246f1d7-bb5a-4715-8f46-1e50b38836a2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi05LTEtMS05MjcxOA_b65f1891-c54f-452d-9e27-053fde960c15">48,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0xMS0xLTEtOTI3MTg_eb8b81a0-84bc-411a-bc03-225f6fe7e57f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy0xLTEtMS0xMDkyOTQ_920d2e19-cdd8-415a-8386-5cee61bcfa3a">340,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy0zLTEtMS0xMDkzMDE_cf4f14d5-ef26-4228-911f-8b8e2f75b4ca">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31b13090f3d4d6896d08faf55e51eed_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy01LTEtMS0xMDkyOTY_9879c45e-9470-4370-afc9-e9d9bec308b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af9a202b4c453dbe1982d3176037d3_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy05LTEtMS0xMDkyOTk_132fedba-659d-47b2-b4c4-a6e3eba8a1d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Access-Smiths Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xLTEtMS0xMDkyOTQ_f2a1766d-e50a-4dfc-b187-8c2e54bb6231">326,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0zLTEtMS0xMDkzMDE_62686619-588e-44bd-876c-a850ddd82252">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3486eaebd0f44d4582e0714314d501cb_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC01LTEtMS0xMDkyOTY_bcebf7e5-4868-4bb4-b103-fc17c0dc19c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic383a5944210457b97aab0db2bac248d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC05LTEtMS0xMDkyOTk_5945009f-9559-44f0-95e2-6a27d836db73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Care-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS0xLTEtMS0xMDkyOTQ_00d1bc99-eaff-43cd-86ba-52f7626ea879">284,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS0zLTEtMS0xMDkzMDE_14a01f28-4f36-4cb5-aa89-34d10a02cdf9">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75defc870864b6e98d462140afc25c7_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS01LTEtMS0xMDkyOTY_da427970-de32-4ed9-863f-bb1b496553d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95a1fa30baf4c46a60229408037bef6_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS05LTEtMS0xMDkyOTk_7a0b29f6-5c8a-4d1b-a6d5-e313ffb4f2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xLTEtMS05MjcxOA_34f18f0f-1f31-45dc-8437-5078b8302810">2,279,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0zLTEtMS05MjcxOA_5c1f1492-2c06-40ec-8a75-93719c31bfc7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC01LTEtMS05MjcxOA_21f58e80-d4ad-45b7-a157-9ccae6ab3554">1,316,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC03LTEtMS05MjcxOA_23364eab-3266-4991-a8cd-3e0e1fa60d09">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC05LTEtMS05MjcxOA_ec01642c-a320-4156-b8ab-e884fb6eba83">1,271,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="2" name="icui:Percentageofrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xMS0xLTEtOTI3MTg_879364c8-2b69-41b7-99a5-6649e6a9a4eb">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by geography (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5d195a2f43424289b5f672c125f20da4" continuedAt="i23ea15c45705459b86c80ffb6d292522"><ix:continuation id="ia18efaa7be2f448ebf638e695949546d"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geography</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi0xLTEtMS05MjcxOA_40bf1d13-57fb-4aed-b83f-46cf9fe2c11e">1,460,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi0zLTEtMS05MjcxOA_5edc4edd-8d88-4415-866a-55b4225d0e18">941,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi01LTEtMS05MjcxOA_ee713514-c8aa-49ea-81d9-9118e399a899">910,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, the Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1baa88a6474f1ca1bde91733d99703_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0xLTEtMS0xMTEyNjY_cfd4d3db-d334-43ca-b1ab-6b80e87f9916">367,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3ea0f082c144ce87ee7b48799015d0_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0zLTEtMS0xMTEyNjY_b079d59a-16e5-457e-8bef-eeee7454f400">147,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b1c128a1684402a9045faf165e1fc4_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy01LTEtMS0xMTEyNjY_c06db375-161d-4882-8bde-b76e67816b6b">132,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdf4b4d10d049fc8afa1abd2cc0db5c_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC0xLTEtMS0xMTEyNjY_9fe7e6db-c8a4-47b9-8118-3cf20339e7a5">257,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002db38129f24286874e3dd53ccdaf95_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC0zLTEtMS0xMTEyNjY_7630ce88-77a2-4407-a53f-ac2407283c64">85,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8c28deaeb448d887fa9af7b3d8346a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC01LTEtMS0xMTEyNjY_fa2e56c4-b89d-4871-8182-c001cbc0dbaa">79,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f21e80f577f43c19fd1aa42008e7706_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0xLTEtMS0xMDkzMDQ_b49e4c07-17b3-4abd-af78-19ef71f14983">195,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e71756005b40d2933a4ea6f87d56f1_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0zLTEtMS0xMDkzMDg_07768186-aa6c-4970-9f93-9b4bb1480b11">141,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df4b017e9b041fa969010720463d6c6_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy01LTEtMS0xMDkzMTA_2e2b763d-ec35-4fff-a0fd-e3cf9b93dd3a">148,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi0xLTEtMS05MjcxOA_ed42a8e1-d17a-4dd4-b5ed-f40334c9e7a4">2,279,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi0zLTEtMS05MjcxOA_245d1fb2-6d84-4ba0-bd69-812c2b1a14dc">1,316,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi01LTEtMS05MjcxOA_41c04eae-13b8-4d19-bc1d-f70494836bcc">1,271,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic sales accounted for <ix:nonFraction unitRef="number" contextRef="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ3Ng_216f977a-5ed8-4cf5-b21e-2130c16a8383">64</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ4MA_f0edf14b-0560-49dc-acc7-640b47a945cc">72</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ4Nw_20d32820-708f-402b-b2a5-398c47d407eb">72</ix:nonFraction>% of total revenue in 2022, 2021 and 2020, respectively.  International sales accounted for <ix:nonFraction unitRef="number" contextRef="if45f71d7222548f6aa04eb33ce7241ca_D20220101-20221231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU3NA_501bfaa8-ed19-4705-b542-587cb526b828">36</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i5482a1d0e20f424fbf824e580d6a9199_D20210101-20211231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU3OA_0d90d603-66bb-4740-b1f3-49b729a1d873">28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie96a185ecb1c4a958fca6ce4a87a4b19_D20200101-20201231" decimals="2" name="icui:Percentoftotalrevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU4NQ_7080c441-17ca-47b3-9989-ef086aa1a625">28</ix:nonFraction>% of total revenue in 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract balances</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTMwMA_ff85b3fd-c991-4c16-8b2a-6fa7285bae51" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMS0xLTEtMS05MjcxOA_82b49d60-41cb-447e-b6e8-c5239ccce9c3">6,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMi0xLTEtMS05MjcxOA_6bd17bf9-a1e7-4c60-afb0-c36131d486d7">10,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMy0xLTEtMS05MjcxOA_85fe9a46-74f5-4b0d-b435-9b2f39cacb43">13,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNC0xLTEtMS05MjcxOA_c6f84935-736e-4604-816f-a19d8809d3fb">7,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNS0xLTEtMS05MjcxOA_25a2523d-c5cf-4846-ae6f-e6a820b9ab6a">4,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNi0xLTEtMS05MjcxOA_7089a22f-fb2a-4967-a1f1-cc312821fb9b">7,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of acquired deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNy0xLTEtMS0xMDkzMjI_ad8c0d39-1ed4-497c-ba3c-ab9074a8876f">51,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNy0xLTEtMS05MjcxOA_c01e165e-2f62-4384-b8b8-2ea34ff5e63c">32,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfOC0xLTEtMS05MjcxOA_bef85d58-e5d6-4b1e-9e92-975464e61eab">20,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfOS0xLTEtMS05MjcxOA_725f8272-68a8-4dfb-b62f-e45ae7ce2e22">16,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTAtMS0xLTEtOTI3MTg_9ee4dd5f-54c2-4e95-90fd-5945e7ccbb80">17,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTItMS0xLTEtMTA5MzI0_612ff7c7-0eb2-479a-b7f0-fb1f45fcf441">3,729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTMtMS0xLTEtMTA5MzI0_b033994c-54c1-4513-be9b-b65e2d0bfe60">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231" decimals="-3" name="us-gaap:DeferredRevenueAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTQtMS0xLTEtMTA5MzI0_33f01673-ee9a-4ef8-8df0-a1641927043b">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTUtMS0xLTEtMTA5MzI0_f54a7983-2189-45c8-a326-6ec7ef564f76">5,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTEtMS0xLTEtOTI3MTg_da84ed0b-bfd9-4a7b-974f-4801d8947444">45,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTQ5NzU1ODIwMDky_beac7a34-30ce-4573-9626-d57d664cb62a">7.5</ix:nonFraction> million in revenue that was included in the opening contract balances as of December 31, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTQ5NzU1ODIwMDgz_063b4f37-e2ad-4e29-ac18-7b1e7e60eb33" continuedAt="i786eea21e3e9487e90e26cf325ee4675" escape="true">As of December 31, 2022, revenue from remaining performance obligations is as follows:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i23ea15c45705459b86c80ffb6d292522"><div><ix:continuation id="i786eea21e3e9487e90e26cf325ee4675"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognition Timing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&lt;12 Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&gt; 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34be06a38704454ba49d54c4642a8be6_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMi0xLTEtMS0xMDkzMjY_d48af24a-e0bb-48ec-a2a4-876163ae74d2">15,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i801bb622fa854aa8aa887087ba287be2_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMi0zLTEtMS0xMDkzMjk_dc7d2309-0248-42b1-ae01-e95bb7e268e9">982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad7155363879401cb075f883b3c05618_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMy0xLTEtMS0xMDkzMjY_15dfd342-048d-4ec1-8c3f-9bedeaf8f9f9">8,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib153ddca67ce46f9a87db324f5e82b2c_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMy0zLTEtMS0xMDkzMjk_ae3e2ab9-31ab-41fe-94df-9cb2f6a6c249">1,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb08893e609946fb8063faaad20c4476_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNC0xLTEtMS0xMDkzMjY_69808c86-84cd-4f13-ac8a-b908bd394449">1,422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8688bac62fd54e49817ebdf4ef330a22_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNC0zLTEtMS0xMDkzMjk_c297fcef-2649-4df3-8500-fd745d4ea0ad">12,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec83df23cc984ae1bb81bac0c2d32d43_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNS0xLTEtMS0xMDkzMjY_12b2782e-8c1c-420a-98df-dddd58ef080e">4,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if24294e168244b4d800b76ebe275bb94_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNS0zLTEtMS0xMDkzMjk_95818919-1397-405a-bb06-3135c92043a0">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7b424d053745b89be43013214212ba_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNi0xLTEtMS0xMDkzMjY_483ead92-16f2-414b-885f-8230a97ea56f">29,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b46600611854ead8201632b540aa737_I20221231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNi0zLTEtMS0xMDkzMjk_f96401a4-51e4-4dc0-a9f5-0e201b6a811b">16,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Other deferred revenue includes pump development programs, purchased training and extended warranty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC Topic 606, we have elected to expense these costs as incurred as the period of benefit is less than one year.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical expedients and exemptions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the practical expedient applied to sales commissions, under ASC Topic 606, we elected to apply the practical expedient for shipping and handling costs incurred after the customer has obtained control of a good. We will continue to treat these costs as a fulfillment cost rather than as an additional promised service.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:LesseeOperatingAndFinanceLeaseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYyNg_99ee0064-4622-40bf-8282-9decacaf4b8d" continuedAt="if3f4740f95eb4a2583e06d2bf6053663" escape="true">LEASES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if3f4740f95eb4a2583e06d2bf6053663" continuedAt="ia957a341558e4f37961edc8c7ef6e6df"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our consolidated balance sheets. Our lease liabilities are included in accrued liabilities, and other long-term liabilities on our consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have stated lease payments, which may include fixed rental increases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases are for corporate, research and development and sales and support offices, distribution facilities, device service centers and certain equipment. Our leases have original lease terms of <ix:nonNumeric contextRef="ic71707c2dff14fa99b1f7a37aa00d176_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTM4OQ_14d4fbd9-d821-48a5-9f74-65af4ff7a841">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i455063291da94c4e933985b9ba288cce_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTM5NQ_fd4670c7-9b9b-4594-bc8a-4d40a29e9551">fifteen years</ix:nonNumeric>, some of which include options to extend the leases for up to an additional <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:Optiontoextendinyears" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTQ3NA_94ab1fa7-b5d7-40be-b0a9-66b641a7b11e">five years</ix:nonNumeric>. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYzNg_6eeb6bd9-302c-4fba-93af-a70095e65a3b" continuedAt="id531096a767e4f43a5ff0576903053f8" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease cost (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0xLTEtMS0xMDkzMzc_09800b6e-9b3d-4836-be0a-09fa8e653b5f">22,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0xLTEtMS05MjcxOA_576f1237-8795-4355-8116-4c9a2cba1b5b">11,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0zLTEtMS05MjcxOA_ce609de1-a1f7-4a03-8db4-bed8bc662d9a">11,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0xLTEtMS0xMDkzMzc_b339843f-4cc5-4105-afae-87de285babc5">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0xLTEtMS05MjcxOA_6bba6104-d891-499c-8106-40c14df0a5e4">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0zLTEtMS05MjcxOA_38ae292e-a737-4163-88a5-f77ff53541eb">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; reduction of ROU asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0xLTEtMS0xMDkzMzc_15386afe-754c-4807-9bc4-82eb1521f60f">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0xLTEtMS05MjcxOA_94a20431-6690-4a3d-809d-18aacb5d0865">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0zLTEtMS05MjcxOA_148d838b-ba6c-403e-a27a-762fb8082781">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0xLTEtMS0xMDkzMzc_867c14c6-5cb5-4ee3-b538-333ce19bf28f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0xLTEtMS05MjcxOA_5447459b-3cdc-4315-aa92-7177f2b0f939">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0zLTEtMS05MjcxOA_cd958856-2517-41df-be98-b3d307d8d5e6">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0xLTEtMS0xMDkzMzc_1f6cc0f0-121e-4aba-be5c-88d82a80b99b">22,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0xLTEtMS05MjcxOA_9920aed8-14bb-421b-bfc0-c2f513d9aeb0">12,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0zLTEtMS05MjcxOA_924484f0-5d8f-443c-94da-8b525c1f336e">12,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ia957a341558e4f37961edc8c7ef6e6df" continuedAt="i329239724398410da9c63541bf96133a"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id531096a767e4f43a5ff0576903053f8">Interest expense on our finance leases is included in interest expense, net in our consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our consolidated statements of operations.</ix:continuation></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:SupplementalCashFlowInformationLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYzOA_21863648-5593-4d45-9cbe-425def39c408" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental cash flow information related to our leases (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:58.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0xLTEtMS0xMDkzMzk_f57e10be-0207-44de-9066-dddb6e1f91ce">25,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0xLTEtMS05MjcxOA_8000e286-58e6-412d-baf0-a97aa8b7db3d">11,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0zLTEtMS05MjcxOA_4c781b9c-3e54-4168-83c1-c7c640711317">10,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0xLTEtMS0xMDkzMzk_4a84af21-7854-4bcf-ac26-f99b3f394e47">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0xLTEtMS05MjcxOA_7f8ef8a1-856e-427e-9f72-f8b4a72a7411">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0zLTEtMS05MjcxOA_9d2247fc-faad-46f6-9176-125979f231e1">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0xLTEtMS0xMDkzMzk_91cbc45a-2eeb-491e-b73c-07419ef4b598">5,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0xLTEtMS05MjcxOA_cfa8cfec-d2d1-4942-8dd8-0cc59fd81920">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0zLTEtMS05MjcxOA_efb14a55-5e04-4804-a553-0582d265183f">20,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0xLTEtMS0xMDkzMzk_058d1afd-c354-4ef3-82e6-bb24d48b6d5e">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0xLTEtMS05MjcxOA_6c0f95e8-2bda-41b9-89cd-4b219f65f399">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0zLTEtMS05MjcxOA_e21e4388-61a7-40a3-a18f-39109da68e03">3,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfNTQ5NzU1ODE2ODc1_331598f0-e6a2-4c51-a0d2-80f8bf3542a4">55.2</ix:nonFraction>&#160;million of operating right-of-use assets as part of the Smiths Medical acquisition, see Note 2: Acquisitions.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:SupplementalBalanceSheetInformationLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjY0NA_39a882f5-0e41-4ee9-90ad-721a39ee8b6b" continuedAt="i02e26af111e043aa9d1bc92805fbd0e3" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMy0xLTEtMS05MjcxOA_2f150bec-e81e-4ac3-b386-94d041e56d9d">74,864</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMy0zLTEtMS05MjcxOA_dbbf404a-489b-4961-afc9-634fd6f618f9">39,847</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNS0xLTEtMS05MjcxOA_0538bfa3-13ad-47ce-82f6-81b046e7ef5a">18,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNS0zLTEtMS05MjcxOA_304b20be-14df-40f7-a583-5818ce0e9049">9,009</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNi0xLTEtMS05MjcxOA_ba71e31c-2b37-4440-8337-1ea1bc09b955">60,916</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNi0zLTEtMS05MjcxOA_f5d0b5b0-c3a6-42d9-873a-ba84c0a67a7e">33,971</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNy0xLTEtMS05MjcxOA_4b1529b8-f7eb-479a-aca1-88765fee97bf">79,085</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNy0zLTEtMS05MjcxOA_b891ccd6-bf8c-478f-b874-4aceb414b8ec">42,980</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTAtMS0xLTEtOTI3MTg_1ed0ddd2-3823-4653-97a4-41307c66c50a">6.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTAtMy0xLTEtOTI3MTg_a619c96e-468a-40d5-bf55-c970ecc47b22">5.9</ix:nonNumeric> years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTMtMS0xLTEtOTI3MTg_218f44c5-4122-4c34-80f1-245b917a744a">4.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTMtMy0xLTEtOTI3MTg_94226def-ee83-4e44-af1c-9e9b247f7bd5">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i329239724398410da9c63541bf96133a"><div style="margin-top:5pt;text-align:center"><ix:continuation id="i02e26af111e043aa9d1bc92805fbd0e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMy0xLTEtMS05MjcxOA_6ea3bff6-466f-4891-ba06-f1a13bb36cd4">2,598</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMy0zLTEtMS05MjcxOA_0c8dc8d9-ea3e-4834-9da6-070050f83304">2,673</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNS0xLTEtMS05MjcxOA_fa262d5e-44ec-4ce3-9372-109d906a0b8d">816</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNS0zLTEtMS05MjcxOA_28633736-1981-49ca-b716-3ebabcd5e7d4">643</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNi0xLTEtMS05MjcxOA_987955b2-3038-46a5-9108-5c7e70b72abd">1,855</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNi0zLTEtMS05MjcxOA_9278883a-8f71-4f09-9756-78ae8368e5be">2,067</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNy0xLTEtMS05MjcxOA_55bb08a8-b1b1-47da-8303-cff15442e970">2,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNy0zLTEtMS05MjcxOA_b21618e0-3f33-4987-8210-021c0307814b">2,710</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTAtMS0xLTEtOTI3MTg_e5af185a-6dbf-4074-8b5e-62ff6938c8f1">4.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTAtMy0xLTEtOTI3MTg_daa45bdf-2857-4891-940e-f862e70d5b9b">5.6</ix:nonNumeric> years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTMtMS0xLTEtOTI3MTg_81c08c14-517c-47ee-88a1-9690ed3ec4e7">4.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTMtMy0xLTEtOTI3MTg_4ed2602b-d5e4-467e-8868-0c4b2d943962">4.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjY0NQ_7180dc93-bc83-453f-8a1c-87969b215907" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0xLTEtMS05MjcxOA_9719b647-92a7-444a-9275-4142eb42122c">21,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0zLTEtMS05MjcxOA_27c871d3-3968-4bc0-aaa1-bc5f1ca8b617"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0zLTEtMS05MjcxOA_46b83491-5ea5-468d-acc9-43ed482c2324">914</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMi0xLTEtMS05MjcxOA_08120c82-d3ef-4395-8996-af90af962ed8">17,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMi0zLTEtMS05MjcxOA_6d5990d3-e2e0-48b1-aa1f-dd19bc920874">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMy0xLTEtMS05MjcxOA_56d77ce5-39ae-42b4-b805-0d259f86df65">12,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMy0zLTEtMS05MjcxOA_d264202f-9bcb-42e1-b437-a0f4fbe8d278">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNC0xLTEtMS05MjcxOA_a3b231f9-a76d-4835-bb58-ec16884d0920">11,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNC0zLTEtMS05MjcxOA_9718475d-20c6-4df4-8fb3-d39add7e0955">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNS0xLTEtMS05MjcxOA_c1df0186-2f68-44c5-8fcb-16ac1a791139">7,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNS0zLTEtMS05MjcxOA_2b05c6dd-83c0-46b6-83ec-a219a5d676bb">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNi0xLTEtMS05MjcxOA_286778df-5c1a-454f-9c58-818e80595377">17,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNi0zLTEtMS05MjcxOA_7cad6b35-512c-4b4f-8160-19d61e3773e6">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNy0xLTEtMS05MjcxOA_a6cbad2c-92cf-4cc8-8765-09577bc226f8">88,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNy0zLTEtMS05MjcxOA_d7b5cd5a-95ff-4595-9908-9721aa569c49">2,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOC0xLTEtMS05MjcxOA_877716fd-0c29-4273-bdab-7c951c4a4c12">9,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOC0zLTEtMS05MjcxOA_bc3734e9-ad2e-4e30-af81-4b0dafabb537">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOS0xLTEtMS05MjcxOA_47c5702c-f120-46ef-a9c7-c943515aea5f">79,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOS0zLTEtMS05MjcxOA_6bb177d5-1445-4089-8d25-980a49fa55e0">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NjM_d718eacf-032d-4edc-8ced-38bf994f932c" continuedAt="ibdf90375eb30412cab07a44475d45cf2" escape="true">SHARE-BASED AWARDS</ix:nonNumeric></span></div><ix:continuation id="ibdf90375eb30412cab07a44475d45cf2" continuedAt="i86e1621d78644ffeb0031d5b570939ff"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a stock incentive plan for employees and directors and an employee stock purchase plan.&#160; Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur stock compensation expense for stock options, restricted stock units ("RSU"), performance restricted stock units ("PRSU") and in years prior to 2018 stock purchased under our employee stock purchase plan ("ESPP"), which was suspended in 2017. We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options and vesting of restricted stock units. We also have indirect tax benefits upon exercise of stock options and vesting of restricted stock units related to research and development tax credits which are recorded as a reduction of income tax expense.&#160; </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzY_85e41ca4-58ff-4e13-8b9f-029b59019b3e" continuedAt="i3dc8657ef90c41d2860ff2db72331c03" escape="true">The table below summarizes compensation costs and related tax benefits (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i86e1621d78644ffeb0031d5b570939ff" continuedAt="i83e402f4c7634be886104f695af5cbb0"><div style="margin-top:5pt"><ix:continuation id="i3dc8657ef90c41d2860ff2db72331c03"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi0yLTEtMS05MjcxOA_8275a05c-708b-4d12-b019-7a2ab894687c">36,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi00LTEtMS05MjcxOA_7be36594-267a-40c7-bac1-7367087e2759">27,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi02LTEtMS05MjcxOA_9a9647ea-dd81-4166-804b-656bee8ed15e">23,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy0yLTEtMS05MjcxOA_c993a5ba-b369-477e-b8a8-a70a4781c6eb">4,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy00LTEtMS05MjcxOA_78be0981-6fbe-42d3-9208-b385cac62419">6,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy02LTEtMS05MjcxOA_4077c261-7351-4f20-bc57-b17b0f169344">5,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:IndirectTaxBenefitFromStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC0yLTEtMS05MjcxOA_aa179d44-de9c-461a-a3dc-82ce8059dffc">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:IndirectTaxBenefitFromStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC00LTEtMS05MjcxOA_ad5137ea-bee7-4815-83c9-c92a79ac747a">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:IndirectTaxBenefitFromStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC02LTEtMS05MjcxOA_04c8ce4d-583a-4cc8-8a19-16195253007f">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfOTc3_e8d2902b-952f-461d-8b70-5ce4911f1404">43.0</ix:nonFraction> million of unamortized stock compensation cost which we will recognize as an expense over a weighted-average period of approximately <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTEwNQ_3d7a75c4-eb90-44b0-9872-1f01c6ace238">0.8</ix:nonNumeric> years. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Plans</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2011 Stock Incentive Plan ("2011 Plan") replaced our 2003 Stock Option Plan ("2003 Plan"). Our 2011 Plan initially had <ix:nonFraction unitRef="shares" contextRef="icfc6130bace04212a70134842313f556_I20111231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI2MQ_a84197ee-45d3-4fea-b4c2-c97148ff39d4">650,000</ix:nonFraction> shares available for issuance, plus the remaining available shares for grant from the 2003 Plan and any shares that were forfeited, terminated or expired that would have otherwise returned to the 2003 Plan. In 2012, 2014 and 2017, our stockholders approved amendments to the 2011 plan that increased the shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="if6c41509b0124224b8916fec64855b95_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTYwMQ_29e2b139-a523-4089-af70-38872d1a2ffc">3,275,000</ix:nonFraction>, bringing the initial shares available for issuance to <ix:nonFraction unitRef="shares" contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTY1OQ_e4f4844e-6f28-4987-9160-59ecaef56a91">3,925,000</ix:nonFraction>, plus the remaining <ix:nonFraction unitRef="shares" contextRef="if7f3edab321b4f47b9ab4112053d6a1d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTY4Mg_b4fe7645-5c56-4630-80d4-e77fbaf8412b">248,700</ix:nonFraction> shares that remained available for grant from the 2003 Plan. As of December&#160;31, 2022, the 2011 Plan has <ix:nonFraction unitRef="shares" contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTc3NA_46fa20f8-916f-4fc2-a832-3f847073e7cb">4,188,300</ix:nonFraction> shares of common stock reserved for issuance to employees, which includes <ix:nonFraction unitRef="shares" contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231" decimals="INF" name="icui:Sharestransferredfromsupersededplan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTg1MQ_4c9d67df-cf28-4186-9d70-dd08d63462dd">263,300</ix:nonFraction> shares that transferred from the 2003 Plan.&#160;Shares issued as options or stock appreciation rights ("SARs") are charged against the 2011 Plan's share reserve as one share for one share issued.  Shares subject to awards other than options and SARs are charged against the 2011 Plan's share reserve as 2.09 shares for 1 share issued. Options may be granted with exercise prices at no less than fair market value at date of grant. Options granted under the 2011 Plan may be "non-statutory stock options" which expire no more than ten years from date of grant or "incentive stock options" as defined in Section&#160;422 of the Internal Revenue Code of 1986, as amended.&#160; </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all options granted under 2011 Plan and 2003 Plan have been non-statutory stock options. The majority of the time-based outstanding employee option grants vested 25% after one year from the grant date and the balance vested ratably on a monthly basis over 36 months. The outstanding employee option grants are all fully vested. The majority of the outstanding options granted to non-employee directors vest one year from the grant date. The options generally expire 10 years from the grant date.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of time-based option grants is calculated using the Black-Scholes option valuation model.&#160;The expected term for the option grants was based on historical experience and expected future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock, based on the average expected exercise term. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0OTc_2e9752df-a544-4bb9-81d0-1c32bd8e4654" continuedAt="i5b219b260b2140b3ae9af84cef48fadc" escape="true">The table below summarizes the total time-based stock options granted, total valuation and the weighted-average assumptions (dollars in thousands, except per option amounts):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i5b219b260b2140b3ae9af84cef48fadc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of time-based options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi0yLTEtMS05MjcxOA_9a8297bd-f8b9-42df-b527-943e8d448063">7,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi00LTEtMS05MjcxOA_a221cd3c-6fac-4ab8-b3ca-f88c7bd11fcd">7,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi02LTEtMS05MjcxOA_1c5aef85-570a-4a8c-8936-37402772d077">7,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value of options granted (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="-3" name="icui:Timebasedoptionsgrantdatefairvalue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy0yLTEtMS05MjcxOA_0a998ae1-1dac-4122-8df8-d6307e983234">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="-3" name="icui:Timebasedoptionsgrantdatefairvalue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy00LTEtMS05MjcxOA_eab1f8fd-21b1-4ae3-923b-9b0205dc693d">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="-3" name="icui:Timebasedoptionsgrantdatefairvalue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy02LTEtMS05MjcxOA_7d0046fd-6a57-445e-9cf2-0fc066709027">425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions for stock option valuation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS0yLTEtMS05MjcxOA_a62f7442-4767-47f7-932c-5044e831c52a">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS00LTEtMS05MjcxOA_9aed5358-d2b6-49a4-9e63-5fd757abe6b8">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS02LTEtMS05MjcxOA_dd085366-2d6f-4786-8783-b1ac24344506">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi0yLTEtMS05MjcxOA_19e53b48-c534-48e6-809e-d0c2ee2b884b">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi00LTEtMS05MjcxOA_ad1e321a-6ccd-4e8c-ab3e-345ab728a8d4">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi02LTEtMS05MjcxOA_1dcb34ad-978c-4160-b124-300b33cf7187">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy0yLTEtMS05MjcxOA_057dbdb9-f56b-4309-aad7-5c896dba81d5">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy00LTEtMS05MjcxOA_29e55b44-8727-49b8-afe1-b8c4d28f8cc3">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy02LTEtMS05MjcxOA_d9e1c36f-3e1e-4545-8f1c-197c3059be44">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC0yLTEtMS05MjcxOA_14e0f8d8-a1ec-4c69-b268-f506fed37c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC00LTEtMS05MjcxOA_0ef9138d-2388-45cf-875e-922500660462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC02LTEtMS05MjcxOA_9a16dac5-1e64-494b-a11b-64f4075c1dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-price per option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS0yLTEtMS05MjcxOA_566df40f-cb77-4135-8f07-d7a0894098fa">185.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS00LTEtMS05MjcxOA_961f97ba-c812-4ef3-b84d-6a65412f36a0">200.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS02LTEtMS05MjcxOA_0b339d80-0349-4aa9-8ecc-f29124ae4ef2">181.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtMi0xLTEtOTI3MTg_a25c1e92-fe7e-4113-abab-b26402d24b65">70.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtNC0xLTEtOTI3MTg_7c9d421d-0303-4939-9845-43327ba7c076">66.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtNi0xLTEtOTI3MTg_06ff2f76-cd24-420c-b508-ea943d39117e">59.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i83e402f4c7634be886104f695af5cbb0" continuedAt="i64bc182103044f62b73283538e47f12d"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0ODA_e5056d6f-6e26-42f0-b10f-97ff1abbad52" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity as of and for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ced0ef8f682482e991d67cc95e1bae8_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMS0yLTEtMS05MjcxOA_4cc7bcb0-63e0-4585-aa92-2a6390afc318">663,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ced0ef8f682482e991d67cc95e1bae8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMS00LTEtMS05MjcxOA_62ac98cc-4921-473d-9018-ed9d517eff81">74.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMi0yLTEtMS05MjcxOA_23cf2c56-23f5-4cad-8999-607c5eae33af">7,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMi00LTEtMS05MjcxOA_fd57b222-42d1-4751-8fd6-0f84ff124df2">185.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMy0yLTEtMS05MjcxOA_17575285-cade-4abb-84b9-cacf6838d3f3">142,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMy00LTEtMS05MjcxOA_b8505a02-6592-44f1-a323-09e1aff16586">61.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNC0yLTEtMS05MjcxOA_4fc9c73c-b1fe-4d97-8118-8a7636b6455c">485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNC00LTEtMS05MjcxOA_f64b0ec4-c217-416d-bb97-3a2704027c41">60.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS0yLTEtMS05MjcxOA_4b2ced41-cf90-4bba-a8b6-c60a9839c328">527,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS00LTEtMS05MjcxOA_452b24f5-8e7f-4019-b723-bb9d55ae2c18">79.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS02LTEtMS05MjcxOA_4a52621a-79bd-4860-b839-203986a319fb">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS04LTEtMS05MjcxOA_690cdd0c-5864-4ebb-846d-9ad8619b5ccd">42,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi0yLTEtMS05MjcxOA_091c8198-cb93-4221-83c5-43a966e7652e">519,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi00LTEtMS05MjcxOA_52647336-47a4-4306-b85a-44618b91a5c0">78.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi02LTEtMS05MjcxOA_09bd0279-2d29-42a8-829f-35efb20e5293">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi04LTEtMS05MjcxOA_8ca29589-0d63-4c2b-8b5c-fab867a7adaf">42,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy0yLTEtMS05MjcxOA_7dc09e0d-7465-4ebb-b809-c468409d8ac9">527,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy00LTEtMS05MjcxOA_c3884b0a-7758-4893-af4f-4972b3486381">79.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy02LTEtMS05MjcxOA_a2b4728f-be96-4892-a5e4-89063c552cb2">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy04LTEtMS05MjcxOA_4520d808-f5fc-43f9-b32e-0976625f0b36">42,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic values for options exercisable, outstanding and vested or expected to vest at December&#160;31, 2022 are based on our closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMzg0Ng_a6a4ec00-01cd-4d37-aa1b-757f66837348">157.48</ix:nonFraction> at December&#160;31, 2022 and are before applicable taxes.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:ExercisedOptionsDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzI_92a2d5b6-e635-407c-97f6-e06e8b759752" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi0yLTEtMS05MjcxOA_427709cf-366a-472c-bfcc-57c3a1867c38">17,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi00LTEtMS05MjcxOA_192c637e-7a8d-4640-b8e4-0c2347089e2e">27,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi02LTEtMS05MjcxOA_2767ce1f-242a-4cc4-a93e-c22b78d89b1c">32,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy0yLTEtMS05MjcxOA_4dcfcbb6-505c-492a-a8e9-edc172c8c60b">8,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy00LTEtMS05MjcxOA_6de09945-2fad-466f-aa51-ab9c9bf83f4e">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy02LTEtMS05MjcxOA_1275eb66-d8c5-41f1-89a3-f6fd308e65bc">13,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC0yLTEtMS05MjcxOA_cff2d5bd-305c-463f-b88e-cfdef9f3cb22">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC00LTEtMS05MjcxOA_ce825f82-1c5a-450b-9ca6-62d5c8eda05b">5,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC02LTEtMS05MjcxOA_3161a572-6fc9-4895-9e41-2804bbf62120">5,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Awards</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we granted our annual PRSUs to our executive officers and certain other non-executive employees. These PRSUs will cliff-vest on March 7, 2024  subject to the achievement of net synergy savings targets related to the Smiths Medical acquisition achieved during the performance period commencing on January 1, 2022 and ending on December 31, 2023, which when reviewed against predetermined targets could result in 0% to 200% of the awarded units that could vest. We also granted certain other one-off PRSU awards to non-executive employees with various performance requirements, whereby the performance shares will be earned if the minimum requirements are met within a specified time period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we granted PRSUs to our executive officers. For the executive officers other than the Chief Executive Officer ("CEO"), Chief Operations Officer ("COO") and the Chief Financial Officer ("CFO"), the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2024 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, commencing on January 1, 2021 and ending on December 31, 2023, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we granted PRSUs to our executive officers. For the executive officers other than the CEO, COO and the CFO, the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2023 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO, COO and CFO met their individual performance goals for 2021, therefore one-third of their 2020 PRSU shares awarded vested during 2021. Additionally, during February 2021, the Compensation Committee, modified the potential vesting percentages related to the 2020 PRSU awards for the CEO, COO and CFO, as the original potential percentages were established immediately before the onset of the COVID-19 pandemic. The Compensation Committee determined to adjust the CEO, COO and CFO's potential to earn from between 0% and 250% of the award granted, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i64bc182103044f62b73283538e47f12d" continuedAt="ie2a431d596724d2a8504d1c10f8ea290"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an increased potential to earn between 50% and 300% of the award granted, subject to the same minimum threshold revenue and EPS targets to be achieved by the Company. The additional compensation expense as a result of modifying the 2020 PRSUs granted to our CEO, COO and CFO totaled $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:ModifiedPRSUIncrementalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfNjM3OQ_e5f48021-8761-412d-8ac4-c460195dd3cd">2.1</ix:nonFraction>&#160;million recognized over the remaining amortization period from the date of modification. In February 2023, the Compensation Committee made the determination that the executive officers other than the CEO, CFO and COO met their individual performance goals for 2022, therefore a third of their 2020 PRSU shares awarded vested during 2023. The performance period related to the 2020 CEO and COO PRSUs ended on December 31, 2022 and is subject to the Compensation Committee review and determination of shares earned based on the Cumulative revenue and EPS results achieved during the performance period.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers had met their individual performance goals for the applicable years.  For the CEO and the COO, the performance shares were to cliff-vest on March 6, 2022, subject to the achievement of a minimum Cumulative Adjusted EBITDA and continuous service through that date. If for the three year period ending on December 31, 2021 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA has a growth of over 10%, 200% of the awarded units would have vested. In 2019, we also granted PRSUs to one of our non-executive employees. These PRSUs vested at the end of a three-year period ending on March 31, 2022, based on meeting certain minimum performance goals. In February 2022, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2022, therefore, the final third of their 2019 PRSU shares awarded vested during 2022. The performance period related to the 2019 CEO and COO PRSUs ended on December 31, 2021 and in February 2022 the Compensation Committee determined that zero PRSUs were earned based on the actual Cumulative Adjusted EBITDA achieved during the performance period.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs were vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable year. For the CEO and the COO, the performance shares were to cliff-vest ending on February 15, 2021 subject to the achievement of a minimum Cumulative Adjusted EBITDA.  If for the three year period ending on December 31, 2020 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of over 10%, 200% of the awarded units would vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2021, therefore, one-third of their 2018 PRSU shares awarded vested during 2021. Also on February 15, 2021, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period the CEO and COO's 2018 PRSUs were earned at 100% of the awards granted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we granted PRSUs to our executive officers. The PRSUs were scheduled to vest, if at all, upon the achievement of a minimum Cumulative Adjusted EBITDA, subject to a three-year cliff vesting ending on December 31, 2019.  If at that date, our Cumulative Adjusted EBITDA was at least $600 million but less than $650 million, 100% of the awarded units would vest.  If our Cumulative Adjusted EBITDA was at least $650 million but less than $700 million, 200% of the awarded units would vest. If our Cumulative Adjusted EBITDA is at least $700 million, 300% of the awarded units would vest. On January 17, 2020, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period that the 2017 PRSU shares were earned by our executive officers at the 300% achievement level.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units are granted annually to our non-employee directors and vest on the first anniversary of the grant date, or the date of our annual meeting, whichever occurs first. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, we granted RSUs to certain employees that vest ratably on the anniversary of the grant over three years. We recognize forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair market value of our PRSUs and RSUs is determined by our stock price on the grant date.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzM_05451dbd-f325-4f5e-95b6-bf4a6f987906" continuedAt="i5267b91c39f04f3ab6f4ae804d692076" escape="true">The table below summarizes our restricted stock award activity (dollars in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ie2a431d596724d2a8504d1c10f8ea290"><div style="margin-top:5pt;text-align:center"><ix:continuation id="i5267b91c39f04f3ab6f4ae804d692076"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy0yLTEtMS05MjcxOA_8f6cbfa3-0585-4232-9be5-e577fb27f235">60,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy00LTEtMS05MjcxOA_a922bd71-990e-4991-b1df-5a0f87c97446">53,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy02LTEtMS05MjcxOA_9a49881d-17b8-4163-9791-c50255cfa9b9">38,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares earned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c67054a7a594d6983252a6891238d26_D20220101-20221231" decimals="0" name="icui:PerformanceSharesEarned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC0yLTEtMS05MjcxOA_5ad1ed06-af34-4888-845b-d390479814a0">46,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9241e754a3e241929d3a847fe66556ed_D20210101-20211231" decimals="0" name="icui:PerformanceSharesEarned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC00LTEtMS05MjcxOA_0849ac5e-029c-434f-a2c4-77ae7d6e8a49">32,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41a074cf04634fb682ff822fe3155504_D20200101-20201231" decimals="0" name="icui:PerformanceSharesEarned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC02LTEtMS05MjcxOA_16c81588-c8c7-4434-bf56-861bd0d02c1f">80,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS0yLTEtMS05MjcxOA_65e8823b-252a-4f2e-a3ea-5799de5a0f29">230.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS00LTEtMS05MjcxOA_11c99689-76bb-4dd6-8a9b-148472267eed">198.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS02LTEtMS05MjcxOA_2895de8c-9e7e-47f1-bb79-660afcdbd764">188.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231" decimals="-3" name="icui:Grantdatefairvalueperformancerestrictedstockunits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi0yLTEtMS05MjcxOA_0d20ff94-792e-449e-95d5-12d6caf4e99b">13,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231" decimals="-3" name="icui:Grantdatefairvalueperformancerestrictedstockunits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi00LTEtMS05MjcxOA_ccd99f12-f896-4886-9a06-61e90fb775fa">10,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231" decimals="-3" name="icui:Grantdatefairvalueperformancerestrictedstockunits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi02LTEtMS05MjcxOA_0979e875-30ee-4dbd-a44b-2a0cbce95b9f">7,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy0yLTEtMS05MjcxOA_60a727de-e77e-4004-81d9-21ee22776400">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy00LTEtMS05MjcxOA_a2935681-4fed-4d3f-9244-3a8019f3b25f">6,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy02LTEtMS05MjcxOA_6c62dcd9-00fc-470b-bcf1-5dc54e72fa98">15,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtMi0xLTEtOTI3MTg_8b7de27f-d2db-4e0e-b13c-826bf14207c7">116,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtNC0xLTEtOTI3MTg_7749f649-2d9d-4107-8947-ce554fe7aed9">84,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtNi0xLTEtOTI3MTg_57b86b06-888f-4042-ba9e-321d2b843bf5">87,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtMi0xLTEtOTI3MTg_34b9e97e-b77e-484e-8479-8d350b58e0ef">221.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtNC0xLTEtOTI3MTg_16f5d29a-3f7f-460c-b798-cf4392bcfd1d">199.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtNi0xLTEtOTI3MTg_70975bae-1b83-44de-8650-dc27cc379de1">188.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231" decimals="-3" name="icui:Grantdatefairvalueofrestrictedstockunitsgranted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItMi0xLTEtOTI3MTg_975f77ae-583a-4c3c-8939-7590d4b59f66">25,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231" decimals="-3" name="icui:Grantdatefairvalueofrestrictedstockunitsgranted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItNC0xLTEtOTI3MTg_0cb6bdcd-bd8b-4248-9c64-8c7ed1322e20">16,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231" decimals="-3" name="icui:Grantdatefairvalueofrestrictedstockunitsgranted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItNi0xLTEtOTI3MTg_b993fc20-a1a2-4e8f-a979-e9bd7775d140">16,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtMi0xLTEtOTI3MTg_ce49502e-5f3c-471d-aa16-c13ba2c4590a">16,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtNC0xLTEtOTI3MTg_a51a21b3-d3b1-4fce-8fa6-324dd2c72084">13,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtNi0xLTEtOTI3MTg_e75be9d1-0240-421c-a4b2-fb8b0df6ead1">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PRSU shares earned in 2020 were related to performance awards granted to executives in 2017, 2018 and 2019. PRSU shares earned in 2021 were related to performance awards granted to executives in 2018, 2019 and 2020. PRSU shares earned in 2022 were related to performance awards granted to executives in 2019, 2020 and 2021 and performance awards granted to a non-executive employee in 2019, 2020 and 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0OTk_ea779bf3-a890-40f3-a4d2-cd2be8c593f4" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of our PRSU and RSU activity as of and for the year ended December&#160;31, 2022: &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant-Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7744c2c44b6e49a192f49a29131c1146_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMS0yLTEtMS05MjcxOA_6af3e141-1885-48ac-9a58-48893abddd44">275,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7744c2c44b6e49a192f49a29131c1146_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMS00LTEtMS05MjcxOA_454e7618-fba5-46bb-9962-73c7e29c8757">201.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in units due to performance expectations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="0" name="icui:Changeinunitsduetoperformanceexpectations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMi0yLTEtMS05MjcxOA_f4a63842-b366-478b-a5b7-d198a6779e22">32,346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="2" name="icui:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMi00LTEtMS05MjcxOA_a05ed3b0-e9ee-4b02-99b3-c58a15ec5f95">239.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMy0yLTEtMS05MjcxOA_7d7bc56b-21ea-4e21-b35d-014f982d4c1a">177,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMy00LTEtMS05MjcxOA_d4849dfd-b32f-40d8-b48d-a0aa4e65fca7">224.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNC0yLTEtMS05MjcxOA_1db88b3f-170e-4df8-9af4-1fc794d59d19">118,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNC00LTEtMS05MjcxOA_3797cf01-3863-4b91-b1b2-1b65f22f26d2">206.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNS0yLTEtMS05MjcxOA_28229b63-43ae-444b-94a7-6173e88ee655">13,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNS00LTEtMS05MjcxOA_1d3b932a-364d-4312-8718-e329dbf240fa">218.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested and expected to vest at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi0yLTEtMS05MjcxOA_7abd227f-e1ee-449a-b2ea-86a12272046d">354,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi00LTEtMS05MjcxOA_524825b0-5965-4a0a-914c-b56b1631bf98">213.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi02LTEtMS05MjcxOA_7c09624a-8c69-4570-b14f-7ce7928e5169">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi04LTEtMS05MjcxOA_27dc3f0e-9221-4cad-a95a-bc205bf39d16">55,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relates to net adjustments to 2019, 2020, 2021 and 2022 PRSUs granted to executives and certain non-executive employees. PRSUs granted assumes attainment of an increased payout rate based on performance expectations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ESPP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP under which U.S. employees may purchase up to $25,000 annually of common stock at 85% of its fair market value at the beginning or the end of a six-month offering period, whichever is lower. There are <ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="icui:ESPPOriginalIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTE5Nzg_f0106b07-22d0-40b5-9f30-5731e85dd12b">750,000</ix:nonFraction> shares of common stock reserved for issuance under the ESPP, which is subject to an annual increase of the least of <ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="icui:ESPPAnnualIssuanceIncreaseLimit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTIwOTc_e17dc49a-872f-46b2-b6ed-36b9ba4df4c4">300,000</ix:nonFraction> shares, two percent of the shares outstanding or such a number as determined by the Board.&#160;To date, there have been no increases.&#160;As of December&#160;31, 2022, there were no shares available for future issuance, all shares unissued under the plan expired during 2022. The ESPP is intended to constitute an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Internal Revenue Code.  We suspended our ESPP in 2017.</span></div></ix:continuation><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwMQ_ba074e59-72c2-4c8b-b559-d477e617611b" continuedAt="i639fe11a14624b21b92ab954299b283a" escape="true">DERIVATIVES AND HEDGING ACTIVITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i639fe11a14624b21b92ab954299b283a" continuedAt="if3970d5fdb5642c2bd677f552ae475b9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Accounting and Hedging Program</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purposes of our cash flow hedging programs are to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit, and to manage floating interest rate </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="if3970d5fdb5642c2bd677f552ae475b9" continuedAt="i5de826e5a0234307a281d677128246a7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk associated with future interest payments on variable-rate term loans issued in January 2022. We do not issue derivatives for trading or speculative purposes.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract and forward-starting interest rate swaps are designated and qualify as cash flow hedges. Our derivative instruments are recorded at fair value on the consolidated balance sheets and are classified based on the instrument's maturity date. We record changes in the fair value of the effective portion of the gain or loss on the derivative instrument as a component of other comprehensive (loss) income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Exchange Forward Contracts</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses to minimize the effect of foreign exchange rate movements on the related cash flows. These contracts are agreements to buy or sell a quantity of a currency at a predetermined future date and at a predetermined exchange rate. Our foreign exchange forward contracts hedge exposures principally denominated in Mexican Pesos ("MXN"), Euros, Czech Koruna ("CZK"), Japanese Yen ("JPY"), U.S. Dollar ("USD"), Chinese Renminbi ("CNH"), Canadian Dollar ("CAD") and Australian Dollar ("AUD") and have varying maturities with an average term of approximately twelve months. The total notional amount of these outstanding derivative contracts as of December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjQy_d47fae1d-5be0-4392-b243-1b039864a024">206.0</ix:nonFraction>&#160;million, which included the notional equivalent of $<ix:nonFraction unitRef="usd" contextRef="ie512243dc7bc4d1a8e0708ea1460f39e_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NTk3_27809657-b17f-440a-9404-7e804abf50f1">61.3</ix:nonFraction>&#160;million in MXN, $<ix:nonFraction unitRef="usd" contextRef="i1c33090ddb2c4c7eb6ff7538c7bb476b_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjEy_26700807-d58d-42c8-9ce7-6b1e3378ec0f">31.7</ix:nonFraction>&#160;million in Euros, $<ix:nonFraction unitRef="usd" contextRef="ie6789c74e7e04a6795307d8a02ddf4b4_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjI3_138fd31b-ae93-448f-aa76-648d41967f83">13.9</ix:nonFraction>&#160;million in CZK, $<ix:nonFraction unitRef="usd" contextRef="i0541d3f55fc040d3ac00d6c25ff32778_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjU4_da8bf70d-9b83-458c-8cda-34d07ffe7a1d">15.3</ix:nonFraction>&#160;million in JPY, $<ix:nonFraction unitRef="usd" contextRef="ia728542369a84272b8c445494962161e_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3Njcz_37a272d0-ae3b-443f-85c4-d881877c52a8">11.5</ix:nonFraction>&#160;million in CNH, $<ix:nonFraction unitRef="usd" contextRef="if3b3f4f1317a42f2be3e756d642c8e7d_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3Njg4_220e2539-8714-42c2-9516-e19e20add33a">43.2</ix:nonFraction>&#160;million in USD, $<ix:nonFraction unitRef="usd" contextRef="i99be33b784264317acca70b9f25f1a88_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzAz_a881ac6f-cdc6-4782-8dff-abeee6f4bca7">11.6</ix:nonFraction>&#160;million in CAD, $<ix:nonFraction unitRef="usd" contextRef="i184372b7fd1647f08adb94357659448d_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzE4_65aa7c09-15c8-4e42-ba37-235ca34923ce">11.9</ix:nonFraction>&#160;million in AUD and $<ix:nonFraction unitRef="usd" contextRef="idf68976ce40345619a3f5648dcaacb18_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzMz_e3161b19-9397-40de-97b0-4f4fff2900a8">5.6</ix:nonFraction>&#160;million in other foreign currencies, with terms currently through February 2024. Certain contracts were acquired as part of the Smiths Medical acquisition. We did not have such derivative contracts as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency Par Forward Contracts</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into cross-currency par forward contracts to hedge a portion of our Mexico forecasted expenses denominated in MXN. These contracts are agreements to exchange cash flows from one currency to another at specified intervals over the contract term with all exchanges occurring at the same predetermined rate. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we hedged a portion of our Mexico forecasted expenses denominated in Pesos ("MXN") by entering into a one-year cross-currency par forward contract. The term of the one-year hedge was November 1, 2019 to November 3, 2020. The derivative instrument matured in equal monthly amounts at a fixed forward rate of <ix:nonFraction unitRef="number" contextRef="ifbb5e6d91a92409d9ef474923b762b07_I20221231" decimals="2" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjI2NQ_9f28fb56-ed33-4359-a9db-40e8463e352e">22.11</ix:nonFraction> MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2020 was approximately <ix:nonFraction unitRef="usd" contextRef="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjQ1Ng_32b29bfe-1edc-42de-94c4-ba4e38abc093">436.8</ix:nonFraction> million MXN. The term of this one-year contract was November 3, 2020 to December 1, 2021. The derivative instrument matured in equal monthly amounts at a fixed forward rate of <ix:nonFraction unitRef="number" contextRef="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231" decimals="2" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjYyNw_6137235f-e9d7-4df2-ba72-3db4a6b121cb">24.26</ix:nonFraction> MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2021 was approximately <ix:nonFraction unitRef="usd" contextRef="ia79af1c5b1914270838bef1b8ec536a1_I20221231" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjgyMQ_6501b6c5-2744-4f57-a7ba-247f6fed7c82">413.1</ix:nonFraction> million MXN. The term of this one-year contract is December 1, 2021 to December 1, 2022. The derivative instrument matured in equal monthly amounts at a fixed forward rate of <ix:nonFraction unitRef="number" contextRef="ia79af1c5b1914270838bef1b8ec536a1_I20221231" decimals="2" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjk5MQ_0f082552-9adb-4c19-b1ff-e3ca2e766798">21.60</ix:nonFraction> MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Floating Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, in anticipation of entering into the new senior secured credit facilities in January 2022, which included a variable-rate term loan A and a variable-rate term loan B (see Note 11: Long-term Debt), we entered into two forward-starting interest rate swaps. In February 2022, certain terms under the agreements were amended to reflect the transition from LIBOR to the Secured Overnight Financing Rate ("SOFR"), an alternative reference rate. Under the interest rate swap agreements we exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. The term loan A swap, as amended, has an initial notional amount of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5de826e5a0234307a281d677128246a7" continuedAt="i2c221d441bc448778a428340ed0d0e0c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i394377fd918340248b6debe2d54beff5_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzU4Mg_f65b0ac5-eafd-471c-aa75-09b5a0fd7405">300.0</ix:nonFraction>&#160;million, reducing to $<ix:nonFraction unitRef="usd" contextRef="i8d3e73355e5a46779e8b500f773bcabb_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzU5OA_d014cef2-9623-4b83-ba88-a472078f04b8">150.0</ix:nonFraction>&#160;million evenly on a quarterly basis through its final maturity on March 30, 2027. We will pay a fixed rate of <ix:nonFraction unitRef="number" contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231" decimals="4" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzY5OQ_8bb5ab91-4630-4a38-92ab-748e0b5752f4">1.32</ix:nonFraction>% and will receive the greater of 3-month USD SOFR or (<ix:nonFraction unitRef="number" contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231" decimals="4" sign="-" name="icui:DerivativeInterestRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzc1NQ_7937093e-ccbd-4470-b759-dfd3b1e5e6ac">0.15</ix:nonFraction>)%. The term loan B swap, as amended, has an initial notional amount of $<ix:nonFraction unitRef="usd" contextRef="i099ba0834fb64e019127f5cf439531b2_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzgxNA_ae9286e1-d4b0-4aa6-8b4f-cd173395ecc1">750.0</ix:nonFraction>&#160;million, reducing to $<ix:nonFraction unitRef="usd" contextRef="i7b1f546a435746b6a9e083834063101e_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzgzMA_b4f72474-eeb5-420c-a1d2-0addae0cefdf">46.9</ix:nonFraction>&#160;million evenly on a quarterly basis excluding its final maturity on March 30, 2026. We will pay a fixed rate of <ix:nonFraction unitRef="number" contextRef="ia825f2d41f694d229f7aba34643141dc_I20221231" decimals="4" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzkzMQ_d607f592-5f49-4d97-ad67-991bf1d885d0">1.17</ix:nonFraction>% and will receive the greater of 3-month USD SOFR or <ix:nonFraction unitRef="number" contextRef="ia825f2d41f694d229f7aba34643141dc_I20221231" decimals="4" name="icui:DerivativeInterestRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDg5Ng_097b6500-7cd1-4eac-9e46-9fb2ff422a75">0.35</ix:nonFraction>%. These forward-starting swaps will effectively convert the relevant portion of the floating-rate term loans to fixed rates.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwNw_cce08752-7b9f-4700-9f8c-68b457e8d594" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivative instruments included within the consolidated balance sheets (in thousands):  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Location</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68398fc85c9b4c69a9d24ac18c9275b2_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS0yLTEtMS05MjcxOA_c9c21636-a821-48f0-aa82-36f67b392f1d">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181b26114ca442d3aaba5f83684bef22_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS00LTEtMS05MjcxOA_506d8b6a-42be-43ba-a8ad-305144c09753">28,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0e5b7233314ac39c225315b21f33ca_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS02LTEtMS05MjcxOA_0038c760-c8a0-4f65-8f07-9fa637140669">33,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7144ed377e460497e6a92365d659ba_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi0yLTEtMS05MjcxOA_0afdecbc-3580-48a5-b1fa-3ca6f6504cca">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0764c13b084d4be3bc783f9c9b3ff993_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi00LTEtMS05MjcxOA_6ba91c43-f841-4327-8ab7-82d935daa173">26,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8884b7e467144a1abd07dd5529d382c_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi02LTEtMS05MjcxOA_4ca7dc52-7c3d-498a-8ca8-c0bd39b8e160">26,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858ccda502774a3c8bcffb5a5e2125f9_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy0yLTEtMS05MjcxOA_f8a30dea-1822-49ea-a871-154891cd67b7">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9d60c60bed4ebea68c80e275f8e3d7_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy00LTEtMS05MjcxOA_69282224-3daf-43f1-b243-3f3989b03da8">55,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia039837b279e455ca2dc2d46edc4b550_I20221231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy02LTEtMS05MjcxOA_f7ba4a63-04f0-495e-a653-7d28262384f9">60,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820fd306ff3d43e2b341018522bb3760_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS0yLTEtMS05MjcxOA_28719924-758e-49b2-99da-9668147fbde3">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d376e7b6d2421fae5fe8fa52db03b3_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS00LTEtMS05MjcxOA_14a96b0d-9996-4cb3-99d7-f190b2884c8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ec86e2578c4dc9a435e041179ae4c7_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS02LTEtMS05MjcxOA_05964c0d-77c4-4810-a0fc-68011892c4c1">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc61959aa8d4d67bc160b2ede121548_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtMi0xLTEtOTI3MTg_a22ff8c2-dc45-45b3-9a75-607a3ac55555">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5824bf85f4040b1976e55e688d916b7_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtNC0xLTEtOTI3MTg_be6552a4-e46e-4a62-8332-01e6166daa5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735eafbcc4e744f1a518604a58b733d5_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtNi0xLTEtOTI3MTg_f77e791a-bb9d-4589-bb48-0bd2473e3a8e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01412f1ac55c4cd89cb8ff97582fb41d_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtMi0xLTEtOTI3MTg_fc8c003f-39ae-4034-8727-9a538c26ceee">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2ef219571e4d04b73e0b06787c1ad9_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtNC0xLTEtOTI3MTg_a12adf57-b436-48aa-a364-87a4120377bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f036a93e924d5fa456f3b1b062e994_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtNi0xLTEtOTI3MTg_88b16fda-c81d-49fc-9425-00b2e3a833b2">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward-Starting Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0b9ad85694f8f94491a20a88c9179_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtMi0xLTEtOTI3MTg_d6ff55e8-5ae4-41f5-a36d-b5e277b4ba7f">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28be753e1e4e43a0042554fc467ca7_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtNC0xLTEtOTI3MTg_5ac0e7e0-ec07-49ed-beb2-0b4cc8229152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8aaf3d494f04e50ba69cff6e04ff60b_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtNi0xLTEtOTI3MTg_460947b9-357e-46c5-b5b6-002661e7c551">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20054b0c9f4b47ac8c1e534ba6ea3ce9_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtMi0xLTEtOTI3MTg_6f60a176-3286-48c3-a7d9-e2212c199765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08778ed5abe4561b708b5b722eeb93e_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtNC0xLTEtOTI3MTg_17e875bc-0417-4516-ad3f-0926dc859ccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia728d4a36f3f4749a1126fa36fef1423_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtNi0xLTEtOTI3MTg_edbc3b42-1279-49cf-bfa1-d9143260473f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836cf2e65d5e413682ba9671638f8619_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtMi0xLTEtOTI3MTg_fe21e96a-fa56-4c80-aacf-c1a486dc4ba7">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14489f445c94e4c8d8946d9f09ab71b_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtNC0xLTEtOTI3MTg_0558daaa-b88d-4035-92f7-18524f00b81f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4670f805e84ec88fcc239984f42f1e_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtNi0xLTEtOTI3MTg_b8074add-df37-402d-9ca0-8714bd2e7f60">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28bced960bf4b37988c086fd5dd0698_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtMi0xLTEtOTI3MTg_12576bc9-dd9d-4fa5-a280-2f7f6f5c6d41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8dd0869a16144b0a67bc6b37b8b72bf_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtNC0xLTEtOTI3MTg_ea41cb7c-3c99-46df-8892-300137b7db45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b2cef3151a4d45a40c618a6d750d32_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtNi0xLTEtOTI3MTg_e9f3f2f8-30d2-42e0-9318-c81374447814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde680e06fbf430e8e5775077493e0c1_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktMi0xLTEtOTI3MTg_cbc23a8f-ce2c-495e-a361-4144fd23efad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1677095d03d54c6cad7ffddc26a40aea_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktNC0xLTEtOTI3MTg_fc749a34-b872-49b2-8155-6af4c6f752cf">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120db90932414ec390afe7cf3a633cc0_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktNi0xLTEtOTI3MTg_612884b0-475e-48ae-b4b6-ff7bb88420a5">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253805333c4f482db81b9d675244447d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtMi0xLTEtOTI3MTg_e24b7ae0-e498-4d78-a0e4-55d2958d306a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d08049edd740bb914aa46bd7090759_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtNC0xLTEtOTI3MTg_d12498ce-00cc-4bed-b838-07169567098a">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec03ea5060745ba8354c6aad5437d98_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtNi0xLTEtOTI3MTg_6ed8b024-8442-44d2-be15-b830af0ff454">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effects of our derivative instruments designated as cash flow hedges on the Consolidated Statements of Operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain Reclassified From Accumulated Other Comprehensive (Loss) Income into Net (Loss) Income</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain in the Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06fe49c746ff44d19762274cadbe0d7a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC0zLTEtMS0xMTAxODM_744e05e0-586b-4468-90b8-289f4c188b13">3,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7152ead34514d1f9d4453e1a803d747_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC01LTEtMS0xMTAxODU_4b9ab56d-317d-49d0-b7c3-1928c4a097a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb45b8279f94588a9bb6ea15ea5b6e2_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC03LTEtMS0xMTAxODg_c9f77928-3bd9-4943-9815-cea6476ce887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c5dc156f3d4065a5ac61ee8ad07be7_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy0zLTEtMS05MjcxOA_107fc5a0-721c-483e-a3a4-2d9edf1fadab">7,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e281a61518246b28c211682f9b80e67_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy01LTEtMS05MjcxOA_7aa54d18-7b18-4404-9c15-4ff84a93b3fd">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54664f90ad4843079c7700ad05a8cd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy03LTEtMS05MjcxOA_b5f19f54-c66b-44cd-9998-2a1e1a54b727">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9694c6e8455346248c473df62e0ab068_D20220101-20221231" decimals="-3" name="us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC0zLTEtMS05MjcxOA_5dd3ab47-e43d-4d91-bd27-6a0c8a07b900">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8ea47f15d34f9b8c4166744ab1524e_D20210101-20211231" decimals="-3" name="us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC01LTEtMS05MjcxOA_1228cb2a-5fb8-4c27-b88b-3936377c4b9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie345d2cbe6234906900704fc912fcdb4_D20200101-20201231" decimals="-3" name="us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC03LTEtMS05MjcxOA_a6e35098-c91f-48d1-9d1b-6314b74474a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy0zLTEtMS0xMTAxOTA_123f5978-978d-40dc-9a1b-ad5402a394d7">6,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c5dcea53454983887455c2111ad23b_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy01LTEtMS0xMTAxOTI_37d81147-9a10-43c7-bffe-eea45217a513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb2d02e47f4de1added70760728782_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy03LTEtMS0xMTAxOTQ_eaa4083a-5f62-4b54-9b4e-29d236f86a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC0zLTEtMS0xMDAzNDQ_27baf31a-d21e-47db-a713-1f27afdb5f62">18,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC01LTEtMS0xMDAzNDQ_084bbcfb-8e98-48fc-b75f-d97cc08415c1">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC03LTEtMS0xMDAzNDQ_d4cb6884-91f5-46f2-9113-9b9d254dbbe3">790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Represents location of gain reclassified from accumulated other comprehensive (loss) income to net (loss) income as a result of a forecasted transaction being no longer probable of occurring.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i2c221d441bc448778a428340ed0d0e0c"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwNQ_fa4d4c57-384f-4d3e-bf3a-5168649e4f7e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on our derivative instruments designated as cash flow hedges in other comprehensive (loss) income before reclassifications to net (loss) income (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:64.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e04f05c0ec4c2c82f5854eb7872516_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC0yLTEtMS05MjcxOA_23e23cc5-4890-432e-83d2-d3cd9fbe1556">9,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886d8381dfd34aec845daca43861614f_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC00LTEtMS05MjcxOA_7d99e6cb-ad7f-4ded-99b6-4086e969de88">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b89fe4e5804575a068ee1b69c7ef41_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC02LTEtMS05MjcxOA_8a87e5f1-24a4-47a6-89f5-b76656e616a6">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS0yLTEtMS05MjcxOA_1a50bc05-54b7-48c4-ad6f-9548bb400f39">62,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c5dcea53454983887455c2111ad23b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS00LTEtMS05MjcxOA_cb5b7498-ee27-49d7-8e55-7da4ddf072f1">1,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb2d02e47f4de1added70760728782_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS02LTEtMS05MjcxOA_a9334f9a-bd27-4a69-bee5-4f8dd46fb0e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi0yLTEtMS05MjcxOA_2f2d385b-ce50-41be-8ddd-f174bd5e315a">72,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi00LTEtMS05MjcxOA_ddfeff1f-f785-40db-81b3-0627d0bc1fa1">530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi02LTEtMS05MjcxOA_57ceacab-9c5f-4f97-a131-e560a696e75d">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we expect an estimated $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDU0OQ_a2dc992f-56c5-43d0-ae5a-395c620a8934">3.0</ix:nonFraction> million in deferred gains on the outstanding foreign exchange forward contract and an estimated $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDY0MA_f5e8afb2-d75f-4eea-a187-6e457267887e">29.3</ix:nonFraction>&#160;million in deferred gains on the forward-starting interest rate swaps will be reclassified from accumulated other comprehensive loss to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYxOQ_448faced-2307-4976-a115-55b20f200ba1" continuedAt="i8f2b9e1b184b4a37acd043eb332be13d" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8f2b9e1b184b4a37acd043eb332be13d" continuedAt="i78ebad85704b463d87d385195d953272"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1:  quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:  inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:  unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out liabilities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit (see Note 2: Acquisitions). Pursuit's former equity holders were entitled up to $<ix:nonFraction unitRef="usd" contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMTM2MA_3b6b8418-caae-43db-afe1-df3e63195e71">50.0</ix:nonFraction> million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out was calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $<ix:nonFraction unitRef="usd" contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMTY1MA_7018241a-6300-4871-97ee-ba83af5b10f3">50.0</ix:nonFraction> million. During the earn-out period, we used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilized multiple input variables to determine the value of the earn-out liability including historical volatility, a risk-free interest rate, counter party credit risk and projected future gross profit (see the simulation input table below related to Pursuit). The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate was equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that was commensurate with the term of the earn-out. The counter party credit risk was based on a synthetic credit rating of B1. As of June 30, 2021, the earn-out measurement period ended. Based on the actual sales and gross profit achieved during the measurement period, we calculated the actual earn-out amount to be $<ix:nonFraction unitRef="usd" contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMjU4OQ_31301665-5c6e-47a0-871f-7ba0fba7972b">26.3</ix:nonFraction>&#160;million. The $<ix:nonFraction unitRef="usd" contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMjU5Nw_9945cafd-9a50-4be3-b2c6-bb300872ebf1">26.3</ix:nonFraction>&#160;million earn-out calculation was finalized and accepted by Pursuit's former equity holders and was paid out in the fourth quarter of 2021. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i78ebad85704b463d87d385195d953272" continuedAt="iae995ffa57ef4fdb80923e96216cd4c2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out payment shall not exceed $<ix:nonFraction unitRef="usd" contextRef="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzA2OA_08711c0f-b734-43a2-98c6-158daa3a3e79">6.0</ix:nonFraction>&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $<ix:nonFraction unitRef="usd" contextRef="ia073c52ce185453aad5151952a58609f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzQ3NA_a4704e0b-36a3-406f-97a0-747809c701cc">2.6</ix:nonFraction>&#160;million. The estimated fair value of the contingent earn-out is calculated using a probability-weighted cash flow model based on historical revenue streams and the likelihood that the revenue targets will be met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzg0Nw_a93b9654-3869-4ca2-b818-86f127e45d61">2.5</ix:nonFraction>&#160;million, consisting of (i) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-6" name="icui:ShortTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzg4Nw_04925574-5ed6-46dc-ba74-cab9e81692c0">1.0</ix:nonFraction>&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:LongTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNDAzNA_48efbd95-753a-4607-aeab-e7764b0f0dfe">1.5</ix:nonFraction>&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024.  As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical with a combination of cash consideration and share consideration issued at closing. Total consideration for the acquisition includes a potential earn-out payment of $<ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjIw_3ee484c3-589f-4e15-927e-1be3c8261401">100.0</ix:nonFraction>&#160;million in cash contingent on our common stock achieving certain Price Targets from the closing date to either the third or fourth anniversary of closing (see Note 2: Acquisitions) and provided Smiths beneficially owns at least <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="8" name="icui:OwnershipRequirementForEarnoutPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjUy_d93fe998-3b40-4a10-9ec3-d73c7a8b7ba7">50.0</ix:nonFraction>% of the shares of common stock issued at closing at the time the Price Target is achieved. The initial estimated fair value of the earn-out was determined to be $<ix:nonFraction unitRef="usd" contextRef="ic34de2470df94313bd4a853cb4b2bf53_I20220106" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjM2_10dbdc2c-51b3-45a6-a99b-1396aaa4b750">53.5</ix:nonFraction>&#160;million using a Monte Carlo simulation model. The model utilized several assumptions including volatility and the risk-free interest rate. The assumed volatility is based on the average of the historical volatility of our common stock price and the implied volatility of certain at-the-money traded options. The risk-free interest rate is equal to the yield on U.S. Treasury securities at constant maturity for the period commensurate with the term of the earn-out. At each reporting date subsequent to the acquisition, we remeasure the earn-out liability and recognize any changes in its fair value in our consolidated statements of operations. If the probability of achieving the Price Targets during their respective measurement periods is significantly greater than initially anticipated, the realization of an additional liability and related expense will have a significant impact on our consolidated financial statements in the period recognized. As of December 31, 2022, the estimated fair value of the contingent earn-out is $<ix:nonFraction unitRef="usd" contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjUw_caf6ce41-b763-4de5-b2e9-af0ee4e62e69">21.0</ix:nonFraction> million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingent earn-out liabilities are separately stated on our consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYyMw_aedafad2-4820-4733-95a7-c92afacc3e7b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earn-out Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMS0yLTEtMS05MjcxOA_ee8b229d-1a79-4da4-8db7-e69773acb69d">17,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMi0yLTEtMS05MjcxOA_bbf9ba47-ca3e-444b-97bc-660f55685fea">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNC0yLTEtMS05MjcxOA_5c42bb37-83d4-4f2d-9dbc-b2e7b858e692">26,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent earn-out con-compete arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNS0yLTEtMS05NTY0Mw_75bae62e-b14d-40b3-a8c8-00e7780d5d24">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of Pursuit earn-out liability into Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNi0yLTEtMS05MjcxOA_b59b2d67-9a0c-4660-931e-9ff6704deb5d">26,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNy0yLTEtMS05MjcxOA_e95b9749-5132-4bc7-b967-786ff8410c5d">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition date fair value estimate of earn-out</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfOS0yLTEtMS0xMTAyMjc_384fcd05-668f-4ff2-a2dd-d4ea17f2d1aa">55,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfOS0yLTEtMS05MjcxOA_518342c2-19f1-43ce-a952-cd296409b984">32,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:CurrencyTranslationOnEarnOut" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMTMtMi0xLTEtMTEwMjI5_73306bd7-e369-493a-8f7a-784d55dcc62e">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMTEtMi0xLTEtOTI3MTg_9c712eb4-045c-4903-97e7-2fa49d9fb889">25,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="iae995ffa57ef4fdb80923e96216cd4c2" continuedAt="i3302596674a14f7594143ba7c5947567"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Pursuit earn-out increased during 2020 primarily due to changes in the probabilities within the valuation model.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pursuit earn-out was transferred out of Level 3 and into Level 2 in the third quarter of 2021 when the amount of the actual payment was known, and subsequently settled during the fourth quarter of 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;$<ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjU5_4ecd3333-3e9a-4f48-9e97-4aea2bd59a23">53.5</ix:nonFraction>&#160;million relates to our acquisition of Smiths Medical and $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0Njc0_8cd42ddd-3f4b-40e3-8bb0-2ba97962fc69">1.6</ix:nonFraction>&#160;million relates to our acquisition of a small foreign infusions systems supplier in the fourth quarter of 2021 (see Note 2: Acquisitions).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes an adjustment to reduce to zero a contingent earn-out issued as part of the 2021 acquisition of a small foreign infusion systems supplier. The contingent earn-out was not earned based on our determination that the threshold target was not met.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical and Pursuit:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smiths Medical Earn-out</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At Acquisition<br/>January 6, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Simulation Input</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fb0ac701d04472195a9beec28ba8137_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMi0zLTEtMS0xMTAyNDU_fe5e07ed-4124-4220-9036-74a0aa31f6e7">38.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id04b91b0851c487e8d69fa69f80b7e71_I20220106" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMi01LTEtMS0xMTAyNDE_8918534e-c95d-4fc8-b2e8-94dc4276aaef">37.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-Free Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icad841eb6c614e71bdb127b3ac3d2546_I20221231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMy0zLTEtMS0xMTAyNDU_0acdcfc7-a588-40f4-ac30-1ed27a1f0b46">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3edb4cd0b8bb40dda8c7263ec544dba8_I20220106" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMy01LTEtMS0xMTAyNDE_c4dd9337-4862-4e60-a5e8-80e4bf644734">1.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><ix:nonNumeric contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYyNA_179e58b4-e344-44d1-a15b-c65d965eaf7a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pursuit Earn-out</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of<br/>December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At Acquisition<br/>November 2, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Simulation Input</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue/Gross Profit Volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdcc27cec606429689f360f5df15a62d_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMi0zLTEtMS05MjcxOA_9af566c1-4610-4675-9749-1607c40f644b">25.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e89e9c91139472a80f40636d2e26639_I20191102" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMi01LTEtMS05MjcxOA_1a27e753-4531-4058-9fd9-391bb5587745">20.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i941468b2385e4f209a986c7dff3b8af1_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMy0zLTEtMS05MjcxOA_470f643a-af1a-4823-a847-843fb0106ed5">12.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98bde5dfe72e41209cdbda2cfb7fc991_I20191102" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMy01LTEtMS05MjcxOA_c1a318a4-020d-4f69-a9ad-3bed8d9c6e24">15.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia08eae0f4c494ccd87126117aa4a660d_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNC0zLTEtMS05MjcxOA_c9c2c8ff-480e-43d7-9b53-77b84c9b0a46">0.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife89f6478b684cf2b18ee6b3e0ad8937_I20191102" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNC01LTEtMS05MjcxOA_e6245b1a-5167-4fdf-a33c-bddf969eb8c6">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Counter Party Risk</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae7d1235c8584e3eb8cb944747cce27f_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNS0zLTEtMS05MjcxOA_b3985eb9-3786-4551-9b15-6398af30e98e">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad35dba2b3944b4fa96b9b4a1230664d_I20191102" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNS01LTEtMS05MjcxOA_7470e7ed-d2df-4377-bd78-df70ca6f451c">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments, Foreign Currency Contracts and Interest Rate Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of corporate and government bonds and U.S treasury securities. The fair value of our corporate and government bonds are estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs. The fair value of our U.S. treasury securities are based on quoted market prices in active markets and are included in the Level 1 fair value hierarchy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our Level 2 forward currency contracts is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our Level 2 interest rate swaps is estimated using a pricing model that reflects the terms of the contracts, including the period to maturity, and relies on observable market inputs such as known notional value amounts and USD interest rate curves. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Pursuit earn-out liability described above, there were no transfers between levels in 2022 or 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYzMw_f47da56a-d751-4071-ab70-29981a22e26c" continuedAt="ifa6ea52fe87040fd8c564908ce09414c" escape="true">Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):&#160;</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i3302596674a14f7594143ba7c5947567" continuedAt="i29057897982744448f35afece88128e4"><ix:continuation id="ifa6ea52fe87040fd8c564908ce09414c" continuedAt="iccd6f39c1a394863bc29f81a2ef7c39a"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5686278e7c91400b845a73fe1fcf028f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC0xLTEtMS05MjcxOA_c36c64cd-5c95-4ef0-a0e0-478c3d18cd0a">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3a9546be5e4813b1774877849c0367_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC0zLTEtMS05MjcxOA_135cccbd-5d0d-4b01-8c43-bb7bc5a9188a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be252f91ca24066a82707f0ccc864f8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC01LTEtMS05MjcxOA_3d5e15dd-467a-4c65-992b-7d07c4086817">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689ac27a1ce141ea907010394c836e09_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC03LTEtMS05MjcxOA_8ba5daec-869c-4e74-875e-369515b809e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50fd4be30c6481e89383764b9f60a6f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0xLTEtMS0xMTAyNDc_e436b496-2e53-44a3-a6b3-281b98520250">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc33001b56c64b11b1bc56c135168d51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0zLTEtMS05NTY4Ng_a3276918-7b6c-4dba-a64b-a2f84777d231">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422117d39c024ae298b2e44b34ec42d8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS01LTEtMS0xMTAyNDk_1025089e-81d6-40ca-ae95-a555e2506fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i323ab94bdb574beaa5f3b95de704e67e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS03LTEtMS0xMTAyNTI_bbf1bc78-857f-49a9-8c16-5fd4451fcf18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi0xLTEtMS0xMTAyNTQ_f0b65560-1c0b-43f3-b45b-74f245e31f0f">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e66814fa7f4fe3ac2057be6b115992_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi0zLTEtMS0xMDM0MTI_f3fe9556-f848-40bb-a74a-e21af4685f2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f770a2cbd548a0b79e3ff8f05781c5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi01LTEtMS0xMDMzODU_2bc00d75-ba81-43cd-9a44-26bad364bc35">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5aa933f00841e28eb62458bbde9491_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi03LTEtMS0xMDM0MDQ_87e11deb-3c9c-4d09-9ab8-f3507e4c74ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5686278e7c91400b845a73fe1fcf028f_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0xLTEtMS05MjcxOA_cdf181e7-cc2b-4dfa-8911-7b065064c3d6">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3a9546be5e4813b1774877849c0367_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0zLTEtMS05MjcxOA_2e71cac5-e5e2-42c0-8bb8-228c25963376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be252f91ca24066a82707f0ccc864f8_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS01LTEtMS05MjcxOA_05a1c34a-8d71-47f5-9533-d3b2b3679aa5">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689ac27a1ce141ea907010394c836e09_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS03LTEtMS05MjcxOA_2eaee5b1-284f-4911-b38c-7bd3ead5499f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547287843f834e908b791ca319cb5472_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy0xLTEtMS05MjcxOA_cf2df07f-bcfb-4247-9bab-64fc850507be">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30434229a1be41d2b746928edc9596bd_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy0zLTEtMS05MjcxOA_80ba637a-76e7-4778-8bd3-c1c2f5856864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d5d4dbdf274858bc9380796f898b48_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy01LTEtMS05MjcxOA_2b84edfb-7cb0-42ba-b4cc-56f3e99c240c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f03abc412b44071b8f3a13dd339e879_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy03LTEtMS05MjcxOA_c754b6a9-0681-4942-b43f-2b75c4494ae7">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109a7c7dcc9143cbaa84164f7f3d1725_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItMS0xLTEtMTEwMjU2_4af1e25d-0dfc-4346-b0a3-d5597c401dde">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i139196726adc4d44903147af425499fc_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItMy0xLTEtMTEwMjU2_d8694a18-c6ab-4be4-a6a8-7c4ec026bb8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42498a38a5c743788e5c175074a9c29f_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItNS0xLTEtMTEwMjU2_439c76a5-b3e6-4c72-8bdd-9430a532568e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8551f6edca8a4836b92c3f8ac634761f_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItNy0xLTEtMTEwMjU2_e7dd3c98-5236-4af9-8274-5516183b4e61">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cb6e64c7b7454eb5293e9be41c37fc_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtMS0xLTEtMTEwMjYw_d68ea4e3-58c5-47db-96a7-d506e568e618">28,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a809ee047749f983c3b7fb473a8eb2_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtMy0xLTEtMTEwMjYw_8f4d1c29-8bef-41a2-b787-348bb2325432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3bf5b1a2204bf9bc64adbee638216b_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtNS0xLTEtMTEwMjYw_c4382cc8-ac66-4a1b-afb6-66dfb752468c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9659021b124e4d70badd33a6c9cda626_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtNy0xLTEtMTEwMjYw_c29c7846-c518-4fb3-ab95-23f5f6cd61c1">28,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f064e9a451f45aab673c4e82dcbc340_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS0xLTEtMS05MjcxOA_67b92e20-0eb9-4622-85f0-aff77f059b01">26,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28cf3e1c65474a53a54292b2f298eedb_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS0zLTEtMS05MjcxOA_dcf712e0-b267-4850-8261-ac18a6e590a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7925fa17894fb08b1ed1fcb9abe902_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS01LTEtMS05MjcxOA_6c476f61-c4c3-41e8-9c0d-7a1233c40694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c59017357e4d0eb7f04b926d3edfb1_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS03LTEtMS05MjcxOA_e015ab21-b51c-498b-ae75-1de434fc821c">26,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtMS0xLTEtOTI3MTg_b436f621-66b4-4ae8-a2d0-cb06a0e8a419">64,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052d13e776b84488abcb5580ea31dbe2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtMy0xLTEtOTI3MTg_e1f659c1-723f-4117-af9a-d0775eb35372">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2071503a8441eb91e6e1a18cbcc84f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtNS0xLTEtOTI3MTg_0dbbc0b9-dcb2-4444-aa96-44f370c23929">3,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f436b1a47f14d0dae8fe3ff7fc02609_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtNy0xLTEtOTI3MTg_379a0659-13d1-4808-802f-84d11f96b567">60,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30307f3e17834aff9e9b9bfbe9740d2c_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtMS0xLTEtOTI3MTg_91470858-3f47-4073-b4b6-4de307304eb6">25,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0b9c47fb4a4632ae6c2ec0c8a0fe8b_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtMy0xLTEtOTI3MTg_20660d9f-f0b1-4925-9f8e-eeb0a4e06241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63099355b56b44639735fd719595c0ec_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtNS0xLTEtOTI3MTg_08042768-4975-4774-ad6e-28d9f2efee36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49cc40992cd148db92c3dc165f590efb_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtNy0xLTEtOTI3MTg_56f253c3-2d83-41db-b1b7-8d513de8c8a7">25,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34247cf421ab44c3a642063a2a64781a_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtMS0xLTEtOTI3MTg_ea703983-61f3-4b32-a4b9-2db770065f1b">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d86d123e7649bc9a08ba202f8cbb1b_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtMy0xLTEtOTI3MTg_ecb20f19-1917-455d-8260-b5aa394b7f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a169b1291f4fae8f8673b8db33720e_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtNS0xLTEtOTI3MTg_9aebfe39-a452-40bc-97de-e62eec193865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7bcaa2cb0c40ec9f2f05572f36effb_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtNy0xLTEtOTI3MTg_76b3f138-6468-4f17-b99f-7f8c01b2f89a">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154538596c24715a9b857081ebbf2c2_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtMS0xLTEtOTI3MTg_d35f5aff-edc1-48a1-a128-afa1314c934a">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb24c12f52c4ed4bfd923928efb0545_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtMy0xLTEtOTI3MTg_68f5cf3b-ee63-4839-be4c-60582ad56205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ea28028ba24e559823c8e265b177a8_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtNS0xLTEtOTI3MTg_ff2dc8ba-0410-4d46-9a1c-9756f4296c46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib694e789a9e14a96a033168b758bb8b8_I20221231" decimals="-3" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtNy0xLTEtOTI3MTg_da0e5b64-0a53-4afb-ac36-e2a11e8c469c">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e8fec49f6742c484f4ed39291aac3c_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktMS0xLTEtOTI3MTg_34ccf886-06e4-46c9-8a4d-b4cafe1e60d8">27,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137f448db78e447e98bb2714c16ee9d8_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktMy0xLTEtOTI3MTg_263d78ec-35ef-4f9e-8d04-48cb45e53e65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3909bff053c54be18d8308bc23b1552c_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktNS0xLTEtOTI3MTg_5962d98c-6a7a-48a8-96c0-788e7c33170b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d3b6e5dace4cfcb820e268951f1c59_I20221231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktNy0xLTEtOTI3MTg_65eaa994-1c3c-447c-a23c-17b806aed4f4">27,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><div style="text-align:center"><ix:continuation id="i29057897982744448f35afece88128e4"><ix:continuation id="iccd6f39c1a394863bc29f81a2ef7c39a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC0xLTEtMS05MjcxOA_dd7df3f9-e412-45c8-b016-44b80abb0c61">14,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC0zLTEtMS05MjcxOA_9cf28164-529a-4918-b598-cdbed94440e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC01LTEtMS05MjcxOA_29292883-c00b-4177-8e45-1c0569ec33a4">14,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC03LTEtMS05MjcxOA_4a8404fa-5fc8-421a-85ff-28a7fc8d510c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS0xLTEtMS05MjcxOA_93b48927-065b-46cf-adc5-9cb9aac2e63b">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS0zLTEtMS05MjcxOA_55446b4d-831d-407b-b4aa-1a46b70ea066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS01LTEtMS05MjcxOA_3866381b-9e61-44c2-aed9-7c5b6d5f6dee">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS03LTEtMS05MjcxOA_79599710-6a51-4156-b362-2a5090ce7f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia357ea3684bd486e9a953093cc31299a_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy0xLTEtMS05MjcxOA_85bebdae-63de-4362-ac38-72646a7ac672">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dc2b3b6d1643f08f096152319ae32f_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy0zLTEtMS05MjcxOA_451cfd6b-83e8-46e4-9b64-bed9c9321462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739de8efcf0847099e2173cceabc811e_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy01LTEtMS05MjcxOA_9c8f720d-5f76-4a6f-8181-2249d22d3e0a">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a361b33fe1423ba9980571550cb413_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy03LTEtMS05MjcxOA_e5da79c7-dcdc-4d71-bc97-7ed8b320b25a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS0xLTEtMS05MjcxOA_11d93b03-bcd1-4aa6-99fa-ee663fbf007b">20,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS0zLTEtMS05MjcxOA_f557936e-8931-408a-80fe-38d830638059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS01LTEtMS05MjcxOA_bc445dc1-70d2-4d6f-a305-fd8a3ff8d1e3">20,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS03LTEtMS05MjcxOA_f0d456bd-cadb-42d9-9ca0-e647fe1b894d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122ee70217fb4cbd8648c12f53e80c04_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItMS0xLTEtOTI3MTg_31d15a4e-45ab-4b55-8ada-80e98706ef91">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fe6f3df45e4383a8f40e6ae0c2e20f_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItMy0xLTEtOTI3MTg_0b419a5e-2e93-4c0c-a6ed-fbd6005c6b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0627ac618c7845f1bb5092afa5095fb5_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItNS0xLTEtOTI3MTg_e2a92905-6036-4096-a052-bdd15cae7c5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd40f9b169a94661afad5c82b59ee442_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItNy0xLTEtOTI3MTg_5c8cbbed-0927-4908-9c0a-47d18cbcbd88">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11793d1454d04740869956397beef53f_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtMS0xLTEtOTU3MjE_83109b30-e359-4fca-b180-f38295a6196a">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95679179f944cce9f35afb1724a6e06_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtMy0xLTEtOTU3MjE_c4418caa-65b5-4fea-be4e-43b4765dc795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c51ce9a1aa4ba2803e09d904c5763f_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtNS0xLTEtOTU3MjE_f6d73aa1-9b0d-4043-88d4-8bbbe18e2bd9">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814802c25f134344bd1ca05e7f8d0ef7_I20211231" decimals="-3" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtNy0xLTEtOTU3MjE_6c1e35a9-65f9-4080-a8f4-b26444415459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f7481192424f469ce8b17fa4645692_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtMS0xLTEtOTI3MTg_e53c9355-326c-45bd-a0ec-fd3ccf0ad28b">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c5d747a44f4274ba30ffb47647922f_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtMy0xLTEtOTI3MTg_a9c02d67-8ff5-4e28-b9e5-3887c793dcdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if231634d16b94cbcb21a0c638c4ef8b1_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtNS0xLTEtOTI3MTg_24f7b98e-8016-4dbe-b485-2c5e6ec51189">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec9f0f2f05443f99f93d8d000ec554d_I20211231" decimals="-3" name="us-gaap:NonfinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtNy0xLTEtOTI3MTg_614df102-6b22-4306-a39c-23afd5815789">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfMjIy_ee8a0d8e-a5c4-4d10-b257-097846b850eb" continuedAt="i054a0a9eafd0475f8adf473baf934f43" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS AND OTHER ASSETS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i054a0a9eafd0475f8adf473baf934f43" continuedAt="i7cd97098991846eba6f17422296c55db"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfMjE5_c1b4a95f-e9a0-4620-bbbe-c2e26fa49536" continuedAt="ic9843beb6baf4a79a054761012150263" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMi0xLTEtMS05MjcxOA_0505f19f-a908-4ce8-8074-5cb61fbba6c0">21,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMi0zLTEtMS05MjcxOA_c79ba235-d0c9-4316-97c8-61196a69fed9">14,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid vendor expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:PrepaidVendorExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0xLTEtMS05NTUwMg_51a7b61f-4923-4e73-b7c2-833ba16ec800">3,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:PrepaidVendorExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0zLTEtMS05NTQ5NQ_821c5df0-29dc-4773-a987-d47ca56224d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredCostsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0xLTEtMS05MjcxOA_4ad700c0-1251-426e-8891-d73b6e1ad72c">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DeferredCostsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0zLTEtMS05MjcxOA_1aa27a5e-c1c7-4d32-930c-b72a741f69c5">12,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance and property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Prepaidinsuranceandpropertytaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNC0xLTEtMS05MjcxOA_a7226758-a51c-4211-ab19-83e267b30283">16,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Prepaidinsuranceandpropertytaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNC0zLTEtMS05MjcxOA_50bc6dce-2d5d-4a68-bda2-6cb7cdc65bcd">6,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT/GST receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Prepaidothertaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNS0xLTEtMS05MjcxOA_7e77a385-3e8b-45c8-b5bf-7e5fac4f5170">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Prepaidothertaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNS0zLTEtMS05MjcxOA_e203958b-942b-4655-a27b-4823366968b3">4,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Deferredtaxcharge" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNi0xLTEtMS05MjcxOA_1b3abf9b-8143-450a-84f1-97ab3e785ffd">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Deferredtaxcharge" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNi0zLTEtMS05MjcxOA_62777856-40d7-4fa1-b3ef-991964639a57">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNy0xLTEtMS05MjcxOA_5c20fe29-c243-4b77-81a2-6d448bfdd407">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNy0zLTEtMS05MjcxOA_7788a266-5b4f-4ffa-ac2e-49e638169dc2">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547287843f834e908b791ca319cb5472_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0xLTEtMS05NTUyMQ_adbf9715-8525-4afb-b5b9-77f76f5b9920">28,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia357ea3684bd486e9a953093cc31299a_I20211231" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0zLTEtMS05NTUxNA_d7974f85-16d4-4ae6-8a33-0d88ac1ef75d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DepositAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOC0xLTEtMS05MjcxOA_b3203cbf-dfa0-48f7-856f-d084b54daeb9">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DepositAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOC0zLTEtMS05MjcxOA_57aacbb3-9285-4c74-a4c4-a6bcdf511daa">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0xLTEtMS05MjcxOA_04d5d65f-fc70-4d87-86d3-38660c64cbae">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0zLTEtMS05MjcxOA_1ddc081d-9e98-4b9e-a58a-e7d868fab3c6">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMTAtMS0xLTEtOTI3MTg_b9f64d6a-47e9-4bb9-a2b5-5abefbbb2067">88,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMTAtMy0xLTEtOTI3MTg_79e795c9-2cb1-4305-b0e5-a79b79c0bf5f">46,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfNTQ5NzU1ODE0MTg3_5705ad7c-a871-4abb-bf3a-620d55926ac6" continuedAt="i2a1e63a3bd1a4138aad02aa8d4787b24" escape="true">Other assets consist of the following (in thousands):</ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="i7cd97098991846eba6f17422296c55db"><ix:continuation id="ic9843beb6baf4a79a054761012150263"><ix:continuation id="i2a1e63a3bd1a4138aad02aa8d4787b24"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pump lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMi0xLTEtMS05MjcxOA_14704186-eb3d-4672-a018-f418ce492f87">27,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMi0zLTEtMS05MjcxOA_7b2da541-212f-44ac-af23-81383aa41d05">25,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spare parts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:SpareParts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMy0xLTEtMS05MjcxOA_04e71ffe-788c-4954-ae54-1c08c1de8245">38,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:SpareParts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMy0zLTEtMS05MjcxOA_261fa665-4378-4596-8294-c06b846c2f7d">28,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNC0xLTEtMS05MjcxOA_43deb6ef-dd21-4a63-979e-66614158cc16">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNC0zLTEtMS05MjcxOA_2b472053-befb-447c-b93b-1ca8c5fe2ab4">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNS0xLTEtMS05MjcxOA_d1a3f5aa-d151-4cdb-b5f6-4a9b5942a8b1">26,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ced24d07c14cf4ab00eabf97854594_I20211231" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNS0zLTEtMS05MjcxOA_7c7f846b-4fe7-4c00-88b0-e6737734118f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNi0xLTEtMS05MjcxOA_b496e477-d8f4-4f28-a853-7d0442ba8b0e">5,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNi0zLTEtMS05MjcxOA_a13f7ab3-3461-46e2-bd57-c71edb302edf">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNy0xLTEtMS05MjcxOA_54f9e00f-b406-4b2f-8484-b8fd9e525b6f">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNy0zLTEtMS05MjcxOA_e5e07b05-8771-4f2d-854e-66d3c2d568b3">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOC0xLTEtMS05MjcxOA_11a0787d-acda-40b8-ad4c-5a58b70ec21a">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOC0zLTEtMS05MjcxOA_9a049233-ae03-49ff-a0a1-69070850289a">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOS0xLTEtMS05MjcxOA_a19f0f6d-19dc-4178-8b7c-972302daa67b">105,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOS0zLTEtMS05MjcxOA_1e216392-c455-466c-b3a3-b70c939e65cb">63,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="margin-top:5pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_100"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzM2OA_90b6b9a6-8c1f-4bb3-908c-d1e96fca7d39" continuedAt="i23aa142f9b0244208670c1bb2bb4c249" escape="true">ACCRUED LIABILITIES AND OTHER LONG-TERM LIABILITIES</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:36pt"><span><br/></span></div><ix:continuation id="i23aa142f9b0244208670c1bb2bb4c249" continuedAt="i324e44bb9e54406f8b83bd598478f4ed"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzM2MA_47fc3e78-38fa-455c-bd00-dec742c1f1b6" escape="true"><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:AccruedSalariesAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzItMi0xLTEtOTI3MTg_7c385ff1-fa0c-4b5a-9e2f-44089fa5ba96">44,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:AccruedSalariesAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzItNC0xLTEtOTI3MTg_7e4f21f3-69e3-4090-b21c-1ab73293ec66">27,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzMtMi0xLTEtOTI3MTg_cac08b2d-4487-4294-bee0-7403ff72c8b1">30,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzMtNC0xLTEtOTI3MTg_7cd052f0-937d-40c3-84a1-f11a5730d5b9">33,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-ST</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzUtMi0xLTEtOTI3MTg_c369b38c-7a3e-48e7-afe6-5a0974b53fd3">18,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzUtNC0xLTEtOTI3MTg_6a0541e6-7e6a-497f-ab95-ea6317bc59ee">9,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzYtMi0xLTEtOTI3MTg_ad8fabed-fd4a-4e2e-8b2c-194db13a11c3">5,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzYtNC0xLTEtOTI3MTg_8c26b017-2b83-4b27-a3ba-64ce70010b01">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:AccruedProductFieldAction." format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzctMi0xLTEtOTI3MTg_5483f384-d40c-4abe-873c-353faec0e43d">24,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:AccruedProductFieldAction." format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzctNC0xLTEtOTI3MTg_219400f8-8d39-4973-8274-54071e9b32db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal accrual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Accruedlegalfees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEwLTItMS0xLTkyNzE4_599a2fc5-fa04-45e8-94df-1fd285a2cced">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Accruedlegalfees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEwLTQtMS0xLTkyNzE4_28cebc75-258f-4b0a-a981-326e0ab7832c">3,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Accruedsalestaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzExLTItMS0xLTkyNzE4_078a24e2-d50f-4796-adde-cb92db96063c">5,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Accruedsalestaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzExLTQtMS0xLTkyNzE4_a72945c0-fdbe-4b0d-9562-71015ca5b5a6">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties and returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEyLTItMS0xLTkyNzE4_fafb30eb-1f81-443e-abba-49ec8b20e2f4">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEyLTQtMS0xLTkyNzE4_5fad1169-ea15-4fed-9b6c-333ed12ae7fa">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEzLTItMS0xLTkyNzE4_b0f48918-0d91-4375-843e-63e748528bb2">30,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEzLTQtMS0xLTkyNzE4_de82a37d-b560-4420-a419-e5f496295c64">12,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Accruedothertaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE1LTItMS0xLTkyNzE4_a0a7381a-95a0-49e9-a01a-19190c88b61e">5,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Accruedothertaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE1LTQtMS0xLTkyNzE4_aa65db57-c2f6-4f85-860a-0db9d217449e">4,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Outsidesalescommissions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE2LTItMS0xLTkyNzE4_df6b4582-ae47-4817-8f61-346e02baf357">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Outsidesalescommissions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE2LTQtMS0xLTkyNzE4_7d87d0b5-1700-4ab4-86e1-7a471aa09160">5,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued freight</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Accruedfreight" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE3LTItMS0xLTkyNzE4_e0b7e2fb-e689-4637-815e-5c84b070d866">17,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Accruedfreight" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE3LTQtMS0xLTkyNzE4_d6a075a5-61a6-4b80-b34d-abcb1abf21e7">9,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE4LTItMS0xLTkyNzE4_a5d478b2-399e-4d29-af5d-262e9e0ccb54">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:RestructuringReserveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE4LTQtMS0xLTkyNzE4_9ee6d74f-2082-4585-aff7-491d2ce9a662">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4092f2517f47dc82182e9da5e14d64_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE5LTItMS0xLTEwMzUxNg_178a7f10-0f2e-48f9-a4e7-b003fb138522">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3aed3c3b2c4c3bb0a41361e73b80b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE5LTQtMS0xLTEwMzUyNA_7f82a894-9c1f-4eff-9b52-e904b8e6622c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued audit fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:AccruedAuditFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIwLTItMS0xLTEwMzU0OA_c2a20ad2-9367-497f-8e01-3429ecbad593">6,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:AccruedAuditFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIwLTQtMS0xLTEwMzU1Ng_ee9bad3c-28ca-4a83-920f-cb72c4c6399c">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIxLTItMS0xLTEwMzUwMA_5ae9142d-98af-4654-abc5-a364db16540b">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIxLTQtMS0xLTEwMzUwOA_95b05ecc-e9fb-4232-8f28-91b7f66d3123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIyLTItMS0xLTEwMzUzMg_d5ca1f02-6eba-4bea-be28-20812c14f639">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIyLTQtMS0xLTEwMzU0MA_4d35ed62-cd17-4d0f-9916-6a764c8e0069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:AccruedResearchAndDevelopmentLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIzLTItMS0xLTkyNzE4_8abeeb9a-03f1-44c5-860c-7eeeeaee415e">3,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:AccruedResearchAndDevelopmentLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIzLTQtMS0xLTkyNzE4_9b865544-8ddc-4fe7-9e1f-4fd523a41d12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI0LTItMS0xLTkyNzE4_7f6d8adb-4e57-44cb-b8df-b0547a2754c9">14,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI0LTQtMS0xLTkyNzE4_9b535c10-dbaa-4577-8216-b45002c73633">8,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI1LTItMS0xLTkyNzE4_d484b011-e670-4177-a663-b4df7faa7d0d">242,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI1LTQtMS0xLTkyNzE4_2acb19cd-c341-43b7-af13-8e7f80344e84">118,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i324e44bb9e54406f8b83bd598478f4ed"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:OtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzU0OTc1NTgxNTA3Nw_e0c91e4a-2241-4f58-819e-95226310003c" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-LT</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzItMS0xLTEtOTI3MTg_4ee8c5a3-d664-44f1-bfd1-06d97c05ec04">60,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzItMy0xLTEtOTI3MTg_c56fd335-5ad6-4033-90a5-64f7e942719c">33,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability-LT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzMtMS0xLTEtOTI3MTg_0ba574df-2d07-45dc-b1e6-724bcfff3d7a">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzMtMy0xLTEtOTI3MTg_e38e1300-5198-424a-a05c-cde8df2be9fc">2,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzUtMS0xLTEtOTI3MTg_4959fa19-c1e6-4449-b4ab-902242bb0cb7">16,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzUtMy0xLTEtOTI3MTg_1ec39851-dfb4-4b85-a400-f352a4cd8cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzYtMS0xLTEtOTI3MTg_9308fde8-a17f-499a-8682-9bf37e200726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzYtMy0xLTEtOTI3MTg_527848d0-5f9a-445c-9f05-ca3440fe48c3">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzctMS0xLTEtOTI3MTg_36c7ccc8-77c1-48c3-ab5c-0f9ac1e75db1">5,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzctMy0xLTEtOTI3MTg_e5bcf6af-d5d8-4a44-94b8-369f34c017bf">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b46600611854ead8201632b540aa737_I20221231" decimals="-3" name="us-gaap:ProductLiabilityAccrualComponentAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzgtMS0xLTEtOTI3MTg_8d123c3a-1f71-46b0-a2b5-bb1ae6024787">25,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f16fd75aa948d082f729515410eecc_I20211231" decimals="-3" name="us-gaap:ProductLiabilityAccrualComponentAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzgtMy0xLTEtOTI3MTg_dc76ae15-36fc-42da-aae2-b8d0740b92f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:AccruedRentCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzktMS0xLTEtOTI3MTg_524edf3c-094d-4583-abaa-1cfe9d577bc8">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:AccruedRentCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzktMy0xLTEtOTI3MTg_897c03c2-9f55-4965-a155-605e6c542969">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzExLTEtMS0xLTkyNzE4_c426c2e0-1e17-44d0-b680-64c34f8e63ef">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzExLTMtMS0xLTkyNzE4_64eb2a88-7a86-4b9a-8e16-cee09497228b">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzEyLTEtMS0xLTkyNzE4_6270651d-1b4f-45de-bed8-191f27ebde96">114,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzEyLTMtMS0xLTkyNzE4_1953358a-ff08-4d40-8bec-f320272e4544">41,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzAwNQ_67c8ea0d-1879-4a19-9718-ee4cec615735" continuedAt="i33ef10a5f4b4498ba28d97f0a9dd4173" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i33ef10a5f4b4498ba28d97f0a9dd4173" continuedAt="ia5bd215723f74f12970056d33d24e3ff"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, in connection with the acquisition of Smiths Medical, we entered into a Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, Wells Fargo Securities, LLC, Barclays Bank PLC and certain other financial institutions (the &#8220;Lenders&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-6" name="icui:TotalSeniorSecuredCreditFacility" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjYyMQ_79ff3837-0404-4a8f-a359-3e8c5e2c1c63">2.2</ix:nonFraction>&#160;billion of senior secured credit facilities. The senior secured credit facilities include (i) a five-year Tranche A term loan of $<ix:nonFraction unitRef="usd" contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjYzNQ_70b789ec-417c-466e-9362-6aa986be76ba">850.0</ix:nonFraction>&#160;million (the "Term Loan A"), (ii) a seven-year Tranche B term loan of $<ix:nonFraction unitRef="usd" contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY2Nw_c7f78926-a18e-426b-871f-1296a17ac949">850.0</ix:nonFraction>&#160;million (the "Term Loan B") and (iii) a five-year revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="idc72f3e18557464b95e8f93f95cf00e1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY1MQ_9ac2200d-b6d6-4eae-9512-a27abcf0830a">500.0</ix:nonFraction>&#160;million (the "Revolving Credit Facility"), with separate sub-limits of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-6" name="icui:RevolverSubLimits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY4Mw_37e24f20-adee-4dc6-a77b-618fbf0a88ec">50.0</ix:nonFraction>&#160;million for letters of credit and swingline loans (collectively, the "Senior Secured Credit Facilities"). We used the proceeds from borrowings under the Term Loan A and the Term Loan B (collectively, the "Term Loans") to fund a portion of the cash consideration for the purchase of Smiths Medical and the related fees and expenses incurred in connection with the acquisition. We did not incur borrowings under the Revolving Credit Facility on the closing date of the acquisition. The proceeds from any future borrowings under the Revolving Credit Facility may be used for working capital and other general corporate purposes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Credit Agreement, during the period ended March 31, 2022, we incurred $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY5OA_5ebde36d-70c0-4961-a6c9-2f901ac38b68">37.8</ix:nonFraction>&#160;million in debt discount and issuance costs, which were allocated to the Term Loan A, the Term Loan B and the Revolving Credit Facility based on lender commitment amounts relative to each type of fees paid. The lender and third-party discount and issuance costs allocated to the Term Loan A and the Term Loan B were $<ix:nonFraction unitRef="usd" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcxMw_4d76931a-5668-4d9e-acc1-5268393b6e7a">15.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcyNw_ce01433d-693e-4ce6-b53d-6fa527c98b50">13.4</ix:nonFraction> million, respectively, and are reflected as a direct deduction from the face amount of the corresponding term loans on the consolidated balance sheet. These costs are being amortized to interest expense over the respective terms of the loans using the effective interest method. The issuance costs allocated to the Revolving Credit Facility were $<ix:nonFraction unitRef="usd" contextRef="idc72f3e18557464b95e8f93f95cf00e1_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzA0Nw_40d3c5ba-d0c1-4835-9dac-565d2f0ff219">8.6</ix:nonFraction>&#160;million, which are capitalized and included in prepaid expenses and other current assets and other assets on our consolidated balance sheets. These costs are being amortized to interest expense over the term of the Revolving Credit Facility using the straight-line method. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net funds received from the Term Loan A and the Term Loan B, after deducting debt issuance costs, were $<ix:nonFraction unitRef="usd" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcyOQ_24dfb1fc-29b8-42b3-a8ea-b65683a05597">834.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc0NQ_bffc6585-c737-4487-83f8-c1772b4629bb">836.6</ix:nonFraction>&#160;million, respectively.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity Dates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity date for the Term Loan A and the Revolving Credit Facility is <ix:nonNumeric contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg0MQ_6ab5f223-a2b6-4ddc-a922-a32cbcb4c387">January 6, 2027</ix:nonNumeric> and the maturity date for the Term Loan B is <ix:nonNumeric contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg0Mw_97f9796d-6195-4c0c-b3d4-afb498b507ab">January 6, 2029</ix:nonNumeric>. Pursuant to the terms and conditions of the Credit Agreement, the maturity dates of the Term Loans and the Revolving Credit Facility may be extended upon our request, subject to the consent of the Lenders.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="ia5bd215723f74f12970056d33d24e3ff" continuedAt="i9a6fb408ac70450480019cc8b36661b4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Terms</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Term Loans and borrowings under the Revolving Credit Facility denominated in U.S. dollars bear interest, at our option, on either: (1) the Base Rate, as defined below, plus the applicable margin, as indicated below ("Base Rate Loans") or (2) the Adjusted Term Secured Overnight Financing Rate ("Adjusted Term SOFR"), as defined below, plus the applicable margin, as indicated below ("Term SOFR Loans"). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Rate is defined as the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="3" name="icui:InterestPercentageAddedToFederalFundsRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg2MA_23a4ec75-c1b7-4f91-9ef7-22546125e99f">0.50</ix:nonFraction>% and (c) Adjusted Term SOFR (as defined below) for a one-month period plus, in each case, <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="2" name="icui:InterestPercentageAddedToBaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg2Nw_0b84d350-5866-4ff1-b7ad-97a31990daab">1.00</ix:nonFraction>%.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Term SOFR is the rate per annum equal to (a) the Term SOFR plus (b) the Term SOFR Adjustment. Term SOFR is the forward-looking term rate based on SOFR and is calculated separately for Term SOFR Loans and Base Rate Loans, as specified in the Credit Agreement. The Term SOFR Adjustment is a percentage per annum of <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="3" name="icui:TerSOFRInterestRateAdjustmentForBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg4OA_7226d2d2-5f71-4020-89f7-b4bf81c8bddc">0.10</ix:nonFraction>% for Base Rate Loans and between <ix:nonFraction unitRef="number" contextRef="ic71707c2dff14fa99b1f7a37aa00d176_I20221231" decimals="3" name="icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg3NA_101b3b64-8080-4e80-8958-650c230f2fe3">0.10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i455063291da94c4e933985b9ba288cce_I20221231" decimals="8" name="icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg4MQ_6df09948-d6c7-43f2-98d4-4d7bbc1f383c">0.25</ix:nonFraction>% for Term SOFR Loans based on the applicable interest period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility Commitment Fee</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility has a per annum commitment fee at an initial rate of <ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg5NQ_b3291a03-c6e9-4d99-b352-e0657201744e">0.25</ix:nonFraction>% which is applied to the available amount of the Revolving Credit Facility. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the commitment fee will be determined by reference to the leverage ratio in effect from time to time as set forth in the table below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Applicable Interest Margins</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan A and borrowings under the Revolving Credit Facility have an initial applicable margin of <ix:nonFraction unitRef="number" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkwOQ_622dce24-eddc-4703-b0b3-1ef241df8b72">0.75</ix:nonFraction>% per annum for Base Rate Loans and <ix:nonFraction unitRef="number" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkwMg_68f6a8b3-e4f7-40db-ad8c-a35b829731cc">1.75</ix:nonFraction>% per annum for Term SOFR Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:InterestMarginandCommitmentFeeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2MA_f52d4a2a-ef47-468e-88e2-8de0dfdc68e7" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3512d069dc6a415ebe18d0c8a10b509a_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMS0xLTEtMTEwNDIz_46c49e8c-fd92-490e-bb3f-cf55654a4e75">2.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3512d069dc6a415ebe18d0c8a10b509a_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMi0xLTEtMTEwNDIz_73f335df-599f-4701-a2ed-35ada0ac02dc">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85c800885ad645afbf1ee8116a89418e_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMy0xLTEtMTEwNDIz_ef619792-4c68-4327-bbe0-a8216c3eb7c9">0.35</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcafc35b7a454888b107f59bd07d6378_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMS0xLTEtMTEwNDIz_97004f00-7f9f-49be-8ecf-9d0083ed4ec2">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcafc35b7a454888b107f59bd07d6378_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMi0xLTEtMTEwNDIz_833e1bfa-13ef-44a7-93d9-9f1b68069fda">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3270e97d056d47e8942bc86735a9953e_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMy0xLTEtMTEwNDIz_f5c5567a-23e7-4d17-99e5-3a21036c9c18">0.30</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i561277523fc640f3a0134d32b5168980_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMS0xLTEtMTEwNDIz_2c0067d7-09a8-4aeb-ab57-d6c6f33509a7">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i561277523fc640f3a0134d32b5168980_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMi0xLTEtMTEwNDIz_1ff90697-799c-41e7-92b6-6944648b6321">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cba9d0dc8fe4d66bbb43d02faad4c58_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMy0xLTEtMTEwNDIz_3433cc69-0410-4c6a-ac2d-fe546974ba48">0.25</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i732e1f9dac654f7d8f641f5c8da76012_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMS0xLTEtMTEwNDIz_d7716f2f-e0c8-4b66-aa64-1faf75141579">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i732e1f9dac654f7d8f641f5c8da76012_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMi0xLTEtMTEwNDIz_f79d42a1-aca9-49a0-804c-628ed97acca2">0.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940aefe82dbf46ca9e966ea0b26dd508_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMy0xLTEtMTEwNDIz_36dae88d-7100-4e8d-84fb-665b16139e18">0.20</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1c38a7e4a4342929faf1d4648044fa0_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMS0xLTEtMTEwNDIz_0f4aa7b5-a50d-48ef-960c-6c677e2f9a35">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1c38a7e4a4342929faf1d4648044fa0_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMi0xLTEtMTEwNDIz_6d029f76-e48a-4d66-a751-040d265e4794">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e4c6ec34d394489821d50e1ab61b2a5_D20220101-20221231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMy0xLTEtMTEwNDIz_30b49295-6119-4dfa-8b37-658f7c43f6ba">0.15</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan B has an initial applicable margin of <ix:nonFraction unitRef="number" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkxNg_7d053697-6fff-418f-bea0-df3b3520afe7">1.5</ix:nonFraction>% per annum for Base Rate Loans and <ix:nonFraction unitRef="number" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkyMg_a16ebd55-51f5-4859-83f6-67a7c80d5793">2.5</ix:nonFraction>% per annum for Term SOFR Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:ApplicableMarginOnLoanTypeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2MQ_b46b9741-042c-4bc2-8d5a-d5845909b77f" continuedAt="i5eb9ed3607544cf49d84c0f88cbf63d6" escape="true">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: </ix:nonNumeric></span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i9a6fb408ac70450480019cc8b36661b4" continuedAt="iad8fc60f9dcb45ee93b07c9ec2635170"><div><ix:continuation id="i5eb9ed3607544cf49d84c0f88cbf63d6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id34fa01e4d2b483792e00d21e1d5819a_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzEtMS0xLTEtMTEwNDY4_fcd73493-5900-48b6-a97a-c1354ea8b76d">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id34fa01e4d2b483792e00d21e1d5819a_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzEtMi0xLTEtMTEwNDY4_ef9b3c85-6b1a-415d-88e2-06c32a37fff4">1.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231" decimals="4" name="icui:ApplicableMarginTermSOFRLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzItMS0xLTEtMTEwNDY4_1222c2f2-c892-4431-bf7f-16b60f5c611c">2.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231" decimals="4" name="icui:ApplicableMarginBaseRateLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzItMi0xLTEtMTEwNDY4_ecf33647-50ab-4114-8113-70f01b6c3311">1.25</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Payments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on the Term Loans are due on the last day of each calendar quarter commencing on June 30, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan A will amortize in nineteen consecutive quarterly installments in an amount equal to <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="3" name="icui:TermAPrincipalPaymentFirst2Years" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkyOA_6ce807d9-7ede-4658-9495-b135eb44c506">2.50</ix:nonFraction>% of the original principal amount in each of the first two years, <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="8" name="icui:TermAPrincipalPaymentYear3And4" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk0Mg_fe42fdf1-32ec-4224-86fe-7dfb31d5c402">5.00</ix:nonFraction>% in each of the third and fourth years and <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="3" name="icui:TermAPrincipalPaymentInYear5" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkzNQ_fa57315d-0b8f-496b-a696-c60991356180">7.50</ix:nonFraction>% in the fifth year, with a final payment of the remaining outstanding principal balance due on the maturity date.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan B matures in twenty-seven consecutive quarterly installments in an amount equal to <ix:nonFraction unitRef="number" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="4" name="icui:TermLoanBPrincipalPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk0OQ_88232e6f-2cd8-49ca-a2fd-03e48c63747b">0.25</ix:nonFraction>% of the original principal amount, with a final payment of the remaining outstanding principal balance due on the maturity date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may borrow, prepay and re-borrow amounts under the Revolving Credit Facility, in accordance with the terms and conditions of the Credit Agreement, with all outstanding amounts due at maturity. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, we prepaid $<ix:nonFraction unitRef="usd" contextRef="ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjgxMg_49db7514-a0ca-43fb-9720-18580153790a">16.0</ix:nonFraction>&#160;million in principal payments on the Term Loan A principal balance. For the year ended December 31, 2022, including the prepayment, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjgyNw_4650de60-5037-451e-a4ed-8b2047423c76">22.4</ix:nonFraction>&#160;million in principal payments on both Term Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Payments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest payments on Base Rate Loans are payable quarterly in arrears on the last business day of each calendar quarter and the applicable maturity date. Interest periods on Term SOFR Loans will be determined, at our option, as either one, three or six months and will be payable on the last day of each interest period and the applicable maturity date. In the case of any interest periods of more than three months' duration, the interest payment will be payable on each day prior to the last day of such interest period that occurs at three-month intervals.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commitment fee on the Revolving Credit Facility is payable quarterly in arrears on the third business day following the last day of each calendar quarter and at the maturity date. The commitment fee is included in interest expense in our consolidated statements of operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantors and Collateral</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Credit Agreement are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Covenants</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains affirmative and negative covenants, including certain financial covenants. The negative covenants include restrictions regarding the incurrence of liens and indebtedness, certain merger and acquisition transactions, asset sales and other dispositions, other investments, dividends, share purchases and payments affecting subsidiaries, changes in nature of business, fiscal year or organizational documents, prepayments and redemptions of subordinated and other junior debt, transactions with affiliates, and other matters.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenants include the Senior Secured Leverage Ratio and the Interest Coverage Ratio, both defined below, and pertain to the Term Loan A and the Revolving Credit Facility.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Leverage Ratio is defined, at any measurement date, as the ratio of: (a) all Funded Debt, as defined in the Credit Agreement, that is secured by a lien on any asset or property minus the lesser of (i) all unrestricted cash and cash </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="iad8fc60f9dcb45ee93b07c9ec2635170" continuedAt="i5ed6ee87be8746c4a1baa99d20044ab4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents and (ii) $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-6" name="icui:LeverageRatioCalculationCeilingSubtractedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk1Ng_5886b21c-bf52-4f27-8854-65a3bffe614f">500.0</ix:nonFraction>&#160;million, to (b) Consolidated EBITDA, as defined in the Credit Agreement, for the most recently completed four fiscal quarters, calculated on a pro forma basis. The maximum Senior Secured Leverage Ratio is 4.50 to 1.00 until June 30, 2024. Thereafter, the maximum Senior Secured Leverage Ratio is 4.00 to 1.00, with limited permitted exception.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interest Coverage ratio is defined, at any measurement date, as the ratio of Consolidated EBITDA, as defined in the Credit Agreement, to Consolidated Interest Expense, as defined in the Credit Agreement, paid or payable in cash, for the most recently completed four fiscal quarters. The minimum Interest Coverage ratio is 3.00 to 1.00.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all financial covenants as of December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary events of default, including, among others: non-payments of principal and interest; breach of representations and warranties; covenant defaults; cross-defaults and cross-acceleration to certain other material indebtedness; the existence of bankruptcy or insolvency proceedings; certain events under ERISA; material judgments; and a change of control. If an event of default occurs and is not cured within any applicable grace period or is not waived, the administrative agent and the Lenders are entitled to take various actions, including, without limitation, the acceleration of all amounts due and the termination of commitments under the Senior Secured Credit Facilities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On November 8, 2017, we entered into a five-year senior secured revolving credit facility with various lenders for $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc5Ng_0d6855bd-7d0f-4350-927c-295c83475ec3">150.0</ix:nonFraction>&#160;million, with Wells Fargo Bank, National Association as the administrative agent, swingline lender and issuing lender (the "Credit Facility"). The Credit Facility, which was set to mature on <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:LineOfCreditFacilityExpirationDate1" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk4Nw_440c5f8f-c2cf-443c-a8ad-8c3ab4eba84d">November 8, 2022</ix:nonNumeric>, was terminated in connection with entering into the Credit Agreement on January 6, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:LinesOfCreditCurrent" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzAwNA_34cc0a5d-7240-40a2-a9e3-a5d5c727550b">no</ix:nonFraction> borrowings outstanding under the Credit Facility at that date or at December 31, 2021. The remaining unamortized deferred debt issuance costs related to the Credit Facility were not material and were expensed in connection with its termination. </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Mg_7e1ad3eb-eac3-4a88-8636-34ca02ae6a12" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our long-term debt consist of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.838%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of <br/>December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzMtMS0xLTEtMTEwNDI4_5c0ea1e4-842e-494d-bc1d-a6908ab554cc">3.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzMtMy0xLTEtMTEwNDI1_8ab60aca-4d27-4a19-8ec8-e9a211acea08">834,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B &#8212; principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzQtMS0xLTEtMTEwNDI4_519d7c71-1d38-4ff1-a716-600a58caa4f4">4.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzQtMy0xLTEtMTEwNDI1_4145f227-f3cd-4207-94eb-09119f2318af">843,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96000b832d5e4e13bd5d06c79eee6056_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzUtMS0xLTEtMTEwNDI4_0516ce8e-78ad-4f63-b06d-ddf83a8d76c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzUtMy0xLTEtMTEwNDI1_badb2ce4-140e-4c67-849e-bb481acd5f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzYtMy0xLTEtMTEwNDI1_3d425739-1be4-4107-acc9-ffe6515975f3">24,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzctMy0xLTEtMTEwNDI1_b28502af-6de0-40a2-bcb0-34e4972bed8c">1,653,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzgtMy0xLTEtMTEwNDI1_dd1b0afa-cb8f-480c-b2e9-76546843e3d5">29,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzktMy0xLTEtMTEwNDI1_3f7d0eaa-7d8b-4006-8501-728697721490">1,623,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of $<ix:nonFraction unitRef="usd" contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Ng_9db97635-c4a9-4f14-a235-fd995819056f">12.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc4MQ_5f77ff67-0cbf-45cd-9852-edb596a33991">11.7</ix:nonFraction>&#160;million relating to the Term Loan A and the Term Loan B, respectively.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Mw_49e14b38-ee44-4fd4-a756-28ee1fb4ff3e" continuedAt="i06e627dff7e54fab952798ac40e0f109" escape="true">As of December 31 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><ix:continuation id="i5ed6ee87be8746c4a1baa99d20044ab4"><div style="text-align:center;text-indent:36pt"><ix:continuation id="i06e627dff7e54fab952798ac40e0f109"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzAtMi0xLTEtMTEwNDQz_2e144102-e199-4a84-8bb1-4dabf7081cb7">29,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzEtMi0xLTEtMTEwNDQz_88b46a8c-71b2-4cbb-8e51-c71ce1c4fa72">51,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzItMi0xLTEtMTEwNDQz_7e01014a-41b2-4ba6-8f3e-58b06291e06e">51,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzMtMi0xLTEtMTEwNDQz_c4a7fd38-5b3f-4f79-9937-8bcfacb63aaa">72,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzQtMi0xLTEtMTEwNDQz_57004413-0fcb-4135-8859-79f60e1eff8e">672,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzUtMi0xLTEtMTEwNDQz_691a0fb4-12bf-4aca-9868-d07ac448e4e8">801,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzYtMi0xLTEtMTEwNDQz_00224689-4484-4c2b-81b0-4f12ca2256be">1,677,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:InterestExpenseOnLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2NA_38b007b5-f98f-4830-a0be-4375f2fd7dd0" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total interest expense related to our long-term debt (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="INF" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItMS0xLTEtMTEwNDQ2_e8a9686f-76f3-46d7-baa9-e75baabd8518">66,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="INF" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItMy0xLTEtMTEwNDQ5_673fb1f5-977d-4663-ade1-b394f0c01f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="INF" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItNS0xLTEtMTEwNDUx_c0ae9ff0-9ec2-41a0-9116-8402cf83127f">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="INF" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtMS0xLTEtMTEwNDQ2_545dd4d3-e063-4e8f-b25f-ac3863401303">6,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="INF" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtMy0xLTEtMTEwNDQ5_0026fc02-99cb-43c4-a10a-1a09ae25a75c">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="INF" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtNS0xLTEtMTEwNDUx_b2ea3a1f-f30b-4d12-b742-6148b82440f5">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee &#8212; Revolving Credit Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtMS0xLTEtMTEwNDQ2_b1b94114-d29a-4441-b3b6-6cfdb8ef3f0a">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtMy0xLTEtMTEwNDQ5_042f8fde-3fd2-49dd-90ba-c4a5a02fbbcf">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtNS0xLTEtMTEwNDUx_9b6b270f-c99f-42ce-9a20-d8b89088da82">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt-related  interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="INF" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtMS0xLTEtMTEwNDQ2_6d623337-1e89-4106-8c00-a5d3fb7a818c">75,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="INF" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtMy0xLTEtMTEwNDQ5_fa1fd633-f439-4a78-901a-dd8e3b79d392">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="INF" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtNS0xLTEtMTEwNDUx_45486513-bfa7-4e92-911f-73e423e131fa">1,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDg_d803a75d-88a8-481c-a6ac-2d54ad3eef9a" continuedAt="i59ffba9e7acf4130947e946f6b5bfaf2" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i59ffba9e7acf4130947e946f6b5bfaf2" continuedAt="i54aab91412274e00baed1a098f2ab0e1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDk_72eaae84-d148-4e89-9d3f-99de20a2c41a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItMi0xLTEtOTI3MTg_6bf5be7a-0288-44cc-aee6-ad6779789053">135,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItNC0xLTEtOTI3MTg_f7b9eee2-89a8-473f-b3e4-8d3e003a226c">81,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItNi0xLTEtOTI3MTg_f176c54e-13c7-4abd-9dd4-a223b92c0cde">41,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtMi0xLTEtOTI3MTg_951e8088-0571-40b1-a1fd-2be87414519d">21,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtNC0xLTEtOTI3MTg_3c6ca2f2-19ff-474e-8887-c266ed244974">41,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtNi0xLTEtOTI3MTg_e23ae715-d96e-4930-a487-b84abb71b19c">56,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtMi0xLTEtOTI3MTg_a3a9adec-449d-4124-af14-c7ac667a6753">114,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtNC0xLTEtOTI3MTg_15292b1a-5372-4a99-9f2b-239660c150b9">123,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtNi0xLTEtOTI3MTg_3ef1ead5-5eca-467f-8d1d-1bccd2e22e8c">97,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxMjM_66dc3acf-469e-45c2-8d27-cbf2fc666981" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtMi0xLTEtOTI3MTg_3e0f0fa4-3081-46b0-8229-4a13bd580fb7">4,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtNC0xLTEtOTI3MTg_132cda64-7e62-4090-91c9-7f6a79a79ee9">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtNi0xLTEtOTI3MTg_695e65db-bf29-4aa0-ac3b-564b3333b603">6,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtMi0xLTEtOTI3MTg_a9284721-35fb-46c6-a8eb-3efbd19920aa">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtNC0xLTEtOTI3MTg_592f4d75-e930-4628-9202-2dcb2f8762c6">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtNi0xLTEtOTI3MTg_ab2b4c85-6b4b-4845-868c-c36476720017">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtMi0xLTEtOTI3MTg_d2605a6e-55e7-43fd-84d4-6bf024750d29">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtNC0xLTEtOTI3MTg_21ff9cfe-3893-403c-98ed-24c0ceadc338">7,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtNi0xLTEtOTI3MTg_10ccb575-f5ea-40bd-96b2-1138adb03cb1">7,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtMi0xLTEtOTI3MTg_befcd6cb-34eb-402a-9d0a-9bb884102b4f">20,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtNC0xLTEtOTI3MTg_648b9d15-0f07-4e52-873f-d96385ab68cf">31,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtNi0xLTEtOTI3MTg_f3e9cd83-a776-4f29-b9d7-8572bc445a09">15,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtMi0xLTEtOTI3MTg_8d254729-04fe-4b7c-a2e4-41abbe480e4a">42,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtNC0xLTEtOTI3MTg_2c14d985-bbb4-4a65-9335-13a86cac399f">8,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtNi0xLTEtOTI3MTg_ccd6ab97-536f-42f8-86eb-cd4615de6dbd">5,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktMi0xLTEtOTI3MTg_ce471bde-a3e9-491e-a36f-5412817cab28">11,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktNC0xLTEtOTI3MTg_800591c4-31b2-4b3d-9b39-d47178c272f9">1,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktNi0xLTEtOTI3MTg_7def941f-6f56-4790-a27d-ee72880bd7be">1,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTItMS0xLTkyNzE4_3fd2a395-1b0e-40cc-8a7b-672e7fcd4d8f">7,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTQtMS0xLTkyNzE4_efc40317-d493-4a48-8e9a-85a4d61c2e47">1,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTYtMS0xLTkyNzE4_d8b697ff-0a2c-4aae-b7ca-7eaf487c2d6c">2,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTItMS0xLTkyNzE4_e8592662-9a4b-482e-afd7-d3b167760f4e">60,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTQtMS0xLTkyNzE4_2e820914-35ae-4bac-85c7-8eef8e47d8ca">11,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTYtMS0xLTkyNzE4_add3e1a9-9151-4ff1-abae-d28a9f221ba6">5,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTItMS0xLTkyNzE4_ee5e4661-b205-4fb3-9f88-59d6455b53b3">40,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTQtMS0xLTkyNzE4_92170c04-21f5-4ea8-b0e0-e3b58d8fe4dc">20,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTYtMS0xLTkyNzE4_6c2e4903-c4ab-4aa7-8089-c01d56664fc7">10,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for tax contingencies for potential tax assessments, and in 2022 we recognized a $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzMwNg_2dd8b9b2-dcae-43c5-ad18-f4215af53cf4">2.0</ix:nonFraction> million net increase, most of which related to various federal, state and foreign tax reserves.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDM_d759da95-734e-478b-b68b-e751f17ee8ab" continuedAt="i6dc05e9adf7c48a6b564f30bbbe31384" escape="true">A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i54aab91412274e00baed1a098f2ab0e1" continuedAt="ifa8f320c449b4e998e70e2e490941da1"><div style="margin-top:5pt"><ix:continuation id="i6dc05e9adf7c48a6b564f30bbbe31384"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at the expected statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMi0xLTEtOTI3MTg_15dde096-90bd-4d4a-8589-579e1058fba0">24,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtNC0xLTEtOTI3MTg_8a49c9a9-9b80-407b-92c0-327ce99892d5">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtNi0xLTEtOTI3MTg_d9cba88b-a313-4ee2-bb45-802e54e457c4">25,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtOC0xLTEtOTI3MTg_ae40b8a1-2f8f-4efe-88ad-2fb1201aab4e">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMTAtMS0xLTkyNzE4_66ff754b-5261-43b2-a519-643a5cac7af0">20,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMTItMS0xLTkyNzE4_a885c96e-7b57-45ae-b6c7-375a1795fa02">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal effect</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMi0xLTEtOTI3MTg_d2b165f2-190e-4585-a85b-ece4cb185e09">5,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtNC0xLTEtOTI3MTg_f1b8eab8-40e4-402f-ba44-baa9dbfad180">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtNi0xLTEtOTI3MTg_2c8c753a-1259-4a72-bf59-cb39a65f6747">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtOC0xLTEtOTI3MTg_2779603e-a7f5-46b5-882f-cad4f31575e5">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMTAtMS0xLTkyNzE4_51399d35-adea-4b2e-aca4-e5a973301588">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMTItMS0xLTkyNzE4_8b08177b-f7b8-4305-8c51-b9572f79fc3f">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMi0xLTEtOTI3MTg_c5c1942b-d439-46ad-8554-50de6b251132">3,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtNC0xLTEtOTI3MTg_b2ece893-0c86-4268-a802-106aba610030">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtNi0xLTEtOTI3MTg_06a5876a-73b6-43a2-8060-bb4084e06be8">2,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtOC0xLTEtOTI3MTg_9c052af4-feaf-46b9-be10-79603131e7db">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMTAtMS0xLTkyNzE4_8210d288-6a62-47a4-85e0-846f41d316b6">3,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMTItMS0xLTkyNzE4_5523b9d8-56c5-454c-b5b4-509b33ee2965">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:GILTItaxexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMi0xLTEtOTI3MTg_43865e70-590b-4290-b0e7-87c0d07f7e7c">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" sign="-" name="icui:GILTItaxexpensepercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctNC0xLTEtOTI3MTg_cf8004bf-28c2-4cae-a135-dd164c3c7ad8">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:GILTItaxexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctNi0xLTEtOTI3MTg_fac6792f-e178-487f-b0dc-c87ad9896b77">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="icui:GILTItaxexpensepercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctOC0xLTEtOTI3MTg_bc7dfe9f-3f0a-44da-811e-7725654fc77d">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:GILTItaxexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMTAtMS0xLTkyNzE4_eed3277c-c147-490a-9591-52538b005609">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="icui:GILTItaxexpensepercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMTItMS0xLTkyNzE4_aaa58d2e-da0c-4b01-91cf-66019a760eb9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMi0xLTEtOTI3MTg_b4fae609-818d-43e6-8539-6e148ceff3c2">2,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtNC0xLTEtOTI3MTg_5e2b393d-7e88-48ce-8885-6e0f2fc3a97e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtNi0xLTEtOTI3MTg_6dd1cc59-54db-442d-88d4-2d2224969f3b">2,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtOC0xLTEtOTI3MTg_1dea2b20-c880-4c32-a6f9-c69e14f49a96">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMTAtMS0xLTkyNzE4_121a06bf-2f5a-4095-8d5e-23bfd20f6fd3">3,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMTItMS0xLTkyNzE4_477d08f1-9137-4fc0-b5e4-c8e437a131f2">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMi0xLTEtOTI3MTg_be90a980-2fa4-40e0-97bf-0960785d9a0d">3,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktNC0xLTEtOTI3MTg_e5023201-0941-4f16-a401-cc9d1852029f">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktNi0xLTEtOTI3MTg_530b2125-05b9-418a-b635-843019388039">4,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktOC0xLTEtOTI3MTg_32753846-def4-4799-8fe2-9805c387fd9d">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMTAtMS0xLTkyNzE4_b56666e4-9ff8-4dcc-947c-3f1c41b768a7">4,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMTItMS0xLTkyNzE4_5458a512-9008-4d4e-8edd-46121b2d95a9">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTItMS0xLTkyNzE4_4248f74e-8dd0-49dc-b75f-45eb04ab180c">2,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTQtMS0xLTkyNzE4_5c7cc4a9-09d5-4b17-a96f-2680eb4fb2fe">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTYtMS0xLTkyNzE4_072ac430-953d-4d9d-b08c-a2ec58293c45">3,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTgtMS0xLTkyNzE4_554c6992-f15f-43f9-844d-dadc1377ff63">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTEwLTEtMS05MjcxOA_b7c9082c-1f94-47ba-b582-f081feca282b">2,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTEyLTEtMS05MjcxOA_be5d00c0-5316-46ab-8d3c-8e100718c7c9">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:EffectiveIncomeTaxRateReconciliationTransactionCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTItMS0xLTkyNzE4_9044215f-a096-4334-a5a6-a5b23f2ec416">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" sign="-" name="icui:EffectiveTaxRateReconcilationTransactionCostPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTQtMS0xLTkyNzE4_fc8a564b-1088-40e1-ba05-e5bcc0a390f8">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:EffectiveIncomeTaxRateReconciliationTransactionCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTYtMS0xLTkyNzE4_f7c81905-3045-472c-bdf6-380c6f935d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="icui:EffectiveTaxRateReconcilationTransactionCostPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTgtMS0xLTkyNzE4_ca328dfa-5c14-459e-9cad-0f1e8094ec65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:EffectiveIncomeTaxRateReconciliationTransactionCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTEwLTEtMS05MjcxOA_c464cc9c-4595-4530-bac3-fefb5c650784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="icui:EffectiveTaxRateReconcilationTransactionCostPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTEyLTEtMS05MjcxOA_749fc071-ec89-4059-97af-b446041611cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTItMS0xLTkyNzE4_610e3df8-4e45-41fc-9ceb-41e534283bbf">6,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTQtMS0xLTkyNzE4_951f903a-04c4-4e3a-856c-c9a131efaf02">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTYtMS0xLTkyNzE4_a9d492f1-7e2c-45b9-b8da-d3dd7450eff4">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTgtMS0xLTkyNzE4_d9c7f255-769e-4de5-b5ee-3f06c867f779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTEwLTEtMS05MjcxOA_2714b449-2608-4e66-b71e-f0403ac21831">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTEyLTEtMS05MjcxOA_1de7f453-26c2-43f5-ba79-bcd72af43bd7">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:Effectiveincometaxreconciliationnondeductiblecompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTItMS0xLTkyNzE4_a35477e3-9f00-4a00-b63d-3cc41e83e377">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" sign="-" name="icui:Effectivetaxratereconciliationnondeductiblecomppercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTQtMS0xLTkyNzE4_580382c6-8d52-4b5f-a8d1-e1834f462dc5">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:Effectiveincometaxreconciliationnondeductiblecompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTYtMS0xLTkyNzE4_e6b5cc6e-119a-44cc-9027-a9a9f1936503">1,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="icui:Effectivetaxratereconciliationnondeductiblecomppercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTgtMS0xLTkyNzE4_9b9ec65b-0889-49be-85a3-f60a35a6ced5">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:Effectiveincometaxreconciliationnondeductiblecompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTEwLTEtMS05MjcxOA_605e2577-238f-4e5f-9d92-40c9fd3a08d2">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="icui:Effectivetaxratereconciliationnondeductiblecomppercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTEyLTEtMS05MjcxOA_762c6d45-a4cf-47fa-b6be-238be86d088c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTItMS0xLTkyNzE4_061ccd6a-aff8-49a0-ab3d-b34eb7517d73">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTQtMS0xLTkyNzE4_23e4b293-dda1-46fc-942c-731d78ce7a83">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTYtMS0xLTkyNzE4_f29fe840-961d-47b3-8fca-d2b347c7f7ae">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTgtMS0xLTkyNzE4_a6fbd8d3-94d3-4c8c-aad0-081d622ec39a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTEwLTEtMS05MjcxOA_68480443-253b-428c-b83d-b7b9decf1775">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTEyLTEtMS05MjcxOA_38fcd061-a057-4521-b27b-bce1b8fde168">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTItMS0xLTkyNzE4_0f31423b-32f9-489c-9c1d-00dca92510aa">40,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTQtMS0xLTkyNzE4_bb548354-9a3a-4ff7-a8ea-49714357a29d">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTYtMS0xLTkyNzE4_306454f6-d9ce-45c2-84ce-d744075863a2">20,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTgtMS0xLTkyNzE4_65635aab-29df-4155-b0d7-3c17e20993fd">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTEwLTEtMS05MjcxOA_155bfcd5-481c-4ae9-9ab2-954d0b780fcf">10,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTEyLTEtMS05MjcxOA_aa46bff1-923b-41cf-9009-dd1e601e80a4">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits in 2022, 2021 and 2020 consist principally of research and developmental tax credits.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxMjY_ea8bad57-8763-4773-ab9a-20eb4f03c5c4" escape="true"><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred income tax assets (liabilities) are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzUtMi0xLTEtOTI3MTg_32391a23-a5f8-4104-a7ed-cde55742be37">17,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzUtNC0xLTEtOTI3MTg_1484a756-b54a-4690-922b-4d08356660a2">7,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired future tax deductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzktMi0xLTEtOTI3MTg_0f37dec5-6dce-40e1-a6a2-c440f82cc0ac">14,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzktNC0xLTEtOTI3MTg_f92a4b9c-367d-4e02-a017-9daee4e85b51">5,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEwLTItMS0xLTkyNzE4_5d15d0e7-e8a7-4a92-a755-743b74450659">6,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEwLTQtMS0xLTkyNzE4_7286aeb6-61dd-49a2-9b0d-28ae4b0e76db">7,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzExLTItMS0xLTkyNzE4_2366225d-e016-4ae5-9e0e-4ecc699a6b95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzExLTQtMS0xLTkyNzE4_84a5496f-423e-427d-85eb-55e12c54a0f6">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="icui:NoncurrentDeferredTaxAssetTaxCreditsState" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEyLTItMS0xLTkyNzE4_8f97e691-5be2-4e38-9f60-dba39f407ede">12,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="icui:NoncurrentDeferredTaxAssetTaxCreditsState" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEyLTQtMS0xLTkyNzE4_7b087f98-8bda-4ef9-b577-333621a5117b">11,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE0LTItMS0xLTkyNzE4_c190268f-1bc7-411b-a859-24c88c477f27">25,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE0LTQtMS0xLTkyNzE4_70c7afc3-8b4f-413a-9046-02c0c922aa06">8,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE1LTItMS0xLTEwODg5NQ_09e606b0-7374-4581-a3a3-8759a330fc86">13,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE1LTQtMS0xLTEwODkwMw_7dd4fbb4-6b93-440a-a955-51ccf2aebcc1">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 163(j)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="icui:DeferredTaxAssetSection163j" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE2LTItMS0xLTEwODkxMQ_5522db2d-9d55-4efc-8e3a-a1ce09487cff">9,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="icui:DeferredTaxAssetSection163j" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE2LTQtMS0xLTEwODkxOQ_67f5b7b7-2c2e-4f4b-8d89-611e211af374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks, discounts, customer concessions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE3LTItMS0xLTkyNzE4_436259b4-125f-4732-b9b6-0f355d02c660">39,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE3LTQtMS0xLTkyNzE4_f4b50fa3-e00b-4ba9-99ce-531f67aabf37">27,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE4LTItMS0xLTkyNzE4_0bea6634-55cb-43f4-9bff-0c3288f93f8c">11,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE4LTQtMS0xLTkyNzE4_48439bd4-2304-4595-a588-809568c7da7e">2,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:Noncurrentdeferredtaxasset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE5LTItMS0xLTkyNzE4_e7ab84db-434d-4fc8-ab1a-304a762d086c">126,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="icui:Noncurrentdeferredtaxasset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE5LTQtMS0xLTkyNzE4_dbd867f1-621a-4644-9429-0db36392dac0">69,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231" decimals="-3" name="icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzIxLTItMS0xLTkyNzE4_df6db091-3977-400f-b890-0c42bfc0b424">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if184142ad50b45d9b675340cb944b665_I20211231" decimals="-3" name="icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzIxLTQtMS0xLTkyNzE4_ceb0c2c4-24aa-4158-8921-79f991160628">2,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231" decimals="-3" name="icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI0LTItMS0xLTkyNzE4_671345b8-a617-464f-8b34-d9034d50976f">209,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if184142ad50b45d9b675340cb944b665_I20211231" decimals="-3" name="icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI0LTQtMS0xLTkyNzE4_9b5e9c0d-c036-4691-ad30-5a70e4de220d">20,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 481(a) adjustment - change in accounting method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02d613a9e034e6baa9929b53040a7cf_D20220101-20221231" decimals="-3" name="icui:Deferredtaxliabilitychangeinaccountingmethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI1LTItMS0xLTkyNzE4_5e64c1a5-e62e-4cef-85a9-253b122b773f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b20d6909b144f7b28ddd68e4ad46d8_D20210101-20211231" decimals="-3" name="icui:Deferredtaxliabilitychangeinaccountingmethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI1LTQtMS0xLTkyNzE4_2a677eeb-5ef6-4e03-8259-4d40ca925003">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI4LTItMS0xLTkyNzE4_5f6a120c-f8b9-411f-9f49-d927e5424b6b">9,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if184142ad50b45d9b675340cb944b665_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI4LTQtMS0xLTkyNzE4_354e880d-ac11-42f9-8650-fba45237ef23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI5LTItMS0xLTkyNzE4_e760ae16-7197-471c-b83f-e608b77e8fee">221,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if184142ad50b45d9b675340cb944b665_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI5LTQtMS0xLTkyNzE4_1aec7ca5-9fb7-4923-98dc-778fd54e61fd">28,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (liability) asset, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzMxLTItMS0xLTkyNzE4_0a06c257-ca87-4b3a-873e-12711c3f94d0">94,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzMxLTQtMS0xLTkyNzE4_ecf98949-f5a2-4127-9d5c-a3be7523eee7">41,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Holidays and Carryforwards</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss ("NOL") carryforwards consist of: (a) federal NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ic74afdfeacf44457849b250892ba31a7_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzEwNjc_1d0e0647-5b59-4836-b38e-604b4aef5af9">1.9</ix:nonFraction> million which will expire at various dates from 2023 to indefinite carryforward periods, (b) state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i0f12929d589749c8b6a43800619acc14_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzExODI_3f3ba9f5-3166-4f8b-a268-43acd091b5d5">4.3</ix:nonFraction> million which will expire at various dates from 2026 to indefinite carryforward periods and (c) foreign NOL carryforwards of  $<ix:nonFraction unitRef="usd" contextRef="i4edba33e66d94d07a0c91f5f1eff0b0f_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzEzMDI_01441fc1-30a0-4648-ba04-30f6e19a076f">46.3</ix:nonFraction> million which will expire at various dates from 2023 to indefinite carryforward periods. We believe that it is more likely than not that the benefit </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ifa8f320c449b4e998e70e2e490941da1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from certain foreign NOL carryforwards will not be realized. In recognition of this risk, we have provided a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE0OQ_cc4f094e-bb4e-450c-aae0-a959abac1bc9">11.5</ix:nonFraction>&#160;million on the $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE2NA_51b306dd-cf1c-470c-851f-a78c6aaac5e8">12.7</ix:nonFraction>&#160;million DTAs related to these foreign NOL carryforwards. Under Section&#160;382 of the Internal Revenue Code, certain ownership changes limit the utilization of the NOL carryforwards, and the amount of federal NOL carryforwards recorded is the net federal benefit available.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other carryforwards include state research and development (&#8220;R&amp;D&#8221;) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzE2OTU_a71b90b2-396a-4856-8047-e9cdba624a5b">18.5</ix:nonFraction> million, which have an indefinite carryforward period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations in Costa Rica operate under various tax holiday and tax incentive programs due to expire in whole or in part in 2029. Certain of the holidays may be extended if specific conditions are met. The net impact of these tax holiday and tax incentives was an increase to our net earnings by $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIwODQ_ec3af848-881c-4a94-b4fb-7903b9b06392">8.1</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIwOTA_4bdb6838-07dc-4aaa-8862-068e8fe3381f">0.34</ix:nonFraction> per diluted share in 2022 and by $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIxMjY_7eadabb9-2af5-4c8a-b154-64850043f55a">9.8</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIxMzI_78e0feab-c3ef-46b4-922b-72c94b4c88d0">0.45</ix:nonFraction> per diluted share in 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, and related tax effects, are an element of &#8220;other comprehensive income&#8221; and are not included in net income other than the revaluation of the associated deferred tax asset due to the Tax Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have estimated $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzI0NDE_dc960a79-e176-4b8a-924f-49821fd7561f">209.2</ix:nonFraction> million of undistributed foreign earnings and profits. Such earnings were previously subject to U.S. tax as a result of the Tax Act and much of any future remittances would generally be subject to no U.S. tax as a result of dividends received deductions and/or foreign tax credit relief. We intend to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we incur significant additional costs upon repatriation of such amounts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various states and foreign jurisdictions. Our U.S. federal income tax returns for tax years 2019 and forward are subject to examination by the Internal Revenue Service. Our principal state income tax returns for tax years 2012 and forward are subject to examination by the state tax authorities. The total gross amount of unrecognized tax benefits as of December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzMzOTM_98d4cd72-5492-4a43-9ce9-303d59ceb01f">54.1</ix:nonFraction> million which, if recognized, would impact the effective tax rate.  We believe that adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax examinations cannot be predicted with certainty. As of December 31, 2022, it is reasonably possible that the expiration of the U.S. federal statute of limitations will cause the gross amount of unrecognized tax benefits to decrease by $7.8 million. It is not possible to estimate any other amount of change, if any, in the unrecognized tax benefits that is reasonably possible within the next twelve months. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We have accrued for penalties and interest of $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE3OQ_ab7925be-f9bb-422d-9dae-4d797ae40620">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE5Mw_8b760f9f-1241-4ff3-b429-aefe0c370054">2.2</ix:nonFraction>&#160;million, respectively as of December 31, 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNjE_bfd63ca0-da8d-4619-9ff8-ee27c8706c9a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItMi0xLTEtOTI3MTg_8a98b6d4-c054-4f63-ae87-d39bb2fe247e">21,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItNC0xLTEtOTI3MTg_a5ef1456-9589-4851-87b2-2c0b3932b9f4">18,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItNi0xLTEtOTI3MTg_83377ac0-bc91-4437-aceb-87664fc6e37d">15,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtMi0xLTEtOTI3MTg_89bfdc1e-e64f-49de-b498-38404c0d3ecb">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtNC0xLTEtOTI3MTg_8404b016-e762-4eb8-9b24-4fed8cd4369e">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtNi0xLTEtOTI3MTg_08bee8be-4648-4a84-9749-66d041c6eaa8">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtMi0xLTEtOTI3MTg_6a749b4f-1526-45f0-8ebf-2ee180299653">29,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtNC0xLTEtOTI3MTg_b069df77-b52e-4e49-a85f-d58f29332f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtNi0xLTEtOTI3MTg_d13b98de-05c1-4640-a9a2-7d591ceffcf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtMi0xLTEtOTI3MTg_616c69d3-f0cb-49c0-b282-e5420b201fd2">4,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtNC0xLTEtOTI3MTg_9c0948ff-3d0a-4911-ae12-75e6e69a5508">3,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtNi0xLTEtOTI3MTg_83683a36-f2c7-4693-870a-3f6838c7ff91">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctMi0xLTEtOTI3MTg_30855e4c-9850-467a-8148-27cd23857195">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctNC0xLTEtOTI3MTg_58dd0d4a-8cbd-467c-b07b-fdabadce427e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctNi0xLTEtOTI3MTg_74092fb4-5cc7-47f0-a2fe-08b21e919111">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktMi0xLTEtOTI3MTg_af37c235-31f7-443e-abe8-b6fd473e2da6">1,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktNC0xLTEtOTI3MTg_3ad9ff1e-db8f-4db5-b9e4-d1a4aaed0d89">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktNi0xLTEtOTI3MTg_3b33cf51-1a9c-40df-afe4-737e7ad428d0">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to settlements with tax authorities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTItMS0xLTkyNzE4_7a946afc-0773-463e-a669-8f3f63af00c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTQtMS0xLTkyNzE4_aa207c33-a2e0-42fa-8bb7-dff9e61cd5aa">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTYtMS0xLTkyNzE4_774df7ec-c8ab-4f40-ab39-d9652691203e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTItMS0xLTkyNzE4_83ba9580-28ef-49d3-9288-b679b0ddfd10">54,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTQtMS0xLTkyNzE4_612239e8-6949-4c9b-a7da-33fab9aaa81e">21,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTYtMS0xLTkyNzE4_07d1e3aa-619f-4b45-88d3-9f253f7e177c">18,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="icui:InformationbyGeographicAreaandCustomerConcentrationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU5Mg_0ab487b4-9883-44bd-ba72-0c6fc80e86e1" continuedAt="i40db60cbca784fd5a37f64a8fea3a282" escape="true">GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i40db60cbca784fd5a37f64a8fea3a282" continuedAt="i23a996e68ec14d739c35d22ebe60e43c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i23a996e68ec14d739c35d22ebe60e43c"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. In 2022, we had worldwide net sales to Medline of <ix:nonFraction unitRef="number" contextRef="iacef78c490d44ef6a148c9eb69aec7b1_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU0OTc1NTgxNDgzNQ_5c41fdfb-a2b6-4dbd-8603-f7da4b42a96a">15</ix:nonFraction>% of consolidated net sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic Information</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU5MQ_4306648e-54c1-4db3-81d2-13545b0e07eb" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8e28b05ab3410580b2d84dbdd0ff1a_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzItMi0xLTEtOTI3MTg_3cb8ebf0-dc64-49f3-bd2a-4ba0571796b8">128,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab8e7d8411f469b8720f601291c4a1c_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzItNC0xLTEtOTI3MTg_09638e49-3aba-4be7-87a2-d6d21397cc4e">115,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87d1ef443a94425bc7fef55aeffbb03_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzMtMi0xLTEtOTI3MTg_47d00c11-62c5-4d65-9b56-06ad34ac864b">99,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28ae14b327942628ff1906d2fa400b6_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzMtNC0xLTEtOTI3MTg_27ebaaae-9542-4c5a-8f55-58804b0e89c3">79,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other LATAM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62f26db34af43bf98b7eb60c5ef5415_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzQtMi0xLTEtOTI3MTg_8a7fd5b0-b9c8-4f58-8679-a5fda464b5c5">39,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ccbff4571344c18aff14611e8b7d41_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzQtNC0xLTEtOTI3MTg_a03e23b2-c59b-4343-bc54-be8cd5fa7a03">36,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5cc1fca5304ed09aeff7464d1e1b88_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzUtMi0xLTEtOTI3MTg_32723148-6a9f-4edc-a689-43b38ddad3c9">5,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb2ffbc07f548e4b7b499325d1200f0_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzUtNC0xLTEtOTI3MTg_d7e16a13-787c-405c-ae19-745526382a48">4,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeed5a4cba574b72b53f8a7432ccc8cb_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzYtMi0xLTEtOTI3MTg_982b8f74-5a1e-40f7-9700-5a2769a723c6">24,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie430db3a6d1b4b528af030bd7dd26f8f_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzYtNC0xLTEtOTI3MTg_3a34f6f6-ac8f-4a84-9723-e6787d77acb1">12,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858b45f5d29a4f37939d46ac810c5f30_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEwLTItMS0xLTkyNzE4_94c2ef43-f11f-442d-b9bf-7841c182a2f2">18,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d6d0becacb4e22863dabc259d16c28_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEwLTQtMS0xLTkyNzE4_a8fc5e96-3bae-4c9f-9c5a-44a8ad6ae1ea">13,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab060b29dc6441d9456425aa02c761d_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTItMS0xLTEwNjMxMw_1cd7c137-ee10-40e7-94c4-8d6bf46cfb03">10,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2962b814b7d0406e9adeda9d07ebf1f6_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTQtMS0xLTEwNjMyMQ_c066b404-1375-499c-a7ab-a804117778ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e5eb1e1a8649b3ad0d53df35a54ddb_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTItMS0xLTkyNzE4_244de794-5c66-417d-8d78-5defae20b6af">11,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica41d22848d442c7a94244fcacf01646_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTQtMS0xLTkyNzE4_899be0a3-573e-4db4-aee3-4d8fa72d171f">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied976c6e3e0a43d5aeb99cdfef5e2e64_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEyLTItMS0xLTkyNzE4_e1546fb3-2be0-4874-9a2a-22b3123fe626">20,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636799cc86f54ffb9c9c4e4c13426aa6_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEyLTQtMS0xLTkyNzE4_c2a3c017-8485-49eb-8853-5a63a613798b">20,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Foreign </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ba3be1285c44ab8b8349e837ac9991_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEzLTItMS0xLTkyNzE4_420a29be-f462-460c-b261-16d114fec01b">358,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7753094a85f4264af0e886e818d2987_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEzLTQtMS0xLTkyNzE4_cb7543f4-df90-4388-a8e8-e2df31af5aec">286,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447520138d3742d59dc3a80450bc8093_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE0LTItMS0xLTkyNzE4_5b758f92-70ac-47ad-8e6d-f0f433477ed4">803,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706aa6c5c3ab47198dd4e501b7d0d5a6_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE0LTQtMS0xLTkyNzE4_333075d2-5bab-4828-8f77-19b22a9cad11">618,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE1LTItMS0xLTkyNzE4_7bbed31b-2308-43b7-b18e-895b2325ecdb">1,162,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE1LTQtMS0xLTkyNzE4_0b32b580-301a-4367-b94d-26031e15872a">905,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0OTg_e161bdbb-04c3-4391-8c2f-40c7b88f715b" continuedAt="i5bf2df81963443edbceeb47b3fb5b30b" escape="true">STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5bf2df81963443edbceeb47b3fb5b30b" continuedAt="i6c10845afc434433b82d2660cbb174cc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2019, our Board of Directors approved a common stock purchase plan to purchase up to $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0Nw_8c7e86ee-2906-4e37-86cf-f5442e355103">100.0</ix:nonFraction> million of our common stock. This plan has no expiration date. We have $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzIxMw_d4950257-d96f-4734-b5e4-c85431e87dcb">100.0</ix:nonFraction> million remaining on this purchase plan. We did not purchase any of our common stock under our common stock purchase plan in 2022, 2021 or 2020. We are limited on share purchases in accordance with the terms and conditions of our Senior Secured Credit Facilities (see Note 11: Long-Term Obligations).&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we withheld <ix:nonFraction unitRef="shares" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzUxNQ_a49938f1-b53b-41e6-9c02-1fda7b050f19">47,664</ix:nonFraction> shares of our common stock from employee vested restricted stock units in consideration for $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzYxMA_2c0a76c2-f203-49ec-954b-96c0f52cb0f6">10.9</ix:nonFraction> million in payments for the employees' share award income tax withholding obligations. We had <ix:nonFraction unitRef="shares" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="0" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzY5OQ_554d9463-7033-441b-b318-730cdbd03b25">1,633</ix:nonFraction> shares remaining in treasury at December 31, 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we withheld <ix:nonFraction unitRef="shares" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzc3NQ_aa93b86f-47c0-44b7-b49e-ffa9421dc62c">40,350</ix:nonFraction> shares of our common stock from employee vested restricted stock units in consideration for $<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzg3MA_063bca95-c682-49f1-a671-5491180a6edd">8.3</ix:nonFraction> million in payments for the employees' share award income tax withholding obligations. We had <ix:nonFraction unitRef="shares" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="0" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzk1OQ_ead47285-0013-44e7-ab20-e20aff87339b">119</ix:nonFraction> shares remaining in treasury at December 31, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we withheld <ix:nonFraction unitRef="shares" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzEwMzU_0fc1798e-397b-45af-89e5-42414e7eedaa">67,041</ix:nonFraction> shares of our common stock from employee vested restricted stock units in consideration for $<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzExMzA_18af2f79-a01c-4fca-94b2-3ede8cb6362a">12.9</ix:nonFraction> million in payments for the employees' share award income tax withholding obligations. We had <ix:nonFraction unitRef="shares" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="0" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzEyMTk_43fb04d5-f6d8-4733-9d26-d92ad55505e4">209</ix:nonFraction> shares remaining in treasury at December 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use treasury stock to issue shares for stock option exercises and restricted stock grants.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive (Loss) Income ("AOCI")</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0OTc_6c2ad44b-3edd-4fcc-9d72-02f3f88e33df" continuedAt="i2268fffcb84d4065b0c693d20c76e7d1" escape="true">The components of AOCI, net of tax, were as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i6c10845afc434433b82d2660cbb174cc"><ix:continuation id="i2268fffcb84d4065b0c693d20c76e7d1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fa663d5f8034bcf82e68c00868a0197_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtMi0xLTEtOTI3MTg_cdfc2bd7-5800-489f-a130-2e0789aa6303">17,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92a0b79cf4e4de386c722e094de46b9_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtNC0xLTEtOTI3MTg_012bb946-0c4d-4294-a94c-b073d396e10d">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09229c1123194f28a17b163cf6604124_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtNi0xLTEtOTI3MTg_4fc8caeb-a113-4e28-b65f-018e28702e44">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtOC0xLTEtOTI3MTg_2699e058-8399-402f-ad4f-93c3d3896319">15,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItMi0xLTEtOTI3MTg_2c22ccdb-c85b-4b76-85bc-37f745ff1d48">12,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItNC0xLTEtOTI3MTg_23996646-6c3c-48d3-84fe-bb171a8fb1fb">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItNi0xLTEtOTI3MTg_3e79c8b2-fa01-42ba-bee3-4d2fcfda85f6">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItOC0xLTEtOTI3MTg_5182f92b-c016-4956-92f4-7e6f5a8a49ed">14,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtMi0xLTEtOTI3MTg_41ca38dd-0e29-4737-8200-2521217d1fa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtNC0xLTEtOTI3MTg_4a2f017d-2d35-4574-8962-ae3a2f0eba87">601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtNi0xLTEtOTI3MTg_182b8e46-2bc2-44d8-a0c8-245a36941cd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtOC0xLTEtOTI3MTg_d871b2cf-b50f-4a61-9edd-30f7a354441f">601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtMi0xLTEtOTI3MTg_193960ab-318a-4d8c-9bee-58b681b77bdc">12,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtNC0xLTEtOTI3MTg_4a6f461b-0bdc-460b-88e0-5fbafb540abf">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtNi0xLTEtOTI3MTg_681b74eb-b051-423c-8a23-453d29a21173">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtOC0xLTEtOTI3MTg_5c63bdeb-f804-492e-a404-8839bac0841a">13,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0da14f54cad34e0a8daba92db8c33fc9_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtMi0xLTEtOTI3MTg_25c4e66d-9ede-4ca9-aec2-07112991f9b8">4,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0caf14d09a404492b64fca8be909ef3a_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtNC0xLTEtOTI3MTg_15545646-dbc7-4f28-bb72-4d95fcc61091">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd1f43f9b9842828a851bba915574e2_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtNi0xLTEtOTI3MTg_aee59b83-aaf7-41c0-8d60-0286122c30b8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtOC0xLTEtOTI3MTg_cc9533e0-3a07-4757-a03e-43d09d91ae66">1,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtMi0xLTEtOTI3MTg_41b6c2c0-936c-4533-96e7-ffee598d772a">14,664</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtNC0xLTEtOTI3MTg_71fe0a0c-2f81-452c-aa7d-4ea53f43f965">403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtNi0xLTEtOTI3MTg_644c0e25-3b2f-4236-a1d3-f693f3f95e1f">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtOC0xLTEtOTI3MTg_dc4fbd37-eee7-4204-8ff5-2ee388b8bc22">15,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctMi0xLTEtOTI3MTg_e82f39d9-889f-4542-a5f5-0b9dc2c3a6dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctNC0xLTEtOTI3MTg_a72ca660-cfbf-48a4-bc35-a68e890d2c7d">2,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctNi0xLTEtOTI3MTg_3ebad9ea-c3e4-4612-bfdb-e057e60105bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctOC0xLTEtOTI3MTg_791efbe2-30dc-460f-a3a0-ee871d5cb922">2,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtMi0xLTEtOTI3MTg_93da741d-109c-46cc-8325-e90cb58f1266">14,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtNC0xLTEtOTI3MTg_da928bf7-62a6-43e2-ad82-1ee5e770eb06">3,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtNi0xLTEtOTI3MTg_900f0734-c637-4ac1-9c4d-fc99968aefe2">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtOC0xLTEtOTI3MTg_dbb4586a-f63f-45e5-aaae-075734e4df9a">17,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e9f0ccbbf147428b431dbee759a035_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktMi0xLTEtOTI3MTg_68b46925-83c6-4b37-98f3-32ba5b69559d">19,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5a149a148884f35a6590fc0b706383d_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktNC0xLTEtOTI3MTg_012bd12d-4a61-45f1-aeb8-6a7975f7436e">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0310811c16e34b749b6d6d1c6f540f0f_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktNi0xLTEtOTI3MTg_d1be27c6-90f9-4879-903a-310738bbeee5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktOC0xLTEtOTI3MTg_deb376a0-08fa-4272-9114-2aa4bf2f08cb">19,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTItMS0xLTkyNzE4_c3aa9c87-5e6a-4da6-ae0e-b651d946369d">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTQtMS0xLTkyNzE4_af237210-14aa-4a0f-a900-6a0eba43c3ae">54,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTYtMS0xLTkyNzE4_5be73da5-a221-472c-8710-deee9493e729">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTgtMS0xLTkyNzE4_7c800c0e-7584-4775-8a11-88c2e228c665">47,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTItMS0xLTkyNzE4_151adfc4-9415-445d-9a0b-6f4cb1bc9738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTQtMS0xLTkyNzE4_d7255759-0fe3-42ed-ac46-f5b40001d688">13,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231" decimals="-3" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTYtMS0xLTkyNzE4_e7958479-eb59-4536-80f1-38f811e03981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTgtMS0xLTkyNzE4_44df4bdd-bfdb-42e7-b9f4-47f980717bdd">13,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTItMS0xLTkyNzE4_7c85e8f0-ddd7-4860-af50-0a2a8fc090ba">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTQtMS0xLTkyNzE4_85006261-962d-435c-b565-fbd4e3df5720">41,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTYtMS0xLTkyNzE4_3e772b32-1ff5-4725-954e-df3709ddebdc">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTgtMS0xLTkyNzE4_75f6fbb6-041b-46a8-9be7-5666cdcae80b">61,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib851d69906c841cea381d2520fe3324a_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTItMS0xLTkyNzE4_8e41b2db-86c3-4886-a309-1f69c0b27c46">122,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b545d554f247d7a0a02f76642e67d6_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTQtMS0xLTkyNzE4_2a719b28-086d-4b32-9e96-60d25e564603">40,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fc00bdab17483ebbb47afc85c0dab2_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTYtMS0xLTkyNzE4_4b59d088-c28a-41c5-a7f1-6731dc10107e">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTgtMS0xLTkyNzE4_6d4c0525-f173-4de0-b5ad-d491935b146f">80,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzM4OTA_b558f6ef-3372-4bf8-b498-235dcb325703" continuedAt="i9c2de8f539844ec7a8a5de9a57bac0f6" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9c2de8f539844ec7a8a5de9a57bac0f6" continuedAt="i32a14b16d7824b718951023bd32cc235"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business.&#160; Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off Balance Sheet Arrangements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products.&#160;There is no maximum limit on the indemnification that may be required under these agreements.&#160;We have never incurred, nor do we expect to incur, any liability for indemnification.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2019, we acquired Pursuit (see Note 2: Acquisitions). Total consideration for the acquisition included a potential contractual earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzE5MjU_70d1caa7-9c06-4683-912b-c7b7c1e6a070">50.0</ix:nonFraction> million to be paid to former Pursuit equity holders, calculated based upon the achievement of certain performance targets during the earn-out period. As of June 30, 2021, the earn-out measurement period had ended and based on the actual sales and gross profit achieved during the measurement period we calculated the actual earn-out to be $<ix:nonFraction unitRef="usd" contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzIyNTk_101e0331-4d73-4a15-853f-124b5ad8c2ac">26.3</ix:nonFraction>&#160;million. In October 2021, the $<ix:nonFraction unitRef="usd" contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzIyODQ_1bc6f3bc-26cd-4018-ac0c-2c5d35cb40ec">26.3</ix:nonFraction>&#160;million earn-out was finalized and paid to the former Pursuit equity holders (see Note 8: Fair Value Measurements).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out shall not exceed $<ix:nonFraction unitRef="usd" contextRef="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzI3MjM_f55b5d46-dd60-4663-bb81-417bc5774732">6.0</ix:nonFraction>&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $<ix:nonFraction unitRef="usd" contextRef="ia073c52ce185453aad5151952a58609f_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMxMjk_bb0b62fc-e92c-48c3-b897-9e6cde035e80">2.6</ix:nonFraction>&#160;million (see Note 8: Fair Value Measurements).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="i32a14b16d7824b718951023bd32cc235"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $<ix:nonFraction unitRef="usd" contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMzMzY_66906601-a7b1-4b36-9d9f-9014d4254e7e">2.5</ix:nonFraction>&#160;million, consisting of (i) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-6" name="icui:ShortTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMzNzY_87846d7f-f643-44cb-8225-1ae7a9cb4786">1.0</ix:nonFraction>&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:LongTermContingentConsiderationGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzM1MjM_e0e526dd-52e5-4944-941c-0ec89e377ccb">1.5</ix:nonFraction>&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-5" name="icui:ContingentConsiderationGrossLT" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzE1OA_b194b990-669c-4246-9532-4fa4e297fce6">1.5</ix:nonFraction>&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical. Total consideration for the acquisition includes a potential earn-out payment of $<ix:nonFraction unitRef="usd" contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231" decimals="-5" name="icui:Contingentconsiderationgross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzExMg_a841dba7-7f93-48c6-ae07-66afe3466624">100.0</ix:nonFraction>&#160;million in cash contingent on our common stock achieving a certain volume-weighted average price from the closing date to either the third or fourth anniversary of closing. As of December 31, 2022, the estimated fair value of the contingent earn-out is $<ix:nonFraction unitRef="usd" contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231" decimals="-4" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzEyOA_c8e1bfa8-3cdf-41de-ac6c-003b5e85e44a">21.0</ix:nonFraction>&#160;million (see Note 8: Fair Value Measurements).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to being acquired, during 2021, Smiths Medical received a Warning Letter from the FDA following an inspection of Smiths Medical&#8217;s Oakdale, Minnesota Facility. The Warning Letter cited, among other things, failures to comply with FDA's medical device reporting requirements and failures to comply with applicable portions of the Quality System Regulation. A provision for the estimated costs related to the field service corrective action was recorded on the opening acquired balance sheet of Smiths Medical. The initial estimate recorded was based on a probability-weighted estimate of the costs required to settle the obligation. The actual costs to be incurred are dependent upon the scope of the work necessary to achieve regulatory clearance and could differ from the original estimate. The estimated field service corrective action recorded at December 31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:ProductLiabilityAccrualComponentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzE0Mw_fd61afef-f587-446b-8649-e8d1675b72e0">49.8</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have non-cancelable operating lease agreements where we are contractually obligated to pay certain lease payment amounts (see Note 5: Leases).</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTgvZnJhZzo0YmMyMjg5YjE2YWQ0M2Y5YTNmZTJlZWM1M2QzM2NjYi90ZXh0cmVnaW9uOjRiYzIyODliMTZhZDQzZjlhM2ZlMmVlYzUzZDMzY2NiXzE4NzM_c108b6e6-b05e-4083-be90-20d8245ed245" continuedAt="idb73bbbc01b442c6954b3782fb198c9f" escape="true">COLLABORATIVE AND OTHER ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="idb73bbbc01b442c6954b3782fb198c9f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs") whereby (i) Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On January 1, 2021, we amended our MSA with Pfizer, whereby we manufacture and supply certain agreed upon products to Pfizer. The amendments included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes to the terms of the MSA included (i) amendments to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products. On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum (the "Product Addendum") to our MSA agreement, whereby Pfizer manufactures and supplies to us certain agreed upon products. The Product Addendum includes the supply of additional product to us subject to certain time and pricing terms and conditions. The Product Addendum included a minimum purchase obligation of $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTgvZnJhZzo0YmMyMjg5YjE2YWQ0M2Y5YTNmZTJlZWM1M2QzM2NjYi90ZXh0cmVnaW9uOjRiYzIyODliMTZhZDQzZjlhM2ZlMmVlYzUzZDMzY2NiXzE4MTg_d8829ede-c0df-4928-9ea6-a30ca8463af2">29.6</ix:nonFraction>&#160;million. The minimum purchase obligation under the addendum was satisfied during 2022. The Product Addendum expired on November 30, 2022.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_1448"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNDQ4L2ZyYWc6MGU1NzEwYzAzYzkwNDBiZjkwMjIzMDg1OTVkZTA0ZGYvdGV4dHJlZ2lvbjowZTU3MTBjMDNjOTA0MGJmOTAyMjMwODU5NWRlMDRkZl81NDk3NTU4MTczODI_3d2602e0-98c8-476f-a63d-e7d26c6cdda5" continuedAt="i461fd339ff074e10bab78e06bff5d9cf" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i461fd339ff074e10bab78e06bff5d9cf">On January 19, 2023, we entered into a revolving $<ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-5" name="icui:AccountsReceivablePurchaseProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNDQ4L2ZyYWc6MGU1NzEwYzAzYzkwNDBiZjkwMjIzMDg1OTVkZTA0ZGYvdGV4dHJlZ2lvbjowZTU3MTBjMDNjOTA0MGJmOTAyMjMwODU5NWRlMDRkZl81NDk3NTU4MTczODQ_c8762112-583a-46ef-b19c-f0ec63a1134c">150</ix:nonFraction>&#160;million uncommitted receivables purchase agreement with Bank of The West ("BOW") which provides for a less expensive form of capital. The discount rate applied to the sold receivables equals, a rate per annum equal to the sum of (i) an applicable margin of 1.75%, plus (ii) Term SOFR for a period equal to the discount period which is calculated with respect to the payment terms of the specific receivable. The accounts receivable to be sold have payment terms ranging between 30 and 60 days, and are related to customer accounts with good credit history. The transfer of the purchased accounts receivable under the agreement is intended to be an absolute and irrevocable transfer constituting a true sale as the transferred receivables have been isolated beyond the reach of the Company and our creditors, even in bankruptcy or other receivership. We will not retain effective control over the sold receivables and BOW will have the right upon purchase to pledge and/or exchange the transferred assets without restrictions. The Company will act as collection agent for BOW, collection services will be undertaken by our accounts receivable personnel in their normal course of business and collected funds will be remitted to BOW. The discount rate has been negotiated net of consideration for the collection services, the cost of collection is expected to be immaterial to the Company.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.&#160;</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations on Effectiveness of Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving  the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e)&#160;and 15(d)-15(e)&#160;under the Securities Exchange Act of 1934) as of the end of the period covered by this Report. Disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the Securities Exchange Commission, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.  B</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ased upon that evaluation, our principal executive officer and our principal financial officer concluded that, as of December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by related SEC staff interpretive guidance for newly acquired businesses, the internal control over financial reporting of Smiths Medical was excluded from the evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022. Smiths Medical, which we acquired in January 2022, constituted approximately 40% of our total assets and 42% of our total revenues as of and for the year ended December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected or is reasonably likely to materially affect our internal control over financial reporting, other than  changes resulting from the acquisition and integration of Smiths Medical.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has used the criteria in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of its internal control over financial reporting.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this criteria, management of the Company has concluded that the Company has maintained effective internal control over its financial reporting as of December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by related SEC staff interpretive guidance, we have excluded from the scope of our assessment of internal control over financial reporting the operations and related assets of Smiths Medical. Smiths Medical constituted approximately 40% of our total assets and 42% of our total revenues as of and for the year ended December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our independent registered public accounting firm that audited the December&#160;31, 2022 financial statements included in this Annual Report on Form&#160;10-K has independently assessed the effectiveness of our internal control over financial reporting and its report is below.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_136"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists the names, ages, certain positions and offices held by our executive officers and directors as of January 31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Held</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivek Jain</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer ("CEO") and Chairman of the Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Bonnell</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer ("CFO") and Treasurer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Voigtlander</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer ("COO")</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Woolson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Vice President, General Manager - Infusion Systems</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia Sanzone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Vice President, General Counsel</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">George A. Lopez, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Greenberg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elisha Finney</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Hoffmeister</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald Abbey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurie Hernandez</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kolleen T. Kennedy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Seeger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Jain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joined the Company in February 2014 as Chairman of the Board and Chief Executive Officer. Mr. Jain served as CareFusion Corporation's ("CareFusion") President of Procedural Solutions from 2011 to February 2014. Mr. Jain served as President, Medical Technologies and Services of CareFusion from 2009 until 2011. Mr. Jain served as the Executive Vice-President-Strategy and Corporate Development of Cardinal Health from 2007 until 2009. Mr. Jain served as Senior Vice President, Business Development and M&amp;A for the Philips Medical Systems business of Koninklijke Philips Electronics N.V., an electronics company from 2006 to August 2007.  Mr. Jain served as an investment banker at J.P. Morgan Securities, Inc., an investment banking firm, from 1994 to 2006. Mr. Jain's last position with J.P. Morgan was as Co-Head of Global Healthcare Investment Banking from 2002 to 2006.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Mr. Voigtlander </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Operating Officer since January 2018. From February 2017 to January 2018, Mr. Voigtlander served as the Company&#8217;s Corporate Vice President, Business Development and General Manager, Infusion Solutions. From June 2015 to February 2017, Mr. Voigtlander served as the Company&#8217;s Vice President, Business Development. Prior to May 2015, Mr. Voigtlander held various roles at CareFusion and last served as Senior Vice President, Business Development and Strategy. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Bonnell </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer and Treasurer since March 3, 2020. From May 2018 until March 2020, Mr. Bonnell served as the Company&#8217;s Corporate Vice President, Finance. Prior to joining the Company, Mr. Bonnell served as Treasurer and Head of Financial Planning and Analysis at Alere Inc. from May 2015 until December 2017. Prior to May 2015, Mr. Bonnell held various roles at CareFusion Corporation in Finance and last served as Senior Vice President, Tax and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasurer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Woolson </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Corporate Vice President, General Manager - Infusion Systems since January 2017. Mr. Woolson served as President, Respiratory Solutions for Becton Dickinson from March 2015 to November 2016. Prior to March 2015, Mr. Woolson held various roles at CareFusion and last served as Vice President/General Manager, Specialty Disposables.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. Sanzone </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Corporate Vice President, General Counsel and Secretary since January 2018.&#160; Ms. Sanzone also serves as our Compliance Officer.&#160; Ms. Sanzone served as the Company&#8217;s Vice President, General Counsel from August of 2015 to January 2018. Prior to August of 2015, Ms. Sanzone held various roles at CareFusion and last served as Senior Vice President, Associate General Counsel - Business Segments &amp; Americas.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr. George A. Lopez, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since 1984. He is the founder of the Company and served as Chairman of the Board, President and CEO from 1989 to October 2013, stepping down from these positions for health reasons. The Board believes Mr. Lopez should serve as a director due to his extensive experience with the Company and industry knowledge provides an invaluable insight to the Board on issues involving the Company and its goals.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. David C. Greenberg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since 2015, serves as Lead Independent Director and Chair of the Compensation Committee and is a member of the Audit Committee.  Mr. Greenberg is currently serving as Chief Executive Officer of HomeThrive, Inc. Mr. Greenberg joined HomeThrive, Inc. in October 2018. Mr. Greenberg was Executive Vice President, Strategy of Medline Industries, Inc. (&#8220;Medline&#8221;) from June 2008 to October 2018.  Medline is a privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care.  In that capacity, Mr. Greenberg was a member of Medline&#8217;s Executive Board and advised top leadership/ownership on all aspects of the business. Mr. Greenberg was responsible for Strategy, Business Development and M&amp;A. Additionally, Mr. Greenberg was a Group President and had responsibility for Medline&#8217;s distribution business and several manufacturing and marketing divisions. Mr. Greenberg has served on the board of directors for Amendia, Inc., a spinal implant company. Previously, Mr. Greenberg spent thirteen years in a variety of leadership positions within Aon Corporation, including Chief Financial Officer of its Aon Global subsidiary. Mr. Greenberg previously served as a director at Potrero Medical, Inc., the latest spinout of medical device incubator Theranova, LLC. Currently Mr. Greenberg serves on the board of directors of HomeThrive, Inc. since October 2018 and Canadian Hospital Specialties, a privately held medical device manufacturer and specialty distributor, since April 2021. The Board believes Mr. Greenberg should serve as a director due to his extensive knowledge and experience in the medical industry, demonstrated executive leadership in business and insight into financial matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. Elisha W. Finney</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since January 2016, and serves as Chair of the Nominating and Governance Committee and is a member of the Audit Committee.  Ms. Finney, now retired, was named Vice President, Finance and CFO of Varian Medical Systems in April 1999. In January 2005, she was promoted to Senior Vice President and given additional management responsibility for the Corporate Information Systems group. She was named Executive Vice President in February 2012. Varian Medical Systems is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Ms. Finney managed a worldwide staff of 400. Her management responsibilities included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury, and corporate information systems.  Ms. Finney joined Varian as risk manager in 1988 and has assumed a wide variety of finance functions over her last 29 years with the company.  Prior to joining Varian, Ms. Finney was with the Fox Group in Foster City, CA, and Beatrice Foods, a major food processing company, in Chicago, IL.  Ms. Finney has served on the boards of: NanoString Technologies, a company that specializes in development of cancer diagnostics tools, since May 2017; Mettler Toledo, a multinational manufacturer of scales and analytical instruments, since November 2017; and Viatris, a global pharmaceutical and healthcare corporation, since December 2022.  Ms. Finney previously served on the boards of directors of: Laserscope from August 2005 until July 2006 when Laserscope was sold to American Medical Systems; Thoratec, a developer, manufacturer and marketer of proprietary medical devices for mechanical circulatory support from July 2007 to May 2013; Altera Corporation, a manufacturer of programmable logic devices from September 2011 until December 2015, when Altera was sold to Intel; Cutera, Inc. a global provider of laser and other energy-based aesthetic systems, from November 2017 to May 2019; and iRobot Corporation, a robotics technology company, from January 2017 to November 2021. The Board believes Ms. Finney should serve as a director due to her extensive knowledge and experience in the medical industry and her financial knowledge and experience, particularly with respect to her service on the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. David F. Hoffmeister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been director since January 2018 and serves as Chair of the Audit Committee and a member of the Compensation Committee.  Mr. Hoffmeister served as Senior Vice President and Chief Financial Officer of Life Technologies Corp. from 2004 to 2014. Prior to joining Life Technologies, Mr. Hoffmeister was a senior partner with McKinsey &amp; Co., focusing on health care, private equity and chemicals industries. Before joining McKinsey, Mr. Hoffmeister held financial positions at GTE Corp. and W.R. Grace and Co. Mr. Hoffmeister currently serves on the boards of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals and has since November of 2014. Mr. Hoffmeister currently serves on the Board of Directors of Glaukos Corp. and has since 2014; Celanese Corp., since 2005; and Stepstone Group, Inc. since 2020. Mr. Hoffmeister received a bachelor&#8217;s of science degree from University of Minnesota and a M.B.A. from University of Chicago. The Board believes Mr. Hoffmeister should serve as a director due to his strong finance background and extensive experience as a chief financial officer of a global biotechnology company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mr. Donald M. Abbey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since January 2018 and is a member of the Nominating Governance Committee and the Compensation Committee. Mr. Abbey is currently serving as Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at Dexcom, Inc. (&#8220;Dexcom&#8221;). Mr. Abbey joined Dexcom in May of 2016. Prior to joining Dexcom, Mr. Abbey was with Becton Dickinson (who acquired CareFusion Corporation in 2015 and which was spun out of Cardinal Health in 2009 (collectively, &#8220;BD&#8221;) from 2007. Mr. Abbey served in many roles over his years at BD including most recently as the Senior Vice President, Quality and Regulatory. Prior to his time at BD, Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions with increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E from Washington State University and a M.B.A from University of Washington.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board believes Mr. Abbey should serve as a director due to his extensive knowledge and experience in the medical industry and particularly, his knowledge of compliance and regulatory requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ms. Laurie Hernandez</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director since July 2021 and is a member of the Nominating and Governance Committee. Ms. Hernandez is a retired healthcare executive with over 25 years of strategic healthcare experience. Ms. Hernandez joined Baxter Healthcare Corporation (&#8220;Baxter&#8221;) in November of 2007 and has assumed a wide variety of strategic positions over her 10 years with that company. Prior to joining Baxter, Ms. Hernandez was with Hospira Inc. in Lake Forest, Illinois. Ms. Hernandez previously served on the boards of Sinai Health System in Chicago, Illinois and Lambs Farm in Libertyville, Illinois. The Board believes Ms. Hernandez should serve as a director due to her extensive experience in the medical industry. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ms. Kolleen T. Kennedy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has been a director since December 2021 and recently retired as President, Proton Solutions &amp; Chief Growth Officer at Varian Medical Systems (&#8220;Varian&#8221;) in December  2021. Ms. Kennedy joined Varian in 1997 as Marketing Manager for radiation therapy delivery systems, and assumed other strategic roles over 24 years including Executive Vice President of Varian Oncology Systems, the market leading radiation therapy business division with nearly 7,000 employees worldwide. Prior to joining Varian, Ms. Kennedy was with Siemens Medical Systems and Radiation Oncology Computer Systems in oncology product sales and marketing.  Ms. Kennedy received BS degrees in Radiation Oncology and Psychology from Wayne State University as well as an MS degree in Medical Physics from the University of Colorado.  Ms. Kennedy currently serves on the board of Wayne State University Foundation since 2018, served on the board of the City Cancer Challenge Foundation from 2018 to 2022, and served on the board of the Radiation Oncology Institute from 2018 to 2021. The Board believes Ms. Kennedy should serve as a director due to her relevant knowledge and history in the medical industry.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mr. William Seeger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has been a director since February 2022.  Mr Seeger, now retired, joined GKN plc, a global engineering group, in 2003 and was Group Finance Director until his retirement in 2014. At GKN plc he also held the roles of CEO of the Propulsion Systems Division, and CFO of the Aerospace Division. Earlier in his career Mr. Seeger spent 30 years at TRW, a U.S.-based automotive and aerospace group, where he held various senior finance positions.  Mr. Seeger currently serves on the board of Spectris plc since 2015, Smiths Group PLC since 2014 and served on the board of GKN plc from 2007 to 2014. As mentioned above, in connection with the Company's issuance of stock consideration for the acquisition of Smiths, the Company and Smiths Group entered into a Shareholder's Agreement which gives Smiths Group the right to designate one individual for election to the Board so long as Smiths Group beneficially owns at least 5% of the total outstanding shares of the Company stock. Mr. Seeger is Smiths Group&#8217;s designated director.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Code of Business Conduct and Ethics applicable to all our directors, officers, and other employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy is available on our website, www.icumed.com in the "Investors" section. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any future amendments to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq's requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information as required by this Item 10 of Form 10-K will be set forth under the captions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Officers, Election of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive Proxy Statement to be filed in connection with our 2023 Annual Meeting of Stockholders, and such information is incorporated herein by reference.&#160; </span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11 of Form 10-K will be set forth under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Officer and Director Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive Proxy Statement to be filed in connection with our 2023 Annual Meeting of Stockholders, and such information is incorporated herein by reference.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 of Form 10-K will be set forth under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation Plan Information </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our definitive Proxy Statement to be filed in connection with our 2023 Annual Meeting of Stockholders, and such information is incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 13 of Form 10-K will be set forth under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Related Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policies and Procedures Regarding Transactions with Related Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Independence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive Proxy Statement to be filed in connection with our 2023 Annual Meeting of Stockholders, and such information is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about aggregate fees billed to us by our principal accountant, Deloitte &amp; Touche LLP (PCAOB No. <ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTEvZnJhZzoyMzE5NmFlMjFjMTE0MjEyODQ3NzlhMGViYmFjYjMwYy90ZXh0cmVnaW9uOjIzMTk2YWUyMWMxMTQyMTI4NDc3OWEwZWJiYWNiMzBjXzE2Nw_8e3f82e1-d5c8-4784-8550-2951c333d6ed">34</ix:nonNumeric>) as required by this Item 14 of Form 10-K will be set forth under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ratification of Auditors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive Proxy Statement to be filed in connection with our 2023 Annual Meeting of Stockholders, and such information is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form 10-K Page No.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following documents are filed as part of this report:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Financial Statements.  See Index to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_46">56</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_160">Exhibits</a>. The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this Form 10-K.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_160">113</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statement Schedules.  The Financial Statement Schedules required to be filed as a part of this Report are:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_163">Schedule II &#8212; Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i33c36cedce9946f68c08b8ced8cb1174_163">115</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_160"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000883984/000119312521267387/d228927dex21.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Sale and Purchase Agreement, dated September 8, 2021, by and between Smiths Group International Holdings Limited, a private limited company incorporated in England and Wales, and ICU Medical, Inc., a Delaware corporation. Filed as an Exhibit to Registrant's Current Report on Form 8-K filed September 8, 2021.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000119312521267387/d228927dex22.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put Option Deed from ICU Medical, Inc., a Delaware corporation to Smiths Group International Holdings Limited, a private limited company incorporated in England and Wales. Filed as an Exhibit to Registrant's Current Report on Form 8-K filed September 8, 2021.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398414000046/exhibitamendedandrestatedc.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant's Certificate of Incorporation, as amended and restated. Filed as an exhibit to Registrant's Current Report on Form 8-K filed on June 10, 2014.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398416000073/exhibit31amendedandrestate.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant's Bylaws, as amended and restated. Filed as an Exhibit&#160;to Registrant's Current Report on Form 8-K filed August 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398420000014/exhibit41descriptionof.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities Registered Under Section 12 of the Exchange Act. Filed as an Exhibit to Registrant's Annual Report on Form 10-K for the year ended December 31, 2019, filed March 2, 3020.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000110465910053238/a10-17276_1ex10d1.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Indemnification Agreement with Directors and Executive Officers. Filed as an Exhibit&#160;to Registrant's Quarterly Report on Form&#160;10-Q for the Quarter ended September&#160;30, 2010, filed October 22, 2010 (File No. 001-34634).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000101968702000543/icu_def14a-040202.txt">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant's 2002 Employee Stock Purchase Plan.*  Filed as an Exhibit&#160;to Registrant's definitive Proxy Statement filed pursuant to Regulation 14A on April&#160;3, 2002 (File No. 000-19974).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103executiveofficer.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive officer compensation*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104non-employeedire.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-employee director compensation*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398413000019/icui-def14ax2013.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Performance-Based Incentive Plan, as amended.*  Filed as Annex A&#160;to Registrant's proxy statement filed April 3, 2013 (File No. 001-34634).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106amendedandrestat.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan.*  <br/>&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398420000014/exhibit1012firstamendm.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to ICU Medical, Inc. Amended and Restated 2011 Stock Incentive Plan. Filed as an exhibit to Registrant's Annual Report on Form 10-K for the year ended December 31, 2019, filed March 2, 2020 (File No.001-34634).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/883984/000088398422000026/exhibit101_41522.htm">10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.8</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Executive Employment Agreement, dated as of April 15, 2022, by and between ICU Medical, Inc. and Vivek Jain.*  Filed as an Exhibit&#160;to Registrant's Current Report on Form&#160;8-K filed April 20, 2022.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398419000017/icui-ex101.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter agreement between the Registrant and Alison Burcar, effective April 1, 2019. Filed as an Exhibit&#160;to Registrant's Quarterly Report on Form&#160;10-Q for the Quarter ended March 31, 2019.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398417000006/exhibit101icumedicalincexe.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICU Medical, Inc. Executive Severance Plan.* Filed as an Exhibit to Registrant&#8217;s Current Report on Form 8-K filed January 6, 2017.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398420000002/exhibit101.htm">10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to the ICU Medical, Inc. Executive Severance Plan. *Filed as an Exhibit to Registrant's Current Report on Form 8-K filed January 6, 2020.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398423000003/exhibit101_123022.htm">10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to the ICU Medical, Inc. Executive Severance Plan. *Filed as an Exhibit to Registrant's Current Report on Form 8-K filed January 3, 2023.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398422000005/exhibit102.htm">10.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated as of January 6, 2022, by and among ICU Medical, Inc. as Borrower, certain subsidiaries as guarantors, Wells Fargo Bank, National Association, as Administrative Agent, Wells Fargo Securities, LLC and Barclays Bank PLC as joint bookrunners and joint lead arrangers and the other joint bookrunners and joint lead arrangers listed therein.# Filed as an Exhibit to Registrant's Current Report on Form 8-K filed January 7, 2022.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/883984/000088398422000005/exhibit101.htm">10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.14</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders Agreement, dated as of January 6, 2022, by and between ICU Medical, Inc. and Smiths Group International Holdings Limited. Filed as an Exhibit to Registrant's Current Report on Form 8-K filed January 7, 2022.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21subsidiariesofreg.htm">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of Registrant.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231consentofdeloitt.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Deloitte&#160;&amp; Touche LLP</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311123122.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312123122.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32123122.htm">32</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The instance document does not appear in the interactive data file because its XBRL (Extensible Business Reporting Language) tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Executive compensation plan or other arrangement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># Annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5)(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ICU MEDICAL,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">VALUATION&#160;AND&#160;QUALIFYING&#160;ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90ZXh0cmVnaW9uOmU0Y2I5YjczZDYzYzQ0Y2FiODg0YjYyMDc0MGYxZTUyXzc3_f9fd2896-6274-40c2-b594-a83fb230b1fa" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:43.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts&#160;in&#160;thousands)<br/>Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning&#160;of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged&#160;to<br/>Costs&#160;and<br/>Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged&#160;to<br/>Other&#160;Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Write-off/<br/>Disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at&#160;End<br/>of&#160;Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4fdf1f07a54b639ac859a24b648c8c_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtMi0xLTEtOTI3MTg_d09b1d27-6783-4395-b804-f33f11650027">20,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtNC0xLTEtOTI3MTg_643e4b6b-3671-43aa-b11a-04bb80345847">7,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtNi0xLTEtOTI3MTg_cb289c70-7b76-4bbe-ad0b-3a083f2dc8d9">5,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtOC0xLTEtOTI3MTg_e42a4703-3a13-4d47-8a14-48d2e43920da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ac49fefe63465a8912d34fb790031a_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtMTAtMS0xLTkyNzE4_e0c90701-17fb-4ace-a1e4-3a9d0f2bf425">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf00748957594ed9924d63ec3390253e_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtMi0xLTEtOTI3MTg_71fe373c-ebb6-4c91-902a-09cc4a161b2f">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtNC0xLTEtOTI3MTg_81fa1369-1607-4ff8-835b-f0fbbde4159e">3,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtNi0xLTEtOTI3MTg_ac77e3f6-2094-40d2-92f6-5050c2cf6e05">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtOC0xLTEtOTI3MTg_4ac2a7fa-fdff-4db6-b1f3-525fec6d2c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0549fbba004248979b80bb6b02218da9_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtMTAtMS0xLTkyNzE4_38df6904-f2e9-4f5d-aac3-237a2eb57aa8">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtMi0xLTEtOTI3MTg_fc9b8b47-6946-4b75-928b-78199d31bafc">3,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:WarrantyAndReturnReserveCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtNC0xLTEtOTI3MTg_604727b2-079c-42a4-9443-6e133fe60362">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtNi0xLTEtOTI3MTg_6d78df7d-6247-4d2b-9c56-9a5153034cdf">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231" decimals="-3" name="icui:WarrantyAndReturnReserveInventoryWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtOC0xLTEtOTI3MTg_1637e5b0-af7f-40b9-a640-a506870b076a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtMTAtMS0xLTkyNzE4_6f65b3ee-a539-49d6-9c30-3bd85cc5f20e">1,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322d334cb60e40d4a61f1bc09d5257bc_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtMi0xLTEtOTI3MTg_fe859b4c-6b4c-4747-9729-6d584e0a951b">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtNC0xLTEtOTI3MTg_d47819ff-c21a-48be-8384-53c39b2e8df6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtNi0xLTEtOTI3MTg_c33ef2ee-822c-4fa1-8fd7-2d4465ca7a15">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtOC0xLTEtOTI3MTg_18630cc4-7db2-4413-b8e0-dda6f4eb8fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f182769ad646e3bddd9c4239760f1d_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtMTAtMS0xLTkyNzE4_08ee06be-1ee7-48fe-8454-d5a0ee5ce5af">3,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ac49fefe63465a8912d34fb790031a_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktMi0xLTEtOTI3MTg_a88ed933-ef45-4ce9-861e-c67dcd94ffcf">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktNC0xLTEtOTI3MTg_8746978a-9b45-426e-9780-f5e4c9a5dbd5">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktNi0xLTEtOTI3MTg_077d3ad4-8844-40f2-a979-cc03931542eb">14,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktOC0xLTEtOTI3MTg_2f785c30-0954-47c9-9a57-280269be7b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktMTAtMS0xLTkyNzE4_43b0becf-a610-4c54-871d-141fa7a1e245">7,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0549fbba004248979b80bb6b02218da9_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTItMS0xLTkyNzE4_9da0e491-c7b0-426d-b68c-021dbae73d8b">2,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTQtMS0xLTkyNzE4_4c08e06a-dbc9-4413-a3a8-f3872f72f85f">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTYtMS0xLTkyNzE4_916363d5-b406-4c20-ae6e-0cc8482df921">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTgtMS0xLTkyNzE4_821588af-132b-4495-91c3-07ef23444cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271cf17cf0844a2a04595bf20873f7f_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTEwLTEtMS05MjcxOA_5d57d7a2-f2b9-4bf5-b229-12ec9505417b">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTItMS0xLTkyNzE4_6cb79dcf-57d4-4b7b-bf5a-81ef382f241f">1,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:WarrantyAndReturnReserveCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTQtMS0xLTkyNzE4_5e6c968e-eecc-40aa-8554-3fa800cd2d09">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTYtMS0xLTkyNzE4_f2167d54-b957-4976-b043-0c9df0eeb6d2">533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231" decimals="-3" name="icui:WarrantyAndReturnReserveInventoryWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTgtMS0xLTkyNzE4_8550902e-6aa8-4663-8ab8-8f3bc95830e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTEwLTEtMS05MjcxOA_4a397911-1cdf-4297-ac8a-090b4d1f66f8">1,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f182769ad646e3bddd9c4239760f1d_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTItMS0xLTkyNzE4_f5b0583c-b0d0-47df-9ba8-a83d9d36f6f9">3,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTQtMS0xLTkyNzE4_76cdde13-df3a-41dd-98cd-1779d55f89dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTYtMS0xLTkyNzE4_dbd5dd38-3466-438d-9669-c819edd969f0">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTgtMS0xLTkyNzE4_5454b38a-a268-44ec-a03e-90f02b4d8830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTEwLTEtMS05MjcxOA_70a15287-b3c9-43c4-9889-456e4ecaf268">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTItMS0xLTkyNzE4_c6692f6e-4cb8-4119-b1e3-0069a9f57c73">7,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTQtMS0xLTkyNzE4_1898849c-492b-4c9b-bd51-d99b620b3df7">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTYtMS0xLTkyNzE4_0686b269-6394-4d9b-8908-0efdbdb0f721">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTgtMS0xLTkyNzE4_2f40fad3-f03b-42ea-8076-a205ab8c5a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fef45bfc2f422c819e0dbb81290ea7_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTEwLTEtMS05MjcxOA_c35bbb28-d093-44ea-811c-7a4e040f6978">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0271cf17cf0844a2a04595bf20873f7f_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTItMS0xLTkyNzE4_79bdec25-59c4-49c3-8b78-f90c71f4ee35">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTQtMS0xLTkyNzE4_8304f597-73ef-4c38-807f-a9e787be4032">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTYtMS0xLTkyNzE4_7396f59e-ab2c-46dd-960f-0de80bc14c07">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTgtMS0xLTkyNzE4_22aa6966-e8a3-451a-878a-65db8e279bb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205528742f3c4d1db554ed4a86cd9547_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTEwLTEtMS05MjcxOA_9a9d816c-2652-4978-ad39-ba3b3734b20e">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory/accrued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTItMS0xLTkyNzE4_1befc47d-579d-4d17-82fb-b039f529869f">1,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:WarrantyAndReturnReserveCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTQtMS0xLTkyNzE4_0ffd34b7-1e33-443e-b2fc-a5b46531567b">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" sign="-" name="icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTYtMS0xLTkyNzE4_15a18cee-28b3-4652-93c6-7d36196bcb22">47,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231" decimals="-3" name="icui:WarrantyAndReturnReserveInventoryWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTgtMS0xLTkyNzE4_68b40632-cf35-465c-9600-7d407295ee11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231" decimals="-3" name="icui:WarrantyAndReturnReserveInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTEwLTEtMS05MjcxOA_bfc25418-3de2-4afd-8824-6037e7c97f8b">50,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTItMS0xLTkyNzE4_85804376-01f3-475e-ae68-604fb4f9fccf">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTQtMS0xLTkyNzE4_e389fa72-cd7f-4bac-963f-545890fd0e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTYtMS0xLTkyNzE4_f8ce1d4e-7074-409d-97fa-bd7cbb87cb99">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTgtMS0xLTkyNzE4_15db4188-dea3-415f-819e-9d7e747d7a03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8f43d24ee94d6093c1c5f148e1cf17_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTEwLTEtMS05MjcxOA_752f9020-c165-45d1-ad01-730a9698b9c0">11,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes an acquired balance of $3.8 million related to the Smiths Medical acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes an acquired balance of $55.2 million in short-term and long-term accrued warranty reserve related to the Smiths Medical acquisition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i33c36cedce9946f68c08b8ced8cb1174_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None</span></div><div><span><br/></span></div><div id="i33c36cedce9946f68c08b8ced8cb1174_169"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU MEDICAL,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Vivek Jain</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vivek Jain</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Vivek Jain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman of the Board and</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vivek Jain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Brian M. Bonnell</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brian M. Bonnell</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ George A. Lopez, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">George A. Lopez, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ David C. Greenberg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">David C. Greenberg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Elisha W. Finney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elisha W. Finney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ David F. Hoffmeister</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">David F. Hoffmeister</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Donald M. Abbey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Donald M. Abbey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Laurie Hernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laurie Hernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ Kolleen T. Kennedy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kolleen T. Kennedy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/s/ William Seeger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">William Seeger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>exhibit103executiveofficer.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i04eee2270b2b468f9de782c29ccbe3b0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;10.3</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officer Compensation</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, the annual base salaries for our executive officers are as follows&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivek Jain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,000&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Bonnell</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Voigtlander</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Woolson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Vice President, General Manager - Infusion Systems</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia Sanzone</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Vice President, General Counsel</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exhibit104non-employeedire.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idd16d516791947459da17df1b4bc907b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;10.4</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Director Compensation</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently pay our non-employee directors the following&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">annual retainer of $93,500 for the Lead Director  </font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">annual retainer of $102,000 for the Chairperson of the Audit Committee</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">annual retainer of $92,500 for the Chairperson of the Compensation Committee</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity component of the director's compensation is valued at $180,000.  The annual equity package consists of 50% in stock options and 50% in restricted stock units.   The options become exercisable one year after the grant date and expire ten years after the grant date.  The restricted stock units vest one year from the grant date.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>exhibit106amendedandrestat.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icb4d4c51ac844a7dae9e3c65743ed2ea_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purposes of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company&#8217;s business. The Plan amends and restates in its entirety the ICU Medical, Inc. 2011 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Original Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following definitions shall apply as used herein and in the individual Award Agreements except as defined otherwise in an individual Award Agreement. In the event a term is separately defined in an individual Award Agreement, such definition shall supersede the definition contained in this Section 2.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board or any of the Committees appointed to administer the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Associate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have the respective meanings ascribed to such terms in Rule 12b-2 promulgated under the Exchange Act.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the legal requirements relating to the Plan and the Awards under applicable provisions of federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange or national market system, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assumed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that pursuant to a Corporate Transaction or Change in Control either (i) the Award is expressly affirmed by the Company or (ii) the contractual obligations represented by the Award are expressly assumed (and not simply by operation of law) by the successor entity or its Parent in connection with the transaction with appropriate adjustments to the number and type of securities of the successor entity or its Parent subject to the Award and the exercise or purchase price thereof which at least preserves the compensation element of the Award existing at the time of the transaction as determined in accordance with the instruments evidencing the agreement to assume the Award.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the grant of an Option, SAR, Dividend Equivalent Right, Restricted Stock, Restricted Stock Unit or other right or benefit under the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including any amendments thereto.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to the termination by the Company or a Related Entity of the Grantee&#8217;s Continuous Service, that such termination is for &#8220;Cause&#8221; as such term (or word of like import) is expressly defined in a then-effective written agreement between the Grantee and the Company or such Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator, the Grantee&#8217;s&#58; (i) performance of any act or failure to perform any act in bad faith and to the detriment of the Company or a Related Entity&#59; (ii) dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity&#59; or (iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person&#59; provided, however, that with regard to any agreement that defines &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; on the occurrence of or in connection with a Corporate Transaction or a Change in Control, such definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall not apply until a Corporate Transaction or a Change in Control actually occurs.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;With respect to an Award granted prior to the Effective Date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as defined in the Original Plan&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;With respect to an Award granted on or after the Effective Date, a change in ownership or control of the Company effected through either of the following transactions&#58;</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 50% or more of either (A) the then-outstanding shares of common stock of the Company (the &#8220;Outstanding Company Common Stock&#8221;) or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the &#8220;Outstanding Company Voting Securities&#8221;)&#59; provided, however, that for purposes of this subsection, the following acquisitions shall not constitute a Change in Control&#58; (i) any acquisition from the Company, (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iv) any acquisition by any corporation pursuant to a transaction which complies with all of clauses (A), (B) and (C) of subsection (c) of this section&#59; or</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;individuals who, as of the date hereof, constitute the members of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incumbent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) ceasing for any reason to constitute at least a majority of the Board&#59; provided, however, that any individual becoming a director subsequent to the date hereof whose election or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least a majority of the Incumbent Directors then in office shall be deemed to be an Incumbent Director (except that this proviso shall not apply to any individual whose initial election as a director occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board)&#59; or</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;the consummation of a reorganization, merger or consolidation involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless, immediately following such Business Combination, each of the following three conditions is satisfied&#58; (A) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries)(such resulting or acquiring corporation is referred to as the &#8220;Acquiring Corporation&#8221;) in substantially the same proportions, relative to one another, as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or the Acquiring Corporation) beneficially owns, directly or indirectly, 50% or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding voting securities of such corporation (except to the extent that such ownership existed prior to the Business Combination) and (C) a majority of the members of the board of directors of the Acquiring Corporation were Incumbent Directors at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination&#59; or</font></div><div style="text-indent:144pt"><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;approval of the stockholders of the Company of a complete liquidation or dissolution of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section 409A of the Code, to the extent required to avoid the imposition of additional taxes under Section 409A of the Code, the transaction or event described in subsection (A), (B), (C) or (D) with respect to such Award (or portion thereof) shall only </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">change in control event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any committee composed of members of the Board appointed by the Board to administer the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the common stock of the Company.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means ICU Medical, Inc., a Delaware corporation, or any successor entity that assumes the Plan in connection with a Change in Control.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person (other than an Employee or a Director, solely with respect to rendering services in such person&#8217;s capacity as a Director) who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or such Related Entity.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;&#8220;Continuing Directors&#8221; means members of the Board who either (i) have been Board members continuously for a period of at least twelve (12) months or (ii) have been Board members for less than twelve (12) months and were elected or nominated for election as Board members by at least a majority of the Board members described in clause (i) who were still in office at the time such election or nomination was approved by the Board.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that the provision of services to the Company or a Related Entity in any capacity of Employee, Director or Consultant is not interrupted or terminated. In jurisdictions requiring notice in advance of an effective termination as an Employee, Director or Consultant, Continuous Service shall be deemed terminated upon the actual cessation of providing services to the Company or a Related Entity notwithstanding any required notice period that must be fulfilled before a termination as an Employee, Director or Consultant can be effective under Applicable Laws. A Grantee&#8217;s Continuous Service shall be deemed to have terminated either upon an actual termination of Continuous Service or upon the entity for which the Grantee provides services ceasing to be a Related Entity. Continuous Service shall not be considered interrupted in the case of (i) any approved leave of absence, (ii) transfers among the Company, any Related Entity, or any successor, in any capacity of Employee, Director or Consultant, or (iii) any change in status as long as the individual remains in the service of the Company or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement). Notwithstanding the foregoing, except as otherwise determined by the Administrator, in the event of any spin-off of a Related Entity, service as an Employee, Director or Consultant for such Related Entity following such spin-off shall be deemed to be Continuous Service for purposes of the Plan and any Award under the Plan. An approved leave of absence shall include sick leave, military leave, or any other authorized personal leave. For purposes of each Incentive Stock Option granted under the Plan, if such leave exceeds three (3) months, and reemployment upon expiration of such leave is not guaranteed by statute or contract, then the Incentive Stock Option shall be treated as a Non-Qualified Stock Option on the day three (3) months and one (1) day following the expiration of such three (3) month period.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any of the following transactions&#59; provided, however, that the Administrator shall determine under parts (iv) and (v) whether multiple transactions are related, and its determination shall be final, binding and conclusive&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated&#59;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the sale, transfer or other disposition of all or substantially all of the assets of the Company&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the complete liquidation or dissolution of the Company&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the shares of Common Stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than forty percent (40%) of the total combined voting power of the Company&#8217;s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger, but excluding any such transaction or series of related transactions that the Administrator determines shall not be a Corporate Transaction&#59; or</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule 13d&#8209;3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities but excluding any such transaction or series of related transactions that the Administrator determines shall not be a Corporate Transaction.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Employee who is a &#8220;covered employee&#8221; under Section 162(m)(3) of the Code.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a member of the Board or the board of directors of any Related Entity.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means as defined under the long-term disability policy of the Company or the Related Entity to which the Grantee provides services regardless of whether the Grantee is covered by such policy. If the Company or the Related Entity to which the Grantee provides services does not have a long-term disability plan in place, &#8220;Disability&#8221; means that a Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determinable physical or mental impairment for a period of not less than ninety (90) consecutive days. A Grantee will not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Administrator in its discretion.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Equivalent Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a right entitling the Grantee to compensation measured by dividends paid with respect to Common Stock.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for purposes of the Plan (as amended and restated), the date on which the Plan is approved by the Company&#8217;s stockholders&#59; provided, however, that solely for purposes of the last sentence of Section 12, the Effective Date shall be the date on which the Plan (as amended and restated) is adopted by the Board, subject to approval of the Plan (as amended and restated) by the Company&#8217;s stockholders. Notwithstanding the foregoing, the Original Plan shall remain in effect on its existing terms unless and until the Plan (as amended and restated) is approved by the Company&#8217;s stockholders.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person, including an Officer or Director, who is in the employ of the Company or any Related Entity, subject to the control and direction of the Company or any Related Entity as to both the work to be performed and the manner and method of performance. The payment of a Director&#8217;s fee by the Company or a Related Entity shall not be sufficient to constitute &#8220;employment&#8221; by the Company.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of Common Stock determined as follows&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If the Common Stock is listed on one or more established stock exchanges or national market systems, including without limitation The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market of The NASDAQ Stock Market LLC, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on the principal exchange </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or system on which the Common Stock is listed (as determined by the Administrator) on the date of determination (or, if no closing sales price or closing bid was reported on that date, as applicable, on the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable&#59;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;If the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable&#59; or</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;In the absence of an established market for the Common Stock of the type described in (i) and (ii), above, the Fair Market Value thereof shall be determined by the Administrator in good faith.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Employee, Director or Consultant who receives an Award under the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Qualified Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Option not intended to qualify as an Incentive Stock Option.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ab)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person who is an officer of the Company or a Related Entity within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ac)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an option to purchase Shares pursuant to an Award Agreement granted under the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ad)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">parent corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; whether now or hereafter existing, as defined in Section 424(e) of the Code.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ae)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means compensation qualifying as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(af)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means this Amended and Restated 2011 Stock Incentive Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ag)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Parent or Subsidiary of the Company.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ah)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Replaced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that pursuant to a Change in Control or Corporate Transaction the Award is replaced with a comparable stock award or a cash incentive program of the Company, the successor entity (if applicable) or Parent of either of them which preserves the compensation element of such Award existing at the time of the transaction and provides for subsequent payout in accordance with the same (or a more favorable) vesting schedule applicable to such Award. The determination of Award comparability shall be made by the Administrator and its determination shall be final, binding and conclusive.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ai)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions on transfer, rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established by the Administrator.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(aj)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Award which may be earned in whole or in part upon the passage of time or the attainment of performance criteria established by the Administrator and which may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settled for cash, Shares or other securities or a combination of cash, Shares or other securities as established by the Administrator.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ak)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor thereto.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(al)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a stock appreciation right entitling the Grantee to Shares or cash compensation, as established by the Administrator, measured by appreciation in the value of Common Stock.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(am)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a share of the Common Stock.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(an)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">subsidiary corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; whether now or hereafter existing, as defined in Section 424(f) of the Code.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Subject to the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the provisions of Section 10, below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive Stock Options) is equal to the sum of 4,179,510 Shares (the &#8220;Share Limit&#8221;). The maximum aggregate number of Shares which may be issued pursuant to all Awards of Incentive Stock Options is 4,179,510 Shares. Notwithstanding the foregoing, any Shares covered by Awards other than Options and SARs shall be counted against the limit set forth herein as 2.09 Shares for every one (1) Share issued in connection with such Award (and shall be counted as 2.09 Shares for every one (1) Share returned or deemed not have been issued from the Plan pursuant to Section 3(b) below in connection with Awards other than Options and SARs). SARs payable in Shares shall reduce the maximum aggregate number of Shares which may be issued under the Plan only by the gross number of actual Shares issued to the Grantee upon exercise of the SAR. The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the Plan. Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan and shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by the Company at the lower of their original purchase price or their Fair Market Value at the time of repurchase, such Shares shall become available for future grant under the Plan. Notwithstanding anything to the contrary contained herein&#58; (i) Shares tendered or withheld in payment of an Option exercise price shall not be returned to the Plan and shall not become available for future issuance under the Plan&#59; (ii) Shares withheld by the Company to satisfy any tax withholding obligation shall not be returned to the Plan and shall not become available for future issuance under the Plan&#59; (iii) all Shares covered by the portion of an SAR that is exercised (whether or not Shares are actually issued to the Grantee upon exercise of the SAR) shall be considered issued pursuant to the Plan&#59; and (iv) Shares purchased on the open market by the Company with the cash proceeds received from the exercise of Options shall not be returned to the Plan and shall not become available for future issuance under the Plan.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Plan Administrator.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration with Respect to Directors and Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to grants of Awards to Directors or Employees who are also Officers or Directors of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b&#8209;3. Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration with Respect to Consultants and Other Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to grants of Awards to Employees or Consultants who are neither Directors nor Officers of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which Committee shall be constituted in such a manner as to satisfy the Applicable Laws. Once appointed, such Committee shall continue to serve in its designated capacity until otherwise directed by the Board. The Board may authorize one or more Officers to grant such Awards and may limit such authority as the Board determines from time to time.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration with Respect to Covered Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, grants of Awards to any Covered Employee intended to qualify as Performance-Based Compensation shall be made only by a Committee (or subcommittee of a Committee) which is comprised solely of two or more Directors eligible to serve on a committee making Awards intended to qualify as Performance-Based Compensation. In the case of such Awards granted to Covered Employees, references to the &#8220;Administrator&#8221; or to a &#8220;Committee&#8221; shall be deemed to be references to such Committee or subcommittee.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration Errors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event an Award is granted in a manner inconsistent with the provisions of this subsection (a), such Award shall be presumptively valid as of its grant date to the extent permitted by the Applicable Laws.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Powers of the Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to determine whether and to what extent Awards are granted hereunder&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;to determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;to approve forms of Award Agreements for use under the Plan&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;to determine the terms and conditions of any Award granted hereunder&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;to amend the terms of any outstanding Award granted under the Plan, provided that (A) any amendment that would adversely affect the Grantee&#8217;s rights under an outstanding Award shall not be made without the Grantee&#8217;s written consent&#59; provided, however, that an amendment or modification that may cause an Incentive Stock Option to become a Non-Qualified Stock Option shall not be treated as adversely affecting the rights of the Grantee, (B) the reduction of the exercise price of any Option awarded under the Plan and the base appreciation amount of any SAR awarded under the Plan shall be subject to stockholder approval and (C) canceling an Option or SAR at a time when its exercise price or base appreciation amount (as applicable) exceeds the Fair Market Value of the underlying Shares, in exchange for cash or for another Option, SAR, Restricted Stock or other Award shall be subject to stockholder approval, unless the cancellation and exchange occurs in connection with a Corporate Transaction or Change in Control. Notwithstanding the foregoing, canceling an Option or SAR in exchange for another Option, SAR, Restricted Stock or other Award with an exercise price, purchase price or base appreciation amount (as applicable) that is equal to or greater than the exercise price or base appreciation amount (as applicable) of the original Option or SAR shall not be subject to stockholder approval&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;to construe and interpret the terms of the Plan and Awards, including without limitation, any notice of award or Award Agreement, granted pursuant to the Plan&#59;</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;to grant Awards to Employees, Directors and Consultants employed outside the United States on such terms and conditions different from those specified in the Plan as may, in the judgment of the Administrator, be necessary or desirable to further the purpose of the Plan&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;to take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The express grant in the Plan of any specific power to the Administrator shall not be construed as limiting any power or authority of the Administrator, provided that the Administrator may not exercise any right or power reserved to the Board. Any decision made, or action taken, by the Administrator in connection with the administration of this Plan shall be final, conclusive and binding on all persons having an interest in the Plan.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Indemnification. In addition to such other rights of indemnification as they may have as members of the Board or as Officers or Employees of the Company or a Related Entity, members of the Board and any Officers or Employees of the Company or a Related Entity to whom authority to act for the Board, the Administrator or the Company is delegated shall be defended and indemnified by the Company to the extent permitted by law on an after-tax basis against all reasonable expenses, including attorneys&#8217; fees, actually and necessarily incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such claim, investigation, action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct&#59; provided, however, that within thirty (30) days after the institution of such claim, investigation, action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at the Company&#8217;s expense to defend the same.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants. Incentive Stock Options may be granted only to Employees of the Company or a Parent or a Subsidiary of the Company. An Employee, Director or Consultant who has been granted an Award may, if otherwise eligible, be granted additional Awards. Awards may be granted to such Employees, Directors or Consultants who are residing in non-U.S. jurisdictions as the Administrator may determine from time to time.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Terms and Conditions of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Types of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant that is not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i) Shares, (ii) cash or (iii) an Option, a SAR, or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions. Such Awards include, without limitation, Options, SARs, sales or bonuses of Restricted Stock, Restricted Stock Units or Dividend Equivalent Rights, and an Award may consist of one such security or benefit, or two (2) or more of them in any combination or alternative&#59; provided, however, that a Dividend Equivalent Right may not be granted or payable with respect to an Option or SAR.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Designation of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Award shall be designated in the Award Agreement. In the case of an Option, the Option shall be designated as either an Incentive Stock Option or a Non-Qualified Stock Option. However, notwithstanding such designation, an Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section 422(d) of the Code is not exceeded. The $100,000 limitation of Section 422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to Options designated as Incentive Stock Options which become exercisable for the first time by a Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company). For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares shall be determined as of the grant date of the relevant Option. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair Market Value of Shares permitted to be subject to Incentive Stock Options, then such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Subject to the terms of the Plan, the Administrator shall determine the provisions, terms and conditions of each Award including, but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment (cash, Shares or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of any performance criteria. The performance criteria established by the Administrator may be based on any one of, or combination of, the following&#58; (i) change in share price&#59; (ii) operating earnings, operating profit margins, earnings before interest, taxes, depreciation, or amortization, net earnings, earnings per share (basic or diluted) or other measure of earnings&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) total stockholder return&#59; (iv) operating margin&#59; (v) gross margin&#59; (vi) balance sheet performance, including debt, long- or short-term, inventory, accounts payable or receivable, working capital, or shareholders&#8217; equity&#59; (vii) return measures, including return on invested capital, sales, assets or equity&#59; (viii) days&#8217; sales outstanding&#59; (ix) operating income&#59; (x) net operating income&#59; (xi) pre-tax profit&#59; (xii) cash flow, including cash flow from operations, investing, or financing activities, before or after dividends, investments or capital expenditures&#59; (xiii) revenue&#59; (xiv) expenses, including cost of goods sold, operating expenses, marketing and administrative expense, research and development, restructuring or other special or unusual items, interest, tax expense or other measures of savings&#59; (xv) earnings before interest, taxes and depreciation&#59; (xvi) economic value created or added&#59; (xvii) market share&#59; (xviii) sales or net sales&#59; (xix) sales or net sales of particular products&#59; (xx) gross profits&#59; (xxi) net income&#59; (xxii) inventory turns&#59; (xxiii) revenue per employee&#59; and (xxiv) implementation or completion of critical projects involving acquisitions, divestitures, process improvements, product or production quality, attainment of other strategic objectives relating to market penetration, geographic expansion, product development, regulatory or quality performance, innovation or research goals. The performance criteria may be applicable to the Company, Related Entities and&#47;or any individual business units of the Company or any Related Entity. Partial achievement of the specified criteria may result in a payment or vesting corresponding to the degree of achievement as specified in the Award Agreement. In addition, the performance criteria shall be calculated in accordance with generally accepted accounting principles, but excluding the effect (whether positive or negative) of any change in accounting standards and any extraordinary, unusual or nonrecurring item, as determined by the Administrator, occurring after the establishment of the performance criteria applicable to the Award intended to be performance-based compensation. Each such adjustment, if any, shall be made solely for the purpose of providing a consistent basis from period to period for the calculation of performance criteria in order to prevent the dilution or enlargement of the Grantee&#8217;s rights with respect to an Award intended to be performance-based compensation.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Administrator, in its sole discretion, may provide for inclusion or exclusion of the impact of an event or occurrence which the Administrator determines should appropriately be excluded, including (i) restructurings, discontinued operations, special items, and other unusual, infrequently occurring or non-recurring charges, events or items&#59; (ii) asset sales or write-downs&#59; (iii) litigation or claim judgments or settlements&#59; (iv) acquisitions or divestitures&#59; (v) reorganization or change in the corporate structure or capital structure of the Company&#59; (vi) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management&#59; (vii) foreign exchange gains and losses&#59; (viii) a change in the fiscal year of the Company&#59; (ix) the refinancing or repurchase of bank loans or debt securities&#59; (x) unbudgeted capital expenditures&#59; (xi) the issuance or repurchase of equity securities and other changes in the number of outstanding shares&#59; (xii) conversion of some or all of convertible securities to Common Stock&#59; (xiii) any business interruption event&#59; (xiv) changes in pricing&#59; (xv) changes in foreign currency exchange rates&#59; (xvi) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles&#59; (xvii) gains and losses that are treated as unusual in nature or that occur infrequently under Accounting Standards Codification Topic 225&#59; or (xviii) the effect of changes in other laws or regulatory rules affecting reported results.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions and Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may issue Awards under the Plan in settlement, assumption or substitution for, outstanding awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity, an interest in another entity or an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other form of transaction, and any Shares subject to such Awards will not count against the Share Limit.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral of Award Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent consistent with Applicable Laws, the Administrator may establish one or more programs under the Plan to permit selected Grantees the opportunity to elect to defer receipt of consideration upon vesting, exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Grantee to payment or receipt of Shares or other consideration under an Award. The Administrator may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, Shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Administrator deems advisable for the administration of any such deferral program.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Separate Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular forms of Awards to one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Individual Limitations on Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Individual Limit for Options and SARs. The maximum number of Shares with respect to which Options and SARs may be granted to any Grantee in any calendar year shall be five hundred thousand (500,000) Shares. The foregoing limitation shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section 10, below. To the extent required by Section 162(m) of the Code or the regulations thereunder, in applying the foregoing limitation with respect to a Grantee, if any Option or SAR is canceled, the canceled Option or SAR shall continue to count against the maximum number of Shares with respect to which Options and SARs may be granted to the Grantee. For this purpose, the repricing of an Option (or in the case of a SAR, the base amount on which the stock appreciation is calculated is reduced to reflect a reduction in the Fair Market Value of the Common Stock) shall be treated as the cancellation of the existing Option or SAR and the grant of a new Option or SAR.</font></div><div><font><br></font></div><div style="text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Individual Limit for Restricted Stock and Restricted Stock Units. For awards of Restricted Stock and Restricted Stock Units that are intended to be Performance-Based Compensation, the maximum number of Shares with respect to which such Awards may be granted to any Grantee in any calendar year shall be two hundred fifty thousand (250,000) Shares. The foregoing limitation shall be adjusted proportionately in connection with any change in the Company&#8217;s capitalization pursuant to Section 10, below.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Director Award Limit. Notwithstanding any provision to the contrary in the Plan, the sum of any cash compensation and the grant date fair value (determined as of the date of the grant under Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all Awards granted under the Plan to a non-employee Director during any calendar year shall not exceed the amount equal to $750,000.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the vesting or receipt of Shares under an Award is deferred to a later date, any amount (whether denominated in Shares or cash) paid in addition to the original number of Shares subject to such Award will not be treated as an increase in the number of Shares subject to the Award if the additional amount is based either on a reasonable rate of interest or on one or more predetermined actual investments such that the amount payable by the Company at the later date will be based on the actual rate of return of a specific investment (including any decrease as well as any increase in the value of an investment).</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Early Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director or Consultant to exercise any part or all of the Award prior to full vesting of the Award. Any unvested Shares received pursuant to such exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction the Administrator determines to be appropriate.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The term of each Option and SAR shall be the term stated in the Award Agreement, provided, however, that the term of any Award shall be no more than ten (10) years from the date of grant thereof. However, in the case of an Incentive Stock Option granted to a Grantee who, at the time the Option is granted, owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive Stock Option shall be five (5) years from the date of grant thereof or such shorter term as may be provided in the Award Agreement. Notwithstanding the foregoing, the specified term of any Award shall not include any period for which the Grantee has elected to defer the receipt of the Shares or cash issuable pursuant to the Award.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Incentive Stock Options may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Grantee, only by the Grantee. Other Awards shall be transferable (i) by will and by the laws of descent and distribution and (ii) during the lifetime of the Grantee, to the extent and in the manner authorized by the Administrator but only to the extent such transfers are made to family members, to family trusts, to family controlled entities, to charitable organizations, and pursuant to domestic relations orders or agreements, in all cases without payment for such transfers to the Grantee. Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Award, in the event of the Grantee&#8217;s death, on a beneficiary designation form provided by the Administrator.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Time of Granting Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination to grant such Award, or such other later date as is determined by the Administrator.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend and Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Dividends and Dividend Equivalent Rights with respect to an Award shall only be paid to the Grantee to the extent that the applicable vesting conditions are subsequently satisfied and the Award vests.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Award Vesting Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Plan to the contrary, but subject to Section 11, Awards granted under the Plan on or after the Effective Date shall vest no earlier than the first anniversary of the date the Award is granted&#59; provided, however, that, notwithstanding the foregoing, Awards that result in the issuance of an aggregate of up to 5% of the Shares available pursuant to Section 3.1(a) as of the Effective Date may be granted to any one or more Grantees without respect to such minimum vesting provisions. Nothing in this Section 6(n) shall preclude the Administrator from taking action, in its sole discretion, to accelerate the vesting of any Award in connection with or following a Grantee&#8217;s death, disability, termination of Continuous Service or the consummation of a Change in Control.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Award Exercise or Purchase Price, Consideration and Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise or Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The exercise or purchase price, if any, for an Award shall be as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;In the case of an Incentive Stock Option&#58;</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;granted to an Employee who, at the time of the grant of such Incentive Stock Option owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the per Share exercise price shall be not less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant&#59; or</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;granted to any Employee other than an Employee described in the preceding paragraph, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;In the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div><font><br></font></div><div style="text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;In the case of Awards intended to qualify as Performance-Based Compensation, the exercise or purchase price, if any, shall be not less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;In the case of SARs, the base appreciation amount shall not be less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;In the case of other Awards, such price as is determined by the Administrator.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of this Section 7(a), in the case of an Award issued pursuant to Section 6(d), above, the exercise or purchase price for the Award shall be determined in accordance with the provisions of the relevant instrument evidencing the agreement to issue such Award.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award, including the method of payment, shall be determined by the Administrator. In addition to any other types of consideration the Administrator may determine, the Administrator is authorized to accept as consideration for Shares issued under the Plan the following, provided that the portion of the consideration equal to the par value of the Shares must be paid in cash or other legal consideration permitted by the Delaware General Corporation Law&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;cash&#59;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;check&#59;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;surrender of Shares or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate exercise price of the Shares as to which said Award shall be exercised&#59;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;with respect to Options, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (A) shall provide written instructions to a Company-designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (B) shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction&#59;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;with respect to Options, payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i) the number of Shares as to which the Option is being exercised, multiplied by (ii) a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares)&#59; or</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any combination of the foregoing methods of payment.</font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator may at any time or from time to time, by adoption of or by amendment to the standard forms of Award Agreement described in Section 4(b)(iv), or by other means, grant Awards which do not permit all of the foregoing forms of consideration to be used in payment for the Shares or which otherwise restrict one or more forms of consideration.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements acceptable to the Administrator for the satisfaction of any non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S., federal, state, or local income and employment tax withholding obligations, including, without limitation, obligations incident to the receipt of Shares. Upon exercise or vesting of an Award, the Company shall withhold or collect from the Grantee an amount sufficient to satisfy such tax obligations, including, but not limited to, by surrender of the whole number of Shares covered by the Award sufficient to satisfy the minimum applicable tax withholding obligations incident to the exercise or vesting of an Award (reduced to the lowest whole number of Shares if such number of Shares withheld would result in withholding a fractional Share with any remaining tax withholding settled in cash).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure for Exercise&#59; Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Any Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the terms of the Plan and specified in the Award Agreement.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;An Award shall be deemed to be exercised when written notice of such exercise has been given to the Company in accordance with the terms of the Award by the person entitled to exercise the Award and full payment for the Shares with respect to which the Award is exercised has been made, including, to the extent selected, use of the broker-dealer sale and remittance procedure to pay the purchase price as provided in Section 7(b)(iv).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Award Following Termination of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;An Award may not be exercised after the termination date of such Award set forth in the Award Agreement and may be exercised following the termination of a Grantee&#8217;s Continuous Service only to the extent provided in the Award Agreement.</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Where the Award Agreement permits a Grantee to exercise an Award following the termination of the Grantee&#8217;s Continuous Service for a specified period, the Award shall terminate to the extent not exercised on the last day of the specified period or the last day of the original term of the Award, whichever occurs first.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Any Award designated as an Incentive Stock Option to the extent not exercised within the time permitted by law for the exercise of Incentive Stock Options following the termination of a Grantee&#8217;s Continuous Service shall convert automatically to a Non-Qualified Stock Option and thereafter shall be exercisable as such to the extent exercisable by its terms for the period specified in the Award Agreement.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions upon Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If at any time the Administrator determines that the delivery of Shares pursuant to the exercise, vesting or any other provision of an Award is or may be unlawful under Applicable Laws, the vesting or right to exercise an Award or to otherwise receive Shares pursuant to the terms of an Award shall be suspended until the Administrator determines that such delivery is lawful and shall be further subject to the approval of counsel for the Company with respect to such compliance. The Company shall have no obligation to effect any registration or qualification of the Shares under federal or state laws.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments upon Changes in Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to any required action by the stockholders of the Company and Section 11 hereof, the number of Shares covered by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, the maximum number of Shares with respect to which Awards may be granted as incentive stock options or to any Grantee in any calendar year, as well as any other terms that the Administrator determines require adjustment, shall be proportionately adjusted for (i) any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, or similar transaction affecting the Shares, (ii) any other increase or decrease in the number of issued Shares effected without receipt of consideration by the Company, or (iii) any other transaction with respect to Common Stock including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction&#59; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been &#8220;effected without receipt of consideration.&#8221; In the event of any distribution of cash or other assets to stockholders other than a normal cash dividend, the Administrator shall also make such adjustments as provided in this Section 10 or substitute, exchange or grant Awards to effect such adjustments (collectively &#8220;adjustments&#8221;). Any such adjustments to outstanding Awards will be effected in a manner that precludes the enlargement of rights and benefits under such Awards. In connection with the foregoing adjustments, the Administrator may, in its discretion, prohibit the exercise of Awards or other issuance of Shares, cash or other consideration pursuant to Awards during certain periods of time. Except as the Administrator determines, no issuance by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Transactions and Changes in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;With respect to Awards granted prior to the Effective Date&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Award to Extent Not Assumed in Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Effective upon the consummation of a Corporate Transaction, all outstanding Awards under the Plan shall terminate. However, all such Awards shall not terminate to the extent they are Assumed in connection with the Corporate Transaction.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration of Award upon Corporate Transaction or Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as provided otherwise in an individual Award Agreement, in the event of a Corporate Transaction, for the portion of each Award that is neither Assumed nor Replaced, such portion of the Award shall automatically become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value) for all of the Shares (or other consideration) at the time represented by such portion of the Award, immediately prior to the specified effective date of such Corporate Transaction, provided that the Grantee&#8217;s Continuous Service has not terminated prior to such date.</font></div><div style="text-indent:144pt"><font><br></font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as provided otherwise in an individual Award Agreement, in the event of a Change in Control (other than a Change in Control which also is a Corporate Transaction), each Award which is at the time outstanding under the Plan automatically shall become fully vested and exercisable and be released from any repurchase or forfeiture rights (other than repurchase rights exercisable at Fair Market Value), immediately prior to the specified effective date of such Change in Control, for all of the Shares (or other consideration) at the time represented by such Award, provided that the Grantee&#8217;s Continuous Service has not terminated prior to such date.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;With respect to Awards granted on or after the Effective Date, if a Change in Control occurs and a Participant&#8217;s outstanding Awards are not Assumed or Replaced by the surviving or successor entity in such Change in Control, in any case, as determined by the Administrator, then immediately prior to the Change in Control such outstanding Awards, to the extent not Assumed or Replaced, shall become fully vested and, as applicable, exercisable and shall be deemed exercised or canceled in exchange for payment of the transaction consideration (net of any applicable exercise or purchase price due) immediately prior to the consummation of such transaction, and all forfeiture, repurchase and other restrictions on such Awards shall lapse immediately prior to such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction. If an Award vests and, as applicable, is exercised or canceled and paid out in lieu of being Assumed or Replaced in connection with a Change in Control, the Award shall terminate upon the Change in Control.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Effect of Acceleration on Incentive Stock Options. Any Incentive Stock Option accelerated under this Section 11 in connection with a Corporate Transaction or Change in Control shall remain exercisable as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section 422(d) of the Code is not exceeded.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date and Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan (as amended and restated) shall become effective upon the Effective Date. The Plan (as amended and restated) shall continue in effect for a term of ten (10) years from the Effective Date.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Board may at any time amend, suspend or terminate the Plan&#59; provided, however, that no such amendment shall be made without the approval of the Company&#8217;s stockholders to the extent such approval is required by Applicable Laws, or if such amendment would lessen the stockholder approval requirements of Section 4(b)(vi) or this Section 13(a).</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;No Award may be granted during any suspension of the Plan or after termination of the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No suspension or termination of the Plan (including termination of the Plan under Section 11, above) shall adversely affect any rights under Awards already granted to a Grantee.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reservation of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company, during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Effect on Terms of Employment&#47;Consulting Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan shall not confer upon any Grantee any right with respect to the Grantee&#8217;s Continuous Service, nor shall it interfere in any way with his or her right or the right of the Company or any Related Entity to terminate the Grantee&#8217;s Continuous Service at any time, with or without Cause including, but not limited to, Cause, and with or without notice. The ability of the Company or any Related Entity to terminate the employment of a Grantee who is employed at will is in no way affected by its determination that the Grantee&#8217;s Continuous Service has been terminated for Cause for the purposes of this Plan.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Effect on Retirement and Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as specifically provided in a retirement or other benefit plan of the Company or a Related Entity, Awards shall not be deemed compensation for purposes of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits under any other benefit plan of any kind or any benefit plan subsequently instituted under which the availability or amount of benefits is related to level of compensation. The Plan is not a &#8220;Pension Plan&#8221; or &#8220;Welfare Plan&#8221; under the Employee Retirement Income Security Act of 1974, as amended.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan (as amended and restated) will be submitted for the approval of the Company&#8217;s stockholders within twelve (12) months after the date of the Board&#8217;s initial adoption of the Plan (as amended and restated). Awards may be granted or awarded under the Plan (as amended and restated) and subject to the terms and conditions of the Original Plan following the Board&#8217;s adoption of the Plan (as amended and restated) unless and until the Plan (as amended and restated) receives stockholder approval. Awards granted from and after </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholder approval of the Plan (as amended and restated) will be subject to the terms and conditions of the Plan (as amended and restated). If the Plan (as amended and restated) is not approved by stockholders within twelve (12) months after its adoption by the Board, then the Original Plan shall continue on its existing terms and conditions and the Plan (as amended and restated) shall be of no force or effect.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unfunded Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Grantees shall have the status of general unsecured creditors of the Company. Any amounts payable to Grantees pursuant to the Plan shall be unfunded and unsecured obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974, as amended. Neither the Company nor any Related Entity shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations. The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Grantee account shall not create or constitute a trust or fiduciary relationship between the Administrator, the Company or any Related Entity and a Grantee, or otherwise create any vested or beneficial interest in any Grantee or the Grantee&#8217;s creditors in any assets of the Company or a Related Entity. The Grantees shall have no claim against the Company or any Related Entity for any changes in the value of any assets that may be invested or reinvested by the Company with respect to the Plan.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nonexclusivity of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Neither the adoption of the Plan (as amended and restated) by the Board, the submission of the Plan (as amended and restated) to the stockholders of the Company for approval, nor any provision of the Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of Awards otherwise than under the Plan, and such arrangements may be either generally applicable or applicable only in specific cases.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan and any agreements hereunder shall be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>exhibit21subsidiariesofreg.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia8b14d05a4414256b9c4f8966166e439_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiaries of Registrant</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State&#160;or Country of&#160;Incorporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXC Holding Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excelsior Medical Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tangent Medical Technologies, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Sales,&#160;Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical de Mexico, S. de R. L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Bidco Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU World,&#160;Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical ASD, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Izoard Sub. Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medex Cardio-Pulmonary, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Canada Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Bahamas, Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bahamas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Costa Rica, Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bahamas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical SA Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Australia Holdings Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medima s.p. z.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Latam LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Canada Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Hong Kong Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Philippines, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Europe S.r.l.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Aust MLA Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Italia S.r.l.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical France S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Ireland Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Australia Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Argentina S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospira Chile Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Chile Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Colombia Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical HIS Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Peru S.R.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical India LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU UK Medical Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Productos Farmac&#233;uticos y Hospitalarios, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Australia Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medivet Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical 2020 Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICU Medical Group Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Group Deutschland Gmbh</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Do Brasil Produts Hospitalares Ltda</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brazil</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Graseby Medical Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical (Portugal) Unipessoal Lda</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Espana S.L.U</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Schweiz AG</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Czech Republic A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical (Shanghai) Co. Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical France SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Italia Srl</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Danmark Aps</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Osterreich Gmbh</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Sverige AB</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Nederland BV</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Belgium NV</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SI Overseas Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Healthcare Manufacturing SA de CV</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Japan Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Australasia Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical International Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Graesby Medical Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Hong Kong Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Graesby Medical Instrument (Zhejiang) Co Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medex Medical Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ashfield Medical Systems Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical Singapore Pte Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PneuPac Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smiths Medical (Beijing) Co Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit231consentofdeloitt.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i31bef6ee302d46ada2730552cb3f2d93_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in Registration Statement No.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">333-90464,</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> 333-175239, 333-198256, and 333-219106 </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">on Form S</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">-</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8 </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">333</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">-</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">228390 on </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Form S</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">- </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> of our reports </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">dated February 27, 2023, relating</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> to the financial statements of ICU Medical, Inc. and the effectiveness of ICU Medical Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">December&#160;31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DELOITTE &#38; TOUCHE LLP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Mesa, California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit311123122.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia06686a6cb9746eaa8e3f58bc0785207_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Vivek Jain, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of ICU Medical,&#160;Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:108pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:40.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Vivek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit312123122.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i88cfb7316b2f4835a11e9ec582ea322d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian M. Bonnell, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%;padding-left:24pt">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this annual report on Form&#160;10-K of ICU Medical,&#160;Inc.&#59;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian M. Bonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(principal financial officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit32123122.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4d4dedc36a5b4be19f144ca11503dc07_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of ICU Medical,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Vivek Jain, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Vivek Jain</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of ICU Medical,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Brian M. Bonnell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian M. Bonnell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Bonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>icui-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:icui="http://www.icumed.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.icumed.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="icui-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="icui-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="icui-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="icui-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.icumed.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.icumed.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.icumed.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofComprehensiveIncomeStatement" roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement">
        <link:definition>0000005 - Statement - Statement of Comprehensive Income (Statement)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000008 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofComprehensiveIncomeParanthetical" roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical">
        <link:definition>0000009 - Statement - Statement of Comprehensive Income (Paranthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPolicies" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - General and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNotes" roleURI="http://www.icumed.com/role/AcquisitionsNotes">
        <link:definition>0000011 - Disclosure - Acquisitions (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringStrategicTransactionandIntegrationNotes" roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes">
        <link:definition>0000012 - Disclosure - Restructuring, Strategic Transaction and Integration (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNotes" roleURI="http://www.icumed.com/role/RevenueNotes">
        <link:definition>0000013 - Disclosure - Revenue (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNotes" roleURI="http://www.icumed.com/role/LeasesNotes">
        <link:definition>0000014 - Disclosure - Leases (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardShareawardsNotes" roleURI="http://www.icumed.com/role/ShareBasedAwardShareawardsNotes">
        <link:definition>0000015 - Disclosure - Share Based Award Share awards (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesNotes" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes">
        <link:definition>0000016 - Disclosure - Derivatives and Hedging Activities (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNotes" roleURI="http://www.icumed.com/role/FairValueMeasurementNotes">
        <link:definition>0000017 - Disclosure - Fair Value Measurement (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherCurrentAssetsNotes" roleURI="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes">
        <link:definition>0000018 - Disclosure - Prepaids and Other Current Assets (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesanOtherLongtermLiabilities" roleURI="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities">
        <link:definition>0000019 - Disclosure - Accrued Liabilities an Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.icumed.com/role/Debt">
        <link:definition>0000020 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.icumed.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes:</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes" roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes">
        <link:definition>0000022 - Disclosure - Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.icumed.com/role/StockholdersEquity">
        <link:definition>0000023 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.icumed.com/role/CommitmentsandContingencies">
        <link:definition>0000024 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherArrangementsNotes" roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes">
        <link:definition>0000025 - Disclosure - Collaborative and Other Arrangements (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.icumed.com/role/SubsequentEvents">
        <link:definition>0000026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SECScheduleArticle1209ValuationandQualifyingAccounts" roleURI="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts">
        <link:definition>0000027 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000028 - Disclosure - General and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000029 - Disclosure - General and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationandAssetAcquisitionTables" roleURI="http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables">
        <link:definition>0000030 - Disclosure - Business Combination and Asset Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables" roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables">
        <link:definition>0000031 - Disclosure - Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.icumed.com/role/RevenueTables">
        <link:definition>0000032 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.icumed.com/role/LeasesTables">
        <link:definition>0000033 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardTables" roleURI="http://www.icumed.com/role/ShareBasedAwardTables">
        <link:definition>0000034 - Disclosure - Share Based Award (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesTables" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesTables">
        <link:definition>0000035 - Disclosure - Derivatives and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.icumed.com/role/FairValueMeasurementTables">
        <link:definition>0000036 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherCurrentAssetsTables" roleURI="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables">
        <link:definition>0000037 - Disclosure - Prepaids and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesanOtherLongtermLiabilitiesTables" roleURI="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables">
        <link:definition>0000038 - Disclosure - Accrued Liabilities an Other Long-term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.icumed.com/role/DebtTables">
        <link:definition>0000039 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncometaxdisclosureTables" roleURI="http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables">
        <link:definition>0000040 - Disclosure - Income Taxes Income tax disclosure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandSignificantCustomersGeographicInformationTables" roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables">
        <link:definition>0000041 - Disclosure - Geographic Information and Significant Customers Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.icumed.com/role/StockholdersEquityTables">
        <link:definition>0000042 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.icumed.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000043 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherArrangementsTables" roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsTables">
        <link:definition>0000044 - Disclosure - Collaborative and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsTables" roleURI="http://www.icumed.com/role/SubsequentEventsTables">
        <link:definition>0000045 - Disclosure - Subsequent Events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails">
        <link:definition>0000046 - Disclosure - General and Summary of Significant Accounting Policies Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>0000047 - Disclosure - General and Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details">
        <link:definition>0000048 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #1 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details">
        <link:definition>0000049 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details">
        <link:definition>0000050 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails">
        <link:definition>0000051 - Disclosure - General and Summary of Significant Accounting Policies Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details">
        <link:definition>0000052 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #1 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details">
        <link:definition>0000053 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #2 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails">
        <link:definition>0000054 - Disclosure - General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails">
        <link:definition>0000055 - Disclosure - General and Summary of Significant Accounting Policies Other Investments(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>0000056 - Disclosure - General and Summary of Significant Accounting Policies Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails">
        <link:definition>0000057 - Disclosure - General and Summary of Significant Accounting Policies Investments-Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails">
        <link:definition>0000058 - Disclosure - General and Summary of Significant Accounting Policies Foreign Currency (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails">
        <link:definition>0000059 - Disclosure - General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails">
        <link:definition>0000060 - Disclosure - General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails">
        <link:definition>0000061 - Disclosure - General and Summary of Significant Accounting Policies Other (expense) income, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails">
        <link:definition>0000062 - Disclosure - General and Summary of Significant Accounting Policies Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails" roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails">
        <link:definition>0000063 - Disclosure - General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTextDetails" roleURI="http://www.icumed.com/role/AcquisitionsTextDetails">
        <link:definition>0000064 - Disclosure - Acquisitions Text (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSmithsMedical2020LimitedTableDetails" roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails">
        <link:definition>0000065 - Disclosure - Acquisitions Smiths Medical 2020 Limited Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSmithsMedical2020LimitedIntangibleDetails" roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails">
        <link:definition>0000066 - Disclosure - Acquisitions Smiths Medical 2020 Limited Intangible (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsForeignInfusionSystemsSupplierDetails" roleURI="http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails">
        <link:definition>0000067 - Disclosure - Acquisitions Foreign Infusion Systems Supplier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSmithsMedicalProFormaDetails" roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails">
        <link:definition>0000068 - Disclosure - Acquisitions Smiths Medical Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringStrategicTransactionandIntegrationDetails1" roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1">
        <link:definition>0000069 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringStrategicTransactionandIntegrationDetails2" roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2">
        <link:definition>0000070 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails" roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails">
        <link:definition>0000071 - Disclosure - Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenueProductLineDetails" roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails">
        <link:definition>0000072 - Disclosure - Revenue Disaggregation of Revenue - Product Line (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographyDetails" roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails">
        <link:definition>0000073 - Disclosure - Revenue Disaggregation of Revenue by Geography (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>0000074 - Disclosure - Revenue Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesTextDetails" roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails">
        <link:definition>0000075 - Disclosure - Revenue Contract Liabilities Text (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRemainingPerformanceObligationRecognitionTimingDetails" roleURI="http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails">
        <link:definition>0000076 - Disclosure - Revenue Remaining Performance Obligation Recognition Timing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.icumed.com/role/LeasesDetails">
        <link:definition>0000077 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.icumed.com/role/LeasesLeaseCostDetails">
        <link:definition>0000078 - Disclosure - Leases Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowLeaseInformationDetails" roleURI="http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails">
        <link:definition>0000079 - Disclosure - Leases Supplemental Cash Flow Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetLeaseinformationDetails" roleURI="http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails">
        <link:definition>0000080 - Disclosure - Leases Supplemental Balance Sheet Lease information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinanceLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000081 - Disclosure - Finance Leases Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseMaturityDetails" roleURI="http://www.icumed.com/role/LeasesLeaseMaturityDetails">
        <link:definition>0000082 - Disclosure - Leases Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFinanceLeaseMaturityDetails" roleURI="http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails">
        <link:definition>0000083 - Disclosure - Leases Finance Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardStockBasedCompensationDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails">
        <link:definition>0000084 - Disclosure - Share Based Award Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardStockOptionPlansDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails">
        <link:definition>0000085 - Disclosure - Share Based Award Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardStockOptionsGrantedandValuationDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails">
        <link:definition>0000086 - Disclosure - Share Based Award Stock Options Granted and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardStockOptionActivityDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails">
        <link:definition>0000087 - Disclosure - Share Based Award Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardShareAwarddataDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails">
        <link:definition>0000088 - Disclosure - Share Based Award Share Award data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardOptionsexerciseddataDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails">
        <link:definition>0000089 - Disclosure - Share Based Award Options exercised data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardRSUandPRSUDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails">
        <link:definition>0000090 - Disclosure - Share Based Award RSU and PRSU (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardRSUandPRSURollforwardDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails">
        <link:definition>0000091 - Disclosure - Share Based Award RSU and PRSU Roll forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedAwardESPPNarrativeDetails" roleURI="http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails">
        <link:definition>0000092 - Disclosure - Share Based Award ESPP Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails">
        <link:definition>0000093 - Disclosure - Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesInterestRateContractsDetails" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails">
        <link:definition>0000094 - Disclosure - Derivatives and Hedging Activities Interest Rate Contracts(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails">
        <link:definition>0000095 - Disclosure - Derivatives and Hedging Activities Derivative Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails">
        <link:definition>0000096 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000097 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSmithsMedicalDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails">
        <link:definition>0000098 - Disclosure - Fair Value Measurement Smiths Medical(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTextPursuitDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails">
        <link:definition>0000099 - Disclosure - Fair Value Measurement Text Pursuit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementRollForwardDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementRollForwardDetails">
        <link:definition>0000100 - Disclosure - Fair Value Measurement Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails">
        <link:definition>0000101 - Disclosure - Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSmithsMedicalSimulationInputsDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails">
        <link:definition>0000102 - Disclosure - Fair Value Measurement Smiths Medical Simulation Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails">
        <link:definition>0000103 - Disclosure - Fair Value Measurement Fair Value Measurements, Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000104 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidsandOtherNoncurrentAssetsDetails" roleURI="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails">
        <link:definition>0000105 - Disclosure - Prepaids and Other Noncurrent Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.icumed.com/role/AccruedLiabilitiesDetails">
        <link:definition>0000106 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesDetails" roleURI="http://www.icumed.com/role/OtherLiabilitiesDetails">
        <link:definition>0000107 - Disclosure - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ApplicableMarginBasedonLeverageRatioTermLoanADetails" roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails">
        <link:definition>0000108 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan A(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ApplicableMarginBasedonLeverageRatioTermLoanBDetails" roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails">
        <link:definition>0000109 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan B (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.icumed.com/role/DebtDetails">
        <link:definition>0000110 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtMaturityDetails" roleURI="http://www.icumed.com/role/DebtMaturityDetails">
        <link:definition>0000111 - Disclosure - Debt Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.icumed.com/role/DebtInterestExpenseDetails">
        <link:definition>0000112 - Disclosure - Debt Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2022CreditFacilityTextDetails" roleURI="http://www.icumed.com/role/A2022CreditFacilityTextDetails">
        <link:definition>0000113 - Disclosure - 2022 Credit Facility Text (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalPaymentsDetails" roleURI="http://www.icumed.com/role/PrincipalPaymentsDetails">
        <link:definition>0000114 - Disclosure - Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A2017CreditFacilityDetails" roleURI="http://www.icumed.com/role/A2017CreditFacilityDetails">
        <link:definition>0000115 - Disclosure - 2017 Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeLossfromContinuingOperationsDetails" roleURI="http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails">
        <link:definition>0000116 - Disclosure - Income Taxes Income (Loss) from Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxProvisionDetails" roleURI="http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails">
        <link:definition>0000117 - Disclosure - Income Taxes Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeintaxespayableDetails" roleURI="http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails">
        <link:definition>0000118 - Disclosure - Income Taxes Change in taxes payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectivetaxrateDetails" roleURI="http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails">
        <link:definition>0000119 - Disclosure - Income Taxes Effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredincometaxassetsliabilitiesDetails" roleURI="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails">
        <link:definition>0000120 - Disclosure - Income Taxes Deferred income tax assets (liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails">
        <link:definition>0000121 - Disclosure - Income Taxes Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxCarryforwardsDetails" roleURI="http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails">
        <link:definition>0000122 - Disclosure - Income Taxes Tax Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxHolidayDetails" roleURI="http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails">
        <link:definition>0000123 - Disclosure - Income Taxes Tax Holiday (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUndistributedforeignearningsDetails" roleURI="http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails">
        <link:definition>0000124 - Disclosure - Income Taxes Undistributed foreign earnings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedtaxbenefitsDetails" roleURI="http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails">
        <link:definition>0000125 - Disclosure - Income Taxes Unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails" roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails">
        <link:definition>0000126 - Disclosure - Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.icumed.com/role/StockholdersEquityDetails">
        <link:definition>0000127 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000128 - Disclosure - Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesContingenciesDetails" roleURI="http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails">
        <link:definition>0000129 - Disclosure - Commitments and Contingencies Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherArrangementsDetails" roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails">
        <link:definition>0000130 - Disclosure - Collaborative and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.icumed.com/role/SubsequentEventsDetails">
        <link:definition>0000131 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SECScheduleArticle1209ValuationandQualifyingAccountsDetails" roleURI="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails">
        <link:definition>0000132 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="icui_ScheduleOfAccruedLiabilitiesLineItems" abstract="true" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_Contractsettlements" abstract="false" name="Contractsettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Accruedothertaxes" abstract="false" name="Accruedothertaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Sharestransferredfromsupersededplan" abstract="false" name="Sharestransferredfromsupersededplan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="icui_ApplicableMarginBasedOnLeverageRatioLineItems" abstract="true" name="ApplicableMarginBasedOnLeverageRatioLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_MinimumStockPriceTargetForEarnOutPayment" abstract="false" name="MinimumStockPriceTargetForEarnOutPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_PrepaidVendorExpenses" abstract="false" name="PrepaidVendorExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ForeignDistibutorMember" abstract="true" name="ForeignDistibutorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_LeverageRatioLevelAxis" abstract="true" name="LeverageRatioLevelAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_ClassificationAxis" abstract="true" name="ClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_RestructuringAdjustmentsSeveranceAndFacility" abstract="false" name="RestructuringAdjustmentsSeveranceAndFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_LongTermMember" abstract="true" name="LongTermMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Grantdatefairvalueperformancerestrictedstockunits" abstract="false" name="Grantdatefairvalueperformancerestrictedstockunits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_IVSolutionsMember" abstract="true" name="IVSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_RequiredShareHoldingOfStockIssuedAtAcquisition" abstract="false" name="RequiredShareHoldingOfStockIssuedAtAcquisition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_Deferredtaxcharge" abstract="false" name="Deferredtaxcharge" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" abstract="false" name="Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ApplicableMarginTermSOFRLoans" abstract="false" name="ApplicableMarginTermSOFRLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_ExercisedOptionsDataTableTextBlock" abstract="false" name="ExercisedOptionsDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_EquipmentrevenueMember" abstract="true" name="EquipmentrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_DeferredtaxassetsandliabilitiesTable" abstract="true" name="DeferredtaxassetsandliabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" abstract="true" name="LessThanOrEqualTo400To100ButGreaterThan300To100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" abstract="false" name="NoncurrentDeferredTaxLiabilityStateIncomeTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ApplicableMarginBaseRateLoans" abstract="false" name="ApplicableMarginBaseRateLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_ShortTermMember" abstract="true" name="ShortTermMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ApplicableMarginBasedOnLeverageRatioTable" abstract="true" name="ApplicableMarginBasedOnLeverageRatioTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_RevolverSubLimits" abstract="false" name="RevolverSubLimits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_SupplementalCashFlowInformationLeasesTableTextBlock" abstract="false" name="SupplementalCashFlowInformationLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_AccruedAuditFees" abstract="false" name="AccruedAuditFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ClassificationDomain" abstract="true" name="ClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_DerivativeInterestRateFloor" abstract="false" name="DerivativeInterestRateFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" abstract="false" name="EffectiveIncomeTaxRateReconciliationContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_PerformanceRestrictedStockUnitsPRSUsMember" abstract="true" name="PerformanceRestrictedStockUnitsPRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InterestPercentageAddedToBaseRate" abstract="false" name="InterestPercentageAddedToBaseRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_ShareawarddataAbstract" abstract="true" name="ShareawarddataAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_Prepaidothertaxes" abstract="false" name="Prepaidothertaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_InterestExpenseIncomeNetLineItems" abstract="true" name="InterestExpenseIncomeNetLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_TermLoanDomain" abstract="true" name="TermLoanDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_GILTItaxexpensepercent" abstract="false" name="GILTItaxexpensepercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_AccruedResearchAndDevelopmentLiability" abstract="false" name="AccruedResearchAndDevelopmentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_RevenueRecognitionTimingLineItems" abstract="true" name="RevenueRecognitionTimingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_ApplicableMarginOnLoanTypeTableTextBlock" abstract="false" name="ApplicableMarginOnLoanTypeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_TermAPrincipalPaymentFirst2Years" abstract="false" name="TermAPrincipalPaymentFirst2Years" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_InterestExpenseIncomeNetAxis" abstract="true" name="InterestExpenseIncomeNetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_ContractassetandliabilitybalancesLineItems" abstract="true" name="ContractassetandliabilitybalancesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_Changeinunitsduetoperformanceexpectations" abstract="false" name="Changeinunitsduetoperformanceexpectations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="icui_OtherLiabilitiesLineItems" abstract="true" name="OtherLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_NoncurrentDeferredTaxLiabilityMember" abstract="true" name="NoncurrentDeferredTaxLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_RevenueGrossProfitVolatilityMember" abstract="true" name="RevenueGrossProfitVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" abstract="false" name="InformationbyGeographicAreaandCustomerConcentrationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_PerformanceSharesEarned" abstract="false" name="PerformanceSharesEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="icui_GovernmentGrantRevenueMember" abstract="true" name="GovernmentGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_TermLoanAxis" abstract="true" name="TermLoanAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_PursuitVascularLLCMember" abstract="true" name="PursuitVascularLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Noncurrentdeferredtaxasset" abstract="false" name="Noncurrentdeferredtaxasset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_OperatinglosscarryforwardsAbstract" abstract="true" name="OperatinglosscarryforwardsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_Percentageofrevenue" abstract="false" name="Percentageofrevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_PursuitVascularInc.Member" abstract="true" name="PursuitVascularInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ProFormaAdjustmentAmortization" abstract="false" name="ProFormaAdjustmentAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_InterestExpenseIncomeNetDomain" abstract="true" name="InterestExpenseIncomeNetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Contingentconsiderationgross" abstract="false" name="Contingentconsiderationgross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_NonCurrentDeferredTaxAssetGrossTotalMember" abstract="true" name="NonCurrentDeferredTaxAssetGrossTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ESPPAnnualIssuanceIncreaseLimit" abstract="false" name="ESPPAnnualIssuanceIncreaseLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="icui_EarnoutliabilityMember" abstract="true" name="EarnoutliabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" abstract="false" name="NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_VitalCareMember" abstract="true" name="VitalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_GreaterThan275To100Member" abstract="true" name="GreaterThan275To100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ProFormaAdjustmentFinanceCosts" abstract="false" name="ProFormaAdjustmentFinanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" abstract="false" name="WarrantyAndReturnReserveInventoryChargedToOtherAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Deferredtaxliabilitychangeinaccountingmethod" abstract="false" name="Deferredtaxliabilitychangeinaccountingmethod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" abstract="false" name="BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_InterestMarginandCommitmentFeeTableTextBlock" abstract="false" name="InterestMarginandCommitmentFeeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_ShortTermContingentConsiderationGross" abstract="false" name="ShortTermContingentConsiderationGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_TimebasedstockoptionMember" abstract="true" name="TimebasedstockoptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_NoncurrentDeferredTaxAssetTaxCreditsState" abstract="false" name="NoncurrentDeferredTaxAssetTaxCreditsState" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_PrepaidNoncurrentAssetsLineItems" abstract="true" name="PrepaidNoncurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_WarrantyAndReturnReserveCosts" abstract="false" name="WarrantyAndReturnReserveCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_IndirectTaxBenefitFromStockOptions" abstract="false" name="IndirectTaxBenefitFromStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_LeverageRatioCalculationCeilingSubtractedAmount" abstract="false" name="LeverageRatioCalculationCeilingSubtractedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_WarrantyAndReturnReserveInventoryWriteOffs" abstract="false" name="WarrantyAndReturnReserveInventoryWriteOffs" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" abstract="false" name="NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_InfusionConsumablesSmithsMedicalMember" abstract="true" name="InfusionConsumablesSmithsMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_SoftwarerevenueMember" abstract="true" name="SoftwarerevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Grantdatefairvalueofrestrictedstockunitsgranted" abstract="false" name="Grantdatefairvalueofrestrictedstockunitsgranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ScheduleOfAccruedLiabilitiesTable" abstract="true" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_StrategicTransactionandIntegration" abstract="false" name="StrategicTransactionandIntegration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_TermAPrincipalPaymentYear3And4" abstract="false" name="TermAPrincipalPaymentYear3And4" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_VascularAccessMember" abstract="true" name="VascularAccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ForeignInfusionSystemSupplierMember" abstract="true" name="ForeignInfusionSystemSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Sparepartsusage" abstract="false" name="Sparepartsusage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_DeferredTaxAssetSection163j" abstract="false" name="DeferredTaxAssetSection163j" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_FurniturefixturesandmoldsMember" abstract="true" name="FurniturefixturesandmoldsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Greaterthan400to100Member" abstract="true" name="Greaterthan400to100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_SmithsMedical2020LimitedMember" abstract="true" name="SmithsMedical2020LimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InstrumentsPlacedwithCustomersMember" abstract="true" name="InstrumentsPlacedwithCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_TimingDomain" abstract="true" name="TimingDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_NetCashPaidReceivedforcurrentandprioracquisitions" abstract="false" name="NetCashPaidReceivedforcurrentandprioracquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" abstract="false" name="ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_SpareParts" abstract="false" name="SpareParts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Prepaidinsuranceandpropertytaxes" abstract="false" name="Prepaidinsuranceandpropertytaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_IncomeTaxDisclosuredeferredtaxesAbstract" abstract="true" name="IncomeTaxDisclosuredeferredtaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_LongTermDebtTypeTable" abstract="true" name="LongTermDebtTypeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_OwnershipRequirementForEarnoutPayment" abstract="false" name="OwnershipRequirementForEarnoutPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_LongTermContingentConsiderationGross" abstract="false" name="LongTermContingentConsiderationGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Hedge5Member" abstract="true" name="Hedge5Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_UnrecognizedTaxBenefitsRollForwardRollForward" abstract="true" name="UnrecognizedTaxBenefitsRollForwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_AmortizationOfInventoryStepUp" abstract="false" name="AmortizationOfInventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_InterestExpenseIncomeNetTable" abstract="true" name="InterestExpenseIncomeNetTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_InfusionSystemsMember" abstract="true" name="InfusionSystemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherDeferredRevenueMember" abstract="true" name="OtherDeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherforeigncountriesMember" abstract="true" name="OtherforeigncountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InterestExpenseOnLongTermDebtTableTextBlock" abstract="false" name="InterestExpenseOnLongTermDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_ForeignMember" abstract="true" name="ForeignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherExpenseIncomeNetDomain" abstract="true" name="OtherExpenseIncomeNetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_StockIncentivePlansTable" abstract="true" name="StockIncentivePlansTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_PrepaidAssetsCurrentLineItems" abstract="true" name="PrepaidAssetsCurrentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_ModifiedPRSUIncrementalExpense" abstract="false" name="ModifiedPRSUIncrementalExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_LessThanOrEqualTo200To100Member" abstract="true" name="LessThanOrEqualTo200To100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_A2011PlanMember" abstract="true" name="A2011PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Effectiveincometaxreconciliationnondeductiblecompensation" abstract="false" name="Effectiveincometaxreconciliationnondeductiblecompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Restructuringandstrategictransactionexpense" abstract="false" name="Restructuringandstrategictransactionexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_Srt_MultipleCurrencyAxisDomain" abstract="true" name="Srt_MultipleCurrencyAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherExpenseIncomeNetLineItems" abstract="true" name="OtherExpenseIncomeNetLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_Effectivetaxratereconciliationnondeductiblecomppercent" abstract="false" name="Effectivetaxratereconciliationnondeductiblecomppercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_ProFormaAdjustmentInventory" abstract="false" name="ProFormaAdjustmentInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ItalyPropertyAndEquipmentMember" abstract="true" name="ItalyPropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_AccountsReceivablePurchaseProgram" abstract="false" name="AccountsReceivablePurchaseProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_OtherExpenseIncomeNetTable" abstract="true" name="OtherExpenseIncomeNetTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_LesseeOperatingAndFinanceLeaseTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_Accruedsalestaxes" abstract="false" name="Accruedsalestaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" abstract="false" name="Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="icui_Accruedlegalfees" abstract="false" name="Accruedlegalfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_LongTermDebtTypeLineItems" abstract="true" name="LongTermDebtTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_BusinessCombinationConsiderationCashHoldback" abstract="false" name="BusinessCombinationConsiderationCashHoldback" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_CurrentMember" abstract="true" name="CurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_WarrantyAndReturnReserveInventory" abstract="false" name="WarrantyAndReturnReserveInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" abstract="true" name="LessThanOrEqualTo250To100ButGreaterThan200To100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_AccruedSalariesAndBenefits" abstract="false" name="AccruedSalariesAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ESPPOriginalIssuance" abstract="false" name="ESPPOriginalIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="icui_APACDomain" abstract="true" name="APACDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Timebasedoptionsgrantdatefairvalue" abstract="false" name="Timebasedoptionsgrantdatefairvalue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_EffectiveTaxRateReconcilationTransactionCostPercent" abstract="false" name="EffectiveTaxRateReconcilationTransactionCostPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_SmithsMedicalMember" abstract="true" name="SmithsMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherExpenseIncomeNetAxis" abstract="true" name="OtherExpenseIncomeNetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_EffectiveIncomeTaxRateReconciliationTransactionCost" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_InterestRatesLineItems" abstract="true" name="InterestRatesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_TermAPrincipalPaymentInYear5" abstract="false" name="TermAPrincipalPaymentInYear5" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_DeferredtaxassetsandliabilitiesLineItems" abstract="true" name="DeferredtaxassetsandliabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_TermLoanBPrincipalPayment" abstract="false" name="TermLoanBPrincipalPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_UsGaap_InterestRateSwap2Member" abstract="true" name="UsGaap_InterestRateSwap2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherLiabilitiesTable" abstract="true" name="OtherLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_NonpublicCompanyMember" abstract="true" name="NonpublicCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_PrepaidNoncurrentAssetsTable" abstract="true" name="PrepaidNoncurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_TermLoanBMember" abstract="true" name="TermLoanBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InternationalSalesDomain" abstract="true" name="InternationalSalesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" abstract="false" name="SupplementalBalanceSheetInformationLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" abstract="false" name="TerSOFRInterestRateAdjustmentForBaseRateLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_GILTItaxexpense" abstract="false" name="GILTItaxexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Hedge4Member" abstract="true" name="Hedge4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InterestRatesTable" abstract="true" name="InterestRatesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_ContingentConsiderationGrossLT" abstract="false" name="ContingentConsiderationGrossLT" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Outsidesalescommissions" abstract="false" name="Outsidesalescommissions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_NoncurrentMember" abstract="true" name="NoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_UnitedStatespropertyandequipmentMember" abstract="true" name="UnitedStatespropertyandequipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Srt_MultipleCurrencyAxisAxis" abstract="true" name="Srt_MultipleCurrencyAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_AccruedProductFieldAction." abstract="false" name="AccruedProductFieldAction." nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Hedge3MemberMember" abstract="true" name="Hedge3MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_TimingAxis" abstract="true" name="TimingAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_InfusionConsumablesMember" abstract="true" name="InfusionConsumablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_LeverageRatioLevelDomain" abstract="true" name="LeverageRatioLevelDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Accruedfreight" abstract="false" name="Accruedfreight" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_ProvisionForWarrantyAndReturns" abstract="false" name="ProvisionForWarrantyAndReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_OtherCurrenciesMember" abstract="true" name="OtherCurrenciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" abstract="false" name="IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_Optiontoextendinyears" abstract="false" name="Optiontoextendinyears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" abstract="false" name="TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_LessThan275To100Member" abstract="true" name="LessThan275To100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_StockIncentivePlansLineItems" abstract="true" name="StockIncentivePlansLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_PrepaidAssetsCurrentTable" abstract="true" name="PrepaidAssetsCurrentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_InternationalDistributorMember" abstract="true" name="InternationalDistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_CommonStockSharesMember" abstract="true" name="CommonStockSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_CurrencyTranslationOnEarnOut" abstract="false" name="CurrencyTranslationOnEarnOut" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_RevenueRecognitionTimingTable" abstract="true" name="RevenueRecognitionTimingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_COntractLiabilityRollforwardRollForward" abstract="true" name="COntractLiabilityRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="icui_LessThanOrEqual300To100ButGreaterThan250to100Member" abstract="true" name="LessThanOrEqual300To100ButGreaterThan250to100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_OtherLATAMMember" abstract="true" name="OtherLATAMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_BusinessCombinationConsiderationTransferredCash" abstract="false" name="BusinessCombinationConsiderationTransferredCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_A2003PlanMember" abstract="true" name="A2003PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_MoldsMember" abstract="true" name="MoldsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_Percentoftotalrevenue" abstract="false" name="Percentoftotalrevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="icui_TotalSeniorSecuredCreditFacility" abstract="false" name="TotalSeniorSecuredCreditFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_MiscellaneousIncomeNet" abstract="false" name="MiscellaneousIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="icui_MexicoPropertyAndEquipmentMember" abstract="true" name="MexicoPropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_InterestPercentageAddedToFederalFundsRate" abstract="false" name="InterestPercentageAddedToFederalFundsRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="icui_CriticalCareMember" abstract="true" name="CriticalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="icui_ContractassetandliabilitybalancesTable" abstract="true" name="ContractassetandliabilitybalancesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" abstract="false" name="PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAndPerformanceRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>icui-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ddbb4ef-1cce-4390-848d-bd8438d3c519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_822c7d2e-f432-4b41-b6a4-a51ee34ed070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ddbb4ef-1cce-4390-848d-bd8438d3c519" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_822c7d2e-f432-4b41-b6a4-a51ee34ed070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4b766694-35d6-454a-b5fa-94a6365faf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ddbb4ef-1cce-4390-848d-bd8438d3c519" xlink:to="loc_us-gaap_LongTermDebtCurrent_4b766694-35d6-454a-b5fa-94a6365faf1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d76a447c-36b9-412b-9956-c3c452c1f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ddbb4ef-1cce-4390-848d-bd8438d3c519" xlink:to="loc_us-gaap_AccountsPayableCurrent_d76a447c-36b9-412b-9956-c3c452c1f41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1e1c2442-aa7a-4150-8af4-b9b8135e34be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ddbb4ef-1cce-4390-848d-bd8438d3c519" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1e1c2442-aa7a-4150-8af4-b9b8135e34be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1ce1d974-f7ec-40fe-9512-961a655261f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_add9c45e-5fd4-45f3-ab52-6ec83e2045a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1ce1d974-f7ec-40fe-9512-961a655261f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_add9c45e-5fd4-45f3-ab52-6ec83e2045a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_eab69caa-057f-47f2-b5af-de135dd2b531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1ce1d974-f7ec-40fe-9512-961a655261f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_eab69caa-057f-47f2-b5af-de135dd2b531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d980c4dd-a468-4e83-b570-7035c8ba341e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d980c4dd-a468-4e83-b570-7035c8ba341e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6a04bf86-d19e-4540-85b3-2655ab48303d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_AssetsCurrent_6a04bf86-d19e-4540-85b3-2655ab48303d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed7717b8-c973-4e38-86fd-9ce32f302e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed7717b8-c973-4e38-86fd-9ce32f302e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7dac9586-0628-45b9-b07e-e2b73b8ade09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_Goodwill_7dac9586-0628-45b9-b07e-e2b73b8ade09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0cb8dd6e-d8c2-4c1e-a340-d2924bac2a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0cb8dd6e-d8c2-4c1e-a340-d2924bac2a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d464e29f-5bdc-4b3a-98e3-9bb7e8649b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d464e29f-5bdc-4b3a-98e3-9bb7e8649b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_da05b4d9-fade-447e-9801-9ce3cf2b1f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_da05b4d9-fade-447e-9801-9ce3cf2b1f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_db9c4c5d-32b7-444a-8fbb-0e9a22d02135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a96ecb9-a91d-428b-9d0d-b32d83825835" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_db9c4c5d-32b7-444a-8fbb-0e9a22d02135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_2d7f6ade-c9e9-4cd2-a49b-c31af3017ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_2d7f6ade-c9e9-4cd2-a49b-c31af3017ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_33b6b4ce-1026-4646-a178-ad3b640f33e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_CommonStockValue_33b6b4ce-1026-4646-a178-ad3b640f33e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bb1df682-91c7-43a6-8750-73dff27f5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bb1df682-91c7-43a6-8750-73dff27f5db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6a3c7c16-0a53-4f83-a4ac-54e9a564d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_TreasuryStockValue_6a3c7c16-0a53-4f83-a4ac-54e9a564d0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b3e7cb3-a9a0-4cb7-9283-de5e48c39c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b3e7cb3-a9a0-4cb7-9283-de5e48c39c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cbb54041-15a1-4de2-b24c-ee26deff9ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc92a8d-b708-40b0-ad14-f16fffb4faac" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cbb54041-15a1-4de2-b24c-ee26deff9ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_705f9440-4399-4c77-a8b7-dad464c35bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_705f9440-4399-4c77-a8b7-dad464c35bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b74266f6-8b16-4e2d-8e5e-d2b73df00991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b74266f6-8b16-4e2d-8e5e-d2b73df00991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bdb0fb57-db0b-4ba9-aad2-7584635a9424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:to="loc_us-gaap_InventoryNet_bdb0fb57-db0b-4ba9-aad2-7584635a9424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_89953448-4928-48dc-8aa2-98e40a05a906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:to="loc_us-gaap_PrepaidTaxes_89953448-4928-48dc-8aa2-98e40a05a906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7e0c964-64fc-4da5-9b00-cf1c0c8486dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3be2571f-65ec-4a78-ac70-3e8007faf0bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7e0c964-64fc-4da5-9b00-cf1c0c8486dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ad4512bd-dc66-442a-9ed6-a42b50b3ed51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_LiabilitiesCurrent_ad4512bd-dc66-442a-9ed6-a42b50b3ed51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b99a5ed2-62e2-4421-ab30-bb85729ef248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b99a5ed2-62e2-4421-ab30-bb85729ef248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_2641a2dd-f25d-4ed6-a712-75ba6a6662b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_SecuredLongTermDebt_2641a2dd-f25d-4ed6-a712-75ba6a6662b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_8f51fb0f-e421-421c-986e-7d902abdc06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_OtherLiabilities_8f51fb0f-e421-421c-986e-7d902abdc06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_49ebed04-d848-4df3-8a52-fd0559d1ad40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_49ebed04-d848-4df3-8a52-fd0559d1ad40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_315fcd4e-24e9-45a0-92f2-0c5f4dc856ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_315fcd4e-24e9-45a0-92f2-0c5f4dc856ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_283a25c1-55f5-4177-bf91-36795bb784d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a15d2dc2-ee21-4b90-b55b-224567c97705" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_283a25c1-55f5-4177-bf91-36795bb784d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_996e1fa6-2a9b-417a-8a00-c453f7e72e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e141ece5-8a4a-450f-b0b0-c9f4c7f3c940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_996e1fa6-2a9b-417a-8a00-c453f7e72e44" xlink:to="loc_us-gaap_Revenues_e141ece5-8a4a-450f-b0b0-c9f4c7f3c940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c37ce703-c1bd-4065-9a81-66d3e775719b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_996e1fa6-2a9b-417a-8a00-c453f7e72e44" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c37ce703-c1bd-4065-9a81-66d3e775719b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8c374a81-fbb5-4a20-bbf1-de41b683da4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8c374a81-fbb5-4a20-bbf1-de41b683da4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_123d4933-49bd-4827-bd54-60c5bc844429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_123d4933-49bd-4827-bd54-60c5bc844429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Restructuringandstrategictransactionexpense_4023488a-0ffe-4803-8dd1-e852399161cb" xlink:href="icui-20221231.xsd#icui_Restructuringandstrategictransactionexpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:to="loc_icui_Restructuringandstrategictransactionexpense_4023488a-0ffe-4803-8dd1-e852399161cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91681a93-5d8e-4d6e-9baf-cf8cd9b3b243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91681a93-5d8e-4d6e-9baf-cf8cd9b3b243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contractsettlements_d74c4a46-05db-42dc-bea4-636db0e3e79a" xlink:href="icui-20221231.xsd#icui_Contractsettlements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_47f6c202-7e43-4d7e-b258-125c5c503713" xlink:to="loc_icui_Contractsettlements_d74c4a46-05db-42dc-bea4-636db0e3e79a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f4ff67ca-15d5-45a5-95ed-fe5559216051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_c4bb2534-a391-4f0d-ba98-c4d9718b181f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_f4ff67ca-15d5-45a5-95ed-fe5559216051" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_c4bb2534-a391-4f0d-ba98-c4d9718b181f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bfce8129-688b-495e-8958-8936eaae79d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_f4ff67ca-15d5-45a5-95ed-fe5559216051" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bfce8129-688b-495e-8958-8936eaae79d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef37b52a-1628-4c62-b4ac-9d2b02dc9a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_f4ff67ca-15d5-45a5-95ed-fe5559216051" xlink:to="loc_us-gaap_OperatingIncomeLoss_ef37b52a-1628-4c62-b4ac-9d2b02dc9a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d37240b-de8f-4cd6-b1dd-5f1a3e63f12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b6345b2-4a6f-49ca-a203-bc4fdc8b0014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3d37240b-de8f-4cd6-b1dd-5f1a3e63f12b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b6345b2-4a6f-49ca-a203-bc4fdc8b0014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_1a81f998-dfd5-4396-8d81-0a583cd1e937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3d37240b-de8f-4cd6-b1dd-5f1a3e63f12b" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_1a81f998-dfd5-4396-8d81-0a583cd1e937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fb4e95f6-63da-42ad-aa53-0dce22f77b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a4ca16dc-8b4a-4adc-8d1f-0a10f284e035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fb4e95f6-63da-42ad-aa53-0dce22f77b2a" xlink:to="loc_us-gaap_GrossProfit_a4ca16dc-8b4a-4adc-8d1f-0a10f284e035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6aef7258-ae6f-4e6a-a953-fc3df7f4c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fb4e95f6-63da-42ad-aa53-0dce22f77b2a" xlink:to="loc_us-gaap_OperatingExpenses_6aef7258-ae6f-4e6a-a953-fc3df7f4c15c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="simple" xlink:href="icui-20221231.xsd#StatementofComprehensiveIncomeStatement"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cc3516c-4a78-49f1-8fab-5a5652463ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c5c5d1ff-171c-40b7-86db-3758a71ec4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cc3516c-4a78-49f1-8fab-5a5652463ccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c5c5d1ff-171c-40b7-86db-3758a71ec4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ef3e8660-4928-4571-8596-19cf62054a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cc3516c-4a78-49f1-8fab-5a5652463ccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ef3e8660-4928-4571-8596-19cf62054a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dfd58562-ca40-43e6-ae81-a52256ecc2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cc3516c-4a78-49f1-8fab-5a5652463ccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_dfd58562-ca40-43e6-ae81-a52256ecc2e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa9e3c3-d4d8-4db2-81c9-75156c3c5124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_45585623-b9b3-482f-a231-9fa3bd1df9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa9e3c3-d4d8-4db2-81c9-75156c3c5124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_45585623-b9b3-482f-a231-9fa3bd1df9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aaf71811-aefa-4c60-86f7-22e79d634b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa9e3c3-d4d8-4db2-81c9-75156c3c5124" xlink:to="loc_us-gaap_NetIncomeLoss_aaf71811-aefa-4c60-86f7-22e79d634b89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_07628e81-e5b1-4258-8d8f-725abf3711ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_NetIncomeLoss_07628e81-e5b1-4258-8d8f-725abf3711ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76172cf0-c7f8-4dad-a735-5c157359455f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76172cf0-c7f8-4dad-a735-5c157359455f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AmortizationOfInventoryStepUp_2dbc4d4a-b48c-4f35-b77a-9d19361e3261" xlink:href="icui-20221231.xsd#icui_AmortizationOfInventoryStepUp"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_icui_AmortizationOfInventoryStepUp_2dbc4d4a-b48c-4f35-b77a-9d19361e3261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_98ab460c-03af-4151-9a6f-474833088568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_98ab460c-03af-4151-9a6f-474833088568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e7babf9e-0b3a-4fc0-b02c-8f72b29d0016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e7babf9e-0b3a-4fc0-b02c-8f72b29d0016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProvisionForWarrantyAndReturns_777890d3-72f8-4d0c-9fdb-10542361b83b" xlink:href="icui-20221231.xsd#icui_ProvisionForWarrantyAndReturns"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_icui_ProvisionForWarrantyAndReturns_777890d3-72f8-4d0c-9fdb-10542361b83b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e222532b-a17a-4c81-b71e-dceb00d8a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_ShareBasedCompensation_e222532b-a17a-4c81-b71e-dceb00d8a19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_70e0ec96-a08f-4cf1-b11d-6941f8f3e528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_70e0ec96-a08f-4cf1-b11d-6941f8f3e528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_6835cc64-bbdb-4eb9-8594-17a378f41c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_6835cc64-bbdb-4eb9-8594-17a378f41c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_4065f601-8b74-4331-a4bf-a75e908aac26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_4065f601-8b74-4331-a4bf-a75e908aac26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b1963c78-6c75-422e-89b2-cde37d51c5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b1963c78-6c75-422e-89b2-cde37d51c5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fcaba975-d3c7-4d9c-a3cf-b7c0d3330202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fcaba975-d3c7-4d9c-a3cf-b7c0d3330202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_52cc3a60-2759-4502-99f1-20b22c48edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_52cc3a60-2759-4502-99f1-20b22c48edf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sparepartsusage_fbbccc2e-db19-489f-b9f4-a9176abd37c2" xlink:href="icui-20221231.xsd#icui_Sparepartsusage"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_icui_Sparepartsusage_fbbccc2e-db19-489f-b9f4-a9176abd37c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d246fca2-cbfd-441b-aea3-eb7772476785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d246fca2-cbfd-441b-aea3-eb7772476785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01c6ac58-3f59-4f74-93e3-8d2d9c0d0827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01c6ac58-3f59-4f74-93e3-8d2d9c0d0827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eb806bb7-65dc-4651-8de7-ff134cf2a9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eb806bb7-65dc-4651-8de7-ff134cf2a9cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_df2b905b-2b13-44eb-991c-da657f1069fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_df2b905b-2b13-44eb-991c-da657f1069fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ad77b7ae-3043-4207-8afb-5517f20e7d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ad77b7ae-3043-4207-8afb-5517f20e7d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b33d5459-6484-4d02-afbb-f0ede78fbad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b33d5459-6484-4d02-afbb-f0ede78fbad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2bed6128-163d-440f-9de4-5fec3d4fea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2bed6128-163d-440f-9de4-5fec3d4fea5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_a8394088-a9be-4955-a971-7b1673713a93" xlink:href="icui-20221231.xsd#icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a239964b-79d8-42d4-928b-5ed96da1ead2" xlink:to="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_a8394088-a9be-4955-a971-7b1673713a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2c5ef78-9f74-45c6-a283-22e056fc4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e35f0918-1543-4361-a743-7b121c418e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2c5ef78-9f74-45c6-a283-22e056fc4b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e35f0918-1543-4361-a743-7b121c418e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f360eef3-811b-4348-8ec5-43ea480e342e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2c5ef78-9f74-45c6-a283-22e056fc4b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f360eef3-811b-4348-8ec5-43ea480e342e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc74b6e1-d568-4294-986f-3381f48a8ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2c5ef78-9f74-45c6-a283-22e056fc4b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc74b6e1-d568-4294-986f-3381f48a8ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81be2629-c427-44d0-a051-004d143a9a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2c5ef78-9f74-45c6-a283-22e056fc4b0d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81be2629-c427-44d0-a051-004d143a9a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_d2c74a6d-88b0-4a84-a88a-28e75a729604" xlink:href="icui-20221231.xsd#icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_d2c74a6d-88b0-4a84-a88a-28e75a729604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c3e7981d-c3ff-4cda-b5bc-57126a799ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c3e7981d-c3ff-4cda-b5bc-57126a799ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1ce18aa-f6c8-40c9-ac5e-a3daa1f632c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f1ce18aa-f6c8-40c9-ac5e-a3daa1f632c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_03c7dfb0-1d4f-40b0-a97d-27a05304cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_03c7dfb0-1d4f-40b0-a97d-27a05304cd68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_07543fb9-65dd-424c-a3a7-212d1959074b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_07543fb9-65dd-424c-a3a7-212d1959074b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f517d445-7d76-44bb-8f94-e4f9181320c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f517d445-7d76-44bb-8f94-e4f9181320c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6e41a3b2-bc73-46ca-89f8-d97b4eae51a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6e41a3b2-bc73-46ca-89f8-d97b4eae51a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3124e906-cef3-4738-9c24-49e1f8f3c4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3124e906-cef3-4738-9c24-49e1f8f3c4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b9a59fe4-33c7-4b9e-b9a8-869d6b667c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8eb01ad5-4aba-4bd6-9ed4-8126e3c61225" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b9a59fe4-33c7-4b9e-b9a8-869d6b667c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2d3d4a49-3137-4a60-a4df-db310a711e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2d3d4a49-3137-4a60-a4df-db310a711e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_7f0a2e22-6dd6-4020-8008-046e3b745a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_7f0a2e22-6dd6-4020-8008-046e3b745a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c7a4694b-bb23-40ba-8919-680ff8026f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c7a4694b-bb23-40ba-8919-680ff8026f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_86eb0a8b-0cc9-46ae-98d0-02f97a9d9d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_86eb0a8b-0cc9-46ae-98d0-02f97a9d9d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_07b1c706-e11b-4106-b1fd-a3bc19ed68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_07b1c706-e11b-4106-b1fd-a3bc19ed68f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fcd242d1-41ce-41ff-bf31-fc1b954339e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fcd242d1-41ce-41ff-bf31-fc1b954339e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a6137d71-68e8-41d0-8d26-0fa6a97d892a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad188bf6-c3c2-4e3b-a309-bd644bd6ae10" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a6137d71-68e8-41d0-8d26-0fa6a97d892a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dfee5df2-5cf5-4d0f-8502-93ea60ef39f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ced9c9a4-52d4-4eae-b585-98109ce30225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dfee5df2-5cf5-4d0f-8502-93ea60ef39f8" xlink:to="loc_us-gaap_InventoryRawMaterials_ced9c9a4-52d4-4eae-b585-98109ce30225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_b5fd8672-97b2-4d1f-9d99-38768c7acf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dfee5df2-5cf5-4d0f-8502-93ea60ef39f8" xlink:to="loc_us-gaap_InventoryWorkInProcess_b5fd8672-97b2-4d1f-9d99-38768c7acf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b26162c0-a0a5-43c4-b138-ef0ec5402980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dfee5df2-5cf5-4d0f-8502-93ea60ef39f8" xlink:to="loc_us-gaap_InventoryFinishedGoods_b26162c0-a0a5-43c4-b138-ef0ec5402980" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b7bd580f-f8b6-4e6a-bea6-0f944d5cdf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a978da11-b484-4650-8e54-d47976309641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b7bd580f-f8b6-4e6a-bea6-0f944d5cdf1a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a978da11-b484-4650-8e54-d47976309641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ada16f49-91a8-4e57-bd76-8e3cd15e921e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b7bd580f-f8b6-4e6a-bea6-0f944d5cdf1a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ada16f49-91a8-4e57-bd76-8e3cd15e921e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2237576e-fc8f-4021-b8fc-14e61cd30b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_OtherAssetsCurrent_2237576e-fc8f-4021-b8fc-14e61cd30b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidothertaxes_73697cad-7cea-4a90-a14c-05ef7c1c644a" xlink:href="icui-20221231.xsd#icui_Prepaidothertaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_icui_Prepaidothertaxes_73697cad-7cea-4a90-a14c-05ef7c1c644a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidVendorExpenses_27b7f638-cb06-48c2-8461-638ef6b92568" xlink:href="icui-20221231.xsd#icui_PrepaidVendorExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_icui_PrepaidVendorExpenses_27b7f638-cb06-48c2-8461-638ef6b92568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxcharge_75d4119b-89f4-4785-84d0-451a50543dd0" xlink:href="icui-20221231.xsd#icui_Deferredtaxcharge"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_icui_Deferredtaxcharge_75d4119b-89f4-4785-84d0-451a50543dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsAndOtherAssets_b0f4a59d-dd0e-4511-8b21-9993e54d0e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_DeferredCostsAndOtherAssets_b0f4a59d-dd0e-4511-8b21-9993e54d0e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidinsuranceandpropertytaxes_96203d64-7518-4dff-8fad-8cd5d5d3e0f6" xlink:href="icui-20221231.xsd#icui_Prepaidinsuranceandpropertytaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_icui_Prepaidinsuranceandpropertytaxes_96203d64-7518-4dff-8fad-8cd5d5d3e0f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_b3cbba8e-d766-4620-a5a6-5065e7c2788b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_DepositAssets_b3cbba8e-d766-4620-a5a6-5065e7c2788b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_98c35ef9-ad20-4a2f-b7f8-eae484d8b53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_98c35ef9-ad20-4a2f-b7f8-eae484d8b53a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ee0a9e98-4b99-4e2a-9cb0-bb4989957e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ee0a9e98-4b99-4e2a-9cb0-bb4989957e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4a5ce323-84ba-46a6-9522-df7a2108dc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_980f8008-9507-49b5-89a5-e1e648c86599" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4a5ce323-84ba-46a6-9522-df7a2108dc65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidsandOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cd03ff74-868d-41d3-ad36-b8f0ebf4098f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_EquityMethodInvestments_cd03ff74-868d-41d3-ad36-b8f0ebf4098f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_7e284cf4-7095-4b21-9602-9d104628b251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_7e284cf4-7095-4b21-9602-9d104628b251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SpareParts_4acca0cc-40e6-4750-826b-a129a54447fa" xlink:href="icui-20221231.xsd#icui_SpareParts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_icui_SpareParts_4acca0cc-40e6-4750-826b-a129a54447fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a4d4b682-bf1f-48a5-bc15-2621997a2a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a4d4b682-bf1f-48a5-bc15-2621997a2a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_1053b2c6-f245-425b-8724-9f89526a59e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_1053b2c6-f245-425b-8724-9f89526a59e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eeef66df-e6d2-46c7-924b-3c7e6978e904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_eeef66df-e6d2-46c7-924b-3c7e6978e904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_6fd3d32f-74e2-4019-906b-3a1cf4f33b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_4a24593f-446a-422e-a074-38c7edbff484" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_6fd3d32f-74e2-4019-906b-3a1cf4f33b79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesEffectivetaxrateDetails"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_db2034c8-e81c-41cf-b55b-850fb578d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_db2034c8-e81c-41cf-b55b-850fb578d6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d67a6a87-9ff6-4fe9-ab63-2062843ebd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d67a6a87-9ff6-4fe9-ab63-2062843ebd14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4df3dba7-5296-4079-9a1b-85948bc68fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4df3dba7-5296-4079-9a1b-85948bc68fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GILTItaxexpense_f8994af3-bbb2-42b0-bf58-bab28b723b98" xlink:href="icui-20221231.xsd#icui_GILTItaxexpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_icui_GILTItaxexpense_f8994af3-bbb2-42b0-bf58-bab28b723b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_890d3e7c-e5f0-4a7e-8c54-d4f34bd5e4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_890d3e7c-e5f0-4a7e-8c54-d4f34bd5e4bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_4475683d-b072-4147-a672-88fae360ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_4475683d-b072-4147-a672-88fae360ef02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_b98e79cc-eca4-4e26-9b15-cae991888c43" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_b98e79cc-eca4-4e26-9b15-cae991888c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_3a079438-8baf-4f40-9d9a-5ae58eb1ade3" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationTransactionCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_3a079438-8baf-4f40-9d9a-5ae58eb1ade3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_94c28d5c-677e-4afd-bc53-2beef14ced7e" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationContingentConsideration"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_94c28d5c-677e-4afd-bc53-2beef14ced7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation_85671290-0cf2-463a-a1a1-56843346affc" xlink:href="icui-20221231.xsd#icui_Effectiveincometaxreconciliationnondeductiblecompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation_85671290-0cf2-463a-a1a1-56843346affc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b17e60f1-2bdb-4382-a5fe-daaca2989bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c7aac0b8-a344-475b-975c-39a4f56399d4" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b17e60f1-2bdb-4382-a5fe-daaca2989bd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesDeferredincometaxassetsliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ca59100c-a58f-4b0a-9556-b5929d0a9c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0cbcd56c-aea3-4f1b-bad5-78824f20789b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ca59100c-a58f-4b0a-9556-b5929d0a9c7d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0cbcd56c-aea3-4f1b-bad5-78824f20789b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>icui-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.icumed.com/role/AuditInformation" xlink:type="simple" xlink:href="icui-20221231.xsd#AuditInformation"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AuditInformation" xlink:type="extended" id="ic11df6a13c514dedb788120018013216_AuditInformation">
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_034edc53-ced7-4210-91fa-ca724e230d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorName_034edc53-ced7-4210-91fa-ca724e230d6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_1cde656f-5548-45ba-a704-98a6445a7ad6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorLocation_1cde656f-5548-45ba-a704-98a6445a7ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_239cf816-994f-4e30-9b96-b21d71805f56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorFirmId_239cf816-994f-4e30-9b96-b21d71805f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:to="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_206ebc5c-3a67-42a6-9391-f1e1d14f59c4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:to="loc_dei_EntityDomain_206ebc5c-3a67-42a6-9391-f1e1d14f59c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f9025bc9-54d9-4583-9d20-0f0506efdec1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:to="loc_dei_EntityDomain_f9025bc9-54d9-4583-9d20-0f0506efdec1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i8766d0ce84c1471aa4614e9391c9bad4_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:to="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03a805f6-0338-4d91-a39d-25d23dd0b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03a805f6-0338-4d91-a39d-25d23dd0b667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f33f8419-a8a1-4477-9d06-a84c3da5a3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f33f8419-a8a1-4477-9d06-a84c3da5a3cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c7b65957-e6b9-473f-a1b6-5c50a6d8595d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c7b65957-e6b9-473f-a1b6-5c50a6d8595d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aea3f6e7-304e-4691-aa49-d4c766cccbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aea3f6e7-304e-4691-aa49-d4c766cccbe0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6bf497bb-fae1-49e4-b65f-26cc4ac2cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_InventoryNet_6bf497bb-fae1-49e4-b65f-26cc4ac2cddd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_a2a1ad68-e847-47dd-a44d-ca39b2ba4359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_PrepaidTaxes_a2a1ad68-e847-47dd-a44d-ca39b2ba4359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c6622c5-eb37-4bd2-9e1a-8529a01486ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c6622c5-eb37-4bd2-9e1a-8529a01486ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_21ac4f44-23d3-4196-8d55-a4759395ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AssetsCurrent_21ac4f44-23d3-4196-8d55-a4759395ae79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_51adef93-d804-45ff-92aa-9f0584f27785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_51adef93-d804-45ff-92aa-9f0584f27785" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e73fd60-8f48-4162-8492-c5e330dcec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e73fd60-8f48-4162-8492-c5e330dcec4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_14493a79-acea-4d80-bb54-e0538f7df63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_14493a79-acea-4d80-bb54-e0538f7df63a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b002a518-ccf3-4c99-b5ad-3d4e71f88fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_Goodwill_b002a518-ccf3-4c99-b5ad-3d4e71f88fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_713bc2c8-2b85-4787-ad3c-d9f8f52c8bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_713bc2c8-2b85-4787-ad3c-d9f8f52c8bb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_09f018ef-ce64-4e62-9e1d-d8848aa36c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_09f018ef-ce64-4e62-9e1d-d8848aa36c3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0a811e6d-a0fd-47ea-a02e-bbc7bdebc301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0a811e6d-a0fd-47ea-a02e-bbc7bdebc301" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_acde154b-61ef-4db4-a1bf-921c655e8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_Assets_acde154b-61ef-4db4-a1bf-921c655e8c66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e43d46d6-8c62-4cff-9545-f8c4bb4d9b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccountsPayableCurrent_e43d46d6-8c62-4cff-9545-f8c4bb4d9b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4758ef14-b367-46df-a9f2-24decd52b36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4758ef14-b367-46df-a9f2-24decd52b36e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7c0116ce-627c-4a3c-b851-b7c038ec8ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_LongTermDebtCurrent_7c0116ce-627c-4a3c-b851-b7c038ec8ac4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_69790d35-aedb-4c93-83a9-e6ed01b92074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_69790d35-aedb-4c93-83a9-e6ed01b92074" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b07860a5-7aae-4c14-882d-3b4812a333e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_LiabilitiesCurrent_b07860a5-7aae-4c14-882d-3b4812a333e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b19504d1-5964-44bd-b3a4-132dae527c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b19504d1-5964-44bd-b3a4-132dae527c0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_3e4f01b2-f4ca-44d7-88d4-9713412fb92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_SecuredLongTermDebt_3e4f01b2-f4ca-44d7-88d4-9713412fb92e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_f5dc0bd8-8a83-41d9-ac6c-038b71223700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_OtherLiabilities_f5dc0bd8-8a83-41d9-ac6c-038b71223700" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b03e7d93-6f60-4101-91dd-8018ac3ff56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b03e7d93-6f60-4101-91dd-8018ac3ff56c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_5fdce83f-bcef-4a6c-b70d-74915b34b7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_5fdce83f-bcef-4a6c-b70d-74915b34b7fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6dcac311-a7a5-4ade-9575-a3be13e40c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6dcac311-a7a5-4ade-9575-a3be13e40c8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_6f2327af-6a39-4c3b-8728-2b694a82483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_6f2327af-6a39-4c3b-8728-2b694a82483a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_15d01764-f256-4770-bb96-9730eedd5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_CommonStockValue_15d01764-f256-4770-bb96-9730eedd5ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4ba0e5a-7f1a-4c08-a2ad-3b1d5204414e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4ba0e5a-7f1a-4c08-a2ad-3b1d5204414e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f0108272-0c2f-4516-9f8e-0143854ab7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_TreasuryStockValue_f0108272-0c2f-4516-9f8e-0143854ab7d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6888831f-42c6-41e0-8ac4-fe85307face6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6888831f-42c6-41e0-8ac4-fe85307face6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_613ee75c-ee24-4b06-8633-a64e7caf199a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_613ee75c-ee24-4b06-8633-a64e7caf199a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aeb31ee4-18b6-4278-b546-67237ce3aab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aeb31ee4-18b6-4278-b546-67237ce3aab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_16606e95-6732-4ce3-b3f4-676b247dc191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_16606e95-6732-4ce3-b3f4-676b247dc191" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:to="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:to="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a88ac7b1-39ee-4943-bce7-fbc28ef2824a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a88ac7b1-39ee-4943-bce7-fbc28ef2824a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i221ef6392624477da3736a4c580df1fc_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fcbb7832-8fdf-4ec8-bac5-dce4f41cde08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:to="loc_us-gaap_Revenues_fcbb7832-8fdf-4ec8-bac5-dce4f41cde08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_efefb7b0-c199-4539-8077-92b38953eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_efefb7b0-c199-4539-8077-92b38953eb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_58ab30f6-2f71-4637-b495-76fea7e1565d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_GrossProfit_58ab30f6-2f71-4637-b495-76fea7e1565d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9adfddc-14f4-44a1-8ca8-7ddebf8854aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9adfddc-14f4-44a1-8ca8-7ddebf8854aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b0408548-39f7-4691-9b3d-5a696329f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b0408548-39f7-4691-9b3d-5a696329f4c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Restructuringandstrategictransactionexpense_7a36d0fe-f9aa-45a4-91ad-90b8ba2b3136" xlink:href="icui-20221231.xsd#icui_Restructuringandstrategictransactionexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_icui_Restructuringandstrategictransactionexpense_7a36d0fe-f9aa-45a4-91ad-90b8ba2b3136" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f2474e03-6fc4-473c-b3b0-962f3b93c584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f2474e03-6fc4-473c-b3b0-962f3b93c584" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contractsettlements_5177fd58-5c8a-4229-8350-3f1a5967d1cc" xlink:href="icui-20221231.xsd#icui_Contractsettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_icui_Contractsettlements_5177fd58-5c8a-4229-8350-3f1a5967d1cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a729df63-0cd8-4a16-b34e-6f3e7fae15f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_OperatingExpenses_a729df63-0cd8-4a16-b34e-6f3e7fae15f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4e5d757-8335-4e20-b221-f86ab3652a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4e5d757-8335-4e20-b221-f86ab3652a3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_e4be76e5-40b6-4fcc-9cf3-a02d3050e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_e4be76e5-40b6-4fcc-9cf3-a02d3050e11c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5deea686-0257-435a-b581-4235fff77d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5deea686-0257-435a-b581-4235fff77d26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_381bb609-ef91-4aff-8463-cc9153a1919d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_381bb609-ef91-4aff-8463-cc9153a1919d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a33ac66-a637-46e4-a41e-000d6e2d1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a33ac66-a637-46e4-a41e-000d6e2d1aff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a20adefb-94ea-4b30-b9b3-d1f693daa417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_NetIncomeLoss_a20adefb-94ea-4b30-b9b3-d1f693daa417" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b6532cea-aa8b-4df1-9ff6-b4cfb13850ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_EarningsPerShareBasic_b6532cea-aa8b-4df1-9ff6-b4cfb13850ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_91df7dfc-335f-4876-88d2-28501bc7c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_91df7dfc-335f-4876-88d2-28501bc7c2f2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_736c56e7-9a11-4189-8969-0a243f97f0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_736c56e7-9a11-4189-8969-0a243f97f0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47d77e74-566b-4f23-8d9b-87a4445b76c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47d77e74-566b-4f23-8d9b-87a4445b76c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:to="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_083eab4d-f706-4921-8b8b-8a5be336a81a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:to="loc_srt_ProductsAndServicesDomain_083eab4d-f706-4921-8b8b-8a5be336a81a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5fa3834-9bbf-4c97-8648-bc1b6da856b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:to="loc_srt_ProductsAndServicesDomain_e5fa3834-9bbf-4c97-8648-bc1b6da856b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="simple" xlink:href="icui-20221231.xsd#StatementofComprehensiveIncomeStatement"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="extended" id="i5cf8bae564714473b72f1f3bb8cf9d2f_StatementofComprehensiveIncomeStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93ff8d69-0c1f-49f5-a30f-f7722e81f7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_NetIncomeLoss_93ff8d69-0c1f-49f5-a30f-f7722e81f7ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8a449082-9fb2-4534-bd2f-d09b9fe8eb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8a449082-9fb2-4534-bd2f-d09b9fe8eb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1bf74234-9722-473b-9afd-ef0fe6322081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1bf74234-9722-473b-9afd-ef0fe6322081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a5718ac4-c2ac-4649-8288-0a2c2fb97af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a5718ac4-c2ac-4649-8288-0a2c2fb97af2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_35dc80d0-a335-4fe9-bbfe-f3efba7613c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_35dc80d0-a335-4fe9-bbfe-f3efba7613c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_60a933da-5365-4451-861c-511d4bf9b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_60a933da-5365-4451-861c-511d4bf9b39e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:to="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_df7ea23c-9859-47cf-87d4-6311d739f3ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:to="loc_srt_ScenarioUnspecifiedDomain_df7ea23c-9859-47cf-87d4-6311d739f3ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_44e89073-acb0-44e4-a080-1d17bbed46fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:to="loc_srt_ScenarioUnspecifiedDomain_44e89073-acb0-44e4-a080-1d17bbed46fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="id1c5a97c6cf541979075b5b814fb98d7_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0abd0078-8356-4080-8f4d-93e8b5ffd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0abd0078-8356-4080-8f4d-93e8b5ffd44b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f55d8ee5-7cec-46c6-9381-baba2b779cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockholdersEquity_f55d8ee5-7cec-46c6-9381-baba2b779cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8f1796e-2cb2-45ee-a444-3bdb4fb2e4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8f1796e-2cb2-45ee-a444-3bdb4fb2e4ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_59d14a9d-f8ed-47d7-b48c-d338f3a21f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_59d14a9d-f8ed-47d7-b48c-d338f3a21f64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_38645852-7ebb-4a44-954f-f16dfacfa698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_38645852-7ebb-4a44-954f-f16dfacfa698" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a6e43d00-c9bd-416d-b07c-febc8784d4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a6e43d00-c9bd-416d-b07c-febc8784d4a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48c8d2df-cff2-4b96-938c-ded282497bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48c8d2df-cff2-4b96-938c-ded282497bdc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1e8693ce-6e12-49a6-8416-7eadbd69205f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1e8693ce-6e12-49a6-8416-7eadbd69205f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_baa5b0da-d93e-4620-836e-5557792089e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_baa5b0da-d93e-4620-836e-5557792089e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e0397f4-18d2-4335-ac8d-1838df75d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_NetIncomeLoss_1e0397f4-18d2-4335-ac8d-1838df75d50f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0fe6c2f-8466-4fc5-bfdc-44000edb25b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_42dee300-b9e6-4a77-ab16-7497feb82e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_00a28a1e-8b23-4862-aff6-7cd3552909fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_00a28a1e-8b23-4862-aff6-7cd3552909fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_92e7f7cf-e657-4457-8e9c-6799db7bbf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_92e7f7cf-e657-4457-8e9c-6799db7bbf07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09d873d9-110d-4ab4-8201-8c385b3f745a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:to="loc_us-gaap_EquityComponentDomain_09d873d9-110d-4ab4-8201-8c385b3f745a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:to="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CommonStockSharesMember_fc9f1487-c0bc-4d88-acc0-24e8eaef0a41" xlink:href="icui-20221231.xsd#icui_CommonStockSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_icui_CommonStockSharesMember_fc9f1487-c0bc-4d88-acc0-24e8eaef0a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c4f4038a-71b9-4238-ae92-d170c124e25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_CommonStockMember_c4f4038a-71b9-4238-ae92-d170c124e25f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bc12235a-4c67-4939-bb7f-e1c5971642f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bc12235a-4c67-4939-bb7f-e1c5971642f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d3129b3b-cb8a-4626-9bac-77552d36dec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_TreasuryStockMember_d3129b3b-cb8a-4626-9bac-77552d36dec3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c184f43-7597-4624-b0ec-72c5025e1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_RetainedEarningsMember_3c184f43-7597-4624-b0ec-72c5025e1c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dca35ee6-c964-4144-ac8a-dd2f0e012218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dca35ee6-c964-4144-ac8a-dd2f0e012218" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i849edbd8b6da455ab8cd3fb0b7ec2ff7_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e50f1c18-29d8-4ecd-be17-dcdeb1512b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_NetIncomeLoss_e50f1c18-29d8-4ecd-be17-dcdeb1512b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5d67a4b4-16fb-4791-ac90-e3635168dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5d67a4b4-16fb-4791-ac90-e3635168dd7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AmortizationOfInventoryStepUp_66379e65-1739-423d-8750-ceceff8a4f57" xlink:href="icui-20221231.xsd#icui_AmortizationOfInventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_AmortizationOfInventoryStepUp_66379e65-1739-423d-8750-ceceff8a4f57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_115c364a-83e7-4d2e-a3c3-ef869509513b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_115c364a-83e7-4d2e-a3c3-ef869509513b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_625973d1-bb9f-436d-9434-8a0fab9625a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_625973d1-bb9f-436d-9434-8a0fab9625a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProvisionForWarrantyAndReturns_676d8ea0-f8b0-429d-a2fc-501d557d19f0" xlink:href="icui-20221231.xsd#icui_ProvisionForWarrantyAndReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_ProvisionForWarrantyAndReturns_676d8ea0-f8b0-429d-a2fc-501d557d19f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_72d1a42f-4523-4bc7-9cf5-18a3bbcfe249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ShareBasedCompensation_72d1a42f-4523-4bc7-9cf5-18a3bbcfe249" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ffd1a81d-ad11-4bb2-a9c4-ca35abddd161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ffd1a81d-ad11-4bb2-a9c4-ca35abddd161" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_5048a5e5-356d-4dc5-b4ee-b7fd553a7b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_5048a5e5-356d-4dc5-b4ee-b7fd553a7b6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_50decc67-8f9f-46dc-b265-d7619863be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_50decc67-8f9f-46dc-b265-d7619863be2d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_eb1031f4-27c8-40c1-a148-25a87f716e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_eb1031f4-27c8-40c1-a148-25a87f716e41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f8a0f885-3e87-4e4d-a6af-703299e6b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f8a0f885-3e87-4e4d-a6af-703299e6b7aa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_bd254de8-5595-45ae-814c-7116f2023b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_bd254de8-5595-45ae-814c-7116f2023b26" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sparepartsusage_870f960e-4dea-4f0a-9826-0407cad24ad7" xlink:href="icui-20221231.xsd#icui_Sparepartsusage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_Sparepartsusage_870f960e-4dea-4f0a-9826-0407cad24ad7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_81f5ca3a-1278-400f-a550-4fd099709391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_81f5ca3a-1278-400f-a550-4fd099709391" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eae59951-1100-42e9-aab6-632fdebefd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eae59951-1100-42e9-aab6-632fdebefd3b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6f72e8cc-606d-427a-bd13-dbe5358fdfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6f72e8cc-606d-427a-bd13-dbe5358fdfdc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff65ea16-6543-4d29-a9f3-9100c1568f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff65ea16-6543-4d29-a9f3-9100c1568f6a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce183cb7-1475-433e-9866-40cbd085df36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce183cb7-1475-433e-9866-40cbd085df36" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34c00a22-12e8-45b9-bc0f-42c1be985c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34c00a22-12e8-45b9-bc0f-42c1be985c92" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efa63517-2eda-41ee-9368-ddecf3f2a32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efa63517-2eda-41ee-9368-ddecf3f2a32a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_5ac90cec-32e8-463f-b285-b9c90bf8508f" xlink:href="icui-20221231.xsd#icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_5ac90cec-32e8-463f-b285-b9c90bf8508f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a7371c4-7bc8-4ffb-890f-ff18dd08c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a7371c4-7bc8-4ffb-890f-ff18dd08c3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11861486-2f7c-4f0f-87f6-451d7e5dd08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11861486-2f7c-4f0f-87f6-451d7e5dd08c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_3e147f35-6bde-441c-8839-1be99e5999b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_3e147f35-6bde-441c-8839-1be99e5999b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ab54191-2b16-4c34-9fd0-b357d1270ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ab54191-2b16-4c34-9fd0-b357d1270ec3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e121425d-c064-414e-93df-943963c2e701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e121425d-c064-414e-93df-943963c2e701" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2eb243aa-feab-4ade-b10e-eccdbf61d8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2eb243aa-feab-4ade-b10e-eccdbf61d8cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_777d66fa-746a-4a48-a474-b66f82d72804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_777d66fa-746a-4a48-a474-b66f82d72804" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1918c200-3d59-42c1-aaaa-bda5eb6c06a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1918c200-3d59-42c1-aaaa-bda5eb6c06a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_577263b1-8472-4322-b796-b6a3d909f79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_577263b1-8472-4322-b796-b6a3d909f79d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_523955ca-9919-415f-8eaa-eae775777376" xlink:href="icui-20221231.xsd#icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_523955ca-9919-415f-8eaa-eae775777376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c6809b15-8b54-46b4-a726-995178a1947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c6809b15-8b54-46b4-a726-995178a1947f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ed14d00-ec96-40d1-9608-d3cd5ae5b893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ed14d00-ec96-40d1-9608-d3cd5ae5b893" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_d7a99654-2e3c-4584-a09a-ffb08c6ca67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_d7a99654-2e3c-4584-a09a-ffb08c6ca67d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_48c568b0-b4d1-4c22-b3b6-06239f713683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_48c568b0-b4d1-4c22-b3b6-06239f713683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f6f99088-798b-4acd-8e6c-89dbc0bd63c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f6f99088-798b-4acd-8e6c-89dbc0bd63c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6cbda617-9017-4100-afb0-5cdba1fc0f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6cbda617-9017-4100-afb0-5cdba1fc0f51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_399dc65f-fdeb-482d-8668-e5f2b2e072b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_399dc65f-fdeb-482d-8668-e5f2b2e072b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf9ca93-a886-4d95-8dcd-f37e421a2ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf9ca93-a886-4d95-8dcd-f37e421a2ee8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1347ef5-11a5-4795-b29b-f56e28d617ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1347ef5-11a5-4795-b29b-f56e28d617ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d368ccc-8721-4b4f-a105-fa4fdaaee6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d368ccc-8721-4b4f-a105-fa4fdaaee6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0df367a9-3e26-4de0-841a-032b01e4a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0df367a9-3e26-4de0-841a-032b01e4a5a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fccd677-6bdb-41af-853e-1225361d7606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fccd677-6bdb-41af-853e-1225361d7606" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_cae592f0-5aa2-421d-9cd9-e067519111c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:to="loc_us-gaap_IncomeTaxesPaid_cae592f0-5aa2-421d-9cd9-e067519111c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_57f26773-67bb-4ca3-abaf-f3880c08d410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:to="loc_us-gaap_InterestPaidNet_57f26773-67bb-4ca3-abaf-f3880c08d410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ecd29db6-6be2-481b-afa8-81bea8a04b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ecd29db6-6be2-481b-afa8-81bea8a04b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_e2a73366-6202-4b1c-9133-3c308202540c" xlink:href="icui-20221231.xsd#icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_e2a73366-6202-4b1c-9133-3c308202540c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2d3b6bbf-fca5-4873-9ece-e595c15a54a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2d3b6bbf-fca5-4873-9ece-e595c15a54a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions_e46c6755-c662-4806-a017-670722ab5ad6" xlink:href="icui-20221231.xsd#icui_NetCashPaidReceivedforcurrentandprioracquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions_e46c6755-c662-4806-a017-670722ab5ad6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_60e08c97-06bf-43b4-af9f-8d30571db76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_60e08c97-06bf-43b4-af9f-8d30571db76b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_e94b9692-7b7c-4977-b6a4-8e77e9940161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_e94b9692-7b7c-4977-b6a4-8e77e9940161" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0a0bc1d9-ab65-4227-9e56-bcb3b1f18724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0a0bc1d9-ab65-4227-9e56-bcb3b1f18724" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_20261b1a-bf72-4104-a300-b46ad1ad341b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_LiabilitiesAssumed1_20261b1a-bf72-4104-a300-b46ad1ad341b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:to="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f761367b-52f4-475e-a11e-e176182fa680_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f761367b-52f4-475e-a11e-e176182fa680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9db3ec85-7636-44b2-a00f-d472aef84ec6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9db3ec85-7636-44b2-a00f-d472aef84ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_67866abd-04b9-43a3-9518-5f454fe71b7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_67866abd-04b9-43a3-9518-5f454fe71b7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_897e6782-5efe-45ef-a6b7-8fba5d525319" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_SmithsMedicalMember_897e6782-5efe-45ef-a6b7-8fba5d525319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalDistributorMember_b8062eae-bccd-495e-93c4-d3ea43708b5f" xlink:href="icui-20221231.xsd#icui_InternationalDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_InternationalDistributorMember_b8062eae-bccd-495e-93c4-d3ea43708b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_cd59659d-4df1-41e0-bb6a-f1fbf3d776df" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_cd59659d-4df1-41e0-bb6a-f1fbf3d776df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementTables" xlink:type="extended" id="i643b40ddafa94e68a4e16fd357e8d8c3_FairValueMeasurementTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_db69afc6-e0ef-48b7-bd7e-1394d3b68798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_db69afc6-e0ef-48b7-bd7e-1394d3b68798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_76e958a9-41b8-451d-b274-f27d1468a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_76e958a9-41b8-451d-b274-f27d1468a9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f21d3daa-c9be-49ad-87bb-be0f665ceb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f21d3daa-c9be-49ad-87bb-be0f665ceb8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636c77f6-1365-4859-b9b0-9a51ba67b055_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636c77f6-1365-4859-b9b0-9a51ba67b055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_6011b939-0490-4d54-8597-9aa9a3e53da3" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:to="loc_icui_PursuitVascularInc.Member_6011b939-0490-4d54-8597-9aa9a3e53da3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="extended" id="i20a30da247064e089b21bbd8fb467b7f_GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9396aeaa-823f-4458-a435-4bccf6b8e453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9396aeaa-823f-4458-a435-4bccf6b8e453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8df39428-c024-42bc-9d51-513630862863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8df39428-c024-42bc-9d51-513630862863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b53c38e-4ec8-42cd-b22a-702e8e1ca23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b53c38e-4ec8-42cd-b22a-702e8e1ca23b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d308ebb-4085-47c6-82d9-e96b81bd6c11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d308ebb-4085-47c6-82d9-e96b81bd6c11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c43c5628-6325-4f12-92c5-55305c0b15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c43c5628-6325-4f12-92c5-55305c0b15d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandBuildingsAndImprovementsMember_a5f0b273-5488-46f4-ae44-c3b697a06cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandBuildingsAndImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_LandBuildingsAndImprovementsMember_a5f0b273-5488-46f4-ae44-c3b697a06cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MoldsMember_9845384a-51af-4125-a57e-123e2a956d51" xlink:href="icui-20221231.xsd#icui_MoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_MoldsMember_9845384a-51af-4125-a57e-123e2a956d51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ComputerEquipmentAndSoftwareMember_4cf9fd4a-404b-4416-a922-f7b42f6a43be" xlink:href="icui-20221231.xsd#icui_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_ComputerEquipmentAndSoftwareMember_4cf9fd4a-404b-4416-a922-f7b42f6a43be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b5522a1b-741b-4802-9fcd-fc1a95542739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b5522a1b-741b-4802-9fcd-fc1a95542739" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InstrumentsPlacedwithCustomersMember_7a75d7b2-dacb-4f0d-899e-c41d987fffb3" xlink:href="icui-20221231.xsd#icui_InstrumentsPlacedwithCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_InstrumentsPlacedwithCustomersMember_7a75d7b2-dacb-4f0d-899e-c41d987fffb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e965e045-5783-4050-b647-04bc1070eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_ConstructionInProgressMember_e965e045-5783-4050-b647-04bc1070eeed" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details" xlink:type="extended" id="ib031ca3f94aa47d695f56876d5a53f99_GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_df27cd89-6670-4814-b5b5-6c56ba885a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_df27cd89-6670-4814-b5b5-6c56ba885a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb698c42-8ddb-4234-be0f-dbc30a97d8e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb698c42-8ddb-4234-be0f-dbc30a97d8e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9e2dfc4c-f6ed-48fd-858d-13e42117ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_BuildingMember_9e2dfc4c-f6ed-48fd-858d-13e42117ad78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_0fb42ac3-717f-4115-89f0-bb13268d4edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_BuildingImprovementsMember_0fb42ac3-717f-4115-89f0-bb13268d4edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a46b71a9-b541-4bca-ae39-13c1a16963a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a46b71a9-b541-4bca-ae39-13c1a16963a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_FurniturefixturesandmoldsMember_54f0dc16-f5b5-4f91-90c6-ecfa6fde830b" xlink:href="icui-20221231.xsd#icui_FurniturefixturesandmoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_FurniturefixturesandmoldsMember_54f0dc16-f5b5-4f91-90c6-ecfa6fde830b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ComputerEquipmentAndSoftwareMember_c10f3b7d-529d-46ac-9609-f4f76844f41c" xlink:href="icui-20221231.xsd#icui_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_ComputerEquipmentAndSoftwareMember_c10f3b7d-529d-46ac-9609-f4f76844f41c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InstrumentsPlacedwithCustomersMember_5c4da177-dca5-4f88-8ac0-3f0c9f1da2f2" xlink:href="icui-20221231.xsd#icui_InstrumentsPlacedwithCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_InstrumentsPlacedwithCustomersMember_5c4da177-dca5-4f88-8ac0-3f0c9f1da2f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:to="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c76e2420-c9a4-4a7a-9324-47af88ed1666_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:to="loc_srt_RangeMember_c76e2420-c9a4-4a7a-9324-47af88ed1666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:to="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9677703-bf54-4da5-b13b-df2a6b478aa4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:to="loc_srt_MinimumMember_e9677703-bf54-4da5-b13b-df2a6b478aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b89d318-394b-46ce-8563-b4109605d218" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:to="loc_srt_MaximumMember_5b89d318-394b-46ce-8563-b4109605d218" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended" id="i5e0ab116acc04bde916a31468848cc6f_GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:to="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9d9ed99-30cc-4aca-b290-1442cb4ac5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_Goodwill_f9d9ed99-30cc-4aca-b290-1442cb4ac5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b763b13-9f17-40a6-b735-639aa90e5598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b763b13-9f17-40a6-b735-639aa90e5598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e49f6683-cdd6-43f5-b542-7f637ce51587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e49f6683-cdd6-43f5-b542-7f637ce51587" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4a35196-8df0-4d1c-9351-09da4ad962ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4a35196-8df0-4d1c-9351-09da4ad962ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5920e06a-f8a7-4d03-8626-95a0781390be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5920e06a-f8a7-4d03-8626-95a0781390be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb1d68f2-7b0d-48f6-9d0c-3628c5773369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f63547ec-5e72-4d77-8810-67a8bfe319a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f63547ec-5e72-4d77-8810-67a8bfe319a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_653dc885-92ce-41a0-9bb1-7b0c5e52e0d9" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:to="loc_icui_PursuitVascularLLCMember_653dc885-92ce-41a0-9bb1-7b0c5e52e0d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_4c073731-2511-448e-8137-28a97b7645f3" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_4c073731-2511-448e-8137-28a97b7645f3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details" xlink:type="extended" id="ifee4a016ab5942d8baaa4289f4fd10c4_GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84673784-bc67-4940-bd8d-2db8b81ddedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84673784-bc67-4940-bd8d-2db8b81ddedc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b9e3c77-f99a-4f45-a3d2-fad5b8f71f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b9e3c77-f99a-4f45-a3d2-fad5b8f71f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb532dcf-0335-4120-a2a2-b152dacf0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb532dcf-0335-4120-a2a2-b152dacf0b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b739ebd7-b311-47c1-b4c3-04493e553d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b739ebd7-b311-47c1-b4c3-04493e553d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ca2ed9d-dbb2-4bf5-aeb7-a35f2d824174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ca2ed9d-dbb2-4bf5-aeb7-a35f2d824174" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9502d25e-76d8-4d04-b4cf-82e70eb9a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9502d25e-76d8-4d04-b4cf-82e70eb9a6f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50c03f52-932b-4625-871c-2bb913badb0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50c03f52-932b-4625-871c-2bb913badb0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_092a7663-d88d-4e98-aa70-51c208fdd7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_PatentsMember_092a7663-d88d-4e98-aa70-51c208fdd7d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember_ce2fe8db-9088-47ce-abd5-aef348956dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_CustomerContractsMember_ce2fe8db-9088-47ce-abd5-aef348956dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_8df542ca-3ced-4498-a0cf-f70235a0bdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_8df542ca-3ced-4498-a0cf-f70235a0bdc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8331be76-82e6-435f-99c5-e26ddc2a83db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_TrademarksMember_8331be76-82e6-435f-99c5-e26ddc2a83db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7517d3bf-c639-457d-8844-918d8a109675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_TradeNamesMember_7517d3bf-c639-457d-8844-918d8a109675" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2954d0be-2b54-4f6c-b98f-f92be3166fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2954d0be-2b54-4f6c-b98f-f92be3166fd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cf61d482-4601-4dbf-870a-d42078d88cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cf61d482-4601-4dbf-870a-d42078d88cd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6a06114-333f-4d89-98d2-3f8b8cbecf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6a06114-333f-4d89-98d2-3f8b8cbecf5d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails" xlink:type="extended" id="i23c0cc152ed741fc9df104c881545fe3_GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_974e8ec9-3f70-4c50-9367-772dfa541fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_974e8ec9-3f70-4c50-9367-772dfa541fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_659e86fb-1ab6-41fd-ad69-b178d1e723f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_659e86fb-1ab6-41fd-ad69-b178d1e723f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_951586a1-8447-4323-b9d9-d88e17245a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_951586a1-8447-4323-b9d9-d88e17245a85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34a5f964-c54a-4b1b-b76d-0828b65a5988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34a5f964-c54a-4b1b-b76d-0828b65a5988" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_76a0c7c5-9d51-4ddf-aaba-fb62ffb1865a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_76a0c7c5-9d51-4ddf-aaba-fb62ffb1865a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f269c6ad-2d3b-4ac0-a35c-85b899b03a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f269c6ad-2d3b-4ac0-a35c-85b899b03a5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9264adb3-d42a-4142-87c4-d957c9339847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9264adb3-d42a-4142-87c4-d957c9339847" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_35b2df20-a98e-445e-bd49-0d869a5b4dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_35b2df20-a98e-445e-bd49-0d869a5b4dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d28c85c-8851-48a2-972b-7ad05a2af401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d28c85c-8851-48a2-972b-7ad05a2af401" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended" id="icae543c523204bb6af141a8500c01173_GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_474b31c3-7a06-45e1-9f79-e697e6365933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_474b31c3-7a06-45e1-9f79-e697e6365933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6556dfbe-a9b3-45e3-894b-e8a6ef0adc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6556dfbe-a9b3-45e3-894b-e8a6ef0adc10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b3d99363-6b63-4c5b-80fb-93526dc42157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b3d99363-6b63-4c5b-80fb-93526dc42157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c8723da-4100-4646-9719-eab6495f81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c8723da-4100-4646-9719-eab6495f81ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_381ff6e6-72ef-4777-a6fe-404cb76efa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_381ff6e6-72ef-4777-a6fe-404cb76efa6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_590a5551-a265-4745-99f1-bddce85bcd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_590a5551-a265-4745-99f1-bddce85bcd2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_ce9ab587-d7f7-4489-9edf-c7739b7b7299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_ce9ab587-d7f7-4489-9edf-c7739b7b7299" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dec6122b-76a9-4fc5-b875-184b57a22b3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dec6122b-76a9-4fc5-b875-184b57a22b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b7078dd4-1d49-4381-9ef4-6ef4fd12aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b7078dd4-1d49-4381-9ef4-6ef4fd12aff6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1d3932bc-4373-4ecc-8577-5323beb67797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1d3932bc-4373-4ecc-8577-5323beb67797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3830f0f1-0560-45eb-9725-437280d4ed11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3830f0f1-0560-45eb-9725-437280d4ed11" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails" xlink:type="extended" id="i5b07f593a3bb44b8b8238d3fe1d58be6_GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c7b8cb6c-b870-4743-9640-08b7ef0c152e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c7b8cb6c-b870-4743-9640-08b7ef0c152e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_6d210d72-7020-48c9-bcd3-29fd63c977c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_6d210d72-7020-48c9-bcd3-29fd63c977c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9ad1e3fd-4bc8-4d39-9a85-af10d1cc08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestments_9ad1e3fd-4bc8-4d39-9a85-af10d1cc08e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f90e61cc-042d-44bc-b417-4e2e37474864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f90e61cc-042d-44bc-b417-4e2e37474864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonpublicCompanyMember_1465c9a2-ffc6-485e-9b25-b61efd81d0b5" xlink:href="icui-20221231.xsd#icui_NonpublicCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:to="loc_icui_NonpublicCompanyMember_1465c9a2-ffc6-485e-9b25-b61efd81d0b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4358887f-69d7-4c3a-82b2-88d4bb57255e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4358887f-69d7-4c3a-82b2-88d4bb57255e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonpublicCompanyMember_05be61bf-74bf-4f7a-b91e-6bfdbe6bb5be" xlink:href="icui-20221231.xsd#icui_NonpublicCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:to="loc_icui_NonpublicCompanyMember_05be61bf-74bf-4f7a-b91e-6bfdbe6bb5be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails" xlink:type="extended" id="i048986e0d9fd4ab0869134448e9b7d9c_GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_20ba4b9d-b326-499b-9761-1372651bd65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestExpense_20ba4b9d-b326-499b-9761-1372651bd65d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_67063ec4-0d49-43f5-9235-d2b91408ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestIncomeOther_67063ec4-0d49-43f5-9235-d2b91408ae95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c4c78f1c-04ae-45e0-9196-f2f9496c3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c4c78f1c-04ae-45e0-9196-f2f9496c3c07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:to="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetDomain_81f4f1d3-bea4-4543-91cd-1d33004d4fff_default" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:to="loc_icui_InterestExpenseIncomeNetDomain_81f4f1d3-bea4-4543-91cd-1d33004d4fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetDomain_9161d4e2-4165-4ebb-afc8-51cd02096df3" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:to="loc_icui_InterestExpenseIncomeNetDomain_9161d4e2-4165-4ebb-afc8-51cd02096df3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails" xlink:type="extended" id="i8e5ba7e86e9449bfa365bf235bc05182_GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_067d93b3-dd43-43a3-9aa7-7563f123903a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_067d93b3-dd43-43a3-9aa7-7563f123903a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_f67ff08d-3d54-496a-9282-15fe9bff2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_f67ff08d-3d54-496a-9282-15fe9bff2c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MiscellaneousIncomeNet_a9a480c3-9bf0-4e01-96ef-18cbe0ab9d63" xlink:href="icui-20221231.xsd#icui_MiscellaneousIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_icui_MiscellaneousIncomeNet_a9a480c3-9bf0-4e01-96ef-18cbe0ab9d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_dee37655-48ac-4871-8f66-3b9733b78fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_dee37655-48ac-4871-8f66-3b9733b78fa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:to="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetDomain_de7be1aa-ea31-4050-aded-b10a900c1557_default" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:to="loc_icui_OtherExpenseIncomeNetDomain_de7be1aa-ea31-4050-aded-b10a900c1557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetDomain_13df1036-6eef-4884-b59d-695be87c0fbc" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:to="loc_icui_OtherExpenseIncomeNetDomain_13df1036-6eef-4884-b59d-695be87c0fbc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails" xlink:type="extended" id="i7132ce19c9e4439cbd096f6e0fa0f841_GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21ad3a6e-87c0-47bd-ab68-df4aa9767407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_NetIncomeLoss_21ad3a6e-87c0-47bd-ab68-df4aa9767407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42791270-b161-4510-b85d-751e0a479e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42791270-b161-4510-b85d-751e0a479e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e3b4cb89-0955-4285-9c7f-8f979a52b3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e3b4cb89-0955-4285-9c7f-8f979a52b3a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aee0838-107f-439d-bf0a-ac2724325a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aee0838-107f-439d-bf0a-ac2724325a3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_473e6e17-13ca-41a9-8299-0af4fc82b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_EarningsPerShareBasic_473e6e17-13ca-41a9-8299-0af4fc82b95e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c43a4b55-41fe-4d8d-b92a-74dbed10618b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c43a4b55-41fe-4d8d-b92a-74dbed10618b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cfa5528-42a6-4360-8b89-38ab8a979641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cfa5528-42a6-4360-8b89-38ab8a979641" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0485bb8e-2b40-4ff4-bb70-1f029f513064_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0485bb8e-2b40-4ff4-bb70-1f029f513064_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e797233-3c67-4fd6-bfeb-b7ea66871a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e797233-3c67-4fd6-bfeb-b7ea66871a03" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsTextDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AcquisitionsTextDetails" xlink:type="extended" id="i7617720a4d1c4e9fa4518ebf219389a2_AcquisitionsTextDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f46d8d30-1dcd-442e-8a8c-6ebb5df91efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f46d8d30-1dcd-442e-8a8c-6ebb5df91efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4e7310-bad5-4228-ad90-32728f369d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4e7310-bad5-4228-ad90-32728f369d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c7c5e273-b69d-437b-979d-36df30b540c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c7c5e273-b69d-437b-979d-36df30b540c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9609745a-4c39-41fe-9cc4-8b731e356975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9609745a-4c39-41fe-9cc4-8b731e356975" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MinimumStockPriceTargetForEarnOutPayment_509f1b55-62b1-4f10-8978-ede3ac28617a" xlink:href="icui-20221231.xsd#icui_MinimumStockPriceTargetForEarnOutPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_MinimumStockPriceTargetForEarnOutPayment_509f1b55-62b1-4f10-8978-ede3ac28617a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_73878064-ddb6-4810-b28d-fcf59078e5de" xlink:href="icui-20221231.xsd#icui_RequiredShareHoldingOfStockIssuedAtAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_73878064-ddb6-4810-b28d-fcf59078e5de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b680292d-d5ff-49f5-8a5d-daa2dc304078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b680292d-d5ff-49f5-8a5d-daa2dc304078" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationTransferredCash_2c7a1c62-8b12-45f5-bfcc-3195e7da734e" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationTransferredCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_BusinessCombinationConsiderationTransferredCash_2c7a1c62-8b12-45f5-bfcc-3195e7da734e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_fa3804fe-7f10-4c82-b346-0f3c7899826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_fa3804fe-7f10-4c82-b346-0f3c7899826e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_7ea2534e-fa9a-4ae2-a77f-749e18e1fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_7ea2534e-fa9a-4ae2-a77f-749e18e1fa4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47048b32-5799-4cc3-b631-7120136dcdb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47048b32-5799-4cc3-b631-7120136dcdb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_549ccd4f-34b8-41e1-b78b-a13636dbd754" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:to="loc_icui_SmithsMedical2020LimitedMember_549ccd4f-34b8-41e1-b78b-a13636dbd754" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedical2020LimitedTableDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails" xlink:type="extended" id="i89d03f2c37404bee953ff3d4d69ea6ab_AcquisitionsSmithsMedical2020LimitedTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cb0a688-433f-4f68-9ab2-8f74cb41d822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cb0a688-433f-4f68-9ab2-8f74cb41d822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cae1894d-3706-486e-b457-8e6f9d388f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cae1894d-3706-486e-b457-8e6f9d388f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a6b43c93-c31d-4ff1-9462-a92f316eba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a6b43c93-c31d-4ff1-9462-a92f316eba07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_65a68e36-18cf-46f2-bbed-77ed56bf1daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_65a68e36-18cf-46f2-bbed-77ed56bf1daa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0e614c11-8c4a-4f4e-aca6-1f605974f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0e614c11-8c4a-4f4e-aca6-1f605974f11f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30bf9293-878a-47ee-b1b0-a668fcfcdc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30bf9293-878a-47ee-b1b0-a668fcfcdc5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6c98068e-a1ca-4a61-bb9c-53af347da4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6c98068e-a1ca-4a61-bb9c-53af347da4d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_93642cd3-6040-430d-80fc-b19c0eb5ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_93642cd3-6040-430d-80fc-b19c0eb5ae02" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_728dfe9e-65cb-4ff3-85a6-ea3ac87ad164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_728dfe9e-65cb-4ff3-85a6-ea3ac87ad164" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f0a4fcd3-5189-47b5-a7ac-ee26d93583a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f0a4fcd3-5189-47b5-a7ac-ee26d93583a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7888733f-cf04-4cbb-bedc-e3263543ed82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7888733f-cf04-4cbb-bedc-e3263543ed82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_db6f2df8-2b78-4898-b985-2de79e86e022" xlink:href="icui-20221231.xsd#icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_db6f2df8-2b78-4898-b985-2de79e86e022" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ebed2363-5296-4655-8444-a7cb6c3d1a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ebed2363-5296-4655-8444-a7cb6c3d1a22" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_199df1b9-e114-4e3e-89e6-36c188d50a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_199df1b9-e114-4e3e-89e6-36c188d50a92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_175afa05-b157-4e2a-a636-0ec76debbcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_175afa05-b157-4e2a-a636-0ec76debbcc4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8f30f094-16c8-4df8-a4e2-f76464eeb3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8f30f094-16c8-4df8-a4e2-f76464eeb3f5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_fe1a7524-b159-4595-868b-e7fff5e9dcb8" xlink:href="icui-20221231.xsd#icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_fe1a7524-b159-4595-868b-e7fff5e9dcb8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_024bd410-d5a7-4b67-b9d7-9afc0942de22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_024bd410-d5a7-4b67-b9d7-9afc0942de22" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b8f3fe90-83dc-4b4b-91f9-130df682145d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b8f3fe90-83dc-4b4b-91f9-130df682145d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e4644e31-3abb-454d-862d-9d2023771c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e4644e31-3abb-454d-862d-9d2023771c8b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2113349c-7609-45cc-8ea5-4beea585d164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_Goodwill_2113349c-7609-45cc-8ea5-4beea585d164" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e73c17d1-f29b-44c4-8ec9-96e4d29ad021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e73c17d1-f29b-44c4-8ec9-96e4d29ad021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_13b2ad25-baf4-475f-8b64-2aede452b9ca" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:to="loc_icui_SmithsMedical2020LimitedMember_13b2ad25-baf4-475f-8b64-2aede452b9ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedical2020LimitedIntangibleDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails" xlink:type="extended" id="i70a470330cb146069fd26d08edd5596e_AcquisitionsSmithsMedical2020LimitedIntangibleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f528ce3e-c979-4c05-8e04-e606085222c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f528ce3e-c979-4c05-8e04-e606085222c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea03abe9-8a0c-4ba8-9a18-988773f32d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea03abe9-8a0c-4ba8-9a18-988773f32d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27ea3b41-2469-4622-95f9-4693837709a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27ea3b41-2469-4622-95f9-4693837709a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_52c4a98e-3d81-47e7-ba20-2b70a59d764d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_52c4a98e-3d81-47e7-ba20-2b70a59d764d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_577d4cc6-7ffd-4557-813b-748ff7442f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_577d4cc6-7ffd-4557-813b-748ff7442f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a4509b22-7f2c-4e40-b55e-d9c87fec5355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a4509b22-7f2c-4e40-b55e-d9c87fec5355" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_679156a8-72c0-475a-8d93-e38b3b3df490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_TrademarksMember_679156a8-72c0-475a-8d93-e38b3b3df490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_c731abfe-3d96-439a-860c-9e92ae6a350b" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:to="loc_icui_SmithsMedical2020LimitedMember_c731abfe-3d96-439a-860c-9e92ae6a350b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsForeignInfusionSystemsSupplierDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails" xlink:type="extended" id="i7cba817b99ee4a03b2dc64cada4c3e80_AcquisitionsForeignInfusionSystemsSupplierDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_e0b97b49-257f-4a88-84a9-54306163fe42" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_Contingentconsiderationgross_e0b97b49-257f-4a88-84a9-54306163fe42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_f033fefb-1627-469b-a41f-97ae76acec4f" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_ShortTermContingentConsiderationGross_f033fefb-1627-469b-a41f-97ae76acec4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_042f68e2-e66c-41d1-b6e8-feda01bee299" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_LongTermContingentConsiderationGross_042f68e2-e66c-41d1-b6e8-feda01bee299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9ed44ad8-d06b-4ca8-889e-d0bf4f1097ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9ed44ad8-d06b-4ca8-889e-d0bf4f1097ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationCashHoldback_2ad6c5e0-a02d-466e-97f2-f709efae0fce" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationCashHoldback"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_BusinessCombinationConsiderationCashHoldback_2ad6c5e0-a02d-466e-97f2-f709efae0fce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f851417d-b77a-4213-988c-166a0a025027_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f851417d-b77a-4213-988c-166a0a025027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_21b71290-af2f-441f-8362-5a605987649e" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_21b71290-af2f-441f-8362-5a605987649e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedicalProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails" xlink:type="extended" id="ib79b5f09181a491aa7af38e176238dd0_AcquisitionsSmithsMedicalProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bd309b32-735e-4d3b-81de-f6406f00994f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_Revenues_bd309b32-735e-4d3b-81de-f6406f00994f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_871dc5ac-62e0-47ed-924d-d8efa4b67638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_ProfitLoss_871dc5ac-62e0-47ed-924d-d8efa4b67638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_125d2a1b-7ee4-4b21-bf75-5730d7535d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_125d2a1b-7ee4-4b21-bf75-5730d7535d0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_c14ea746-3a6f-4d12-9bc0-163c9f223493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_c14ea746-3a6f-4d12-9bc0-163c9f223493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentAmortization_a3bb0531-66f0-4085-b4a6-6fc6bdbcb006" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentAmortization_a3bb0531-66f0-4085-b4a6-6fc6bdbcb006" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentInventory_a39cf828-5a57-48b4-b683-7d269513c43d" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentInventory_a39cf828-5a57-48b4-b683-7d269513c43d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentFinanceCosts_4c05953c-d514-4a5e-a811-eddfe6d7cb98" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentFinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentFinanceCosts_4c05953c-d514-4a5e-a811-eddfe6d7cb98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b367b297-c1f6-4e61-960d-2bfb21176dfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b367b297-c1f6-4e61-960d-2bfb21176dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_63910380-1c01-4064-865e-a206c3b76dd5" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:to="loc_icui_SmithsMedical2020LimitedMember_63910380-1c01-4064-865e-a206c3b76dd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationDetails1"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1" xlink:type="extended" id="i47a4ee5ba667478092874b4dff2f0bc4_RestructuringStrategicTransactionandIntegrationDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_cb5658cb-88ed-4247-8e5d-1aa4912bf892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_cb5658cb-88ed-4247-8e5d-1aa4912bf892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestructuringAdjustmentsSeveranceAndFacility_8f331dae-79d4-4ba0-8c40-70ff44907599" xlink:href="icui-20221231.xsd#icui_RestructuringAdjustmentsSeveranceAndFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:to="loc_icui_RestructuringAdjustmentsSeveranceAndFacility_8f331dae-79d4-4ba0-8c40-70ff44907599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_04a90d2e-2727-4e55-b9e4-58937c2c704a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_04a90d2e-2727-4e55-b9e4-58937c2c704a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_6623c159-9a7f-44d2-b604-8b69eb0cb37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:to="loc_us-gaap_FacilityClosingMember_6623c159-9a7f-44d2-b604-8b69eb0cb37b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationDetails2"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2" xlink:type="extended" id="i77ec6830d0de4d54978adcdc91fd2ce2_RestructuringStrategicTransactionandIntegrationDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_930e0b26-b314-46f8-a8aa-ee8b6d32932c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserve_930e0b26-b314-46f8-a8aa-ee8b6d32932c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_4e2958e6-3cde-4bb9-9a68-8f93c23bf381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringCosts_4e2958e6-3cde-4bb9-9a68-8f93c23bf381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_2b7f4343-da07-44e0-9d69-683589151964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_PaymentsForRestructuring_2b7f4343-da07-44e0-9d69-683589151964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_f3b03248-3ad5-47fa-9a87-5eda67702e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_f3b03248-3ad5-47fa-9a87-5eda67702e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_72376011-abe4-42e5-9b3f-03ca25e21564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_72376011-abe4-42e5-9b3f-03ca25e21564" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_cc2c5c7d-e11a-42a5-a78a-d2e8ebd96bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_cc2c5c7d-e11a-42a5-a78a-d2e8ebd96bff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cc53f9d0-a4cb-4077-b84f-dddedebf6a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cc53f9d0-a4cb-4077-b84f-dddedebf6a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0bd9eb07-29d4-4a21-8ea4-2ca03b5ba56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0bd9eb07-29d4-4a21-8ea4-2ca03b5ba56c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_97c39000-1af5-4330-b920-54930daec4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:to="loc_us-gaap_FacilityClosingMember_97c39000-1af5-4330-b920-54930daec4d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueDisaggregationofRevenueProductLineDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails" xlink:type="extended" id="ie697cd3140194e6ab3355a2aa4f1d4d1_RevenueDisaggregationofRevenueProductLineDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ca72ac90-aed4-4448-a0a4-b874698480e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:to="loc_us-gaap_Revenues_ca72ac90-aed4-4448-a0a4-b874698480e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentageofrevenue_61000ff6-4275-46d0-8b6f-2eb57bf15f6f" xlink:href="icui-20221231.xsd#icui_Percentageofrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:to="loc_icui_Percentageofrevenue_61000ff6-4275-46d0-8b6f-2eb57bf15f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:to="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53b0fcd1-ab59-4837-a421-f42c7b9719e3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:to="loc_srt_ProductsAndServicesDomain_53b0fcd1-ab59-4837-a421-f42c7b9719e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:to="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesMember_0cb915e7-7b1a-4146-83ed-0e2c63fcfba6" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionConsumablesMember_0cb915e7-7b1a-4146-83ed-0e2c63fcfba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionSystemsMember_6a0646f0-b52a-4fc9-a405-9e6c2985355d" xlink:href="icui-20221231.xsd#icui_InfusionSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionSystemsMember_6a0646f0-b52a-4fc9-a405-9e6c2985355d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IVSolutionsMember_5916aa44-a7bb-4897-b77c-4a370c528e7e" xlink:href="icui-20221231.xsd#icui_IVSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_IVSolutionsMember_5916aa44-a7bb-4897-b77c-4a370c528e7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CriticalCareMember_854684c4-0166-499b-a54c-698212de458a" xlink:href="icui-20221231.xsd#icui_CriticalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_CriticalCareMember_854684c4-0166-499b-a54c-698212de458a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesSmithsMedicalMember_327b716f-f0c7-431c-89b1-eab9eb30c661" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesSmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionConsumablesSmithsMedicalMember_327b716f-f0c7-431c-89b1-eab9eb30c661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VascularAccessMember_23d5ff0d-1850-4e32-afdd-48fb3ca8c578" xlink:href="icui-20221231.xsd#icui_VascularAccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_VascularAccessMember_23d5ff0d-1850-4e32-afdd-48fb3ca8c578" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VitalCareMember_6131fc02-55fe-4c9f-8ea1-20fca6976cd4" xlink:href="icui-20221231.xsd#icui_VitalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_VitalCareMember_6131fc02-55fe-4c9f-8ea1-20fca6976cd4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueDisaggregationofRevenuebyGeographyDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails" xlink:type="extended" id="iba123d9d42a2427686fe20628b35e08d_RevenueDisaggregationofRevenuebyGeographyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74aeef46-5fef-4df2-a885-3d5f35485080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:to="loc_us-gaap_Revenues_74aeef46-5fef-4df2-a885-3d5f35485080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentoftotalrevenue_792a94bc-697c-428a-8eb6-3bf15ae29ae5" xlink:href="icui-20221231.xsd#icui_Percentoftotalrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:to="loc_icui_Percentoftotalrevenue_792a94bc-697c-428a-8eb6-3bf15ae29ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:to="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0aecac49-496c-4f5f-bc3f-370709065e38_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:to="loc_srt_SegmentGeographicalDomain_0aecac49-496c-4f5f-bc3f-370709065e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:to="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_25771253-9b70-4c08-8dc5-534257c462d2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_country_US_25771253-9b70-4c08-8dc5-534257c462d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a84d415c-3b56-44cd-9e7b-b17ab5374e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_us-gaap_EMEAMember_a84d415c-3b56-44cd-9e7b-b17ab5374e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_APACDomain_d5e98cb0-9ef3-4ba6-af45-cfb7a59f4e33" xlink:href="icui-20221231.xsd#icui_APACDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_APACDomain_d5e98cb0-9ef3-4ba6-af45-cfb7a59f4e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherforeigncountriesMember_a7c21855-26fe-4958-abea-4863af867b4d" xlink:href="icui-20221231.xsd#icui_OtherforeigncountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_OtherforeigncountriesMember_a7c21855-26fe-4958-abea-4863af867b4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalSalesDomain_d7147e19-b8a6-4437-b797-a4ea8db59a61" xlink:href="icui-20221231.xsd#icui_InternationalSalesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_InternationalSalesDomain_d7147e19-b8a6-4437-b797-a4ea8db59a61" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended" id="i3701630bd422485abd15022d5d7911fd_RevenueContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:href="icui-20221231.xsd#icui_COntractLiabilityRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:to="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f77abe7b-711c-4a45-8fd0-126dbc0c0cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f77abe7b-711c-4a45-8fd0-126dbc0c0cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12164b0e-10f7-4e56-875a-12829352a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12164b0e-10f7-4e56-875a-12829352a3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAdditions_4d44816f-a41b-444b-be91-c2f33253df0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_DeferredRevenueAdditions_4d44816f-a41b-444b-be91-c2f33253df0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c79a2f4b-64b8-468c-b1af-15ed4746a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:to="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2373340e-d30a-43de-8123-3afaf7fd499d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:to="loc_srt_ProductsAndServicesDomain_2373340e-d30a-43de-8123-3afaf7fd499d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:to="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_57b78a2c-5370-4195-bbd5-73a116bda5ca" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_EquipmentrevenueMember_57b78a2c-5370-4195-bbd5-73a116bda5ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_88df0def-291d-4601-89e2-d4f64be7ef6a" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_SoftwarerevenueMember_88df0def-291d-4601-89e2-d4f64be7ef6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GovernmentGrantRevenueMember_5a6de974-dacd-4555-bccf-ffad9827156a" xlink:href="icui-20221231.xsd#icui_GovernmentGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_GovernmentGrantRevenueMember_5a6de974-dacd-4555-bccf-ffad9827156a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherDeferredRevenueMember_ededf9fe-a360-4a49-a9e4-77b57c8d367a" xlink:href="icui-20221231.xsd#icui_OtherDeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_OtherDeferredRevenueMember_ededf9fe-a360-4a49-a9e4-77b57c8d367a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_57377b2e-d078-47bf-b43c-8d6b2b021982" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:to="loc_icui_SmithsMedicalMember_57377b2e-d078-47bf-b43c-8d6b2b021982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_7dd36154-c0fd-4de6-baf4-26a7f238050f_default" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:to="loc_icui_TimingDomain_7dd36154-c0fd-4de6-baf4-26a7f238050f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:to="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermMember_fc4a057f-a058-4e4d-97a0-e22f198e873b" xlink:href="icui-20221231.xsd#icui_ShortTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:to="loc_icui_ShortTermMember_fc4a057f-a058-4e4d-97a0-e22f198e873b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_aabcf446-c193-46b8-aaa8-5277dfe1e325" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:to="loc_icui_LongTermMember_aabcf446-c193-46b8-aaa8-5277dfe1e325" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueContractLiabilitiesTextDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails" xlink:type="extended" id="ia49cd349844c4f73890b0bd24f63bb9a_RevenueContractLiabilitiesTextDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_c2c3e20f-cf6b-42c3-946f-3e2491aace3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_c2c3e20f-cf6b-42c3-946f-3e2491aace3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:to="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:to="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:to="loc_srt_ProductsAndServicesDomain_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:to="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_9c297b8b-ed13-427c-bab4-fa8a691c45e2" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:to="loc_icui_EquipmentrevenueMember_9c297b8b-ed13-427c-bab4-fa8a691c45e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_40906be6-34c7-4cb1-8a2e-2e6471b0e189" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:to="loc_icui_SoftwarerevenueMember_40906be6-34c7-4cb1-8a2e-2e6471b0e189" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueRemainingPerformanceObligationRecognitionTimingDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails" xlink:type="extended" id="i9d278183561e4ef2979c9b93956383c8_RevenueRemainingPerformanceObligationRecognitionTimingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e179eb45-4cf2-40a2-87d0-d109f09fa487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e179eb45-4cf2-40a2-87d0-d109f09fa487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:to="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:to="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_0cdc0762-86e7-4270-bd38-88035011cbb1_default" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:to="loc_icui_TimingDomain_0cdc0762-86e7-4270-bd38-88035011cbb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:to="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermMember_96727259-b78d-44dc-8d1f-b909c838a8a0" xlink:href="icui-20221231.xsd#icui_ShortTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:to="loc_icui_ShortTermMember_96727259-b78d-44dc-8d1f-b909c838a8a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_64ba2bd3-3f10-4430-a685-532671c25c27" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:to="loc_icui_LongTermMember_64ba2bd3-3f10-4430-a685-532671c25c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:to="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4687b1e3-f9a9-4f3d-b78e-e96519b4a467_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:to="loc_srt_ProductsAndServicesDomain_4687b1e3-f9a9-4f3d-b78e-e96519b4a467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:to="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_6a048782-7872-45ef-b0bf-70b1e17247c6" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_EquipmentrevenueMember_6a048782-7872-45ef-b0bf-70b1e17247c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_6efaced2-b0dc-40d3-9594-e5f8281fee70" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_SoftwarerevenueMember_6efaced2-b0dc-40d3-9594-e5f8281fee70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GovernmentGrantRevenueMember_8e9b2fee-eb09-4ec6-bfb3-61a8d3900cd2" xlink:href="icui-20221231.xsd#icui_GovernmentGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_GovernmentGrantRevenueMember_8e9b2fee-eb09-4ec6-bfb3-61a8d3900cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherDeferredRevenueMember_be1a4229-a726-4844-be75-b1ad70f6768e" xlink:href="icui-20221231.xsd#icui_OtherDeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_OtherDeferredRevenueMember_be1a4229-a726-4844-be75-b1ad70f6768e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/LeasesDetails" xlink:type="extended" id="i3bd970525891477c96908d34dad4707a_LeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Optiontoextendinyears_619e2f54-e38e-4378-845e-cecdcb4e6963" xlink:href="icui-20221231.xsd#icui_Optiontoextendinyears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:to="loc_icui_Optiontoextendinyears_619e2f54-e38e-4378-845e-cecdcb4e6963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a33c13d3-971f-495a-bda5-7564bb88321e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a33c13d3-971f-495a-bda5-7564bb88321e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:to="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d2bbe9e-b37b-4219-b1eb-0ad970468593_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:to="loc_srt_RangeMember_4d2bbe9e-b37b-4219-b1eb-0ad970468593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:to="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a39fd49b-1f45-444d-b77c-9b7079bb0b4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:to="loc_srt_MinimumMember_a39fd49b-1f45-444d-b77c-9b7079bb0b4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbab318f-da31-4df5-97f4-c942cb7f0b6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:to="loc_srt_MaximumMember_cbab318f-da31-4df5-97f4-c942cb7f0b6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionPlansDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails" xlink:type="extended" id="if3ab23079b2b4e979959e1fa918e9eaf_ShareBasedAwardStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a69132cb-f1a1-4fc8-a580-41b476e5c996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a69132cb-f1a1-4fc8-a580-41b476e5c996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b7b42e8c-bb3a-4900-837d-8d2b4198138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b7b42e8c-bb3a-4900-837d-8d2b4198138d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sharestransferredfromsupersededplan_dd4aa01c-a190-497d-8a88-a776a91644cc" xlink:href="icui-20221231.xsd#icui_Sharestransferredfromsupersededplan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_icui_Sharestransferredfromsupersededplan_dd4aa01c-a190-497d-8a88-a776a91644cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_119dcce4-92f4-44f4-9848-23bfe9f17217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_119dcce4-92f4-44f4-9848-23bfe9f17217" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:to="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b38677e-7393-41af-8e26-90a389ae1712_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b38677e-7393-41af-8e26-90a389ae1712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25269066-386a-4f75-9cc0-fef31c18cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25269066-386a-4f75-9cc0-fef31c18cff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88d8e616-b976-4a40-8154-3b4661f470a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88d8e616-b976-4a40-8154-3b4661f470a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:to="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d055b3e4-c00f-435f-9c55-78d8825e85a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:to="loc_us-gaap_PlanNameDomain_d055b3e4-c00f-435f-9c55-78d8825e85a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:to="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2011PlanMember_cb1fa91b-aca5-48b3-af41-546359368b0b" xlink:href="icui-20221231.xsd#icui_A2011PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:to="loc_icui_A2011PlanMember_cb1fa91b-aca5-48b3-af41-546359368b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2003PlanMember_5d1548f7-c120-4a3f-aa84-b934e680d219" xlink:href="icui-20221231.xsd#icui_A2003PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:to="loc_icui_A2003PlanMember_5d1548f7-c120-4a3f-aa84-b934e680d219" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionsGrantedandValuationDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails" xlink:type="extended" id="i7b574a84752144d881663d2d3b4196f9_ShareBasedAwardStockOptionsGrantedandValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327bb1fc-e687-4816-8df2-cb8046ad66d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327bb1fc-e687-4816-8df2-cb8046ad66d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Timebasedoptionsgrantdatefairvalue_6c295f01-c473-407a-a918-1451878520c0" xlink:href="icui-20221231.xsd#icui_Timebasedoptionsgrantdatefairvalue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_icui_Timebasedoptionsgrantdatefairvalue_6c295f01-c473-407a-a918-1451878520c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ddf224c9-13aa-40df-86a9-6fd8eda5130a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ddf224c9-13aa-40df-86a9-6fd8eda5130a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c349bac-9143-440a-b90e-9149f593f544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c349bac-9143-440a-b90e-9149f593f544" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c6693823-ea61-41f7-8efe-b6d72551ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c6693823-ea61-41f7-8efe-b6d72551ae5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dc422cc7-db7b-42ae-a2a1-b1eb16a99d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dc422cc7-db7b-42ae-a2a1-b1eb16a99d2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9c853fed-55d8-42ed-86ad-432915f8ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9c853fed-55d8-42ed-86ad-432915f8ded2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d46862d7-def9-4940-8443-9a5590d9c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d46862d7-def9-4940-8443-9a5590d9c8a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:to="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9c2f5756-c946-49bf-a749-57eeb6c6a3a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:to="loc_us-gaap_PlanNameDomain_9c2f5756-c946-49bf-a749-57eeb6c6a3a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:to="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2011PlanMember_ab3d03e1-4ace-4b46-94bb-2cad80c1dc35" xlink:href="icui-20221231.xsd#icui_A2011PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:to="loc_icui_A2011PlanMember_ab3d03e1-4ace-4b46-94bb-2cad80c1dc35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2003PlanMember_dd28b6a6-1f36-4712-b97f-a535ea1b7b4e" xlink:href="icui-20221231.xsd#icui_A2003PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:to="loc_icui_A2003PlanMember_dd28b6a6-1f36-4712-b97f-a535ea1b7b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:to="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_002a9096-6f01-4b28-b772-2187b8c0da90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_002a9096-6f01-4b28-b772-2187b8c0da90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimebasedstockoptionMember_b9f79c18-1154-49bd-9078-8972f5940ac5" xlink:href="icui-20221231.xsd#icui_TimebasedstockoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:to="loc_icui_TimebasedstockoptionMember_b9f79c18-1154-49bd-9078-8972f5940ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9b50400-ef9d-4f97-8949-9ed504df3af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9b50400-ef9d-4f97-8949-9ed504df3af8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails" xlink:type="extended" id="ic6fec37f23f648ef8ab523b4f9f5d75e_ShareBasedAwardStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0cfeb3b0-1a90-4754-8ab9-d3bee41d0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0cfeb3b0-1a90-4754-8ab9-d3bee41d0e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b53db83-a180-47a0-9d7d-89054b1f8493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b53db83-a180-47a0-9d7d-89054b1f8493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_877225c8-1e8a-4496-bc0f-81d20485a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_877225c8-1e8a-4496-bc0f-81d20485a5ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_02dbeb3d-f42c-4a62-951f-341601eed269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_02dbeb3d-f42c-4a62-951f-341601eed269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d6a167-0b03-48df-8201-23f2fd02abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c536618-9e1b-42bd-b395-a9b193353359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c536618-9e1b-42bd-b395-a9b193353359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_424d96a4-12b6-4923-b2a0-e6586a629000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_424d96a4-12b6-4923-b2a0-e6586a629000" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a30a458-0913-46df-bab2-6f48b3f9d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a30a458-0913-46df-bab2-6f48b3f9d96d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a05cebb8-ffe4-4b44-8145-6b9620a3ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a05cebb8-ffe4-4b44-8145-6b9620a3ed7f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608e9678-91c8-4a3c-a767-e69f78a5eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608e9678-91c8-4a3c-a767-e69f78a5eeb1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c9b4025-7edb-4d3c-a57e-e7568c0e80f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c9b4025-7edb-4d3c-a57e-e7568c0e80f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91930ff9-7eff-4ef2-b813-0dad4e67f078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_7a776c0b-4aff-42a0-a2f2-1cf402a4b9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_7a776c0b-4aff-42a0-a2f2-1cf402a4b9de" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7465936b-78ef-42e3-834c-da40cb639eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7465936b-78ef-42e3-834c-da40cb639eb7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_840cb851-2f05-49bd-804a-82e027e53d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_840cb851-2f05-49bd-804a-82e027e53d4e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f07898f5-28f9-4ff8-b791-7650318e26d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f07898f5-28f9-4ff8-b791-7650318e26d4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4ae8e94e-7bd8-49a5-ad31-1b4898b80c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4ae8e94e-7bd8-49a5-ad31-1b4898b80c5c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_996625ea-efde-496c-b34b-606c1c739079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_996625ea-efde-496c-b34b-606c1c739079" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a84974d-b977-49de-9957-1c25cf3831c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a84974d-b977-49de-9957-1c25cf3831c8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0113f4c5-e315-4ea2-86bf-18f682e26185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0113f4c5-e315-4ea2-86bf-18f682e26185" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:to="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef200785-9076-4a99-9be4-0ac9b14f13f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef200785-9076-4a99-9be4-0ac9b14f13f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df44ab2f-10ec-43aa-ab97-4dc7dc3f27a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df44ab2f-10ec-43aa-ab97-4dc7dc3f27a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardRSUandPRSUDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails" xlink:type="extended" id="i5f36d945d67f4026bb0ffd02f1a14617_ShareBasedAwardRSUandPRSUDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec24c435-0757-4b8f-9088-91e6386674ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec24c435-0757-4b8f-9088-91e6386674ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceSharesEarned_8f1c3b7c-f6eb-4379-9984-c8348119ae76" xlink:href="icui-20221231.xsd#icui_PerformanceSharesEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_PerformanceSharesEarned_8f1c3b7c-f6eb-4379-9984-c8348119ae76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33f9df16-c537-4f99-83e8-eb93504ebc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33f9df16-c537-4f99-83e8-eb93504ebc65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueperformancerestrictedstockunits_c7d18b21-a59d-4b16-9e33-08508421d4ae" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueperformancerestrictedstockunits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_Grantdatefairvalueperformancerestrictedstockunits_c7d18b21-a59d-4b16-9e33-08508421d4ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted_69380ecf-b5d8-40a5-9ae5-40287857f552" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueofrestrictedstockunitsgranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted_69380ecf-b5d8-40a5-9ae5-40287857f552" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_11c4a23d-0901-4782-81ab-0eceab329f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_11c4a23d-0901-4782-81ab-0eceab329f4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ModifiedPRSUIncrementalExpense_9f3d983a-2172-4ec7-a301-3defd5aaecbe" xlink:href="icui-20221231.xsd#icui_ModifiedPRSUIncrementalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_ModifiedPRSUIncrementalExpense_9f3d983a-2172-4ec7-a301-3defd5aaecbe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:to="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2380b8b6-ed83-4e04-ba6d-252adf8cfc43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2380b8b6-ed83-4e04-ba6d-252adf8cfc43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember_4a08bb93-e166-42f9-9bf7-69d0dc763309" xlink:href="icui-20221231.xsd#icui_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember_4a08bb93-e166-42f9-9bf7-69d0dc763309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d83c355e-e33b-4a4e-8df5-3ccf25819148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_us-gaap_PerformanceSharesMember_d83c355e-e33b-4a4e-8df5-3ccf25819148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41a6413-fd80-4464-ba18-5c22f72bd73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41a6413-fd80-4464-ba18-5c22f72bd73f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardRSUandPRSURollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails" xlink:type="extended" id="ife21a424fa4c4f9b9cbfd8c2c4877fd2_ShareBasedAwardRSUandPRSURollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dabd5d17-83a6-465e-ab8a-14ab8e005ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dabd5d17-83a6-465e-ab8a-14ab8e005ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39aa20c2-46da-4272-aa3d-ae83177256a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39aa20c2-46da-4272-aa3d-ae83177256a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Changeinunitsduetoperformanceexpectations_cdc60be3-37bd-4992-a2b7-f0a46eb61495" xlink:href="icui-20221231.xsd#icui_Changeinunitsduetoperformanceexpectations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_icui_Changeinunitsduetoperformanceexpectations_cdc60be3-37bd-4992-a2b7-f0a46eb61495" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_8c9c0fe8-22a7-46cd-9196-3685ba43c48c" xlink:href="icui-20221231.xsd#icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_8c9c0fe8-22a7-46cd-9196-3685ba43c48c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60e7f4e5-3927-4dbb-b1ca-1ab81fc89945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60e7f4e5-3927-4dbb-b1ca-1ab81fc89945" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b09cfd89-284e-441f-993d-e7e60f902ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b09cfd89-284e-441f-993d-e7e60f902ef1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b78dccd7-0cce-40ac-b634-e63bb245e402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b78dccd7-0cce-40ac-b634-e63bb245e402" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_980f49dc-4150-49f0-817a-9ffda1b93ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_980f49dc-4150-49f0-817a-9ffda1b93ba0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4906f1fe-9332-4220-a071-37688feda874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4906f1fe-9332-4220-a071-37688feda874" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_87d4c402-5770-41d0-89d4-26b7cec93d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_87d4c402-5770-41d0-89d4-26b7cec93d1e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_23e1376b-4f2d-4232-ab3f-dd186e70e197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_23e1376b-4f2d-4232-ab3f-dd186e70e197" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b827653c-784b-4b8c-8286-c1181df4549f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b827653c-784b-4b8c-8286-c1181df4549f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:to="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92d92454-7dc6-4802-b4fd-1852dc421fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92d92454-7dc6-4802-b4fd-1852dc421fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_1d81ffb6-345e-4e18-b84f-deb0f8ced475" xlink:href="icui-20221231.xsd#icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:to="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_1d81ffb6-345e-4e18-b84f-deb0f8ced475" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails" xlink:type="extended" id="i0d55e5a2031e4350be6e61858762dc3f_DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ba979d54-885c-4676-bdd2-be7533f9fa78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ba979d54-885c-4676-bdd2-be7533f9fa78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeForwardExchangeRate1_0ee11b91-d356-41df-9e95-1db0611b42f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeForwardExchangeRate1_0ee11b91-d356-41df-9e95-1db0611b42f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_f6bc822c-dc83-47e6-aac5-cadc5de81fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_f6bc822c-dc83-47e6-aac5-cadc5de81fd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_cf87188e-0c61-4ddc-891d-528b72481cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_cf87188e-0c61-4ddc-891d-528b72481cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_44f2d776-894f-4122-a54d-c5c0fcafd9da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_44f2d776-894f-4122-a54d-c5c0fcafd9da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge3MemberMember_d48014dd-bbdd-4ced-babd-170a838efc30" xlink:href="icui-20221231.xsd#icui_Hedge3MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge3MemberMember_d48014dd-bbdd-4ced-babd-170a838efc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge4Member_d6e6e81e-f3da-401a-a176-ada5bb00499f" xlink:href="icui-20221231.xsd#icui_Hedge4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge4Member_d6e6e81e-f3da-401a-a176-ada5bb00499f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge5Member_5074b311-64c4-475e-92de-90f438747a9b" xlink:href="icui-20221231.xsd#icui_Hedge5Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge5Member_5074b311-64c4-475e-92de-90f438747a9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_80746ef0-ea76-43fd-9637-3795de4ccd7f_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:to="loc_currency_AllCurrenciesDomain_80746ef0-ea76-43fd-9637-3795de4ccd7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:to="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_MXN_b28b132b-24e2-4ff9-a9e4-70ce759aa303" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MXN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_MXN_b28b132b-24e2-4ff9-a9e4-70ce759aa303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_40848c6a-4c7e-4155-9fea-a68ac6ad7dc9" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_EUR_40848c6a-4c7e-4155-9fea-a68ac6ad7dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CZK_4a8de672-cf9c-4e37-9fb8-e009556ee48d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CZK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CZK_4a8de672-cf9c-4e37-9fb8-e009556ee48d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_6bf9842a-570c-4a9d-92a1-e173ed05c03a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_JPY_6bf9842a-570c-4a9d-92a1-e173ed05c03a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_3710040a-a9bd-4648-9302-8388789dc623" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CNY_3710040a-a9bd-4648-9302-8388789dc623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_eb9fb8bf-a6fd-42a2-93b7-cdc6cb71fe75" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_USD_eb9fb8bf-a6fd-42a2-93b7-cdc6cb71fe75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_92ee22f3-7f17-452a-8be1-67da676e4a13" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CAD_92ee22f3-7f17-452a-8be1-67da676e4a13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_1a79406f-250d-4722-835a-1c3cf1393cbf" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_AUD_1a79406f-250d-4722-835a-1c3cf1393cbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisDomain_5e0261a9-f34a-4533-aa2f-6503fe1d632f_default" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:to="loc_icui_Srt_MultipleCurrencyAxisDomain_5e0261a9-f34a-4533-aa2f-6503fe1d632f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:to="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherCurrenciesMember_1f61a863-b45f-4267-8ac1-5d69b7dc373e" xlink:href="icui-20221231.xsd#icui_OtherCurrenciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:to="loc_icui_OtherCurrenciesMember_1f61a863-b45f-4267-8ac1-5d69b7dc373e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesInterestRateContractsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails" xlink:type="extended" id="i9cd2a7a6c8644c72a59cf8fe14cc2d9d_DerivativesandHedgingActivitiesInterestRateContractsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_089e0f10-fc27-42bb-84a9-13625da6f9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_089e0f10-fc27-42bb-84a9-13625da6f9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c3a74a4a-7f41-4d88-94b5-ca09d6495b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c3a74a4a-7f41-4d88-94b5-ca09d6495b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DerivativeInterestRateFloor_6b71336f-4a7d-4bf9-8d29-35a5933c09b7" xlink:href="icui-20221231.xsd#icui_DerivativeInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_icui_DerivativeInterestRateFloor_6b71336f-4a7d-4bf9-8d29-35a5933c09b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bfd07215-780c-4e9b-8e5c-f58e485d4de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bfd07215-780c-4e9b-8e5c-f58e485d4de6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:to="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae5d921c-ba27-47a5-b19f-de95349d313f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:to="loc_srt_RangeMember_ae5d921c-ba27-47a5-b19f-de95349d313f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:to="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_82b00671-39b4-4706-ab5d-4aa64f411c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:to="loc_srt_MaximumMember_82b00671-39b4-4706-ab5d-4aa64f411c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_755aea7e-e0f6-4f27-8e8f-bd75d2453701" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:to="loc_srt_MinimumMember_755aea7e-e0f6-4f27-8e8f-bd75d2453701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_36fc1423-2e00-453e-b6fa-b800be934432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_36fc1423-2e00-453e-b6fa-b800be934432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_9c7afe10-b72e-4661-b409-25d89e2fd325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:to="loc_us-gaap_InterestRateSwapMember_9c7afe10-b72e-4661-b409-25d89e2fd325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UsGaap_InterestRateSwap2Member_a3fad6aa-8d2b-43fa-80d2-7b50935c6f4c" xlink:href="icui-20221231.xsd#icui_UsGaap_InterestRateSwap2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:to="loc_icui_UsGaap_InterestRateSwap2Member_a3fad6aa-8d2b-43fa-80d2-7b50935c6f4c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails" xlink:type="extended" id="i496b943a742b4620a3b95f3286ccf51d_DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_161972d5-528a-4f53-b09e-e3c6aa1309ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:to="loc_us-gaap_DerivativeAssets_161972d5-528a-4f53-b09e-e3c6aa1309ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5f42816a-6b7a-48ff-8671-5abb838395cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:to="loc_us-gaap_DerivativeLiabilities_5f42816a-6b7a-48ff-8671-5abb838395cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a4514c34-d1ca-4a24-a71b-388b3e0a8a67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a4514c34-d1ca-4a24-a71b-388b3e0a8a67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f00abd4c-0843-4da9-8723-a696549eb8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f00abd4c-0843-4da9-8723-a696549eb8d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_722ba597-324f-44a9-92fa-6f0ea03461ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_InterestRateSwapMember_722ba597-324f-44a9-92fa-6f0ea03461ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_ea854317-26b2-4c0d-b14f-e0183ecdcb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_ea854317-26b2-4c0d-b14f-e0183ecdcb50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_346b3fe6-16a4-4f8f-a688-0fd883f6a459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_346b3fe6-16a4-4f8f-a688-0fd883f6a459" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_1d606599-6444-4682-93da-fc9f9c492102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_AssetsTotalMember_1d606599-6444-4682-93da-fc9f9c492102" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_c6882d3e-bf78-42ea-a036-2ec3068f24c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_LiabilitiesTotalMember_c6882d3e-bf78-42ea-a036-2ec3068f24c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_97c7d122-cdeb-4ffc-9d71-447a51aaca56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:to="loc_us-gaap_HedgingDesignationDomain_97c7d122-cdeb-4ffc-9d71-447a51aaca56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:to="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b0f60ef7-8aee-45d5-907b-fed117432428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b0f60ef7-8aee-45d5-907b-fed117432428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4742e85b-bafc-4d20-8ce7-92cdd103db3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4742e85b-bafc-4d20-8ce7-92cdd103db3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_664a4aba-eec4-4006-8407-2ef96e011665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_664a4aba-eec4-4006-8407-2ef96e011665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ee7db667-3a28-466d-af59-19f42d3d12b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ee7db667-3a28-466d-af59-19f42d3d12b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_2c6ebc3e-53f3-4090-bc30-66337a918470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_OtherAssetsMember_2c6ebc3e-53f3-4090-bc30-66337a918470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9f95441a-3085-4608-8b92-420d5f9c831d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9f95441a-3085-4608-8b92-420d5f9c831d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_31958ce7-9e51-47c9-88e5-21d0d055916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_OtherLiabilitiesMember_31958ce7-9e51-47c9-88e5-21d0d055916d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_0e10c15d-3430-4291-88f6-bfa0fb76239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_AssetsTotalMember_0e10c15d-3430-4291-88f6-bfa0fb76239c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_a597734f-7146-4297-8121-b82aec26141d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_a597734f-7146-4297-8121-b82aec26141d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_6748b484-5043-4acd-94fe-4c3fb08e9ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_LiabilitiesTotalMember_6748b484-5043-4acd-94fe-4c3fb08e9ca6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails" xlink:type="extended" id="i1c21cfc77ff642839fbf58b99f699b8b_DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_8739367f-f604-43c0-ab53-ff5ac43d716f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_8739367f-f604-43c0-ab53-ff5ac43d716f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_a6c40d1f-0df8-48bb-8523-2ef987bb13f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_a6c40d1f-0df8-48bb-8523-2ef987bb13f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_8c0dc49d-b135-4387-8fce-60639b165bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_8c0dc49d-b135-4387-8fce-60639b165bd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ae243ecb-3ec1-46a3-9c30-ba5070b6e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ae243ecb-3ec1-46a3-9c30-ba5070b6e3e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3250f7bb-bc07-4a6c-8d66-d001fa7947f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3250f7bb-bc07-4a6c-8d66-d001fa7947f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0db2825e-f905-484e-a64e-fffcd8caf307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0db2825e-f905-484e-a64e-fffcd8caf307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3223d8c-8542-4875-8830-739cac882da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:to="loc_us-gaap_InterestRateSwapMember_b3223d8c-8542-4875-8830-739cac882da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3f9b2a69-3447-4381-bf1f-569a57a5bf88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3f9b2a69-3447-4381-bf1f-569a57a5bf88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:to="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4479029d-226a-4039-b869-fff09e3b36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:to="loc_us-gaap_CashFlowHedgingMember_4479029d-226a-4039-b869-fff09e3b36e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingRevenueMember_dc8c84ad-c988-48b4-8647-3400554b22f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:to="loc_us-gaap_TradingRevenueMember_dc8c84ad-c988-48b4-8647-3400554b22f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_48131141-01d7-4de7-b2e0-2cb9f44f491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:to="loc_us-gaap_CostOfSalesMember_48131141-01d7-4de7-b2e0-2cb9f44f491b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ie5eaf04c037849b1b9437d8019a8f666_DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_8f0c8451-541f-42e8-ae63-d52fae2d1cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_8f0c8451-541f-42e8-ae63-d52fae2d1cb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b7abb74f-44a4-4efc-8d70-d1474b6347c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b7abb74f-44a4-4efc-8d70-d1474b6347c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_22685cf1-a9cb-4abe-9113-f8d982fd8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:to="loc_us-gaap_CashFlowHedgingMember_22685cf1-a9cb-4abe-9113-f8d982fd8f00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70e25692-3e78-4c51-b270-07c9e64cd1e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70e25692-3e78-4c51-b270-07c9e64cd1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9903a714-6e69-4555-afca-a9e01aaaf0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:to="loc_us-gaap_CostOfSalesMember_9903a714-6e69-4555-afca-a9e01aaaf0d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_82eb4a4d-579f-4926-8f93-0b2ad99a0983_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_82eb4a4d-579f-4926-8f93-0b2ad99a0983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_9b393718-0d41-45e4-b856-9e15b27e42d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_9b393718-0d41-45e4-b856-9e15b27e42d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1eb94ddd-c6da-4c00-8f85-8450f7cdac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_CashFlowHedgingMember_1eb94ddd-c6da-4c00-8f85-8450f7cdac9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2d41d929-a63c-4cab-83b4-cc1cf7f58f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_InterestRateSwapMember_2d41d929-a63c-4cab-83b4-cc1cf7f58f1a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementSmithsMedicalDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails" xlink:type="extended" id="i99ed8bcadfa04478ab35c6a81002813a_FairValueMeasurementSmithsMedicalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_eeed9319-c432-40a5-ac98-f06b631c0718" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_icui_Contingentconsiderationgross_eeed9319-c432-40a5-ac98-f06b631c0718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_78fe3540-bef5-4af1-9b76-a048dbbe9525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_78fe3540-bef5-4af1-9b76-a048dbbe9525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_c7b86018-52c5-48c4-b8b2-bb2a0b88886a" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OwnershipRequirementForEarnoutPayment_3561cf5a-e53a-434e-8000-9ecf2cee45dd" xlink:href="icui-20221231.xsd#icui_OwnershipRequirementForEarnoutPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_icui_OwnershipRequirementForEarnoutPayment_3561cf5a-e53a-434e-8000-9ecf2cee45dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_527a6802-d5f0-4b26-94c8-b5c13bb62ab0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_527a6802-d5f0-4b26-94c8-b5c13bb62ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_2b3902a0-4ad4-4167-8324-37d43e3ed3de" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:to="loc_icui_SmithsMedicalMember_2b3902a0-4ad4-4167-8324-37d43e3ed3de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementTextPursuitDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails" xlink:type="extended" id="i2e8833f92e7743b0ab3db10129786190_FairValueMeasurementTextPursuitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_84c1fc46-79ab-4020-8a23-dc0889e84601" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_Contingentconsiderationgross_84c1fc46-79ab-4020-8a23-dc0889e84601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_59b8391a-e069-42c9-b9c6-cc3023b57aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_59b8391a-e069-42c9-b9c6-cc3023b57aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_3980925d-7d9f-44f2-b560-85880fa22f6c" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_ShortTermContingentConsiderationGross_3980925d-7d9f-44f2-b560-85880fa22f6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_b41eb112-a012-48b2-8c98-aaa122b472f0" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_LongTermContingentConsiderationGross_b41eb112-a012-48b2-8c98-aaa122b472f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_319b96d7-dac6-4336-a9e2-a197579cc5d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_319b96d7-dac6-4336-a9e2-a197579cc5d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_08a32a4f-bc8b-4696-b6c8-5d27fdde7d22" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_PursuitVascularInc.Member_08a32a4f-bc8b-4696-b6c8-5d27fdde7d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_151f55f7-ae5a-4f8c-81bf-56c2bd09c937" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_PursuitVascularLLCMember_151f55f7-ae5a-4f8c-81bf-56c2bd09c937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignDistibutorMember_eb08383c-44dd-4062-8bbf-9ccad782a80e" xlink:href="icui-20221231.xsd#icui_ForeignDistibutorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_ForeignDistibutorMember_eb08383c-44dd-4062-8bbf-9ccad782a80e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_f38c243d-2ad3-44ee-8d0d-cb46b0f6c7b0" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_f38c243d-2ad3-44ee-8d0d-cb46b0f6c7b0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementRollForwardDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementRollForwardDetails" xlink:type="extended" id="i67d328ec22fa4d758b99a9bfb4a9b0ac_FairValueMeasurementRollForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_19d6dbc0-eca6-4f2b-ba70-095ab4fd67b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_19d6dbc0-eca6-4f2b-ba70-095ab4fd67b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8a69cb5a-4028-4f33-a21e-96432f557af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8a69cb5a-4028-4f33-a21e-96432f557af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cc143884-e401-4fb6-9f87-0464d66cf10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cc143884-e401-4fb6-9f87-0464d66cf10f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_ca188a92-61d1-4dc7-9fae-24133e222487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_ca188a92-61d1-4dc7-9fae-24133e222487" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d0f43d72-f6d1-4a77-a053-ea0d1c413d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d0f43d72-f6d1-4a77-a053-ea0d1c413d0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrencyTranslationOnEarnOut_8c405b96-6009-43b3-b179-667a2df4b3ea" xlink:href="icui-20221231.xsd#icui_CurrencyTranslationOnEarnOut"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_icui_CurrencyTranslationOnEarnOut_8c405b96-6009-43b3-b179-667a2df4b3ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_fa7d9902-9c94-4fdb-9f02-3ebd8d247d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_fa7d9902-9c94-4fdb-9f02-3ebd8d247d2c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24dd0b20-f3c0-4856-88c9-e24fab2b29a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24dd0b20-f3c0-4856-88c9-e24fab2b29a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_1dedc794-0c74-4762-90d4-72f17eea5fb3" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_PursuitVascularInc.Member_1dedc794-0c74-4762-90d4-72f17eea5fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_7798c167-ca0a-4b78-b633-8e98542615fe" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_PursuitVascularLLCMember_7798c167-ca0a-4b78-b633-8e98542615fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_1092e82e-830e-4bd6-a844-9f21a0f26c34" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_SmithsMedicalMember_1092e82e-830e-4bd6-a844-9f21a0f26c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_2dae5358-af28-4803-853a-b0e34ff7151d" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_2dae5358-af28-4803-853a-b0e34ff7151d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails" xlink:type="extended" id="if9eb3d60d6004b3c8749fd41e56c59a6_FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5afe7c7d-b94c-439e-8a93-47fb46e45c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5afe7c7d-b94c-439e-8a93-47fb46e45c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7b64b03-e6b3-409f-919f-731f116dc57c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7b64b03-e6b3-409f-919f-731f116dc57c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_57bb4925-3a41-4af9-ad36-82677f81ab1c" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:to="loc_icui_PursuitVascularInc.Member_57bb4925-3a41-4af9-ad36-82677f81ab1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5e40a81c-7903-4458-a572-7fd23a38f1d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5e40a81c-7903-4458-a572-7fd23a38f1d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueGrossProfitVolatilityMember_41650c3e-8d25-462c-995f-5a5244194b8e" xlink:href="icui-20221231.xsd#icui_RevenueGrossProfitVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_icui_RevenueGrossProfitVolatilityMember_41650c3e-8d25-462c-995f-5a5244194b8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_420c56f3-c03d-4547-956a-aeb146be0d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_420c56f3-c03d-4547-956a-aeb146be0d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a7a5566f-a927-453a-bba7-9e2f3fe0d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a7a5566f-a927-453a-bba7-9e2f3fe0d6bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditRiskMember_86d77240-aa08-4ab1-a34a-fbad99bbea52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_CreditRiskMember_86d77240-aa08-4ab1-a34a-fbad99bbea52" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementSmithsMedicalSimulationInputsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails" xlink:type="extended" id="ib766b3ebc2cd4c7e877b777da8507a6f_FairValueMeasurementSmithsMedicalSimulationInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb067254-e636-45ff-af42-32a1c41e2659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb067254-e636-45ff-af42-32a1c41e2659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c205f2bb-d958-496f-8d7e-1e023e3c680e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c205f2bb-d958-496f-8d7e-1e023e3c680e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_1353d31d-b5bf-4b23-9380-f3af9903a872" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:to="loc_icui_SmithsMedicalMember_1353d31d-b5bf-4b23-9380-f3af9903a872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ddf7933c-77e3-49f5-9487-da35404c70b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ddf7933c-77e3-49f5-9487-da35404c70b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0ba2e16-7863-4cb7-b22b-935d1b4e183c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0ba2e16-7863-4cb7-b22b-935d1b4e183c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2ca550be-c20f-47df-a319-c4f28a462c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2ca550be-c20f-47df-a319-c4f28a462c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e34a122a-0a0f-480d-903f-00ee4be587e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e34a122a-0a0f-480d-903f-00ee4be587e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59969cb1-f2ea-496c-8a35-22c67bf0fe96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59969cb1-f2ea-496c-8a35-22c67bf0fe96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f785654c-4ccb-41c8-a443-b4e8012d9425_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:to="loc_srt_RangeMember_f785654c-4ccb-41c8-a443-b4e8012d9425_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43ab29f7-abe2-4e66-849f-b99c70b7c2fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:to="loc_srt_RangeMember_43ab29f7-abe2-4e66-849f-b99c70b7c2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_c99127bd-6158-4a9f-9f61-96a5dd98505f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_c99127bd-6158-4a9f-9f61-96a5dd98505f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9d676778-fb13-40e4-92fe-e2499c0de41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9d676778-fb13-40e4-92fe-e2499c0de41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1bac9ca-5b25-49e7-8d17-89629425afd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1bac9ca-5b25-49e7-8d17-89629425afd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1257c757-1b45-4348-8995-7fc3084877bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1257c757-1b45-4348-8995-7fc3084877bc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" id="i9d147a8c67d84d6399d7f01a29351a2b_FairValueMeasurementFairValueMeasurementsRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc562402-7d42-4237-bb13-619d6a6f37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc562402-7d42-4237-bb13-619d6a6f37e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d3219b5-8093-4f9c-a70e-ac3c8a939243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d3219b5-8093-4f9c-a70e-ac3c8a939243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_d7be7c49-405a-4d75-8a9c-a4a3d09e53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_d7be7c49-405a-4d75-8a9c-a4a3d09e53fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_28fdd7b9-32f8-444f-8211-80c76999747f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_28fdd7b9-32f8-444f-8211-80c76999747f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_26c683b7-aec9-4493-a96c-a6b1f681e5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_26c683b7-aec9-4493-a96c-a6b1f681e5c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e92d80ed-2b6f-4ae3-824c-2bf9806506c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e92d80ed-2b6f-4ae3-824c-2bf9806506c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_e23da815-dde1-4ab3-b303-712b33bc6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_e23da815-dde1-4ab3-b303-712b33bc6a40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eaade9a-f97a-4978-9b89-56edf3b9c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eaade9a-f97a-4978-9b89-56edf3b9c4f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a9cab47b-d005-4304-8728-6101814da807_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a9cab47b-d005-4304-8728-6101814da807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EarnoutliabilityMember_155853a3-eb8b-474b-80e5-8183b704f6ec" xlink:href="icui-20221231.xsd#icui_EarnoutliabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:to="loc_icui_EarnoutliabilityMember_155853a3-eb8b-474b-80e5-8183b704f6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_79529e0d-040d-453f-b972-97a7da645d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:to="loc_us-gaap_LiabilitiesTotalMember_79529e0d-040d-453f-b972-97a7da645d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ee11b5ca-f718-4f51-884e-cc1683e28878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ee11b5ca-f718-4f51-884e-cc1683e28878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_aeac42cf-5b27-42ce-ba69-d3d1a8e36692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_aeac42cf-5b27-42ce-ba69-d3d1a8e36692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_5f65e6aa-7dd7-4907-93d6-d1ad669d1f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_OtherLiabilitiesMember_5f65e6aa-7dd7-4907-93d6-d1ad669d1f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_f8710d3a-1c4b-47a6-b518-9147d3989457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_OtherAssetsMember_f8710d3a-1c4b-47a6-b518-9147d3989457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_34705e05-6d4f-4ef6-ab00-7ad371892138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_34705e05-6d4f-4ef6-ab00-7ad371892138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cca9269-be23-44e5-84aa-10e17e1f0f73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cca9269-be23-44e5-84aa-10e17e1f0f73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1295bb5b-32c0-4d9a-8b0d-701860a2d3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1295bb5b-32c0-4d9a-8b0d-701860a2d3e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_785a9bbd-ffc5-46c6-9d1f-4878915d4248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_785a9bbd-ffc5-46c6-9d1f-4878915d4248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfd342e9-4dc8-4f0b-b4f4-c08c0831bb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfd342e9-4dc8-4f0b-b4f4-c08c0831bb15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9913cb8e-e89a-46b8-9b23-3f36b2a69577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9913cb8e-e89a-46b8-9b23-3f36b2a69577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dc365858-8c91-4217-ae1a-06b431cf3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dc365858-8c91-4217-ae1a-06b431cf3a48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_191f4fce-a32d-4823-a86b-c2c15cddf141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_191f4fce-a32d-4823-a86b-c2c15cddf141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af279df0-a9be-4ecc-b002-f32e50ef85f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af279df0-a9be-4ecc-b002-f32e50ef85f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:href="icui-20221231.xsd#icui_ClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationDomain_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e_default" xlink:href="icui-20221231.xsd#icui_ClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:to="loc_icui_ClassificationDomain_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:href="icui-20221231.xsd#icui_ClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:to="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentMember_f67272a0-264d-41bd-8254-1332bcbbbe3e" xlink:href="icui-20221231.xsd#icui_NoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:to="loc_icui_NoncurrentMember_f67272a0-264d-41bd-8254-1332bcbbbe3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrentMember_fc92a977-c5b7-4a8f-bb37-aeaea53055b5" xlink:href="icui-20221231.xsd#icui_CurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:to="loc_icui_CurrentMember_fc92a977-c5b7-4a8f-bb37-aeaea53055b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b31de6c3-d9fc-46d7-be0f-42c676c41043_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b31de6c3-d9fc-46d7-be0f-42c676c41043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_478ef5ef-1f32-47cf-b81e-c738c7b220d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_478ef5ef-1f32-47cf-b81e-c738c7b220d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i16580aa967164401a7efe9d0336d459f_PrepaidExpensesandOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9c13ed55-d47a-4fce-9c13-0bbdfcc609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9c13ed55-d47a-4fce-9c13-0bbdfcc609eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidVendorExpenses_de3dddc8-f58e-4b17-91d9-97c2e20ab984" xlink:href="icui-20221231.xsd#icui_PrepaidVendorExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_PrepaidVendorExpenses_de3dddc8-f58e-4b17-91d9-97c2e20ab984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsAndOtherAssets_779beb42-7e27-492f-b446-25881ded4159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DeferredCostsAndOtherAssets_779beb42-7e27-492f-b446-25881ded4159" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidinsuranceandpropertytaxes_abb88e84-d9ad-445c-872b-5337eee913f8" xlink:href="icui-20221231.xsd#icui_Prepaidinsuranceandpropertytaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Prepaidinsuranceandpropertytaxes_abb88e84-d9ad-445c-872b-5337eee913f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidothertaxes_201b622d-c56f-4656-8782-7dd43d284bcb" xlink:href="icui-20221231.xsd#icui_Prepaidothertaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Prepaidothertaxes_201b622d-c56f-4656-8782-7dd43d284bcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxcharge_00b3a071-9702-4357-af13-c75378d39198" xlink:href="icui-20221231.xsd#icui_Deferredtaxcharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Deferredtaxcharge_00b3a071-9702-4357-af13-c75378d39198" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_fe8a29c9-168f-4ce1-96d4-27a88f4c0c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_fe8a29c9-168f-4ce1-96d4-27a88f4c0c13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_e03ac9bb-8eeb-47fc-bc53-bf933ecde934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_e03ac9bb-8eeb-47fc-bc53-bf933ecde934" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_c756ced0-03a3-4e5f-9319-1342991c1af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DepositAssets_c756ced0-03a3-4e5f-9319-1342991c1af3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ba35784d-21a6-49d0-853a-cbbae04b2741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_OtherAssetsCurrent_ba35784d-21a6-49d0-853a-cbbae04b2741" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95244cb4-ad09-4798-b203-91dd5d5fab96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95244cb4-ad09-4798-b203-91dd5d5fab96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_352ea72f-8546-489d-95fc-3eac9152cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_352ea72f-8546-489d-95fc-3eac9152cbd3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidsandOtherNoncurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="extended" id="i039efa49a88d4cfd922a541f1ba8c199_PrepaidsandOtherNoncurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1a7b598e-2375-479c-a39b-da3bbd5512ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1a7b598e-2375-479c-a39b-da3bbd5512ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SpareParts_6b556f8c-a563-4e15-b555-34f8cde3dcd3" xlink:href="icui-20221231.xsd#icui_SpareParts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_icui_SpareParts_6b556f8c-a563-4e15-b555-34f8cde3dcd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_698fe5d0-017e-4b80-a781-a623db4ecf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_EquityMethodInvestments_698fe5d0-017e-4b80-a781-a623db4ecf97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_03a950c2-fe00-4280-b7c0-bd1d2f19dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_03a950c2-fe00-4280-b7c0-bd1d2f19dca0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_33615401-e697-44d8-904e-10aba54e54a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_33615401-e697-44d8-904e-10aba54e54a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_990d340b-6984-47f1-b0c7-f17839648ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_990d340b-6984-47f1-b0c7-f17839648ec5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d0b2a60b-6402-4936-8a52-5de576a6a582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d0b2a60b-6402-4936-8a52-5de576a6a582" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_74094673-8664-461c-abb6-deaae33b1545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_74094673-8664-461c-abb6-deaae33b1545" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3da98e55-de99-47d6-9959-146a04df7e9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3da98e55-de99-47d6-9959-146a04df7e9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6716f4d1-3479-4bbb-9853-1cb83c1702c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:to="loc_us-gaap_InterestRateSwapMember_6716f4d1-3479-4bbb-9853-1cb83c1702c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/AccruedLiabilitiesDetails" xlink:type="extended" id="ic05930b85b304fb3b061b324b58cdb8d_AccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedSalariesAndBenefits_81bea948-5713-429a-9bed-5cbaf241729b" xlink:href="icui-20221231.xsd#icui_AccruedSalariesAndBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedSalariesAndBenefits_81bea948-5713-429a-9bed-5cbaf241729b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_47f3cb17-8bed-46c2-9020-23240561a5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedBonusesCurrent_47f3cb17-8bed-46c2-9020-23240561a5f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3f83be2-9f9c-40a8-a7b9-fc465a838a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3f83be2-9f9c-40a8-a7b9-fc465a838a69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_df726b58-02e7-4032-ad2e-b6f90cb78af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_df726b58-02e7-4032-ad2e-b6f90cb78af3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedProductFieldAction._d1562dad-9af2-4438-b489-53448cc98a73" xlink:href="icui-20221231.xsd#icui_AccruedProductFieldAction."/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedProductFieldAction._d1562dad-9af2-4438-b489-53448cc98a73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedlegalfees_fc5c8c9b-0549-4981-a19c-f7833fb63278" xlink:href="icui-20221231.xsd#icui_Accruedlegalfees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedlegalfees_fc5c8c9b-0549-4981-a19c-f7833fb63278" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedsalestaxes_69ed85f4-ab1e-4c07-811e-9e350dbadbbd" xlink:href="icui-20221231.xsd#icui_Accruedsalestaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedsalestaxes_69ed85f4-ab1e-4c07-811e-9e350dbadbbd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_75c5799d-b176-48db-9754-557f8560a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_75c5799d-b176-48db-9754-557f8560a05e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_af9915b5-f064-4816-a1a1-c8dcaa492d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_af9915b5-f064-4816-a1a1-c8dcaa492d48" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedothertaxes_bba40fe1-501c-4ee2-8779-7b47bd12f848" xlink:href="icui-20221231.xsd#icui_Accruedothertaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedothertaxes_bba40fe1-501c-4ee2-8779-7b47bd12f848" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Outsidesalescommissions_a2c927d9-c1a8-49b9-9a2b-8c5701d39e7d" xlink:href="icui-20221231.xsd#icui_Outsidesalescommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Outsidesalescommissions_a2c927d9-c1a8-49b9-9a2b-8c5701d39e7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedfreight_df71c41a-febe-4971-9329-517b2bcbaf04" xlink:href="icui-20221231.xsd#icui_Accruedfreight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedfreight_df71c41a-febe-4971-9329-517b2bcbaf04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_e5606fa9-2c9a-4b21-829a-32264e9b08bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_RestructuringReserveCurrent_e5606fa9-2c9a-4b21-829a-32264e9b08bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_858db184-fad2-4ffd-b6e0-924e1bb2c047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_858db184-fad2-4ffd-b6e0-924e1bb2c047" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedAuditFees_c23021c8-d78f-4d8e-8665-d9e1ea1637f9" xlink:href="icui-20221231.xsd#icui_AccruedAuditFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedAuditFees_c23021c8-d78f-4d8e-8665-d9e1ea1637f9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4787e55d-74e1-47ce-9536-b12928a47531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4787e55d-74e1-47ce-9536-b12928a47531" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_a8040536-9d70-414f-bd27-eb08864f0c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_a8040536-9d70-414f-bd27-eb08864f0c3b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedResearchAndDevelopmentLiability_98196630-816a-410f-8a4f-aa0898791a7e" xlink:href="icui-20221231.xsd#icui_AccruedResearchAndDevelopmentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedResearchAndDevelopmentLiability_98196630-816a-410f-8a4f-aa0898791a7e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b1cc93-98fb-4990-8311-01163c6b1682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b1cc93-98fb-4990-8311-01163c6b1682" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba34c860-9dd5-460c-b04c-8f5f82129ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ba34c860-9dd5-460c-b04c-8f5f82129ce4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e355d0ed-3013-4dd8-9054-9dc5eb991ccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e355d0ed-3013-4dd8-9054-9dc5eb991ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeMember_1407cc4a-e7f0-4ea9-9257-8cee0b4b6e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:to="loc_us-gaap_ForeignExchangeMember_1407cc4a-e7f0-4ea9-9257-8cee0b4b6e61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#OtherLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/OtherLiabilitiesDetails" xlink:type="extended" id="id879261c28a2406a993dbd3056548754_OtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b6be54d-726c-4252-ace7-92439406a2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b6be54d-726c-4252-ace7-92439406a2e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ae2c74a3-373e-4b0b-9dcd-9b28e98d46e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ae2c74a3-373e-4b0b-9dcd-9b28e98d46e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ecd21a0-0d02-493b-822f-023a9ec77e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ecd21a0-0d02-493b-822f-023a9ec77e31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_c033c5e3-fc09-428d-b6be-3bb8932dcc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_c033c5e3-fc09-428d-b6be-3bb8932dcc11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_6344aabc-f8d1-47d9-b58f-5e20e76acbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_6344aabc-f8d1-47d9-b58f-5e20e76acbae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualComponentAmount_1b8b603c-c0e6-4040-8ca7-8e074ac0d9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualComponentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_ProductLiabilityAccrualComponentAmount_1b8b603c-c0e6-4040-8ca7-8e074ac0d9d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_5fea94b2-ab7e-4175-8353-53acbb2b1140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_5fea94b2-ab7e-4175-8353-53acbb2b1140" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_0f058091-130f-4cb5-b0fe-7716e2a2a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_0f058091-130f-4cb5-b0fe-7716e2a2a53f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_df608444-60c4-497c-aba7-cf688ef4ecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_df608444-60c4-497c-aba7-cf688ef4ecd8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:to="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_739c8cdc-50ad-46b8-a078-920494faaa5c_default" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:to="loc_icui_TimingDomain_739c8cdc-50ad-46b8-a078-920494faaa5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:to="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_63197827-15cf-4428-9507-22c2de4345f3" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:to="loc_icui_LongTermMember_63197827-15cf-4428-9507-22c2de4345f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ApplicableMarginBasedonLeverageRatioTermLoanADetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails" xlink:type="extended" id="i7cae8ef61dc14a1898fa8795c8709024_ApplicableMarginBasedonLeverageRatioTermLoanADetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans_3cfbea66-d54d-4f45-8476-4c20b04b184c" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_icui_ApplicableMarginTermSOFRLoans_3cfbea66-d54d-4f45-8476-4c20b04b184c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans_f168cda0-b836-4465-8923-f9924608a4bf" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_icui_ApplicableMarginBaseRateLoans_f168cda0-b836-4465-8923-f9924608a4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dc02ce0f-5ce4-4a30-b996-f5901f7319de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dc02ce0f-5ce4-4a30-b996-f5901f7319de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:to="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_05148e47-6ca1-4230-899a-e5d6c32de343_default" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:to="loc_icui_LeverageRatioLevelDomain_05148e47-6ca1-4230-899a-e5d6c32de343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:to="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Greaterthan400to100Member_6c1bcb29-5952-4753-8cbb-fe5c607a3453" xlink:href="icui-20221231.xsd#icui_Greaterthan400to100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_Greaterthan400to100Member_6c1bcb29-5952-4753-8cbb-fe5c607a3453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_359b04f2-1383-49ad-8b27-a2430626cc31" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_359b04f2-1383-49ad-8b27-a2430626cc31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_46ec7460-2f18-4154-85d6-6f1781907ef9" xlink:href="icui-20221231.xsd#icui_LessThanOrEqual300To100ButGreaterThan250to100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_46ec7460-2f18-4154-85d6-6f1781907ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_1c90fba6-bdb6-430e-848f-d0342690bba2" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_1c90fba6-bdb6-430e-848f-d0342690bba2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo200To100Member_f61b011d-ae41-4db6-9b4a-f37b41a5306b" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo200To100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo200To100Member_f61b011d-ae41-4db6-9b4a-f37b41a5306b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:to="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_8b388d5b-57ae-4977-8032-ec13a8301763_default" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:to="loc_icui_TermLoanDomain_8b388d5b-57ae-4977-8032-ec13a8301763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:to="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_401f7971-7797-4a74-b65c-9dd80aadf0ed" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:to="loc_icui_TermLoanAMember_401f7971-7797-4a74-b65c-9dd80aadf0ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ApplicableMarginBasedonLeverageRatioTermLoanBDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails" xlink:type="extended" id="i875eab01485d4b66864ca65a79b646b2_ApplicableMarginBasedonLeverageRatioTermLoanBDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans_1fae0458-dafd-4c8e-acf6-23c649ec5f78" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:to="loc_icui_ApplicableMarginTermSOFRLoans_1fae0458-dafd-4c8e-acf6-23c649ec5f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans_05485dc5-5d20-4d5e-8aff-e7510ad65371" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:to="loc_icui_ApplicableMarginBaseRateLoans_05485dc5-5d20-4d5e-8aff-e7510ad65371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:to="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_f491c8ca-babf-4f2b-9ffd-320262d9adbd_default" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:to="loc_icui_LeverageRatioLevelDomain_f491c8ca-babf-4f2b-9ffd-320262d9adbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:to="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GreaterThan275To100Member_00345115-45b1-409b-a772-40818a363acf" xlink:href="icui-20221231.xsd#icui_GreaterThan275To100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:to="loc_icui_GreaterThan275To100Member_00345115-45b1-409b-a772-40818a363acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThan275To100Member_51da7ad1-3fe0-45c3-93c1-0d5963c7aeee" xlink:href="icui-20221231.xsd#icui_LessThan275To100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:to="loc_icui_LessThan275To100Member_51da7ad1-3fe0-45c3-93c1-0d5963c7aeee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:to="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_bd3e0075-0648-4369-980d-1291e6b95290_default" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:to="loc_icui_TermLoanDomain_bd3e0075-0648-4369-980d-1291e6b95290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:to="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_9553ff1c-f004-4161-a999-4b3d958eb7a0" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:to="loc_icui_TermLoanBMember_9553ff1c-f004-4161-a999-4b3d958eb7a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DebtDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/DebtDetails" xlink:type="extended" id="id5f9386f8767476e9b2e212cfef09c18_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aafa5cf4-2554-47e1-ae66-76b5ce3d5584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aafa5cf4-2554-47e1-ae66-76b5ce3d5584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_314c3025-48f9-413d-a44f-37bf1b12b56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_314c3025-48f9-413d-a44f-37bf1b12b56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_25608fd5-c323-4d01-887f-d9707063775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_25608fd5-c323-4d01-887f-d9707063775a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b6196ada-6380-4727-a6b6-6277397f8937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtCurrent_b6196ada-6380-4727-a6b6-6277397f8937" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2cc9b9aa-cde0-4917-8703-06ae526d54c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2cc9b9aa-cde0-4917-8703-06ae526d54c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ef377ce7-348e-415f-9b6e-f847b1d2a6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ef377ce7-348e-415f-9b6e-f847b1d2a6ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aaadcd9a-7a86-40c8-910d-87ab23cc163c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aaadcd9a-7a86-40c8-910d-87ab23cc163c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:to="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_2f27147e-f9fc-4c33-b565-5ef7e26a0464_default" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:to="loc_icui_TermLoanDomain_2f27147e-f9fc-4c33-b565-5ef7e26a0464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:to="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_10d800a2-651c-479f-99c7-536099342145" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:to="loc_icui_TermLoanAMember_10d800a2-651c-479f-99c7-536099342145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_3925c027-c39a-4d67-8114-6d2f838ab92c" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:to="loc_icui_TermLoanBMember_3925c027-c39a-4d67-8114-6d2f838ab92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fbbc825d-5bc2-471d-92da-58b73dbd84c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fbbc825d-5bc2-471d-92da-58b73dbd84c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f922b5e4-9149-4b5f-b32d-270a768f3ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f922b5e4-9149-4b5f-b32d-270a768f3ef1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/A2022CreditFacilityTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#A2022CreditFacilityTextDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/A2022CreditFacilityTextDetails" xlink:type="extended" id="i3ed36b83aff045a2b3fe43e8e5732449_A2022CreditFacilityTextDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:href="icui-20221231.xsd#icui_InterestRatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_a713801d-0b57-450c-a245-6f80b6010eb9" xlink:href="icui-20221231.xsd#icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:to="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_a713801d-0b57-450c-a245-6f80b6010eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:href="icui-20221231.xsd#icui_InterestRatesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:to="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:to="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78d6ebac-7def-4012-8436-bb0b7fe76b17_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:to="loc_srt_RangeMember_78d6ebac-7def-4012-8436-bb0b7fe76b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:to="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_439046f4-a391-4f4b-9475-28dcf226344b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:to="loc_srt_MinimumMember_439046f4-a391-4f4b-9475-28dcf226344b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_57352085-7f24-4a95-919e-e70e0de228eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:to="loc_srt_MaximumMember_57352085-7f24-4a95-919e-e70e0de228eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:to="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_9accde84-a5e8-46a3-b268-4e508c006c9b_default" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:to="loc_icui_TermLoanDomain_9accde84-a5e8-46a3-b268-4e508c006c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:to="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_3f232577-04ce-4c21-9a13-5410f91c9fce" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:to="loc_icui_TermLoanAMember_3f232577-04ce-4c21-9a13-5410f91c9fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da42f79e-19d3-4c02-b984-fc9f1f478d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da42f79e-19d3-4c02-b984-fc9f1f478d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f0d0799b-d778-403f-b15e-dcc03fe3b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f0d0799b-d778-403f-b15e-dcc03fe3b8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_88f00202-ec95-41f0-af66-cd87be59749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_LongTermDebt_88f00202-ec95-41f0-af66-cd87be59749d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_bdb4d417-ec55-4455-bf3d-ef7ca66e8e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_bdb4d417-ec55-4455-bf3d-ef7ca66e8e13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_34f1d386-f875-41d1-be01-899f52dd17c8" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:to="loc_icui_TermLoanAxis_34f1d386-f875-41d1-be01-899f52dd17c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_34f1d386-f875-41d1-be01-899f52dd17c8_default" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_f65c02ac-934b-44df-855f-cef00d1b6a6f" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_1a9459cd-6ec2-4f75-8a4f-9e4f2e89b555" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_4beda801-837b-4285-b3fe-9e42da5f2929" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_TermLoanDomain_f65c02ac-934b-44df-855f-cef00d1b6a6f" xlink:to="loc_icui_TermLoanBMember_4beda801-837b-4285-b3fe-9e42da5f2929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f2ef74a5-93b9-47db-84c6-90ae00a71f5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f2ef74a5-93b9-47db-84c6-90ae00a71f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1ae488db-21e9-42c0-9064-e62c8f459719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1ae488db-21e9-42c0-9064-e62c8f459719" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesDeferredincometaxassetsliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="extended" id="i656eed4ceb9b4a62a25373d192fc6e25_IncomeTaxesDeferredincometaxassetsliabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0f915b63-1aaf-4a70-b63d-33025eda704c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0f915b63-1aaf-4a70-b63d-33025eda704c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_b59e6086-5848-40c8-9bb7-29b9a0b02a40" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_b59e6086-5848-40c8-9bb7-29b9a0b02a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b23c7454-891a-4ea0-80eb-00b99351fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b23c7454-891a-4ea0-80eb-00b99351fc34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_76585e35-0536-4983-8b37-3116f0b3dd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_76585e35-0536-4983-8b37-3116f0b3dd2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState_e11a6645-b281-4401-8126-6bc338612412" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxAssetTaxCreditsState"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState_e11a6645-b281-4401-8126-6bc338612412" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_6cf2c0b8-28d5-4749-86e6-74b2e846eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_6cf2c0b8-28d5-4749-86e6-74b2e846eca0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_aae26c9e-ce06-45cc-8bf5-31b3ec076e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_aae26c9e-ce06-45cc-8bf5-31b3ec076e6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredTaxAssetSection163j_2dd1112d-2c08-4a3e-935c-332968d387f3" xlink:href="icui-20221231.xsd#icui_DeferredTaxAssetSection163j"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_DeferredTaxAssetSection163j_2dd1112d-2c08-4a3e-935c-332968d387f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_de0554f3-df47-4b76-b366-0027fc18cde2" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_de0554f3-df47-4b76-b366-0027fc18cde2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4caf7ae5-5c64-48c4-8dd7-22fe26ea40e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4caf7ae5-5c64-48c4-8dd7-22fe26ea40e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxasset_227e95b1-aeb8-4e94-b32a-934d092b7497" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxasset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxasset_227e95b1-aeb8-4e94-b32a-934d092b7497" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_fdf8a568-12fe-4cba-a38a-dd731db43ccc" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_fdf8a568-12fe-4cba-a38a-dd731db43ccc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_cbf41624-fe53-43f8-85cc-ab03c5e32fee" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_cbf41624-fe53-43f8-85cc-ab03c5e32fee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxliabilitychangeinaccountingmethod_f24c78c9-7d65-4418-8600-efa06894df82" xlink:href="icui-20221231.xsd#icui_Deferredtaxliabilitychangeinaccountingmethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Deferredtaxliabilitychangeinaccountingmethod_f24c78c9-7d65-4418-8600-efa06894df82" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_52ded2ed-17a6-4879-b9be-b39dda871dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_52ded2ed-17a6-4879-b9be-b39dda871dd7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_196c5844-d48b-4a70-a6d5-6e2831225ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxLiabilities_196c5844-d48b-4a70-a6d5-6e2831225ece" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a5d5d1cc-26e7-43be-8359-4cf86dbdf0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a5d5d1cc-26e7-43be-8359-4cf86dbdf0cc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7978928c-3b8e-42b0-909a-0645b8baf85a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7978928c-3b8e-42b0-909a-0645b8baf85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember_3b458254-1d8d-4c37-b3b7-93b5d386f61b" xlink:href="icui-20221231.xsd#icui_NonCurrentDeferredTaxAssetGrossTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:to="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember_3b458254-1d8d-4c37-b3b7-93b5d386f61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityMember_6ac60f44-4732-44a6-9921-724d16070aec" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityMember_6ac60f44-4732-44a6-9921-724d16070aec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" id="i4563432e0a2944b7aae0848ccd4f7183_IncomeTaxesOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_61de7128-55f0-4725-8693-5aab24ab6011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_61de7128-55f0-4725-8693-5aab24ab6011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f955522c-ec58-46d7-b3df-8cb4a2e06ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f955522c-ec58-46d7-b3df-8cb4a2e06ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d7ce1739-1fea-426a-ac46-985d6df8afb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_country_US_d7ce1739-1fea-426a-ac46-985d6df8afb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1da69cdc-235a-450e-8179-0fa0c5394787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1da69cdc-235a-450e-8179-0fa0c5394787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_15b66a8e-5c38-49a9-b777-8a8f76956187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_us-gaap_ForeignCountryMember_15b66a8e-5c38-49a9-b777-8a8f76956187" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesTaxHolidayDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails" xlink:type="extended" id="ibda98e9f1a2d491ea767012cc2115b48_IncomeTaxesTaxHolidayDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_d8a3d8b5-e378-4d82-a0a4-4c9d2f5fb6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_d8a3d8b5-e378-4d82-a0a4-4c9d2f5fb6c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_66b0ba98-acca-4499-bb44-29a019ed89f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_66b0ba98-acca-4499-bb44-29a019ed89f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5fa3518a-0a85-44cd-84c2-a712d7a19e19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5fa3518a-0a85-44cd-84c2-a712d7a19e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_17a12594-144a-4b4f-b48c-525c6703add6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_17a12594-144a-4b4f-b48c-525c6703add6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails" xlink:type="extended" id="i61b64a3ffa0047f3b0cc09f7589d9843_GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_de407591-8ec3-4d6e-87d9-54bc3bb22678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_de407591-8ec3-4d6e-87d9-54bc3bb22678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_494edc8b-8f81-4cff-b9cb-cb64a5724f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:to="loc_us-gaap_NoncurrentAssets_494edc8b-8f81-4cff-b9cb-cb64a5724f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a35d5b1f-6834-4585-8bba-448cfe6d76bb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:to="loc_srt_ProductsAndServicesDomain_a35d5b1f-6834-4585-8bba-448cfe6d76bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:to="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_1b4d7826-7e12-43c1-808c-9715b0cf308f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_1b4d7826-7e12-43c1-808c-9715b0cf308f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7116cb6f-6b42-4376-bf55-007b3ad3aee2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7116cb6f-6b42-4376-bf55-007b3ad3aee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d15a3156-b6fe-4ac5-8e63-6bb32b2c9633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:to="loc_us-gaap_SalesRevenueNetMember_d15a3156-b6fe-4ac5-8e63-6bb32b2c9633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e866aa8e-b5dc-4164-a846-dc12a116aeaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e866aa8e-b5dc-4164-a846-dc12a116aeaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f27e8189-e3fa-44c4-8c5a-bf168b9192e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f27e8189-e3fa-44c4-8c5a-bf168b9192e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79a3e39d-457f-4c0d-b3a7-e97537b3480a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:to="loc_srt_SegmentGeographicalDomain_79a3e39d-457f-4c0d-b3a7-e97537b3480a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:to="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR_949f2efc-4f37-40f0-bd2e-d47710106a2e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_CR_949f2efc-4f37-40f0-bd2e-d47710106a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MexicoPropertyAndEquipmentMember_aa82a4ab-d844-44d4-9231-4020a9af062c" xlink:href="icui-20221231.xsd#icui_MexicoPropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_MexicoPropertyAndEquipmentMember_aa82a4ab-d844-44d4-9231-4020a9af062c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLATAMMember_68c2643e-9116-40a5-846f-c9c1bf70c0c9" xlink:href="icui-20221231.xsd#icui_OtherLATAMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_OtherLATAMMember_68c2643e-9116-40a5-846f-c9c1bf70c0c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_d99d8724-85d1-4b18-98d3-ed148ed02b15" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_CA_d99d8724-85d1-4b18-98d3-ed148ed02b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ItalyPropertyAndEquipmentMember_de48e2a2-b44e-4650-8483-f412f8b57366" xlink:href="icui-20221231.xsd#icui_ItalyPropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_ItalyPropertyAndEquipmentMember_de48e2a2-b44e-4650-8483-f412f8b57366" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_485f16f5-3f5f-4460-ab13-5cef7292575b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_ES_485f16f5-3f5f-4460-ab13-5cef7292575b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CZK_c8332bea-64fa-4a43-a65c-201dbc7b0bda" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CZK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_currency_CZK_c8332bea-64fa-4a43-a65c-201dbc7b0bda" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_52ec1659-4310-4d07-8a44-201141c4d8da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_srt_EuropeMember_52ec1659-4310-4d07-8a44-201141c4d8da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_896d2e36-af64-4198-a73f-e6f3a2111796" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_srt_AsiaPacificMember_896d2e36-af64-4198-a73f-e6f3a2111796" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignMember_94459c61-34b7-497d-9237-9c8fee4700b3" xlink:href="icui-20221231.xsd#icui_ForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_ForeignMember_94459c61-34b7-497d-9237-9c8fee4700b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UnitedStatespropertyandequipmentMember_b54024bf-9fd7-4003-bafd-aae3b5327a23" xlink:href="icui-20221231.xsd#icui_UnitedStatespropertyandequipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_UnitedStatespropertyandequipmentMember_b54024bf-9fd7-4003-bafd-aae3b5327a23" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/StockholdersEquityDetails" xlink:type="extended" id="icc00ad0b93f041359f154496244ab9e5_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0e774e76-e804-448e-96c0-b88ad37e1f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0e774e76-e804-448e-96c0-b88ad37e1f2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9884b948-941c-4b37-8be4-7db43cee7b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9884b948-941c-4b37-8be4-7db43cee7b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_856803a4-6de1-4243-a12a-cde9a9277b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_856803a4-6de1-4243-a12a-cde9a9277b99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4df14596-f465-49a6-9b63-8b59bcb9bb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4df14596-f465-49a6-9b63-8b59bcb9bb54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c03456cb-6abb-4c10-b69b-e521b327c6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_c03456cb-6abb-4c10-b69b-e521b327c6f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b25e1f4e-b257-4ecc-af94-d63834c1231a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:to="loc_us-gaap_EquityComponentDomain_b25e1f4e-b257-4ecc-af94-d63834c1231a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca213efe-6c23-4257-bd12-9c1bafb81677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:to="loc_us-gaap_EquityComponentDomain_ca213efe-6c23-4257-bd12-9c1bafb81677" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i85a3ac5dba374f7996d8ab49971702ab_StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1da188a-2ff2-4ad8-ab17-fd14c589b765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1da188a-2ff2-4ad8-ab17-fd14c589b765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4bf56ca-23ca-431e-9189-5a79fb656b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4bf56ca-23ca-431e-9189-5a79fb656b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_58408955-c088-4cf4-a94e-20312f21ee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_58408955-c088-4cf4-a94e-20312f21ee0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_636304c2-b557-46fa-9b8e-b5100c961e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_636304c2-b557-46fa-9b8e-b5100c961e01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_911095f3-9990-48ef-9ff8-b7cb507094a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:to="loc_us-gaap_EquityComponentDomain_911095f3-9990-48ef-9ff8-b7cb507094a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:to="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a6bd548c-5468-4149-ad11-2d0bed9fb9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a6bd548c-5468-4149-ad11-2d0bed9fb9e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_d4cea040-eb72-4331-b8ac-6ac7c9cd5073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_d4cea040-eb72-4331-b8ac-6ac7c9cd5073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5e820d4a-1c9d-4757-bcc5-5c1aed92d859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5e820d4a-1c9d-4757-bcc5-5c1aed92d859" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#CommitmentsandContingenciesContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails" xlink:type="extended" id="ic4da39cdf4c4471bbf253b3381279e85_CommitmentsandContingenciesContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_cfcaf099-609d-42cd-8e2f-37f79093ac7b" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_Contingentconsiderationgross_cfcaf099-609d-42cd-8e2f-37f79093ac7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63da0d77-6c32-4b3f-90b5-1512684dce98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63da0d77-6c32-4b3f-90b5-1512684dce98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_7f42dbd5-ac44-4eda-8bf8-bd2814ffc9f0" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_ShortTermContingentConsiderationGross_7f42dbd5-ac44-4eda-8bf8-bd2814ffc9f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_56b0449c-be4b-4ca9-9e5c-19775ae655ab" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_LongTermContingentConsiderationGross_56b0449c-be4b-4ca9-9e5c-19775ae655ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContingentConsiderationGrossLT_7d332496-2955-4485-aa06-85478190ab6e" xlink:href="icui-20221231.xsd#icui_ContingentConsiderationGrossLT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_ContingentConsiderationGrossLT_7d332496-2955-4485-aa06-85478190ab6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ade45356-b7ad-4cc7-8f2e-b3db34043a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ade45356-b7ad-4cc7-8f2e-b3db34043a48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualComponentAmount_a7b988d4-777d-4bbc-a434-d9eaf5f9c457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualComponentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_ProductLiabilityAccrualComponentAmount_a7b988d4-777d-4bbc-a434-d9eaf5f9c457" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc55f5c7-90e8-4dba-95b3-2ee8b1377249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dc55f5c7-90e8-4dba-95b3-2ee8b1377249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_cefd6b91-866f-43e4-a7b9-fa846d74e921" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_PursuitVascularInc.Member_cefd6b91-866f-43e4-a7b9-fa846d74e921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_0d0ad0ad-1d8d-4995-b4bd-edb668c7e427" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_PursuitVascularLLCMember_0d0ad0ad-1d8d-4995-b4bd-edb668c7e427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignDistibutorMember_a2aa02a5-a05b-4036-b66f-470fdab09c51" xlink:href="icui-20221231.xsd#icui_ForeignDistibutorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_ForeignDistibutorMember_a2aa02a5-a05b-4036-b66f-470fdab09c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_518da2d9-9807-409c-ad2a-20ce3f128200" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_518da2d9-9807-409c-ad2a-20ce3f128200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_f7d828a9-887e-43ec-bac8-9d66dcc3a262" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_SmithsMedicalMember_f7d828a9-887e-43ec-bac8-9d66dcc3a262" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/SubsequentEventsDetails" xlink:type="extended" id="i46e61a58296248fc89302ecb842b311a_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccountsReceivablePurchaseProgram_37887465-804e-4edc-b3d6-e17884773ac0" xlink:href="icui-20221231.xsd#icui_AccountsReceivablePurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:to="loc_icui_AccountsReceivablePurchaseProgram_37887465-804e-4edc-b3d6-e17884773ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:to="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_610ccdff-1bfd-4579-b676-29e11aa29719_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_610ccdff-1bfd-4579-b676-29e11aa29719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b0fc7a00-d77e-4700-b0cf-63485e03456f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b0fc7a00-d77e-4700-b0cf-63485e03456f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#SECScheduleArticle1209ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails" xlink:type="extended" id="ibba94d7ff93543d6aa6689cdbd026cb4_SECScheduleArticle1209ValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_856e82d6-a3f0-4fa5-a3ad-b8520dedbfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_856e82d6-a3f0-4fa5-a3ad-b8520dedbfec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d0c8485e-cbc7-407e-ad1a-c23f60d93866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d0c8485e-cbc7-407e-ad1a-c23f60d93866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b6d5486-8762-4aeb-9853-f1a7fbdebe22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b6d5486-8762-4aeb-9853-f1a7fbdebe22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c6502a5e-c46a-4395-a046-8b0ef5ad1728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c6502a5e-c46a-4395-a046-8b0ef5ad1728" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_13a15728-758e-49db-88d0-fbdab60cafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs_b89623fc-0e1b-49e2-b0ca-a59c9202a166" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs_b89623fc-0e1b-49e2-b0ca-a59c9202a166" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_d5962085-c131-4aee-be3d-91903f89b874" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_d5962085-c131-4aee-be3d-91903f89b874" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveCosts_f5327acb-0668-4506-88e6-580499f50362" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveCosts_f5327acb-0668-4506-88e6-580499f50362" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventory_c12b6c9c-61bb-47ed-b7e6-e73fecce108b" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventory_c12b6c9c-61bb-47ed-b7e6-e73fecce108b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_bdc1b931-14a3-41e5-96d6-6dfb071defd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_bdc1b931-14a3-41e5-96d6-6dfb071defd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantyReservesMember_669722bd-8c87-4528-a1a8-6a3f40f5ed7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantyReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_WarrantyReservesMember_669722bd-8c87-4528-a1a8-6a3f40f5ed7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_35c78eae-e37c-4b31-833d-887021d73ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_35c78eae-e37c-4b31-833d-887021d73ce6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>icui-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3e1cdcb0-fdc1-4c54-991c-723218677a46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_FurniturefixturesandmoldsMember_a03ff9a6-99ef-459e-921d-ebcdf4649070_terseLabel_en-US" xlink:label="lab_icui_FurniturefixturesandmoldsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and molds [Member]</link:label>
    <link:label id="lab_icui_FurniturefixturesandmoldsMember_label_en-US" xlink:label="lab_icui_FurniturefixturesandmoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and molds [Member]</link:label>
    <link:label id="lab_icui_FurniturefixturesandmoldsMember_documentation_en-US" xlink:label="lab_icui_FurniturefixturesandmoldsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and molds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_FurniturefixturesandmoldsMember" xlink:href="icui-20221231.xsd#icui_FurniturefixturesandmoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_FurniturefixturesandmoldsMember" xlink:to="lab_icui_FurniturefixturesandmoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_eef940e6-e773-4123-8949-c2853a931283_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Accruedfreight_40f741c2-8ea7-47b7-8652-870786848404_terseLabel_en-US" xlink:label="lab_icui_Accruedfreight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued freight</link:label>
    <link:label id="lab_icui_Accruedfreight_label_en-US" xlink:label="lab_icui_Accruedfreight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued freight</link:label>
    <link:label id="lab_icui_Accruedfreight_documentation_en-US" xlink:label="lab_icui_Accruedfreight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued freight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedfreight" xlink:href="icui-20221231.xsd#icui_Accruedfreight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Accruedfreight" xlink:to="lab_icui_Accruedfreight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_323f877a-cccf-461b-95be-0129f21562d7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_ee50eec3-ae9c-4251-82b1-23d031670009_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_58e33bcb-3760-4026-9866-689160f6ad6d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_8d58a8de-76c7-4e45-b3de-14218b544125_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermLoanBPrincipalPayment_2674cb71-faeb-48eb-8aeb-255669b6be75_terseLabel_en-US" xlink:label="lab_icui_TermLoanBPrincipalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Principal Payment %</link:label>
    <link:label id="lab_icui_TermLoanBPrincipalPayment_label_en-US" xlink:label="lab_icui_TermLoanBPrincipalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Principal Payment %</link:label>
    <link:label id="lab_icui_TermLoanBPrincipalPayment_documentation_en-US" xlink:label="lab_icui_TermLoanBPrincipalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Principal Payment %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBPrincipalPayment" xlink:href="icui-20221231.xsd#icui_TermLoanBPrincipalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermLoanBPrincipalPayment" xlink:to="lab_icui_TermLoanBPrincipalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_1eb0aed1-4f8f-4d05-bbab-bd09eb98f999_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsTable_2c4b10d6-0fb1-4618-b61a-ee07899e8445_terseLabel_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Table]</link:label>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsTable_label_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Table]</link:label>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsTable_documentation_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsTable" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidNoncurrentAssetsTable" xlink:to="lab_icui_PrepaidNoncurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InternationalDistributorMember_ebfd97e6-1f6e-4b38-bc04-50396737cb70_terseLabel_en-US" xlink:label="lab_icui_InternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Distributor</link:label>
    <link:label id="lab_icui_InternationalDistributorMember_label_en-US" xlink:label="lab_icui_InternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Distributor [Member]</link:label>
    <link:label id="lab_icui_InternationalDistributorMember_documentation_en-US" xlink:label="lab_icui_InternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalDistributorMember" xlink:href="icui-20221231.xsd#icui_InternationalDistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InternationalDistributorMember" xlink:to="lab_icui_InternationalDistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_a1c67350-fea7-473a-a11f-a6ef3316070a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_7f633da4-f64e-4749-875b-783b2781b2a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_98d83b96-de84-4d42-94dc-2f10fed6eca3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_69a398cf-8c5b-4538-99d6-78adcc73d342_negatedTerseLabel_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_label_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_documentation_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:to="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_26b21f47-e69c-41b6-8f33-407f133e582f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_9441fa3e-d10d-45a9-ba4a-44091f0ec569_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_cde66b8e-f549-454b-b204-62a443219f5d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_a9274216-30de-4d66-9624-086853a4bc2f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherCurrenciesMember_594d4f38-767c-495b-b2a2-26e0eca5de49_terseLabel_en-US" xlink:label="lab_icui_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other currencies</link:label>
    <link:label id="lab_icui_OtherCurrenciesMember_label_en-US" xlink:label="lab_icui_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other currencies [Member]</link:label>
    <link:label id="lab_icui_OtherCurrenciesMember_documentation_en-US" xlink:label="lab_icui_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other currencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherCurrenciesMember" xlink:href="icui-20221231.xsd#icui_OtherCurrenciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherCurrenciesMember" xlink:to="lab_icui_OtherCurrenciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AccruedAuditFees_6645611c-8d89-43bf-853f-bd0e420951af_terseLabel_en-US" xlink:label="lab_icui_AccruedAuditFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued audit fees</link:label>
    <link:label id="lab_icui_AccruedAuditFees_label_en-US" xlink:label="lab_icui_AccruedAuditFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued audit fees</link:label>
    <link:label id="lab_icui_AccruedAuditFees_documentation_en-US" xlink:label="lab_icui_AccruedAuditFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued audit fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedAuditFees" xlink:href="icui-20221231.xsd#icui_AccruedAuditFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AccruedAuditFees" xlink:to="lab_icui_AccruedAuditFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7afd064d-59c0-4acd-abd1-a42e0b7f7220_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e2ed9ae4-7c48-4b54-aa18-17b95ed52214_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6122dc78-f0cc-4c73-9f40-8e9e6c036391_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_3092df49-d9e7-4abe-9cf3-14f7503f5fc8_terseLabel_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationTransaction cost</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_label_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationTransaction cost</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_documentation_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationTransaction cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:to="lab_icui_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_e1232ab2-81ec-4395-87a2-d432af4d9408_negatedTerseLabel_en-US" xlink:label="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable</link:label>
    <link:label id="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_label_en-US" xlink:label="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable</link:label>
    <link:label id="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_documentation_en-US" xlink:label="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:href="icui-20221231.xsd#icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:to="lab_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_24cbd9c7-8208-4849-8509-a0644c5c5470_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock and exercise of stock options, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_03c68e77-882c-4245-b8d7-62fb717ee013_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_83a5064b-113f-44ba-a5fc-c39473fe6d3e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0be64e15-35e3-43d8-ae02-4ea256a74c30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_0c743e1b-a1f8-448e-b41b-ce40fc0c9c3d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Timebasedoptionsgrantdatefairvalue_57ef26d1-77b8-4075-81b4-1f841f5520b9_terseLabel_en-US" xlink:label="lab_icui_Timebasedoptionsgrantdatefairvalue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time based options grant date fair value</link:label>
    <link:label id="lab_icui_Timebasedoptionsgrantdatefairvalue_label_en-US" xlink:label="lab_icui_Timebasedoptionsgrantdatefairvalue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time based options grant date fair value</link:label>
    <link:label id="lab_icui_Timebasedoptionsgrantdatefairvalue_documentation_en-US" xlink:label="lab_icui_Timebasedoptionsgrantdatefairvalue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time based options grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Timebasedoptionsgrantdatefairvalue" xlink:href="icui-20221231.xsd#icui_Timebasedoptionsgrantdatefairvalue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Timebasedoptionsgrantdatefairvalue" xlink:to="lab_icui_Timebasedoptionsgrantdatefairvalue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SoftwarerevenueMember_7d6ff1d9-9ef0-44cb-8412-341d5d7c9e41_terseLabel_en-US" xlink:label="lab_icui_SoftwarerevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software revenue [Member]</link:label>
    <link:label id="lab_icui_SoftwarerevenueMember_label_en-US" xlink:label="lab_icui_SoftwarerevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software revenue [Member]</link:label>
    <link:label id="lab_icui_SoftwarerevenueMember_documentation_en-US" xlink:label="lab_icui_SoftwarerevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SoftwarerevenueMember" xlink:to="lab_icui_SoftwarerevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ExercisedOptionsDataTableTextBlock_200c26c0-9ec7-41ec-8949-eb48e00a8180_terseLabel_en-US" xlink:label="lab_icui_ExercisedOptionsDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Options Data [Table Text Block]</link:label>
    <link:label id="lab_icui_ExercisedOptionsDataTableTextBlock_label_en-US" xlink:label="lab_icui_ExercisedOptionsDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Options Data [Table Text Block]</link:label>
    <link:label id="lab_icui_ExercisedOptionsDataTableTextBlock_documentation_en-US" xlink:label="lab_icui_ExercisedOptionsDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised Options Data [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ExercisedOptionsDataTableTextBlock" xlink:href="icui-20221231.xsd#icui_ExercisedOptionsDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ExercisedOptionsDataTableTextBlock" xlink:to="lab_icui_ExercisedOptionsDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c328206f-c2a7-4743-a65e-27b533d793e2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6fd6d2ad-790e-40f1-8461-b08819443405_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_91d2413b-adae-48eb-b1de-cd1e6b4221ee_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_6a220935-97b3-4a8b-90bd-71ac812b6b4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cd887f94-db17-40a6-a537-62505592cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ecb51936-3214-4ce0-940e-9ed036fc42fe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_efca376e-9eb9-4c02-934b-e21e17db4f3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_0643ac5e-d776-4778-b222-be3371cceb62_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_401f2298-fd14-495f-97f8-f67775c2503d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5d8dc011-2602-42e4-a63f-54a10050d151_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_95adf91e-27a7-4b1b-bc70-ef4a3a7fb4da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a915b66a-afc9-4120-9575-7b16f9720b75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bde4c082-d6df-4f7e-81bd-0e0aa4fb5a05_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ead207b1-23ad-4437-80e1-402c7e0c16cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9e2b5cbb-4f8a-40bc-a8df-61951b5f100d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f8f90f11-c01f-4377-9b7f-ffb711aaa4e1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_cda1b32c-fcb9-4fdf-a2a1-02e2c770a4f1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a8d85dda-ee1c-4019-9a04-a8e4c29c2598_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_88a77b89-7ad2-4725-b2d9-1b5fe90f8d4a_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_b16eae9e-ce77-4623-8046-b356dfe5f862_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3e527608-3515-49a2-b7c6-c2eecebc93bd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_72e8e215-22c2-408c-a899-10bebd7cf6d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestRatesTable_da14c6f2-5a7a-4f48-aeda-a82e24f302ac_terseLabel_en-US" xlink:label="lab_icui_InterestRatesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Table]</link:label>
    <link:label id="lab_icui_InterestRatesTable_label_en-US" xlink:label="lab_icui_InterestRatesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Table]</link:label>
    <link:label id="lab_icui_InterestRatesTable_documentation_en-US" xlink:label="lab_icui_InterestRatesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesTable" xlink:href="icui-20221231.xsd#icui_InterestRatesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestRatesTable" xlink:to="lab_icui_InterestRatesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5725251b-6d24-4e48-b03d-0458636e2836_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidAssetsCurrentTable_736db5ac-91a4-44a5-834b-96126632028f_terseLabel_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Table]</link:label>
    <link:label id="lab_icui_PrepaidAssetsCurrentTable_label_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Table]</link:label>
    <link:label id="lab_icui_PrepaidAssetsCurrentTable_documentation_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentTable" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidAssetsCurrentTable" xlink:to="lab_icui_PrepaidAssetsCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_cae8e1ab-11d2-4db9-aacd-1d924f51b2e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_712b7d6b-8d0d-4c98-add2-98640c959d8f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_17c85189-115a-488b-bfaf-84102178dd06_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1186cd94-e3d3-4881-ba8a-f1a70bda6193_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_5700a0ea-c2b3-4d23-b557-2c6d68ed0a5b_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0eea8eda-a800-4059-8ddf-db3ff29a4423_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestPercentageAddedToBaseRate_dec387ae-460c-486b-9320-13dd62bf4687_terseLabel_en-US" xlink:label="lab_icui_InterestPercentageAddedToBaseRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Base Rate</link:label>
    <link:label id="lab_icui_InterestPercentageAddedToBaseRate_label_en-US" xlink:label="lab_icui_InterestPercentageAddedToBaseRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Base Rate</link:label>
    <link:label id="lab_icui_InterestPercentageAddedToBaseRate_documentation_en-US" xlink:label="lab_icui_InterestPercentageAddedToBaseRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestPercentageAddedToBaseRate" xlink:href="icui-20221231.xsd#icui_InterestPercentageAddedToBaseRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestPercentageAddedToBaseRate" xlink:to="lab_icui_InterestPercentageAddedToBaseRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b5fb99ec-3680-4f4d-80f0-6b516e1509ef_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestExpenseIncomeNetLineItems_60bfdaf8-44c0-4afb-9473-37181e0c3273_terseLabel_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Line Items]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetLineItems_label_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Line Items]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetLineItems_documentation_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetLineItems" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems" xlink:to="lab_icui_InterestExpenseIncomeNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_9491ed60-0c3f-4ba0-be8d-fb7b240b6639_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_740fec2d-adc7-4d65-bc2f-eba79b7b42b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeMember_e1463c5d-dae9-4ae0-b1c5-afe891ad2a86_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeMember" xlink:to="lab_us-gaap_ForeignExchangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_268363c9-8a31-42e1-b717-d3fb4eed9b9d_terseLabel_en-US" xlink:label="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal 3.00 to 1.00 but greater than 2.50to1.00</link:label>
    <link:label id="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_label_en-US" xlink:label="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal 3.00 to 1.00 but greater than 2.50to1.00 [Member]</link:label>
    <link:label id="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_documentation_en-US" xlink:label="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal 3.00 to 1.00 but greater than 2.50to1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:href="icui-20221231.xsd#icui_LessThanOrEqual300To100ButGreaterThan250to100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:to="lab_icui_LessThanOrEqual300To100ButGreaterThan250to100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Percentageofrevenue_9363b249-9af6-44c4-8644-4b1c5b977413_terseLabel_en-US" xlink:label="lab_icui_Percentageofrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue</link:label>
    <link:label id="lab_icui_Percentageofrevenue_label_en-US" xlink:label="lab_icui_Percentageofrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue</link:label>
    <link:label id="lab_icui_Percentageofrevenue_documentation_en-US" xlink:label="lab_icui_Percentageofrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentageofrevenue" xlink:href="icui-20221231.xsd#icui_Percentageofrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Percentageofrevenue" xlink:to="lab_icui_Percentageofrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2cf95a3d-b7be-444a-a5ad-38b5a297cbb6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e3b86f80-f97f-4642-b294-898a8bf276d7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_106985dd-0d7f-4108-abd8-0ca002eadb4c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_dfe5fc1a-2f87-439d-8d6e-e8fb02b31194_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rent</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ebdf5df0-d4f3-4320-9579-ce196cf2b165_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_3ed758d3-9b61-440b-90d6-427b55606bc5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EarnoutliabilityMember_0796263a-2df4-481e-bd77-e73c4b24ade6_terseLabel_en-US" xlink:label="lab_icui_EarnoutliabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out liability [Member]</link:label>
    <link:label id="lab_icui_EarnoutliabilityMember_label_en-US" xlink:label="lab_icui_EarnoutliabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out liability [Member]</link:label>
    <link:label id="lab_icui_EarnoutliabilityMember_documentation_en-US" xlink:label="lab_icui_EarnoutliabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EarnoutliabilityMember" xlink:href="icui-20221231.xsd#icui_EarnoutliabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EarnoutliabilityMember" xlink:to="lab_icui_EarnoutliabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6ce86e85-e10a-4391-970c-34ece9b2ae49_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_793136e9-4cbd-4845-95d7-9cb118e2c12d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_69091044-987a-4313-8f56-46bee60b6a56_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ShortTermContingentConsiderationGross_f1bd63c8-2b09-40f7-b5f1-4a4a8a3d096c_terseLabel_en-US" xlink:label="lab_icui_ShortTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration-gross</link:label>
    <link:label id="lab_icui_ShortTermContingentConsiderationGross_label_en-US" xlink:label="lab_icui_ShortTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration-gross</link:label>
    <link:label id="lab_icui_ShortTermContingentConsiderationGross_documentation_en-US" xlink:label="lab_icui_ShortTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration-gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ShortTermContingentConsiderationGross" xlink:to="lab_icui_ShortTermContingentConsiderationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_95dc8ba8-7136-40a1-a52d-7c8860ffe086_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a1ad86f1-c7b3-47e0-a8ae-c87246655706_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_UsGaap_InterestRateSwap2Member_d9d945a2-14be-4feb-8c27-ce7d52a01319_terseLabel_en-US" xlink:label="lab_icui_UsGaap_InterestRateSwap2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">us-gaap_InterestRateSwap 2</link:label>
    <link:label id="lab_icui_UsGaap_InterestRateSwap2Member_label_en-US" xlink:label="lab_icui_UsGaap_InterestRateSwap2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">us-gaap_InterestRateSwap 2 [Member]</link:label>
    <link:label id="lab_icui_UsGaap_InterestRateSwap2Member_documentation_en-US" xlink:label="lab_icui_UsGaap_InterestRateSwap2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">us-gaap_InterestRateSwap 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UsGaap_InterestRateSwap2Member" xlink:href="icui-20221231.xsd#icui_UsGaap_InterestRateSwap2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_UsGaap_InterestRateSwap2Member" xlink:to="lab_icui_UsGaap_InterestRateSwap2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SmithsMedical2020LimitedMember_66a20853-5391-4dea-9a4f-a54aaabb8945_terseLabel_en-US" xlink:label="lab_icui_SmithsMedical2020LimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical 2020 Limited</link:label>
    <link:label id="lab_icui_SmithsMedical2020LimitedMember_label_en-US" xlink:label="lab_icui_SmithsMedical2020LimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical 2020 Limited [Member]</link:label>
    <link:label id="lab_icui_SmithsMedical2020LimitedMember_documentation_en-US" xlink:label="lab_icui_SmithsMedical2020LimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical 2020 Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SmithsMedical2020LimitedMember" xlink:to="lab_icui_SmithsMedical2020LimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4d108857-2f3b-4da4-be81-f1c87782e99a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8deee60d-226d-4138-98d5-cc7582808d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_e3f65aae-e728-4b70-9891-59e822cfe2ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94100cd8-9d67-40cd-8ddb-f3a4825752de_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_38c15b93-b9c7-4153-8b88-60f575da3417_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_06932d78-8878-4813-b4ad-b8ba48171853_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a6385eb-f17d-43d2-b102-5986a3604f27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_2389c063-dee0-47c0-8747-8f4b8c71fcd4_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_108720e6-b73d-446b-946f-1973474100c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_CollaborativeandOtherArrangementsAbstract_86551c70-e67d-4795-97c0-609e8329af16_terseLabel_en-US" xlink:label="lab_icui_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_icui_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_icui_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_icui_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_icui_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CollaborativeandOtherArrangementsAbstract" xlink:href="icui-20221231.xsd#icui_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_icui_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_28694809-38d1-4f05-a3c2-9eda211971c7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Restructuringandstrategictransactionexpense_49eefadf-af40-468e-bcfb-787ab193735b_terseLabel_en-US" xlink:label="lab_icui_Restructuringandstrategictransactionexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, strategic transaction and integration expenses</link:label>
    <link:label id="lab_icui_Restructuringandstrategictransactionexpense_label_en-US" xlink:label="lab_icui_Restructuringandstrategictransactionexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and strategic transaction expense</link:label>
    <link:label id="lab_icui_Restructuringandstrategictransactionexpense_documentation_en-US" xlink:label="lab_icui_Restructuringandstrategictransactionexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and strategic transaction expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Restructuringandstrategictransactionexpense" xlink:href="icui-20221231.xsd#icui_Restructuringandstrategictransactionexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Restructuringandstrategictransactionexpense" xlink:to="lab_icui_Restructuringandstrategictransactionexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_MexicoPropertyAndEquipmentMember_9165facd-24f8-450f-b78d-7f6bcf664bcc_terseLabel_en-US" xlink:label="lab_icui_MexicoPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico Property and Equipment [Member]</link:label>
    <link:label id="lab_icui_MexicoPropertyAndEquipmentMember_label_en-US" xlink:label="lab_icui_MexicoPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico Property and Equipment [Member]</link:label>
    <link:label id="lab_icui_MexicoPropertyAndEquipmentMember_documentation_en-US" xlink:label="lab_icui_MexicoPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign property and equipment: Mexico</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MexicoPropertyAndEquipmentMember" xlink:href="icui-20221231.xsd#icui_MexicoPropertyAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_MexicoPropertyAndEquipmentMember" xlink:to="lab_icui_MexicoPropertyAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_b25f507b-5f22-4026-b2d5-7035650c5df3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee1bcbe3-7a4d-432f-9c96-611edc0006c1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeForwardExchangeRate1_06754e2b-77e8-4b77-bc3c-2ae4e1ccd953_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeForwardExchangeRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:label id="lab_us-gaap_DerivativeForwardExchangeRate1_label_en-US" xlink:label="lab_us-gaap_DerivativeForwardExchangeRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeForwardExchangeRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeForwardExchangeRate1" xlink:to="lab_us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermLoanBMember_8857bfbb-20a4-4ce5-96d6-08dd0bc7b322_terseLabel_en-US" xlink:label="lab_icui_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_icui_TermLoanBMember_label_en-US" xlink:label="lab_icui_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B [Member]</link:label>
    <link:label id="lab_icui_TermLoanBMember_documentation_en-US" xlink:label="lab_icui_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermLoanBMember" xlink:to="lab_icui_TermLoanBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2b5ccef-3cc9-40f6-8c7a-b0cde0ee8910_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent_1ce0c5eb-c695-46f6-9f20-a01c7c231637_terseLabel_en-US" xlink:label="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveTaxRateReconcilationTransaction cost,Percent</link:label>
    <link:label id="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent_label_en-US" xlink:label="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveTaxRateReconcilationTransaction cost,Percent</link:label>
    <link:label id="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent_documentation_en-US" xlink:label="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveTaxRateReconcilationTransaction cost,Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:href="icui-20221231.xsd#icui_EffectiveTaxRateReconcilationTransactionCostPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:to="lab_icui_EffectiveTaxRateReconcilationTransactionCostPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_77cf2b1f-1ca8-4bed-9f9f-767453509eb8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_dba99bca-a803-4592-b7d0-efb4b38fa1cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ESPPOriginalIssuance_84e367a4-3e19-4c0a-aab7-1b2ed2fe9f40_terseLabel_en-US" xlink:label="lab_icui_ESPPOriginalIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Original Issuance</link:label>
    <link:label id="lab_icui_ESPPOriginalIssuance_label_en-US" xlink:label="lab_icui_ESPPOriginalIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Original Issuance</link:label>
    <link:label id="lab_icui_ESPPOriginalIssuance_documentation_en-US" xlink:label="lab_icui_ESPPOriginalIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Original Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ESPPOriginalIssuance" xlink:href="icui-20221231.xsd#icui_ESPPOriginalIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ESPPOriginalIssuance" xlink:to="lab_icui_ESPPOriginalIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_76475515-3c8c-4c29-855f-1b2ed6dd2703_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8bbb8e79-f234-4df7-901a-2e2720be9535_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_A2003PlanMember_fb650c00-415e-4d7c-ad5e-59e392f8e1d3_terseLabel_en-US" xlink:label="lab_icui_A2003PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Plan [Member]</link:label>
    <link:label id="lab_icui_A2003PlanMember_label_en-US" xlink:label="lab_icui_A2003PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Plan [Member]</link:label>
    <link:label id="lab_icui_A2003PlanMember_documentation_en-US" xlink:label="lab_icui_A2003PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2003PlanMember" xlink:href="icui-20221231.xsd#icui_A2003PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_A2003PlanMember" xlink:to="lab_icui_A2003PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherDeferredRevenueMember_2daf8458-9184-4780-8efa-f463deb380d6_terseLabel_en-US" xlink:label="lab_icui_OtherDeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred revenue</link:label>
    <link:label id="lab_icui_OtherDeferredRevenueMember_label_en-US" xlink:label="lab_icui_OtherDeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred revenue [Member]</link:label>
    <link:label id="lab_icui_OtherDeferredRevenueMember_documentation_en-US" xlink:label="lab_icui_OtherDeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherDeferredRevenueMember" xlink:href="icui-20221231.xsd#icui_OtherDeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherDeferredRevenueMember" xlink:to="lab_icui_OtherDeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_dd832af5-1904-43b6-8ffb-e33b0979f000_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0ada1d1f-04c1-4aab-8ca6-638eb56ac818_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ca56a7af-15ea-4bec-bd63-d1576a161208_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_38597e7f-7903-4332-80ee-08345c9079df_terseLabel_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - depreciation and amortization</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_label_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - depreciation and amortization</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_documentation_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:to="lab_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0651ef65-4f38-42f2-92a8-6f86df7d6b87_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_75574aba-3c0e-4a20-bbf4-e62a403eece1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_646b6e29-a3c7-4939-8f8f-ba4ef1cf1cbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_17de521d-9e85-43bf-aad1-287ab973289e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_75bb1812-ed00-4f98-b8c6-fc7c5ce52077_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_70812114-29ed-472f-99da-6324fc797178_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_e3f92d1c-8c37-4122-ad2d-d4bd22a38a63_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_StrategicTransactionandIntegration_d78f9ed9-68c0-4a67-b39e-0e4db5b3f141_terseLabel_en-US" xlink:label="lab_icui_StrategicTransactionandIntegration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Transaction and Integration</link:label>
    <link:label id="lab_icui_StrategicTransactionandIntegration_label_en-US" xlink:label="lab_icui_StrategicTransactionandIntegration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Transaction and Integration</link:label>
    <link:label id="lab_icui_StrategicTransactionandIntegration_documentation_en-US" xlink:label="lab_icui_StrategicTransactionandIntegration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Transaction and Integration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StrategicTransactionandIntegration" xlink:href="icui-20221231.xsd#icui_StrategicTransactionandIntegration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_StrategicTransactionandIntegration" xlink:to="lab_icui_StrategicTransactionandIntegration" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherLATAMMember_32071f63-96c9-4d4c-a3f6-fad315e36ec7_terseLabel_en-US" xlink:label="lab_icui_OtherLATAMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other LATAM [Member]</link:label>
    <link:label id="lab_icui_OtherLATAMMember_label_en-US" xlink:label="lab_icui_OtherLATAMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other LATAM [Member]</link:label>
    <link:label id="lab_icui_OtherLATAMMember_documentation_en-US" xlink:label="lab_icui_OtherLATAMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other LATAM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLATAMMember" xlink:href="icui-20221231.xsd#icui_OtherLATAMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherLATAMMember" xlink:to="lab_icui_OtherLATAMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_40061c89-a2f2-496c-889d-f6265e3d436b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d206c567-8d35-49e1-80ae-96f9f12821f5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d1ee58c3-5577-4767-87b6-81272ffca83e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_ca471080-4d6b-42f0-ae94-5615e9f2dd7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_6151380a-c001-4c33-9e48-c6feb1e0f10a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6f2d7e21-0634-4d50-8f7a-a277619f0ab1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NonpublicCompanyMember_a767b713-3f6b-4152-ba00-f61cf5a1e235_terseLabel_en-US" xlink:label="lab_icui_NonpublicCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nonpublic company</link:label>
    <link:label id="lab_icui_NonpublicCompanyMember_label_en-US" xlink:label="lab_icui_NonpublicCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nonpublic company [Member]</link:label>
    <link:label id="lab_icui_NonpublicCompanyMember_documentation_en-US" xlink:label="lab_icui_NonpublicCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nonpublic company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonpublicCompanyMember" xlink:href="icui-20221231.xsd#icui_NonpublicCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NonpublicCompanyMember" xlink:to="lab_icui_NonpublicCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6de356e4-310c-4d8e-b592-3f88c681b18d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock_d574cc7c-30ff-49e4-b043-f9fc5f06de28_terseLabel_en-US" xlink:label="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids, other current assets and other noncurrent assets [Text Block]</link:label>
    <link:label id="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock_label_en-US" xlink:label="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids, other current assets and other noncurrent assets [Text Block]</link:label>
    <link:label id="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids, other current assets and other noncurrent assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:href="icui-20221231.xsd#icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:to="lab_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24a3529a-6db8-421c-b50b-4ba90f50e0ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8c2dd1ac-b3f2-455a-8adf-7cf02330536b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_0e22c975-dacf-4d56-92b1-d4aa144007ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a25dad06-1808-4aed-a255-0d74e8cf246b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6f5d0258-e4fc-480d-895f-59aaa6c1e921_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_c7b2c4f5-24ed-4644-882e-33e8160ffe33_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_92c0a8e8-23ee-4a66-a67b-1b8cbeeb93e8_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufactured Product, Other</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f9bb3806-e86e-4615-b45b-407ed062e3ea_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_850582a8-445f-426d-82d3-57418b503551_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_aa9fbea3-5467-4067-8a64-316d3ff5c464_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount_b3bd7a2b-4d0b-4fcd-9ce1-f27f20f37857_terseLabel_en-US" xlink:label="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Calculation Ceiling Subtracted Amount</link:label>
    <link:label id="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount_label_en-US" xlink:label="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Calculation Ceiling Subtracted Amount</link:label>
    <link:label id="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount_documentation_en-US" xlink:label="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Calculation Ceiling Subtracted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:href="icui-20221231.xsd#icui_LeverageRatioCalculationCeilingSubtractedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:to="lab_icui_LeverageRatioCalculationCeilingSubtractedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_58b1c840-a781-4a48-97a0-6a77af84ab04_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_28b48e0d-a334-43bb-94cc-4c90bec1e059_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesTable_96ce021f-5b9e-4a5d-8621-70fecc3225df_terseLabel_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesTable_label_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesTable" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesTable" xlink:to="lab_icui_ScheduleOfAccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_54a58223-b984-444f-a52c-37dc5dbd64fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ProFormaAdjustmentAmortization_25057ce2-8611-4ff3-83bb-6e11ad6d6659_terseLabel_en-US" xlink:label="lab_icui_ProFormaAdjustmentAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Amortization</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentAmortization_label_en-US" xlink:label="lab_icui_ProFormaAdjustmentAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Amortization</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentAmortization_documentation_en-US" xlink:label="lab_icui_ProFormaAdjustmentAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentAmortization" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ProFormaAdjustmentAmortization" xlink:to="lab_icui_ProFormaAdjustmentAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_7891053e-042e-4c1b-a281-9008dd733633_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_00962b1d-dc46-43a0-ac70-3ee8c6e660b2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_GreaterThan275To100Member_631c59f4-8b6e-4719-9c72-8d11b6df36ac_terseLabel_en-US" xlink:label="lab_icui_GreaterThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greater than 2.75 to1.00</link:label>
    <link:label id="lab_icui_GreaterThan275To100Member_label_en-US" xlink:label="lab_icui_GreaterThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greater than 2.75 to1.00 [Member]</link:label>
    <link:label id="lab_icui_GreaterThan275To100Member_documentation_en-US" xlink:label="lab_icui_GreaterThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greater than 2.75 to1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GreaterThan275To100Member" xlink:href="icui-20221231.xsd#icui_GreaterThan275To100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_GreaterThan275To100Member" xlink:to="lab_icui_GreaterThan275To100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_480c3507-fcbe-493f-a5e2-1c91872a1c4e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b598149-a47b-4d36-afcb-a463ae9370c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_CriticalCareMember_5011bfb4-c9e3-4cc0-b8c0-1954bd15b451_terseLabel_en-US" xlink:label="lab_icui_CriticalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Care [Member]</link:label>
    <link:label id="lab_icui_CriticalCareMember_label_en-US" xlink:label="lab_icui_CriticalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Care [Member]</link:label>
    <link:label id="lab_icui_CriticalCareMember_documentation_en-US" xlink:label="lab_icui_CriticalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CriticalCareMember" xlink:href="icui-20221231.xsd#icui_CriticalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_CriticalCareMember" xlink:to="lab_icui_CriticalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_MXN_be5c2999-c6fb-494f-a0a8-e51f330b0c0b_terseLabel_en-US" xlink:label="lab_currency_MXN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico, Pesos</link:label>
    <link:label id="lab_currency_MXN_label_en-US" xlink:label="lab_currency_MXN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico, Pesos</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_MXN" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MXN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_MXN" xlink:to="lab_currency_MXN" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b9657f37-e83f-4afd-8f42-338be46961e1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherExpenseIncomeNetDomain_70136faf-04bb-4841-8c96-5636349baee0_terseLabel_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Domain]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetDomain_label_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Domain]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetDomain_documentation_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetDomain" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherExpenseIncomeNetDomain" xlink:to="lab_icui_OtherExpenseIncomeNetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_18ee4387-6dac-49d8-946b-0fe7f0e5cdc0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_782cd275-d540-4cb6-bd49-3cdfccc8ea91_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_a687c080-18ea-46c3-a232-69f21018b7e4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe2e9dc5-1e05-4f23-a59c-97286729d428_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3df349d-261d-4a73-bc83-6cf6fa462e5a_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2fdbec69-fa2e-47ee-8967-4bdedfd3ea5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_ae116c5c-494d-4e95-8cb4-317a91fcf43a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2077f5ea-93f1-4e73-85ca-8ad7dbb9f69e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5075d136-1fb0-4abf-8aad-63383d99d26a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_ed5b72c4-348c-497c-bea0-0bdcd52dca62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ForeignDistibutorMember_8abf79d5-9849-4880-a52e-4de03275f6e5_terseLabel_en-US" xlink:label="lab_icui_ForeignDistibutorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Distibutor [Member]</link:label>
    <link:label id="lab_icui_ForeignDistibutorMember_label_en-US" xlink:label="lab_icui_ForeignDistibutorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Distibutor [Member]</link:label>
    <link:label id="lab_icui_ForeignDistibutorMember_documentation_en-US" xlink:label="lab_icui_ForeignDistibutorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Distibutor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignDistibutorMember" xlink:href="icui-20221231.xsd#icui_ForeignDistibutorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ForeignDistibutorMember" xlink:to="lab_icui_ForeignDistibutorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LeverageRatioLevelDomain_be6d3afd-5cc0-49ba-ad84-827bc29b375c_terseLabel_en-US" xlink:label="lab_icui_LeverageRatioLevelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level [Domain]</link:label>
    <link:label id="lab_icui_LeverageRatioLevelDomain_label_en-US" xlink:label="lab_icui_LeverageRatioLevelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level [Domain]</link:label>
    <link:label id="lab_icui_LeverageRatioLevelDomain_documentation_en-US" xlink:label="lab_icui_LeverageRatioLevelDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LeverageRatioLevelDomain" xlink:to="lab_icui_LeverageRatioLevelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_817b9e55-489d-49e3-a267-d20036d111c3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_e7080e07-ee7d-4382-ab0a-a7b4252ecb15_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c2b83b8-0443-4fa6-ae84-19515b20c004_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_19533dc5-4631-4793-ace0-c48f3aceceb7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d2975aff-7e0e-45ad-ad8a-f50ef135bf20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b0311db0-b735-4463-9a20-e73bd420d6d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Deferredtaxliabilitychangeinaccountingmethod_2290eafb-8c63-4d9d-9d0d-bab2480d2f9b_terseLabel_en-US" xlink:label="lab_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, change in accounting method</link:label>
    <link:label id="lab_icui_Deferredtaxliabilitychangeinaccountingmethod_label_en-US" xlink:label="lab_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, change in accounting method</link:label>
    <link:label id="lab_icui_Deferredtaxliabilitychangeinaccountingmethod_documentation_en-US" xlink:label="lab_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, change in accounting method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:href="icui-20221231.xsd#icui_Deferredtaxliabilitychangeinaccountingmethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:to="lab_icui_Deferredtaxliabilitychangeinaccountingmethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_897036fc-74a1-47c6-9c84-a4c0026e4320_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e523ae41-c9bd-4ba6-ac5b-f3ab7e5fe450_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_734c03b9-cb60-46a7-a7fd-5e029c8bdee7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestRatesLineItems_7a9d25cd-b578-4df2-afb0-2a7ba2e1b70f_terseLabel_en-US" xlink:label="lab_icui_InterestRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Line Items]</link:label>
    <link:label id="lab_icui_InterestRatesLineItems_label_en-US" xlink:label="lab_icui_InterestRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Line Items]</link:label>
    <link:label id="lab_icui_InterestRatesLineItems_documentation_en-US" xlink:label="lab_icui_InterestRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rates [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesLineItems" xlink:href="icui-20221231.xsd#icui_InterestRatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestRatesLineItems" xlink:to="lab_icui_InterestRatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f5369b73-d54a-495e-b1a8-6af4dd52d54a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9324d094-2e2a-4f4b-82c0-b0c2962ffcde_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_0644dca4-fa42-44d5-a950-de6cf96725df_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ef1cc972-e24a-4455-8fe1-47f19dc4f829_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8700721f-b5e9-4925-af6b-a8f77c28367e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earn-out Liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_985e84c5-b9a0-4c71-9596-83f0b0ad5a69_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8195981f-ae19-4340-92d4-b4eab437368b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earn-out liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e921659a-21bc-4976-80d9-7fe766dd294b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9c02a3cd-5a86-48ea-88c1-b56090641d7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_1e6ff943-60b7-41da-a714-0362dd112143_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_5c58d077-b607-4717-9627-be22066fe04e_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e34a6fe9-fde3-4ffd-9818-dbc7cd8a7dd6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9bcc3439-c193-4ad6-875a-6fc79073bdfc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3c37420f-db3d-4920-8a12-4fd8a894a5a9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_9c48cf01-bb85-4d1c-9531-b199bbb0e84b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_83e38925-6974-437f-8997-4e41e2af76b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SmithsMedicalMember_8c38db98-7401-4eac-aefa-2a64981de544_terseLabel_en-US" xlink:label="lab_icui_SmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical</link:label>
    <link:label id="lab_icui_SmithsMedicalMember_label_en-US" xlink:label="lab_icui_SmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical [Member]</link:label>
    <link:label id="lab_icui_SmithsMedicalMember_documentation_en-US" xlink:label="lab_icui_SmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smiths Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SmithsMedicalMember" xlink:to="lab_icui_SmithsMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Contingentconsiderationgross_f9024d15-3857-4d25-b8df-be32899218b9_terseLabel_en-US" xlink:label="lab_icui_Contingentconsiderationgross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration gross</link:label>
    <link:label id="lab_icui_Contingentconsiderationgross_label_en-US" xlink:label="lab_icui_Contingentconsiderationgross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration gross</link:label>
    <link:label id="lab_icui_Contingentconsiderationgross_documentation_en-US" xlink:label="lab_icui_Contingentconsiderationgross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">contingent consideration gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Contingentconsiderationgross" xlink:to="lab_icui_Contingentconsiderationgross" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent_80ec16c5-7244-40bc-a0f8-1b04bbf2f43d_terseLabel_en-US" xlink:label="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectivetaxratereconciliationnondeductiblecomppercent</link:label>
    <link:label id="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent_label_en-US" xlink:label="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectivetaxratereconciliationnondeductiblecomppercent</link:label>
    <link:label id="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent_documentation_en-US" xlink:label="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectivetaxratereconciliationnondeductiblecomppercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:href="icui-20221231.xsd#icui_Effectivetaxratereconciliationnondeductiblecomppercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:to="lab_icui_Effectivetaxratereconciliationnondeductiblecomppercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_7d1e3d9e-c235-4648-9fa4-ddc9ccf3bb15_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bond premium amortization</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ApplicableMarginTermSOFRLoans_c104fc2e-4f30-486f-811e-e5f64faba09c_terseLabel_en-US" xlink:label="lab_icui_ApplicableMarginTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Term SOFR Loans</link:label>
    <link:label id="lab_icui_ApplicableMarginTermSOFRLoans_label_en-US" xlink:label="lab_icui_ApplicableMarginTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Term SOFR Loans</link:label>
    <link:label id="lab_icui_ApplicableMarginTermSOFRLoans_documentation_en-US" xlink:label="lab_icui_ApplicableMarginTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Term SOFR Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ApplicableMarginTermSOFRLoans" xlink:to="lab_icui_ApplicableMarginTermSOFRLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fc269f53-b2ff-475b-a943-c7e59e5b9849_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract_4407c135-34da-4f51-b4a0-e7c3950861a4_terseLabel_en-US" xlink:label="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure deferred taxes [Abstract]</link:label>
    <link:label id="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract_label_en-US" xlink:label="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure deferred taxes [Abstract]</link:label>
    <link:label id="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract_documentation_en-US" xlink:label="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure deferred taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:href="icui-20221231.xsd#icui_IncomeTaxDisclosuredeferredtaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:to="lab_icui_IncomeTaxDisclosuredeferredtaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b91c79f7-b297-457c-8796-dc33d46691a7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a98b08a3-f915-4c69-a561-89a35428021e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestExpenseIncomeNetTable_f83de4f5-48a4-4026-8a31-38211aff0002_terseLabel_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Table]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetTable_label_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Table]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetTable_documentation_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetTable" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestExpenseIncomeNetTable" xlink:to="lab_icui_InterestExpenseIncomeNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsAndOtherAssets_ebe523d1-03d0-42c8-894e-2534ea410e65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs and Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCostsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsAndOtherAssets" xlink:to="lab_us-gaap_DeferredCostsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_WarrantyAndReturnReserveCosts_175253e0-c60e-406d-9681-65324eb0fed1_terseLabel_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and Return Reserve costs</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveCosts_label_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and Return Reserve costs</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveCosts_documentation_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and Return Reserve costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveCosts" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_WarrantyAndReturnReserveCosts" xlink:to="lab_icui_WarrantyAndReturnReserveCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesLineItems_168092f9-548d-43ac-a04a-07d10301c9e6_terseLabel_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities [Line Items]</link:label>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesLineItems_label_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities [Line Items]</link:label>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesLineItems_documentation_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Deferred tax assets and liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:to="lab_icui_DeferredtaxassetsandliabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_04f102f2-0cd7-4280-9d01-2afb77360bdf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_9fb7545a-9886-4dd6-ad08-68109a07854a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_242b6741-44df-4388-8dba-ef47ca5fb029_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1a82273a-cfe4-43c8-adf6-75904c8f0a5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9fbca734-a780-4df1-940c-3194820fa600_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs_20c3aabd-910c-4540-85e9-9f25f6dbb10c_terseLabel_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory write-offs</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs_label_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory write-offs</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs_documentation_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory write-offs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:to="lab_icui_WarrantyAndReturnReserveInventoryWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_1b7fa6c7-e767-4eff-abd1-89af734ce427_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_70e918da-d78c-438f-b8bc-7f421c7a075f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_f2e4fa0b-158e-4106-808a-890eea898a3d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayTable" xlink:to="lab_us-gaap_IncomeTaxHolidayTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_UnrecognizedTaxBenefitsRollForwardRollForward_label_en-US" xlink:label="lab_icui_UnrecognizedTaxBenefitsRollForwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits roll forward [Roll Forward]</link:label>
    <link:label id="lab_icui_UnrecognizedTaxBenefitsRollForwardRollForward_documentation_en-US" xlink:label="lab_icui_UnrecognizedTaxBenefitsRollForwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits roll forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward" xlink:href="icui-20221231.xsd#icui_UnrecognizedTaxBenefitsRollForwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward" xlink:to="lab_icui_UnrecognizedTaxBenefitsRollForwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_994b3046-8104-47cb-8d1c-5606f1ea4229_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ce348a05-212f-4f53-85ef-949b5a920334_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3a75ac30-41cb-4dc2-af76-3c46df73808c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_62c42264-2d80-45d0-9f97-ed9a40276615_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_68731105-daa0-4bbb-9251-b940c0465872_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_424556f8-730b-454f-8da3-36adc255115d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d69489-e3d6-46c3-ac86-6e71915ee33b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_6323d120-3d37-4c66-bb6c-594361cd3d2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_59b969cc-6010-4589-8453-d6064f5c059f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_01c54c4e-ed1e-4bb7-b226-b4d09f3ef933_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_eb24891e-ba84-4729-92ba-b1b820d9e9ce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueAdditions_e32c80df-ec25-413a-a3ff-45aed46c33a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueAdditions_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAdditions" xlink:to="lab_us-gaap_DeferredRevenueAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1bd5b39-274b-4891-99db-31c89e86c82f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8e2db251-8c0c-41aa-ad7f-1319e681ac44_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_fc6c3a94-7cce-4ac6-905b-030540b53935_terseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b370a148-039e-4a0b-90c5-74c112055d3e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d7a773b6-ec40-48a5-b330-eb331496eaad_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3362bcaf-6ebe-40d2-a4ed-3cf9487cfa1f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AmortizationOfInventoryStepUp_0d6d1706-3717-4b7e-9f18-7a05c2989cda_terseLabel_en-US" xlink:label="lab_icui_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Inventory Step-up</link:label>
    <link:label id="lab_icui_AmortizationOfInventoryStepUp_label_en-US" xlink:label="lab_icui_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Inventory Step-up</link:label>
    <link:label id="lab_icui_AmortizationOfInventoryStepUp_documentation_en-US" xlink:label="lab_icui_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Inventory Step-up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AmortizationOfInventoryStepUp" xlink:href="icui-20221231.xsd#icui_AmortizationOfInventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AmortizationOfInventoryStepUp" xlink:to="lab_icui_AmortizationOfInventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_79d01b1a-d9ba-47e7-928f-e9ecdf2ab20b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4d14a91e-12a8-4bea-9adb-ea335ad1a2f1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_4bc04baa-b7ec-43e8-b2c0-9496f95c3391_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_e25107a7-d03b-4532-a832-bc34a10ad402_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_eca02261-396b-4d17-8c07-c70479c36158_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_01b22d81-42ef-409a-87df-c54d1e595e24_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TimingAxis_1d3c8f0e-2342-4b7a-a0f6-0fa31c750b05_terseLabel_en-US" xlink:label="lab_icui_TimingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing [Axis]</link:label>
    <link:label id="lab_icui_TimingAxis_label_en-US" xlink:label="lab_icui_TimingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing [Axis]</link:label>
    <link:label id="lab_icui_TimingAxis_documentation_en-US" xlink:label="lab_icui_TimingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TimingAxis" xlink:to="lab_icui_TimingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b9d92324-fe26-4cff-8efd-1cf51672417b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8a7d6f54-f856-49ad-bd2f-6b0ea07d4c9e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_64762dee-2f6a-467e-ac16-9f620d61b6df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7590a975-b4a9-4e61-866d-074d395f478f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_us-gaap_Goodwill_5c729fbb-1ba2-4c67-9932-0a0d444c904d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_us-gaap_Goodwill_8a3f75ea-d5d7-43d0-83c7-cf921e0c85cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_1fff0f31-e772-4368-9002-39fae16f7732_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_48cae348-7249-4c07-875b-b6bfd0416ea8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_03eb1b88-7f38-44b6-93aa-8bcd17b6ee9e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b7a79887-e7a6-4ba8-a7eb-f2852a847051_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98b6f758-3cf1-4c6c-829f-409d6c8690f5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_CommonStockSharesMember_9c83388f-db9e-48c1-83ee-b9a48d6e1395_terseLabel_en-US" xlink:label="lab_icui_CommonStockSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares [Member]</link:label>
    <link:label id="lab_icui_CommonStockSharesMember_label_en-US" xlink:label="lab_icui_CommonStockSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares [Member]</link:label>
    <link:label id="lab_icui_CommonStockSharesMember_documentation_en-US" xlink:label="lab_icui_CommonStockSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CommonStockSharesMember" xlink:href="icui-20221231.xsd#icui_CommonStockSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_CommonStockSharesMember" xlink:to="lab_icui_CommonStockSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ApplicableMarginBaseRateLoans_eaa5099e-f890-4ed5-a7a1-a3e9d0111415_terseLabel_en-US" xlink:label="lab_icui_ApplicableMarginBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Base Rate Loans</link:label>
    <link:label id="lab_icui_ApplicableMarginBaseRateLoans_label_en-US" xlink:label="lab_icui_ApplicableMarginBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Base Rate Loans</link:label>
    <link:label id="lab_icui_ApplicableMarginBaseRateLoans_documentation_en-US" xlink:label="lab_icui_ApplicableMarginBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Base Rate Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ApplicableMarginBaseRateLoans" xlink:to="lab_icui_ApplicableMarginBaseRateLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Accruedothertaxes_fdaabfdc-7473-44be-90c9-52e3f65c559d_terseLabel_en-US" xlink:label="lab_icui_Accruedothertaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other taxes</link:label>
    <link:label id="lab_icui_Accruedothertaxes_label_en-US" xlink:label="lab_icui_Accruedothertaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other taxes</link:label>
    <link:label id="lab_icui_Accruedothertaxes_documentation_en-US" xlink:label="lab_icui_Accruedothertaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedothertaxes" xlink:href="icui-20221231.xsd#icui_Accruedothertaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Accruedothertaxes" xlink:to="lab_icui_Accruedothertaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Hedge5Member_b69f39d9-f368-4a89-b969-88e0af11f787_terseLabel_en-US" xlink:label="lab_icui_Hedge5Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 5</link:label>
    <link:label id="lab_icui_Hedge5Member_label_en-US" xlink:label="lab_icui_Hedge5Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 5 [Member]</link:label>
    <link:label id="lab_icui_Hedge5Member_documentation_en-US" xlink:label="lab_icui_Hedge5Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge5Member" xlink:href="icui-20221231.xsd#icui_Hedge5Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Hedge5Member" xlink:to="lab_icui_Hedge5Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_55885ad2-9844-47fb-b7b8-bc594c7be04a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_896b6c56-ce41-4640-9f79-22725181231e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_471191b2-2e0f-4cac-8e18-5c9e27d2d3dd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0c55548c-6749-4584-902e-70468242b329_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8681b657-95ea-4302-8889-0e4e388f0062_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_cef05c69-b090-4295-93a3-89abf651bd8e_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_2c02e9e3-95cd-4685-a257-e1d72f0c323e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81d40730-ee53-4848-a17c-df6e9cbc57f9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_aa74a8d1-87cb-440b-bacf-1262f2b753b7_terseLabel_en-US" xlink:label="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</link:label>
    <link:label id="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_label_en-US" xlink:label="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</link:label>
    <link:label id="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_documentation_en-US" xlink:label="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:href="icui-20221231.xsd#icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:to="lab_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_df0af2ed-ad51-4029-95ca-0922981fe243_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1eece57d-f1e6-4028-b79d-1f18bc467264_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_MoldsMember_d9a1db0e-292f-406a-925a-8045451958bb_terseLabel_en-US" xlink:label="lab_icui_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds [Member]</link:label>
    <link:label id="lab_icui_MoldsMember_label_en-US" xlink:label="lab_icui_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds [Member]</link:label>
    <link:label id="lab_icui_MoldsMember_documentation_en-US" xlink:label="lab_icui_MoldsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MoldsMember" xlink:href="icui-20221231.xsd#icui_MoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_MoldsMember" xlink:to="lab_icui_MoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e7923f5a-bab3-40f8-9f49-b7e6a534ce1d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_3d8ab749-afa0-487a-8377-3b79b056b291_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc7bae5d-570f-47cb-8d7a-1dfec18e2313_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_601136ab-3ff2-4f0b-a368-fe432ac4d915_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_5ced3d95-d534-49f0-9155-5c99c709bad8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_a83b0aec-7e75-4d27-9f91-7407f2eb3abd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_31ad485a-8c39-4cd9-9922-f5dabb3a1b80_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,995 and 21,280 shares at December 31, 2022 and 2021, respectively, and outstanding 23,993 and 21,280 shares at December 31, 2022 and 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_65ddb4ba-4020-4627-bc39-f4248bb878fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TimingDomain_fd7ef9d9-c6e9-4822-9c38-20f6093fe2ea_terseLabel_en-US" xlink:label="lab_icui_TimingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing [Domain]</link:label>
    <link:label id="lab_icui_TimingDomain_label_en-US" xlink:label="lab_icui_TimingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing [Domain]</link:label>
    <link:label id="lab_icui_TimingDomain_documentation_en-US" xlink:label="lab_icui_TimingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TimingDomain" xlink:to="lab_icui_TimingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_7016a9fc-7c6a-40de-86b7-38b9d39accc5_terseLabel_en-US" xlink:label="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Restricted Stock Units [Member]</link:label>
    <link:label id="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_label_en-US" xlink:label="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Restricted Stock Units [Member]</link:label>
    <link:label id="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:href="icui-20221231.xsd#icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:to="lab_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d4224f42-b46e-460f-b793-4d814cdd1628_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_8077f200-717b-48da-97d0-3e4018af937e_terseLabel_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - state income taxes</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_label_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - state income taxes</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_documentation_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability - state income taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:to="lab_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_07cb5486-4dc4-4f56-bdcc-fe40092eb40c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged&#160;to Other&#160;Accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_b1e0f6bd-0fdc-4962-83b9-3d2f0ef453e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Disclosure, Nonoperating</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ed411b2d-f52f-488d-a097-3ef5b179e40b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_fa0f4586-db71-44cf-944b-42ee23f649df_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember_d1191de5-e2c7-47a7-8aba-273c0fb6eecb_terseLabel_en-US" xlink:label="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
    <link:label id="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember_label_en-US" xlink:label="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
    <link:label id="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember_documentation_en-US" xlink:label="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units (PRSUs) stock units issued if the measurement period goal is met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:href="icui-20221231.xsd#icui_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:to="lab_icui_PerformanceRestrictedStockUnitsPRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock_2d1410a5-5905-400c-befb-92a01dd1421d_terseLabel_en-US" xlink:label="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Geographic Area and Customer Concentration [Text Block]</link:label>
    <link:label id="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock_label_en-US" xlink:label="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Geographic Area and Customer Concentration [Text Block]</link:label>
    <link:label id="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock_documentation_en-US" xlink:label="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Geographic Area and Customer Concentration [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:href="icui-20221231.xsd#icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:to="lab_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cfb1b22-0c83-4685-9e81-c8733783a6c8_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_GILTItaxexpense_a1a1dd2f-3829-4fef-9a58-f41f31ea9c27_terseLabel_en-US" xlink:label="lab_icui_GILTItaxexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpense</link:label>
    <link:label id="lab_icui_GILTItaxexpense_label_en-US" xlink:label="lab_icui_GILTItaxexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpense</link:label>
    <link:label id="lab_icui_GILTItaxexpense_documentation_en-US" xlink:label="lab_icui_GILTItaxexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GILTItaxexpense" xlink:href="icui-20221231.xsd#icui_GILTItaxexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_GILTItaxexpense" xlink:to="lab_icui_GILTItaxexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5b73ef75-fe03-4712-ac7c-bb12f5dbbe71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_de286b40-c669-41aa-9742-7e9aa3b1f259_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bacf70a6-944f-4e54-8ffc-c0f48bcbd7e5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7780abf6-b125-44a5-8926-ca8613a1d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_530c8527-cfa6-4a87-ad8b-5ff3ee153edf_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_5ac04668-0282-4574-b8fc-827ecfc53a93_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a06286a1-1027-4d53-8b49-4baed27b6ce4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingRevenueMember_aa113c7b-e400-469e-b130-035bf0532f8d_terseLabel_en-US" xlink:label="lab_us-gaap_TradingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Revenue</link:label>
    <link:label id="lab_us-gaap_TradingRevenueMember_label_en-US" xlink:label="lab_us-gaap_TradingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingRevenueMember" xlink:to="lab_us-gaap_TradingRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ef884e17-e301-4ae7-87b9-119160192e69_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_fc6dc16d-f422-4641-96c4-cea82eeac03e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e269e34a-8045-4f0b-bddd-059578ec95e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_99dedabc-b0ac-45dc-ab3e-fe1c76090a8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Percentoftotalrevenue_5544cedf-9818-48ae-b4ba-9f273b82e518_terseLabel_en-US" xlink:label="lab_icui_Percentoftotalrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_icui_Percentoftotalrevenue_label_en-US" xlink:label="lab_icui_Percentoftotalrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_icui_Percentoftotalrevenue_documentation_en-US" xlink:label="lab_icui_Percentoftotalrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentoftotalrevenue" xlink:href="icui-20221231.xsd#icui_Percentoftotalrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Percentoftotalrevenue" xlink:to="lab_icui_Percentoftotalrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b3bb0e61-ab8e-42d0-ba60-5394865959ff_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8fcca846-1e04-4a90-93b2-80e29ad7a0ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Amortization Life in Years</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3db61a8a-1963-4c40-b431-019123dfc7f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_db278cfe-bbfc-417c-9b8c-6e6476e2755b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ec849991-f077-44be-a862-a1dc9c54fba7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d978a54b-c1c8-4333-a5a9-1ba4775b603c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherExpenseIncomeNetAxis_ff09aaee-bbfe-444f-959e-9d836ef7527c_terseLabel_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Axis]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetAxis_label_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Axis]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetAxis_documentation_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetAxis" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherExpenseIncomeNetAxis" xlink:to="lab_icui_OtherExpenseIncomeNetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_APACDomain_870dda54-1546-4668-98a3-8177e6ee70d3_terseLabel_en-US" xlink:label="lab_icui_APACDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC [Domain]</link:label>
    <link:label id="lab_icui_APACDomain_label_en-US" xlink:label="lab_icui_APACDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC [Domain]</link:label>
    <link:label id="lab_icui_APACDomain_documentation_en-US" xlink:label="lab_icui_APACDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_APACDomain" xlink:href="icui-20221231.xsd#icui_APACDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_APACDomain" xlink:to="lab_icui_APACDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9e178e8c-693c-4fa6-8d4b-8501d756e1db_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_de67bff4-b056-42a5-9874-829605bfea6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_fa3fba5c-bcf2-41d9-b1c6-a9a0ebf87be1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring accrual</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0e77425a-c56b-495c-8b86-6674ac7bbf18_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6a508051-d913-4c79-a7ec-5cbcbe8b1bd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4ee3bb51-f6be-4e72-a55c-9085cb0b1fac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f76e7474-f4b9-4d09-a009-99d7dc53f7ee_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_71b12ece-1dcf-44cf-b847-e63dbc16b639_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0ab61c07-ff96-42b0-afd7-fb51be0bda48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_221d1ccd-c8d4-48bf-9ad9-195216928c9f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_CurrentMember_927f7424-6162-4bc4-811d-38c4cd2d0608_terseLabel_en-US" xlink:label="lab_icui_CurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">current</link:label>
    <link:label id="lab_icui_CurrentMember_label_en-US" xlink:label="lab_icui_CurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">current [Member]</link:label>
    <link:label id="lab_icui_CurrentMember_documentation_en-US" xlink:label="lab_icui_CurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrentMember" xlink:href="icui-20221231.xsd#icui_CurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_CurrentMember" xlink:to="lab_icui_CurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3d5afb86-3f47-4080-ba35-01b8c3f94654_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_865c5101-e4fa-4c15-9358-8818d91d547c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ContractassetandliabilitybalancesTable_669da240-b502-4f4e-95de-fab568c3afb1_terseLabel_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset and liability balances [Table]</link:label>
    <link:label id="lab_icui_ContractassetandliabilitybalancesTable_label_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset and liability balances [Table]</link:label>
    <link:label id="lab_icui_ContractassetandliabilitybalancesTable_documentation_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset and liability balances [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesTable" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ContractassetandliabilitybalancesTable" xlink:to="lab_icui_ContractassetandliabilitybalancesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_32f41bcd-0192-4bba-ac2a-ac26a740c6fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b8c1b45e-0005-4517-b415-bf4c8b51b1ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_05e55b99-d9f9-475d-93d2-56512fa4acc2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherLiabilitiesLineItems_b127a616-2c65-4132-9f10-be7b1cf78d6e_terseLabel_en-US" xlink:label="lab_icui_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Line Items]</link:label>
    <link:label id="lab_icui_OtherLiabilitiesLineItems_label_en-US" xlink:label="lab_icui_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Line Items]</link:label>
    <link:label id="lab_icui_OtherLiabilitiesLineItems_documentation_en-US" xlink:label="lab_icui_OtherLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesLineItems" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherLiabilitiesLineItems" xlink:to="lab_icui_OtherLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_e6fe5a71-bf83-444b-9fcb-e9ce30e1703a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9c391e94-ada6-4bbf-b40a-660777897922_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0c98e053-5eaa-4c52-a4aa-7099c62c949c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_GovernmentGrantRevenueMember_6aa7c66d-3b56-48ec-b0f6-1f449047f19c_terseLabel_en-US" xlink:label="lab_icui_GovernmentGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant Revenue</link:label>
    <link:label id="lab_icui_GovernmentGrantRevenueMember_label_en-US" xlink:label="lab_icui_GovernmentGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant Revenue [Member]</link:label>
    <link:label id="lab_icui_GovernmentGrantRevenueMember_documentation_en-US" xlink:label="lab_icui_GovernmentGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GovernmentGrantRevenueMember" xlink:href="icui-20221231.xsd#icui_GovernmentGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_GovernmentGrantRevenueMember" xlink:to="lab_icui_GovernmentGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_8a9a6a60-31a3-4582-809b-731101c11c24_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_73b56a9d-11ab-4f31-abf7-251405af5caa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_bbf7fff2-df9e-4205-906c-ee2cb9707aaf_terseLabel_en-US" xlink:label="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required Share Holding Of Stock Issued At Acquisition</link:label>
    <link:label id="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_label_en-US" xlink:label="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required Share Holding Of Stock Issued At Acquisition</link:label>
    <link:label id="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_documentation_en-US" xlink:label="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required Share Holding Of Stock Issued At Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:href="icui-20221231.xsd#icui_RequiredShareHoldingOfStockIssuedAtAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:to="lab_icui_RequiredShareHoldingOfStockIssuedAtAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_75888acf-79f0-463e-b385-5ff3721e712c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_be8caa46-7116-44c8-8914-7d0310e2d352_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_ae3e8884-603e-4a04-8a9f-8ffa3051cfcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_260ce099-3755-4a97-ab55-68d32dc37ec0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments, net of taxes of $0 for all periods</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95ef4271-a429-4375-8365-5ae76502e3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8f9663fc-29b4-45a2-98ab-5b0e78f395b8_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5c57c0ee-9d58-4849-9a9b-7244141448c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock and exercise of stock options, including excess income tax benefits</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6c422e25-1709-4cb9-92f5-9cf36eaa8a4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_45a73f5c-83ec-4973-9c0f-b82f1aa34b20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_6c1a619a-14a3-4603-af38-062fbba61ec8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7138ae36-46c9-4955-87e9-d8946069eab5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ab1343dc-f31b-4308-86f0-85369bed7a2d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisDomain_c8af0d8f-7f36-4342-812a-5ce018c04bd5_terseLabel_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis [Domain]</link:label>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisDomain_label_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis [Domain]</link:label>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisDomain_documentation_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisDomain" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Srt_MultipleCurrencyAxisDomain" xlink:to="lab_icui_Srt_MultipleCurrencyAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75dc347b-0caa-4913-915b-fa0da034ef9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2c18395-541d-4656-b268-71318da3540f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_31586b11-8fd9-41e0-81d4-0902cf029579_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d8a57a4e-713a-4136-a663-8d2beeee17f0_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ForeignMember_f75343b5-4243-4634-82c2-0e10cfc9ee14_terseLabel_en-US" xlink:label="lab_icui_ForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:label id="lab_icui_ForeignMember_label_en-US" xlink:label="lab_icui_ForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:label id="lab_icui_ForeignMember_documentation_en-US" xlink:label="lab_icui_ForeignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignMember" xlink:href="icui-20221231.xsd#icui_ForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ForeignMember" xlink:to="lab_icui_ForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_8a51bbcf-84af-472f-98cf-1349141f46ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1ee4eb40-3323-4a78-bed7-1c97e8ee7c2a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermLoanAMember_8162f469-34b2-48cf-b62c-3fc8e9a9a51c_terseLabel_en-US" xlink:label="lab_icui_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_icui_TermLoanAMember_label_en-US" xlink:label="lab_icui_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_icui_TermLoanAMember_documentation_en-US" xlink:label="lab_icui_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermLoanAMember" xlink:to="lab_icui_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d76a3812-7f38-479f-9e22-7b6e4a11e7da_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_StockIncentivePlansLineItems_a325eef7-cf3d-4e88-86ad-cbf5a23fd390_terseLabel_en-US" xlink:label="lab_icui_StockIncentivePlansLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans [Line Items]</link:label>
    <link:label id="lab_icui_StockIncentivePlansLineItems_label_en-US" xlink:label="lab_icui_StockIncentivePlansLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans [Line Items]</link:label>
    <link:label id="lab_icui_StockIncentivePlansLineItems_documentation_en-US" xlink:label="lab_icui_StockIncentivePlansLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Stock Incentive Plans [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansLineItems" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_StockIncentivePlansLineItems" xlink:to="lab_icui_StockIncentivePlansLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_fd63bd0f-56d9-47b2-aea8-3f09557d8b07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_611f8152-6faf-4336-a7ae-8adfb51fc1ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InternationalSalesDomain_618e3a1c-5659-44d9-9c31-eb0cfd6457fa_terseLabel_en-US" xlink:label="lab_icui_InternationalSalesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Sales [Domain]</link:label>
    <link:label id="lab_icui_InternationalSalesDomain_label_en-US" xlink:label="lab_icui_InternationalSalesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Sales [Domain]</link:label>
    <link:label id="lab_icui_InternationalSalesDomain_documentation_en-US" xlink:label="lab_icui_InternationalSalesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Sales [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalSalesDomain" xlink:href="icui-20221231.xsd#icui_InternationalSalesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InternationalSalesDomain" xlink:to="lab_icui_InternationalSalesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9b56199c-7e91-4dca-8e35-b26c63126373_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ea5edef0-f4f8-4291-a759-ce075866cb95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fccf5208-43d4-4674-ac8e-79e83b9c73a2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_MinimumStockPriceTargetForEarnOutPayment_008ee2c3-e265-4106-8963-5b4ecafb09a4_terseLabel_en-US" xlink:label="lab_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Stock Price Target for Earn-out Payment</link:label>
    <link:label id="lab_icui_MinimumStockPriceTargetForEarnOutPayment_label_en-US" xlink:label="lab_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Stock Price Target for Earn-out Payment</link:label>
    <link:label id="lab_icui_MinimumStockPriceTargetForEarnOutPayment_documentation_en-US" xlink:label="lab_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Stock Price Target for Earn-out Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:href="icui-20221231.xsd#icui_MinimumStockPriceTargetForEarnOutPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:to="lab_icui_MinimumStockPriceTargetForEarnOutPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8db41d1a-cb10-42fd-8e79-d17db2246b7e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_31eda84d-4f3e-49b4-a56a-16c25b9be071_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f8959f20-eb57-4b38-a532-39f5923d319e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_3adb5e53-245c-441d-8959-3ec4a81bceb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_35af1d33-4f6c-462f-8649-80b463259c4e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RevenueGrossProfitVolatilityMember_c07b8aa9-cfaa-4542-bbff-4cd47570729b_terseLabel_en-US" xlink:label="lab_icui_RevenueGrossProfitVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue/Gross Profit Volatility [Member]</link:label>
    <link:label id="lab_icui_RevenueGrossProfitVolatilityMember_label_en-US" xlink:label="lab_icui_RevenueGrossProfitVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue/Gross Profit Volatility [Member]</link:label>
    <link:label id="lab_icui_RevenueGrossProfitVolatilityMember_documentation_en-US" xlink:label="lab_icui_RevenueGrossProfitVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue/Gross Profit Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueGrossProfitVolatilityMember" xlink:href="icui-20221231.xsd#icui_RevenueGrossProfitVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RevenueGrossProfitVolatilityMember" xlink:to="lab_icui_RevenueGrossProfitVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_ecc8f502-cc0d-4fc7-a1bf-35bf13b624dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_c73a3ce9-097c-4de5-90fd-abedb2907d16_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_638c85e8-0676-4324-b553-2378edfd8ad4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ItalyPropertyAndEquipmentMember_16291d8a-dc99-41dd-a19a-967d1961ef75_terseLabel_en-US" xlink:label="lab_icui_ItalyPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy Property and Equipment [Member]</link:label>
    <link:label id="lab_icui_ItalyPropertyAndEquipmentMember_label_en-US" xlink:label="lab_icui_ItalyPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy Property and Equipment [Member]</link:label>
    <link:label id="lab_icui_ItalyPropertyAndEquipmentMember_documentation_en-US" xlink:label="lab_icui_ItalyPropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign property and equipment: Italy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ItalyPropertyAndEquipmentMember" xlink:href="icui-20221231.xsd#icui_ItalyPropertyAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ItalyPropertyAndEquipmentMember" xlink:to="lab_icui_ItalyPropertyAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_02dc70cc-8cc2-4934-ab4c-cf6210195e46_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_6f7caced-698b-42e4-b9c0-8fd287c5364f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0333064d-b978-44af-83eb-3ca70544ed41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a0e12d2-c5f2-4a26-bb33-541bf2a92ad0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_af06c352-191a-4fc7-99de-f076e9d0dce2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment, net of taxes of $0 for all periods</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_55ba1f77-e59d-47f3-bb68-075634420462_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc4db473-befb-43bf-884d-b15eeaa034dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_629d9a2f-f79c-44aa-a971-505c0a5f64a9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_df6c0dbe-d854-41d7-a163-3daeb07e30e3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_78d3aff1-5a92-415f-a40b-8d92cad5078e_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_58e930c1-69ab-4270-a17b-f93b9bc83cef_terseLabel_en-US" xlink:label="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.50 to1.00 but greater than 2.00 to1.00</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_label_en-US" xlink:label="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.50 to1.00 but greater than 2.00 to1.00 [Member]</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_documentation_en-US" xlink:label="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.50 to1.00 but greater than 2.00 to1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:to="lab_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4ac85929-2891-480e-817c-ab1b6c45e085_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_339574d4-5d02-48e5-b909-49756ed202bf_negatedTerseLabel_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory - charged to other accounts</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_label_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory - charged to other accounts</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_documentation_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory - charged to other accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:to="lab_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_128451b8-cbf9-4957-89e6-bd7f499b4116_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7c0c4f78-bd0c-4a4a-acda-f3ad249d8825_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestExpenseIncomeNetAxis_ef1994f2-ab27-4c5e-ae31-3a8336e7e3a2_terseLabel_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Axis]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetAxis_label_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Axis]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetAxis_documentation_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetAxis" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestExpenseIncomeNetAxis" xlink:to="lab_icui_InterestExpenseIncomeNetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_98684892-8741-4a4d-8e19-94115721bead_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Liabilities Arising from Contingencies, Amount Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="lab_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a98e162-3d60-4962-8fb9-425560976f1a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ef29017-7956-4c9e-8fc9-00b8633c8f7e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (basic)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_BusinessCombinationConsiderationTransferredCash_9ba428da-0370-4cea-850d-06f162172a53_terseLabel_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Cash</link:label>
    <link:label id="lab_icui_BusinessCombinationConsiderationTransferredCash_label_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Cash</link:label>
    <link:label id="lab_icui_BusinessCombinationConsiderationTransferredCash_documentation_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationTransferredCash" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationTransferredCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_BusinessCombinationConsiderationTransferredCash" xlink:to="lab_icui_BusinessCombinationConsiderationTransferredCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_76738373-1be6-4c4c-af61-d63ebfb8cbd9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_e7f537cc-94e3-4b33-81c9-24bb4d63842c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d52e432b-dd58-4f1c-a7b5-23dd5fb7d68b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_fb8bc921-3a16-4477-a121-7f83eaaa2ab2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_7713e310-8842-42f2-9e5b-72fdbb85c98f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_052089e9-52c6-4359-8f7e-ad407192799a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f2b47fd0-f4a8-486b-b3cc-f22e37024469_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation_47224032-a0f9-4e8d-905d-be3d04ab3908_terseLabel_en-US" xlink:label="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectiveincometaxreconciliation,nondeductiblecompensation</link:label>
    <link:label id="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation_label_en-US" xlink:label="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectiveincometaxreconciliation,nondeductiblecompensation</link:label>
    <link:label id="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation_documentation_en-US" xlink:label="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effectiveincometaxreconciliation,nondeductiblecompensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:href="icui-20221231.xsd#icui_Effectiveincometaxreconciliationnondeductiblecompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:to="lab_icui_Effectiveincometaxreconciliationnondeductiblecompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SpareParts_c6b503f2-88dc-4d93-977c-34790e0291c8_terseLabel_en-US" xlink:label="lab_icui_SpareParts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spare parts</link:label>
    <link:label id="lab_icui_SpareParts_label_en-US" xlink:label="lab_icui_SpareParts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spare parts</link:label>
    <link:label id="lab_icui_SpareParts_documentation_en-US" xlink:label="lab_icui_SpareParts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spare parts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SpareParts" xlink:href="icui-20221231.xsd#icui_SpareParts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SpareParts" xlink:to="lab_icui_SpareParts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_24c0bea4-1f49-40fd-8a28-0e97d7cde701_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_03946baa-e4b7-4d0c-a37a-1e22ec45a8d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_bda73a07-0819-4dcc-bf09-9c5025fd047d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1b9f0300-d6f8-46fe-990b-9d8f7464d77f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e441952f-5083-4628-89ce-87e520e2d671_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investment Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_250a7866-db29-4899-9040-d762e790d4f2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_5f43f87f-23e3-4805-af02-60620ce01c03_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_0ec75049-15f5-401e-8fc6-5590f659c65f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ClassificationDomain_ca51ef4b-42fa-49e5-87d1-b635db9e14ec_terseLabel_en-US" xlink:label="lab_icui_ClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification [Domain]</link:label>
    <link:label id="lab_icui_ClassificationDomain_label_en-US" xlink:label="lab_icui_ClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification [Domain]</link:label>
    <link:label id="lab_icui_ClassificationDomain_documentation_en-US" xlink:label="lab_icui_ClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationDomain" xlink:href="icui-20221231.xsd#icui_ClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ClassificationDomain" xlink:to="lab_icui_ClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LongTermDebtTypeLineItems_ca4fb6fc-d00a-4c51-bf96-8229f388f9ed_terseLabel_en-US" xlink:label="lab_icui_LongTermDebtTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Line Items]</link:label>
    <link:label id="lab_icui_LongTermDebtTypeLineItems_label_en-US" xlink:label="lab_icui_LongTermDebtTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Line Items]</link:label>
    <link:label id="lab_icui_LongTermDebtTypeLineItems_documentation_en-US" xlink:label="lab_icui_LongTermDebtTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeLineItems" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LongTermDebtTypeLineItems" xlink:to="lab_icui_LongTermDebtTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_dc13fcaf-1f38-445c-a4d8-32f2182b57f1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ProFormaAdjustmentInventory_f25194a2-d4f2-4dff-93ef-0b07cfc531a5_terseLabel_en-US" xlink:label="lab_icui_ProFormaAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Inventory</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentInventory_label_en-US" xlink:label="lab_icui_ProFormaAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Inventory</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentInventory_documentation_en-US" xlink:label="lab_icui_ProFormaAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentInventory" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ProFormaAdjustmentInventory" xlink:to="lab_icui_ProFormaAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_4f126950-0a84-42eb-a971-c973ec2e5833_terseLabel_en-US" xlink:label="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination, recognized identifiable asset acquired and liability assumed,</link:label>
    <link:label id="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_label_en-US" xlink:label="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination, recognized identifiable asset acquired and liability assumed,</link:label>
    <link:label id="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_documentation_en-US" xlink:label="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination, recognized identifiable asset acquired and liability assumed,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:href="icui-20221231.xsd#icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:to="lab_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_05298202-444e-4a44-ab5f-c04e85cc2265_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ProvisionForWarrantyAndReturns_f6671274-30d2-4d2d-ad5b-d38fe0b8fa88_terseLabel_en-US" xlink:label="lab_icui_ProvisionForWarrantyAndReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for warranty and returns</link:label>
    <link:label id="lab_icui_ProvisionForWarrantyAndReturns_label_en-US" xlink:label="lab_icui_ProvisionForWarrantyAndReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for warranty and returns</link:label>
    <link:label id="lab_icui_ProvisionForWarrantyAndReturns_documentation_en-US" xlink:label="lab_icui_ProvisionForWarrantyAndReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for warranty and returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProvisionForWarrantyAndReturns" xlink:href="icui-20221231.xsd#icui_ProvisionForWarrantyAndReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ProvisionForWarrantyAndReturns" xlink:to="lab_icui_ProvisionForWarrantyAndReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_89bf6a0e-35a6-4ac5-8be9-5ed97fef2f35_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_153c8994-bc1a-45a4-9270-69a540f8a1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0150a1b1-6652-4bb0-bce9-ec8a0179e1de_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ContingentConsiderationGrossLT_865a6cd3-9930-4fbf-af71-7940a3afa078_terseLabel_en-US" xlink:label="lab_icui_ContingentConsiderationGrossLT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Gross LT</link:label>
    <link:label id="lab_icui_ContingentConsiderationGrossLT_label_en-US" xlink:label="lab_icui_ContingentConsiderationGrossLT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Gross LT</link:label>
    <link:label id="lab_icui_ContingentConsiderationGrossLT_documentation_en-US" xlink:label="lab_icui_ContingentConsiderationGrossLT" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Gross LT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContingentConsiderationGrossLT" xlink:href="icui-20221231.xsd#icui_ContingentConsiderationGrossLT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ContingentConsiderationGrossLT" xlink:to="lab_icui_ContingentConsiderationGrossLT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerContractsMember_866b6951-149f-4f1f-b854-8cc9d6cceff2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contracts [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerContractsMember_label_en-US" xlink:label="lab_us-gaap_CustomerContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerContractsMember" xlink:to="lab_us-gaap_CustomerContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_df0eb7d1-f45c-48b2-a33c-d66f1f415474_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_f999962a-adcd-4061-8575-106bd8be5caa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3c9f19df-31d9-4677-a67e-0aeb67b0eb06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_be809f1f-d727-4ac7-9dd9-e4ff7379b3f9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesTable_494bfe98-a592-418e-aaf4-8202d6fb0b80_terseLabel_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities [Table]</link:label>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesTable_label_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities [Table]</link:label>
    <link:label id="lab_icui_DeferredtaxassetsandliabilitiesTable_documentation_en-US" xlink:label="lab_icui_DeferredtaxassetsandliabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesTable" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesTable" xlink:to="lab_icui_DeferredtaxassetsandliabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7499da41-4596-4b91-bf1b-5bd5ae0235e0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_79e8bfde-e04c-4ca8-a8f1-d1c4c6e6f9d1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_72a5348f-abb8-4e82-936e-cc3431adb8cc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1aa1cbf7-ad5c-40c8-be28-a587f254e6be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7226fa7f-3879-41fc-87ef-04b39b9e3afb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2d469f15-8eab-402b-a672-38caa3860758_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b3f5ce95-5948-4593-bc50-d29bca58a291_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cd983607-6b65-4d9a-9091-8f8a9644e852_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_0c5edd32-931c-4fe9-b5fb-b237ec7e72f0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_2e47296b-baff-4a72-a045-a5e81e04dfbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted_0a4fbe66-eaa1-4b5d-8cdc-3a3c057a7c1b_terseLabel_en-US" xlink:label="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock units granted</link:label>
    <link:label id="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted_label_en-US" xlink:label="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock units granted</link:label>
    <link:label id="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted_documentation_en-US" xlink:label="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock units granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueofrestrictedstockunitsgranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:to="lab_icui_Grantdatefairvalueofrestrictedstockunitsgranted" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_DeferredTaxAssetSection163j_fc3c175f-546d-41d3-95a9-71a9f926ef5c_terseLabel_en-US" xlink:label="lab_icui_DeferredTaxAssetSection163j" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Section 163(j)</link:label>
    <link:label id="lab_icui_DeferredTaxAssetSection163j_label_en-US" xlink:label="lab_icui_DeferredTaxAssetSection163j" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Section 163(j)</link:label>
    <link:label id="lab_icui_DeferredTaxAssetSection163j_documentation_en-US" xlink:label="lab_icui_DeferredTaxAssetSection163j" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Section 163(j)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredTaxAssetSection163j" xlink:href="icui-20221231.xsd#icui_DeferredTaxAssetSection163j"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_DeferredTaxAssetSection163j" xlink:to="lab_icui_DeferredTaxAssetSection163j" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_b6c7df85-cf8a-4fbc-8f67-aff743d0592d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_dad99d82-8b4d-49a0-b004-7f584bea3ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RevolverSubLimits_9a68336f-4125-4824-8858-9ffcc1817883_terseLabel_en-US" xlink:label="lab_icui_RevolverSubLimits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Sub limits</link:label>
    <link:label id="lab_icui_RevolverSubLimits_label_en-US" xlink:label="lab_icui_RevolverSubLimits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Sub limits</link:label>
    <link:label id="lab_icui_RevolverSubLimits_documentation_en-US" xlink:label="lab_icui_RevolverSubLimits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Sub limits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevolverSubLimits" xlink:href="icui-20221231.xsd#icui_RevolverSubLimits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RevolverSubLimits" xlink:to="lab_icui_RevolverSubLimits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_5506fcd5-e847-4d3e-90fc-aa38d9491665_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityMember_862ab6b2-4e87-4458-9f37-7a6d5f01c434_terseLabel_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability [Member]</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityMember_label_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability [Member]</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxLiabilityMember_documentation_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityMember" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncurrentDeferredTaxLiabilityMember" xlink:to="lab_icui_NoncurrentDeferredTaxLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9bdda2a0-52a8-4a2d-ba4b-ef1b16cd7a09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LongTermMember_c0b24ec1-3211-4403-880c-61b52275fbf3_terseLabel_en-US" xlink:label="lab_icui_LongTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term</link:label>
    <link:label id="lab_icui_LongTermMember_label_en-US" xlink:label="lab_icui_LongTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term [Member]</link:label>
    <link:label id="lab_icui_LongTermMember_documentation_en-US" xlink:label="lab_icui_LongTermMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LongTermMember" xlink:to="lab_icui_LongTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherExpenseIncomeNetLineItems_0ecbe5af-d5c9-47dd-8a84-1825ca68b8c5_terseLabel_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Line Items]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetLineItems_label_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Line Items]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetLineItems_documentation_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetLineItems" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems" xlink:to="lab_icui_OtherExpenseIncomeNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1a344ce9-8351-4968-b4d3-d9e91562cbb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermAPrincipalPaymentInYear5_0bda3229-8d94-469b-9c95-09ad6655383f_terseLabel_en-US" xlink:label="lab_icui_TermAPrincipalPaymentInYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % in Year 5</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentInYear5_label_en-US" xlink:label="lab_icui_TermAPrincipalPaymentInYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % in Year 5</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentInYear5_documentation_en-US" xlink:label="lab_icui_TermAPrincipalPaymentInYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % in Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentInYear5" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentInYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermAPrincipalPaymentInYear5" xlink:to="lab_icui_TermAPrincipalPaymentInYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_962260f1-db6f-435b-9f55-915f09888e97_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d709e8d9-1db5-4533-bd87-dd9ed9fe5704_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_68d5012c-082a-4c90-945e-73bd705e4e1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a70e269d-0736-4561-8409-286a9ef24442_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e386445a-498d-4e75-85b5-afea1ba4b1cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b4fbef45-c8a0-4524-83ee-63f4e006ad90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_b7411300-d207-4db1-8cab-17316ccf11c1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_99e7b4fd-f718-4485-838a-f6ca3997ef9d_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7e1d7db4-b93c-4d09-ac41-9a15cb048a6f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4d25d001-b8e0-41ed-9db8-3f996601729a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidVendorExpenses_6b25a34d-797f-4747-95e2-4a54cb909185_terseLabel_en-US" xlink:label="lab_icui_PrepaidVendorExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid vendor expenses</link:label>
    <link:label id="lab_icui_PrepaidVendorExpenses_label_en-US" xlink:label="lab_icui_PrepaidVendorExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid vendor expenses</link:label>
    <link:label id="lab_icui_PrepaidVendorExpenses_documentation_en-US" xlink:label="lab_icui_PrepaidVendorExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid vendor expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidVendorExpenses" xlink:href="icui-20221231.xsd#icui_PrepaidVendorExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidVendorExpenses" xlink:to="lab_icui_PrepaidVendorExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_af340ef6-f089-410b-8a0b-f6999fcb7c20_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_c4f8df4b-a133-4be2-9415-14df316822d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2963154c-6c5b-48b2-8999-c78c023e8bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_5d57694e-a656-4f9d-837f-7e727b343b5e_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_3163ce0d-2025-4b63-907f-f4d6c60d635f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_bf5f8b98-0102-4109-812c-efdf71c3167a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_f6f0b9dd-1ee6-4faa-a08a-47026a4a2f97_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OwnershipRequirementForEarnoutPayment_ea38a263-bd92-49fe-af19-7223912f2490_terseLabel_en-US" xlink:label="lab_icui_OwnershipRequirementForEarnoutPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership requirement for Earnout Payment</link:label>
    <link:label id="lab_icui_OwnershipRequirementForEarnoutPayment_label_en-US" xlink:label="lab_icui_OwnershipRequirementForEarnoutPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership requirement for Earnout Payment</link:label>
    <link:label id="lab_icui_OwnershipRequirementForEarnoutPayment_documentation_en-US" xlink:label="lab_icui_OwnershipRequirementForEarnoutPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership requirement for Earnout Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OwnershipRequirementForEarnoutPayment" xlink:href="icui-20221231.xsd#icui_OwnershipRequirementForEarnoutPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OwnershipRequirementForEarnoutPayment" xlink:to="lab_icui_OwnershipRequirementForEarnoutPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3063ebbd-53f2-4cdf-a132-347721f80c58_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_ca07ece1-54cd-44c8-a702-da9f52064135_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off/ Disposals</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f03acc87-f411-4f79-a30f-901a6ff33253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidAssetsCurrentLineItems_95736f35-1fbf-4241-9cb6-0ea7f406b559_terseLabel_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Line Items]</link:label>
    <link:label id="lab_icui_PrepaidAssetsCurrentLineItems_label_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Line Items]</link:label>
    <link:label id="lab_icui_PrepaidAssetsCurrentLineItems_documentation_en-US" xlink:label="lab_icui_PrepaidAssetsCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets Current [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentLineItems" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems" xlink:to="lab_icui_PrepaidAssetsCurrentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_f3142c08-002d-4fd4-b467-20d8c6e2e585_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring</link:label>
    <link:label id="lab_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_label_en-US" xlink:label="lab_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" xlink:to="lab_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_56d458f6-feee-4a94-8ccf-7e1f99e139c8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_738674c1-4cae-4c8c-a340-3fcb4a4efb7d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2822e6c8-f851-44d2-8203-1b3d9773357e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, State and Local Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_c80d94ef-ff66-4a01-8158-e1aadba47394_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2222145f-4308-4f3b-9e84-676627bc6d69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f3621638-9475-4db8-b80d-1fa05ab89e43_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AccruedSalariesAndBenefits_d160306a-75f2-40d7-a245-f0d0a3b568be_terseLabel_en-US" xlink:label="lab_icui_AccruedSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_icui_AccruedSalariesAndBenefits_label_en-US" xlink:label="lab_icui_AccruedSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued salaries and benefits</link:label>
    <link:label id="lab_icui_AccruedSalariesAndBenefits_documentation_en-US" xlink:label="lab_icui_AccruedSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued salaries and benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedSalariesAndBenefits" xlink:href="icui-20221231.xsd#icui_AccruedSalariesAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AccruedSalariesAndBenefits" xlink:to="lab_icui_AccruedSalariesAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_45522e53-7a27-4918-9235-445cffc71d04_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ef07ca59-af8b-4c16-8c83-314a2a566023_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60b45393-cfa0-4875-802d-bca2c278bfe6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_6d02b2de-0914-4a22-a84a-f04f7dc43d57_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc477727-14e9-4746-b2f4-7b4a70679d89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_85c6eb69-12a1-4391-8822-2e186aff6012_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_7ca760a8-558e-4905-a43d-51af03a3ace8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationDate1_126d6f15-ce0e-4986-a477-a1cda6e37799_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Date</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationDate1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_cc4d1be2-f5c3-4e19-bb27-f3b125a51c20_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2216d793-1cb1-4f88-b2ff-d1e92d2e0a96_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_50be7ff7-50aa-452b-91bd-ea8037590b21_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2db0fa39-7d90-496e-9559-0435def6a9c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorTable_68c3efc9-4e94-4f17-ac94-8d58b30f72b6_terseLabel_en-US" xlink:label="lab_dei_AuditorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Table]</link:label>
    <link:label id="lab_dei_AuditorTable_label_en-US" xlink:label="lab_dei_AuditorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorTable" xlink:to="lab_dei_AuditorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_781d2fff-271e-41ed-b0f5-55e0dd8bf9ce_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_StockIncentivePlansTable_2cb6c527-4ea7-4062-a2c8-eb9f526e5412_terseLabel_en-US" xlink:label="lab_icui_StockIncentivePlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans [Table]</link:label>
    <link:label id="lab_icui_StockIncentivePlansTable_label_en-US" xlink:label="lab_icui_StockIncentivePlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans [Table]</link:label>
    <link:label id="lab_icui_StockIncentivePlansTable_documentation_en-US" xlink:label="lab_icui_StockIncentivePlansTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansTable" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_StockIncentivePlansTable" xlink:to="lab_icui_StockIncentivePlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_3ab58ae0-5f26-4931-b0bd-7c40e03821ec_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_77035b14-5302-4405-b917-399ba13e6653_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RestructuringAdjustmentsSeveranceAndFacility_54512235-cf60-4904-9178-f445fe31a2fc_terseLabel_en-US" xlink:label="lab_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Adjustments - Severance and Facility</link:label>
    <link:label id="lab_icui_RestructuringAdjustmentsSeveranceAndFacility_label_en-US" xlink:label="lab_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Adjustments - Severance and Facility</link:label>
    <link:label id="lab_icui_RestructuringAdjustmentsSeveranceAndFacility_documentation_en-US" xlink:label="lab_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Adjustments - Severance and Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:href="icui-20221231.xsd#icui_RestructuringAdjustmentsSeveranceAndFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:to="lab_icui_RestructuringAdjustmentsSeveranceAndFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_7ee5c2df-42de-49b6-82ed-00a0fd02c0ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermAPrincipalPaymentYear3And4_28cb6e94-5351-4727-8d75-3a8e720cefcc_terseLabel_en-US" xlink:label="lab_icui_TermAPrincipalPaymentYear3And4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % Year 3 and 4</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentYear3And4_label_en-US" xlink:label="lab_icui_TermAPrincipalPaymentYear3And4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % Year 3 and 4</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentYear3And4_documentation_en-US" xlink:label="lab_icui_TermAPrincipalPaymentYear3And4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Principal Payment % Year 3 and 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentYear3And4" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentYear3And4"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermAPrincipalPaymentYear3And4" xlink:to="lab_icui_TermAPrincipalPaymentYear3And4" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_019a5c14-aac9-4cb4-a846-47651775ab5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df2da223-4c70-479e-a630-0b62435edc97_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_5d020f5c-f0c7-4133-81bc-fd6c4129292b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c5842249-4f38-4939-a469-b812caeb66c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_a8b91fbc-d660-419d-a219-163fb8dd72d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25f1c72d-535b-4163-aa08-58d55b573831_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value per option</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ContractassetandliabilitybalancesLineItems_d5780621-9396-4e5f-8fed-f12b79f75620_terseLabel_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset and liability balances [Line Items]</link:label>
    <link:label id="lab_icui_ContractassetandliabilitybalancesLineItems_label_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset and liability balances [Line Items]</link:label>
    <link:label id="lab_icui_ContractassetandliabilitybalancesLineItems_documentation_en-US" xlink:label="lab_icui_ContractassetandliabilitybalancesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Contract asset and liability balances [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesLineItems" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems" xlink:to="lab_icui_ContractassetandliabilitybalancesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ce8f4cd-2ad7-4c3a-96dc-f2e8304f0df5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6c32f3cc-c252-4e84-9ea1-f3f1db28c713_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b8bdd487-ad2e-4171-8ebf-8456d6df5b7a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_47782b0c-cdd4-4d99-8732-312176e116b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_VascularAccessMember_b66c730e-7ba2-4a6f-88fb-a1efa004a418_terseLabel_en-US" xlink:label="lab_icui_VascularAccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vascular Access</link:label>
    <link:label id="lab_icui_VascularAccessMember_label_en-US" xlink:label="lab_icui_VascularAccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vascular Access [Member]</link:label>
    <link:label id="lab_icui_VascularAccessMember_documentation_en-US" xlink:label="lab_icui_VascularAccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vascular Access</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VascularAccessMember" xlink:href="icui-20221231.xsd#icui_VascularAccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_VascularAccessMember" xlink:to="lab_icui_VascularAccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_79ddb9b3-5dde-40f7-acd7-16a1279f54c0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_d9bf4875-938a-4e78-9ecb-892b395e010f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3ff11805-abec-4d42-a0f3-fa176d2580e0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LessThan275To100Member_f9c36ff0-6238-4862-9056-bb84b0eece37_terseLabel_en-US" xlink:label="lab_icui_LessThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than 2.75 to1.00</link:label>
    <link:label id="lab_icui_LessThan275To100Member_label_en-US" xlink:label="lab_icui_LessThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than 2.75 to1.00 [Member]</link:label>
    <link:label id="lab_icui_LessThan275To100Member_documentation_en-US" xlink:label="lab_icui_LessThan275To100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than 2.75:1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThan275To100Member" xlink:href="icui-20221231.xsd#icui_LessThan275To100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LessThan275To100Member" xlink:to="lab_icui_LessThan275To100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherLiabilitiesTable_273dc750-955c-4c0d-ab49-9cfbc415f37b_terseLabel_en-US" xlink:label="lab_icui_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Table]</link:label>
    <link:label id="lab_icui_OtherLiabilitiesTable_label_en-US" xlink:label="lab_icui_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Table]</link:label>
    <link:label id="lab_icui_OtherLiabilitiesTable_documentation_en-US" xlink:label="lab_icui_OtherLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesTable" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherLiabilitiesTable" xlink:to="lab_icui_OtherLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9e83ecc-2cf8-4a1b-bf98-c9f317c23d58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57d4c81c-f7c4-4811-aebb-430d8492080d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d850f5fc-a211-4fe0-aa67-b4a1f57e2e34_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_155811b5-4888-4270-874f-fba93ae0a121_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_33475fa2-29be-4fec-a4a3-eec8d89e8343_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c599543f-39cd-4176-9157-0f9f6d0ca635_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans_09c86555-257f-4839-8d42-d5bae028e757_terseLabel_en-US" xlink:label="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ter SOFR Interest Rate % Adjustment for Base Rate Loans</link:label>
    <link:label id="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans_label_en-US" xlink:label="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ter SOFR Interest Rate % Adjustment for Base Rate Loans</link:label>
    <link:label id="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans_documentation_en-US" xlink:label="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ter SOFR Interest Rate % Adjustment for Base Rate Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:href="icui-20221231.xsd#icui_TerSOFRInterestRateAdjustmentForBaseRateLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:to="lab_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_805d992d-190f-46d8-b327-17bbbc071666_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9422c084-1917-473f-ad90-9e88a32f6696_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Changeinunitsduetoperformanceexpectations_1e982e30-f628-4c2b-a74c-3cdcee124100_terseLabel_en-US" xlink:label="lab_icui_Changeinunitsduetoperformanceexpectations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in units due to performance expectations</link:label>
    <link:label id="lab_icui_Changeinunitsduetoperformanceexpectations_label_en-US" xlink:label="lab_icui_Changeinunitsduetoperformanceexpectations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in units due to performance expectations</link:label>
    <link:label id="lab_icui_Changeinunitsduetoperformanceexpectations_documentation_en-US" xlink:label="lab_icui_Changeinunitsduetoperformanceexpectations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in units due to performance expectations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Changeinunitsduetoperformanceexpectations" xlink:href="icui-20221231.xsd#icui_Changeinunitsduetoperformanceexpectations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Changeinunitsduetoperformanceexpectations" xlink:to="lab_icui_Changeinunitsduetoperformanceexpectations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_aa3cdb24-c173-4889-ae6c-aefd7c9257a1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_e65d007f-77cd-4de4-85d5-051ae7d2be43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_ef12e119-587d-4457-9400-b447ef5ede65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e9a5b2bb-3f42-40b5-bd0e-d96997a114d1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_b423c8a7-bc61-4d1b-891e-ea37f50667d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_c39ff5f5-c235-49b2-ba3f-ea6f9ad25f10_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8d04dfda-592d-4280-8d04-c8e087e73255_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d23fc3d5-46dc-4b2a-ac6f-73cdba0a6936_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1b3df891-9a4c-480d-b8ce-3167ec893707_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_062b810a-b8f8-4b3d-9504-0dcc839ec915_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4f0d4829-64f7-459f-85cd-bfbce7cc1343_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ab97ca1d-058b-4d4e-922a-45e91553eea1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4d053cb9-62ca-4432-b7b3-b7961a479e4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b3f278cd-6c2e-4237-809a-cbcc43ad3601_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesLineItems_33cd8cd8-9c21-4239-86f5-bd1cc839b6c2_terseLabel_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_icui_ScheduleOfAccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:to="lab_icui_ScheduleOfAccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4ad1156e-93aa-4761-9ef2-8ad059976aae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a6b71742-4fdf-4584-a5b8-ed20456e126e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_51956ab8-bec0-48b6-94f3-969f2dd01c54_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_44742795-3d03-4d75-9499-930f98fa31fd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_GILTItaxexpensepercent_1fc0887e-3716-44b0-9165-dabb8cfd302c_terseLabel_en-US" xlink:label="lab_icui_GILTItaxexpensepercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpensepercent</link:label>
    <link:label id="lab_icui_GILTItaxexpensepercent_label_en-US" xlink:label="lab_icui_GILTItaxexpensepercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpensepercent</link:label>
    <link:label id="lab_icui_GILTItaxexpensepercent_documentation_en-US" xlink:label="lab_icui_GILTItaxexpensepercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTItaxexpensepercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GILTItaxexpensepercent" xlink:href="icui-20221231.xsd#icui_GILTItaxexpensepercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_GILTItaxexpensepercent" xlink:to="lab_icui_GILTItaxexpensepercent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems_e351ca0f-aedb-45d4-8faf-30919260d304_terseLabel_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Based on Leverage Ratio [Line Items]</link:label>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems_label_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Based on Leverage Ratio [Line Items]</link:label>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems_documentation_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Based on Leverage Ratio [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:to="lab_icui_ApplicableMarginBasedOnLeverageRatioLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8933c467-1298-4a63-8cc9-b8bbfb274bb2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Deferredtaxcharge_39dce278-bb5a-4b50-9167-529b8a132e28_terseLabel_en-US" xlink:label="lab_icui_Deferredtaxcharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax charge</link:label>
    <link:label id="lab_icui_Deferredtaxcharge_label_en-US" xlink:label="lab_icui_Deferredtaxcharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax charge</link:label>
    <link:label id="lab_icui_Deferredtaxcharge_documentation_en-US" xlink:label="lab_icui_Deferredtaxcharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxcharge" xlink:href="icui-20221231.xsd#icui_Deferredtaxcharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Deferredtaxcharge" xlink:to="lab_icui_Deferredtaxcharge" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LongTermContingentConsiderationGross_9c5d9e21-78d8-4ae4-ba6a-9436b7a82cc1_terseLabel_en-US" xlink:label="lab_icui_LongTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent consideration-gross</link:label>
    <link:label id="lab_icui_LongTermContingentConsiderationGross_label_en-US" xlink:label="lab_icui_LongTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent consideration-gross</link:label>
    <link:label id="lab_icui_LongTermContingentConsiderationGross_documentation_en-US" xlink:label="lab_icui_LongTermContingentConsiderationGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent consideration-gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LongTermContingentConsiderationGross" xlink:to="lab_icui_LongTermContingentConsiderationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_19e2c5fb-7cc2-4a93-8f9c-a0934419766c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e8749e51-949a-4b9d-9311-f17c12056317_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_7cf94af9-6024-4fa4-97ba-e91c9cc4f8fa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_91f88f82-f30f-4c0f-b609-6a99c0f982df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c746cb1f-fba1-4d2b-a69b-d08db0363154_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Sharestransferredfromsupersededplan_14feebe8-4e31-4259-a6f5-10c10ffc164e_terseLabel_en-US" xlink:label="lab_icui_Sharestransferredfromsupersededplan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares transferred from superseded plan</link:label>
    <link:label id="lab_icui_Sharestransferredfromsupersededplan_label_en-US" xlink:label="lab_icui_Sharestransferredfromsupersededplan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares transferred from superseded plan</link:label>
    <link:label id="lab_icui_Sharestransferredfromsupersededplan_documentation_en-US" xlink:label="lab_icui_Sharestransferredfromsupersededplan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares transferred from superseded plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sharestransferredfromsupersededplan" xlink:href="icui-20221231.xsd#icui_Sharestransferredfromsupersededplan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Sharestransferredfromsupersededplan" xlink:to="lab_icui_Sharestransferredfromsupersededplan" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions_a88e50c6-f9f8-4a81-9cc6-ea29369f3538_negatedTerseLabel_en-US" xlink:label="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions_label_en-US" xlink:label="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Paid (Received) for current and prior acquisitions</link:label>
    <link:label id="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions_documentation_en-US" xlink:label="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Paid (Received) for current and prior acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:href="icui-20221231.xsd#icui_NetCashPaidReceivedforcurrentandprioracquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:to="lab_icui_NetCashPaidReceivedforcurrentandprioracquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8aad57d7-0f6f-4b41-a21f-17ac9286143a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_e25b1125-8672-4557-a068-1893756195e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract_3c49fc6e-fc5a-4ac5-9611-47ce7db2d032_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Areas, Long-Lived Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Areas, Long-Lived Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:to="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_3029e6a3-8700-4d1d-8518-ddcad9f29a24_terseLabel_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_label_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_documentation_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:to="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_89c0fdf9-f83d-4092-9f77-ac67ced10b37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8ee94e1f-f167-49a0-aab1-560ab37eda6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_46590904-3f8e-4b4f-bdd9-388ac1e8fd3d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_230f2ffc-9a0c-4de6-860e-0f6b9d7287ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bcff6101-51ce-4350-9ab8-87e11f361638_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_11d5b30c-ca6b-403c-8b4d-147434fda22e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState_e70c32ff-4d56-4741-b5c2-4605d59f8788_terseLabel_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - tax credits state</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState_label_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - tax credits state</link:label>
    <link:label id="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState_documentation_en-US" xlink:label="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - tax credits state</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxAssetTaxCreditsState"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:to="lab_icui_NoncurrentDeferredTaxAssetTaxCreditsState" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6375081f-6b4c-400b-8cd0-1a7bb54c6ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_706a9b6f-460c-4824-aabf-0d61bfe53738_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_126753f4-894b-46ea-91a2-9682fdebf9e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f1848f65-5562-4189-a2eb-9910d57d70f9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Hedge4Member_bd1fc207-e330-4f1a-b518-4843ec8790ae_terseLabel_en-US" xlink:label="lab_icui_Hedge4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 4</link:label>
    <link:label id="lab_icui_Hedge4Member_label_en-US" xlink:label="lab_icui_Hedge4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 4 [Member]</link:label>
    <link:label id="lab_icui_Hedge4Member_documentation_en-US" xlink:label="lab_icui_Hedge4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge4Member" xlink:href="icui-20221231.xsd#icui_Hedge4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Hedge4Member" xlink:to="lab_icui_Hedge4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4faeaa0f-e3ff-49ee-845b-d1f856e92a5e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6e19e429-ab3c-4b1d-9a76-a4f96af192d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_186d5c7b-c49d-4629-8823-fec747eb5b05_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_c0824779-b575-41fc-81a0-e6bf8d9b161f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AccountsReceivablePurchaseProgram_53d102e8-f037-4ef9-97ac-0f64f02986f0_terseLabel_en-US" xlink:label="lab_icui_AccountsReceivablePurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accounts receivable purchase program</link:label>
    <link:label id="lab_icui_AccountsReceivablePurchaseProgram_label_en-US" xlink:label="lab_icui_AccountsReceivablePurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accounts receivable purchase program</link:label>
    <link:label id="lab_icui_AccountsReceivablePurchaseProgram_documentation_en-US" xlink:label="lab_icui_AccountsReceivablePurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accounts receivable purchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccountsReceivablePurchaseProgram" xlink:href="icui-20221231.xsd#icui_AccountsReceivablePurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AccountsReceivablePurchaseProgram" xlink:to="lab_icui_AccountsReceivablePurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Outsidesalescommissions_2ae7ab3e-602e-4f66-930b-2bb11b993ba4_terseLabel_en-US" xlink:label="lab_icui_Outsidesalescommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside commissions</link:label>
    <link:label id="lab_icui_Outsidesalescommissions_label_en-US" xlink:label="lab_icui_Outsidesalescommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside sales commissions</link:label>
    <link:label id="lab_icui_Outsidesalescommissions_documentation_en-US" xlink:label="lab_icui_Outsidesalescommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside sales commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Outsidesalescommissions" xlink:href="icui-20221231.xsd#icui_Outsidesalescommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Outsidesalescommissions" xlink:to="lab_icui_Outsidesalescommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_994a0846-f442-4546-80a8-9d58b52c4ce4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_6c30920a-9cbc-4dd2-a129-58015ddd896a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_a6690d63-373a-40f1-b364-820771ff0beb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:to="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1a3efbae-28ea-4fa0-a93a-bf608f970d03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_16a67b91-2b4f-4da1-8c97-fe31532b05a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_16996d46-802f-4d36-b6a1-4db251d698fd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investment securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AUD_b32e8969-47d7-4889-a9e7-2dc31b383508_terseLabel_en-US" xlink:label="lab_currency_AUD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia, Dollars</link:label>
    <link:label id="lab_currency_AUD_label_en-US" xlink:label="lab_currency_AUD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AUD" xlink:to="lab_currency_AUD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c418e249-b5a8-427a-be77-ff709bd92b6f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_85057952-7660-45bd-af21-ab3e45301dc7_terseLabel_en-US" xlink:label="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Non-compete agreement with associated contingent earn-out liability</link:label>
    <link:label id="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_label_en-US" xlink:label="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Non-compete agreement with associated contingent earn-out liability</link:label>
    <link:label id="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_documentation_en-US" xlink:label="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Non-compete agreement with associated contingent earn-out liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:href="icui-20221231.xsd#icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:to="lab_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_467b43c7-b568-4677-94c8-7dbd87915708_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1838a4d5-f606-46b3-90aa-5b9fe65d0d53_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_8a3811c8-90fe-4fc1-9db5-91726142de74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Receivable, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Receivable, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquiredReceivablesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f617d630-7868-45c8-8453-5f9e137d61e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember_92dc74af-a31a-4000-879e-b6f25fe3557c_terseLabel_en-US" xlink:label="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset, gross total [Member]</link:label>
    <link:label id="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember_label_en-US" xlink:label="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset, gross total [Member]</link:label>
    <link:label id="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember_documentation_en-US" xlink:label="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of gross non-current deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:href="icui-20221231.xsd#icui_NonCurrentDeferredTaxAssetGrossTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:to="lab_icui_NonCurrentDeferredTaxAssetGrossTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_2141d143-296b-4f0f-8a2e-f451019cb1cb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3b511558-c22f-49a7-94a8-4d2d87344cb4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_17818083-7331-461d-aca7-13adeae78116_terseLabel_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_label_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_documentation_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:to="lab_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InfusionConsumablesMember_335a6156-3b66-4a72-b6b7-4df5849f8edb_terseLabel_en-US" xlink:label="lab_icui_InfusionConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables [Member]</link:label>
    <link:label id="lab_icui_InfusionConsumablesMember_label_en-US" xlink:label="lab_icui_InfusionConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables [Member]</link:label>
    <link:label id="lab_icui_InfusionConsumablesMember_documentation_en-US" xlink:label="lab_icui_InfusionConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesMember" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InfusionConsumablesMember" xlink:to="lab_icui_InfusionConsumablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ae1214ea-0f61-43ca-9d97-e64bbc42eecc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a0e2bf75-7b70-4d72-aa2c-c4a9579463e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f5c52d9b-1cee-4fa1-af70-efe3575576dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f7c4ce0b-95da-4d85-ba11-409094bd50af_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9ae5c30a-8d6a-4830-a3c9-17d6c235e540_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_db072438-3038-4899-94e6-68c8b2ed6b32_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_aacc788f-8a41-459d-bbed-935fedcab502_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_cb71d5b1-1c7b-4cc3-ab6a-9bbb8666e159_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_d301445d-c6d5-4bec-8405-efb98bff7e97_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_37500f61-1fae-4bdf-98c9-1e58b7c7d157_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_640f504a-3472-4c1b-917b-4d2986e93481_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:to="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_252913f1-7e45-4aee-a2dd-d3c37a23e1d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranties and returns</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_40969858-a694-4bbc-825c-b712eb032472_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_681ff8bf-ca7d-461f-8131-4ad85a31965f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLineItems_3cd51eea-28e2-4861-887f-874f5b53896a_terseLabel_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:label id="lab_dei_AuditorLineItems_label_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLineItems" xlink:to="lab_dei_AuditorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CZK_65ab8591-fcba-4401-af6e-658799156d7c_terseLabel_en-US" xlink:label="lab_currency_CZK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Czech Republic, Koruny</link:label>
    <link:label id="lab_currency_CZK_label_en-US" xlink:label="lab_currency_CZK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Czech Republic, Koruny</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CZK" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CZK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CZK" xlink:to="lab_currency_CZK" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_15792ea5-d831-482b-ba85-e196f8e0c75e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6b801629-15d2-4597-a9c4-5ee5bf8857e3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_47720a3f-d54e-478a-b5a9-bcc3e16ea944_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Grantdatefairvalueperformancerestrictedstockunits_e3788f95-0360-4f88-be66-7322b79e1159_terseLabel_en-US" xlink:label="lab_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value performance restricted stock units</link:label>
    <link:label id="lab_icui_Grantdatefairvalueperformancerestrictedstockunits_label_en-US" xlink:label="lab_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value performance restricted stock units</link:label>
    <link:label id="lab_icui_Grantdatefairvalueperformancerestrictedstockunits_documentation_en-US" xlink:label="lab_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value performance restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueperformancerestrictedstockunits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:to="lab_icui_Grantdatefairvalueperformancerestrictedstockunits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aea2b861-621b-43bc-8d89-17286f5d1399_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fec24a7a-9b65-4738-a9fd-34428a6f7f12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_635a9ec1-a468-47be-ba20-f156ffad1a25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_24638d19-4a64-449d-b961-b96f89d01925_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_475d903b-30cf-4e43-bc72-c310cc67cb0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ff842fcf-bb68-41f5-9ded-2e67797c8188_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_cfefffa6-b704-4560-94aa-512d2573195f_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantyReservesMember_3c145e92-7db4-4385-a6e0-85edb217d2f6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantyReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Warranty</link:label>
    <link:label id="lab_us-gaap_WarrantyReservesMember_label_en-US" xlink:label="lab_us-gaap_WarrantyReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Warranty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantyReservesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantyReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantyReservesMember" xlink:to="lab_us-gaap_WarrantyReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_28013c13-9d21-454d-8439-3a50438cf7d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_25a69edb-2794-444b-9a81-5aa02a8bcc14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember_bc4031dd-46b6-467d-a24f-26567e163811_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac0cff9c-bb02-42e4-9a22-e3b1c0b845c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ShortTermMember_8a95ce37-32cb-4aea-b710-57920ee8255e_terseLabel_en-US" xlink:label="lab_icui_ShortTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term</link:label>
    <link:label id="lab_icui_ShortTermMember_label_en-US" xlink:label="lab_icui_ShortTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term [Member]</link:label>
    <link:label id="lab_icui_ShortTermMember_documentation_en-US" xlink:label="lab_icui_ShortTermMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermMember" xlink:href="icui-20221231.xsd#icui_ShortTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ShortTermMember" xlink:to="lab_icui_ShortTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_MiscellaneousIncomeNet_2b37d3f4-c5fe-482d-a42c-20a950116299_terseLabel_en-US" xlink:label="lab_icui_MiscellaneousIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">miscellaneous income, net</link:label>
    <link:label id="lab_icui_MiscellaneousIncomeNet_label_en-US" xlink:label="lab_icui_MiscellaneousIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">miscellaneous income, net</link:label>
    <link:label id="lab_icui_MiscellaneousIncomeNet_documentation_en-US" xlink:label="lab_icui_MiscellaneousIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">miscellaneous income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MiscellaneousIncomeNet" xlink:href="icui-20221231.xsd#icui_MiscellaneousIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_MiscellaneousIncomeNet" xlink:to="lab_icui_MiscellaneousIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5433de51-1c8c-4bbf-a6b3-4dc0506b1899_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandBuildingsAndImprovementsMember_52cad7e0-e3f0-4c91-afd5-573f5842b31b_terseLabel_en-US" xlink:label="lab_us-gaap_LandBuildingsAndImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Buildings and Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LandBuildingsAndImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandBuildingsAndImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Buildings and Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandBuildingsAndImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandBuildingsAndImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandBuildingsAndImprovementsMember" xlink:to="lab_us-gaap_LandBuildingsAndImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1e03b03a-778c-4b09-be24-da799865beb2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8ba40c27-69b7-48a0-b95a-e1b93f41f802_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CR_6b20d50c-2eb1-492c-a7a7-bb25badc19eb_terseLabel_en-US" xlink:label="lab_country_CR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COSTA RICA</link:label>
    <link:label id="lab_country_CR_label_en-US" xlink:label="lab_country_CR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COSTA RICA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CR" xlink:to="lab_country_CR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_b8c95a82-564e-44ab-bd50-142d3ef75d8c_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_bcc7ac76-eb73-4a34-b188-46a7551a1879_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_16d6cebe-dd6f-4363-af00-58b3a9338f3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherforeigncountriesMember_06c4331e-591d-4381-af37-124b1b08c083_terseLabel_en-US" xlink:label="lab_icui_OtherforeigncountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries [Member]</link:label>
    <link:label id="lab_icui_OtherforeigncountriesMember_label_en-US" xlink:label="lab_icui_OtherforeigncountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries [Member]</link:label>
    <link:label id="lab_icui_OtherforeigncountriesMember_documentation_en-US" xlink:label="lab_icui_OtherforeigncountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherforeigncountriesMember" xlink:href="icui-20221231.xsd#icui_OtherforeigncountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherforeigncountriesMember" xlink:to="lab_icui_OtherforeigncountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_08624c72-a306-4888-9dd8-ce3364b51b4e_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_ebf82684-5474-4344-85de-29fe5a914803_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dd464df4-6b45-47c3-b982-8d385ce03310_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_NoncurrentMember_2b3d26d1-95ec-4a69-a608-76e0aa9d5eaf_terseLabel_en-US" xlink:label="lab_icui_NoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">noncurrent</link:label>
    <link:label id="lab_icui_NoncurrentMember_label_en-US" xlink:label="lab_icui_NoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">noncurrent [Member]</link:label>
    <link:label id="lab_icui_NoncurrentMember_documentation_en-US" xlink:label="lab_icui_NoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentMember" xlink:href="icui-20221231.xsd#icui_NoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_NoncurrentMember" xlink:to="lab_icui_NoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_742f4965-9836-4bbf-a28e-83acc7cdf5b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_31d6757f-3899-4f78-85b1-df41c1929848_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_e60650ff-0b28-448c-894a-5fbf0a71252b_terseLabel_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_label_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent</link:label>
    <link:label id="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_documentation_en-US" xlink:label="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:to="lab_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermAPrincipalPaymentFirst2Years_0a94ea7d-3d6e-48ff-9195-6e4fad9c2f78_terseLabel_en-US" xlink:label="lab_icui_TermAPrincipalPaymentFirst2Years" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A principal payment % First 2 Years</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentFirst2Years_label_en-US" xlink:label="lab_icui_TermAPrincipalPaymentFirst2Years" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A principal payment % First 2 Years</link:label>
    <link:label id="lab_icui_TermAPrincipalPaymentFirst2Years_documentation_en-US" xlink:label="lab_icui_TermAPrincipalPaymentFirst2Years" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A principal payment % First 2 Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentFirst2Years" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentFirst2Years"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermAPrincipalPaymentFirst2Years" xlink:to="lab_icui_TermAPrincipalPaymentFirst2Years" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c1d42d3f-0cdd-4ee5-acb7-986c6c5c6bc0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_0f6e6a11-386e-48d8-a438-93059f627561_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0a26de12-6e2b-4828-b420-724f1e90d83f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_41fc37b4-640e-4ec1-8047-1280fc293a97_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a326fb24-67c7-438b-961f-8d9aa27f7c08_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8327c85a-c9cb-4a1c-9446-0e07ab3815ea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_c1cf89b3-1f0f-4268-a66d-d219abc345d8_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1f87ee80-ec42-4a94-b92c-620c03951417_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_a3e65769-3cf3-4f6c-811f-185156328d56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_49b6717d-8fa5-4689-9b26-bf641eedca6a_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_a8bcc3ef-e3ec-462e-9f61-44cebd3f01f0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_f2b04a09-87c8-421b-8ebf-e6cea54af035_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b396fe16-f068-437b-8442-5142db33cec3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3b0b96da-4584-4021-8e43-98440b4859a2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_VitalCareMember_803c7fb9-4c0b-45ba-93d1-91d50dbd9f4d_terseLabel_en-US" xlink:label="lab_icui_VitalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Care</link:label>
    <link:label id="lab_icui_VitalCareMember_label_en-US" xlink:label="lab_icui_VitalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Care [Member]</link:label>
    <link:label id="lab_icui_VitalCareMember_documentation_en-US" xlink:label="lab_icui_VitalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VitalCareMember" xlink:href="icui-20221231.xsd#icui_VitalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_VitalCareMember" xlink:to="lab_icui_VitalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_12cb43e9-d3c3-49dc-88d3-4e54b7584193_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PerformanceSharesEarned_2914ea2e-4df4-4ff0-957f-8ddbdd714de8_terseLabel_en-US" xlink:label="lab_icui_PerformanceSharesEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares Earned</link:label>
    <link:label id="lab_icui_PerformanceSharesEarned_label_en-US" xlink:label="lab_icui_PerformanceSharesEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares Earned</link:label>
    <link:label id="lab_icui_PerformanceSharesEarned_documentation_en-US" xlink:label="lab_icui_PerformanceSharesEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceSharesEarned" xlink:href="icui-20221231.xsd#icui_PerformanceSharesEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PerformanceSharesEarned" xlink:to="lab_icui_PerformanceSharesEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_094c007e-17e0-4db0-95e3-b0c5a2d29369_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioTable_f9bff879-89ce-4d9d-8726-84247191e449_terseLabel_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin on Loan Type</link:label>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioTable_label_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Based on Leverage Ratio [Table]</link:label>
    <link:label id="lab_icui_ApplicableMarginBasedOnLeverageRatioTable_documentation_en-US" xlink:label="lab_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin Based on Leverage Ratio [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:to="lab_icui_ApplicableMarginBasedOnLeverageRatioTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditRiskMember_bc64ce67-8fdb-473a-a01d-f57cd1a11fcd_terseLabel_en-US" xlink:label="lab_us-gaap_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CreditRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditRiskMember" xlink:to="lab_us-gaap_CreditRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Hedge3MemberMember_50ff8f23-d123-4692-8dcb-8237e6ad7653_terseLabel_en-US" xlink:label="lab_icui_Hedge3MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 3 [Member] [Member]</link:label>
    <link:label id="lab_icui_Hedge3MemberMember_label_en-US" xlink:label="lab_icui_Hedge3MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 3 [Member] [Member]</link:label>
    <link:label id="lab_icui_Hedge3MemberMember_documentation_en-US" xlink:label="lab_icui_Hedge3MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge3MemberMember" xlink:href="icui-20221231.xsd#icui_Hedge3MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Hedge3MemberMember" xlink:to="lab_icui_Hedge3MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_19950d45-48ac-49ba-88e6-374b9d8f44ed_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_56cce078-99a5-42c0-8d01-cffea19c59f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ac321599-1425-4eec-aa8f-ace6a2706e50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1b491560-5c80-487f-b65a-baf8fd02f945_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_dd188b2d-999a-4550-9ceb-5ab2577bafc7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7cb54e07-615f-4fd9-83b6-23869310bfe6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_e5768ef4-c5fe-4c2b-b696-5e67d9dcc622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f45f8bc0-5ca0-423d-b8b3-0a8a3b5965f8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_DerivativeInterestRateFloor_739b563b-f2e3-424b-80bf-446e608e1d26_terseLabel_en-US" xlink:label="lab_icui_DerivativeInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Interest Rate Floor</link:label>
    <link:label id="lab_icui_DerivativeInterestRateFloor_label_en-US" xlink:label="lab_icui_DerivativeInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Interest Rate Floor</link:label>
    <link:label id="lab_icui_DerivativeInterestRateFloor_documentation_en-US" xlink:label="lab_icui_DerivativeInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Interest Rate Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DerivativeInterestRateFloor" xlink:href="icui-20221231.xsd#icui_DerivativeInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_DerivativeInterestRateFloor" xlink:to="lab_icui_DerivativeInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d5b6f3d-1beb-4e1f-b9de-c86a0761ca81_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3bd218ba-1a14-4b46-9e49-8af0ee4357ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_24786238-b4c7-407a-a1ae-6441a053cb65_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3c40391f-f6d5-40bb-bf66-aad1ced1c329_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_08a7e429-ebe6-4f41-9bdb-581b03d5935f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1ceb0529-839c-43c2-806b-9e015a67456d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestExpenseIncomeNetDomain_5e16e315-93a6-404b-a437-d40709c640d3_terseLabel_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Domain]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetDomain_label_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net [Domain]</link:label>
    <link:label id="lab_icui_InterestExpenseIncomeNetDomain_documentation_en-US" xlink:label="lab_icui_InterestExpenseIncomeNetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetDomain" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestExpenseIncomeNetDomain" xlink:to="lab_icui_InterestExpenseIncomeNetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ClassificationAxis_13df79d3-2e58-4e2b-bf73-c7a7c42c4433_terseLabel_en-US" xlink:label="lab_icui_ClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification [Axis]</link:label>
    <link:label id="lab_icui_ClassificationAxis_label_en-US" xlink:label="lab_icui_ClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification [Axis]</link:label>
    <link:label id="lab_icui_ClassificationAxis_documentation_en-US" xlink:label="lab_icui_ClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationAxis" xlink:href="icui-20221231.xsd#icui_ClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ClassificationAxis" xlink:to="lab_icui_ClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_84e87397-fa7d-4f3b-a828-82fe895eb17a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c37e7596-1500-40e3-af35-469f15ded92f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63deb3f0-a4a4-47d5-8520-e40e63bcb3d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_5fd655cc-6445-4324-b007-9752d015806d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_71879fe6-3181-4059-90e5-905fe2d1dcd3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_bc6f2b52-e24f-4e4b-8493-ff830e075f24_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d92f7ac2-fce7-43b7-a3da-162213e8b98f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_38b508f0-3f7b-436c-9de6-a6130329253e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositAssets_df026d2f-81bf-4836-b11f-4accbc1b0070_terseLabel_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets</link:label>
    <link:label id="lab_us-gaap_DepositAssets_label_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7e40ff6f-4265-4c40-a88a-20a399e6d240_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_3784b5d7-a8f7-4bd0-a6a6-ec3021c83d3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock_84ff0e2c-3624-4293-94f2-0217da6c2c8c_terseLabel_en-US" xlink:label="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Leases</link:label>
    <link:label id="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock_label_en-US" xlink:label="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Leases [Table Text Block]</link:label>
    <link:label id="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock_documentation_en-US" xlink:label="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:href="icui-20221231.xsd#icui_SupplementalBalanceSheetInformationLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:to="lab_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_98554ec0-08ba-49ac-a703-2323cd046bfd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e45672e2-4b64-4c94-9821-d419cd2e0ed9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Contractsettlements_5c09c409-aa8c-49f1-929f-5b1a38e581d9_terseLabel_en-US" xlink:label="lab_icui_Contractsettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractsettlements</link:label>
    <link:label id="lab_icui_Contractsettlements_label_en-US" xlink:label="lab_icui_Contractsettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractsettlements</link:label>
    <link:label id="lab_icui_Contractsettlements_documentation_en-US" xlink:label="lab_icui_Contractsettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractsettlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contractsettlements" xlink:href="icui-20221231.xsd#icui_Contractsettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Contractsettlements" xlink:to="lab_icui_Contractsettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_bb08d26c-c709-43c6-b7bb-5e4947697491_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_281a2151-172e-43dd-a638-f093080caefc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7602472b-c21f-49cb-aadf-5c882f195fa7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ee0745d3-896f-4886-b243-f185df166aa4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_858042e3-75ad-4d43-bcc9-c35edc2f52b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_fa675088-b871-4048-bfbc-33c7d4bfb130_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c465108c-2c16-4ca6-8fc2-ddd59722ebe8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_7294f378-46d4-41f8-93ad-513a2d46661f_terseLabel_en-US" xlink:label="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes, including excess tax benefits and deferred income taxes</link:label>
    <link:label id="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_label_en-US" xlink:label="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in income taxes, including excess tax benefits and deferred income taxes</link:label>
    <link:label id="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_documentation_en-US" xlink:label="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the carrying amount as of the balance sheet date of payments made for taxes. Also includes the net change during the reporting period in the account that represents the temporary difference that results from income (loss) that is recognized for accounting purposes but not for tax purposes and vice versa.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:href="icui-20221231.xsd#icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:to="lab_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_910f67fa-5716-4c60-b731-e88246c34b33_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c9d03961-80d5-4e3c-b12f-ebf858bc1726_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ModifiedPRSUIncrementalExpense_8ac17254-1507-4c34-b548-057df7348c9c_terseLabel_en-US" xlink:label="lab_icui_ModifiedPRSUIncrementalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modified PRSU Incremental Expense</link:label>
    <link:label id="lab_icui_ModifiedPRSUIncrementalExpense_label_en-US" xlink:label="lab_icui_ModifiedPRSUIncrementalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modified PRSU Incremental Expense</link:label>
    <link:label id="lab_icui_ModifiedPRSUIncrementalExpense_documentation_en-US" xlink:label="lab_icui_ModifiedPRSUIncrementalExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modified PRSU Incremental Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ModifiedPRSUIncrementalExpense" xlink:href="icui-20221231.xsd#icui_ModifiedPRSUIncrementalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ModifiedPRSUIncrementalExpense" xlink:to="lab_icui_ModifiedPRSUIncrementalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_beb52f66-7064-484b-95f8-35685f98eea4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1b53a90b-682a-4fbc-bf81-d77cb3aef84f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_89aa4722-dcd4-4e56-abcd-ee5f12271f92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3bc481e0-18a3-4b5e-9631-71aa6f117ace_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestPercentageAddedToFederalFundsRate_6450207e-db94-4cfc-b0f6-bed5deabf4db_terseLabel_en-US" xlink:label="lab_icui_InterestPercentageAddedToFederalFundsRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Federal Funds Rate</link:label>
    <link:label id="lab_icui_InterestPercentageAddedToFederalFundsRate_label_en-US" xlink:label="lab_icui_InterestPercentageAddedToFederalFundsRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Federal Funds Rate</link:label>
    <link:label id="lab_icui_InterestPercentageAddedToFederalFundsRate_documentation_en-US" xlink:label="lab_icui_InterestPercentageAddedToFederalFundsRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Percentage Added to Federal Funds Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestPercentageAddedToFederalFundsRate" xlink:href="icui-20221231.xsd#icui_InterestPercentageAddedToFederalFundsRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestPercentageAddedToFederalFundsRate" xlink:to="lab_icui_InterestPercentageAddedToFederalFundsRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0a01fc7f-ae47-4d7c-aaa6-74abc5c4c39a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AccruedProductFieldAction._8e2ece21-8374-4ddb-9b99-3c609b684443_terseLabel_en-US" xlink:label="lab_icui_AccruedProductFieldAction." xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Field Action.</link:label>
    <link:label id="lab_icui_AccruedProductFieldAction._label_en-US" xlink:label="lab_icui_AccruedProductFieldAction." xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Field Action.</link:label>
    <link:label id="lab_icui_AccruedProductFieldAction._documentation_en-US" xlink:label="lab_icui_AccruedProductFieldAction." xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Field Action.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedProductFieldAction." xlink:href="icui-20221231.xsd#icui_AccruedProductFieldAction."/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AccruedProductFieldAction." xlink:to="lab_icui_AccruedProductFieldAction." xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c7b3f9bb-9a94-4c52-8d76-d8d926f4aec9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b08795f0-6402-419f-a5bb-c5042b802f14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f1f350dd-84cb-45b5-afa9-081541300e15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_80c12613-68e6-41d7-b478-2d007db56d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $8,530 at December 31, 2022 and $7,038 at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_541ad623-5339-4a2d-accd-cf46b5e11416_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_90e90b03-e634-4f06-bb6e-c26e9109f996_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cd7b7e87-0700-41bd-98e4-a466a27fed64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisAxis_2151a0fe-a12f-4be1-ae95-986412bfa9be_terseLabel_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis [Axis]</link:label>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisAxis_label_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis [Axis]</link:label>
    <link:label id="lab_icui_Srt_MultipleCurrencyAxisAxis_documentation_en-US" xlink:label="lab_icui_Srt_MultipleCurrencyAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">srt_MultipleCurrencyAxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisAxis" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Srt_MultipleCurrencyAxisAxis" xlink:to="lab_icui_Srt_MultipleCurrencyAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad0516c2-1284-4c8b-acb6-42644fdd8eef_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TotalSeniorSecuredCreditFacility_a298c9ff-a7bf-4950-bc8b-ad71f80528b2_terseLabel_en-US" xlink:label="lab_icui_TotalSeniorSecuredCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalSeniorSecuredCreditFacility</link:label>
    <link:label id="lab_icui_TotalSeniorSecuredCreditFacility_label_en-US" xlink:label="lab_icui_TotalSeniorSecuredCreditFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalSeniorSecuredCreditFacility</link:label>
    <link:label id="lab_icui_TotalSeniorSecuredCreditFacility_documentation_en-US" xlink:label="lab_icui_TotalSeniorSecuredCreditFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalSeniorSecuredCreditFacility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TotalSeniorSecuredCreditFacility" xlink:href="icui-20221231.xsd#icui_TotalSeniorSecuredCreditFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TotalSeniorSecuredCreditFacility" xlink:to="lab_icui_TotalSeniorSecuredCreditFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_673fde8c-9f91-4740-b151-859bd695e076_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7eeadfc9-9480-4f75-9c36-786ea2003f25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_IVSolutionsMember_472fe1ab-d03a-4af3-a2d1-4a2d43803f0e_terseLabel_en-US" xlink:label="lab_icui_IVSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IV Solutions [Member]</link:label>
    <link:label id="lab_icui_IVSolutionsMember_label_en-US" xlink:label="lab_icui_IVSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IV Solutions [Member]</link:label>
    <link:label id="lab_icui_IVSolutionsMember_documentation_en-US" xlink:label="lab_icui_IVSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IV Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IVSolutionsMember" xlink:href="icui-20221231.xsd#icui_IVSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_IVSolutionsMember" xlink:to="lab_icui_IVSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Noncurrentdeferredtaxasset_afff8064-cf66-481b-a61d-db0bd84f2d04_terseLabel_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxasset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxasset_label_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxasset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxasset_documentation_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxasset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxasset" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxasset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Noncurrentdeferredtaxasset" xlink:to="lab_icui_Noncurrentdeferredtaxasset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_b7d751de-7847-495a-865a-e85c625b1f2e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:to="lab_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_47cad6a1-7220-454b-a4e5-b84efb755eef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PursuitVascularInc.Member_3ada0519-c357-4bf7-b82c-c953264afd87_terseLabel_en-US" xlink:label="lab_icui_PursuitVascularInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular, Inc. [Member]</link:label>
    <link:label id="lab_icui_PursuitVascularInc.Member_label_en-US" xlink:label="lab_icui_PursuitVascularInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular, Inc. [Member]</link:label>
    <link:label id="lab_icui_PursuitVascularInc.Member_documentation_en-US" xlink:label="lab_icui_PursuitVascularInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular, Inc. [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PursuitVascularInc.Member" xlink:to="lab_icui_PursuitVascularInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_2a9238ea-ccef-45ec-b94d-0b8ead60419b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_af196cf6-d66b-4deb-901c-2d50deaf5877_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INCOME,NET</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_007b9ff6-3ad4-4452-b2d4-e7bb0b60052b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4af50475-2ae6-427b-8476-e8722adcb2da_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_92414495-2927-47fe-9198-2c8cacd8bd7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent earn-out</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7e2de253-ba07-4e22-8c25-9105fafebb76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e5b2be3-591d-4eb3-9fdf-064798a7005e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_d47fab1a-eedd-483b-b3df-4d947066ba0b_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1722a43f-919e-4f07-a527-7fcf6fa4aefd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_COntractLiabilityRollforwardRollForward_1c083df3-7625-4d71-817b-bf34913dc864_terseLabel_en-US" xlink:label="lab_icui_COntractLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COntract Liability Rollforward [Roll Forward]</link:label>
    <link:label id="lab_icui_COntractLiabilityRollforwardRollForward_label_en-US" xlink:label="lab_icui_COntractLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COntract Liability Rollforward [Roll Forward]</link:label>
    <link:label id="lab_icui_COntractLiabilityRollforwardRollForward_documentation_en-US" xlink:label="lab_icui_COntractLiabilityRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COntract Liability Rollforward [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_COntractLiabilityRollforwardRollForward" xlink:href="icui-20221231.xsd#icui_COntractLiabilityRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward" xlink:to="lab_icui_COntractLiabilityRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PursuitVascularLLCMember_5a87f498-94d9-43f2-8093-75ca2c4461fb_terseLabel_en-US" xlink:label="lab_icui_PursuitVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular LLC</link:label>
    <link:label id="lab_icui_PursuitVascularLLCMember_label_en-US" xlink:label="lab_icui_PursuitVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular LLC [Member]</link:label>
    <link:label id="lab_icui_PursuitVascularLLCMember_documentation_en-US" xlink:label="lab_icui_PursuitVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuit Vascular LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PursuitVascularLLCMember" xlink:to="lab_icui_PursuitVascularLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_c123b18f-4a09-4b10-9cb9-f6925cbb5d43_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_407edf34-d0d0-478e-988b-9e2abec7e3a9_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c2f540e8-ba54-4c2b-9fad-cc604841e705_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_38b4c356-084b-420e-b6a3-00a7182cf16d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1bb7113c-52ce-42ed-a579-76d5331a0269_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_dbb95bf4-93db-48d9-a104-cace3af5e91b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e9a6d95a-47df-4c38-a6ac-94a7282583de_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_746c491e-6243-42b8-add9-12759891f018_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fdcb7b84-47d7-4db6-9ecc-8b09d3619ef4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_9b693214-4862-4551-96da-13eda65c6d6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_af6b9617-114f-46f5-83d0-5466f3db86f1_terseLabel_en-US" xlink:label="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</link:label>
    <link:label id="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_label_en-US" xlink:label="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</link:label>
    <link:label id="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_documentation_en-US" xlink:label="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:href="icui-20221231.xsd#icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:to="lab_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LessThanOrEqualTo200To100Member_71351e7e-ffcb-4a3e-893f-0b6fbab1cb82_terseLabel_en-US" xlink:label="lab_icui_LessThanOrEqualTo200To100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.00 to 1.00</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo200To100Member_label_en-US" xlink:label="lab_icui_LessThanOrEqualTo200To100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.00 to 1.00 [Member]</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo200To100Member_documentation_en-US" xlink:label="lab_icui_LessThanOrEqualTo200To100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 2.00 to 1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo200To100Member" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo200To100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LessThanOrEqualTo200To100Member" xlink:to="lab_icui_LessThanOrEqualTo200To100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9f7b8c5-83e1-4ca0-b281-1ee750cdb7ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_cf4f5a56-6cf4-4838-acf8-54f24e23a4dc_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualComponentAmount_85c227d5-71a7-4a18-b058-1312b533cbae_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualComponentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Component Amount</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityAccrualComponentAmount_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityAccrualComponentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Accrual, Component Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualComponentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualComponentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityAccrualComponentAmount" xlink:to="lab_us-gaap_ProductLiabilityAccrualComponentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Optiontoextendinyears_ba37d0a9-3561-4097-8a58-717abe55d046_terseLabel_en-US" xlink:label="lab_icui_Optiontoextendinyears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optiontoextendinyears</link:label>
    <link:label id="lab_icui_Optiontoextendinyears_label_en-US" xlink:label="lab_icui_Optiontoextendinyears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optiontoextendinyears</link:label>
    <link:label id="lab_icui_Optiontoextendinyears_documentation_en-US" xlink:label="lab_icui_Optiontoextendinyears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optiontoextendinyears</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Optiontoextendinyears" xlink:href="icui-20221231.xsd#icui_Optiontoextendinyears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Optiontoextendinyears" xlink:to="lab_icui_Optiontoextendinyears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_267f7a03-e8b8-4b9a-8827-caf2cf621352_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RevenueRecognitionTimingTable_a6c0f9a0-b2f7-4343-8f23-1de8e4ba7098_terseLabel_en-US" xlink:label="lab_icui_RevenueRecognitionTimingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Table]</link:label>
    <link:label id="lab_icui_RevenueRecognitionTimingTable_label_en-US" xlink:label="lab_icui_RevenueRecognitionTimingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Table]</link:label>
    <link:label id="lab_icui_RevenueRecognitionTimingTable_documentation_en-US" xlink:label="lab_icui_RevenueRecognitionTimingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingTable" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RevenueRecognitionTimingTable" xlink:to="lab_icui_RevenueRecognitionTimingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d1a93475-2604-409a-81a1-f2a687d34120_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Foreign Income Tax Rate Differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_fcdbd851-970c-4098-b9f1-1bed9c1eedd5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_e1eafc74-4e3d-4021-9c3f-2448f1ac050f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a69d39b8-ad9d-4339-8e8d-3db6be919fb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_592daf04-785a-4036-86d1-dfadd8640cf2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8dba4493-1eae-4bc5-9e01-2d692434ae54_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0b129c84-fdef-4c56-aa9d-09ae5202fdad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cf9309b7-6f30-47f4-9a3d-9915e9e7b25f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4d3d627-7e43-4739-9222-ad1291db255d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6f3fed9-a015-4a2f-8282-30801bbfd074_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_00d27aad-76cb-4cde-825f-8a136b0e9314_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c8c840a2-1186-4efe-93d9-f77f8423b14d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0d435ce9-a3d0-4250-a740-bd72e3654070_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesTotalMember_ca2bfec9-9cad-48ef-b7f7-59dbee7cd75d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Total [Member]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesTotalMember_label_en-US" xlink:label="lab_us-gaap_LiabilitiesTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesTotalMember" xlink:to="lab_us-gaap_LiabilitiesTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5ddadb30-eca9-495d-ac22-b77f96f6f371_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_fc770b7a-0e5a-47af-872b-38ff690ba6a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42724637-3aef-4a0b-ad56-316980383d0f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e684d15-4b1f-4193-9bba-9a9077330506_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average common and common equivalent shares outstandding (diluted)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_888f82f0-37be-44e3-836a-897fa170790b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4aaba96d-3c6b-4893-8683-01333e500694_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2072abfc-08b0-40ad-84f5-1e22dc290ed9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_001e49c5-80f5-4208-9d82-b09894d75464_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a8387a8d-b2e7-40ba-adea-4837a80bf8f0_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_78f9e510-cfe9-4da7-8c43-d41f2056b758_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsLineItems_636eff8b-244a-4437-aba6-81f7553a16c0_terseLabel_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Line Items]</link:label>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsLineItems_label_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Line Items]</link:label>
    <link:label id="lab_icui_PrepaidNoncurrentAssetsLineItems_documentation_en-US" xlink:label="lab_icui_PrepaidNoncurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Noncurrent Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsLineItems" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems" xlink:to="lab_icui_PrepaidNoncurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TimebasedstockoptionMember_225e3aa6-ca84-4032-9923-faa2fcd233e6_terseLabel_en-US" xlink:label="lab_icui_TimebasedstockoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option [Member]</link:label>
    <link:label id="lab_icui_TimebasedstockoptionMember_label_en-US" xlink:label="lab_icui_TimebasedstockoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option [Member]</link:label>
    <link:label id="lab_icui_TimebasedstockoptionMember_documentation_en-US" xlink:label="lab_icui_TimebasedstockoptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimebasedstockoptionMember" xlink:href="icui-20221231.xsd#icui_TimebasedstockoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TimebasedstockoptionMember" xlink:to="lab_icui_TimebasedstockoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_IndirectTaxBenefitFromStockOptions_b9e67e02-ae3b-4e68-a0b2-17f4b9859769_terseLabel_en-US" xlink:label="lab_icui_IndirectTaxBenefitFromStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect tax benefit</link:label>
    <link:label id="lab_icui_IndirectTaxBenefitFromStockOptions_label_en-US" xlink:label="lab_icui_IndirectTaxBenefitFromStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect tax benefit from stock options</link:label>
    <link:label id="lab_icui_IndirectTaxBenefitFromStockOptions_documentation_en-US" xlink:label="lab_icui_IndirectTaxBenefitFromStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect tax benefit from the stock compensation cost received upon the exercise of stock options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IndirectTaxBenefitFromStockOptions" xlink:href="icui-20221231.xsd#icui_IndirectTaxBenefitFromStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_IndirectTaxBenefitFromStockOptions" xlink:to="lab_icui_IndirectTaxBenefitFromStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e0bc3b00-a10a-4f84-9db1-f56b1abf27b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_28ebf30b-3a43-4d4b-bd67-4f67300f500c_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_7aebf46b-f216-4bfd-a6d4-a90d109a3780_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6f7670ce-a3f8-4f88-a535-5d74cca94c0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ShareawarddataAbstract_8cb22979-7356-4c67-a884-a5fb838298a0_terseLabel_en-US" xlink:label="lab_icui_ShareawarddataAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share award data [Abstract]</link:label>
    <link:label id="lab_icui_ShareawarddataAbstract_label_en-US" xlink:label="lab_icui_ShareawarddataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share award data [Abstract]</link:label>
    <link:label id="lab_icui_ShareawarddataAbstract_documentation_en-US" xlink:label="lab_icui_ShareawarddataAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share award data [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShareawarddataAbstract" xlink:href="icui-20221231.xsd#icui_ShareawarddataAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ShareawarddataAbstract" xlink:to="lab_icui_ShareawarddataAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_030b9fb5-307c-43eb-9c3e-d76587e4960b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_fc02f283-6375-4c9a-adc4-00cbe81e948d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_00f03cf7-580c-44c4-b251-5bd8cce162eb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_a833e900-1e1e-412f-b876-5c326ed6d37e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive compensation</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c5e7d467-9d1d-49a3-b3ab-d06cdc7f959e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_eaa9bf92-e8e2-4c6f-9ca9-f2b69401b99e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_38a87c2b-2a0b-41c5-bb20-d622ddc8f266_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_72f94869-eb39-495f-9023-a10602d58687_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_00298303-724a-4c88-8852-fcbca0af4827_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_599ed730-2821-4e3a-8b61-85d4abb38925_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_707e49c1-1304-40eb-9774-b51176c416b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestMarginandCommitmentFeeTableTextBlock_15e400c8-c0b3-483d-b95b-af68455dffe7_terseLabel_en-US" xlink:label="lab_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Margin and Commitment Fee [Table Text Block]</link:label>
    <link:label id="lab_icui_InterestMarginandCommitmentFeeTableTextBlock_label_en-US" xlink:label="lab_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Margin and Commitment Fee [Table Text Block]</link:label>
    <link:label id="lab_icui_InterestMarginandCommitmentFeeTableTextBlock_documentation_en-US" xlink:label="lab_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Margin and Commitment Fee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:href="icui-20221231.xsd#icui_InterestMarginandCommitmentFeeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:to="lab_icui_InterestMarginandCommitmentFeeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ff3a1f2d-3b58-4e8a-b6aa-9f85f266720b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable for property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_877408b2-c8da-45d0-824b-4e22f03b160b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_4c56aa5e-79c9-49bc-a285-3b2e26fabfa4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab96356a-e913-430c-bcb7-262636234aa6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_a6283585-4086-47a0-bc57-726697695ae6_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8f67f8a6-50ff-4683-9967-0e27731fdee5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_a9a3fcd0-438c-4716-b727-24554e38767b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_3a2af657-de7b-4ff3-bcc8-b7c0a1db321b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_411c9b19-03eb-4cdb-a98b-af2d65547d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_51a9b3c6-6b3f-4361-921d-c84b929d50c5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_bfbf230c-2e01-47b8-86f7-45aee185f6bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Other Adjustments, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_814ca110-f00f-434f-b319-c12d0e2d4c18_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ESPPAnnualIssuanceIncreaseLimit_a78d2004-8ea9-455d-8033-c136ba321320_terseLabel_en-US" xlink:label="lab_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Annual Issuance Increase Limit</link:label>
    <link:label id="lab_icui_ESPPAnnualIssuanceIncreaseLimit_label_en-US" xlink:label="lab_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Annual Issuance Increase Limit</link:label>
    <link:label id="lab_icui_ESPPAnnualIssuanceIncreaseLimit_documentation_en-US" xlink:label="lab_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Annual Issuance Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:href="icui-20221231.xsd#icui_ESPPAnnualIssuanceIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:to="lab_icui_ESPPAnnualIssuanceIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_CurrencyTranslationOnEarnOut_e0b1531c-b477-4d37-9e2d-69b0d9f04ce4_negatedTerseLabel_en-US" xlink:label="lab_icui_CurrencyTranslationOnEarnOut" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation on earn-out</link:label>
    <link:label id="lab_icui_CurrencyTranslationOnEarnOut_label_en-US" xlink:label="lab_icui_CurrencyTranslationOnEarnOut" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation on earn-out</link:label>
    <link:label id="lab_icui_CurrencyTranslationOnEarnOut_documentation_en-US" xlink:label="lab_icui_CurrencyTranslationOnEarnOut" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation on earn-out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrencyTranslationOnEarnOut" xlink:href="icui-20221231.xsd#icui_CurrencyTranslationOnEarnOut"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_CurrencyTranslationOnEarnOut" xlink:to="lab_icui_CurrencyTranslationOnEarnOut" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_f32a4267-a4ea-49d8-87d6-a46216be5554_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f2669eb7-9c0b-4b05-a7f7-c4fbaa7956cc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_da89219b-4fa7-4625-8245-5e895b700cbd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CNY_c79aca36-a004-43eb-a06f-7c8b316460ba_terseLabel_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China, Yuan Renminbi</link:label>
    <link:label id="lab_currency_CNY_label_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China, Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CNY" xlink:to="lab_currency_CNY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c80b58a0-650d-49e1-b67e-8d1fa1df9515_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_eba71453-6bb2-4207-a8a5-777627cc60fb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_fe38101b-f8c9-44de-a94d-43846cafddfb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_25861880-d674-4d69-bd32-859e14f666c5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged&#160;to Costs&#160;and Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b9439128-0595-4d28-81f6-efbd6e989c68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_fb02a47b-ff5c-4571-824f-62e96d73af0f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2de9b9b7-33f2-40d1-ad01-d4241d53afb5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_af8d0c79-b946-4311-b92e-220d88a8e17b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_a552b2bd-8f7f-47a7-a430-d889e5dd027e_terseLabel_en-US" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonfinancial Liabilities Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonfinancial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_c6401a27-8a06-4b47-9371-a078ca05eb5a_terseLabel_en-US" xlink:label="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of lender debt issuance costs</link:label>
    <link:label id="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_label_en-US" xlink:label="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of lender debt issuance costs</link:label>
    <link:label id="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_documentation_en-US" xlink:label="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, net of lender debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:href="icui-20221231.xsd#icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:to="lab_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9a7698c1-cda2-4b7f-86a8-6268f99c20dc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_6ad28ed0-cfbd-4e62-b9fd-fa24d50e40b3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Greaterthan400to100Member_196f16a6-3e58-4856-8309-772b6bdd20a8_terseLabel_en-US" xlink:label="lab_icui_Greaterthan400to100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greaterthan4.00to1.00</link:label>
    <link:label id="lab_icui_Greaterthan400to100Member_label_en-US" xlink:label="lab_icui_Greaterthan400to100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greaterthan4.00to1.00 [Member]</link:label>
    <link:label id="lab_icui_Greaterthan400to100Member_documentation_en-US" xlink:label="lab_icui_Greaterthan400to100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">greaterthan4.00to1.00</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Greaterthan400to100Member" xlink:href="icui-20221231.xsd#icui_Greaterthan400to100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Greaterthan400to100Member" xlink:to="lab_icui_Greaterthan400to100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c75e6ccf-0ffe-410c-9d65-583541c6733a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_74b87e2e-4651-411a-a743-d13eab60da91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_37682b3a-2b51-4e06-ba66-d748ef2eb4f4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2695bb7b-2336-4d62-9b86-d12c781798f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OperatinglosscarryforwardsAbstract_b0212990-0d5c-4744-8959-5c344b89ad7f_terseLabel_en-US" xlink:label="lab_icui_OperatinglosscarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards [Abstract]</link:label>
    <link:label id="lab_icui_OperatinglosscarryforwardsAbstract_label_en-US" xlink:label="lab_icui_OperatinglosscarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards [Abstract]</link:label>
    <link:label id="lab_icui_OperatinglosscarryforwardsAbstract_documentation_en-US" xlink:label="lab_icui_OperatinglosscarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OperatinglosscarryforwardsAbstract" xlink:href="icui-20221231.xsd#icui_OperatinglosscarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OperatinglosscarryforwardsAbstract" xlink:to="lab_icui_OperatinglosscarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b5fc45cf-dcaf-4201-b5d8-e542798f6297_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_749052c0-ed03-414f-9986-4c9776d68265_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_08b31ad8-f17d-4bfb-b32d-4afc17c177ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_390cfa54-05ff-4a9e-8d7a-cbcdd8083415_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InfusionConsumablesSmithsMedicalMember_a4ee77ec-fe0a-4a57-abb2-772775d91d11_terseLabel_en-US" xlink:label="lab_icui_InfusionConsumablesSmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables-Smiths Medical</link:label>
    <link:label id="lab_icui_InfusionConsumablesSmithsMedicalMember_label_en-US" xlink:label="lab_icui_InfusionConsumablesSmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables-Smiths Medical [Member]</link:label>
    <link:label id="lab_icui_InfusionConsumablesSmithsMedicalMember_documentation_en-US" xlink:label="lab_icui_InfusionConsumablesSmithsMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Consumables-Smiths Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesSmithsMedicalMember" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesSmithsMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InfusionConsumablesSmithsMedicalMember" xlink:to="lab_icui_InfusionConsumablesSmithsMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_165d2a69-c0ad-43b2-a3af-2ceeca33b22a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09f26773-eecb-49cf-8521-da35c168248c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earn-out liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_615aa074-d709-469e-9e3e-9f750ad4b787_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca6fcd31-ac80-4086-9df1-712a8cbea92b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_9e50d311-d25a-46fe-8d65-f9091cbffcbf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fe4d6493-736a-4407-83f4-679d14193381_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_31a6ad4d-cc80-40f1-a69c-4b604e244738_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_72305c69-a9b4-44be-b50c-bb498119ea92_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c58cfa54-c87f-498f-a39e-fac32902e810_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b7ac02ec-586d-422b-8d3e-c695bda04dd9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9ccb08b0-2ef1-484a-a012-44438f0e41ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock_b540688b-18ef-4cf6-841e-f0dfce1bc886_terseLabel_en-US" xlink:label="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on long-term debt</link:label>
    <link:label id="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on long-term debt [Table Text Block]</link:label>
    <link:label id="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock_documentation_en-US" xlink:label="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on long-term debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:href="icui-20221231.xsd#icui_InterestExpenseOnLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:to="lab_icui_InterestExpenseOnLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a004ead6-8ca0-4d09-a1fd-191dd3019013_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_21e30638-a21c-43e5-af01-49a871e43d2b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2985ceb7-92b5-4841-9b9d-820b5eedbec0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ProFormaAdjustmentFinanceCosts_ae1c2578-2bf1-4f4e-9c31-f0cba369167c_terseLabel_en-US" xlink:label="lab_icui_ProFormaAdjustmentFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Finance Costs</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentFinanceCosts_label_en-US" xlink:label="lab_icui_ProFormaAdjustmentFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Finance Costs</link:label>
    <link:label id="lab_icui_ProFormaAdjustmentFinanceCosts_documentation_en-US" xlink:label="lab_icui_ProFormaAdjustmentFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Adjustment - Finance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentFinanceCosts" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ProFormaAdjustmentFinanceCosts" xlink:to="lab_icui_ProFormaAdjustmentFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_f638c1a9-92b3-4088-8a3b-c5b7f974d629_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_abae28d2-2cda-4df3-921f-7d56ea578329_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9ad58d60-ba58-49d7-b528-be2ac53d49ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2f98b41e-2982-433a-b989-572d25d1a134_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_02969656-81a5-405e-ac26-6009a9eef077_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_A2011PlanMember_f8e30e1d-541f-4322-85f5-9ec289a4bb5c_terseLabel_en-US" xlink:label="lab_icui_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:label id="lab_icui_A2011PlanMember_label_en-US" xlink:label="lab_icui_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:label id="lab_icui_A2011PlanMember_documentation_en-US" xlink:label="lab_icui_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2011PlanMember" xlink:href="icui-20221231.xsd#icui_A2011PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_A2011PlanMember" xlink:to="lab_icui_A2011PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_e093f2e5-4668-4a6c-bcc5-0cc8ba20e572_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER LONG-TERM LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Other than Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f47d0146-d45f-43ab-97a6-c5edb12895a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_e0dbf4bb-c07c-4f00-b1ba-bbeb97a98a16_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_9431aad8-b1ab-4577-bab1-6f40dbe3dce9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_7c3a6f79-daf1-4ae3-acd2-bd51ba31cee7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2174174f-3142-4161-9411-6a75b76b5a30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_73ce3370-e3d8-430e-be50-60701d58962c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_34117243-88d1-40cb-9fd0-95941f20308e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at Beginning&#160;of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4df17795-0b2d-445f-a447-b0116466d15e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at&#160;End of&#160;Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_d2d2935b-e792-4f9c-a4e0-d94edee33d5c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermLoanAxis_23292d1a-2658-44f1-89cc-8a86f6aa7c18_terseLabel_en-US" xlink:label="lab_icui_TermLoanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Axis]</link:label>
    <link:label id="lab_icui_TermLoanAxis_label_en-US" xlink:label="lab_icui_TermLoanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Axis]</link:label>
    <link:label id="lab_icui_TermLoanAxis_documentation_en-US" xlink:label="lab_icui_TermLoanAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermLoanAxis" xlink:to="lab_icui_TermLoanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_763fd1ef-9ae3-4b10-a475-d10d483835a2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_99f9a26c-7729-44b6-a847-d96b7e8a9231_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c540df37-7cc7-4c1d-bba6-e912597e64ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a81ab8b6-623f-4428-9fa6-fe5805e3b666_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_d476d386-079e-4b87-a02f-6b12258533d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset additions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsTotalMember_ce502e93-f9a7-4026-a0c2-6c195aa05ad4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total</link:label>
    <link:label id="lab_us-gaap_AssetsTotalMember_label_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsTotalMember" xlink:to="lab_us-gaap_AssetsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InstrumentsPlacedwithCustomersMember_ff1bad99-1e04-411e-b90b-5053faea5f1d_terseLabel_en-US" xlink:label="lab_icui_InstrumentsPlacedwithCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments Placed with Customers [Member]</link:label>
    <link:label id="lab_icui_InstrumentsPlacedwithCustomersMember_label_en-US" xlink:label="lab_icui_InstrumentsPlacedwithCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments Placed with Customers [Member]</link:label>
    <link:label id="lab_icui_InstrumentsPlacedwithCustomersMember_documentation_en-US" xlink:label="lab_icui_InstrumentsPlacedwithCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments Placed with Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InstrumentsPlacedwithCustomersMember" xlink:href="icui-20221231.xsd#icui_InstrumentsPlacedwithCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InstrumentsPlacedwithCustomersMember" xlink:to="lab_icui_InstrumentsPlacedwithCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_60adf378-573e-4bc8-b95b-47d8f3df7a41_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b04da8ab-1d3e-47ce-bc92-460d724ed1e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ForeignInfusionSystemSupplierMember_92cca89d-612b-488d-a919-f32062ff13eb_terseLabel_en-US" xlink:label="lab_icui_ForeignInfusionSystemSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Infusion System Supplier</link:label>
    <link:label id="lab_icui_ForeignInfusionSystemSupplierMember_label_en-US" xlink:label="lab_icui_ForeignInfusionSystemSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Infusion System Supplier [Member]</link:label>
    <link:label id="lab_icui_ForeignInfusionSystemSupplierMember_documentation_en-US" xlink:label="lab_icui_ForeignInfusionSystemSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Infusion System Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ForeignInfusionSystemSupplierMember" xlink:to="lab_icui_ForeignInfusionSystemSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cb1e06cb-1a42-4373-a63b-4bd35d3adb06_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a42d027c-9bc3-4b70-9ce7-e2a50001d5fa_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_4e37664f-272e-462c-94fb-303d507ad2b2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_f23b24a1-0cfe-4c98-ab4d-53002ce5eeed_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_eb156661-aceb-4ab5-9170-123a2a1ac060_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_752b5110-944b-4065-ab1c-98317ef1080a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5d2ef78f-809d-42a2-bcb8-93a1dc585889_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_2c0c8a8a-6940-4262-9092-1c4c684421d6_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_EquipmentrevenueMember_4f1ee8d4-8295-430f-b351-39f7b0f14bbf_terseLabel_en-US" xlink:label="lab_icui_EquipmentrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment revenue [Member]</link:label>
    <link:label id="lab_icui_EquipmentrevenueMember_label_en-US" xlink:label="lab_icui_EquipmentrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment revenue [Member]</link:label>
    <link:label id="lab_icui_EquipmentrevenueMember_documentation_en-US" xlink:label="lab_icui_EquipmentrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_EquipmentrevenueMember" xlink:to="lab_icui_EquipmentrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5552b0ac-d88e-4162-9d4f-9d7934f3edb2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d8eace1f-eaf2-4bde-aea5-fc9b6439fa96_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_075af001-5a0b-4989-a916-118e19899a63_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_25a6d7f7-be69-4e76-93a3-1cb7157ff283_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a3e971e8-8dc2-4d70-8ec3-1fb24d140c54_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1b77a183-beff-477d-9189-e4fa748e4794_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_094c6d81-5dbe-4b7f-84d7-65fc7261ec81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cbff4447-5068-4db3-aeb5-a036cad480ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0ab5382a-529c-48c0-9b77-cef05b906e89_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5ae029f2-db56-4c13-b2a0-6daf2036d75a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ComputerEquipmentAndSoftwareMember_4836076d-b116-47e3-ac81-855362724fb0_terseLabel_en-US" xlink:label="lab_icui_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_icui_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_icui_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_icui_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_icui_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ComputerEquipmentAndSoftwareMember" xlink:href="icui-20221231.xsd#icui_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ComputerEquipmentAndSoftwareMember" xlink:to="lab_icui_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_72708beb-452d-4bd0-aff6-d413619fe1ef_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a7761e37-9c8d-4592-b9c5-bf468058f75c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_e850455e-722a-4a35-b4e1-6e56b0e856d7_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_45828704-2202-4a17-b959-0d2ca2ba43df_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_74df3cc4-2ea6-4671-96a7-b183ed252e4d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_e21e24d2-d12b-4141-91f3-a30aa2bf134c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_30ea092d-c601-438d-897a-2c946140679f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_4ea4dd51-8f59-4030-9302-e60cb1575b83_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_9a7f9011-c7f6-4ec4-bdb6-818d402b10f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_89b95431-65ba-4fb3-9156-0af70c897355_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7cde1563-d68d-4708-a0b2-200393933107_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3d2db8e3-edad-43f9-95a4-1bb1dc7f7368_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_81dd1068-1fd7-4336-b47c-ea65a487e95c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock_fed644c7-50bf-4dde-928a-862463a4f37e_terseLabel_en-US" xlink:label="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin on Loan Type</link:label>
    <link:label id="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock_label_en-US" xlink:label="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin on Loan Type [Table Text Block]</link:label>
    <link:label id="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock_documentation_en-US" xlink:label="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Margin on Loan Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:href="icui-20221231.xsd#icui_ApplicableMarginOnLoanTypeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:to="lab_icui_ApplicableMarginOnLoanTypeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_79d31466-4088-4e0c-8876-72a0dad977cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Tax Credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9a3a7cd0-b004-493d-9ebb-8ced8737e0a0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cedefcde-bb0c-43e3-8c3a-dc914e83e7fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_90f07088-6b1a-4b0b-98d5-247c5cf1e5e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock purchase plan remaining available</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_f2e91e2d-302a-498b-9508-acca7f4b2f70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a76c84f9-b3a5-4490-b25c-2e5daaebdd8c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d59573cf-fcfc-42ad-a589-fc9b7ec26901_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_721d0411-63b1-4d72-916f-1fb8e77f15a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_492fe71f-99b6-4b62-820b-e8e869bce499_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_dbce2bc0-dbbb-4624-b84f-eb2bd5d38828_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_RevenueRecognitionTimingLineItems_af562189-57a8-4678-b130-f03b1bd967d3_terseLabel_en-US" xlink:label="lab_icui_RevenueRecognitionTimingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Line Items]</link:label>
    <link:label id="lab_icui_RevenueRecognitionTimingLineItems_label_en-US" xlink:label="lab_icui_RevenueRecognitionTimingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Line Items]</link:label>
    <link:label id="lab_icui_RevenueRecognitionTimingLineItems_documentation_en-US" xlink:label="lab_icui_RevenueRecognitionTimingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Timing [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingLineItems" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_RevenueRecognitionTimingLineItems" xlink:to="lab_icui_RevenueRecognitionTimingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_35fb6801-844e-4a0e-8ffc-885b801d3852_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4659cb3e-a0a9-4ce9-a6f6-ea3d8c886ddf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_21ccaf6b-f77b-405f-ac96-ad65fc5c2894_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_ce2ae3aa-bdbf-49a5-9c10-5b15d0e60ee4_terseLabel_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_label_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_documentation_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:to="lab_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_AccruedResearchAndDevelopmentLiability_03258b1c-3195-4db8-890a-cb0d229d93b5_terseLabel_en-US" xlink:label="lab_icui_AccruedResearchAndDevelopmentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development liability</link:label>
    <link:label id="lab_icui_AccruedResearchAndDevelopmentLiability_label_en-US" xlink:label="lab_icui_AccruedResearchAndDevelopmentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development liability</link:label>
    <link:label id="lab_icui_AccruedResearchAndDevelopmentLiability_documentation_en-US" xlink:label="lab_icui_AccruedResearchAndDevelopmentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedResearchAndDevelopmentLiability" xlink:href="icui-20221231.xsd#icui_AccruedResearchAndDevelopmentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_AccruedResearchAndDevelopmentLiability" xlink:to="lab_icui_AccruedResearchAndDevelopmentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b9595e45-4883-462b-867b-b879995ea698_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3b4e9f2f-8e41-46c7-98e3-aa6bb4253950_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_InfusionSystemsMember_ce5ad508-897c-4525-a092-b225e75a62f2_terseLabel_en-US" xlink:label="lab_icui_InfusionSystemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Systems [Member]</link:label>
    <link:label id="lab_icui_InfusionSystemsMember_label_en-US" xlink:label="lab_icui_InfusionSystemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Systems [Member]</link:label>
    <link:label id="lab_icui_InfusionSystemsMember_documentation_en-US" xlink:label="lab_icui_InfusionSystemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infusion Systems [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionSystemsMember" xlink:href="icui-20221231.xsd#icui_InfusionSystemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_InfusionSystemsMember" xlink:to="lab_icui_InfusionSystemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Sparepartsusage_43735cc5-8ba5-4c36-969e-9f3a773eb5f1_terseLabel_en-US" xlink:label="lab_icui_Sparepartsusage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sparepartsusage</link:label>
    <link:label id="lab_icui_Sparepartsusage_label_en-US" xlink:label="lab_icui_Sparepartsusage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sparepartsusage</link:label>
    <link:label id="lab_icui_Sparepartsusage_documentation_en-US" xlink:label="lab_icui_Sparepartsusage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sparepartsusage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sparepartsusage" xlink:href="icui-20221231.xsd#icui_Sparepartsusage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Sparepartsusage" xlink:to="lab_icui_Sparepartsusage" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Prepaidinsuranceandpropertytaxes_a9461ceb-68a9-4fc0-a442-e8e3bbc27274_terseLabel_en-US" xlink:label="lab_icui_Prepaidinsuranceandpropertytaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance and property taxes</link:label>
    <link:label id="lab_icui_Prepaidinsuranceandpropertytaxes_label_en-US" xlink:label="lab_icui_Prepaidinsuranceandpropertytaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance and property taxes</link:label>
    <link:label id="lab_icui_Prepaidinsuranceandpropertytaxes_documentation_en-US" xlink:label="lab_icui_Prepaidinsuranceandpropertytaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance and property taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidinsuranceandpropertytaxes" xlink:href="icui-20221231.xsd#icui_Prepaidinsuranceandpropertytaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Prepaidinsuranceandpropertytaxes" xlink:to="lab_icui_Prepaidinsuranceandpropertytaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5be7aa93-dd56-4694-941c-6ea8f5784305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_99962d54-8e93-4088-84b1-7e967012d4c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c2ebb957-d87d-4614-9e30-238b86a7b587_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_40f8b39b-44f6-4b3f-870b-1e304d46b041_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_750ddbb9-c504-436b-9c2f-880e371bbeec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and Expected to Vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_d77a64b9-c389-433d-866b-1975f99b6d55_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4006c708-3ed2-402b-ac97-804a9a2374a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a10fc71d-7b3c-409f-80e5-f55e8ab96b30_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_fdb80d43-befd-48ec-982b-a490368dfcc1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyAbstract" xlink:to="lab_us-gaap_ForeignCurrencyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_4b3d1ac6-3838-4ca1-a474-3ac039596fb7_terseLabel_en-US" xlink:label="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 4.00 to 1.00 but greater than 3.00 to100</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_label_en-US" xlink:label="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 4.00 to 1.00 but greater than 3.00 to100 [Member]</link:label>
    <link:label id="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_documentation_en-US" xlink:label="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less than or equal to 4.00 to 1.00 but greater than 3.00 to100</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:to="lab_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d1b2ffc0-5226-4438-a63b-d0789f8cec05_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7c02ff89-8f0f-4610-8fa0-07ebc6e7400d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b1ef7b15-d9b4-4cab-9be6-6003be191f2e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_fe7e3a89-be9d-4b7c-8676-a89085c6645d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_31c899a4-7764-4925-ac1e-1f6b3c1296e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_9f1db6cc-60d7-4db1-a15f-80bef676e514_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_762067b2-9a93-4265-b29f-3202bb8de11b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_a5347f94-2ace-4d36-a06d-31edb275356a_terseLabel_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - acquired future tax deductions</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_label_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - acquired future tax deductions</link:label>
    <link:label id="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_documentation_en-US" xlink:label="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax asset - acquired future tax deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:to="lab_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8a8fa683-7b66-42de-a0da-96b29b63e62f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c19ba46a-33b9-4e66-b77e-5008c3bda2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_cb7f43c7-35fc-4ada-afff-d068c141a65b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_75d82d38-9b0a-42f8-acac-d350672c4f31_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d00c301a-8707-4078-92d3-3e3613988033_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_TermLoanDomain_3544f275-b05a-49bb-b6d0-0bb6987b48ff_terseLabel_en-US" xlink:label="lab_icui_TermLoanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Domain]</link:label>
    <link:label id="lab_icui_TermLoanDomain_label_en-US" xlink:label="lab_icui_TermLoanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Domain]</link:label>
    <link:label id="lab_icui_TermLoanDomain_documentation_en-US" xlink:label="lab_icui_TermLoanDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_TermLoanDomain" xlink:to="lab_icui_TermLoanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a71fd344-aa95-4ec6-a668-ff40153b6100_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ded4d5d0-f1b2-4460-9c37-f8af276faac9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_f8b901b2-217a-456d-84f6-f2e8b1fbe1aa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_961293e6-3262-4202-a75c-cd092a68b614_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_6796dd07-d77f-43d1-8ead-40013802d08d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_ff699514-4cd6-41b6-bd6a-f73843ed89a6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer-Related Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_CustomerRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_UnitedStatespropertyandequipmentMember_070ba050-ab9b-4444-b9ae-1c6980db1f82_terseLabel_en-US" xlink:label="lab_icui_UnitedStatespropertyandequipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States property and equipment [Member]</link:label>
    <link:label id="lab_icui_UnitedStatespropertyandequipmentMember_label_en-US" xlink:label="lab_icui_UnitedStatespropertyandequipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States property and equipment [Member]</link:label>
    <link:label id="lab_icui_UnitedStatespropertyandequipmentMember_documentation_en-US" xlink:label="lab_icui_UnitedStatespropertyandequipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States property and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UnitedStatespropertyandequipmentMember" xlink:href="icui-20221231.xsd#icui_UnitedStatespropertyandequipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_UnitedStatespropertyandequipmentMember" xlink:to="lab_icui_UnitedStatespropertyandequipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Accruedlegalfees_6ec79751-f2b9-4b3f-aa00-2605cbf715ea_terseLabel_en-US" xlink:label="lab_icui_Accruedlegalfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal accrual</link:label>
    <link:label id="lab_icui_Accruedlegalfees_label_en-US" xlink:label="lab_icui_Accruedlegalfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal fees</link:label>
    <link:label id="lab_icui_Accruedlegalfees_documentation_en-US" xlink:label="lab_icui_Accruedlegalfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedlegalfees" xlink:href="icui-20221231.xsd#icui_Accruedlegalfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Accruedlegalfees" xlink:to="lab_icui_Accruedlegalfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c0fbb36-3ec7-43ad-bb98-6b1bf0d30f25_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_7f45a33b-5da6-4706-907a-18018a4571a7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Prepaidothertaxes_b597a140-455a-41d7-b208-5d79aa5865d8_terseLabel_en-US" xlink:label="lab_icui_Prepaidothertaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid other taxes</link:label>
    <link:label id="lab_icui_Prepaidothertaxes_label_en-US" xlink:label="lab_icui_Prepaidothertaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid other taxes</link:label>
    <link:label id="lab_icui_Prepaidothertaxes_documentation_en-US" xlink:label="lab_icui_Prepaidothertaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid other taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidothertaxes" xlink:href="icui-20221231.xsd#icui_Prepaidothertaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Prepaidothertaxes" xlink:to="lab_icui_Prepaidothertaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c013dc80-db07-460b-afc7-7f1fe258a2b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_BusinessCombinationConsiderationCashHoldback_27e5a7fa-a1fb-4629-8aaa-5b45816fed7d_terseLabel_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationCashHoldback" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination consideration - cash holdback</link:label>
    <link:label id="lab_icui_BusinessCombinationConsiderationCashHoldback_label_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationCashHoldback" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination consideration - cash holdback</link:label>
    <link:label id="lab_icui_BusinessCombinationConsiderationCashHoldback_documentation_en-US" xlink:label="lab_icui_BusinessCombinationConsiderationCashHoldback" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">business combination consideration - cash holdback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationCashHoldback" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationCashHoldback"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_BusinessCombinationConsiderationCashHoldback" xlink:to="lab_icui_BusinessCombinationConsiderationCashHoldback" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_31548362-d667-47c1-9af8-04d94e96b9a5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_52fc185c-2d6e-40a1-99c1-9a3a6f4e1744_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock_0432709c-2674-4410-87cd-28074abb1a8d_terseLabel_en-US" xlink:label="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Leases</link:label>
    <link:label id="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock_label_en-US" xlink:label="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Leases [Table Text Block]</link:label>
    <link:label id="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock_documentation_en-US" xlink:label="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:href="icui-20221231.xsd#icui_SupplementalCashFlowInformationLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:to="lab_icui_SupplementalCashFlowInformationLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock_530a68aa-8689-4979-b725-eaab695332a6_terseLabel_en-US" xlink:label="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease</link:label>
    <link:label id="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock_label_en-US" xlink:label="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease [Text Block]</link:label>
    <link:label id="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock_documentation_en-US" xlink:label="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:href="icui-20221231.xsd#icui_LesseeOperatingAndFinanceLeaseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:to="lab_icui_LesseeOperatingAndFinanceLeaseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f94c6b54-6d2e-4960-b3a6-1ee9a1664d21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_Accruedsalestaxes_5cd6af1b-c594-4c2f-ac29-e76f1c29a5fc_terseLabel_en-US" xlink:label="lab_icui_Accruedsalestaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales taxes</link:label>
    <link:label id="lab_icui_Accruedsalestaxes_label_en-US" xlink:label="lab_icui_Accruedsalestaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales taxes</link:label>
    <link:label id="lab_icui_Accruedsalestaxes_documentation_en-US" xlink:label="lab_icui_Accruedsalestaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedsalestaxes" xlink:href="icui-20221231.xsd#icui_Accruedsalestaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_Accruedsalestaxes" xlink:to="lab_icui_Accruedsalestaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_ea99a29c-a41e-4b43-a1e3-c06a56107c2c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_07729de4-72c5-46f5-8495-5c25782aa24a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_OtherExpenseIncomeNetTable_0a997508-0145-4bb5-98b7-3967b488b901_terseLabel_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Table]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetTable_label_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Table]</link:label>
    <link:label id="lab_icui_OtherExpenseIncomeNetTable_documentation_en-US" xlink:label="lab_icui_OtherExpenseIncomeNetTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetTable" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_OtherExpenseIncomeNetTable" xlink:to="lab_icui_OtherExpenseIncomeNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5427b612-9658-49ee-b0b2-f5c0bafa973d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_34261111-8add-4ef2-ab3d-a97c79333fbf_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a7a5a9b6-e425-4e98-9402-b54d9c5eb9b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventory_3f620f97-4714-4621-9425-b405e3cea5eb_terseLabel_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventory_label_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory</link:label>
    <link:label id="lab_icui_WarrantyAndReturnReserveInventory_documentation_en-US" xlink:label="lab_icui_WarrantyAndReturnReserveInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and return reserve - inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventory" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_WarrantyAndReturnReserveInventory" xlink:to="lab_icui_WarrantyAndReturnReserveInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_09c1ce33-15f4-4abd-a375-429a57c14754_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LongTermDebtTypeTable_0bd931b3-88bd-445f-a255-1e8e500bd195_terseLabel_en-US" xlink:label="lab_icui_LongTermDebtTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Table]</link:label>
    <link:label id="lab_icui_LongTermDebtTypeTable_label_en-US" xlink:label="lab_icui_LongTermDebtTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Table]</link:label>
    <link:label id="lab_icui_LongTermDebtTypeTable_documentation_en-US" xlink:label="lab_icui_LongTermDebtTypeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeTable" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LongTermDebtTypeTable" xlink:to="lab_icui_LongTermDebtTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_LeverageRatioLevelAxis_e343bed0-91ae-4b29-96d8-6107ad267e20_terseLabel_en-US" xlink:label="lab_icui_LeverageRatioLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level [Axis]</link:label>
    <link:label id="lab_icui_LeverageRatioLevelAxis_label_en-US" xlink:label="lab_icui_LeverageRatioLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level [Axis]</link:label>
    <link:label id="lab_icui_LeverageRatioLevelAxis_documentation_en-US" xlink:label="lab_icui_LeverageRatioLevelAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelAxis" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_LeverageRatioLevelAxis" xlink:to="lab_icui_LeverageRatioLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_29cab4fe-3072-40cd-8f2b-bf7627c8613c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock_23e907c4-e55d-43ea-a6e1-71ef92ae340f_terseLabel_en-US" xlink:label="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock compensation and related tax benefits [Table Text Block]</link:label>
    <link:label id="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock_label_en-US" xlink:label="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock compensation and related tax benefits [Table Text Block]</link:label>
    <link:label id="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock_documentation_en-US" xlink:label="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock compensation and related tax benefits [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:href="icui-20221231.xsd#icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:to="lab_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b2a605b4-8d18-446e-a6bd-40ca9f0d8699_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_e73d5bf1-bcb6-4134-83d5-c2efbc3ce6b1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_14e5ec12-ae15-4950-96b9-8565d5367161_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_1037e9d7-579c-4fb4-b454-a53c53472ad0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4cfdaea3-2cd5-4957-8659-43acf15e7999_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_38c979e0-8729-4dca-8015-7ce663c0a5f8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>icui-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:36fa8451-09bf-4ce7-a42e-354c469e8213,g:1ffacc3e-ba5e-4528-858f-05696fdb278b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.icumed.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="icui-20221231.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bf985d3c-008e-4f29-b675-4690ae354efc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentType_bf985d3c-008e-4f29-b675-4690ae354efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_bc93b9a9-90b6-4bd4-9c72-37c330e1c412" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentAnnualReport_bc93b9a9-90b6-4bd4-9c72-37c330e1c412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dda4d125-3fc0-4eb7-9770-9ba3451bc8ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentPeriodEndDate_dda4d125-3fc0-4eb7-9770-9ba3451bc8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ad3723c5-c858-4c3e-b3a5-30431039d4b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentTransitionReport_ad3723c5-c858-4c3e-b3a5-30431039d4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0cd2ca42-e82e-442a-a544-df16e3a12948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityFileNumber_0cd2ca42-e82e-442a-a544-df16e3a12948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6d54792f-86cc-4874-8693-c9da3b9dc2dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityRegistrantName_6d54792f-86cc-4874-8693-c9da3b9dc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_48a851fb-d213-411b-b307-c56b3c7117e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityCentralIndexKey_48a851fb-d213-411b-b307-c56b3c7117e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a9eddf31-dfd7-42eb-a74c-1f929292cbe3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_CurrentFiscalYearEndDate_a9eddf31-dfd7-42eb-a74c-1f929292cbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_12408bc2-1d1c-46d8-b3e7-2b3eef76f956" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentFiscalYearFocus_12408bc2-1d1c-46d8-b3e7-2b3eef76f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f302ef9d-1a36-45d5-870d-300a06a7efa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f302ef9d-1a36-45d5-870d-300a06a7efa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7feea3f7-379b-435d-984b-d56add2f0d04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_AmendmentFlag_7feea3f7-379b-435d-984b-d56add2f0d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b846caf2-8a0f-4fa4-bb49-a0d48ad64867" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b846caf2-8a0f-4fa4-bb49-a0d48ad64867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_01c6c806-2ca6-4845-b305-4599d8ad1a89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityTaxIdentificationNumber_01c6c806-2ca6-4845-b305-4599d8ad1a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_34d29383-552d-4495-b0cb-dc74ea463a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityAddressAddressLine1_34d29383-552d-4495-b0cb-dc74ea463a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_145a818e-c00b-485d-b706-2659f8efb51b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityAddressCityOrTown_145a818e-c00b-485d-b706-2659f8efb51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_233017e3-12cb-4f92-93fa-133885d0c559" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityAddressStateOrProvince_233017e3-12cb-4f92-93fa-133885d0c559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_92bccd7d-e8a6-4ffd-adb6-c615d2e6c25c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityAddressPostalZipCode_92bccd7d-e8a6-4ffd-adb6-c615d2e6c25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ed0156a-8c01-4f03-bcda-012c34d81e2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_CityAreaCode_8ed0156a-8c01-4f03-bcda-012c34d81e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b4a84dc4-4e52-40a8-b91c-4a93a69f7b59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_LocalPhoneNumber_b4a84dc4-4e52-40a8-b91c-4a93a69f7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2e4a1d6c-482e-4231-83aa-5cd8b274604e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_Security12bTitle_2e4a1d6c-482e-4231-83aa-5cd8b274604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7b1fa4dd-c65b-46d3-b1ca-be7b95098a79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_TradingSymbol_7b1fa4dd-c65b-46d3-b1ca-be7b95098a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_512fce53-4e65-434a-964d-45784a60ddb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_SecurityExchangeName_512fce53-4e65-434a-964d-45784a60ddb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_75e892b7-0e2a-4017-adaf-8ec076dd2a76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_75e892b7-0e2a-4017-adaf-8ec076dd2a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3b8aeeb7-3b8e-4828-a2b8-5863a1208775" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityVoluntaryFilers_3b8aeeb7-3b8e-4828-a2b8-5863a1208775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_230b7eeb-beef-400f-9b72-35e1b6b668cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityCurrentReportingStatus_230b7eeb-beef-400f-9b72-35e1b6b668cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_90e60cdf-361b-4f24-8474-15ed1cafd87e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityInteractiveDataCurrent_90e60cdf-361b-4f24-8474-15ed1cafd87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_206d26a1-0963-46b8-bb0d-bd2b38e9f71a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityFilerCategory_206d26a1-0963-46b8-bb0d-bd2b38e9f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dde9ee9b-73b2-46cd-b153-a71fce2d19a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntitySmallBusiness_dde9ee9b-73b2-46cd-b153-a71fce2d19a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a3c860eb-6d04-416e-b15a-59d1ce1fbec0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityEmergingGrowthCompany_a3c860eb-6d04-416e-b15a-59d1ce1fbec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_244a1eb6-1ffc-49cd-a2f6-013a311bf462" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_IcfrAuditorAttestationFlag_244a1eb6-1ffc-49cd-a2f6-013a311bf462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_932b6ee5-9f5b-42b5-84cc-167c7817b599" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityShellCompany_932b6ee5-9f5b-42b5-84cc-167c7817b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d830151b-63fa-4feb-a8f2-a5cb98246467" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityPublicFloat_d830151b-63fa-4feb-a8f2-a5cb98246467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c93aea16-7825-4c73-ad75-736458475404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c93aea16-7825-4c73-ad75-736458475404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_189c2d71-7ac8-4f5b-b6e7-f82d20ed6965" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29104bf1-3552-47c1-8663-8751e96b8307" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_189c2d71-7ac8-4f5b-b6e7-f82d20ed6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AuditInformation" xlink:type="simple" xlink:href="icui-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:to="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f9025bc9-54d9-4583-9d20-0f0506efdec1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_206ebc5c-3a67-42a6-9391-f1e1d14f59c4" xlink:to="loc_dei_EntityDomain_f9025bc9-54d9-4583-9d20-0f0506efdec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorTable_3a5023f4-47b6-4e82-a0b9-803edfc19d79" xlink:to="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_034edc53-ced7-4210-91fa-ca724e230d6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorName_034edc53-ced7-4210-91fa-ca724e230d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_1cde656f-5548-45ba-a704-98a6445a7ad6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorLocation_1cde656f-5548-45ba-a704-98a6445a7ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_239cf816-994f-4e30-9b96-b21d71805f56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1bf52eea-bc93-4adc-8265-04ac1b4b39eb" xlink:to="loc_dei_AuditorFirmId_239cf816-994f-4e30-9b96-b21d71805f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_52b8101d-014a-4045-b982-5aae1f01c711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52b8101d-014a-4045-b982-5aae1f01c711" xlink:to="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:to="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a88ac7b1-39ee-4943-bce7-fbc28ef2824a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9e57c65d-68d8-4f13-baa6-1c944fcc7ca2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a88ac7b1-39ee-4943-bce7-fbc28ef2824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46b12077-8fc3-4b33-bf46-afb9df55d03d" xlink:to="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:to="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03a805f6-0338-4d91-a39d-25d23dd0b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03a805f6-0338-4d91-a39d-25d23dd0b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f33f8419-a8a1-4477-9d06-a84c3da5a3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f33f8419-a8a1-4477-9d06-a84c3da5a3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c7b65957-e6b9-473f-a1b6-5c50a6d8595d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c7b65957-e6b9-473f-a1b6-5c50a6d8595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aea3f6e7-304e-4691-aa49-d4c766cccbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aea3f6e7-304e-4691-aa49-d4c766cccbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6bf497bb-fae1-49e4-b65f-26cc4ac2cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_InventoryNet_6bf497bb-fae1-49e4-b65f-26cc4ac2cddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_a2a1ad68-e847-47dd-a44d-ca39b2ba4359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_PrepaidTaxes_a2a1ad68-e847-47dd-a44d-ca39b2ba4359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c6622c5-eb37-4bd2-9e1a-8529a01486ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c6622c5-eb37-4bd2-9e1a-8529a01486ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_21ac4f44-23d3-4196-8d55-a4759395ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e81ed4fb-4ef0-4eb0-b675-62e078cd3f42" xlink:to="loc_us-gaap_AssetsCurrent_21ac4f44-23d3-4196-8d55-a4759395ae79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_51adef93-d804-45ff-92aa-9f0584f27785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_51adef93-d804-45ff-92aa-9f0584f27785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e73fd60-8f48-4162-8492-c5e330dcec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e73fd60-8f48-4162-8492-c5e330dcec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_14493a79-acea-4d80-bb54-e0538f7df63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_14493a79-acea-4d80-bb54-e0538f7df63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b002a518-ccf3-4c99-b5ad-3d4e71f88fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_Goodwill_b002a518-ccf3-4c99-b5ad-3d4e71f88fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_713bc2c8-2b85-4787-ad3c-d9f8f52c8bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_713bc2c8-2b85-4787-ad3c-d9f8f52c8bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_09f018ef-ce64-4e62-9e1d-d8848aa36c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_09f018ef-ce64-4e62-9e1d-d8848aa36c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0a811e6d-a0fd-47ea-a02e-bbc7bdebc301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0a811e6d-a0fd-47ea-a02e-bbc7bdebc301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_acde154b-61ef-4db4-a1bf-921c655e8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75349908-47de-4c1e-b3a4-b74fa15b4644" xlink:to="loc_us-gaap_Assets_acde154b-61ef-4db4-a1bf-921c655e8c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_384d6cdc-5c28-45c5-812b-50bfa9e7afef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e43d46d6-8c62-4cff-9545-f8c4bb4d9b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccountsPayableCurrent_e43d46d6-8c62-4cff-9545-f8c4bb4d9b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4758ef14-b367-46df-a9f2-24decd52b36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4758ef14-b367-46df-a9f2-24decd52b36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7c0116ce-627c-4a3c-b851-b7c038ec8ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_LongTermDebtCurrent_7c0116ce-627c-4a3c-b851-b7c038ec8ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_69790d35-aedb-4c93-83a9-e6ed01b92074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_69790d35-aedb-4c93-83a9-e6ed01b92074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b07860a5-7aae-4c14-882d-3b4812a333e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a01732e-df0b-4660-9087-ebdea731c3b8" xlink:to="loc_us-gaap_LiabilitiesCurrent_b07860a5-7aae-4c14-882d-3b4812a333e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b19504d1-5964-44bd-b3a4-132dae527c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b19504d1-5964-44bd-b3a4-132dae527c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_3e4f01b2-f4ca-44d7-88d4-9713412fb92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_SecuredLongTermDebt_3e4f01b2-f4ca-44d7-88d4-9713412fb92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_f5dc0bd8-8a83-41d9-ac6c-038b71223700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_OtherLiabilities_f5dc0bd8-8a83-41d9-ac6c-038b71223700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b03e7d93-6f60-4101-91dd-8018ac3ff56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b03e7d93-6f60-4101-91dd-8018ac3ff56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_5fdce83f-bcef-4a6c-b70d-74915b34b7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_5fdce83f-bcef-4a6c-b70d-74915b34b7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6dcac311-a7a5-4ade-9575-a3be13e40c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6dcac311-a7a5-4ade-9575-a3be13e40c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_6f2327af-6a39-4c3b-8728-2b694a82483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_6f2327af-6a39-4c3b-8728-2b694a82483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_15d01764-f256-4770-bb96-9730eedd5ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_CommonStockValue_15d01764-f256-4770-bb96-9730eedd5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4ba0e5a-7f1a-4c08-a2ad-3b1d5204414e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e4ba0e5a-7f1a-4c08-a2ad-3b1d5204414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f0108272-0c2f-4516-9f8e-0143854ab7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_TreasuryStockValue_f0108272-0c2f-4516-9f8e-0143854ab7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6888831f-42c6-41e0-8ac4-fe85307face6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6888831f-42c6-41e0-8ac4-fe85307face6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_613ee75c-ee24-4b06-8633-a64e7caf199a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_613ee75c-ee24-4b06-8633-a64e7caf199a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aeb31ee4-18b6-4278-b546-67237ce3aab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d5c4cc83-b3a3-4879-a0c8-3a34c800f8bf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aeb31ee4-18b6-4278-b546-67237ce3aab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_16606e95-6732-4ce3-b3f4-676b247dc191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f10cdb2-952b-4530-8c42-b7866bbc7f1e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_16606e95-6732-4ce3-b3f4-676b247dc191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dfd590bc-3546-42a1-a5a9-fbabde3a5d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dfd590bc-3546-42a1-a5a9-fbabde3a5d88" xlink:to="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:to="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5fa3834-9bbf-4c97-8648-bc1b6da856b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_083eab4d-f706-4921-8b8b-8a5be336a81a" xlink:to="loc_srt_ProductsAndServicesDomain_e5fa3834-9bbf-4c97-8648-bc1b6da856b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_451cda8c-fc17-4369-83cc-44f87f9fd52d" xlink:to="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fcbb7832-8fdf-4ec8-bac5-dce4f41cde08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_fff621fd-3f3b-41f8-8e5c-7548ac4ba067" xlink:to="loc_us-gaap_Revenues_fcbb7832-8fdf-4ec8-bac5-dce4f41cde08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_efefb7b0-c199-4539-8077-92b38953eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_efefb7b0-c199-4539-8077-92b38953eb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_58ab30f6-2f71-4637-b495-76fea7e1565d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_GrossProfit_58ab30f6-2f71-4637-b495-76fea7e1565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9adfddc-14f4-44a1-8ca8-7ddebf8854aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9adfddc-14f4-44a1-8ca8-7ddebf8854aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b0408548-39f7-4691-9b3d-5a696329f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b0408548-39f7-4691-9b3d-5a696329f4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Restructuringandstrategictransactionexpense_7a36d0fe-f9aa-45a4-91ad-90b8ba2b3136" xlink:href="icui-20221231.xsd#icui_Restructuringandstrategictransactionexpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_icui_Restructuringandstrategictransactionexpense_7a36d0fe-f9aa-45a4-91ad-90b8ba2b3136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f2474e03-6fc4-473c-b3b0-962f3b93c584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f2474e03-6fc4-473c-b3b0-962f3b93c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contractsettlements_5177fd58-5c8a-4229-8350-3f1a5967d1cc" xlink:href="icui-20221231.xsd#icui_Contractsettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_icui_Contractsettlements_5177fd58-5c8a-4229-8350-3f1a5967d1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a729df63-0cd8-4a16-b34e-6f3e7fae15f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_43395948-654f-410d-89b5-e04ff740a2a7" xlink:to="loc_us-gaap_OperatingExpenses_a729df63-0cd8-4a16-b34e-6f3e7fae15f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a4e5d757-8335-4e20-b221-f86ab3652a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_OperatingIncomeLoss_a4e5d757-8335-4e20-b221-f86ab3652a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_e4be76e5-40b6-4fcc-9cf3-a02d3050e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_e4be76e5-40b6-4fcc-9cf3-a02d3050e11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5deea686-0257-435a-b581-4235fff77d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5deea686-0257-435a-b581-4235fff77d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_381bb609-ef91-4aff-8463-cc9153a1919d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_381bb609-ef91-4aff-8463-cc9153a1919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a33ac66-a637-46e4-a41e-000d6e2d1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a33ac66-a637-46e4-a41e-000d6e2d1aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a20adefb-94ea-4b30-b9b3-d1f693daa417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_NetIncomeLoss_a20adefb-94ea-4b30-b9b3-d1f693daa417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b6532cea-aa8b-4df1-9ff6-b4cfb13850ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_EarningsPerShareBasic_b6532cea-aa8b-4df1-9ff6-b4cfb13850ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_91df7dfc-335f-4876-88d2-28501bc7c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_91df7dfc-335f-4876-88d2-28501bc7c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aefb5e41-103a-42ec-ae71-00ec3b40ac76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_736c56e7-9a11-4189-8969-0a243f97f0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_736c56e7-9a11-4189-8969-0a243f97f0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47d77e74-566b-4f23-8d9b-87a4445b76c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0971cc98-95e2-4891-8b8b-c3dadf120335" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47d77e74-566b-4f23-8d9b-87a4445b76c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="simple" xlink:href="icui-20221231.xsd#StatementofComprehensiveIncomeStatement"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StatementofComprehensiveIncomeStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5bf338c2-b78c-4a21-9734-6767193e9ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5bf338c2-b78c-4a21-9734-6767193e9ddb" xlink:to="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:to="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_44e89073-acb0-44e4-a080-1d17bbed46fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_df7ea23c-9859-47cf-87d4-6311d739f3ca" xlink:to="loc_srt_ScenarioUnspecifiedDomain_44e89073-acb0-44e4-a080-1d17bbed46fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f2b564d-2d4a-49ec-89a2-94176fc7335e" xlink:to="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93ff8d69-0c1f-49f5-a30f-f7722e81f7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_NetIncomeLoss_93ff8d69-0c1f-49f5-a30f-f7722e81f7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8a449082-9fb2-4534-bd2f-d09b9fe8eb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8a449082-9fb2-4534-bd2f-d09b9fe8eb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1bf74234-9722-473b-9afd-ef0fe6322081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1bf74234-9722-473b-9afd-ef0fe6322081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a5718ac4-c2ac-4649-8288-0a2c2fb97af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a5718ac4-c2ac-4649-8288-0a2c2fb97af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_35dc80d0-a335-4fe9-bbfe-f3efba7613c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_35dc80d0-a335-4fe9-bbfe-f3efba7613c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_60a933da-5365-4451-861c-511d4bf9b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b57a646c-bc83-407e-9e56-199f636630c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_60a933da-5365-4451-861c-511d4bf9b39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5456fb6f-6e0e-43ed-9b3b-ad69c3969a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5456fb6f-6e0e-43ed-9b3b-ad69c3969a9c" xlink:to="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_09d873d9-110d-4ab4-8201-8c385b3f745a" xlink:to="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CommonStockSharesMember_fc9f1487-c0bc-4d88-acc0-24e8eaef0a41" xlink:href="icui-20221231.xsd#icui_CommonStockSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_icui_CommonStockSharesMember_fc9f1487-c0bc-4d88-acc0-24e8eaef0a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c4f4038a-71b9-4238-ae92-d170c124e25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_CommonStockMember_c4f4038a-71b9-4238-ae92-d170c124e25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bc12235a-4c67-4939-bb7f-e1c5971642f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bc12235a-4c67-4939-bb7f-e1c5971642f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_d3129b3b-cb8a-4626-9bac-77552d36dec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_TreasuryStockMember_d3129b3b-cb8a-4626-9bac-77552d36dec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c184f43-7597-4624-b0ec-72c5025e1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_RetainedEarningsMember_3c184f43-7597-4624-b0ec-72c5025e1c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dca35ee6-c964-4144-ac8a-dd2f0e012218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0913e2ee-53da-4e4c-a591-db6e6a59a433" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dca35ee6-c964-4144-ac8a-dd2f0e012218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ca1b756-c964-498d-9e0c-9f6322380476" xlink:to="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0abd0078-8356-4080-8f4d-93e8b5ffd44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0abd0078-8356-4080-8f4d-93e8b5ffd44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f55d8ee5-7cec-46c6-9381-baba2b779cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockholdersEquity_f55d8ee5-7cec-46c6-9381-baba2b779cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8f1796e-2cb2-45ee-a444-3bdb4fb2e4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8f1796e-2cb2-45ee-a444-3bdb4fb2e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_59d14a9d-f8ed-47d7-b48c-d338f3a21f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_59d14a9d-f8ed-47d7-b48c-d338f3a21f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_38645852-7ebb-4a44-954f-f16dfacfa698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_38645852-7ebb-4a44-954f-f16dfacfa698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a6e43d00-c9bd-416d-b07c-febc8784d4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a6e43d00-c9bd-416d-b07c-febc8784d4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48c8d2df-cff2-4b96-938c-ded282497bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48c8d2df-cff2-4b96-938c-ded282497bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1e8693ce-6e12-49a6-8416-7eadbd69205f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1e8693ce-6e12-49a6-8416-7eadbd69205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_baa5b0da-d93e-4620-836e-5557792089e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_baa5b0da-d93e-4620-836e-5557792089e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e0397f4-18d2-4335-ac8d-1838df75d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_NetIncomeLoss_1e0397f4-18d2-4335-ac8d-1838df75d50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0fe6c2f-8466-4fc5-bfdc-44000edb25b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_StockholdersEquity_b0fe6c2f-8466-4fc5-bfdc-44000edb25b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_42dee300-b9e6-4a77-ab16-7497feb82e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dec1a62-2ca8-4c48-8047-a792bdbed7be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_42dee300-b9e6-4a77-ab16-7497feb82e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_00a28a1e-8b23-4862-aff6-7cd3552909fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_00a28a1e-8b23-4862-aff6-7cd3552909fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_92e7f7cf-e657-4457-8e9c-6799db7bbf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f888deec-5a6d-4338-bc37-3df1e30d4fb1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_92e7f7cf-e657-4457-8e9c-6799db7bbf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_660bec57-0cd8-4b1f-9218-22d189ad865b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_660bec57-0cd8-4b1f-9218-22d189ad865b" xlink:to="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:to="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9db3ec85-7636-44b2-a00f-d472aef84ec6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f761367b-52f4-475e-a11e-e176182fa680" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9db3ec85-7636-44b2-a00f-d472aef84ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_67866abd-04b9-43a3-9518-5f454fe71b7a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_897e6782-5efe-45ef-a6b7-8fba5d525319" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_SmithsMedicalMember_897e6782-5efe-45ef-a6b7-8fba5d525319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalDistributorMember_b8062eae-bccd-495e-93c4-d3ea43708b5f" xlink:href="icui-20221231.xsd#icui_InternationalDistributorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_InternationalDistributorMember_b8062eae-bccd-495e-93c4-d3ea43708b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_cd59659d-4df1-41e0-bb6a-f1fbf3d776df" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39e70303-0d66-4d87-a03f-54b7c344643f" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_cd59659d-4df1-41e0-bb6a-f1fbf3d776df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e23c18eb-62cc-4506-b305-103dbca9b424" xlink:to="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_e640631a-20be-434b-a687-f7d367523cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e50f1c18-29d8-4ecd-be17-dcdeb1512b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_NetIncomeLoss_e50f1c18-29d8-4ecd-be17-dcdeb1512b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5d67a4b4-16fb-4791-ac90-e3635168dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5d67a4b4-16fb-4791-ac90-e3635168dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AmortizationOfInventoryStepUp_66379e65-1739-423d-8750-ceceff8a4f57" xlink:href="icui-20221231.xsd#icui_AmortizationOfInventoryStepUp"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_AmortizationOfInventoryStepUp_66379e65-1739-423d-8750-ceceff8a4f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_115c364a-83e7-4d2e-a3c3-ef869509513b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_115c364a-83e7-4d2e-a3c3-ef869509513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_625973d1-bb9f-436d-9434-8a0fab9625a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_625973d1-bb9f-436d-9434-8a0fab9625a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProvisionForWarrantyAndReturns_676d8ea0-f8b0-429d-a2fc-501d557d19f0" xlink:href="icui-20221231.xsd#icui_ProvisionForWarrantyAndReturns"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_ProvisionForWarrantyAndReturns_676d8ea0-f8b0-429d-a2fc-501d557d19f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_72d1a42f-4523-4bc7-9cf5-18a3bbcfe249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ShareBasedCompensation_72d1a42f-4523-4bc7-9cf5-18a3bbcfe249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ffd1a81d-ad11-4bb2-a9c4-ca35abddd161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ffd1a81d-ad11-4bb2-a9c4-ca35abddd161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_5048a5e5-356d-4dc5-b4ee-b7fd553a7b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_5048a5e5-356d-4dc5-b4ee-b7fd553a7b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_50decc67-8f9f-46dc-b265-d7619863be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_50decc67-8f9f-46dc-b265-d7619863be2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_eb1031f4-27c8-40c1-a148-25a87f716e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_eb1031f4-27c8-40c1-a148-25a87f716e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f8a0f885-3e87-4e4d-a6af-703299e6b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f8a0f885-3e87-4e4d-a6af-703299e6b7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_bd254de8-5595-45ae-814c-7116f2023b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_bd254de8-5595-45ae-814c-7116f2023b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sparepartsusage_870f960e-4dea-4f0a-9826-0407cad24ad7" xlink:href="icui-20221231.xsd#icui_Sparepartsusage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_Sparepartsusage_870f960e-4dea-4f0a-9826-0407cad24ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_81f5ca3a-1278-400f-a550-4fd099709391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_81f5ca3a-1278-400f-a550-4fd099709391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eae59951-1100-42e9-aab6-632fdebefd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eae59951-1100-42e9-aab6-632fdebefd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6f72e8cc-606d-427a-bd13-dbe5358fdfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6f72e8cc-606d-427a-bd13-dbe5358fdfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff65ea16-6543-4d29-a9f3-9100c1568f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff65ea16-6543-4d29-a9f3-9100c1568f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce183cb7-1475-433e-9866-40cbd085df36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce183cb7-1475-433e-9866-40cbd085df36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34c00a22-12e8-45b9-bc0f-42c1be985c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_34c00a22-12e8-45b9-bc0f-42c1be985c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efa63517-2eda-41ee-9368-ddecf3f2a32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efa63517-2eda-41ee-9368-ddecf3f2a32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_5ac90cec-32e8-463f-b285-b9c90bf8508f" xlink:href="icui-20221231.xsd#icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1eeb2f9-0b38-422d-865b-ec8a2bb9e04a" xlink:to="loc_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes_5ac90cec-32e8-463f-b285-b9c90bf8508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a7371c4-7bc8-4ffb-890f-ff18dd08c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a7371c4-7bc8-4ffb-890f-ff18dd08c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11861486-2f7c-4f0f-87f6-451d7e5dd08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11861486-2f7c-4f0f-87f6-451d7e5dd08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_3e147f35-6bde-441c-8839-1be99e5999b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_3e147f35-6bde-441c-8839-1be99e5999b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ab54191-2b16-4c34-9fd0-b357d1270ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ab54191-2b16-4c34-9fd0-b357d1270ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e121425d-c064-414e-93df-943963c2e701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e121425d-c064-414e-93df-943963c2e701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2eb243aa-feab-4ade-b10e-eccdbf61d8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2eb243aa-feab-4ade-b10e-eccdbf61d8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_777d66fa-746a-4a48-a474-b66f82d72804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_777d66fa-746a-4a48-a474-b66f82d72804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1918c200-3d59-42c1-aaaa-bda5eb6c06a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_362deee4-764a-4add-b99b-8752cbd1d5ba" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1918c200-3d59-42c1-aaaa-bda5eb6c06a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_577263b1-8472-4322-b796-b6a3d909f79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_577263b1-8472-4322-b796-b6a3d909f79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_523955ca-9919-415f-8eaa-eae775777376" xlink:href="icui-20221231.xsd#icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts_523955ca-9919-415f-8eaa-eae775777376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c6809b15-8b54-46b4-a726-995178a1947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c6809b15-8b54-46b4-a726-995178a1947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ed14d00-ec96-40d1-9608-d3cd5ae5b893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ed14d00-ec96-40d1-9608-d3cd5ae5b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_d7a99654-2e3c-4584-a09a-ffb08c6ca67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_d7a99654-2e3c-4584-a09a-ffb08c6ca67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_48c568b0-b4d1-4c22-b3b6-06239f713683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_48c568b0-b4d1-4c22-b3b6-06239f713683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f6f99088-798b-4acd-8e6c-89dbc0bd63c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f6f99088-798b-4acd-8e6c-89dbc0bd63c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6cbda617-9017-4100-afb0-5cdba1fc0f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6cbda617-9017-4100-afb0-5cdba1fc0f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_399dc65f-fdeb-482d-8668-e5f2b2e072b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_399dc65f-fdeb-482d-8668-e5f2b2e072b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf9ca93-a886-4d95-8dcd-f37e421a2ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b7751f-b57a-4751-a592-fb81ee5b02c8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fdf9ca93-a886-4d95-8dcd-f37e421a2ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1347ef5-11a5-4795-b29b-f56e28d617ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1347ef5-11a5-4795-b29b-f56e28d617ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract_99fecb21-38a8-4238-a82b-293f63390afc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d368ccc-8721-4b4f-a105-fa4fdaaee6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d368ccc-8721-4b4f-a105-fa4fdaaee6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0df367a9-3e26-4de0-841a-032b01e4a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0df367a9-3e26-4de0-841a-032b01e4a5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fccd677-6bdb-41af-853e-1225361d7606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_987f9850-73b1-4811-9443-ce3605ae3782" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fccd677-6bdb-41af-853e-1225361d7606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_cae592f0-5aa2-421d-9cd9-e067519111c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:to="loc_us-gaap_IncomeTaxesPaid_cae592f0-5aa2-421d-9cd9-e067519111c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_57f26773-67bb-4ca3-abaf-f3880c08d410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a02f04ce-99ac-456d-9ef2-b336ab4a0cc6" xlink:to="loc_us-gaap_InterestPaidNet_57f26773-67bb-4ca3-abaf-f3880c08d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ea17860-89e2-433d-973f-ded217dd0065" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ecd29db6-6be2-481b-afa8-81bea8a04b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ecd29db6-6be2-481b-afa8-81bea8a04b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_e2a73366-6202-4b1c-9133-3c308202540c" xlink:href="icui-20221231.xsd#icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability_e2a73366-6202-4b1c-9133-3c308202540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_2d3b6bbf-fca5-4873-9ece-e595c15a54a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_2d3b6bbf-fca5-4873-9ece-e595c15a54a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions_e46c6755-c662-4806-a017-670722ab5ad6" xlink:href="icui-20221231.xsd#icui_NetCashPaidReceivedforcurrentandprioracquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_icui_NetCashPaidReceivedforcurrentandprioracquisitions_e46c6755-c662-4806-a017-670722ab5ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_60e08c97-06bf-43b4-af9f-8d30571db76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_60e08c97-06bf-43b4-af9f-8d30571db76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_e94b9692-7b7c-4977-b6a4-8e77e9940161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_e94b9692-7b7c-4977-b6a4-8e77e9940161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0a0bc1d9-ab65-4227-9e56-bcb3b1f18724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_0a0bc1d9-ab65-4227-9e56-bcb3b1f18724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_20261b1a-bf72-4104-a300-b46ad1ad341b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b89d0e80-a5db-447b-a864-4cd581e8f522" xlink:to="loc_us-gaap_LiabilitiesAssumed1_20261b1a-bf72-4104-a300-b46ad1ad341b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="icui-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2233e15a-6f0f-4272-ad55-1c50973b888d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2233e15a-6f0f-4272-ad55-1c50973b888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24bcbbd6-4505-4ed7-88f2-1ef72bbdf8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24bcbbd6-4505-4ed7-88f2-1ef72bbdf8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c874ba30-0125-4ae1-b0b1-dad619152ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c874ba30-0125-4ae1-b0b1-dad619152ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ade91eb2-9996-49ff-a558-f4929bd0bb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ade91eb2-9996-49ff-a558-f4929bd0bb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6dc2362-7f12-4788-a7b4-c415656d902e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f6dc2362-7f12-4788-a7b4-c415656d902e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ac46e280-723c-4ab8-b653-e7693eed90b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ac46e280-723c-4ab8-b653-e7693eed90b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cd868f6c-ee4f-4add-b0a8-d4e15d477a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CommonStockSharesIssued_cd868f6c-ee4f-4add-b0a8-d4e15d477a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_ba710d24-0594-491f-825b-79f937552a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CommonStockValueOutstanding_ba710d24-0594-491f-825b-79f937552a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b7ec77fd-17f1-4c69-9c33-3cfdb7c4bdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b7ec77fd-17f1-4c69-9c33-3cfdb7c4bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5e3727de-47cf-4a66-aa68-27aba567b8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_TreasuryStockShares_5e3727de-47cf-4a66-aa68-27aba567b8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc42b397-7ed3-4416-9334-c274186037e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb8b1a2e-d6bb-4f18-8ec9-4d150306d305" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc42b397-7ed3-4416-9334-c274186037e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical" xlink:type="simple" xlink:href="icui-20221231.xsd#StatementofComprehensiveIncomeParanthetical"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5e8a149e-6470-43b4-9d58-786eebb8a2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_50083c00-facc-427e-a690-d93e96852b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5e8a149e-6470-43b4-9d58-786eebb8a2f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_50083c00-facc-427e-a690-d93e96852b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_876aaa7b-4ec5-4d5f-8d92-e322fd9ffd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5e8a149e-6470-43b4-9d58-786eebb8a2f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_876aaa7b-4ec5-4d5f-8d92-e322fd9ffd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e5b489ca-ca13-41a3-9993-474e7985e662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5e8a149e-6470-43b4-9d58-786eebb8a2f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e5b489ca-ca13-41a3-9993-474e7985e662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f08cf4fd-6715-491d-a80d-17229fb0b34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ab928735-b003-4780-b76a-0b9dc2da457a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f08cf4fd-6715-491d-a80d-17229fb0b34f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ab928735-b003-4780-b76a-0b9dc2da457a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_02b01f5a-4bc1-46da-bbbf-ac2c528dee62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0e000a87-f7d6-408d-89ad-be1b1b8416bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_02b01f5a-4bc1-46da-bbbf-ac2c528dee62" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0e000a87-f7d6-408d-89ad-be1b1b8416bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_028bd250-55ed-487d-8929-57937c016a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a147eff7-e6b4-441b-bf41-67c17757a1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_028bd250-55ed-487d-8929-57937c016a78" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a147eff7-e6b4-441b-bf41-67c17757a1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_160af718-d26d-4b7e-a7f5-ee70988a1add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6362bada-c7d3-4063-b453-282bb67b564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_160af718-d26d-4b7e-a7f5-ee70988a1add" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6362bada-c7d3-4063-b453-282bb67b564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36fdc33d-4552-42d5-9414-9ebf2879f465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LesseeOperatingAndFinanceLeaseTextBlock_d83649f2-072d-4055-a261-1b816cd56471" xlink:href="icui-20221231.xsd#icui_LesseeOperatingAndFinanceLeaseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36fdc33d-4552-42d5-9414-9ebf2879f465" xlink:to="loc_icui_LesseeOperatingAndFinanceLeaseTextBlock_d83649f2-072d-4055-a261-1b816cd56471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardShareawardsNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardShareawardsNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardShareawardsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb77069d-531a-49fd-9b98-7c7aa7ef95a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4a745d21-515f-4766-b880-2663865a61e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb77069d-531a-49fd-9b98-7c7aa7ef95a5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4a745d21-515f-4766-b880-2663865a61e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_509cfe29-cc2b-47d8-a7e7-112ace7e1f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d6dff8a2-4eb4-4a21-b82c-51f416d1ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_509cfe29-cc2b-47d8-a7e7-112ace7e1f7f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d6dff8a2-4eb4-4a21-b82c-51f416d1ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8f6487e-18c2-4607-9ae5-4027cb494c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_97dfdcf2-cebb-4825-a341-6266140e312a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8f6487e-18c2-4607-9ae5-4027cb494c28" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_97dfdcf2-cebb-4825-a341-6266140e312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidsandOtherCurrentAssetsNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_96d8a50f-5d10-4eba-9995-8ef98da92e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock_b2b47fea-7b4e-4393-87cd-c6633c645505" xlink:href="icui-20221231.xsd#icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_96d8a50f-5d10-4eba-9995-8ef98da92e4e" xlink:to="loc_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock_b2b47fea-7b4e-4393-87cd-c6633c645505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities" xlink:type="simple" xlink:href="icui-20221231.xsd#AccruedLiabilitiesanOtherLongtermLiabilities"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1bee39dc-2b3c-48f5-93db-8d56f5e598e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8c56bc39-9baa-40ab-990f-7459e66cc4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_1bee39dc-2b3c-48f5-93db-8d56f5e598e4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8c56bc39-9baa-40ab-990f-7459e66cc4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/Debt" xlink:type="simple" xlink:href="icui-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eb0d07d0-8595-47db-88c3-eec11a33b7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a642906c-2331-415c-bc2f-e74560effa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eb0d07d0-8595-47db-88c3-eec11a33b7c0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a642906c-2331-415c-bc2f-e74560effa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0dcd9d4a-b36a-4630-844a-9d1118e4af0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0c7d3b0a-ae5d-4936-ba40-6cb8f6e0af04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0dcd9d4a-b36a-4630-844a-9d1118e4af0f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0c7d3b0a-ae5d-4936-ba40-6cb8f6e0af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_01eacfe8-5c2f-480d-82bd-eab34165fde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock_2698c018-077f-4c79-968c-7fbfef9cb5a7" xlink:href="icui-20221231.xsd#icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_01eacfe8-5c2f-480d-82bd-eab34165fde2" xlink:to="loc_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock_2698c018-077f-4c79-968c-7fbfef9cb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6f002932-e5ec-468a-99c2-cf0892844fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_423c8711-5c50-4c80-9004-312b9361ed64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f002932-e5ec-468a-99c2-cf0892844fc7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_423c8711-5c50-4c80-9004-312b9361ed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="icui-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9e56c9a1-0488-49c9-81f1-b92226891f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4226c7e4-bd02-45ea-82ef-932d4f7669af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9e56c9a1-0488-49c9-81f1-b92226891f54" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4226c7e4-bd02-45ea-82ef-932d4f7669af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes" xlink:type="simple" xlink:href="icui-20221231.xsd#CollaborativeandOtherArrangementsNotes"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_CollaborativeandOtherArrangementsAbstract_5dbc61c1-429a-4e49-9358-6d20f6fc305d" xlink:href="icui-20221231.xsd#icui_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4422da60-60ef-4e0c-827c-8981d7414f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_CollaborativeandOtherArrangementsAbstract_5dbc61c1-429a-4e49-9358-6d20f6fc305d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4422da60-60ef-4e0c-827c-8981d7414f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="icui-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c1390be3-a002-4219-87f0-9445ce408e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_46e7a74d-f4de-4c94-92e4-516a05f1a109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c1390be3-a002-4219-87f0-9445ce408e73" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_46e7a74d-f4de-4c94-92e4-516a05f1a109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="icui-20221231.xsd#SECScheduleArticle1209ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_25c68286-2e66-4068-a0df-9a76ea1f1486" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c6366887-1f63-4ec9-847a-a54e700b98ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_25c68286-2e66-4068-a0df-9a76ea1f1486" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c6366887-1f63-4ec9-847a-a54e700b98ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4cb7b299-9986-41d0-bdc3-b2f56fd2de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4cb7b299-9986-41d0-bdc3-b2f56fd2de9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5c255e46-677f-41e7-8ee8-960ff3d1d579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5c255e46-677f-41e7-8ee8-960ff3d1d579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_77aa85ea-0e0a-4804-b116-011d00b55eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_UseOfEstimates_77aa85ea-0e0a-4804-b116-011d00b55eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1718bca1-bca5-44f1-9617-9e0e8ba59bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1718bca1-bca5-44f1-9617-9e0e8ba59bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_1ece1518-96e7-4c15-8732-ba1e09491c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_1ece1518-96e7-4c15-8732-ba1e09491c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9a2320ff-ed48-4a11-b40c-5207cb744005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9a2320ff-ed48-4a11-b40c-5207cb744005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_530a00cc-651c-44f5-92f2-6bff56cbec71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_530a00cc-651c-44f5-92f2-6bff56cbec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c2e2447b-111d-4b01-ae74-9dd065715cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c2e2447b-111d-4b01-ae74-9dd065715cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1c4f7ed1-4cd8-45fc-a9ce-eca0cff5a006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_1c4f7ed1-4cd8-45fc-a9ce-eca0cff5a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8322b2a5-b406-4365-ad76-8803a68f685e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8322b2a5-b406-4365-ad76-8803a68f685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_0ada9064-e06d-40a5-ad41-0dfc3eb78ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_0ada9064-e06d-40a5-ad41-0dfc3eb78ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_90eaa5b6-3463-4f0a-b5b6-d3528f833851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_90eaa5b6-3463-4f0a-b5b6-d3528f833851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_20c67afa-a656-49b1-aee5-e9d9b27e1191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_20c67afa-a656-49b1-aee5-e9d9b27e1191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_72fcd5d9-324f-4364-aa7d-b59d9e735564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_72fcd5d9-324f-4364-aa7d-b59d9e735564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b819af1d-aedf-412a-8e57-4de5d5fc2c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b819af1d-aedf-412a-8e57-4de5d5fc2c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_02bd1aca-f9a7-4b2c-8fef-efcf05136095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_02bd1aca-f9a7-4b2c-8fef-efcf05136095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a273bbb2-2f2f-4f55-b21c-870ef5e5c7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a273bbb2-2f2f-4f55-b21c-870ef5e5c7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_eb10fadc-c805-4769-bcfc-390036e0225c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fe612f-7c4d-4888-9282-255943a03dbd" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_eb10fadc-c805-4769-bcfc-390036e0225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ebb8a6ff-562a-4f1d-824f-482864d3160c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ebb8a6ff-562a-4f1d-824f-482864d3160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fb3f0783-9b40-4de9-bf52-9f6de8973e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fb3f0783-9b40-4de9-bf52-9f6de8973e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_0ee658e0-59a5-443b-92ad-3fc7c04ae17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_0ee658e0-59a5-443b-92ad-3fc7c04ae17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_27b4ffb5-eb7e-40b5-bad4-533dd5f6b46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_27b4ffb5-eb7e-40b5-bad4-533dd5f6b46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_98a62712-cf59-41a0-927e-b606eae990a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_98a62712-cf59-41a0-927e-b606eae990a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cf285980-fd6e-40d6-978d-190fefed8e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_cf285980-fd6e-40d6-978d-190fefed8e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_1972e493-b137-4644-83ca-059b7dedaf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_1972e493-b137-4644-83ca-059b7dedaf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_2bd7445a-a5d3-44d5-b68d-fc705976fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_2bd7445a-a5d3-44d5-b68d-fc705976fa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_aad3f44c-5fc4-4386-af18-b40b79e834f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_aad3f44c-5fc4-4386-af18-b40b79e834f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_45f42357-d88d-4d1c-a1fd-6e2ce2c5ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f51ce2-60ec-49f1-9dcc-e84fb1c7f1a1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_45f42357-d88d-4d1c-a1fd-6e2ce2c5ee0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables" xlink:type="simple" xlink:href="icui-20221231.xsd#BusinessCombinationandAssetAcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c0ba4354-0f8e-4c06-86ef-83ef57469cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_00bd6076-3808-4b94-a0c7-6738143f42dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c0ba4354-0f8e-4c06-86ef-83ef57469cef" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_00bd6076-3808-4b94-a0c7-6738143f42dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4e54afdf-8e17-44f4-92bb-fb5a8e1cac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c0ba4354-0f8e-4c06-86ef-83ef57469cef" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4e54afdf-8e17-44f4-92bb-fb5a8e1cac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b9288f9e-f413-451d-b61f-0836a581b055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_554966cf-fcba-4689-b6a8-39145ced42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b9288f9e-f413-451d-b61f-0836a581b055" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_554966cf-fcba-4689-b6a8-39145ced42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueTables" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16723ac7-44c7-4cd5-a5b0-e3fadb3d7e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7512d6ec-aa2a-4bf8-98d6-1caffe0eaee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16723ac7-44c7-4cd5-a5b0-e3fadb3d7e7c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7512d6ec-aa2a-4bf8-98d6-1caffe0eaee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ccef3864-095e-4d49-83e7-8c0aa1c02c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16723ac7-44c7-4cd5-a5b0-e3fadb3d7e7c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ccef3864-095e-4d49-83e7-8c0aa1c02c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_447142a5-46e5-4831-bbc8-8d4bd41e1b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_16723ac7-44c7-4cd5-a5b0-e3fadb3d7e7c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_447142a5-46e5-4831-bbc8-8d4bd41e1b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesTables" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c737ef3b-796b-49e2-8fd7-aa5fefaf32d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4d9a3b57-ef8c-4aff-9c0e-3b2359ee4b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c737ef3b-796b-49e2-8fd7-aa5fefaf32d9" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4d9a3b57-ef8c-4aff-9c0e-3b2359ee4b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SupplementalCashFlowInformationLeasesTableTextBlock_d41e031b-3835-4dc0-a1b8-884d0a62c0b3" xlink:href="icui-20221231.xsd#icui_SupplementalCashFlowInformationLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c737ef3b-796b-49e2-8fd7-aa5fefaf32d9" xlink:to="loc_icui_SupplementalCashFlowInformationLeasesTableTextBlock_d41e031b-3835-4dc0-a1b8-884d0a62c0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock_762e382f-0da7-475b-a495-416b7cec46fc" xlink:href="icui-20221231.xsd#icui_SupplementalBalanceSheetInformationLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c737ef3b-796b-49e2-8fd7-aa5fefaf32d9" xlink:to="loc_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock_762e382f-0da7-475b-a495-416b7cec46fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b0676f0-6363-4eba-b4ca-c825f62283b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c737ef3b-796b-49e2-8fd7-aa5fefaf32d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b0676f0-6363-4eba-b4ca-c825f62283b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardTables" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock_e54813e3-7f24-4139-9ea2-d3da6de22ea1" xlink:href="icui-20221231.xsd#icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock_e54813e3-7f24-4139-9ea2-d3da6de22ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1372952d-d638-4875-ac39-36f165202f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1372952d-d638-4875-ac39-36f165202f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d2c83a4-c88e-488f-b042-f6dd5a09c6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d2c83a4-c88e-488f-b042-f6dd5a09c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ExercisedOptionsDataTableTextBlock_f5bd2a8f-06b9-42d3-8eb6-74054e621223" xlink:href="icui-20221231.xsd#icui_ExercisedOptionsDataTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_icui_ExercisedOptionsDataTableTextBlock_f5bd2a8f-06b9-42d3-8eb6-74054e621223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ce7a8b84-5b98-464e-90d4-951e9f0589ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ce7a8b84-5b98-464e-90d4-951e9f0589ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_8db6216c-7e19-4231-b353-7a80f2ee8885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306e7b46-295b-4574-bd31-37abd261e50d" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_8db6216c-7e19-4231-b353-7a80f2ee8885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f5a1c88-db62-420e-973b-8fc99b0e982f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_acc320e1-18ef-432d-b523-a65cb647ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f5a1c88-db62-420e-973b-8fc99b0e982f" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_acc320e1-18ef-432d-b523-a65cb647ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e14fff73-7b27-4320-be50-31e89e0b2384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f5a1c88-db62-420e-973b-8fc99b0e982f" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e14fff73-7b27-4320-be50-31e89e0b2384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a22aea9-6c81-4658-932c-497a867080b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a22aea9-6c81-4658-932c-497a867080b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636c77f6-1365-4859-b9b0-9a51ba67b055" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_6011b939-0490-4d54-8597-9aa9a3e53da3" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83692b8c-6dad-44ca-aa66-898e60c02d19" xlink:to="loc_icui_PursuitVascularInc.Member_6011b939-0490-4d54-8597-9aa9a3e53da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f65d06bd-d1bb-4b79-9391-ad9e95a490e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_db69afc6-e0ef-48b7-bd7e-1394d3b68798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_db69afc6-e0ef-48b7-bd7e-1394d3b68798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_76e958a9-41b8-451d-b274-f27d1468a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_76e958a9-41b8-451d-b274-f27d1468a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f21d3daa-c9be-49ad-87bb-be0f665ceb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a69e8988-91b8-44f0-b00c-5cd35590f43d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f21d3daa-c9be-49ad-87bb-be0f665ceb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidsandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_a9df29f6-e144-4ffc-b358-8e999aa4183a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_3ff9fd9f-e19d-44c5-a3bd-e04ac9f25724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_a9df29f6-e144-4ffc-b358-8e999aa4183a" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_3ff9fd9f-e19d-44c5-a3bd-e04ac9f25724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_f2511a35-b39f-4cf9-a58e-d9776f813668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_a9df29f6-e144-4ffc-b358-8e999aa4183a" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_f2511a35-b39f-4cf9-a58e-d9776f813668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="icui-20221231.xsd#AccruedLiabilitiesanOtherLongtermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e6340dbe-0e20-4433-878d-20a0468bcdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c4a96058-7a5f-4398-80a0-8c5f00c4b972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e6340dbe-0e20-4433-878d-20a0468bcdcb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c4a96058-7a5f-4398-80a0-8c5f00c4b972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_6404517e-a02b-458c-8472-3da067c53b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e6340dbe-0e20-4433-878d-20a0468bcdcb" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_6404517e-a02b-458c-8472-3da067c53b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DebtTables" xlink:type="simple" xlink:href="icui-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestMarginandCommitmentFeeTableTextBlock_b479e53f-b5c1-495f-a603-2ebf964d257e" xlink:href="icui-20221231.xsd#icui_InterestMarginandCommitmentFeeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:to="loc_icui_InterestMarginandCommitmentFeeTableTextBlock_b479e53f-b5c1-495f-a603-2ebf964d257e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginOnLoanTypeTableTextBlock_6e445681-1136-4cf2-a8fd-07655366bd39" xlink:href="icui-20221231.xsd#icui_ApplicableMarginOnLoanTypeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:to="loc_icui_ApplicableMarginOnLoanTypeTableTextBlock_6e445681-1136-4cf2-a8fd-07655366bd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_16472775-a2d6-4d13-9f27-e20b2e1ae2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_16472775-a2d6-4d13-9f27-e20b2e1ae2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_86602f73-ad9c-410b-b123-01c1b0bf1661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_86602f73-ad9c-410b-b123-01c1b0bf1661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseOnLongTermDebtTableTextBlock_5f6ae3e3-c91e-4a17-af93-b5945fd23177" xlink:href="icui-20221231.xsd#icui_InterestExpenseOnLongTermDebtTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8100b09-ee41-4cae-9837-b68019db60fa" xlink:to="loc_icui_InterestExpenseOnLongTermDebtTableTextBlock_5f6ae3e3-c91e-4a17-af93-b5945fd23177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesIncometaxdisclosureTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_270ed9b4-bfc8-4500-aab1-2bd26d84e9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_270ed9b4-bfc8-4500-aab1-2bd26d84e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0bea1062-56f0-4bba-9c0e-cd97f0ff0678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0bea1062-56f0-4bba-9c0e-cd97f0ff0678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_90ba78d4-eae6-462c-8a0a-ee466c6f7dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_90ba78d4-eae6-462c-8a0a-ee466c6f7dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e6dc4d34-7488-4f58-a03f-7b7752f5d247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e6dc4d34-7488-4f58-a03f-7b7752f5d247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_a45c64ac-9274-4d43-a69f-f3d0e920ecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8ac5763-cd0f-467b-9147-99b63d2eee36" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_a45c64ac-9274-4d43-a69f-f3d0e920ecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables" xlink:type="simple" xlink:href="icui-20221231.xsd#GeographicInformationandSignificantCustomersGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_a76ef510-c6cc-418c-a404-28cc94547f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_6b7763d4-aa9e-407e-8be6-fffdc0127b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_a76ef510-c6cc-418c-a404-28cc94547f27" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_6b7763d4-aa9e-407e-8be6-fffdc0127b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7a058216-7e06-44b9-b3ff-325f6beee735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7dfb8bbc-ce26-4835-801e-86581f7c0778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7a058216-7e06-44b9-b3ff-325f6beee735" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7dfb8bbc-ce26-4835-801e-86581f7c0778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="icui-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsTables" xlink:type="simple" xlink:href="icui-20221231.xsd#CollaborativeandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CollaborativeandOtherArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.icumed.com/role/SubsequentEventsTables" xlink:type="simple" xlink:href="icui-20221231.xsd#SubsequentEventsTables"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/SubsequentEventsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ea63d613-51ff-499e-88e9-7d77b8ee74b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_100ada5a-d782-46f4-8340-a2c335e6cc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_de12e573-7966-4dc1-baa2-15e052ed7d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_100ada5a-d782-46f4-8340-a2c335e6cc00" xlink:to="loc_us-gaap_NumberOfOperatingSegments_de12e573-7966-4dc1-baa2-15e052ed7d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d261bc94-5f5e-49c2-a512-f8e00473fa49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0c2c9396-89b9-476e-9cba-be082fd9279b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d261bc94-5f5e-49c2-a512-f8e00473fa49" xlink:to="loc_us-gaap_InventoryRawMaterials_0c2c9396-89b9-476e-9cba-be082fd9279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_2607d4a7-1351-45ee-9873-a75cfe7a5165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d261bc94-5f5e-49c2-a512-f8e00473fa49" xlink:to="loc_us-gaap_InventoryWorkInProcess_2607d4a7-1351-45ee-9873-a75cfe7a5165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9d38bac1-198d-46c0-8e41-b9569fc9b177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d261bc94-5f5e-49c2-a512-f8e00473fa49" xlink:to="loc_us-gaap_InventoryFinishedGoods_9d38bac1-198d-46c0-8e41-b9569fc9b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0c827687-4637-4da3-b014-6a6bbabc5b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d261bc94-5f5e-49c2-a512-f8e00473fa49" xlink:to="loc_us-gaap_InventoryNet_0c827687-4637-4da3-b014-6a6bbabc5b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9768beb7-3f13-4b08-abd3-267694f69614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9768beb7-3f13-4b08-abd3-267694f69614" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d308ebb-4085-47c6-82d9-e96b81bd6c11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c43c5628-6325-4f12-92c5-55305c0b15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c43c5628-6325-4f12-92c5-55305c0b15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandBuildingsAndImprovementsMember_a5f0b273-5488-46f4-ae44-c3b697a06cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandBuildingsAndImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_LandBuildingsAndImprovementsMember_a5f0b273-5488-46f4-ae44-c3b697a06cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MoldsMember_9845384a-51af-4125-a57e-123e2a956d51" xlink:href="icui-20221231.xsd#icui_MoldsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_MoldsMember_9845384a-51af-4125-a57e-123e2a956d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ComputerEquipmentAndSoftwareMember_4cf9fd4a-404b-4416-a922-f7b42f6a43be" xlink:href="icui-20221231.xsd#icui_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_ComputerEquipmentAndSoftwareMember_4cf9fd4a-404b-4416-a922-f7b42f6a43be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b5522a1b-741b-4802-9fcd-fc1a95542739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b5522a1b-741b-4802-9fcd-fc1a95542739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InstrumentsPlacedwithCustomersMember_7a75d7b2-dacb-4f0d-899e-c41d987fffb3" xlink:href="icui-20221231.xsd#icui_InstrumentsPlacedwithCustomersMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_icui_InstrumentsPlacedwithCustomersMember_7a75d7b2-dacb-4f0d-899e-c41d987fffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e965e045-5783-4050-b647-04bc1070eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48cfe85f-1439-47f4-a62a-f41762cf219f" xlink:to="loc_us-gaap_ConstructionInProgressMember_e965e045-5783-4050-b647-04bc1070eeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_290d5224-db44-4956-806e-9333050bf5c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9396aeaa-823f-4458-a435-4bccf6b8e453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9396aeaa-823f-4458-a435-4bccf6b8e453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8df39428-c024-42bc-9d51-513630862863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8df39428-c024-42bc-9d51-513630862863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b53c38e-4ec8-42cd-b22a-702e8e1ca23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_924aa30f-1487-48b0-bcff-db18790bfd42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b53c38e-4ec8-42cd-b22a-702e8e1ca23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07982b7d-77d3-4f5c-b99c-b3b668b0f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07982b7d-77d3-4f5c-b99c-b3b668b0f6d6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fb698c42-8ddb-4234-be0f-dbc30a97d8e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9e2dfc4c-f6ed-48fd-858d-13e42117ad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_BuildingMember_9e2dfc4c-f6ed-48fd-858d-13e42117ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_0fb42ac3-717f-4115-89f0-bb13268d4edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_BuildingImprovementsMember_0fb42ac3-717f-4115-89f0-bb13268d4edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a46b71a9-b541-4bca-ae39-13c1a16963a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a46b71a9-b541-4bca-ae39-13c1a16963a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_FurniturefixturesandmoldsMember_54f0dc16-f5b5-4f91-90c6-ecfa6fde830b" xlink:href="icui-20221231.xsd#icui_FurniturefixturesandmoldsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_FurniturefixturesandmoldsMember_54f0dc16-f5b5-4f91-90c6-ecfa6fde830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ComputerEquipmentAndSoftwareMember_c10f3b7d-529d-46ac-9609-f4f76844f41c" xlink:href="icui-20221231.xsd#icui_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_ComputerEquipmentAndSoftwareMember_c10f3b7d-529d-46ac-9609-f4f76844f41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InstrumentsPlacedwithCustomersMember_5c4da177-dca5-4f88-8ac0-3f0c9f1da2f2" xlink:href="icui-20221231.xsd#icui_InstrumentsPlacedwithCustomersMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27bde946-69b5-42e4-a32b-84ed7a10d21f" xlink:to="loc_icui_InstrumentsPlacedwithCustomersMember_5c4da177-dca5-4f88-8ac0-3f0c9f1da2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:to="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c76e2420-c9a4-4a7a-9324-47af88ed1666" xlink:to="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9677703-bf54-4da5-b13b-df2a6b478aa4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:to="loc_srt_MinimumMember_e9677703-bf54-4da5-b13b-df2a6b478aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5b89d318-394b-46ce-8563-b4109605d218" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5c83725e-c2ac-425e-8c8c-ee22ce3dbe88" xlink:to="loc_srt_MaximumMember_5b89d318-394b-46ce-8563-b4109605d218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40918f45-65cf-479b-90e8-44acfef8a3bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_df27cd89-6670-4814-b5b5-6c56ba885a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_51390ce8-0491-4e82-bdae-d9e1006c0fe9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_df27cd89-6670-4814-b5b5-6c56ba885a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75aefe3f-f2b5-4204-8aa5-f91653927590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8b4afddf-0f07-4fa8-96cd-537387d9f407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75aefe3f-f2b5-4204-8aa5-f91653927590" xlink:to="loc_us-gaap_Depreciation_8b4afddf-0f07-4fa8-96cd-537387d9f407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_492490b9-3ab5-4fb7-bf18-bb8b566c6dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_492490b9-3ab5-4fb7-bf18-bb8b566c6dad" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f63547ec-5e72-4d77-8810-67a8bfe319a9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_653dc885-92ce-41a0-9bb1-7b0c5e52e0d9" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:to="loc_icui_PursuitVascularLLCMember_653dc885-92ce-41a0-9bb1-7b0c5e52e0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_4c073731-2511-448e-8137-28a97b7645f3" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_499e0178-2cc1-437d-ba64-b82c9773f6c0" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_4c073731-2511-448e-8137-28a97b7645f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7cd89cba-ac14-4ec4-adb9-5027fbfb2ba2" xlink:to="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_87599b85-e9c4-4abc-866a-a2bbb39558ff" xlink:to="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9d9ed99-30cc-4aca-b290-1442cb4ac5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_Goodwill_f9d9ed99-30cc-4aca-b290-1442cb4ac5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b763b13-9f17-40a6-b735-639aa90e5598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5b763b13-9f17-40a6-b735-639aa90e5598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e49f6683-cdd6-43f5-b542-7f637ce51587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e49f6683-cdd6-43f5-b542-7f637ce51587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4a35196-8df0-4d1c-9351-09da4ad962ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_d4a35196-8df0-4d1c-9351-09da4ad962ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5920e06a-f8a7-4d03-8626-95a0781390be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5920e06a-f8a7-4d03-8626-95a0781390be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb1d68f2-7b0d-48f6-9d0c-3628c5773369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ae8fd06e-b234-43e0-bbbe-0459803ff809" xlink:to="loc_us-gaap_Goodwill_eb1d68f2-7b0d-48f6-9d0c-3628c5773369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e43c3b60-e9b7-482c-a136-ce8b7e7df8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e43c3b60-e9b7-482c-a136-ce8b7e7df8ae" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50c03f52-932b-4625-871c-2bb913badb0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_092a7663-d88d-4e98-aa70-51c208fdd7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_PatentsMember_092a7663-d88d-4e98-aa70-51c208fdd7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember_ce2fe8db-9088-47ce-abd5-aef348956dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_CustomerContractsMember_ce2fe8db-9088-47ce-abd5-aef348956dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_8df542ca-3ced-4498-a0cf-f70235a0bdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_CustomerRelatedIntangibleAssetsMember_8df542ca-3ced-4498-a0cf-f70235a0bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8331be76-82e6-435f-99c5-e26ddc2a83db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_TrademarksMember_8331be76-82e6-435f-99c5-e26ddc2a83db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7517d3bf-c639-457d-8844-918d8a109675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_TradeNamesMember_7517d3bf-c639-457d-8844-918d8a109675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2954d0be-2b54-4f6c-b98f-f92be3166fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2954d0be-2b54-4f6c-b98f-f92be3166fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cf61d482-4601-4dbf-870a-d42078d88cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cf61d482-4601-4dbf-870a-d42078d88cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6a06114-333f-4d89-98d2-3f8b8cbecf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed298af1-78b7-41c7-af71-ae2149045a37" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a6a06114-333f-4d89-98d2-3f8b8cbecf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_208a949f-bdc3-4afd-b1c7-149ce4e605f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84673784-bc67-4940-bd8d-2db8b81ddedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_84673784-bc67-4940-bd8d-2db8b81ddedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b9e3c77-f99a-4f45-a3d2-fad5b8f71f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b9e3c77-f99a-4f45-a3d2-fad5b8f71f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb532dcf-0335-4120-a2a2-b152dacf0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb532dcf-0335-4120-a2a2-b152dacf0b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b739ebd7-b311-47c1-b4c3-04493e553d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b739ebd7-b311-47c1-b4c3-04493e553d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ca2ed9d-dbb2-4bf5-aeb7-a35f2d824174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ca2ed9d-dbb2-4bf5-aeb7-a35f2d824174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9502d25e-76d8-4d04-b4cf-82e70eb9a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2e1f1bd-fc61-45c7-8903-b597ab0b40ba" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9502d25e-76d8-4d04-b4cf-82e70eb9a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05e30df1-55be-4bc5-9eb6-bba337bb030f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3fae9e25-00c3-4baa-a804-29100dcb3240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05e30df1-55be-4bc5-9eb6-bba337bb030f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3fae9e25-00c3-4baa-a804-29100dcb3240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56958762-8ab9-4054-ad5e-36df6978df8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56958762-8ab9-4054-ad5e-36df6978df8c" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d28c85c-8851-48a2-972b-7ad05a2af401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35b2df20-a98e-445e-bd49-0d869a5b4dfb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8d28c85c-8851-48a2-972b-7ad05a2af401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_ee35bfb3-c2c4-4b2d-b4dd-159a5c3f550a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_974e8ec9-3f70-4c50-9367-772dfa541fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_974e8ec9-3f70-4c50-9367-772dfa541fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_659e86fb-1ab6-41fd-ad69-b178d1e723f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_659e86fb-1ab6-41fd-ad69-b178d1e723f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_951586a1-8447-4323-b9d9-d88e17245a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_951586a1-8447-4323-b9d9-d88e17245a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34a5f964-c54a-4b1b-b76d-0828b65a5988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34a5f964-c54a-4b1b-b76d-0828b65a5988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_76a0c7c5-9d51-4ddf-aaba-fb62ffb1865a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_76a0c7c5-9d51-4ddf-aaba-fb62ffb1865a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f269c6ad-2d3b-4ac0-a35c-85b899b03a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f269c6ad-2d3b-4ac0-a35c-85b899b03a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9264adb3-d42a-4142-87c4-d957c9339847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_63a20b20-fd09-4051-b7c5-3b6133715957" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9264adb3-d42a-4142-87c4-d957c9339847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1e0d9cd2-c4df-4ccb-85f1-5726fe95f096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_722eac63-37a4-435e-bac3-0c836e8f777f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e0d9cd2-c4df-4ccb-85f1-5726fe95f096" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_722eac63-37a4-435e-bac3-0c836e8f777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0d7e58f-4ff5-43f2-8a2a-ccc1f9cb95cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0d7e58f-4ff5-43f2-8a2a-ccc1f9cb95cc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_dec6122b-76a9-4fc5-b875-184b57a22b3a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b7078dd4-1d49-4381-9ef4-6ef4fd12aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b7078dd4-1d49-4381-9ef4-6ef4fd12aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1d3932bc-4373-4ecc-8577-5323beb67797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1d3932bc-4373-4ecc-8577-5323beb67797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_3830f0f1-0560-45eb-9725-437280d4ed11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45d9d78b-9159-4764-9164-b3da6f08c756" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_3830f0f1-0560-45eb-9725-437280d4ed11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4d1557a6-bf32-4048-a4cd-3db7245572ff" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_474b31c3-7a06-45e1-9f79-e697e6365933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_474b31c3-7a06-45e1-9f79-e697e6365933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6556dfbe-a9b3-45e3-894b-e8a6ef0adc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6556dfbe-a9b3-45e3-894b-e8a6ef0adc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b3d99363-6b63-4c5b-80fb-93526dc42157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_b3d99363-6b63-4c5b-80fb-93526dc42157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c8723da-4100-4646-9719-eab6495f81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c8723da-4100-4646-9719-eab6495f81ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_381ff6e6-72ef-4777-a6fe-404cb76efa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_381ff6e6-72ef-4777-a6fe-404cb76efa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_590a5551-a265-4745-99f1-bddce85bcd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_590a5551-a265-4745-99f1-bddce85bcd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_ce9ab587-d7f7-4489-9edf-c7739b7b7299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53979658-6c4d-4642-901c-4e5a7e1c1697" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_ce9ab587-d7f7-4489-9edf-c7739b7b7299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f90e61cc-042d-44bc-b417-4e2e37474864" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonpublicCompanyMember_1465c9a2-ffc6-485e-9b25-b61efd81d0b5" xlink:href="icui-20221231.xsd#icui_NonpublicCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_afe2bca6-c8e1-4124-b97e-7679faa872ac" xlink:to="loc_icui_NonpublicCompanyMember_1465c9a2-ffc6-485e-9b25-b61efd81d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4358887f-69d7-4c3a-82b2-88d4bb57255e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonpublicCompanyMember_05be61bf-74bf-4f7a-b91e-6bfdbe6bb5be" xlink:href="icui-20221231.xsd#icui_NonpublicCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9eacab0-42ff-4f28-86bc-c18dfc25e96e" xlink:to="loc_icui_NonpublicCompanyMember_05be61bf-74bf-4f7a-b91e-6bfdbe6bb5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_2773c4d6-9d9f-4b1d-9aa0-a12add896e54" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c7b8cb6c-b870-4743-9640-08b7ef0c152e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c7b8cb6c-b870-4743-9640-08b7ef0c152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_6d210d72-7020-48c9-bcd3-29fd63c977c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_6d210d72-7020-48c9-bcd3-29fd63c977c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9ad1e3fd-4bc8-4d39-9a85-af10d1cc08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_339ec4aa-b607-4180-bf3e-8b0827f70175" xlink:to="loc_us-gaap_EquityMethodInvestments_9ad1e3fd-4bc8-4d39-9a85-af10d1cc08e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_9d8040dd-bf0b-447d-b651-d33ca80c932b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_9667c1cc-b09e-45d1-98c9-2316826ac9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_9d8040dd-bf0b-447d-b651-d33ca80c932b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_9667c1cc-b09e-45d1-98c9-2316826ac9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d2bb4ef-ded7-4ed3-91df-8f5d13be1d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_217ec4dd-b2b9-4206-b97c-2d8a453e993e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d2bb4ef-ded7-4ed3-91df-8f5d13be1d49" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_217ec4dd-b2b9-4206-b97c-2d8a453e993e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_550cf99b-d2a6-4910-8d29-e04742eb7e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_550cf99b-d2a6-4910-8d29-e04742eb7e98" xlink:to="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:to="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetDomain_9161d4e2-4165-4ebb-afc8-51cd02096df3" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetAxis_81f4f1d3-bea4-4543-91cd-1d33004d4fff" xlink:to="loc_icui_InterestExpenseIncomeNetDomain_9161d4e2-4165-4ebb-afc8-51cd02096df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:href="icui-20221231.xsd#icui_InterestExpenseIncomeNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetTable_579f6700-a323-402f-83e2-190f1ab36fde" xlink:to="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_20ba4b9d-b326-499b-9761-1372651bd65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestExpense_20ba4b9d-b326-499b-9761-1372651bd65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_67063ec4-0d49-43f5-9235-d2b91408ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestIncomeOther_67063ec4-0d49-43f5-9235-d2b91408ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c4c78f1c-04ae-45e0-9196-f2f9496c3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestExpenseIncomeNetLineItems_f155e3e3-a719-4588-9378-c3e7b6e820e1" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c4c78f1c-04ae-45e0-9196-f2f9496c3c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b00db1b2-6d9f-48bc-9dfe-802a6e889266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00db1b2-6d9f-48bc-9dfe-802a6e889266" xlink:to="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:to="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetDomain_13df1036-6eef-4884-b59d-695be87c0fbc" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetAxis_de7be1aa-ea31-4050-aded-b10a900c1557" xlink:to="loc_icui_OtherExpenseIncomeNetDomain_13df1036-6eef-4884-b59d-695be87c0fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:href="icui-20221231.xsd#icui_OtherExpenseIncomeNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetTable_c7ece7bf-9c7c-4280-afa1-0382383e8ba4" xlink:to="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_067d93b3-dd43-43a3-9aa7-7563f123903a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_067d93b3-dd43-43a3-9aa7-7563f123903a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_f67ff08d-3d54-496a-9282-15fe9bff2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_f67ff08d-3d54-496a-9282-15fe9bff2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MiscellaneousIncomeNet_a9a480c3-9bf0-4e01-96ef-18cbe0ab9d63" xlink:href="icui-20221231.xsd#icui_MiscellaneousIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_icui_MiscellaneousIncomeNet_a9a480c3-9bf0-4e01-96ef-18cbe0ab9d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_dee37655-48ac-4871-8f66-3b9733b78fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherExpenseIncomeNetLineItems_481f5b59-1b1a-47d6-96fa-d286deee5065" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_dee37655-48ac-4871-8f66-3b9733b78fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e797233-3c67-4fd6-bfeb-b7ea66871a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0485bb8e-2b40-4ff4-bb70-1f029f513064" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e797233-3c67-4fd6-bfeb-b7ea66871a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_368399a4-d35e-4406-a227-0fc8e391ed91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21ad3a6e-87c0-47bd-ab68-df4aa9767407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_NetIncomeLoss_21ad3a6e-87c0-47bd-ab68-df4aa9767407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42791270-b161-4510-b85d-751e0a479e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42791270-b161-4510-b85d-751e0a479e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e3b4cb89-0955-4285-9c7f-8f979a52b3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e3b4cb89-0955-4285-9c7f-8f979a52b3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aee0838-107f-439d-bf0a-ac2724325a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aee0838-107f-439d-bf0a-ac2724325a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_473e6e17-13ca-41a9-8299-0af4fc82b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_EarningsPerShareBasic_473e6e17-13ca-41a9-8299-0af4fc82b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c43a4b55-41fe-4d8d-b92a-74dbed10618b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c43a4b55-41fe-4d8d-b92a-74dbed10618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cfa5528-42a6-4360-8b89-38ab8a979641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7500ab84-78da-4a7c-9277-898c6e5e865b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cfa5528-42a6-4360-8b89-38ab8a979641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_6a864911-f8a1-4986-b77c-5ea10d834a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_188e6f69-016d-4892-a484-e19a93067143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_6a864911-f8a1-4986-b77c-5ea10d834a4f" xlink:to="loc_us-gaap_AccountingPoliciesAbstract_188e6f69-016d-4892-a484-e19a93067143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_24d5f60c-26ba-4608-a709-1d1944440bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188e6f69-016d-4892-a484-e19a93067143" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_24d5f60c-26ba-4608-a709-1d1944440bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a5de715b-ef15-452a-8208-14f1429b3b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsTextDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsTextDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3075aed8-b56f-4485-be7b-bffff98a5812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3075aed8-b56f-4485-be7b-bffff98a5812" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_47048b32-5799-4cc3-b631-7120136dcdb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_549ccd4f-34b8-41e1-b78b-a13636dbd754" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72c59372-afe2-41ec-a233-5e4447ab31ca" xlink:to="loc_icui_SmithsMedical2020LimitedMember_549ccd4f-34b8-41e1-b78b-a13636dbd754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_91449e5b-3914-4b32-a48e-aef972883b34" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f46d8d30-1dcd-442e-8a8c-6ebb5df91efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f46d8d30-1dcd-442e-8a8c-6ebb5df91efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4e7310-bad5-4228-ad90-32728f369d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4e7310-bad5-4228-ad90-32728f369d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c7c5e273-b69d-437b-979d-36df30b540c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c7c5e273-b69d-437b-979d-36df30b540c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9609745a-4c39-41fe-9cc4-8b731e356975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9609745a-4c39-41fe-9cc4-8b731e356975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MinimumStockPriceTargetForEarnOutPayment_509f1b55-62b1-4f10-8978-ede3ac28617a" xlink:href="icui-20221231.xsd#icui_MinimumStockPriceTargetForEarnOutPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_MinimumStockPriceTargetForEarnOutPayment_509f1b55-62b1-4f10-8978-ede3ac28617a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_73878064-ddb6-4810-b28d-fcf59078e5de" xlink:href="icui-20221231.xsd#icui_RequiredShareHoldingOfStockIssuedAtAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_RequiredShareHoldingOfStockIssuedAtAcquisition_73878064-ddb6-4810-b28d-fcf59078e5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b680292d-d5ff-49f5-8a5d-daa2dc304078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b680292d-d5ff-49f5-8a5d-daa2dc304078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationTransferredCash_2c7a1c62-8b12-45f5-bfcc-3195e7da734e" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationTransferredCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_icui_BusinessCombinationConsiderationTransferredCash_2c7a1c62-8b12-45f5-bfcc-3195e7da734e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_fa3804fe-7f10-4c82-b346-0f3c7899826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_fa3804fe-7f10-4c82-b346-0f3c7899826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_7ea2534e-fa9a-4ae2-a77f-749e18e1fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d03765f5-e4fc-4bae-8634-cd2dc18ac804" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_7ea2534e-fa9a-4ae2-a77f-749e18e1fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedical2020LimitedTableDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5b6bcb3a-ec09-4aaa-b793-aa9ccca77ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5b6bcb3a-ec09-4aaa-b793-aa9ccca77ec9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e73c17d1-f29b-44c4-8ec9-96e4d29ad021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_13b2ad25-baf4-475f-8b64-2aede452b9ca" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5de9a5d-212b-472b-abb4-79e2eea02c6b" xlink:to="loc_icui_SmithsMedical2020LimitedMember_13b2ad25-baf4-475f-8b64-2aede452b9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_35d94498-cbfe-4037-858b-f645db0915fc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cb0a688-433f-4f68-9ab2-8f74cb41d822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cb0a688-433f-4f68-9ab2-8f74cb41d822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cae1894d-3706-486e-b457-8e6f9d388f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_cae1894d-3706-486e-b457-8e6f9d388f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a6b43c93-c31d-4ff1-9462-a92f316eba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a6b43c93-c31d-4ff1-9462-a92f316eba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_65a68e36-18cf-46f2-bbed-77ed56bf1daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_65a68e36-18cf-46f2-bbed-77ed56bf1daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0e614c11-8c4a-4f4e-aca6-1f605974f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0e614c11-8c4a-4f4e-aca6-1f605974f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30bf9293-878a-47ee-b1b0-a668fcfcdc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30bf9293-878a-47ee-b1b0-a668fcfcdc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6c98068e-a1ca-4a61-bb9c-53af347da4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6c98068e-a1ca-4a61-bb9c-53af347da4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_93642cd3-6040-430d-80fc-b19c0eb5ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesFairValue_93642cd3-6040-430d-80fc-b19c0eb5ae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_728dfe9e-65cb-4ff3-85a6-ea3ac87ad164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_728dfe9e-65cb-4ff3-85a6-ea3ac87ad164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f0a4fcd3-5189-47b5-a7ac-ee26d93583a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f0a4fcd3-5189-47b5-a7ac-ee26d93583a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7888733f-cf04-4cbb-bedc-e3263543ed82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_7888733f-cf04-4cbb-bedc-e3263543ed82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_db6f2df8-2b78-4898-b985-2de79e86e022" xlink:href="icui-20221231.xsd#icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_db6f2df8-2b78-4898-b985-2de79e86e022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ebed2363-5296-4655-8444-a7cb6c3d1a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ebed2363-5296-4655-8444-a7cb6c3d1a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_199df1b9-e114-4e3e-89e6-36c188d50a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_199df1b9-e114-4e3e-89e6-36c188d50a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_175afa05-b157-4e2a-a636-0ec76debbcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_175afa05-b157-4e2a-a636-0ec76debbcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8f30f094-16c8-4df8-a4e2-f76464eeb3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8f30f094-16c8-4df8-a4e2-f76464eeb3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_fe1a7524-b159-4595-868b-e7fff5e9dcb8" xlink:href="icui-20221231.xsd#icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable_fe1a7524-b159-4595-868b-e7fff5e9dcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_024bd410-d5a7-4b67-b9d7-9afc0942de22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_024bd410-d5a7-4b67-b9d7-9afc0942de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b8f3fe90-83dc-4b4b-91f9-130df682145d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b8f3fe90-83dc-4b4b-91f9-130df682145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e4644e31-3abb-454d-862d-9d2023771c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e4644e31-3abb-454d-862d-9d2023771c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2113349c-7609-45cc-8ea5-4beea585d164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423f6614-7261-40d8-9d7f-bf125488194a" xlink:to="loc_us-gaap_Goodwill_2113349c-7609-45cc-8ea5-4beea585d164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedical2020LimitedIntangibleDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_49ee5e21-dd7d-4e80-ac0f-98e6bb475cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_49ee5e21-dd7d-4e80-ac0f-98e6bb475cc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_27ea3b41-2469-4622-95f9-4693837709a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_52c4a98e-3d81-47e7-ba20-2b70a59d764d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_52c4a98e-3d81-47e7-ba20-2b70a59d764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_577d4cc6-7ffd-4557-813b-748ff7442f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_577d4cc6-7ffd-4557-813b-748ff7442f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a4509b22-7f2c-4e40-b55e-d9c87fec5355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a4509b22-7f2c-4e40-b55e-d9c87fec5355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_679156a8-72c0-475a-8d93-e38b3b3df490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c39c1174-f939-4b8d-8cd8-0323c790dc2e" xlink:to="loc_us-gaap_TrademarksMember_679156a8-72c0-475a-8d93-e38b3b3df490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec3db1a0-d7fd-4ef8-93ac-a70dbe1dd08e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_c731abfe-3d96-439a-860c-9e92ae6a350b" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5edda01-5f30-4a1c-a3fa-2f7878571f09" xlink:to="loc_icui_SmithsMedical2020LimitedMember_c731abfe-3d96-439a-860c-9e92ae6a350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_a4374172-e2fe-4eae-9a65-c6c765d41c93" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f528ce3e-c979-4c05-8e04-e606085222c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f528ce3e-c979-4c05-8e04-e606085222c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea03abe9-8a0c-4ba8-9a18-988773f32d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3a21ad66-7cbc-4883-bf52-547e3339aefc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea03abe9-8a0c-4ba8-9a18-988773f32d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsForeignInfusionSystemsSupplierDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6695b03c-a7ae-4b52-bb28-2cc07e06d238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6695b03c-a7ae-4b52-bb28-2cc07e06d238" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f851417d-b77a-4213-988c-166a0a025027" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_21b71290-af2f-441f-8362-5a605987649e" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a49bff1b-674c-4c7c-a699-39cc964c43b8" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_21b71290-af2f-441f-8362-5a605987649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_99844b8f-d2ba-4148-aa79-86f6e47aec39" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_e0b97b49-257f-4a88-84a9-54306163fe42" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_Contingentconsiderationgross_e0b97b49-257f-4a88-84a9-54306163fe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_f033fefb-1627-469b-a41f-97ae76acec4f" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_ShortTermContingentConsiderationGross_f033fefb-1627-469b-a41f-97ae76acec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_042f68e2-e66c-41d1-b6e8-feda01bee299" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_LongTermContingentConsiderationGross_042f68e2-e66c-41d1-b6e8-feda01bee299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9ed44ad8-d06b-4ca8-889e-d0bf4f1097ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9ed44ad8-d06b-4ca8-889e-d0bf4f1097ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationConsiderationCashHoldback_2ad6c5e0-a02d-466e-97f2-f709efae0fce" xlink:href="icui-20221231.xsd#icui_BusinessCombinationConsiderationCashHoldback"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7b12a434-964d-426c-93c4-e75ce603e4a9" xlink:to="loc_icui_BusinessCombinationConsiderationCashHoldback_2ad6c5e0-a02d-466e-97f2-f709efae0fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AcquisitionsSmithsMedicalProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dae44af2-183d-4981-809f-fa47b4e21648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dae44af2-183d-4981-809f-fa47b4e21648" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b367b297-c1f6-4e61-960d-2bfb21176dfa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedical2020LimitedMember_63910380-1c01-4064-865e-a206c3b76dd5" xlink:href="icui-20221231.xsd#icui_SmithsMedical2020LimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0bdc57d-1dbb-4838-b50e-ce14e0e9d451" xlink:to="loc_icui_SmithsMedical2020LimitedMember_63910380-1c01-4064-865e-a206c3b76dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable_883f8b53-19ba-4301-b7eb-d5b4c1c0ada3" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bd309b32-735e-4d3b-81de-f6406f00994f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_Revenues_bd309b32-735e-4d3b-81de-f6406f00994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_871dc5ac-62e0-47ed-924d-d8efa4b67638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_ProfitLoss_871dc5ac-62e0-47ed-924d-d8efa4b67638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_125d2a1b-7ee4-4b21-bf75-5730d7535d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_125d2a1b-7ee4-4b21-bf75-5730d7535d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_c14ea746-3a6f-4d12-9bc0-163c9f223493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_c14ea746-3a6f-4d12-9bc0-163c9f223493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentAmortization_a3bb0531-66f0-4085-b4a6-6fc6bdbcb006" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentAmortization_a3bb0531-66f0-4085-b4a6-6fc6bdbcb006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentInventory_a39cf828-5a57-48b4-b683-7d269513c43d" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentInventory_a39cf828-5a57-48b4-b683-7d269513c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ProFormaAdjustmentFinanceCosts_4c05953c-d514-4a5e-a811-eddfe6d7cb98" xlink:href="icui-20221231.xsd#icui_ProFormaAdjustmentFinanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems_07fbbc50-54a6-42bf-8526-d3ea68fd1d81" xlink:to="loc_icui_ProFormaAdjustmentFinanceCosts_4c05953c-d514-4a5e-a811-eddfe6d7cb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationDetails1"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_83a0197f-6fee-49a6-94b9-e3b7b724e206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Restructuringandstrategictransactionexpense_4a6cab35-552d-40b7-bdfa-4aa5970506c4" xlink:href="icui-20221231.xsd#icui_Restructuringandstrategictransactionexpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_83a0197f-6fee-49a6-94b9-e3b7b724e206" xlink:to="loc_icui_Restructuringandstrategictransactionexpense_4a6cab35-552d-40b7-bdfa-4aa5970506c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_11123f27-489a-4eee-b0fd-69f7b69f14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_83a0197f-6fee-49a6-94b9-e3b7b724e206" xlink:to="loc_us-gaap_RestructuringCharges_11123f27-489a-4eee-b0fd-69f7b69f14e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_541235ca-115b-4e01-a4c1-90bd650a8ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_83a0197f-6fee-49a6-94b9-e3b7b724e206" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_541235ca-115b-4e01-a4c1-90bd650a8ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_83a0197f-6fee-49a6-94b9-e3b7b724e206" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_04a90d2e-2727-4e55-b9e4-58937c2c704a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_6623c159-9a7f-44d2-b604-8b69eb0cb37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e46560f0-7559-4526-9c7c-f45d01f7d2c8" xlink:to="loc_us-gaap_FacilityClosingMember_6623c159-9a7f-44d2-b604-8b69eb0cb37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_40bdb537-f0f3-46ac-be81-78bd31bb61af" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_cb5658cb-88ed-4247-8e5d-1aa4912bf892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_cb5658cb-88ed-4247-8e5d-1aa4912bf892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestructuringAdjustmentsSeveranceAndFacility_8f331dae-79d4-4ba0-8c40-70ff44907599" xlink:href="icui-20221231.xsd#icui_RestructuringAdjustmentsSeveranceAndFacility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f9a445a3-3082-47d0-82e4-1959dbed8012" xlink:to="loc_icui_RestructuringAdjustmentsSeveranceAndFacility_8f331dae-79d4-4ba0-8c40-70ff44907599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationDetails2"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e6b85f4-1649-4c8a-917e-58fd73e859ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e6b85f4-1649-4c8a-917e-58fd73e859ce" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cc53f9d0-a4cb-4077-b84f-dddedebf6a48" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0bd9eb07-29d4-4a21-8ea4-2ca03b5ba56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0bd9eb07-29d4-4a21-8ea4-2ca03b5ba56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_97c39000-1af5-4330-b920-54930daec4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_65c7de85-e422-47ba-8f66-7b0905b94b72" xlink:to="loc_us-gaap_FacilityClosingMember_97c39000-1af5-4330-b920-54930daec4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a3c10b80-1b08-45ac-91ee-bd846abce7a4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_930e0b26-b314-46f8-a8aa-ee8b6d32932c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserve_930e0b26-b314-46f8-a8aa-ee8b6d32932c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_4e2958e6-3cde-4bb9-9a68-8f93c23bf381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringCosts_4e2958e6-3cde-4bb9-9a68-8f93c23bf381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_2b7f4343-da07-44e0-9d69-683589151964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_PaymentsForRestructuring_2b7f4343-da07-44e0-9d69-683589151964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_f3b03248-3ad5-47fa-9a87-5eda67702e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_f3b03248-3ad5-47fa-9a87-5eda67702e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_72376011-abe4-42e5-9b3f-03ca25e21564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_72376011-abe4-42e5-9b3f-03ca25e21564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_cc2c5c7d-e11a-42a5-a78a-d2e8ebd96bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bbd5bcc2-c1b7-44c8-bccb-cfaa3e6dab87" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_cc2c5c7d-e11a-42a5-a78a-d2e8ebd96bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_08c4bc9f-8601-4179-b9fc-48ad653dc4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StrategicTransactionandIntegration_38de9bb2-b25a-4659-973e-a709d9b6bee7" xlink:href="icui-20221231.xsd#icui_StrategicTransactionandIntegration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_08c4bc9f-8601-4179-b9fc-48ad653dc4d8" xlink:to="loc_icui_StrategicTransactionandIntegration_38de9bb2-b25a-4659-973e-a709d9b6bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueDisaggregationofRevenueProductLineDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4196528c-57bb-4358-96d5-139fa827df5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4196528c-57bb-4358-96d5-139fa827df5c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:to="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_53b0fcd1-ab59-4837-a421-f42c7b9719e3" xlink:to="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesMember_0cb915e7-7b1a-4146-83ed-0e2c63fcfba6" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionConsumablesMember_0cb915e7-7b1a-4146-83ed-0e2c63fcfba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionSystemsMember_6a0646f0-b52a-4fc9-a405-9e6c2985355d" xlink:href="icui-20221231.xsd#icui_InfusionSystemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionSystemsMember_6a0646f0-b52a-4fc9-a405-9e6c2985355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IVSolutionsMember_5916aa44-a7bb-4897-b77c-4a370c528e7e" xlink:href="icui-20221231.xsd#icui_IVSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_IVSolutionsMember_5916aa44-a7bb-4897-b77c-4a370c528e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CriticalCareMember_854684c4-0166-499b-a54c-698212de458a" xlink:href="icui-20221231.xsd#icui_CriticalCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_CriticalCareMember_854684c4-0166-499b-a54c-698212de458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InfusionConsumablesSmithsMedicalMember_327b716f-f0c7-431c-89b1-eab9eb30c661" xlink:href="icui-20221231.xsd#icui_InfusionConsumablesSmithsMedicalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_InfusionConsumablesSmithsMedicalMember_327b716f-f0c7-431c-89b1-eab9eb30c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VascularAccessMember_23d5ff0d-1850-4e32-afdd-48fb3ca8c578" xlink:href="icui-20221231.xsd#icui_VascularAccessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_VascularAccessMember_23d5ff0d-1850-4e32-afdd-48fb3ca8c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_VitalCareMember_6131fc02-55fe-4c9f-8ea1-20fca6976cd4" xlink:href="icui-20221231.xsd#icui_VitalCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1daef7c6-8b7d-4adb-bb8a-3e16599dc49e" xlink:to="loc_icui_VitalCareMember_6131fc02-55fe-4c9f-8ea1-20fca6976cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0509e738-7541-4d24-89fc-38de26bc5a88" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ca72ac90-aed4-4448-a0a4-b874698480e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:to="loc_us-gaap_Revenues_ca72ac90-aed4-4448-a0a4-b874698480e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentageofrevenue_61000ff6-4275-46d0-8b6f-2eb57bf15f6f" xlink:href="icui-20221231.xsd#icui_Percentageofrevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf387fa3-1d22-4fd5-a4a8-8ad26fb3b503" xlink:to="loc_icui_Percentageofrevenue_61000ff6-4275-46d0-8b6f-2eb57bf15f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueDisaggregationofRevenuebyGeographyDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_36118280-92ed-49f8-95f0-7980c6df8864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_36118280-92ed-49f8-95f0-7980c6df8864" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:to="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0aecac49-496c-4f5f-bc3f-370709065e38" xlink:to="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_25771253-9b70-4c08-8dc5-534257c462d2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_country_US_25771253-9b70-4c08-8dc5-534257c462d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a84d415c-3b56-44cd-9e7b-b17ab5374e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_us-gaap_EMEAMember_a84d415c-3b56-44cd-9e7b-b17ab5374e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_APACDomain_d5e98cb0-9ef3-4ba6-af45-cfb7a59f4e33" xlink:href="icui-20221231.xsd#icui_APACDomain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_APACDomain_d5e98cb0-9ef3-4ba6-af45-cfb7a59f4e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherforeigncountriesMember_a7c21855-26fe-4958-abea-4863af867b4d" xlink:href="icui-20221231.xsd#icui_OtherforeigncountriesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_OtherforeigncountriesMember_a7c21855-26fe-4958-abea-4863af867b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InternationalSalesDomain_d7147e19-b8a6-4437-b797-a4ea8db59a61" xlink:href="icui-20221231.xsd#icui_InternationalSalesDomain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d244ac6-798b-47b3-8616-ce94dadb617d" xlink:to="loc_icui_InternationalSalesDomain_d7147e19-b8a6-4437-b797-a4ea8db59a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_35f3c194-da3b-4d87-a640-2d5f960dd642" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74aeef46-5fef-4df2-a885-3d5f35485080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:to="loc_us-gaap_Revenues_74aeef46-5fef-4df2-a885-3d5f35485080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Percentoftotalrevenue_792a94bc-697c-428a-8eb6-3bf15ae29ae5" xlink:href="icui-20221231.xsd#icui_Percentoftotalrevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f1d0e34d-d062-4cfb-809d-74e5737a1743" xlink:to="loc_icui_Percentoftotalrevenue_792a94bc-697c-428a-8eb6-3bf15ae29ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c21a4a0f-9242-47d7-894c-d33728067eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c21a4a0f-9242-47d7-894c-d33728067eb5" xlink:to="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2373340e-d30a-43de-8123-3afaf7fd499d" xlink:to="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_57b78a2c-5370-4195-bbd5-73a116bda5ca" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_EquipmentrevenueMember_57b78a2c-5370-4195-bbd5-73a116bda5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_88df0def-291d-4601-89e2-d4f64be7ef6a" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_SoftwarerevenueMember_88df0def-291d-4601-89e2-d4f64be7ef6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GovernmentGrantRevenueMember_5a6de974-dacd-4555-bccf-ffad9827156a" xlink:href="icui-20221231.xsd#icui_GovernmentGrantRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_GovernmentGrantRevenueMember_5a6de974-dacd-4555-bccf-ffad9827156a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherDeferredRevenueMember_ededf9fe-a360-4a49-a9e4-77b57c8d367a" xlink:href="icui-20221231.xsd#icui_OtherDeferredRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4f939cec-9619-4dcf-a306-3b5a92bca9f9" xlink:to="loc_icui_OtherDeferredRevenueMember_ededf9fe-a360-4a49-a9e4-77b57c8d367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cdbb88f9-6c7c-420a-9d86-952c9ee07d0f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_57377b2e-d078-47bf-b43c-8d6b2b021982" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58e933c5-8617-4ab0-a18a-34537b071046" xlink:to="loc_icui_SmithsMedicalMember_57377b2e-d078-47bf-b43c-8d6b2b021982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingAxis_7dd36154-c0fd-4de6-baf4-26a7f238050f" xlink:to="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermMember_fc4a057f-a058-4e4d-97a0-e22f198e873b" xlink:href="icui-20221231.xsd#icui_ShortTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:to="loc_icui_ShortTermMember_fc4a057f-a058-4e4d-97a0-e22f198e873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_aabcf446-c193-46b8-aaa8-5277dfe1e325" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingDomain_b6774bd3-4a42-41b5-b661-d93d975f227b" xlink:to="loc_icui_LongTermMember_aabcf446-c193-46b8-aaa8-5277dfe1e325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_9a5f4722-cc1c-4f3a-aa45-7022494c397b" xlink:to="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:href="icui-20221231.xsd#icui_COntractLiabilityRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_7a7aae6f-e711-48ee-b20a-72dc0bc2e6dd" xlink:to="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f77abe7b-711c-4a45-8fd0-126dbc0c0cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f77abe7b-711c-4a45-8fd0-126dbc0c0cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12164b0e-10f7-4e56-875a-12829352a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12164b0e-10f7-4e56-875a-12829352a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAdditions_4d44816f-a41b-444b-be91-c2f33253df0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_DeferredRevenueAdditions_4d44816f-a41b-444b-be91-c2f33253df0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c79a2f4b-64b8-468c-b1af-15ed4746a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_COntractLiabilityRollforwardRollForward_720a5e5e-7ddd-4892-b0cf-776b57afaeb8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c79a2f4b-64b8-468c-b1af-15ed4746a0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueContractLiabilitiesTextDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a8ae5362-1a87-4b25-b258-6d463b280102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a8ae5362-1a87-4b25-b258-6d463b280102" xlink:to="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:to="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aa02bc3a-ada7-4876-ab9a-71cefe42f5b6" xlink:to="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_9c297b8b-ed13-427c-bab4-fa8a691c45e2" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:to="loc_icui_EquipmentrevenueMember_9c297b8b-ed13-427c-bab4-fa8a691c45e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_40906be6-34c7-4cb1-8a2e-2e6471b0e189" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d167f13a-0013-426f-a8d1-4152d3c3c36f" xlink:to="loc_icui_SoftwarerevenueMember_40906be6-34c7-4cb1-8a2e-2e6471b0e189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:href="icui-20221231.xsd#icui_ContractassetandliabilitybalancesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesTable_77676db3-9ca4-4439-bf6f-8c3961162c6c" xlink:to="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_c2c3e20f-cf6b-42c3-946f-3e2491aace3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ContractassetandliabilitybalancesLineItems_8299991b-ca3a-4a79-9626-6c10f71ae5f3" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_c2c3e20f-cf6b-42c3-946f-3e2491aace3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#RevenueRemainingPerformanceObligationRecognitionTimingDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1a8a6cf0-9392-443d-a2ba-2a04a2649b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1a8a6cf0-9392-443d-a2ba-2a04a2649b89" xlink:to="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:to="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingAxis_0cdc0762-86e7-4270-bd38-88035011cbb1" xlink:to="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermMember_96727259-b78d-44dc-8d1f-b909c838a8a0" xlink:href="icui-20221231.xsd#icui_ShortTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:to="loc_icui_ShortTermMember_96727259-b78d-44dc-8d1f-b909c838a8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_64ba2bd3-3f10-4430-a685-532671c25c27" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingDomain_e95af8ed-f6c0-4035-816d-193b47796df3" xlink:to="loc_icui_LongTermMember_64ba2bd3-3f10-4430-a685-532671c25c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:to="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4687b1e3-f9a9-4f3d-b78e-e96519b4a467" xlink:to="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EquipmentrevenueMember_6a048782-7872-45ef-b0bf-70b1e17247c6" xlink:href="icui-20221231.xsd#icui_EquipmentrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_EquipmentrevenueMember_6a048782-7872-45ef-b0bf-70b1e17247c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SoftwarerevenueMember_6efaced2-b0dc-40d3-9594-e5f8281fee70" xlink:href="icui-20221231.xsd#icui_SoftwarerevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_SoftwarerevenueMember_6efaced2-b0dc-40d3-9594-e5f8281fee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GovernmentGrantRevenueMember_8e9b2fee-eb09-4ec6-bfb3-61a8d3900cd2" xlink:href="icui-20221231.xsd#icui_GovernmentGrantRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_GovernmentGrantRevenueMember_8e9b2fee-eb09-4ec6-bfb3-61a8d3900cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherDeferredRevenueMember_be1a4229-a726-4844-be75-b1ad70f6768e" xlink:href="icui-20221231.xsd#icui_OtherDeferredRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e08c071c-7104-467f-934e-aae359e62cf3" xlink:to="loc_icui_OtherDeferredRevenueMember_be1a4229-a726-4844-be75-b1ad70f6768e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:href="icui-20221231.xsd#icui_RevenueRecognitionTimingLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_RevenueRecognitionTimingTable_a999d6fd-3e48-4f86-9f61-e20b335c1320" xlink:to="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e179eb45-4cf2-40a2-87d0-d109f09fa487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_RevenueRecognitionTimingLineItems_30e93bb5-92cf-4acd-878f-921269fe512b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e179eb45-4cf2-40a2-87d0-d109f09fa487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1498a8ce-55eb-4cfe-84f2-09e83f506b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1498a8ce-55eb-4cfe-84f2-09e83f506b7e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:to="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4d2bbe9e-b37b-4219-b1eb-0ad970468593" xlink:to="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a39fd49b-1f45-444d-b77c-9b7079bb0b4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:to="loc_srt_MinimumMember_a39fd49b-1f45-444d-b77c-9b7079bb0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbab318f-da31-4df5-97f4-c942cb7f0b6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3987867-55a7-4ee0-9491-9b25542f1c95" xlink:to="loc_srt_MaximumMember_cbab318f-da31-4df5-97f4-c942cb7f0b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51089cf5-5e6d-4e5a-9bd3-a893d10d8924" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Optiontoextendinyears_619e2f54-e38e-4378-845e-cecdcb4e6963" xlink:href="icui-20221231.xsd#icui_Optiontoextendinyears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:to="loc_icui_Optiontoextendinyears_619e2f54-e38e-4378-845e-cecdcb4e6963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a33c13d3-971f-495a-bda5-7564bb88321e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4916ea4e-f3e9-487b-912f-e04ba8c732a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a33c13d3-971f-495a-bda5-7564bb88321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3d94821a-ea75-44df-a871-edea35775912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:to="loc_us-gaap_OperatingLeaseCost_3d94821a-ea75-44df-a871-edea35775912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_64654576-3109-4985-a76f-dae894114245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_64654576-3109-4985-a76f-dae894114245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e3d78b27-a57b-4f6c-8ea6-08f1f603fcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e3d78b27-a57b-4f6c-8ea6-08f1f603fcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_6f21a23f-0dd3-4511-ac6f-d062a85c3b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:to="loc_us-gaap_ShortTermLeaseCost_6f21a23f-0dd3-4511-ac6f-d062a85c3b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fceb9b08-30b8-4ae5-9951-b5eea6beee47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_564275a3-75df-4931-8a4d-6cf79d914a91" xlink:to="loc_us-gaap_LeaseCost_fceb9b08-30b8-4ae5-9951-b5eea6beee47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesSupplementalCashFlowLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_85bb6f3e-da54-40d3-b48b-32d7631dfe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:to="loc_us-gaap_OperatingLeasePayments_85bb6f3e-da54-40d3-b48b-32d7631dfe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c0b1a579-694e-4804-baf3-93079b1855a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c0b1a579-694e-4804-baf3-93079b1855a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_86bdbc3b-88a1-48c4-9754-3edc562a3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_86bdbc3b-88a1-48c4-9754-3edc562a3b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_62941349-203f-45ac-86e2-9edd4777c68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_62941349-203f-45ac-86e2-9edd4777c68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_a66411d4-6d09-41fd-9ca1-c9b8854725fe" xlink:href="icui-20221231.xsd#icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1805976e-a636-4755-8146-b325b4a73e97" xlink:to="loc_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed_a66411d4-6d09-41fd-9ca1-c9b8854725fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesSupplementalBalanceSheetLeaseinformationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_34c43a82-c987-4a70-b7f5-073354757147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_34c43a82-c987-4a70-b7f5-073354757147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_157398cc-cfdc-4d9c-89c2-73b760716093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_157398cc-cfdc-4d9c-89c2-73b760716093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a6d7b54-42ca-4fc9-af02-e8131a118f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a6d7b54-42ca-4fc9-af02-e8131a118f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_69935d41-3d54-48a1-a3f4-fc7de191bee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseLiability_69935d41-3d54-48a1-a3f4-fc7de191bee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e6e9efaf-43b3-4f0d-abc4-752c8c59e65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e6e9efaf-43b3-4f0d-abc4-752c8c59e65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_027d0374-163b-49c9-920a-e9d4c3e43f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_027d0374-163b-49c9-920a-e9d4c3e43f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_065e79c8-8504-472c-b4e7-77749c485381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_065e79c8-8504-472c-b4e7-77749c485381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c649bec5-4707-4772-8c04-90f25b970ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e367a4f-749f-4192-97a4-399e1fbe0cdd" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c649bec5-4707-4772-8c04-90f25b970ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FinanceLeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_79a1f757-27b7-4ed4-8d2c-bd57abc303cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_79a1f757-27b7-4ed4-8d2c-bd57abc303cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e9b469e-a025-4a0c-ad33-9a2117ad2332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e9b469e-a025-4a0c-ad33-9a2117ad2332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2b8c931-0343-4ff5-846f-e49e4386ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2b8c931-0343-4ff5-846f-e49e4386ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_7ba69a29-3de1-490a-8313-6c2695e41506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseLiability_7ba69a29-3de1-490a-8313-6c2695e41506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1de5a278-5cb9-44c2-ac81-56e365db714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1de5a278-5cb9-44c2-ac81-56e365db714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0961cadb-e258-4a45-a9c8-1527b004b243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0961cadb-e258-4a45-a9c8-1527b004b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ed526017-03b7-40b0-ae07-84bbb6e09fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ed526017-03b7-40b0-ae07-84bbb6e09fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f0ebcaf3-195e-4803-8558-c28841826c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f0ebcaf3-195e-4803-8558-c28841826c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_37a0177a-e696-4f77-89ec-f135ef111487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ff4a0533-4162-44a8-9187-856ac9799727" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_37a0177a-e696-4f77-89ec-f135ef111487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesLeaseMaturityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4439b708-5371-4722-ab7c-1cf67c3525fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4439b708-5371-4722-ab7c-1cf67c3525fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88783453-0b80-4028-9770-c10f011e0193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88783453-0b80-4028-9770-c10f011e0193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c248eea0-1ac6-4d9b-b0e4-2f7fc367e3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c248eea0-1ac6-4d9b-b0e4-2f7fc367e3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_45925cc4-3e3c-4135-bf9e-68bf72c78fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_45925cc4-3e3c-4135-bf9e-68bf72c78fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1dfd34df-3a9b-48ea-aa2a-f6c25a6e1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1dfd34df-3a9b-48ea-aa2a-f6c25a6e1e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b37ead86-129a-41bc-b15c-5cfa0b14e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b37ead86-129a-41bc-b15c-5cfa0b14e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fafab0ff-14af-4fc4-b258-d2fc98499274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fafab0ff-14af-4fc4-b258-d2fc98499274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6664f47d-04e9-49dc-b3c5-ec89d9d90423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6664f47d-04e9-49dc-b3c5-ec89d9d90423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ce3c8869-98c9-41a8-a061-6779853021ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35684b20-9ef9-46df-b97d-7d7cb39a7c61" xlink:to="loc_us-gaap_OperatingLeaseLiability_ce3c8869-98c9-41a8-a061-6779853021ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#LeasesFinanceLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1a925c0f-b862-41dd-beed-94b080ac3924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1a925c0f-b862-41dd-beed-94b080ac3924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e4016c49-f37c-4aae-83af-ff776cd1eee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e4016c49-f37c-4aae-83af-ff776cd1eee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6756f7a6-7326-4740-88e5-2902092a3bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6756f7a6-7326-4740-88e5-2902092a3bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ddb04216-bf73-4bb4-be90-15213c5a3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ddb04216-bf73-4bb4-be90-15213c5a3744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5e49c5bd-bd8c-4390-a9d5-f02dd4887dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5e49c5bd-bd8c-4390-a9d5-f02dd4887dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2ac37fa7-6df3-4740-bfc9-1b79c23b9f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2ac37fa7-6df3-4740-bfc9-1b79c23b9f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d7586e82-b610-4741-8c98-0ceebc05e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d7586e82-b610-4741-8c98-0ceebc05e1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_69ddf2ba-98b1-4bbe-964d-571a5212a796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_69ddf2ba-98b1-4bbe-964d-571a5212a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_75069b51-ad11-4a1d-890d-13abbb157f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbb110e9-c587-464a-861f-3e20d0e2eaf2" xlink:to="loc_us-gaap_FinanceLeaseLiability_75069b51-ad11-4a1d-890d-13abbb157f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_41541168-51c4-4fec-befc-637b1e4dec0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:to="loc_us-gaap_ShareBasedCompensation_41541168-51c4-4fec-befc-637b1e4dec0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_88c4c365-1740-45e8-b1b1-dbe48fcf7966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_88c4c365-1740-45e8-b1b1-dbe48fcf7966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_IndirectTaxBenefitFromStockOptions_9ff8bc1c-aa05-4b96-8809-e2b217865d25" xlink:href="icui-20221231.xsd#icui_IndirectTaxBenefitFromStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:to="loc_icui_IndirectTaxBenefitFromStockOptions_9ff8bc1c-aa05-4b96-8809-e2b217865d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec7fe83b-496f-4535-9607-d0859a126994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec7fe83b-496f-4535-9607-d0859a126994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fe05a13-01f9-4969-a361-c801bbce3ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_024a147f-f47e-4f4a-b583-4132262ba876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3fe05a13-01f9-4969-a361-c801bbce3ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_035e4f6b-298f-43d7-89ab-0d23ad9b5adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_035e4f6b-298f-43d7-89ab-0d23ad9b5adc" xlink:to="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:to="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3b38677e-7393-41af-8e26-90a389ae1712" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25269066-386a-4f75-9cc0-fef31c18cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25269066-386a-4f75-9cc0-fef31c18cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88d8e616-b976-4a40-8154-3b4661f470a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_022d31ad-1892-4fc8-99ed-e2aea0e5f09b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88d8e616-b976-4a40-8154-3b4661f470a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:to="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d055b3e4-c00f-435f-9c55-78d8825e85a1" xlink:to="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2011PlanMember_cb1fa91b-aca5-48b3-af41-546359368b0b" xlink:href="icui-20221231.xsd#icui_A2011PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:to="loc_icui_A2011PlanMember_cb1fa91b-aca5-48b3-af41-546359368b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2003PlanMember_5d1548f7-c120-4a3f-aa84-b934e680d219" xlink:href="icui-20221231.xsd#icui_A2003PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9fa2bf46-373c-4dcb-a3f0-892aa1c9eb6d" xlink:to="loc_icui_A2003PlanMember_5d1548f7-c120-4a3f-aa84-b934e680d219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:href="icui-20221231.xsd#icui_StockIncentivePlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansTable_14b33f81-7e3f-4e16-a680-7647efc98894" xlink:to="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a69132cb-f1a1-4fc8-a580-41b476e5c996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a69132cb-f1a1-4fc8-a580-41b476e5c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b7b42e8c-bb3a-4900-837d-8d2b4198138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b7b42e8c-bb3a-4900-837d-8d2b4198138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Sharestransferredfromsupersededplan_dd4aa01c-a190-497d-8a88-a776a91644cc" xlink:href="icui-20221231.xsd#icui_Sharestransferredfromsupersededplan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_icui_Sharestransferredfromsupersededplan_dd4aa01c-a190-497d-8a88-a776a91644cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_119dcce4-92f4-44f4-9848-23bfe9f17217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_StockIncentivePlansLineItems_d93643c7-601a-4430-98e2-e4bf721ba9f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_119dcce4-92f4-44f4-9848-23bfe9f17217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionsGrantedandValuationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11695435-5342-4206-b4f9-7dce06fe7f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11695435-5342-4206-b4f9-7dce06fe7f02" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:to="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9c2f5756-c946-49bf-a749-57eeb6c6a3a4" xlink:to="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2011PlanMember_ab3d03e1-4ace-4b46-94bb-2cad80c1dc35" xlink:href="icui-20221231.xsd#icui_A2011PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:to="loc_icui_A2011PlanMember_ab3d03e1-4ace-4b46-94bb-2cad80c1dc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_A2003PlanMember_dd28b6a6-1f36-4712-b97f-a535ea1b7b4e" xlink:href="icui-20221231.xsd#icui_A2003PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40e2faae-1d4e-4234-a8dc-c8301b405e19" xlink:to="loc_icui_A2003PlanMember_dd28b6a6-1f36-4712-b97f-a535ea1b7b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:to="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_002a9096-6f01-4b28-b772-2187b8c0da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimebasedstockoptionMember_b9f79c18-1154-49bd-9078-8972f5940ac5" xlink:href="icui-20221231.xsd#icui_TimebasedstockoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:to="loc_icui_TimebasedstockoptionMember_b9f79c18-1154-49bd-9078-8972f5940ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b9b50400-ef9d-4f97-8949-9ed504df3af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25c51cbb-19e7-4b61-a0a7-a618e799fd30" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b9b50400-ef9d-4f97-8949-9ed504df3af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1db8fce9-1568-47ff-a675-bf2f7637d24c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327bb1fc-e687-4816-8df2-cb8046ad66d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327bb1fc-e687-4816-8df2-cb8046ad66d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Timebasedoptionsgrantdatefairvalue_6c295f01-c473-407a-a918-1451878520c0" xlink:href="icui-20221231.xsd#icui_Timebasedoptionsgrantdatefairvalue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_icui_Timebasedoptionsgrantdatefairvalue_6c295f01-c473-407a-a918-1451878520c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ddf224c9-13aa-40df-86a9-6fd8eda5130a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ddf224c9-13aa-40df-86a9-6fd8eda5130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c349bac-9143-440a-b90e-9149f593f544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5c349bac-9143-440a-b90e-9149f593f544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c6693823-ea61-41f7-8efe-b6d72551ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c6693823-ea61-41f7-8efe-b6d72551ae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dc422cc7-db7b-42ae-a2a1-b1eb16a99d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dc422cc7-db7b-42ae-a2a1-b1eb16a99d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9c853fed-55d8-42ed-86ad-432915f8ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9c853fed-55d8-42ed-86ad-432915f8ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d46862d7-def9-4940-8443-9a5590d9c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b7e2174-95a8-42be-b343-edf257beb429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d46862d7-def9-4940-8443-9a5590d9c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6958cd-ea08-41fb-8fc2-6eeefc0b398c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a6958cd-ea08-41fb-8fc2-6eeefc0b398c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:to="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ef200785-9076-4a99-9be4-0ac9b14f13f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df44ab2f-10ec-43aa-ab97-4dc7dc3f27a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8420a74c-fd8b-439d-ac80-5b90a3331db3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df44ab2f-10ec-43aa-ab97-4dc7dc3f27a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_57a632c5-0206-41f2-909e-9c589acf14d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0cfeb3b0-1a90-4754-8ab9-d3bee41d0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0cfeb3b0-1a90-4754-8ab9-d3bee41d0e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b53db83-a180-47a0-9d7d-89054b1f8493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b53db83-a180-47a0-9d7d-89054b1f8493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_877225c8-1e8a-4496-bc0f-81d20485a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_877225c8-1e8a-4496-bc0f-81d20485a5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_02dbeb3d-f42c-4a62-951f-341601eed269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_02dbeb3d-f42c-4a62-951f-341601eed269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d6a167-0b03-48df-8201-23f2fd02abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8d6a167-0b03-48df-8201-23f2fd02abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c536618-9e1b-42bd-b395-a9b193353359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6c536618-9e1b-42bd-b395-a9b193353359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_424d96a4-12b6-4923-b2a0-e6586a629000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_424d96a4-12b6-4923-b2a0-e6586a629000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a30a458-0913-46df-bab2-6f48b3f9d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a30a458-0913-46df-bab2-6f48b3f9d96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a05cebb8-ffe4-4b44-8145-6b9620a3ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a05cebb8-ffe4-4b44-8145-6b9620a3ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608e9678-91c8-4a3c-a767-e69f78a5eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_608e9678-91c8-4a3c-a767-e69f78a5eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c9b4025-7edb-4d3c-a57e-e7568c0e80f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c9b4025-7edb-4d3c-a57e-e7568c0e80f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91930ff9-7eff-4ef2-b813-0dad4e67f078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91930ff9-7eff-4ef2-b813-0dad4e67f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_7a776c0b-4aff-42a0-a2f2-1cf402a4b9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_7a776c0b-4aff-42a0-a2f2-1cf402a4b9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7465936b-78ef-42e3-834c-da40cb639eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7465936b-78ef-42e3-834c-da40cb639eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_840cb851-2f05-49bd-804a-82e027e53d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_840cb851-2f05-49bd-804a-82e027e53d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f07898f5-28f9-4ff8-b791-7650318e26d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f07898f5-28f9-4ff8-b791-7650318e26d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4ae8e94e-7bd8-49a5-ad31-1b4898b80c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4ae8e94e-7bd8-49a5-ad31-1b4898b80c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_996625ea-efde-496c-b34b-606c1c739079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_996625ea-efde-496c-b34b-606c1c739079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a84974d-b977-49de-9957-1c25cf3831c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a84974d-b977-49de-9957-1c25cf3831c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0113f4c5-e315-4ea2-86bf-18f682e26185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8469e2bc-2c5e-4588-b04e-8f7dc4baf3a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0113f4c5-e315-4ea2-86bf-18f682e26185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardShareAwarddataDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShareawarddataAbstract_983f610f-8905-4534-af14-a607d35d1ffd" xlink:href="icui-20221231.xsd#icui_ShareawarddataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ae0d6c2f-1da8-4c14-8652-c3b4521c8515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ShareawarddataAbstract_983f610f-8905-4534-af14-a607d35d1ffd" xlink:to="loc_us-gaap_SharePrice_ae0d6c2f-1da8-4c14-8652-c3b4521c8515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardOptionsexerciseddataDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4fd2c6e8-6179-4a96-85b1-bdd8ed13870b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98326356-5a2c-4280-ac8c-12e2f96cdaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4fd2c6e8-6179-4a96-85b1-bdd8ed13870b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98326356-5a2c-4280-ac8c-12e2f96cdaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2a2d7840-6f43-4237-a351-ec06ba881ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4fd2c6e8-6179-4a96-85b1-bdd8ed13870b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2a2d7840-6f43-4237-a351-ec06ba881ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3a1d5788-e998-4f27-aef7-1aa0bd1b7321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4fd2c6e8-6179-4a96-85b1-bdd8ed13870b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3a1d5788-e998-4f27-aef7-1aa0bd1b7321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardRSUandPRSUDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87785dda-e6b6-49fe-8813-e5fa4bc59999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87785dda-e6b6-49fe-8813-e5fa4bc59999" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:to="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2380b8b6-ed83-4e04-ba6d-252adf8cfc43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember_4a08bb93-e166-42f9-9bf7-69d0dc763309" xlink:href="icui-20221231.xsd#icui_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_icui_PerformanceRestrictedStockUnitsPRSUsMember_4a08bb93-e166-42f9-9bf7-69d0dc763309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d83c355e-e33b-4a4e-8df5-3ccf25819148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_us-gaap_PerformanceSharesMember_d83c355e-e33b-4a4e-8df5-3ccf25819148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41a6413-fd80-4464-ba18-5c22f72bd73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0186bfea-b950-4c9b-a68f-cf13e77940f8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41a6413-fd80-4464-ba18-5c22f72bd73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_854ce62f-1933-49da-bd7e-ad02ec47dd94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec24c435-0757-4b8f-9088-91e6386674ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ec24c435-0757-4b8f-9088-91e6386674ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PerformanceSharesEarned_8f1c3b7c-f6eb-4379-9984-c8348119ae76" xlink:href="icui-20221231.xsd#icui_PerformanceSharesEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_PerformanceSharesEarned_8f1c3b7c-f6eb-4379-9984-c8348119ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33f9df16-c537-4f99-83e8-eb93504ebc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33f9df16-c537-4f99-83e8-eb93504ebc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueperformancerestrictedstockunits_c7d18b21-a59d-4b16-9e33-08508421d4ae" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueperformancerestrictedstockunits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_Grantdatefairvalueperformancerestrictedstockunits_c7d18b21-a59d-4b16-9e33-08508421d4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted_69380ecf-b5d8-40a5-9ae5-40287857f552" xlink:href="icui-20221231.xsd#icui_Grantdatefairvalueofrestrictedstockunitsgranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_Grantdatefairvalueofrestrictedstockunitsgranted_69380ecf-b5d8-40a5-9ae5-40287857f552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_11c4a23d-0901-4782-81ab-0eceab329f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_11c4a23d-0901-4782-81ab-0eceab329f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ModifiedPRSUIncrementalExpense_9f3d983a-2172-4ec7-a301-3defd5aaecbe" xlink:href="icui-20221231.xsd#icui_ModifiedPRSUIncrementalExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68cba17f-586a-4e45-a7e2-829159eaa8a3" xlink:to="loc_icui_ModifiedPRSUIncrementalExpense_9f3d983a-2172-4ec7-a301-3defd5aaecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardRSUandPRSURollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce1b324c-3e11-4089-82ec-075c4fc44a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce1b324c-3e11-4089-82ec-075c4fc44a76" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:to="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92d92454-7dc6-4802-b4fd-1852dc421fa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_1d81ffb6-345e-4e18-b84f-deb0f8ced475" xlink:href="icui-20221231.xsd#icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91487ae9-d4b7-4e72-b5fc-e9d859fb9824" xlink:to="loc_icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember_1d81ffb6-345e-4e18-b84f-deb0f8ced475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2a6de1ff-2f04-41fc-99e0-3e33848c45d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dabd5d17-83a6-465e-ab8a-14ab8e005ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dabd5d17-83a6-465e-ab8a-14ab8e005ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39aa20c2-46da-4272-aa3d-ae83177256a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39aa20c2-46da-4272-aa3d-ae83177256a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Changeinunitsduetoperformanceexpectations_cdc60be3-37bd-4992-a2b7-f0a46eb61495" xlink:href="icui-20221231.xsd#icui_Changeinunitsduetoperformanceexpectations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_icui_Changeinunitsduetoperformanceexpectations_cdc60be3-37bd-4992-a2b7-f0a46eb61495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_8c9c0fe8-22a7-46cd-9196-3685ba43c48c" xlink:href="icui-20221231.xsd#icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue_8c9c0fe8-22a7-46cd-9196-3685ba43c48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60e7f4e5-3927-4dbb-b1ca-1ab81fc89945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60e7f4e5-3927-4dbb-b1ca-1ab81fc89945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b09cfd89-284e-441f-993d-e7e60f902ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b09cfd89-284e-441f-993d-e7e60f902ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b78dccd7-0cce-40ac-b634-e63bb245e402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b78dccd7-0cce-40ac-b634-e63bb245e402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_980f49dc-4150-49f0-817a-9ffda1b93ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_980f49dc-4150-49f0-817a-9ffda1b93ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4906f1fe-9332-4220-a071-37688feda874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4906f1fe-9332-4220-a071-37688feda874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_87d4c402-5770-41d0-89d4-26b7cec93d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_87d4c402-5770-41d0-89d4-26b7cec93d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_23e1376b-4f2d-4232-ab3f-dd186e70e197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_23e1376b-4f2d-4232-ab3f-dd186e70e197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b827653c-784b-4b8c-8286-c1181df4549f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29fad075-36b7-49f3-b2f6-60c8b999c174" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b827653c-784b-4b8c-8286-c1181df4549f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ShareBasedAwardESPPNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6efb72e3-5e9d-4983-8369-14cccd0df86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ESPPOriginalIssuance_37c60206-c6a8-400c-8194-c8cc50b18c26" xlink:href="icui-20221231.xsd#icui_ESPPOriginalIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6efb72e3-5e9d-4983-8369-14cccd0df86e" xlink:to="loc_icui_ESPPOriginalIssuance_37c60206-c6a8-400c-8194-c8cc50b18c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ESPPAnnualIssuanceIncreaseLimit_8f189aaf-34fa-45b5-86c8-7a72cdd8f564" xlink:href="icui-20221231.xsd#icui_ESPPAnnualIssuanceIncreaseLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6efb72e3-5e9d-4983-8369-14cccd0df86e" xlink:to="loc_icui_ESPPAnnualIssuanceIncreaseLimit_8f189aaf-34fa-45b5-86c8-7a72cdd8f564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f0108e5-0454-449f-94f7-e970885b6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4f0108e5-0454-449f-94f7-e970885b6d5c" xlink:to="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_44f2d776-894f-4122-a54d-c5c0fcafd9da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge3MemberMember_d48014dd-bbdd-4ced-babd-170a838efc30" xlink:href="icui-20221231.xsd#icui_Hedge3MemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge3MemberMember_d48014dd-bbdd-4ced-babd-170a838efc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge4Member_d6e6e81e-f3da-401a-a176-ada5bb00499f" xlink:href="icui-20221231.xsd#icui_Hedge4Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge4Member_d6e6e81e-f3da-401a-a176-ada5bb00499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Hedge5Member_5074b311-64c4-475e-92de-90f438747a9b" xlink:href="icui-20221231.xsd#icui_Hedge5Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6bdeb761-17f2-4697-b8d7-3dc189750404" xlink:to="loc_icui_Hedge5Member_5074b311-64c4-475e-92de-90f438747a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_80746ef0-ea76-43fd-9637-3795de4ccd7f" xlink:to="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_MXN_b28b132b-24e2-4ff9-a9e4-70ce759aa303" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MXN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_MXN_b28b132b-24e2-4ff9-a9e4-70ce759aa303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_40848c6a-4c7e-4155-9fea-a68ac6ad7dc9" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_EUR_40848c6a-4c7e-4155-9fea-a68ac6ad7dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CZK_4a8de672-cf9c-4e37-9fb8-e009556ee48d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CZK"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CZK_4a8de672-cf9c-4e37-9fb8-e009556ee48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_6bf9842a-570c-4a9d-92a1-e173ed05c03a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_JPY_6bf9842a-570c-4a9d-92a1-e173ed05c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_3710040a-a9bd-4648-9302-8388789dc623" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CNY_3710040a-a9bd-4648-9302-8388789dc623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_eb9fb8bf-a6fd-42a2-93b7-cdc6cb71fe75" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_USD_eb9fb8bf-a6fd-42a2-93b7-cdc6cb71fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_92ee22f3-7f17-452a-8be1-67da676e4a13" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_CAD_92ee22f3-7f17-452a-8be1-67da676e4a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_1a79406f-250d-4722-835a-1c3cf1393cbf" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_0f39c03c-cedd-45ff-8e1f-67ea6673686b" xlink:to="loc_currency_AUD_1a79406f-250d-4722-835a-1c3cf1393cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:href="icui-20221231.xsd#icui_Srt_MultipleCurrencyAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_Srt_MultipleCurrencyAxisAxis_5e0261a9-f34a-4533-aa2f-6503fe1d632f" xlink:to="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherCurrenciesMember_1f61a863-b45f-4267-8ac1-5d69b7dc373e" xlink:href="icui-20221231.xsd#icui_OtherCurrenciesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_Srt_MultipleCurrencyAxisDomain_6d4a8764-f91b-4401-8dec-02e53ccdb9c5" xlink:to="loc_icui_OtherCurrenciesMember_1f61a863-b45f-4267-8ac1-5d69b7dc373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0292bc87-2623-4541-b817-02cbd7803baf" xlink:to="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ba979d54-885c-4676-bdd2-be7533f9fa78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ba979d54-885c-4676-bdd2-be7533f9fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeForwardExchangeRate1_0ee11b91-d356-41df-9e95-1db0611b42f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeForwardExchangeRate1_0ee11b91-d356-41df-9e95-1db0611b42f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_f6bc822c-dc83-47e6-aac5-cadc5de81fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_f6bc822c-dc83-47e6-aac5-cadc5de81fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_cf87188e-0c61-4ddc-891d-528b72481cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_95e2c493-2735-4e3e-83fa-26a79053663b" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_cf87188e-0c61-4ddc-891d-528b72481cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesInterestRateContractsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2240dc23-64c9-4b19-805d-0a6278ae1849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2240dc23-64c9-4b19-805d-0a6278ae1849" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:to="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae5d921c-ba27-47a5-b19f-de95349d313f" xlink:to="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_82b00671-39b4-4706-ab5d-4aa64f411c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:to="loc_srt_MaximumMember_82b00671-39b4-4706-ab5d-4aa64f411c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_755aea7e-e0f6-4f27-8e8f-bd75d2453701" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_979b08f2-3c51-4942-a16d-689a64bc86b1" xlink:to="loc_srt_MinimumMember_755aea7e-e0f6-4f27-8e8f-bd75d2453701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_36fc1423-2e00-453e-b6fa-b800be934432" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_9c7afe10-b72e-4661-b409-25d89e2fd325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:to="loc_us-gaap_InterestRateSwapMember_9c7afe10-b72e-4661-b409-25d89e2fd325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UsGaap_InterestRateSwap2Member_a3fad6aa-8d2b-43fa-80d2-7b50935c6f4c" xlink:href="icui-20221231.xsd#icui_UsGaap_InterestRateSwap2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_45c3bf8e-94d9-4c3c-8f7c-28813a3bf663" xlink:to="loc_icui_UsGaap_InterestRateSwap2Member_a3fad6aa-8d2b-43fa-80d2-7b50935c6f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_202e57f6-f429-4423-b3ef-f5419ee430d0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_089e0f10-fc27-42bb-84a9-13625da6f9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_089e0f10-fc27-42bb-84a9-13625da6f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c3a74a4a-7f41-4d88-94b5-ca09d6495b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c3a74a4a-7f41-4d88-94b5-ca09d6495b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DerivativeInterestRateFloor_6b71336f-4a7d-4bf9-8d29-35a5933c09b7" xlink:href="icui-20221231.xsd#icui_DerivativeInterestRateFloor"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_icui_DerivativeInterestRateFloor_6b71336f-4a7d-4bf9-8d29-35a5933c09b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bfd07215-780c-4e9b-8e5c-f58e485d4de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_fcf9c5c0-35e3-4016-afac-5ddb8f51b655" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bfd07215-780c-4e9b-8e5c-f58e485d4de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ff29187a-9310-4d54-b325-29e423cb6819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ff29187a-9310-4d54-b325-29e423cb6819" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a4514c34-d1ca-4a24-a71b-388b3e0a8a67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f00abd4c-0843-4da9-8723-a696549eb8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f00abd4c-0843-4da9-8723-a696549eb8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_722ba597-324f-44a9-92fa-6f0ea03461ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_InterestRateSwapMember_722ba597-324f-44a9-92fa-6f0ea03461ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_ea854317-26b2-4c0d-b14f-e0183ecdcb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_ea854317-26b2-4c0d-b14f-e0183ecdcb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_346b3fe6-16a4-4f8f-a688-0fd883f6a459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_346b3fe6-16a4-4f8f-a688-0fd883f6a459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_1d606599-6444-4682-93da-fc9f9c492102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_AssetsTotalMember_1d606599-6444-4682-93da-fc9f9c492102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_c6882d3e-bf78-42ea-a036-2ec3068f24c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7b756ef-d02d-46c5-9288-ba58072067b8" xlink:to="loc_us-gaap_LiabilitiesTotalMember_c6882d3e-bf78-42ea-a036-2ec3068f24c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_97c7d122-cdeb-4ffc-9d71-447a51aaca56" xlink:to="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b0f60ef7-8aee-45d5-907b-fed117432428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_229f6a06-c00b-4a32-be3b-b8fb47da02f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b0f60ef7-8aee-45d5-907b-fed117432428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4742e85b-bafc-4d20-8ce7-92cdd103db3e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_664a4aba-eec4-4006-8407-2ef96e011665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_664a4aba-eec4-4006-8407-2ef96e011665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ee7db667-3a28-466d-af59-19f42d3d12b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_ee7db667-3a28-466d-af59-19f42d3d12b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_2c6ebc3e-53f3-4090-bc30-66337a918470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_OtherAssetsMember_2c6ebc3e-53f3-4090-bc30-66337a918470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9f95441a-3085-4608-8b92-420d5f9c831d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9f95441a-3085-4608-8b92-420d5f9c831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_31958ce7-9e51-47c9-88e5-21d0d055916d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_OtherLiabilitiesMember_31958ce7-9e51-47c9-88e5-21d0d055916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_0e10c15d-3430-4291-88f6-bfa0fb76239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_AssetsTotalMember_0e10c15d-3430-4291-88f6-bfa0fb76239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_a597734f-7146-4297-8121-b82aec26141d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_a597734f-7146-4297-8121-b82aec26141d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_6748b484-5043-4acd-94fe-4c3fb08e9ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb6a9947-b648-4167-bcf2-6edecdf65725" xlink:to="loc_us-gaap_LiabilitiesTotalMember_6748b484-5043-4acd-94fe-4c3fb08e9ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7c7efe19-9250-4b03-92b2-10b6d13cdce5" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_161972d5-528a-4f53-b09e-e3c6aa1309ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:to="loc_us-gaap_DerivativeAssets_161972d5-528a-4f53-b09e-e3c6aa1309ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5f42816a-6b7a-48ff-8671-5abb838395cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_441338c8-3600-4f9e-8bcf-68aa7f6c055c" xlink:to="loc_us-gaap_DerivativeLiabilities_5f42816a-6b7a-48ff-8671-5abb838395cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c69ebaf-b494-4a0a-a15d-07c034cc4001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1ba5e4e6-bd3b-4a98-9ae0-e5a5b66b0d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c69ebaf-b494-4a0a-a15d-07c034cc4001" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_1ba5e4e6-bd3b-4a98-9ae0-e5a5b66b0d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_b99f52e0-2896-40e3-bedc-317d9ed8d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c69ebaf-b494-4a0a-a15d-07c034cc4001" xlink:to="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_b99f52e0-2896-40e3-bedc-317d9ed8d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_92bf72ab-e0f6-4f91-b1d7-5465cbd0ff05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c69ebaf-b494-4a0a-a15d-07c034cc4001" xlink:to="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_92bf72ab-e0f6-4f91-b1d7-5465cbd0ff05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8c69ebaf-b494-4a0a-a15d-07c034cc4001" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3250f7bb-bc07-4a6c-8d66-d001fa7947f6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0db2825e-f905-484e-a64e-fffcd8caf307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0db2825e-f905-484e-a64e-fffcd8caf307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3223d8c-8542-4875-8830-739cac882da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_61e59182-5d61-466c-9215-35a3afef0211" xlink:to="loc_us-gaap_InterestRateSwapMember_b3223d8c-8542-4875-8830-739cac882da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3f9b2a69-3447-4381-bf1f-569a57a5bf88" xlink:to="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_4479029d-226a-4039-b869-fff09e3b36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_22e3eb63-c513-4448-bdd9-533bd4043555" xlink:to="loc_us-gaap_CashFlowHedgingMember_4479029d-226a-4039-b869-fff09e3b36e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0fd8965-6c90-4efe-9c70-d5bc9ceed1de" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingRevenueMember_dc8c84ad-c988-48b4-8647-3400554b22f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:to="loc_us-gaap_TradingRevenueMember_dc8c84ad-c988-48b4-8647-3400554b22f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_48131141-01d7-4de7-b2e0-2cb9f44f491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c932cb39-487b-4c2d-beb1-c7d45c0f48d3" xlink:to="loc_us-gaap_CostOfSalesMember_48131141-01d7-4de7-b2e0-2cb9f44f491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c56539dc-c24e-4153-a848-4268ce1cc17e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_8739367f-f604-43c0-ab53-ff5ac43d716f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_8739367f-f604-43c0-ab53-ff5ac43d716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_a6c40d1f-0df8-48bb-8523-2ef987bb13f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring_a6c40d1f-0df8-48bb-8523-2ef987bb13f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_8c0dc49d-b135-4387-8fce-60639b165bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_8c0dc49d-b135-4387-8fce-60639b165bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ae243ecb-3ec1-46a3-9c30-ba5070b6e3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_79fe38ee-b57a-425e-900f-84a1eac923e6" xlink:to="loc_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ae243ecb-3ec1-46a3-9c30-ba5070b6e3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_786f1d59-de48-409b-b85e-48c4f268175e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_786f1d59-de48-409b-b85e-48c4f268175e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b7abb74f-44a4-4efc-8d70-d1474b6347c7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_22685cf1-a9cb-4abe-9113-f8d982fd8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d710870d-be83-4f8a-a714-8b624ecb29f0" xlink:to="loc_us-gaap_CashFlowHedgingMember_22685cf1-a9cb-4abe-9113-f8d982fd8f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70e25692-3e78-4c51-b270-07c9e64cd1e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9903a714-6e69-4555-afca-a9e01aaaf0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a186936c-028f-427f-8b9a-028d8513bf45" xlink:to="loc_us-gaap_CostOfSalesMember_9903a714-6e69-4555-afca-a9e01aaaf0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_82eb4a4d-579f-4926-8f93-0b2ad99a0983" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_9b393718-0d41-45e4-b856-9e15b27e42d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_9b393718-0d41-45e4-b856-9e15b27e42d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1eb94ddd-c6da-4c00-8f85-8450f7cdac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_CashFlowHedgingMember_1eb94ddd-c6da-4c00-8f85-8450f7cdac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2d41d929-a63c-4cab-83b4-cc1cf7f58f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9f23a8d2-1ffe-44d9-bc15-5d53e574fecd" xlink:to="loc_us-gaap_InterestRateSwapMember_2d41d929-a63c-4cab-83b4-cc1cf7f58f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_42da4768-bff8-48ed-a875-8a2620eb4cc0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_8f0c8451-541f-42e8-ae63-d52fae2d1cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_c377022d-b8bb-454b-8270-555c1ba4611a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_8f0c8451-541f-42e8-ae63-d52fae2d1cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementSmithsMedicalDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3464ce62-ed39-4a7b-b63a-b8a70a6633cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3464ce62-ed39-4a7b-b63a-b8a70a6633cd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_527a6802-d5f0-4b26-94c8-b5c13bb62ab0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_2b3902a0-4ad4-4167-8324-37d43e3ed3de" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_814e18c9-5033-40f2-9f01-9817946d6c9e" xlink:to="loc_icui_SmithsMedicalMember_2b3902a0-4ad4-4167-8324-37d43e3ed3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38d1535a-66a9-493f-8a3a-8f6d234a516c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_eeed9319-c432-40a5-ac98-f06b631c0718" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_icui_Contingentconsiderationgross_eeed9319-c432-40a5-ac98-f06b631c0718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_78fe3540-bef5-4af1-9b76-a048dbbe9525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_78fe3540-bef5-4af1-9b76-a048dbbe9525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_c7b86018-52c5-48c4-b8b2-bb2a0b88886a" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OwnershipRequirementForEarnoutPayment_3561cf5a-e53a-434e-8000-9ecf2cee45dd" xlink:href="icui-20221231.xsd#icui_OwnershipRequirementForEarnoutPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_56c8d069-b00d-4c67-9d46-70c6c88e8961" xlink:to="loc_icui_OwnershipRequirementForEarnoutPayment_3561cf5a-e53a-434e-8000-9ecf2cee45dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementTextPursuitDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b01dd07d-8405-41dc-954b-525211ce49e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b01dd07d-8405-41dc-954b-525211ce49e4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_319b96d7-dac6-4336-a9e2-a197579cc5d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_08a32a4f-bc8b-4696-b6c8-5d27fdde7d22" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_PursuitVascularInc.Member_08a32a4f-bc8b-4696-b6c8-5d27fdde7d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_151f55f7-ae5a-4f8c-81bf-56c2bd09c937" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_PursuitVascularLLCMember_151f55f7-ae5a-4f8c-81bf-56c2bd09c937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignDistibutorMember_eb08383c-44dd-4062-8bbf-9ccad782a80e" xlink:href="icui-20221231.xsd#icui_ForeignDistibutorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_ForeignDistibutorMember_eb08383c-44dd-4062-8bbf-9ccad782a80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_f38c243d-2ad3-44ee-8d0d-cb46b0f6c7b0" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cb936db-1f4e-4dd2-b917-4339ba930d77" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_f38c243d-2ad3-44ee-8d0d-cb46b0f6c7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_409bc696-cf13-4086-b91b-1ee3e731e403" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_84c1fc46-79ab-4020-8a23-dc0889e84601" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_Contingentconsiderationgross_84c1fc46-79ab-4020-8a23-dc0889e84601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_59b8391a-e069-42c9-b9c6-cc3023b57aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_59b8391a-e069-42c9-b9c6-cc3023b57aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_3980925d-7d9f-44f2-b560-85880fa22f6c" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_ShortTermContingentConsiderationGross_3980925d-7d9f-44f2-b560-85880fa22f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_b41eb112-a012-48b2-8c98-aaa122b472f0" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f3412eed-450c-4dc2-b8ff-abb264138e95" xlink:to="loc_icui_LongTermContingentConsiderationGross_b41eb112-a012-48b2-8c98-aaa122b472f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementRollForwardDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dfc09af9-8b28-46bf-9409-62a5e3567ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dfc09af9-8b28-46bf-9409-62a5e3567ac4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24dd0b20-f3c0-4856-88c9-e24fab2b29a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_1dedc794-0c74-4762-90d4-72f17eea5fb3" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_PursuitVascularInc.Member_1dedc794-0c74-4762-90d4-72f17eea5fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_7798c167-ca0a-4b78-b633-8e98542615fe" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_PursuitVascularLLCMember_7798c167-ca0a-4b78-b633-8e98542615fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_1092e82e-830e-4bd6-a844-9f21a0f26c34" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_SmithsMedicalMember_1092e82e-830e-4bd6-a844-9f21a0f26c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_2dae5358-af28-4803-853a-b0e34ff7151d" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31ace74e-6ba4-4748-973a-4dfc8bcada81" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_2dae5358-af28-4803-853a-b0e34ff7151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e07f314-4eab-41b5-9335-f39353ce8bff" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_19d6dbc0-eca6-4f2b-ba70-095ab4fd67b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_19d6dbc0-eca6-4f2b-ba70-095ab4fd67b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8a69cb5a-4028-4f33-a21e-96432f557af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_8a69cb5a-4028-4f33-a21e-96432f557af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cc143884-e401-4fb6-9f87-0464d66cf10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_cc143884-e401-4fb6-9f87-0464d66cf10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_ca188a92-61d1-4dc7-9fae-24133e222487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_ca188a92-61d1-4dc7-9fae-24133e222487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d0f43d72-f6d1-4a77-a053-ea0d1c413d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d0f43d72-f6d1-4a77-a053-ea0d1c413d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrencyTranslationOnEarnOut_8c405b96-6009-43b3-b179-667a2df4b3ea" xlink:href="icui-20221231.xsd#icui_CurrencyTranslationOnEarnOut"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_icui_CurrencyTranslationOnEarnOut_8c405b96-6009-43b3-b179-667a2df4b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_fa7d9902-9c94-4fdb-9f02-3ebd8d247d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d1bd9133-0476-4f7e-8403-2ae25cf4391d" xlink:to="loc_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList_fa7d9902-9c94-4fdb-9f02-3ebd8d247d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_071c202d-e6b3-4086-9f87-d08e955954fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_071c202d-e6b3-4086-9f87-d08e955954fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7b64b03-e6b3-409f-919f-731f116dc57c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_57bb4925-3a41-4af9-ad36-82677f81ab1c" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2908415b-6e9d-4d08-a145-b9e607a2e654" xlink:to="loc_icui_PursuitVascularInc.Member_57bb4925-3a41-4af9-ad36-82677f81ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5e40a81c-7903-4458-a572-7fd23a38f1d8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevenueGrossProfitVolatilityMember_41650c3e-8d25-462c-995f-5a5244194b8e" xlink:href="icui-20221231.xsd#icui_RevenueGrossProfitVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_icui_RevenueGrossProfitVolatilityMember_41650c3e-8d25-462c-995f-5a5244194b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_420c56f3-c03d-4547-956a-aeb146be0d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_420c56f3-c03d-4547-956a-aeb146be0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a7a5566f-a927-453a-bba7-9e2f3fe0d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a7a5566f-a927-453a-bba7-9e2f3fe0d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditRiskMember_86d77240-aa08-4ab1-a34a-fbad99bbea52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ef397b06-3e93-4537-987e-ea27b7ac15dc" xlink:to="loc_us-gaap_CreditRiskMember_86d77240-aa08-4ab1-a34a-fbad99bbea52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a3da3ed6-9d14-43d9-bbf9-69f43540c0d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5afe7c7d-b94c-439e-8a93-47fb46e45c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_460c4f92-d833-4037-b6ad-da3df658f0c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5afe7c7d-b94c-439e-8a93-47fb46e45c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementSmithsMedicalSimulationInputsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ce52bc7-d594-4994-98cc-497589b48cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ce52bc7-d594-4994-98cc-497589b48cc8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c205f2bb-d958-496f-8d7e-1e023e3c680e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_1353d31d-b5bf-4b23-9380-f3af9903a872" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b3c04d3-c63e-49a1-83bf-c25c63dcba78" xlink:to="loc_icui_SmithsMedicalMember_1353d31d-b5bf-4b23-9380-f3af9903a872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ddf7933c-77e3-49f5-9487-da35404c70b1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0ba2e16-7863-4cb7-b22b-935d1b4e183c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0ba2e16-7863-4cb7-b22b-935d1b4e183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2ca550be-c20f-47df-a319-c4f28a462c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d442721e-2e48-42f4-be0e-e34907c8f690" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2ca550be-c20f-47df-a319-c4f28a462c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59969cb1-f2ea-496c-8a35-22c67bf0fe96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e34a122a-0a0f-480d-903f-00ee4be587e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59969cb1-f2ea-496c-8a35-22c67bf0fe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43ab29f7-abe2-4e66-849f-b99c70b7c2fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f785654c-4ccb-41c8-a443-b4e8012d9425" xlink:to="loc_srt_RangeMember_43ab29f7-abe2-4e66-849f-b99c70b7c2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9d676778-fb13-40e4-92fe-e2499c0de41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c99127bd-6158-4a9f-9f61-96a5dd98505f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9d676778-fb13-40e4-92fe-e2499c0de41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1257c757-1b45-4348-8995-7fc3084877bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1bac9ca-5b25-49e7-8d17-89629425afd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1257c757-1b45-4348-8995-7fc3084877bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0da879ae-17bc-4d1d-92d7-fc881dbe6025" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb067254-e636-45ff-af42-32a1c41e2659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a9a584d7-5365-42e7-a312-f2312bb0c6d8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb067254-e636-45ff-af42-32a1c41e2659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aecf4207-fab2-49a3-a074-cf704ee58bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aecf4207-fab2-49a3-a074-cf704ee58bee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9cab47b-d005-4304-8728-6101814da807" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EarnoutliabilityMember_155853a3-eb8b-474b-80e5-8183b704f6ec" xlink:href="icui-20221231.xsd#icui_EarnoutliabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:to="loc_icui_EarnoutliabilityMember_155853a3-eb8b-474b-80e5-8183b704f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesTotalMember_79529e0d-040d-453f-b972-97a7da645d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_484297d1-6d02-4064-946b-6649c01cce2e" xlink:to="loc_us-gaap_LiabilitiesTotalMember_79529e0d-040d-453f-b972-97a7da645d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee11b5ca-f718-4f51-884e-cc1683e28878" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_aeac42cf-5b27-42ce-ba69-d3d1a8e36692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_aeac42cf-5b27-42ce-ba69-d3d1a8e36692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_5f65e6aa-7dd7-4907-93d6-d1ad669d1f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_OtherLiabilitiesMember_5f65e6aa-7dd7-4907-93d6-d1ad669d1f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_f8710d3a-1c4b-47a6-b518-9147d3989457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_OtherAssetsMember_f8710d3a-1c4b-47a6-b518-9147d3989457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_34705e05-6d4f-4ef6-ab00-7ad371892138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d6afd4e-529b-4404-8821-eec9ba75de59" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_34705e05-6d4f-4ef6-ab00-7ad371892138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cca9269-be23-44e5-84aa-10e17e1f0f73" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1295bb5b-32c0-4d9a-8b0d-701860a2d3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1295bb5b-32c0-4d9a-8b0d-701860a2d3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_785a9bbd-ffc5-46c6-9d1f-4878915d4248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_785a9bbd-ffc5-46c6-9d1f-4878915d4248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfd342e9-4dc8-4f0b-b4f4-c08c0831bb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_614a8184-8878-4d5b-8263-cdcba310b566" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfd342e9-4dc8-4f0b-b4f4-c08c0831bb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9913cb8e-e89a-46b8-9b23-3f36b2a69577" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dc365858-8c91-4217-ae1a-06b431cf3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dc365858-8c91-4217-ae1a-06b431cf3a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_191f4fce-a32d-4823-a86b-c2c15cddf141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_191f4fce-a32d-4823-a86b-c2c15cddf141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_af279df0-a9be-4ecc-b002-f32e50ef85f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c311492d-2480-41cd-babe-080597a8cd15" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_af279df0-a9be-4ecc-b002-f32e50ef85f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:href="icui-20221231.xsd#icui_ClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:href="icui-20221231.xsd#icui_ClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ClassificationAxis_98ab7ebc-daf3-44c5-a0da-8c9936c27e2e" xlink:to="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentMember_f67272a0-264d-41bd-8254-1332bcbbbe3e" xlink:href="icui-20221231.xsd#icui_NoncurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:to="loc_icui_NoncurrentMember_f67272a0-264d-41bd-8254-1332bcbbbe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_CurrentMember_fc92a977-c5b7-4a8f-bb37-aeaea53055b5" xlink:href="icui-20221231.xsd#icui_CurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ClassificationDomain_d4e3fd95-e9b1-41bc-94ae-1df5f382758c" xlink:to="loc_icui_CurrentMember_fc92a977-c5b7-4a8f-bb37-aeaea53055b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_b31de6c3-d9fc-46d7-be0f-42c676c41043" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_478ef5ef-1f32-47cf-b81e-c738c7b220d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_f81563ac-f8b3-4e48-bc6b-9ce0e747f2b8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_478ef5ef-1f32-47cf-b81e-c738c7b220d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9fb4672-8618-4120-af5e-cd14e4ffa3ad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc562402-7d42-4237-bb13-619d6a6f37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc562402-7d42-4237-bb13-619d6a6f37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d3219b5-8093-4f9c-a70e-ac3c8a939243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0d3219b5-8093-4f9c-a70e-ac3c8a939243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_d7be7c49-405a-4d75-8a9c-a4a3d09e53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_d7be7c49-405a-4d75-8a9c-a4a3d09e53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_28fdd7b9-32f8-444f-8211-80c76999747f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_28fdd7b9-32f8-444f-8211-80c76999747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_26c683b7-aec9-4493-a96c-a6b1f681e5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_26c683b7-aec9-4493-a96c-a6b1f681e5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e92d80ed-2b6f-4ae3-824c-2bf9806506c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e92d80ed-2b6f-4ae3-824c-2bf9806506c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_e23da815-dde1-4ab3-b303-712b33bc6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosure_e23da815-dde1-4ab3-b303-712b33bc6a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eaade9a-f97a-4978-9b89-56edf3b9c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54a739f8-4d4d-4235-9963-1bc783f7969b" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_9eaade9a-f97a-4978-9b89-56edf3b9c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_93582d72-363f-4021-a573-b979730d839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_93582d72-363f-4021-a573-b979730d839d" xlink:to="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2cb66f8e-aeab-44c6-8284-fc2e1fc30bfa" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_352ea72f-8546-489d-95fc-3eac9152cbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bf1a4bcb-e2c0-4097-9384-1def0317e4c6" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_352ea72f-8546-489d-95fc-3eac9152cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:href="icui-20221231.xsd#icui_PrepaidAssetsCurrentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentTable_adb9df90-05aa-4a8c-92ed-62e3f2cc8055" xlink:to="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9c13ed55-d47a-4fce-9c13-0bbdfcc609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9c13ed55-d47a-4fce-9c13-0bbdfcc609eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidVendorExpenses_de3dddc8-f58e-4b17-91d9-97c2e20ab984" xlink:href="icui-20221231.xsd#icui_PrepaidVendorExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_PrepaidVendorExpenses_de3dddc8-f58e-4b17-91d9-97c2e20ab984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsAndOtherAssets_779beb42-7e27-492f-b446-25881ded4159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DeferredCostsAndOtherAssets_779beb42-7e27-492f-b446-25881ded4159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidinsuranceandpropertytaxes_abb88e84-d9ad-445c-872b-5337eee913f8" xlink:href="icui-20221231.xsd#icui_Prepaidinsuranceandpropertytaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Prepaidinsuranceandpropertytaxes_abb88e84-d9ad-445c-872b-5337eee913f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Prepaidothertaxes_201b622d-c56f-4656-8782-7dd43d284bcb" xlink:href="icui-20221231.xsd#icui_Prepaidothertaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Prepaidothertaxes_201b622d-c56f-4656-8782-7dd43d284bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxcharge_00b3a071-9702-4357-af13-c75378d39198" xlink:href="icui-20221231.xsd#icui_Deferredtaxcharge"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_icui_Deferredtaxcharge_00b3a071-9702-4357-af13-c75378d39198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_fe8a29c9-168f-4ce1-96d4-27a88f4c0c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_fe8a29c9-168f-4ce1-96d4-27a88f4c0c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_e03ac9bb-8eeb-47fc-bc53-bf933ecde934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_e03ac9bb-8eeb-47fc-bc53-bf933ecde934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_c756ced0-03a3-4e5f-9319-1342991c1af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_DepositAssets_c756ced0-03a3-4e5f-9319-1342991c1af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ba35784d-21a6-49d0-853a-cbbae04b2741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_OtherAssetsCurrent_ba35784d-21a6-49d0-853a-cbbae04b2741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95244cb4-ad09-4798-b203-91dd5d5fab96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidAssetsCurrentLineItems_fe0928c6-a2e1-42fb-8185-a1481b223f04" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_95244cb4-ad09-4798-b203-91dd5d5fab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrepaidsandOtherNoncurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_316d4551-e305-4381-8866-47d393a0cb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_316d4551-e305-4381-8866-47d393a0cb43" xlink:to="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3da98e55-de99-47d6-9959-146a04df7e9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6716f4d1-3479-4bbb-9853-1cb83c1702c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_705fe1a4-9a7c-4d85-a1db-27b29b7b1295" xlink:to="loc_us-gaap_InterestRateSwapMember_6716f4d1-3479-4bbb-9853-1cb83c1702c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:href="icui-20221231.xsd#icui_PrepaidNoncurrentAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsTable_c64a7235-d878-4804-9c6f-f1309c2ae38b" xlink:to="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1a7b598e-2375-479c-a39b-da3bbd5512ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1a7b598e-2375-479c-a39b-da3bbd5512ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SpareParts_6b556f8c-a563-4e15-b555-34f8cde3dcd3" xlink:href="icui-20221231.xsd#icui_SpareParts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_icui_SpareParts_6b556f8c-a563-4e15-b555-34f8cde3dcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_698fe5d0-017e-4b80-a781-a623db4ecf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_EquityMethodInvestments_698fe5d0-017e-4b80-a781-a623db4ecf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_03a950c2-fe00-4280-b7c0-bd1d2f19dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_03a950c2-fe00-4280-b7c0-bd1d2f19dca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_33615401-e697-44d8-904e-10aba54e54a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_33615401-e697-44d8-904e-10aba54e54a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_990d340b-6984-47f1-b0c7-f17839648ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_990d340b-6984-47f1-b0c7-f17839648ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d0b2a60b-6402-4936-8a52-5de576a6a582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d0b2a60b-6402-4936-8a52-5de576a6a582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_74094673-8664-461c-abb6-deaae33b1545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_PrepaidNoncurrentAssetsLineItems_cef0a870-d5c2-4711-b772-7c6619c1e4f7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_74094673-8664-461c-abb6-deaae33b1545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_755da408-3339-4a57-8b21-188538179677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_755da408-3339-4a57-8b21-188538179677" xlink:to="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e355d0ed-3013-4dd8-9054-9dc5eb991ccc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeMember_1407cc4a-e7f0-4ea9-9257-8cee0b4b6e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c1a19cd-490a-4e08-aca4-ba3ca23e16fd" xlink:to="loc_us-gaap_ForeignExchangeMember_1407cc4a-e7f0-4ea9-9257-8cee0b4b6e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:href="icui-20221231.xsd#icui_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesTable_65c0ad06-77c8-44d7-9d4b-dc951cfec9f3" xlink:to="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedSalariesAndBenefits_81bea948-5713-429a-9bed-5cbaf241729b" xlink:href="icui-20221231.xsd#icui_AccruedSalariesAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedSalariesAndBenefits_81bea948-5713-429a-9bed-5cbaf241729b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_47f3cb17-8bed-46c2-9020-23240561a5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedBonusesCurrent_47f3cb17-8bed-46c2-9020-23240561a5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3f83be2-9f9c-40a8-a7b9-fc465a838a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f3f83be2-9f9c-40a8-a7b9-fc465a838a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_df726b58-02e7-4032-ad2e-b6f90cb78af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_df726b58-02e7-4032-ad2e-b6f90cb78af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedProductFieldAction._d1562dad-9af2-4438-b489-53448cc98a73" xlink:href="icui-20221231.xsd#icui_AccruedProductFieldAction."/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedProductFieldAction._d1562dad-9af2-4438-b489-53448cc98a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedlegalfees_fc5c8c9b-0549-4981-a19c-f7833fb63278" xlink:href="icui-20221231.xsd#icui_Accruedlegalfees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedlegalfees_fc5c8c9b-0549-4981-a19c-f7833fb63278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedsalestaxes_69ed85f4-ab1e-4c07-811e-9e350dbadbbd" xlink:href="icui-20221231.xsd#icui_Accruedsalestaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedsalestaxes_69ed85f4-ab1e-4c07-811e-9e350dbadbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_75c5799d-b176-48db-9754-557f8560a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_75c5799d-b176-48db-9754-557f8560a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_af9915b5-f064-4816-a1a1-c8dcaa492d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_af9915b5-f064-4816-a1a1-c8dcaa492d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedothertaxes_bba40fe1-501c-4ee2-8779-7b47bd12f848" xlink:href="icui-20221231.xsd#icui_Accruedothertaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedothertaxes_bba40fe1-501c-4ee2-8779-7b47bd12f848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Outsidesalescommissions_a2c927d9-c1a8-49b9-9a2b-8c5701d39e7d" xlink:href="icui-20221231.xsd#icui_Outsidesalescommissions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Outsidesalescommissions_a2c927d9-c1a8-49b9-9a2b-8c5701d39e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Accruedfreight_df71c41a-febe-4971-9329-517b2bcbaf04" xlink:href="icui-20221231.xsd#icui_Accruedfreight"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_Accruedfreight_df71c41a-febe-4971-9329-517b2bcbaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_e5606fa9-2c9a-4b21-829a-32264e9b08bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_RestructuringReserveCurrent_e5606fa9-2c9a-4b21-829a-32264e9b08bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_858db184-fad2-4ffd-b6e0-924e1bb2c047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_858db184-fad2-4ffd-b6e0-924e1bb2c047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedAuditFees_c23021c8-d78f-4d8e-8665-d9e1ea1637f9" xlink:href="icui-20221231.xsd#icui_AccruedAuditFees"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedAuditFees_c23021c8-d78f-4d8e-8665-d9e1ea1637f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4787e55d-74e1-47ce-9536-b12928a47531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4787e55d-74e1-47ce-9536-b12928a47531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_a8040536-9d70-414f-bd27-eb08864f0c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_a8040536-9d70-414f-bd27-eb08864f0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccruedResearchAndDevelopmentLiability_98196630-816a-410f-8a4f-aa0898791a7e" xlink:href="icui-20221231.xsd#icui_AccruedResearchAndDevelopmentLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_icui_AccruedResearchAndDevelopmentLiability_98196630-816a-410f-8a4f-aa0898791a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b1cc93-98fb-4990-8311-01163c6b1682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64b1cc93-98fb-4990-8311-01163c6b1682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba34c860-9dd5-460c-b04c-8f5f82129ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ScheduleOfAccruedLiabilitiesLineItems_e725e7be-63bd-4384-9321-ee9518d4610b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ba34c860-9dd5-460c-b04c-8f5f82129ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#OtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d65055f6-b6e2-4073-92d6-64bb8049e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d65055f6-b6e2-4073-92d6-64bb8049e9cf" xlink:to="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:href="icui-20221231.xsd#icui_TimingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:to="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:href="icui-20221231.xsd#icui_TimingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingAxis_739c8cdc-50ad-46b8-a078-920494faaa5c" xlink:to="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermMember_63197827-15cf-4428-9507-22c2de4345f3" xlink:href="icui-20221231.xsd#icui_LongTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TimingDomain_711b1864-cf42-4ca7-b4bb-24b130165503" xlink:to="loc_icui_LongTermMember_63197827-15cf-4428-9507-22c2de4345f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:href="icui-20221231.xsd#icui_OtherLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesTable_71fb7f41-6ff9-4cad-9021-d2e64ca4fe63" xlink:to="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b6be54d-726c-4252-ace7-92439406a2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b6be54d-726c-4252-ace7-92439406a2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ae2c74a3-373e-4b0b-9dcd-9b28e98d46e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ae2c74a3-373e-4b0b-9dcd-9b28e98d46e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ecd21a0-0d02-493b-822f-023a9ec77e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ecd21a0-0d02-493b-822f-023a9ec77e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_c033c5e3-fc09-428d-b6be-3bb8932dcc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_c033c5e3-fc09-428d-b6be-3bb8932dcc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_6344aabc-f8d1-47d9-b58f-5e20e76acbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_6344aabc-f8d1-47d9-b58f-5e20e76acbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualComponentAmount_1b8b603c-c0e6-4040-8ca7-8e074ac0d9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualComponentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_ProductLiabilityAccrualComponentAmount_1b8b603c-c0e6-4040-8ca7-8e074ac0d9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_5fea94b2-ab7e-4175-8353-53acbb2b1140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_5fea94b2-ab7e-4175-8353-53acbb2b1140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_0f058091-130f-4cb5-b0fe-7716e2a2a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_0f058091-130f-4cb5-b0fe-7716e2a2a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_df608444-60c4-497c-aba7-cf688ef4ecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OtherLiabilitiesLineItems_49ae62c7-6038-4af4-959b-73c094d87172" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_df608444-60c4-497c-aba7-cf688ef4ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ApplicableMarginBasedonLeverageRatioTermLoanADetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_237bdb01-9c1f-415c-9881-f3f8811330ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_237bdb01-9c1f-415c-9881-f3f8811330ff" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:to="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelAxis_05148e47-6ca1-4230-899a-e5d6c32de343" xlink:to="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Greaterthan400to100Member_6c1bcb29-5952-4753-8cbb-fe5c607a3453" xlink:href="icui-20221231.xsd#icui_Greaterthan400to100Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_Greaterthan400to100Member_6c1bcb29-5952-4753-8cbb-fe5c607a3453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_359b04f2-1383-49ad-8b27-a2430626cc31" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member_359b04f2-1383-49ad-8b27-a2430626cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_46ec7460-2f18-4154-85d6-6f1781907ef9" xlink:href="icui-20221231.xsd#icui_LessThanOrEqual300To100ButGreaterThan250to100Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqual300To100ButGreaterThan250to100Member_46ec7460-2f18-4154-85d6-6f1781907ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_1c90fba6-bdb6-430e-848f-d0342690bba2" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member_1c90fba6-bdb6-430e-848f-d0342690bba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThanOrEqualTo200To100Member_f61b011d-ae41-4db6-9b4a-f37b41a5306b" xlink:href="icui-20221231.xsd#icui_LessThanOrEqualTo200To100Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_9494f610-05c0-415c-839b-3bb52f1496c3" xlink:to="loc_icui_LessThanOrEqualTo200To100Member_f61b011d-ae41-4db6-9b4a-f37b41a5306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:to="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanAxis_8b388d5b-57ae-4977-8032-ec13a8301763" xlink:to="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_401f7971-7797-4a74-b65c-9dd80aadf0ed" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_2cd92312-7c43-45e5-ad42-eaff73e4be8f" xlink:to="loc_icui_TermLoanAMember_401f7971-7797-4a74-b65c-9dd80aadf0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_597294d2-8934-4da1-afb9-64f8020392e2" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans_3cfbea66-d54d-4f45-8476-4c20b04b184c" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_icui_ApplicableMarginTermSOFRLoans_3cfbea66-d54d-4f45-8476-4c20b04b184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans_f168cda0-b836-4465-8923-f9924608a4bf" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_icui_ApplicableMarginBaseRateLoans_f168cda0-b836-4465-8923-f9924608a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dc02ce0f-5ce4-4a30-b996-f5901f7319de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_af179d60-d856-41e8-8a18-d646cd0eba2b" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_dc02ce0f-5ce4-4a30-b996-f5901f7319de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#ApplicableMarginBasedonLeverageRatioTermLoanBDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2da322af-fd50-400d-b6e6-2315abd35e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2da322af-fd50-400d-b6e6-2315abd35e58" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:to="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:href="icui-20221231.xsd#icui_LeverageRatioLevelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelAxis_f491c8ca-babf-4f2b-9ffd-320262d9adbd" xlink:to="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GreaterThan275To100Member_00345115-45b1-409b-a772-40818a363acf" xlink:href="icui-20221231.xsd#icui_GreaterThan275To100Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:to="loc_icui_GreaterThan275To100Member_00345115-45b1-409b-a772-40818a363acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LessThan275To100Member_51da7ad1-3fe0-45c3-93c1-0d5963c7aeee" xlink:href="icui-20221231.xsd#icui_LessThan275To100Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LeverageRatioLevelDomain_0534720d-a58d-4ec7-be31-7db90870fb66" xlink:to="loc_icui_LessThan275To100Member_51da7ad1-3fe0-45c3-93c1-0d5963c7aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:to="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanAxis_bd3e0075-0648-4369-980d-1291e6b95290" xlink:to="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_9553ff1c-f004-4161-a999-4b3d958eb7a0" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_1eaa169f-7cd4-456f-8085-3d90949e93b5" xlink:to="loc_icui_TermLoanBMember_9553ff1c-f004-4161-a999-4b3d958eb7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBasedOnLeverageRatioLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioTable_906479f2-2a9e-4cd2-863d-3c4d4b257ccc" xlink:to="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans_1fae0458-dafd-4c8e-acf6-23c649ec5f78" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:to="loc_icui_ApplicableMarginTermSOFRLoans_1fae0458-dafd-4c8e-acf6-23c649ec5f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans_05485dc5-5d20-4d5e-8aff-e7510ad65371" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_ApplicableMarginBasedOnLeverageRatioLineItems_c4d24c52-9246-45cc-896d-f2d540ae3f96" xlink:to="loc_icui_ApplicableMarginBaseRateLoans_05485dc5-5d20-4d5e-8aff-e7510ad65371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DebtDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_96e8be36-cd82-413d-9574-db728d7f6f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_96e8be36-cd82-413d-9574-db728d7f6f2d" xlink:to="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:to="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanAxis_2f27147e-f9fc-4c33-b565-5ef7e26a0464" xlink:to="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_10d800a2-651c-479f-99c7-536099342145" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:to="loc_icui_TermLoanAMember_10d800a2-651c-479f-99c7-536099342145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_3925c027-c39a-4d67-8114-6d2f838ab92c" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_c1bd9e74-f939-42e7-bc2d-93f4c7810d19" xlink:to="loc_icui_TermLoanBMember_3925c027-c39a-4d67-8114-6d2f838ab92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fbbc825d-5bc2-471d-92da-58b73dbd84c5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f922b5e4-9149-4b5f-b32d-270a768f3ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dab4a5e7-9754-49de-a260-b35cc017e7bb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f922b5e4-9149-4b5f-b32d-270a768f3ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a9f457c8-1659-4991-b265-b097e25412fb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aafa5cf4-2554-47e1-ae66-76b5ce3d5584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aafa5cf4-2554-47e1-ae66-76b5ce3d5584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_314c3025-48f9-413d-a44f-37bf1b12b56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_314c3025-48f9-413d-a44f-37bf1b12b56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_25608fd5-c323-4d01-887f-d9707063775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_25608fd5-c323-4d01-887f-d9707063775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b6196ada-6380-4727-a6b6-6277397f8937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtCurrent_b6196ada-6380-4727-a6b6-6277397f8937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2cc9b9aa-cde0-4917-8703-06ae526d54c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2cc9b9aa-cde0-4917-8703-06ae526d54c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ef377ce7-348e-415f-9b6e-f847b1d2a6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ef377ce7-348e-415f-9b6e-f847b1d2a6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aaadcd9a-7a86-40c8-910d-87ab23cc163c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8b33eea-24da-4a46-b62d-c2a68b10cf8a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_aaadcd9a-7a86-40c8-910d-87ab23cc163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DebtMaturityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DebtMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DebtMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_088a9fd6-f1e3-4ec0-ba65-562bf70d506d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_088a9fd6-f1e3-4ec0-ba65-562bf70d506d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c77718d8-0faa-468b-9c1c-3c01fe335b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c77718d8-0faa-468b-9c1c-3c01fe335b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5fcdce4e-16d8-48e7-ab0c-be637647a62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5fcdce4e-16d8-48e7-ab0c-be637647a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9b8427da-a9f6-4928-a90d-b054a63ba91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9b8427da-a9f6-4928-a90d-b054a63ba91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_46f6991b-21ba-4309-ae70-7537a1247542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_46f6991b-21ba-4309-ae70-7537a1247542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2abf6215-ab90-4b6b-b6f4-f8ac463497be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2abf6215-ab90-4b6b-b6f4-f8ac463497be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f94d8107-db37-4bc3-93ca-9b00b2fc8a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf79d675-4de9-40b0-b89e-26128cb1e40d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f94d8107-db37-4bc3-93ca-9b00b2fc8a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bdf5246e-4a2c-45b0-9c2a-b35be3c42fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_9748c929-e8f2-426c-bfd2-f8299720f490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf5246e-4a2c-45b0-9c2a-b35be3c42fde" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_9748c929-e8f2-426c-bfd2-f8299720f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b9cbb76a-b323-468b-bba9-a759c41f77b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf5246e-4a2c-45b0-9c2a-b35be3c42fde" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b9cbb76a-b323-468b-bba9-a759c41f77b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_7f283508-b6b9-46a8-9fc5-2d556bcf9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf5246e-4a2c-45b0-9c2a-b35be3c42fde" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_7f283508-b6b9-46a8-9fc5-2d556bcf9ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_dcc6afd1-5a6d-4568-a5e5-7a14167d2294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf5246e-4a2c-45b0-9c2a-b35be3c42fde" xlink:to="loc_us-gaap_InterestExpenseDebt_dcc6afd1-5a6d-4568-a5e5-7a14167d2294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/A2022CreditFacilityTextDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#A2022CreditFacilityTextDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/A2022CreditFacilityTextDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TotalSeniorSecuredCreditFacility_9eaab1bc-2000-4a40-9502-c6a36fd59f09" xlink:href="icui-20221231.xsd#icui_TotalSeniorSecuredCreditFacility"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TotalSeniorSecuredCreditFacility_9eaab1bc-2000-4a40-9502-c6a36fd59f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3a4657e9-8fc1-4d96-8400-5dd991c68a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3a4657e9-8fc1-4d96-8400-5dd991c68a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_RevolverSubLimits_1652a57a-66aa-4e10-80d6-d148329fe5e1" xlink:href="icui-20221231.xsd#icui_RevolverSubLimits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_RevolverSubLimits_1652a57a-66aa-4e10-80d6-d148329fe5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_640726b1-1e74-4d90-9304-387a281811ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_640726b1-1e74-4d90-9304-387a281811ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestPercentageAddedToFederalFundsRate_c4316397-8a1a-4870-8778-9d5790fa1c0f" xlink:href="icui-20221231.xsd#icui_InterestPercentageAddedToFederalFundsRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_InterestPercentageAddedToFederalFundsRate_c4316397-8a1a-4870-8778-9d5790fa1c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestPercentageAddedToBaseRate_4c10f1f0-2a77-43c7-a85b-d447ebb49196" xlink:href="icui-20221231.xsd#icui_InterestPercentageAddedToBaseRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_InterestPercentageAddedToBaseRate_4c10f1f0-2a77-43c7-a85b-d447ebb49196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans_6718442b-b3f8-473a-8e55-e408d312e621" xlink:href="icui-20221231.xsd#icui_TerSOFRInterestRateAdjustmentForBaseRateLoans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans_6718442b-b3f8-473a-8e55-e408d312e621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_45066ac7-67ff-4c8d-afb0-810e55fa922a" xlink:href="icui-20221231.xsd#icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_45066ac7-67ff-4c8d-afb0-810e55fa922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e66ee9e8-af45-4213-8606-5312f63bea1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e66ee9e8-af45-4213-8606-5312f63bea1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginBaseRateLoans_9797c3cf-dcee-4ed1-af42-e00261405f9f" xlink:href="icui-20221231.xsd#icui_ApplicableMarginBaseRateLoans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_ApplicableMarginBaseRateLoans_9797c3cf-dcee-4ed1-af42-e00261405f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ApplicableMarginTermSOFRLoans_067eaa21-c273-4c43-8636-854e2b0a84c0" xlink:href="icui-20221231.xsd#icui_ApplicableMarginTermSOFRLoans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_ApplicableMarginTermSOFRLoans_067eaa21-c273-4c43-8636-854e2b0a84c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentFirst2Years_dc526791-3b6a-4158-8d28-ceaec7216ada" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentFirst2Years"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TermAPrincipalPaymentFirst2Years_dc526791-3b6a-4158-8d28-ceaec7216ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentYear3And4_7fe57e09-6e3a-4a98-a1b0-376afec956bb" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentYear3And4"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TermAPrincipalPaymentYear3And4_7fe57e09-6e3a-4a98-a1b0-376afec956bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermAPrincipalPaymentInYear5_fe2c76f1-1316-4731-ade9-6e3679cb9331" xlink:href="icui-20221231.xsd#icui_TermAPrincipalPaymentInYear5"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TermAPrincipalPaymentInYear5_fe2c76f1-1316-4731-ade9-6e3679cb9331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBPrincipalPayment_72deaff8-a9fc-46d2-bb3e-0906ede33247" xlink:href="icui-20221231.xsd#icui_TermLoanBPrincipalPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_TermLoanBPrincipalPayment_72deaff8-a9fc-46d2-bb3e-0906ede33247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LeverageRatioCalculationCeilingSubtractedAmount_4cd412fb-1ff2-4e83-b6a6-a3f059004f92" xlink:href="icui-20221231.xsd#icui_LeverageRatioCalculationCeilingSubtractedAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_LeverageRatioCalculationCeilingSubtractedAmount_4cd412fb-1ff2-4e83-b6a6-a3f059004f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:href="icui-20221231.xsd#icui_InterestRatesTable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:to="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_78d6ebac-7def-4012-8436-bb0b7fe76b17" xlink:to="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_439046f4-a391-4f4b-9475-28dcf226344b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:to="loc_srt_MinimumMember_439046f4-a391-4f4b-9475-28dcf226344b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_57352085-7f24-4a95-919e-e70e0de228eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0a857fe8-2363-4815-b41c-bcd8a7c709e1" xlink:to="loc_srt_MaximumMember_57352085-7f24-4a95-919e-e70e0de228eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:to="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanAxis_9accde84-a5e8-46a3-b268-4e508c006c9b" xlink:to="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_3f232577-04ce-4c21-9a13-5410f91c9fce" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_3def062f-3136-454c-8655-81d03807ab1a" xlink:to="loc_icui_TermLoanAMember_3f232577-04ce-4c21-9a13-5410f91c9fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:href="icui-20221231.xsd#icui_InterestRatesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestRatesTable_0813a53d-9b24-47d1-8393-b74d76eb2b1b" xlink:to="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_a713801d-0b57-450c-a245-6f80b6010eb9" xlink:href="icui-20221231.xsd#icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_InterestRatesLineItems_c4a02b54-3160-4888-9e5d-937723dd0184" xlink:to="loc_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans_a713801d-0b57-450c-a245-6f80b6010eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeTable"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a6b52c61-3621-476d-96a2-e623a017f2ae" xlink:to="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAxis_34f1d386-f875-41d1-be01-899f52dd17c8" xlink:href="icui-20221231.xsd#icui_TermLoanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:to="loc_icui_TermLoanAxis_34f1d386-f875-41d1-be01-899f52dd17c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanDomain_f65c02ac-934b-44df-855f-cef00d1b6a6f" xlink:href="icui-20221231.xsd#icui_TermLoanDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanAMember_1a9459cd-6ec2-4f75-8a4f-9e4f2e89b555" xlink:href="icui-20221231.xsd#icui_TermLoanAMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_TermLoanBMember_4beda801-837b-4285-b3fe-9e42da5f2929" xlink:href="icui-20221231.xsd#icui_TermLoanBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_TermLoanDomain_f65c02ac-934b-44df-855f-cef00d1b6a6f" xlink:to="loc_icui_TermLoanBMember_4beda801-837b-4285-b3fe-9e42da5f2929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f2ef74a5-93b9-47db-84c6-90ae00a71f5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1ae488db-21e9-42c0-9064-e62c8f459719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0de3df64-fe9f-4b0a-bcd8-d46f342e7796" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1ae488db-21e9-42c0-9064-e62c8f459719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:href="icui-20221231.xsd#icui_LongTermDebtTypeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeTable_6ffabd64-85df-448d-9190-058dd2a5b537" xlink:to="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da42f79e-19d3-4c02-b984-fc9f1f478d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da42f79e-19d3-4c02-b984-fc9f1f478d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f0d0799b-d778-403f-b15e-dcc03fe3b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f0d0799b-d778-403f-b15e-dcc03fe3b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_88f00202-ec95-41f0-af66-cd87be59749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_LongTermDebt_88f00202-ec95-41f0-af66-cd87be59749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_bdb4d417-ec55-4455-bf3d-ef7ca66e8e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_LongTermDebtTypeLineItems_7b1c2ebe-c666-401e-b724-70a575b12fdf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_bdb4d417-ec55-4455-bf3d-ef7ca66e8e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/PrincipalPaymentsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#PrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/PrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ef3ab82-efdb-4ecb-ac13-808d8be3b259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b360cc7f-532c-4aad-a0ef-026ce69e99cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ef3ab82-efdb-4ecb-ac13-808d8be3b259" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b360cc7f-532c-4aad-a0ef-026ce69e99cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/A2017CreditFacilityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#A2017CreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/A2017CreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_02875a9c-dd9d-46cc-8eee-74b6cfe0ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ebf85401-c43d-452e-b8fe-e7af8392c079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02875a9c-dd9d-46cc-8eee-74b6cfe0ddc9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ebf85401-c43d-452e-b8fe-e7af8392c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_49a81d9c-c450-4808-9325-926fd7bddc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02875a9c-dd9d-46cc-8eee-74b6cfe0ddc9" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_49a81d9c-c450-4808-9325-926fd7bddc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_de399352-021e-440a-82d2-d47410753bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02875a9c-dd9d-46cc-8eee-74b6cfe0ddc9" xlink:to="loc_us-gaap_LinesOfCreditCurrent_de399352-021e-440a-82d2-d47410753bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesIncomeLossfromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_644b7c7e-0813-45e2-86cd-e878f46fc49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a6b652e2-f7d4-4ce5-9947-0a2467b322ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_644b7c7e-0813-45e2-86cd-e878f46fc49c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a6b652e2-f7d4-4ce5-9947-0a2467b322ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_42aeb2b9-3ed9-4901-a8de-3f8c42558afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_644b7c7e-0813-45e2-86cd-e878f46fc49c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_42aeb2b9-3ed9-4901-a8de-3f8c42558afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_81a1257f-2483-4887-9cec-63bf417bfa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_644b7c7e-0813-45e2-86cd-e878f46fc49c" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_81a1257f-2483-4887-9cec-63bf417bfa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesTaxProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bb9c3629-2151-42ca-bcca-69e50c111904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bb9c3629-2151-42ca-bcca-69e50c111904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3381e334-7300-4596-87cd-5dd7bd51caa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3381e334-7300-4596-87cd-5dd7bd51caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4e9fdcb4-cb33-4f3d-96d2-e9860571d682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4e9fdcb4-cb33-4f3d-96d2-e9860571d682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2ab20461-126e-4210-9092-29985e117e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2ab20461-126e-4210-9092-29985e117e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6e9077ca-b054-4665-b3bc-1f291b69043e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6e9077ca-b054-4665-b3bc-1f291b69043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_243d502e-dfda-48ad-b013-273973ebe1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_243d502e-dfda-48ad-b013-273973ebe1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ea4e93c5-f91a-47be-99aa-4a6bfca9e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ea4e93c5-f91a-47be-99aa-4a6bfca9e91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71a378fe-9b0b-46d5-afaa-65a28069fb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71a378fe-9b0b-46d5-afaa-65a28069fb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c8e1500-2ed6-4fdb-a52e-9be30d8c8cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05868478-c2f6-444e-b8e8-d9cd95e8aa4a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c8e1500-2ed6-4fdb-a52e-9be30d8c8cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesChangeintaxespayableDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ca4cde6-78b4-43e1-9d27-e8fb80a3a019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_753cdd60-581a-443a-8cb6-4515f36a85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ca4cde6-78b4-43e1-9d27-e8fb80a3a019" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_753cdd60-581a-443a-8cb6-4515f36a85b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesEffectivetaxrateDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6b09e62b-cb57-4096-bf52-de2b0938effe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6b09e62b-cb57-4096-bf52-de2b0938effe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_cdca086c-7c0a-4b4b-99fe-7efea7f01b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_cdca086c-7c0a-4b4b-99fe-7efea7f01b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_2875549e-9ae8-4d5f-89db-8f7a25e8aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_2875549e-9ae8-4d5f-89db-8f7a25e8aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GILTItaxexpense_5f59f9a0-ac00-4796-852a-b366c8f1245b" xlink:href="icui-20221231.xsd#icui_GILTItaxexpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_GILTItaxexpense_5f59f9a0-ac00-4796-852a-b366c8f1245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_90d14900-fe6e-4a5c-b8e6-9624e5071b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_90d14900-fe6e-4a5c-b8e6-9624e5071b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_67a8cd72-9b7d-4d4c-aaa5-44ade1d9d70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_67a8cd72-9b7d-4d4c-aaa5-44ade1d9d70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_c40789a5-1164-4b2a-933f-aebff1303f86" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome_c40789a5-1164-4b2a-933f-aebff1303f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_16a148b4-b82b-4192-be15-f5440624e5d9" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationContingentConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration_16a148b4-b82b-4192-be15-f5440624e5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation_20cdb0c5-a657-4727-a666-b384cbf4ca04" xlink:href="icui-20221231.xsd#icui_Effectiveincometaxreconciliationnondeductiblecompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_Effectiveincometaxreconciliationnondeductiblecompensation_20cdb0c5-a657-4727-a666-b384cbf4ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_35031a4a-170a-4dfc-8a5d-051169a42d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_35031a4a-170a-4dfc-8a5d-051169a42d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f186de81-af05-4e34-a977-8b212bca0817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f186de81-af05-4e34-a977-8b212bca0817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31ddc89d-c7b5-460e-aa86-17f2f5017fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31ddc89d-c7b5-460e-aa86-17f2f5017fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2c251302-ba2d-434b-a26f-0acdd7c45997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2c251302-ba2d-434b-a26f-0acdd7c45997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f4f74052-fec4-420a-bb2b-cb8513f6ab2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f4f74052-fec4-420a-bb2b-cb8513f6ab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_GILTItaxexpensepercent_e1b62535-e98b-4745-b52f-74ce7fa02053" xlink:href="icui-20221231.xsd#icui_GILTItaxexpensepercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_GILTItaxexpensepercent_e1b62535-e98b-4745-b52f-74ce7fa02053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a83d362c-ea65-4908-8579-5beb22787d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a83d362c-ea65-4908-8579-5beb22787d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_02f13745-17d3-44c7-90fb-51203d720fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_02f13745-17d3-44c7-90fb-51203d720fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_fdbbb91b-7887-472a-9985-c13787cc0158" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_fdbbb91b-7887-472a-9985-c13787cc0158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveTaxRateReconcilationTransactionCostPercent_c9f8a70d-0f7d-4ff9-bceb-4fae5d5f28e6" xlink:href="icui-20221231.xsd#icui_EffectiveTaxRateReconcilationTransactionCostPercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveTaxRateReconcilationTransactionCostPercent_c9f8a70d-0f7d-4ff9-bceb-4fae5d5f28e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_fb8b85fe-99bc-4745-80cc-7c35d06c6d1a" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationTransactionCost"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationTransactionCost_fb8b85fe-99bc-4745-80cc-7c35d06c6d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_6079a65b-9f31-4649-b6d7-cf5a8387d90a" xlink:href="icui-20221231.xsd#icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent_6079a65b-9f31-4649-b6d7-cf5a8387d90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Effectivetaxratereconciliationnondeductiblecomppercent_36707da8-4b5a-4c3d-9998-9ebc2025a1ea" xlink:href="icui-20221231.xsd#icui_Effectivetaxratereconciliationnondeductiblecomppercent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_icui_Effectivetaxratereconciliationnondeductiblecomppercent_36707da8-4b5a-4c3d-9998-9ebc2025a1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9664ba05-fcd6-4fb7-b38c-6b56c098e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9664ba05-fcd6-4fb7-b38c-6b56c098e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d9a77f3c-2589-404d-acb6-a61a59f0635e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b5492a2f-d2ff-4781-bc52-86f3cdb29121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d9a77f3c-2589-404d-acb6-a61a59f0635e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesDeferredincometaxassetsliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_IncomeTaxDisclosuredeferredtaxesAbstract_573c6a9b-7f2e-403d-9a2f-5aa5f3fc8ab0" xlink:href="icui-20221231.xsd#icui_IncomeTaxDisclosuredeferredtaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_IncomeTaxDisclosuredeferredtaxesAbstract_573c6a9b-7f2e-403d-9a2f-5aa5f3fc8ab0" xlink:to="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7978928c-3b8e-42b0-909a-0645b8baf85a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember_3b458254-1d8d-4c37-b3b7-93b5d386f61b" xlink:href="icui-20221231.xsd#icui_NonCurrentDeferredTaxAssetGrossTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:to="loc_icui_NonCurrentDeferredTaxAssetGrossTotalMember_3b458254-1d8d-4c37-b3b7-93b5d386f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityMember_6ac60f44-4732-44a6-9921-724d16070aec" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91980237-6bb7-4ffe-a4d9-357f5f19b340" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityMember_6ac60f44-4732-44a6-9921-724d16070aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:href="icui-20221231.xsd#icui_DeferredtaxassetsandliabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesTable_5bc11a91-237b-4b99-91bd-f441a3cc749e" xlink:to="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0f915b63-1aaf-4a70-b63d-33025eda704c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_0f915b63-1aaf-4a70-b63d-33025eda704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_b59e6086-5848-40c8-9bb7-29b9a0b02a40" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions_b59e6086-5848-40c8-9bb7-29b9a0b02a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b23c7454-891a-4ea0-80eb-00b99351fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b23c7454-891a-4ea0-80eb-00b99351fc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_76585e35-0536-4983-8b37-3116f0b3dd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_76585e35-0536-4983-8b37-3116f0b3dd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState_e11a6645-b281-4401-8126-6bc338612412" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxAssetTaxCreditsState"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxAssetTaxCreditsState_e11a6645-b281-4401-8126-6bc338612412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_6cf2c0b8-28d5-4749-86e6-74b2e846eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_6cf2c0b8-28d5-4749-86e6-74b2e846eca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_aae26c9e-ce06-45cc-8bf5-31b3ec076e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_aae26c9e-ce06-45cc-8bf5-31b3ec076e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_DeferredTaxAssetSection163j_2dd1112d-2c08-4a3e-935c-332968d387f3" xlink:href="icui-20221231.xsd#icui_DeferredTaxAssetSection163j"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_DeferredTaxAssetSection163j_2dd1112d-2c08-4a3e-935c-332968d387f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_de0554f3-df47-4b76-b366-0027fc18cde2" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions_de0554f3-df47-4b76-b366-0027fc18cde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4caf7ae5-5c64-48c4-8dd7-22fe26ea40e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4caf7ae5-5c64-48c4-8dd7-22fe26ea40e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Noncurrentdeferredtaxasset_227e95b1-aeb8-4e94-b32a-934d092b7497" xlink:href="icui-20221231.xsd#icui_Noncurrentdeferredtaxasset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Noncurrentdeferredtaxasset_227e95b1-aeb8-4e94-b32a-934d092b7497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_fdf8a568-12fe-4cba-a38a-dd731db43ccc" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes_fdf8a568-12fe-4cba-a38a-dd731db43ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_cbf41624-fe53-43f8-85cc-ab03c5e32fee" xlink:href="icui-20221231.xsd#icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization_cbf41624-fe53-43f8-85cc-ab03c5e32fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Deferredtaxliabilitychangeinaccountingmethod_f24c78c9-7d65-4418-8600-efa06894df82" xlink:href="icui-20221231.xsd#icui_Deferredtaxliabilitychangeinaccountingmethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_icui_Deferredtaxliabilitychangeinaccountingmethod_f24c78c9-7d65-4418-8600-efa06894df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_52ded2ed-17a6-4879-b9be-b39dda871dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_52ded2ed-17a6-4879-b9be-b39dda871dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_196c5844-d48b-4a70-a6d5-6e2831225ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxLiabilities_196c5844-d48b-4a70-a6d5-6e2831225ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a5d5d1cc-26e7-43be-8359-4cf86dbdf0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_DeferredtaxassetsandliabilitiesLineItems_223f7521-e932-4d98-8f49-10c1e732f78f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a5d5d1cc-26e7-43be-8359-4cf86dbdf0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_OperatinglosscarryforwardsAbstract_982ed8e8-11ac-4d5a-ac81-75cbcbe0eb73" xlink:href="icui-20221231.xsd#icui_OperatinglosscarryforwardsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_OperatinglosscarryforwardsAbstract_982ed8e8-11ac-4d5a-ac81-75cbcbe0eb73" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f955522c-ec58-46d7-b3df-8cb4a2e06ca7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d7ce1739-1fea-426a-ac46-985d6df8afb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_country_US_d7ce1739-1fea-426a-ac46-985d6df8afb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1da69cdc-235a-450e-8179-0fa0c5394787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1da69cdc-235a-450e-8179-0fa0c5394787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_15b66a8e-5c38-49a9-b777-8a8f76956187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10dc1b5d-0b4e-4fff-a648-7ce8beb3d650" xlink:to="loc_us-gaap_ForeignCountryMember_15b66a8e-5c38-49a9-b777-8a8f76956187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5fd8d30-9719-4049-88f2-f4facb22ae24" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_61de7128-55f0-4725-8693-5aab24ab6011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f588483e-9608-490e-8455-d452f1d8b68c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_61de7128-55f0-4725-8693-5aab24ab6011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesTaxCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bda5f9a7-684c-432f-8bbc-de60371a46cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_cd66a458-de99-493a-97af-9d52e1c9f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda5f9a7-684c-432f-8bbc-de60371a46cd" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_cd66a458-de99-493a-97af-9d52e1c9f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_971a3e8a-bbd6-4448-a5e9-6cba33e19bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda5f9a7-684c-432f-8bbc-de60371a46cd" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_971a3e8a-bbd6-4448-a5e9-6cba33e19bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d903539-0ada-4264-93a7-7683facb5f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bda5f9a7-684c-432f-8bbc-de60371a46cd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d903539-0ada-4264-93a7-7683facb5f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesTaxHolidayDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c6b6d5-0ca4-43c8-bd99-bfa8a71b048f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9c6b6d5-0ca4-43c8-bd99-bfa8a71b048f" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_17a12594-144a-4b4f-b48c-525c6703add6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5fa3518a-0a85-44cd-84c2-a712d7a19e19" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_17a12594-144a-4b4f-b48c-525c6703add6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_80cb086b-0667-44d9-825e-265cb40cde96" xlink:to="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_d8a3d8b5-e378-4d82-a0a4-4c9d2f5fb6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_d8a3d8b5-e378-4d82-a0a4-4c9d2f5fb6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_66b0ba98-acca-4499-bb44-29a019ed89f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_46fce89f-2a62-4af5-ae0f-a71c4727a64e" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_66b0ba98-acca-4499-bb44-29a019ed89f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesUndistributedforeignearningsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8b971900-ff7e-4d99-a2f7-32283ae8cc69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_0fc083c8-3bac-4e21-8da5-8cb81eeb25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8b971900-ff7e-4d99-a2f7-32283ae8cc69" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_0fc083c8-3bac-4e21-8da5-8cb81eeb25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#IncomeTaxesUnrecognizedtaxbenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:href="icui-20221231.xsd#icui_UnrecognizedTaxBenefitsRollForwardRollForward"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b998ca20-d0da-4490-ae9b-c604c47710bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b998ca20-d0da-4490-ae9b-c604c47710bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ee6b3334-363d-4da7-9bbf-15a48fc4b46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ee6b3334-363d-4da7-9bbf-15a48fc4b46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8eabf69-9d67-4433-8df5-075df06fdb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8eabf69-9d67-4433-8df5-075df06fdb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_69a19da3-e9b5-42ed-86f7-e84fc8df8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_69a19da3-e9b5-42ed-86f7-e84fc8df8e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_19391571-4632-41a5-bc68-9d976d572448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_19391571-4632-41a5-bc68-9d976d572448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_64a64723-202c-4b8c-a7f8-de1fea14994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_64a64723-202c-4b8c-a7f8-de1fea14994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_f50a2533-984d-4ab0-a0f5-5493dd65c138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_f50a2533-984d-4ab0-a0f5-5493dd65c138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_7c5819b7-a4d1-45cc-bb34-0b117d721dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_7c5819b7-a4d1-45cc-bb34-0b117d721dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_04595f7b-c110-4218-8d7a-7e05de7c7781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_UnrecognizedTaxBenefitsRollForwardRollForward_fe71f669-efa0-4768-a61d-68723431abf5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_04595f7b-c110-4218-8d7a-7e05de7c7781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_ffae2c5c-7987-46b8-aba9-34d351b0a498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_ffae2c5c-7987-46b8-aba9-34d351b0a498" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a35d5b1f-6834-4585-8bba-448cfe6d76bb" xlink:to="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_1b4d7826-7e12-43c1-808c-9715b0cf308f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c0159f5-d438-455d-aef5-ccbf98949919" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_1b4d7826-7e12-43c1-808c-9715b0cf308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7116cb6f-6b42-4376-bf55-007b3ad3aee2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d15a3156-b6fe-4ac5-8e63-6bb32b2c9633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c5999954-0855-48e2-bc98-68c0bf050500" xlink:to="loc_us-gaap_SalesRevenueNetMember_d15a3156-b6fe-4ac5-8e63-6bb32b2c9633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e866aa8e-b5dc-4164-a846-dc12a116aeaf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f27e8189-e3fa-44c4-8c5a-bf168b9192e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_050575ff-26f3-4aed-b874-07d80f0b2245" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f27e8189-e3fa-44c4-8c5a-bf168b9192e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_79a3e39d-457f-4c0d-b3a7-e97537b3480a" xlink:to="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CR_949f2efc-4f37-40f0-bd2e-d47710106a2e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_CR_949f2efc-4f37-40f0-bd2e-d47710106a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_MexicoPropertyAndEquipmentMember_aa82a4ab-d844-44d4-9231-4020a9af062c" xlink:href="icui-20221231.xsd#icui_MexicoPropertyAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_MexicoPropertyAndEquipmentMember_aa82a4ab-d844-44d4-9231-4020a9af062c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_OtherLATAMMember_68c2643e-9116-40a5-846f-c9c1bf70c0c9" xlink:href="icui-20221231.xsd#icui_OtherLATAMMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_OtherLATAMMember_68c2643e-9116-40a5-846f-c9c1bf70c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_d99d8724-85d1-4b18-98d3-ed148ed02b15" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_CA_d99d8724-85d1-4b18-98d3-ed148ed02b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ItalyPropertyAndEquipmentMember_de48e2a2-b44e-4650-8483-f412f8b57366" xlink:href="icui-20221231.xsd#icui_ItalyPropertyAndEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_ItalyPropertyAndEquipmentMember_de48e2a2-b44e-4650-8483-f412f8b57366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_485f16f5-3f5f-4460-ab13-5cef7292575b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_country_ES_485f16f5-3f5f-4460-ab13-5cef7292575b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CZK_c8332bea-64fa-4a43-a65c-201dbc7b0bda" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CZK"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_currency_CZK_c8332bea-64fa-4a43-a65c-201dbc7b0bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_52ec1659-4310-4d07-8a44-201141c4d8da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_srt_EuropeMember_52ec1659-4310-4d07-8a44-201141c4d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_896d2e36-af64-4198-a73f-e6f3a2111796" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_srt_AsiaPacificMember_896d2e36-af64-4198-a73f-e6f3a2111796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignMember_94459c61-34b7-497d-9237-9c8fee4700b3" xlink:href="icui-20221231.xsd#icui_ForeignMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_ForeignMember_94459c61-34b7-497d-9237-9c8fee4700b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_UnitedStatespropertyandequipmentMember_b54024bf-9fd7-4003-bafd-aae3b5327a23" xlink:href="icui-20221231.xsd#icui_UnitedStatespropertyandequipmentMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8462dd63-3281-46b4-900f-34c3c66428db" xlink:to="loc_icui_UnitedStatespropertyandequipmentMember_b54024bf-9fd7-4003-bafd-aae3b5327a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1a6f32bb-f9de-4140-ac99-4efbc9017458" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_de407591-8ec3-4d6e-87d9-54bc3bb22678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_de407591-8ec3-4d6e-87d9-54bc3bb22678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_494edc8b-8f81-4cff-b9cb-cb64a5724f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_667c39d8-01c6-42cf-b3a1-ecdbf4d6dd83" xlink:to="loc_us-gaap_NoncurrentAssets_494edc8b-8f81-4cff-b9cb-cb64a5724f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f5d5911b-0d58-4e45-9841-42421bdb0d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f5d5911b-0d58-4e45-9841-42421bdb0d62" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca213efe-6c23-4257-bd12-9c1bafb81677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b25e1f4e-b257-4ecc-af94-d63834c1231a" xlink:to="loc_us-gaap_EquityComponentDomain_ca213efe-6c23-4257-bd12-9c1bafb81677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_07b88a24-03c8-408f-96a2-36147d57fa7b" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0e774e76-e804-448e-96c0-b88ad37e1f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0e774e76-e804-448e-96c0-b88ad37e1f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9884b948-941c-4b37-8be4-7db43cee7b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9884b948-941c-4b37-8be4-7db43cee7b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_856803a4-6de1-4243-a12a-cde9a9277b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_856803a4-6de1-4243-a12a-cde9a9277b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4df14596-f465-49a6-9b63-8b59bcb9bb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4df14596-f465-49a6-9b63-8b59bcb9bb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c03456cb-6abb-4c10-b69b-e521b327c6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7b81a7-812c-4a0a-ad85-4475a36fcfa2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_c03456cb-6abb-4c10-b69b-e521b327c6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_dff47b93-a081-4db2-9378-0d64a339d058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_dff47b93-a081-4db2-9378-0d64a339d058" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_911095f3-9990-48ef-9ff8-b7cb507094a0" xlink:to="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a6bd548c-5468-4149-ad11-2d0bed9fb9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a6bd548c-5468-4149-ad11-2d0bed9fb9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_d4cea040-eb72-4331-b8ac-6ac7c9cd5073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_d4cea040-eb72-4331-b8ac-6ac7c9cd5073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5e820d4a-1c9d-4757-bcc5-5c1aed92d859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1bb1aba-b4a4-41e5-b67e-123967539a92" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5e820d4a-1c9d-4757-bcc5-5c1aed92d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_edd2fa3e-9fb0-453a-8888-3011bf03fa6c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1da188a-2ff2-4ad8-ab17-fd14c589b765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1da188a-2ff2-4ad8-ab17-fd14c589b765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4bf56ca-23ca-431e-9189-5a79fb656b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b4bf56ca-23ca-431e-9189-5a79fb656b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_58408955-c088-4cf4-a94e-20312f21ee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_58408955-c088-4cf4-a94e-20312f21ee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_636304c2-b557-46fa-9b8e-b5100c961e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9d63210f-dd3a-45fd-a08f-f8e27d8d73f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_636304c2-b557-46fa-9b8e-b5100c961e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#CommitmentsandContingenciesContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e372e6a4-72f7-4628-96c0-72bcb1b2dd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e372e6a4-72f7-4628-96c0-72bcb1b2dd1b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dc55f5c7-90e8-4dba-95b3-2ee8b1377249" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularInc.Member_cefd6b91-866f-43e4-a7b9-fa846d74e921" xlink:href="icui-20221231.xsd#icui_PursuitVascularInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_PursuitVascularInc.Member_cefd6b91-866f-43e4-a7b9-fa846d74e921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_PursuitVascularLLCMember_0d0ad0ad-1d8d-4995-b4bd-edb668c7e427" xlink:href="icui-20221231.xsd#icui_PursuitVascularLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_PursuitVascularLLCMember_0d0ad0ad-1d8d-4995-b4bd-edb668c7e427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignDistibutorMember_a2aa02a5-a05b-4036-b66f-470fdab09c51" xlink:href="icui-20221231.xsd#icui_ForeignDistibutorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_ForeignDistibutorMember_a2aa02a5-a05b-4036-b66f-470fdab09c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ForeignInfusionSystemSupplierMember_518da2d9-9807-409c-ad2a-20ce3f128200" xlink:href="icui-20221231.xsd#icui_ForeignInfusionSystemSupplierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_ForeignInfusionSystemSupplierMember_518da2d9-9807-409c-ad2a-20ce3f128200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_SmithsMedicalMember_f7d828a9-887e-43ec-bac8-9d66dcc3a262" xlink:href="icui-20221231.xsd#icui_SmithsMedicalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f6c07bd-5775-4443-85a7-84309a6837c9" xlink:to="loc_icui_SmithsMedicalMember_f7d828a9-887e-43ec-bac8-9d66dcc3a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_46b729b6-8dac-413e-a6df-e7487ed6e256" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_Contingentconsiderationgross_cfcaf099-609d-42cd-8e2f-37f79093ac7b" xlink:href="icui-20221231.xsd#icui_Contingentconsiderationgross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_Contingentconsiderationgross_cfcaf099-609d-42cd-8e2f-37f79093ac7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63da0d77-6c32-4b3f-90b5-1512684dce98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63da0d77-6c32-4b3f-90b5-1512684dce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ShortTermContingentConsiderationGross_7f42dbd5-ac44-4eda-8bf8-bd2814ffc9f0" xlink:href="icui-20221231.xsd#icui_ShortTermContingentConsiderationGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_ShortTermContingentConsiderationGross_7f42dbd5-ac44-4eda-8bf8-bd2814ffc9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_LongTermContingentConsiderationGross_56b0449c-be4b-4ca9-9e5c-19775ae655ab" xlink:href="icui-20221231.xsd#icui_LongTermContingentConsiderationGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_LongTermContingentConsiderationGross_56b0449c-be4b-4ca9-9e5c-19775ae655ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_ContingentConsiderationGrossLT_7d332496-2955-4485-aa06-85478190ab6e" xlink:href="icui-20221231.xsd#icui_ContingentConsiderationGrossLT"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_icui_ContingentConsiderationGrossLT_7d332496-2955-4485-aa06-85478190ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ade45356-b7ad-4cc7-8f2e-b3db34043a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ade45356-b7ad-4cc7-8f2e-b3db34043a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityAccrualComponentAmount_a7b988d4-777d-4bbc-a434-d9eaf5f9c457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityAccrualComponentAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_af65cd3c-5033-4da3-8ce9-8bd0e12db653" xlink:to="loc_us-gaap_ProductLiabilityAccrualComponentAmount_a7b988d4-777d-4bbc-a434-d9eaf5f9c457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#CollaborativeandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_icui_CollaborativeandOtherArrangementsAbstract_04489763-3d84-4fbe-af24-59e508bc9b09" xlink:href="icui-20221231.xsd#icui_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_ecb24993-efe9-4fe4-abc9-891cf598993b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_icui_CollaborativeandOtherArrangementsAbstract_04489763-3d84-4fbe-af24-59e508bc9b09" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_ecb24993-efe9-4fe4-abc9-891cf598993b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3c1264f8-9fdb-4eb3-a3ae-6e6039f1ca44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3c1264f8-9fdb-4eb3-a3ae-6e6039f1ca44" xlink:to="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b0fc7a00-d77e-4700-b0cf-63485e03456f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_610ccdff-1bfd-4579-b676-29e11aa29719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b0fc7a00-d77e-4700-b0cf-63485e03456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9c8ab7f5-0291-40ba-aa91-7fd23e28dd2b" xlink:to="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_AccountsReceivablePurchaseProgram_37887465-804e-4edc-b3d6-e17884773ac0" xlink:href="icui-20221231.xsd#icui_AccountsReceivablePurchaseProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_67950491-6dd6-4fee-8d9e-e889b396f9df" xlink:to="loc_icui_AccountsReceivablePurchaseProgram_37887465-804e-4edc-b3d6-e17884773ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="icui-20221231.xsd#SECScheduleArticle1209ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_aca02b51-b75b-4c78-8843-a1c0ed8417a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_aca02b51-b75b-4c78-8843-a1c0ed8417a6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5b55aab-a06c-4d62-a848-8c5ba8cb8dd7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_bdc1b931-14a3-41e5-96d6-6dfb071defd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_bdc1b931-14a3-41e5-96d6-6dfb071defd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantyReservesMember_669722bd-8c87-4528-a1a8-6a3f40f5ed7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantyReservesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_WarrantyReservesMember_669722bd-8c87-4528-a1a8-6a3f40f5ed7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_35c78eae-e37c-4b31-833d-887021d73ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1cd167c8-f9fb-4fbf-ac00-743b54a47886" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_35c78eae-e37c-4b31-833d-887021d73ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d5e7369e-a2a2-4d9d-82bc-1c9f5601c765" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_68a7a7b7-6c9b-42a3-a50e-7c0dd07f5e83" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_856e82d6-a3f0-4fa5-a3ad-b8520dedbfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_856e82d6-a3f0-4fa5-a3ad-b8520dedbfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d0c8485e-cbc7-407e-ad1a-c23f60d93866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_d0c8485e-cbc7-407e-ad1a-c23f60d93866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b6d5486-8762-4aeb-9853-f1a7fbdebe22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_9b6d5486-8762-4aeb-9853-f1a7fbdebe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c6502a5e-c46a-4395-a046-8b0ef5ad1728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c6502a5e-c46a-4395-a046-8b0ef5ad1728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_13a15728-758e-49db-88d0-fbdab60cafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_13a15728-758e-49db-88d0-fbdab60cafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs_b89623fc-0e1b-49e2-b0ca-a59c9202a166" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryWriteOffs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventoryWriteOffs_b89623fc-0e1b-49e2-b0ca-a59c9202a166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_d5962085-c131-4aee-be3d-91903f89b874" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts_d5962085-c131-4aee-be3d-91903f89b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveCosts_f5327acb-0668-4506-88e6-580499f50362" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveCosts_f5327acb-0668-4506-88e6-580499f50362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_icui_WarrantyAndReturnReserveInventory_c12b6c9c-61bb-47ed-b7e6-e73fecce108b" xlink:href="icui-20221231.xsd#icui_WarrantyAndReturnReserveInventory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_762bbdb7-3d30-42e3-8ae8-2df46890a7b6" xlink:to="loc_icui_WarrantyAndReturnReserveInventory_c12b6c9c-61bb-47ed-b7e6-e73fecce108b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>icui-20221231_g1.jpg
<TEXT>
begin 644 icui-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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MK]C?XE_&3]E'X[^(?C/X;D\+>*OVA-5U'4[31M1!$FC0,K_V?'.,9#([%BN
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]&FUWMI=\'>(.6\6U)8=0=*LE?E;NFNKC*RO;JFD^NNMN^HHHKX,^_"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HIES<V]G;O=W=PD442%Y)9'"JB@9))/  ]:^
M<OCS_P %)_A#\-6FT#X:1_\ "7:PI*![27;91-TYFP?,^D8(/3<*]7*<DS7/
M,1[' TG-];;+U;T7S9Y.;YYE.18?VV.K*$>E]WZ):M^B9Q?_  5U_M3_ (1K
MP/Y._P"Q?;K[[1C.WS=D/EY]]OFX_&OA^OK=O@9^VO\ MRS1^(_BWJR>&O#Z
M$S:=9W\#0Q*Q!VF*U'SMP<>9*<[6.&;I7S[\6?V>/C#\%-9FTGQ_X(O;=(W(
MBU"&%I+6<=F24#:<CG!PP[@'BOZ6X$KY=E65T\EGB:<L13NY*,K_ !2;M?2[
M5[.U[=>A_,/'V'S+-LUJ9W##5(8>IRJ+G&WPQ2O;6R=KJ^_3J<57W!_P2*_M
M3_A&O''G;_L7VZQ^SYSM\W9-YF/?;Y6?PKY0^&'[/WQD^,=^+#X>?#_4+\8)
M>Z,7EVZ?[TKX0'VSD]@:^K/^";_QV\+>!4N_V8/'>@KH'B!=5FDMYKA3&;VX
M.%:&4-]V90H51P&50/O#YL_$BLL9PMB<+A;5*D>1RBFG*$5*_,UO;W;;;7>R
M9KX9T7@^*\-BL5>G3ESJ$FFHSDXVY5*UK^]??>RW:/L>BBBOY8/ZO"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'(LZE>?_ "YJO:K%='VJ+JNOF[.7T-1117P)^@A1110 4444 %%%% !1110
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M=:?&CVNE2W19L%8B,K[\T 6Z*Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6M>-B\:NR%25!*GJ/:@!:*** "BBB@ HHHH *^0/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4.N:B[>8]HLC>0'/)+L?FE.?7 ]0:]PLK&RTRTCT_3K.*W@A0+%!!&$1%'0
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MCAWBW+\_P]TG3JQ=IPEHXR6Z?Z;7^\]7HH!!&0:*Z#ZH**** "BBB@ HHHH
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M^(FE^)-),IB:[TNZ$@CD !,;K]Z-\$':P!P0<<BNJH **\D^,/[=_P"Q_P#
M'QDOP\^+WQ_T#1=;8*9-,FG:26 ,,J91&K>3D$$;]N00>AKTWPWXE\.^,M L
M_%7A'7;/5-,U"W6>QU'3[E9H+B)AE71T)5E(Z$'% %ZBO&/$O_!1#]B+P?\
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MA]J?C+1O#^BZOKUWX-T7P_\ VK<ZS/<(T%K"MJ?EDQ);%OFPH ;)KO?V:_\
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MM9?"KQ)=_P#""MYS,^E0:GYB01QL3D")U\P?[;,3UKUK_@D+\:? 7@7]C8?
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M[:6RQ2V_E$[O,9T^1<9<.A4'<*S_ /@C/\._$_@7]A?1=<\7Z<]G?>,-9O\
MQ$;652&2*YEQ$V#V>*-)!_LN* /JJBBB@ HHJIJNCVNL1I%=22J$;(\J4J?T
MH MT5C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%
MM1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q
M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MH^G-BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
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M  +:C_A!](_Y^;W_ ,"VK^MDDE9'VQL45C_\(/I'_/S>_P#@6U'_  @^D?\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
MX0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_
M )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC
M_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]
M_P# MJ /%?VV?V-++X]:0?'_ ( ACM/&>G1 Q.K!!J4:\B)SVD'\#GI]T\8*
MX7[$/[9E[XVG'P&^.$TEGXOTYFM[.ZO@4>_V9!BD#<BX7!!SRX&?O Y^A_\
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M=@'NY(RD$0]6D(P/IR3V!K[#^%7P&\/?#3P;;^&XKZYEG_UE]<QS%!-,0-S
M#H. !WP!7E^$7#V9UN(89FX.-&FI>\U92<HN*2[VO=VT5E?='JY'A:TL4JUK
M15_GT.\HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ_I\^O-BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M^]Q+C)'_ $S /M7K?@#]E_X.?#[9<67AA=0NTZ7NK$3OGU"D;%/N%!KT$ *
MJ@  < 5']@<8Y[KFV.]A3?\ R[P^C]'4?O>J5TQ?5L?B?X]3E7:/^9\^>$/V
M&TO;S^W/B]XZN=2NI#NF@LI&^8_[4TF6;\ I]Z]D\%?"[X??#NW\CP9X3L[$
M[=K31Q[I7'^U(V6;\36_17T.3<(\/9"^;"8=*?\ ._>F_P#MZ5WKY67D=5#
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M17X"?T(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%>*_'3]O/X#?!/SM*76_P#A
M(=:CRO\ 96BNL@C;TEE^Y'SU&2P_NUWY=E>8YMB%0P=*5279*]O-O9+S=D>?
MF6:Y;E&'=?&U8TX=V[7\DMV_)79[57D/QT_;=^!'P*\[3-4\1?VOK,>1_8NC
M%994;TD;.R+GJ&.['(4U\ZR>//VZ_P!N61K3P/IK>$O",[%6N8I'MK=TZ'?<
M$>;<>A6,;3W45Z[\#/\ @FU\%OAD8=:\?@^+M63#?Z?%MLXV_P!F#)#_ /;0
ML#UP*^R_U;R#A_WL]Q/-47_+FBU*7I.?PQ\TM>S/BO\ 6;B'B+W<APW)2?\
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M:WH7P;TW[1&^Z-KV6:Z5&Z@A9W=01VP.*]05550JJ  ,  =*WXP\4:6<Y9/
MY?2E",])2E:]NJ23:UV;;VNK:W7/P;X55<DS2&/S&K&<J;O&,+VOT;;2>FZ2
M6]G?2S6BBBOQL_:0HHHH ***CN[RTL+9[V_NHX(8UW22S.%51ZDG@4FU%7>P
M;$E%>5>/_P!L3X/>"]]KI>I2:Y=KD"+2P#&#[RG"X]UW?2O.7^-G[4WQU<VW
MPM\(OI&G2''VN!,<=\W$N%R/]@ U\7F/'W#V"K_5\/)XBMTA17M']Z]U>>MU
MV//JYGA:<N2+YY=HZ_\  /H;Q7XZ\'>!;+^T/%_B6STZ(@E3<SA6?V5>K'V
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MN[NVUM3@3PW_ -5\6\=C*BG6LU%1ORQON[NS;:TV5E?>^A1117Y:?JP4444
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MU_@']AWX<>'REYXVU&YUVY'+1$F"WS_NJ=Q_%L'TKYG_ %GXHSO3)< X0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML\?.,_R?(:'M<?64%T3W?I%:OY(^E;N[M;"UDO;ZYCAAB0O+-*X544<DDG@
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M=R.7M,-07M/YY>]-OOS2NU\K(^VH8'"X=WA'7N]7]X4445].=84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXGDP7M;6<RRD?W6E?(7Z*"/0BOH32M(TG0K"/2]$TRWL[:(8CM[6%8T4>RJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7R2?F;T,NPU&7.US2[O5A1117UYW!1110 4444 %%%% !1110 4444 %%%%
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MVE9]][GMM%%%?U*?D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P ['A7_  J;]J#Q+_R'/B']D1OOH=5=?_'85P:DMOV/]1U"7[5XH^([RO\
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M.R=.$E[2#=[-NZ?D]?R9\:>#OAIXU\=WR6?AS09Y%9L/<NA6&,>K.>!].I[
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M%\0VGPM^#\MWK-_XJU[1Y;&/5]5E1%@M[9)0&?RVC1BV!@%P0/D+/U+Q??\
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M'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M+;B[Q2B[/=*[M:U];V1R99EF)EB8SJ1<5%WUTV.SHHHK^I#[$**** "BBB@
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MHPRS)\?F]=TL/'5;MZ)>O^6Y[G17R]I'[4_Q;T^\$^H:E:W\6[YH+BR1 1Z
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M_.N_T?X"_"/1,&U\$6DK#^*\+3Y_"0D?I73Z?I.E:3%Y&E:9;VR?W+>%4'Y
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M/R=F?.XO!8K UG2Q$'&79_IW]4%%%%>@<P4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %9OB3PAX8\86@L?$^A6U
M[&N=@GC!*'U4]5/T(K2HK*O0H8FDZ5:*E%[II-/U3T+IU*E*:G!M-=5HSDM(
M^!7PDT*\%_I_@BU\U3E3.[S 'U D9@/RKK0 !@# '0445SX++<NRV#AA*,*:
M>ZA%13^Y(TKXK%8J7-7FYOS;?YA1117:8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45
M]86.J6DEAJ5G%<02KMEAFC#*X]"#P:EHJ91C.+C)73&FXNZW/(?'O[*NE7<Y
MUSX::FVDWJ-O2V>1O*W?[+#YHS^8] *Q-'^.?Q5^$E^GASXP>'9[RW!Q'=D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH]@_9Z_9:^$/[-7P1A^ ?@#1'GT39-_:;ZJPGFU2688GFN6( D>0<'@#: H
M4   K?LB^+] UC]COX;^,H-1A73S\.]*FEG9P$B5+*/?N/;:58'T*GTKPO\
MX(>Z?>#]B63Q7-;O';>(_'>LZEI^]<;H3,L61_P*%Q^%+-_P2;N]*\/7_P &
MOAU^V=\1O#GPHU2XE:[^'MFT$@BAE8M+;07<@,D4+98%,-D,=VXLQ/U+\,_A
MOX+^#_P_TCX7_#O0X]-T/0K".STVRB)(CB08&2>68\DL22Q)))))H W****
M"JFJPZQ-&@T>\BA8-\YECW BK=% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_
M &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q1
M0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (UKQAQ&HE8%MHW$#@FEHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**R/B!XK?P)X#UOQQ%X=U#6&T;2+F^72=(@\V[O3#$TGD0I_'*^W:J]V8"@#
M7HK\X[#XF_MG?$+_ (*C_ 'Q7^TCX83P1H.NIXBD\)_#R#4#+-8P1Z7-NFO2
MH"O/(73@_<"8VH<Y^H_V\_ _[4_Q7\+>%?A'^S;J]YH>G^(/$\,/Q!\6:5J4
M-M>Z3HP(\TVY=U8R-GK'EL1D=&- 'O-%?GE^W/\ LN>$O^"</P0A_:W_ &5_
MBUXPT#Q5X=URP2>QU?Q5<7UKXG2:98Y+>XAE8J[%2TGRX&V-\ ':R_0?_!2/
MXD^(=$_8@UG2/#=J]KXD^(BV/A30[&1L/]KU21+=HL]=RQ/,>.<I0!]%45\H
M_%;]B/XK?%SXB^!/@/>^-K[0?V?O!7@>&VN=-\-:X]G?:[J$(6&*"X\L!A;B
M(*P )Y1^A92O%_!329/V3/\ @ISIO[)7P&^(^O:YX"\0^ KC5?$?A/5];DU)
M/"]U$S^5-&\C,\ DQ&NQCD^<"<@Q[0#[BHKYF_;J^,W[8-O<7OP+_9(^$T]O
M=3^&&U+6_BIK$@BTW0[8^<K)!P3/>8B)"C.S?&Q4ALJW_@CEJ6HZO_P3?^&^
MI:M?S75S,FJF6XN)2[N?[6O>2S$DT ?3=%?,>NG_ (73_P %4]$T=?WVE_!;
MX<W&I3$<B+6-7?R(T8>OV.)W![;CCJ:^=/\ @KO\=_VT/'?P3\>V?@SX:WO@
M#X6^$=:BT_5_$6K7!AU#Q9,+U+=5M(U^9+3>1)O.!*JC#8+1D _2>BN+^(OP
MLTSXW?!&Y^%NM^)M;TBVUG3((IM3\.W_ -EO8 "C[HI=K;#E<$X/!([U\'_M
MV?L4_![]D?X-IXB\/_M(_'O7/&7B+48M&\!^&Q\1MS:EJ<QVQ@JL 8QKG<V"
M,_*@(+J: /TDHKR#]AC]GGQ?^S)^SAHOPT^(GQ#U+Q/XB;=>Z]J>I7[W&VZE
M"EX8G<EO*CP$7)YP6P-V!Z_0 4444 %%%% !1110 445D?$#Q6_@3P'K?CB+
MP[J&L-HVD7-\NDZ1!YMW>F&)I/(A3^.5]NU5[LP% &O17YQV'Q-_;.^(7_!4
M?X ^*_VD?#">"-!UU/$4GA/X>0:@99K&"/2YMTUZ5 5YY"Z<'[@3&U#G/U'^
MWGX'_:G^*_A;PK\(_P!FW5[S0]/\0>)X8?B#XLTK4H;:]TG1@1YIMR[JQD;/
M6/+8C(Z,: />:*_/+]N?]ESPE_P3A^"$/[6_[*_Q:\8:!XJ\.ZY8)/8ZOXJN
M+ZU\3I-,L<EO<0RL5=BI:3Y<#;&^ #M9?H/_ (*1_$GQ#HG[$&LZ1X;M7M?$
MGQ$6Q\*:'8R-A_M>J2);M%GKN6)YCQSE* /HJBOE'XK?L1_%;XN?$7P)\![W
MQM?:#^S]X*\#PVUSIOAK7'L[[7=0A"PQ07'E@,+<1!6 !/*/T+*5XOX*:3)^
MR9_P4YTW]DKX#?$?7M<\!>(? 5QJOB/PGJ^MR:DGA>ZB9_*FC>1F> 28C78Q
MR?.!.08]H!]Q45\S?MU?&;]L&WN+WX%_LD?":>WNI_##:EK?Q4UB01:;H=L?
M.5D@X)GO,1$A1G9OC8J0V5;_ ,$<M2U'5_\ @F_\-]2U:_FNKF9-5,MQ<2EW
M<_VM>\EF))H ^FZ*^8]=/_"Z?^"J>B:.O[[2_@M\.;C4IB.1%K&KOY$:,/7[
M'$[@]MQQU-?.G_!7?X[_ +:'COX)^/;/P9\-;WP!\+?".M1:?J_B+5K@PZAX
MLF%ZENJVD:_,EIO(DWG E51AL%HR ?I/17"?&#QCXN^'_P"S/XG\?> ]*-_K
MNB^![R_T>S\LOY]U#9O)$FT<MEU48')Z5\&?"W]F/X1_%K_@GW<_MU^._P!J
MSQHWQ)E\/7FM77C^/QQ/#_9&HQ[V6S6%'"(JNJ1>5C<<X0KN0  _2ZBO'/\
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MW]1570M9T_Q'HEGXATF;S+6_M8[BVDQC=&ZAE/Y$5:H **** "BBB@ HHHH
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M)-)UCU+4@0,OC!6(CVPJ[O.[?]I#_B\G_!0;X*? 6/\ >V'@NRU#XA^(H#R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXRXH [6BO'?V*/VP_#'[:'POO_'NC>$KWPYJ.C:]<:1KOAW4Y0]Q87,6TX?
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M_M.?#O\ :]^!VC_''X;3,MIJ*&.\L)G!FT^[3B6VEQ_$IZ'C<K*PX85E:?\
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MP_XSO?#TMO=W:S-,]O'"YE!51A6\X#'4;>M>OT %%%% !1110 4444 %%%%
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MO$-E;>&OAI$WCSQF;R[2.)[Q,+80-O(!8,48KWCN6/.#5?\ 8V\8>'_V<O\
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M/ ^L:)\.?"$IY7?!>1W.IN.V?M#H@8=5R,]J^I_V^?VM/&_@KXI?#?\ 8_\
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MCM^S=^V#\$9=#N]*U#Q;\9M=N?#CZK:O!'=ND\=Q;NK.!F)Y(D7S!D8)/.*
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M(AX8^XP3W->F45YV9Y3EN=85X;'4E4@^C[]T]T_--,RK4:6(AR5%='S[H7[
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M27HE9+SL@R?(,GR"BZ67T533WM=M^K=V_*[T"BBBO(/8"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755019408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ICU MEDICAL INC/DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0022692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Calle Amanecer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Clemente<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">366-2183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.10 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ICUI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,305,900,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,998,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Proxy Statement for registrant&#8217;s 2023 Annual Meeting of Stockholders filed or to be filed pursuant to Regulation 14A within 120 days following registrant&#8217;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760487536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DELOITTE & TOUCHE LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Costa Mesa, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755113984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 208,784<span></span>
</td>
<td class="nump">$ 552,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES</a></td>
<td class="nump">213,008<span></span>
</td>
<td class="nump">567,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $8,530 at December 31, 2022 and $7,038 at December 31, 2021</a></td>
<td class="nump">221,719<span></span>
</td>
<td class="nump">105,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">696,009<span></span>
</td>
<td class="nump">290,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">15,528<span></span>
</td>
<td class="nump">19,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">88,932<span></span>
</td>
<td class="nump">46,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,235,196<span></span>
</td>
<td class="nump">1,029,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY, PLANT AND EQUIPMENT, net</a></td>
<td class="nump">636,113<span></span>
</td>
<td class="nump">468,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Assets</a></td>
<td class="nump">74,864<span></span>
</td>
<td class="nump">39,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">GOODWILL</a></td>
<td class="nump">1,449,258<span></span>
</td>
<td class="nump">43,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">INTANGIBLE ASSETS, net</a></td>
<td class="nump">982,766<span></span>
</td>
<td class="nump">188,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred Income Tax Assets, Net</a></td>
<td class="nump">31,466<span></span>
</td>
<td class="nump">42,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">105,462<span></span>
</td>
<td class="nump">63,743<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">4,515,641<span></span>
</td>
<td class="nump">1,880,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">215,902<span></span>
</td>
<td class="nump">81,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">242,769<span></span>
</td>
<td class="nump">118,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-Term Debt, Current Maturities</a></td>
<td class="nump">29,688<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued Income Taxes, Current</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">494,559<span></span>
</td>
<td class="nump">200,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">25,572<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-Term Debt, Noncurrent</a></td>
<td class="nump">1,623,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other long-term Liabilities</a></td>
<td class="nump">114,104<span></span>
</td>
<td class="nump">41,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Tax Liabilities, Net</a></td>
<td class="nump">126,007<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="nump">41,796<span></span>
</td>
<td class="nump">18,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue', window );">Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,995 and 21,280 shares at December 31, 2022 and 2021, respectively, and outstanding 23,993 and 21,280 shares at December 31, 2022 and 2021, respectively.</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">2,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,331,249<span></span>
</td>
<td class="nump">721,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">837,501<span></span>
</td>
<td class="nump">911,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(80,978)<span></span>
</td>
<td class="num">(19,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">2,089,928<span></span>
</td>
<td class="nump">1,616,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 4,515,641<span></span>
</td>
<td class="nump">$ 1,880,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755209248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,279,997<span></span>
</td>
<td class="nump">$ 1,316,308<span></span>
</td>
<td class="nump">$ 1,271,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods Sold</a></td>
<td class="nump">1,582,236<span></span>
</td>
<td class="nump">824,818<span></span>
</td>
<td class="nump">809,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">697,761<span></span>
</td>
<td class="nump">491,490<span></span>
</td>
<td class="nump">461,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">608,345<span></span>
</td>
<td class="nump">302,583<span></span>
</td>
<td class="nump">283,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">92,984<span></span>
</td>
<td class="nump">47,498<span></span>
</td>
<td class="nump">42,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Restructuringandstrategictransactionexpense', window );">Restructuring, strategic transaction and integration expenses</a></td>
<td class="nump">71,421<span></span>
</td>
<td class="nump">18,037<span></span>
</td>
<td class="nump">28,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent earn-out</a></td>
<td class="num">(32,091)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contractsettlements', window );">Contractsettlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">740,659<span></span>
</td>
<td class="nump">368,245<span></span>
</td>
<td class="nump">363,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="num">(42,898)<span></span>
</td>
<td class="nump">123,245<span></span>
</td>
<td class="nump">98,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest Income (Expense), Net</a></td>
<td class="num">(66,375)<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">OTHER INCOME,NET</a></td>
<td class="num">(5,136)<span></span>
</td>
<td class="num">(2,041)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="num">(114,409)<span></span>
</td>
<td class="nump">123,186<span></span>
</td>
<td class="nump">97,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">40,123<span></span>
</td>
<td class="num">(20,051)<span></span>
</td>
<td class="num">(10,624)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="num">$ (74,286)<span></span>
</td>
<td class="nump">$ 103,135<span></span>
</td>
<td class="nump">$ 86,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">23,868<span></span>
</td>
<td class="nump">21,206<span></span>
</td>
<td class="nump">20,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">23,868<span></span>
</td>
<td class="nump">21,781<span></span>
</td>
<td class="nump">21,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Contractsettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractsettlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Contractsettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Restructuringandstrategictransactionexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and strategic transaction expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Restructuringandstrategictransactionexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753369760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Comprehensive Income (Statement) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="num">$ (74,286)<span></span>
</td>
<td class="nump">$ 103,135<span></span>
</td>
<td class="nump">$ 86,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</a></td>
<td class="nump">41,016<span></span>
</td>
<td class="num">(3,021)<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of taxes of $0 for all periods</a></td>
<td class="num">(103,928)<span></span>
</td>
<td class="num">(14,664)<span></span>
</td>
<td class="nump">12,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Other adjustments, net of taxes of $0 for all periods</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(61,709)<span></span>
</td>
<td class="num">(17,747)<span></span>
</td>
<td class="nump">13,880<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (135,995)<span></span>
</td>
<td class="nump">$ 85,388<span></span>
</td>
<td class="nump">$ 100,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752677520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock Shares [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,377,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="nump">$ 668,947<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
<td class="nump">$ 721,782<span></span>
</td>
<td class="num">$ (15,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, including excess income tax benefits</a></td>
<td class="nump">13,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">12,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations</a></td>
<td class="num">(12,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">23,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">13,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="nump">86,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">1,502,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">693,068<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">808,652<span></span>
</td>
<td class="num">(1,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, including excess income tax benefits</a></td>
<td class="nump">9,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">8,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations</a></td>
<td class="num">(8,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">27,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(17,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="nump">103,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,616,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,128<span></span>
</td>
<td class="nump">721,412<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">911,787<span></span>
</td>
<td class="num">(19,269)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">21,280,000<span></span>
</td>
<td class="nump">21,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of restricted stock and exercise of stock options, including excess income tax benefits</a></td>
<td class="nump">$ 8,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(1,903)<span></span>
</td>
<td class="nump">10,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations</a></td>
<td class="num">(10,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustments to Additional Paid in Capital, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(61,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="num">(74,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,089,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">1,331,249<span></span>
</td>
<td class="num">$ (243)<span></span>
</td>
<td class="nump">$ 837,501<span></span>
</td>
<td class="num">$ (80,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 575,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 575,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751009280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="num">$ (74,286)<span></span>
</td>
<td class="nump">$ 103,135<span></span>
</td>
<td class="nump">$ 86,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">235,151<span></span>
</td>
<td class="nump">89,698<span></span>
</td>
<td class="nump">85,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AmortizationOfInventoryStepUp', window );">Amortization of Inventory Step-up</a></td>
<td class="nump">26,519<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating Lease, Right-of-Use Asset, Amortization Expense</a></td>
<td class="nump">23,651<span></span>
</td>
<td class="nump">9,594<span></span>
</td>
<td class="nump">9,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">7,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ProvisionForWarrantyAndReturns', window );">Provision for warranty and returns</a></td>
<td class="nump">4,902<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="num">(1,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation</a></td>
<td class="nump">36,025<span></span>
</td>
<td class="nump">27,341<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (Loss) on Disposition of Property Plant Equipment</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
<td class="num">(1,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Bond premium amortization</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance cost amortization</a></td>
<td class="nump">6,972<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent earn-out</a></td>
<td class="num">(32,091)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Production Related Impairments or Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
<td class="nump">2,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Sparepartsusage', window );">Sparepartsusage</a></td>
<td class="nump">11,924<span></span>
</td>
<td class="nump">13,046<span></span>
</td>
<td class="nump">11,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">6,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase (Decrease) in Accounts Receivable</a></td>
<td class="num">(19,151)<span></span>
</td>
<td class="nump">13,755<span></span>
</td>
<td class="nump">78,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase (Decrease) in Inventories</a></td>
<td class="num">(201,095)<span></span>
</td>
<td class="nump">20,815<span></span>
</td>
<td class="nump">19,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase (Decrease) in Prepaid Expense and Other Assets</a></td>
<td class="nump">22,903<span></span>
</td>
<td class="num">(7,973)<span></span>
</td>
<td class="num">(4,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Increase (Decrease) in Other Operating Assets</a></td>
<td class="num">(21,290)<span></span>
</td>
<td class="num">(21,038)<span></span>
</td>
<td class="num">(16,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">37,472<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
<td class="num">(46,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(55,834)<span></span>
</td>
<td class="nump">6,259<span></span>
</td>
<td class="num">(29,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes', window );">Income taxes, including excess tax benefits and deferred income taxes</a></td>
<td class="num">(66,734)<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="num">(18,037)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="num">(62,129)<span></span>
</td>
<td class="nump">267,538<span></span>
</td>
<td class="nump">222,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(90,311)<span></span>
</td>
<td class="num">(68,542)<span></span>
</td>
<td class="num">(92,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment', window );">Proceeds from Sale of Other Property, Plant, and Equipment</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">6,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible asset additions</a></td>
<td class="num">(9,018)<span></span>
</td>
<td class="num">(12,627)<span></span>
</td>
<td class="num">(8,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="num">(1,844,164)<span></span>
</td>
<td class="num">(14,452)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investment securities</a></td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(10,034)<span></span>
</td>
<td class="num">(32,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of investment securities</a></td>
<td class="nump">36,433<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,909,468)<span></span>
</td>
<td class="num">(90,687)<span></span>
</td>
<td class="num">(98,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts', window );">Proceeds from issuance of long-term debt, net of lender debt issuance costs</a></td>
<td class="nump">1,664,362<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term obligations</a></td>
<td class="num">(22,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="num">(2,177)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Long-term Lines of Credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of Short-Term Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8,785<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">13,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease, Principal Payments</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for Contingent Consideration Liability, Financing Activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(10,883)<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
<td class="num">(12,876)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">1,637,032<span></span>
</td>
<td class="num">(16,870)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>Effect of Exchange Rate on Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</a></td>
<td class="num">(9,478)<span></span>
</td>
<td class="num">(3,251)<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="num">(344,043)<span></span>
</td>
<td class="nump">156,730<span></span>
</td>
<td class="nump">127,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</a></td>
<td class="nump">208,784<span></span>
</td>
<td class="nump">552,827<span></span>
</td>
<td class="nump">396,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the year for income taxes</a></td>
<td class="nump">27,504<span></span>
</td>
<td class="nump">19,562<span></span>
</td>
<td class="nump">31,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="nump">63,713<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable for property and equipment</a></td>
<td class="nump">4,854<span></span>
</td>
<td class="nump">9,338<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">1,606,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NetCashPaidReceivedforcurrentandprioracquisitions', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="num">(1,844,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="num">(575,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized', window );">Contingent consideration</a></td>
<td class="num">(55,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill, Period Increase (Decrease)</a></td>
<td class="nump">1,462,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities Assumed</a></td>
<td class="nump">593,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_InternationalDistributorMember', window );">International Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability', window );">Noncash Non-compete agreement with associated contingent earn-out liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NetCashPaidReceivedforcurrentandprioracquisitions', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill, Period Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AmortizationOfInventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Inventory Step-up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AmortizationOfInventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the carrying amount as of the balance sheet date of payments made for taxes. Also includes the net change during the reporting period in the account that represents the temporary difference that results from income (loss) that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_NetCashPaidReceivedforcurrentandprioracquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Paid (Received) for current and prior acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_NetCashPaidReceivedforcurrentandprioracquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Non-compete agreement with associated contingent earn-out liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of long-term debt, net of lender debt issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ProvisionForWarrantyAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for warranty and returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ProvisionForWarrantyAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Sparepartsusage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sparepartsusage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Sparepartsusage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_InternationalDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_InternationalDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753374528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 8,530,000<span></span>
</td>
<td class="nump">$ 7,038,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,995,000<span></span>
</td>
<td class="nump">21,280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, Value, Outstanding</a></td>
<td class="nump">$ 23,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 208,784,000<span></span>
</td>
<td class="nump">$ 552,827,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760514544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Comprehensive Income (Paranthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Other Comprehensive (Income) Loss, Other Adjustments, Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</a></td>
<td class="nump">$ 12,941,000<span></span>
</td>
<td class="num">$ (954,000)<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520759973392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICU Medical,&#160;Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our wide-ranging product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We also manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients. Our recent acquisition of Smiths Medical broadened our product portfolio to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices, silicone and PVC tracheotomy tubes. ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell the majority of our products globally through our direct sales force and through independent distributors. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All subsidiaries are wholly owned and are included in the consolidated financial statements.&#160;All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the prior year financial statements and footnotes to conform to the presentation used in the current year. In the statements of operations we reclassified interest income to interest (expense) income, net from other income (expense), net and in Note 4: Revenues, certain reclassifications were made to revenues disaggregated by geography. These reclassifications had no impact on net (loss) income, shareholder's equity or cash flows as previously reported.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical 2020 Limited ("Smiths Medical"), see Note 2: Acquisitions. Our consolidated statement of operations includes the results of operations for Smiths Medical from January 7, 2022 through December 31, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ from those estimates.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounts Receivable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated at net realizable value.&#160;An allowance is provided for estimated collection losses based on an assessment of various factors.&#160; We consider prior payment trends, the age of the accounts receivable balances, the financial status of our customers and other factors to estimate the cash which ultimately will be received.&#160; Such amounts cannot be known with certainty at the financial statement date.&#160; We regularly review individual past due balances for collectability.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&#160; Inventory costs include material, labor and overhead related to the manufacturing of our products.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,235&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162,557&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,104&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment and molds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred.&#160;The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $95.8 million, $65.9 million and $62.4 million in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We test goodwill for impairment on an annual basis in the month of November, or more frequently if an event occurs or circumstances change that would indicate that impairment may exist.&#160;In 2022, we bypassed a qualitative assessment and performed a quantitative assessment to determine whether an impairment exists. We determine the fair value of our reporting unit using the income approach and market approach to valuation, as well as other generally accepted valuation methodologies. The income approach utilizes a discounted cash flow analysis using management's assumptions. The market approach compares our reporting unit to similar companies with the assumption that companies operating in the same industry will share similar characteristics and that company values will correlate to those characteristics. If the carrying amount of the reporting unit exceeds the reporting unit&#8217;s fair value, we recognize an impairment loss equal to the difference between the carrying amount and the estimated fair value of the reporting unit. We concluded that there was no impairment of goodwill during fiscal 2022, 2021, or 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of our goodwill for 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, "Other" primarily relates to a $1.3&#160;million measurement period adjustment to deferred taxes related to the 2019 acquisition of Pursuit Vascular, Inc. and foreign currency translation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2021, we acquired a small foreign infusion systems supplier, which resulted in $10.6&#160;million of goodwill.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Relates to the sale of a certain line of infusion products in China.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234,717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $139.4 million, $23.8 million and $23.2 million in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets that are not subject to amortization are reviewed annually for impairment or more often if there are indications of possible impairment. We perform our annual intangible assets impairment test in November of each year. We did not have any intangible asset impairments in 2022, 2021 or 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk. We did not have any long-lived asset impairments in 2022, 2021 or 2020.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition).  Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Available-for-sale Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment securities are considered available-for-sale and currently consist of short and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds. These securities are considered &#8220;investment grade&#8221; and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the carrying value is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive (loss) income. We did not have any investments in available-for-sale debt securities in unrealized loss positions as of December 31, 2022 or 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of the debt securities and U.S treasury securities is adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in interest (expense) income, net in the consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2023 and 2024. All short-term investment securities are callable within one year.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investment securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Non-Marketable Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, we acquired approximately a 20.0% non-marketable equity interest in a nonpublic company and entered into a three-year distribution agreement where we have the exclusive rights to market, sell and distribute the company's products in exchange for a cash payment of $3.3&#160;million. In addition, we were granted an exclusive license for all of the seller's intellectual property. At the expiration of the distribution agreement we have the right but not the obligation to acquire the remaining interest in the business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other expense, net in our consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on the consolidated balance sheets. We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. During 2022 and 2021, there were no indications that our non-marketable equity method investment was impaired. Our recorded share of the investee's loss was not material for the year ended December 31, 2022 and 2021. We did not receive any dividend distributions from this investment during 2022 and 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-marketable equity method investment consists of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in non-marketable debt securities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter 2022, we received $19.0&#160;million in proceeds from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is &#8220;more likely than not&#8221; that all or a portion of the deferred tax assets will not be realized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars.&#160;In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process.&#160;Translation adjustments are recorded as a component of accumulated other comprehensive loss, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows.&#160;Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our consolidated statements of operations in other expense, net, see below other expense, net table. Foreign currency transaction losses (gains), net were $5.8 million, $1.0 million and $7.2 million in 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Vascular Access and Vital Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Deliverables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and related software implementation services, as well as infusion consumables, IV solutions and extended warranties. Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.  Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shipping Costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Post-retirement and Post-employment Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a Section&#160;401(k)&#160;retirement plan ("plan") for employees.&#160;Our contributions to our 401(k) plan were approximately $14.6 million, $11.0 million and $10.7 million in 2022, 2021 and 2020, respectively. We also have post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our research and development costs are expensed as incurred.  In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets.  Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest (expense) income, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents interest (expense) income, net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,805)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,375)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other expense, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents other income (expense), net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,177)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposition of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other miscellaneous income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,041)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,592)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net (Loss) Income Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding plus any dilutive potential securities.&#160;Dilutive potential securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock, are not included in the treasury stock method calculation. Restricted stock units that are anti-dilutive are not included in the treasury stock method. Due to the net loss for the year ended December 31, 2022 the inclusion of any potential securities is antidilutive, accordingly, basic and diluted net loss per share is the same for this period. There were 12,354 and 12,083 anti-dilutive shares in 2021 and 2020, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of net earnings per common share (&#8220;EPS&#8221;) &#8212; basic and diluted (in thousands, except per share data):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding (basic)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,206&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,907&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common and common equivalent shares outstanding&#160;(diluted)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,781&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,591&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards </span></div>In March 2020, the Financial Accounting Standards Board ("FASB")  issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU were effective for all entities as of March 12, 2020 through December 31, 2022. ASU No. 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap references LIBOR, these swaps were amended in early 2022 to transition to an alternative reference rate (see Note 7: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that allowed us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and allowed us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging or the optional expedient under this ASU is elected. The impact of these ASU's on our contracts has not been and is not expected to be material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520759973392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
<td class="text">ACQUISITIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired 100% of the equity interests in Smiths Medical, the holding company of Smiths Group plc's global medical device business, from Smiths Group International Holdings Limited (&#8220;Smiths&#8221;). The acquisition of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smiths Medical aligns with our strategic growth plans, enabling us to broaden our product offerings to include syringe and ambulatory infusion devices, vascular access, and vital care products and to strengthen and expand our global market reach.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash consideration for the acquisition was $1.9 billion, which was financed with existing cash balances and proceeds from the credit agreement entered into on January 6, 2022 (see Note 11: Long-Term Debt). We also issued share consideration to Smiths of 2.5&#160;million shares of our common stock. The fair value of the common shares issued to Smiths was determined based on the opening market price of our common stock on the acquisition date. Smiths may be entitled to an additional $100.0&#160;million in cash consideration contingent on our common stock achieving certain price targets for certain periods after closing in accordance with the terms of the Share Sale and Purchase Agreement (the "Purchase Agreement"). In the event that (a) on or prior to the third anniversary of closing the 30-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share or (b) on or prior to the fourth anniversary of closing the 45-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share (each a "Price Target"), and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved, then Smiths will be entitled to receive the additional $100.0&#160;million in cash consideration. The fair value of the contingent consideration was determined using an option pricing model, specifically the Monte Carlo Simulation. In the analysis, the determinants of payout are simulated in a risk neutral framework over a large number of simulation paths. The fair value of the contingent consideration is then calculated as the average present value across all simulated paths. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smiths became a related party to us when we issued 2.5&#160;million shares of our common stock as partial consideration for the acquisition of Smiths Medical. Additionally, we entered in to a transition services agreement ("TSA") with certain members of Smiths Group, plc. The TSA includes certain information technology, human resource and tax support services for an initial term of twelve months with the option to extend up to 24 months. During 2022, we expensed $37.6&#160;million for services provided under the TSA. As of December 31, 2022, we have $5.1&#160;million in open payables related to the services received under the TSA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Final Price Allocation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for acquired assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration payable to Smiths</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ICU Medical, Inc. common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price per share (ICU's opening market price on the acquisition date)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ICU shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill - not tax deductible</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets included $510.0 million of customer relationships, $400.0 million of developed technology, $30.0&#160;million of internally developed software, and $5.0 million of trade mark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine years, and, for each identifiable intangible asset is estimated as follows: eight years for customer relationships, ten years for developed technology, five years for internally developed software, and six months for the trade mark.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identifiable intangible assets and other long-lived assets acquired have been valued utilizing Level 3 inputs as defined in Note 8: Fair Value Measurements. The fair value of identifiable intangible assets were generally developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and/or estimated useful lives. Certain other intangible assets were valued using a cost to replace method, estimating the labor and non-labor costs required to replace the asset under the premise that it was not part of the transaction. Property, plant and equipment was valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence which we estimate to approximate replacement cost, the work in process inventory was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Information</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smiths Medical is included in our consolidated results beginning on January 7, 2022. Total revenues and net loss attributable to Smiths Medical for the period from January 7, 2022 to December 31, 2022 were $950.7&#160;million and $(74.3)&#160;million, respectively. The net loss figure is an estimate as the results by company are less identifiable due to integration. The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Twelve months ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results presented above include the impact of the following adjustments: incremental amortization expense on intangible assets acquired of $1.9&#160;million and $24.7&#160;million for the twelve months ended December 31, 2022, and 2021, respectively, incremental interest expense, including amortization of debt discount and debt issuance costs, on the Credit Facilities of $1.2&#160;million and $73.5&#160;million for the twelve months ended December 31, 2022, and 2021, respectively and a $27.4&#160;million expense related to the increase in fair value of inventory for the twelve months ended December 31, 2021. The unaudited pro forma results include IFRS to U.S. GAAP adjustments for Smiths Medical historical results and adjustments for accounting policy alignment, which were materially similar to the Company. Any differences in accounting policies were adjusted to reflect the accounting policies of the Company in the unaudited pro forma results presented. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier and paid an initial gross cash payment of approximately $15.4&#160;million. In addition to the initial cash consideration, total consideration for the acquisition includes an additional holdback of $0.5&#160;million, to be paid two years from the completion date of the acquisition, and also a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. The contingent earn-out based on the achievement of certain revenue targets obtained for the annual period ending December 31, 2022 was forfeited at December 31, 2022 as the minimum threshold for earning the earn-out was not met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758822256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Strategic Transaction and Integration (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Related Activities Disclosure [Text Block]</a></td>
<td class="text">RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, strategic transaction and integration expenses were $71.4 million, $18.0 million and $28.4 million in 2022, 2021 and 2020, respectively.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges were $9.7 million, $(1.8) million and $7.9 million in 2022, 2021 and 2020, respectively, and are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we incurred restructuring charges primarily related to severance in connection with the January 6, 2022 acquisition of Smiths Medical, see Note 2: Acquisitions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we adjusted certain facility restructuring liabilities by $2.0&#160;million, shown in the table below under "Other adjustments," to reflect actual amounts owed which resulted in net restructuring credits of $(1.8)&#160;million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, restructuring charges were primarily related to severance and costs related to office and other facility closures.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Severance Pay and Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retention and Facility Closure Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Transaction and Integration Expenses</span></div>We incurred $61.7 million, $19.8 million and $20.5 million in strategic transaction and integration expenses in 2022, 2021 and 2020, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2022 were primarily related to transaction and integration expenses associated with our acquisition of Smiths Medical on January 6, 2022 (see Note 2: Acquisitions) which primarily included legal expenses, bank fees, employee costs and a United Kingdom stamp tax. The strategic transaction and integration expenses during 2021 were related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into a definitive agreement to acquire Smiths Medical. The integration expenses during 2020 were related to the integration of HIS and included expenses for the migration of IT systems at our Austin facility.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750990880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">REVENUE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisition of Smiths Medical our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and  renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to both our distribution and end customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts in order to determine the transaction price, we use information available at the time, including our historical experience.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Performance Obligations</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into arrangements which include multiple performance obligations, (see Note 1: Basis of Presentation and Summary of Significant Accounting Policies). </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant judgments related to these arrangements include: </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying the various performance obligations of these arrangements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue disaggregated</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product line</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Consumables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV Solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Access-Smiths Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Care-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by geography (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:60.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geography</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, the Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316,308&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively.  International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract balances</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,430)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of acquired deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,866)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During 2022, we recognized $7.5 million in revenue that was included in the opening contract balances as of December 31, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, revenue from remaining performance obligations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognition Timing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&lt;12 Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&gt; 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,627)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,239)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Other deferred revenue includes pump development programs, purchased training and extended warranty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC Topic 606, we have elected to expense these costs as incurred as the period of benefit is less than one year.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical expedients and exemptions</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the practical expedient applied to sales commissions, under ASC Topic 606, we elected to apply the practical expedient for shipping and handling costs incurred after the customer has obtained control of a good. We will continue to treat these costs as a fulfillment cost rather than as an additional promised service.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750990880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LesseeOperatingAndFinanceLeaseTextBlock', window );">Lessee, Operating and Finance Lease</a></td>
<td class="text">LEASES<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our consolidated balance sheets. Our lease liabilities are included in accrued liabilities, and other long-term liabilities on our consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have stated lease payments, which may include fixed rental increases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases are for corporate, research and development and sales and support offices, distribution facilities, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease cost (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; reduction of ROU asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on our finance leases is included in interest expense, net in our consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our consolidated statements of operations.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental cash flow information related to our leases (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:58.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired $55.2&#160;million of operating right-of-use assets as part of the Smiths Medical acquisition, see Note 2: Acquisitions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,864</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,847</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,916</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,971</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,085</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,980</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LesseeOperatingAndFinanceLeaseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Finance Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LesseeOperatingAndFinanceLeaseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758795424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Share awards (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">SHARE-BASED AWARDS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a stock incentive plan for employees and directors and an employee stock purchase plan.&#160; Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur stock compensation expense for stock options, restricted stock units ("RSU"), performance restricted stock units ("PRSU") and in years prior to 2018 stock purchased under our employee stock purchase plan ("ESPP"), which was suspended in 2017. We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options and vesting of restricted stock units. We also have indirect tax benefits upon exercise of stock options and vesting of restricted stock units related to research and development tax credits which are recorded as a reduction of income tax expense.&#160; </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes compensation costs and related tax benefits (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $43.0 million of unamortized stock compensation cost which we will recognize as an expense over a weighted-average period of approximately 0.8 years. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Plans</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2011 Stock Incentive Plan ("2011 Plan") replaced our 2003 Stock Option Plan ("2003 Plan"). Our 2011 Plan initially had 650,000 shares available for issuance, plus the remaining available shares for grant from the 2003 Plan and any shares that were forfeited, terminated or expired that would have otherwise returned to the 2003 Plan. In 2012, 2014 and 2017, our stockholders approved amendments to the 2011 plan that increased the shares available for issuance by 3,275,000, bringing the initial shares available for issuance to 3,925,000, plus the remaining 248,700 shares that remained available for grant from the 2003 Plan. As of December&#160;31, 2022, the 2011 Plan has 4,188,300 shares of common stock reserved for issuance to employees, which includes 263,300 shares that transferred from the 2003 Plan.&#160;Shares issued as options or stock appreciation rights ("SARs") are charged against the 2011 Plan's share reserve as one share for one share issued.  Shares subject to awards other than options and SARs are charged against the 2011 Plan's share reserve as 2.09 shares for 1 share issued. Options may be granted with exercise prices at no less than fair market value at date of grant. Options granted under the 2011 Plan may be "non-statutory stock options" which expire no more than ten years from date of grant or "incentive stock options" as defined in Section&#160;422 of the Internal Revenue Code of 1986, as amended.&#160; </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all options granted under 2011 Plan and 2003 Plan have been non-statutory stock options. The majority of the time-based outstanding employee option grants vested 25% after one year from the grant date and the balance vested ratably on a monthly basis over 36 months. The outstanding employee option grants are all fully vested. The majority of the outstanding options granted to non-employee directors vest one year from the grant date. The options generally expire 10 years from the grant date.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of time-based option grants is calculated using the Black-Scholes option valuation model.&#160;The expected term for the option grants was based on historical experience and expected future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock, based on the average expected exercise term. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The table below summarizes the total time-based stock options granted, total valuation and the weighted-average assumptions (dollars in thousands, except per option amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of time-based options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value of options granted (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions for stock option valuation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-price per option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity as of and for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic values for options exercisable, outstanding and vested or expected to vest at December&#160;31, 2022 are based on our closing stock price of $157.48 at December&#160;31, 2022 and are before applicable taxes.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Awards</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we granted our annual PRSUs to our executive officers and certain other non-executive employees. These PRSUs will cliff-vest on March 7, 2024  subject to the achievement of net synergy savings targets related to the Smiths Medical acquisition achieved during the performance period commencing on January 1, 2022 and ending on December 31, 2023, which when reviewed against predetermined targets could result in 0% to 200% of the awarded units that could vest. We also granted certain other one-off PRSU awards to non-executive employees with various performance requirements, whereby the performance shares will be earned if the minimum requirements are met within a specified time period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we granted PRSUs to our executive officers. For the executive officers other than the Chief Executive Officer ("CEO"), Chief Operations Officer ("COO") and the Chief Financial Officer ("CFO"), the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2024 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, commencing on January 1, 2021 and ending on December 31, 2023, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we granted PRSUs to our executive officers. For the executive officers other than the CEO, COO and the CFO, the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2023 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO, COO and CFO met their individual performance goals for 2021, therefore one-third of their 2020 PRSU shares awarded vested during 2021. Additionally, during February 2021, the Compensation Committee, modified the potential vesting percentages related to the 2020 PRSU awards for the CEO, COO and CFO, as the original potential percentages were established immediately before the onset of the COVID-19 pandemic. The Compensation Committee determined to adjust the CEO, COO and CFO's potential to earn from between 0% and 250% of the award granted, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an increased potential to earn between 50% and 300% of the award granted, subject to the same minimum threshold revenue and EPS targets to be achieved by the Company. The additional compensation expense as a result of modifying the 2020 PRSUs granted to our CEO, COO and CFO totaled $2.1&#160;million recognized over the remaining amortization period from the date of modification. In February 2023, the Compensation Committee made the determination that the executive officers other than the CEO, CFO and COO met their individual performance goals for 2022, therefore a third of their 2020 PRSU shares awarded vested during 2023. The performance period related to the 2020 CEO and COO PRSUs ended on December 31, 2022 and is subject to the Compensation Committee review and determination of shares earned based on the Cumulative revenue and EPS results achieved during the performance period.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers had met their individual performance goals for the applicable years.  For the CEO and the COO, the performance shares were to cliff-vest on March 6, 2022, subject to the achievement of a minimum Cumulative Adjusted EBITDA and continuous service through that date. If for the three year period ending on December 31, 2021 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA has a growth of over 10%, 200% of the awarded units would have vested. In 2019, we also granted PRSUs to one of our non-executive employees. These PRSUs vested at the end of a three-year period ending on March 31, 2022, based on meeting certain minimum performance goals. In February 2022, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2022, therefore, the final third of their 2019 PRSU shares awarded vested during 2022. The performance period related to the 2019 CEO and COO PRSUs ended on December 31, 2021 and in February 2022 the Compensation Committee determined that zero PRSUs were earned based on the actual Cumulative Adjusted EBITDA achieved during the performance period.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs were vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable year. For the CEO and the COO, the performance shares were to cliff-vest ending on February 15, 2021 subject to the achievement of a minimum Cumulative Adjusted EBITDA.  If for the three year period ending on December 31, 2020 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of over 10%, 200% of the awarded units would vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2021, therefore, one-third of their 2018 PRSU shares awarded vested during 2021. Also on February 15, 2021, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period the CEO and COO's 2018 PRSUs were earned at 100% of the awards granted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we granted PRSUs to our executive officers. The PRSUs were scheduled to vest, if at all, upon the achievement of a minimum Cumulative Adjusted EBITDA, subject to a three-year cliff vesting ending on December 31, 2019.  If at that date, our Cumulative Adjusted EBITDA was at least $600 million but less than $650 million, 100% of the awarded units would vest.  If our Cumulative Adjusted EBITDA was at least $650 million but less than $700 million, 200% of the awarded units would vest. If our Cumulative Adjusted EBITDA is at least $700 million, 300% of the awarded units would vest. On January 17, 2020, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period that the 2017 PRSU shares were earned by our executive officers at the 300% achievement level.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units are granted annually to our non-employee directors and vest on the first anniversary of the grant date, or the date of our annual meeting, whichever occurs first. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, we granted RSUs to certain employees that vest ratably on the anniversary of the grant over three years. We recognize forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair market value of our PRSUs and RSUs is determined by our stock price on the grant date.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our restricted stock award activity (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares earned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PRSU shares earned in 2020 were related to performance awards granted to executives in 2017, 2018 and 2019. PRSU shares earned in 2021 were related to performance awards granted to executives in 2018, 2019 and 2020. PRSU shares earned in 2022 were related to performance awards granted to executives in 2019, 2020 and 2021 and performance awards granted to a non-executive employee in 2019, 2020 and 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of our PRSU and RSU activity as of and for the year ended December&#160;31, 2022: &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant-Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in units due to performance expectations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested and expected to vest at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relates to net adjustments to 2019, 2020, 2021 and 2022 PRSUs granted to executives and certain non-executive employees. PRSUs granted assumes attainment of an increased payout rate based on performance expectations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ESPP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP under which U.S. employees may purchase up to $25,000 annually of common stock at 85% of its fair market value at the beginning or the end of a six-month offering period, whichever is lower. There are 750,000 shares of common stock reserved for issuance under the ESPP, which is subject to an annual increase of the least of 300,000 shares, two percent of the shares outstanding or such a number as determined by the Board.&#160;To date, there have been no increases.&#160;As of December&#160;31, 2022, there were no shares available for future issuance, all shares unissued under the plan expired during 2022. The ESPP is intended to constitute an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Internal Revenue Code.  We suspended our ESPP in 2017.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758794032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities Disclosure [Text Block]</a></td>
<td class="text">DERIVATIVES AND HEDGING ACTIVITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedge Accounting and Hedging Program</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purposes of our cash flow hedging programs are to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit, and to manage floating interest rate </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk associated with future interest payments on variable-rate term loans issued in January 2022. We do not issue derivatives for trading or speculative purposes.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract and forward-starting interest rate swaps are designated and qualify as cash flow hedges. Our derivative instruments are recorded at fair value on the consolidated balance sheets and are classified based on the instrument's maturity date. We record changes in the fair value of the effective portion of the gain or loss on the derivative instrument as a component of other comprehensive (loss) income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Exchange Forward Contracts</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses to minimize the effect of foreign exchange rate movements on the related cash flows. These contracts are agreements to buy or sell a quantity of a currency at a predetermined future date and at a predetermined exchange rate. Our foreign exchange forward contracts hedge exposures principally denominated in Mexican Pesos ("MXN"), Euros, Czech Koruna ("CZK"), Japanese Yen ("JPY"), U.S. Dollar ("USD"), Chinese Renminbi ("CNH"), Canadian Dollar ("CAD") and Australian Dollar ("AUD") and have varying maturities with an average term of approximately twelve months. The total notional amount of these outstanding derivative contracts as of December 31, 2022 was $206.0&#160;million, which included the notional equivalent of $61.3&#160;million in MXN, $31.7&#160;million in Euros, $13.9&#160;million in CZK, $15.3&#160;million in JPY, $11.5&#160;million in CNH, $43.2&#160;million in USD, $11.6&#160;million in CAD, $11.9&#160;million in AUD and $5.6&#160;million in other foreign currencies, with terms currently through February 2024. Certain contracts were acquired as part of the Smiths Medical acquisition. We did not have such derivative contracts as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency Par Forward Contracts</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into cross-currency par forward contracts to hedge a portion of our Mexico forecasted expenses denominated in MXN. These contracts are agreements to exchange cash flows from one currency to another at specified intervals over the contract term with all exchanges occurring at the same predetermined rate. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we hedged a portion of our Mexico forecasted expenses denominated in Pesos ("MXN") by entering into a one-year cross-currency par forward contract. The term of the one-year hedge was November 1, 2019 to November 3, 2020. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 22.11 MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2020 was approximately 436.8 million MXN. The term of this one-year contract was November 3, 2020 to December 1, 2021. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 24.26 MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2021 was approximately 413.1 million MXN. The term of this one-year contract is December 1, 2021 to December 1, 2022. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 21.60 MXN/USD.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Floating Interest Rate Risk</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, in anticipation of entering into the new senior secured credit facilities in January 2022, which included a variable-rate term loan A and a variable-rate term loan B (see Note 11: Long-term Debt), we entered into two forward-starting interest rate swaps. In February 2022, certain terms under the agreements were amended to reflect the transition from LIBOR to the Secured Overnight Financing Rate ("SOFR"), an alternative reference rate. Under the interest rate swap agreements we exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. The term loan A swap, as amended, has an initial notional amount of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0&#160;million, reducing to $150.0&#160;million evenly on a quarterly basis through its final maturity on March 30, 2027. We will pay a fixed rate of 1.32% and will receive the greater of 3-month USD SOFR or (0.15)%. The term loan B swap, as amended, has an initial notional amount of $750.0&#160;million, reducing to $46.9&#160;million evenly on a quarterly basis excluding its final maturity on March 30, 2026. We will pay a fixed rate of 1.17% and will receive the greater of 3-month USD SOFR or 0.35%. These forward-starting swaps will effectively convert the relevant portion of the floating-rate term loans to fixed rates.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivative instruments included within the consolidated balance sheets (in thousands):  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Location</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward-Starting Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effects of our derivative instruments designated as cash flow hedges on the Consolidated Statements of Operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain Reclassified From Accumulated Other Comprehensive (Loss) Income into Net (Loss) Income</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain in the Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Represents location of gain reclassified from accumulated other comprehensive (loss) income to net (loss) income as a result of a forecasted transaction being no longer probable of occurring.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on our derivative instruments designated as cash flow hedges in other comprehensive (loss) income before reclassifications to net (loss) income (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:64.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we expect an estimated $3.0 million in deferred gains on the outstanding foreign exchange forward contract and an estimated $29.3&#160;million in deferred gains on the forward-starting interest rate swaps will be reclassified from accumulated other comprehensive loss to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520757876832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1:  quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:  inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:  unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out liabilities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit (see Note 2: Acquisitions). Pursuit's former equity holders were entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out was calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. During the earn-out period, we used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilized multiple input variables to determine the value of the earn-out liability including historical volatility, a risk-free interest rate, counter party credit risk and projected future gross profit (see the simulation input table below related to Pursuit). The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate was equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that was commensurate with the term of the earn-out. The counter party credit risk was based on a synthetic credit rating of B1. As of June 30, 2021, the earn-out measurement period ended. Based on the actual sales and gross profit achieved during the measurement period, we calculated the actual earn-out amount to be $26.3&#160;million. The $26.3&#160;million earn-out calculation was finalized and accepted by Pursuit's former equity holders and was paid out in the fourth quarter of 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out payment shall not exceed $6.0&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $2.6&#160;million. The estimated fair value of the contingent earn-out is calculated using a probability-weighted cash flow model based on historical revenue streams and the likelihood that the revenue targets will be met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024.  As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical with a combination of cash consideration and share consideration issued at closing. Total consideration for the acquisition includes a potential earn-out payment of $100.0&#160;million in cash contingent on our common stock achieving certain Price Targets from the closing date to either the third or fourth anniversary of closing (see Note 2: Acquisitions) and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved. The initial estimated fair value of the earn-out was determined to be $53.5&#160;million using a Monte Carlo simulation model. The model utilized several assumptions including volatility and the risk-free interest rate. The assumed volatility is based on the average of the historical volatility of our common stock price and the implied volatility of certain at-the-money traded options. The risk-free interest rate is equal to the yield on U.S. Treasury securities at constant maturity for the period commensurate with the term of the earn-out. At each reporting date subsequent to the acquisition, we remeasure the earn-out liability and recognize any changes in its fair value in our consolidated statements of operations. If the probability of achieving the Price Targets during their respective measurement periods is significantly greater than initially anticipated, the realization of an additional liability and related expense will have a significant impact on our consolidated financial statements in the period recognized. As of December 31, 2022, the estimated fair value of the contingent earn-out is $21.0 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingent earn-out liabilities are separately stated on our consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earn-out Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent earn-out con-compete arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of Pursuit earn-out liability into Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition date fair value estimate of earn-out</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Pursuit earn-out increased during 2020 primarily due to changes in the probabilities within the valuation model.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pursuit earn-out was transferred out of Level 3 and into Level 2 in the third quarter of 2021 when the amount of the actual payment was known, and subsequently settled during the fourth quarter of 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;$53.5&#160;million relates to our acquisition of Smiths Medical and $1.6&#160;million relates to our acquisition of a small foreign infusions systems supplier in the fourth quarter of 2021 (see Note 2: Acquisitions).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes an adjustment to reduce to zero a contingent earn-out issued as part of the 2021 acquisition of a small foreign infusion systems supplier. The contingent earn-out was not earned based on our determination that the threshold target was not met.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical and Pursuit:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Smiths Medical Earn-out</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At Acquisition<br/>January 6, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Simulation Input</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-Free Rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pursuit Earn-out</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of<br/>December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At Acquisition<br/>November 2, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Simulation Input</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue/Gross Profit Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Counter Party Risk</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments, Foreign Currency Contracts and Interest Rate Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of corporate and government bonds and U.S treasury securities. The fair value of our corporate and government bonds are estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs. The fair value of our U.S. treasury securities are based on quoted market prices in active markets and are included in the Level 1 fair value hierarchy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our Level 2 forward currency contracts is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our Level 2 interest rate swaps is estimated using a pricing model that reflects the terms of the contracts, including the period to maturity, and relies on observable market inputs such as known notional value amounts and USD interest rate curves. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Pursuit earn-out liability described above, there were no transfers between levels in 2022 or 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760168208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock', window );">Prepaids, other current assets and other noncurrent assets [Text Block]</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS AND OTHER ASSETS<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid vendor expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance and property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT/GST receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets consist of the following (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pump lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spare parts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaids, other current assets and other noncurrent assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520856838528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities an Other Long-term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">ACCRUED LIABILITIES AND OTHER LONG-TERM LIABILITIES<div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-ST</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal accrual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties and returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued freight</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued audit fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-LT</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability-LT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761317328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, in connection with the acquisition of Smiths Medical, we entered into a Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, Wells Fargo Securities, LLC, Barclays Bank PLC and certain other financial institutions (the &#8220;Lenders&#8221;) for $2.2&#160;billion of senior secured credit facilities. The senior secured credit facilities include (i) a five-year Tranche A term loan of $850.0&#160;million (the "Term Loan A"), (ii) a seven-year Tranche B term loan of $850.0&#160;million (the "Term Loan B") and (iii) a five-year revolving credit facility of $500.0&#160;million (the "Revolving Credit Facility"), with separate sub-limits of $50.0&#160;million for letters of credit and swingline loans (collectively, the "Senior Secured Credit Facilities"). We used the proceeds from borrowings under the Term Loan A and the Term Loan B (collectively, the "Term Loans") to fund a portion of the cash consideration for the purchase of Smiths Medical and the related fees and expenses incurred in connection with the acquisition. We did not incur borrowings under the Revolving Credit Facility on the closing date of the acquisition. The proceeds from any future borrowings under the Revolving Credit Facility may be used for working capital and other general corporate purposes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Credit Agreement, during the period ended March 31, 2022, we incurred $37.8&#160;million in debt discount and issuance costs, which were allocated to the Term Loan A, the Term Loan B and the Revolving Credit Facility based on lender commitment amounts relative to each type of fees paid. The lender and third-party discount and issuance costs allocated to the Term Loan A and the Term Loan B were $15.8&#160;million and $13.4 million, respectively, and are reflected as a direct deduction from the face amount of the corresponding term loans on the consolidated balance sheet. These costs are being amortized to interest expense over the respective terms of the loans using the effective interest method. The issuance costs allocated to the Revolving Credit Facility were $8.6&#160;million, which are capitalized and included in prepaid expenses and other current assets and other assets on our consolidated balance sheets. These costs are being amortized to interest expense over the term of the Revolving Credit Facility using the straight-line method. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net funds received from the Term Loan A and the Term Loan B, after deducting debt issuance costs, were $834.2&#160;million and $836.6&#160;million, respectively.   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity Dates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity date for the Term Loan A and the Revolving Credit Facility is January 6, 2027 and the maturity date for the Term Loan B is January 6, 2029. Pursuant to the terms and conditions of the Credit Agreement, the maturity dates of the Term Loans and the Revolving Credit Facility may be extended upon our request, subject to the consent of the Lenders.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Terms</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Term Loans and borrowings under the Revolving Credit Facility denominated in U.S. dollars bear interest, at our option, on either: (1) the Base Rate, as defined below, plus the applicable margin, as indicated below ("Base Rate Loans") or (2) the Adjusted Term Secured Overnight Financing Rate ("Adjusted Term SOFR"), as defined below, plus the applicable margin, as indicated below ("Term SOFR Loans"). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Base Rate is defined as the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) Adjusted Term SOFR (as defined below) for a one-month period plus, in each case, 1.00%.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Term SOFR is the rate per annum equal to (a) the Term SOFR plus (b) the Term SOFR Adjustment. Term SOFR is the forward-looking term rate based on SOFR and is calculated separately for Term SOFR Loans and Base Rate Loans, as specified in the Credit Agreement. The Term SOFR Adjustment is a percentage per annum of 0.10% for Base Rate Loans and between 0.10% to 0.25% for Term SOFR Loans based on the applicable interest period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility Commitment Fee</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility has a per annum commitment fee at an initial rate of 0.25% which is applied to the available amount of the Revolving Credit Facility. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the commitment fee will be determined by reference to the leverage ratio in effect from time to time as set forth in the table below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Applicable Interest Margins</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan A and borrowings under the Revolving Credit Facility have an initial applicable margin of 0.75% per annum for Base Rate Loans and 1.75% per annum for Term SOFR Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan B has an initial applicable margin of 1.5% per annum for Base Rate Loans and 2.5% per annum for Term SOFR Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Payments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on the Term Loans are due on the last day of each calendar quarter commencing on June 30, 2022. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan A will amortize in nineteen consecutive quarterly installments in an amount equal to 2.50% of the original principal amount in each of the first two years, 5.00% in each of the third and fourth years and 7.50% in the fifth year, with a final payment of the remaining outstanding principal balance due on the maturity date.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan B matures in twenty-seven consecutive quarterly installments in an amount equal to 0.25% of the original principal amount, with a final payment of the remaining outstanding principal balance due on the maturity date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may borrow, prepay and re-borrow amounts under the Revolving Credit Facility, in accordance with the terms and conditions of the Credit Agreement, with all outstanding amounts due at maturity. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, we prepaid $16.0&#160;million in principal payments on the Term Loan A principal balance. For the year ended December 31, 2022, including the prepayment, we paid a total of $22.4&#160;million in principal payments on both Term Loans.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Payments</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest payments on Base Rate Loans are payable quarterly in arrears on the last business day of each calendar quarter and the applicable maturity date. Interest periods on Term SOFR Loans will be determined, at our option, as either one, three or six months and will be payable on the last day of each interest period and the applicable maturity date. In the case of any interest periods of more than three months' duration, the interest payment will be payable on each day prior to the last day of such interest period that occurs at three-month intervals.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commitment fee on the Revolving Credit Facility is payable quarterly in arrears on the third business day following the last day of each calendar quarter and at the maturity date. The commitment fee is included in interest expense in our consolidated statements of operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantors and Collateral</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Credit Agreement are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Covenants</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains affirmative and negative covenants, including certain financial covenants. The negative covenants include restrictions regarding the incurrence of liens and indebtedness, certain merger and acquisition transactions, asset sales and other dispositions, other investments, dividends, share purchases and payments affecting subsidiaries, changes in nature of business, fiscal year or organizational documents, prepayments and redemptions of subordinated and other junior debt, transactions with affiliates, and other matters.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenants include the Senior Secured Leverage Ratio and the Interest Coverage Ratio, both defined below, and pertain to the Term Loan A and the Revolving Credit Facility.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Leverage Ratio is defined, at any measurement date, as the ratio of: (a) all Funded Debt, as defined in the Credit Agreement, that is secured by a lien on any asset or property minus the lesser of (i) all unrestricted cash and cash </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents and (ii) $500.0&#160;million, to (b) Consolidated EBITDA, as defined in the Credit Agreement, for the most recently completed four fiscal quarters, calculated on a pro forma basis. The maximum Senior Secured Leverage Ratio is 4.50 to 1.00 until June 30, 2024. Thereafter, the maximum Senior Secured Leverage Ratio is 4.00 to 1.00, with limited permitted exception.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interest Coverage ratio is defined, at any measurement date, as the ratio of Consolidated EBITDA, as defined in the Credit Agreement, to Consolidated Interest Expense, as defined in the Credit Agreement, paid or payable in cash, for the most recently completed four fiscal quarters. The minimum Interest Coverage ratio is 3.00 to 1.00.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were in compliance with all financial covenants as of December 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary events of default, including, among others: non-payments of principal and interest; breach of representations and warranties; covenant defaults; cross-defaults and cross-acceleration to certain other material indebtedness; the existence of bankruptcy or insolvency proceedings; certain events under ERISA; material judgments; and a change of control. If an event of default occurs and is not cured within any applicable grace period or is not waived, the administrative agent and the Lenders are entitled to take various actions, including, without limitation, the acceleration of all amounts due and the termination of commitments under the Senior Secured Credit Facilities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On November 8, 2017, we entered into a five-year senior secured revolving credit facility with various lenders for $150.0&#160;million, with Wells Fargo Bank, National Association as the administrative agent, swingline lender and issuing lender (the "Credit Facility"). The Credit Facility, which was set to mature on November 8, 2022, was terminated in connection with entering into the Credit Agreement on January 6, 2022. There were no borrowings outstanding under the Credit Facility at that date or at December 31, 2021. The remaining unamortized deferred debt issuance costs related to the Credit Facility were not material and were expensed in connection with its termination. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our long-term debt consist of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of <br/>December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B &#8212; principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of $12.6&#160;million and $11.7&#160;million relating to the Term Loan A and the Term Loan B, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total interest expense related to our long-term debt (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee &#8212; Revolving Credit Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt-related  interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760249168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes:<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,646)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,409)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,275)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for tax contingencies for potential tax assessments, and in 2022 we recognized a $2.0 million net increase, most of which related to various federal, state and foreign tax reserves.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at the expected statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,026)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal effect</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits in 2022, 2021 and 2020 consist principally of research and developmental tax credits.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred income tax assets (liabilities) are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired future tax deductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 163(j)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks, discounts, customer concessions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 481(a) adjustment - change in accounting method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (liability) asset, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,552)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Holidays and Carryforwards</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss ("NOL") carryforwards consist of: (a) federal NOL carryforwards of $1.9 million which will expire at various dates from 2023 to indefinite carryforward periods, (b) state NOL carryforwards of $4.3 million which will expire at various dates from 2026 to indefinite carryforward periods and (c) foreign NOL carryforwards of  $46.3 million which will expire at various dates from 2023 to indefinite carryforward periods. We believe that it is more likely than not that the benefit </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from certain foreign NOL carryforwards will not be realized. In recognition of this risk, we have provided a valuation allowance of $11.5&#160;million on the $12.7&#160;million DTAs related to these foreign NOL carryforwards. Under Section&#160;382 of the Internal Revenue Code, certain ownership changes limit the utilization of the NOL carryforwards, and the amount of federal NOL carryforwards recorded is the net federal benefit available.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other carryforwards include state research and development (&#8220;R&amp;D&#8221;) tax credit carryforwards of $18.5 million, which have an indefinite carryforward period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations in Costa Rica operate under various tax holiday and tax incentive programs due to expire in whole or in part in 2029. Certain of the holidays may be extended if specific conditions are met. The net impact of these tax holiday and tax incentives was an increase to our net earnings by $8.1 million or $0.34 per diluted share in 2022 and by $9.8 million or $0.45 per diluted share in 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, and related tax effects, are an element of &#8220;other comprehensive income&#8221; and are not included in net income other than the revaluation of the associated deferred tax asset due to the Tax Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have estimated $209.2 million of undistributed foreign earnings and profits. Such earnings were previously subject to U.S. tax as a result of the Tax Act and much of any future remittances would generally be subject to no U.S. tax as a result of dividends received deductions and/or foreign tax credit relief. We intend to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we incur significant additional costs upon repatriation of such amounts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various states and foreign jurisdictions. Our U.S. federal income tax returns for tax years 2019 and forward are subject to examination by the Internal Revenue Service. Our principal state income tax returns for tax years 2012 and forward are subject to examination by the state tax authorities. The total gross amount of unrecognized tax benefits as of December&#160;31, 2022 was $54.1 million which, if recognized, would impact the effective tax rate.  We believe that adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax examinations cannot be predicted with certainty. As of December 31, 2022, it is reasonably possible that the expiration of the U.S. federal statute of limitations will cause the gross amount of unrecognized tax benefits to decrease by $7.8 million. It is not possible to estimate any other amount of change, if any, in the unrecognized tax benefits that is reasonably possible within the next twelve months. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We have accrued for penalties and interest of $2.3&#160;million and $2.2&#160;million, respectively as of December 31, 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to settlements with tax authorities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760249168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasLongLivedAssetsAbstract', window );"><strong>Geographic Areas, Long-Lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock', window );">Information by Geographic Area and Customer Concentration [Text Block]</a></td>
<td class="text">GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. In 2022, we had worldwide net sales to Medline of 15% of consolidated net sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic Information</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other LATAM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Foreign </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information by Geographic Area and Customer Concentration [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasLongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasLongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761291392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">STOCKHOLDERS' EQUITY<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2019, our Board of Directors approved a common stock purchase plan to purchase up to $100.0 million of our common stock. This plan has no expiration date. We have $100.0 million remaining on this purchase plan. We did not purchase any of our common stock under our common stock purchase plan in 2022, 2021 or 2020. We are limited on share purchases in accordance with the terms and conditions of our Senior Secured Credit Facilities (see Note 11: Long-Term Obligations).&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we withheld 47,664 shares of our common stock from employee vested restricted stock units in consideration for $10.9 million in payments for the employees' share award income tax withholding obligations. We had 1,633 shares remaining in treasury at December 31, 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we withheld 40,350 shares of our common stock from employee vested restricted stock units in consideration for $8.3 million in payments for the employees' share award income tax withholding obligations. We had 119 shares remaining in treasury at December 31, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we withheld 67,041 shares of our common stock from employee vested restricted stock units in consideration for $12.9 million in payments for the employees' share award income tax withholding obligations. We had 209 shares remaining in treasury at December 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use treasury stock to issue shares for stock option exercises and restricted stock grants.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive (Loss) Income ("AOCI")</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI, net of tax, were as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,664)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,021)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,928)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,709)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,973)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760468864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business.&#160; Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off Balance Sheet Arrangements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products.&#160;There is no maximum limit on the indemnification that may be required under these agreements.&#160;We have never incurred, nor do we expect to incur, any liability for indemnification.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2019, we acquired Pursuit (see Note 2: Acquisitions). Total consideration for the acquisition included a potential contractual earn-out of up to $50.0 million to be paid to former Pursuit equity holders, calculated based upon the achievement of certain performance targets during the earn-out period. As of June 30, 2021, the earn-out measurement period had ended and based on the actual sales and gross profit achieved during the measurement period we calculated the actual earn-out to be $26.3&#160;million. In October 2021, the $26.3&#160;million earn-out was finalized and paid to the former Pursuit equity holders (see Note 8: Fair Value Measurements).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out shall not exceed $6.0&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $2.6&#160;million (see Note 8: Fair Value Measurements).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2022, we acquired Smiths Medical. Total consideration for the acquisition includes a potential earn-out payment of $100.0&#160;million in cash contingent on our common stock achieving a certain volume-weighted average price from the closing date to either the third or fourth anniversary of closing. As of December 31, 2022, the estimated fair value of the contingent earn-out is $21.0&#160;million (see Note 8: Fair Value Measurements).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to being acquired, during 2021, Smiths Medical received a Warning Letter from the FDA following an inspection of Smiths Medical&#8217;s Oakdale, Minnesota Facility. The Warning Letter cited, among other things, failures to comply with FDA's medical device reporting requirements and failures to comply with applicable portions of the Quality System Regulation. A provision for the estimated costs related to the field service corrective action was recorded on the opening acquired balance sheet of Smiths Medical. The initial estimate recorded was based on a probability-weighted estimate of the costs required to settle the obligation. The actual costs to be incurred are dependent upon the scope of the work necessary to achieve regulatory clearance and could differ from the original estimate. The estimated field service corrective action recorded at December 31, 2022 is $49.8&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have non-cancelable operating lease agreements where we are contractually obligated to pay certain lease payment amounts (see Note 5: Leases).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760249168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Arrangements (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">COLLABORATIVE AND OTHER ARRANGEMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs") whereby (i) Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On January 1, 2021, we amended our MSA with Pfizer, whereby we manufacture and supply certain agreed upon products to Pfizer. The amendments included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes to the terms of the MSA included (i) amendments to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products. On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum (the "Product Addendum") to our MSA agreement, whereby Pfizer manufactures and supplies to us certain agreed upon products. The Product Addendum includes the supply of additional product to us subject to certain time and pricing terms and conditions. The Product Addendum included a minimum purchase obligation of $29.6&#160;million. The minimum purchase obligation under the addendum was satisfied during 2022. The Product Addendum expired on November 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761123200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSOn January 19, 2023, we entered into a revolving $150&#160;million uncommitted receivables purchase agreement with Bank of The West ("BOW") which provides for a less expensive form of capital. The discount rate applied to the sold receivables equals, a rate per annum equal to the sum of (i) an applicable margin of 1.75%, plus (ii) Term SOFR for a period equal to the discount period which is calculated with respect to the payment terms of the specific receivable. The accounts receivable to be sold have payment terms ranging between 30 and 60 days, and are related to customer accounts with good credit history. The transfer of the purchased accounts receivable under the agreement is intended to be an absolute and irrevocable transfer constituting a true sale as the transferred receivables have been isolated beyond the reach of the Company and our creditors, even in bankruptcy or other receivership. We will not retain effective control over the sold receivables and BOW will have the right upon purchase to pledge and/or exchange the transferred assets without restrictions. The Company will act as collection agent for BOW, collection services will be undertaken by our accounts receivable personnel in their normal course of business and collected funds will be remitted to BOW. The discount rate has been negotiated net of consideration for the collection services, the cost of collection is expected to be immaterial to the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760289632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:43.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts&#160;in&#160;thousands)<br/>Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning&#160;of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged&#160;to<br/>Costs&#160;and<br/>Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged&#160;to<br/>Other&#160;Accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Write-off/<br/>Disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at&#160;End<br/>of&#160;Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty and return reserve - inventory/accrued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755117936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICU Medical,&#160;Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our wide-ranging product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We also manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients. Our recent acquisition of Smiths Medical broadened our product portfolio to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices, silicone and PVC tracheotomy tubes. ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell the majority of our products globally through our direct sales force and through independent distributors. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All subsidiaries are wholly owned and are included in the consolidated financial statements.&#160;All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.</span></div>The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy</a></td>
<td class="text">ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</a></td>
<td class="text">Accounts receivable are stated at net realizable value.&#160;An allowance is provided for estimated collection losses based on an assessment of various factors.&#160; We consider prior payment trends, the age of the accounts receivable balances, the financial status of our customers and other factors to estimate the cash which ultimately will be received.&#160; Such amounts cannot be known with certainty at the financial statement date.&#160; We regularly review individual past due balances for collectability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text">Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment and molds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred.&#160;The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are </span></div>removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $95.8 million, $65.9 million and $62.4 million in 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We test goodwill for impairment on an annual basis in the month of November, or more frequently if an event occurs or circumstances change that would indicate that impairment may exist.&#160;In 2022, we bypassed a qualitative assessment and performed a quantitative assessment to determine whether an impairment exists. We determine the fair value of our reporting unit using the income approach and market approach to valuation, as well as other generally accepted valuation methodologies. The income approach utilizes a discounted cash flow analysis using management's assumptions. The market approach compares our reporting unit to similar companies with the assumption that companies operating in the same industry will share similar characteristics and that company values will correlate to those characteristics. If the carrying amount of the reporting unit exceeds the reporting unit&#8217;s fair value, we recognize an impairment loss equal to the difference between the carrying amount and the estimated fair value of the reporting unit. We concluded that there was no impairment of goodwill during fiscal 2022, 2021, or 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk. We did not have any long-lived asset impairments in 2022, 2021 or 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition).  Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Available-for-sale Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment securities are considered available-for-sale and currently consist of short and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds. These securities are considered &#8220;investment grade&#8221; and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the carrying value is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive (loss) income. We did not have any investments in available-for-sale debt securities in unrealized loss positions as of December 31, 2022 or 2021.</span></div>The amortized cost of the debt securities and U.S treasury securities is adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in interest (expense) income, net in the consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2023 and 2024. All short-term investment securities are callable within one year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other expense, net in our consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on the consolidated balance sheets. We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is &#8220;more likely than not&#8221; that all or a portion of the deferred tax assets will not be realized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars.&#160;In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process.&#160;Translation adjustments are recorded as a component of accumulated other comprehensive loss, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows.&#160;Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our consolidated statements of operations in other expense, net, see below other expense, net table. Foreign currency transaction losses (gains), net were $5.8 million, $1.0 million and $7.2 million in 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Vascular Access and Vital Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with Multiple Deliverables</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses </span></div>and related software implementation services, as well as infusion consumables, IV solutions and extended warranties. Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.  Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension and Other Postretirement Plans, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Post-retirement and Post-employment Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a Section&#160;401(k)&#160;retirement plan ("plan") for employees.&#160;Our contributions to our 401(k) plan were approximately $14.6 million, $11.0 million and $10.7 million in 2022, 2021 and 2020, respectively. We also have post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our research and development costs are expensed as incurred.  In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets.  Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net (Loss) Income Per Share</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding plus any dilutive potential securities.&#160;Dilutive potential securities </span></div>include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock, are not included in the treasury stock method calculation. Restricted stock units that are anti-dilutive are not included in the treasury stock method.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755125744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,235&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consists of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162,557&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,104&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,365&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment and molds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments placed with customers<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of our goodwill for 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, "Other" primarily relates to a $1.3&#160;million measurement period adjustment to deferred taxes related to the 2019 acquisition of Pursuit Vascular, Inc. and foreign currency translation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2021, we acquired a small foreign infusion systems supplier, which resulted in $10.6&#160;million of goodwill.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Relates to the sale of a certain line of infusion products in China.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234,717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Amortization Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contractual customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">As of December 31, 2022, estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investment securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-marketable equity method investment consists of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest (expense) income, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents interest (expense) income, net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,805)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,375)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other expense, net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents other income (expense), net (in thousands):&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,177)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposition of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other miscellaneous income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,136)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,041)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,592)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of net earnings per common share (&#8220;EPS&#8221;) &#8212; basic and diluted (in thousands, except per share data):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding (basic)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,206&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,907&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common and common equivalent shares outstanding&#160;(diluted)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,781&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,591&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8212; diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761171264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Final Price Allocation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for acquired assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration payable to Smiths</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ICU Medical, Inc. common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price per share (ICU's opening market price on the acquisition date)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ICU shares issued to Smiths</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price Allocation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill - not tax deductible</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase Consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets included $510.0 million of customer relationships, $400.0 million of developed technology, $30.0&#160;million of internally developed software, and $5.0 million of trade mark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine years, and, for each identifiable intangible asset is estimated as follows: eight years for customer relationships, ten years for developed technology, five years for internally developed software, and six months for the trade mark.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text">The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Twelve months ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (Loss) Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761239040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Severance Pay and Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retention and Facility Closure Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_______________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758948112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product line</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Consumables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV Solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infusion Systems-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular Access-Smiths Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Care-Smiths Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our revenues disaggregated by geography (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:60.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geography</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, the Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316,308&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively.  International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,430)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of acquired deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue deferred due to implementation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,866)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</a></td>
<td class="text">As of December 31, 2022, revenue from remaining performance obligations is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognition Timing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&lt;12 Months</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&gt; 12 Months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred revenue*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,627)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,239)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760476112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of our lease cost (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.959%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost &#8212; reduction of ROU asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Interest expense on our finance leases is included in interest expense, net in our consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_SupplementalCashFlowInformationLeasesTableTextBlock', window );">Supplemental Cash Flow Information Leases</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental cash flow information related to our leases (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:58.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired $55.2&#160;million of operating right-of-use assets as part of the Smiths Medical acquisition, see Note 2: Acquisitions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock', window );">Supplemental Balance Sheet Information Leases</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,864</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,847</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,916</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,971</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,085</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,980</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Lease Payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_SupplementalBalanceSheetInformationLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_SupplementalBalanceSheetInformationLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_SupplementalCashFlowInformationLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_SupplementalCashFlowInformationLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751058720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock', window );">Schedule of stock compensation and related tax benefits [Table Text Block]</a></td>
<td class="text">The table below summarizes compensation costs and related tax benefits (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">The table below summarizes the total time-based stock options granted, total valuation and the weighted-average assumptions (dollars in thousands, except per option amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of time-based options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value of options granted (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions for stock option valuation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-price per option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value per option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity as of and for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ExercisedOptionsDataTableTextBlock', window );">Exercised Options Data [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">The table below summarizes our restricted stock award activity (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year&#160;ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRSU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares earned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant-date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a summary of our PRSU and RSU activity as of and for the year ended December&#160;31, 2022: &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant-Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in units due to performance expectations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested and expected to vest at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ExercisedOptionsDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercised Options Data [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ExercisedOptionsDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of stock compensation and related tax benefits [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761184304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivative instruments included within the consolidated balance sheets (in thousands):  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Location</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Cash Flow Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward-Starting Interest Rate Swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table presents the effects of our derivative instruments designated as cash flow hedges on the Consolidated Statements of Operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain Reclassified From Accumulated Other Comprehensive (Loss) Income into Net (Loss) Income</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain in the Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on our derivative instruments designated as cash flow hedges in other comprehensive (loss) income before reclassifications to net (loss) income (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:64.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Other Comprehensive (Loss) Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivatives designated as cash flow hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752677392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earn-out Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent earn-out con-compete arrangement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of Pursuit earn-out liability into Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition date fair value estimate of earn-out</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earn-out (included in income from operations as a separate line item)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent earn-out liability, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):&#160;<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;carrying<br/>value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical<br/>assets&#160;(level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs&#160;(level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs&#160;(level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forwards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out liability - LT</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Pursuit Vascular, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pursuit Earn-out</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of<br/>December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At Acquisition<br/>November 2, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Simulation Input</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue/Gross Profit Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Counter Party Risk</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758811520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaids and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): &#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses and receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid vendor expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance and property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT/GST receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets consist of the following (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pump lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spare parts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text">Other assets consist of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pump lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spare parts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758957072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities an Other Long-term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-ST</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal accrual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranties and returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued freight</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring accrual</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued audit fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability-LT</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liability-LT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field service corrective action</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  &#160;&#160;&#160;&#160;Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760498288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestMarginandCommitmentFeeTableTextBlock', window );">Interest Margin and Commitment Fee [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to 2.00 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginOnLoanTypeTableTextBlock', window );">Applicable Margin on Loan Type</a></td>
<td class="text">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Term SOFR Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Margin for Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 2.75 to 1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our long-term debt consist of the following (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of <br/>December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B &#8212; principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility &#8212; principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less unamortized debt issuance costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprised of $12.6&#160;million and $11.7&#160;million relating to the Term Loan A and the Term Loan B, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text">As of December 31 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestExpenseOnLongTermDebtTableTextBlock', window );">Interest expense on long-term debt</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total interest expense related to our long-term debt (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee &#8212; Revolving Credit Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt-related  interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginOnLoanTypeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin on Loan Type</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginOnLoanTypeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestExpenseOnLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense on long-term debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestExpenseOnLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestMarginandCommitmentFeeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Margin and Commitment Fee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestMarginandCommitmentFeeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750842560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income tax disclosure (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of the following (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,646)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,409)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,275)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at the expected statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,026)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal effect</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax differential</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,721)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred income tax assets (liabilities) are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired future tax deductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 163(j)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks, discounts, customer concessions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 481(a) adjustment - change in accounting method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-31.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (liability) asset, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,552)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease related to settlements with tax authorities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753303280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Significant Customers Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasLongLivedAssetsAbstract', window );"><strong>Geographic Areas, Long-Lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other LATAM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Foreign </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasLongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasLongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761087056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</a></td>
<td class="text">The components of AOCI, net of tax, were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:39.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,664)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,021)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,928)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,709)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,973)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750518128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755166704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw Materials</a></td>
<td class="nump">$ 286,964<span></span>
</td>
<td class="nump">$ 135,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in Process</a></td>
<td class="nump">73,795<span></span>
</td>
<td class="nump">36,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished Goods</a></td>
<td class="nump">335,250<span></span>
</td>
<td class="nump">118,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 696,009<span></span>
</td>
<td class="nump">$ 290,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753403024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Property and Equipment #1 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">$ 1,162,557<span></span>
</td>
<td class="nump">$ 905,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">526,444<span></span>
</td>
<td class="nump">436,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">636,113<span></span>
</td>
<td class="nump">468,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">414,811<span></span>
</td>
<td class="nump">321,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember', window );">Land, Buildings and Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">274,063<span></span>
</td>
<td class="nump">243,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_MoldsMember', window );">Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">77,203<span></span>
</td>
<td class="nump">60,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">115,214<span></span>
</td>
<td class="nump">102,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">29,876<span></span>
</td>
<td class="nump">7,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember', window );">Instruments Placed with Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">98,481<span></span>
</td>
<td class="nump">97,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">$ 152,909<span></span>
</td>
<td class="nump">$ 72,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_MoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_MoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752729088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_FurniturefixturesandmoldsMember', window );">Furniture, fixtures and molds [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_FurniturefixturesandmoldsMember', window );">Furniture, fixtures and molds [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember', window );">Instruments Placed with Customers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember', window );">Instruments Placed with Customers [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_FurniturefixturesandmoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_FurniturefixturesandmoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=icui_InstrumentsPlacedwithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761057312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Property and Equipment #3 (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 95.8<span></span>
</td>
<td class="nump">$ 65.9<span></span>
</td>
<td class="nump">$ 62.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755182704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">GOODWILL</a></td>
<td class="nump">$ 43,439<span></span>
</td>
<td class="nump">$ 33,001<span></span>
</td>
<td class="nump">$ 31,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">1,469,880<span></span>
</td>
<td class="nump">10,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="num">(7,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Goodwill, Other Increase (Decrease)</a></td>
<td class="num">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Goodwill, Foreign Currency Translation Gain (Loss)</a></td>
<td class="num">(56,283)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">GOODWILL</a></td>
<td class="nump">1,449,258<span></span>
</td>
<td class="nump">43,439<span></span>
</td>
<td class="nump">$ 33,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember', window );">Pursuit Vascular LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Acquired During Period</a></td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753162192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Intangible Assets #1 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 1,202,911<span></span>
</td>
<td class="nump">$ 275,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">251,951<span></span>
</td>
<td class="nump">112,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">950,960<span></span>
</td>
<td class="nump">162,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">1,234,717<span></span>
</td>
<td class="nump">301,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">INTANGIBLE ASSETS, net</a></td>
<td class="nump">$ 982,766<span></span>
</td>
<td class="nump">$ 188,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 29,998<span></span>
</td>
<td class="nump">$ 27,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">18,610<span></span>
</td>
<td class="nump">16,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 11,388<span></span>
</td>
<td class="nump">$ 10,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember', window );">Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 10,026<span></span>
</td>
<td class="nump">$ 10,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">6,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 3,583<span></span>
</td>
<td class="nump">$ 4,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember', window );">Customer-Related Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 546,935<span></span>
</td>
<td class="nump">$ 57,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">101,556<span></span>
</td>
<td class="nump">33,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 445,379<span></span>
</td>
<td class="nump">$ 24,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5,425<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,425<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 18,251<span></span>
</td>
<td class="nump">$ 18,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="nump">4,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 12,292<span></span>
</td>
<td class="nump">$ 13,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 583,176<span></span>
</td>
<td class="nump">$ 152,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">108,708<span></span>
</td>
<td class="nump">49,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 474,468<span></span>
</td>
<td class="nump">$ 103,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Amortization Life in Years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">3,850<span></span>
</td>
<td class="nump">6,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 31,806<span></span>
</td>
<td class="nump">$ 25,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761349616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Intangible Assets #2 (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 139.4<span></span>
</td>
<td class="nump">$ 23.8<span></span>
</td>
<td class="nump">$ 23.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750546400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</a></td>
<td class="nump">$ 130,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">130,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">123,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">122,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="nump">114,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</a></td>
<td class="nump">328,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 950,960<span></span>
</td>
<td class="nump">$ 162,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761185008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Other Investments(Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from Sale and Maturity of Other Investments</a></td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753142576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investment Securities, Amortized Cost</a></td>
<td class="nump">$ 4,740<span></span>
</td>
<td class="nump">$ 19,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investment Securities</a></td>
<td class="nump">4,740<span></span>
</td>
<td class="nump">19,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751120688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Investments-Equity Method (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 3,178<span></span>
</td>
<td class="nump">$ 3,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=icui_NonpublicCompanyMember', window );">nonpublic company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=icui_NonpublicCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=icui_NonpublicCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761110688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Foreign Currency (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign Currency Transaction Gain (Loss), Realized</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761176144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</a></td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753305376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestExpenseIncomeNetLineItems', window );"><strong>Interest (expense) income, net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="num">$ (70,805)<span></span>
</td>
<td class="num">$ (858)<span></span>
</td>
<td class="num">$ (1,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="num">$ (66,375)<span></span>
</td>
<td class="nump">$ 1,982<span></span>
</td>
<td class="nump">$ 1,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestExpenseIncomeNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest (expense) income, net [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestExpenseIncomeNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751118672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Other (expense) income, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_OtherExpenseIncomeNetLineItems', window );"><strong>Other (expense) income, net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign Currency Transaction Loss, before Tax</a></td>
<td class="num">$ (5,780)<span></span>
</td>
<td class="num">$ (1,017)<span></span>
</td>
<td class="num">$ (7,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (Loss) on Disposition of Other Assets</a></td>
<td class="num">(2,554)<span></span>
</td>
<td class="num">(1,651)<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_MiscellaneousIncomeNet', window );">miscellaneous income, net</a></td>
<td class="nump">3,198<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Income Disclosure, Nonoperating</a></td>
<td class="num">$ (5,136)<span></span>
</td>
<td class="num">$ (2,041)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_MiscellaneousIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>miscellaneous income, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_MiscellaneousIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_OtherExpenseIncomeNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other (expense) income, net [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_OtherExpenseIncomeNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751016736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET INCOME PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income</a></td>
<td class="num">$ (74,286)<span></span>
</td>
<td class="nump">$ 103,135<span></span>
</td>
<td class="nump">$ 86,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding (basic)</a></td>
<td class="nump">23,868,000<span></span>
</td>
<td class="nump">21,206,000<span></span>
</td>
<td class="nump">20,907,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average common and common equivalent shares outstandding (diluted)</a></td>
<td class="nump">23,868,000<span></span>
</td>
<td class="nump">21,781,000<span></span>
</td>
<td class="nump">21,591,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.11)<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,354<span></span>
</td>
<td class="nump">12,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520759049120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Accounting Standards Update and Change in Accounting Principle</a></td>
<td class="text">Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board ("FASB")  issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU were effective for all entities as of March 12, 2020 through December 31, 2022. ASU No. 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap references LIBOR, these swaps were amended in early 2022 to transition to an alternative reference rate (see Note 7: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that allowed us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and allowed us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging or the optional expedient under this ASU is elected. The impact of these ASU's on our contracts has not been and is not expected to be material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750875856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Text (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">$ 25,572,000<span></span>
</td>
<td class="nump">$ 2,589,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="num">$ (5,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember', window );">Smiths Medical 2020 Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 1,922,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_MinimumStockPriceTargetForEarnOutPayment', window );">Minimum Stock Price Target for Earn-out Payment</a></td>
<td class="nump">$ 300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RequiredShareHoldingOfStockIssuedAtAcquisition', window );">Required Share Holding Of Stock Issued At Acquisition</a></td>
<td class="nump">0.500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 945,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationConsiderationTransferredCash', window );">Business Combination, Consideration Transferred, Cash</a></td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_BusinessCombinationConsiderationTransferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_BusinessCombinationConsiderationTransferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_MinimumStockPriceTargetForEarnOutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Stock Price Target for Earn-out Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_MinimumStockPriceTargetForEarnOutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_RequiredShareHoldingOfStockIssuedAtAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required Share Holding Of Stock Issued At Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_RequiredShareHoldingOfStockIssuedAtAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753207088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Smiths Medical 2020 Limited Table (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">$ 55,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed', window );">business combination, recognized identifiable asset acquired and liability assumed,</a></td>
<td class="nump">55,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">GOODWILL</a></td>
<td class="nump">1,449,258<span></span>
</td>
<td class="nump">$ 43,439<span></span>
</td>
<td class="nump">$ 33,001<span></span>
</td>
<td class="nump">$ 31,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember', window );">Smiths Medical 2020 Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">1,922,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">$ 53,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business Acquisition, Share Price</a></td>
<td class="nump">$ 230.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</a></td>
<td class="nump">$ 575,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">2,552,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</a></td>
<td class="nump">78,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquiredReceivablesFairValue', window );">Business Combination, Acquired Receivable, Fair Value</a></td>
<td class="nump">106,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</a></td>
<td class="nump">228,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</a></td>
<td class="nump">53,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="nump">206,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed', window );">business combination, recognized identifiable asset acquired and liability assumed,</a></td>
<td class="nump">55,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="num">(105,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</a></td>
<td class="num">(173,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable', window );">Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable</a></td>
<td class="num">(40,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</a></td>
<td class="num">(85,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</a></td>
<td class="num">(187,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="nump">1,082,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">GOODWILL</a></td>
<td class="nump">$ 1,469,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>business combination, recognized identifiable asset acquired and liability assumed,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquiredReceivablesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of acquired receivable from business combination, excluding certain loans and debt securities acquired in transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquiredReceivablesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751047392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Smiths Medical 2020 Limited Intangible (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember', window );">Smiths Medical 2020 Limited</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 945,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 510,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752544624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Foreign Infusion Systems Supplier (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationConsiderationCashHoldback', window );">business combination consideration - cash holdback</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_BusinessCombinationConsiderationCashHoldback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>business combination consideration - cash holdback</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_BusinessCombinationConsiderationCashHoldback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Contingentconsiderationgross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>contingent consideration gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Contingentconsiderationgross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LongTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LongTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ShortTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ShortTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753408384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Smiths Medical Pro Forma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems', window );"><strong>Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,279,997<span></span>
</td>
<td class="nump">$ 1,316,308<span></span>
</td>
<td class="nump">$ 1,271,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business Acquisition, Pro Forma Revenue</a></td>
<td class="nump">2,300,371<span></span>
</td>
<td class="nump">2,509,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business Acquisition, Pro Forma Net Income (Loss)</a></td>
<td class="num">(70,286)<span></span>
</td>
<td class="nump">37,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ProFormaAdjustmentAmortization', window );">Pro Forma Adjustment - Amortization</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ProFormaAdjustmentInventory', window );">Pro Forma Adjustment - Inventory</a></td>
<td class="nump">27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ProFormaAdjustmentFinanceCosts', window );">Pro Forma Adjustment - Finance Costs</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 73,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember', window );">Smiths Medical 2020 Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems', window );"><strong>Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">950,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">$ (74,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ProFormaAdjustmentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pro Forma Adjustment - Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ProFormaAdjustmentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ProFormaAdjustmentFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pro Forma Adjustment - Finance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ProFormaAdjustmentFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ProFormaAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pro Forma Adjustment - Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ProFormaAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedical2020LimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520754334240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Strategic Transaction and Integration (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Restructuringandstrategictransactionexpense', window );">Restructuring, strategic transaction and integration expenses</a></td>
<td class="nump">$ 71,421<span></span>
</td>
<td class="nump">$ 18,037<span></span>
</td>
<td class="nump">$ 28,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RestructuringAdjustmentsSeveranceAndFacility', window );">Restructuring Adjustments - Severance and Facility</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_RestructuringAdjustmentsSeveranceAndFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Adjustments - Severance and Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_RestructuringAdjustmentsSeveranceAndFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Restructuringandstrategictransactionexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and strategic transaction expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Restructuringandstrategictransactionexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753091184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Strategic Transaction and Integration (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">$ 5,923,000<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="nump">$ 3,421,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="nump">9,725,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(11,351,000)<span></span>
</td>
<td class="num">(969,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</a></td>
<td class="nump">613,000<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,957,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities</a></td>
<td class="nump">7,536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">4,416,000<span></span>
</td>
<td class="nump">499,000<span></span>
</td>
<td class="nump">1,858,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="nump">9,667,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(11,083,000)<span></span>
</td>
<td class="num">(969,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(528,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities</a></td>
<td class="nump">5,796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">1,507,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">$ 1,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(268,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</a></td>
<td class="nump">188,000<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Restructuring Reserve, Accrual Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (1,429,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities</a></td>
<td class="nump">$ 1,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents liabilities associated with restructuring or exit activities of the acquiree, existing at the acquisition date (present liabilities of the acquiree).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761092896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_StrategicTransactionandIntegration', window );">Strategic Transaction and Integration</a></td>
<td class="nump">$ 61.7<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_StrategicTransactionandIntegration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic Transaction and Integration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_StrategicTransactionandIntegration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753272160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation of Revenue - Product Line (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,279,997<span></span>
</td>
<td class="nump">$ 1,316,308<span></span>
</td>
<td class="nump">$ 1,271,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_InfusionConsumablesMember', window );">Infusion Consumables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 566,617<span></span>
</td>
<td class="nump">$ 555,189<span></span>
</td>
<td class="nump">$ 473,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_InfusionSystemsMember', window );">Infusion Systems [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 351,080<span></span>
</td>
<td class="nump">$ 352,321<span></span>
</td>
<td class="nump">$ 359,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_IVSolutionsMember', window );">IV Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 363,472<span></span>
</td>
<td class="nump">$ 359,477<span></span>
</td>
<td class="nump">$ 388,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_CriticalCareMember', window );">Critical Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 47,330<span></span>
</td>
<td class="nump">$ 49,321<span></span>
</td>
<td class="nump">$ 48,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_InfusionConsumablesSmithsMedicalMember', window );">Infusion Consumables-Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 340,124<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_VascularAccessMember', window );">Vascular Access</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 326,765<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_VitalCareMember', window );">Vital Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 284,609<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentageofrevenue', window );">Percentage of revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Percentageofrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Percentageofrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_InfusionConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_InfusionConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_InfusionSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_InfusionSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_IVSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_IVSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_CriticalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_CriticalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_InfusionConsumablesSmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_InfusionConsumablesSmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_VascularAccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_VascularAccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_VitalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_VitalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751082304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation of Revenue by Geography (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,279,997<span></span>
</td>
<td class="nump">$ 1,316,308<span></span>
</td>
<td class="nump">$ 1,271,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,460,069<span></span>
</td>
<td class="nump">$ 941,809<span></span>
</td>
<td class="nump">$ 910,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentoftotalrevenue', window );">Percent of total revenue</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 367,411<span></span>
</td>
<td class="nump">$ 147,488<span></span>
</td>
<td class="nump">$ 132,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_APACDomain', window );">APAC [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">257,208<span></span>
</td>
<td class="nump">85,692<span></span>
</td>
<td class="nump">79,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_OtherforeigncountriesMember', window );">Other foreign countries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 195,309<span></span>
</td>
<td class="nump">$ 141,319<span></span>
</td>
<td class="nump">$ 148,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_InternationalSalesDomain', window );">International Sales [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Percentoftotalrevenue', window );">Percent of total revenue</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Percentoftotalrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of total revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Percentoftotalrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_APACDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_APACDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_OtherforeigncountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_OtherforeigncountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_InternationalSalesDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_InternationalSalesDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751894464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="num">$ (7,461)<span></span>
</td>
<td class="num">$ (6,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="num">(45,866)<span></span>
</td>
<td class="num">(7,461)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="num">(51,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_EquipmentrevenueMember', window );">Equipment revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (Decrease) in Deferred Revenue</a></td>
<td class="num">(32,252)<span></span>
</td>
<td class="num">(10,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">20,332<span></span>
</td>
<td class="nump">13,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_SoftwarerevenueMember', window );">Software revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (Decrease) in Deferred Revenue</a></td>
<td class="num">(16,277)<span></span>
</td>
<td class="num">(7,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">17,557<span></span>
</td>
<td class="nump">$ 4,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_GovernmentGrantRevenueMember', window );">Government Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (Decrease) in Deferred Revenue</a></td>
<td class="num">(1,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=icui_OtherDeferredRevenueMember', window );">Other deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_COntractLiabilityRollforwardRollForward', window );"><strong>COntract Liability Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (Decrease) in Deferred Revenue</a></td>
<td class="num">(5,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_COntractLiabilityRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COntract Liability Rollforward [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_COntractLiabilityRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_EquipmentrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_EquipmentrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_SoftwarerevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_SoftwarerevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_GovernmentGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_GovernmentGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_OtherDeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_OtherDeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761297344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Contract Liabilities Text (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ContractassetandliabilitybalancesLineItems', window );"><strong>Contract asset and liability balances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred Revenue, Revenue Recognized</a></td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ContractassetandliabilitybalancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Contract asset and liability balances [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ContractassetandliabilitybalancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755463296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Remaining Performance Obligation Recognition Timing (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_ShortTermMember', window );">Short Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">$ (29,627)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_ShortTermMember', window );">Short Term | Equipment revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(15,144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_ShortTermMember', window );">Short Term | Software revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(8,277)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_ShortTermMember', window );">Short Term | Government Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(1,422)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_ShortTermMember', window );">Short Term | Other deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(4,784)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(16,239)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term | Equipment revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(982)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term | Software revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(1,026)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term | Government Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">(12,797)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term | Other deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevenueRecognitionTimingLineItems', window );"><strong>Revenue Recognition Timing [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="num">$ (1,434)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_RevenueRecognitionTimingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Timing [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_RevenueRecognitionTimingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TimingAxis=icui_ShortTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TimingAxis=icui_ShortTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_EquipmentrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_EquipmentrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_SoftwarerevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_SoftwarerevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_GovernmentGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_GovernmentGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=icui_OtherDeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=icui_OtherDeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TimingAxis=icui_LongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TimingAxis=icui_LongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760498448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Optiontoextendinyears', window );">Optiontoextendinyears</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Optiontoextendinyears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Optiontoextendinyears</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Optiontoextendinyears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758405520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 22,038<span></span>
</td>
<td class="nump">$ 11,251<span></span>
</td>
<td class="nump">$ 11,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance Lease, Interest Expense</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance Lease, Right-of-Use Asset, Amortization</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term Lease, Cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">$ 22,869<span></span>
</td>
<td class="nump">$ 12,035<span></span>
</td>
<td class="nump">$ 12,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758396848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Supplemental Cash Flow Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 25,225<span></span>
</td>
<td class="nump">$ 11,256<span></span>
</td>
<td class="nump">$ 10,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance Lease, Interest Payment on Liability</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">5,994<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">20,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">$ 3,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed', window );">business combination, recognized identifiable asset acquired and liability assumed,</a></td>
<td class="nump">$ 55,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>business combination, recognized identifiable asset acquired and liability assumed,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751016992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Supplemental Balance Sheet Lease information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Assets</a></td>
<td class="nump">$ 74,864<span></span>
</td>
<td class="nump">$ 39,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">9,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">60,916<span></span>
</td>
<td class="nump">33,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 79,085<span></span>
</td>
<td class="nump">$ 42,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term Liabilities<span></span>
</td>
<td class="text">Other long-term Liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">4.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753122000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Leases Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</a></td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">$ 2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance Lease, Liability, Current</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease, Liability, Noncurrent</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">2,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability</a></td>
<td class="nump">$ 2,671<span></span>
</td>
<td class="nump">$ 2,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term Liabilities<span></span>
</td>
<td class="text">Other long-term Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751017120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</a></td>
<td class="nump">$ 21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">17,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">12,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due Year Four</a></td>
<td class="nump">11,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due Year Five</a></td>
<td class="nump">7,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Year Five</a></td>
<td class="nump">17,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="nump">88,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="num">(9,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 79,085<span></span>
</td>
<td class="nump">$ 42,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751017408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Finance Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease, Liability, to be Paid, Year Two</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease, Liability, to be Paid, Year Three</a></td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease, Liability, to be Paid, Year Four</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease, Liability, to be Paid, Year Five</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance Lease, Liability, to be Paid, after Year Five</a></td>
<td class="nump">426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Lease, Liability, Payment, Due</a></td>
<td class="nump">2,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="num">(279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability</a></td>
<td class="nump">$ 2,671<span></span>
</td>
<td class="nump">$ 2,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758566496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Stock Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation</a></td>
<td class="nump">$ 36,025<span></span>
</td>
<td class="nump">$ 27,341<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from stock-based compensation cost</a></td>
<td class="nump">4,636<span></span>
</td>
<td class="nump">6,391<span></span>
</td>
<td class="nump">5,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_IndirectTaxBenefitFromStockOptions', window );">Indirect tax benefit</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_IndirectTaxBenefitFromStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect tax benefit from the stock compensation cost received upon the exercise of stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_IndirectTaxBenefitFromStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751034288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Stock Option Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=icui_A2011PlanMember', window );">2011 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_StockIncentivePlansLineItems', window );"><strong>Stock Incentive Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">3,925,000<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">3,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Sharestransferredfromsupersededplan', window );">Shares transferred from superseded plan</a></td>
<td class="nump">263,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">4,188,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=icui_A2003PlanMember', window );">2003 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_StockIncentivePlansLineItems', window );"><strong>Stock Incentive Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">248,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Sharestransferredfromsupersededplan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares transferred from superseded plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Sharestransferredfromsupersededplan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_StockIncentivePlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Stock Incentive Plans [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_StockIncentivePlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=icui_A2011PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=icui_A2011PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=icui_A2003PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=icui_A2003PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752797184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Stock Options Granted and Valuation (Details) - Time-based stock option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">7,620<span></span>
</td>
<td class="nump">7,910<span></span>
</td>
<td class="nump">7,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Timebasedoptionsgrantdatefairvalue', window );">Time based options grant date fair value</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 185.79<span></span>
</td>
<td class="nump">$ 200.07<span></span>
</td>
<td class="nump">$ 181.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per option</a></td>
<td class="nump">$ 70.86<span></span>
</td>
<td class="nump">$ 66.78<span></span>
</td>
<td class="nump">$ 59.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Timebasedoptionsgrantdatefairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Time based options grant date fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Timebasedoptionsgrantdatefairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=icui_TimebasedstockoptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=icui_TimebasedstockoptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751066288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Stock Option Activity (Details) - Share-based Payment Arrangement, Option [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Number | shares</a></td>
<td class="nump">663,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">7,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(142,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited or expired | shares</a></td>
<td class="num">(485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Number | shares</a></td>
<td class="nump">527,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable | shares</a></td>
<td class="nump">519,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and Expected to Vest | shares</a></td>
<td class="nump">527,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 74.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">185.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercises in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">61.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">60.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">79.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price Range, Exercisable Options, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">78.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 79.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Intrinsic Value | $</a></td>
<td class="nump">$ 42,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options, Exercisable, Intrinsic Value | $</a></td>
<td class="nump">42,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 42,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760227616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Based Award Share Award data (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShareawarddataAbstract', window );"><strong>Share award data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 157.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ShareawarddataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share award data [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ShareawarddataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751093120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award Options exercised data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 17,340<span></span>
</td>
<td class="nump">$ 27,534<span></span>
</td>
<td class="nump">$ 32,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options</a></td>
<td class="nump">8,785<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
<td class="nump">13,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock option exercises</a></td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="nump">$ 5,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753098544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award RSU and PRSU (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ModifiedPRSUIncrementalExpense', window );">Modified PRSU Incremental Expense</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=icui_PerformanceRestrictedStockUnitsPRSUsMember', window );">Performance Restricted Stock Units (PRSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">60,383<span></span>
</td>
<td class="nump">53,246<span></span>
</td>
<td class="nump">38,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 230.31<span></span>
</td>
<td class="nump">$ 198.16<span></span>
</td>
<td class="nump">$ 188.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Grantdatefairvalueperformancerestrictedstockunits', window );">Grant date fair value performance restricted stock units</a></td>
<td class="nump">$ 13,907<span></span>
</td>
<td class="nump">$ 10,551<span></span>
</td>
<td class="nump">$ 7,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</a></td>
<td class="nump">$ 10,487<span></span>
</td>
<td class="nump">$ 6,777<span></span>
</td>
<td class="nump">$ 15,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PerformanceSharesEarned', window );">Performance Shares Earned</a></td>
<td class="nump">46,317<span></span>
</td>
<td class="nump">32,013<span></span>
</td>
<td class="nump">80,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">116,870<span></span>
</td>
<td class="nump">84,388<span></span>
</td>
<td class="nump">87,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 221.65<span></span>
</td>
<td class="nump">$ 199.13<span></span>
</td>
<td class="nump">$ 188.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Grantdatefairvalueofrestrictedstockunitsgranted', window );">Grant date fair value of restricted stock units granted</a></td>
<td class="nump">$ 25,905<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
<td class="nump">$ 16,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</a></td>
<td class="nump">$ 16,438<span></span>
</td>
<td class="nump">$ 13,681<span></span>
</td>
<td class="nump">$ 12,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Grantdatefairvalueofrestrictedstockunitsgranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of restricted stock units granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Grantdatefairvalueofrestrictedstockunitsgranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Grantdatefairvalueperformancerestrictedstockunits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value performance restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Grantdatefairvalueperformancerestrictedstockunits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ModifiedPRSUIncrementalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified PRSU Incremental Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ModifiedPRSUIncrementalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_PerformanceSharesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance Shares Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_PerformanceSharesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=icui_PerformanceRestrictedStockUnitsPRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=icui_PerformanceRestrictedStockUnitsPRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751083616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Award RSU and PRSU Roll forward (Details) - Restricted Stock and Performance Restricted Stock Units [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">354,004<span></span>
</td>
<td class="nump">275,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 213.95<span></span>
</td>
<td class="nump">$ 201.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Changeinunitsduetoperformanceexpectations', window );">Change in units due to performance expectations</a></td>
<td class="nump">32,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue', window );">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</a></td>
<td class="nump">$ 239.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">177,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 224.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="num">(118,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</a></td>
<td class="nump">$ 206.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="num">(13,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</a></td>
<td class="nump">$ 218.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</a></td>
<td class="nump">$ 55,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Changeinunitsduetoperformanceexpectations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in units due to performance expectations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Changeinunitsduetoperformanceexpectations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761239040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Based Award ESPP Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ESPPOriginalIssuance', window );">ESPP Original Issuance</a></td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ESPPAnnualIssuanceIncreaseLimit', window );">ESPP Annual Issuance Increase Limit</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ESPPAnnualIssuanceIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Annual Issuance Increase Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ESPPAnnualIssuanceIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ESPPOriginalIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ESPP Original Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ESPPOriginalIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752117776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 206,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Srt_MultipleCurrencyAxisAxis=icui_OtherCurrenciesMember', window );">other currencies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_MXN', window );">Mexico, Pesos</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">61,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">31,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CZK', window );">Czech Republic, Koruny</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">13,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">15,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">China, Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">11,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">43,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canada, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">11,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 11,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge3MemberMember', window );">Hedge 3 [Member] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="nump">22.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge4Member', window );">Hedge 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="nump">24.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="nump">$ 436,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge5Member', window );">Hedge 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="nump">21.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative Asset, Notional Amount</a></td>
<td class="nump">$ 413,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Srt_MultipleCurrencyAxisAxis=icui_OtherCurrenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Srt_MultipleCurrencyAxisAxis=icui_OtherCurrenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_MXN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_MXN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CZK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CZK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge3MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge3MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=icui_Hedge5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753278512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities Interest Rate Contracts(Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</a></td>
<td class="nump">$ 29,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">1.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DerivativeInterestRateFloor', window );">Derivative Interest Rate Floor</a></td>
<td class="num">(0.15%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=icui_UsGaap_InterestRateSwap2Member', window );">us-gaap_InterestRateSwap 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="nump">1.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DerivativeInterestRateFloor', window );">Derivative Interest Rate Floor</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | us-gaap_InterestRateSwap 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | us-gaap_InterestRateSwap 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">$ 46,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_DerivativeInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Interest Rate Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_DerivativeInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=icui_UsGaap_InterestRateSwap2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=icui_UsGaap_InterestRateSwap2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752198672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities Derivative Balance Sheet Location (Details) - Designated as Hedging Instrument [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">$ 4,860<span></span>
</td>
<td class="nump">$ 1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward [Member] | Liabilities, Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">28,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">26,753<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">55,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Liabilities, Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember', window );">Derivative Financial Instruments, Assets | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">33,291<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember', window );">Derivative Financial Instruments, Assets | Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">26,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember', window );">Derivative Financial Instruments, Assets | Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">60,138<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member] | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member] | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member] | Liabilities, Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">$ 2,014<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752082816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion', window );">Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion</a></td>
<td class="nump">$ 18,419<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion', window );">Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion</a></td>
<td class="nump">$ 18,419<span></span>
</td>
<td class="nump">3,444<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest Income (Expense), Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring', window );">Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring</a></td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring', window );">Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Cash Flow Hedging [Member] | Trading Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="num">(3,829)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Cash Flow Hedging [Member] | Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="nump">7,751<span></span>
</td>
<td class="nump">3,444<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="num">(7,751)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="nump">6,122<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</a></td>
<td class="num">$ (6,122)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of gain reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain reclassified into earnings in the period when cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_TradingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_TradingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752601488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other Comprehensive Income (Loss), before Tax</a></td>
<td class="nump">$ 72,374<span></span>
</td>
<td class="num">$ (530)<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign Exchange Forward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other Comprehensive Income (Loss), before Tax</a></td>
<td class="nump">9,588<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other Comprehensive Income (Loss), before Tax</a></td>
<td class="nump">$ 62,786<span></span>
</td>
<td class="num">$ (1,480)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750954976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement Smiths Medical(Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 06, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_OwnershipRequirementForEarnoutPayment', window );">Ownership requirement for Earnout Payment</a></td>
<td class="nump">0.500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 53,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Contingentconsiderationgross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>contingent consideration gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Contingentconsiderationgross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_OwnershipRequirementForEarnoutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership requirement for Earnout Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_OwnershipRequirementForEarnoutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751685616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement Text Pursuit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">$ 25,572<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Pursuit Vascular, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember', window );">Pursuit Vascular LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember', window );">Foreign Distibutor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Contingentconsiderationgross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>contingent consideration gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Contingentconsiderationgross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LongTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LongTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ShortTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ShortTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751918048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">$ 25,572<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)</a></td>
<td class="num">(32,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">55,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_CurrencyTranslationOnEarnOut', window );">Currency translation on earn-out</a></td>
<td class="num">$ (84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of contingent earn-out<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember', window );">Pursuit Vascular LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">53,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent earn-out liability, Noncurrent</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_CurrencyTranslationOnEarnOut">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency translation on earn-out</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_CurrencyTranslationOnEarnOut</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes unrealized gain (loss) from liability measured at fair value using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753241360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details) - Pursuit Vascular, Inc. [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 02, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Revenue/Gross Profit Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.2500<span></span>
</td>
<td class="nump">0.2000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.1250<span></span>
</td>
<td class="nump">0.1500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0009<span></span>
</td>
<td class="nump">0.0155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Credit Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0310<span></span>
</td>
<td class="nump">0.0600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=icui_RevenueGrossProfitVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=icui_RevenueGrossProfitVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758428496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement Smiths Medical Simulation Inputs (Details) - Smiths Medical<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 06, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.3800<span></span>
</td>
<td class="nump">0.3700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0417<span></span>
</td>
<td class="nump">0.0131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520748824256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement Fair Value Measurements, Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">$ 4,224<span></span>
</td>
<td class="nump">$ 14,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">64,878<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ClassificationAxis=icui_NoncurrentMember', window );">noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ClassificationAxis=icui_CurrentMember', window );">current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">28,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">3,328<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">60,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">28,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term Investment Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt Securities, Noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">28,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign Currency Contract, Asset, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">26,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">26,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign Currency Contracts, Liability, Fair Value Disclosure</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember', window );">Earn-out liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">25,572<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember', window );">Earn-out liability [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember', window );">Earn-out liability [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember', window );">Earn-out liability [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">25,572<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember', window );">Liabilities, Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">27,586<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember', window );">Liabilities, Total [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember', window );">Liabilities, Total [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember', window );">Liabilities, Total [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Nonfinancial Liabilities Fair Value Disclosure</a></td>
<td class="nump">$ 27,586<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ClassificationAxis=icui_NoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ClassificationAxis=icui_NoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ClassificationAxis=icui_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ClassificationAxis=icui_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=icui_EarnoutliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758530448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidAssetsCurrentLineItems', window );"><strong>Prepaid Assets Current [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other Prepaid Expense, Current</a></td>
<td class="nump">$ 21,635<span></span>
</td>
<td class="nump">$ 14,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidVendorExpenses', window );">Prepaid vendor expenses</a></td>
<td class="nump">3,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsAndOtherAssets', window );">Deferred Costs and Other Assets</a></td>
<td class="nump">2,395<span></span>
</td>
<td class="nump">12,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Prepaidinsuranceandpropertytaxes', window );">Prepaid insurance and property taxes</a></td>
<td class="nump">16,322<span></span>
</td>
<td class="nump">6,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Prepaidothertaxes', window );">Prepaid other taxes</a></td>
<td class="nump">3,546<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Deferredtaxcharge', window );">Deferred tax charge</a></td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative Asset, Current</a></td>
<td class="nump">4,860<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposit Assets</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets, Current</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">88,932<span></span>
</td>
<td class="nump">46,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidAssetsCurrentLineItems', window );"><strong>Prepaid Assets Current [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest Rate Derivative Assets, at Fair Value</a></td>
<td class="nump">$ 28,431<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Deferredtaxcharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Deferredtaxcharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_PrepaidAssetsCurrentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Assets Current [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_PrepaidAssetsCurrentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_PrepaidVendorExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid vendor expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_PrepaidVendorExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Prepaidinsuranceandpropertytaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid insurance and property taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Prepaidinsuranceandpropertytaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Prepaidothertaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid other taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Prepaidothertaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost assets and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750590672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaids and Other Noncurrent Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidNoncurrentAssetsLineItems', window );"><strong>Prepaid Noncurrent Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, Operating Lease, Payments to be Received</a></td>
<td class="nump">$ 27,086<span></span>
</td>
<td class="nump">$ 25,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_SpareParts', window );">Spare parts</a></td>
<td class="nump">38,498<span></span>
</td>
<td class="nump">28,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt Issuance Costs, Noncurrent, Net</a></td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">2,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</a></td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other Assets, Miscellaneous, Noncurrent</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">105,462<span></span>
</td>
<td class="nump">63,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_PrepaidNoncurrentAssetsLineItems', window );"><strong>Prepaid Noncurrent Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative Asset, Noncurrent</a></td>
<td class="nump">$ 26,753<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_PrepaidNoncurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Noncurrent Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_PrepaidNoncurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_SpareParts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Spare parts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_SpareParts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751710800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AccruedSalariesAndBenefits', window );">Salaries and benefits</a></td>
<td class="nump">$ 44,304<span></span>
</td>
<td class="nump">$ 27,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Incentive compensation</a></td>
<td class="nump">30,254<span></span>
</td>
<td class="nump">33,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">18,169<span></span>
</td>
<td class="nump">9,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued Professional Fees</a></td>
<td class="nump">5,317<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AccruedProductFieldAction.', window );">Accrued Product Field Action.</a></td>
<td class="nump">24,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Accruedlegalfees', window );">Legal accrual</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Accruedsalestaxes', window );">Accrued sales taxes</a></td>
<td class="nump">5,844<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranties and returns</a></td>
<td class="nump">3,097<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="nump">30,838<span></span>
</td>
<td class="nump">12,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Accruedothertaxes', window );">Accrued other taxes</a></td>
<td class="nump">5,794<span></span>
</td>
<td class="nump">4,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Outsidesalescommissions', window );">Outside commissions</a></td>
<td class="nump">17,063<span></span>
</td>
<td class="nump">5,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Accruedfreight', window );">Accrued freight</a></td>
<td class="nump">17,988<span></span>
</td>
<td class="nump">9,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring accrual</a></td>
<td class="nump">5,923<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AccruedAuditFees', window );">Accrued audit fees</a></td>
<td class="nump">6,279<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Liability, Defined Benefit Plan, Current</a></td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AccruedResearchAndDevelopmentLiability', window );">Accrued research and development liability</a></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">14,899<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">242,769<span></span>
</td>
<td class="nump">118,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeMember', window );">Foreign Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability, Current</a></td>
<td class="nump">$ 1,847<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AccruedAuditFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued audit fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AccruedAuditFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AccruedProductFieldAction.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Field Action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AccruedProductFieldAction.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AccruedResearchAndDevelopmentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AccruedResearchAndDevelopmentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AccruedSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued salaries and benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AccruedSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Accruedfreight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued freight</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Accruedfreight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Accruedlegalfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued legal fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Accruedlegalfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Accruedothertaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued other taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Accruedothertaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Accruedsalestaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued sales taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Accruedsalestaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Outsidesalescommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outside sales commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Outsidesalescommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accrued Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752141872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_OtherLiabilitiesLineItems', window );"><strong>Other liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 60,916<span></span>
</td>
<td class="nump">$ 33,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease, Liability, Noncurrent</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">2,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="nump">16,239<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest Rate Derivative Liabilities, at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Benefits</a></td>
<td class="nump">5,314<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualComponentAmount', window );">Product Liability Accrual, Component Amount</a></td>
<td class="nump">49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Accrued rent</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">OTHER LONG-TERM LIABILITIES</a></td>
<td class="nump">114,104<span></span>
</td>
<td class="nump">41,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TimingAxis=icui_LongTermMember', window );">Long Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_OtherLiabilitiesLineItems', window );"><strong>Other liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualComponentAmount', window );">Product Liability Accrual, Component Amount</a></td>
<td class="nump">$ 25,294<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_OtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_OtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualComponentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded amount of the accrual for a material component of a product liability contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualComponentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TimingAxis=icui_LongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TimingAxis=icui_LongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760353920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Applicable Margin Based on Leverage Ratio Term Loan A(Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanAxis=icui_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_Greaterthan400to100Member', window );">greaterthan4.00to1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_Greaterthan400to100Member', window );">greaterthan4.00to1.00 | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member', window );">less than or equal to 4.00 to 1.00 but greater than 3.00 to100</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member', window );">less than or equal to 4.00 to 1.00 but greater than 3.00 to100 | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqual300To100ButGreaterThan250to100Member', window );">less than or equal 3.00 to 1.00 but greater than 2.50to1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqual300To100ButGreaterThan250to100Member', window );">less than or equal 3.00 to 1.00 but greater than 2.50to1.00 | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member', window );">less than or equal to 2.50 to1.00 but greater than 2.00 to1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member', window );">less than or equal to 2.50 to1.00 but greater than 2.00 to1.00 | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo200To100Member', window );">less than or equal to 2.00 to 1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo200To100Member', window );">less than or equal to 2.00 to 1.00 | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginBaseRateLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Base Rate Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginBaseRateLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Based on Leverage Ratio [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginBasedOnLeverageRatioLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginTermSOFRLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Term SOFR Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginTermSOFRLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_Greaterthan400to100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_Greaterthan400to100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqual300To100ButGreaterThan250to100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_LessThanOrEqual300To100ButGreaterThan250to100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo200To100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_LessThanOrEqualTo200To100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753192272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Applicable Margin Based on Leverage Ratio Term Loan B (Details) - Term Loan B<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_GreaterThan275To100Member', window );">greater than 2.75 to1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioLevelAxis=icui_LessThan275To100Member', window );">less than 2.75 to1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems', window );"><strong>Applicable Margin Based on Leverage Ratio [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginBaseRateLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Base Rate Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginBaseRateLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginBasedOnLeverageRatioLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Based on Leverage Ratio [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginBasedOnLeverageRatioLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginTermSOFRLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Term SOFR Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginTermSOFRLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_GreaterThan275To100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_GreaterThan275To100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioLevelAxis=icui_LessThan275To100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioLevelAxis=icui_LessThan275To100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751086480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 1,677,625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Line of Credit Facility, Fair Value of Amount Outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, Long-Term and Short-Term, Combined Amount</a></td>
<td class="nump">1,653,363,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, Current</a></td>
<td class="nump">29,688,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt, Excluding Current Maturities</a></td>
<td class="nump">1,623,675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="num">(24,262,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanAxis=icui_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 834,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="nump">3.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanAxis=icui_TermLoanBMember', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 843,625,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="nump">4.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="nump">$ 11,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758508048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-Term Debt, Maturity, Year One</a></td>
<td class="nump">$ 29,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-Term Debt, Maturity, Year Two</a></td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-Term Debt, Maturity, Year Three</a></td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-Term Debt, Maturity, Year Four</a></td>
<td class="nump">72,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-Term Debt, Maturity, Year Five</a></td>
<td class="nump">672,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Long-Term Debt, Maturity, after Year Five</a></td>
<td class="nump">801,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 1,677,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520754246448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Interest Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense, Debt, Excluding Amortization</a></td>
<td class="nump">$ 66,770,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,251,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of Debt Issuance Costs and Discounts</a></td>
<td class="nump">6,972,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Line of Credit Facility, Commitment Fee Amount</a></td>
<td class="nump">1,290,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="nump">$ 75,032,000<span></span>
</td>
<td class="nump">$ 461,000<span></span>
</td>
<td class="nump">$ 1,649,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751738896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2022 Credit Facility Text (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TotalSeniorSecuredCreditFacility', window );">TotalSeniorSecuredCreditFacility</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">1,677,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_RevolverSubLimits', window );">Revolver Sub limits</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestPercentageAddedToFederalFundsRate', window );">Interest Percentage Added to Federal Funds Rate</a></td>
<td class="nump">0.0050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestPercentageAddedToBaseRate', window );">Interest Percentage Added to Base Rate</a></td>
<td class="nump">0.0100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans', window );">Ter SOFR Interest Rate % Adjustment for Base Rate Loans</a></td>
<td class="nump">0.0010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermAPrincipalPaymentFirst2Years', window );">Term A principal payment % First 2 Years</a></td>
<td class="nump">0.0250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermAPrincipalPaymentYear3And4', window );">Term A Principal Payment % Year 3 and 4</a></td>
<td class="nump">0.0500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermAPrincipalPaymentInYear5', window );">Term A Principal Payment % in Year 5</a></td>
<td class="nump">0.0750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanBPrincipalPayment', window );">Term Loan B Principal Payment %</a></td>
<td class="nump">0.0025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LeverageRatioCalculationCeilingSubtractedAmount', window );">Leverage Ratio Calculation Ceiling Subtracted Amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermDebtTypeLineItems', window );"><strong>Long-term Debt Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="nump">37,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanAxis=icui_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 834,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jan.  06,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.0075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.0175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermDebtTypeLineItems', window );"><strong>Long-term Debt Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="nump">15,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 834,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jan.  06,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermLoanAxis=icui_TermLoanBMember', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 843,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jan.  06,  2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginBaseRateLoans', window );">Applicable Margin Base Rate Loans</a></td>
<td class="nump">0.015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ApplicableMarginTermSOFRLoans', window );">Applicable Margin Term SOFR Loans</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermDebtTypeLineItems', window );"><strong>Long-term Debt Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="nump">13,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 836,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jan.  06,  2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-Term Debt, Gross</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermDebtTypeLineItems', window );"><strong>Long-term Debt Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="nump">$ 8,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans', window );">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</a></td>
<td class="nump">0.0010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestRatesLineItems', window );"><strong>Interest Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans', window );">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</a></td>
<td class="nump">0.0010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans', window );">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</a></td>
<td class="nump">0.0025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_InterestRatesLineItems', window );"><strong>Interest Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans', window );">Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</a></td>
<td class="nump">0.0025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginBaseRateLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Base Rate Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginBaseRateLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ApplicableMarginTermSOFRLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Term SOFR Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ApplicableMarginTermSOFRLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestPercentageAddedToBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Percentage Added to Base Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestPercentageAddedToBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestPercentageAddedToFederalFundsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Percentage Added to Federal Funds Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestPercentageAddedToFederalFundsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_InterestRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rates [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_InterestRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LeverageRatioCalculationCeilingSubtractedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Calculation Ceiling Subtracted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LeverageRatioCalculationCeilingSubtractedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LongTermDebtTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt Type [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LongTermDebtTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_RevolverSubLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revolver Sub limits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_RevolverSubLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TerSOFRInterestRateAdjustmentForBaseRateLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ter SOFR Interest Rate % Adjustment for Base Rate Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TerSOFRInterestRateAdjustmentForBaseRateLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermAPrincipalPaymentFirst2Years">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term A principal payment % First 2 Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermAPrincipalPaymentFirst2Years</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermAPrincipalPaymentInYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term A Principal Payment % in Year 5</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermAPrincipalPaymentInYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermAPrincipalPaymentYear3And4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term A Principal Payment % Year 3 and 4</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermAPrincipalPaymentYear3And4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanBPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan B Principal Payment %</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanBPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TotalSeniorSecuredCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>TotalSeniorSecuredCreditFacility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TotalSeniorSecuredCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_TermLoanAxis=icui_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_TermLoanAxis=icui_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761431344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758782688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2017 Credit Facility (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of Credit Facility, Expiration Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of Credit, Current</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752564368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income (Loss) from Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="num">$ (135,646)<span></span>
</td>
<td class="nump">$ 81,484<span></span>
</td>
<td class="nump">$ 41,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income (Loss) from Continuing Operations before Income Taxes, Foreign</a></td>
<td class="nump">21,237<span></span>
</td>
<td class="nump">41,702<span></span>
</td>
<td class="nump">56,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="num">$ (114,409)<span></span>
</td>
<td class="nump">$ 123,186<span></span>
</td>
<td class="nump">$ 97,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751051488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current Federal Tax Expense (Benefit)</a></td>
<td class="nump">$ 4,128<span></span>
</td>
<td class="nump">$ 20,646<span></span>
</td>
<td class="nump">$ 6,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current State and Local Tax Expense (Benefit)</a></td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">3,444<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current Foreign Tax Expense (Benefit)</a></td>
<td class="nump">12,924<span></span>
</td>
<td class="nump">7,236<span></span>
</td>
<td class="nump">7,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
<td class="nump">20,851<span></span>
</td>
<td class="nump">31,326<span></span>
</td>
<td class="nump">15,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred Federal Income Tax Expense (Benefit)</a></td>
<td class="num">(42,012)<span></span>
</td>
<td class="num">(8,154)<span></span>
</td>
<td class="num">(5,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred State and Local Income Tax Expense (Benefit)</a></td>
<td class="num">(11,239)<span></span>
</td>
<td class="num">(1,815)<span></span>
</td>
<td class="num">(1,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred Foreign Income Tax Expense (Benefit)</a></td>
<td class="num">(7,723)<span></span>
</td>
<td class="num">(1,306)<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="num">(60,974)<span></span>
</td>
<td class="num">(11,275)<span></span>
</td>
<td class="num">(5,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">$ (40,123)<span></span>
</td>
<td class="nump">$ 20,051<span></span>
</td>
<td class="nump">$ 10,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758396576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Change in taxes payable (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Increase (Decrease) in Income Taxes Payable</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750684544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Effective tax rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate</a></td>
<td class="num">$ (24,026)<span></span>
</td>
<td class="nump">$ 25,869<span></span>
</td>
<td class="nump">$ 20,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Income Tax Reconciliation, State and Local Income Taxes</a></td>
<td class="num">(5,050)<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Income Tax Reconciliation, Tax Credits</a></td>
<td class="num">(3,636)<span></span>
</td>
<td class="num">(2,443)<span></span>
</td>
<td class="num">(3,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_GILTItaxexpense', window );">GILTItaxexpense</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Income Tax Reconciliation, Foreign Income Tax Rate Differential</a></td>
<td class="num">(2,943)<span></span>
</td>
<td class="num">(2,983)<span></span>
</td>
<td class="num">(3,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="num">(4,263)<span></span>
</td>
<td class="num">(4,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome', window );">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</a></td>
<td class="num">(2,269)<span></span>
</td>
<td class="num">(3,775)<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration', window );">Effective Income Tax Rate Reconciliation, Contingent Consideration</a></td>
<td class="num">(6,830)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Effectiveincometaxreconciliationnondeductiblecompensation', window );">Effectiveincometaxreconciliation,nondeductiblecompensation</a></td>
<td class="nump">3,942<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</a></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">$ (40,123)<span></span>
</td>
<td class="nump">$ 20,051<span></span>
</td>
<td class="nump">$ 10,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Effective Income Tax Rate Reconciliation, Tax Credits</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_GILTItaxexpensepercent', window );">GILTItaxexpensepercent</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent', window );">EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveTaxRateReconcilationTransactionCostPercent', window );">EffectiveTaxRateReconcilationTransaction cost,Percent</a></td>
<td class="num">(0.020)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveIncomeTaxRateReconciliationTransactionCost', window );">EffectiveIncomeTaxRateReconciliationTransaction cost</a></td>
<td class="nump">$ 2,299<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent', window );">Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Effectivetaxratereconciliationnondeductiblecomppercent', window );">Effectivetaxratereconciliationnondeductiblecomppercent</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate, Continuing Operations</a></td>
<td class="nump">35.10%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveIncomeTaxRateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveIncomeTaxRateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveIncomeTaxRateReconciliationTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EffectiveIncomeTaxRateReconciliationTransaction cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveIncomeTaxRateReconciliationTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_EffectiveTaxRateReconcilationTransactionCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EffectiveTaxRateReconcilationTransaction cost,Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_EffectiveTaxRateReconcilationTransactionCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Effectiveincometaxreconciliationnondeductiblecompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effectiveincometaxreconciliation,nondeductiblecompensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Effectiveincometaxreconciliationnondeductiblecompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Effectivetaxratereconciliationnondeductiblecomppercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effectivetaxratereconciliationnondeductiblecomppercent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Effectivetaxratereconciliationnondeductiblecomppercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_GILTItaxexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GILTItaxexpense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_GILTItaxexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_GILTItaxexpensepercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GILTItaxexpensepercent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_GILTItaxexpensepercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752172608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Deferred income tax assets (liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DeferredtaxassetsandliabilitiesLineItems', window );"><strong>Deferred tax assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Noncurrentdeferredtaxasset', window );">Non-current deferred tax asset</a></td>
<td class="nump">$ 126,532<span></span>
</td>
<td class="nump">$ 69,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">94,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=icui_NonCurrentDeferredTaxAssetGrossTotalMember', window );">Non-current deferred tax asset, gross total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DeferredtaxassetsandliabilitiesLineItems', window );"><strong>Deferred tax assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</a></td>
<td class="nump">17,351<span></span>
</td>
<td class="nump">7,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions', window );">Noncurrent deferred tax asset - acquired future tax deductions</a></td>
<td class="nump">14,186<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
<td class="nump">6,240<span></span>
</td>
<td class="nump">7,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Deferred Tax Assets, Unrealized Currency Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NoncurrentDeferredTaxAssetTaxCreditsState', window );">Noncurrent deferred tax asset - tax credits state</a></td>
<td class="nump">12,906<span></span>
</td>
<td class="nump">11,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Deferred Tax Assets, Inventory</a></td>
<td class="nump">25,100<span></span>
</td>
<td class="nump">8,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</a></td>
<td class="nump">13,241<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DeferredTaxAssetSection163j', window );">Deferred Tax Asset, Section 163(j)</a></td>
<td class="nump">9,166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions', window );">Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</a></td>
<td class="nump">39,508<span></span>
</td>
<td class="nump">27,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">11,166<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=icui_NoncurrentDeferredTaxLiabilityMember', window );">Noncurrent deferred tax liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_DeferredtaxassetsandliabilitiesLineItems', window );"><strong>Deferred tax assets and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes', window );">Noncurrent deferred tax liability - state income taxes</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">2,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization', window );">Noncurrent deferred tax liability - depreciation and amortization</a></td>
<td class="nump">209,687<span></span>
</td>
<td class="nump">20,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Deferredtaxliabilitychangeinaccountingmethod', window );">Deferred tax liability, change in accounting method</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome', window );">Deferred Tax Liabilities, Other Comprehensive Income</a></td>
<td class="nump">9,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="nump">$ 221,084<span></span>
</td>
<td class="nump">$ 28,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_DeferredTaxAssetSection163j">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Section 163(j)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_DeferredTaxAssetSection163j</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_DeferredtaxassetsandliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Deferred tax assets and liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_DeferredtaxassetsandliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Deferredtaxliabilitychangeinaccountingmethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability, change in accounting method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Deferredtaxliabilitychangeinaccountingmethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_NoncurrentDeferredTaxAssetTaxCreditsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent deferred tax asset - tax credits state</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_NoncurrentDeferredTaxAssetTaxCreditsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent deferred tax liability - depreciation and amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent deferred tax liability - state income taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Noncurrentdeferredtaxasset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current deferred tax asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Noncurrentdeferredtaxasset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent deferred tax asset - acquired future tax deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=icui_NonCurrentDeferredTaxAssetGrossTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=icui_NonCurrentDeferredTaxAssetGrossTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=icui_NoncurrentDeferredTaxLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=icui_NoncurrentDeferredTaxLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520753358432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Operating Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 46.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758563904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Tax Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 18.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520758918240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Tax Holiday (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Income Tax Holiday, Aggregate Dollar Amount</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Income Tax Holiday, Income Tax Benefits Per Share</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761316768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Undistributed foreign earnings (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed Earnings of Foreign Subsidiaries</a></td>
<td class="nump">$ 209.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520755285696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_UnrecognizedTaxBenefitsRollForwardRollForward', window );"><strong>Unrecognized tax benefits roll forward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 54,053<span></span>
</td>
<td class="nump">$ 21,537<span></span>
</td>
<td class="nump">$ 18,443<span></span>
</td>
<td class="nump">$ 15,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions</a></td>
<td class="nump">4,706<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">2,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</a></td>
<td class="num">(222)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations</a></td>
<td class="num">(1,722)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Unrecognized Tax Benefits, Increase Resulting from Acquisition</a></td>
<td class="nump">29,606<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties Expense</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized Tax Benefits, Interest on Income Taxes Expense</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_UnrecognizedTaxBenefitsRollForwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits roll forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_UnrecognizedTaxBenefitsRollForwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752418528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">$ 1,162,557<span></span>
</td>
<td class="nump">$ 905,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CR', window );">COSTA RICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">128,179<span></span>
</td>
<td class="nump">115,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_MexicoPropertyAndEquipmentMember', window );">Mexico Property and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">99,849<span></span>
</td>
<td class="nump">79,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_OtherLATAMMember', window );">Other LATAM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">39,270<span></span>
</td>
<td class="nump">36,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">5,374<span></span>
</td>
<td class="nump">4,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_ItalyPropertyAndEquipmentMember', window );">Italy Property and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">24,323<span></span>
</td>
<td class="nump">12,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">18,948<span></span>
</td>
<td class="nump">13,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=currency_CZK', window );">Czech Republic, Koruny</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">10,732<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">11,375<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">20,930<span></span>
</td>
<td class="nump">20,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_ForeignMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">358,980<span></span>
</td>
<td class="nump">286,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=icui_UnitedStatespropertyandequipmentMember', window );">United States property and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">$ 803,577<span></span>
</td>
<td class="nump">$ 618,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Manufactured Product, Other | Revenue Benchmark [Member] | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_MexicoPropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_MexicoPropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_OtherLATAMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_OtherLATAMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_ItalyPropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_ItalyPropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=currency_CZK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=currency_CZK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_ForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_ForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=icui_UnitedStatespropertyandequipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=icui_UnitedStatespropertyandequipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520750883696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Treasury stock purchase plan</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Treasury stock purchase plan remaining available</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</a></td>
<td class="nump">47,664<span></span>
</td>
<td class="nump">40,350<span></span>
</td>
<td class="nump">67,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment, Tax Withholding, Share-based Payment Arrangement</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752219072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (80,978)<span></span>
</td>
<td class="num">$ (19,269)<span></span>
</td>
<td class="num">$ (1,522)<span></span>
</td>
<td class="num">$ (15,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="num">(47,763)<span></span>
</td>
<td class="num">(15,129)<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="num">(13,946)<span></span>
</td>
<td class="num">(2,618)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(61,709)<span></span>
</td>
<td class="num">(17,747)<span></span>
</td>
<td class="nump">13,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(122,973)<span></span>
</td>
<td class="num">(19,045)<span></span>
</td>
<td class="num">(4,381)<span></span>
</td>
<td class="num">(17,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="num">(103,928)<span></span>
</td>
<td class="num">(14,664)<span></span>
</td>
<td class="nump">12,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(103,928)<span></span>
</td>
<td class="num">(14,664)<span></span>
</td>
<td class="nump">12,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">40,779<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">54,962<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="num">(13,946)<span></span>
</td>
<td class="num">(2,618)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">41,016<span></span>
</td>
<td class="num">(3,021)<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520751867600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 06, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">$ 25,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ContingentConsiderationGrossLT', window );">Contingent Consideration, Gross LT</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualComponentAmount', window );">Product Liability Accrual, Component Amount</a></td>
<td class="nump">49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member', window );">Pursuit Vascular, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember', window );">Pursuit Vascular LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember', window );">Foreign Distibutor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent Earn-out Liability</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember', window );">Foreign Infusion System Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_ShortTermContingentConsiderationGross', window );">Short-term contingent consideration-gross</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_LongTermContingentConsiderationGross', window );">Long-term contingent consideration-gross</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember', window );">Smiths Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_Contingentconsiderationgross', window );">contingent consideration gross</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 53,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ContingentConsiderationGrossLT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Gross LT</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ContingentConsiderationGrossLT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_Contingentconsiderationgross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>contingent consideration gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_Contingentconsiderationgross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_LongTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_LongTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_ShortTermContingentConsiderationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term contingent consideration-gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_ShortTermContingentConsiderationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualComponentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded amount of the accrual for a material component of a product liability contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualComponentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_PursuitVascularLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignDistibutorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_ForeignInfusionSystemSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=icui_SmithsMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520761297344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Arrangements (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase Commitment, Remaining Minimum Amount Committed</a></td>
<td class="nump">$ 29.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520852004032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_AccountsReceivablePurchaseProgram', window );">accounts receivable purchase program</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_AccountsReceivablePurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>accounts receivable purchase program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_AccountsReceivablePurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520752308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_WarrantyAndReturnReserveInventoryWriteOffs', window );">Warranty and return reserve - inventory write-offs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts', window );">Warranty and return reserve - inventory - charged to other accounts</a></td>
<td class="nump">47,436<span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_WarrantyAndReturnReserveCosts', window );">Warranty and Return Reserve costs</a></td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_icui_WarrantyAndReturnReserveInventory', window );">Warranty and return reserve - inventory</a></td>
<td class="nump">50,819<span></span>
</td>
<td class="num">(1,883)<span></span>
</td>
<td class="num">(1,613)<span></span>
</td>
<td class="num">$ (3,477)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">SEC Schedule, 12-09, Allowance, Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning&#160;of Period</a></td>
<td class="nump">7,038<span></span>
</td>
<td class="nump">21,490<span></span>
</td>
<td class="nump">20,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged&#160;to Costs&#160;and Expenses</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">7,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged&#160;to Other&#160;Accounts</a></td>
<td class="nump">456<span></span>
</td>
<td class="num">(14,797)<span></span>
</td>
<td class="num">(5,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Write-off/ Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at&#160;End of&#160;Period</a></td>
<td class="nump">8,530<span></span>
</td>
<td class="nump">7,038<span></span>
</td>
<td class="nump">21,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_WarrantyReservesMember', window );">SEC Schedule, 12-09, Reserve, Warranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning&#160;of Period</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged&#160;to Costs&#160;and Expenses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="num">(3,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged&#160;to Other&#160;Accounts</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="num">(790)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Write-off/ Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at&#160;End of&#160;Period</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning&#160;of Period</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="nump">3,891<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged&#160;to Costs&#160;and Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged&#160;to Other&#160;Accounts</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Write-off/ Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at&#160;End of&#160;Period</a></td>
<td class="nump">$ 11,166<span></span>
</td>
<td class="nump">$ 2,934<span></span>
</td>
<td class="nump">$ 3,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_WarrantyAndReturnReserveCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty and Return Reserve costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_WarrantyAndReturnReserveCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_WarrantyAndReturnReserveInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty and return reserve - inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_WarrantyAndReturnReserveInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty and return reserve - inventory - charged to other accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_icui_WarrantyAndReturnReserveInventoryWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty and return reserve - inventory write-offs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">icui_WarrantyAndReturnReserveInventoryWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>icui_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_WarrantyReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_WarrantyReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520760247040">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
<td class="nump">$ 268,670,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>icui-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:icui="http://www.icumed.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="icui-20221231.xsd" xlink:type="simple"/>
    <context id="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08f3fdac040a4646ae49b87760e750b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie2e9049c6fe84be399e3b04481dcd237_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i0db73ebe00014b429d98a2767a3858eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if024b016189942d089f44d314d97476f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2f128dabbbb42f790c9b42b1a52d19f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic98ea3f4a06d4a69b875b005c4bfdee8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51a94223681d4d6f8e75c3e7b836cbec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ee1b6542ad84492b4d2ec455fa9ae81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0ece853202944e484c25ad349453bf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idde6dfbd9e9b4a638c3f365c3f9bb4f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie33927c32f4649af822a8418053d8d99_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79543f41864548a996a0edce3cc373f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1337f299defe4eaf888a017913e309b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5603cb92819e4c3ca2de991234b01760_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7a7c4b10df94a5cadb8f2ccb5d91e45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib68360870df24c48b23f24f3a787a64c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied10183a5d8941e6b5c8713d7c2eadd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if792565cf68b4836a7b528942b2852fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff8979ceb98e47dfb43a3711dcf7912a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11a5d2a2a4af46a3974d2432b63c41cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15893976f8864a729360aae7e272b56e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3688a319945e4943a3dc05ede3f036d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81e7eed8de8c409a833960699b90df5c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i801a4fae42184517928aa871ec10a664_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbd88657bbd04d46a2104ab8bc2406fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b5dce62564e466793e72557cf0c42bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ca5a22717754de18e1be8d99bab4c9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d9952ba8ae7440abb7a7c721d75b664_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf7a0a723cc04a34b8b697b0e8fb25cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic703ef27cbce4420b73d994faaa947af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic19e854fbfba4ab0abc5e57ea4e706e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffbdea58d0184ec48cf84b1a702fc5df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie18d81392ae04265a3d03510728b3646_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6dfd2e0db2834b9db1915caf0df77a09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7131fb5352c74f58a87b1b96952be01d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47136614a9cc4f309d163a050608f73e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">icui:CommonStockSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e4f2ecd87ce4d80bea7d0755b982f2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f29b1e5a63a431c8553eb9154631953_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idad27c484ae8448cb258c0b5ad63372b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30d33b6f5efb437681ee2b0b9b8c6a33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e09627e54ce4d96a945c0e3e3954f4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b3a16252c2743e49ad12be60705c508_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie803115e33c64a30a2d7ac04ce489aea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i168c102715d143b4a73cd3d48cb2d99e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:InternationalDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7994fbbb85834a97aa927e80e978ecc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id96caeb3085f40b895b3276026ce87e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie306a7088186433b94994c8694798078_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib75bb3ec5a414a9a96e90db458d22e9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7ec5e5fae0c44acbe28b5e7256bc13a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcede7ef2d55454586263cb1b17b8a37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandBuildingsAndImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a1ce0276d2342909b3efc93b1f90403_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:MoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bd24511b6794dbcafe3d83a5a8388c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:MoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7048468f159a46b288ae8a59cedfde98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i980f10b9f96e4b5eb86cb041b7ed672c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a64d4f3e84f40458ca24bfae02314b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b924222777c44f6a4235eca23a1b5cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8f0d2af3e944dc69bd9763b0d42c3aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia90ea729e60647e7a9038b89c6e8eb51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb27ccb900a343b1ac254cb8fd9889ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6808b2296ffa42588ac59c587abb2eca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ace55fc527e48da922598ef7519c606_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5cc8766a58304d02b111521f7ddb4326_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5412a571299e4c32bbdeaa48ca22375a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6f9efdcab0a462a9331fcb0b2523f10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iace321f41b4548e6821dc5e27a26dd08_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc2d38102dd74397953e5e63739100de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:FurniturefixturesandmoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f3efe5e11e941069af3153789ec8247_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:FurniturefixturesandmoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d3d6cb7b6924d47969dd4919c9df187_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07984db0625c4d03845107295d7e5a5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9543871e1aba478483a1228b53651327_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iebcf08c085424ee38ab6ffd24290c1d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">icui:InstrumentsPlacedwithCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d433759863a438d9e188a8521981691_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e546dd32ee14e3eb76d201f21872bb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8cae05c39a724907b4e3c7bec42a8d15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i460a86abca634dc9802438855b8286df_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8fa54f208913446db511b39d4c19420d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf83aec391f64db6afb221796f3b44d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75e941f5fc5947699c7c61518ca1ab67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3856be9b89747b993110c792a39aabb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id46d0ee7b3624110a0d31e8dbeb2f227_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44f47d5a4f3247508475ee667ae3091f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i369fa34137ce41348503313048b70075_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84420d968625493db489841b6ba9cd22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib343098582894c1b8730d6b3ee859c16_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63c86efa20674a879fa6ed36fec4b168_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8552f5934714f03a7223229598d0a2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2be404c6e2704f988bf6f30f9911074b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1df8661f299c437396b33cccb1c6eac8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63886e254baf421a9707d4d5eb8bab28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ca30aa64779494ca3499ac96dcc8ff4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e43ff19422d4545a2da37ba9a92b601_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf5f275b31a74d0897b0a32abeeeb534_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id41f8b67700946dd803fdd98061bc244_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id77c83d365be429dbcf3b8e60f6471c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i057559badebc49ff81913d91205892d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a2d444d9cee49b99776001b30841e74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93ff0b8f85bb402b839b0f6cb69bfaa0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1b990e41a8c4816ac9862a30699ee0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief7bb5378ae8468895c202125d15e129_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc33001b56c64b11b1bc56c135168d51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0de82ccd51af439091344dc5996e1a43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if50fd4be30c6481e89383764b9f60a6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c2609bce6c04e03995a81ac43177271_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i70941f166b074b6aa1687d9f7338fae8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0029a1b43ec54a29b829f135a48f9cfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">icui:NonpublicCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7437d14a12be4025b5493cb7d897d472_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedical2020LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedical2020LimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbf4360bc208465f843ef61d1768b5e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1129dd1b04d7446c9d3d06c36614788e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic98b9ae2742141cea974ed1a1041b446_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05325f7dac154ac19707c10ed7936bd5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignInfusionSystemSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22c99d7dca834fc9b8ba44f702ce5c97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71cb42b4cdb34217bf31e9da4cf6cfaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c4925743ff242b0b2ee65ecd693dd3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92c10763b02e45ea9ffe7f02507e2e8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55936ad0651e4e25a3f22368ebb27543_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i404ace05705b44778677860b518b5b99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8dfdc44868074605937528148921ca05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7c134c659424d68b063d67180a61ce0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:IVSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a974801206342f69077c517deb2da0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:CriticalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia31b13090f3d4d6896d08faf55e51eed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49af9a202b4c453dbe1982d3176037d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:InfusionConsumablesSmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3486eaebd0f44d4582e0714314d501cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic383a5944210457b97aab0db2bac248d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VascularAccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id75defc870864b6e98d462140afc25c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie95a1fa30baf4c46a60229408037bef6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:VitalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica1baa88a6474f1ca1bde91733d99703_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e3ea0f082c144ce87ee7b48799015d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32b1c128a1684402a9045faf165e1fc4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcdf4b4d10d049fc8afa1abd2cc0db5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i002db38129f24286874e3dd53ccdaf95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f8c28deaeb448d887fa9af7b3d8346a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:APACDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f21e80f577f43c19fd1aa42008e7706_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24e71756005b40d2933a4ea6f87d56f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4df4b017e9b041fa969010720463d6c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherforeigncountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if45f71d7222548f6aa04eb33ce7241ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5482a1d0e20f424fbf824e580d6a9199_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie96a185ecb1c4a958fca6ce4a87a4b19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:InternationalSalesDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34be06a38704454ba49d54c4642a8be6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i801bb622fa854aa8aa887087ba287be2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:EquipmentrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad7155363879401cb075f883b3c05618_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib153ddca67ce46f9a87db324f5e82b2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:SoftwarerevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb08893e609946fb8063faaad20c4476_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8688bac62fd54e49817ebdf4ef330a22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:GovernmentGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec83df23cc984ae1bb81bac0c2d32d43_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if24294e168244b4d800b76ebe275bb94_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">icui:OtherDeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c7b424d053745b89be43013214212ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:ShortTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b46600611854ead8201632b540aa737_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic71707c2dff14fa99b1f7a37aa00d176_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i455063291da94c4e933985b9ba288cce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfc6130bace04212a70134842313f556_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="if6c41509b0124224b8916fec64855b95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e1f7b608a83444d93727a50a57cc19c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7f3edab321b4f47b9ab4112053d6a1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">icui:A2003PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f933b32da444865b80e747cabb2916d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:TimebasedstockoptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ced0ef8f682482e991d67cc95e1bae8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd58a5889bd341b6a832c886185b7b3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c67054a7a594d6983252a6891238d26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9241e754a3e241929d3a847fe66556ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41a074cf04634fb682ff822fe3155504_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7744c2c44b6e49a192f49a29131c1146_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i754c391455cd4db0bb5e009228c4ed88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">icui:RestrictedStockAndPerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie512243dc7bc4d1a8e0708ea1460f39e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MXN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c33090ddb2c4c7eb6ff7538c7bb476b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6789c74e7e04a6795307d8a02ddf4b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CZK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0541d3f55fc040d3ac00d6c25ff32778_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia728542369a84272b8c445494962161e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3b3f4f1317a42f2be3e756d642c8e7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99be33b784264317acca70b9f25f1a88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i184372b7fd1647f08adb94357659448d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf68976ce40345619a3f5648dcaacb18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:Srt_MultipleCurrencyAxisAxis">icui:OtherCurrenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbb5e6d91a92409d9ef474923b762b07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge3MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia79af1c5b1914270838bef1b8ec536a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:Hedge5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i394377fd918340248b6debe2d54beff5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d3e73355e5a46779e8b500f773bcabb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i099ba0834fb64e019127f5cf439531b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b1f546a435746b6a9e083834063101e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia825f2d41f694d229f7aba34643141dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">icui:UsGaap_InterestRateSwap2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68398fc85c9b4c69a9d24ac18c9275b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i181b26114ca442d3aaba5f83684bef22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f0e5b7233314ac39c225315b21f33ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e7144ed377e460497e6a92365d659ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0764c13b084d4be3bc783f9c9b3ff993_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8884b7e467144a1abd07dd5529d382c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i858ccda502774a3c8bcffb5a5e2125f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d9d60c60bed4ebea68c80e275f8e3d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia039837b279e455ca2dc2d46edc4b550_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i820fd306ff3d43e2b341018522bb3760_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24d376e7b6d2421fae5fe8fa52db03b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15ec86e2578c4dc9a435e041179ae4c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddc61959aa8d4d67bc160b2ede121548_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5824bf85f4040b1976e55e688d916b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i735eafbcc4e744f1a518604a58b733d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01412f1ac55c4cd89cb8ff97582fb41d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice2ef219571e4d04b73e0b06787c1ad9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73f036a93e924d5fa456f3b1b062e994_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9d0b9ad85694f8f94491a20a88c9179_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b28be753e1e4e43a0042554fc467ca7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8aaf3d494f04e50ba69cff6e04ff60b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20054b0c9f4b47ac8c1e534ba6ea3ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia08778ed5abe4561b708b5b722eeb93e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia728d4a36f3f4749a1126fa36fef1423_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i836cf2e65d5e413682ba9671638f8619_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib14489f445c94e4c8d8946d9f09ab71b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e4670f805e84ec88fcc239984f42f1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib28bced960bf4b37988c086fd5dd0698_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8dd0869a16144b0a67bc6b37b8b72bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4b2cef3151a4d45a40c618a6d750d32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifde680e06fbf430e8e5775077493e0c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1677095d03d54c6cad7ffddc26a40aea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i120db90932414ec390afe7cf3a633cc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i253805333c4f482db81b9d675244447d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43d08049edd740bb914aa46bd7090759_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaec03ea5060745ba8354c6aad5437d98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06fe49c746ff44d19762274cadbe0d7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia7152ead34514d1f9d4453e1a803d747_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fb45b8279f94588a9bb6ea15ea5b6e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:TradingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38c5dc156f3d4065a5ac61ee8ad07be7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e281a61518246b28c211682f9b80e67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54664f90ad4843079c7700ad05a8cd6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9694c6e8455346248c473df62e0ab068_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc8ea47f15d34f9b8c4166744ab1524e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie345d2cbe6234906900704fc912fcdb4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57c5dcea53454983887455c2111ad23b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34fb2d02e47f4de1added70760728782_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8e04f05c0ec4c2c82f5854eb7872516_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i886d8381dfd34aec845daca43861614f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03b89fe4e5804575a068ee1b69c7ef41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia66661620e064610aa37046c932752c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignDistibutorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia073c52ce185453aad5151952a58609f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:ForeignDistibutorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic34de2470df94313bd4a853cb4b2bf53_I20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-06</instant>
        </period>
    </context>
    <context id="i4fb0ac701d04472195a9beec28ba8137_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id04b91b0851c487e8d69fa69f80b7e71_I20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-06</instant>
        </period>
    </context>
    <context id="icad841eb6c614e71bdb127b3ac3d2546_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3edb4cd0b8bb40dda8c7263ec544dba8_I20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:SmithsMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-06</instant>
        </period>
    </context>
    <context id="ibdcc27cec606429689f360f5df15a62d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">icui:RevenueGrossProfitVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e89e9c91139472a80f40636d2e26639_I20191102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">icui:RevenueGrossProfitVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-02</instant>
        </period>
    </context>
    <context id="i941468b2385e4f209a986c7dff3b8af1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98bde5dfe72e41209cdbda2cfb7fc991_I20191102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-02</instant>
        </period>
    </context>
    <context id="ia08eae0f4c494ccd87126117aa4a660d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife89f6478b684cf2b18ee6b3e0ad8937_I20191102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-02</instant>
        </period>
    </context>
    <context id="iae7d1235c8584e3eb8cb944747cce27f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad35dba2b3944b4fa96b9b4a1230664d_I20191102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">icui:PursuitVascularInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-02</instant>
        </period>
    </context>
    <context id="i5686278e7c91400b845a73fe1fcf028f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd3a9546be5e4813b1774877849c0367_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3be252f91ca24066a82707f0ccc864f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i689ac27a1ce141ea907010394c836e09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i422117d39c024ae298b2e44b34ec42d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i323ab94bdb574beaa5f3b95de704e67e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86e66814fa7f4fe3ac2057be6b115992_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7f770a2cbd548a0b79e3ff8f05781c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a5aa933f00841e28eb62458bbde9491_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i547287843f834e908b791ca319cb5472_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30434229a1be41d2b746928edc9596bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42d5d4dbdf274858bc9380796f898b48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f03abc412b44071b8f3a13dd339e879_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i109a7c7dcc9143cbaa84164f7f3d1725_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i139196726adc4d44903147af425499fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42498a38a5c743788e5c175074a9c29f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8551f6edca8a4836b92c3f8ac634761f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:NoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8cb6e64c7b7454eb5293e9be41c37fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7a809ee047749f983c3b7fb473a8eb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab3bf5b1a2204bf9bc64adbee638216b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9659021b124e4d70badd33a6c9cda626_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:ClassificationAxis">icui:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f064e9a451f45aab673c4e82dcbc340_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28cf3e1c65474a53a54292b2f298eedb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf7925fa17894fb08b1ed1fcb9abe902_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68c59017357e4d0eb7f04b926d3edfb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i052d13e776b84488abcb5580ea31dbe2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f2071503a8441eb91e6e1a18cbcc84f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f436b1a47f14d0dae8fe3ff7fc02609_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30307f3e17834aff9e9b9bfbe9740d2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a0b9c47fb4a4632ae6c2ec0c8a0fe8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63099355b56b44639735fd719595c0ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49cc40992cd148db92c3dc165f590efb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34247cf421ab44c3a642063a2a64781a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84d86d123e7649bc9a08ba202f8cbb1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8a169b1291f4fae8f8673b8db33720e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a7bcaa2cb0c40ec9f2f05572f36effb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8154538596c24715a9b857081ebbf2c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideb24c12f52c4ed4bfd923928efb0545_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9ea28028ba24e559823c8e265b177a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib694e789a9e14a96a033168b758bb8b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56e8fec49f6742c484f4ed39291aac3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i137f448db78e447e98bb2714c16ee9d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3909bff053c54be18d8308bc23b1552c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94d3b6e5dace4cfcb820e268951f1c59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i897c4914d2304f7eba66e3d057bfbd11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a8f66bb87b841b5a46011fe3af927e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia357ea3684bd486e9a953093cc31299a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72dc2b3b6d1643f08f096152319ae32f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i739de8efcf0847099e2173cceabc811e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73a361b33fe1423ba9980571550cb413_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i122ee70217fb4cbd8648c12f53e80c04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11fe6f3df45e4383a8f40e6ae0c2e20f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0627ac618c7845f1bb5092afa5095fb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd40f9b169a94661afad5c82b59ee442_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">icui:EarnoutliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11793d1454d04740869956397beef53f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie95679179f944cce9f35afb1724a6e06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9c51ce9a1aa4ba2803e09d904c5763f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i814802c25f134344bd1ca05e7f8d0ef7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27f7481192424f469ce8b17fa4645692_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48c5d747a44f4274ba30ffb47647922f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if231634d16b94cbcb21a0c638c4ef8b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibec9f0f2f05443f99f93d8d000ec554d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39ced24d07c14cf4ab00eabf97854594_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f4092f2517f47dc82182e9da5e14d64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e3aed3c3b2c4c3bb0a41361e73b80b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87f16fd75aa948d082f729515410eecc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TimingAxis">icui:LongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc72f3e18557464b95e8f93f95cf00e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3e83c70755646978896ceeb0d4640fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04e492dc437f484fa3e50ad7d36f77eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3512d069dc6a415ebe18d0c8a10b509a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:Greaterthan400to100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85c800885ad645afbf1ee8116a89418e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:Greaterthan400to100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifcafc35b7a454888b107f59bd07d6378_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo400To100ButGreaterThan300To100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3270e97d056d47e8942bc86735a9953e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo400To100ButGreaterThan300To100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i561277523fc640f3a0134d32b5168980_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqual300To100ButGreaterThan250to100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cba9d0dc8fe4d66bbb43d02faad4c58_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqual300To100ButGreaterThan250to100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i732e1f9dac654f7d8f641f5c8da76012_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo250To100ButGreaterThan200To100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i940aefe82dbf46ca9e966ea0b26dd508_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo250To100ButGreaterThan200To100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1c38a7e4a4342929faf1d4648044fa0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo200To100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e4c6ec34d394489821d50e1ab61b2a5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThanOrEqualTo200To100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id34fa01e4d2b483792e00d21e1d5819a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:GreaterThan275To100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="icui:LeverageRatioLevelAxis">icui:LessThan275To100Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="icui:TermLoanAxis">icui:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96000b832d5e4e13bd5d06c79eee6056_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7925517a758c4a05a8e9da61378b7c92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NonCurrentDeferredTaxAssetGrossTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NonCurrentDeferredTaxAssetGrossTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i794337b645e5444f81f7183e04ce3f2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if184142ad50b45d9b675340cb944b665_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie02d613a9e034e6baa9929b53040a7cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie4b20d6909b144f7b28ddd68e4ad46d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">icui:NoncurrentDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic74afdfeacf44457849b250892ba31a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f12929d589749c8b6a43800619acc14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4edba33e66d94d07a0c91f5f1eff0b0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacef78c490d44ef6a148c9eb69aec7b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d8e28b05ab3410580b2d84dbdd0ff1a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ab8e7d8411f469b8720f601291c4a1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id87d1ef443a94425bc7fef55aeffbb03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:MexicoPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic28ae14b327942628ff1906d2fa400b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:MexicoPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if62f26db34af43bf98b7eb60c5ef5415_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherLATAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1ccbff4571344c18aff14611e8b7d41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:OtherLATAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f5cc1fca5304ed09aeff7464d1e1b88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3eb2ffbc07f548e4b7b499325d1200f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibeed5a4cba574b72b53f8a7432ccc8cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ItalyPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie430db3a6d1b4b528af030bd7dd26f8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ItalyPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i858b45f5d29a4f37939d46ac810c5f30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07d6d0becacb4e22863dabc259d16c28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ab060b29dc6441d9456425aa02c761d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:CZK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2962b814b7d0406e9adeda9d07ebf1f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:CZK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e5eb1e1a8649b3ad0d53df35a54ddb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica41d22848d442c7a94244fcacf01646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied976c6e3e0a43d5aeb99cdfef5e2e64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i636799cc86f54ffb9c9c4e4c13426aa6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68ba3be1285c44ab8b8349e837ac9991_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia7753094a85f4264af0e886e818d2987_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:ForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i447520138d3742d59dc3a80450bc8093_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:UnitedStatespropertyandequipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i706aa6c5c3ab47198dd4e501b7d0d5a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">icui:UnitedStatespropertyandequipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa663d5f8034bcf82e68c00868a0197_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id92a0b79cf4e4de386c722e094de46b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09229c1123194f28a17b163cf6604124_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1faf359ab764117901453deb57409c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0da14f54cad34e0a8daba92db8c33fc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0caf14d09a404492b64fca8be909ef3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcd1f43f9b9842828a851bba915574e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79dba0899e1d41e29b803de02336e957_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82e9f0ccbbf147428b431dbee759a035_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5a149a148884f35a6590fc0b706383d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0310811c16e34b749b6d6d1c6f540f0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88345fb489ed47658151750624bb4497_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib851d69906c841cea381d2520fe3324a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88b545d554f247d7a0a02f76642e67d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3fc00bdab17483ebbb47afc85c0dab2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e4fdf1f07a54b639ac859a24b648c8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93ac49fefe63465a8912d34fb790031a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf00748957594ed9924d63ec3390253e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0549fbba004248979b80bb6b02218da9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i322d334cb60e40d4a61f1bc09d5257bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15f182769ad646e3bddd9c4239760f1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0271cf17cf0844a2a04595bf20873f7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59fef45bfc2f422c819e0dbb81290ea7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i205528742f3c4d1db554ed4a86cd9547_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:WarrantyReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4b8f43d24ee94d6093c1c5f148e1cf17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883984</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>icui:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y18zLTEtMS0xLTkyNzE4_6418db18-23b3-4eb2-baad-6110aec2726f">0000883984</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y180LTEtMS0xLTkyNzE4_4b3b42ce-a25a-4049-b5f2-acc85c3f99bd">ICU MEDICAL INC/DE</dei:EntityRegistrantName>
    <dei:AmendmentFlag
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y182LTEtMS0xLTkyNzE4_5eb7ac31-d5b1-4ad6-a5b1-c3994792bac4">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y183LTEtMS0xLTkyNzE4_df71bfe2-c970-49a7-b921-82920e1c483d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y184LTEtMS0xLTkyNzE4_98f2c735-79d7-486a-829a-21a997781d15">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80L2ZyYWc6Mjc1YzU0ZDAyZTc1NGMyZWE2MzkwYTZlNmFmNjI4ZWYvdGFibGU6N2U0NDk5Y2FmMGNkNDc3ZDgxOGVkYjBkNjEyZWY3NWMvdGFibGVyYW5nZTo3ZTQ0OTljYWYwY2Q0NzdkODE4ZWRiMGQ2MTJlZjc1Y185LTEtMS0xLTkyNzE4_3b7bbcc7-bbd2-4fac-85cc-3430d8a1a06d">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfMy0wLTEtMS05MjcxOA_87be4e6e-5c6b-4b54-a61e-d3584033c7ae">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfMy0wLTEtMS05MjcxOA_ed4f727a-6287-404e-b9d0-15b912195527">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_0baea7bd-78b0-43d2-bd4f-02c6f89301a8">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_1f984f27-4206-4068-beff-770acc19eaac">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_7947a7fc-e7b3-4d8a-96b0-7becbc4f0baa">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNC0wLTEtMS05MjcxOA_ff39d26a-47e9-47c8-b024-f7e2b3ee2934">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_0aeb4fa6-cd6e-459f-be2f-a304576549f2">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_20ab121e-d6fa-4a69-988d-418f6ea7508d">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_436ec06d-b89d-489c-b40e-f5f35b02dc52">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84NS9mcmFnOjJlNjQwZTkyMzVlYzQxYzY4N2FmZDYxMDQ3NTA1MGRlL3RhYmxlOjZlN2Q1MTFlMzFlODQ0NGFiYTE4Y2NlMDc3ZDQ0YWM3L3RhYmxlcmFuZ2U6NmU3ZDUxMWUzMWU4NDQ0YWJhMThjY2UwNzdkNDRhYzdfNS0wLTEtMS05MjcxOA_628a96ea-3825-43b0-ac31-f230969c82ef">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTI2L2ZyYWc6ODc1ZDYzYTI4NjhhNDgzY2IxOTZiMmQ5ZmU3NDMyMzIvdGFibGU6N2FkMWI4YTVjM2JmNDIzNDg1OTI2MzE5OWExZDA3ZjkvdGFibGVyYW5nZTo3YWQxYjhhNWMzYmY0MjM0ODU5MjYzMTk5YTFkMDdmOV8wLTAtMS0xLTExMDk1NQ_3cb7e75f-e2ad-4531-903e-6efe90dde60a">http://fasb.org/us-gaap/2022#InterestIncomeExpenseNet</us-gaap:DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTM1L2ZyYWc6MzlmNzM2ZjU1NTcxNDI3ZWEzODQzY2EyODJiZDI5MmIvdGFibGU6Y2EyMmM5MmY1M2I2NDI5MjhiNjI0ZmQ2Njk4MGQ5OTcvdGFibGVyYW5nZTpjYTIyYzkyZjUzYjY0MjkyOGI2MjRmZDY2OTgwZDk5N18wLTAtMS0xLTExMDk4MQ_c06eacfe-8478-4d76-901b-19012a422dab">http://fasb.org/us-gaap/2022#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</us-gaap:FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList>
    <dei:DocumentType
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ0_ad9c3ee5-f8a9-42d0-9742-c13a68cb0bef">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ1_543c53eb-2a30-4ec4-908a-60c06f1b8292">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8yMDc_8317e49e-608e-42cc-ab32-8e8b9708a206">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ2_de296777-c40c-43c9-a56e-6c95259b0c00">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM5_32831637-cd6c-476d-9ec1-14242ce4d78b">001-34634</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6ZGM3Nzk4ZGZmYzBkNDgzMzkxMzkxYmNhNzE0MzFlZTcvdGFibGVyYW5nZTpkYzc3OThkZmZjMGQ0ODMzOTEzOTFiY2E3MTQzMWVlN18wLTAtMS0xLTkyNzE4_396592cb-de79-441f-8d2f-db4e1afe3bcc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6ZGM3Nzk4ZGZmYzBkNDgzMzkxMzkxYmNhNzE0MzFlZTcvdGFibGVyYW5nZTpkYzc3OThkZmZjMGQ0ODMzOTEzOTFiY2E3MTQzMWVlN18wLTItMS0xLTkyNzE4_2917becc-5acf-4068-b3c5-e834bebfeead">33-0022692</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8wLTAtMS0xLTkyNzE4_89a99d8e-146e-4ced-bc22-d5bbae4c7e8b">951 Calle Amanecer</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTAtMS0xLTkyNzE4_d6310e9d-045a-4e7a-9951-7ed12559b7ad">San Clemente</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTItMS0xLTkyNzE4_c5f3e819-643c-4eb7-8ffa-fae63cdd140b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MTU0YTZjY2Y2NTI1NDMzOThkYjcxNzYwZGQxNjliNTgvdGFibGVyYW5nZToxNTRhNmNjZjY1MjU0MzM5OGRiNzE3NjBkZDE2OWI1OF8xLTQtMS0xLTkyNzE4_7fdb546f-5302-4d26-908f-94e4c1f317ba">92673</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM2_a7979850-6d05-4838-94c9-03b7d8c04395">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQw_2e7ff73a-c594-420a-abeb-1874ac7fbb32">366-2183</dei:LocalPhoneNumber>
    <dei:SecurityExchangeName
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8xLTItMS0xLTkyNzE4_89708fbf-ffc1-4d17-9237-0b0a5061a326">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8yLTAtMS0xLTkyNzE4_7fc59886-e132-42b5-856a-a000ad87a4e6">Common stock, par value $0.10 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6Y2RjZDBjODU4YTE4NDY1ZDhhOWE0MDkyOTY1NzljNjgvdGFibGVyYW5nZTpjZGNkMGM4NThhMTg0NjVkOGE5YTQwOTI5NjU3OWM2OF8yLTEtMS0xLTkyNzE4_0ce85d9f-0ecc-415f-874f-68201782a443">ICUI</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQx_2ddce5fa-43f1-40fb-97ed-522e4406b1a2">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQy_1ee15ea5-c16b-4965-8648-bd31345190ee">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM3_bf4aca89-c52a-4118-88ea-514a229d8c9e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQz_b0599bb7-aeda-40e3-87e0-bc8a18b50116">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV8wLTAtMS0xLTkyNzE4_c54e793b-f7ac-46b1-a9d3-c1c04f627367">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV8yLTQtMS0xLTkyNzE4_2d294407-cd6d-4b67-bd9a-2928bddc451d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGFibGU6MjI5MGUxYmM1MGMyNGIyYThmZjBlNzk1MTYyMzY1MzkvdGFibGVyYW5nZToyMjkwZTFiYzUwYzI0YjJhOGZmMGU3OTUxNjIzNjUzOV80LTQtMS0xLTkyNzE4_1d82b554-621f-4a28-ad97-7f2e3631da86">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM4_65314b62-1085-4829-87a9-510801b370fe">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTM1_0ea9e469-55f2-44b7-a670-29a43f218880">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i08f3fdac040a4646ae49b87760e750b8_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8yOTEx_cceb2827-5856-485b-be61-cc6d8c9b226a"
      unitRef="usd">3305900983</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie2e9049c6fe84be399e3b04481dcd237_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zMDEw_eef4ad02-7939-47c8-b8c0-d34edc4fba01"
      unitRef="shares">23998252</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xL2ZyYWc6Y2RiOTNlZmZjMzBkNGU3M2JhZGJhMmZlNWMyZGU3YWYvdGV4dHJlZ2lvbjpjZGI5M2VmZmMzMGQ0ZTczYmFkYmEyZmU1YzJkZTdhZl8zNTQ3_e2d10b1a-774a-47e3-be0f-00b509277074">Portions of the Proxy Statement for registrant&#x2019;s 2023 Annual Meeting of Stockholders filed or to be filed pursuant to Regulation 14A within 120 days following registrant&#x2019;s fiscal year ended December&#160;31, 2022, are incorporated by reference into Part III of this Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80OS9mcmFnOjMwNWY1MTlhZDJlNDRkZTNhYzQ0YmJlYTc2YWE0YmRkL3RleHRyZWdpb246MzA1ZjUxOWFkMmU0NGRlM2FjNDRiYmVhNzZhYTRiZGRfNjUxMQ_3c2ffe68-05d2-4930-9da0-ac22d917f198">DELOITTE &amp; TOUCHE LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF80OS9mcmFnOjMwNWY1MTlhZDJlNDRkZTNhYzQ0YmJlYTc2YWE0YmRkL3RleHRyZWdpb246MzA1ZjUxOWFkMmU0NGRlM2FjNDRiYmVhNzZhYTRiZGRfNjUxMg_015a3f04-9acc-4d8e-91ec-53417303e038">Costa Mesa, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNC0xLTEtMS05MjcxOA_c2b78b83-feb4-4dfb-8cf5-82acd1cd16f0"
      unitRef="usd">208784000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNC0zLTEtMS05MjcxOA_b60286c8-9e4d-4312-aa98-a5621302eb76"
      unitRef="usd">552827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNS0xLTEtMS05MjcxOA_70e18950-1229-4f74-a690-0cab28a5ca27"
      unitRef="usd">4224000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNS0zLTEtMS05MjcxOA_cd589bbd-7468-4002-9d55-6266a8c6c168"
      unitRef="usd">14420000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNi0xLTEtMS05MjcxOA_bd0c6421-ee3a-44b1-8e2a-6655c841da9b"
      unitRef="usd">213008000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNi0zLTEtMS05MjcxOA_0f9a7ee5-b5e7-40aa-b7ec-1918f243c966"
      unitRef="usd">567247000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjVkY2I0ZDdjMTY4YjQ2ZTZhN2YyYjZkMmEzODQ3M2YyXzY3_d30f64b5-b95f-41c2-84ef-4f804ef8f58f"
      unitRef="usd">8530000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjVkY2I0ZDdjMTY4YjQ2ZTZhN2YyYjZkMmEzODQ3M2YyXzc0_051fdbb1-5158-4bdd-a83f-2a281951170b"
      unitRef="usd">7038000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0xLTEtMS05MjcxOA_77228d58-20b1-46a5-8397-e98a6002e3a1"
      unitRef="usd">221719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNy0zLTEtMS05MjcxOA_ec8c378a-ca98-4569-b7fe-b0fc07bc74c3"
      unitRef="usd">105894000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOC0xLTEtMS05MjcxOA_d5964a34-6e81-4ac1-a305-46d5586f2c10"
      unitRef="usd">696009000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOC0zLTEtMS05MjcxOA_42c93e37-a8d9-4f37-82d5-adcf016575b3"
      unitRef="usd">290235000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOS0xLTEtMS05MjcxOA_ae883563-e770-42fb-a5f1-e94b3be93211"
      unitRef="usd">15528000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfOS0zLTEtMS05MjcxOA_dd3b4b97-54a8-4a40-b0c5-18275a2b865d"
      unitRef="usd">19586000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTAtMS0xLTEtOTI3MTg_468ffd4c-4d29-4039-97e1-e9a33a6a915c"
      unitRef="usd">88932000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTAtMy0xLTEtOTI3MTg_86020281-e5e9-4225-9bc7-9a9919d58cef"
      unitRef="usd">46847000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTQtMS0xLTEtOTI3MTg_895802eb-4020-4798-8797-49e7527602d7"
      unitRef="usd">1235196000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTQtMy0xLTEtOTI3MTg_a259c734-582d-4abc-935f-1f89f94f6599"
      unitRef="usd">1029809000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTYtMS0xLTEtOTI3MTg_6aafb7f3-f46b-4914-8329-3fed5ce05749"
      unitRef="usd">636113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTYtMy0xLTEtOTI3MTg_c530a14a-84fc-42e5-b5d1-6a6076a99f3e"
      unitRef="usd">468365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTctMS0xLTEtOTI3MTg_c9fa2965-4d1e-417f-98de-e535e495a8f3"
      unitRef="usd">74864000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTctMy0xLTEtOTI3MTg_79cb0c9b-4f5f-4b46-b450-49e31c00a9bf"
      unitRef="usd">39847000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTgtMS0xLTEtOTI3MTg_cad77f83-54a5-407e-b891-908400c3423b"
      unitRef="usd">516000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTgtMy0xLTEtOTI3MTg_ea5967ff-e0bb-4edd-9414-5f3557b1ef9f"
      unitRef="usd">4620000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:Goodwill
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTktMS0xLTEtOTI3MTg_fdc18405-2b7e-4b2d-a018-4e70ba3604ad"
      unitRef="usd">1449258000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMTktMy0xLTEtOTI3MTg_48b1a00d-5a23-488d-8520-62c188aba726"
      unitRef="usd">43439000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjAtMS0xLTEtOTI3MTg_c69e5619-3902-4587-9a0f-6b7b60dba91d"
      unitRef="usd">982766000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjAtMy0xLTEtOTI3MTg_a2909ba7-d91d-47a6-8b22-194184cec9e1"
      unitRef="usd">188311000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjEtMS0xLTEtOTI3MTg_74d29916-9df2-4f6a-94ca-b9ff04893533"
      unitRef="usd">31466000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjEtMy0xLTEtOTI3MTg_b2d18948-21b7-4779-963f-c244dacbe9c6"
      unitRef="usd">42604000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjItMS0xLTEtOTI3MTg_cd899f92-cd21-4288-9b71-7b71df385d7e"
      unitRef="usd">105462000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjItMy0xLTEtOTI3MTg_a9e7fc9d-c87a-46c5-9898-8f297b64ccaa"
      unitRef="usd">63743000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjMtMS0xLTEtOTI3MTg_9da084e2-9470-45fa-a497-b4c646a0fd36"
      unitRef="usd">4515641000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjMtMy0xLTEtOTI3MTg_0eaa3875-2024-4e38-8d68-6bd6175014c3"
      unitRef="usd">1880738000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjYtMS0xLTEtOTI3MTg_215cb268-dee2-4144-b48d-f3d94bf9d785"
      unitRef="usd">215902000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjYtMy0xLTEtOTI3MTg_148a48df-1e17-4166-9ca9-ada55535da6b"
      unitRef="usd">81128000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjctMS0xLTEtOTI3MTg_e5df3d22-56f2-419a-a67a-b98899f106c7"
      unitRef="usd">242769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjctMy0xLTEtOTI3MTg_113c0bd2-2797-4e7b-b20c-ca5c2ff5327c"
      unitRef="usd">118195000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMS0xLTEtOTI5MzE_f1ab566e-61fc-4832-bab6-ab25c6ff93f7"
      unitRef="usd">29688000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMy0xLTEtOTI5Mzg_a16e3421-eb67-44d3-8f42-345b7963cb1b"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMS0xLTEtOTI3MTg_4cece5fc-9ec2-4d0a-aba4-0a5788c8eb30"
      unitRef="usd">6200000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMjgtMy0xLTEtOTI3MTg_09b30176-f3c2-4828-ba7e-e0e3e7a54024"
      unitRef="usd">1454000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzAtMS0xLTEtOTI3MTg_cbd04090-5719-41a4-ac7a-6b1e5098a972"
      unitRef="usd">494559000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzAtMy0xLTEtOTI3MTg_ef949798-a475-4005-ab0e-2906ed4e8c7d"
      unitRef="usd">200777000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzItMS0xLTEtOTI3MTg_670ee70e-4317-4dc3-911a-436908d4a37b"
      unitRef="usd">25572000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzItMy0xLTEtOTI3MTg_30d455da-248e-4d4c-8839-53ae26abd04e"
      unitRef="usd">2589000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzMtMS0xLTEtOTI3MTg_8c944757-790c-47c7-9c3d-a3b44d5aa10a"
      unitRef="usd">1623675000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzMtMy0xLTEtOTI3MTg_e4c087d7-4b35-4b1b-ad30-75bc599dc446"
      unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:OtherLiabilities
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzQtMS0xLTEtOTI3MTg_8a4a22ff-9483-4520-a40c-84c1d789a766"
      unitRef="usd">114104000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzQtMy0xLTEtOTI3MTg_cd16075b-a87e-40e5-80be-4327c4fb1845"
      unitRef="usd">41830000</us-gaap:OtherLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzUtMS0xLTEtOTI3MTg_4f7b7b97-2250-49cc-8260-35d750a7c1bd"
      unitRef="usd">126007000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzUtMy0xLTEtOTI3MTg_63167ff8-ec8c-4798-a180-0373c3b323c3"
      unitRef="usd">1490000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzYtMS0xLTEtOTI3MTg_5544cf4b-d31a-4c31-a1fa-f6e4e9967451"
      unitRef="usd">41796000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzYtMy0xLTEtOTI3MTg_1b31f9e2-1968-4d9e-95ff-208528f62419"
      unitRef="usd">18021000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzctMS0xLTEtOTI3MTg_3b2006d5-e631-4f34-90ae-a4a2e90b7298"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzctMy0xLTEtOTI3MTg_28f53e38-2b20-4449-869f-ec881aec2c37"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY18zMw_61a563e7-9e6f-4ee4-b63c-dbbc418130bd"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY18zMw_f8f55c9d-37a5-4160-8917-43637a6ec07c"
      unitRef="usdPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY181OA_06e94a56-2d60-4749-9cd3-67207eec8442"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY181OA_15502392-8e42-4b8d-b764-5518dc2a6272"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY185Mw_5a6f9dc0-1854-4c78-98b0-6fd41f5f858a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjo3NGFmYmQ3MzJjMzI0NzJlYWYyMDVjNTdhZWQ4NWExY185Mw_940bfab4-3f87-4223-bab1-d1757e3bc45f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMS0xLTEtOTI3MTg_83fcb538-a9c7-4ea0-bf69-ad2a9aefdfb5"
      unitRef="usd">0</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfMzktMy0xLTEtOTI3MTg_9ecd4795-e2a6-4b8d-ab01-f7303fc02164"
      unitRef="usd">0</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xOA_375fa254-d5f8-4a41-9502-95932a127407"
      unitRef="usdPerShare">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xOA_97a7541a-5eed-4485-aa0b-f39e4d81bcf1"
      unitRef="usdPerShare">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV80Mw_7399b948-6d17-473a-9e2d-2cbf4a09cc60"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV80Mw_7401c29d-49ce-4748-879d-48652de24b74"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV82MQ_4333a4df-1631-46a9-bfb2-a31a6d8ec9c7"
      unitRef="shares">23995000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV82OA_1c34dd24-7bf8-46c2-a796-5b8c17e8965d"
      unitRef="shares">21280000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xMzk_920e9bcd-ecee-46ca-9902-bddcb11098d8"
      unitRef="usd">23993000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjpkZDg1NDYxZWIyMzU0NjY0ODE1YWQ0ZmExMjM4ZmYyMV8xNDY_5adef0a5-bd5d-413c-9a39-d423f9ca581d"
      unitRef="shares">21280000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMS0xLTEtOTI3MTg_14bdee59-ef40-4396-87ca-359cc1b52748"
      unitRef="usd">2399000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDAtMy0xLTEtOTI3MTg_fb2cdd4f-8b3c-497d-925e-f09f347bb1e3"
      unitRef="usd">2128000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDEtMS0xLTEtOTI3MTg_b62b6435-4447-4b00-858c-959de463b0d5"
      unitRef="usd">1331249000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDEtMy0xLTEtOTI3MTg_fe123bb3-f95d-42c0-9972-93f5e0615f5d"
      unitRef="usd">721412000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjoxYTA4MWM2NTJkM2Y0OTIxYmZlOTJjMDA5N2NiMTcyN18yOQ_7a43331f-da6e-475c-9210-346a8339ab54"
      unitRef="shares">1633</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMC0xLTEtOTI3MTgvdGV4dHJlZ2lvbjoxYTA4MWM2NTJkM2Y0OTIxYmZlOTJjMDA5N2NiMTcyN18zNg_3df35819-3b65-4c06-92b3-172a5d049079"
      unitRef="shares">119</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMS0xLTEtOTI3MTg_fef73bfc-8eea-47a8-8e7e-7e537e975d04"
      unitRef="usd">243000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDItMy0xLTEtOTI3MTg_f61f2d2a-9840-44f0-b3fb-959f889d1b79"
      unitRef="usd">27000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDMtMS0xLTEtOTI3MTg_1583197b-7ab3-4214-abdb-a67fb4300dd3"
      unitRef="usd">837501000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDMtMy0xLTEtOTI3MTg_03fd6892-2ecb-473e-ba7a-e27782af52f2"
      unitRef="usd">911787000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDQtMS0xLTEtOTI3MTg_84480987-e13d-40df-baab-5afccf49efcc"
      unitRef="usd">-80978000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDQtMy0xLTEtOTI3MTg_819c5e60-4dae-47e3-a3bf-63bc5fa36827"
      unitRef="usd">-19269000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDUtMS0xLTEtOTI3MTg_cedb5d74-a7c7-4ee7-9699-51d2708f3f2e"
      unitRef="usd">2089928000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDUtMy0xLTEtOTI3MTg_4b73972b-599e-45d0-bc54-cb38254fbb9e"
      unitRef="usd">1616031000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDYtMS0xLTEtOTI3MTg_2690b620-adc9-4238-b3fa-6194f1faab9f"
      unitRef="usd">4515641000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81Mi9mcmFnOjM4MjliNjU5Y2RiMDQzMTJiMTQ1NTBlZDA4NzliZjI3L3RhYmxlOmM2ZjYyYzhkNGQ2ZDQ3OGNhOThhOWI0Y2Q0YTI4Mzg3L3RhYmxlcmFuZ2U6YzZmNjJjOGQ0ZDZkNDc4Y2E5OGE5YjRjZDRhMjgzODdfNDYtMy0xLTEtOTI3MTg_3b47cacc-ea2e-44a5-b29e-2dc95c31f251"
      unitRef="usd">1880738000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC0xLTEtMS05MjcxOA_b431045a-4cd2-4aed-9687-aa21b740310d"
      unitRef="usd">2279997000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC0zLTEtMS05MjcxOA_01c95fd0-7778-4df7-bab2-57c27c688be6"
      unitRef="usd">1316308000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNC01LTEtMS05MjcxOA_2f732ce4-7791-4e71-8dbf-915603968d3b"
      unitRef="usd">1271004000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS0xLTEtMS05MjcxOA_33cd86ab-4675-4c64-b2b8-bbf904b11d6c"
      unitRef="usd">1582236000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS0zLTEtMS05MjcxOA_b0569c71-fdcf-441e-a485-d5ec61468278"
      unitRef="usd">824818000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNS01LTEtMS05MjcxOA_bbdaeceb-21d6-4212-82ec-2d5fc8782126"
      unitRef="usd">809507000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi0xLTEtMS05MjcxOA_03cf0f58-4855-437c-a72c-237409ab9470"
      unitRef="usd">697761000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi0zLTEtMS05MjcxOA_7ebd7de2-a507-4998-8a79-aa01031834b3"
      unitRef="usd">491490000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfNi01LTEtMS05MjcxOA_c425548b-93ed-4b51-92de-ae9b1a95407b"
      unitRef="usd">461497000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC0xLTEtMS05MjcxOA_b18355ff-fec6-4353-b71e-0ff4da2c52a0"
      unitRef="usd">608345000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC0zLTEtMS05MjcxOA_b3101192-4061-42f3-81ba-69015c62e039"
      unitRef="usd">302583000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOC01LTEtMS05MjcxOA_c99a9f82-09ae-4f74-b3d2-f72977d9ac7d"
      unitRef="usd">283953000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS0xLTEtMS05MjcxOA_b24d7547-983a-46e4-adf1-812eca761653"
      unitRef="usd">92984000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS0zLTEtMS05MjcxOA_2a0ff442-e875-43b8-a7d3-995c9ae415e1"
      unitRef="usd">47498000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfOS01LTEtMS05MjcxOA_00b23ebc-f7ed-47b1-baa2-0b0d162c3d3a"
      unitRef="usd">42948000</us-gaap:ResearchAndDevelopmentExpense>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtMS0xLTEtOTI3MTg_e709b353-9c2d-470e-8903-2e070c00540a"
      unitRef="usd">71421000</icui:Restructuringandstrategictransactionexpense>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtMy0xLTEtOTI3MTg_f18638e5-019c-4800-a3a5-39a3476c7584"
      unitRef="usd">18037000</icui:Restructuringandstrategictransactionexpense>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTAtNS0xLTEtOTI3MTg_bed65e77-4251-43d3-aee8-6e9ca1aa41c9"
      unitRef="usd">28409000</icui:Restructuringandstrategictransactionexpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtMS0xLTEtOTI3MTg_a9e22fec-cda7-4f0f-a46d-31b106a8792d"
      unitRef="usd">-32091000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtMy0xLTEtOTI3MTg_3e1d3c91-aeeb-4a2c-bbd9-308d38c178da"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTEtNS0xLTEtOTI3MTg_e32faa30-bc03-46bd-826c-6eba5d4d8f78"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <icui:Contractsettlements
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItMS0xLTEtOTI3MTg_6c043c64-469f-43bb-85bf-948a503023f9"
      unitRef="usd">0</icui:Contractsettlements>
    <icui:Contractsettlements
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItMy0xLTEtOTI3MTg_057323c1-8e5f-4391-b5d0-eee15473fd17"
      unitRef="usd">127000</icui:Contractsettlements>
    <icui:Contractsettlements
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTItNS0xLTEtOTI3MTg_35be9190-2454-4dca-a6e2-292d08f93c09"
      unitRef="usd">-975000</icui:Contractsettlements>
    <us-gaap:OperatingExpenses
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtMS0xLTEtOTI3MTg_f18b0845-20b6-46d8-8502-718ac929c0fc"
      unitRef="usd">740659000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtMy0xLTEtOTI3MTg_e96aa2e7-7610-4b00-ac80-fc6545350ecc"
      unitRef="usd">368245000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTYtNS0xLTEtOTI3MTg_2e99c34a-ff01-45cc-8b30-d27a67d2d1aa"
      unitRef="usd">363335000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctMS0xLTEtOTI3MTg_fa204c95-5855-4352-bbcc-957c75f3dbb1"
      unitRef="usd">-42898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctMy0xLTEtOTI3MTg_24f545b4-2bb9-44be-b0c5-3c0078a82fb0"
      unitRef="usd">123245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTctNS0xLTEtOTI3MTg_c7736f28-8e39-4462-8e93-b1ab8e4c76f5"
      unitRef="usd">98162000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktMS0xLTEtOTI3MTg_49f620ff-9c92-417c-aa85-aab7ef41a4ae"
      unitRef="usd">-66375000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktMy0xLTEtOTI3MTg_07d61f04-6c00-4fe8-a1a3-da7483281aee"
      unitRef="usd">1982000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMTktNS0xLTEtOTI3MTg_d53b91ef-7b2f-4f20-b5e6-427b94c0c332"
      unitRef="usd">1924000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtMS0xLTEtOTI3MTg_ce540d90-f6d5-498b-9fdc-ce0a1f91049c"
      unitRef="usd">-5136000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtMy0xLTEtOTI3MTg_9be77489-21cd-4d95-88b9-89a85df326d0"
      unitRef="usd">-2041000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjAtNS0xLTEtOTI3MTg_39918b3e-614d-478e-bc37-5acbde2be73c"
      unitRef="usd">-2592000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtMS0xLTEtOTI3MTg_afc97c94-918b-48b3-ad7c-fd16d6955855"
      unitRef="usd">-114409000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtMy0xLTEtOTI3MTg_a671a7f3-275f-4017-9c45-754d7da65988"
      unitRef="usd">123186000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjEtNS0xLTEtOTI3MTg_cb1c86c3-6f7e-414c-aa9b-80c901c72354"
      unitRef="usd">97494000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItMS0xLTEtOTI3MTg_c1493f3a-017a-4e0f-b673-c8061e93d2e0"
      unitRef="usd">-40123000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItMy0xLTEtOTI3MTg_0ea5ee4c-20b9-4b6b-99a8-4c8c5fe75ea9"
      unitRef="usd">20051000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjItNS0xLTEtOTI3MTg_fd6b1b9f-ffbe-4ac0-bfd9-1f68182c7e97"
      unitRef="usd">10624000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtMS0xLTEtOTI3MTg_a0dad0cd-0ff6-4f03-bac1-95f6e3a9b6f3"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtMy0xLTEtOTI3MTg_b49e549c-c017-407c-96c0-aec8467c16d1"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjMtNS0xLTEtOTI3MTg_cc035317-e07d-4b00-9f49-946c79b2a32d"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtMS0xLTEtOTI3MTg_832f9d16-8e43-4ef9-bb54-028313bf0d3e"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtMy0xLTEtOTI3MTg_1efb354c-29ec-41dd-b242-3dbb5bc9c12b"
      unitRef="usdPerShare">4.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjUtNS0xLTEtOTI3MTg_18cafea1-112f-49d1-b022-e9fb0a79fa8f"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtMS0xLTEtOTI3MTg_2eb99c72-03b3-4a90-a73f-2112da33917d"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtMy0xLTEtOTI3MTg_bbe62a88-46d2-489f-bc7e-79506ae8be7d"
      unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjYtNS0xLTEtOTI3MTg_0656f5a2-a554-4ae6-9247-88e7d3d5585c"
      unitRef="usdPerShare">4.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtMS0xLTEtOTI3MTg_2b86867b-afaa-4e88-b216-d770547f244d"
      unitRef="shares">23868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtMy0xLTEtOTI3MTg_897e6f2d-33ee-4632-adcf-0fc9946b5c5c"
      unitRef="shares">21206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjgtNS0xLTEtOTI3MTg_bbf16e3c-3f4b-412a-8693-c0976acfc7be"
      unitRef="shares">20907000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktMS0xLTEtOTI3MTg_adfd0e5f-a627-43ec-97c9-7d002a83a1ce"
      unitRef="shares">23868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktMy0xLTEtOTI3MTg_5914d297-b8ed-496c-92cd-a6cc2b964107"
      unitRef="shares">21781000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81NS9mcmFnOjgwNzU0YTEwNWYwMDQ1NWU4MTZjY2Q3NjEyMzQ4NzA5L3RhYmxlOmIxZTRlOWIzOTA5YzQxOWM5MGYxMTRkZGJiZTEyMWE0L3RhYmxlcmFuZ2U6YjFlNGU5YjM5MDljNDE5YzkwZjExNGRkYmJlMTIxYTRfMjktNS0xLTEtOTI3MTg_e6ac2651-910a-4438-b950-ab17171d7f20"
      unitRef="shares">21591000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi0xLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi0zLTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfMi01LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzQ3_14b2faff-4bdb-4163-9c7d-f6f4f8f540ce"
      unitRef="usd">12941000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzUx_d629246d-3206-49c5-915c-544a13be3da0"
      unitRef="usd">-954000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOmE5MjhlYjU4MGEyMjQxODE5ZTQyYjJlNWVjOTkzYTIxXzU4_b746e2a2-85a5-4a2c-b264-b18d925311e8"
      unitRef="usd">285000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0xLTEtMS05MjcxOA_16b6f9d8-917b-44a4-9ef8-0040eb49ee67"
      unitRef="usd">41016000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC0zLTEtMS05MjcxOA_f5daecf6-de9e-4408-b876-1df86d87dcfe"
      unitRef="usd">-3021000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNC01LTEtMS05MjcxOA_467f5a20-04cb-4cdc-ab6b-8c367326ef1c"
      unitRef="usd">904000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_098038fc-f6fe-49e6-955d-0ff78d67a87a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_0ad006c5-9d78-4838-90d5-5ba4741f14ea"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhMWI5MzE3M2Q3MDQ1M2JiN2JlZTdiOGZhMDZiM2NmXzU5_ba89c985-caf2-49b5-a3d8-f37640612719"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0xLTEtMS05MjcxOA_fe1e734f-c126-4af9-8102-57594dba8b26"
      unitRef="usd">-103928000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS0zLTEtMS05MjcxOA_9210c8c9-9632-4999-80bd-89b90c88b91e"
      unitRef="usd">-14664000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNS01LTEtMS05MjcxOA_797228af-6358-4446-8e63-e7742c4953bc"
      unitRef="usd">12929000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_1a64d531-346a-4f1f-9f91-40c5074aa190"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_41aebc5a-9643-43b6-98b4-58e13e85a2f8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0wLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg4MzIyNmUxYzNjODQ4N2Y4YTFkYTI5N2QxNmE4OTBiXzM3_cac3437e-0120-4db1-b86e-d65b5953a315"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0xLTEtMS05MjcxOA_87044ab5-09c3-4686-bf19-314b80164aa6"
      unitRef="usd">-1203000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi0zLTEtMS05MjcxOA_66919ae2-8fa5-4c36-be9c-e14c24a32e6c"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNi01LTEtMS05MjcxOA_1ca7a8b2-6db2-4075-a7ba-f561e472a73c"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy0xLTEtMS05MjcxOA_cdbe5d5d-2a1b-40e6-a00c-4387853be82a"
      unitRef="usd">-61709000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy0zLTEtMS05MjcxOA_ffe8b398-bea5-4d32-81d1-65692d9e83a1"
      unitRef="usd">-17747000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfNy01LTEtMS05MjcxOA_3cbb6581-60d5-4eec-a127-ee2e1f29d4bc"
      unitRef="usd">13880000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC0xLTEtMS05MjcxOA_3396d3c0-3621-4120-a7b8-ec2cd27e8c56"
      unitRef="usd">-135995000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC0zLTEtMS05MjcxOA_704483be-aa45-443b-9418-f32c2f1e8cb2"
      unitRef="usd">85388000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF81OC9mcmFnOmY4ZTM1YzJhM2Y1MDQwM2Q5MTYwNGQxY2YwOWUzMTFjL3RhYmxlOmY1NDdkZjY1M2NkMTQ2ODhhYjZkODc3Nzg0YjNhMTNlL3RhYmxlcmFuZ2U6ZjU0N2RmNjUzY2QxNDY4OGFiNmQ4Nzc3ODRiM2ExM2VfOC01LTEtMS05MjcxOA_e81a48f9-dd49-4888-928f-d4e2ba42fe3c"
      unitRef="usd">100750000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie2f128dabbbb42f790c9b42b1a52d19f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0yLTEtMS05MjcxOA_4c3b9c4e-78c7-4257-930d-96689c0a5f16"
      unitRef="shares">20742000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic98ea3f4a06d4a69b875b005c4bfdee8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy00LTEtMS05MjcxOA_2af14be3-07a5-4587-87f3-578d5beaf13f"
      unitRef="usd">2074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51a94223681d4d6f8e75c3e7b836cbec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy02LTEtMS05MjcxOA_5cf5466a-a535-4bf0-90fd-e5023e4b6330"
      unitRef="usd">668947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ee1b6542ad84492b4d2ec455fa9ae81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy04LTEtMS05MjcxOA_1312e222-88f4-425f-8b4c-6196957998db"
      unitRef="usd">-157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0ece853202944e484c25ad349453bf0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xMC0xLTEtOTI3MTg_17a6909d-483c-4b78-83b6-bdb74f802362"
      unitRef="usd">721782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idde6dfbd9e9b4a638c3f365c3f9bb4f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xMi0xLTEtOTI3MTg_f1f13b1c-8a0f-40ab-acf0-17531230d5b1"
      unitRef="usd">-15402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMy0xNC0xLTEtOTI3MTg_1fd3bdbc-4a36-43f9-b1ad-220c3bc96b3b"
      unitRef="usd">1377244000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS0yLTEtMS05MjcxOA_f58a97bb-421b-4cc6-93a6-2e565dd40ff2"
      unitRef="shares">383000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie33927c32f4649af822a8418053d8d99_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS00LTEtMS05MjcxOA_79f82e80-8460-4eea-b4d7-42c023c4f840"
      unitRef="usd">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS02LTEtMS05MjcxOA_0d3e4c0a-61bd-423f-bc27-07449e4dbeee"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1337f299defe4eaf888a017913e309b5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS04LTEtMS05MjcxOA_3c4a6b47-0577-4479-9df2-7becca1a7d35"
      unitRef="usd">12994000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNS0xNC0xLTEtOTI3MTg_35a24389-4bc9-4d8e-ac57-2a6bc8eec9c3"
      unitRef="usd">13193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iae5f3bbd3eaf4a3f8869d658825bf6a8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi0yLTEtMS05MjcxOA_9639ff33-c64d-4bdf-95a5-c19e4134d0eb"
      unitRef="shares">67000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi02LTEtMS05MjcxOA_5efbee8a-1626-41e0-af5e-f5a0bdb97a8b"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1337f299defe4eaf888a017913e309b5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi04LTEtMS05MjcxOA_594c51c2-539f-4d87-9dfa-b889df216d30"
      unitRef="usd">12876000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfNi0xNC0xLTEtOTI3MTg_aa399f55-9ec7-4ce9-b68d-f0e4afaf4260"
      unitRef="usd">12876000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i79543f41864548a996a0edce3cc373f1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOC02LTEtMS05MjcxOA_06224470-c0c5-49f5-85e8-6befb87d192a"
      unitRef="usd">23954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOC0xNC0xLTEtOTI3MTg_639e619a-a11a-4202-959a-a8149481b546"
      unitRef="usd">23954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i5603cb92819e4c3ca2de991234b01760_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOS0xMi0xLTEtOTI3MTg_a4b5e841-78da-40f9-a146-2a358b85b3d3"
      unitRef="usd">13880000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfOS0xNC0xLTEtOTI3MTg_e86d334c-dbdb-4dd0-9603-0c67ac597295"
      unitRef="usd">13880000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a7c4b10df94a5cadb8f2ccb5d91e45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTAtMTAtMS0xLTkyNzE4_cd3f145c-86bd-4010-9890-7490bd8eaa20"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTAtMTQtMS0xLTkyNzE4_1f78ae6e-66ee-4696-9b98-8c5e3aea225a"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib68360870df24c48b23f24f3a787a64c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMi0xLTEtOTI3MTg_431beebe-aaa1-4102-89e0-577154cb3463"
      unitRef="shares">21058000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ied10183a5d8941e6b5c8713d7c2eadd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtNC0xLTEtOTI3MTg_6c9056ee-9e2e-4e9e-ace2-7b63bf49bcf3"
      unitRef="usd">2106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if792565cf68b4836a7b528942b2852fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtNi0xLTEtOTI3MTg_b1a630a2-b71a-4266-995a-307fda4d210f"
      unitRef="usd">693068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff8979ceb98e47dfb43a3711dcf7912a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtOC0xLTEtOTI3MTg_174fa6f1-31dd-4846-a9ef-a88af2fc1a1a"
      unitRef="usd">-39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11a5d2a2a4af46a3974d2432b63c41cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTAtMS0xLTkyNzE4_3a756d32-8db8-4fd9-999b-5e5ca67b1594"
      unitRef="usd">808652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15893976f8864a729360aae7e272b56e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTItMS0xLTkyNzE4_3b869864-968f-416e-8adb-41e32120bcf7"
      unitRef="usd">-1522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTEtMTQtMS0xLTkyNzE4_fdc0ccf0-f675-4cad-a99b-6e293aa38ac1"
      unitRef="usd">1502265000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtMi0xLTEtOTI3MTg_22c638b9-fe0d-4991-aee1-bc6738ef45f4"
      unitRef="shares">262000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i81e7eed8de8c409a833960699b90df5c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtNC0xLTEtOTI3MTg_d17cd20a-b710-4b0b-9eea-dca72e1bed06"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtNi0xLTEtOTI3MTg_554f3ae3-e184-4b8d-9d34-b09b41461807"
      unitRef="usd">1003000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i801a4fae42184517928aa871ec10a664_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtOC0xLTEtOTI3MTg_5c4f9138-e5d2-4f74-ae6f-6667490a3231"
      unitRef="usd">8347000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTMtMTQtMS0xLTkyNzE4_390706dd-6167-472b-b4e4-3e35d6baa689"
      unitRef="usd">9372000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i36ca26542e7c40ffb67ad216f2e434c8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtMi0xLTEtOTI3MTg_d13f3ba9-f3f6-4bb9-86ca-79606f013fd3"
      unitRef="shares">40000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtNi0xLTEtOTI3MTg_067f319b-75ac-408d-b6dc-7080f02c307f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i801a4fae42184517928aa871ec10a664_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtOC0xLTEtOTI3MTg_61c8196d-33a2-4b3b-95c0-ddd25014bd18"
      unitRef="usd">8335000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTQtMTQtMS0xLTkyNzE4_7a389abe-f6a3-470d-b36a-11554407d84a"
      unitRef="usd">8335000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia205b1e9bf62442798a9b6572e77fc2c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTYtNi0xLTEtOTI3MTg_85770381-0a55-4f62-a7c4-164d6b9bb34f"
      unitRef="usd">27341000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTYtMTQtMS0xLTkyNzE4_bbea180b-a64b-4c67-81b8-bcf56f5f1324"
      unitRef="usd">27341000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="icbd88657bbd04d46a2104ab8bc2406fa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTctMTItMS0xLTkyNzE4_bbce13d7-07cd-48c2-8d62-89d7cbb28af9"
      unitRef="usd">-17747000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTctMTQtMS0xLTkyNzE4_dd8343c5-b7e2-4ad0-b5b0-ef36a7f19519"
      unitRef="usd">-17747000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1b5dce62564e466793e72557cf0c42bf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTgtMTAtMS0xLTkyNzE4_b8ff7e3d-b5f3-4db8-9679-9325b88f4b3f"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTgtMTQtMS0xLTkyNzE4_d6fc54cd-1fed-4e36-9740-cc34d74769c4"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3ca5a22717754de18e1be8d99bab4c9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMi0xLTEtOTI3MTg_13d058c1-a926-4f7b-80b9-bb4fd4e5168c"
      unitRef="shares">21280000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9d9952ba8ae7440abb7a7c721d75b664_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktNC0xLTEtOTI3MTg_5cd5e945-c807-433f-a1cd-96b1912f4729"
      unitRef="usd">2128000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf7a0a723cc04a34b8b697b0e8fb25cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktNi0xLTEtOTI3MTg_331ab4da-0ba3-4e47-ab4a-69890562a119"
      unitRef="usd">721412000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic703ef27cbce4420b73d994faaa947af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktOC0xLTEtOTI3MTg_0aa2b934-7e07-4ec1-a0be-d34a62e6ba58"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic19e854fbfba4ab0abc5e57ea4e706e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTAtMS0xLTkyNzE4_d6a04248-f2f8-4507-9834-ce233631912a"
      unitRef="usd">911787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffbdea58d0184ec48cf84b1a702fc5df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTItMS0xLTkyNzE4_4c81a45f-2b01-4fbb-9f53-01ac33ee38d5"
      unitRef="usd">-19269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMTktMTQtMS0xLTkyNzE4_765bfd0f-d548-4a55-b9b1-c802dc9e23ca"
      unitRef="usd">1616031000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie18d81392ae04265a3d03510728b3646_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtMi0xLTEtOTI3MTg_24aaaabd-9c5a-4ac3-8664-9799c514b0b9"
      unitRef="shares">263000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtNC0xLTEtOTI3MTg_20ff6df0-0b4a-49fd-b48b-3640e72c3e18"
      unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtNi0xLTEtOTI3MTg_7338f110-f2ed-4cb4-8b93-cff92d24961f"
      unitRef="usd">-1903000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtOC0xLTEtOTI3MTg_a6b6c813-aec6-4b2d-bea8-c4d55fe457c0"
      unitRef="usd">10667000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjEtMTQtMS0xLTkyNzE4_ccb03a2e-d9fa-411a-b1c1-74c13f94f0b6"
      unitRef="usd">8785000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie18d81392ae04265a3d03510728b3646_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItMi0xLTEtOTI3MTg_c3ec6d91-72a0-4e1e-83ab-b2449863fdde"
      unitRef="shares">48000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItNi0xLTEtOTI3MTg_3ff09843-f97d-4813-81a0-6da191b79fca"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iddfdb1d1869b4478b93acdf0154a676b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItOC0xLTEtOTI3MTg_d6877973-2bac-4ed7-b018-d995c218e940"
      unitRef="usd">10883000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjItMTQtMS0xLTkyNzE4_8381cf13-ef68-429a-9ab8-ccbbe7d06d4d"
      unitRef="usd">10883000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtMi0xLTEtOTMxOTE_68f27f47-9702-44b3-a95f-6d3c826592b3"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="icffec3a2d3184599bf34f7c2a260cf9d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtNC0xLTEtOTMxOTg_be11e3cd-c082-4a63-af61-febe5a076924"
      unitRef="usd">250000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtNi0xLTEtOTMyMDU_05722b94-1258-45a5-9fb1-724f4edbf31e"
      unitRef="usd">575725000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjMtMTQtMS0xLTkzMjM4_1395810e-0c8a-45fe-ac82-4246688ce484"
      unitRef="usd">575975000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjQtNi0xLTEtOTI3MTg_a9e61fca-39c3-4cd6-88ab-fc0b9b056a93"
      unitRef="usd">36025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjQtMTQtMS0xLTkyNzE4_ce95c77b-7b1f-4421-a877-6f444d7c1964"
      unitRef="usd">36025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ifda776f91ca546d4b11792d1ea86d286_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtNi0xLTEtOTI3MTg_8238f7b5-4f52-4f93-8c0f-5753c003d304"
      unitRef="usd">-10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i6dfd2e0db2834b9db1915caf0df77a09_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtMTItMS0xLTkyNzE4_f2440ff1-2741-4f55-afe2-d44ab2c18cee"
      unitRef="usd">-61709000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjUtMTQtMS0xLTkyNzE4_aa245ad7-adf9-4f6a-a640-0737d74d0e29"
      unitRef="usd">-61719000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7131fb5352c74f58a87b1b96952be01d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjYtMTAtMS0xLTkyNzE4_954ea2ec-7fa0-4e65-a39b-618ac64c8b52"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjYtMTQtMS0xLTkyNzE4_093d6da1-5304-4adb-b39f-bb0029e15b6a"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47136614a9cc4f309d163a050608f73e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMi0xLTEtOTI3MTg_34f84548-baf1-4e9a-ae39-c56f1a9a8cbc"
      unitRef="shares">23995000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0e4f2ecd87ce4d80bea7d0755b982f2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctNC0xLTEtOTI3MTg_21ceac05-063a-4e83-ac85-c8ee282b5acc"
      unitRef="usd">2399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f29b1e5a63a431c8553eb9154631953_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctNi0xLTEtOTI3MTg_067380c7-751b-4133-af8a-3febb50a0d38"
      unitRef="usd">1331249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idad27c484ae8448cb258c0b5ad63372b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctOC0xLTEtOTI3MTg_a8df8638-a63c-40ee-ae3b-5f1a4c8c1f7d"
      unitRef="usd">-243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30d33b6f5efb437681ee2b0b9b8c6a33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTAtMS0xLTkyNzE4_ff974f34-cc72-45c6-8af4-8e3c60aaef5c"
      unitRef="usd">837501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e09627e54ce4d96a945c0e3e3954f4d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTItMS0xLTkyNzE4_8d9fb2e6-1fea-49d3-8d97-3022e2304362"
      unitRef="usd">-80978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82MS9mcmFnOjk3ZjFiZWVjNjdkMzRiZDFhY2ZjYWMwNWU0OTY3M2FjL3RhYmxlOjE1N2UwZGExZDY1MzRiMDM5YTZiMDk5MGJkNzQ1ODU1L3RhYmxlcmFuZ2U6MTU3ZTBkYTFkNjUzNGIwMzlhNmIwOTkwYmQ3NDU4NTVfMjctMTQtMS0xLTkyNzE4_8731fd36-b459-4df5-b9bd-26b9b12bc78f"
      unitRef="usd">2089928000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy0xLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy0zLTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMy01LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS0xLTEtMS05MjcxOA_bf9a046d-ff7f-4488-9acd-95b3204c3200"
      unitRef="usd">235151000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS0zLTEtMS05MjcxOA_c78771cd-98d7-4d80-b43b-4a526ba9d3b8"
      unitRef="usd">89698000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNS01LTEtMS05MjcxOA_151db1c3-855b-4f58-82f6-8733300c006c"
      unitRef="usd">85631000</us-gaap:DepreciationDepletionAndAmortization>
    <icui:AmortizationOfInventoryStepUp
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0xLTEtMS0xMDcyMjc_a6c3b8c3-0a68-4645-93a8-6aff6136f03a"
      unitRef="usd">26519000</icui:AmortizationOfInventoryStepUp>
    <icui:AmortizationOfInventoryStepUp
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0zLTEtMS0xMDcyMzY_802bd53d-65b8-440d-af0f-267090412dca"
      unitRef="usd">0</icui:AmortizationOfInventoryStepUp>
    <icui:AmortizationOfInventoryStepUp
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi01LTEtMS0xMDcyNDQ_84e55a18-f816-4208-8936-0de9e10e3f4e"
      unitRef="usd">0</icui:AmortizationOfInventoryStepUp>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0xLTEtMS05MjcxOA_b4770eb1-1d3a-4c88-b45e-affaa3cc35cc"
      unitRef="usd">23651000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi0zLTEtMS05MjcxOA_ad60229b-7902-498f-af62-c09cf437d16b"
      unitRef="usd">9594000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNi01LTEtMS05MjcxOA_b7196b5c-db53-44cd-8232-023049856993"
      unitRef="usd">9216000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy0xLTEtMS05MjcxOA_7a72e8c1-c445-4495-b214-d369f72e44ea"
      unitRef="usd">1036000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy0zLTEtMS05MjcxOA_0b36fcde-b5ee-4623-91c1-321ca3ca7653"
      unitRef="usd">345000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNy01LTEtMS05MjcxOA_09dbcc0f-edc7-413a-aeb2-b9e34aaf6468"
      unitRef="usd">7137000</us-gaap:ProvisionForDoubtfulAccounts>
    <icui:ProvisionForWarrantyAndReturns
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC0xLTEtMS05MjcxOA_52de0a1a-3b76-44f7-907b-1cc6efdd5df9"
      unitRef="usd">4902000</icui:ProvisionForWarrantyAndReturns>
    <icui:ProvisionForWarrantyAndReturns
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC0zLTEtMS05MjcxOA_77122821-6648-40ab-af5e-3bdd2b603139"
      unitRef="usd">831000</icui:ProvisionForWarrantyAndReturns>
    <icui:ProvisionForWarrantyAndReturns
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOC01LTEtMS05MjcxOA_e5f80142-9739-4e6a-b604-15fffcc91265"
      unitRef="usd">-1576000</icui:ProvisionForWarrantyAndReturns>
    <us-gaap:ShareBasedCompensation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS0xLTEtMS05MjcxOA_8275a05c-708b-4d12-b019-7a2ab894687c"
      unitRef="usd">36025000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS0zLTEtMS05MjcxOA_7be36594-267a-40c7-bac1-7367087e2759"
      unitRef="usd">27341000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfOS01LTEtMS05MjcxOA_9a9647ea-dd81-4166-804b-656bee8ed15e"
      unitRef="usd">23954000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtMS0xLTEtOTI3MTg_3f2cee2d-104f-4305-9e3b-b8acae2c9082"
      unitRef="usd">-2010000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtMy0xLTEtOTI3MTg_d1d79098-1bb4-4998-9a3e-5f30ca541367"
      unitRef="usd">-1652000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTAtNS0xLTEtOTI3MTg_8e494ea0-c6b6-454e-921a-67e4cdb035d0"
      unitRef="usd">1789000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtMS0xLTEtMTA1Mjg5_591ac336-16b1-4f70-8b61-e4e18f7ba717"
      unitRef="usd">374000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtMy0xLTEtMTA1Mjk4_fb5b3172-c1bb-40fd-b8d9-7baa9511aa05"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTEtNS0xLTEtMTA1MzA2_caa35d2c-1e8f-40d9-acf1-977d0e46c025"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtMS0xLTEtOTI3MTg_2416d8c0-bf28-4c5a-8598-9733ec87a539"
      unitRef="usd">264000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtMy0xLTEtOTI3MTg_b09d0408-bf51-44e4-9d72-022e0df6f13d"
      unitRef="usd">655000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTMtNS0xLTEtOTI3MTg_1052194a-6fe4-4462-8cfc-163804cf4ad8"
      unitRef="usd">231000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtMS0xLTEtOTI3MTg_a6cee758-9415-4ab9-954b-138f0ca71117"
      unitRef="usd">6972000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtMy0xLTEtOTI3MTg_9eddc78a-e6ce-47eb-b410-3c08e7c90608"
      unitRef="usd">240000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTQtNS0xLTEtOTI3MTg_5d874611-e44b-4bda-a3b0-d1f8a002a546"
      unitRef="usd">288000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtMS0xLTEtOTI3MTg_085ed495-4aef-4e47-a50d-1903a3da8505"
      unitRef="usd">-32091000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtMy0xLTEtOTI3MTg_bade1224-7730-46ac-92fd-dcff103ecb8c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTYtNS0xLTEtOTI3MTg_dee79be7-3061-4bf5-a202-b32730d32087"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctMS0xLTEtOTI3MTg_f098b2ad-aa9a-405b-bdf2-e407d71acd84"
      unitRef="usd">0</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctMy0xLTEtOTI3MTg_81aab270-da7e-40d2-affe-857ddca5e737"
      unitRef="usd">3380000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTctNS0xLTEtOTI3MTg_91ad3d1e-3a7a-4097-9912-d3e8319f039e"
      unitRef="usd">2626000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <icui:Sparepartsusage
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtMS0xLTEtOTI3MTg_de6ae0b0-83e0-4ed1-bd9a-fda10bae0677"
      unitRef="usd">11924000</icui:Sparepartsusage>
    <icui:Sparepartsusage
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtMy0xLTEtOTI3MTg_32b666ca-cbb9-4f84-bf3d-5158f86afc2f"
      unitRef="usd">13046000</icui:Sparepartsusage>
    <icui:Sparepartsusage
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTgtNS0xLTEtOTI3MTg_57c118dd-3b6c-4d49-8eb6-e4d2d622836b"
      unitRef="usd">11191000</icui:Sparepartsusage>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktMS0xLTEtOTI3MTg_fdc7d88d-f034-4ebd-acad-f0f29553b78f"
      unitRef="usd">-103000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktMy0xLTEtOTI3MTg_26db62c4-830d-497f-ae6f-ada1d8be35d5"
      unitRef="usd">2582000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMTktNS0xLTEtOTI3MTg_6008fb52-c659-432e-94a8-02f0e3f6a029"
      unitRef="usd">6939000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtMS0xLTEtOTI3MTg_d799c25f-9fde-46e5-98ff-4eb57facfe4f"
      unitRef="usd">19151000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtMy0xLTEtOTI3MTg_b34f66b6-1b53-477f-802d-feaac9e10bf1"
      unitRef="usd">-13755000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjEtNS0xLTEtOTI3MTg_5c8cf90e-5b72-4117-9b56-7ed758638bbf"
      unitRef="usd">-78049000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItMS0xLTEtOTI3MTg_27c7d9e6-4aa3-45f5-b2ac-b1719cc87a03"
      unitRef="usd">201095000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItMy0xLTEtOTI3MTg_d1bbe72c-6633-4030-b085-1e6873b994ac"
      unitRef="usd">-20815000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjItNS0xLTEtOTI3MTg_f6e41d10-e918-40e2-81a0-f64a8a7604ad"
      unitRef="usd">-19196000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtMS0xLTEtOTI3MTg_016bb748-3fe7-4531-9306-a434f43fc70c"
      unitRef="usd">-22903000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtMy0xLTEtOTI3MTg_c1e17ee0-7c10-4c2e-9004-4396f8a66f16"
      unitRef="usd">7973000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjMtNS0xLTEtOTI3MTg_1f3ff817-5888-4c89-83dd-c33b3ed1bb21"
      unitRef="usd">4311000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtMS0xLTEtOTI3MTg_ba2ed376-20b6-436e-972d-a68641376248"
      unitRef="usd">21290000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtMy0xLTEtOTI3MTg_82e62fdb-7a9f-4db2-8b95-40d801ee78e1"
      unitRef="usd">21038000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjQtNS0xLTEtOTI3MTg_8183dd01-a335-40fe-b9db-079bd4c43765"
      unitRef="usd">16069000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtMS0xLTEtOTI3MTg_765ca36d-e634-4832-9912-32350904b483"
      unitRef="usd">37472000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtMy0xLTEtOTI3MTg_20638271-75da-465c-8a69-5e83058b06aa"
      unitRef="usd">2347000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjUtNS0xLTEtOTI3MTg_a89350cb-cbfb-484d-9ad9-250d8e138c8c"
      unitRef="usd">-46415000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtMS0xLTEtOTI3MTg_b7202e76-a8e3-48b6-99da-b352471de5c2"
      unitRef="usd">-55834000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtMy0xLTEtOTI3MTg_44273b9f-ffc3-4b06-bf2e-5d50f817378d"
      unitRef="usd">6259000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjYtNS0xLTEtOTI3MTg_8ec41770-b346-42c9-af60-0b69fd783fb3"
      unitRef="usd">-29379000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctMS0xLTEtOTI3MTg_4ef90a19-3c4f-4336-bec7-34d633e416f7"
      unitRef="usd">-66734000</icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes>
    <icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctMy0xLTEtOTI3MTg_b27eb4dd-bbe6-43cb-b9b0-06b61560b561"
      unitRef="usd">874000</icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes>
    <icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjctNS0xLTEtOTI3MTg_07e08982-415e-4e01-9a9b-95804d42b0e9"
      unitRef="usd">-18037000</icui:IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtMS0xLTEtOTI3MTg_2575f69d-3bed-4625-b2cf-d2817cb08c81"
      unitRef="usd">-62129000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtMy0xLTEtOTI3MTg_418facf1-3aed-4cd1-85cd-f8d800fd3832"
      unitRef="usd">267538000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMjgtNS0xLTEtOTI3MTg_5aeee896-19e7-4f78-95c4-5fde96ecd844"
      unitRef="usd">222752000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtMS0xLTEtOTI3MTg_30fe7cc4-aff2-41b4-816d-898f95ba62ef"
      unitRef="usd">90311000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtMy0xLTEtOTI3MTg_f6da02da-a4a0-41c3-9a5a-23775b300757"
      unitRef="usd">68542000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzAtNS0xLTEtOTI3MTg_20b4cffe-6fb3-4b0c-9f5b-9fbc1f99e87e"
      unitRef="usd">92005000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtMS0xLTEtOTI3MTg_97576681-e711-42ad-8e69-7f1bd83e4096"
      unitRef="usd">989000</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtMy0xLTEtOTI3MTg_58236630-4a62-4300-90ad-3ebd8dd89ee1"
      unitRef="usd">218000</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzEtNS0xLTEtOTI3MTg_b5188269-df6f-47df-8dbb-03e71eae4ea4"
      unitRef="usd">6176000</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtMS0xLTEtOTI3MTg_82d68b1e-7b41-48d9-9011-5caecfddba67"
      unitRef="usd">9018000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtMy0xLTEtOTI3MTg_d77dff5a-dbb2-437f-a9f4-1eb38fd0ae23"
      unitRef="usd">12627000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzMtNS0xLTEtOTI3MTg_36168faf-2fab-4e41-86f8-7bd1274759fc"
      unitRef="usd">8385000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtMS0xLTEtOTI3MTg_89e2a82d-1dab-495b-ade8-3968523be239"
      unitRef="usd">1844164000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtMy0xLTEtOTI3MTg_db0cce48-e184-40ad-abfc-f9e97fd6e516"
      unitRef="usd">14452000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzQtNS0xLTEtOTI3MTg_9e213e8a-3257-47f6-ad0a-aa3506b73986"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtMS0xLTEtOTI3MTg_a561926e-6966-4a71-9202-8c0445f8e4ae"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtMy0xLTEtOTI3MTg_d0c65606-2d82-4dcd-9144-9133a7604a52"
      unitRef="usd">3250000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzYtNS0xLTEtOTI3MTg_115f5a58-b0f3-405f-bb2b-5e24d03f54c1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctMS0xLTEtOTI3MTg_c4cb2606-6a50-491c-9ab1-cf831a756620"
      unitRef="usd">3397000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctMy0xLTEtOTI3MTg_eb2684ef-923c-4b08-9a2d-865749f5a9bd"
      unitRef="usd">10034000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzctNS0xLTEtOTI3MTg_8e1840b3-1e56-4d4e-b207-dc5cabbf7aaa"
      unitRef="usd">32825000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtMS0xLTEtOTI3MTg_a699287b-aaac-48ba-bddd-5f4a33855f58"
      unitRef="usd">36433000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtMy0xLTEtOTI3MTg_21cd741a-42e0-40dd-92fa-8fbfef0b040f"
      unitRef="usd">18000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzgtNS0xLTEtOTI3MTg_480e5381-0978-4f02-8b2b-ab9f1ddcc1f1"
      unitRef="usd">28900000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktMS0xLTEtOTI3MTg_92f3bd18-6ab2-432f-94b5-96187bcb19ae"
      unitRef="usd">-1909468000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktMy0xLTEtOTI3MTg_d13167db-fa53-4d60-831e-327857a4b14b"
      unitRef="usd">-90687000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfMzktNS0xLTEtOTI3MTg_176b1bdb-f341-4fef-9fdb-3ec2a95f8dc0"
      unitRef="usd">-98139000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMS0xLTEtOTMyNzQ_23432094-5f7f-4cb7-b115-e8eaa9b40329"
      unitRef="usd">1664362000</icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts>
    <icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMy0xLTEtOTMyODE_863361a2-7d48-403c-b44d-3fabb3632cb6"
      unitRef="usd">0</icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts>
    <icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtNS0xLTEtOTMyODg_178a3da0-938b-4de2-9092-1428acddb482"
      unitRef="usd">0</icui:ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMS0xLTEtOTMyNzQ_815d7c34-6722-43ed-a197-748d0e662b9b"
      unitRef="usd">22375000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMy0xLTEtOTMyODE_5982933b-6a0c-4526-9725-2b10bcc68074"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItNS0xLTEtOTMyODg_e9e9ba3a-1b43-4159-bfb0-de77d95818ee"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMS0xLTEtOTMyNzQ_2a6bd159-6cf1-4f09-b818-e80b38343da0"
      unitRef="usd">2177000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMy0xLTEtOTMyODE_a11c25e5-4c5a-4fc7-8ee5-ceaddfda6343"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtNS0xLTEtOTMyODg_b80226e5-9f0b-41c0-ba03-b7cc4ba0cecd"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMS0xLTEtOTI3MTg_30f195d9-7b60-4643-8ac1-c4f1d9e33825"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtMy0xLTEtOTI3MTg_49f2c22f-dfd0-497a-a308-8846f32d65ec"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDEtNS0xLTEtOTI3MTg_d5c0139a-eb90-4b50-996d-7460e1b37c17"
      unitRef="usd">150000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMS0xLTEtOTI3MTg_2bde277d-1fa2-44fc-8a1f-298ca65130f3"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItMy0xLTEtOTI3MTg_46b848cb-ee7e-48d4-8525-e52a002c822f"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDItNS0xLTEtOTI3MTg_02a48116-1c63-4f1e-bac4-96b00deac002"
      unitRef="usd">150000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMS0xLTEtOTI3MTg_4dcfcbb6-505c-492a-a8e9-edc172c8c60b"
      unitRef="usd">8785000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtMy0xLTEtOTI3MTg_6de09945-2fad-466f-aa51-ab9c9bf83f4e"
      unitRef="usd">9372000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDMtNS0xLTEtOTI3MTg_1275eb66-d8c5-41f1-89a3-f6fd308e65bc"
      unitRef="usd">13193000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtMS0xLTEtOTI3MTg_23020ba5-d7da-4d8b-8693-f46eff944693"
      unitRef="usd">680000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtMy0xLTEtOTI3MTg_14c495eb-d49b-41da-a4f1-065aa3c68b2d"
      unitRef="usd">607000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDQtNS0xLTEtOTI3MTg_a363bd8b-4556-477a-ba0b-e323983ae20c"
      unitRef="usd">357000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtMS0xLTEtOTI3MTg_51604830-da4c-4fe0-9d00-10fa5826a24f"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtMy0xLTEtOTI3MTg_bd0fed6d-b1a8-4e5d-a859-03c003fa4bd5"
      unitRef="usd">17300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDUtNS0xLTEtOTI3MTg_8e311e7b-3d6b-4971-9049-042e030d7afe"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtMS0xLTEtOTI3MTg_6028cc20-88b7-40c2-a582-8f5639fcd67f"
      unitRef="usd">10883000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtMy0xLTEtOTI3MTg_a667a22b-595b-471c-90d2-2d4ed221c48f"
      unitRef="usd">8335000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDYtNS0xLTEtOTI3MTg_70e47aca-37c8-4cef-8407-1541e9ab0b9c"
      unitRef="usd">12876000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctMS0xLTEtOTI3MTg_536b05ef-635d-40ee-911f-224b24e88d5b"
      unitRef="usd">1637032000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctMy0xLTEtOTI3MTg_a88e5822-9dcd-428f-9ff2-212ce52d0f7e"
      unitRef="usd">-16870000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDctNS0xLTEtOTI3MTg_af6aac03-17d2-4a5d-bfb6-aa1af2446e15"
      unitRef="usd">-40000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtMS0xLTEtOTI3MTg_8be2892b-bff3-44c6-a554-f98497e92416"
      unitRef="usd">-9478000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtMy0xLTEtOTI3MTg_97a19ecb-ddd3-46c4-ac40-f56fa70d8568"
      unitRef="usd">-3251000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDgtNS0xLTEtOTI3MTg_9097ed8b-8f62-4886-8f4d-32785867c897"
      unitRef="usd">2854000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktMS0xLTEtOTI3MTg_a1f48188-86ba-44ef-b645-473f3ceab390"
      unitRef="usd">-344043000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktMy0xLTEtOTI3MTg_a5079a7e-acbb-40e5-94ed-02e4ba9b3e5a"
      unitRef="usd">156730000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNDktNS0xLTEtOTI3MTg_90311d32-8307-4282-a771-ac39b8a371ec"
      unitRef="usd">127427000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtMS0xLTEtOTI3MTg_b60286c8-9e4d-4312-aa98-a5621302eb76"
      unitRef="usd">552827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtMy0xLTEtOTI3MTg_5bc16c48-f04f-4aba-b63f-24add1b30045"
      unitRef="usd">396097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTAtNS0xLTEtOTI3MTg_dfc88b44-4b2d-48fb-8cf8-0c5cc08a92d2"
      unitRef="usd">268670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtMS0xLTEtOTI3MTg_eb5fe535-9c10-4482-8159-4599c1439178"
      unitRef="usd">208784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtMy0xLTEtOTI3MTg_998b24e3-124f-46f4-bd4a-291a011bced8"
      unitRef="usd">552827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOmRjNDFiNDlkZmY0YjQ2NDBiN2YzYzViOTA0YzhlYWYyL3RhYmxlcmFuZ2U6ZGM0MWI0OWRmZjRiNDY0MGI3ZjNjNWI5MDRjOGVhZjJfNTEtNS0xLTEtOTI3MTg_548ebe57-856b-46e6-b526-741874d7d147"
      unitRef="usd">396097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy0xLTEtMS05MjcxOA_02905293-a464-410b-82bd-7fde86c4f8c1"
      unitRef="usd">27504000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy0zLTEtMS05MjcxOA_e48247cb-3522-4df2-b353-dc3cc3b3e53b"
      unitRef="usd">19562000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMy01LTEtMS05MjcxOA_cbf2637f-2b7f-41a5-872a-13dcf1bb363f"
      unitRef="usd">31628000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC0xLTEtMS05MjcxOA_58e80130-c1d6-4b39-8ebb-5d7ad24fb2af"
      unitRef="usd">63713000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC0zLTEtMS05MjcxOA_bf75fd01-4e04-4a28-bdcd-f472ccb31bac"
      unitRef="usd">858000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNC01LTEtMS05MjcxOA_f0d6cc58-7373-43b6-9be6-3fe06cc10aad"
      unitRef="usd">1753000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy0xLTEtMS05MjcxOA_b684a41e-5cc1-43a9-bec6-926e6c750e08"
      unitRef="usd">4854000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy0zLTEtMS05MjcxOA_54ccc5f2-ba2b-4f41-be06-65cdf7ad5e8f"
      unitRef="usd">9338000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfNy01LTEtMS05MjcxOA_a36e40e4-2abd-43c2-97a2-4a87a463eb4d"
      unitRef="usd">2211000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability
      contextRef="i3b3a16252c2743e49ad12be60705c508_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC0xLTEtMS05MjcxOA_846e7f3d-55f0-4b60-98f5-7c63a47bc164"
      unitRef="usd">0</icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability>
    <icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability
      contextRef="ie803115e33c64a30a2d7ac04ce489aea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC0zLTEtMS05MjcxOA_d6c3393e-2ae5-435d-b04b-07c73041f8ec"
      unitRef="usd">2589000</icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability>
    <icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability
      contextRef="i168c102715d143b4a73cd3d48cb2d99e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfOC01LTEtMS05MjcxOA_dd234f89-e0f3-4128-81d2-b945a46138e2"
      unitRef="usd">0</icui:NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTEtMS0xLTEtOTI3MTg_c94c49f6-a4cb-48ee-9589-068d072ad458"
      unitRef="usd">1606300000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTEtMy0xLTEtMTA5MTU0_6f212b0a-5e40-4004-9b09-7f83477f1be4"
      unitRef="usd">4592000</us-gaap:FairValueOfAssetsAcquired>
    <icui:NetCashPaidReceivedforcurrentandprioracquisitions
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTItMS0xLTEtOTI3MTg_c73c2dfc-8dce-48af-baf9-951b12c8fe9f"
      unitRef="usd">1844164000</icui:NetCashPaidReceivedforcurrentandprioracquisitions>
    <icui:NetCashPaidReceivedforcurrentandprioracquisitions
      contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTItMy0xLTEtMTA5MTU0_cb467643-728f-44c7-8c3f-82f58d134232"
      unitRef="usd">14452000</icui:NetCashPaidReceivedforcurrentandprioracquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMS0xLTEtMTA5MTUy_322b9afc-d0df-4214-a3a9-f66f25e74c59"
      unitRef="usd">575975000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMy0xLTEtMTA5MTU0_644f3144-4bee-4a4f-8ac3-762631d5fba6"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
      contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTMtMS0xLTEtOTI3MTg_1a0338fc-6539-4a1b-95d7-d7358fbb73e4"
      unitRef="usd">55158000</us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
      contextRef="id96caeb3085f40b895b3276026ce87e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTQtMy0xLTEtMTA5MTU0_0b03ea4a-bf32-4425-bf83-b39264aaa6e7"
      unitRef="usd">0</us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTQtMS0xLTEtOTI3MTg_5496cb45-78e3-4475-a779-4880c9ba8492"
      unitRef="usd">1462752000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTUtMy0xLTEtMTA5MTU0_8d17e1c5-b476-4f86-b590-02fcc1165fcd"
      unitRef="usd">10626000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTUtMS0xLTEtOTI3MTg_b7d2349d-4dde-4fcb-8577-de53a8f89f7c"
      unitRef="usd">593755000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i4d9776e92ea54c4caed0f3dd9d2db637_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF82NC9mcmFnOjdiZTM1Zjg2MDY2YjQ5MzBiMmYwYWQ1YzAzYjZmNWZmL3RhYmxlOjYxZTJiOGE1ZDljMzRhZjlhMGViNzQ1MjA2YjIxYmRlL3RhYmxlcmFuZ2U6NjFlMmI4YTVkOWMzNGFmOWEwZWI3NDUyMDZiMjFiZGVfMTYtMy0xLTEtMTA5MTU0_5803e217-5e6e-4dfa-81c2-05da0c846a4c"
      unitRef="usd">766000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MjA_0e53d93d-56f7-4191-985e-1031c1c7378e">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ICU Medical,&#160;Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our wide-ranging product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We also manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients. Our recent acquisition of Smiths Medical broadened our product portfolio to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices, silicone and PVC tracheotomy tubes. ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell the majority of our products globally through our direct sales force and through independent distributors. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All subsidiaries are wholly owned and are included in the consolidated financial statements.&#160;All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the prior year financial statements and footnotes to conform to the presentation used in the current year. In the statements of operations we reclassified interest income to interest (expense) income, net from other income (expense), net and in Note 4: Revenues, certain reclassifications were made to revenues disaggregated by geography. These reclassifications had no impact on net (loss) income, shareholder's equity or cash flows as previously reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2022, we acquired Smiths Medical 2020 Limited ("Smiths Medical"), see Note 2: Acquisitions. Our consolidated statement of operations includes the results of operations for Smiths Medical from January 7, 2022 through December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ from those estimates.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are stated at net realizable value.&#160;An allowance is provided for estimated collection losses based on an assessment of various factors.&#160; We consider prior payment trends, the age of the accounts receivable balances, the financial status of our customers and other factors to estimate the cash which ultimately will be received.&#160; Such amounts cannot be known with certainty at the financial statement date.&#160; We regularly review individual past due balances for collectability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&#160; Inventory costs include material, labor and overhead related to the manufacturing of our products.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consists of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments placed with customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment and molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments placed with customers&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred.&#160;The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $95.8 million, $65.9 million and $62.4 million in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We test goodwill for impairment on an annual basis in the month of November, or more frequently if an event occurs or circumstances change that would indicate that impairment may exist.&#160;In 2022, we bypassed a qualitative assessment and performed a quantitative assessment to determine whether an impairment exists. We determine the fair value of our reporting unit using the income approach and market approach to valuation, as well as other generally accepted valuation methodologies. The income approach utilizes a discounted cash flow analysis using management's assumptions. The market approach compares our reporting unit to similar companies with the assumption that companies operating in the same industry will share similar characteristics and that company values will correlate to those characteristics. If the carrying amount of the reporting unit exceeds the reporting unit&#x2019;s fair value, we recognize an impairment loss equal to the difference between the carrying amount and the estimated fair value of the reporting unit. We concluded that there was no impairment of goodwill during fiscal 2022, 2021, or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of our goodwill for 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, "Other" primarily relates to a $1.3&#160;million measurement period adjustment to deferred taxes related to the 2019 acquisition of Pursuit Vascular, Inc. and foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In 2021, we acquired a small foreign infusion systems supplier, which resulted in $10.6&#160;million of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Relates to the sale of a certain line of infusion products in China.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Amortization Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contractual customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Amortization Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contractual customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $139.4 million, $23.8 million and $23.2 million in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our intangible assets that are not subject to amortization are reviewed annually for impairment or more often if there are indications of possible impairment. We perform our annual intangible assets impairment test in November of each year. We did not have any intangible asset impairments in 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk. We did not have any long-lived asset impairments in 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition).  Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Available-for-sale Securities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment securities are considered available-for-sale and currently consist of short and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds. These securities are considered &#x201c;investment grade&#x201d; and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the carrying value is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive (loss) income. We did not have any investments in available-for-sale debt securities in unrealized loss positions as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost of the debt securities and U.S treasury securities is adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in interest (expense) income, net in the consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2023 and 2024. All short-term investment securities are callable within one year.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains (Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains (Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, we acquired approximately a 20.0% non-marketable equity interest in a nonpublic company and entered into a three-year distribution agreement where we have the exclusive rights to market, sell and distribute the company's products in exchange for a cash payment of $3.3&#160;million. In addition, we were granted an exclusive license for all of the seller's intellectual property. At the expiration of the distribution agreement we have the right but not the obligation to acquire the remaining interest in the business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other expense, net in our consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on the consolidated balance sheets. We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. During 2022 and 2021, there were no indications that our non-marketable equity method investment was impaired. Our recorded share of the investee's loss was not material for the year ended December 31, 2022 and 2021. We did not receive any dividend distributions from this investment during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our non-marketable equity method investment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in non-marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter 2022, we received $19.0&#160;million in proceeds from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is &#x201c;more likely than not&#x201d; that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars.&#160;In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process.&#160;Translation adjustments are recorded as a component of accumulated other comprehensive loss, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows.&#160;Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our consolidated statements of operations in other expense, net, see below other expense, net table. Foreign currency transaction losses (gains), net were $5.8 million, $1.0 million and $7.2 million in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Vascular Access and Vital Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with Multiple Deliverables&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and related software implementation services, as well as infusion consumables, IV solutions and extended warranties. Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.  Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shipping Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Post-retirement and Post-employment Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a Section&#160;401(k)&#160;retirement plan ("plan") for employees.&#160;Our contributions to our 401(k) plan were approximately $14.6 million, $11.0 million and $10.7 million in 2022, 2021 and 2020, respectively. We also have post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our research and development costs are expensed as incurred.  In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets.  Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents interest (expense) income, net (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents other income (expense), net (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange losses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on disposition of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other miscellaneous income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net (Loss) Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding plus any dilutive potential securities.&#160;Dilutive potential securities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock, are not included in the treasury stock method calculation. Restricted stock units that are anti-dilutive are not included in the treasury stock method. Due to the net loss for the year ended December 31, 2022 the inclusion of any potential securities is antidilutive, accordingly, basic and diluted net loss per share is the same for this period. There were 12,354 and 12,083 anti-dilutive shares in 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of net earnings per common share (&#x201c;EPS&#x201d;) &#x2014; basic and diluted (in thousands, except per share data):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding (basic)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common and common equivalent shares outstanding&#160;(diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EPS &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EPS &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;In March 2020, the Financial Accounting Standards Board ("FASB")  issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU were effective for all entities as of March 12, 2020 through December 31, 2022. ASU No. 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap references LIBOR, these swaps were amended in early 2022 to transition to an alternative reference rate (see Note 7: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that allowed us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and allowed us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging or the optional expedient under this ASU is elected. The impact of these ASU's on our contracts has not been and is not expected to be material.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1OTU_ac20e23a-9232-4832-9a66-6534506e0122">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ICU Medical,&#160;Inc. ("ICU" or "we"), a Delaware corporation, develops, manufactures and sells infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our wide-ranging product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We also manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients. Our recent acquisition of Smiths Medical broadened our product portfolio to include, among other products, syringe and ambulatory pumps, peripheral IV catheters, fluid warming and respiratory devices, silicone and PVC tracheotomy tubes. ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell the majority of our products globally through our direct sales force and through independent distributors. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All subsidiaries are wholly owned and are included in the consolidated financial statements.&#160;All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.&lt;/span&gt;&lt;/div&gt;The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.  These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM0_4379c6fc-e55f-4a55-b16e-8775bc3f606a">ICU's business activities are interrelated and leverage shared manufacturing, supply chain, IT and other supporting infrastructure. All significant operating decisions are based on analysis of ICU as a single global business, accordingly we operate in one business segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgz_012f287b-005c-4b09-9488-f0427e33e10a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1ODQ_dd766043-e0eb-4ac7-95c3-643c606eefc4">Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2Mzg_99243504-7d7d-46d0-ac4c-4b1d467b1fc7">Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2Mzc_40077082-e571-4b0c-9ed8-05e3e3101fe4">Accounts receivable are stated at net realizable value.&#160;An allowance is provided for estimated collection losses based on an assessment of various factors.&#160; We consider prior payment trends, the age of the accounts receivable balances, the financial status of our customers and other factors to estimate the cash which ultimately will be received.&#160; Such amounts cannot be known with certainty at the financial statement date.&#160; We regularly review individual past due balances for collectability.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MTg_3a21bded-9046-4826-8a6a-3e6914e1dc1c">Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NTE_09a6439e-25cb-4ddd-a72d-90338b46066a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMi0xLTEtMS05MjcxOA_112b3d72-e411-43ba-8d68-d13afaad395a"
      unitRef="usd">286964000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMi0zLTEtMS05MjcxOA_9e10b229-8780-4342-99e3-e7254b997846"
      unitRef="usd">135528000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMy0xLTEtMS05MjcxOA_ac9cb540-9d43-4d5d-a0b1-e32aa969905d"
      unitRef="usd">73795000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfMy0zLTEtMS05MjcxOA_5505ef79-6de8-4f17-b963-79146ac39336"
      unitRef="usd">36490000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNC0xLTEtMS05MjcxOA_f8d0b7a1-d3be-48f4-9023-9b826bbd20f8"
      unitRef="usd">335250000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNC0zLTEtMS05MjcxOA_f89d368c-756e-4e91-88e1-b40e589f9324"
      unitRef="usd">118217000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNS0xLTEtMS05MjcxOA_ef6a0046-3407-43ac-9322-45d6e52e5540"
      unitRef="usd">696009000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjM0MmNhYmVmYjJhNzQ1ZDI4YzMyYmM3MDZmNzM0YzE0L3RhYmxlcmFuZ2U6MzQyY2FiZWZiMmE3NDVkMjhjMzJiYzcwNmY3MzRjMTRfNS0zLTEtMS05MjcxOA_23887f5b-41b6-49c8-8b5f-a0341349679c"
      unitRef="usd">290235000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Mzc_1e62a568-9371-4cd6-b279-3358b957a4ca">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consists of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments placed with customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment and molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments placed with customers&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie306a7088186433b94994c8694798078_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMi0xLTEtMS05MjcxOA_7040f316-7f4a-44c1-a004-436bac954fc2"
      unitRef="usd">414811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib75bb3ec5a414a9a96e90db458d22e9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMi0zLTEtMS05MjcxOA_a42f8340-4055-40d0-ab70-36853c2f1796"
      unitRef="usd">321078000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7ec5e5fae0c44acbe28b5e7256bc13a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMy0xLTEtMS05MjcxOA_ad33a414-512d-4304-8759-2eda02747f8c"
      unitRef="usd">274063000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idcede7ef2d55454586263cb1b17b8a37_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMy0zLTEtMS05MjcxOA_1c2f0e1e-f69a-48f3-8453-e0b3d2e0edde"
      unitRef="usd">243377000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a1ce0276d2342909b3efc93b1f90403_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNC0xLTEtMS05MjcxOA_b8f760c4-78d7-4676-a5d1-a0716f940b83"
      unitRef="usd">77203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3bd24511b6794dbcafe3d83a5a8388c9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNC0zLTEtMS05MjcxOA_7a060cd3-ea0c-4bbe-81c4-760819ac7393"
      unitRef="usd">60463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7048468f159a46b288ae8a59cedfde98_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNS0xLTEtMS05MjcxOA_0288790b-e8a1-4075-a46c-ff6dea37e40e"
      unitRef="usd">115214000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i980f10b9f96e4b5eb86cb041b7ed672c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNS0zLTEtMS05MjcxOA_a18e3c55-efa1-4896-969c-d0f92647b0ec"
      unitRef="usd">102979000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a64d4f3e84f40458ca24bfae02314b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNi0xLTEtMS05MjcxOA_94e9a56e-ce5e-4620-a5ec-5041d2372333"
      unitRef="usd">29876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4b924222777c44f6a4235eca23a1b5cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNi0zLTEtMS05MjcxOA_06641b6a-023d-4f07-8700-d397a6b7020a"
      unitRef="usd">7670000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8f0d2af3e944dc69bd9763b0d42c3aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNy0xLTEtMS05MjcxOA_233603f3-f540-40d2-bd7e-f89c533f91bd"
      unitRef="usd">98481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia90ea729e60647e7a9038b89c6e8eb51_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfNy0zLTEtMS05MjcxOA_ca1d04cd-c549-4a9c-bacf-f558d67ad535"
      unitRef="usd">97384000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icb27ccb900a343b1ac254cb8fd9889ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOC0xLTEtMS05MjcxOA_20873d23-3d06-45e2-ad6f-db5142f947fb"
      unitRef="usd">152909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6808b2296ffa42588ac59c587abb2eca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOC0zLTEtMS05MjcxOA_4afee7db-3a93-4ff9-82de-725fa2e1f276"
      unitRef="usd">72153000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOS0xLTEtMS05MjcxOA_12c8b6c1-48d1-42dd-9d54-05187fb1fd40"
      unitRef="usd">1162557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfOS0zLTEtMS05MjcxOA_4873ca48-1f50-42d8-9dc6-0e01ef705c6b"
      unitRef="usd">905104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTAtMS0xLTEtOTI3MTg_4099d875-688e-4f28-8c12-a900a88c1593"
      unitRef="usd">526444000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTAtMy0xLTEtOTI3MTg_aafc0264-270d-4021-850a-5b30d15f9c18"
      unitRef="usd">436739000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTEtMS0xLTEtOTI3MTg_092dabf4-4db8-47ca-a063-8c6b3d3a3f48"
      unitRef="usd">636113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI5NGQxYTc3NDU0NzRiYjZiYjNkYzdjZjQyOTA0YTc4L3RhYmxlcmFuZ2U6Mjk0ZDFhNzc0NTQ3NGJiNmJiM2RjN2NmNDI5MDRhNzhfMTEtMy0xLTEtOTI3MTg_81ce7e3e-0fba-4815-93dd-08a86774bbc3"
      unitRef="usd">468365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NDU_1e44dc8c-2c53-4dea-8ead-7eabd1dc7c06">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All property, plant and equipment are stated at cost.&#160;We use the straight-line method for depreciating property, plant  and equipment over their estimated useful lives.&#160; Estimated useful lives are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment and molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments placed with customers&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred.&#160;The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are &lt;/span&gt;&lt;/div&gt;removed from the accounts and any gain or loss is reflected in the statements of operations at the time of disposal. Depreciation expense was $95.8 million, $65.9 million and $62.4 million in 2022, 2021 and 2020, respectively.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmU1N2RkZDA2YmYwMjQyMTBhY2I4OWJkZTdjMzdjOGJhXzQ_3528d871-5593-45e9-8920-76fa1cd37525">15</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i5ace55fc527e48da922598ef7519c606_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmU1N2RkZDA2YmYwMjQyMTBhY2I4OWJkZTdjMzdjOGJhXzk_38ff8daf-17ab-4af3-9718-544e1b8ab058">30</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i5cc8766a58304d02b111521f7ddb4326_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmUxMGI1OTcyM2RlYTQ4MjdiZmVmZDNkMDJkOTE4ZWNiXzQ_79151fc4-83f1-447f-a517-dae602b01ba9">15</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i5412a571299e4c32bbdeaa48ca22375a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOmUxMGI1OTcyM2RlYTQ4MjdiZmVmZDNkMDJkOTE4ZWNiXzk_383171e1-e9ae-4329-adfc-4d9e4637e3f7">30</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="ib6f9efdcab0a462a9331fcb0b2523f10_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMi0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg2ZTc4Y2E4MjRmMDQ2NjI4OWFmNWVjZDM2ODQ4ZTdkXzQ_e076c270-1e10-4580-b0b0-6c40a07233e9">2</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="iace321f41b4548e6821dc5e27a26dd08_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMi0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjg2ZTc4Y2E4MjRmMDQ2NjI4OWFmNWVjZDM2ODQ4ZTdkXzk_fc7e72af-76be-4e85-9cfb-b35fc709eae6">15</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="ifc2d38102dd74397953e5e63739100de_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMy0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjdjMzRiYTUyN2UwNTQwYzg5ZDk3MWU0NzczNTJkZThjXzQ_703d47f2-2c51-4f20-8c13-b6703c099c65">2</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i1f3efe5e11e941069af3153789ec8247_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfMy0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjdjMzRiYTUyN2UwNTQwYzg5ZDk3MWU0NzczNTJkZThjXzk_7a3790d8-d562-495c-91e7-40ead34e61e6">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i7d3d6cb7b6924d47969dd4919c9df187_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhOGVhMjg0YmE1NTRhYjE5OWQ4YTJiM2M3MjIyMmI4XzQ_47545695-c236-4f11-a649-74965a5fcd86">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i07984db0625c4d03845107295d7e5a5c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNC0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjRhOGVhMjg0YmE1NTRhYjE5OWQ4YTJiM2M3MjIyMmI4Xzk_defb04c5-1a94-4847-8568-53717fd4464f">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i9543871e1aba478483a1228b53651327_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjAyMTI1MDBkYjRjZjQ2ODBiYjdhZDVjMzc0NjJhODA5XzQ_85e06cd4-1769-4edd-970b-caabbe5ca5c9">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="iebcf08c085424ee38ab6ffd24290c1d4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmRhNGMxMDE4ZTZmYjQ4ZWY4ZTFmM2Q3ZjhiNGJmMTYyL3RhYmxlcmFuZ2U6ZGE0YzEwMThlNmZiNDhlZjhlMWYzZDdmOGI0YmYxNjJfNS0xLTEtMS05MjcxOC90ZXh0cmVnaW9uOjAyMTI1MDBkYjRjZjQ2ODBiYjdhZDVjMzc0NjJhODA5Xzk_1c0b9776-1e8a-4be4-879d-f1f0a3e197c0">10</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:Depreciation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg2Mw_c9d98b98-8a3b-4e91-8c6a-0f6faa945ed9"
      unitRef="usd">95800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg2Nw_d589c39e-d03b-4111-899e-a1e365d7fb86"
      unitRef="usd">65900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMzg3NA_ed4596f8-59b1-4151-ae83-5b436c86a0ed"
      unitRef="usd">62400000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0Nzg_4a7e015d-f8de-4a47-8b83-3159a890eb5e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We test goodwill for impairment on an annual basis in the month of November, or more frequently if an event occurs or circumstances change that would indicate that impairment may exist.&#160;In 2022, we bypassed a qualitative assessment and performed a quantitative assessment to determine whether an impairment exists. We determine the fair value of our reporting unit using the income approach and market approach to valuation, as well as other generally accepted valuation methodologies. The income approach utilizes a discounted cash flow analysis using management's assumptions. The market approach compares our reporting unit to similar companies with the assumption that companies operating in the same industry will share similar characteristics and that company values will correlate to those characteristics. If the carrying amount of the reporting unit exceeds the reporting unit&#x2019;s fair value, we recognize an impairment loss equal to the difference between the carrying amount and the estimated fair value of the reporting unit. We concluded that there was no impairment of goodwill during fiscal 2022, 2021, or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NDE_66e03f2b-99ca-4390-860c-8062d7f8dc94">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amount of our goodwill for 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, "Other" primarily relates to a $1.3&#160;million measurement period adjustment to deferred taxes related to the 2019 acquisition of Pursuit Vascular, Inc. and foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In 2021, we acquired a small foreign infusion systems supplier, which resulted in $10.6&#160;million of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Relates to the sale of a certain line of infusion products in China.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMS0yLTEtMS05MjcxOA_4414a3ca-441c-4401-96da-bb3b8c020339"
      unitRef="usd">31245000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMy0yLTEtMS05MjcxOA_b5f847ff-1f73-4720-adf9-5ecd9cba64f3"
      unitRef="usd">1756000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNC0yLTEtMS05MjcxOA_8dd6d85d-4feb-453c-ae3d-6efd24e140d4"
      unitRef="usd">33001000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNS0yLTEtMS05MjcxOA_f6d68719-c006-4a94-a25b-b3b5a179aaf2"
      unitRef="usd">10626000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNi0yLTEtMS05MjcxOA_3b93fc38-48ee-4d11-9dc6-09934a632cef"
      unitRef="usd">-188000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfNy0yLTEtMS05MjcxOA_48b1a00d-5a23-488d-8520-62c188aba726"
      unitRef="usd">43439000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOC0yLTEtMS05MjcxOA_90276d41-decb-4119-b34c-a6f6b2f75667"
      unitRef="usd">1469880000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOS0yLTEtMS05NDg2NQ_b7d1e251-e698-4f5e-9a7d-af59c12b17c6"
      unitRef="usd">-7128000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMTAtMi0xLTEtMTA1MzU3_9ae5be30-3101-44df-a52b-c1b4e1cca622"
      unitRef="usd">-650000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfOS0yLTEtMS05MjcxOA_5748e054-1459-489b-b016-7eaa64c22a82"
      unitRef="usd">-56283000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQxZDgxZWZkNjVkMDRhZGY5OTQ5OTEwNjc5OTcxZWNiL3RhYmxlcmFuZ2U6NDFkODFlZmQ2NWQwNGFkZjk5NDk5MTA2Nzk5NzFlY2JfMTAtMi0xLTEtOTI3MTg_fdc18405-2b7e-4b2d-a018-4e70ba3604ad"
      unitRef="usd">1449258000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i7d433759863a438d9e188a8521981691_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTgzMw_bf8a78e1-05d8-47a5-9454-c6baff9bba04"
      unitRef="usd">1300000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjAzOQ_8b2f5fef-e1eb-4ddb-b935-c249950e3e9d"
      unitRef="usd">10600000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MTU_c9fa7637-9d41-414f-b51b-928f05170d84">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Amortization Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contractual customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Amortization Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contractual customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortized intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1OTg_a4c52ae7-c3df-4a45-a293-be595ce3f866">Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7e546dd32ee14e3eb76d201f21872bb8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi0yLTEtMS05MjcxOA_69e57b02-deeb-41dc-8d6f-d3abde2e9059">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi00LTEtMS05MjcxOA_048511bb-b855-4411-8a03-065cb401a200"
      unitRef="usd">29998000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi02LTEtMS05MjcxOA_40ba7dbd-ee56-4ccc-9a03-b0ba525c9bc8"
      unitRef="usd">18610000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8cae05c39a724907b4e3c7bec42a8d15_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMi04LTEtMS05MjcxOA_02e7717d-7d41-43fb-853b-1a02587b3bea"
      unitRef="usd">11388000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i460a86abca634dc9802438855b8286df_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy0yLTEtMS05MjcxOA_e8029fd2-8ea0-498e-8b8a-59bbe9e13c57">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8fa54f208913446db511b39d4c19420d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy00LTEtMS05MjcxOA_d3faba1f-9c8f-4d71-9ee0-4c1c0d81f35c"
      unitRef="usd">10026000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8fa54f208913446db511b39d4c19420d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy02LTEtMS05MjcxOA_577907a0-df28-4715-8b7f-1ab9261a105d"
      unitRef="usd">6443000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8fa54f208913446db511b39d4c19420d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMy04LTEtMS05MjcxOA_2b2a2816-9868-4787-b5a2-595b125c072d"
      unitRef="usd">3583000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idf83aec391f64db6afb221796f3b44d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC0yLTEtMS05MjcxOA_601e24a8-3f59-4873-a860-c515dd17a7f7">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC00LTEtMS05MjcxOA_33e66d2b-8c24-4e49-9269-b981ee8e8667"
      unitRef="usd">546935000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC02LTEtMS05MjcxOA_73dd033e-5f36-4859-8a60-f4eb1907ff03"
      unitRef="usd">101556000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i75e941f5fc5947699c7c61518ca1ab67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNC04LTEtMS05MjcxOA_1ec0bc73-814b-4720-b17b-66b587ad2722"
      unitRef="usd">445379000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS0yLTEtMS05MjcxOA_17d25174-c9a9-4542-9557-50970ca6cf2e">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia3856be9b89747b993110c792a39aabb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS00LTEtMS05MjcxOA_ce6a7189-9e5e-4e9b-bd78-289042a31d67"
      unitRef="usd">5425000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia3856be9b89747b993110c792a39aabb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS02LTEtMS05MjcxOA_63f57798-4506-4729-ba7d-00976e46336b"
      unitRef="usd">5425000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia3856be9b89747b993110c792a39aabb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNS04LTEtMS05MjcxOA_775ee2db-27e3-4398-8acb-a0cc307d3f4a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id46d0ee7b3624110a0d31e8dbeb2f227_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi0yLTEtMS05MjcxOA_64b3cd06-b10f-4ef3-9ef8-2a130197f570">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi00LTEtMS05MjcxOA_5bd71093-ba09-41b9-9cf5-1525e7fffb47"
      unitRef="usd">18251000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi02LTEtMS05MjcxOA_af1b7b60-626b-4f53-8111-a045bbf2ac37"
      unitRef="usd">5959000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i44f47d5a4f3247508475ee667ae3091f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNi04LTEtMS05MjcxOA_44ce1a1c-60ea-4e08-bc60-6cd426cdd668"
      unitRef="usd">12292000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i369fa34137ce41348503313048b70075_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy0yLTEtMS05MjcxOA_62a078fa-58ee-412e-8f4b-2c47c4c0c1bb">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i84420d968625493db489841b6ba9cd22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy00LTEtMS05MjcxOA_7bb26396-f7cb-4e86-9d25-018d7133dcce"
      unitRef="usd">583176000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i84420d968625493db489841b6ba9cd22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy02LTEtMS05MjcxOA_1b0b404f-510c-49dc-bd03-ae29a4922fc6"
      unitRef="usd">108708000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i84420d968625493db489841b6ba9cd22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfNy04LTEtMS05MjcxOA_992b68ee-709c-4a0a-bc8f-1efa72cfdca3"
      unitRef="usd">474468000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib343098582894c1b8730d6b3ee859c16_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC0yLTEtMS05MjcxOA_64cfc698-e6ce-446f-8aeb-b4fdad32f938">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC00LTEtMS05MjcxOA_1595479c-befb-44eb-b702-9bd0018363a7"
      unitRef="usd">9100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC02LTEtMS05MjcxOA_57a35560-1e74-4181-a8c3-4f0d553be05b"
      unitRef="usd">5250000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i63c86efa20674a879fa6ed36fec4b168_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOC04LTEtMS05MjcxOA_5326e27c-5ac1-4738-98c5-bf0188e9fcec"
      unitRef="usd">3850000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS00LTEtMS05MjcxOA_b0905bae-aa26-4de3-b905-28306898d6ba"
      unitRef="usd">1202911000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS02LTEtMS05MjcxOA_863c2820-ca1e-414f-b21f-a059359895b9"
      unitRef="usd">251951000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfOS04LTEtMS05MjcxOA_0db7b3b3-f1b5-4431-9ad5-3985e84713df"
      unitRef="usd">950960000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie8552f5934714f03a7223229598d0a2a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTEtNC0xLTEtOTI3MTg_bb79078d-ab8f-485c-a5bd-5a4a7ccf622e"
      unitRef="usd">31806000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie8552f5934714f03a7223229598d0a2a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTEtOC0xLTEtOTI3MTg_779e4c3e-bc4d-4472-9c0a-7778053b0563"
      unitRef="usd">31806000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtNC0xLTEtOTI3MTg_e1729f53-e8da-4f08-9c96-67e80d2c1a14"
      unitRef="usd">1234717000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtNi0xLTEtOTI3MTg_11ff5d57-5f7d-48a8-80e8-ad5cde586a79"
      unitRef="usd">251951000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjcxYjcwNDEyMTZiZDRlZTRiOWM1YWRjYWY2ODVhMmQ4L3RhYmxlcmFuZ2U6NzFiNzA0MTIxNmJkNGVlNGI5YzVhZGNhZjY4NWEyZDhfMTMtOC0xLTEtOTI3MTg_4906f543-30f3-45ae-8035-0d31a3d06644"
      unitRef="usd">982766000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2be404c6e2704f988bf6f30f9911074b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi0yLTEtMS05MjcxOA_99c834bf-5a9d-417d-8957-842f5abb6f4e">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi00LTEtMS05MjcxOA_423da94f-af90-45c1-b7b8-245e2150bc03"
      unitRef="usd">27429000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi02LTEtMS05MjcxOA_64570fba-2fb9-4107-b459-6df026c480bd"
      unitRef="usd">16764000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1df8661f299c437396b33cccb1c6eac8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMi04LTEtMS05MjcxOA_a9174f94-9d25-435a-b917-1c60a177d4ac"
      unitRef="usd">10665000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i63886e254baf421a9707d4d5eb8bab28_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy0yLTEtMS05MjcxOA_9268dc06-cfb7-4cc2-95b2-43cc42bbe1db">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy00LTEtMS05MjcxOA_c76a187f-d9d9-4192-90a4-d8a9e0853e39"
      unitRef="usd">10412000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy02LTEtMS05MjcxOA_25f953ef-676b-490d-9832-b8dd79fbd1bf"
      unitRef="usd">6196000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i92366c1a9c6d4e8b8f676ad095b3b061_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMy04LTEtMS05MjcxOA_a3d7cf0b-cd86-4ff5-9469-ea598997c327"
      unitRef="usd">4216000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9ca30aa64779494ca3499ac96dcc8ff4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC0yLTEtMS05MjcxOA_895d5c98-1ed7-4272-b4bd-c5f09b9ed6ac">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC00LTEtMS05MjcxOA_ce5db37b-c099-4a2d-a7cb-fb9506384734"
      unitRef="usd">57316000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC02LTEtMS05MjcxOA_f420c2f5-4b10-47d7-b9ef-19b2ba98ce7d"
      unitRef="usd">33004000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e43ff19422d4545a2da37ba9a92b601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNC04LTEtMS05MjcxOA_3711aed2-7ca0-40ce-b3cf-c4fa5881174f"
      unitRef="usd">24312000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icf5f275b31a74d0897b0a32abeeeb534_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS0yLTEtMS05MjcxOA_e6aba315-2d84-4bcc-b761-1d64655e5be4">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id41f8b67700946dd803fdd98061bc244_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS00LTEtMS05MjcxOA_fd73b983-b498-4efd-a8eb-565e11fb5a06"
      unitRef="usd">425000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id41f8b67700946dd803fdd98061bc244_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS02LTEtMS05MjcxOA_496a5c70-9d40-402d-92f6-f71c8413fbad"
      unitRef="usd">425000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id41f8b67700946dd803fdd98061bc244_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNS04LTEtMS05MjcxOA_c411a5b8-beff-452c-87eb-b417bd2709a9"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id77c83d365be429dbcf3b8e60f6471c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi0yLTEtMS05MjcxOA_45265e61-83e2-47ab-85d6-f6fd79e2f296">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i057559badebc49ff81913d91205892d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi00LTEtMS05MjcxOA_fcf4a56e-1fab-4a33-bf4c-c300ac278c28"
      unitRef="usd">18260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i057559badebc49ff81913d91205892d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi02LTEtMS05MjcxOA_2118abf9-2fdf-40e3-aa08-41ceeb86025f"
      unitRef="usd">4731000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i057559badebc49ff81913d91205892d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNi04LTEtMS05MjcxOA_970f7eb7-e96a-4f5f-8422-cb6afef0f729"
      unitRef="usd">13529000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1a2d444d9cee49b99776001b30841e74_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy0yLTEtMS05MjcxOA_c468e8d8-89a5-43ce-ab6e-f7b9badfdd3f">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy00LTEtMS05MjcxOA_0d4c5a6c-250f-4b6e-a98b-ef88da101c88"
      unitRef="usd">152893000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy02LTEtMS05MjcxOA_92b6119f-aeef-4a27-bf32-5085f9cdd2d2"
      unitRef="usd">49406000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a9b0087c1fe4570adcd26c7886c04fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfNy04LTEtMS05MjcxOA_d661b7df-316d-446b-881c-d0b921300b32"
      unitRef="usd">103487000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i93ff0b8f85bb402b839b0f6cb69bfaa0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC0yLTEtMS05MjcxOA_bfd1c9a6-1ebe-42b0-bda8-6296084391bd">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC00LTEtMS05MjcxOA_3f7fcbbf-73f7-429d-b6af-c2d09e8fa337"
      unitRef="usd">9100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC02LTEtMS05MjcxOA_2733f712-bcfa-4a64-a247-2db213ee08d4"
      unitRef="usd">2356000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1b990e41a8c4816ac9862a30699ee0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOC04LTEtMS05MjcxOA_82206cab-17fe-4755-8fae-a2d737a0deeb"
      unitRef="usd">6744000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS00LTEtMS05MjcxOA_0256b2fd-d1d0-4a5e-878e-f5658df3057d"
      unitRef="usd">275835000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS02LTEtMS05MjcxOA_c4f4fb03-81c9-43f0-bfa2-ef53f74e39f3"
      unitRef="usd">112882000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfOS04LTEtMS05MjcxOA_98a6c950-3331-403a-b60f-0e63c9ee43fb"
      unitRef="usd">162953000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTEtNC0xLTEtOTI3MTg_451dc3a6-d3e9-4e38-8615-5bb0611b0305"
      unitRef="usd">25358000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27a6c53ad126450ba9b2d4f4c0ec2d02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTEtOC0xLTEtOTI3MTg_22fff3c3-03ce-485e-824c-967b67249d7d"
      unitRef="usd">25358000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtNC0xLTEtOTI3MTg_786b50c2-34a5-4d3c-9a05-0904b5533f48"
      unitRef="usd">301193000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtNi0xLTEtOTI3MTg_1520da28-a7b6-40b8-bc8b-26296bc45c6b"
      unitRef="usd">112882000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmJlNzhmYTI3NDY0ODRkOGY5ODE1MjM3YzIzMGQxMWE5L3RhYmxlcmFuZ2U6YmU3OGZhMjc0NjQ4NGQ4Zjk4MTUyMzdjMjMwZDExYTlfMTMtOC0xLTEtOTI3MTg_87b45d1f-9cb9-4443-8691-7e7a8bd8b22a"
      unitRef="usd">188311000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU2OQ_ce2dc02e-5247-4011-a943-45b4698de766"
      unitRef="usd">139400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU3Mw_7623885c-1be3-4297-85df-db89cae5b244"
      unitRef="usd">23800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNjU4MA_7e99e475-04f4-467a-85ea-cd6555a025ad"
      unitRef="usd">23200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MzE_d0f4fd98-7feb-42de-8850-2e446f2c2b5a">As of December 31, 2022, estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMC0yLTEtMS05MjcxOA_0ae1b94d-7414-4775-97d6-39d41a15f076"
      unitRef="usd">130972000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMS0yLTEtMS05MjcxOA_0be329be-b660-4b57-a99b-6cbf76e1a807"
      unitRef="usd">130882000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMi0yLTEtMS05MjcxOA_074ddec1-ec35-4e4c-9cee-5307e56aa89e"
      unitRef="usd">123223000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfMy0yLTEtMS05MjcxOA_66b7d1f7-27d0-4b8f-bfda-2fc3130ba4dd"
      unitRef="usd">122654000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNC0yLTEtMS05MjcxOA_415b7122-d4a2-4ea2-aae0-149fba27d7e6"
      unitRef="usd">114622000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNS0yLTEtMS05MjcxOA_d442aaef-89ae-4bbf-ab38-6b69d503cc90"
      unitRef="usd">328607000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjU1ZjBiZjMwMTk4NjRlODlhZDg4ZWJhNWU2MDcxMGNhL3RhYmxlcmFuZ2U6NTVmMGJmMzAxOTg2NGU4OWFkODhlYmE1ZTYwNzEwY2FfNi0yLTEtMS05MjcxOA_f6fd1235-c3ba-4e15-abd5-7f21f775262a"
      unitRef="usd">950960000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1MjY_179f8f75-5013-45e6-a49b-d5c0083f3a30">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk. We did not have any long-lived asset impairments in 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0OTI_a6349ff7-f8d6-4dfe-96cc-97fc3e61b095">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year at the time of acquisition).  Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in Available-for-sale Securities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment securities are considered available-for-sale and currently consist of short and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds. These securities are considered &#x201c;investment grade&#x201d; and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the carrying value is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive (loss) income. We did not have any investments in available-for-sale debt securities in unrealized loss positions as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;The amortized cost of the debt securities and U.S treasury securities is adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in interest (expense) income, net in the consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2023 and 2024. All short-term investment securities are callable within one year.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Mjc_d0e64522-a39a-416d-a944-0d1d06eb80bd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains (Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Gains (Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi0xLTEtMS05MjcxOA_0fdb481f-5129-46bf-a0eb-9f0f04dc6b16"
      unitRef="usd">2314000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="ief7bb5378ae8468895c202125d15e129_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi0zLTEtMS05MjcxOA_59cc9226-e83f-4766-b8f3-850a10ef2108"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMi01LTEtMS05MjcxOA_4408b424-1c7d-4c02-9aaf-f5d50d15961a"
      unitRef="usd">2314000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idc33001b56c64b11b1bc56c135168d51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0xLTEtMS05NTU4NQ_a3276918-7b6c-4dba-a64b-a2f84777d231"
      unitRef="usd">1412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i0de82ccd51af439091344dc5996e1a43_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0zLTEtMS0xMDkxNjM_4fa67be5-65c2-4bae-a5d4-12d3366165f0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if50fd4be30c6481e89383764b9f60a6f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy01LTEtMS0xMDkxNjc_079a6b8c-c6f8-42e9-bf06-4a5c4aac75ff"
      unitRef="usd">1412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0xLTEtMS0xMDMyOTQ_240e55db-d89d-45b9-bd93-679b651bcd55"
      unitRef="usd">498000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i6c2609bce6c04e03995a81ac43177271_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0zLTEtMS0xMDkxNjM_7d500db6-b4f5-4f40-a29e-81fc9c778690"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC01LTEtMS0xMDkxNjc_f502ada5-56be-4b05-a531-ffcf6af4fe20"
      unitRef="usd">498000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS0xLTEtMS0xMDkxNTc_950c71c8-1f88-4076-8b19-ebf6eee2fb70"
      unitRef="usd">4224000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS0zLTEtMS0xMDkxNjM_e2382b82-bf9d-4f88-9fdc-0de2acd03ffb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNS01LTEtMS0xMDkxNjc_5ac49916-4e38-44d7-b31a-05e735b8ad87"
      unitRef="usd">4224000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0xLTEtMS05MjcxOA_f1b91036-91c6-44f2-a8a4-84de4349bd46"
      unitRef="usd">516000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="ief7bb5378ae8468895c202125d15e129_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy0zLTEtMS05MjcxOA_ea195286-b3a3-44eb-941c-450b36269c62"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if63e97d232fe4a9e993b1fb15ba7a2c8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMy01LTEtMS05MjcxOA_3a7bfa60-c0aa-4d64-89f7-11840f267249"
      unitRef="usd">516000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0xLTEtMS05MjcxOA_75637cd2-dec6-405a-9aed-8428f98dc283"
      unitRef="usd">4740000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC0zLTEtMS05MjcxOA_a8120e41-436b-4d91-9680-c08c537f00f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfNC01LTEtMS05MjcxOA_9aa2a2da-a38f-47c7-988a-75a880f3bc0f"
      unitRef="usd">4740000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC0xLTEtMS05MjcxOA_88492634-c21c-4bea-8ed8-7d0d8f8f8204"
      unitRef="usd">14420000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC0zLTEtMS05MjcxOA_55480cb1-e9b9-4e08-8420-6eaf8bbce62d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOC01LTEtMS05MjcxOA_8ab41293-2273-4ba9-a226-ce8ba8cd3319"
      unitRef="usd">14420000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS0xLTEtMS05MjcxOA_4be8b15a-0623-42cc-b651-e5a30139a809"
      unitRef="usd">4620000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i5ef924a6022c47828f5bd24573dbff10_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS0zLTEtMS05MjcxOA_900052c6-f287-4e40-a8a7-0ecc55908cbe"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70941f166b074b6aa1687d9f7338fae8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfOS01LTEtMS05MjcxOA_74407e3e-a2d8-44fc-ad5b-2eae42dca5a2"
      unitRef="usd">4620000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtMS0xLTEtOTI3MTg_724eaa06-65e1-49b9-8359-3d5308041fb5"
      unitRef="usd">19040000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtMy0xLTEtOTI3MTg_455a31cb-1c8b-4ef5-acef-b66c00b8034c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjI3OWViZDUxZTYyZDQwOTg5MWVhYzYzZDdlOTJiNWE2L3RhYmxlcmFuZ2U6Mjc5ZWJkNTFlNjJkNDA5ODkxZWFjNjNkN2U5MmI1YTZfMTAtNS0xLTEtOTI3MTg_c2f9d8cd-9488-4983-966c-a85fe84b972b"
      unitRef="usd">19040000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0029a1b43ec54a29b829f135a48f9cfb_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTA0MTA_bb986738-94e3-47fa-9161-a74091bbe4ad"
      unitRef="number">0.200</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTA2NDM_20b3186e-2cee-4df3-9b2a-0d4002dbec19"
      unitRef="usd">3300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0ODY_4cbe23f6-2ee4-4beb-b4ad-f4b8eb8df257">We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other expense, net in our consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on the consolidated balance sheets. We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0OTc_d586a459-d9f5-4c32-8ac4-cc4d14c4f175">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our non-marketable equity method investment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmMyYzA3N2QxODVmNDRhODk5ZWY0OTk4YzNhZDZjMDcyL3RhYmxlcmFuZ2U6YzJjMDc3ZDE4NWY0NGE4OTllZjQ5OThjM2FkNmMwNzJfMi0xLTEtMS05MjcxOA_106dde71-0153-4c3b-99db-28d9100f1503"
      unitRef="usd">3178000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmMyYzA3N2QxODVmNDRhODk5ZWY0OTk4YzNhZDZjMDcyL3RhYmxlcmFuZ2U6YzJjMDc3ZDE4NWY0NGE4OTllZjQ5OThjM2FkNmMwNzJfMi0zLTEtMS05MjcxOA_e53cc4f9-841b-4662-8c1b-9de23690ebd2"
      unitRef="usd">3238000</us-gaap:EquityMethodInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjQw_211923ba-aa51-4e9e-9d0b-50995442b60d"
      unitRef="usd">19000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2NjE_da10fa7a-6754-4905-92e3-1546e5fe7274">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is &#x201c;more likely than not&#x201d; that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NTc_59b50816-5865-4cb6-9301-aad0598fc108">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars.&#160;In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process.&#160;Translation adjustments are recorded as a component of accumulated other comprehensive loss, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows.&#160;Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our consolidated statements of operations in other expense, net, see below other expense, net table. Foreign currency transaction losses (gains), net were $5.8 million, $1.0 million and $7.2 million in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0NjQ_e5c4da5d-16bb-45c7-a847-1fb3c2d8c076"
      unitRef="usd">-5800000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0Njg_b2d7e702-dc5d-429e-b284-e19b20cff062"
      unitRef="usd">-1000000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTQ0NzU_6ee250f3-76b2-4ceb-b72a-8d72c7d03816"
      unitRef="usd">-7200000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI0NjM_43566a5d-06f5-487e-ad71-0b4c8ab95bf7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenues when we transfer control of promised goods to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods. We offer certain volume-based rebates to our distribution customers, which we consider variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between prices we charge our distribution customers and contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts for use in determining the transaction price, we use information available at the time, including our historical experience. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available and our historical experience. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vast majority of our sales of Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Vascular Access and Vital Care products are sold on a standalone basis and control of these products transfers to the customer upon shipment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with Multiple Deliverables&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers.  These bundled arrangements typically consist of the sale of infusion systems equipment, along with annual software licenses &lt;/span&gt;&lt;/div&gt;and related software implementation services, as well as infusion consumables, IV solutions and extended warranties. Our most significant judgments related to these arrangements are (i) identifying the various performance obligations and (ii) estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.  Revenue related to the bundled equipment, software and software implementation services are typically combined into a single performance obligation and recognized upon implementation. As annual software licenses are renewed, we recognize revenue for the license at a point in time, at the start of each annual renewal period. The transaction price allocated to the extended service-type warranty is recognized as revenue over the period the warranty service is provided. Consumables and solutions are separate performance obligations, recognized at a point in time.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NzM_d8f33f3a-bef0-4c0c-87d2-bc02528fb81b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Post-retirement and Post-employment Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a Section&#160;401(k)&#160;retirement plan ("plan") for employees.&#160;Our contributions to our 401(k) plan were approximately $14.6 million, $11.0 million and $10.7 million in 2022, 2021 and 2020, respectively. We also have post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgxOTE_d0a6110f-8ea1-4843-9f81-711ef8dc992b"
      unitRef="usd">14600000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgxOTU_dd1638bf-1a7d-411d-b501-b8f7faa931b7"
      unitRef="usd">11000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTgyMDI_8d415fa6-add9-4820-b6a9-26b2d0126962"
      unitRef="usd">10700000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MjY_77bd347c-ef7d-4e78-974d-a30194d88edf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our research and development costs are expensed as incurred.  In certain circumstances when an asset will have an alternative future use we capitalize the costs related to those assets.  Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM3_11ef2c13-0514-4e49-95f6-9e2672f8157e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents interest (expense) income, net (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0xLTEtMS0xMDkyMDU_c7efe032-bfd6-458b-bbd4-c5583c72a923"
      unitRef="usd">70805000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0zLTEtMS0xMDkyMDg_891b7859-6a88-4e45-9513-587d1f094c8a"
      unitRef="usd">858000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi01LTEtMS0xMDkyMTA_d38892c8-9745-4c0e-a2f0-eba1e0a10542"
      unitRef="usd">1753000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy0xLTEtMS0xMDkyMTM_6d7ac9fc-63f4-421c-bade-c64a98037449"
      unitRef="usd">4430000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy0zLTEtMS0xMDkyMTU_c73d4f41-635a-4fb5-818f-c9d9e16b4df3"
      unitRef="usd">2840000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMy01LTEtMS0xMDkyMTc_1094a4bc-afd9-42d8-9d55-720f4cd7e159"
      unitRef="usd">3677000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0xLTEtMS0xMDA2NzM_10e6c440-b020-4bf7-9e8f-bb5462be1a04"
      unitRef="usd">-66375000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfMi0zLTEtMS0xMDA2NzM_1c5c4b03-e813-4023-80f6-0dee5079a3b9"
      unitRef="usd">1982000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmQ0NzdjZmFhMjFjNTRiNjBiMDcxNTQyZTg2MmRjOGM5L3RhYmxlcmFuZ2U6ZDQ3N2NmYWEyMWM1NGI2MGIwNzE1NDJlODYyZGM4YzlfNC01LTEtMS0xMDkyMjM_e55f2ec1-6d2c-4ea6-bf59-81b51474b533"
      unitRef="usd">1924000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfNTQ5NzU1ODUyNjM4_f7174dc9-405f-4cb6-bd95-620e3d3b02c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents other income (expense), net (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange losses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on disposition of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other miscellaneous income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi0xLTEtMS0xMDkyMjk_ecadb222-370a-4ed5-8c91-cd708a7e3763"
      unitRef="usd">5780000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi0zLTEtMS0xMDkyMzI_4c693d04-3d7b-4902-bcef-6829ab7cee33"
      unitRef="usd">1017000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMi01LTEtMS0xMDkyMzQ_62d23c52-4395-4334-8be7-c774dd3d4715"
      unitRef="usd">7177000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy0xLTEtMS0xMDkyMzY_8de112b3-2696-49b0-b881-fbf99d742183"
      unitRef="usd">-2554000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy0zLTEtMS0xMDkyMzg_2571eeac-4d0b-4aef-9ad3-141c72df9f47"
      unitRef="usd">-1651000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfMy01LTEtMS0xMDkyNDA_8ec687d9-7abd-42ef-99c7-f15c60b93948"
      unitRef="usd">1773000</us-gaap:GainLossOnSaleOfOtherAssets>
    <icui:MiscellaneousIncomeNet
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC0xLTEtMS0xMDkyNDI_740daedd-de68-43a3-ab26-9f8ba793632f"
      unitRef="usd">3198000</icui:MiscellaneousIncomeNet>
    <icui:MiscellaneousIncomeNet
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC0zLTEtMS0xMDkyNDQ_5fc798a4-2372-42f4-a2ea-35e3d91cdbde"
      unitRef="usd">627000</icui:MiscellaneousIncomeNet>
    <icui:MiscellaneousIncomeNet
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNC01LTEtMS0xMDkyNDY_3f6584d7-2f3c-4b8c-9b45-7be2fba5977f"
      unitRef="usd">2812000</icui:MiscellaneousIncomeNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS0xLTEtMS0xMDkyNDg_23aa3018-abe1-4148-ad2d-34d68f67b3e6"
      unitRef="usd">-5136000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS0zLTEtMS0xMDkyNTA_7a8e6d8b-229a-48d4-8532-8c1f7ac61e7d"
      unitRef="usd">-2041000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOjQ0MzA5NzI5OWJmNTRhOWQ5ZmQyNzQ4MjU5MWZiYTQ5L3RhYmxlcmFuZ2U6NDQzMDk3Mjk5YmY1NGE5ZDlmZDI3NDgyNTkxZmJhNDlfNS01LTEtMS0xMDkyNTI_0264c665-6b80-4319-8456-9a563d2c872b"
      unitRef="usd">-2592000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1ODM_180142c9-fb27-4392-a3f7-ac65e38da0d2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net (Loss) Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding plus any dilutive potential securities.&#160;Dilutive potential securities &lt;/span&gt;&lt;/div&gt;include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock, are not included in the treasury stock method calculation. Restricted stock units that are anti-dilutive are not included in the treasury stock method.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTk2NzA_0c3230d5-5b38-41d4-9fee-8be036a95772"
      unitRef="shares">12354</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMTk2Nzc_f91f55ec-e14a-4c8d-9cfc-5533f541eb73"
      unitRef="shares">12083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI2MDE_86998e38-056c-42fd-97be-77b0f6d52c5f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of net earnings per common share (&#x201c;EPS&#x201d;) &#x2014; basic and diluted (in thousands, except per share data):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding (basic)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common and common equivalent shares outstanding&#160;(diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EPS &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EPS &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi0yLTEtMS05MjcxOA_275c5cdd-9834-4b1c-89bb-248b22ee9ebf"
      unitRef="usd">-74286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi00LTEtMS05MjcxOA_3a269878-9c24-47c7-9212-596f9c9dd0c3"
      unitRef="usd">103135000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMi02LTEtMS05MjcxOA_afd0ccf8-21f4-408c-a00a-7463598003f6"
      unitRef="usd">86870000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy0yLTEtMS05MjcxOA_2b86867b-afaa-4e88-b216-d770547f244d"
      unitRef="shares">23868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy00LTEtMS05MjcxOA_897e6f2d-33ee-4632-adcf-0fc9946b5c5c"
      unitRef="shares">21206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfMy02LTEtMS05MjcxOA_bbf16e3c-3f4b-412a-8693-c0976acfc7be"
      unitRef="shares">20907000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC0yLTEtMS05MjcxOA_cb4e2ab5-b500-40e5-b133-3821dad10b7f"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC00LTEtMS05MjcxOA_9a1f47f2-0b1e-41a2-93be-8953c20f54ba"
      unitRef="shares">575000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNC02LTEtMS05MjcxOA_9fd20b5c-a9ac-4f2d-9b71-dbaff30ad4e1"
      unitRef="shares">684000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS0yLTEtMS05MjcxOA_51ef550d-0b54-421a-8339-5f7a58e56fb4"
      unitRef="shares">23868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS00LTEtMS05MjcxOA_e00e68ea-ab61-4949-ba29-503325c893d5"
      unitRef="shares">21781000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNS02LTEtMS05MjcxOA_0ddf36b0-8720-4d34-8fc5-69ee8f6b376c"
      unitRef="shares">21591000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi0yLTEtMS05MjcxOA_5d1e6492-4771-42a1-9128-3d41573ec206"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi00LTEtMS05MjcxOA_cd3d4b9f-aa86-44a8-bb3c-de0710c17c33"
      unitRef="usdPerShare">4.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNi02LTEtMS05MjcxOA_464b637a-e6a0-4411-bc55-3f547694560b"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy0yLTEtMS05MjcxOA_2f5f1b43-c2cd-4fab-962d-02d40d37b308"
      unitRef="usdPerShare">-3.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy00LTEtMS05MjcxOA_61c360bb-4996-477a-9564-19850936d306"
      unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RhYmxlOmZlNjgzM2NmODNmYTQ4ODQ5MWQ4YTA1ZDE0MjRjODUwL3RhYmxlcmFuZ2U6ZmU2ODMzY2Y4M2ZhNDg4NDkxZDhhMDVkMTQyNGM4NTBfNy02LTEtMS05MjcxOA_437014e7-df90-4ae4-aed1-f0da905064e7"
      unitRef="usdPerShare">4.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1NTA_a6dcdbf8-7d5d-4ab5-b770-60a5a078ff6a"
      xsi:nil="true"/>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83MC9mcmFnOjhjNTk3Y2U3MzFjYjRmMDZhZjM0MjAxODE3MGUyYjM4L3RleHRyZWdpb246OGM1OTdjZTczMWNiNGYwNmFmMzQyMDE4MTcwZTJiMzhfMjI1Nzc_9576bedb-8a91-4bb8-a32e-b063a32731d4">Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board ("FASB")  issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU were effective for all entities as of March 12, 2020 through December 31, 2022. ASU No. 2022-06, Reference Rate Reform: Deferral of the Sunset Date of Topic 848 deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap references LIBOR, these swaps were amended in early 2022 to transition to an alternative reference rate (see Note 7: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that allowed us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and allowed us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging or the optional expedient under this ASU is elected. The impact of these ASU's on our contracts has not been and is not expected to be material.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzQyNg_560adf45-55ba-467c-83ed-01c3215f9008">ACQUISITIONS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2022, we acquired 100% of the equity interests in Smiths Medical, the holding company of Smiths Group plc's global medical device business, from Smiths Group International Holdings Limited (&#x201c;Smiths&#x201d;). The acquisition of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Smiths Medical aligns with our strategic growth plans, enabling us to broaden our product offerings to include syringe and ambulatory infusion devices, vascular access, and vital care products and to strengthen and expand our global market reach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash consideration for the acquisition was $1.9 billion, which was financed with existing cash balances and proceeds from the credit agreement entered into on January 6, 2022 (see Note 11: Long-Term Debt). We also issued share consideration to Smiths of 2.5&#160;million shares of our common stock. The fair value of the common shares issued to Smiths was determined based on the opening market price of our common stock on the acquisition date. Smiths may be entitled to an additional $100.0&#160;million in cash consideration contingent on our common stock achieving certain price targets for certain periods after closing in accordance with the terms of the Share Sale and Purchase Agreement (the "Purchase Agreement"). In the event that (a) on or prior to the third anniversary of closing the 30-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share or (b) on or prior to the fourth anniversary of closing the 45-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share (each a "Price Target"), and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved, then Smiths will be entitled to receive the additional $100.0&#160;million in cash consideration. The fair value of the contingent consideration was determined using an option pricing model, specifically the Monte Carlo Simulation. In the analysis, the determinants of payout are simulated in a risk neutral framework over a large number of simulation paths. The fair value of the contingent consideration is then calculated as the average present value across all simulated paths. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Smiths became a related party to us when we issued 2.5&#160;million shares of our common stock as partial consideration for the acquisition of Smiths Medical. Additionally, we entered in to a transition services agreement ("TSA") with certain members of Smiths Group, plc. The TSA includes certain information technology, human resource and tax support services for an initial term of twelve months with the option to extend up to 24 months. During 2022, we expensed $37.6&#160;million for services provided under the TSA. As of December 31, 2022, we have $5.1&#160;million in open payables related to the services received under the TSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Final Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for acquired assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration payable to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of ICU Medical, Inc. common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares issued to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Price per share (ICU's opening market price on the acquisition date)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of ICU shares issued to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill - not tax deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identifiable intangible assets included $510.0 million of customer relationships, $400.0 million of developed technology, $30.0&#160;million of internally developed software, and $5.0 million of trade mark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine years, and, for each identifiable intangible asset is estimated as follows: eight years for customer relationships, ten years for developed technology, five years for internally developed software, and six months for the trade mark.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The identifiable intangible assets and other long-lived assets acquired have been valued utilizing Level 3 inputs as defined in Note 8: Fair Value Measurements. The fair value of identifiable intangible assets were generally developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and/or estimated useful lives. Certain other intangible assets were valued using a cost to replace method, estimating the labor and non-labor costs required to replace the asset under the premise that it was not part of the transaction. Property, plant and equipment was valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence which we estimate to approximate replacement cost, the work in process inventory was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Pro Forma Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Smiths Medical is included in our consolidated results beginning on January 7, 2022. Total revenues and net loss attributable to Smiths Medical for the period from January 7, 2022 to December 31, 2022 were $950.7&#160;million and $(74.3)&#160;million, respectively. The net loss figure is an estimate as the results by company are less identifiable due to integration. The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Twelve months ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma results presented above include the impact of the following adjustments: incremental amortization expense on intangible assets acquired of $1.9&#160;million and $24.7&#160;million for the twelve months ended December 31, 2022, and 2021, respectively, incremental interest expense, including amortization of debt discount and debt issuance costs, on the Credit Facilities of $1.2&#160;million and $73.5&#160;million for the twelve months ended December 31, 2022, and 2021, respectively and a $27.4&#160;million expense related to the increase in fair value of inventory for the twelve months ended December 31, 2021. The unaudited pro forma results include IFRS to U.S. GAAP adjustments for Smiths Medical historical results and adjustments for accounting policy alignment, which were materially similar to the Company. Any differences in accounting policies were adjusted to reflect the accounting policies of the Company in the unaudited pro forma results presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, we acquired a small foreign infusion systems supplier and paid an initial gross cash payment of approximately $15.4&#160;million. In addition to the initial cash consideration, total consideration for the acquisition includes an additional holdback of $0.5&#160;million, to be paid two years from the completion date of the acquisition, and also a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. The contingent earn-out based on the achievement of certain revenue targets obtained for the annual period ending December 31, 2022 was forfeited at December 31, 2022 as the minimum threshold for earning the earn-out was not met.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNzk_eeb6dec8-83ee-429c-aad6-3474b9d999bb"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <icui:BusinessCombinationConsiderationTransferredCash
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTQy_470321a0-7b4c-449a-a4e2-12ba50fecb74"
      unitRef="usd">1900000000</icui:BusinessCombinationConsiderationTransferredCash>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5Mjkz_12715cba-4e51-4441-a253-117eb5a10fcd"
      unitRef="shares">2500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzA2_76a5f4d6-7d85-410b-9d23-0649857d44f0"
      unitRef="usd">100000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <icui:MinimumStockPriceTargetForEarnOutPayment
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzIy_86f15aaf-4be1-45c6-a6ec-92df38334d52"
      unitRef="usd">300.00</icui:MinimumStockPriceTargetForEarnOutPayment>
    <icui:MinimumStockPriceTargetForEarnOutPayment
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzMx_b04f9442-2a46-4b69-8eca-6dd27883ac0c"
      unitRef="usd">300.00</icui:MinimumStockPriceTargetForEarnOutPayment>
    <icui:RequiredShareHoldingOfStockIssuedAtAcquisition
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzU2_f5d3eb35-bda6-4486-8faf-be41e359c18b"
      unitRef="number">0.500</icui:RequiredShareHoldingOfStockIssuedAtAcquisition>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5MzQw_0bd34393-5b66-44ba-af9f-483686fe44c8"
      unitRef="usd">100000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1ODgx_13b60b7d-60e0-4033-a645-f4e707e36980"
      unitRef="shares">2500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1ODk0_dc63351f-9d6d-4dc4-bfb4-d7ace6e98f9a"
      unitRef="usd">37600000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1OTA5_35cc817f-83e3-45b9-8505-694f49527bce"
      unitRef="usd">-5100000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI5Mjkx_79ac9928-5094-4282-954d-9ae893424400">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Final Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for acquired assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration payable to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of ICU Medical, Inc. common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares issued to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Price per share (ICU's opening market price on the acquisition date)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of ICU shares issued to Smiths&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill - not tax deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identifiable intangible assets included $510.0 million of customer relationships, $400.0 million of developed technology, $30.0&#160;million of internally developed software, and $5.0 million of trade mark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine years, and, for each identifiable intangible asset is estimated as follows: eight years for customer relationships, ten years for developed technology, five years for internally developed software, and six months for the trade mark.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMC0yLTEtMS05MjcxOA_c2967db1-c4e1-44cc-9e91-fdba602a9f21"
      unitRef="usd">1922955000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMS0yLTEtMS05MjcxOA_688c7c31-66ef-4310-9b2e-969dd908e6d0"
      unitRef="usd">53520000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNC0yLTEtMS05NjI4Mg_0e1d082e-1151-40c8-b1bc-66db0690adf7"
      unitRef="shares">2500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNS0yLTEtMS05NjI4Mg_f1c7f680-d09d-4222-b8e2-6403e897f9f1"
      unitRef="usdPerShare">230.39</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNi0yLTEtMS05NjI4Mg_17c905fe-c02b-4e6d-bb01-b95cab77a777"
      unitRef="usd">575975000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMi0yLTEtMS05MjcxOA_76578396-f627-411f-89b1-847340d4566f"
      unitRef="usd">2552450000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTAtMi0xLTEtOTYyODU_03194f04-ee57-42ce-887a-aa5bdfda74b9"
      unitRef="usd">78791000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationAcquiredReceivablesFairValue
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNS0yLTEtMS05MjcxOA_a086fcb1-1f5d-4ec2-aeeb-a4c3dec6b938"
      unitRef="usd">106132000</us-gaap:BusinessCombinationAcquiredReceivablesFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNi0yLTEtMS05MjcxOA_723b5f16-ac63-4eb0-a8e7-92316438a219"
      unitRef="usd">228919000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfNy0yLTEtMS05MjcxOA_094a1904-d694-4e70-8d33-c1dab91e7d96"
      unitRef="usd">53554000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfOC0yLTEtMS05MjcxOA_0052a46e-70d7-4b1e-9fce-52ad6ff423cc"
      unitRef="usd">206333000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTUtMi0xLTEtOTYyODU_3d93c503-78fe-41fb-be84-37f6f6f2a37c"
      unitRef="usd">55161000</icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfOS0yLTEtMS05MjcxOA_f9872ce1-f01a-45f1-8575-8c461f9a59f4"
      unitRef="usd">945000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTgtMi0xLTEtOTYyODU_aaedb236-953e-4d3c-8567-385594b412c9"
      unitRef="usd">379000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTAtMi0xLTEtOTI3MTg_9f91bce5-de79-467a-a097-97de3d003fb7"
      unitRef="usd">105291000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTEtMi0xLTEtOTI3MTg_59456a2e-833d-4c01-9c6b-81a2cf9c2cbb"
      unitRef="usd">173151000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <icui:BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMjEtMi0xLTEtOTYyODU_00c83115-2998-45a4-87ae-2578c91cca55"
      unitRef="usd">40312000</icui:BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMjItMi0xLTEtOTYyODU_fddaf415-28d9-47e6-a79f-1f8d768a7575"
      unitRef="usd">85490000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTgtMi0xLTEtOTUwNzA_84b56d8f-7da3-41ca-aac3-1614f4e7286b"
      unitRef="usd">187455000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTItMi0xLTEtOTI3MTg_67467447-e248-4b9f-9ade-8f884f4d00b6"
      unitRef="usd">1082570000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i7437d14a12be4025b5493cb7d897d472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTMtMi0xLTEtOTI3MTg_f9feecfb-31fc-4d18-8e9f-f02ef6746244"
      unitRef="usd">1469880000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOmEyOWFlNDc3M2NhNzRlMWFiYzRlYmQ1MDA3YWZkZDhkL3RhYmxlcmFuZ2U6YTI5YWU0NzczY2E3NGUxYWJjNGViZDUwMDdhZmRkOGRfMTUtMi0xLTEtOTI3MTg_2b8e5006-36fb-480b-be13-a27524e2e41c"
      unitRef="usd">2552450000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="icbf4360bc208465f843ef61d1768b5e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM1MA_562b05de-5e7a-4056-a288-c6dd8d2bbee9"
      unitRef="usd">510000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i84420d968625493db489841b6ba9cd22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM3OA_b982391f-5088-4ae3-bde9-c29360f78021"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1129dd1b04d7446c9d3d06c36614788e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4MTAx_31e21fe0-7b5f-45ee-a1cc-77e563b3a83d"
      unitRef="usd">30000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ia3856be9b89747b993110c792a39aabb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTM5OQ_8d883ac0-7c88-45bf-9761-3350e60e130c"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTUzOQ_f0a10630-2fca-4782-889c-36aa1d30b675">P9Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic98b9ae2742141cea974ed1a1041b446_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTU2OA_d8c043a1-7ba6-4bc6-af87-0cc9c26faedb">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i369fa34137ce41348503313048b70075_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMTU5MA_cfa2ec71-7caf-4303-b6bc-086ff9164f30">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i05325f7dac154ac19707c10ed7936bd5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4ODI1_6ddf1c49-949e-4880-b786-794208adab4d">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib4e1332c392b472a8c02f513a992eb09_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODI4ODI2_137b894d-9a4a-41c0-bdd1-404526cfd569">P6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Revenues
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzAw_53235ec6-b71c-40f0-bd30-8f3f0311933f"
      unitRef="usd">950700000</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzE0_72e9aac0-59e4-4cd1-b1e6-d0ae990bef9e"
      unitRef="usd">-74300000</us-gaap:ProfitLoss>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyNDEx_86aba4fb-8600-4c0f-9da9-291709de0e74">The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Twelve months ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMi0xLTEtMS05NjQwMA_52d153f1-5280-453c-b381-846d132d29cb"
      unitRef="usd">2300371000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMi0zLTEtMS05NjQwMg_e81e3330-16be-414d-a95d-89e572a8e601"
      unitRef="usd">2509830000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMy0xLTEtMS05NjQwMA_fef4039f-c319-4514-8a2d-5b5df8476b25"
      unitRef="usd">-70286000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RhYmxlOjIzZWFiNTMzYmQwZjRiNWJiODQ3YmJiM2MyNjRlOGJiL3RhYmxlcmFuZ2U6MjNlYWI1MzNiZDBmNGI1YmI4NDdiYmIzYzI2NGU4YmJfMy0zLTEtMS05NjQwMg_baee43c2-786b-445a-94ce-15ee7f2eb618"
      unitRef="usd">37454000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <icui:ProFormaAdjustmentAmortization
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzI4_ef8bb7c1-3c4a-40b8-bf82-42a519b8d0b0"
      unitRef="usd">1900000</icui:ProFormaAdjustmentAmortization>
    <icui:ProFormaAdjustmentAmortization
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1NzIx_95800ff0-588e-491f-803c-d7b7a75f52d4"
      unitRef="usd">24700000</icui:ProFormaAdjustmentAmortization>
    <icui:ProFormaAdjustmentFinanceCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzQy_e948eaba-4360-4efe-9f96-c2711d3248c2"
      unitRef="usd">1200000</icui:ProFormaAdjustmentFinanceCosts>
    <icui:ProFormaAdjustmentFinanceCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODM1NzM2_2cd01b3c-c834-4207-aff6-79b6ffc38ea6"
      unitRef="usd">73500000</icui:ProFormaAdjustmentFinanceCosts>
    <icui:ProFormaAdjustmentInventory
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfNTQ5NzU1ODMyMzU2_c8b8433f-d4e3-4acf-8615-29ebb562bd1b"
      unitRef="usd">27400000</icui:ProFormaAdjustmentInventory>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMjc4Ng_4a7613fd-ecfe-4535-92e6-8191f9b8bcbb"
      unitRef="usd">15400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <icui:BusinessCombinationConsiderationCashHoldback
      contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzAyNA_34733cac-f564-4469-b33b-6f0a7109a4cf"
      unitRef="usd">500000</icui:BusinessCombinationConsiderationCashHoldback>
    <icui:Contingentconsiderationgross
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzE0MQ_010be1dc-f331-4319-ace0-3c2fef18c55a"
      unitRef="usd">2500000</icui:Contingentconsiderationgross>
    <icui:ShortTermContingentConsiderationGross
      contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzE4MQ_0694232b-a581-4bee-9762-48ccc05106c1"
      unitRef="usd">1000000</icui:ShortTermContingentConsiderationGross>
    <icui:LongTermContingentConsiderationGross
      contextRef="i072f1ec910ff4ca6afc8bca0e90efc73_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83My9mcmFnOjdhODQ5ZjhmMzEyYjQ5NTBhMDMyZTE1MTgxMmI1MGIxL3RleHRyZWdpb246N2E4NDlmOGYzMTJiNDk1MGEwMzJlMTUxODEyYjUwYjFfMzMyOA_5536ea34-efe8-4114-96db-3830b5636bed"
      unitRef="usd">1500000</icui:LongTermContingentConsiderationGross>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjk4Ng_63341a27-644f-4bef-b02d-3e0e13db6aba">RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, strategic transaction and integration expenses were $71.4 million, $18.0 million and $28.4 million in 2022, 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges were $9.7 million, $(1.8) million and $7.9 million in 2022, 2021 and 2020, respectively, and are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we incurred restructuring charges primarily related to severance in connection with the January 6, 2022 acquisition of Smiths Medical, see Note 2: Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we adjusted certain facility restructuring liabilities by $2.0&#160;million, shown in the table below under "Other adjustments," to reflect actual amounts owed which resulted in net restructuring credits of $(1.8)&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, restructuring charges were primarily related to severance and costs related to office and other facility closures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Severance Pay and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retention and Facility Closure Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Strategic Transaction and Integration Expenses&lt;/span&gt;&lt;/div&gt;We incurred $61.7 million, $19.8 million and $20.5 million in strategic transaction and integration expenses in 2022, 2021 and 2020, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2022 were primarily related to transaction and integration expenses associated with our acquisition of Smiths Medical on January 6, 2022 (see Note 2: Acquisitions) which primarily included legal expenses, bank fees, employee costs and a United Kingdom stamp tax. The strategic transaction and integration expenses during 2021 were related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer, one-time costs incurred to comply with regulatory initiatives and transaction expenses incurred in connection with entering into a definitive agreement to acquire Smiths Medical. The integration expenses during 2020 were related to the integration of HIS and included expenses for the migration of IT systems at our Austin facility.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTM1_dd0817cc-6986-4f13-b7c6-1f8491ff0141"
      unitRef="usd">71400000</icui:Restructuringandstrategictransactionexpense>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTQw_5264755c-a7b4-47d8-95e3-7bcfe0db351e"
      unitRef="usd">18000000</icui:Restructuringandstrategictransactionexpense>
    <icui:Restructuringandstrategictransactionexpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTQ4_19373457-dcf8-4812-a227-956b0168376c"
      unitRef="usd">28400000</icui:Restructuringandstrategictransactionexpense>
    <us-gaap:RestructuringCharges
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjI4_0df602ba-02e6-4fe5-8688-8c374bf9b46e"
      unitRef="usd">9700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjMy_a16283c9-7f42-43d9-8a98-cd7e88e2b76f"
      unitRef="usd">-1800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjM5_608492ad-8dd5-4c65-bb4f-20e22286ebfb"
      unitRef="usd">7900000</us-gaap:RestructuringCharges>
    <icui:RestructuringAdjustmentsSeveranceAndFacility
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfNDc5_f83645c7-fdaa-46b6-a458-549635565ded"
      unitRef="usd">2000000</icui:RestructuringAdjustmentsSeveranceAndFacility>
    <us-gaap:RestructuringCharges
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfNjEz_1f838971-b720-46fc-9e4b-4b363ebb1d10"
      unitRef="usd">-1800000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMjk3OQ_e308c383-a69a-41f6-b4a3-971351acaa48">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Severance Pay and Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retention and Facility Closure Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;_______________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated liabilities related to a prior year's facility closure restructuring were adjusted to actual amounts owed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i22c99d7dca834fc9b8ba44f702ce5c97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS0yLTEtMS05MjcxOA_432a6179-0f88-4de2-ad1d-d7c700dbcac1"
      unitRef="usd">1858000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i71cb42b4cdb34217bf31e9da4cf6cfaa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS02LTEtMS05MjcxOA_387c27b7-eea8-4f8f-a29c-02233da01559"
      unitRef="usd">1563000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMS04LTEtMS05MjcxOA_e27439cc-886d-4aa5-96a4-503f64d9ae50"
      unitRef="usd">3421000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi0yLTEtMS05MjcxOA_0cefad4f-9412-4412-9efe-b124b78b4fb1"
      unitRef="usd">140000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi02LTEtMS05MjcxOA_56fc45c2-fd6c-46f6-aad5-da24aafb20d3"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMi04LTEtMS05MjcxOA_cc7a1911-4671-44cf-a3d4-5149936d2f6f"
      unitRef="usd">140000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy0yLTEtMS05MjcxOA_da4f7d50-3b6d-4eeb-918d-ec68e5b84532"
      unitRef="usd">969000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy02LTEtMS05MjcxOA_d35e364b-6093-4547-b761-c23f89732747"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMy04LTEtMS05MjcxOA_a75be518-974a-403c-9ca9-aef9c38b49c0"
      unitRef="usd">969000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC0yLTEtMS05MjcxOA_0afb7275-0273-4919-b5d9-52768159b4bb"
      unitRef="usd">2000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC02LTEtMS05MjcxOA_601af04a-d58e-44e8-a0b7-fb6d22322ace"
      unitRef="usd">-31000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNC04LTEtMS05MjcxOA_69933e06-99a7-4a3f-a45a-de4d70af0f6c"
      unitRef="usd">-29000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i31fb4b9142364bb29438a8bc524eb02c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS0yLTEtMS05OTYwMA_f4dbfee9-28ac-4ca9-af36-b67fa623e6fe"
      unitRef="usd">528000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="if843a5b34fd641f9a7f757dc6ce30b67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS02LTEtMS05OTYyMQ_52a63989-3b1a-49e7-ac54-0d99e03f1e39"
      unitRef="usd">1429000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS03LTEtMS0xMDkyODI_0829365d-7b5b-4e11-befc-834597530af4"
      unitRef="usd">1957000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="i4c4925743ff242b0b2ee65ecd693dd3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS0yLTEtMS05MjcxOA_b4f2f8e4-d8a5-4687-b98d-345279ebb8c7"
      unitRef="usd">499000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i92c10763b02e45ea9ffe7f02507e2e8c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS02LTEtMS05MjcxOA_7e6b4e48-b2f2-4e88-afa3-fa992b6916c3"
      unitRef="usd">165000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNS04LTEtMS05MjcxOA_609254a7-11d9-4eee-b53e-f5c8d6d07d7a"
      unitRef="usd">664000</us-gaap:RestructuringReserve>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities
      contextRef="i55936ad0651e4e25a3f22368ebb27543_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy0yLTEtMS0xMDkyODg_1212a7d2-5665-4e27-ae67-3db3e776724b"
      unitRef="usd">5796000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities
      contextRef="i404ace05705b44778677860b518b5b99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy01LTEtMS0xMDkyOTA_c4b12b5e-89c9-421e-8516-3448201d4cf4"
      unitRef="usd">1740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy03LTEtMS0xMDkyOTI_f2452ca7-668d-4178-8224-50a29c8c943b"
      unitRef="usd">7536000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities>
    <us-gaap:RestructuringCosts
      contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi0yLTEtMS05MjcxOA_a492d5ac-2d09-4d46-8078-56bec5422a3c"
      unitRef="usd">9667000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi02LTEtMS05MjcxOA_7f7b9adf-c01c-456c-ab9e-5d68bca62960"
      unitRef="usd">58000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNi04LTEtMS05MjcxOA_02b93277-e0af-4ba2-a949-9314920d4038"
      unitRef="usd">9725000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy0yLTEtMS05MjcxOA_873b107a-3b6e-4070-a416-e7038a91e0d3"
      unitRef="usd">11083000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy02LTEtMS05MjcxOA_e9ac8564-6ee6-4e44-a374-2f52e3aa5721"
      unitRef="usd">268000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfNy04LTEtMS05MjcxOA_229aca5c-494d-44d6-881a-4a375b6fd136"
      unitRef="usd">11351000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC0yLTEtMS05MjcxOA_9e66f78d-fef1-4bae-b06e-e6bce64db774"
      unitRef="usd">425000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC02LTEtMS05MjcxOA_68795c52-033d-465d-8b09-efaf1e67203f"
      unitRef="usd">188000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOC04LTEtMS05MjcxOA_3989c974-3507-440a-b49e-bb3ec01a74a1"
      unitRef="usd">613000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i33e8b50b6e6c4c4ba7e365fd1495f2e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS0yLTEtMS05MjcxOA_48e0eac7-6d83-4ae5-b751-7abf99f8add4"
      unitRef="usd">38000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i8dfdc44868074605937528148921ca05_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS02LTEtMS05MjcxOA_0f756256-44f2-4e87-acff-26e0a7c48b8a"
      unitRef="usd">0</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfOS04LTEtMS05MjcxOA_ed43a592-fa8d-428e-ba53-c5983f52f106"
      unitRef="usd">38000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="i55936ad0651e4e25a3f22368ebb27543_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtMi0xLTEtOTI3MTg_f141babf-5240-40c3-b901-4abd81961fd8"
      unitRef="usd">4416000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i404ace05705b44778677860b518b5b99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtNi0xLTEtOTI3MTg_b6aa3a15-54cb-490f-9b8f-a930045aaefa"
      unitRef="usd">1507000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RhYmxlOmI2YzdkYmE2YzNmYjQwMTk5ZjUwMjAwNGM1ODczY2I1L3RhYmxlcmFuZ2U6YjZjN2RiYTZjM2ZiNDAxOTlmNTAyMDA0YzU4NzNjYjVfMTAtOC0xLTEtOTI3MTg_f291549e-1de4-4dbf-b409-3df726fcaf8e"
      unitRef="usd">5923000</us-gaap:RestructuringReserve>
    <icui:StrategicTransactionandIntegration
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgxMA_b2d59d89-d010-4088-80b7-2cf1410dcf9f"
      unitRef="usd">61700000</icui:StrategicTransactionandIntegration>
    <icui:StrategicTransactionandIntegration
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgxNA_8b179daf-4f8c-4e88-b028-fb871d1cacb1"
      unitRef="usd">19800000</icui:StrategicTransactionandIntegration>
    <icui:StrategicTransactionandIntegration
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83Ni9mcmFnOjc0OGY4YjhjYmU3MDQwZWU4ZDQ4MzQ3ZDIyMDc0MzdhL3RleHRyZWdpb246NzQ4ZjhiOGNiZTcwNDBlZThkNDgzNDdkMjIwNzQzN2FfMTgyMQ_4dc2a204-89b3-479a-89be-eefbd7517800"
      unitRef="usd">20500000</icui:StrategicTransactionandIntegration>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTI5NA_90c0746a-951d-4020-a2e9-03446934b988">REVENUE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the acquisition of Smiths Medical our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and  renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to both our distribution and end customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts in order to determine the transaction price, we use information available at the time, including our historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into arrangements which include multiple performance obligations, (see Note 1: Basis of Presentation and Summary of Significant Accounting Policies). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant judgments related to these arrangements include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identifying the various performance obligations of these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue disaggregated&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product line&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Consumables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Critical Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Systems-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vascular Access-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vital Care-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents our revenues disaggregated by geography (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Geography&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, the Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively.  International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract balances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of acquired deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During 2022, we recognized $7.5 million in revenue that was included in the opening contract balances as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, revenue from remaining performance obligations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Recognition Timing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&amp;lt;12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&amp;gt; 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;____________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Other deferred revenue includes pump development programs, purchased training and extended warranty.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC Topic 606, we have elected to expense these costs as incurred as the period of benefit is less than one year.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical expedients and exemptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the practical expedient applied to sales commissions, under ASC Topic 606, we elected to apply the practical expedient for shipping and handling costs incurred after the customer has obtained control of a good. We will continue to treat these costs as a fulfillment cost rather than as an additional promised service.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTI5Nw_09cb95bb-168e-4156-8f8f-9788d3120c6d">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product line&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Consumables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Critical Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Infusion Systems-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vascular Access-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vital Care-Smiths Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents our revenues disaggregated by geography (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Geography&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, the Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively.  International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0xLTEtMS05MjcxOA_8b2359fb-2b8b-494e-bbed-92ff7a3cf310"
      unitRef="usd">566617000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i8edc85ef36844d62aa6f704e8281864b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0zLTEtMS05MjcxOA_09843070-cd39-4a2b-9c6c-6d56f8db74f4"
      unitRef="number">0.25</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy01LTEtMS05MjcxOA_123c814f-0a7f-47fe-9458-582dd6258060"
      unitRef="usd">555189000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="ie65fb11f30174cf9adc5baa560744694_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy03LTEtMS05MjcxOA_7f9e4032-0795-4a55-98dc-f07ccfe6afce"
      unitRef="number">0.42</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy05LTEtMS05MjcxOA_5b47a815-19a6-449b-8fb0-796ca9cf22d6"
      unitRef="usd">473740000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i01bf3a2689f94932af4d5a35cce335aa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfMy0xMS0xLTEtOTI3MTg_01a86b8f-b4a7-4a5f-a9c5-cc4831a58d66"
      unitRef="number">0.37</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0xLTEtMS05MjcxOA_f537f2c1-f4e2-4fe0-a98c-380a22e760ef"
      unitRef="usd">351080000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i63df6e0cf2c2446a89ddad31226f5f93_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0zLTEtMS05MjcxOA_7ec0a5d1-0bdb-47dd-ba05-e1951bc92863"
      unitRef="number">0.15</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC01LTEtMS05MjcxOA_6afc87e5-a86f-40e5-a4d2-c0173c125768"
      unitRef="usd">352321000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i9b7e90102edb42159adadfcb9c36e6dd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC03LTEtMS05MjcxOA_43864408-80d4-4658-8ed1-909cfd771e6f"
      unitRef="number">0.27</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC05LTEtMS05MjcxOA_c6d5e84c-e4c4-4001-88b8-d6d6fa6c6105"
      unitRef="usd">359691000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i7958e690406d48efb1aaf893f715ba34_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNC0xMS0xLTEtOTI3MTg_8ca25d8f-dc61-44db-aec3-0e0f94b0de4a"
      unitRef="number">0.28</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="id7c134c659424d68b063d67180a61ce0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0xLTEtMS05MjcxOA_f4310667-2d03-4eb1-9ca3-9543dee0404e"
      unitRef="usd">363472000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="id7c134c659424d68b063d67180a61ce0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0zLTEtMS05MjcxOA_39f0a0ee-0e7e-4ca9-bdf6-87a6aab83d7b"
      unitRef="number">0.16</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS01LTEtMS05MjcxOA_167d1577-972b-4e95-977f-e735b44355ab"
      unitRef="usd">359477000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i2dde2c070f044d3b8d7950e3ce431511_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS03LTEtMS05MjcxOA_3712d31e-ae09-4519-9976-2beb2a94ada6"
      unitRef="number">0.27</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS05LTEtMS05MjcxOA_aeccf982-a1b8-4e71-9358-f722e47f33c6"
      unitRef="usd">388971000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="if9304b3d4b7f4507b1d74fc4b7c26c3a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNS0xMS0xLTEtOTI3MTg_384661ec-d1d5-44a8-8de7-db8ab29b4d2e"
      unitRef="number">0.31</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0xLTEtMS05MjcxOA_efd52dcf-1b84-4a85-bbf5-87f5a508dd99"
      unitRef="usd">47330000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="iaf9ed2b14fbe445fa1f2395e24e8201f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0zLTEtMS05MjcxOA_ec07693c-82dd-427f-bb1f-0c97d8dde3cd"
      unitRef="number">0.02</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i4a974801206342f69077c517deb2da0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi01LTEtMS05MjcxOA_2be68399-f5aa-490c-a748-ae1657127bec"
      unitRef="usd">49321000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i4a974801206342f69077c517deb2da0b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi03LTEtMS05MjcxOA_3246f1d7-bb5a-4715-8f46-1e50b38836a2"
      unitRef="number">0.04</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi05LTEtMS05MjcxOA_b65f1891-c54f-452d-9e27-053fde960c15"
      unitRef="usd">48602000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="ia723916fce3d4aefbb0f6180527a0c6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNi0xMS0xLTEtOTI3MTg_eb8b81a0-84bc-411a-bc03-225f6fe7e57f"
      unitRef="number">0.04</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy0xLTEtMS0xMDkyOTQ_920d2e19-cdd8-415a-8386-5cee61bcfa3a"
      unitRef="usd">340124000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="id8c10485efc04904b68e4645d3be4b4a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy0zLTEtMS0xMDkzMDE_cf4f14d5-ef26-4228-911f-8b8e2f75b4ca"
      unitRef="number">0.15</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="ia31b13090f3d4d6896d08faf55e51eed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy01LTEtMS0xMDkyOTY_9879c45e-9470-4370-afc9-e9d9bec308b9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49af9a202b4c453dbe1982d3176037d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfNy05LTEtMS0xMDkyOTk_132fedba-659d-47b2-b4c4-a6e3eba8a1d1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xLTEtMS0xMDkyOTQ_f2a1766d-e50a-4dfc-b187-8c2e54bb6231"
      unitRef="usd">326765000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i7845c2060e2b40b4bcf255e1a1d8170d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0zLTEtMS0xMDkzMDE_62686619-588e-44bd-876c-a850ddd82252"
      unitRef="number">0.14</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i3486eaebd0f44d4582e0714314d501cb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC01LTEtMS0xMDkyOTY_bcebf7e5-4868-4bb4-b103-fc17c0dc19c4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic383a5944210457b97aab0db2bac248d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC05LTEtMS0xMDkyOTk_5945009f-9559-44f0-95e2-6a27d836db73"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS0xLTEtMS0xMDkyOTQ_00d1bc99-eaff-43cd-86ba-52f7626ea879"
      unitRef="usd">284609000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="ic65c0e3c67ee40938b2560012e5ae123_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS0zLTEtMS0xMDkzMDE_14a01f28-4f36-4cb5-aa89-34d10a02cdf9"
      unitRef="number">0.13</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="id75defc870864b6e98d462140afc25c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS01LTEtMS0xMDkyOTY_da427970-de32-4ed9-863f-bb1b496553d1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie95a1fa30baf4c46a60229408037bef6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOS05LTEtMS0xMDkyOTk_7a0b29f6-5c8a-4d1b-a6d5-e313ffb4f2ff"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xLTEtMS05MjcxOA_34f18f0f-1f31-45dc-8437-5078b8302810"
      unitRef="usd">2279997000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0zLTEtMS05MjcxOA_5c1f1492-2c06-40ec-8a75-93719c31bfc7"
      unitRef="number">1</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC01LTEtMS05MjcxOA_21f58e80-d4ad-45b7-a157-9ccae6ab3554"
      unitRef="usd">1316308000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC03LTEtMS05MjcxOA_23364eab-3266-4991-a8cd-3e0e1fa60d09"
      unitRef="number">1</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC05LTEtMS05MjcxOA_ec01642c-a320-4156-b8ab-e884fb6eba83"
      unitRef="usd">1271004000</us-gaap:Revenues>
    <icui:Percentageofrevenue
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOmJhN2UzZjcyMjg0NjQwNDlhOGE4NjllMDI0NzE1MWRjL3RhYmxlcmFuZ2U6YmE3ZTNmNzIyODQ2NDA0OWE4YTg2OWUwMjQ3MTUxZGNfOC0xMS0xLTEtOTI3MTg_879364c8-2b69-41b7-99a5-6649e6a9a4eb"
      unitRef="number">1</icui:Percentageofrevenue>
    <us-gaap:Revenues
      contextRef="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi0xLTEtMS05MjcxOA_40bf1d13-57fb-4aed-b83f-46cf9fe2c11e"
      unitRef="usd">1460069000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi0zLTEtMS05MjcxOA_5edc4edd-8d88-4415-866a-55b4225d0e18"
      unitRef="usd">941809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMi01LTEtMS05MjcxOA_ee713514-c8aa-49ea-81d9-9118e399a899"
      unitRef="usd">910627000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica1baa88a6474f1ca1bde91733d99703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0xLTEtMS0xMTEyNjY_cfd4d3db-d334-43ca-b1ab-6b80e87f9916"
      unitRef="usd">367411000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e3ea0f082c144ce87ee7b48799015d0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0zLTEtMS0xMTEyNjY_b079d59a-16e5-457e-8bef-eeee7454f400"
      unitRef="usd">147488000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32b1c128a1684402a9045faf165e1fc4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy01LTEtMS0xMTEyNjY_c06db375-161d-4882-8bde-b76e67816b6b"
      unitRef="usd">132763000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcdf4b4d10d049fc8afa1abd2cc0db5c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC0xLTEtMS0xMTEyNjY_9fe7e6db-c8a4-47b9-8118-3cf20339e7a5"
      unitRef="usd">257208000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i002db38129f24286874e3dd53ccdaf95_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC0zLTEtMS0xMTEyNjY_7630ce88-77a2-4407-a53f-ac2407283c64"
      unitRef="usd">85692000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f8c28deaeb448d887fa9af7b3d8346a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNC01LTEtMS0xMTEyNjY_fa2e56c4-b89d-4871-8182-c001cbc0dbaa"
      unitRef="usd">79610000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f21e80f577f43c19fd1aa42008e7706_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0xLTEtMS0xMDkzMDQ_b49e4c07-17b3-4abd-af78-19ef71f14983"
      unitRef="usd">195309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24e71756005b40d2933a4ea6f87d56f1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy0zLTEtMS0xMDkzMDg_07768186-aa6c-4970-9f93-9b4bb1480b11"
      unitRef="usd">141319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4df4b017e9b041fa969010720463d6c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfMy01LTEtMS0xMDkzMTA_2e2b763d-ec35-4fff-a0fd-e3cf9b93dd3a"
      unitRef="usd">148004000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi0xLTEtMS05MjcxOA_ed42a8e1-d17a-4dd4-b5ed-f40334c9e7a4"
      unitRef="usd">2279997000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi0zLTEtMS05MjcxOA_245d1fb2-6d84-4ba0-bd69-812c2b1a14dc"
      unitRef="usd">1316308000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjNkYjM0ZDIzOWYzMTRmZjA4ZTYwZjI5ZjJlZjQ0NWE5L3RhYmxlcmFuZ2U6M2RiMzRkMjM5ZjMxNGZmMDhlNjBmMjlmMmVmNDQ1YTlfNi01LTEtMS05MjcxOA_41c04eae-13b8-4d19-bc1d-f70494836bcc"
      unitRef="usd">1271004000</us-gaap:Revenues>
    <icui:Percentoftotalrevenue
      contextRef="i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ3Ng_216f977a-5ed8-4cf5-b21e-2130c16a8383"
      unitRef="number">0.64</icui:Percentoftotalrevenue>
    <icui:Percentoftotalrevenue
      contextRef="i983ff83908ac47578b98e58a57be2dbb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ4MA_f0edf14b-0560-49dc-acc7-640b47a945cc"
      unitRef="number">0.72</icui:Percentoftotalrevenue>
    <icui:Percentoftotalrevenue
      contextRef="i872cb84c011f43a8bf054eebf89e176d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzQ4Nw_20d32820-708f-402b-b2a5-398c47d407eb"
      unitRef="number">0.72</icui:Percentoftotalrevenue>
    <icui:Percentoftotalrevenue
      contextRef="if45f71d7222548f6aa04eb33ce7241ca_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU3NA_501bfaa8-ed19-4705-b542-587cb526b828"
      unitRef="number">0.36</icui:Percentoftotalrevenue>
    <icui:Percentoftotalrevenue
      contextRef="i5482a1d0e20f424fbf824e580d6a9199_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU3OA_0d90d603-66bb-4740-b1f3-49b729a1d873"
      unitRef="number">0.28</icui:Percentoftotalrevenue>
    <icui:Percentoftotalrevenue
      contextRef="ie96a185ecb1c4a958fca6ce4a87a4b19_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfMzU4NQ_7080c441-17ca-47b3-9989-ef086aa1a625"
      unitRef="number">0.28</icui:Percentoftotalrevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTMwMA_ff85b3fd-c991-4c16-8b2a-6fa7285bae51">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of acquired deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue deferred due to implementation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMS0xLTEtMS05MjcxOA_82b49d60-41cb-447e-b6e8-c5239ccce9c3"
      unitRef="usd">6430000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMi0xLTEtMS05MjcxOA_6bd17bf9-a1e7-4c60-afb0-c36131d486d7"
      unitRef="usd">-10048000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:DeferredRevenueAdditions
      contextRef="i20ae444c3ee7469084f04ed7bbfcdf9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMy0xLTEtMS05MjcxOA_85fe9a46-74f5-4b0d-b435-9b2f39cacb43"
      unitRef="usd">13725000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNC0xLTEtMS05MjcxOA_c6f84935-736e-4604-816f-a19d8809d3fb"
      unitRef="usd">-7261000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:DeferredRevenueAdditions
      contextRef="i3142ec9241714ad1a302fe7c07fb2995_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNS0xLTEtMS05MjcxOA_25a2523d-c5cf-4846-ae6f-e6a820b9ab6a"
      unitRef="usd">4615000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNi0xLTEtMS05MjcxOA_7089a22f-fb2a-4967-a1f1-cc312821fb9b"
      unitRef="usd">7461000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNy0xLTEtMS0xMDkzMjI_ad8c0d39-1ed4-497c-ba3c-ab9074a8876f"
      unitRef="usd">51245000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfNy0xLTEtMS05MjcxOA_c01e165e-2f62-4384-b8b8-2ea34ff5e63c"
      unitRef="usd">-32252000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:DeferredRevenueAdditions
      contextRef="i1e95e6c719b2416a9803492bc1ef33c1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfOC0xLTEtMS05MjcxOA_bef85d58-e5d6-4b1e-9e92-975464e61eab"
      unitRef="usd">20332000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfOS0xLTEtMS05MjcxOA_725f8272-68a8-4dfb-b62f-e45ae7ce2e22"
      unitRef="usd">-16277000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:DeferredRevenueAdditions
      contextRef="if066a8a8edff45c0ad722274a4ff2404_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTAtMS0xLTEtOTI3MTg_9ee4dd5f-54c2-4e95-90fd-5945e7ccbb80"
      unitRef="usd">17557000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions
      contextRef="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTItMS0xLTEtMTA5MzI0_612ff7c7-0eb2-479a-b7f0-fb1f45fcf441"
      unitRef="usd">3729000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i172b2d6efb8643148266aae86a1c2f0c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTMtMS0xLTEtMTA5MzI0_b033994c-54c1-4513-be9b-b65e2d0bfe60"
      unitRef="usd">-1514000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:DeferredRevenueAdditions
      contextRef="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTQtMS0xLTEtMTA5MzI0_33f01673-ee9a-4ef8-8df0-a1641927043b"
      unitRef="usd">1500000</us-gaap:DeferredRevenueAdditions>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i40b09d8669cd44a481bcf225369a15ba_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTUtMS0xLTEtMTA5MzI0_f54a7983-2189-45c8-a326-6ec7ef564f76"
      unitRef="usd">-5915000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjhjNDE2YjBmYjA4OTQ2YmNiZGQ0ODBlODk2OGY2YjU3L3RhYmxlcmFuZ2U6OGM0MTZiMGZiMDg5NDZiY2JkZDQ4MGU4OTY4ZjZiNTdfMTEtMS0xLTEtOTI3MTg_da84ed0b-bfd9-4a7b-974f-4801d8947444"
      unitRef="usd">45866000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTQ5NzU1ODIwMDky_beac7a34-30ce-4573-9626-d57d664cb62a"
      unitRef="usd">7500000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RleHRyZWdpb246OGNjYmJkNGFjOTM0NDlkNTg0NTgwYTNhNmNiOWIzODJfNTQ5NzU1ODIwMDgz_063b4f37-e2ad-4e29-ac18-7b1e7e60eb33">As of December 31, 2022, revenue from remaining performance obligations is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Recognition Timing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&amp;lt;12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&amp;gt; 12 Months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other deferred revenue*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i34be06a38704454ba49d54c4642a8be6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMi0xLTEtMS0xMDkzMjY_d48af24a-e0bb-48ec-a2a4-876163ae74d2"
      unitRef="usd">15144000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i801bb622fa854aa8aa887087ba287be2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMi0zLTEtMS0xMDkzMjk_dc7d2309-0248-42b1-ae01-e95bb7e268e9"
      unitRef="usd">982000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iad7155363879401cb075f883b3c05618_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMy0xLTEtMS0xMDkzMjY_15dfd342-048d-4ec1-8c3f-9bedeaf8f9f9"
      unitRef="usd">8277000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib153ddca67ce46f9a87db324f5e82b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfMy0zLTEtMS0xMDkzMjk_ae3e2ab9-31ab-41fe-94df-9cb2f6a6c249"
      unitRef="usd">1026000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ifb08893e609946fb8063faaad20c4476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNC0xLTEtMS0xMDkzMjY_69808c86-84cd-4f13-ac8a-b908bd394449"
      unitRef="usd">1422000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i8688bac62fd54e49817ebdf4ef330a22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNC0zLTEtMS0xMDkzMjk_c297fcef-2649-4df3-8500-fd745d4ea0ad"
      unitRef="usd">12797000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iec83df23cc984ae1bb81bac0c2d32d43_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNS0xLTEtMS0xMDkzMjY_12b2782e-8c1c-420a-98df-dddd58ef080e"
      unitRef="usd">4784000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if24294e168244b4d800b76ebe275bb94_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNS0zLTEtMS0xMDkzMjk_95818919-1397-405a-bb06-3135c92043a0"
      unitRef="usd">1434000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0c7b424d053745b89be43013214212ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNi0xLTEtMS0xMDkzMjY_483ead92-16f2-414b-885f-8230a97ea56f"
      unitRef="usd">29627000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9b46600611854ead8201632b540aa737_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF83OS9mcmFnOjhjY2JiZDRhYzkzNDQ5ZDU4NDU4MGEzYTZjYjliMzgyL3RhYmxlOjU1MzlhMzM0YTc2ODQ2ZjFiMzczMzJhMzk5OTE1MGNkL3RhYmxlcmFuZ2U6NTUzOWEzMzRhNzY4NDZmMWIzNzMzMmEzOTk5MTUwY2RfNi0zLTEtMS0xMDkzMjk_f96401a4-51e4-4dc0-a9f5-0e201b6a811b"
      unitRef="usd">16239000</us-gaap:RevenueRemainingPerformanceObligation>
    <icui:LesseeOperatingAndFinanceLeaseTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYyNg_99ee0064-4622-40bf-8282-9decacaf4b8d">LEASES&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our consolidated balance sheets. Our lease liabilities are included in accrued liabilities, and other long-term liabilities on our consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have stated lease payments, which may include fixed rental increases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases are for corporate, research and development and sales and support offices, distribution facilities, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our lease cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost &#x2014; interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost &#x2014; reduction of ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on our finance leases is included in interest expense, net in our consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental cash flow information related to our leases (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We acquired $55.2&#160;million of operating right-of-use assets as part of the Smiths Medical acquisition, see Note 2: Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,864&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,847&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,916&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,980&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</icui:LesseeOperatingAndFinanceLeaseTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic71707c2dff14fa99b1f7a37aa00d176_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTM4OQ_14d4fbd9-d821-48a5-9f74-65af4ff7a841">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i455063291da94c4e933985b9ba288cce_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTM5NQ_fd4670c7-9b9b-4594-bc8a-4d40a29e9551">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <icui:Optiontoextendinyears
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMTQ3NA_94ab1fa7-b5d7-40be-b0a9-66b641a7b11e">P5Y</icui:Optiontoextendinyears>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYzNg_6eeb6bd9-302c-4fba-93af-a70095e65a3b">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of our lease cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost &#x2014; interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost &#x2014; reduction of ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Interest expense on our finance leases is included in interest expense, net in our consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our consolidated statements of operations.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0xLTEtMS0xMDkzMzc_09800b6e-9b3d-4836-be0a-09fa8e653b5f"
      unitRef="usd">22038000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0xLTEtMS05MjcxOA_576f1237-8795-4355-8116-4c9a2cba1b5b"
      unitRef="usd">11251000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMi0zLTEtMS05MjcxOA_ce609de1-a1f7-4a03-8db4-bed8bc662d9a"
      unitRef="usd">11284000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0xLTEtMS0xMDkzMzc_b339843f-4cc5-4105-afae-87de285babc5"
      unitRef="usd">112000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0xLTEtMS05MjcxOA_6bba6104-d891-499c-8106-40c14df0a5e4"
      unitRef="usd">122000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfMy0zLTEtMS05MjcxOA_38ae292e-a737-4163-88a5-f77ff53541eb"
      unitRef="usd">91000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0xLTEtMS0xMDkzMzc_15386afe-754c-4807-9bc4-82eb1521f60f"
      unitRef="usd">712000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0xLTEtMS05MjcxOA_94a20431-6690-4a3d-809d-18aacb5d0865"
      unitRef="usd">648000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNC0zLTEtMS05MjcxOA_148d838b-ba6c-403e-a27a-762fb8082781"
      unitRef="usd">383000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShortTermLeaseCost
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0xLTEtMS0xMDkzMzc_867c14c6-5cb5-4ee3-b538-333ce19bf28f"
      unitRef="usd">7000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0xLTEtMS05MjcxOA_5447459b-3cdc-4315-aa92-7177f2b0f939"
      unitRef="usd">14000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNS0zLTEtMS05MjcxOA_cd958856-2517-41df-be98-b3d307d8d5e6"
      unitRef="usd">263000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0xLTEtMS0xMDkzMzc_1f6cc0f0-121e-4aba-be5c-88d82a80b99b"
      unitRef="usd">22869000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0xLTEtMS05MjcxOA_9920aed8-14bb-421b-bfc0-c2f513d9aeb0"
      unitRef="usd">12035000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjVkMzBkNmNmNWQ0NDQ2ZWI5MDM5MzEzMDg4ZWQ5ZDllL3RhYmxlcmFuZ2U6NWQzMGQ2Y2Y1ZDQ0NDZlYjkwMzkzMTMwODhlZDlkOWVfNi0zLTEtMS05MjcxOA_924484f0-5d8f-443c-94da-8b525c1f336e"
      unitRef="usd">12021000</us-gaap:LeaseCost>
    <icui:SupplementalCashFlowInformationLeasesTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjYzOA_21863648-5593-4d45-9cbe-425def39c408">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental cash flow information related to our leases (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We acquired $55.2&#160;million of operating right-of-use assets as part of the Smiths Medical acquisition, see Note 2: Acquisitions.&lt;/span&gt;&lt;/div&gt;</icui:SupplementalCashFlowInformationLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0xLTEtMS0xMDkzMzk_f57e10be-0207-44de-9066-dddb6e1f91ce"
      unitRef="usd">25225000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0xLTEtMS05MjcxOA_8000e286-58e6-412d-baf0-a97aa8b7db3d"
      unitRef="usd">11256000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfMy0zLTEtMS05MjcxOA_4c781b9c-3e54-4168-83c1-c7c640711317"
      unitRef="usd">10185000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0xLTEtMS0xMDkzMzk_4a84af21-7854-4bcf-ac26-f99b3f394e47"
      unitRef="usd">112000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0xLTEtMS05MjcxOA_7f8ef8a1-856e-427e-9f72-f8b4a72a7411"
      unitRef="usd">122000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNC0zLTEtMS05MjcxOA_9d2247fc-faad-46f6-9176-125979f231e1"
      unitRef="usd">91000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0xLTEtMS0xMDkzMzk_91cbc45a-2eeb-491e-b73c-07419ef4b598"
      unitRef="usd">5994000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0xLTEtMS05MjcxOA_cfa8cfec-d2d1-4942-8dd8-0cc59fd81920"
      unitRef="usd">2589000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfNy0zLTEtMS05MjcxOA_efb14a55-5e04-4804-a553-0582d265183f"
      unitRef="usd">20847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0xLTEtMS0xMDkzMzk_058d1afd-c354-4ef3-82e6-bb24d48b6d5e"
      unitRef="usd">715000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0xLTEtMS05MjcxOA_6c0f95e8-2bda-41b9-89cd-4b219f65f399"
      unitRef="usd">558000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmZmZDNhNTY0MTZkMTQ4NDJhYjI3YmNmNmEwMzEzNzc3L3RhYmxlcmFuZ2U6ZmZkM2E1NjQxNmQxNDg0MmFiMjdiY2Y2YTAzMTM3NzdfOC0zLTEtMS05MjcxOA_e21e4388-61a7-40a3-a18f-39109da68e03"
      unitRef="usd">3062000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfNTQ5NzU1ODE2ODc1_331598f0-e6a2-4c51-a0d2-80f8bf3542a4"
      unitRef="usd">55200000</icui:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed>
    <icui:SupplementalBalanceSheetInformationLeasesTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjY0NA_39a882f5-0e41-4ee9-90ad-721a39ee8b6b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,864&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,847&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,916&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,980&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</icui:SupplementalBalanceSheetInformationLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMy0xLTEtMS05MjcxOA_2f150bec-e81e-4ac3-b386-94d041e56d9d"
      unitRef="usd">74864000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMy0zLTEtMS05MjcxOA_dbbf404a-489b-4961-afc9-634fd6f618f9"
      unitRef="usd">39847000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNS0xLTEtMS05MjcxOA_0538bfa3-13ad-47ce-82f6-81b046e7ef5a"
      unitRef="usd">18169000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNS0zLTEtMS05MjcxOA_304b20be-14df-40f7-a583-5818ce0e9049"
      unitRef="usd">9009000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNi0xLTEtMS05MjcxOA_ba71e31c-2b37-4440-8337-1ea1bc09b955"
      unitRef="usd">60916000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNi0zLTEtMS05MjcxOA_f5d0b5b0-c3a6-42d9-873a-ba84c0a67a7e"
      unitRef="usd">33971000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNy0xLTEtMS05MjcxOA_4b1529b8-f7eb-479a-aca1-88765fee97bf"
      unitRef="usd">79085000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfNy0zLTEtMS05MjcxOA_b891ccd6-bf8c-478f-b874-4aceb414b8ec"
      unitRef="usd">42980000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTAtMS0xLTEtOTI3MTg_1ed0ddd2-3823-4653-97a4-41307c66c50a">P6Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTAtMy0xLTEtOTI3MTg_a619c96e-468a-40d5-bf55-c970ecc47b22">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTMtMS0xLTEtOTI3MTg_218f44c5-4122-4c34-80f1-245b917a744a"
      unitRef="number">0.0434</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjgwOTgyZTQxODRhMzQ1MzQ4NTgwNTNiZjdlOWMxMzJkL3RhYmxlcmFuZ2U6ODA5ODJlNDE4NGEzNDUzNDg1ODA1M2JmN2U5YzEzMmRfMTMtMy0xLTEtOTI3MTg_94226def-ee83-4e44-af1c-9e9b247f7bd5"
      unitRef="number">0.0498</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMy0xLTEtMS05MjcxOA_6ea3bff6-466f-4891-ba06-f1a13bb36cd4"
      unitRef="usd">2598000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMy0zLTEtMS05MjcxOA_0c8dc8d9-ea3e-4834-9da6-070050f83304"
      unitRef="usd">2673000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNS0xLTEtMS05MjcxOA_fa262d5e-44ec-4ce3-9372-109d906a0b8d"
      unitRef="usd">816000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNS0zLTEtMS05MjcxOA_28633736-1981-49ca-b716-3ebabcd5e7d4"
      unitRef="usd">643000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNi0xLTEtMS05MjcxOA_987955b2-3038-46a5-9108-5c7e70b72abd"
      unitRef="usd">1855000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNi0zLTEtMS05MjcxOA_9278883a-8f71-4f09-9756-78ae8368e5be"
      unitRef="usd">2067000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNy0xLTEtMS05MjcxOA_55bb08a8-b1b1-47da-8303-cff15442e970"
      unitRef="usd">2671000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfNy0zLTEtMS05MjcxOA_b21618e0-3f33-4987-8210-021c0307814b"
      unitRef="usd">2710000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTAtMS0xLTEtOTI3MTg_e5af185a-6dbf-4074-8b5e-62ff6938c8f1">P4Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTAtMy0xLTEtOTI3MTg_daa45bdf-2857-4891-940e-f862e70d5b9b">P5Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTMtMS0xLTEtOTI3MTg_81c08c14-517c-47ee-88a1-9690ed3ec4e7"
      unitRef="number">0.0423</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOjUxOTJmOWRlYjgyZjRjNWU5MDVmNDY2ODNkYzdlNGMyL3RhYmxlcmFuZ2U6NTE5MmY5ZGViODJmNGM1ZTkwNWY0NjY4M2RjN2U0YzJfMTMtMy0xLTEtOTI3MTg_4ed2602b-d5e4-467e-8868-0c4b2d943962"
      unitRef="number">0.0428</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RleHRyZWdpb246Zjc4OGI5Y2YzYzcwNDM4ZTgxMDEyMzBjYmQzYWQ5YzVfMjY0NQ_7180dc93-bc83-453f-8a1c-87969b215907">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0xLTEtMS05MjcxOA_9719b647-92a7-444a-9275-4142eb42122c"
      unitRef="usd">21800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0zLTEtMS05MjcxOA_27c871d3-3968-4bc0-aaa1-bc5f1ca8b617"
      unitRef="usd">914000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMS0zLTEtMS05MjcxOA_46b83491-5ea5-468d-acc9-43ed482c2324"
      unitRef="usd">914000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMi0xLTEtMS05MjcxOA_08120c82-d3ef-4395-8996-af90af962ed8"
      unitRef="usd">17786000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMi0zLTEtMS05MjcxOA_6d5990d3-e2e0-48b1-aa1f-dd19bc920874"
      unitRef="usd">657000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMy0xLTEtMS05MjcxOA_56d77ce5-39ae-42b4-b805-0d259f86df65"
      unitRef="usd">12699000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfMy0zLTEtMS05MjcxOA_d264202f-9bcb-42e1-b437-a0f4fbe8d278"
      unitRef="usd">442000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNC0xLTEtMS05MjcxOA_a3b231f9-a76d-4835-bb58-ec16884d0920"
      unitRef="usd">11297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNC0zLTEtMS05MjcxOA_9718475d-20c6-4df4-8fb3-d39add7e0955"
      unitRef="usd">322000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNS0xLTEtMS05MjcxOA_c1df0186-2f68-44c5-8fcb-16ac1a791139"
      unitRef="usd">7830000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNS0zLTEtMS05MjcxOA_2b05c6dd-83c0-46b6-83ec-a219a5d676bb"
      unitRef="usd">189000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNi0xLTEtMS05MjcxOA_286778df-5c1a-454f-9c58-818e80595377"
      unitRef="usd">17346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNi0zLTEtMS05MjcxOA_7cad6b35-512c-4b4f-8160-19d61e3773e6"
      unitRef="usd">426000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNy0xLTEtMS05MjcxOA_a6cbad2c-92cf-4cc8-8765-09577bc226f8"
      unitRef="usd">88758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfNy0zLTEtMS05MjcxOA_d7b5cd5a-95ff-4595-9908-9721aa569c49"
      unitRef="usd">2950000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOC0xLTEtMS05MjcxOA_877716fd-0c29-4273-bdab-7c951c4a4c12"
      unitRef="usd">9673000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOC0zLTEtMS05MjcxOA_bc3734e9-ad2e-4e30-af81-4b0dafabb537"
      unitRef="usd">279000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOS0xLTEtMS05MjcxOA_47c5702c-f120-46ef-a9c7-c943515aea5f"
      unitRef="usd">79085000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84Mi9mcmFnOmY3ODhiOWNmM2M3MDQzOGU4MTAxMjMwY2JkM2FkOWM1L3RhYmxlOmJhOGI3OGY3MDAzMzQ1MzQ5MjY3NGIzNzI5NDVkZDEwL3RhYmxlcmFuZ2U6YmE4Yjc4ZjcwMDMzNDUzNDkyNjc0YjM3Mjk0NWRkMTBfOS0zLTEtMS05MjcxOA_6bb177d5-1445-4089-8d25-980a49fa55e0"
      unitRef="usd">2671000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NjM_d718eacf-032d-4edc-8ced-38bf994f932c">SHARE-BASED AWARDS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a stock incentive plan for employees and directors and an employee stock purchase plan.&#160; Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur stock compensation expense for stock options, restricted stock units ("RSU"), performance restricted stock units ("PRSU") and in years prior to 2018 stock purchased under our employee stock purchase plan ("ESPP"), which was suspended in 2017. We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options and vesting of restricted stock units. We also have indirect tax benefits upon exercise of stock options and vesting of restricted stock units related to research and development tax credits which are recorded as a reduction of income tax expense.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes compensation costs and related tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indirect tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had $43.0 million of unamortized stock compensation cost which we will recognize as an expense over a weighted-average period of approximately 0.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 2011 Stock Incentive Plan ("2011 Plan") replaced our 2003 Stock Option Plan ("2003 Plan"). Our 2011 Plan initially had 650,000 shares available for issuance, plus the remaining available shares for grant from the 2003 Plan and any shares that were forfeited, terminated or expired that would have otherwise returned to the 2003 Plan. In 2012, 2014 and 2017, our stockholders approved amendments to the 2011 plan that increased the shares available for issuance by 3,275,000, bringing the initial shares available for issuance to 3,925,000, plus the remaining 248,700 shares that remained available for grant from the 2003 Plan. As of December&#160;31, 2022, the 2011 Plan has 4,188,300 shares of common stock reserved for issuance to employees, which includes 263,300 shares that transferred from the 2003 Plan.&#160;Shares issued as options or stock appreciation rights ("SARs") are charged against the 2011 Plan's share reserve as one share for one share issued.  Shares subject to awards other than options and SARs are charged against the 2011 Plan's share reserve as 2.09 shares for 1 share issued. Options may be granted with exercise prices at no less than fair market value at date of grant. Options granted under the 2011 Plan may be "non-statutory stock options" which expire no more than ten years from date of grant or "incentive stock options" as defined in Section&#160;422 of the Internal Revenue Code of 1986, as amended.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-based Stock Options&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, all options granted under 2011 Plan and 2003 Plan have been non-statutory stock options. The majority of the time-based outstanding employee option grants vested 25% after one year from the grant date and the balance vested ratably on a monthly basis over 36 months. The outstanding employee option grants are all fully vested. The majority of the outstanding options granted to non-employee directors vest one year from the grant date. The options generally expire 10 years from the grant date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of time-based option grants is calculated using the Black-Scholes option valuation model.&#160;The expected term for the option grants was based on historical experience and expected future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock, based on the average expected exercise term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The table below summarizes the total time-based stock options granted, total valuation and the weighted-average assumptions (dollars in thousands, except per option amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of time-based options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value of options granted (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions for stock option valuation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-price per option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity as of and for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic values for options exercisable, outstanding and vested or expected to vest at December&#160;31, 2022 are based on our closing stock price of $157.48 at December&#160;31, 2022 and are before applicable taxes.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information regarding stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock option exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we granted our annual PRSUs to our executive officers and certain other non-executive employees. These PRSUs will cliff-vest on March 7, 2024  subject to the achievement of net synergy savings targets related to the Smiths Medical acquisition achieved during the performance period commencing on January 1, 2022 and ending on December 31, 2023, which when reviewed against predetermined targets could result in 0% to 200% of the awarded units that could vest. We also granted certain other one-off PRSU awards to non-executive employees with various performance requirements, whereby the performance shares will be earned if the minimum requirements are met within a specified time period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we granted PRSUs to our executive officers. For the executive officers other than the Chief Executive Officer ("CEO"), Chief Operations Officer ("COO") and the Chief Financial Officer ("CFO"), the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2024 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, commencing on January 1, 2021 and ending on December 31, 2023, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we granted PRSUs to our executive officers. For the executive officers other than the CEO, COO and the CFO, the PRSUs will vest subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable years. For the CEO, COO and the CFO, the performance shares will cliff-vest ending on March 6, 2023 and further be subject to the achievement of minimum three-year cumulative revenue and EPS targets, which when reviewed against a predetermined vesting matrix could result in 0% to 250% of the awarded units that could vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO, COO and CFO met their individual performance goals for 2021, therefore one-third of their 2020 PRSU shares awarded vested during 2021. Additionally, during February 2021, the Compensation Committee, modified the potential vesting percentages related to the 2020 PRSU awards for the CEO, COO and CFO, as the original potential percentages were established immediately before the onset of the COVID-19 pandemic. The Compensation Committee determined to adjust the CEO, COO and CFO's potential to earn from between 0% and 250% of the award granted, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to an increased potential to earn between 50% and 300% of the award granted, subject to the same minimum threshold revenue and EPS targets to be achieved by the Company. The additional compensation expense as a result of modifying the 2020 PRSUs granted to our CEO, COO and CFO totaled $2.1&#160;million recognized over the remaining amortization period from the date of modification. In February 2023, the Compensation Committee made the determination that the executive officers other than the CEO, CFO and COO met their individual performance goals for 2022, therefore a third of their 2020 PRSU shares awarded vested during 2023. The performance period related to the 2020 CEO and COO PRSUs ended on December 31, 2022 and is subject to the Compensation Committee review and determination of shares earned based on the Cumulative revenue and EPS results achieved during the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers had met their individual performance goals for the applicable years.  For the CEO and the COO, the performance shares were to cliff-vest on March 6, 2022, subject to the achievement of a minimum Cumulative Adjusted EBITDA and continuous service through that date. If for the three year period ending on December 31, 2021 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would have vested. If on the vesting date the Cumulative Adjusted EBITDA has a growth of over 10%, 200% of the awarded units would have vested. In 2019, we also granted PRSUs to one of our non-executive employees. These PRSUs vested at the end of a three-year period ending on March 31, 2022, based on meeting certain minimum performance goals. In February 2022, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2022, therefore, the final third of their 2019 PRSU shares awarded vested during 2022. The performance period related to the 2019 CEO and COO PRSUs ended on December 31, 2021 and in February 2022 the Compensation Committee determined that zero PRSUs were earned based on the actual Cumulative Adjusted EBITDA achieved during the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, we granted PRSUs to our executive officers. For the executive officers other than the CEO and the COO, the PRSUs were vested subject to a three-year time vesting and further subject to a determination by the Compensation Committee that the officers have met their individual performance goals for the applicable year. For the CEO and the COO, the performance shares were to cliff-vest ending on February 15, 2021 subject to the achievement of a minimum Cumulative Adjusted EBITDA.  If for the three year period ending on December 31, 2020 the Cumulative Adjusted EBITDA had a growth of at least 6% to 8%, 50% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of between 8% to 10%, 100% of the awarded units would vest. If on the vesting date the Cumulative Adjusted EBITDA had a growth of over 10%, 200% of the awarded units would vest. On February 15, 2021, the Compensation Committee made the determination that the executive officers other than the CEO and COO met their individual performance goals for 2021, therefore, one-third of their 2018 PRSU shares awarded vested during 2021. Also on February 15, 2021, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period the CEO and COO's 2018 PRSUs were earned at 100% of the awards granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we granted PRSUs to our executive officers. The PRSUs were scheduled to vest, if at all, upon the achievement of a minimum Cumulative Adjusted EBITDA, subject to a three-year cliff vesting ending on December 31, 2019.  If at that date, our Cumulative Adjusted EBITDA was at least $600 million but less than $650 million, 100% of the awarded units would vest.  If our Cumulative Adjusted EBITDA was at least $650 million but less than $700 million, 200% of the awarded units would vest. If our Cumulative Adjusted EBITDA is at least $700 million, 300% of the awarded units would vest. On January 17, 2020, the Compensation Committee determined that based on the actual Cumulative Adjusted EBITDA achieved during the performance period that the 2017 PRSU shares were earned by our executive officers at the 300% achievement level.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units are granted annually to our non-employee directors and vest on the first anniversary of the grant date, or the date of our annual meeting, whichever occurs first. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, we granted RSUs to certain employees that vest ratably on the anniversary of the grant over three years. We recognize forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair market value of our PRSUs and RSUs is determined by our stock price on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes our restricted stock award activity (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares earned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PRSU shares earned in 2020 were related to performance awards granted to executives in 2017, 2018 and 2019. PRSU shares earned in 2021 were related to performance awards granted to executives in 2018, 2019 and 2020. PRSU shares earned in 2022 were related to performance awards granted to executives in 2019, 2020 and 2021 and performance awards granted to a non-executive employee in 2019, 2020 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of our PRSU and RSU activity as of and for the year ended December&#160;31, 2022: &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant-Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in units due to performance expectations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested and expected to vest at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Relates to net adjustments to 2019, 2020, 2021 and 2022 PRSUs granted to executives and certain non-executive employees. PRSUs granted assumes attainment of an increased payout rate based on performance expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an ESPP under which U.S. employees may purchase up to $25,000 annually of common stock at 85% of its fair market value at the beginning or the end of a six-month offering period, whichever is lower. There are 750,000 shares of common stock reserved for issuance under the ESPP, which is subject to an annual increase of the least of 300,000 shares, two percent of the shares outstanding or such a number as determined by the Board.&#160;To date, there have been no increases.&#160;As of December&#160;31, 2022, there were no shares available for future issuance, all shares unissued under the plan expired during 2022. The ESPP is intended to constitute an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section&#160;423 of the Internal Revenue Code.  We suspended our ESPP in 2017.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <icui:ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzY_85e41ca4-58ff-4e13-8b9f-029b59019b3e">The table below summarizes compensation costs and related tax benefits (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indirect tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</icui:ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi0yLTEtMS05MjcxOA_8275a05c-708b-4d12-b019-7a2ab894687c"
      unitRef="usd">36025000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi00LTEtMS05MjcxOA_7be36594-267a-40c7-bac1-7367087e2759"
      unitRef="usd">27341000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMi02LTEtMS05MjcxOA_9a9647ea-dd81-4166-804b-656bee8ed15e"
      unitRef="usd">23954000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy0yLTEtMS05MjcxOA_c993a5ba-b369-477e-b8a8-a70a4781c6eb"
      unitRef="usd">4636000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy00LTEtMS05MjcxOA_78be0981-6fbe-42d3-9208-b385cac62419"
      unitRef="usd">6391000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfMy02LTEtMS05MjcxOA_4077c261-7351-4f20-bc57-b17b0f169344"
      unitRef="usd">5564000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <icui:IndirectTaxBenefitFromStockOptions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC0yLTEtMS05MjcxOA_aa179d44-de9c-461a-a3dc-82ce8059dffc"
      unitRef="usd">749000</icui:IndirectTaxBenefitFromStockOptions>
    <icui:IndirectTaxBenefitFromStockOptions
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC00LTEtMS05MjcxOA_ad5137ea-bee7-4815-83c9-c92a79ac747a"
      unitRef="usd">285000</icui:IndirectTaxBenefitFromStockOptions>
    <icui:IndirectTaxBenefitFromStockOptions
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmM2ZWEyYWI0ZTU2YTRmMzBhMDA4YzAzZjg5ZmJmZWJlL3RhYmxlcmFuZ2U6YzZlYTJhYjRlNTZhNGYzMGEwMDhjMDNmODlmYmZlYmVfNC02LTEtMS05MjcxOA_04c8ce4d-583a-4cc8-8a19-16195253007f"
      unitRef="usd">1203000</icui:IndirectTaxBenefitFromStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfOTc3_e8d2902b-952f-461d-8b70-5ce4911f1404"
      unitRef="usd">43000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTEwNQ_3d7a75c4-eb90-44b0-9872-1f01c6ace238">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="icfc6130bace04212a70134842313f556_I20111231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI2MQ_a84197ee-45d3-4fea-b4c2-c97148ff39d4"
      unitRef="shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if6c41509b0124224b8916fec64855b95_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTYwMQ_29e2b139-a523-4089-af70-38872d1a2ffc"
      unitRef="shares">3275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTY1OQ_e4f4844e-6f28-4987-9160-59ecaef56a91"
      unitRef="shares">3925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if7f3edab321b4f47b9ab4112053d6a1d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTY4Mg_b4fe7645-5c56-4630-80d4-e77fbaf8412b"
      unitRef="shares">248700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTc3NA_46fa20f8-916f-4fc2-a832-3f847073e7cb"
      unitRef="shares">4188300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <icui:Sharestransferredfromsupersededplan
      contextRef="i6e1f7b608a83444d93727a50a57cc19c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTg1MQ_4c9d67df-cf28-4186-9d70-dd08d63462dd"
      unitRef="shares">263300</icui:Sharestransferredfromsupersededplan>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0OTc_2e9752df-a544-4bb9-81d0-1c32bd8e4654">The table below summarizes the total time-based stock options granted, total valuation and the weighted-average assumptions (dollars in thousands, except per option amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of time-based options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value of options granted (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions for stock option valuation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-price per option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value per option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi0yLTEtMS05MjcxOA_9a8297bd-f8b9-42df-b527-943e8d448063"
      unitRef="shares">7620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi00LTEtMS05MjcxOA_a221cd3c-6fac-4ab8-b3ca-f88c7bd11fcd"
      unitRef="shares">7910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMi02LTEtMS05MjcxOA_1c5aef85-570a-4a8c-8936-37402772d077"
      unitRef="shares">7190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <icui:Timebasedoptionsgrantdatefairvalue
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy0yLTEtMS05MjcxOA_0a998ae1-1dac-4122-8df8-d6307e983234"
      unitRef="usd">540000</icui:Timebasedoptionsgrantdatefairvalue>
    <icui:Timebasedoptionsgrantdatefairvalue
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy00LTEtMS05MjcxOA_eab1f8fd-21b1-4ae3-923b-9b0205dc693d"
      unitRef="usd">528000</icui:Timebasedoptionsgrantdatefairvalue>
    <icui:Timebasedoptionsgrantdatefairvalue
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMy02LTEtMS05MjcxOA_7d0046fd-6a57-445e-9cf2-0fc066709027"
      unitRef="usd">425000</icui:Timebasedoptionsgrantdatefairvalue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS0yLTEtMS05MjcxOA_a62f7442-4767-47f7-932c-5044e831c52a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS00LTEtMS05MjcxOA_9aed5358-d2b6-49a4-9e63-5fd757abe6b8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNS02LTEtMS05MjcxOA_dd085366-2d6f-4786-8783-b1ac24344506">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi0yLTEtMS05MjcxOA_19e53b48-c534-48e6-809e-d0c2ee2b884b"
      unitRef="number">0.360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi00LTEtMS05MjcxOA_ad1e321a-6ccd-4e8c-ab3e-345ab728a8d4"
      unitRef="number">0.350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNi02LTEtMS05MjcxOA_1dcb34ad-978c-4160-b124-300b33cf7187"
      unitRef="number">0.350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy0yLTEtMS05MjcxOA_057dbdb9-f56b-4309-aad7-5c896dba81d5"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy00LTEtMS05MjcxOA_29e55b44-8727-49b8-afe1-b8c4d28f8cc3"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfNy02LTEtMS05MjcxOA_d9e1c36f-3e1e-4545-8f1c-197c3059be44"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC0yLTEtMS05MjcxOA_14e0f8d8-a1ec-4c69-b268-f506fed37c35"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC00LTEtMS05MjcxOA_0ef9138d-2388-45cf-875e-922500660462"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOC02LTEtMS05MjcxOA_9a16dac5-1e64-494b-a11b-64f4075c1dab"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS0yLTEtMS05MjcxOA_566df40f-cb77-4135-8f07-d7a0894098fa"
      unitRef="usdPerShare">185.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS00LTEtMS05MjcxOA_961f97ba-c812-4ef3-b84d-6a65412f36a0"
      unitRef="usdPerShare">200.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfOS02LTEtMS05MjcxOA_0b339d80-0349-4aa9-8ecc-f29124ae4ef2"
      unitRef="usdPerShare">181.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtMi0xLTEtOTI3MTg_a25c1e92-fe7e-4113-abab-b26402d24b65"
      unitRef="usdPerShare">70.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibb50e087f18d440eb1046e74f3bfbf25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtNC0xLTEtOTI3MTg_7c9d421d-0303-4939-9845-43327ba7c076"
      unitRef="usdPerShare">66.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9f933b32da444865b80e747cabb2916d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjYwMmYzZGMxZDA5ODRkYTU5NTNiNDcxZWNjOGM0ZWZmL3RhYmxlcmFuZ2U6NjAyZjNkYzFkMDk4NGRhNTk1M2I0NzFlY2M4YzRlZmZfMTAtNi0xLTEtOTI3MTg_06ff2f76-cd24-420c-b508-ea943d39117e"
      unitRef="usdPerShare">59.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0ODA_e5056d6f-6e26-42f0-b10f-97ff1abbad52">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity as of and for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0ced0ef8f682482e991d67cc95e1bae8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMS0yLTEtMS05MjcxOA_4cc7bcb0-63e0-4585-aa92-2a6390afc318"
      unitRef="shares">663098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0ced0ef8f682482e991d67cc95e1bae8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMS00LTEtMS05MjcxOA_62ac98cc-4921-473d-9018-ed9d517eff81"
      unitRef="usdPerShare">74.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMi0yLTEtMS05MjcxOA_23cf2c56-23f5-4cad-8999-607c5eae33af"
      unitRef="shares">7620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMi00LTEtMS05MjcxOA_fd57b222-42d1-4751-8fd6-0f84ff124df2"
      unitRef="usdPerShare">185.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMy0yLTEtMS05MjcxOA_17575285-cade-4abb-84b9-cacf6838d3f3"
      unitRef="shares">142772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfMy00LTEtMS05MjcxOA_b8505a02-6592-44f1-a323-09e1aff16586"
      unitRef="usdPerShare">61.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNC0yLTEtMS05MjcxOA_4fc9c73c-b1fe-4d97-8118-8a7636b6455c"
      unitRef="shares">485</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNC00LTEtMS05MjcxOA_f64b0ec4-c217-416d-bb97-3a2704027c41"
      unitRef="usdPerShare">60.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS0yLTEtMS05MjcxOA_4b2ced41-cf90-4bba-a8b6-c60a9839c328"
      unitRef="shares">527461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS00LTEtMS05MjcxOA_452b24f5-8e7f-4019-b723-bb9d55ae2c18"
      unitRef="usdPerShare">79.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS02LTEtMS05MjcxOA_4a52621a-79bd-4860-b839-203986a319fb">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNS04LTEtMS05MjcxOA_690cdd0c-5864-4ebb-846d-9ad8619b5ccd"
      unitRef="usd">42708000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi0yLTEtMS05MjcxOA_091c8198-cb93-4221-83c5-43a966e7652e"
      unitRef="shares">519841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi00LTEtMS05MjcxOA_52647336-47a4-4306-b85a-44618b91a5c0"
      unitRef="usdPerShare">78.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi02LTEtMS05MjcxOA_09bd0279-2d29-42a8-829f-35efb20e5293">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNi04LTEtMS05MjcxOA_8ca29589-0d63-4c2b-8b5c-fab867a7adaf"
      unitRef="usd">42708000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy0yLTEtMS05MjcxOA_7dc09e0d-7465-4ebb-b809-c468409d8ac9"
      unitRef="shares">527461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy00LTEtMS05MjcxOA_c3884b0a-7758-4893-af4f-4972b3486381"
      unitRef="usdPerShare">79.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9593d4bd28f04254898f8a3fee874130_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy02LTEtMS05MjcxOA_a2b4728f-be96-4892-a5e4-89063c552cb2">P1Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="icd58a5889bd341b6a832c886185b7b3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmMyNWIzMTE3NjJjYjQwMWM5ZmNmNDI3ZGExY2EzODU3L3RhYmxlcmFuZ2U6YzI1YjMxMTc2MmNiNDAxYzlmY2Y0MjdkYTFjYTM4NTdfNy04LTEtMS05MjcxOA_4520d808-f5fc-43f9-b32e-0976625f0b36"
      unitRef="usd">42708000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMzg0Ng_a6a4ec00-01cd-4d37-aa1b-757f66837348"
      unitRef="usdPerShare">157.48</us-gaap:SharePrice>
    <icui:ExercisedOptionsDataTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzI_92a2d5b6-e635-407c-97f6-e06e8b759752">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information regarding stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock option exercises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</icui:ExercisedOptionsDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi0yLTEtMS05MjcxOA_427709cf-366a-472c-bfcc-57c3a1867c38"
      unitRef="usd">17340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi00LTEtMS05MjcxOA_192c637e-7a8d-4640-b8e4-0c2347089e2e"
      unitRef="usd">27534000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMi02LTEtMS05MjcxOA_2767ce1f-242a-4cc4-a93e-c22b78d89b1c"
      unitRef="usd">32915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy0yLTEtMS05MjcxOA_4dcfcbb6-505c-492a-a8e9-edc172c8c60b"
      unitRef="usd">8785000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy00LTEtMS05MjcxOA_6de09945-2fad-466f-aa51-ab9c9bf83f4e"
      unitRef="usd">9372000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfMy02LTEtMS05MjcxOA_1275eb66-d8c5-41f1-89a3-f6fd308e65bc"
      unitRef="usd">13193000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC0yLTEtMS05MjcxOA_cff2d5bd-305c-463f-b88e-cfdef9f3cb22"
      unitRef="usd">3637000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC00LTEtMS05MjcxOA_ce825f82-1c5a-450b-9ca6-62d5c8eda05b"
      unitRef="usd">5092000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjE0ZmYzODRkOTZiZDRkNWViYWEwMjkxYjAzNDJlMjYzL3RhYmxlcmFuZ2U6MTRmZjM4NGQ5NmJkNGQ1ZWJhYTAyOTFiMDM0MmUyNjNfNC02LTEtMS05MjcxOA_3161a572-6fc9-4895-9e41-2804bbf62120"
      unitRef="usd">5179000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <icui:ModifiedPRSUIncrementalExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfNjM3OQ_e5f48021-8761-412d-8ac4-c460195dd3cd"
      unitRef="usd">2100000</icui:ModifiedPRSUIncrementalExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0NzM_05451dbd-f325-4f5e-95b6-bf4a6f987906">The table below summarizes our restricted stock award activity (dollars in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year&#160;ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares earned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant-date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrinsic value vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy0yLTEtMS05MjcxOA_8f6cbfa3-0585-4232-9be5-e577fb27f235"
      unitRef="shares">60383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy00LTEtMS05MjcxOA_a922bd71-990e-4991-b1df-5a0f87c97446"
      unitRef="shares">53246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMy02LTEtMS05MjcxOA_9a49881d-17b8-4163-9791-c50255cfa9b9"
      unitRef="shares">38633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <icui:PerformanceSharesEarned
      contextRef="i7c67054a7a594d6983252a6891238d26_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC0yLTEtMS05MjcxOA_5ad1ed06-af34-4888-845b-d390479814a0"
      unitRef="shares">46317</icui:PerformanceSharesEarned>
    <icui:PerformanceSharesEarned
      contextRef="i9241e754a3e241929d3a847fe66556ed_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC00LTEtMS05MjcxOA_0849ac5e-029c-434f-a2c4-77ae7d6e8a49"
      unitRef="shares">32013</icui:PerformanceSharesEarned>
    <icui:PerformanceSharesEarned
      contextRef="i41a074cf04634fb682ff822fe3155504_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNC02LTEtMS05MjcxOA_16c81588-c8c7-4434-bf56-861bd0d02c1f"
      unitRef="shares">80654</icui:PerformanceSharesEarned>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS0yLTEtMS05MjcxOA_65e8823b-252a-4f2e-a3ea-5799de5a0f29"
      unitRef="usdPerShare">230.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS00LTEtMS05MjcxOA_11c99689-76bb-4dd6-8a9b-148472267eed"
      unitRef="usdPerShare">198.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNS02LTEtMS05MjcxOA_2895de8c-9e7e-47f1-bb79-660afcdbd764"
      unitRef="usdPerShare">188.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <icui:Grantdatefairvalueperformancerestrictedstockunits
      contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi0yLTEtMS05MjcxOA_0d20ff94-792e-449e-95d5-12d6caf4e99b"
      unitRef="usd">13907000</icui:Grantdatefairvalueperformancerestrictedstockunits>
    <icui:Grantdatefairvalueperformancerestrictedstockunits
      contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi00LTEtMS05MjcxOA_ccd99f12-f896-4886-9a06-61e90fb775fa"
      unitRef="usd">10551000</icui:Grantdatefairvalueperformancerestrictedstockunits>
    <icui:Grantdatefairvalueperformancerestrictedstockunits
      contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNi02LTEtMS05MjcxOA_0979e875-30ee-4dbd-a44b-2a0cbce95b9f"
      unitRef="usd">7276000</icui:Grantdatefairvalueperformancerestrictedstockunits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i67131fef567f44b0b36141e22863e1c5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy0yLTEtMS05MjcxOA_60a727de-e77e-4004-81d9-21ee22776400"
      unitRef="usd">10487000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ie316e81c77e74d1fa14203e730d7e81a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy00LTEtMS05MjcxOA_a2935681-4fed-4d3f-9244-3a8019f3b25f"
      unitRef="usd">6777000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i00f1a91e4a754dae918e36a90fd8e2e7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfNy02LTEtMS05MjcxOA_6c62dcd9-00fc-470b-bcf1-5dc54e72fa98"
      unitRef="usd">15627000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtMi0xLTEtOTI3MTg_8b7de27f-d2db-4e0e-b13c-826bf14207c7"
      unitRef="shares">116870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtNC0xLTEtOTI3MTg_7749f649-2d9d-4107-8947-ce554fe7aed9"
      unitRef="shares">84388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTAtNi0xLTEtOTI3MTg_57b86b06-888f-4042-ba9e-321d2b843bf5"
      unitRef="shares">87830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtMi0xLTEtOTI3MTg_34b9e97e-b77e-484e-8479-8d350b58e0ef"
      unitRef="usdPerShare">221.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtNC0xLTEtOTI3MTg_16f5d29a-3f7f-460c-b798-cf4392bcfd1d"
      unitRef="usdPerShare">199.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTEtNi0xLTEtOTI3MTg_70975bae-1b83-44de-8650-dc27cc379de1"
      unitRef="usdPerShare">188.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <icui:Grantdatefairvalueofrestrictedstockunitsgranted
      contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItMi0xLTEtOTI3MTg_975f77ae-583a-4c3c-8939-7590d4b59f66"
      unitRef="usd">25905000</icui:Grantdatefairvalueofrestrictedstockunitsgranted>
    <icui:Grantdatefairvalueofrestrictedstockunitsgranted
      contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItNC0xLTEtOTI3MTg_0cb6bdcd-bd8b-4248-9c64-8c7ed1322e20"
      unitRef="usd">16804000</icui:Grantdatefairvalueofrestrictedstockunitsgranted>
    <icui:Grantdatefairvalueofrestrictedstockunitsgranted
      contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTItNi0xLTEtOTI3MTg_b993fc20-a1a2-4e8f-a979-e9bd7775d140"
      unitRef="usd">16523000</icui:Grantdatefairvalueofrestrictedstockunitsgranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i140ad218154a454bbe4931f4c16ccc67_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtMi0xLTEtOTI3MTg_ce49502e-5f3c-471d-aa16-c13ba2c4590a"
      unitRef="usd">16438000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i1bb35936c33a4f73b3783b0791da29ec_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtNC0xLTEtOTI3MTg_a51a21b3-d3b1-4fce-8fa6-324dd2c72084"
      unitRef="usd">13681000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ic934681ed3ff43a798a31a8212d1bc77_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOmJiYWEyNTc4NTNhMzRkMTk5MWEyM2E2ZGVkNDBjNjdlL3RhYmxlcmFuZ2U6YmJhYTI1Nzg1M2EzNGQxOTkxYTIzYTZkZWQ0MGM2N2VfMTMtNi0xLTEtOTI3MTg_e75be9d1-0240-421c-a4b2-fb8b0df6ead1"
      unitRef="usd">12314000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTI0OTk_ea779bf3-a890-40f3-a4d2-cd2be8c593f4">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of our PRSU and RSU activity as of and for the year ended December&#160;31, 2022: &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant-Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in units due to performance expectations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested and expected to vest at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7744c2c44b6e49a192f49a29131c1146_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMS0yLTEtMS05MjcxOA_6af3e141-1885-48ac-9a58-48893abddd44"
      unitRef="shares">275761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7744c2c44b6e49a192f49a29131c1146_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMS00LTEtMS05MjcxOA_454e7618-fba5-46bb-9962-73c7e29c8757"
      unitRef="usdPerShare">201.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <icui:Changeinunitsduetoperformanceexpectations
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMi0yLTEtMS05MjcxOA_f4a63842-b366-478b-a5b7-d198a6779e22"
      unitRef="shares">32346</icui:Changeinunitsduetoperformanceexpectations>
    <icui:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMi00LTEtMS05MjcxOA_a05ed3b0-e9ee-4b02-99b3-c58a15ec5f95"
      unitRef="usdPerShare">239.63</icui:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMy0yLTEtMS05MjcxOA_7d7bc56b-21ea-4e21-b35d-014f982d4c1a"
      unitRef="shares">177253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfMy00LTEtMS05MjcxOA_d4849dfd-b32f-40d8-b48d-a0aa4e65fca7"
      unitRef="usdPerShare">224.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNC0yLTEtMS05MjcxOA_1db88b3f-170e-4df8-9af4-1fc794d59d19"
      unitRef="shares">118321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNC00LTEtMS05MjcxOA_3797cf01-3863-4b91-b1b2-1b65f22f26d2"
      unitRef="usdPerShare">206.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNS0yLTEtMS05MjcxOA_28229b63-43ae-444b-94a7-6173e88ee655"
      unitRef="shares">13035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNS00LTEtMS05MjcxOA_1d3b932a-364d-4312-8718-e329dbf240fa"
      unitRef="usdPerShare">218.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi0yLTEtMS05MjcxOA_7abd227f-e1ee-449a-b2ea-86a12272046d"
      unitRef="shares">354004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi00LTEtMS05MjcxOA_524825b0-5965-4a0a-914c-b56b1631bf98"
      unitRef="usdPerShare">213.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i728c3f51e9834edda1eb1f92b1b1bfd4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi02LTEtMS05MjcxOA_7c09624a-8c69-4570-b14f-7ce7928e5169">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i754c391455cd4db0bb5e009228c4ed88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RhYmxlOjhiNjMwZjI5MjVkZTQwMDA5ZDZiNWI0NzJkYzAzNGE0L3RhYmxlcmFuZ2U6OGI2MzBmMjkyNWRlNDAwMDlkNmI1YjQ3MmRjMDM0YTRfNi04LTEtMS05MjcxOA_27dc3f0e-9221-4cad-a95a-bc205bf39d16"
      unitRef="usd">55749000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <icui:ESPPOriginalIssuance
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTE5Nzg_f0106b07-22d0-40b5-9f30-5731e85dd12b"
      unitRef="shares">750000</icui:ESPPOriginalIssuance>
    <icui:ESPPAnnualIssuanceIncreaseLimit
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF84OC9mcmFnOjhhNjkxY2MzYTYzYzQ3MjJiZDM0ZTFmM2E5NGE2MGU5L3RleHRyZWdpb246OGE2OTFjYzNhNjNjNDcyMmJkMzRlMWYzYTk0YTYwZTlfMTIwOTc_e17dc49a-872f-46b2-b6ed-36b9ba4df4c4"
      unitRef="shares">300000</icui:ESPPAnnualIssuanceIncreaseLimit>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwMQ_ba074e59-72c2-4c8b-b559-d477e617611b">DERIVATIVES AND HEDGING ACTIVITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hedge Accounting and Hedging Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purposes of our cash flow hedging programs are to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit, and to manage floating interest rate &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;risk associated with future interest payments on variable-rate term loans issued in January 2022. We do not issue derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract and forward-starting interest rate swaps are designated and qualify as cash flow hedges. Our derivative instruments are recorded at fair value on the consolidated balance sheets and are classified based on the instrument's maturity date. We record changes in the fair value of the effective portion of the gain or loss on the derivative instrument as a component of other comprehensive (loss) income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Exchange Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward Exchange Forward Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses to minimize the effect of foreign exchange rate movements on the related cash flows. These contracts are agreements to buy or sell a quantity of a currency at a predetermined future date and at a predetermined exchange rate. Our foreign exchange forward contracts hedge exposures principally denominated in Mexican Pesos ("MXN"), Euros, Czech Koruna ("CZK"), Japanese Yen ("JPY"), U.S. Dollar ("USD"), Chinese Renminbi ("CNH"), Canadian Dollar ("CAD") and Australian Dollar ("AUD") and have varying maturities with an average term of approximately twelve months. The total notional amount of these outstanding derivative contracts as of December 31, 2022 was $206.0&#160;million, which included the notional equivalent of $61.3&#160;million in MXN, $31.7&#160;million in Euros, $13.9&#160;million in CZK, $15.3&#160;million in JPY, $11.5&#160;million in CNH, $43.2&#160;million in USD, $11.6&#160;million in CAD, $11.9&#160;million in AUD and $5.6&#160;million in other foreign currencies, with terms currently through February 2024. Certain contracts were acquired as part of the Smiths Medical acquisition. We did not have such derivative contracts as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cross-currency Par Forward Contracts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into cross-currency par forward contracts to hedge a portion of our Mexico forecasted expenses denominated in MXN. These contracts are agreements to exchange cash flows from one currency to another at specified intervals over the contract term with all exchanges occurring at the same predetermined rate. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we hedged a portion of our Mexico forecasted expenses denominated in Pesos ("MXN") by entering into a one-year cross-currency par forward contract. The term of the one-year hedge was November 1, 2019 to November 3, 2020. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 22.11 MXN/USD.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2020 was approximately 436.8 million MXN. The term of this one-year contract was November 3, 2020 to December 1, 2021. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 24.26 MXN/USD.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, we entered into a one-year cross-currency par forward contract. The total notional amount of this outstanding derivative as of December 31, 2021 was approximately 413.1 million MXN. The term of this one-year contract is December 1, 2021 to December 1, 2022. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 21.60 MXN/USD.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Floating Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, in anticipation of entering into the new senior secured credit facilities in January 2022, which included a variable-rate term loan A and a variable-rate term loan B (see Note 11: Long-term Debt), we entered into two forward-starting interest rate swaps. In February 2022, certain terms under the agreements were amended to reflect the transition from LIBOR to the Secured Overnight Financing Rate ("SOFR"), an alternative reference rate. Under the interest rate swap agreements we exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. The term loan A swap, as amended, has an initial notional amount of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$300.0&#160;million, reducing to $150.0&#160;million evenly on a quarterly basis through its final maturity on March 30, 2027. We will pay a fixed rate of 1.32% and will receive the greater of 3-month USD SOFR or (0.15)%. The term loan B swap, as amended, has an initial notional amount of $750.0&#160;million, reducing to $46.9&#160;million evenly on a quarterly basis excluding its final maturity on March 30, 2026. We will pay a fixed rate of 1.17% and will receive the greater of 3-month USD SOFR or 0.35%. These forward-starting swaps will effectively convert the relevant portion of the floating-rate term loans to fixed rates.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivative instruments included within the consolidated balance sheets (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward-Starting Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents the effects of our derivative instruments designated as cash flow hedges on the Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain Reclassified From Accumulated Other Comprehensive (Loss) Income into Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as cash flow hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Represents location of gain reclassified from accumulated other comprehensive (loss) income to net (loss) income as a result of a forecasted transaction being no longer probable of occurring.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on our derivative instruments designated as cash flow hedges in other comprehensive (loss) income before reclassifications to net (loss) income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as cash flow hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we expect an estimated $3.0 million in deferred gains on the outstanding foreign exchange forward contract and an estimated $29.3&#160;million in deferred gains on the forward-starting interest rate swaps will be reclassified from accumulated other comprehensive loss to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjQy_d47fae1d-5be0-4392-b243-1b039864a024"
      unitRef="usd">206000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie512243dc7bc4d1a8e0708ea1460f39e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NTk3_27809657-b17f-440a-9404-7e804abf50f1"
      unitRef="usd">61300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1c33090ddb2c4c7eb6ff7538c7bb476b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjEy_26700807-d58d-42c8-9ce7-6b1e3378ec0f"
      unitRef="usd">31700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie6789c74e7e04a6795307d8a02ddf4b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjI3_138fd31b-ae93-448f-aa76-648d41967f83"
      unitRef="usd">13900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0541d3f55fc040d3ac00d6c25ff32778_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NjU4_da8bf70d-9b83-458c-8cda-34d07ffe7a1d"
      unitRef="usd">15300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia728542369a84272b8c445494962161e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3Njcz_37a272d0-ae3b-443f-85c4-d881877c52a8"
      unitRef="usd">11500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if3b3f4f1317a42f2be3e756d642c8e7d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3Njg4_220e2539-8714-42c2-9516-e19e20add33a"
      unitRef="usd">43200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i99be33b784264317acca70b9f25f1a88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzAz_a881ac6f-cdc6-4782-8dff-abeee6f4bca7"
      unitRef="usd">11600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i184372b7fd1647f08adb94357659448d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzE4_65aa7c09-15c8-4e42-ba37-235ca34923ce"
      unitRef="usd">11900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idf68976ce40345619a3f5648dcaacb18_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNTQ5NzU1ODI3NzMz_e3161b19-9397-40de-97b0-4f4fff2900a8"
      unitRef="usd">5600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="ifbb5e6d91a92409d9ef474923b762b07_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjI2NQ_9f28fb56-ed33-4359-a9db-40e8463e352e"
      unitRef="number">22.11</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjQ1Ng_32b29bfe-1edc-42de-94c4-ba4e38abc093"
      unitRef="usd">436800000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="i2aa87b214b1e4cb2a71ad5e0ab03704f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjYyNw_6137235f-e9d7-4df2-ba72-3db4a6b121cb"
      unitRef="number">24.26</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia79af1c5b1914270838bef1b8ec536a1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjgyMQ_6501b6c5-2744-4f57-a7ba-247f6fed7c82"
      unitRef="usd">413100000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="ia79af1c5b1914270838bef1b8ec536a1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMjk5MQ_0f082552-9adb-4c19-b1ff-e3ca2e766798"
      unitRef="number">21.60</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i394377fd918340248b6debe2d54beff5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzU4Mg_f65b0ac5-eafd-471c-aa75-09b5a0fd7405"
      unitRef="usd">300000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i8d3e73355e5a46779e8b500f773bcabb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzU5OA_d014cef2-9623-4b83-ba88-a472078f04b8"
      unitRef="usd">150000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzY5OQ_8bb5ab91-4630-4a38-92ab-748e0b5752f4"
      unitRef="number">0.0132</us-gaap:DerivativeFixedInterestRate>
    <icui:DerivativeInterestRateFloor
      contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzc1NQ_7937093e-ccbd-4470-b759-dfd3b1e5e6ac"
      unitRef="number">-0.0015</icui:DerivativeInterestRateFloor>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i099ba0834fb64e019127f5cf439531b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzgxNA_ae9286e1-d4b0-4aa6-8b4f-cd173395ecc1"
      unitRef="usd">750000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i7b1f546a435746b6a9e083834063101e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzgzMA_b4f72474-eeb5-420c-a1d2-0addae0cefdf"
      unitRef="usd">46900000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ia825f2d41f694d229f7aba34643141dc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfMzkzMQ_d607f592-5f49-4d97-ad67-991bf1d885d0"
      unitRef="number">0.0117</us-gaap:DerivativeFixedInterestRate>
    <icui:DerivativeInterestRateFloor
      contextRef="ia825f2d41f694d229f7aba34643141dc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDg5Ng_097b6500-7cd1-4eac-9e46-9fb2ff422a75"
      unitRef="number">0.0035</icui:DerivativeInterestRateFloor>
    <us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwNw_cce08752-7b9f-4700-9f8c-68b457e8d594">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivative instruments included within the consolidated balance sheets (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Cash Flow Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Forward Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forward-Starting Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table presents the effects of our derivative instruments designated as cash flow hedges on the Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain Reclassified From Accumulated Other Comprehensive (Loss) Income into Net (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as cash flow hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i68398fc85c9b4c69a9d24ac18c9275b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS0yLTEtMS05MjcxOA_c9c21636-a821-48f0-aa82-36f67b392f1d"
      unitRef="usd">4860000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i181b26114ca442d3aaba5f83684bef22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS00LTEtMS05MjcxOA_506d8b6a-42be-43ba-a8ad-305144c09753"
      unitRef="usd">28431000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7f0e5b7233314ac39c225315b21f33ca_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNS02LTEtMS05MjcxOA_0038c760-c8a0-4f65-8f07-9fa637140669"
      unitRef="usd">33291000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1e7144ed377e460497e6a92365d659ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi0yLTEtMS05MjcxOA_0afdecbc-3580-48a5-b1fa-3ca6f6504cca"
      unitRef="usd">94000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0764c13b084d4be3bc783f9c9b3ff993_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi00LTEtMS05MjcxOA_6ba91c43-f841-4327-8ab7-82d935daa173"
      unitRef="usd">26753000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia8884b7e467144a1abd07dd5529d382c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNi02LTEtMS05MjcxOA_4ca7dc52-7c3d-498a-8ca8-c0bd39b8e160"
      unitRef="usd">26847000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i858ccda502774a3c8bcffb5a5e2125f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy0yLTEtMS05MjcxOA_f8a30dea-1822-49ea-a871-154891cd67b7"
      unitRef="usd">4954000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6d9d60c60bed4ebea68c80e275f8e3d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy00LTEtMS05MjcxOA_69282224-3daf-43f1-b243-3f3989b03da8"
      unitRef="usd">55184000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia039837b279e455ca2dc2d46edc4b550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfNy02LTEtMS05MjcxOA_f7ba4a63-04f0-495e-a653-7d28262384f9"
      unitRef="usd">60138000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i820fd306ff3d43e2b341018522bb3760_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS0yLTEtMS05MjcxOA_28719924-758e-49b2-99da-9668147fbde3"
      unitRef="usd">1847000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i24d376e7b6d2421fae5fe8fa52db03b3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS00LTEtMS05MjcxOA_14a96b0d-9996-4cb3-99d7-f190b2884c8e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i15ec86e2578c4dc9a435e041179ae4c7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfOS02LTEtMS05MjcxOA_05964c0d-77c4-4810-a0fc-68011892c4c1"
      unitRef="usd">1847000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iddc61959aa8d4d67bc160b2ede121548_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtMi0xLTEtOTI3MTg_a22ff8c2-dc45-45b3-9a75-607a3ac55555"
      unitRef="usd">167000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic5824bf85f4040b1976e55e688d916b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtNC0xLTEtOTI3MTg_be6552a4-e46e-4a62-8332-01e6166daa5c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i735eafbcc4e744f1a518604a58b733d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTAtNi0xLTEtOTI3MTg_f77e791a-bb9d-4589-bb48-0bd2473e3a8e"
      unitRef="usd">167000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i01412f1ac55c4cd89cb8ff97582fb41d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtMi0xLTEtOTI3MTg_fc8c003f-39ae-4034-8727-9a538c26ceee"
      unitRef="usd">2014000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ice2ef219571e4d04b73e0b06787c1ad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtNC0xLTEtOTI3MTg_a12adf57-b436-48aa-a364-87a4120377bc"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i73f036a93e924d5fa456f3b1b062e994_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTEtNi0xLTEtOTI3MTg_88b16fda-c81d-49fc-9425-00b2e3a833b2"
      unitRef="usd">2014000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="id9d0b9ad85694f8f94491a20a88c9179_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtMi0xLTEtOTI3MTg_d6ff55e8-5ae4-41f5-a36d-b5e277b4ba7f"
      unitRef="usd">1061000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1b28be753e1e4e43a0042554fc467ca7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtNC0xLTEtOTI3MTg_5ac0e7e0-ec07-49ed-beb2-0b4cc8229152"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id8aaf3d494f04e50ba69cff6e04ff60b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTQtNi0xLTEtOTI3MTg_460947b9-357e-46c5-b5b6-002661e7c551"
      unitRef="usd">1061000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i20054b0c9f4b47ac8c1e534ba6ea3ce9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtMi0xLTEtOTI3MTg_6f60a176-3286-48c3-a7d9-e2212c199765"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia08778ed5abe4561b708b5b722eeb93e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtNC0xLTEtOTI3MTg_17e875bc-0417-4516-ad3f-0926dc859ccf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia728d4a36f3f4749a1126fa36fef1423_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTUtNi0xLTEtOTI3MTg_edbc3b42-1279-49cf-bfa1-d9143260473f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i836cf2e65d5e413682ba9671638f8619_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtMi0xLTEtOTI3MTg_fe21e96a-fa56-4c80-aacf-c1a486dc4ba7"
      unitRef="usd">1061000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib14489f445c94e4c8d8946d9f09ab71b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtNC0xLTEtOTI3MTg_0558daaa-b88d-4035-92f7-18524f00b81f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5e4670f805e84ec88fcc239984f42f1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTYtNi0xLTEtOTI3MTg_b8074add-df37-402d-9ca0-8714bd2e7f60"
      unitRef="usd">1061000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib28bced960bf4b37988c086fd5dd0698_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtMi0xLTEtOTI3MTg_12576bc9-dd9d-4fa5-a280-2f7f6f5c6d41"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic8dd0869a16144b0a67bc6b37b8b72bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtNC0xLTEtOTI3MTg_ea41cb7c-3c99-46df-8892-300137b7db45"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia4b2cef3151a4d45a40c618a6d750d32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTgtNi0xLTEtOTI3MTg_e9f3f2f8-30d2-42e0-9318-c81374447814"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifde680e06fbf430e8e5775077493e0c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktMi0xLTEtOTI3MTg_cbc23a8f-ce2c-495e-a361-4144fd23efad"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1677095d03d54c6cad7ffddc26a40aea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktNC0xLTEtOTI3MTg_fc749a34-b872-49b2-8155-6af4c6f752cf"
      unitRef="usd">1480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i120db90932414ec390afe7cf3a633cc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMTktNi0xLTEtOTI3MTg_612884b0-475e-48ae-b4b6-ff7bb88420a5"
      unitRef="usd">1480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i253805333c4f482db81b9d675244447d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtMi0xLTEtOTI3MTg_e24b7ae0-e498-4d78-a0e4-55d2958d306a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i43d08049edd740bb914aa46bd7090759_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtNC0xLTEtOTI3MTg_d12498ce-00cc-4bed-b838-07169567098a"
      unitRef="usd">1480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iaec03ea5060745ba8354c6aad5437d98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmEzNDg3MjMwY2E0NTRjYWU5M2MzMTVjY2EwM2JmYjYzL3RhYmxlcmFuZ2U6YTM0ODcyMzBjYTQ1NGNhZTkzYzMxNWNjYTAzYmZiNjNfMjAtNi0xLTEtOTI3MTg_6ed8b024-8442-44d2-be15-b830af0ff454"
      unitRef="usd">1480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i06fe49c746ff44d19762274cadbe0d7a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC0zLTEtMS0xMTAxODM_744e05e0-586b-4468-90b8-289f4c188b13"
      unitRef="usd">-3829000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ia7152ead34514d1f9d4453e1a803d747_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC01LTEtMS0xMTAxODU_4b9ab56d-317d-49d0-b7c3-1928c4a097a2"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i9fb45b8279f94588a9bb6ea15ea5b6e2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC03LTEtMS0xMTAxODg_c9f77928-3bd9-4943-9815-cea6476ce887"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i38c5dc156f3d4065a5ac61ee8ad07be7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy0zLTEtMS05MjcxOA_107fc5a0-721c-483e-a3a4-2d9edf1fadab"
      unitRef="usd">-7751000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i5e281a61518246b28c211682f9b80e67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy01LTEtMS05MjcxOA_7aa54d18-7b18-4404-9c15-4ff84a93b3fd"
      unitRef="usd">-3444000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i54664f90ad4843079c7700ad05a8cd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfMy03LTEtMS05MjcxOA_b5f19f54-c66b-44cd-9998-2a1e1a54b727"
      unitRef="usd">-790000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring
      contextRef="i9694c6e8455346248c473df62e0ab068_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC0zLTEtMS05MjcxOA_5dd3ab47-e43d-4d91-bd27-6a0c8a07b900"
      unitRef="usd">717000</us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring>
    <us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring
      contextRef="ifc8ea47f15d34f9b8c4166744ab1524e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC01LTEtMS05MjcxOA_1228cb2a-5fb8-4c27-b88b-3936377c4b9d"
      unitRef="usd">0</us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring>
    <us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring
      contextRef="ie345d2cbe6234906900704fc912fcdb4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNC03LTEtMS05MjcxOA_a6e35098-c91f-48d1-9d1b-6314b74474a6"
      unitRef="usd">0</us-gaap:GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy0zLTEtMS0xMTAxOTA_123f5978-978d-40dc-9a1b-ad5402a394d7"
      unitRef="usd">-6122000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i57c5dcea53454983887455c2111ad23b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy01LTEtMS0xMTAxOTI_37d81147-9a10-43c7-bffe-eea45217a513"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i34fb2d02e47f4de1added70760728782_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfNy03LTEtMS0xMTAxOTQ_eaa4083a-5f62-4b54-9b4e-29d236f86a85"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC0zLTEtMS0xMDAzNDQ_27baf31a-d21e-47db-a713-1f27afdb5f62"
      unitRef="usd">18419000</us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC01LTEtMS0xMDAzNDQ_084bbcfb-8e98-48fc-b75f-d97cc08415c1"
      unitRef="usd">3444000</us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOjU0MzI1OGMyOGViNjQyZmNhNGVmN2ZiNTJmNmE4YWVlL3RhYmxlcmFuZ2U6NTQzMjU4YzI4ZWI2NDJmY2E0ZWY3ZmI1MmY2YThhZWVfOC03LTEtMS0xMDAzNDQ_d4cb6884-91f5-46f2-9113-9b9d254dbbe3"
      unitRef="usd">790000</us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDkwNQ_fa4d4c57-384f-4d3e-bf3a-5168649e4f7e">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on our derivative instruments designated as cash flow hedges in other comprehensive (loss) income before reclassifications to net (loss) income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as cash flow hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="if8e04f05c0ec4c2c82f5854eb7872516_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC0yLTEtMS05MjcxOA_23e23cc5-4890-432e-83d2-d3cd9fbe1556"
      unitRef="usd">9588000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i886d8381dfd34aec845daca43861614f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC00LTEtMS05MjcxOA_7d99e6cb-ad7f-4ded-99b6-4086e969de88"
      unitRef="usd">950000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i03b89fe4e5804575a068ee1b69c7ef41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNC02LTEtMS05MjcxOA_8a87e5f1-24a4-47a6-89f5-b76656e616a6"
      unitRef="usd">1980000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="id0f094ff128e429d8f5f815ab6136547_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS0yLTEtMS05MjcxOA_1a50bc05-54b7-48c4-ad6f-9548bb400f39"
      unitRef="usd">62786000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i57c5dcea53454983887455c2111ad23b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS00LTEtMS05MjcxOA_cb5b7498-ee27-49d7-8e55-7da4ddf072f1"
      unitRef="usd">-1480000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i34fb2d02e47f4de1added70760728782_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNS02LTEtMS05MjcxOA_a9334f9a-bd27-4a69-bee5-4f8dd46fb0e8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi0yLTEtMS05MjcxOA_2f2d385b-ce50-41be-8ddd-f174bd5e315a"
      unitRef="usd">72374000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi00LTEtMS05MjcxOA_ddfeff1f-f785-40db-81b3-0627d0bc1fa1"
      unitRef="usd">-530000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RhYmxlOmVjNjJjMDE1NTE4ZTRiNWNhNjQ1ZmZjMDdiODUxNDQ4L3RhYmxlcmFuZ2U6ZWM2MmMwMTU1MThlNGI1Y2E2NDVmZmMwN2I4NTE0NDhfNi02LTEtMS05MjcxOA_57ceacab-9c5f-4f97-a131-e560a696e75d"
      unitRef="usd">1980000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDU0OQ_a2dc992f-56c5-43d0-ae5a-395c620a8934"
      unitRef="usd">3000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85MS9mcmFnOjM4ZDQyNWQ1ZjA4OTQ2MWQ5ZmVmNGQ1ODE0NGEzZTAxL3RleHRyZWdpb246MzhkNDI1ZDVmMDg5NDYxZDlmZWY0ZDU4MTQ0YTNlMDFfNDY0MA_f5e8afb2-d75f-4eea-a187-6e457267887e"
      unitRef="usd">-29300000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYxOQ_448faced-2307-4976-a115-55b20f200ba1">FAIR VALUE MEASUREMENTS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1:  quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2:  inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3:  unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent earn-out liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit (see Note 2: Acquisitions). Pursuit's former equity holders were entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out was calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. During the earn-out period, we used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilized multiple input variables to determine the value of the earn-out liability including historical volatility, a risk-free interest rate, counter party credit risk and projected future gross profit (see the simulation input table below related to Pursuit). The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate was equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that was commensurate with the term of the earn-out. The counter party credit risk was based on a synthetic credit rating of B1. As of June 30, 2021, the earn-out measurement period ended. Based on the actual sales and gross profit achieved during the measurement period, we calculated the actual earn-out amount to be $26.3&#160;million. The $26.3&#160;million earn-out calculation was finalized and accepted by Pursuit's former equity holders and was paid out in the fourth quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out payment shall not exceed $6.0&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $2.6&#160;million. The estimated fair value of the contingent earn-out is calculated using a probability-weighted cash flow model based on historical revenue streams and the likelihood that the revenue targets will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024.  As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2022, we acquired Smiths Medical with a combination of cash consideration and share consideration issued at closing. Total consideration for the acquisition includes a potential earn-out payment of $100.0&#160;million in cash contingent on our common stock achieving certain Price Targets from the closing date to either the third or fourth anniversary of closing (see Note 2: Acquisitions) and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved. The initial estimated fair value of the earn-out was determined to be $53.5&#160;million using a Monte Carlo simulation model. The model utilized several assumptions including volatility and the risk-free interest rate. The assumed volatility is based on the average of the historical volatility of our common stock price and the implied volatility of certain at-the-money traded options. The risk-free interest rate is equal to the yield on U.S. Treasury securities at constant maturity for the period commensurate with the term of the earn-out. At each reporting date subsequent to the acquisition, we remeasure the earn-out liability and recognize any changes in its fair value in our consolidated statements of operations. If the probability of achieving the Price Targets during their respective measurement periods is significantly greater than initially anticipated, the realization of an additional liability and related expense will have a significant impact on our consolidated financial statements in the period recognized. As of December 31, 2022, the estimated fair value of the contingent earn-out is $21.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contingent earn-out liabilities are separately stated on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earn-out Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent earn-out (included in income from operations as a separate line item)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent earn-out con-compete arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of Pursuit earn-out liability into Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value estimate of earn-out&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent earn-out (included in income from operations as a separate line item)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Pursuit earn-out increased during 2020 primarily due to changes in the probabilities within the valuation model.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pursuit earn-out was transferred out of Level 3 and into Level 2 in the third quarter of 2021 when the amount of the actual payment was known, and subsequently settled during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;$53.5&#160;million relates to our acquisition of Smiths Medical and $1.6&#160;million relates to our acquisition of a small foreign infusions systems supplier in the fourth quarter of 2021 (see Note 2: Acquisitions).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes an adjustment to reduce to zero a contingent earn-out issued as part of the 2021 acquisition of a small foreign infusion systems supplier. The contingent earn-out was not earned based on our determination that the threshold target was not met.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical and Pursuit:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Smiths Medical Earn-out&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At Acquisition&lt;br/&gt;January 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Simulation Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pursuit Earn-out&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At Acquisition&lt;br/&gt;November 2, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Simulation Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue/Gross Profit Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Counter Party Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments, Foreign Currency Contracts and Interest Rate Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments consist of corporate and government bonds and U.S treasury securities. The fair value of our corporate and government bonds are estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs. The fair value of our U.S. treasury securities are based on quoted market prices in active markets and are included in the Level 1 fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our Level 2 forward currency contracts is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our Level 2 interest rate swaps is estimated using a pricing model that reflects the terms of the contracts, including the period to maturity, and relies on observable market inputs such as known notional value amounts and USD interest rate curves. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the Pursuit earn-out liability described above, there were no transfers between levels in 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&lt;br/&gt;assets&#160;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&#160;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&#160;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forwards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out liability - LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&lt;br/&gt;assets&#160;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&#160;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&#160;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forwards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out liability - LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <icui:Contingentconsiderationgross
      contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMTM2MA_3b6b8418-caae-43db-afe1-df3e63195e71"
      unitRef="usd">50000000</icui:Contingentconsiderationgross>
    <icui:Contingentconsiderationgross
      contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMTY1MA_7018241a-6300-4871-97ee-ba83af5b10f3"
      unitRef="usd">50000000</icui:Contingentconsiderationgross>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMjU4OQ_31301665-5c6e-47a0-871f-7ba0fba7972b"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMjU5Nw_9945cafd-9a50-4be3-b2c6-bb300872ebf1"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <icui:Contingentconsiderationgross
      contextRef="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzA2OA_08711c0f-b734-43a2-98c6-158daa3a3e79"
      unitRef="usd">6000000</icui:Contingentconsiderationgross>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia073c52ce185453aad5151952a58609f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzQ3NA_a4704e0b-36a3-406f-97a0-747809c701cc"
      unitRef="usd">2600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <icui:Contingentconsiderationgross
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzg0Nw_a93b9654-3869-4ca2-b818-86f127e45d61"
      unitRef="usd">2500000</icui:Contingentconsiderationgross>
    <icui:ShortTermContingentConsiderationGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfMzg4Nw_04925574-5ed6-46dc-ba74-cab9e81692c0"
      unitRef="usd">1000000</icui:ShortTermContingentConsiderationGross>
    <icui:LongTermContingentConsiderationGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNDAzNA_48efbd95-753a-4607-aeab-e7764b0f0dfe"
      unitRef="usd">1500000</icui:LongTermContingentConsiderationGross>
    <icui:Contingentconsiderationgross
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjIw_3ee484c3-589f-4e15-927e-1be3c8261401"
      unitRef="usd">100000000</icui:Contingentconsiderationgross>
    <icui:OwnershipRequirementForEarnoutPayment
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjUy_d93fe998-3b40-4a10-9ec3-d73c7a8b7ba7"
      unitRef="number">0.500</icui:OwnershipRequirementForEarnoutPayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic34de2470df94313bd4a853cb4b2bf53_I20220106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjM2_10dbdc2c-51b3-45a6-a99b-1396aaa4b750"
      unitRef="usd">53500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjUw_caf6ce41-b763-4de5-b2e9-af0ee4e62e69"
      unitRef="usd">21000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYyMw_aedafad2-4820-4733-95a7-c92afacc3e7b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of our Level 3 earn-out liabilities measured at estimated fair value based on an initial valuation and updated quarterly for the years ended December 31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earn-out Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent earn-out (included in income from operations as a separate line item)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent earn-out con-compete arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfer of Pursuit earn-out liability into Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value estimate of earn-out&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent earn-out (included in income from operations as a separate line item)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent earn-out liability, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMS0yLTEtMS05MjcxOA_ee8b229d-1a79-4da4-8db7-e69773acb69d"
      unitRef="usd">17300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMi0yLTEtMS05MjcxOA_bbf9ba47-ca3e-444b-97bc-660f55685fea"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNC0yLTEtMS05MjcxOA_5c42bb37-83d4-4f2d-9dbc-b2e7b858e692"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNS0yLTEtMS05NTY0Mw_75bae62e-b14d-40b3-a8c8-00e7780d5d24"
      unitRef="usd">2589000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNi0yLTEtMS05MjcxOA_b59b2d67-9a0c-4660-931e-9ff6704deb5d"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfNy0yLTEtMS05MjcxOA_e95b9749-5132-4bc7-b967-786ff8410c5d"
      unitRef="usd">2589000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfOS0yLTEtMS0xMTAyMjc_384fcd05-668f-4ff2-a2dd-d4ea17f2d1aa"
      unitRef="usd">55158000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfOS0yLTEtMS05MjcxOA_518342c2-19f1-43ce-a952-cd296409b984"
      unitRef="usd">-32091000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <icui:CurrencyTranslationOnEarnOut
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMTMtMi0xLTEtMTEwMjI5_73306bd7-e369-493a-8f7a-784d55dcc62e"
      unitRef="usd">84000</icui:CurrencyTranslationOnEarnOut>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdmMGQ4MDAyMTE5ZDRjODU5YmY0OWU5ZWFlMDJhZWQwL3RhYmxlcmFuZ2U6N2YwZDgwMDIxMTlkNGM4NTliZjQ5ZTllYWUwMmFlZDBfMTEtMi0xLTEtOTI3MTg_9c712eb4-045c-4903-97e7-2fa49d9fb889"
      unitRef="usd">25572000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0NjU5_4ecd3333-3e9a-4f48-9e97-4aea2bd59a23"
      unitRef="usd">53500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNTQ5NzU1ODM0Njc0_8cd42ddd-3f4b-40e3-8bb0-2ba97962fc69"
      unitRef="usd">1600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4fb0ac701d04472195a9beec28ba8137_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMi0zLTEtMS0xMTAyNDU_fe5e07ed-4124-4220-9036-74a0aa31f6e7"
      unitRef="number">0.3800</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id04b91b0851c487e8d69fa69f80b7e71_I20220106"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMi01LTEtMS0xMTAyNDE_8918534e-c95d-4fc8-b2e8-94dc4276aaef"
      unitRef="number">0.3700</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icad841eb6c614e71bdb127b3ac3d2546_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMy0zLTEtMS0xMTAyNDU_0acdcfc7-a588-40f4-ac30-1ed27a1f0b46"
      unitRef="number">0.0417</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3edb4cd0b8bb40dda8c7263ec544dba8_I20220106"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjI0NjNhNzIyNTNhMDQyZDhiZmJkMDc1ZjUxYWE3OTg1L3RhYmxlcmFuZ2U6MjQ2M2E3MjI1M2EwNDJkOGJmYmQwNzVmNTFhYTc5ODVfMy01LTEtMS0xMTAyNDE_c4dd9337-4862-4e60-a5e8-80e4bf644734"
      unitRef="number">0.0131</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYyNA_179e58b4-e344-44d1-a15b-c65d965eaf7a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pursuit Earn-out&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At Acquisition&lt;br/&gt;November 2, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Simulation Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue/Gross Profit Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Counter Party Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibdcc27cec606429689f360f5df15a62d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMi0zLTEtMS05MjcxOA_9af566c1-4610-4675-9749-1607c40f644b"
      unitRef="number">0.2500</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i4e89e9c91139472a80f40636d2e26639_I20191102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMi01LTEtMS05MjcxOA_1a27e753-4531-4058-9fd9-391bb5587745"
      unitRef="number">0.2000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i941468b2385e4f209a986c7dff3b8af1_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMy0zLTEtMS05MjcxOA_470f643a-af1a-4823-a847-843fb0106ed5"
      unitRef="number">0.1250</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i98bde5dfe72e41209cdbda2cfb7fc991_I20191102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfMy01LTEtMS05MjcxOA_c1a318a4-020d-4f69-a9ad-3bed8d9c6e24"
      unitRef="number">0.1500</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia08eae0f4c494ccd87126117aa4a660d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNC0zLTEtMS05MjcxOA_c9c2c8ff-480e-43d7-9b53-77b84c9b0a46"
      unitRef="number">0.0009</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ife89f6478b684cf2b18ee6b3e0ad8937_I20191102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNC01LTEtMS05MjcxOA_e6245b1a-5167-4fdf-a33c-bddf969eb8c6"
      unitRef="number">0.0155</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iae7d1235c8584e3eb8cb944747cce27f_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNS0zLTEtMS05MjcxOA_b3985eb9-3786-4551-9b15-6398af30e98e"
      unitRef="number">0.0310</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iad35dba2b3944b4fa96b9b4a1230664d_I20191102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjdlM2E2ZjdlMmZiZTRjNTFiNjc4OTA4YWQ3ZTc4ZmJjL3RhYmxlcmFuZ2U6N2UzYTZmN2UyZmJlNGM1MWI2Nzg5MDhhZDdlNzhmYmNfNS01LTEtMS05MjcxOA_7470e7ed-d2df-4377-bd78-df70ca6f451c"
      unitRef="number">0.0600</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RleHRyZWdpb246YzhlMzZlN2E2NDQ1NGExODg5N2QwY2NmNTliZTc4ZDVfNjYzMw_f47da56a-d751-4071-ab70-29981a22e26c">Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):&#160;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&lt;br/&gt;assets&#160;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&#160;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&#160;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forwards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out liability - LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&#160;carrying&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&lt;br/&gt;assets&#160;(level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&#160;(level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&#160;(level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forwards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out liability - LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5686278e7c91400b845a73fe1fcf028f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC0xLTEtMS05MjcxOA_c36c64cd-5c95-4ef0-a0e0-478c3d18cd0a"
      unitRef="usd">2314000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icd3a9546be5e4813b1774877849c0367_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC0zLTEtMS05MjcxOA_135cccbd-5d0d-4b01-8c43-bb7bc5a9188a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3be252f91ca24066a82707f0ccc864f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC01LTEtMS05MjcxOA_3d5e15dd-467a-4c65-992b-7d07c4086817"
      unitRef="usd">2314000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i689ac27a1ce141ea907010394c836e09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNC03LTEtMS05MjcxOA_8ba5daec-869c-4e74-875e-369515b809e4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if50fd4be30c6481e89383764b9f60a6f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0xLTEtMS0xMTAyNDc_e436b496-2e53-44a3-a6b3-281b98520250"
      unitRef="usd">1412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idc33001b56c64b11b1bc56c135168d51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0zLTEtMS05NTY4Ng_a3276918-7b6c-4dba-a64b-a2f84777d231"
      unitRef="usd">1412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i422117d39c024ae298b2e44b34ec42d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS01LTEtMS0xMTAyNDk_1025089e-81d6-40ca-ae95-a555e2506fa5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i323ab94bdb574beaa5f3b95de704e67e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS03LTEtMS0xMTAyNTI_bbf1bc78-857f-49a9-8c16-5fd4451fcf18"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if5bf0ee5d6094fc7bf86465ab1e215b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi0xLTEtMS0xMTAyNTQ_f0b65560-1c0b-43f3-b45b-74f245e31f0f"
      unitRef="usd">498000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i86e66814fa7f4fe3ac2057be6b115992_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi0zLTEtMS0xMDM0MTI_f3fe9556-f848-40bb-a74a-e21af4685f2b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic7f770a2cbd548a0b79e3ff8f05781c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi01LTEtMS0xMDMzODU_2bc00d75-ba81-43cd-9a44-26bad364bc35"
      unitRef="usd">498000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9a5aa933f00841e28eb62458bbde9491_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNi03LTEtMS0xMDM0MDQ_87e11deb-3c9c-4d09-9ab8-f3507e4c74ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i5686278e7c91400b845a73fe1fcf028f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0xLTEtMS05MjcxOA_cdf181e7-cc2b-4dfa-8911-7b065064c3d6"
      unitRef="usd">516000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="icd3a9546be5e4813b1774877849c0367_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS0zLTEtMS05MjcxOA_2e71cac5-e5e2-42c0-8bb8-228c25963376"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i3be252f91ca24066a82707f0ccc864f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS01LTEtMS05MjcxOA_05a1c34a-8d71-47f5-9533-d3b2b3679aa5"
      unitRef="usd">516000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i689ac27a1ce141ea907010394c836e09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNS03LTEtMS05MjcxOA_2eaee5b1-284f-4911-b38c-7bd3ead5499f"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i547287843f834e908b791ca319cb5472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy0xLTEtMS05MjcxOA_cf2df07f-bcfb-4247-9bab-64fc850507be"
      unitRef="usd">4860000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i30434229a1be41d2b746928edc9596bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy0zLTEtMS05MjcxOA_80ba637a-76e7-4778-8bd3-c1c2f5856864"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i42d5d4dbdf274858bc9380796f898b48_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy01LTEtMS05MjcxOA_2b84edfb-7cb0-42ba-b4cc-56f3e99c240c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8f03abc412b44071b8f3a13dd339e879_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfNy03LTEtMS05MjcxOA_c754b6a9-0681-4942-b43f-2b75c4494ae7"
      unitRef="usd">4860000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i109a7c7dcc9143cbaa84164f7f3d1725_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItMS0xLTEtMTEwMjU2_4af1e25d-0dfc-4346-b0a3-d5597c401dde"
      unitRef="usd">94000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i139196726adc4d44903147af425499fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItMy0xLTEtMTEwMjU2_d8694a18-c6ab-4be4-a6a8-7c4ec026bb8c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i42498a38a5c743788e5c175074a9c29f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItNS0xLTEtMTEwMjU2_439c76a5-b3e6-4c72-8bdd-9430a532568e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8551f6edca8a4836b92c3f8ac634761f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTItNy0xLTEtMTEwMjU2_e7dd3c98-5236-4af9-8274-5516183b4e61"
      unitRef="usd">94000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ie8cb6e64c7b7454eb5293e9be41c37fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtMS0xLTEtMTEwMjYw_d68ea4e3-58c5-47db-96a7-d506e568e618"
      unitRef="usd">28431000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ib7a809ee047749f983c3b7fb473a8eb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtMy0xLTEtMTEwMjYw_8f4d1c29-8bef-41a2-b787-348bb2325432"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="iab3bf5b1a2204bf9bc64adbee638216b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtNS0xLTEtMTEwMjYw_c4382cc8-ac66-4a1b-afb6-66dfb752468c"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i9659021b124e4d70badd33a6c9cda626_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTQtNy0xLTEtMTEwMjYw_c29c7846-c518-4fb3-ab95-23f5f6cd61c1"
      unitRef="usd">28431000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i7f064e9a451f45aab673c4e82dcbc340_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS0xLTEtMS05MjcxOA_67b92e20-0eb9-4622-85f0-aff77f059b01"
      unitRef="usd">26753000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i28cf3e1c65474a53a54292b2f298eedb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS0zLTEtMS05MjcxOA_dcf712e0-b267-4850-8261-ac18a6e590a8"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ibf7925fa17894fb08b1ed1fcb9abe902_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS01LTEtMS05MjcxOA_6c476f61-c4c3-41e8-9c0d-7a1233c40694"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i68c59017357e4d0eb7f04b926d3edfb1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfOS03LTEtMS05MjcxOA_e015ab21-b51c-498b-ae75-1de434fc821c"
      unitRef="usd">26753000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtMS0xLTEtOTI3MTg_b436f621-66b4-4ae8-a2d0-cb06a0e8a419"
      unitRef="usd">64878000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i052d13e776b84488abcb5580ea31dbe2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtMy0xLTEtOTI3MTg_e1f659c1-723f-4117-af9a-d0775eb35372"
      unitRef="usd">1412000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f2071503a8441eb91e6e1a18cbcc84f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtNS0xLTEtOTI3MTg_0dbbc0b9-dcb2-4444-aa96-44f370c23929"
      unitRef="usd">3328000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f436b1a47f14d0dae8fe3ff7fc02609_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTAtNy0xLTEtOTI3MTg_379a0659-13d1-4808-802f-84d11f96b567"
      unitRef="usd">60138000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i30307f3e17834aff9e9b9bfbe9740d2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtMS0xLTEtOTI3MTg_91470858-3f47-4073-b4b6-4de307304eb6"
      unitRef="usd">25572000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i8a0b9c47fb4a4632ae6c2ec0c8a0fe8b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtMy0xLTEtOTI3MTg_20660d9f-f0b1-4925-9f8e-eeb0a4e06241"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i63099355b56b44639735fd719595c0ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtNS0xLTEtOTI3MTg_08042768-4975-4774-ad6e-28d9f2efee36"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i49cc40992cd148db92c3dc165f590efb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTMtNy0xLTEtOTI3MTg_56f253c3-2d83-41db-b1b7-8d513de8c8a7"
      unitRef="usd">25572000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i34247cf421ab44c3a642063a2a64781a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtMS0xLTEtOTI3MTg_ea703983-61f3-4b32-a4b9-2db770065f1b"
      unitRef="usd">1847000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i84d86d123e7649bc9a08ba202f8cbb1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtMy0xLTEtOTI3MTg_ecb20f19-1917-455d-8260-b5aa394b7f46"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ic8a169b1291f4fae8f8673b8db33720e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtNS0xLTEtOTI3MTg_9aebfe39-a452-40bc-97de-e62eec193865"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i9a7bcaa2cb0c40ec9f2f05572f36effb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTUtNy0xLTEtOTI3MTg_76b3f138-6468-4f17-b99f-7f8c01b2f89a"
      unitRef="usd">1847000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8154538596c24715a9b857081ebbf2c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtMS0xLTEtOTI3MTg_d35f5aff-edc1-48a1-a128-afa1314c934a"
      unitRef="usd">167000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ideb24c12f52c4ed4bfd923928efb0545_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtMy0xLTEtOTI3MTg_68f5cf3b-ee63-4839-be4c-60582ad56205"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id9ea28028ba24e559823c8e265b177a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtNS0xLTEtOTI3MTg_ff2dc8ba-0410-4d46-9a1c-9756f4296c46"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib694e789a9e14a96a033168b758bb8b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTYtNy0xLTEtOTI3MTg_da0e5b64-0a53-4afb-ac36-e2a11e8c469c"
      unitRef="usd">167000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i56e8fec49f6742c484f4ed39291aac3c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktMS0xLTEtOTI3MTg_34ccf886-06e4-46c9-8a4d-b4cafe1e60d8"
      unitRef="usd">27586000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i137f448db78e447e98bb2714c16ee9d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktMy0xLTEtOTI3MTg_263d78ec-35ef-4f9e-8d04-48cb45e53e65"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i3909bff053c54be18d8308bc23b1552c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktNS0xLTEtOTI3MTg_5962d98c-6a7a-48a8-96c0-788e7c33170b"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i94d3b6e5dace4cfcb820e268951f1c59_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOmQyM2E3YmY1Y2Y2NTQzNGVhNGY4NDQwYzg4MTc5MGQyL3RhYmxlcmFuZ2U6ZDIzYTdiZjVjZjY1NDM0ZWE0Zjg0NDBjODgxNzkwZDJfMTktNy0xLTEtOTI3MTg_65eaa994-1c3c-447c-a23c-17b806aed4f4"
      unitRef="usd">27586000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC0xLTEtMS05MjcxOA_dd7df3f9-e412-45c8-b016-44b80abb0c61"
      unitRef="usd">14420000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC0zLTEtMS05MjcxOA_9cf28164-529a-4918-b598-cdbed94440e1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC01LTEtMS05MjcxOA_29292883-c00b-4177-8e45-1c0569ec33a4"
      unitRef="usd">14420000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNC03LTEtMS05MjcxOA_4a8404fa-5fc8-421a-85ff-28a7fc8d510c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS0xLTEtMS05MjcxOA_93b48927-065b-46cf-adc5-9cb9aac2e63b"
      unitRef="usd">4620000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS0zLTEtMS05MjcxOA_55446b4d-831d-407b-b4aa-1a46b70ea066"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS01LTEtMS05MjcxOA_3866381b-9e61-44c2-aed9-7c5b6d5f6dee"
      unitRef="usd">4620000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNS03LTEtMS05MjcxOA_79599710-6a51-4156-b362-2a5090ce7f45"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia357ea3684bd486e9a953093cc31299a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy0xLTEtMS05MjcxOA_85bebdae-63de-4362-ac38-72646a7ac672"
      unitRef="usd">1061000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i72dc2b3b6d1643f08f096152319ae32f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy0zLTEtMS05MjcxOA_451cfd6b-83e8-46e4-9b64-bed9c9321462"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i739de8efcf0847099e2173cceabc811e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy01LTEtMS05MjcxOA_9c8f720d-5f76-4a6f-8181-2249d22d3e0a"
      unitRef="usd">1061000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i73a361b33fe1423ba9980571550cb413_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfNy03LTEtMS05MjcxOA_e5da79c7-dcdc-4d71-bc97-7ed8b320b25a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS0xLTEtMS05MjcxOA_11d93b03-bcd1-4aa6-99fa-ee663fbf007b"
      unitRef="usd">20101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i897c4914d2304f7eba66e3d057bfbd11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS0zLTEtMS05MjcxOA_f557936e-8931-408a-80fe-38d830638059"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a8f66bb87b841b5a46011fe3af927e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS01LTEtMS05MjcxOA_bc445dc1-70d2-4d6f-a305-fd8a3ff8d1e3"
      unitRef="usd">20101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i25f6cfdc530a4b5597d13e04ba8e9f19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfOS03LTEtMS05MjcxOA_f0d456bd-cadb-42d9-9ca0-e647fe1b894d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i122ee70217fb4cbd8648c12f53e80c04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItMS0xLTEtOTI3MTg_31d15a4e-45ab-4b55-8ada-80e98706ef91"
      unitRef="usd">2589000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i11fe6f3df45e4383a8f40e6ae0c2e20f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItMy0xLTEtOTI3MTg_0b419a5e-2e93-4c0c-a6ed-fbd6005c6b86"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i0627ac618c7845f1bb5092afa5095fb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItNS0xLTEtOTI3MTg_e2a92905-6036-4096-a052-bdd15cae7c5f"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="ifd40f9b169a94661afad5c82b59ee442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTItNy0xLTEtOTI3MTg_5c8cbbed-0927-4908-9c0a-47d18cbcbd88"
      unitRef="usd">2589000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i11793d1454d04740869956397beef53f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtMS0xLTEtOTU3MjE_83109b30-e359-4fca-b180-f38295a6196a"
      unitRef="usd">1480000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie95679179f944cce9f35afb1724a6e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtMy0xLTEtOTU3MjE_c4418caa-65b5-4fea-be4e-43b4765dc795"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ic9c51ce9a1aa4ba2803e09d904c5763f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtNS0xLTEtOTU3MjE_f6d73aa1-9b0d-4043-88d4-8bbbe18e2bd9"
      unitRef="usd">1480000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i814802c25f134344bd1ca05e7f8d0ef7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTUtNy0xLTEtOTU3MjE_6c1e35a9-65f9-4080-a8f4-b26444415459"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i27f7481192424f469ce8b17fa4645692_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtMS0xLTEtOTI3MTg_e53c9355-326c-45bd-a0ec-fd3ccf0ad28b"
      unitRef="usd">4069000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="i48c5d747a44f4274ba30ffb47647922f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtMy0xLTEtOTI3MTg_a9c02d67-8ff5-4e28-b9e5-3887c793dcdf"
      unitRef="usd">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="if231634d16b94cbcb21a0c638c4ef8b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtNS0xLTEtOTI3MTg_24f7b98e-8016-4dbe-b485-2c5e6ec51189"
      unitRef="usd">1480000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NonfinancialLiabilitiesFairValueDisclosure
      contextRef="ibec9f0f2f05443f99f93d8d000ec554d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85NC9mcmFnOmM4ZTM2ZTdhNjQ0NTRhMTg4OTdkMGNjZjU5YmU3OGQ1L3RhYmxlOjBiOGNkMjRmMTJlNDRjNTU5MzY0ZWMzZjI4Y2FkY2VhL3RhYmxlcmFuZ2U6MGI4Y2QyNGYxMmU0NGM1NTkzNjRlYzNmMjhjYWRjZWFfMTYtNy0xLTEtOTI3MTg_614df102-6b22-4306-a39c-23afd5815789"
      unitRef="usd">2589000</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
    <icui:PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfMjIy_ee8a0d8e-a5c4-4d10-b257-097846b850eb">PREPAID EXPENSES AND OTHER CURRENT ASSETS AND OTHER ASSETS&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid vendor expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance and property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT/GST receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pump lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spare parts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</icui:PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfMjE5_c1b4a95f-e9a0-4620-bbbe-c2e26fa49536">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid vendor expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance and property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT/GST receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange forward contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pump lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spare parts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMi0xLTEtMS05MjcxOA_0505f19f-a908-4ce8-8074-5cb61fbba6c0"
      unitRef="usd">21635000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMi0zLTEtMS05MjcxOA_c79ba235-d0c9-4316-97c8-61196a69fed9"
      unitRef="usd">14763000</us-gaap:OtherPrepaidExpenseCurrent>
    <icui:PrepaidVendorExpenses
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0xLTEtMS05NTUwMg_51a7b61f-4923-4e73-b7c2-833ba16ec800"
      unitRef="usd">3052000</icui:PrepaidVendorExpenses>
    <icui:PrepaidVendorExpenses
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0zLTEtMS05NTQ5NQ_821c5df0-29dc-4773-a987-d47ca56224d6"
      unitRef="usd">0</icui:PrepaidVendorExpenses>
    <us-gaap:DeferredCostsAndOtherAssets
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0xLTEtMS05MjcxOA_4ad700c0-1251-426e-8891-d73b6e1ad72c"
      unitRef="usd">2395000</us-gaap:DeferredCostsAndOtherAssets>
    <us-gaap:DeferredCostsAndOtherAssets
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMy0zLTEtMS05MjcxOA_1aa27a5e-c1c7-4d32-930c-b72a741f69c5"
      unitRef="usd">12746000</us-gaap:DeferredCostsAndOtherAssets>
    <icui:Prepaidinsuranceandpropertytaxes
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNC0xLTEtMS05MjcxOA_a7226758-a51c-4211-ab19-83e267b30283"
      unitRef="usd">16322000</icui:Prepaidinsuranceandpropertytaxes>
    <icui:Prepaidinsuranceandpropertytaxes
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNC0zLTEtMS05MjcxOA_50bc6dce-2d5d-4a68-bda2-6cb7cdc65bcd"
      unitRef="usd">6310000</icui:Prepaidinsuranceandpropertytaxes>
    <icui:Prepaidothertaxes
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNS0xLTEtMS05MjcxOA_7e77a385-3e8b-45c8-b5bf-7e5fac4f5170"
      unitRef="usd">3546000</icui:Prepaidothertaxes>
    <icui:Prepaidothertaxes
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNS0zLTEtMS05MjcxOA_e203958b-942b-4655-a27b-4823366968b3"
      unitRef="usd">4156000</icui:Prepaidothertaxes>
    <icui:Deferredtaxcharge
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNi0xLTEtMS05MjcxOA_1b3abf9b-8143-450a-84f1-97ab3e785ffd"
      unitRef="usd">3830000</icui:Deferredtaxcharge>
    <icui:Deferredtaxcharge
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNi0zLTEtMS05MjcxOA_62777856-40d7-4fa1-b3ef-991964639a57"
      unitRef="usd">4241000</icui:Deferredtaxcharge>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNy0xLTEtMS05MjcxOA_5c20fe29-c243-4b77-81a2-6d448bfdd407"
      unitRef="usd">4860000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfNy0zLTEtMS05MjcxOA_7788a266-5b4f-4ffa-ac2e-49e638169dc2"
      unitRef="usd">1061000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i547287843f834e908b791ca319cb5472_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0xLTEtMS05NTUyMQ_adbf9715-8525-4afb-b5b9-77f76f5b9920"
      unitRef="usd">28431000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ia357ea3684bd486e9a953093cc31299a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0zLTEtMS05NTUxNA_d7974f85-16d4-4ae6-8a33-0d88ac1ef75d"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:DepositAssets
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOC0xLTEtMS05MjcxOA_b3203cbf-dfa0-48f7-856f-d084b54daeb9"
      unitRef="usd">1329000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOC0zLTEtMS05MjcxOA_57aacbb3-9285-4c74-a4c4-a6bcdf511daa"
      unitRef="usd">1343000</us-gaap:DepositAssets>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0xLTEtMS05MjcxOA_04d5d65f-fc70-4d87-86d3-38660c64cbae"
      unitRef="usd">3532000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfOS0zLTEtMS05MjcxOA_1ddc081d-9e98-4b9e-a58a-e7d868fab3c6"
      unitRef="usd">2227000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMTAtMS0xLTEtOTI3MTg_b9f64d6a-47e9-4bb9-a2b5-5abefbbb2067"
      unitRef="usd">88932000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjBhNTA5YzFjNDEzNTRmNzQ4ODNiNzQ2MGUwYmFmYmYwL3RhYmxlcmFuZ2U6MGE1MDljMWM0MTM1NGY3NDg4M2I3NDYwZTBiYWZiZjBfMTAtMy0xLTEtOTI3MTg_79e795c9-2cb1-4305-b0e5-a79b79c0bf5f"
      unitRef="usd">46847000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RleHRyZWdpb246NGZmNmY0MDAwYjJhNDE0ZTliMTVkZjA3Y2E4ZDVmYTRfNTQ5NzU1ODE0MTg3_5705ad7c-a871-4abb-bf3a-620d55926ac6">Other assets consist of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pump lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spare parts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMi0xLTEtMS05MjcxOA_14704186-eb3d-4672-a018-f418ce492f87"
      unitRef="usd">27086000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMi0zLTEtMS05MjcxOA_7b2da541-212f-44ac-af23-81383aa41d05"
      unitRef="usd">25941000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <icui:SpareParts
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMy0xLTEtMS05MjcxOA_04e71ffe-788c-4954-ae54-1c08c1de8245"
      unitRef="usd">38498000</icui:SpareParts>
    <icui:SpareParts
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfMy0zLTEtMS05MjcxOA_261fa665-4378-4596-8294-c06b846c2f7d"
      unitRef="usd">28538000</icui:SpareParts>
    <us-gaap:EquityMethodInvestments
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNC0xLTEtMS05MjcxOA_43deb6ef-dd21-4a63-979e-66614158cc16"
      unitRef="usd">3178000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNC0zLTEtMS05MjcxOA_2b472053-befb-447c-b93b-1ca8c5fe2ab4"
      unitRef="usd">3238000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9c3adc51d3d94dfdbe82a74a4456ac50_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNS0xLTEtMS05MjcxOA_d1a3f5aa-d151-4cdb-b5f6-4a9b5942a8b1"
      unitRef="usd">26753000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i39ced24d07c14cf4ab00eabf97854594_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNS0zLTEtMS05MjcxOA_7c7f846b-4fe7-4c00-88b0-e6737734118f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNi0xLTEtMS05MjcxOA_b496e477-d8f4-4f28-a853-7d0442ba8b0e"
      unitRef="usd">5156000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNi0zLTEtMS05MjcxOA_a13f7ab3-3461-46e2-bd57-c71edb302edf"
      unitRef="usd">2827000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNy0xLTEtMS05MjcxOA_54f9e00f-b406-4b2f-8484-b8fd9e525b6f"
      unitRef="usd">2598000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfNy0zLTEtMS05MjcxOA_e5e07b05-8771-4f2d-854e-66d3c2d568b3"
      unitRef="usd">2673000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOC0xLTEtMS05MjcxOA_11a0787d-acda-40b8-ad4c-5a58b70ec21a"
      unitRef="usd">2193000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOC0zLTEtMS05MjcxOA_9a049233-ae03-49ff-a0a1-69070850289a"
      unitRef="usd">526000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOS0xLTEtMS05MjcxOA_a19f0f6d-19dc-4178-8b7c-972302daa67b"
      unitRef="usd">105462000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF85Ny9mcmFnOjRmZjZmNDAwMGIyYTQxNGU5YjE1ZGYwN2NhOGQ1ZmE0L3RhYmxlOjNmYTY5YWU0YmZmMTQ1MzM5MzM3ZjA1Zjk0ZjYwYzVlL3RhYmxlcmFuZ2U6M2ZhNjlhZTRiZmYxNDUzMzkzMzdmMDVmOTRmNjBjNWVfOS0zLTEtMS05MjcxOA_1e216392-c455-466c-b3a3-b70c939e65cb"
      unitRef="usd">63743000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzM2OA_90b6b9a6-8c1f-4bb3-908c-d1e96fca7d39">ACCRUED LIABILITIES AND OTHER LONG-TERM LIABILITIES&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability-ST&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field service corrective action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranties and returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued freight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued audit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability-LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liability-LT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field service corrective action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &#160;&#160;&#160;&#160;Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzM2MA_47fc3e78-38fa-455c-bd00-dec742c1f1b6">&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability-ST&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field service corrective action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranties and returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued freight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued audit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <icui:AccruedSalariesAndBenefits
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzItMi0xLTEtOTI3MTg_7c385ff1-fa0c-4b5a-9e2f-44089fa5ba96"
      unitRef="usd">44304000</icui:AccruedSalariesAndBenefits>
    <icui:AccruedSalariesAndBenefits
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzItNC0xLTEtOTI3MTg_7e4f21f3-69e3-4090-b21c-1ab73293ec66"
      unitRef="usd">27304000</icui:AccruedSalariesAndBenefits>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzMtMi0xLTEtOTI3MTg_cac08b2d-4487-4294-bee0-7403ff72c8b1"
      unitRef="usd">30254000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzMtNC0xLTEtOTI3MTg_7cd052f0-937d-40c3-84a1-f11a5730d5b9"
      unitRef="usd">33107000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzUtMi0xLTEtOTI3MTg_c369b38c-7a3e-48e7-afe6-5a0974b53fd3"
      unitRef="usd">18169000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzUtNC0xLTEtOTI3MTg_6a0541e6-7e6a-497f-ab95-ea6317bc59ee"
      unitRef="usd">9009000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzYtMi0xLTEtOTI3MTg_ad8fabed-fd4a-4e2e-8b2c-194db13a11c3"
      unitRef="usd">5317000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzYtNC0xLTEtOTI3MTg_8c26b017-2b83-4b27-a3ba-64ce70010b01"
      unitRef="usd">773000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <icui:AccruedProductFieldAction.
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzctMi0xLTEtOTI3MTg_5483f384-d40c-4abe-873c-353faec0e43d"
      unitRef="usd">24517000</icui:AccruedProductFieldAction.>
    <icui:AccruedProductFieldAction.
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzctNC0xLTEtOTI3MTg_219400f8-8d39-4973-8274-54071e9b32db"
      unitRef="usd">0</icui:AccruedProductFieldAction.>
    <icui:Accruedlegalfees
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEwLTItMS0xLTkyNzE4_599a2fc5-fa04-45e8-94df-1fd285a2cced"
      unitRef="usd">3137000</icui:Accruedlegalfees>
    <icui:Accruedlegalfees
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEwLTQtMS0xLTkyNzE4_28cebc75-258f-4b0a-a981-326e0ab7832c"
      unitRef="usd">3897000</icui:Accruedlegalfees>
    <icui:Accruedsalestaxes
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzExLTItMS0xLTkyNzE4_078a24e2-d50f-4796-adde-cb92db96063c"
      unitRef="usd">5844000</icui:Accruedsalestaxes>
    <icui:Accruedsalestaxes
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzExLTQtMS0xLTkyNzE4_a72945c0-fdbe-4b0d-9562-71015ca5b5a6"
      unitRef="usd">1980000</icui:Accruedsalestaxes>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEyLTItMS0xLTkyNzE4_fafb30eb-1f81-443e-abba-49ec8b20e2f4"
      unitRef="usd">3097000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEyLTQtMS0xLTkyNzE4_5fad1169-ea15-4fed-9b6c-333ed12ae7fa"
      unitRef="usd">532000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEzLTItMS0xLTkyNzE4_b0f48918-0d91-4375-843e-63e748528bb2"
      unitRef="usd">30838000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzEzLTQtMS0xLTkyNzE4_de82a37d-b560-4420-a419-e5f496295c64"
      unitRef="usd">12646000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <icui:Accruedothertaxes
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE1LTItMS0xLTkyNzE4_a0a7381a-95a0-49e9-a01a-19190c88b61e"
      unitRef="usd">5794000</icui:Accruedothertaxes>
    <icui:Accruedothertaxes
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE1LTQtMS0xLTkyNzE4_aa65db57-c2f6-4f85-860a-0db9d217449e"
      unitRef="usd">4337000</icui:Accruedothertaxes>
    <icui:Outsidesalescommissions
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE2LTItMS0xLTkyNzE4_df6b4582-ae47-4817-8f61-346e02baf357"
      unitRef="usd">17063000</icui:Outsidesalescommissions>
    <icui:Outsidesalescommissions
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE2LTQtMS0xLTkyNzE4_7d87d0b5-1700-4ab4-86e1-7a471aa09160"
      unitRef="usd">5645000</icui:Outsidesalescommissions>
    <icui:Accruedfreight
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE3LTItMS0xLTkyNzE4_e0b7e2fb-e689-4637-815e-5c84b070d866"
      unitRef="usd">17988000</icui:Accruedfreight>
    <icui:Accruedfreight
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE3LTQtMS0xLTkyNzE4_d6a075a5-61a6-4b80-b34d-abcb1abf21e7"
      unitRef="usd">9194000</icui:Accruedfreight>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE4LTItMS0xLTkyNzE4_a5d478b2-399e-4d29-af5d-262e9e0ccb54"
      unitRef="usd">5923000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE4LTQtMS0xLTkyNzE4_9ee6d74f-2082-4585-aff7-491d2ce9a662"
      unitRef="usd">664000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0f4092f2517f47dc82182e9da5e14d64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE5LTItMS0xLTEwMzUxNg_178a7f10-0f2e-48f9-a4e7-b003fb138522"
      unitRef="usd">1847000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i9e3aed3c3b2c4c3bb0a41361e73b80b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzE5LTQtMS0xLTEwMzUyNA_7f82a894-9c1f-4eff-9b52-e904b8e6622c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <icui:AccruedAuditFees
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIwLTItMS0xLTEwMzU0OA_c2a20ad2-9367-497f-8e01-3429ecbad593"
      unitRef="usd">6279000</icui:AccruedAuditFees>
    <icui:AccruedAuditFees
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIwLTQtMS0xLTEwMzU1Ng_ee9bad3c-28ca-4a83-920f-cb72c4c6399c"
      unitRef="usd">1008000</icui:AccruedAuditFees>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIxLTItMS0xLTEwMzUwMA_5ae9142d-98af-4654-abc5-a364db16540b"
      unitRef="usd">2928000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIxLTQtMS0xLTEwMzUwOA_95b05ecc-e9fb-4232-8f28-91b7f66d3123"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIyLTItMS0xLTEwMzUzMg_d5ca1f02-6eba-4bea-be28-20812c14f639"
      unitRef="usd">1033000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIyLTQtMS0xLTEwMzU0MA_4d35ed62-cd17-4d0f-9916-6a764c8e0069"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <icui:AccruedResearchAndDevelopmentLiability
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIzLTItMS0xLTkyNzE4_8abeeb9a-03f1-44c5-860c-7eeeeaee415e"
      unitRef="usd">3538000</icui:AccruedResearchAndDevelopmentLiability>
    <icui:AccruedResearchAndDevelopmentLiability
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzIzLTQtMS0xLTkyNzE4_9b865544-8ddc-4fe7-9e1f-4fd523a41d12"
      unitRef="usd">0</icui:AccruedResearchAndDevelopmentLiability>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI0LTItMS0xLTkyNzE4_7f6d8adb-4e57-44cb-b8df-b0547a2754c9"
      unitRef="usd">14899000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI0LTQtMS0xLTkyNzE4_9b535c10-dbaa-4577-8216-b45002c73633"
      unitRef="usd">8099000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI1LTItMS0xLTkyNzE4_d484b011-e670-4177-a663-b4df7faa7d0d"
      unitRef="usd">242769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo0NzRiNDg3ZmRhMzI0OTlmODc0OTkzNDFkMTI5MmRkNy90YWJsZXJhbmdlOjQ3NGI0ODdmZGEzMjQ5OWY4NzQ5OTM0MWQxMjkyZGQ3XzI1LTQtMS0xLTkyNzE4_2acb19cd-c341-43b7-af13-8e7f80344e84"
      unitRef="usd">118195000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90ZXh0cmVnaW9uOjVlMDkxNGYxOTk2ZDQyYjViYWYzNmY3YWY3NzcwYzA1XzU0OTc1NTgxNTA3Nw_e0c91e4a-2241-4f58-819e-95226310003c">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability-LT&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liability-LT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field service corrective action&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &#160;&#160;&#160;&#160;Includes field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility, see Note 15: Commitments and Contingencies for further detail.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzItMS0xLTEtOTI3MTg_4ee8c5a3-d664-44f1-bfd1-06d97c05ec04"
      unitRef="usd">60916000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzItMy0xLTEtOTI3MTg_c56fd335-5ad6-4033-90a5-64f7e942719c"
      unitRef="usd">33971000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzMtMS0xLTEtOTI3MTg_0ba574df-2d07-45dc-b1e6-724bcfff3d7a"
      unitRef="usd">1855000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzMtMy0xLTEtOTI3MTg_e38e1300-5198-424a-a05c-cde8df2be9fc"
      unitRef="usd">2067000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzUtMS0xLTEtOTI3MTg_4959fa19-c1e6-4449-b4ab-902242bb0cb7"
      unitRef="usd">16239000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzUtMy0xLTEtOTI3MTg_1ec39851-dfb4-4b85-a400-f352a4cd8cfd"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzYtMS0xLTEtOTI3MTg_9308fde8-a17f-499a-8682-9bf37e200726"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzYtMy0xLTEtOTI3MTg_527848d0-5f9a-445c-9f05-ca3440fe48c3"
      unitRef="usd">1480000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzctMS0xLTEtOTI3MTg_36c7ccc8-77c1-48c3-ab5c-0f9ac1e75db1"
      unitRef="usd">5314000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzctMy0xLTEtOTI3MTg_e5bcf6af-d5d8-4a44-94b8-369f34c017bf"
      unitRef="usd">1369000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:ProductLiabilityAccrualComponentAmount
      contextRef="i9b46600611854ead8201632b540aa737_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzgtMS0xLTEtOTI3MTg_8d123c3a-1f71-46b0-a2b5-bb1ae6024787"
      unitRef="usd">25294000</us-gaap:ProductLiabilityAccrualComponentAmount>
    <us-gaap:ProductLiabilityAccrualComponentAmount
      contextRef="i87f16fd75aa948d082f729515410eecc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzgtMy0xLTEtOTI3MTg_dc76ae15-36fc-42da-aae2-b8d0740b92f5"
      unitRef="usd">0</us-gaap:ProductLiabilityAccrualComponentAmount>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzktMS0xLTEtOTI3MTg_524edf3c-094d-4583-abaa-1cfe9d577bc8"
      unitRef="usd">997000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzktMy0xLTEtOTI3MTg_897c03c2-9f55-4965-a155-605e6c542969"
      unitRef="usd">1262000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzExLTEtMS0xLTkyNzE4_c426c2e0-1e17-44d0-b680-64c34f8e63ef"
      unitRef="usd">3489000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzExLTMtMS0xLTkyNzE4_64eb2a88-7a86-4b9a-8e16-cee09497228b"
      unitRef="usd">1681000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzEyLTEtMS0xLTkyNzE4_6270651d-1b4f-45de-bed8-191f27ebde96"
      unitRef="usd">114104000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDAvZnJhZzo1ZTA5MTRmMTk5NmQ0MmI1YmFmMzZmN2FmNzc3MGMwNS90YWJsZTo4ZWE2MmQ3MzVlOWI0ZDRlYjkyYzQwMWQ5ZmU4MThlZi90YWJsZXJhbmdlOjhlYTYyZDczNWU5YjRkNGViOTJjNDAxZDlmZTgxOGVmXzEyLTMtMS0xLTkyNzE4_1953358a-ff08-4d40-8bec-f320272e4544"
      unitRef="usd">41830000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzAwNQ_67c8ea0d-1879-4a19-9718-ee4cec615735">LONG-TERM OBLIGATIONS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2022, in connection with the acquisition of Smiths Medical, we entered into a Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, Wells Fargo Securities, LLC, Barclays Bank PLC and certain other financial institutions (the &#x201c;Lenders&#x201d;) for $2.2&#160;billion of senior secured credit facilities. The senior secured credit facilities include (i) a five-year Tranche A term loan of $850.0&#160;million (the "Term Loan A"), (ii) a seven-year Tranche B term loan of $850.0&#160;million (the "Term Loan B") and (iii) a five-year revolving credit facility of $500.0&#160;million (the "Revolving Credit Facility"), with separate sub-limits of $50.0&#160;million for letters of credit and swingline loans (collectively, the "Senior Secured Credit Facilities"). We used the proceeds from borrowings under the Term Loan A and the Term Loan B (collectively, the "Term Loans") to fund a portion of the cash consideration for the purchase of Smiths Medical and the related fees and expenses incurred in connection with the acquisition. We did not incur borrowings under the Revolving Credit Facility on the closing date of the acquisition. The proceeds from any future borrowings under the Revolving Credit Facility may be used for working capital and other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with entering into the Credit Agreement, during the period ended March 31, 2022, we incurred $37.8&#160;million in debt discount and issuance costs, which were allocated to the Term Loan A, the Term Loan B and the Revolving Credit Facility based on lender commitment amounts relative to each type of fees paid. The lender and third-party discount and issuance costs allocated to the Term Loan A and the Term Loan B were $15.8&#160;million and $13.4 million, respectively, and are reflected as a direct deduction from the face amount of the corresponding term loans on the consolidated balance sheet. These costs are being amortized to interest expense over the respective terms of the loans using the effective interest method. The issuance costs allocated to the Revolving Credit Facility were $8.6&#160;million, which are capitalized and included in prepaid expenses and other current assets and other assets on our consolidated balance sheets. These costs are being amortized to interest expense over the term of the Revolving Credit Facility using the straight-line method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net funds received from the Term Loan A and the Term Loan B, after deducting debt issuance costs, were $834.2&#160;million and $836.6&#160;million, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity Dates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity date for the Term Loan A and the Revolving Credit Facility is January 6, 2027 and the maturity date for the Term Loan B is January 6, 2029. Pursuant to the terms and conditions of the Credit Agreement, the maturity dates of the Term Loans and the Revolving Credit Facility may be extended upon our request, subject to the consent of the Lenders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, the Term Loans and borrowings under the Revolving Credit Facility denominated in U.S. dollars bear interest, at our option, on either: (1) the Base Rate, as defined below, plus the applicable margin, as indicated below ("Base Rate Loans") or (2) the Adjusted Term Secured Overnight Financing Rate ("Adjusted Term SOFR"), as defined below, plus the applicable margin, as indicated below ("Term SOFR Loans"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Base Rate is defined as the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) Adjusted Term SOFR (as defined below) for a one-month period plus, in each case, 1.00%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted Term SOFR is the rate per annum equal to (a) the Term SOFR plus (b) the Term SOFR Adjustment. Term SOFR is the forward-looking term rate based on SOFR and is calculated separately for Term SOFR Loans and Base Rate Loans, as specified in the Credit Agreement. The Term SOFR Adjustment is a percentage per annum of 0.10% for Base Rate Loans and between 0.10% to 0.25% for Term SOFR Loans based on the applicable interest period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revolving Credit Facility Commitment Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility has a per annum commitment fee at an initial rate of 0.25% which is applied to the available amount of the Revolving Credit Facility. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the commitment fee will be determined by reference to the leverage ratio in effect from time to time as set forth in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Applicable Interest Margins&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan A and borrowings under the Revolving Credit Facility have an initial applicable margin of 0.75% per annum for Base Rate Loans and 1.75% per annum for Term SOFR Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Term SOFR Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Commitment Fee Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than 4.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 2.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan B has an initial applicable margin of 1.5% per annum for Base Rate Loans and 2.5% per annum for Term SOFR Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Term SOFR Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than 2.75 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 2.75 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal payments on the Term Loans are due on the last day of each calendar quarter commencing on June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan A will amortize in nineteen consecutive quarterly installments in an amount equal to 2.50% of the original principal amount in each of the first two years, 5.00% in each of the third and fourth years and 7.50% in the fifth year, with a final payment of the remaining outstanding principal balance due on the maturity date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan B matures in twenty-seven consecutive quarterly installments in an amount equal to 0.25% of the original principal amount, with a final payment of the remaining outstanding principal balance due on the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may borrow, prepay and re-borrow amounts under the Revolving Credit Facility, in accordance with the terms and conditions of the Credit Agreement, with all outstanding amounts due at maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2022, we prepaid $16.0&#160;million in principal payments on the Term Loan A principal balance. For the year ended December 31, 2022, including the prepayment, we paid a total of $22.4&#160;million in principal payments on both Term Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest payments on Base Rate Loans are payable quarterly in arrears on the last business day of each calendar quarter and the applicable maturity date. Interest periods on Term SOFR Loans will be determined, at our option, as either one, three or six months and will be payable on the last day of each interest period and the applicable maturity date. In the case of any interest periods of more than three months' duration, the interest payment will be payable on each day prior to the last day of such interest period that occurs at three-month intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commitment fee on the Revolving Credit Facility is payable quarterly in arrears on the third business day following the last day of each calendar quarter and at the maturity date. The commitment fee is included in interest expense in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantors and Collateral&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Credit Agreement are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains affirmative and negative covenants, including certain financial covenants. The negative covenants include restrictions regarding the incurrence of liens and indebtedness, certain merger and acquisition transactions, asset sales and other dispositions, other investments, dividends, share purchases and payments affecting subsidiaries, changes in nature of business, fiscal year or organizational documents, prepayments and redemptions of subordinated and other junior debt, transactions with affiliates, and other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial covenants include the Senior Secured Leverage Ratio and the Interest Coverage Ratio, both defined below, and pertain to the Term Loan A and the Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Leverage Ratio is defined, at any measurement date, as the ratio of: (a) all Funded Debt, as defined in the Credit Agreement, that is secured by a lien on any asset or property minus the lesser of (i) all unrestricted cash and cash &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equivalents and (ii) $500.0&#160;million, to (b) Consolidated EBITDA, as defined in the Credit Agreement, for the most recently completed four fiscal quarters, calculated on a pro forma basis. The maximum Senior Secured Leverage Ratio is 4.50 to 1.00 until June 30, 2024. Thereafter, the maximum Senior Secured Leverage Ratio is 4.00 to 1.00, with limited permitted exception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Interest Coverage ratio is defined, at any measurement date, as the ratio of Consolidated EBITDA, as defined in the Credit Agreement, to Consolidated Interest Expense, as defined in the Credit Agreement, paid or payable in cash, for the most recently completed four fiscal quarters. The minimum Interest Coverage ratio is 3.00 to 1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We were in compliance with all financial covenants as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary events of default, including, among others: non-payments of principal and interest; breach of representations and warranties; covenant defaults; cross-defaults and cross-acceleration to certain other material indebtedness; the existence of bankruptcy or insolvency proceedings; certain events under ERISA; material judgments; and a change of control. If an event of default occurs and is not cured within any applicable grace period or is not waived, the administrative agent and the Lenders are entitled to take various actions, including, without limitation, the acceleration of all amounts due and the termination of commitments under the Senior Secured Credit Facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On November 8, 2017, we entered into a five-year senior secured revolving credit facility with various lenders for $150.0&#160;million, with Wells Fargo Bank, National Association as the administrative agent, swingline lender and issuing lender (the "Credit Facility"). The Credit Facility, which was set to mature on November 8, 2022, was terminated in connection with entering into the Credit Agreement on January 6, 2022. There were no borrowings outstanding under the Credit Facility at that date or at December 31, 2021. The remaining unamortized deferred debt issuance costs related to the Credit Facility were not material and were expensed in connection with its termination. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our long-term debt consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan B &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Credit Facility &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt issuance costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprised of $12.6&#160;million and $11.7&#160;million relating to the Term Loan A and the Term Loan B, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total interest expense related to our long-term debt (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitment fee &#x2014; Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt-related  interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <icui:TotalSeniorSecuredCreditFacility
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjYyMQ_79ff3837-0404-4a8f-a359-3e8c5e2c1c63"
      unitRef="usd">2200000000</icui:TotalSeniorSecuredCreditFacility>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjYzNQ_70b789ec-417c-466e-9362-6aa986be76ba"
      unitRef="usd">850000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY2Nw_c7f78926-a18e-426b-871f-1296a17ac949"
      unitRef="usd">850000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idc72f3e18557464b95e8f93f95cf00e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY1MQ_9ac2200d-b6d6-4eae-9512-a27abcf0830a"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <icui:RevolverSubLimits
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY4Mw_37e24f20-adee-4dc6-a77b-618fbf0a88ec"
      unitRef="usd">50000000</icui:RevolverSubLimits>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjY5OA_5ebde36d-70c0-4961-a6c9-2f901ac38b68"
      unitRef="usd">37800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcxMw_4d76931a-5668-4d9e-acc1-5268393b6e7a"
      unitRef="usd">15800000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcyNw_ce01433d-693e-4ce6-b53d-6fa527c98b50"
      unitRef="usd">13400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="idc72f3e18557464b95e8f93f95cf00e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzA0Nw_40d3c5ba-d0c1-4835-9dac-565d2f0ff219"
      unitRef="usd">8600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjcyOQ_24dfb1fc-29b8-42b3-a8ea-b65683a05597"
      unitRef="usd">834200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc0NQ_bffc6585-c737-4487-83f8-c1772b4629bb"
      unitRef="usd">836600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg0MQ_6ab5f223-a2b6-4ddc-a922-a32cbcb4c387">2027-01-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg0Mw_97f9796d-6195-4c0c-b3d4-afb498b507ab">2029-01-06</us-gaap:DebtInstrumentMaturityDate>
    <icui:InterestPercentageAddedToFederalFundsRate
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg2MA_23a4ec75-c1b7-4f91-9ef7-22546125e99f"
      unitRef="number">0.0050</icui:InterestPercentageAddedToFederalFundsRate>
    <icui:InterestPercentageAddedToBaseRate
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg2Nw_0b84d350-5866-4ff1-b7ad-97a31990daab"
      unitRef="number">0.0100</icui:InterestPercentageAddedToBaseRate>
    <icui:TerSOFRInterestRateAdjustmentForBaseRateLoans
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg4OA_7226d2d2-5f71-4020-89f7-b4bf81c8bddc"
      unitRef="number">0.0010</icui:TerSOFRInterestRateAdjustmentForBaseRateLoans>
    <icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans
      contextRef="ic71707c2dff14fa99b1f7a37aa00d176_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg3NA_101b3b64-8080-4e80-8958-650c230f2fe3"
      unitRef="number">0.0010</icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans>
    <icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans
      contextRef="i455063291da94c4e933985b9ba288cce_I20221231"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg4MQ_6df09948-d6c7-43f2-98d4-4d7bbc1f383c"
      unitRef="number">0.0025</icui:TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjg5NQ_b3291a03-c6e9-4d99-b352-e0657201744e"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkwOQ_622dce24-eddc-4703-b0b3-1ef241df8b72"
      unitRef="number">0.0075</icui:ApplicableMarginBaseRateLoans>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkwMg_68f6a8b3-e4f7-40db-ad8c-a35b829731cc"
      unitRef="number">0.0175</icui:ApplicableMarginTermSOFRLoans>
    <icui:InterestMarginandCommitmentFeeTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2MA_f52d4a2a-ef47-468e-88e2-8de0dfdc68e7">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Term SOFR Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Commitment Fee Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than 4.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than or equal to 2.00 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</icui:InterestMarginandCommitmentFeeTableTextBlock>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="i3512d069dc6a415ebe18d0c8a10b509a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMS0xLTEtMTEwNDIz_46c49e8c-fd92-490e-bb3f-cf55654a4e75"
      unitRef="number">0.0225</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="i3512d069dc6a415ebe18d0c8a10b509a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMi0xLTEtMTEwNDIz_73f335df-599f-4701-a2ed-35ada0ac02dc"
      unitRef="number">0.0125</icui:ApplicableMarginBaseRateLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i85c800885ad645afbf1ee8116a89418e_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzEtMy0xLTEtMTEwNDIz_ef619792-4c68-4327-bbe0-a8216c3eb7c9"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="ifcafc35b7a454888b107f59bd07d6378_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMS0xLTEtMTEwNDIz_97004f00-7f9f-49be-8ecf-9d0083ed4ec2"
      unitRef="number">0.0200</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="ifcafc35b7a454888b107f59bd07d6378_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMi0xLTEtMTEwNDIz_833e1bfa-13ef-44a7-93d9-9f1b68069fda"
      unitRef="number">0.0100</icui:ApplicableMarginBaseRateLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3270e97d056d47e8942bc86735a9953e_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzItMy0xLTEtMTEwNDIz_f5c5567a-23e7-4d17-99e5-3a21036c9c18"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="i561277523fc640f3a0134d32b5168980_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMS0xLTEtMTEwNDIz_2c0067d7-09a8-4aeb-ab57-d6c6f33509a7"
      unitRef="number">0.0175</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="i561277523fc640f3a0134d32b5168980_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMi0xLTEtMTEwNDIz_1ff90697-799c-41e7-92b6-6944648b6321"
      unitRef="number">0.0075</icui:ApplicableMarginBaseRateLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3cba9d0dc8fe4d66bbb43d02faad4c58_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzMtMy0xLTEtMTEwNDIz_3433cc69-0410-4c6a-ac2d-fe546974ba48"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="i732e1f9dac654f7d8f641f5c8da76012_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMS0xLTEtMTEwNDIz_d7716f2f-e0c8-4b66-aa64-1faf75141579"
      unitRef="number">0.0150</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="i732e1f9dac654f7d8f641f5c8da76012_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMi0xLTEtMTEwNDIz_f79d42a1-aca9-49a0-804c-628ed97acca2"
      unitRef="number">0.0050</icui:ApplicableMarginBaseRateLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i940aefe82dbf46ca9e966ea0b26dd508_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzQtMy0xLTEtMTEwNDIz_36dae88d-7100-4e8d-84fb-665b16139e18"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="ie1c38a7e4a4342929faf1d4648044fa0_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMS0xLTEtMTEwNDIz_0f4aa7b5-a50d-48ef-960c-6c677e2f9a35"
      unitRef="number">0.0125</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="ie1c38a7e4a4342929faf1d4648044fa0_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMi0xLTEtMTEwNDIz_6d029f76-e48a-4d66-a751-040d265e4794"
      unitRef="number">0.0025</icui:ApplicableMarginBaseRateLoans>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3e4c6ec34d394489821d50e1ab61b2a5_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiYzg0OWZhNWU0Y2M0NWM2YTEzOTRkOThiMDQ5MDhlZS90YWJsZXJhbmdlOmJjODQ5ZmE1ZTRjYzQ1YzZhMTM5NGQ5OGIwNDkwOGVlXzUtMy0xLTEtMTEwNDIz_30b49295-6119-4dfa-8b37-658f7c43f6ba"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkxNg_7d053697-6fff-418f-bea0-df3b3520afe7"
      unitRef="number">0.015</icui:ApplicableMarginBaseRateLoans>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkyMg_a16ebd55-51f5-4859-83f6-67a7c80d5793"
      unitRef="number">0.025</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginOnLoanTypeTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2MQ_b46b9741-042c-4bc2-8d5a-d5845909b77f">Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ended June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Term SOFR Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Applicable Margin for Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than 2.75 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 2.75 to 1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</icui:ApplicableMarginOnLoanTypeTableTextBlock>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="id34fa01e4d2b483792e00d21e1d5819a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzEtMS0xLTEtMTEwNDY4_fcd73493-5900-48b6-a97a-c1354ea8b76d"
      unitRef="number">0.0250</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="id34fa01e4d2b483792e00d21e1d5819a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzEtMi0xLTEtMTEwNDY4_ef9b3c85-6b1a-415d-88e2-06c32a37fff4"
      unitRef="number">0.0150</icui:ApplicableMarginBaseRateLoans>
    <icui:ApplicableMarginTermSOFRLoans
      contextRef="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzItMS0xLTEtMTEwNDY4_1222c2f2-c892-4431-bf7f-16b60f5c611c"
      unitRef="number">0.0225</icui:ApplicableMarginTermSOFRLoans>
    <icui:ApplicableMarginBaseRateLoans
      contextRef="id27abd439a6d4e6bafb3e3b1cd8bfecc_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo2ZTVmNjI5ZTkwY2M0MTg2YThkMzBjOTcxMTY1Y2VhNS90YWJsZXJhbmdlOjZlNWY2MjllOTBjYzQxODZhOGQzMGM5NzExNjVjZWE1XzItMi0xLTEtMTEwNDY4_ecf33647-50ab-4114-8113-70f01b6c3311"
      unitRef="number">0.0125</icui:ApplicableMarginBaseRateLoans>
    <icui:TermAPrincipalPaymentFirst2Years
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkyOA_6ce807d9-7ede-4658-9495-b135eb44c506"
      unitRef="number">0.0250</icui:TermAPrincipalPaymentFirst2Years>
    <icui:TermAPrincipalPaymentYear3And4
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk0Mg_fe42fdf1-32ec-4224-86fe-7dfb31d5c402"
      unitRef="number">0.0500</icui:TermAPrincipalPaymentYear3And4>
    <icui:TermAPrincipalPaymentInYear5
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjkzNQ_fa57315d-0b8f-496b-a696-c60991356180"
      unitRef="number">0.0750</icui:TermAPrincipalPaymentInYear5>
    <icui:TermLoanBPrincipalPayment
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk0OQ_88232e6f-2cd8-49ca-a2fd-03e48c63747b"
      unitRef="number">0.0025</icui:TermLoanBPrincipalPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjgxMg_49db7514-a0ca-43fb-9720-18580153790a"
      unitRef="usd">16000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjgyNw_4650de60-5037-451e-a4ed-8b2047423c76"
      unitRef="usd">22400000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <icui:LeverageRatioCalculationCeilingSubtractedAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk1Ng_5886b21c-bf52-4f27-8854-65a3bffe614f"
      unitRef="usd">500000000</icui:LeverageRatioCalculationCeilingSubtractedAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc5Ng_0d6855bd-7d0f-4350-927c-295c83475ec3"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjk4Nw_440c5f8f-c2cf-443c-a8ad-8c3ab4eba84d">2022-11-08</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNzAwNA_34cc0a5d-7240-40a2-a9e3-a5d5c727550b"
      unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Mg_7e1ad3eb-eac3-4a88-8636-34ca02ae6a12">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our long-term debt consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan B &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolving Credit Facility &#x2014; principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less unamortized debt issuance costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprised of $12.6&#160;million and $11.7&#160;million relating to the Term Loan A and the Term Loan B, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i130a2d00bf034aef9f018ca756cd3010_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzMtMS0xLTEtMTEwNDI4_5c0ea1e4-842e-494d-bc1d-a6908ab554cc"
      unitRef="number">0.0399</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzMtMy0xLTEtMTEwNDI1_8ab60aca-4d27-4a19-8ec8-e9a211acea08"
      unitRef="usd">834000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i1004d176af62419091ab2d1c1f8649a7_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzQtMS0xLTEtMTEwNDI4_519d7c71-1d38-4ff1-a716-600a58caa4f4"
      unitRef="number">0.0461</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzQtMy0xLTEtMTEwNDI1_4145f227-f3cd-4207-94eb-09119f2318af"
      unitRef="usd">843625000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i96000b832d5e4e13bd5d06c79eee6056_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzUtMS0xLTEtMTEwNDI4_0516ce8e-78ad-4f63-b06d-ddf83a8d76c9"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzUtMy0xLTEtMTEwNDI1_badb2ce4-140e-4c67-849e-bb481acd5f64"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzYtMy0xLTEtMTEwNDI1_3d425739-1be4-4107-acc9-ffe6515975f3"
      unitRef="usd">-24262000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzctMy0xLTEtMTEwNDI1_b28502af-6de0-40a2-bcb0-34e4972bed8c"
      unitRef="usd">1653363000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzgtMy0xLTEtMTEwNDI1_dd1b0afa-cb8f-480c-b2e9-76546843e3d5"
      unitRef="usd">29688000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTpiM2UyMWQzNDg5MmQ0YzA5YmRhZDA0OGE4YWU2ZWYyZi90YWJsZXJhbmdlOmIzZTIxZDM0ODkyZDRjMDliZGFkMDQ4YThhZTZlZjJmXzktMy0xLTEtMTEwNDI1_3f7d0eaa-7d8b-4006-8501-728697721490"
      unitRef="usd">1623675000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if3e83c70755646978896ceeb0d4640fc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Ng_9db97635-c4a9-4f14-a235-fd995819056f"
      unitRef="usd">12600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i04e492dc437f484fa3e50ad7d36f77eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc4MQ_5f77ff67-0cbf-45cd-9852-edb596a33991"
      unitRef="usd">11700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2Mw_49e14b38-ee44-4fd4-a756-28ee1fb4ff3e">As of December 31 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzAtMi0xLTEtMTEwNDQz_2e144102-e199-4a84-8bb1-4dabf7081cb7"
      unitRef="usd">29688000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzEtMi0xLTEtMTEwNDQz_88b46a8c-71b2-4cbb-8e51-c71ce1c4fa72"
      unitRef="usd">51000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzItMi0xLTEtMTEwNDQz_7e01014a-41b2-4ba6-8f3e-58b06291e06e"
      unitRef="usd">51000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzMtMi0xLTEtMTEwNDQz_c4a7fd38-5b3f-4f79-9937-8bcfacb63aaa"
      unitRef="usd">72250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzQtMi0xLTEtMTEwNDQz_57004413-0fcb-4135-8859-79f60e1eff8e"
      unitRef="usd">672500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzUtMi0xLTEtMTEwNDQz_691a0fb4-12bf-4aca-9868-d07ac448e4e8"
      unitRef="usd">801187000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTo1OTc4YjNiYzAwMDg0Y2QxOTgzYTlmODZkYTA1ZGQ5Yi90YWJsZXJhbmdlOjU5NzhiM2JjMDAwODRjZDE5ODNhOWY4NmRhMDVkZDliXzYtMi0xLTEtMTEwNDQz_00224689-4484-4c2b-81b0-4f12ca2256be"
      unitRef="usd">1677625000</us-gaap:DebtInstrumentCarryingAmount>
    <icui:InterestExpenseOnLongTermDebtTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90ZXh0cmVnaW9uOjliM2Q4M2Y3YTUxODQzZmM4NTFkYmU3YzFhZGJlZThmXzU0OTc1NTgzNjc2NA_38b007b5-f98f-4830-a0be-4375f2fd7dd0">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total interest expense related to our long-term debt (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitment fee &#x2014; Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt-related  interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</icui:InterestExpenseOnLongTermDebtTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItMS0xLTEtMTEwNDQ2_e8a9686f-76f3-46d7-baa9-e75baabd8518"
      unitRef="usd">66770000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItMy0xLTEtMTEwNDQ5_673fb1f5-977d-4663-ade1-b394f0c01f64"
      unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzItNS0xLTEtMTEwNDUx_c0ae9ff0-9ec2-41a0-9116-8402cf83127f"
      unitRef="usd">1251000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtMS0xLTEtMTEwNDQ2_545dd4d3-e063-4e8f-b25f-ac3863401303"
      unitRef="usd">6972000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtMy0xLTEtMTEwNDQ5_0026fc02-99cb-43c4-a10a-1a09ae25a75c"
      unitRef="usd">240000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzMtNS0xLTEtMTEwNDUx_b2ea3a1f-f30b-4d12-b742-6148b82440f5"
      unitRef="usd">288000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtMS0xLTEtMTEwNDQ2_b1b94114-d29a-4441-b3b6-6cfdb8ef3f0a"
      unitRef="usd">1290000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtMy0xLTEtMTEwNDQ5_042f8fde-3fd2-49dd-90ba-c4a5a02fbbcf"
      unitRef="usd">221000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzQtNS0xLTEtMTEwNDUx_9b6b270f-c99f-42ce-9a20-d8b89088da82"
      unitRef="usd">110000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtMS0xLTEtMTEwNDQ2_6d623337-1e89-4106-8c00-a5d3fb7a818c"
      unitRef="usd">75032000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtMy0xLTEtMTEwNDQ5_fa1fd633-f439-4a78-901a-dd8e3b79d392"
      unitRef="usd">461000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDMvZnJhZzo5YjNkODNmN2E1MTg0M2ZjODUxZGJlN2MxYWRiZWU4Zi90YWJsZTowZjM3OWFmNDMxN2M0NTRjODk3NGIzOGZiZDU3Mjg3Yi90YWJsZXJhbmdlOjBmMzc5YWY0MzE3YzQ1NGM4OTc0YjM4ZmJkNTcyODdiXzUtNS0xLTEtMTEwNDUx_45486513-bfa7-4e92-911f-73e423e131fa"
      unitRef="usd">1649000</us-gaap:InterestExpenseDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDg_d803a75d-88a8-481c-a6ac-2d54ad3eef9a">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accrued for tax contingencies for potential tax assessments, and in 2022 we recognized a $2.0 million net increase, most of which related to various federal, state and foreign tax reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at the expected statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income tax differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits in 2022, 2021 and 2020 consist principally of research and developmental tax credits.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred income tax assets (liabilities) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired future tax deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 163(j)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, customer concessions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 481(a) adjustment - change in accounting method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-31.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax (liability) asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Holidays and Carryforwards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss ("NOL") carryforwards consist of: (a) federal NOL carryforwards of $1.9 million which will expire at various dates from 2023 to indefinite carryforward periods, (b) state NOL carryforwards of $4.3 million which will expire at various dates from 2026 to indefinite carryforward periods and (c) foreign NOL carryforwards of  $46.3 million which will expire at various dates from 2023 to indefinite carryforward periods. We believe that it is more likely than not that the benefit &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from certain foreign NOL carryforwards will not be realized. In recognition of this risk, we have provided a valuation allowance of $11.5&#160;million on the $12.7&#160;million DTAs related to these foreign NOL carryforwards. Under Section&#160;382 of the Internal Revenue Code, certain ownership changes limit the utilization of the NOL carryforwards, and the amount of federal NOL carryforwards recorded is the net federal benefit available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other carryforwards include state research and development (&#x201c;R&amp;amp;D&#x201d;) tax credit carryforwards of $18.5 million, which have an indefinite carryforward period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of our manufacturing operations in Costa Rica operate under various tax holiday and tax incentive programs due to expire in whole or in part in 2029. Certain of the holidays may be extended if specific conditions are met. The net impact of these tax holiday and tax incentives was an increase to our net earnings by $8.1 million or $0.34 per diluted share in 2022 and by $9.8 million or $0.45 per diluted share in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments, and related tax effects, are an element of &#x201c;other comprehensive income&#x201d; and are not included in net income other than the revaluation of the associated deferred tax asset due to the Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we have estimated $209.2 million of undistributed foreign earnings and profits. Such earnings were previously subject to U.S. tax as a result of the Tax Act and much of any future remittances would generally be subject to no U.S. tax as a result of dividends received deductions and/or foreign tax credit relief. We intend to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we incur significant additional costs upon repatriation of such amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the U.S. and various states and foreign jurisdictions. Our U.S. federal income tax returns for tax years 2019 and forward are subject to examination by the Internal Revenue Service. Our principal state income tax returns for tax years 2012 and forward are subject to examination by the state tax authorities. The total gross amount of unrecognized tax benefits as of December&#160;31, 2022 was $54.1 million which, if recognized, would impact the effective tax rate.  We believe that adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax examinations cannot be predicted with certainty. As of December 31, 2022, it is reasonably possible that the expiration of the U.S. federal statute of limitations will cause the gross amount of unrecognized tax benefits to decrease by $7.8 million. It is not possible to estimate any other amount of change, if any, in the unrecognized tax benefits that is reasonably possible within the next twelve months. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We have accrued for penalties and interest of $2.3&#160;million and $2.2&#160;million, respectively as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDk_72eaae84-d148-4e89-9d3f-99de20a2c41a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItMi0xLTEtOTI3MTg_6bf5be7a-0288-44cc-aee6-ad6779789053"
      unitRef="usd">-135646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItNC0xLTEtOTI3MTg_f7b9eee2-89a8-473f-b3e4-8d3e003a226c"
      unitRef="usd">81484000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzItNi0xLTEtOTI3MTg_f176c54e-13c7-4abd-9dd4-a223b92c0cde"
      unitRef="usd">41194000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtMi0xLTEtOTI3MTg_951e8088-0571-40b1-a1fd-2be87414519d"
      unitRef="usd">21237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtNC0xLTEtOTI3MTg_3c6ca2f2-19ff-474e-8887-c266ed244974"
      unitRef="usd">41702000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzMtNi0xLTEtOTI3MTg_e23ae715-d96e-4930-a487-b84abb71b19c"
      unitRef="usd">56300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtMi0xLTEtOTI3MTg_a3a9adec-449d-4124-af14-c7ac667a6753"
      unitRef="usd">-114409000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtNC0xLTEtOTI3MTg_15292b1a-5372-4a99-9f2b-239660c150b9"
      unitRef="usd">123186000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozYTY5ZmRmODBmN2U0MzdiYTY5N2Y5ZTM5Zjk3Y2Y4YS90YWJsZXJhbmdlOjNhNjlmZGY4MGY3ZTQzN2JhNjk3ZjllMzlmOTdjZjhhXzQtNi0xLTEtOTI3MTg_3ef1ead5-5eca-467f-8d1d-1bccd2e22e8c"
      unitRef="usd">97494000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxMjM_66dc3acf-469e-45c2-8d27-cbf2fc666981">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtMi0xLTEtOTI3MTg_3e0f0fa4-3081-46b0-8229-4a13bd580fb7"
      unitRef="usd">4128000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtNC0xLTEtOTI3MTg_132cda64-7e62-4090-91c9-7f6a79a79ee9"
      unitRef="usd">20646000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzMtNi0xLTEtOTI3MTg_695e65db-bf29-4aa0-ac3b-564b3333b603"
      unitRef="usd">6032000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtMi0xLTEtOTI3MTg_a9284721-35fb-46c6-a8eb-3efbd19920aa"
      unitRef="usd">3799000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtNC0xLTEtOTI3MTg_592f4d75-e930-4628-9202-2dcb2f8762c6"
      unitRef="usd">3444000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzQtNi0xLTEtOTI3MTg_ab2b4c85-6b4b-4845-868c-c36476720017"
      unitRef="usd">2422000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtMi0xLTEtOTI3MTg_d2605a6e-55e7-43fd-84d4-6bf024750d29"
      unitRef="usd">12924000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtNC0xLTEtOTI3MTg_21ff9cfe-3893-403c-98ed-24c0ceadc338"
      unitRef="usd">7236000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzUtNi0xLTEtOTI3MTg_10ccb575-f5ea-40bd-96b2-1138adb03cb1"
      unitRef="usd">7290000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtMi0xLTEtOTI3MTg_befcd6cb-34eb-402a-9d0a-9bb884102b4f"
      unitRef="usd">20851000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtNC0xLTEtOTI3MTg_648b9d15-0f07-4e52-873f-d96385ab68cf"
      unitRef="usd">31326000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzYtNi0xLTEtOTI3MTg_f3e9cd83-a776-4f29-b9d7-8572bc445a09"
      unitRef="usd">15744000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtMi0xLTEtOTI3MTg_8d254729-04fe-4b7c-a2e4-41abbe480e4a"
      unitRef="usd">-42012000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtNC0xLTEtOTI3MTg_2c14d985-bbb4-4a65-9335-13a86cac399f"
      unitRef="usd">-8154000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzgtNi0xLTEtOTI3MTg_ccd6ab97-536f-42f8-86eb-cd4615de6dbd"
      unitRef="usd">-5319000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktMi0xLTEtOTI3MTg_ce471bde-a3e9-491e-a36f-5412817cab28"
      unitRef="usd">-11239000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktNC0xLTEtOTI3MTg_800591c4-31b2-4b3d-9b39-d47178c272f9"
      unitRef="usd">-1815000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzktNi0xLTEtOTI3MTg_7def941f-6f56-4790-a27d-ee72880bd7be"
      unitRef="usd">-1850000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTItMS0xLTkyNzE4_3fd2a395-1b0e-40cc-8a7b-672e7fcd4d8f"
      unitRef="usd">-7723000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTQtMS0xLTkyNzE4_efc40317-d493-4a48-8e9a-85a4d61c2e47"
      unitRef="usd">-1306000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEwLTYtMS0xLTkyNzE4_d8b697ff-0a2c-4aae-b7ca-7eaf487c2d6c"
      unitRef="usd">2049000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTItMS0xLTkyNzE4_e8592662-9a4b-482e-afd7-d3b167760f4e"
      unitRef="usd">-60974000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTQtMS0xLTkyNzE4_2e820914-35ae-4bac-85c7-8eef8e47d8ca"
      unitRef="usd">-11275000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzExLTYtMS0xLTkyNzE4_add3e1a9-9151-4ff1-abae-d28a9f221ba6"
      unitRef="usd">-5120000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTItMS0xLTkyNzE4_ee5e4661-b205-4fb3-9f88-59d6455b53b3"
      unitRef="usd">-40123000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTQtMS0xLTkyNzE4_92170c04-21f5-4ea8-b0e0-e3b58d8fe4dc"
      unitRef="usd">20051000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTowN2Y3MWE4ODhmZDA0YmE5OWQ4YjFiNGUxNTEzZjg4ZS90YWJsZXJhbmdlOjA3ZjcxYTg4OGZkMDRiYTk5ZDhiMWI0ZTE1MTNmODhlXzEyLTYtMS0xLTkyNzE4_6c2e4903-c4ab-4aa7-8089-c01d56664fc7"
      unitRef="usd">10624000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzMwNg_2dd8b9b2-dcae-43c5-ad18-f4215af53cf4"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNDM_d759da95-734e-478b-b68b-e751f17ee8ab">A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at the expected statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income tax differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMi0xLTEtOTI3MTg_15dde096-90bd-4d4a-8589-579e1058fba0"
      unitRef="usd">-24026000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtNC0xLTEtOTI3MTg_8a49c9a9-9b80-407b-92c0-327ce99892d5"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtNi0xLTEtOTI3MTg_d9cba88b-a313-4ee2-bb45-802e54e457c4"
      unitRef="usd">25869000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtOC0xLTEtOTI3MTg_ae40b8a1-2f8f-4efe-88ad-2fb1201aab4e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMTAtMS0xLTkyNzE4_66ff754b-5261-43b2-a519-643a5cac7af0"
      unitRef="usd">20474000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzMtMTItMS0xLTkyNzE4_a885c96e-7b57-45ae-b6c7-375a1795fa02"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMi0xLTEtOTI3MTg_d2b165f2-190e-4585-a85b-ece4cb185e09"
      unitRef="usd">-5050000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtNC0xLTEtOTI3MTg_f1b8eab8-40e4-402f-ba44-baa9dbfad180"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtNi0xLTEtOTI3MTg_2c8c753a-1259-4a72-bf59-cb39a65f6747"
      unitRef="usd">2907000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtOC0xLTEtOTI3MTg_2779603e-a7f5-46b5-882f-cad4f31575e5"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMTAtMS0xLTkyNzE4_51399d35-adea-4b2e-aca4-e5a973301588"
      unitRef="usd">2099000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzQtMTItMS0xLTkyNzE4_8b08177b-f7b8-4305-8c51-b9572f79fc3f"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMi0xLTEtOTI3MTg_c5c1942b-d439-46ad-8554-50de6b251132"
      unitRef="usd">3636000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtNC0xLTEtOTI3MTg_b2ece893-0c86-4268-a802-106aba610030"
      unitRef="number">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtNi0xLTEtOTI3MTg_06a5876a-73b6-43a2-8060-bb4084e06be8"
      unitRef="usd">2443000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtOC0xLTEtOTI3MTg_9c052af4-feaf-46b9-be10-79603131e7db"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMTAtMS0xLTkyNzE4_8210d288-6a62-47a4-85e0-846f41d316b6"
      unitRef="usd">3269000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzUtMTItMS0xLTkyNzE4_5523b9d8-56c5-454c-b5b4-509b33ee2965"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <icui:GILTItaxexpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMi0xLTEtOTI3MTg_43865e70-590b-4290-b0e7-87c0d07f7e7c"
      unitRef="usd">2303000</icui:GILTItaxexpense>
    <icui:GILTItaxexpensepercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctNC0xLTEtOTI3MTg_cf8004bf-28c2-4cae-a135-dd164c3c7ad8"
      unitRef="number">-0.020</icui:GILTItaxexpensepercent>
    <icui:GILTItaxexpense
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctNi0xLTEtOTI3MTg_fac6792f-e178-487f-b0dc-c87ad9896b77"
      unitRef="usd">711000</icui:GILTItaxexpense>
    <icui:GILTItaxexpensepercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctOC0xLTEtOTI3MTg_bc7dfe9f-3f0a-44da-811e-7725654fc77d"
      unitRef="number">0.006</icui:GILTItaxexpensepercent>
    <icui:GILTItaxexpense
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMTAtMS0xLTkyNzE4_eed3277c-c147-490a-9591-52538b005609"
      unitRef="usd">163000</icui:GILTItaxexpense>
    <icui:GILTItaxexpensepercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzctMTItMS0xLTkyNzE4_aaa58d2e-da0c-4b01-91cf-66019a760eb9"
      unitRef="number">0.002</icui:GILTItaxexpensepercent>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMi0xLTEtOTI3MTg_b4fae609-818d-43e6-8539-6e148ceff3c2"
      unitRef="usd">-2943000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtNC0xLTEtOTI3MTg_5e2b393d-7e88-48ce-8885-6e0f2fc3a97e"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtNi0xLTEtOTI3MTg_6dd1cc59-54db-442d-88d4-2d2224969f3b"
      unitRef="usd">-2983000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtOC0xLTEtOTI3MTg_1dea2b20-c880-4c32-a6f9-c69e14f49a96"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMTAtMS0xLTkyNzE4_121a06bf-2f5a-4095-8d5e-23bfd20f6fd3"
      unitRef="usd">-3888000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzgtMTItMS0xLTkyNzE4_477d08f1-9137-4fc0-b5e4-c8e437a131f2"
      unitRef="number">-0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMi0xLTEtOTI3MTg_be90a980-2fa4-40e0-97bf-0960785d9a0d"
      unitRef="usd">-3721000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktNC0xLTEtOTI3MTg_e5023201-0941-4f16-a401-cc9d1852029f"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktNi0xLTEtOTI3MTg_530b2125-05b9-418a-b635-843019388039"
      unitRef="usd">-4263000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktOC0xLTEtOTI3MTg_32753846-def4-4799-8fe2-9805c387fd9d"
      unitRef="number">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMTAtMS0xLTkyNzE4_b56666e4-9ff8-4dcc-947c-3f1c41b768a7"
      unitRef="usd">-4686000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzktMTItMS0xLTkyNzE4_5458a512-9008-4d4e-8edd-46121b2d95a9"
      unitRef="number">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTItMS0xLTkyNzE4_4248f74e-8dd0-49dc-b75f-45eb04ab180c"
      unitRef="usd">-2269000</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTQtMS0xLTkyNzE4_5c7cc4a9-09d5-4b17-a96f-2680eb4fb2fe"
      unitRef="number">0.020</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTYtMS0xLTkyNzE4_072ac430-953d-4d9d-b08c-a2ec58293c45"
      unitRef="usd">-3775000</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTgtMS0xLTkyNzE4_554c6992-f15f-43f9-844d-dadc1377ff63"
      unitRef="number">-0.031</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTEwLTEtMS05MjcxOA_b7c9082c-1f94-47ba-b582-f081feca282b"
      unitRef="usd">-2718000</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome>
    <icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEwLTEyLTEtMS05MjcxOA_be5d00c0-5316-46ab-8d3c-8e100718c7c9"
      unitRef="number">-0.028</icui:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <icui:EffectiveIncomeTaxRateReconciliationTransactionCost
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTItMS0xLTkyNzE4_9044215f-a096-4334-a5a6-a5b23f2ec416"
      unitRef="usd">2299000</icui:EffectiveIncomeTaxRateReconciliationTransactionCost>
    <icui:EffectiveTaxRateReconcilationTransactionCostPercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTQtMS0xLTkyNzE4_fc8a564b-1088-40e1-ba05-e5bcc0a390f8"
      unitRef="number">-0.020</icui:EffectiveTaxRateReconcilationTransactionCostPercent>
    <icui:EffectiveIncomeTaxRateReconciliationTransactionCost
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTYtMS0xLTkyNzE4_f7c81905-3045-472c-bdf6-380c6f935d1c"
      unitRef="usd">0</icui:EffectiveIncomeTaxRateReconciliationTransactionCost>
    <icui:EffectiveTaxRateReconcilationTransactionCostPercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTgtMS0xLTkyNzE4_ca328dfa-5c14-459e-9cad-0f1e8094ec65"
      unitRef="number">0</icui:EffectiveTaxRateReconcilationTransactionCostPercent>
    <icui:EffectiveIncomeTaxRateReconciliationTransactionCost
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTEwLTEtMS05MjcxOA_c464cc9c-4595-4530-bac3-fefb5c650784"
      unitRef="usd">0</icui:EffectiveIncomeTaxRateReconciliationTransactionCost>
    <icui:EffectiveTaxRateReconcilationTransactionCostPercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzExLTEyLTEtMS05MjcxOA_749fc071-ec89-4059-97af-b446041611cb"
      unitRef="number">0</icui:EffectiveTaxRateReconcilationTransactionCostPercent>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsideration
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTItMS0xLTkyNzE4_610e3df8-4e45-41fc-9ceb-41e534283bbf"
      unitRef="usd">6830000</icui:EffectiveIncomeTaxRateReconciliationContingentConsideration>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTQtMS0xLTkyNzE4_951f903a-04c4-4e3a-856c-c9a131efaf02"
      unitRef="number">0.060</icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsideration
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTYtMS0xLTkyNzE4_a9d492f1-7e2c-45b9-b8da-d3dd7450eff4"
      unitRef="usd">29000</icui:EffectiveIncomeTaxRateReconciliationContingentConsideration>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTgtMS0xLTkyNzE4_d9c7f255-769e-4de5-b5ee-3f06c867f779"
      unitRef="number">0</icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsideration
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTEwLTEtMS05MjcxOA_2714b449-2608-4e66-b71e-f0403ac21831"
      unitRef="usd">-1566000</icui:EffectiveIncomeTaxRateReconciliationContingentConsideration>
    <icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEyLTEyLTEtMS05MjcxOA_1de7f453-26c2-43f5-ba79-bcd72af43bd7"
      unitRef="number">0.016</icui:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent>
    <icui:Effectiveincometaxreconciliationnondeductiblecompensation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTItMS0xLTkyNzE4_a35477e3-9f00-4a00-b63d-3cc41e83e377"
      unitRef="usd">3942000</icui:Effectiveincometaxreconciliationnondeductiblecompensation>
    <icui:Effectivetaxratereconciliationnondeductiblecomppercent
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTQtMS0xLTkyNzE4_580382c6-8d52-4b5f-a8d1-e1834f462dc5"
      unitRef="number">-0.034</icui:Effectivetaxratereconciliationnondeductiblecomppercent>
    <icui:Effectiveincometaxreconciliationnondeductiblecompensation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTYtMS0xLTkyNzE4_e6b5cc6e-119a-44cc-9027-a9a9f1936503"
      unitRef="usd">1812000</icui:Effectiveincometaxreconciliationnondeductiblecompensation>
    <icui:Effectivetaxratereconciliationnondeductiblecomppercent
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTgtMS0xLTkyNzE4_9b9ec65b-0889-49be-85a3-f60a35a6ced5"
      unitRef="number">0.015</icui:Effectivetaxratereconciliationnondeductiblecomppercent>
    <icui:Effectiveincometaxreconciliationnondeductiblecompensation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTEwLTEtMS05MjcxOA_605e2577-238f-4e5f-9d92-40c9fd3a08d2"
      unitRef="usd">1079000</icui:Effectiveincometaxreconciliationnondeductiblecompensation>
    <icui:Effectivetaxratereconciliationnondeductiblecomppercent
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzEzLTEyLTEtMS05MjcxOA_762c6d45-a4cf-47fa-b6be-238be86d088c"
      unitRef="number">0.011</icui:Effectivetaxratereconciliationnondeductiblecomppercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTItMS0xLTkyNzE4_061ccd6a-aff8-49a0-ab3d-b34eb7517d73"
      unitRef="usd">-192000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTQtMS0xLTkyNzE4_23e4b293-dda1-46fc-942c-731d78ce7a83"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTYtMS0xLTkyNzE4_f29fe840-961d-47b3-8fca-d2b347c7f7ae"
      unitRef="usd">2245000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTgtMS0xLTkyNzE4_a6fbd8d3-94d3-4c8c-aad0-081d622ec39a"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTEwLTEtMS05MjcxOA_68480443-253b-428c-b83d-b7b9decf1775"
      unitRef="usd">-196000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE0LTEyLTEtMS05MjcxOA_38fcd061-a057-4521-b27b-bce1b8fde168"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTItMS0xLTkyNzE4_0f31423b-32f9-489c-9c1d-00dca92510aa"
      unitRef="usd">-40123000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTQtMS0xLTkyNzE4_bb548354-9a3a-4ff7-a8ea-49714357a29d"
      unitRef="number">0.351</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTYtMS0xLTkyNzE4_306454f6-d9ce-45c2-84ce-d744075863a2"
      unitRef="usd">20051000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTgtMS0xLTkyNzE4_65635aab-29df-4155-b0d7-3c17e20993fd"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTEwLTEtMS05MjcxOA_155bfcd5-481c-4ae9-9ab2-954d0b780fcf"
      unitRef="usd">10624000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTphZjAwZjZjODJiNjU0Zjc2YWNkOTUwZmNkZjY3NzJlNy90YWJsZXJhbmdlOmFmMDBmNmM4MmI2NTRmNzZhY2Q5NTBmY2RmNjc3MmU3XzE1LTEyLTEtMS05MjcxOA_aa46bff1-923b-41cf-9009-dd1e601e80a4"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxMjY_ea8bad57-8763-4773-ab9a-20eb4f03c5c4">&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred income tax assets (liabilities) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired future tax deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 163(j)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chargebacks, discounts, customer concessions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 481(a) adjustment - change in accounting method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-31.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax (liability) asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzUtMi0xLTEtOTI3MTg_32391a23-a5f8-4104-a7ed-cde55742be37"
      unitRef="usd">17351000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzUtNC0xLTEtOTI3MTg_1484a756-b54a-4690-922b-4d08356660a2"
      unitRef="usd">7796000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzktMi0xLTEtOTI3MTg_0f37dec5-6dce-40e1-a6a2-c440f82cc0ac"
      unitRef="usd">14186000</icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions>
    <icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzktNC0xLTEtOTI3MTg_f92a4b9c-367d-4e02-a017-9daee4e85b51"
      unitRef="usd">5440000</icui:Noncurrentdeferredtaxassetacquiredfuturetaxdeductions>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEwLTItMS0xLTkyNzE4_5d15d0e7-e8a7-4a92-a755-743b74450659"
      unitRef="usd">6240000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEwLTQtMS0xLTkyNzE4_7286aeb6-61dd-49a2-9b0d-28ae4b0e76db"
      unitRef="usd">7283000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzExLTItMS0xLTkyNzE4_2366225d-e016-4ae5-9e0e-4ecc699a6b95"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzExLTQtMS0xLTkyNzE4_84a5496f-423e-427d-85eb-55e12c54a0f6"
      unitRef="usd">3360000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <icui:NoncurrentDeferredTaxAssetTaxCreditsState
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEyLTItMS0xLTkyNzE4_8f97e691-5be2-4e38-9f60-dba39f407ede"
      unitRef="usd">12906000</icui:NoncurrentDeferredTaxAssetTaxCreditsState>
    <icui:NoncurrentDeferredTaxAssetTaxCreditsState
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzEyLTQtMS0xLTkyNzE4_7b087f98-8bda-4ef9-b577-333621a5117b"
      unitRef="usd">11953000</icui:NoncurrentDeferredTaxAssetTaxCreditsState>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE0LTItMS0xLTkyNzE4_c190268f-1bc7-411b-a859-24c88c477f27"
      unitRef="usd">25100000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE0LTQtMS0xLTkyNzE4_70c7afc3-8b4f-413a-9046-02c0c922aa06"
      unitRef="usd">8199000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE1LTItMS0xLTEwODg5NQ_09e606b0-7374-4581-a3a3-8759a330fc86"
      unitRef="usd">13241000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE1LTQtMS0xLTEwODkwMw_7dd4fbb4-6b93-440a-a955-51ccf2aebcc1"
      unitRef="usd">127000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <icui:DeferredTaxAssetSection163j
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE2LTItMS0xLTEwODkxMQ_5522db2d-9d55-4efc-8e3a-a1ce09487cff"
      unitRef="usd">9166000</icui:DeferredTaxAssetSection163j>
    <icui:DeferredTaxAssetSection163j
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE2LTQtMS0xLTEwODkxOQ_67f5b7b7-2c2e-4f4b-8d89-611e211af374"
      unitRef="usd">0</icui:DeferredTaxAssetSection163j>
    <icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE3LTItMS0xLTkyNzE4_436259b4-125f-4732-b9b6-0f355d02c660"
      unitRef="usd">39508000</icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions>
    <icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE3LTQtMS0xLTkyNzE4_f4b50fa3-e00b-4ba9-99ce-531f67aabf37"
      unitRef="usd">27970000</icui:Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7925517a758c4a05a8e9da61378b7c92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE4LTItMS0xLTkyNzE4_0bea6634-55cb-43f4-9bff-0c3288f93f8c"
      unitRef="usd">11166000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i21add1fa1ada4b32b6d02a6ea8f53beb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE4LTQtMS0xLTkyNzE4_48439bd4-2304-4595-a588-809568c7da7e"
      unitRef="usd">2934000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <icui:Noncurrentdeferredtaxasset
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE5LTItMS0xLTkyNzE4_e7ab84db-434d-4fc8-ab1a-304a762d086c"
      unitRef="usd">126532000</icui:Noncurrentdeferredtaxasset>
    <icui:Noncurrentdeferredtaxasset
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzE5LTQtMS0xLTkyNzE4_dbd867f1-621a-4644-9429-0db36392dac0"
      unitRef="usd">69194000</icui:Noncurrentdeferredtaxasset>
    <icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes
      contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzIxLTItMS0xLTkyNzE4_df6db091-3977-400f-b890-0c42bfc0b424"
      unitRef="usd">1816000</icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes>
    <icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes
      contextRef="if184142ad50b45d9b675340cb944b665_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzIxLTQtMS0xLTkyNzE4_ceb0c2c4-24aa-4158-8921-79f991160628"
      unitRef="usd">2724000</icui:NoncurrentDeferredTaxLiabilityStateIncomeTaxes>
    <icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization
      contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI0LTItMS0xLTkyNzE4_671345b8-a617-464f-8b34-d9034d50976f"
      unitRef="usd">209687000</icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization>
    <icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization
      contextRef="if184142ad50b45d9b675340cb944b665_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI0LTQtMS0xLTkyNzE4_9b5e9c0d-c036-4691-ad30-5a70e4de220d"
      unitRef="usd">20483000</icui:NoncurrentDeferredTaxLiabilityDepreciationAndAmortization>
    <icui:Deferredtaxliabilitychangeinaccountingmethod
      contextRef="ie02d613a9e034e6baa9929b53040a7cf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI1LTItMS0xLTkyNzE4_5e64c1a5-e62e-4cef-85a9-253b122b773f"
      unitRef="usd">0</icui:Deferredtaxliabilitychangeinaccountingmethod>
    <icui:Deferredtaxliabilitychangeinaccountingmethod
      contextRef="ie4b20d6909b144f7b28ddd68e4ad46d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI1LTQtMS0xLTkyNzE4_2a677eeb-5ef6-4e03-8259-4d40ca925003"
      unitRef="usd">4873000</icui:Deferredtaxliabilitychangeinaccountingmethod>
    <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome
      contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI4LTItMS0xLTkyNzE4_5f6a120c-f8b9-411f-9f49-d927e5424b6b"
      unitRef="usd">9581000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
    <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome
      contextRef="if184142ad50b45d9b675340cb944b665_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI4LTQtMS0xLTkyNzE4_354e880d-ac11-42f9-8650-fba45237ef23"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i794337b645e5444f81f7183e04ce3f2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI5LTItMS0xLTkyNzE4_e760ae16-7197-471c-b83f-e608b77e8fee"
      unitRef="usd">221084000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if184142ad50b45d9b675340cb944b665_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzI5LTQtMS0xLTkyNzE4_1aec7ca5-9fb7-4923-98dc-778fd54e61fd"
      unitRef="usd">28080000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzMxLTItMS0xLTkyNzE4_0a06c257-ca87-4b3a-873e-12711c3f94d0"
      unitRef="usd">94552000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTozM2Y4ZjhlNjMxOTY0NGM3OTRjM2NjYWI1ODVmMTJkOC90YWJsZXJhbmdlOjMzZjhmOGU2MzE5NjQ0Yzc5NGMzY2NhYjU4NWYxMmQ4XzMxLTQtMS0xLTkyNzE4_ecf98949-f5a2-4127-9d5c-a3be7523eee7"
      unitRef="usd">41114000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic74afdfeacf44457849b250892ba31a7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzEwNjc_1d0e0647-5b59-4836-b38e-604b4aef5af9"
      unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0f12929d589749c8b6a43800619acc14_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzExODI_3f3ba9f5-3166-4f8b-a268-43acd091b5d5"
      unitRef="usd">4300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4edba33e66d94d07a0c91f5f1eff0b0f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzEzMDI_01441fc1-30a0-4648-ba04-30f6e19a076f"
      unitRef="usd">46300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE0OQ_cc4f094e-bb4e-450c-aae0-a959abac1bc9"
      unitRef="usd">11500000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE2NA_51b306dd-cf1c-470c-851f-a78c6aaac5e8"
      unitRef="usd">12700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzE2OTU_a71b90b2-396a-4856-8047-e9cdba624a5b"
      unitRef="usd">18500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIwODQ_ec3af848-881c-4a94-b4fb-7903b9b06392"
      unitRef="usd">8100000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIwOTA_4bdb6838-07dc-4aaa-8862-068e8fe3381f"
      unitRef="usdPerShare">0.34</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIxMjY_7eadabb9-2af5-4c8a-b154-64850043f55a"
      unitRef="usd">9800000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzIxMzI_78e0feab-c3ef-46b4-922b-72c94b4c88d0"
      unitRef="usdPerShare">0.45</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzI0NDE_dc960a79-e176-4b8a-924f-49821fd7561f"
      unitRef="usd">209200000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzMzOTM_98d4cd72-5492-4a43-9ce9-303d59ceb01f"
      unitRef="usd">54100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE3OQ_ab7925be-f9bb-422d-9dae-4d797ae40620"
      unitRef="usd">2300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzU0OTc1NTgxOTE5Mw_8b760f9f-1241-4ff3-b429-aefe0c370054"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90ZXh0cmVnaW9uOjk3NDI4Yjg5MzI5ZjRjZDc4MmZmMWQ2N2MzYjZlNWQwXzQxNjE_bfd63ca0-da8d-4619-9ff8-ee27c8706c9a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease related to settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItMi0xLTEtOTI3MTg_8a98b6d4-c054-4f63-ae87-d39bb2fe247e"
      unitRef="usd">21537000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItNC0xLTEtOTI3MTg_a5ef1456-9589-4851-87b2-2c0b3932b9f4"
      unitRef="usd">18443000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzItNi0xLTEtOTI3MTg_83377ac0-bc91-4437-aceb-87664fc6e37d"
      unitRef="usd">15027000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtMi0xLTEtOTI3MTg_89bfdc1e-e64f-49de-b498-38404c0d3ecb"
      unitRef="usd">148000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtNC0xLTEtOTI3MTg_8404b016-e762-4eb8-9b24-4fed8cd4369e"
      unitRef="usd">231000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzMtNi0xLTEtOTI3MTg_08bee8be-4648-4a84-9749-66d041c6eaa8"
      unitRef="usd">502000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtMi0xLTEtOTI3MTg_6a749b4f-1526-45f0-8ebf-2ee180299653"
      unitRef="usd">29606000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtNC0xLTEtOTI3MTg_b069df77-b52e-4e49-a85f-d58f29332f46"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzQtNi0xLTEtOTI3MTg_d13b98de-05c1-4640-a9a2-7d591ceffcf2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtMi0xLTEtOTI3MTg_616c69d3-f0cb-49c0-b282-e5420b201fd2"
      unitRef="usd">4706000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtNC0xLTEtOTI3MTg_9c0948ff-3d0a-4911-ae12-75e6e69a5508"
      unitRef="usd">3242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzUtNi0xLTEtOTI3MTg_83683a36-f2c7-4693-870a-3f6838c7ff91"
      unitRef="usd">2987000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctMi0xLTEtOTI3MTg_30855e4c-9850-467a-8148-27cd23857195"
      unitRef="usd">222000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctNC0xLTEtOTI3MTg_58dd0d4a-8cbd-467c-b07b-fdabadce427e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzctNi0xLTEtOTI3MTg_74092fb4-5cc7-47f0-a2fe-08b21e919111"
      unitRef="usd">15000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktMi0xLTEtOTI3MTg_af37c235-31f7-443e-abe8-b6fd473e2da6"
      unitRef="usd">1722000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktNC0xLTEtOTI3MTg_3ad9ff1e-db8f-4db5-b9e4-d1a4aaed0d89"
      unitRef="usd">31000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzktNi0xLTEtOTI3MTg_3b33cf51-1a9c-40df-afe4-737e7ad428d0"
      unitRef="usd">58000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTItMS0xLTkyNzE4_7a946afc-0773-463e-a669-8f3f63af00c3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTQtMS0xLTkyNzE4_aa207c33-a2e0-42fa-8bb7-dff9e61cd5aa"
      unitRef="usd">348000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzEwLTYtMS0xLTkyNzE4_774df7ec-c8ab-4f40-ab39-d9652691203e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTItMS0xLTkyNzE4_83ba9580-28ef-49d3-9288-b679b0ddfd10"
      unitRef="usd">54053000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTQtMS0xLTkyNzE4_612239e8-6949-4c9b-a7da-33fab9aaa81e"
      unitRef="usd">21537000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDYvZnJhZzo5NzQyOGI4OTMyOWY0Y2Q3ODJmZjFkNjdjM2I2ZTVkMC90YWJsZTplMDQ3MzdhOGY3NzM0OTRhODkzNmVhMTJjYmJlZmE4NS90YWJsZXJhbmdlOmUwNDczN2E4Zjc3MzQ5NGE4OTM2ZWExMmNiYmVmYTg1XzExLTYtMS0xLTkyNzE4_07d1e3aa-619f-4b45-88d3-9f253f7e177c"
      unitRef="usd">18443000</us-gaap:UnrecognizedTaxBenefits>
    <icui:InformationbyGeographicAreaandCustomerConcentrationTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU5Mg_0ab487b4-9883-44bd-ba72-0c6fc80e86e1">GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. In 2022, we had worldwide net sales to Medline of 15% of consolidated net sales. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other LATAM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Foreign &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</icui:InformationbyGeographicAreaandCustomerConcentrationTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iacef78c490d44ef6a148c9eb69aec7b1_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU0OTc1NTgxNDgzNQ_5c41fdfb-a2b6-4dbd-8603-f7da4b42a96a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90ZXh0cmVnaW9uOjZiNGRiMTQyNTRmOTQwZTA5ZTFhYWRlNTMwNDc1ZTVkXzU5MQ_4306648e-54c1-4db3-81d2-13545b0e07eb">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costa Rica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other LATAM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Foreign &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i0d8e28b05ab3410580b2d84dbdd0ff1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzItMi0xLTEtOTI3MTg_3cb8ebf0-dc64-49f3-bd2a-4ba0571796b8"
      unitRef="usd">128179000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7ab8e7d8411f469b8720f601291c4a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzItNC0xLTEtOTI3MTg_09638e49-3aba-4be7-87a2-d6d21397cc4e"
      unitRef="usd">115187000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id87d1ef443a94425bc7fef55aeffbb03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzMtMi0xLTEtOTI3MTg_47d00c11-62c5-4d65-9b56-06ad34ac864b"
      unitRef="usd">99849000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic28ae14b327942628ff1906d2fa400b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzMtNC0xLTEtOTI3MTg_27ebaaae-9542-4c5a-8f55-58804b0e89c3"
      unitRef="usd">79567000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if62f26db34af43bf98b7eb60c5ef5415_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzQtMi0xLTEtOTI3MTg_8a7fd5b0-b9c8-4f58-8679-a5fda464b5c5"
      unitRef="usd">39270000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if1ccbff4571344c18aff14611e8b7d41_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzQtNC0xLTEtOTI3MTg_a03e23b2-c59b-4343-bc54-be8cd5fa7a03"
      unitRef="usd">36907000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7f5cc1fca5304ed09aeff7464d1e1b88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzUtMi0xLTEtOTI3MTg_32723148-6a9f-4edc-a689-43b38ddad3c9"
      unitRef="usd">5374000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i3eb2ffbc07f548e4b7b499325d1200f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzUtNC0xLTEtOTI3MTg_d7e16a13-787c-405c-ae19-745526382a48"
      unitRef="usd">4716000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ibeed5a4cba574b72b53f8a7432ccc8cb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzYtMi0xLTEtOTI3MTg_982b8f74-5a1e-40f7-9700-5a2769a723c6"
      unitRef="usd">24323000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie430db3a6d1b4b528af030bd7dd26f8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzYtNC0xLTEtOTI3MTg_3a34f6f6-ac8f-4a84-9723-e6787d77acb1"
      unitRef="usd">12435000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i858b45f5d29a4f37939d46ac810c5f30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEwLTItMS0xLTkyNzE4_94c2ef43-f11f-442d-b9bf-7841c182a2f2"
      unitRef="usd">18948000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i07d6d0becacb4e22863dabc259d16c28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEwLTQtMS0xLTkyNzE4_a8fc5e96-3bae-4c9f-9c5a-44a8ad6ae1ea"
      unitRef="usd">13295000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i3ab060b29dc6441d9456425aa02c761d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTItMS0xLTEwNjMxMw_1cd7c137-ee10-40e7-94c4-8d6bf46cfb03"
      unitRef="usd">10732000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2962b814b7d0406e9adeda9d07ebf1f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTQtMS0xLTEwNjMyMQ_c066b404-1375-499c-a7ab-a804117778ae"
      unitRef="usd">0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia4e5eb1e1a8649b3ad0d53df35a54ddb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTItMS0xLTkyNzE4_244de794-5c66-417d-8d78-5defae20b6af"
      unitRef="usd">11375000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ica41d22848d442c7a94244fcacf01646_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzExLTQtMS0xLTkyNzE4_899be0a3-573e-4db4-aee3-4d8fa72d171f"
      unitRef="usd">4171000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ied976c6e3e0a43d5aeb99cdfef5e2e64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEyLTItMS0xLTkyNzE4_e1546fb3-2be0-4874-9a2a-22b3123fe626"
      unitRef="usd">20930000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i636799cc86f54ffb9c9c4e4c13426aa6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEyLTQtMS0xLTkyNzE4_c2a3c017-8485-49eb-8853-5a63a613798b"
      unitRef="usd">20452000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i68ba3be1285c44ab8b8349e837ac9991_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEzLTItMS0xLTkyNzE4_420a29be-f462-460c-b261-16d114fec01b"
      unitRef="usd">358980000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia7753094a85f4264af0e886e818d2987_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzEzLTQtMS0xLTkyNzE4_cb7543f4-df90-4388-a8e8-e2df31af5aec"
      unitRef="usd">286730000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i447520138d3742d59dc3a80450bc8093_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE0LTItMS0xLTkyNzE4_5b758f92-70ac-47ad-8e6d-f0f433477ed4"
      unitRef="usd">803577000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i706aa6c5c3ab47198dd4e501b7d0d5a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE0LTQtMS0xLTkyNzE4_333075d2-5bab-4828-8f77-19b22a9cad11"
      unitRef="usd">618374000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE1LTItMS0xLTkyNzE4_7bbed31b-2308-43b7-b18e-895b2325ecdb"
      unitRef="usd">1162557000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMDkvZnJhZzo2YjRkYjE0MjU0Zjk0MGUwOWUxYWFkZTUzMDQ3NWU1ZC90YWJsZTphM2E0ZmQzMzc3NTc0OGYxOTM0MGZmNjlmZTE3MTAwZi90YWJsZXJhbmdlOmEzYTRmZDMzNzc1NzQ4ZjE5MzQwZmY2OWZlMTcxMDBmXzE1LTQtMS0xLTkyNzE4_0b32b580-301a-4367-b94d-26031e15872a"
      unitRef="usd">905104000</us-gaap:NoncurrentAssets>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0OTg_e161bdbb-04c3-4391-8c2f-40c7b88f715b">STOCKHOLDERS' EQUITY&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2019, our Board of Directors approved a common stock purchase plan to purchase up to $100.0 million of our common stock. This plan has no expiration date. We have $100.0 million remaining on this purchase plan. We did not purchase any of our common stock under our common stock purchase plan in 2022, 2021 or 2020. We are limited on share purchases in accordance with the terms and conditions of our Senior Secured Credit Facilities (see Note 11: Long-Term Obligations).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we withheld 47,664 shares of our common stock from employee vested restricted stock units in consideration for $10.9 million in payments for the employees' share award income tax withholding obligations. We had 1,633 shares remaining in treasury at December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we withheld 40,350 shares of our common stock from employee vested restricted stock units in consideration for $8.3 million in payments for the employees' share award income tax withholding obligations. We had 119 shares remaining in treasury at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we withheld 67,041 shares of our common stock from employee vested restricted stock units in consideration for $12.9 million in payments for the employees' share award income tax withholding obligations. We had 209 shares remaining in treasury at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use treasury stock to issue shares for stock option exercises and restricted stock grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive (Loss) Income ("AOCI")&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI, net of tax, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0Nw_8c7e86ee-2906-4e37-86cf-f5442e355103"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzIxMw_d4950257-d96f-4734-b5e4-c85431e87dcb"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzUxNQ_a49938f1-b53b-41e6-9c02-1fda7b050f19"
      unitRef="shares">47664</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzYxMA_2c0a76c2-f203-49ec-954b-96c0f52cb0f6"
      unitRef="usd">10900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzY5OQ_554d9463-7033-441b-b318-730cdbd03b25"
      unitRef="shares">1633</us-gaap:TreasuryStockCommonShares>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzc3NQ_aa93b86f-47c0-44b7-b49e-ffa9421dc62c"
      unitRef="shares">40350</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzg3MA_063bca95-c682-49f1-a671-5491180a6edd"
      unitRef="usd">8300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2Xzk1OQ_ead47285-0013-44e7-ab20-e20aff87339b"
      unitRef="shares">119</us-gaap:TreasuryStockCommonShares>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzEwMzU_0fc1798e-397b-45af-89e5-42414e7eedaa"
      unitRef="shares">67041</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzExMzA_18af2f79-a01c-4fca-94b2-3ede8cb6362a"
      unitRef="usd">12900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzEyMTk_43fb04d5-f6d8-4733-9d26-d92ad55505e4"
      unitRef="shares">209</us-gaap:TreasuryStockCommonShares>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90ZXh0cmVnaW9uOmEwODZkN2Y3NWE2OTQzMTRhYTI3ZTFiNjFjNTA1Mjk2XzE0OTc_6c2ad44b-3edd-4fcc-9d72-02f3f88e33df">The components of AOCI, net of tax, were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6fa663d5f8034bcf82e68c00868a0197_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtMi0xLTEtOTI3MTg_cdfc2bd7-5800-489f-a130-2e0789aa6303"
      unitRef="usd">-17310000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id92a0b79cf4e4de386c722e094de46b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtNC0xLTEtOTI3MTg_012bb946-0c4d-4294-a94c-b073d396e10d"
      unitRef="usd">1880000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i09229c1123194f28a17b163cf6604124_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtNi0xLTEtOTI3MTg_4fc8caeb-a113-4e28-b65f-018e28702e44"
      unitRef="usd">28000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEtOC0xLTEtOTI3MTg_2699e058-8399-402f-ad4f-93c3d3896319"
      unitRef="usd">-15402000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItMi0xLTEtOTI3MTg_2c22ccdb-c85b-4b76-85bc-37f745ff1d48"
      unitRef="usd">12929000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItNC0xLTEtOTI3MTg_23996646-6c3c-48d3-84fe-bb171a8fb1fb"
      unitRef="usd">1505000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItNi0xLTEtOTI3MTg_3e79c8b2-fa01-42ba-bee3-4d2fcfda85f6"
      unitRef="usd">47000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzItOC0xLTEtOTI3MTg_5182f92b-c016-4956-92f4-7e6f5a8a49ed"
      unitRef="usd">14481000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtMi0xLTEtOTI3MTg_41ca38dd-0e29-4737-8200-2521217d1fa6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtNC0xLTEtOTI3MTg_4a2f017d-2d35-4574-8962-ae3a2f0eba87"
      unitRef="usd">-601000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtNi0xLTEtOTI3MTg_182b8e46-2bc2-44d8-a0c8-245a36941cd3"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzMtOC0xLTEtOTI3MTg_d871b2cf-b50f-4a61-9edd-30f7a354441f"
      unitRef="usd">-601000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie6d67ce43e1241c49701fa104056e0c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtMi0xLTEtOTI3MTg_193960ab-318a-4d8c-9bee-58b681b77bdc"
      unitRef="usd">12929000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id1faf359ab764117901453deb57409c1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtNC0xLTEtOTI3MTg_4a6f461b-0bdc-460b-88e0-5fbafb540abf"
      unitRef="usd">904000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i99cccb5c65b54387909fa8d86fa463d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtNi0xLTEtOTI3MTg_681b74eb-b051-423c-8a23-453d29a21173"
      unitRef="usd">47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzQtOC0xLTEtOTI3MTg_5c63bdeb-f804-492e-a404-8839bac0841a"
      unitRef="usd">13880000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0da14f54cad34e0a8daba92db8c33fc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtMi0xLTEtOTI3MTg_25c4e66d-9ede-4ca9-aec2-07112991f9b8"
      unitRef="usd">-4381000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0caf14d09a404492b64fca8be909ef3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtNC0xLTEtOTI3MTg_15545646-dbc7-4f28-bb72-4d95fcc61091"
      unitRef="usd">2784000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idcd1f43f9b9842828a851bba915574e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtNi0xLTEtOTI3MTg_aee59b83-aaf7-41c0-8d60-0286122c30b8"
      unitRef="usd">75000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzUtOC0xLTEtOTI3MTg_cc9533e0-3a07-4757-a03e-43d09d91ae66"
      unitRef="usd">-1522000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtMi0xLTEtOTI3MTg_41b6c2c0-936c-4533-96e7-ffee598d772a"
      unitRef="usd">-14664000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtNC0xLTEtOTI3MTg_71fe0a0c-2f81-452c-aa7d-4ea53f43f965"
      unitRef="usd">-403000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtNi0xLTEtOTI3MTg_644c0e25-3b2f-4236-a1d3-f693f3f95e1f"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzYtOC0xLTEtOTI3MTg_dc4fbd37-eee7-4204-8ff5-2ee388b8bc22"
      unitRef="usd">-15129000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctMi0xLTEtOTI3MTg_e82f39d9-889f-4542-a5f5-0b9dc2c3a6dc"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctNC0xLTEtOTI3MTg_a72ca660-cfbf-48a4-bc35-a68e890d2c7d"
      unitRef="usd">-2618000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctNi0xLTEtOTI3MTg_3ebad9ea-c3e4-4612-bfdb-e057e60105bc"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzctOC0xLTEtOTI3MTg_791efbe2-30dc-460f-a3a0-ee871d5cb922"
      unitRef="usd">-2618000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i121175f3f73f41df9c571cf28ec7ba36_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtMi0xLTEtOTI3MTg_93da741d-109c-46cc-8325-e90cb58f1266"
      unitRef="usd">-14664000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie911294b2f1046d49912d1b96cae3eba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtNC0xLTEtOTI3MTg_da928bf7-62a6-43e2-ad82-1ee5e770eb06"
      unitRef="usd">-3021000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i79dba0899e1d41e29b803de02336e957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtNi0xLTEtOTI3MTg_900f0734-c637-4ac1-9c4d-fc99968aefe2"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzgtOC0xLTEtOTI3MTg_dbb4586a-f63f-45e5-aaae-075734e4df9a"
      unitRef="usd">-17747000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i82e9f0ccbbf147428b431dbee759a035_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktMi0xLTEtOTI3MTg_68b46925-83c6-4b37-98f3-32ba5b69559d"
      unitRef="usd">-19045000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if5a149a148884f35a6590fc0b706383d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktNC0xLTEtOTI3MTg_012bd12d-4a61-45f1-aeb8-6a7975f7436e"
      unitRef="usd">-237000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0310811c16e34b749b6d6d1c6f540f0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktNi0xLTEtOTI3MTg_d1be27c6-90f9-4879-903a-310738bbeee5"
      unitRef="usd">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzktOC0xLTEtOTI3MTg_deb376a0-08fa-4272-9114-2aa4bf2f08cb"
      unitRef="usd">-19269000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTItMS0xLTkyNzE4_c3aa9c87-5e6a-4da6-ae0e-b651d946369d"
      unitRef="usd">-103928000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTQtMS0xLTkyNzE4_af237210-14aa-4a0f-a900-6a0eba43c3ae"
      unitRef="usd">54962000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTYtMS0xLTkyNzE4_5be73da5-a221-472c-8710-deee9493e729"
      unitRef="usd">1203000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEwLTgtMS0xLTkyNzE4_7c800c0e-7584-4775-8a11-88c2e228c665"
      unitRef="usd">-47763000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTItMS0xLTkyNzE4_151adfc4-9415-445d-9a0b-6f4cb1bc9738"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTQtMS0xLTkyNzE4_d7255759-0fe3-42ed-ac46-f5b40001d688"
      unitRef="usd">-13946000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTYtMS0xLTkyNzE4_e7958479-eb59-4536-80f1-38f811e03981"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzExLTgtMS0xLTkyNzE4_44df4bdd-bfdb-42e7-b9f4-47f980717bdd"
      unitRef="usd">-13946000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia681e77dec1d46eca7cf526e3f259971_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTItMS0xLTkyNzE4_7c85e8f0-ddd7-4860-af50-0a2a8fc090ba"
      unitRef="usd">-103928000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3cbec907fbbd4ef28b94cde46571e912_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTQtMS0xLTkyNzE4_85006261-962d-435c-b565-fbd4e3df5720"
      unitRef="usd">41016000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88345fb489ed47658151750624bb4497_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTYtMS0xLTkyNzE4_3e772b32-1ff5-4725-954e-df3709ddebdc"
      unitRef="usd">1203000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEyLTgtMS0xLTkyNzE4_75f6fbb6-041b-46a8-9be7-5666cdcae80b"
      unitRef="usd">-61709000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib851d69906c841cea381d2520fe3324a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTItMS0xLTkyNzE4_8e41b2db-86c3-4886-a309-1f69c0b27c46"
      unitRef="usd">-122973000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i88b545d554f247d7a0a02f76642e67d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTQtMS0xLTkyNzE4_2a719b28-086d-4b32-9e96-60d25e564603"
      unitRef="usd">40779000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if3fc00bdab17483ebbb47afc85c0dab2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTYtMS0xLTkyNzE4_4b59d088-c28a-41c5-a7f1-6731dc10107e"
      unitRef="usd">1216000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTIvZnJhZzphMDg2ZDdmNzVhNjk0MzE0YWEyN2UxYjYxYzUwNTI5Ni90YWJsZToyYjZhZDg2MDc3Mzc0MWY3YjMwNmVjNTk0YjU1YjI5MC90YWJsZXJhbmdlOjJiNmFkODYwNzczNzQxZjdiMzA2ZWM1OTRiNTViMjkwXzEzLTgtMS0xLTkyNzE4_6d4c0525-f173-4de0-b5ad-d491935b146f"
      unitRef="usd">-80978000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzM4OTA_b558f6ef-3372-4bf8-b498-235dcb325703">COMMITMENTS AND CONTINGENCIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business.&#160; Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Off Balance Sheet Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products.&#160;There is no maximum limit on the indemnification that may be required under these agreements.&#160;We have never incurred, nor do we expect to incur, any liability for indemnification.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2019, we acquired Pursuit (see Note 2: Acquisitions). Total consideration for the acquisition included a potential contractual earn-out of up to $50.0 million to be paid to former Pursuit equity holders, calculated based upon the achievement of certain performance targets during the earn-out period. As of June 30, 2021, the earn-out measurement period had ended and based on the actual sales and gross profit achieved during the measurement period we calculated the actual earn-out to be $26.3&#160;million. In October 2021, the $26.3&#160;million earn-out was finalized and paid to the former Pursuit equity holders (see Note 8: Fair Value Measurements).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out shall not exceed $6.0&#160;million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2022, the fair value of the contingent earn-out was estimated at $2.6&#160;million (see Note 8: Fair Value Measurements).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5&#160;million, consisting of (i) a cash payment of $1.0&#160;million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5&#160;million contingent on certain product-related regulatory certifications obtained by May 26, 2024. As of December 31, 2022, the estimated fair value for the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5&#160;million. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period we determined the fair value of the contingent earn-out was zero as the minimum threshold for earning the earn-out was not met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2022, we acquired Smiths Medical. Total consideration for the acquisition includes a potential earn-out payment of $100.0&#160;million in cash contingent on our common stock achieving a certain volume-weighted average price from the closing date to either the third or fourth anniversary of closing. As of December 31, 2022, the estimated fair value of the contingent earn-out is $21.0&#160;million (see Note 8: Fair Value Measurements).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to being acquired, during 2021, Smiths Medical received a Warning Letter from the FDA following an inspection of Smiths Medical&#x2019;s Oakdale, Minnesota Facility. The Warning Letter cited, among other things, failures to comply with FDA's medical device reporting requirements and failures to comply with applicable portions of the Quality System Regulation. A provision for the estimated costs related to the field service corrective action was recorded on the opening acquired balance sheet of Smiths Medical. The initial estimate recorded was based on a probability-weighted estimate of the costs required to settle the obligation. The actual costs to be incurred are dependent upon the scope of the work necessary to achieve regulatory clearance and could differ from the original estimate. The estimated field service corrective action recorded at December 31, 2022 is $49.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have non-cancelable operating lease agreements where we are contractually obligated to pay certain lease payment amounts (see Note 5: Leases).&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <icui:Contingentconsiderationgross
      contextRef="ia66661620e064610aa37046c932752c1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzE5MjU_70d1caa7-9c06-4683-912b-c7b7c1e6a070"
      unitRef="usd">50000000</icui:Contingentconsiderationgross>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzIyNTk_101e0331-4d73-4a15-853f-124b5ad8c2ac"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1344d8512b724b33a5d3b7ca0c2f339f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzIyODQ_1bc6f3bc-26cd-4018-ac0c-2c5d35cb40ec"
      unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <icui:Contingentconsiderationgross
      contextRef="ibb81450455e74f46b3e364e862bb1ffb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzI3MjM_f55b5d46-dd60-4663-bb81-417bc5774732"
      unitRef="usd">6000000</icui:Contingentconsiderationgross>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia073c52ce185453aad5151952a58609f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMxMjk_bb0b62fc-e92c-48c3-b897-9e6cde035e80"
      unitRef="usd">2600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <icui:Contingentconsiderationgross
      contextRef="ie7de8e0968144e63ab5a48d218387206_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMzMzY_66906601-a7b1-4b36-9d9f-9014d4254e7e"
      unitRef="usd">2500000</icui:Contingentconsiderationgross>
    <icui:ShortTermContingentConsiderationGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzMzNzY_87846d7f-f643-44cb-8225-1ae7a9cb4786"
      unitRef="usd">1000000</icui:ShortTermContingentConsiderationGross>
    <icui:LongTermContingentConsiderationGross
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzM1MjM_e0e526dd-52e5-4944-941c-0ec89e377ccb"
      unitRef="usd">1500000</icui:LongTermContingentConsiderationGross>
    <icui:ContingentConsiderationGrossLT
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzE1OA_b194b990-669c-4246-9532-4fa4e297fce6"
      unitRef="usd">1500000</icui:ContingentConsiderationGrossLT>
    <icui:Contingentconsiderationgross
      contextRef="i185415e7a3f3484984b60ec891e577f7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzExMg_a841dba7-7f93-48c6-ae07-66afe3466624"
      unitRef="usd">100000000</icui:Contingentconsiderationgross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7994fbbb85834a97aa927e80e978ecc8_I20221231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzEyOA_c8e1bfa8-3cdf-41de-ac6c-003b5e85e44a"
      unitRef="usd">21000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ProductLiabilityAccrualComponentAmount
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTUvZnJhZzozYzc1ZGM1MDdlODQ0ZDI2OGQ5ODVlYmRjNDdjZGNkYS90ZXh0cmVnaW9uOjNjNzVkYzUwN2U4NDRkMjY4ZDk4NWViZGM0N2NkY2RhXzU0OTc1NTgyMzE0Mw_fd61afef-f587-446b-8649-e8d1675b72e0"
      unitRef="usd">49800000</us-gaap:ProductLiabilityAccrualComponentAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTgvZnJhZzo0YmMyMjg5YjE2YWQ0M2Y5YTNmZTJlZWM1M2QzM2NjYi90ZXh0cmVnaW9uOjRiYzIyODliMTZhZDQzZjlhM2ZlMmVlYzUzZDMzY2NiXzE4NzM_c108b6e6-b05e-4083-be90-20d8245ed245">COLLABORATIVE AND OTHER ARRANGEMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs") whereby (i) Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On January 1, 2021, we amended our MSA with Pfizer, whereby we manufacture and supply certain agreed upon products to Pfizer. The amendments included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes to the terms of the MSA included (i) amendments to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products. On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum (the "Product Addendum") to our MSA agreement, whereby Pfizer manufactures and supplies to us certain agreed upon products. The Product Addendum includes the supply of additional product to us subject to certain time and pricing terms and conditions. The Product Addendum included a minimum purchase obligation of $29.6&#160;million. The minimum purchase obligation under the addendum was satisfied during 2022. The Product Addendum expired on November 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xMTgvZnJhZzo0YmMyMjg5YjE2YWQ0M2Y5YTNmZTJlZWM1M2QzM2NjYi90ZXh0cmVnaW9uOjRiYzIyODliMTZhZDQzZjlhM2ZlMmVlYzUzZDMzY2NiXzE4MTg_d8829ede-c0df-4928-9ea6-a30ca8463af2"
      unitRef="usd">29600000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNDQ4L2ZyYWc6MGU1NzEwYzAzYzkwNDBiZjkwMjIzMDg1OTVkZTA0ZGYvdGV4dHJlZ2lvbjowZTU3MTBjMDNjOTA0MGJmOTAyMjMwODU5NWRlMDRkZl81NDk3NTU4MTczODI_3d2602e0-98c8-476f-a63d-e7d26c6cdda5">SUBSEQUENT EVENTSOn January 19, 2023, we entered into a revolving $150&#160;million uncommitted receivables purchase agreement with Bank of The West ("BOW") which provides for a less expensive form of capital. The discount rate applied to the sold receivables equals, a rate per annum equal to the sum of (i) an applicable margin of 1.75%, plus (ii) Term SOFR for a period equal to the discount period which is calculated with respect to the payment terms of the specific receivable. The accounts receivable to be sold have payment terms ranging between 30 and 60 days, and are related to customer accounts with good credit history. The transfer of the purchased accounts receivable under the agreement is intended to be an absolute and irrevocable transfer constituting a true sale as the transferred receivables have been isolated beyond the reach of the Company and our creditors, even in bankruptcy or other receivership. We will not retain effective control over the sold receivables and BOW will have the right upon purchase to pledge and/or exchange the transferred assets without restrictions. The Company will act as collection agent for BOW, collection services will be undertaken by our accounts receivable personnel in their normal course of business and collected funds will be remitted to BOW. The discount rate has been negotiated net of consideration for the collection services, the cost of collection is expected to be immaterial to the Company.</us-gaap:SubsequentEventsTextBlock>
    <icui:AccountsReceivablePurchaseProgram
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNDQ4L2ZyYWc6MGU1NzEwYzAzYzkwNDBiZjkwMjIzMDg1OTVkZTA0ZGYvdGV4dHJlZ2lvbjowZTU3MTBjMDNjOTA0MGJmOTAyMjMwODU5NWRlMDRkZl81NDk3NTU4MTczODQ_c8762112-583a-46ef-b19c-f0ec63a1134c"
      unitRef="usd">150000000</icui:AccountsReceivablePurchaseProgram>
    <dei:AuditorFirmId
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNTEvZnJhZzoyMzE5NmFlMjFjMTE0MjEyODQ3NzlhMGViYmFjYjMwYy90ZXh0cmVnaW9uOjIzMTk2YWUyMWMxMTQyMTI4NDc3OWEwZWJiYWNiMzBjXzE2Nw_8e3f82e1-d5c8-4784-8550-2951c333d6ed">34</dei:AuditorFirmId>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90ZXh0cmVnaW9uOmU0Y2I5YjczZDYzYzQ0Y2FiODg0YjYyMDc0MGYxZTUyXzc3_f9fd2896-6274-40c2-b594-a83fb230b1fa">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts&#160;in&#160;thousands)&lt;br/&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;at&lt;br/&gt;Beginning&#160;of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;br/&gt;Costs&#160;and&lt;br/&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;br/&gt;Other&#160;Accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Write-off/&lt;br/&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at&#160;End&lt;br/&gt;of&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warranty and return reserve - inventory/accrued&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7e4fdf1f07a54b639ac859a24b648c8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtMi0xLTEtOTI3MTg_d09b1d27-6783-4395-b804-f33f11650027"
      unitRef="usd">20219000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtNC0xLTEtOTI3MTg_643e4b6b-3671-43aa-b11a-04bb80345847"
      unitRef="usd">7137000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtNi0xLTEtOTI3MTg_cb289c70-7b76-4bbe-ad0b-3a083f2dc8d9"
      unitRef="usd">-5866000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="icfb34caf8b85446181f59663dcd23c04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtOC0xLTEtOTI3MTg_e42a4703-3a13-4d47-8a14-48d2e43920da"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i93ac49fefe63465a8912d34fb790031a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzMtMTAtMS0xLTkyNzE4_e0c90701-17fb-4ace-a1e4-3a9d0f2bf425"
      unitRef="usd">21490000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idf00748957594ed9924d63ec3390253e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtMi0xLTEtOTI3MTg_71fe373c-ebb6-4c91-902a-09cc4a161b2f"
      unitRef="usd">6377000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtNC0xLTEtOTI3MTg_81fa1369-1607-4ff8-835b-f0fbbde4159e"
      unitRef="usd">-3609000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtNi0xLTEtOTI3MTg_ac77e3f6-2094-40d2-92f6-5050c2cf6e05"
      unitRef="usd">-61000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ie1d4a388fa53429eb90eb6b26b6ae28a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtOC0xLTEtOTI3MTg_4ac2a7fa-fdff-4db6-b1f3-525fec6d2c86"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0549fbba004248979b80bb6b02218da9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzQtMTAtMS0xLTkyNzE4_38df6904-f2e9-4f5d-aac3-237a2eb57aa8"
      unitRef="usd">2707000</us-gaap:ValuationAllowancesAndReservesBalance>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtMi0xLTEtOTI3MTg_fc9b8b47-6946-4b75-928b-78199d31bafc"
      unitRef="usd">-3477000</icui:WarrantyAndReturnReserveInventory>
    <icui:WarrantyAndReturnReserveCosts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtNC0xLTEtOTI3MTg_604727b2-079c-42a4-9443-6e133fe60362"
      unitRef="usd">2033000</icui:WarrantyAndReturnReserveCosts>
    <icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtNi0xLTEtOTI3MTg_6d78df7d-6247-4d2b-9c56-9a5153034cdf"
      unitRef="usd">169000</icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts>
    <icui:WarrantyAndReturnReserveInventoryWriteOffs
      contextRef="if024b016189942d089f44d314d97476f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtOC0xLTEtOTI3MTg_1637e5b0-af7f-40b9-a640-a506870b076a"
      unitRef="usd">0</icui:WarrantyAndReturnReserveInventoryWriteOffs>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzUtMTAtMS0xLTkyNzE4_6f65b3ee-a539-49d6-9c30-3bd85cc5f20e"
      unitRef="usd">-1613000</icui:WarrantyAndReturnReserveInventory>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i322d334cb60e40d4a61f1bc09d5257bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtMi0xLTEtOTI3MTg_fe859b4c-6b4c-4747-9729-6d584e0a951b"
      unitRef="usd">3677000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtNC0xLTEtOTI3MTg_d47819ff-c21a-48be-8384-53c39b2e8df6"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtNi0xLTEtOTI3MTg_c33ef2ee-822c-4fa1-8fd7-2d4465ca7a15"
      unitRef="usd">214000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ib2b8d544b6a3449283eca65f49d3d7b2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtOC0xLTEtOTI3MTg_18630cc4-7db2-4413-b8e0-dda6f4eb8fa5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i15f182769ad646e3bddd9c4239760f1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzYtMTAtMS0xLTkyNzE4_08ee06be-1ee7-48fe-8454-d5a0ee5ce5af"
      unitRef="usd">3891000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i93ac49fefe63465a8912d34fb790031a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktMi0xLTEtOTI3MTg_a88ed933-ef45-4ce9-861e-c67dcd94ffcf"
      unitRef="usd">21490000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktNC0xLTEtOTI3MTg_8746978a-9b45-426e-9780-f5e4c9a5dbd5"
      unitRef="usd">345000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktNi0xLTEtOTI3MTg_077d3ad4-8844-40f2-a979-cc03931542eb"
      unitRef="usd">-14797000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="idb764bdbe1484187a10f31ce74dc2bd0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktOC0xLTEtOTI3MTg_2f785c30-0954-47c9-9a57-280269be7b3c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzktMTAtMS0xLTkyNzE4_43b0becf-a610-4c54-871d-141fa7a1e245"
      unitRef="usd">7038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0549fbba004248979b80bb6b02218da9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTItMS0xLTkyNzE4_9da0e491-c7b0-426d-b68c-021dbae73d8b"
      unitRef="usd">2707000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTQtMS0xLTkyNzE4_4c08e06a-dbc9-4413-a3a8-f3872f72f85f"
      unitRef="usd">568000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTYtMS0xLTkyNzE4_916363d5-b406-4c20-ae6e-0cc8482df921"
      unitRef="usd">-790000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i2ce5eddab59f47469095b825e0cb0ddf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTgtMS0xLTkyNzE4_821588af-132b-4495-91c3-07ef23444cc0"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0271cf17cf0844a2a04595bf20873f7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEwLTEwLTEtMS05MjcxOA_5d57d7a2-f2b9-4bf5-b229-12ec9505417b"
      unitRef="usd">2485000</us-gaap:ValuationAllowancesAndReservesBalance>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="i3688a319945e4943a3dc05ede3f036d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTItMS0xLTkyNzE4_6cb79dcf-57d4-4b7b-bf5a-81ef382f241f"
      unitRef="usd">-1613000</icui:WarrantyAndReturnReserveInventory>
    <icui:WarrantyAndReturnReserveCosts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTQtMS0xLTkyNzE4_5e6c968e-eecc-40aa-8554-3fa800cd2d09"
      unitRef="usd">263000</icui:WarrantyAndReturnReserveCosts>
    <icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTYtMS0xLTkyNzE4_f2167d54-b957-4976-b043-0c9df0eeb6d2"
      unitRef="usd">533000</icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts>
    <icui:WarrantyAndReturnReserveInventoryWriteOffs
      contextRef="if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTgtMS0xLTkyNzE4_8550902e-6aa8-4663-8ab8-8f3bc95830e9"
      unitRef="usd">0</icui:WarrantyAndReturnReserveInventoryWriteOffs>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzExLTEwLTEtMS05MjcxOA_4a397911-1cdf-4297-ac8a-090b4d1f66f8"
      unitRef="usd">-1883000</icui:WarrantyAndReturnReserveInventory>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i15f182769ad646e3bddd9c4239760f1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTItMS0xLTkyNzE4_f5b0583c-b0d0-47df-9ba8-a83d9d36f6f9"
      unitRef="usd">3891000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTQtMS0xLTkyNzE4_76cdde13-df3a-41dd-98cd-1779d55f89dd"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTYtMS0xLTkyNzE4_dbd5dd38-3466-438d-9669-c819edd969f0"
      unitRef="usd">-957000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i00e9b431ae3f421b951289c5baae050e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTgtMS0xLTkyNzE4_5454b38a-a268-44ec-a03e-90f02b4d8830"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzEyLTEwLTEtMS05MjcxOA_70a15287-b3c9-43c4-9889-456e4ecaf268"
      unitRef="usd">2934000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1e6c39141beb453d96cbfed4da1fb0d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTItMS0xLTkyNzE4_c6692f6e-4cb8-4119-b1e3-0069a9f57c73"
      unitRef="usd">7038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTQtMS0xLTkyNzE4_1898849c-492b-4c9b-bd51-d99b620b3df7"
      unitRef="usd">1036000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTYtMS0xLTkyNzE4_0686b269-6394-4d9b-8908-0efdbdb0f721"
      unitRef="usd">456000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ic5dab9a32abc4d168637119036495dd1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTgtMS0xLTkyNzE4_2f40fad3-f03b-42ea-8076-a205ab8c5a14"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i59fef45bfc2f422c819e0dbb81290ea7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE1LTEwLTEtMS05MjcxOA_c35bbb28-d093-44ea-811c-7a4e040f6978"
      unitRef="usd">8530000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0271cf17cf0844a2a04595bf20873f7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTItMS0xLTkyNzE4_79bdec25-59c4-49c3-8b78-f90c71f4ee35"
      unitRef="usd">2485000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTQtMS0xLTkyNzE4_8304f597-73ef-4c38-807f-a9e787be4032"
      unitRef="usd">-364000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTYtMS0xLTkyNzE4_7396f59e-ab2c-46dd-960f-0de80bc14c07"
      unitRef="usd">3742000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="if8927af7e54a47b78762d48c3e3a90f6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTgtMS0xLTkyNzE4_22aa6966-e8a3-451a-878a-65db8e279bb7"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i205528742f3c4d1db554ed4a86cd9547_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE2LTEwLTEtMS05MjcxOA_9a9d816c-2652-4978-ad39-ba3b3734b20e"
      unitRef="usd">5863000</us-gaap:ValuationAllowancesAndReservesBalance>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTItMS0xLTkyNzE4_1befc47d-579d-4d17-82fb-b039f529869f"
      unitRef="usd">-1883000</icui:WarrantyAndReturnReserveInventory>
    <icui:WarrantyAndReturnReserveCosts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTQtMS0xLTkyNzE4_0ffd34b7-1e33-443e-b2fc-a5b46531567b"
      unitRef="usd">5266000</icui:WarrantyAndReturnReserveCosts>
    <icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTYtMS0xLTkyNzE4_15a18cee-28b3-4652-93c6-7d36196bcb22"
      unitRef="usd">-47436000</icui:WarrantyAndReturnReserveInventoryChargedToOtherAccounts>
    <icui:WarrantyAndReturnReserveInventoryWriteOffs
      contextRef="i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTgtMS0xLTkyNzE4_68b40632-cf35-465c-9600-7d407295ee11"
      unitRef="usd">0</icui:WarrantyAndReturnReserveInventoryWriteOffs>
    <icui:WarrantyAndReturnReserveInventory
      contextRef="i0db73ebe00014b429d98a2767a3858eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE3LTEwLTEtMS05MjcxOA_bfc25418-3de2-4afd-8824-6037e7c97f8b"
      unitRef="usd">50819000</icui:WarrantyAndReturnReserveInventory>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia0c30824f14b4fa4951cd41cc67f6cac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTItMS0xLTkyNzE4_85804376-01f3-475e-ae68-604fb4f9fccf"
      unitRef="usd">2934000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTQtMS0xLTkyNzE4_e389fa72-cd7f-4bac-963f-545890fd0e0c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTYtMS0xLTkyNzE4_f8ce1d4e-7074-409d-97fa-bd7cbb87cb99"
      unitRef="usd">8232000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ibf33bd5498f04a8ba87ad56605fd9f0f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTgtMS0xLTkyNzE4_15db4188-dea3-415f-819e-9d7e747d7a03"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4b8f43d24ee94d6093c1c5f148e1cf17_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzYzM2Y2VkY2U5OTQ2ZjY4YzA4YjhjZWQ4Y2IxMTc0L3NlYzozM2MzNmNlZGNlOTk0NmY2OGMwOGI4Y2VkOGNiMTE3NF8xNjMvZnJhZzplNGNiOWI3M2Q2M2M0NGNhYjg4NGI2MjA3NDBmMWU1Mi90YWJsZTo4ODNmMTYyNmI1OWU0ZTliOTNhMTQyNTg4ZmQwZGQzMy90YWJsZXJhbmdlOjg4M2YxNjI2YjU5ZTRlOWI5M2ExNDI1ODhmZDBkZDMzXzE4LTEwLTEtMS05MjcxOA_752f9020-c165-45d1-ad01-730a9698b9c0"
      unitRef="usd">11166000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>147
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MA#:U[J:%::X@K8/9WPNA3X8]H&W7Z5]02P,$%     @ Z8M;5F-/N)?E!P
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M4_LT!KL08]+P84A%><1.>8 Q*V Q)C%[C)/&PDMT[B(N5(VZ/C/881R"_FG
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MV,/&J"?(*/P9'?X6_HL_?_:7%[K4EJ:FWC1O&1=\&X3D<B![ B=L3P:3/_]
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M5JLN5)@!L>4:K;I08=@U/,O0UX574_,^Z#2<!"S<%)0BV782NLWW3QT?3XG
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MB+ <(/]?42H.@_P%]6G]Y#]02P,$%     @ Z8M;5EFX.Z5- P  ^0D  !@
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MH30 ^KX60K].S 9=M[?X%U!+ P04    " #IBUM6_+4.%9H)  #65P  &
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MM:(--@PJ;[+ZK5PJ7\L-07L?0=%$D73^-88RL/6@T;5'86&;AJ+V@'K8H+0
ME!:"TB(HFBBKSLC&?VDG&RM\7I?2W@DAJ)4-2O,50Y#-[--&&8+V*X*BB<+K
M_&S\;0QMK'"$'6IB63&@EC8HS3]M" %HTA"4%D'1Q%LA.U^;_%&^-NE;I5/L
M./+>8J[OP%C]@-)\4%H 2@M!:=';LR4*J'.VR>]QMDG?>L4&Q;UE29]DM$A
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M(D>M:,1=623-"EQM*IW@?7575+NT)FKCK-9E#K:K*L7_N)MBJ^6]2M>D=-5
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M6%/I[H[-/C$UQLN8,GY89TT*^8#AEB-8)KNTE+<-W]!["O-8Y-+]^U^OB;4
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MR$3EO*4H35+'%8@O5,EL88'.X[1.E+ ;>@0N\D3(;%ZGLC(E*7)1<\9SLN.
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M4:BNME"Q7E#-@M*(+D$Q)6YDF2('Z8PJ"W/A0T."[XW5UM7E<([,*U9H(3?
M[H),9]U>YP-2E-I^$;FJ40=3I&Z9*0+<PL"=\#8EG8J\SN;X"3JV.1@DH=3O
M5@*LPS:!7+%G0UHG0./ @%W8Y^C)N#3 2]!"AW%_=.->,;@F451X70*[P+JH
MW6LZ#"C'.]&WE01BB8AH*J%?K9Y[(*,OKAM72C<,LMK*QSE<0-NYWTX84W,1
M;3-A[]/==>_$9=*0>C-%1K"[$"LBC.7,@$T!A]AF&Y ']SE<'56\RDUJEF!J
M56>2&C +X6.7DROY@#:N*$Q9M5R1Q)+(:%8'N14;>:U2Q$WF^H,FY7M?AHP
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M-X:]0N%47IBR6^#Z%_.D3 YX=O78M")2?]H2.C_XQ+JHN_=S;X+NWG,O!SQ
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M:-J ];7"P='<D(+N.^W-?P!02P,$%     @ Z8M;5M^@VDYE$P  $$0  !D
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M(09K09VRM>1YFF.V^+"B+V:)! $(@CH 0EN++HOG65$JY&O4VD2?0'10\ZK
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M[UV<_U2TD*0=!"05*A.>R?*>&JA04.ZM[FIJN\<C>*_+[-GL S2P1AJ8OYN
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MOD<RF?#$D37V)N( J:X[MH*)(X(A2 Y$,+$"O^\H78<(Q/@QWSR93FU0KXC
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M !]BEN]>N-U0"X);C81(@"#"XC!P"IF8('?25";A@Y#WX2Q(\#0-+/Y3YJL
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M:.;:&-\-X@J'R];P?&,S2E#061CL6&U.Q>/QJ7@Z&-&6QU'=Y<:(,M?I@75
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MFH#W*P,-#@^T0?-+D1?_ %!+ P04    " #IBUM67L95K>$#  "!"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RM5FV/VC@0_BNCM*I:R=TDS@MA
M"TCL+KWNAVX1T-Y)U7TPB8%H$SNU'=C^^QLG(<OML7RZ+\;VS#SSS$L\C Y2
M/>H=YP:>RD+HL;,SIKIV79WN>,GTE:RX0,E&JI(9/*JMJRO%6=88E85+/2]V
M2Y8+9S)J[N9J,I*U*7+!YPIT799,_;[AA3R,'=\Y7BSR[<[8"W<RJMB6+[GY
M7LT5GMP>)<M++G0N!2B^&3M3__HFM/J-PH^<'_3)'FPD:RD?[>$^&SN>)<0+
MGAJ+P/!GSV]Y45@@I/&KPW1ZE];P=']$_]S$CK&LF>:WLO@SS\QN["0.9'S#
MZL(LY.$+[^*)+%XJ"]VL<&AU!]2!M-9&EITQ,BAST?ZRIRX/)P:)]XH![0QH
MP[MUU+"\8X9-1DH>0%EM1+.;)M3&&LGEPA9E:11*<[0SD[GB%<LS#4QD\,WL
MN(+;6BDN#$RUYD;#^P=IN/XP<@VZLT9NVD'?M-#T%6B?PE<IS$[#3&0\^S>
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MZ8ZIK94G@8=R&OJ [Q:^2@*YHE!L;<[4@2E+3C1MC7I)[(%/O-B'>V$X5M2
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MOY_1 *KZ$;5_,7+EQL*Y-#1DNN62IGI45H#.:TFI;5ZL@^'_A,G?4$L#!!0
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M&72A?BE7>/G?^!6$,,O?JI4T,@/+\NEAK*%>UD.K 2-!Q"H#%?S1[TY(VD<
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M\P"[C!GU-=,\$_,ZP'$#(**2BTT$<+ -X'@7P!$B9_'1Z>G _QUMQ;"^9@/
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M0DF$')J [[,TS8H7VJ#\T=F;?P)02P,$%     @ Z8M;5D<)0M@"#0  :"
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M)AS"<R_+X,F H1K>^3%J^ASUL^9X>IS4>3^@'L7[,;_@>B<DE0AN234\R=(
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MP\G8(]5=@;J&D8V[=IQ+@TN,^RQP:^3*3L#X4N)<LFG8 -M[Z,%_4$L#!!0
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M@0++$^'$[-#H-1BV)C2^"*D&;R(G*V[*M3/T5I*?FU$V2BRT$5P<$%4&%ZY
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ME@AE0;5$BLEQ=R01HRRWD6IX_YA3)*#S0 DT$ZJ 8UO:,K2#,RX84RBP]1R
M4%;_=])#N"%G+BXCK&1&#1)I ;4P[C["E-YYH8CW BO,9<HUDJ&)EHAR7@M-
M9D33M5""$J80"X2OFDS)ETI!"YU,[Z-U4P/V_O#V4V31-J I4VUDBB290A*?
M4,\%E[&*9'R="8?9 *0E1\@]O4\U?1DR9.E3CJ&$X6G@::TFZN02LV*NO?X,
M(-.I9[$%YP$5(+T5RU:1W"M)N4?D)M6V64/6^I^$Q5*/>V@2I"X(CW8<:&^X
M+C%PS'S0*7F-S^EDJT"HO!$IUBZ$BK,BJU1Y#BL@+7CXV9;YMFKB:]'.5I "
MQ21L6J18+J@KS3+=[Q/^U8*OI*("&FI1]PG=J-\51OME\0CE8-CLSTC&]MG8
MGFHVO'FV>_F0/1=0X0H5VS?5H:O'Q1C$ 6PKUPO)$.6#3<-;S08'\HARZBS[
M$FR&*6-J*ZU(),US)]&TVX-5"34:J3/;+(+5A@=]I67I2ZB](4H6Z>SRS4O3
M+#=&:"T?:*K;G\W';0"8YYC&[U*HW4/5D4$0"6? $6A !^VDX1VFW@557,88
M,*>4JHQH[7 +DN\?T[9MJL'=Z02S46Z#W%.OW<A7QF+2 MXFXRC>1X0:*=B@
MC4V_J0>25<>E;EQB".L77S'>M='"VF,VW"MN=]1;&&9=19P?A.=:/>J<7BBY
M[-; S]/?AB_)2"EZ$-&V>7A:!R;.7QMK38VT]-;FD@)F49K<RV>XX5TM^?-)
M:.=ZU4S:.+9_^-3Q8=0["99HEN&\2UW1OG+Q4-@][8[4\WB2W)C'\_B9,+01
M+8UB3J[CX:N#!$P\X\8;I^MPKJ053Z?4<%G0SP(T;$#O<TVGQN:& W0_-&;_
M E!+ P04    " #IBUM6?34J,J$$  !$"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6R-5MMNVS@0_15">T$+&+[ELFW6,1"G*;H+=).-D^9AL0^4
M-):(4*1*4G;\]WN&DA6W=;-]L25QYLR9PYDA9QOK'GU)%,13I8T_3\H0ZK/1
MR&<E5=(/;4T&*ROK*AGPZHJ1KQW)/#I5>C0=CT]'E50FF<_BMQLWG]DF:&7H
MQ@G?5)5TVP5INSE/)LGNPZTJRL ?1O-9+0M:4KBO;QS>1CU*KBHR7EDC'*W.
MDXO)V>*8[:/!)T4;O_<L.)/4VD=^^2,_3\9,B#1E@1$D_M9T25HS$&A\[C"3
M/B0[[C_OT-_'W)%+*CU=6OV@\E">)V\2D=-*-CK<VLT'ZO(Y8;S,:A]_Q::U
MG;Y-1-;X8*O.&0PJ9=I_^=3IL.?P9OP=AVGG,(V\VT"1Y3L9Y'SF[$8XM@8:
M/\14HS?(*<.;L@P.JPI^8;YL4D^?&S)!7*WQZV>C %A>'&4=Q**%F'X'8C(5
M'ZT)I1=7)J?\2X 1^/2DICM2B^F+B.\H&XJCR4!,Q]/I"WA'?9)'$>_H1Y,4
M_URD/CB4Q+^'\FW1C@^C<9N<^5IF=)Z@#SRY-27S7W^:G(Y_?X'K<<_U^"7T
M']N0_X&X7RRO_KZ_^NM.7'W"[_+:B#^E:=!T8O(VJGHT$!L2@"='N5 F6"'1
M8VNKU\H4XN?)R;C-J%):<_<T)K-5I4* N:.,U%JFFKRH&Y>5Z HA"T=4,>V-
M"J582/,H[$K<E20>R ?Q*EE</R2OQ:9462EJ9]<JAS_&"B(#R0MZJKG9U\0?
M*W;.9*V"U,.(DBN?V0;X3@:$JVNMP 7$ Q:]U5_R@H12^P%GQ>8U(8PQ3=4N
M]&Y-C/-*O<9JBYFQ/SK,%<KPVF3XV\DO U'KQL,.AG<$<LOK][<==T KFW^)
MVW/M%MNDE4=&.FNT9!6C3*B?&O-IYU?+;900VU)YCAY)PD*M5+:77ZN(S&(0
MO[? 0&DG1RG77R,Z:0K>WY3"ALB(HS'RSL7I6.1RRVKA13H"8,L1:.T,8OEV
MT2+QPB*M#,6C@B@53-RV)86N,GX%^X[]KD#R@W0;3 P7[9[K!S*A((EG29<.
M[TV*G!K>>%!4CDNUW:D^7F:-#RHT@1.4^-Y !PD+Z6. G:'[JH*C3"FKH1 B
MIIW2UB(,>^&@P\YUN5S:JI9F&SG8QG7Y6P?E:,T !B>$>71-';*M0'58>+DN
M&CE?JGJ(;H""6@MC4<H4<&X*6JTHGDZ<1' X!.RZD^6;PN;8Z*06(W*/-/GP
M$4V-3NT[$MK5FO(B:C8"&WK"@BGH&SFD]]1M+,YM+LK@5#PU?;NIN\1C4$Q-
MUA0G3W^T%KQOW Y@-MA?X>FH,O*M9]IM>)"/4"O=1A$/E07:QEMC2+.D8*L<
MY,(9K('=..2&#4D;C[GG6T6ZD,AEA0C/X1QU,PMB@-NA20*MVNTW5-B@8@$8
MW(9X_D  3"F8<2Z<'RMW(+U!M^ [M]Y M6,M"WTM*UQ^T(SJ>5ATX@X/'1ZC
MO9,=35C$^PMK#_KM(=]_[:](%^W-X-F\O5]]C"/-8]:NX#K&6$O:LMF]!%O'
M>T)J SH^/I:XYI%C ZROK V[%P[07QSG_P%02P,$%     @ Z8M;5O+:QA2R
M P  ]0D  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULG5;;;MLX$/T5
M0C4*&U B47>EM@$[:;'[4"#;H,W#8A]H:60+E40O2=GQW^^0LA4[=;UN7\3;
MS)DY1^20XRT7W^4*0)&7NFKDQ%HIM;YS')FMH&;REJ^AP96"BYHI'(JE(]<"
M6&Z<ZLKQ7#=R:E8VUG1LYA[%=,Q;594-/ HBV[IF8C>'BF\G%K4.$U_*Y4KI
M"6<Z7K,E/('ZNGX4.')ZE+RLH9$E;XB 8F+-Z-T\T/;&X%L)6WG4)YK)@O/O
M>O!G/K%<G1!4D"F-P+#9P#U4E0;"-/[=8UI]2.UXW#^@?S+<D<N"2;CGU7.9
MJ]7$2BR20\':2GWAVS]@SR?4>!FOI/F2;6<;HW'62L7KO3-F4)=-U[*7O0Y'
M#HG[$P=O[^"9O+M )LL'IMAT+/B6"&V-:+ICJ!IO3*YL]$]Y4@)72_13TZ>/
M]^0)_W3>5F"3F5!E5@&AWHV;VN0;JUK6B=?DY*^6566Q*YLEF649;QLEQX["
M'#22D^WCS;MXWD_B48]\YHU:2?*QR2$_!7 P^9Z!=V P]RXB/D!V2WQJ$\_U
MO MX?J^(;_#\JQ2Y5@GR]VPAE<!-]L\Y4;J0P?F0^N#=R37+8&+AR9(@-F!-
MW[^CD?OA J&@)Q1<0C]/Z#!!>'$%N8=29A67K8!SY"Z&/T^.S/*\U"$E&<[J
M+DC9$+7BK<0DY(C,6<6:# A3Y'[%Q!)RHOAQ]UF4"FYX43B]+9Y3A "R R8(
MZ/U%<'= O0!QV"'N'9E56(F,/=8TDO-VH8JVPOJP)SM .]NC*79BF_HQML/0
M3J)HA+WW[Q*/>A^T$;6#U"7/3 C6J)W13H!JA2Y6AB:Y>045F$>Y80M4?$ B
MVX\-K&]';JIAAQ%]@V[';OP_X&6S@49QL>N@@C@>&4_7]_4,C=)3S"&U(^J/
M4),"A- JLA?"I,32OWG= KTZ X+IF3R/20<G8]].4GJ-[O0JW3M)$38(3;Z!
M':?Q*8D8Z26_I7HGZ8"$4:+!X]1]*WF0A+\B^5Y.](R,X*'O_R!XDOR:X%K.
M$X@TC-^FF?K!-9)[UTC>R3D@%-L(VR",3J(E=NC_SB8?TE$OJ=Z=43 R_.+
M.\'7!\N_5G0'(XD6J0Z]T9&\&L6+3/:Q'?BG!$+73O L7_T+.GE/)?#\TZ0I
MM2G&.U>;G:.KN :L5?K!(8D1J+N5^]G^33/KKO)7\^Y!]!E+78D%LH("7=W;
M.+2(Z!X9W4#QM;G8%USA,\%T5_@N Z$-<+W@7!T&.D#_TIO^!U!+ P04
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MPV3)?'KXXU)X_)&\QR,3H8<"UC30NZ2QGXJ\5'!@6=LNI;/C0IT?5>HFYS8
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MF($0*O_W:!VI24E?DY(GUZ1WH_6(8X"P _->1+R]V>@2X]333BA&93E\3/3
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M2H&@%G#&S!(NB'B--UM>!G!MF<7*8Q*^X)+)E#,!EZ@]W66*/A1;.\IPQZ8
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M3H#V%TK9S8<[H'FHS_X%4$L#!!0    ( .F+6U:UIG_O:@8  ( 3   9
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ME"0:-O/@AEW?ID[>"WRMX&!.YL1YLE;JFUM\*N=!Y A!#85U" (_>[B#NG9
M2./[@!F,)IWBZ?R(_L'[CKZLA8$[5?]:E78W#_* E+ 176V_J,-/,/CC"1:J
M-GXDAUXV20)2=,:J9E!&!DTE^Z]X'.)PHI!'SRCP08%[WKTAS_*]L&(QT^I
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M)4_IH@,&:%*/U!F]^2%(_/<MGO8;3_MMVD>?"D/0:M@M5_,,@"VF[$KF>69
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M0,P!9U^@*S-VAT:F>]-V3ZPCWTS+VKYC:G*>#B;[I(2('B"HV;S (NLT^]^
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M% U(7$^=>7"^B,QY>^#W$G?J: Q&R4J(&S.YR*>.;PAAA9DV")Q>M[C$JC)
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M@66Q]H"MP)*L*5F1$%$);L*09502N@8+EI"08 'N&(NV)$G 18 E(HFX!!_
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MRF#TX=0#V5IGV]&B<6:R$-I8DVNNS&N#T@:8^:40>M>Q"_3O5_8/4$L#!!0
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M[E?(!'5CO$"$*OF)=EFLYZ!@H[2(LF3#(&(\_4V_98782\"] PDD2R#5!/]
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MJ6VAE97O'>WXS<^8;(BV"M(26KD@I"@(^:X=,1MN?[F2#JYVCX8H2_O A8/
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M6$)0$X(R,Y65,@\Q423J"[X$8=!:S0S*9)9L;9\R<^UC)?0NU3P5?42&@N1
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M*VW^B3  _7S!N7J;F!>T_TZ,_@=02P,$%     @ Z8M;5E -^EZ%!@  B \
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;,5;VV[;.!#]%<);++J
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MT "!L]L^!'V@I;'-KB2Z)&5G_[XD)<NZ1;4*Y<46I9DS<P[)T8BS$V7?^1Y
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M9P]]_/ )?4 D1E_W-.'2GL],(=-304P_2^4^3<5Y(Q7;08\T%GN.?HT#",H
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MOMP##H I _E\2ZDX#U2 _.!H\2]02P,$%     @ Z8M;5D5,GJH[!0  51X
M !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULS5GO;Z,V&/Y7+#9-/:EI
ML/F1I$LBI>'N5JF5JG:W?9CV@8"3L .<LYWFNK]^-E (M6,E&97N2P/V^SY^
MG\=@/\7C':%?V1IC#KYG:<XFUIKSS76_SZ(USD)V138X%SU+0K.0BUNZZK,-
MQ6%<)&5I']FVW\_")+>FXZ+M@4['9,O3),</%+!MEH7TY0:G9#>QH/7:\)BL
MUEPV]*?C3;C"3YA_V3Q0<=>O4>(DPSE+2 XH7DZL&;P.D"<3BH@_$KQC>]=
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M3H'G'#,W8$X8+V9"-&/ZC,%?=R(>W'*<L;]UXI?@KAY<KB?7;!-&>&*)!:-
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MQF&,J0P0_4M"^.N-'* ^29[^!U!+ P04    " #IBUM6Q-@JJHL"  #W!@
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M'*WD1VGVW&>2J[N1PLG1 ]W3=$<!C@19KSE=D_QQL!4XWIF_@-\H6W.RW;R
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MX3B_]L##,=O(A&;PP)'8I&G$?]Y"PG83"UO/%Q[ITTKJ"W8X7D=/, /Y9?W
MU9E=H<0TA4Q0EB$.RXEU@Z^GQ-,!^8I_*.S$WC'24N:,?=,GG^*)Y6A&D,!"
M:HA(?6UA"DFBD12/[R6H5>VI _>/G]$_Y.*5F'DD8,J2?VDL5Q-K:*$8EM$F
MD8]L]R>4@GR-MV")R#_1KE@;>!9:;(1D:1FL&*0T*[ZC'V4B]@)P<"2 E &D
M'7!L![<,<'.A!;-<UETDHW#,V0YQO5JAZ8,\-WFT4D,S?1MGDJM?J8J3X2-L
M(=L FK),<I53]!>-YC2ADH) ;^] 1C01%^@=^C*[0V_?7* WB&;H[Q7;B"B+
MQ=B6BH2&LA?EAK?%AN3(AIB@>[772J#W60QQ$\!6["L)Y%G"+3$BWL'B"KGX
M$A&'D Y"TU\/QP8Z;I51-\=SC^!-/[<R^1,]LD1WW"[B,?JJ3]"'XNR_KOP5
M\%XWO&[K:[&.%C"Q5-\*X%NPPM]_PX'S1Y?VGL :F?"J3'@F]+"JJ1V5*S3-
MBQGX99V8+O4%I)]#ZO^@;?ANX 7JQFSW976L"CS7J58U^/H57[]_O@5DL,_$
M\X=!T"+<L:PAJT$XJ @'1L*SE.I&NH>8+J*DBYTQ_M1:Z@FL(75021V<MZL&
M?6:B)[!&)H95)H;]5^GPL/Q\3#R_5:7&G5^H:U3I&AEUO?^^H6ME$*1R!\4S
MZ>L]I'/@G;?3B'7J[>P)K"$;._43V#EO:9?X/26C+[1F-O;\"#:6P:=LH>RH
M &T^BJ,+[3CN8 F<0XQ*P]*9!WQ8Y2XA/FE5>=<Z[#C>L/O?&).:.S%R;Y.\
M1#=Q3+5=[39*Y( '<5SW@.[A,NP.B'^$;>U3L/'A'\[84JJ:@E_J-S/6R35V
M#EN":U^"O3-WG-'XG)R-GM":V:A=#S;;GM=T7(>MP0$9#-HEW&5_R#'[@VO_
M@\T&Z-2&"PX[:>#[!VR# W>IK-JQ?JL=##;:@O CVP+/\B?<1QZI3U-B>[4K
M?:$UA=>&!0_/W&X]^9(R&^=P.;BV.=CL<U[3;J..=O.QUZ[?<_@94OL98G0(
MIS9EB;8O2CW=1BU-YCU?JJEV)<3L2C[+%7 ]'BJ4\>/WR QT:JWVA=:471L:
M0L[;N<1HF$[.1D]HS6S4AHF8#=,K.K=$;KZ C7#[_<M,X*4":U]$S .;4SOW
M< J#?<=I:^K5W=A[HT[UVON43X %6K!-)HN1876UFC+?Y+/5UO5;?#TM9L4U
M3#&ZOH_X$\T$2F"I()VK@1+(BVEP<2+9.A^HSIE4[][YX0JB&+A>H'Y?,B:?
M3_0&U4P^_!]02P,$%     @ Z8M;5KO% 2)- @  V@0  !D   !X;"]W;W)K
M<VAE971S+W-H965T-S(N>&UL?5113]LP$/XKIPQ-(*$F35O8NC02I9N&!!*B
ML#U,>W"3:V/AV)GM-&6_?F<GS;H)^A+?V7??]]W9EZ11^MD4B!9VI9!F%A36
M5M,P-%F!)3,#5:&DD[72);/DZDUH*HTL]TFE".,HN@A+QF60)G[O7J>)JJW@
M$N\UF+HLF7Z9HU#-+!@&^XT'OBFLVPC3I&(;7*)]JNXU>6&/DO,2I>%*@L;U
M++@:3N=C%^\#OG%LS($-KI*54L_.N<EG0>0$H<#,.@1&RQ:O40@'1#)^=9A!
M3^D2#^T]^A=?.]6R8@:OE?C.<UO,@@\!Y+AFM; /JOF*73T3AY<I8?P7FC9V
M\C& K#96E5TR*2BY;%>VZ_IPD!#';R3$74+L=;=$7N6"698F6C6@732A.<.7
MZK-)')?N4I96TRFG/)L^X!9EC7"MI-74(KCE;,4%MQP-/.+.PND"+>/"G,$)
M< F/A:H-D[E)0DO\#B7,.JYYRQ6_P36,X8YH"@.?98[YOP A">_5QWOU\_@H
MX@*S 8R&YQ!'<0Q/RP6<GIP=P1WU71EYW-$;N'TWF#$T&%0NB*XO+_0(!),9
MM>?'+:7!C<72_'RM&RW'^'4.-VU34[$,9P&-DT&]Q2!]_VYX$7TZ4L&XKV!\
M#)TZLT:M,8?N@L_W!JV9VDC^^_\+:#6WJ!./Z@9ZFUY.HB@)MX=:PH/W5J+>
M^*DRD*E:VO;I];O]X%ZU[_5O>#OU=TQON#0@<$VIT>"2J'4[2:UC5>5?[TI9
MF@5O%O3S0>T"Z'RME-T[CJ#_G:5_ %!+ P04    " #IBUM6L*,[[_ #  !B
M%P  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6RU6-&.VC@4_14KK5:M
M-)W$#@28!:1.I]NMU*HC:+</51],N)"H24P= UUI/[ZVR<1AF[@,PB]@)[['
MQ]<G/K;'>\:_E0F 0#_RK"@G7B+$YL;WRSB!G);7; .%?+-B/*="5OG:+S<<
MZ%('Y9E/@B#R<YH6WG2LG]WSZ9AM1986<,]1N<USRO^]A8SM)Q[V'A[,TG4B
MU -_.M[0-<Q!?-K<<UGS:Y1EFD-1IJQ '%83[R6^N0UU@&[Q3PK[LE%&:B@+
MQKZIRMOEQ L4(\@@%@J"RK\=O((L4TB2Q_<*U*O[5('-\@/Z7WKP<C +6L(K
MEGU.ER*9>$,/+6%%MYF8L?W?4 VHK_!BEI7Z%^VKMH&'XFTI6%X%2P9Y6AS^
MZ8\J$8T 0CH"2!5 -.]#1YKE'15T.N9LC[AJ+=%400]51TMR::%F92ZX?)O*
M.#&=P0Z*+: 9J"E,BS6Z!ZXGNX@!?5ADZ9KJ],T@9NLBU>6/::Y:/KL#0=.L
M?(Z>HE0^3=BVI,6R'/M",E/X?ERQN#VP(!TL[B"^1B&^0B0@!'V:WZ%G3Y\?
MP_AR8/7H2#TZHG%[';CSA'&!/@+/VSA98]7G<%-N: P33^J]!+X#;_K'$QP%
M?UJ8A36S4*.'O\W[+VG]\DZV16\%Y.77-MJA ]J]FG;/FM"*]M5O]7*%7N9L
M6XBV 1RZZ.LNU*JQF[X@HX@,QOZNA5J_IM8_<:[1?^CU]VVZD8N'D"O'(=%?
MWD.^ -Z:42OPF1F-:MJ1*R%$#F@/:MH#]T(X=!$UA8#[N-=K%\*PIC8\70AS
MMA)[RN$D'5AQSTSHJ&8]<J6#D0/:.# &$KA70M7'D12&9-"Q)."&N^'3M?"&
M[8 7>E5XPZG\K:BW$K+BGIM4XUN8N%(#=F%KV/@:MOK/A>00MJP,/4(ZY&#<
M"]OMZT@.'T0"7.W@@'-8/BP0K72LJ.>FU!@;[CL3@PMKP\;;L-6#+B2&Z%<Q
M] ;##I? QL&PW<+>,4FG:V]HCSTW<<;"\-#9E+MP,6QL#%OMYD)3/FKY_B,2
MCMKGG!BS(G:SJN?\T7M$._"9:27&R AV)0CBPLI(XPAF/X-=1!!5'T>"& T[
M_( 8LR)VLVK*X5$[13ONN3DU/D9ZSM3@PLN(\3)B/Z5=1@W]EN4A(%&''(Q=
M$;M=->7PF,VB'?;<G!HC(P-G:G!A<\38'+$?U2ZCAF&+&LA@U'%X(,;*B-W*
MFG(X?;-H!SWW6LDX7!@XNUAR87&AL;C0?E:[B!BJ/HXNEW O_/]FT6_<F*K;
MY_>4K].B1!FL9%QP/9  _'"A>Z@(MM&7J LF!,MU,0&Z!*X:R/<KQL1#1=W+
MUM?JTY]02P,$%     @ Z8M;5J1QHL:) @  G@@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S0N>&ULM9;;3N,P$(9?Q<I*JUT)D4-/P+:1*-W5(E&!8 \7
M:"_<9-I8Q';6GM+R]MA.:XI4C(34F\2'F=_?>&)/ABNI'G0%@&3-:Z%'4878
MG,6Q+BK@5!_+!H29F4O%*9JN6L2Z44!+Y\3K.$N2?LPI$U$^=&,W*A_*)=9,
MP(TB>LDY54]CJ.5J%*71=N"6+2JT W$^;.@"[@!_-S?*]&*O4C(.0C,IB(+Y
M*#I/S\9I8AV<Q1\&*[W3)C:4F90/MG-9CJ+$$D$-!5H):EZ/< %U;94,Q_^-
M:.37M(Z[[:WZ#Q>\"69&-5S(^B\KL1I%)Q$I84Z7-=[*U4_8!-2S>H6LM7N2
M56O;S2)2+#5*OG$V!)R)]DW7FXW8<4C[;SAD&X?,<;<+.<H)19H/E5P19:V-
MFFVX4)VW@6/"9N4.E9EEQ@_S*S A:?)E DA9K;\.8S2J=BXN-@KC5B%[0R'-
MR%0*K#3Y+DHH7PO$!L<S95NF<194G$!Q3#KI$<F2+ OH=7R,':?7>3-&K0&.
MB(OUB$Q %XHU[J.XOS*VY!*!ZW_[0F^%N_N%[8DYTPTM8!29(Z%!/4*4?_Z4
M]I-O >RNQ^Z&U/-KAX@2U@BB9.()J-+[(,,R/;+'\150SP/U@DI3)AA?<G(_
M!3X#M7?#@@H?W+"^Y^L?*L_] V ///8@N*U;[.L&%$4F%ML ?H'B1,[)A?D*
ME+F^]H&'I5.7^P#CB6<\":>>KM]-?5#A@WMXZOE.#Y7ZTP-@I\G+]9L<+OGO
M:*>!HQ_OE P.:N$*HR:%7 ILJX<?]<7WO"TY+^9MY9Y2M6!"DQKFQC4Y'I@[
M0+7%L.V@;%P!FDDTY<PU*_,# <H:F/FYE+CMV 7\+TG^#%!+ P04    " #I
MBUM6$#<*!PH#  "H"0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6RM
M5EUOFS 4_2L6JZ96:LIG".T2I*2T6J55JYIU>YCVX,!-0 4[LYVDVZ^?;0A+
M@*2=M!>PS3G']UQC^PXWE#WS%$"@ER(G?&2D0BRO3)/'*1287] E$/EE3EF!
MA>RRA<F7#'"B245N.I;EFP7.B!$.]=@#"X=T)?*,P -#?%44F/V:0$XW(\,V
MM@./V2(5:L ,ATN\@"F(I^4#DSVS5DFR @C/*$$,YB-C;%]%@<)KP-<,-GRG
MC923&:7/JG.7C Q+!00YQ$(I8/E:PS7DN1*28?RL-(UZ2D7<;6_5;[5WZ66&
M.5S3_%N6B'1D! 9*8(Y7N7BDFX]0^>DKO9CF7#_1IL3V70/%*RYH49%E!$5&
MRC=^J?*P0[#] P2G(CA-@G> X%8$]ZT$KR)X.C.E%9V'" L<#AG=(*;04DTU
M=#(U6]K/B%KVJ6#R:R9Y(OP$,FD<Z1>ZIER@TP@$SG)^AGKH:1JATY,S=((R
M@KZD=,4Q2?C0%')FQ3?C:I9).8MS8!;;0?>4B)2C&Y) LB]@RI#KN)UMW!/G
MJ&($\05R[7/D6([3$=#UV^EV!SUZ.]TZXL:M5\'5>N[Q5?@^GG'!Y%;XT97B
M4L+KEE#'PQ5?XAA&AMS_'-@:C/#].]NW/G2EYW^*1?]);"]U7ITZ[YAZ^'D)
M#(N,+,I_^%S_Q%WI*V7Z6D8=ANO0<2PW&)KKW;RT4;;M].U]5-2)"KP:M>>D
M7SOI'W5RFQ%,8MCZN","9+H$NGF19SR'+D^EH+\?1\-1!\9I8*(VYM+N-N/7
M9OQ_,:.ODQZ=]Y[D,3/F',0Y&A>4B>PW5N=_ESF_%=2@9:Z-\;W&DD9MC!NX
MW>X&M;O!47?35(;>D^M3O/;7#=HF&A;:"-MK.&A#'/^ @Z!V$!QU\$K80<=F
M"?S+1NAME"VW5+\1?2?*:?Y?YLX=5@!;Z%J HYBNB"BOA7JT+C?&^I9MC$]D
M&5)6#7]ERAKF'K-%1CC*82XEK8N!C(F5=4'9$72I;\H9%?+>U<U4EE+ %$!^
MGU,JMATU05V<A7\ 4$L#!!0    ( .F+6U8\L2L]:0,  +@*   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;*V6;6_;-A#'OPJA%4,+)-&#+5G); %)
MW& !6C1HEN[%L!>T=+:(2J1*4G&R3[\C):NVK @ID#>V2-[]=;_CB;SY5LCO
M*@?0Y*DLN%HXN=;5A>NJ-(>2JC-1 <>5M9 EU3B4&U=5$FAFG<K"#3PO<DO*
MN)/,[=R=3.:BU@7C<">)JLN2RN<K*,1VX?C.;N(KV^3:3+C)O*(;N ?]4-U)
M'+F=2L9*X(H)3B2L%\ZE?[&,C;TU^,9@J_:>B2%9"?'=#&ZSA>.9@*" 5!L%
MBG^/< U%880PC!^MIM.]TCCN/^_4;RP[LJRH@FM1_,TRG2^<V"$9K&E=Z*]B
M^R>T/*'12T6A["_9MK:>0])::5&VSAA!R7CS3Y_:/.PY^-$+#D'K$/0=IB\X
M3%J'R6L=IJW#U&:F0;%Y6%)-D[D46R*--:J9!YM,ZXWXC)MMO]<25QGZZ>03
M8-(4N:^KJ@#<3DT+<DU53FZP((A=);>\*2^S3^^7H"DKU =R2A[NE^3]NP_D
M'6&<_)6+6E&>J;FK,2ZC[J9M#%=-#,$+,?@!^2RXSA7YR#/(#@5<!.JH@AW5
M53"JN(3TC$S\$Q)X03 0T/7KW?T!]^7KW;T1FDFW1Q.K-QG?HW\N5TI+_%#^
M'4IQ(S$=EC"'QX6J: H+!T\'!?(1G.3WW_S(^V,H/6\IMGPCL8/43;O43<?4
MDR\52"Q<OFE*^83<T6=3Y8-5VDB%5LH<EX])$ 9!.'<?]W-S;.7[01@=6BT'
MK#P__JEU0!-V-.$HS0WCE*>P8[GE&C!E>@=%\/O\Q.B*%4P_#P$VZM%AZ#V\
M 9N@9[,\MCGWA\FBCBP:);/7S:E8GS[@>7.I%-YW7U9XT'#(S.'R\2G-*=\
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M1RR&B6KC@>L)ZOJ",?D2Z$:Q^F,0_@=02P,$%     @ Z8M;5C?WY(Y3 P
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MK7KR'R!A"TK^@/HP+-B*-AK0/4D\\!W'.;*@-=%_/;ZO1';@::_VM/>_/)T
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MN81PC19;T;X:5Z$>X3U@J-MIA;TCR.IJCJSEM.9QA\CTN3'E"8O?@,_V(>X
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MNA5*&"4LE1%/D6#3T\X9/O')4#OD%G]$;"E7KI$.9<+Y-WUS%9YV/#TB%K-
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M30\ZP3Q-8"5I^KDT_?\W3@IZ?F,PX@O$.%!)AB[ %&T0 9TZT1J].C=*^I4
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MMPNGJB%BR^0XF\L=?AR)]%@R;\V/S.^2@^*#]GOKQDT/OO<PZ3G\(V1+''%
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MOI5 V@"SOQ)"/T_L==Q]?65_ 5!+ P04    " #IBUM6 ,!TES(.  "HJ@
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&ULS9UM;]RX$<>_BK ]%'>
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MZP>/464JF?=&3!PY<0H. ;XQ&4FFV"0)Y@X\XP_W1?GRFP#.E %G:A=PIJC
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M6<D55WD(S=Q ^I@C7UB?![]RX L*I4DP*AT8D0TBG&X0D0@'"3+F.4]$6,I
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MM'__6I;-X<.\M?]45M^V;2S^#U!+ P04    " #IBUM6!0K)_; #  #B#0
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M/PG?2. NV@7.U:NQ16/<#8T[/_!>53&_BZY[,A:&<5\PC$\!P]C",#YVM7B
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M@;(3\/M22O/0L9>%^JX7_P902P,$%     @ Z8M;5A)E\ T"!   61   !H
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M=.\/PFS0ZPO.U=/$**C_39A\!5!+ P04    " #IBUM6EWU@5(("  !D!P
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M$IEX&_"=PD;NM)%1,N/\R71NLI'CF80@AU09!J(?:YA"GALBG<;OFM-IIC3
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M)D"_GW.NMATS07-3BO\"4$L#!!0    ( .F+6U8@9!C[; 8  -XB   :
M>&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6RUFOUOXC88Q_\5B]U-=U)7L.,
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M[ KY+3RGBJGOS=8@[RJ987S@7]KO93E5S+=JG!UH\!V$!W><P.L(^XYZ@_G
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M?Z9*G,'8,]^W KD!+WW_+HR#3QUP_1:N[]3[>^ Z0_MP;5:CJ0:F?NT"[Q\
M?-""#SJCV@6^B[56&SHU>R5LTK W2OS-#H23%N&D$V&FL0:$>6X0,DS1U[4D
M*B?UL7ZX ;8 N3-NG;*OC%O<0L>'2WA\ /#3%OST31->JX6#K8P/>OW=&1^V
M#,-.!G/AFNN4VVL)G:]U(231SYVI[M1[9<1&+>WH<*D>'0 \#/[>_L&;)KN1
MVS[>@_B_;/M;]<C6]ALL5X0K1&%IS(+>J3F8LBZ7=4>+TI6HA="FX+EF87XQ
M0-H%9GXIA'[IV*K7_K2D?P!02P,$%     @ Z8M;5KDI&2E8 @  904  !H
M  !X;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;(64;4_;,!#'OXJ5H0DDU#1I
M ZA+(Q6J:4A#0S#8BVDOW.3:6CAVYG.:\NUW=M*H;*5[$S_=_>_GNYS31IL7
M7 -8MBVEPFFPMK::A"'F:R@Y#G0%BDZ6VI3<TM*L0JP,\,([E3*,A\.+L.1"
M!5GJ]^Y-ENK:2J'@WC"LRY*;UVN0NID&4;#;>!"KM74;8996? 6/8)^J>T.K
ML%<I1 D*A5;,P'(:S*+)=>+LO<&S@ ;WYLS=9*'UBUO<%M-@Z(! 0FZ= J=A
M S<@I1,BC-^=9M"'=([[\YWZ9W]WNLN"(]QH^4,4=CT-K@)6P)+7TC[HY@MT
M]_& N9;HOZQI;9,D8'F-5I>=,Q&40K4CWW9YV'.(XW<<XLXA]MQM($\YYY9G
MJ=$-,\Z:U-S$7]5[$YQ0KBB/UM"I(#^;W:I<E\"^\RV@^[(;;LPK%;OAID!V
M.@?+A<0S=L*$8G="2LHEIJ&EV$XAS+LXUVV<^)TX<\@';!2=LW@8Q^SI<<Y.
M3\[>RH2$WO/'/7_L=4?_Y6=S@;G46!M@/V<+M(8J_NL0::LX/JSHNF""%<]A
M&M!OCF V$&0?/T07PT]'>$<][^B8>N93;* 0]DVFS]FLU+6RAW!;P2LOZ'IL
MDT57@R0--P<PQCW&^"C&MPH,MT*MV%>-^+;HY^R9RYK[IIE)ZEJN<C@$UH:(
MQOMDT7MD24^6'"6;PQ(,)<B7=(8(EH".X1XB2_Y-63RX_ LLW.L:]P#=<;,2
M"IF$);D-!Y>D8MJF;A=65[Z1%MI26_KIFMY!,,Z SI=:V]W"]6;_LF9_ %!+
M P04    " #IBUM60O)]JY,"  "?!@  &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q,C N>&ULK55=;],P%/TK5V%"FS2:C[9;&6VD?H VB4G5RN !\> EMXDU
MQPZVVV[_'MM)LZQD R3RD-C7]QR?<RW?C'="WJL<4<-#P;B:>+G6Y87OJR3'
M@JB>*)&;E;60!=%F*C-?E1))ZD %\Z,@./,+0KD7CUUL*>.QV&A&.2XEJ$U1
M$/DX0R9V$R_T]H$;FN7:!OQX7)(,5ZAORZ4T,[]A26F!7%'!0>)ZXDW#B_G0
MYKN$KQ1WJC4&Z^1.B'L[N4HG7F %(<-$6P9B/EN<(V.6R,CX67-ZS986V![O
MV3\Y[\;+'5$X%^P;374^\48>I+@F&Z9OQ.X2:S].8"*8<F_8U;F!!\E&:5'4
M8*.@H+SZDH>Z#BU >/8"(*H!T2%@\ *@7P/ZSFBES-E:$$WBL10[D#;;L-F!
MJXU#&S>4VU-<:6E6J<'I^(HGHD#X0AY0V3=<"D93\@C'"]2$,G4"[^!VM8#C
MHQ,X A]43J1)I1QN.=7JU 3-^)HR9DY%C7UM1%EJ/ZD%S"H!T0L"P@BN!=>Y
M@H\\Q?0Y@6_<-):BO:59]"KC I,>],-3B((HZA T_WMX^(J<?E/AON/K_['"
M36V_?S8Y<*6Q4#^Z*E81#KH)[;V^4"5)<.*9BZM0;M&+W[X)SX(/76[_$]DS
M[X/&^^ U]@[OIS#-,HD9T0@+P1B1,"W$ANNN.E3D(T=NV]$V'O7,D6S;]G[/
M>=\;!>WG"?',P[#Q,/QG#ZW8##FNS46 )4I8V<O1Y:3:XKRE,NCU!P=6NI(&
MPP/U?NNN%R@SUP(5)+:&U1UIHDV7G;KF<A"?F>Y;-<LGFJIU7Q.94:Z X=I0
M!KUS(TQ6[;"::%&ZCG(GM.E/;IB;/PA*FV#6UT+H_<1NT/R3XE]02P,$%
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MW$J]*]L*PBDABJ^QAR&$+G(<;]!_:">R;1=8#K3LQDP)T6E"=+0ACC]/OXS
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MOVEY0Z.<%_%8%G_19EMV?-9#42853\I@78.$I=O_X<^R(78"7&]/ "X#\,N
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M6=,? *Q/H/.M,7@,_%2>_BG%7U!+ P04    " #IBUM6<,;+B0<"   F!
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MCR+BHXC$F,E G?Q.)]^*3F.P6&'V0%+ *:!\19A8Q9II3B=<<]-@+VDO]-Q
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MLF9K57/"Z:;>._2)<D[7]>&*X)2P"B!^7U+*7TZJ&W0;W&;_ 5!+ P04
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MJG<'Z-U5[P[0NZO>':!W5[T[0._N'O8&Z-U5[P[0>ZC> Z#W4+T'0.^A>@^
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MEJ+NYB=02P$"% ,4    " #IBUM6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .F+6U:AN(P;[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .F+6U:97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Z8M;5D6,HN/2!P  A2\  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( .F+6U:Y0XB800(  +H%   8              " @140  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #IBUM68T^XE^4'  !I
M'P  &               @(&,$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ Z8M;5B;H[FGF!0  N1<  !@              ("!IQH
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .F+6U99N#NE
M30,  /D)   8              " @<,@  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #IBUM6_+4.%9H)  #65P  &
M@(%&)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Z8M;
M5O5I<@@(#@  ?TT  !@              ("!%BX  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( .F+6U9'KU?#?0,  %@,   8
M      " @50\  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #IBUM6/=GJGNL"  #$"   &               @($'0   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ Z8M;5M>Z[6_5(P  .&D  !D
M             ("!*$,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #IBUM6<GT8_Q4/   O*   &0              @($T9P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .F+6U;' ]SI(P4
M %D,   9              " @8!V  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ Z8M;5MZM'X1)#   _A\  !D              ("!
MVGL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #IBUM6
M/-JLN"L(  "S%0  &0              @(%:B   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( .F+6U;?H-I.91,  !!$   9
M      " @;R0  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ Z8M;5F/P8_24#   2"8  !D              ("!6*0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #IBUM6!YFL33\0   U,@
M&0              @($CL0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( .F+6U9>QE6MX0,  ($(   9              " @9G!  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ Z8M;5LG?5ND9
M!0  ,PP  !D              ("!L<4  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #IBUM6.D_3<4H1  " -@  &0
M@($!RP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .F+
M6U9'"4+8 @T  &@@   9              " @8+<  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ Z8M;5L:#.7%?!   RP@  !D
M         ("!N^D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #IBUM6TB)&?IL%  "3#@  &0              @(%1[@  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .F+6U8H'-@I  D  (07
M   9              " @2/T  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ Z8M;5NX?F[0P!0  = P  !D              ("!6OT
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #IBUM6?34J
M,J$$  !$"@  &0              @('! @$ >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( .F+6U;RVL84L@,  /4)   9
M  " @9D' 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MZ8M;5I'A2Q?C%P  C4D  !D              ("!@@L! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #IBUM6K9&QEE ,  "P(P  &0
M            @(&<(P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( .F+6U9LI$G<B@8  ' /   9              " @2,P 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ Z8M;5K8G7H;* P
M<0@  !D              ("!Y#8! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #IBUM62V7V0\@&  !G$0  &0              @('E
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .F+6U9>
MR!Y2N04   $0   9              " @>1! 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ Z8M;5GM[B!8T!P  \Q0  !D
M     ("!U$<! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F+6U8&/; Q_P4  !<1   9              "
M@8ED 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ Z8M;
M5A00C7#^!P  +Q0  !D              ("!OVH! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #IBUM64^QB)7 #  #Y!@  &0
M        @('T<@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( .F+6U80;T=DTP,  .,(   9              " @9MV 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ Z8M;5H=>&X$] @  UP0
M !D              ("!I7H! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #IBUM6)5DZJJ0"  #\!@  &0              @($9?0$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .F+6U91,@Z^
MLP0  /89   9              " @?1_ 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ Z8M;5@^&'/U=!   \!T  !D
M ("!WH0! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #I
MBUM6.#:/G) "  #'!@  &0              @(%RB0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .F+6U:<S3$]' 0   T3   9
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M970U,BYX;6Q02P$"% ,4    " #IBUM6#38O)($$  #/&   &0
M    @(&>H $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M .F+6U;>_JZZQ0(  !$)   9              " @5:E 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ Z8M;5F-!-.F9 @  SP8  !D
M             ("!4J@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #IBUM6M9LC.ZL"    !P  &0              @($BJP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .F+6U89C;*I[P(
M 'P(   9              " @02N 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ Z8M;5@X^4^U$ P  ;0D  !D              ("!
M*K$! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #IBUM6
MC2TTC.<#  !:#   &0              @(&EM $ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .F+6U90#?I>A08  (@/   9
M      " @<.X 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ Z8M;5NGOW 9[!   -Q$  !D              ("!?[\! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #IBUM6/; N>!,'  #A,
M&0              @($QQ $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( .F+6U;QV_"YW@,  / 2   9              " @7O+ 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ Z8M;5@&FUN'Y
M @  I D  !D              ("!D,\! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " #IBUM69C;!"/X#   N$0  &0
M@(' T@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .F+
M6U:!:JUKW@,  $02   9              " @?76 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ Z8M;5D5,GJH[!0  51X  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( .F+6U:[Q0$B30(  -H$   9
M  " @07R 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
MZ8M;5K"C.^_P P  8A<  !D              ("!B?0! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " #IBUM6I'&BQHD"  ">"   &0
M            @(&P^ $ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( .F+6U80-PH'"@,  *@)   9              " @7#[ 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ Z8M;5CRQ*SUI P
MN H  !D              ("!L?X! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " #IBUM6A)J,^W0#  !O"P  &0              @(%1
M @( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( .F+6U:#
MZU.6CP,  )P,   9              " @?P% @!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ Z8M;5N+\OS(= P  E@P  !D
M     ("!P@D" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F+6U;4!+X D 0  / 1   9              "
M@9H; @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ Z8M;
M5F\0X-_R 0  % 0  !D              ("!82 " 'AL+W=O<FMS:&5E=',O
M<VAE970X-2YX;6Q02P$"% ,4    " #IBUM6VK:M(_0"  !R"   &0
M        @(&*(@( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0
M   ( .F+6U;W"X,@!P4  /@9   9              " @;4E @!X;"]W;W)K
M<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ Z8M;5J=NR8:*!   /Q0
M !D              ("!\RH" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q0
M2P$"% ,4    " #IBUM6@X:8G"H"  "U!   &0              @(&T+P(
M>&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( .F+6U;"O;'U
M\@0  $D<   9              " @14R @!X;"]W;W)K<VAE971S+W-H965T
M.3 N>&UL4$L! A0#%     @ Z8M;5@%A?V;* P  ?A(  !D
M ("!/C<" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " #I
MBUM6DPB X84&  !9-0  &0              @($_.P( >&PO=V]R:W-H965T
M<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( .F+6U93SHP+GP4  ,0E   9
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M970Y-RYX;6Q02P$"% ,4    " #IBUM6T^2[0&,#  "^#P  &0
M    @(%860( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    (
M .F+6U9Y/XAWQ (  (D)   9              " @?)< @!X;"]W;W)K<VAE
M971S+W-H965T.3DN>&UL4$L! A0#%     @ Z8M;5@# =)<R#@  J*H  !H
M             ("![5\" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L!
M A0#%     @ Z8M;5@4*R?VP P  X@T  !H              ("!5VX" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ Z8M;5EM6+:N0
M P  Z@L  !H              ("!/W(" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#(N>&UL4$L! A0#%     @ Z8M;5HGU(S_9!   =Q,  !H
M ("!!W8" 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @
MZ8M;5N;U !NB P  +@T  !H              ("!&'L" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#0N>&UL4$L! A0#%     @ Z8M;5A,*X,7#!   RA\  !H
M             ("!\GX" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L!
M A0#%     @ Z8M;5O,W9#>? @  ]PD  !H              ("![8," 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ Z8M;5A)E\ T"
M!   61   !H              ("!Q(8" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#<N>&UL4$L! A0#%     @ Z8M;5I=]8%2" @  9 <  !H
M ("!_HH" 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @
MZ8M;5C%J$M\$ P  -0D  !H              ("!N(T" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#DN>&UL4$L! A0#%     @ Z8M;5B!D&/ML!@  WB(  !H
M             ("!]) " 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L!
M A0#%     @ Z8M;5J$E'9)7 @  V 4  !H              ("!F)<" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%     @ Z8M;5MX-V;5U
M @  Z@4  !H              ("!)YH" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,3(N>&UL4$L! A0#%     @ Z8M;5AZ6/7[D @  K0@  !H
M ("!U)P" 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @
MZ8M;5A9#<V2P P  G T  !H              ("!\)\" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,30N>&UL4$L! A0#%     @ Z8M;5E#Z7*PX @  S@0  !H
M             ("!V*," 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L!
M A0#%     @ Z8M;5G5R#A<T!@  R1T  !H              ("!2*8" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,38N>&UL4$L! A0#%     @ Z8M;5E."]Y-K
M!0  ?1<  !H              ("!M*P" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,3<N>&UL4$L! A0#%     @ Z8M;5@,ST[2= @  P @  !H
M ("!5[(" 'AL+W=O<FMS:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%     @
MZ8M;5KDI&2E8 @  904  !H              ("!++4" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,3DN>&UL4$L! A0#%     @ Z8M;5D+R?:N3 @  GP8  !H
M             ("!O+<" 'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL4$L!
M A0#%     @ Z8M;5N[1D+$< @  3P0  !H              ("!A[H" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,C$N>&UL4$L! A0#%     @ Z8M;5M0Q16PF
M!   @A(  !H              ("!V[P" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,C(N>&UL4$L! A0#%     @ Z8M;5KQCSL3I!0  12<  !H
M ("!.<$" 'AL+W=O<FMS:&5E=',O<VAE970Q,C,N>&UL4$L! A0#%     @
MZ8M;5H2Y-E10 P  Y@H  !H              ("!6L<" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,C0N>&UL4$L! A0#%     @ Z8M;5NQ1N:;"!0  I20  !H
M             ("!XLH" 'AL+W=O<FMS:&5E=',O<VAE970Q,C4N>&UL4$L!
M A0#%     @ Z8M;5KC0ED_.!0  ;C(  !H              ("!W- " 'AL
M+W=O<FMS:&5E=',O<VAE970Q,C8N>&UL4$L! A0#%     @ Z8M;5F/HC;$=
M @  7P0  !H              ("!XM8" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,C<N>&UL4$L! A0#%     @ Z8M;5G#&RXD' @  )@0  !H
M ("!-]D" 'AL+W=O<FMS:&5E=',O<VAE970Q,C@N>&UL4$L! A0#%     @
MZ8M;5ER3/5 X!@  ["8  !H              ("!=ML" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,CDN>&UL4$L! A0#%     @ Z8M;5B>P#D?G 0  4 0  !H
M             ("!YN$" 'AL+W=O<FMS:&5E=',O<VAE970Q,S N>&UL4$L!
M A0#%     @ Z8M;5F,L12Y1 P  CA4   T              ( !!>0" 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #IBUM6EXJ[',     3 @  "P
M        @ &!YP( 7W)E;',O+G)E;'-02P$"% ,4    " #IBUM6D4U^7C()
M  "350  #P              @ %JZ ( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ Z8M;5H\_#JN) P  /4P  !H              ( !R?$" 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Z8M;5H,N+ VX @
M[T@  !,              ( !BO4" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     (H B@ <)@  <_@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>465</ContextCount>
  <ElementCount>643</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>144</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statement of Comprehensive Income (Statement)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StatementofComprehensiveIncomeStatement</Role>
      <ShortName>Statement of Comprehensive Income (Statement)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Statement of Comprehensive Income (Paranthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical</Role>
      <ShortName>Statement of Comprehensive Income (Paranthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - General and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>General and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisitions (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsNotes</Role>
      <ShortName>Acquisitions (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restructuring, Strategic Transaction and Integration (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes</Role>
      <ShortName>Restructuring, Strategic Transaction and Integration (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenue (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/RevenueNotes</Role>
      <ShortName>Revenue (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/LeasesNotes</Role>
      <ShortName>Leases (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Share Based Award Share awards (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardShareawardsNotes</Role>
      <ShortName>Share Based Award Share awards (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Derivatives and Hedging Activities (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes</Role>
      <ShortName>Derivatives and Hedging Activities (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurement (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementNotes</Role>
      <ShortName>Fair Value Measurement (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Prepaids and Other Current Assets (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes</Role>
      <ShortName>Prepaids and Other Current Assets (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Accrued Liabilities an Other Long-term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities</Role>
      <ShortName>Accrued Liabilities an Other Long-term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes:</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes</Role>
      <ShortName>Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Collaborative and Other Arrangements (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes</Role>
      <ShortName>Collaborative and Other Arrangements (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts</Role>
      <ShortName>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - General and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>General and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - General and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>General and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Business Combination and Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables</Role>
      <ShortName>Business Combination and Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables</Role>
      <ShortName>Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/RevenueNotes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/LeasesNotes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Share Based Award (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardTables</Role>
      <ShortName>Share Based Award (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/ShareBasedAwardShareawardsNotes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Derivatives and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesTables</Role>
      <ShortName>Derivatives and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/FairValueMeasurementNotes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Prepaids and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaids and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Accrued Liabilities an Other Long-term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities an Other Long-term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/Debt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Income Taxes Income tax disclosure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables</Role>
      <ShortName>Income Taxes Income tax disclosure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Geographic Information and Significant Customers Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables</Role>
      <ShortName>Geographic Information and Significant Customers Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.icumed.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - General and Summary of Significant Accounting Policies Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - General and Summary of Significant Accounting Policies Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #1 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details</Role>
      <ShortName>General and Summary of Significant Accounting Policies Property and Equipment #1 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details</Role>
      <ShortName>General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details</Role>
      <ShortName>General and Summary of Significant Accounting Policies Property and Equipment #3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - General and Summary of Significant Accounting Policies Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #1 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details</Role>
      <ShortName>General and Summary of Significant Accounting Policies Intangible Assets #1 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #2 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details</Role>
      <ShortName>General and Summary of Significant Accounting Policies Intangible Assets #2 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - General and Summary of Significant Accounting Policies Other Investments(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Other Investments(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - General and Summary of Significant Accounting Policies Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - General and Summary of Significant Accounting Policies Investments-Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Investments-Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - General and Summary of Significant Accounting Policies Foreign Currency (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Foreign Currency (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - General and Summary of Significant Accounting Policies Other (expense) income, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Other (expense) income, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - General and Summary of Significant Accounting Policies Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails</Role>
      <ShortName>General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Acquisitions Text (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsTextDetails</Role>
      <ShortName>Acquisitions Text (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Acquisitions Smiths Medical 2020 Limited Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails</Role>
      <ShortName>Acquisitions Smiths Medical 2020 Limited Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Acquisitions Smiths Medical 2020 Limited Intangible (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails</Role>
      <ShortName>Acquisitions Smiths Medical 2020 Limited Intangible (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Acquisitions Foreign Infusion Systems Supplier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails</Role>
      <ShortName>Acquisitions Foreign Infusion Systems Supplier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Acquisitions Smiths Medical Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails</Role>
      <ShortName>Acquisitions Smiths Medical Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1</Role>
      <ShortName>Restructuring, Strategic Transaction and Integration (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2</Role>
      <ShortName>Restructuring, Strategic Transaction and Integration (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails</Role>
      <ShortName>Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Revenue Disaggregation of Revenue - Product Line (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails</Role>
      <ShortName>Revenue Disaggregation of Revenue - Product Line (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Revenue Disaggregation of Revenue by Geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails</Role>
      <ShortName>Revenue Disaggregation of Revenue by Geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Revenue Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Revenue Contract Liabilities Text (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails</Role>
      <ShortName>Revenue Contract Liabilities Text (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Revenue Remaining Performance Obligation Recognition Timing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails</Role>
      <ShortName>Revenue Remaining Performance Obligation Recognition Timing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/LeasesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Leases Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Leases Supplemental Cash Flow Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails</Role>
      <ShortName>Leases Supplemental Cash Flow Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Leases Supplemental Balance Sheet Lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails</Role>
      <ShortName>Leases Supplemental Balance Sheet Lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Finance Leases Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Finance Leases Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Leases Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesLeaseMaturityDetails</Role>
      <ShortName>Leases Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Leases Finance Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails</Role>
      <ShortName>Leases Finance Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Share Based Award Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails</Role>
      <ShortName>Share Based Award Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Share Based Award Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails</Role>
      <ShortName>Share Based Award Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Share Based Award Stock Options Granted and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails</Role>
      <ShortName>Share Based Award Stock Options Granted and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Share Based Award Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails</Role>
      <ShortName>Share Based Award Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Share Based Award Share Award data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails</Role>
      <ShortName>Share Based Award Share Award data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Share Based Award Options exercised data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails</Role>
      <ShortName>Share Based Award Options exercised data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Share Based Award RSU and PRSU (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails</Role>
      <ShortName>Share Based Award RSU and PRSU (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Share Based Award RSU and PRSU Roll forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails</Role>
      <ShortName>Share Based Award RSU and PRSU Roll forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Share Based Award ESPP Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails</Role>
      <ShortName>Share Based Award ESPP Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails</Role>
      <ShortName>Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Derivatives and Hedging Activities Interest Rate Contracts(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails</Role>
      <ShortName>Derivatives and Hedging Activities Interest Rate Contracts(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Derivatives and Hedging Activities Derivative Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails</Role>
      <ShortName>Derivatives and Hedging Activities Derivative Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails</Role>
      <ShortName>Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Fair Value Measurement Smiths Medical(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails</Role>
      <ShortName>Fair Value Measurement Smiths Medical(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Fair Value Measurement Text Pursuit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails</Role>
      <ShortName>Fair Value Measurement Text Pursuit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Fair Value Measurement Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementRollForwardDetails</Role>
      <ShortName>Fair Value Measurement Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails</Role>
      <ShortName>Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Fair Value Measurement Smiths Medical Simulation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails</Role>
      <ShortName>Fair Value Measurement Smiths Medical Simulation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Fair Value Measurement Fair Value Measurements, Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement Fair Value Measurements, Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Prepaids and Other Noncurrent Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails</Role>
      <ShortName>Prepaids and Other Noncurrent Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/OtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan A(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails</Role>
      <ShortName>Applicable Margin Based on Leverage Ratio Term Loan A(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan B (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails</Role>
      <ShortName>Applicable Margin Based on Leverage Ratio Term Loan B (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/DebtTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Debt Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DebtMaturityDetails</Role>
      <ShortName>Debt Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Debt Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - 2022 Credit Facility Text (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/A2022CreditFacilityTextDetails</Role>
      <ShortName>2022 Credit Facility Text (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/PrincipalPaymentsDetails</Role>
      <ShortName>Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - 2017 Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/A2017CreditFacilityDetails</Role>
      <ShortName>2017 Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - Income Taxes Income (Loss) from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes Income (Loss) from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - Income Taxes Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails</Role>
      <ShortName>Income Taxes Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - Income Taxes Change in taxes payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails</Role>
      <ShortName>Income Taxes Change in taxes payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - Income Taxes Effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails</Role>
      <ShortName>Income Taxes Effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - Income Taxes Deferred income tax assets (liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails</Role>
      <ShortName>Income Taxes Deferred income tax assets (liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - Income Taxes Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - Income Taxes Tax Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails</Role>
      <ShortName>Income Taxes Tax Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - Income Taxes Tax Holiday (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails</Role>
      <ShortName>Income Taxes Tax Holiday (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - Income Taxes Undistributed foreign earnings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails</Role>
      <ShortName>Income Taxes Undistributed foreign earnings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000125 - Disclosure - Income Taxes Unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails</Role>
      <ShortName>Income Taxes Unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000126 - Disclosure - Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails</Role>
      <ShortName>Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000127 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/StockholdersEquityTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>0000128 - Disclosure - Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>0000129 - Disclosure - Commitments and Contingencies Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>0000130 - Disclosure - Collaborative and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails</Role>
      <ShortName>Collaborative and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>0000131 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/SubsequentEvents</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>0000132 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails</Role>
      <ShortName>SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="icui-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - icui-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - icui-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName -  icui-20221231.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 12 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration, us-gaap:FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList, us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList, us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList, us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList -  icui-20221231.htm 4</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '0000054 - Disclosure - General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)', a level 4, Detail role, appears before '0000055 - Disclosure - General and Summary of Significant Accounting Policies Other Investments(Details)', a level 1, Note role. icui-20221231.xsd 341, 347</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '0000092 - Disclosure - Share Based Award ESPP Narrative (Details)', a level 4, Detail role, appears before '0000093 - Disclosure - Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)', a level 1, Note role. icui-20221231.xsd 569, 575</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '0000097 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)', a level 4, Detail role, appears before '0000098 - Disclosure - Fair Value Measurement Smiths Medical(Details)', a level 1, Note role. icui-20221231.xsd 599, 605</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '0000107 - Disclosure - Other Liabilities (Details)', a level 4, Detail role, appears before '0000108 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan A(Details)', a level 1, Note role. icui-20221231.xsd 659, 665</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="icui-20221231.htm">icui-20221231.htm</File>
    <File>exhibit103executiveofficer.htm</File>
    <File>exhibit104non-employeedire.htm</File>
    <File>exhibit106amendedandrestat.htm</File>
    <File>exhibit21subsidiariesofreg.htm</File>
    <File>exhibit231consentofdeloitt.htm</File>
    <File>exhibit311123122.htm</File>
    <File>exhibit312123122.htm</File>
    <File>exhibit32123122.htm</File>
    <File>icui-20221231.xsd</File>
    <File>icui-20221231_cal.xml</File>
    <File>icui-20221231_def.xml</File>
    <File>icui-20221231_lab.xml</File>
    <File>icui-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>icui-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1585">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>153
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "icui-20221231.htm": {
   "axisCustom": 5,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 1585,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 465,
   "dts": {
    "calculationLink": {
     "local": [
      "icui-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "icui-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "icui-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "icui-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "icui-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "icui-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 1003,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 18
   },
   "keyCustom": 102,
   "keyStandard": 541,
   "memberCustom": 59,
   "memberStandard": 82,
   "nsprefix": "icui",
   "nsuri": "http://www.icumed.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.icumed.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - General and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies",
     "shortName": "General and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Fair Value Measurement Fair Value Measurements, Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
     "shortName": "Fair Value Measurement Fair Value Measurements, Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Prepaids and Other Noncurrent Assets (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails",
     "shortName": "Prepaids and Other Noncurrent Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:AccruedSalariesAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.icumed.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:AccruedSalariesAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:SupplementalBalanceSheetInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.icumed.com/role/OtherLiabilitiesDetails",
     "shortName": "Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan A(Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
     "shortName": "Applicable Margin Based on Leverage Ratio Term Loan A(Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:InterestMarginandCommitmentFeeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i85c800885ad645afbf1ee8116a89418e_D20220101-20221231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i04e492dc437f484fa3e50ad7d36f77eb_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "icui:ApplicableMarginTermSOFRLoans",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Applicable Margin Based on Leverage Ratio Term Loan B (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails",
     "shortName": "Applicable Margin Based on Leverage Ratio Term Loan B (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "id34fa01e4d2b483792e00d21e1d5819a_I20221231",
      "decimals": "4",
      "lang": "en-US",
      "name": "icui:ApplicableMarginTermSOFRLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Debt (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.icumed.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Debt Maturity (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.icumed.com/role/DebtMaturityDetails",
     "shortName": "Debt Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:InterestExpenseOnLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Debt Interest Expense (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.icumed.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:InterestExpenseOnLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Acquisitions (Notes)",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.icumed.com/role/AcquisitionsNotes",
     "shortName": "Acquisitions (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "icui:TotalSeniorSecuredCreditFacility",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - 2022 Credit Facility Text (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
     "shortName": "2022 Credit Facility Text (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "icui:TotalSeniorSecuredCreditFacility",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - Principal Payments (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.icumed.com/role/PrincipalPaymentsDetails",
     "shortName": "Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ia61ffd5ad7fb4909b022b3d1f315f9bf_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - 2017 Credit Facility (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.icumed.com/role/A2017CreditFacilityDetails",
     "shortName": "2017 Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - Income Taxes Income (Loss) from Continuing Operations (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails",
     "shortName": "Income Taxes Income (Loss) from Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - Income Taxes Tax Provision (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails",
     "shortName": "Income Taxes Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - Income Taxes Change in taxes payable (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails",
     "shortName": "Income Taxes Change in taxes payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - Income Taxes Effective tax rate (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails",
     "shortName": "Income Taxes Effective tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:Noncurrentdeferredtaxasset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - Income Taxes Deferred income tax assets (liabilities) (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails",
     "shortName": "Income Taxes Deferred income tax assets (liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:Noncurrentdeferredtaxasset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ic74afdfeacf44457849b250892ba31a7_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - Income Taxes Operating Loss Carryforwards (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ic74afdfeacf44457849b250892ba31a7_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - Income Taxes Tax Carryforwards (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails",
     "shortName": "Income Taxes Tax Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restructuring, Strategic Transaction and Integration (Notes)",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes",
     "shortName": "Restructuring, Strategic Transaction and Integration (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - Income Taxes Tax Holiday (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails",
     "shortName": "Income Taxes Tax Holiday (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - Income Taxes Undistributed foreign earnings (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails",
     "shortName": "Income Taxes Undistributed foreign earnings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000125 - Disclosure - Income Taxes Unrecognized tax benefits (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails",
     "shortName": "Income Taxes Unrecognized tax benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000126 - Disclosure - Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails",
     "shortName": "Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000127 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.icumed.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000128 - Disclosure - Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i3688a319945e4943a3dc05ede3f036d1_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000129 - Disclosure - Commitments and Contingencies Contingencies (Details)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
     "shortName": "Commitments and Contingencies Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "icui:ContingentConsiderationGrossLT",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000130 - Disclosure - Collaborative and Other Arrangements (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails",
     "shortName": "Collaborative and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "icui:AccountsReceivablePurchaseProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000131 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://www.icumed.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "icui:AccountsReceivablePurchaseProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:WarrantyAndReturnReserveInventoryWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000132 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails",
     "shortName": "SEC Schedule, Article 12-09, Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:WarrantyAndReturnReserveInventoryWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Revenue (Notes)",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.icumed.com/role/RevenueNotes",
     "shortName": "Revenue (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:LesseeOperatingAndFinanceLeaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases (Notes)",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.icumed.com/role/LeasesNotes",
     "shortName": "Leases (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:LesseeOperatingAndFinanceLeaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Share Based Award Share awards (Notes)",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.icumed.com/role/ShareBasedAwardShareawardsNotes",
     "shortName": "Share Based Award Share awards (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Derivatives and Hedging Activities (Notes)",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes",
     "shortName": "Derivatives and Hedging Activities (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurement (Notes)",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.icumed.com/role/FairValueMeasurementNotes",
     "shortName": "Fair Value Measurement (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Prepaids and Other Current Assets (Notes)",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes",
     "shortName": "Prepaids and Other Current Assets (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Accrued Liabilities an Other Long-term Liabilities",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities",
     "shortName": "Accrued Liabilities an Other Long-term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.icumed.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.icumed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes:",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.icumed.com/role/IncomeTaxes",
     "shortName": "Income Taxes:",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:InformationbyGeographicAreaandCustomerConcentrationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes",
     "shortName": "Geographic Information and Significant Customers Geographic Information and Significant Customers (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:InformationbyGeographicAreaandCustomerConcentrationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.icumed.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.icumed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Collaborative and Other Arrangements (Notes)",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes",
     "shortName": "Collaborative and Other Arrangements (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.icumed.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - SEC Schedule, Article 12-09, Valuation and Qualifying Accounts",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts",
     "shortName": "SEC Schedule, Article 12-09, Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - General and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "General and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - General and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "General and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.icumed.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Business Combination and Asset Acquisition (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables",
     "shortName": "Business Combination and Asset Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables",
     "shortName": "Restructuring, Strategic Transaction and Integration Schedule of Restructuring and Related Costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.icumed.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.icumed.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Share Based Award (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.icumed.com/role/ShareBasedAwardTables",
     "shortName": "Share Based Award (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Derivatives and Hedging Activities (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesTables",
     "shortName": "Derivatives and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.icumed.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Prepaids and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables",
     "shortName": "Prepaids and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Accrued Liabilities an Other Long-term Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables",
     "shortName": "Accrued Liabilities an Other Long-term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:InterestMarginandCommitmentFeeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.icumed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:InterestMarginandCommitmentFeeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Income Taxes Income tax disclosure (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables",
     "shortName": "Income Taxes Income tax disclosure (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Geographic Information and Significant Customers Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables",
     "shortName": "Geographic Information and Significant Customers Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.icumed.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - General and Summary of Significant Accounting Policies Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails",
     "shortName": "General and Summary of Significant Accounting Policies Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - General and Summary of Significant Accounting Policies Inventory (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails",
     "shortName": "General and Summary of Significant Accounting Policies Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #1 (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
     "shortName": "General and Summary of Significant Accounting Policies Property and Equipment #1 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details",
     "shortName": "General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i922b769632924a0bb27da8d7cbea9a57_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - General and Summary of Significant Accounting Policies Property and Equipment #3 (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details",
     "shortName": "General and Summary of Significant Accounting Policies Property and Equipment #3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - General and Summary of Significant Accounting Policies Goodwill (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "General and Summary of Significant Accounting Policies Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #1 (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details",
     "shortName": "General and Summary of Significant Accounting Policies Intangible Assets #1 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Statement of Comprehensive Income (Statement)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement",
     "shortName": "Statement of Comprehensive Income (Statement)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - General and Summary of Significant Accounting Policies Intangible Assets #2 (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details",
     "shortName": "General and Summary of Significant Accounting Policies Intangible Assets #2 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails",
     "shortName": "General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - General and Summary of Significant Accounting Policies Other Investments(Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails",
     "shortName": "General and Summary of Significant Accounting Policies Other Investments(Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - General and Summary of Significant Accounting Policies Investments (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "shortName": "General and Summary of Significant Accounting Policies Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - General and Summary of Significant Accounting Policies Investments-Equity Method (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails",
     "shortName": "General and Summary of Significant Accounting Policies Investments-Equity Method (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - General and Summary of Significant Accounting Policies Foreign Currency (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails",
     "shortName": "General and Summary of Significant Accounting Policies Foreign Currency (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails",
     "shortName": "General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails",
     "shortName": "General and Summary of Significant Accounting Policies Interest (Expense) Income, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - General and Summary of Significant Accounting Policies Other (expense) income, net (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails",
     "shortName": "General and Summary of Significant Accounting Policies Other (expense) income, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - General and Summary of Significant Accounting Policies Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails",
     "shortName": "General and Summary of Significant Accounting Policies Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ie2f128dabbbb42f790c9b42b1a52d19f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ie2f128dabbbb42f790c9b42b1a52d19f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails",
     "shortName": "General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Acquisitions Text (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.icumed.com/role/AcquisitionsTextDetails",
     "shortName": "Acquisitions Text (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Acquisitions Smiths Medical 2020 Limited Table (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
     "shortName": "Acquisitions Smiths Medical 2020 Limited Table (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i7437d14a12be4025b5493cb7d897d472_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Acquisitions Smiths Medical 2020 Limited Intangible (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
     "shortName": "Acquisitions Smiths Medical 2020 Limited Intangible (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "icf53f5893c744f0caf60cd5f3ccc739d_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "icui:ShortTermContingentConsiderationGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Acquisitions Foreign Infusion Systems Supplier (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
     "shortName": "Acquisitions Foreign Infusion Systems Supplier (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ie7de8e0968144e63ab5a48d218387206_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Acquisitions Smiths Medical Pro Forma (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails",
     "shortName": "Acquisitions Smiths Medical Pro Forma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:Restructuringandstrategictransactionexpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 1)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
     "shortName": "Restructuring, Strategic Transaction and Integration (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Restructuring, Strategic Transaction and Integration (Details 2)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2",
     "shortName": "Restructuring, Strategic Transaction and Integration (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "icui:StrategicTransactionandIntegration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails",
     "shortName": "Restructuring, Strategic Transaction and Integration Strategic Transaction and Integration Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "icui:StrategicTransactionandIntegration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Revenue Disaggregation of Revenue - Product Line (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
     "shortName": "Revenue Disaggregation of Revenue - Product Line (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "icui:Percentageofrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Revenue Disaggregation of Revenue by Geography (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails",
     "shortName": "Revenue Disaggregation of Revenue by Geography (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i5bc0a6dcb17e4cd282514aa6069b38e2_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i5a171dead75d4b24a35a8e7c9e1cc9be_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Revenue Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i3688a319945e4943a3dc05ede3f036d1_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Revenue Contract Liabilities Text (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails",
     "shortName": "Revenue Contract Liabilities Text (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0c7b424d053745b89be43013214212ba_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Revenue Remaining Performance Obligation Recognition Timing (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails",
     "shortName": "Revenue Remaining Performance Obligation Recognition Timing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0c7b424d053745b89be43013214212ba_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:Optiontoextendinyears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.icumed.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "icui:Optiontoextendinyears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Leases Lease Cost (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.icumed.com/role/LeasesLeaseCostDetails",
     "shortName": "Leases Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:SupplementalCashFlowInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Leases Supplemental Cash Flow Lease Information (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails",
     "shortName": "Leases Supplemental Cash Flow Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:SupplementalCashFlowInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:SupplementalBalanceSheetInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Leases Supplemental Balance Sheet Lease information (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails",
     "shortName": "Leases Supplemental Balance Sheet Lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:SupplementalBalanceSheetInformationLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Finance Leases Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Finance Leases Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Leases Lease Maturity (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.icumed.com/role/LeasesLeaseMaturityDetails",
     "shortName": "Leases Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Leases Finance Lease Maturity (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails",
     "shortName": "Leases Finance Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Share Based Award Stock Based Compensation (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails",
     "shortName": "Share Based Award Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6e1f7b608a83444d93727a50a57cc19c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Share Based Award Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
     "shortName": "Share Based Award Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6e1f7b608a83444d93727a50a57cc19c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Share Based Award Stock Options Granted and Valuation (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails",
     "shortName": "Share Based Award Stock Options Granted and Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ic61687d8e96b449382d3c2fbaa158ef3_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0ced0ef8f682482e991d67cc95e1bae8_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Share Based Award Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
     "shortName": "Share Based Award Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0ced0ef8f682482e991d67cc95e1bae8_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Share Based Award Share Award data (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails",
     "shortName": "Share Based Award Share Award data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:ExercisedOptionsDataTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Share Based Award Options exercised data (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails",
     "shortName": "Share Based Award Options exercised data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "icui:ExercisedOptionsDataTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:ModifiedPRSUIncrementalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Share Based Award RSU and PRSU (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
     "shortName": "Share Based Award RSU and PRSU (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "icui:ModifiedPRSUIncrementalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i754c391455cd4db0bb5e009228c4ed88_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Share Based Award RSU and PRSU Roll forward (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails",
     "shortName": "Share Based Award RSU and PRSU Roll forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i754c391455cd4db0bb5e009228c4ed88_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "icui:ESPPOriginalIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Share Based Award ESPP Narrative (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails",
     "shortName": "Share Based Award ESPP Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "icui:ESPPOriginalIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Statement of Comprehensive Income (Paranthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical",
     "shortName": "Statement of Comprehensive Income (Paranthetical)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails",
     "shortName": "Derivatives and Hedging Activities Foreign Exchange Forward Contracts(Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Derivatives and Hedging Activities Interest Rate Contracts(Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
     "shortName": "Derivatives and Hedging Activities Interest Rate Contracts(Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i68398fc85c9b4c69a9d24ac18c9275b2_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Derivatives and Hedging Activities Derivative Balance Sheet Location (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
     "shortName": "Derivatives and Hedging Activities Derivative Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i68398fc85c9b4c69a9d24ac18c9275b2_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
     "shortName": "Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i6bd240ff977940298a71a2a3ed51f1bf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "8",
      "first": true,
      "lang": "en-US",
      "name": "icui:OwnershipRequirementForEarnoutPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Fair Value Measurement Smiths Medical(Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
     "shortName": "Fair Value Measurement Smiths Medical(Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "8",
      "first": true,
      "lang": "en-US",
      "name": "icui:OwnershipRequirementForEarnoutPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Fair Value Measurement Text Pursuit (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails",
     "shortName": "Fair Value Measurement Text Pursuit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i0db73ebe00014b429d98a2767a3858eb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Fair Value Measurement Roll Forward (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
     "shortName": "Fair Value Measurement Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "if62be887c4e8464ca061d2dbeb9d2865_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ibdcc27cec606429689f360f5df15a62d_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
     "shortName": "Fair Value Measurement Fair Value Inputs, Liabilities, Pursuit Quantitative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ibdcc27cec606429689f360f5df15a62d_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i4fb0ac701d04472195a9beec28ba8137_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Fair Value Measurement Smiths Medical Simulation Inputs (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
     "shortName": "Fair Value Measurement Smiths Medical Simulation Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "i4fb0ac701d04472195a9beec28ba8137_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - icui-20221231.htm",
     "menuCat": "Cover",
     "order": "130",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - icui-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "icui-20221231.htm",
      "contextRef": "ia6ebd40efa304c13bdb3f210d0fd1af6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 144,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COSTA RICA",
        "terseLabel": "COSTA RICA"
       }
      }
     },
     "localname": "CR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "SPAIN"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars",
        "terseLabel": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "Canada, Dollars"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CNY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China, Yuan Renminbi",
        "terseLabel": "China, Yuan Renminbi"
       }
      }
     },
     "localname": "CNY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CZK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Czech Republic, Koruny",
        "terseLabel": "Czech Republic, Koruny"
       }
      }
     },
     "localname": "CZK",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails",
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_MXN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mexico, Pesos",
        "terseLabel": "Mexico, Pesos"
       }
      }
     },
     "localname": "MXN",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States of America, Dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]",
        "terseLabel": "Auditor [Line Items]"
       }
      }
     },
     "localname": "AuditorLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]",
        "terseLabel": "Auditor [Table]"
       }
      }
     },
     "localname": "AuditorTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/AuditInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.icumed.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "icui_A2003PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2003 Plan [Member]",
        "label": "2003 Plan [Member]",
        "terseLabel": "2003 Plan [Member]"
       }
      }
     },
     "localname": "A2003PlanMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_A2011PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2011 Plan [Member]",
        "label": "2011 Plan [Member]",
        "terseLabel": "2011 Plan [Member]"
       }
      }
     },
     "localname": "A2011PlanMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_APACDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APAC",
        "label": "APAC [Domain]",
        "terseLabel": "APAC [Domain]"
       }
      }
     },
     "localname": "APACDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_AccountsReceivablePurchaseProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accounts receivable purchase program",
        "label": "accounts receivable purchase program",
        "terseLabel": "accounts receivable purchase program"
       }
      }
     },
     "localname": "AccountsReceivablePurchaseProgram",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_AccruedAuditFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued audit fees",
        "label": "Accrued audit fees",
        "terseLabel": "Accrued audit fees"
       }
      }
     },
     "localname": "AccruedAuditFees",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_AccruedProductFieldAction.": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Product Field Action.",
        "label": "Accrued Product Field Action.",
        "terseLabel": "Accrued Product Field Action."
       }
      }
     },
     "localname": "AccruedProductFieldAction.",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_AccruedResearchAndDevelopmentLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development liability",
        "label": "Accrued research and development liability",
        "terseLabel": "Accrued research and development liability"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentLiability",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_AccruedSalariesAndBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued salaries and benefits",
        "label": "Accrued salaries and benefits",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "AccruedSalariesAndBenefits",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Accruedfreight": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued freight",
        "label": "Accrued freight",
        "terseLabel": "Accrued freight"
       }
      }
     },
     "localname": "Accruedfreight",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Accruedlegalfees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued legal fees",
        "label": "Accrued legal fees",
        "terseLabel": "Legal accrual"
       }
      }
     },
     "localname": "Accruedlegalfees",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Accruedothertaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued other taxes",
        "label": "Accrued other taxes",
        "terseLabel": "Accrued other taxes"
       }
      }
     },
     "localname": "Accruedothertaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Accruedsalestaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued sales taxes",
        "label": "Accrued sales taxes",
        "terseLabel": "Accrued sales taxes"
       }
      }
     },
     "localname": "Accruedsalestaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_AmortizationOfInventoryStepUp": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Inventory Step-up",
        "label": "Amortization of Inventory Step-up",
        "terseLabel": "Amortization of Inventory Step-up"
       }
      }
     },
     "localname": "AmortizationOfInventoryStepUp",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ApplicableMarginBaseRateLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable Margin Base Rate Loans",
        "label": "Applicable Margin Base Rate Loans",
        "terseLabel": "Applicable Margin Base Rate Loans"
       }
      }
     },
     "localname": "ApplicableMarginBaseRateLoans",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_ApplicableMarginBasedOnLeverageRatioLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable Margin Based on Leverage Ratio [Line Items]",
        "label": "Applicable Margin Based on Leverage Ratio [Line Items]",
        "terseLabel": "Applicable Margin Based on Leverage Ratio [Line Items]"
       }
      }
     },
     "localname": "ApplicableMarginBasedOnLeverageRatioLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ApplicableMarginBasedOnLeverageRatioTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable Margin Based on Leverage Ratio [Table]",
        "label": "Applicable Margin Based on Leverage Ratio [Table]",
        "terseLabel": "Applicable Margin on Loan Type"
       }
      }
     },
     "localname": "ApplicableMarginBasedOnLeverageRatioTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ApplicableMarginOnLoanTypeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable Margin on Loan Type",
        "label": "Applicable Margin on Loan Type [Table Text Block]",
        "terseLabel": "Applicable Margin on Loan Type"
       }
      }
     },
     "localname": "ApplicableMarginOnLoanTypeTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_ApplicableMarginTermSOFRLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable Margin Term SOFR Loans",
        "label": "Applicable Margin Term SOFR Loans",
        "terseLabel": "Applicable Margin Term SOFR Loans"
       }
      }
     },
     "localname": "ApplicableMarginTermSOFRLoans",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_BusinessCombinationConsiderationCashHoldback": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "business combination consideration - cash holdback",
        "label": "business combination consideration - cash holdback",
        "terseLabel": "business combination consideration - cash holdback"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationCashHoldback",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_BusinessCombinationConsiderationTransferredCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Cash",
        "label": "Business Combination, Consideration Transferred, Cash",
        "terseLabel": "Business Combination, Consideration Transferred, Cash"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredCash",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "business combination, recognized identifiable asset acquired and liability assumed,",
        "label": "business combination, recognized identifiable asset acquired and liability assumed,",
        "terseLabel": "business combination, recognized identifiable asset acquired and liability assumed,"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumed",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable",
        "label": "Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable",
        "negatedTerseLabel": "Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable"
       }
      }
     },
     "localname": "BusinessCombinationsIdentifiedAssumedLiabilitiesRecognizedIncomeTaxPayable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_COntractLiabilityRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COntract Liability Rollforward [Roll Forward]",
        "label": "COntract Liability Rollforward [Roll Forward]",
        "terseLabel": "COntract Liability Rollforward [Roll Forward]"
       }
      }
     },
     "localname": "COntractLiabilityRollforwardRollForward",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_Changeinunitsduetoperformanceexpectations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in units due to performance expectations",
        "label": "Change in units due to performance expectations",
        "terseLabel": "Change in units due to performance expectations"
       }
      }
     },
     "localname": "Changeinunitsduetoperformanceexpectations",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "icui_ClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "classification",
        "label": "classification [Axis]",
        "terseLabel": "classification [Axis]"
       }
      }
     },
     "localname": "ClassificationAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "classification [Domain]",
        "label": "classification [Domain]",
        "terseLabel": "classification [Domain]"
       }
      }
     },
     "localname": "ClassificationDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]",
        "terseLabel": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.icumed.com/20221231",
     "xbrltype": "stringItemType"
    },
    "icui_CommonStockSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares [Member]",
        "label": "Common Stock Shares [Member]",
        "terseLabel": "Common Stock Shares [Member]"
       }
      }
     },
     "localname": "CommonStockSharesMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ContingentConsiderationGrossLT": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Gross LT",
        "label": "Contingent Consideration, Gross LT",
        "terseLabel": "Contingent Consideration, Gross LT"
       }
      }
     },
     "localname": "ContingentConsiderationGrossLT",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Contingentconsiderationgross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "contingent consideration gross",
        "label": "contingent consideration gross",
        "terseLabel": "contingent consideration gross"
       }
      }
     },
     "localname": "Contingentconsiderationgross",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ContractassetandliabilitybalancesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Contract asset and liability balances [Table]",
        "label": "Contract asset and liability balances [Line Items]",
        "terseLabel": "Contract asset and liability balances [Line Items]"
       }
      }
     },
     "localname": "ContractassetandliabilitybalancesLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ContractassetandliabilitybalancesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract asset and liability balances [Table]",
        "label": "Contract asset and liability balances [Table]",
        "terseLabel": "Contract asset and liability balances [Table]"
       }
      }
     },
     "localname": "ContractassetandliabilitybalancesTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_Contractsettlements": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractsettlements",
        "label": "Contractsettlements",
        "terseLabel": "Contractsettlements"
       }
      }
     },
     "localname": "Contractsettlements",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_CriticalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Critical Care [Member]",
        "label": "Critical Care [Member]",
        "terseLabel": "Critical Care [Member]"
       }
      }
     },
     "localname": "CriticalCareMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_CurrencyTranslationOnEarnOut": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency translation on earn-out",
        "label": "Currency translation on earn-out",
        "negatedTerseLabel": "Currency translation on earn-out"
       }
      }
     },
     "localname": "CurrencyTranslationOnEarnOut",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_CurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "current",
        "label": "current [Member]",
        "terseLabel": "current"
       }
      }
     },
     "localname": "CurrentMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_DeferredTaxAssetSection163j": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Section 163(j)",
        "label": "Deferred Tax Asset, Section 163(j)",
        "terseLabel": "Deferred Tax Asset, Section 163(j)"
       }
      }
     },
     "localname": "DeferredTaxAssetSection163j",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_DeferredtaxassetsandliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Deferred tax assets and liabilities [Table]",
        "label": "Deferred tax assets and liabilities [Line Items]",
        "terseLabel": "Deferred tax assets and liabilities [Line Items]"
       }
      }
     },
     "localname": "DeferredtaxassetsandliabilitiesLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_DeferredtaxassetsandliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets and liabilities [Table]",
        "label": "Deferred tax assets and liabilities [Table]",
        "terseLabel": "Deferred tax assets and liabilities [Table]"
       }
      }
     },
     "localname": "DeferredtaxassetsandliabilitiesTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_Deferredtaxcharge": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax charge",
        "label": "Deferred tax charge",
        "terseLabel": "Deferred tax charge"
       }
      }
     },
     "localname": "Deferredtaxcharge",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Deferredtaxliabilitychangeinaccountingmethod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liability, change in accounting method",
        "label": "Deferred tax liability, change in accounting method",
        "terseLabel": "Deferred tax liability, change in accounting method"
       }
      }
     },
     "localname": "Deferredtaxliabilitychangeinaccountingmethod",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_DerivativeInterestRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Interest Rate Floor",
        "label": "Derivative Interest Rate Floor",
        "terseLabel": "Derivative Interest Rate Floor"
       }
      }
     },
     "localname": "DerivativeInterestRateFloor",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_ESPPAnnualIssuanceIncreaseLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Annual Issuance Increase Limit",
        "label": "ESPP Annual Issuance Increase Limit",
        "terseLabel": "ESPP Annual Issuance Increase Limit"
       }
      }
     },
     "localname": "ESPPAnnualIssuanceIncreaseLimit",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "icui_ESPPOriginalIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Original Issuance",
        "label": "ESPP Original Issuance",
        "terseLabel": "ESPP Original Issuance"
       }
      }
     },
     "localname": "ESPPOriginalIssuance",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardESPPNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "icui_EarnoutliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earn-out liability [Member]",
        "label": "Earn-out liability [Member]",
        "terseLabel": "Earn-out liability [Member]"
       }
      }
     },
     "localname": "EarnoutliabilityMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_EffectiveIncomeTaxRateReconciliationContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Contingent Consideration",
        "label": "Effective Income Tax Rate Reconciliation, Contingent Consideration",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Contingent Consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsideration",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome",
        "label": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome",
        "terseLabel": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent",
        "label": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent",
        "terseLabel": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncome,Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_EffectiveIncomeTaxRateReconciliationTransactionCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveIncomeTaxRateReconciliationTransaction cost",
        "label": "EffectiveIncomeTaxRateReconciliationTransaction cost",
        "terseLabel": "EffectiveIncomeTaxRateReconciliationTransaction cost"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCost",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_EffectiveTaxRateReconcilationTransactionCostPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EffectiveTaxRateReconcilationTransaction cost,Percent",
        "label": "EffectiveTaxRateReconcilationTransaction cost,Percent",
        "terseLabel": "EffectiveTaxRateReconcilationTransaction cost,Percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconcilationTransactionCostPercent",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_Effectiveincometaxreconciliationnondeductiblecompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effectiveincometaxreconciliation,nondeductiblecompensation",
        "label": "Effectiveincometaxreconciliation,nondeductiblecompensation",
        "terseLabel": "Effectiveincometaxreconciliation,nondeductiblecompensation"
       }
      }
     },
     "localname": "Effectiveincometaxreconciliationnondeductiblecompensation",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Effectivetaxratereconciliationnondeductiblecomppercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effectivetaxratereconciliationnondeductiblecomppercent",
        "label": "Effectivetaxratereconciliationnondeductiblecomppercent",
        "terseLabel": "Effectivetaxratereconciliationnondeductiblecomppercent"
       }
      }
     },
     "localname": "Effectivetaxratereconciliationnondeductiblecomppercent",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_EquipmentrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment revenue [Member]",
        "label": "Equipment revenue [Member]",
        "terseLabel": "Equipment revenue [Member]"
       }
      }
     },
     "localname": "EquipmentrevenueMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ExercisedOptionsDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercised Options Data [Table Text Block]",
        "label": "Exercised Options Data [Table Text Block]",
        "terseLabel": "Exercised Options Data [Table Text Block]"
       }
      }
     },
     "localname": "ExercisedOptionsDataTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_ForeignDistibutorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Distibutor",
        "label": "Foreign Distibutor [Member]",
        "terseLabel": "Foreign Distibutor [Member]"
       }
      }
     },
     "localname": "ForeignDistibutorMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ForeignInfusionSystemSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Infusion System Supplier",
        "label": "Foreign Infusion System Supplier [Member]",
        "terseLabel": "Foreign Infusion System Supplier"
       }
      }
     },
     "localname": "ForeignInfusionSystemSupplierMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ForeignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign [Member]",
        "label": "Foreign [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_FurniturefixturesandmoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture, fixtures and molds [Member]",
        "label": "Furniture, fixtures and molds [Member]",
        "terseLabel": "Furniture, fixtures and molds [Member]"
       }
      }
     },
     "localname": "FurniturefixturesandmoldsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_GILTItaxexpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GILTItaxexpense",
        "label": "GILTItaxexpense",
        "terseLabel": "GILTItaxexpense"
       }
      }
     },
     "localname": "GILTItaxexpense",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_GILTItaxexpensepercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GILTItaxexpensepercent",
        "label": "GILTItaxexpensepercent",
        "terseLabel": "GILTItaxexpensepercent"
       }
      }
     },
     "localname": "GILTItaxexpensepercent",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_GovernmentGrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Grant Revenue",
        "label": "Government Grant Revenue [Member]",
        "terseLabel": "Government Grant Revenue"
       }
      }
     },
     "localname": "GovernmentGrantRevenueMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Grantdatefairvalueofrestrictedstockunitsgranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value of restricted stock units granted",
        "label": "Grant date fair value of restricted stock units granted",
        "terseLabel": "Grant date fair value of restricted stock units granted"
       }
      }
     },
     "localname": "Grantdatefairvalueofrestrictedstockunitsgranted",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Grantdatefairvalueperformancerestrictedstockunits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value performance restricted stock units",
        "label": "Grant date fair value performance restricted stock units",
        "terseLabel": "Grant date fair value performance restricted stock units"
       }
      }
     },
     "localname": "Grantdatefairvalueperformancerestrictedstockunits",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_GreaterThan275To100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "greater than 2.75 to1.00",
        "label": "greater than 2.75 to1.00 [Member]",
        "terseLabel": "greater than 2.75 to1.00"
       }
      }
     },
     "localname": "GreaterThan275To100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Greaterthan400to100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "greaterthan4.00to1.00",
        "label": "greaterthan4.00to1.00 [Member]",
        "terseLabel": "greaterthan4.00to1.00"
       }
      }
     },
     "localname": "Greaterthan400to100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Hedge3MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge 3 [Member]",
        "label": "Hedge 3 [Member] [Member]",
        "terseLabel": "Hedge 3 [Member] [Member]"
       }
      }
     },
     "localname": "Hedge3MemberMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Hedge4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge 4",
        "label": "Hedge 4 [Member]",
        "terseLabel": "Hedge 4"
       }
      }
     },
     "localname": "Hedge4Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Hedge5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge 5",
        "label": "Hedge 5 [Member]",
        "terseLabel": "Hedge 5"
       }
      }
     },
     "localname": "Hedge5Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_IVSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IV Solutions [Member]",
        "label": "IV Solutions [Member]",
        "terseLabel": "IV Solutions [Member]"
       }
      }
     },
     "localname": "IVSolutionsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_IncomeTaxDisclosuredeferredtaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure deferred taxes [Abstract]",
        "label": "Income Tax Disclosure deferred taxes [Abstract]",
        "terseLabel": "Income Tax Disclosure deferred taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosuredeferredtaxesAbstract",
     "nsuri": "http://www.icumed.com/20221231",
     "xbrltype": "stringItemType"
    },
    "icui_IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the carrying amount as of the balance sheet date of payments made for taxes. Also includes the net change during the reporting period in the account that represents the temporary difference that results from income (loss) that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase Decrease in income taxes, including excess tax benefits and deferred income taxes",
        "terseLabel": "Income taxes, including excess tax benefits and deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_IndirectTaxBenefitFromStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indirect tax benefit from the stock compensation cost received upon the exercise of stock options",
        "label": "Indirect tax benefit from stock options",
        "terseLabel": "Indirect tax benefit"
       }
      }
     },
     "localname": "IndirectTaxBenefitFromStockOptions",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by Geographic Area and Customer Concentration [Text Block]",
        "label": "Information by Geographic Area and Customer Concentration [Text Block]",
        "terseLabel": "Information by Geographic Area and Customer Concentration [Text Block]"
       }
      }
     },
     "localname": "InformationbyGeographicAreaandCustomerConcentrationTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationandSignificantCustomersNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_InfusionConsumablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infusion Consumables [Member]",
        "label": "Infusion Consumables [Member]",
        "terseLabel": "Infusion Consumables [Member]"
       }
      }
     },
     "localname": "InfusionConsumablesMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InfusionConsumablesSmithsMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infusion Consumables-Smiths Medical",
        "label": "Infusion Consumables-Smiths Medical [Member]",
        "terseLabel": "Infusion Consumables-Smiths Medical"
       }
      }
     },
     "localname": "InfusionConsumablesSmithsMedicalMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InfusionSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infusion Systems [Member]",
        "label": "Infusion Systems [Member]",
        "terseLabel": "Infusion Systems [Member]"
       }
      }
     },
     "localname": "InfusionSystemsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InstrumentsPlacedwithCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments Placed with Customers [Member]",
        "label": "Instruments Placed with Customers [Member]",
        "terseLabel": "Instruments Placed with Customers [Member]"
       }
      }
     },
     "localname": "InstrumentsPlacedwithCustomersMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InterestExpenseIncomeNetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest (expense) income, net",
        "label": "Interest (expense) income, net [Axis]",
        "terseLabel": "Interest (expense) income, net [Axis]"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_InterestExpenseIncomeNetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest (expense) income, net",
        "label": "Interest (expense) income, net [Domain]",
        "terseLabel": "Interest (expense) income, net [Domain]"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InterestExpenseIncomeNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest (expense) income, net [Line Items]",
        "label": "Interest (expense) income, net [Line Items]",
        "terseLabel": "Interest (expense) income, net [Line Items]"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_InterestExpenseIncomeNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest (expense) income, net [Table]",
        "label": "Interest (expense) income, net [Table]",
        "terseLabel": "Interest (expense) income, net [Table]"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_InterestExpenseOnLongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense on long-term debt",
        "label": "Interest expense on long-term debt [Table Text Block]",
        "terseLabel": "Interest expense on long-term debt"
       }
      }
     },
     "localname": "InterestExpenseOnLongTermDebtTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_InterestMarginandCommitmentFeeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Margin and Commitment Fee [Table Text Block]",
        "label": "Interest Margin and Commitment Fee [Table Text Block]",
        "terseLabel": "Interest Margin and Commitment Fee [Table Text Block]"
       }
      }
     },
     "localname": "InterestMarginandCommitmentFeeTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_InterestPercentageAddedToBaseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Percentage Added to Base Rate",
        "label": "Interest Percentage Added to Base Rate",
        "terseLabel": "Interest Percentage Added to Base Rate"
       }
      }
     },
     "localname": "InterestPercentageAddedToBaseRate",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_InterestPercentageAddedToFederalFundsRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Percentage Added to Federal Funds Rate",
        "label": "Interest Percentage Added to Federal Funds Rate",
        "terseLabel": "Interest Percentage Added to Federal Funds Rate"
       }
      }
     },
     "localname": "InterestPercentageAddedToFederalFundsRate",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_InterestRatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rates [Line Items]",
        "label": "Interest Rates [Line Items]",
        "terseLabel": "Interest Rates [Line Items]"
       }
      }
     },
     "localname": "InterestRatesLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_InterestRatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rates [Table]",
        "label": "Interest Rates [Table]",
        "terseLabel": "Interest Rates [Table]"
       }
      }
     },
     "localname": "InterestRatesTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_InternationalDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Distributor",
        "label": "International Distributor [Member]",
        "terseLabel": "International Distributor"
       }
      }
     },
     "localname": "InternationalDistributorMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_InternationalSalesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Sales [Domain]",
        "label": "International Sales [Domain]",
        "terseLabel": "International Sales [Domain]"
       }
      }
     },
     "localname": "InternationalSalesDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_ItalyPropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign property and equipment: Italy",
        "label": "Italy Property and Equipment [Member]",
        "terseLabel": "Italy Property and Equipment [Member]"
       }
      }
     },
     "localname": "ItalyPropertyAndEquipmentMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LessThan275To100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "less than 2.75:1.00",
        "label": "less than 2.75 to1.00 [Member]",
        "terseLabel": "less than 2.75 to1.00"
       }
      }
     },
     "localname": "LessThan275To100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LessThanOrEqual300To100ButGreaterThan250to100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "less than or equal 3.00 to 1.00 but greater than 2.50to1.00",
        "label": "less than or equal 3.00 to 1.00 but greater than 2.50to1.00 [Member]",
        "terseLabel": "less than or equal 3.00 to 1.00 but greater than 2.50to1.00"
       }
      }
     },
     "localname": "LessThanOrEqual300To100ButGreaterThan250to100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LessThanOrEqualTo200To100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "less than or equal to 2.00 to 1.00",
        "label": "less than or equal to 2.00 to 1.00 [Member]",
        "terseLabel": "less than or equal to 2.00 to 1.00"
       }
      }
     },
     "localname": "LessThanOrEqualTo200To100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LessThanOrEqualTo250To100ButGreaterThan200To100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "less than or equal to 2.50 to1.00 but greater than 2.00 to1.00",
        "label": "less than or equal to 2.50 to1.00 but greater than 2.00 to1.00 [Member]",
        "terseLabel": "less than or equal to 2.50 to1.00 but greater than 2.00 to1.00"
       }
      }
     },
     "localname": "LessThanOrEqualTo250To100ButGreaterThan200To100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LessThanOrEqualTo400To100ButGreaterThan300To100Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "less than or equal to 4.00 to 1.00 but greater than 3.00 to100",
        "label": "less than or equal to 4.00 to 1.00 but greater than 3.00 to100 [Member]",
        "terseLabel": "less than or equal to 4.00 to 1.00 but greater than 3.00 to100"
       }
      }
     },
     "localname": "LessThanOrEqualTo400To100ButGreaterThan300To100Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LesseeOperatingAndFinanceLeaseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Finance Lease",
        "label": "Lessee, Operating and Finance Lease [Text Block]",
        "terseLabel": "Lessee, Operating and Finance Lease"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/LeasesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_LeverageRatioCalculationCeilingSubtractedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage Ratio Calculation Ceiling Subtracted Amount",
        "label": "Leverage Ratio Calculation Ceiling Subtracted Amount",
        "terseLabel": "Leverage Ratio Calculation Ceiling Subtracted Amount"
       }
      }
     },
     "localname": "LeverageRatioCalculationCeilingSubtractedAmount",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_LeverageRatioLevelAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage Ratio Level",
        "label": "Leverage Ratio Level [Axis]",
        "terseLabel": "Leverage Ratio Level [Axis]"
       }
      }
     },
     "localname": "LeverageRatioLevelAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_LeverageRatioLevelDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage Ratio Level [Domain]",
        "label": "Leverage Ratio Level [Domain]",
        "terseLabel": "Leverage Ratio Level [Domain]"
       }
      }
     },
     "localname": "LeverageRatioLevelDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_LongTermContingentConsiderationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term contingent consideration-gross",
        "label": "Long-term contingent consideration-gross",
        "terseLabel": "Long-term contingent consideration-gross"
       }
      }
     },
     "localname": "LongTermContingentConsiderationGross",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_LongTermDebtTypeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt Type [Line Items]",
        "label": "Long-term Debt Type [Line Items]",
        "terseLabel": "Long-term Debt Type [Line Items]"
       }
      }
     },
     "localname": "LongTermDebtTypeLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_LongTermDebtTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt Type [Table]",
        "label": "Long-term Debt Type [Table]",
        "terseLabel": "Long-term Debt Type [Table]"
       }
      }
     },
     "localname": "LongTermDebtTypeTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_LongTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term",
        "label": "Long Term [Member]",
        "terseLabel": "Long Term"
       }
      }
     },
     "localname": "LongTermMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_MexicoPropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign property and equipment: Mexico",
        "label": "Mexico Property and Equipment [Member]",
        "terseLabel": "Mexico Property and Equipment [Member]"
       }
      }
     },
     "localname": "MexicoPropertyAndEquipmentMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_MinimumStockPriceTargetForEarnOutPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Stock Price Target for Earn-out Payment",
        "label": "Minimum Stock Price Target for Earn-out Payment",
        "terseLabel": "Minimum Stock Price Target for Earn-out Payment"
       }
      }
     },
     "localname": "MinimumStockPriceTargetForEarnOutPayment",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_MiscellaneousIncomeNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "miscellaneous income, net",
        "label": "miscellaneous income, net",
        "terseLabel": "miscellaneous income, net"
       }
      }
     },
     "localname": "MiscellaneousIncomeNet",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ModifiedPRSUIncrementalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modified PRSU Incremental Expense",
        "label": "Modified PRSU Incremental Expense",
        "terseLabel": "Modified PRSU Incremental Expense"
       }
      }
     },
     "localname": "ModifiedPRSUIncrementalExpense",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_MoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molds [Member]",
        "label": "Molds [Member]",
        "terseLabel": "Molds [Member]"
       }
      }
     },
     "localname": "MoldsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_NetCashPaidReceivedforcurrentandprioracquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Cash Paid (Received) for current and prior acquisitions",
        "label": "Net Cash Paid (Received) for current and prior acquisitions",
        "negatedTerseLabel": "Cash paid for acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "NetCashPaidReceivedforcurrentandprioracquisitions",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NonCurrentDeferredTaxAssetGrossTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of gross non-current deferred tax asset",
        "label": "Non-current deferred tax asset, gross total [Member]",
        "terseLabel": "Non-current deferred tax asset, gross total [Member]"
       }
      }
     },
     "localname": "NonCurrentDeferredTaxAssetGrossTotalMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Non-compete agreement with associated contingent earn-out liability",
        "label": "Noncash Non-compete agreement with associated contingent earn-out liability",
        "terseLabel": "Noncash Non-compete agreement with associated contingent earn-out liability"
       }
      }
     },
     "localname": "NoncashNonCompeteAgreementWithAssociatedContingentEarnOutLiability",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NoncurrentDeferredTaxAssetTaxCreditsState": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent deferred tax asset - tax credits state",
        "label": "Noncurrent deferred tax asset - tax credits state",
        "terseLabel": "Noncurrent deferred tax asset - tax credits state"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxAssetTaxCreditsState",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NoncurrentDeferredTaxLiabilityDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent deferred tax liability - depreciation and amortization",
        "label": "Noncurrent deferred tax liability - depreciation and amortization",
        "terseLabel": "Noncurrent deferred tax liability - depreciation and amortization"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxLiabilityDepreciationAndAmortization",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NoncurrentDeferredTaxLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent deferred tax liability [Member]",
        "label": "Noncurrent deferred tax liability [Member]",
        "terseLabel": "Noncurrent deferred tax liability [Member]"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxLiabilityMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_NoncurrentDeferredTaxLiabilityStateIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent deferred tax liability - state income taxes",
        "label": "Noncurrent deferred tax liability - state income taxes",
        "terseLabel": "Noncurrent deferred tax liability - state income taxes"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxLiabilityStateIncomeTaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "noncurrent",
        "label": "noncurrent [Member]",
        "terseLabel": "noncurrent"
       }
      }
     },
     "localname": "NoncurrentMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Noncurrentdeferredtaxasset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current deferred tax asset",
        "label": "Non-current deferred tax asset",
        "terseLabel": "Non-current deferred tax asset"
       }
      }
     },
     "localname": "Noncurrentdeferredtaxasset",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Noncurrentdeferredtaxassetacquiredfuturetaxdeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent deferred tax asset - acquired future tax deductions",
        "label": "Noncurrent deferred tax asset - acquired future tax deductions",
        "terseLabel": "Noncurrent deferred tax asset - acquired future tax deductions"
       }
      }
     },
     "localname": "Noncurrentdeferredtaxassetacquiredfuturetaxdeductions",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions",
        "label": "Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions",
        "terseLabel": "Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions"
       }
      }
     },
     "localname": "Noncurrentdeferredtaxassetchargebacksdiscountscustomerconcessions",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_NonpublicCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "nonpublic company",
        "label": "nonpublic company [Member]",
        "terseLabel": "nonpublic company"
       }
      }
     },
     "localname": "NonpublicCompanyMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_OperatinglosscarryforwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards [Abstract]",
        "label": "Operating loss carryforwards [Abstract]",
        "terseLabel": "Operating loss carryforwards [Abstract]"
       }
      }
     },
     "localname": "OperatinglosscarryforwardsAbstract",
     "nsuri": "http://www.icumed.com/20221231",
     "xbrltype": "stringItemType"
    },
    "icui_Optiontoextendinyears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optiontoextendinyears",
        "label": "Optiontoextendinyears",
        "terseLabel": "Optiontoextendinyears"
       }
      }
     },
     "localname": "Optiontoextendinyears",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "icui_OtherCurrenciesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "other currencies",
        "label": "other currencies [Member]",
        "terseLabel": "other currencies"
       }
      }
     },
     "localname": "OtherCurrenciesMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_OtherDeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other deferred revenue",
        "label": "Other deferred revenue [Member]",
        "terseLabel": "Other deferred revenue"
       }
      }
     },
     "localname": "OtherDeferredRevenueMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_OtherExpenseIncomeNetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (expense) income, net",
        "label": "Other (expense) income, net [Axis]",
        "terseLabel": "Other (expense) income, net [Axis]"
       }
      }
     },
     "localname": "OtherExpenseIncomeNetAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_OtherExpenseIncomeNetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (expense) income, net",
        "label": "Other (expense) income, net [Domain]",
        "terseLabel": "Other (expense) income, net [Domain]"
       }
      }
     },
     "localname": "OtherExpenseIncomeNetDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_OtherExpenseIncomeNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (expense) income, net [Line Items]",
        "label": "Other (expense) income, net [Line Items]",
        "terseLabel": "Other (expense) income, net [Line Items]"
       }
      }
     },
     "localname": "OtherExpenseIncomeNetLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_OtherExpenseIncomeNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (expense) income, net [Table]",
        "label": "Other (expense) income, net [Table]",
        "terseLabel": "Other (expense) income, net [Table]"
       }
      }
     },
     "localname": "OtherExpenseIncomeNetTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_OtherLATAMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other LATAM [Member]",
        "label": "Other LATAM [Member]",
        "terseLabel": "Other LATAM [Member]"
       }
      }
     },
     "localname": "OtherLATAMMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_OtherLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities [Line Items]",
        "label": "Other liabilities [Line Items]",
        "terseLabel": "Other liabilities [Line Items]"
       }
      }
     },
     "localname": "OtherLiabilitiesLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_OtherLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other liabilities [Table]",
        "label": "Other liabilities [Table]",
        "terseLabel": "Other liabilities [Table]"
       }
      }
     },
     "localname": "OtherLiabilitiesTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_OtherforeigncountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other foreign countries [Member]",
        "label": "Other foreign countries [Member]",
        "terseLabel": "Other foreign countries [Member]"
       }
      }
     },
     "localname": "OtherforeigncountriesMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_Outsidesalescommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside sales commissions",
        "label": "Outside sales commissions",
        "terseLabel": "Outside commissions"
       }
      }
     },
     "localname": "Outsidesalescommissions",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_OwnershipRequirementForEarnoutPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership requirement for Earnout Payment",
        "label": "Ownership requirement for Earnout Payment",
        "terseLabel": "Ownership requirement for Earnout Payment"
       }
      }
     },
     "localname": "OwnershipRequirementForEarnoutPayment",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_Percentageofrevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue",
        "label": "Percentage of revenue",
        "terseLabel": "Percentage of revenue"
       }
      }
     },
     "localname": "Percentageofrevenue",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_Percentoftotalrevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of total revenue",
        "label": "Percent of total revenue",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "Percentoftotalrevenue",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "icui_PerformanceRestrictedStockUnitsPRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Stock Units (PRSUs) stock units issued if the measurement period goal is met.",
        "label": "Performance Restricted Stock Units (PRSUs) [Member]",
        "terseLabel": "Performance Restricted Stock Units (PRSUs) [Member]"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsPRSUsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_PerformanceSharesEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares Earned",
        "label": "Performance Shares Earned",
        "terseLabel": "Performance Shares Earned"
       }
      }
     },
     "localname": "PerformanceSharesEarned",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "icui_PrepaidAssetsCurrentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Assets Current [Line Items]",
        "label": "Prepaid Assets Current [Line Items]",
        "terseLabel": "Prepaid Assets Current [Line Items]"
       }
      }
     },
     "localname": "PrepaidAssetsCurrentLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_PrepaidAssetsCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Assets Current [Table]",
        "label": "Prepaid Assets Current [Table]",
        "terseLabel": "Prepaid Assets Current [Table]"
       }
      }
     },
     "localname": "PrepaidAssetsCurrentTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_PrepaidNoncurrentAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Noncurrent Assets [Line Items]",
        "label": "Prepaid Noncurrent Assets [Line Items]",
        "terseLabel": "Prepaid Noncurrent Assets [Line Items]"
       }
      }
     },
     "localname": "PrepaidNoncurrentAssetsLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_PrepaidNoncurrentAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Noncurrent Assets [Table]",
        "label": "Prepaid Noncurrent Assets [Table]",
        "terseLabel": "Prepaid Noncurrent Assets [Table]"
       }
      }
     },
     "localname": "PrepaidNoncurrentAssetsTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_PrepaidVendorExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid vendor expenses",
        "label": "Prepaid vendor expenses",
        "terseLabel": "Prepaid vendor expenses"
       }
      }
     },
     "localname": "PrepaidVendorExpenses",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Prepaidinsuranceandpropertytaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid insurance and property taxes",
        "label": "Prepaid insurance and property taxes",
        "terseLabel": "Prepaid insurance and property taxes"
       }
      }
     },
     "localname": "Prepaidinsuranceandpropertytaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Prepaidothertaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid other taxes",
        "label": "Prepaid other taxes",
        "terseLabel": "Prepaid other taxes"
       }
      }
     },
     "localname": "Prepaidothertaxes",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaids, other current assets and other noncurrent assets",
        "label": "Prepaids, other current assets and other noncurrent assets [Text Block]",
        "terseLabel": "Prepaids, other current assets and other noncurrent assets [Text Block]"
       }
      }
     },
     "localname": "PrepaidsOtherCurrentAssetsAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_ProFormaAdjustmentAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pro Forma Adjustment - Amortization",
        "label": "Pro Forma Adjustment - Amortization",
        "terseLabel": "Pro Forma Adjustment - Amortization"
       }
      }
     },
     "localname": "ProFormaAdjustmentAmortization",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ProFormaAdjustmentFinanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pro Forma Adjustment - Finance Costs",
        "label": "Pro Forma Adjustment - Finance Costs",
        "terseLabel": "Pro Forma Adjustment - Finance Costs"
       }
      }
     },
     "localname": "ProFormaAdjustmentFinanceCosts",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ProFormaAdjustmentInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pro Forma Adjustment - Inventory",
        "label": "Pro Forma Adjustment - Inventory",
        "terseLabel": "Pro Forma Adjustment - Inventory"
       }
      }
     },
     "localname": "ProFormaAdjustmentInventory",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of long-term debt, net of lender debt issuance costs",
        "label": "Proceeds from issuance of long-term debt, net of lender debt issuance costs",
        "terseLabel": "Proceeds from issuance of long-term debt, net of lender debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebtNetOfLenderDebtIssuanceCosts",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ProvisionForWarrantyAndReturns": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for warranty and returns",
        "label": "Provision for warranty and returns",
        "terseLabel": "Provision for warranty and returns"
       }
      }
     },
     "localname": "ProvisionForWarrantyAndReturns",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_PursuitVascularInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuit Vascular, Inc. [Member] [Member]",
        "label": "Pursuit Vascular, Inc. [Member]",
        "terseLabel": "Pursuit Vascular, Inc. [Member]"
       }
      }
     },
     "localname": "PursuitVascularInc.Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementTables",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_PursuitVascularLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuit Vascular LLC",
        "label": "Pursuit Vascular LLC [Member]",
        "terseLabel": "Pursuit Vascular LLC"
       }
      }
     },
     "localname": "PursuitVascularLLCMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_RequiredShareHoldingOfStockIssuedAtAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required Share Holding Of Stock Issued At Acquisition",
        "label": "Required Share Holding Of Stock Issued At Acquisition",
        "terseLabel": "Required Share Holding Of Stock Issued At Acquisition"
       }
      }
     },
     "localname": "RequiredShareHoldingOfStockIssuedAtAcquisition",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_RestrictedStockAndPerformanceRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Performance Restricted Stock Units [Member]",
        "label": "Restricted Stock and Performance Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock and Performance Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockAndPerformanceRestrictedStockUnitsMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_RestructuringAdjustmentsSeveranceAndFacility": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Adjustments - Severance and Facility",
        "label": "Restructuring Adjustments - Severance and Facility",
        "terseLabel": "Restructuring Adjustments - Severance and Facility"
       }
      }
     },
     "localname": "RestructuringAdjustmentsSeveranceAndFacility",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Restructuringandstrategictransactionexpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and strategic transaction expense",
        "label": "Restructuring and strategic transaction expense",
        "terseLabel": "Restructuring, strategic transaction and integration expenses"
       }
      }
     },
     "localname": "Restructuringandstrategictransactionexpense",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_RevenueGrossProfitVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue/Gross Profit Volatility [Member]",
        "label": "Revenue/Gross Profit Volatility [Member]",
        "terseLabel": "Revenue/Gross Profit Volatility [Member]"
       }
      }
     },
     "localname": "RevenueGrossProfitVolatilityMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_RevenueRecognitionTimingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition Timing [Line Items]",
        "label": "Revenue Recognition Timing [Line Items]",
        "terseLabel": "Revenue Recognition Timing [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionTimingLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_RevenueRecognitionTimingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition Timing [Table]",
        "label": "Revenue Recognition Timing [Table]",
        "terseLabel": "Revenue Recognition Timing [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionTimingTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_RevolverSubLimits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolver Sub limits",
        "label": "Revolver Sub limits",
        "terseLabel": "Revolver Sub limits"
       }
      }
     },
     "localname": "RevolverSubLimits",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Accrued Liabilities [Line Items]",
        "label": "Schedule of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Accrued Liabilities [Table]",
        "label": "Schedule of Accrued Liabilities [Table]",
        "terseLabel": "Schedule of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of stock compensation and related tax benefits [Table Text Block]",
        "label": "Schedule of stock compensation and related tax benefits [Table Text Block]",
        "terseLabel": "Schedule of stock compensation and related tax benefits [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleofstockcompensationandrelatedtaxbenefitsTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue",
        "terseLabel": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceExpectationAdditionsIntrinsicValue",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "icui_ShareawarddataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share award data [Abstract]",
        "label": "Share award data [Abstract]",
        "terseLabel": "Share award data [Abstract]"
       }
      }
     },
     "localname": "ShareawarddataAbstract",
     "nsuri": "http://www.icumed.com/20221231",
     "xbrltype": "stringItemType"
    },
    "icui_Sharestransferredfromsupersededplan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares transferred from superseded plan",
        "label": "Shares transferred from superseded plan",
        "terseLabel": "Shares transferred from superseded plan"
       }
      }
     },
     "localname": "Sharestransferredfromsupersededplan",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "icui_ShortTermContingentConsiderationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term contingent consideration-gross",
        "label": "Short-term contingent consideration-gross",
        "terseLabel": "Short-term contingent consideration-gross"
       }
      }
     },
     "localname": "ShortTermContingentConsiderationGross",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_ShortTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term",
        "label": "Short Term [Member]",
        "terseLabel": "Short Term"
       }
      }
     },
     "localname": "ShortTermMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_SmithsMedical2020LimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smiths Medical 2020 Limited",
        "label": "Smiths Medical 2020 Limited [Member]",
        "terseLabel": "Smiths Medical 2020 Limited"
       }
      }
     },
     "localname": "SmithsMedical2020LimitedMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_SmithsMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smiths Medical",
        "label": "Smiths Medical [Member]",
        "terseLabel": "Smiths Medical"
       }
      }
     },
     "localname": "SmithsMedicalMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_SoftwarerevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software revenue [Member]",
        "label": "Software revenue [Member]",
        "terseLabel": "Software revenue [Member]"
       }
      }
     },
     "localname": "SoftwarerevenueMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_SpareParts": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spare parts",
        "label": "Spare parts",
        "terseLabel": "Spare parts"
       }
      }
     },
     "localname": "SpareParts",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Sparepartsusage": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sparepartsusage",
        "label": "Sparepartsusage",
        "terseLabel": "Sparepartsusage"
       }
      }
     },
     "localname": "Sparepartsusage",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_Srt_MultipleCurrencyAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "srt_MultipleCurrencyAxis",
        "label": "srt_MultipleCurrencyAxis [Axis]",
        "terseLabel": "srt_MultipleCurrencyAxis [Axis]"
       }
      }
     },
     "localname": "Srt_MultipleCurrencyAxisAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_Srt_MultipleCurrencyAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "srt_MultipleCurrencyAxis [Domain]",
        "label": "srt_MultipleCurrencyAxis [Domain]",
        "terseLabel": "srt_MultipleCurrencyAxis [Domain]"
       }
      }
     },
     "localname": "Srt_MultipleCurrencyAxisDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_StockIncentivePlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Stock Incentive Plans [Table]",
        "label": "Stock Incentive Plans [Line Items]",
        "terseLabel": "Stock Incentive Plans [Line Items]"
       }
      }
     },
     "localname": "StockIncentivePlansLineItems",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_StockIncentivePlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plans [Table]",
        "label": "Stock Incentive Plans [Table]",
        "terseLabel": "Stock Incentive Plans [Table]"
       }
      }
     },
     "localname": "StockIncentivePlansTable",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_StrategicTransactionandIntegration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Transaction and Integration",
        "label": "Strategic Transaction and Integration",
        "terseLabel": "Strategic Transaction and Integration"
       }
      }
     },
     "localname": "StrategicTransactionandIntegration",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationStrategicTransactionandIntegrationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_SupplementalBalanceSheetInformationLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information Leases",
        "label": "Supplemental Balance Sheet Information Leases [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information Leases"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationLeasesTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_SupplementalCashFlowInformationLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Information Leases",
        "label": "Supplemental Cash Flow Information Leases [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationLeasesTableTextBlock",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "icui_TerSOFRInterestRateAdjustmentForBaseRateLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ter SOFR Interest Rate % Adjustment for Base Rate Loans",
        "label": "Ter SOFR Interest Rate % Adjustment for Base Rate Loans",
        "terseLabel": "Ter SOFR Interest Rate % Adjustment for Base Rate Loans"
       }
      }
     },
     "localname": "TerSOFRInterestRateAdjustmentForBaseRateLoans",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_TermAPrincipalPaymentFirst2Years": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A principal payment % First 2 Years",
        "label": "Term A principal payment % First 2 Years",
        "terseLabel": "Term A principal payment % First 2 Years"
       }
      }
     },
     "localname": "TermAPrincipalPaymentFirst2Years",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_TermAPrincipalPaymentInYear5": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A Principal Payment % in Year 5",
        "label": "Term A Principal Payment % in Year 5",
        "terseLabel": "Term A Principal Payment % in Year 5"
       }
      }
     },
     "localname": "TermAPrincipalPaymentInYear5",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_TermAPrincipalPaymentYear3And4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A Principal Payment % Year 3 and 4",
        "label": "Term A Principal Payment % Year 3 and 4",
        "terseLabel": "Term A Principal Payment % Year 3 and 4"
       }
      }
     },
     "localname": "TermAPrincipalPaymentYear3And4",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_TermLoanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan",
        "label": "Term Loan [Axis]",
        "terseLabel": "Term Loan [Axis]"
       }
      }
     },
     "localname": "TermLoanAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_TermLoanBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B",
        "label": "Term Loan B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanBMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_TermLoanBPrincipalPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Principal Payment %",
        "label": "Term Loan B Principal Payment %",
        "terseLabel": "Term Loan B Principal Payment %"
       }
      }
     },
     "localname": "TermLoanBPrincipalPayment",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_TermLoanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Domain]",
        "label": "Term Loan [Domain]",
        "terseLabel": "Term Loan [Domain]"
       }
      }
     },
     "localname": "TermLoanDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanBDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans",
        "label": "Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans",
        "terseLabel": "Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans"
       }
      }
     },
     "localname": "TermSOFRAdjustmentInterestRateAdjustmentTermSOFRLoans",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "icui_Timebasedoptionsgrantdatefairvalue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time based options grant date fair value",
        "label": "Time based options grant date fair value",
        "terseLabel": "Time based options grant date fair value"
       }
      }
     },
     "localname": "Timebasedoptionsgrantdatefairvalue",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_TimebasedstockoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based stock option [Member]",
        "label": "Time-based stock option [Member]",
        "terseLabel": "Time-based stock option [Member]"
       }
      }
     },
     "localname": "TimebasedstockoptionMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_TimingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing",
        "label": "Timing [Axis]",
        "terseLabel": "Timing [Axis]"
       }
      }
     },
     "localname": "TimingAxis",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "icui_TimingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing [Domain]",
        "label": "Timing [Domain]",
        "terseLabel": "Timing [Domain]"
       }
      }
     },
     "localname": "TimingDomain",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_TotalSeniorSecuredCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TotalSeniorSecuredCreditFacility",
        "label": "TotalSeniorSecuredCreditFacility",
        "terseLabel": "TotalSeniorSecuredCreditFacility"
       }
      }
     },
     "localname": "TotalSeniorSecuredCreditFacility",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_UnitedStatespropertyandequipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States property and equipment [Member]",
        "label": "United States property and equipment [Member]",
        "terseLabel": "United States property and equipment [Member]"
       }
      }
     },
     "localname": "UnitedStatespropertyandequipmentMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_UnrecognizedTaxBenefitsRollForwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits roll forward",
        "label": "Unrecognized tax benefits roll forward [Roll Forward]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsRollForwardRollForward",
     "nsuri": "http://www.icumed.com/20221231",
     "xbrltype": "stringItemType"
    },
    "icui_UsGaap_InterestRateSwap2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "us-gaap_InterestRateSwap 2",
        "label": "us-gaap_InterestRateSwap 2 [Member]",
        "terseLabel": "us-gaap_InterestRateSwap 2"
       }
      }
     },
     "localname": "UsGaap_InterestRateSwap2Member",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_VascularAccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vascular Access",
        "label": "Vascular Access [Member]",
        "terseLabel": "Vascular Access"
       }
      }
     },
     "localname": "VascularAccessMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_VitalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Care",
        "label": "Vital Care [Member]",
        "terseLabel": "Vital Care"
       }
      }
     },
     "localname": "VitalCareMember",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "icui_WarrantyAndReturnReserveCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty and Return Reserve costs",
        "label": "Warranty and Return Reserve costs",
        "terseLabel": "Warranty and Return Reserve costs"
       }
      }
     },
     "localname": "WarrantyAndReturnReserveCosts",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_WarrantyAndReturnReserveInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty and return reserve - inventory",
        "label": "Warranty and return reserve - inventory",
        "terseLabel": "Warranty and return reserve - inventory"
       }
      }
     },
     "localname": "WarrantyAndReturnReserveInventory",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_WarrantyAndReturnReserveInventoryChargedToOtherAccounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty and return reserve - inventory - charged to other accounts",
        "label": "Warranty and return reserve - inventory - charged to other accounts",
        "negatedTerseLabel": "Warranty and return reserve - inventory - charged to other accounts"
       }
      }
     },
     "localname": "WarrantyAndReturnReserveInventoryChargedToOtherAccounts",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "icui_WarrantyAndReturnReserveInventoryWriteOffs": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty and return reserve - inventory write-offs",
        "label": "Warranty and return reserve - inventory write-offs",
        "terseLabel": "Warranty and return reserve - inventory write-offs"
       }
      }
     },
     "localname": "WarrantyAndReturnReserveInventoryWriteOffs",
     "nsuri": "http://www.icumed.com/20221231",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Asia Pacific.",
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific [Member]"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of Europe.",
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r553",
      "r753",
      "r773",
      "r812",
      "r813",
      "r845",
      "r858",
      "r869",
      "r942",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details",
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r553",
      "r753",
      "r773",
      "r812",
      "r813",
      "r845",
      "r858",
      "r869",
      "r942",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details",
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r401",
      "r755",
      "r846",
      "r867",
      "r937",
      "r938",
      "r946",
      "r1011"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r401",
      "r755",
      "r846",
      "r867",
      "r937",
      "r938",
      "r946",
      "r1011"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r546",
      "r553",
      "r581",
      "r582",
      "r583",
      "r729",
      "r753",
      "r773",
      "r812",
      "r813",
      "r845",
      "r858",
      "r869",
      "r933",
      "r942",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details",
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r546",
      "r553",
      "r581",
      "r582",
      "r583",
      "r729",
      "r753",
      "r773",
      "r812",
      "r813",
      "r845",
      "r858",
      "r869",
      "r933",
      "r942",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details",
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r361",
      "r554",
      "r880",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r343",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r402",
      "r403",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r847",
      "r868",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r402",
      "r403",
      "r798",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r815",
      "r847",
      "r868",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r361",
      "r554",
      "r880",
      "r881",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $8,530 at December 31, 2022 and $7,038 at December 31, 2021"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Incentive compensation"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "auth_ref": [
      "r255",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.",
        "label": "Accrued Employee Benefits",
        "terseLabel": "Benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r250",
      "r268"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued Income Taxes, Current"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r5",
      "r250",
      "r268"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued Income Taxes, Noncurrent"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails",
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r255",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.",
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued Professional Fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrentAndNoncurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r251",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.",
        "label": "Accrued Rent",
        "terseLabel": "Accrued rent"
       }
      }
     },
     "localname": "AccruedRentCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r33",
      "r39",
      "r206",
      "r890",
      "r891",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r124",
      "r289"
     ],
     "calculation": {
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r32",
      "r39",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r38",
      "r39",
      "r296",
      "r768",
      "r778",
      "r781"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r39",
      "r206",
      "r718",
      "r774",
      "r775",
      "r890",
      "r891",
      "r892",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r30",
      "r39",
      "r206",
      "r315",
      "r316",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r908",
      "r909",
      "r910",
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Adjustments to Additional Paid in Capital, Other"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r161",
      "r162",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "SEC Schedule, 12-09, Allowance, Credit Loss"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r297",
      "r407",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r44",
      "r504",
      "r695",
      "r896"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Debt issuance cost amortization"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r504",
      "r695",
      "r843",
      "r844",
      "r896"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of Debt Issuance Costs and Discounts"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r68",
      "r109",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets2Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r248",
      "r266",
      "r293",
      "r331",
      "r385",
      "r395",
      "r399",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r647",
      "r653",
      "r675",
      "r866",
      "r940",
      "r941",
      "r1000"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r283",
      "r301",
      "r331",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r647",
      "r653",
      "r675",
      "r866",
      "r940",
      "r941",
      "r1000"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date.",
        "label": "Assets, Total [Member]",
        "terseLabel": "Assets, Total"
       }
      }
     },
     "localname": "AssetsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r411",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Investment Securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedTerseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r95",
      "r410",
      "r427",
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r94",
      "r427"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investment securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r94",
      "r287",
      "r427"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term Investment Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails",
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r215",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails",
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingImprovementsMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building Improvements [Member]",
        "terseLabel": "Building Improvements [Member]"
       }
      }
     },
     "localname": "BuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r637",
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/FairValueMeasurementTables",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r637",
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/FairValueMeasurementTables",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails",
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]",
        "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]",
        "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r983",
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business Acquisition, Share Price"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r634",
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r634",
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business Acquisition, Pro Forma Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquiredReceivablesFairValue": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of acquired receivable from business combination, excluding certain loans and debt securities acquired in transfer.",
        "label": "Business Combination, Acquired Receivable, Fair Value",
        "terseLabel": "Business Combination, Acquired Receivable, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredReceivablesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r194",
      "r195",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business Combination, Consideration Transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "negatedTerseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r192",
      "r194",
      "r195",
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Contingent earn-out liability, Noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r642",
      "r895"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent earn-out"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r193",
      "r196",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Business Combination, Contingent Consideration, Liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r193",
      "r197"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent earn-out liability, Noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails",
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination Disclosure [Text Block]"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.",
        "label": "Business Combination, Liabilities Arising from Contingencies, Amount Recognized",
        "negatedTerseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents liabilities associated with restructuring or exit activities of the acquiree, existing at the acquisition date (present liabilities of the acquiree).",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restructuring Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r77",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Business Description and Basis of Presentation [Text Block]"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable for property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r70",
      "r286",
      "r825"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r889"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r243"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CollaborativeandOtherArrangementsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r257",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r465",
      "r466",
      "r800",
      "r939"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r908",
      "r909",
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,995 and 21,280 shares at December 31, 2022 and 2021, respectively, and outstanding 23,993 and 21,280 shares at December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common Stock, Value, Outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r310",
      "r312",
      "r320",
      "r764",
      "r770"
     ],
     "calculation": {
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r240",
      "r241",
      "r404",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r240",
      "r241",
      "r404",
      "r782",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r240",
      "r241",
      "r404",
      "r799",
      "r1013"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r83",
      "r84",
      "r240",
      "r241",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r240",
      "r241",
      "r404",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r944"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset and Liability [Table Text Block]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r528",
      "r529",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "negatedPeriodEndLabel": "Contract with Customer, Liability",
        "negatedPeriodStartLabel": "Contract with Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r528",
      "r529",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract with Customer, Liability, Current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r528",
      "r529",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract with Customer, Liability, Noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": {
     "auth_ref": [
      "r7",
      "r137"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.",
        "label": "Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value",
        "verboseLabel": "Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none"
       }
      }
     },
     "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bond Securities"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r853",
      "r855",
      "r1012"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r47",
      "r755"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of Goods Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk that a borrower will fail to pay interest or principal on a loan or debt security when due.",
        "label": "Credit Risk [Member]",
        "terseLabel": "Credit Risk [Member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r899",
      "r979",
      "r981"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current Federal Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r899",
      "r979"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current Foreign Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r176",
      "r614",
      "r625",
      "r899"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r899",
      "r979",
      "r981"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current State and Local Tax Expense (Benefit)"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r82",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerContractsMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Customer Contracts [Member]",
        "terseLabel": "Customer Contracts [Member]"
       }
      }
     },
     "localname": "CustomerContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.",
        "label": "Customer-Related Intangible Assets [Member]",
        "terseLabel": "Customer-Related Intangible Assets [Member]"
       }
      }
     },
     "localname": "CustomerRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Debt, Current"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r329",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498",
      "r505",
      "r506",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r252",
      "r265",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-Term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DebtDetails",
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r24",
      "r245",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument, Interest Rate During Period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r302",
      "r840",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Debt Instrument, Periodic Payment, Principal"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r137",
      "r138",
      "r139",
      "r140",
      "r244",
      "r245",
      "r247",
      "r263",
      "r335",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r696",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r246",
      "r494",
      "r510",
      "r841",
      "r842"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Debt, Long-Term and Short-Term, Combined Amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r427",
      "r915"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r427",
      "r915"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Noncurrent",
        "terseLabel": "Debt Securities, Noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost assets and assets classified as other.",
        "label": "Deferred Costs and Other Assets",
        "terseLabel": "Deferred Costs and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r899",
      "r980",
      "r981"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Federal Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "terseLabel": "Debt Issuance Costs, Noncurrent, Net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r176",
      "r899",
      "r980"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r599",
      "r600"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred Income Tax Assets, Net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r68",
      "r176",
      "r615",
      "r624",
      "r625",
      "r899"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r599",
      "r600"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
        "label": "Deferred Revenue, Additions",
        "terseLabel": "Deferred Revenue, Additions"
       }
      }
     },
     "localname": "DeferredRevenueAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Deferred Revenue, Revenue Recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r899",
      "r980",
      "r981"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Deferred Tax Assets, Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r977"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred Tax Assets, Net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Deferred Tax Assets, Unrealized Currency Losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r164",
      "r977"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome": {
     "auth_ref": [
      "r174",
      "r978"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.",
        "label": "Deferred Tax Liabilities, Other Comprehensive Income",
        "terseLabel": "Deferred Tax Liabilities, Other Comprehensive Income"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesDeferredincometaxassetsliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r883"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Deposit Assets"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r68",
      "r383"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r985",
      "r986",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative Asset, Notional Amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r303",
      "r304",
      "r674",
      "r828"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative Asset, Current"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Derivative Asset, Noncurrent"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative Financial Instruments, Assets [Member]",
        "terseLabel": "Derivative Financial Instruments, Assets"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative Financial Instruments, Liabilities [Member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Derivative, Fixed Interest Rate"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeForwardExchangeRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual rate at which a foreign currency can be purchased or sold.",
        "label": "Derivative, Forward Exchange Rate",
        "terseLabel": "Derivative, Forward Exchange Rate"
       }
      }
     },
     "localname": "DerivativeForwardExchangeRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.",
        "label": "Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeInstrumentGainReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r224",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Text Block]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r213",
      "r216",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r221",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "negatedTerseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of gain reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion",
        "terseLabel": "Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r303",
      "r304",
      "r674",
      "r828"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative Liability, Current"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r985",
      "r986",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r986",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r219",
      "r222",
      "r226",
      "r227",
      "r229",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r539",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r558",
      "r586",
      "r587",
      "r589",
      "r594",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardShareawardsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "EMEA [Member]"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r321",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r364",
      "r366",
      "r369",
      "r370",
      "r371",
      "r373",
      "r661",
      "r662",
      "r765",
      "r771",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r321",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r366",
      "r369",
      "r370",
      "r371",
      "r373",
      "r661",
      "r662",
      "r765",
      "r771",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r682"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]",
        "terseLabel": "Effect of Exchange Rate on Cash [Abstract]"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate, Continuing Operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r333",
      "r602",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r975",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r975",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r974",
      "r975"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r975",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r975",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "verboseLabel": "Tax benefit from stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "verboseLabel": "Tax benefit from stock option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r136",
      "r279",
      "r314",
      "r315",
      "r316",
      "r344",
      "r345",
      "r346",
      "r350",
      "r358",
      "r360",
      "r375",
      "r417",
      "r527",
      "r591",
      "r592",
      "r593",
      "r617",
      "r618",
      "r660",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r718",
      "r774",
      "r775",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r282",
      "r331",
      "r416",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r282",
      "r331",
      "r416",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r103",
      "r386",
      "r882"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r63",
      "r106",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": {
     "auth_ref": [
      "r917",
      "r918",
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value [Table]"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Closing [Member]"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r666",
      "r667",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r667",
      "r726",
      "r727",
      "r728",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r496",
      "r547",
      "r552",
      "r667",
      "r726",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r496",
      "r547",
      "r552",
      "r667",
      "r727",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r667",
      "r728",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes unrealized gain (loss) from liability measured at fair value using unobservable input (level 3) and still held.",
        "label": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "negatedTerseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "terseLabel": "Contingent Earn-out Liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/FairValueMeasurementRollForwardDetails",
      "http://www.icumed.com/role/FairValueMeasurementTextPursuitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r726",
      "r727",
      "r728",
      "r841",
      "r842",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r235",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r215",
      "r219",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r702",
      "r707",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance Lease, Interest Expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Finance Lease, Interest Payment on Liability"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r700",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance Lease, Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance Lease, Liability, Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Finance Lease, Liability, Payment, Due"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Finance Lease, Liability, to be Paid, after Year Five"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "Finance Lease, Liability, to be Paid, Year One"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Finance Lease, Liability, to be Paid, Year Five"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Finance Lease, Liability, to be Paid, Year Four"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Finance Lease, Liability, to be Paid, Year Three"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Finance Lease, Liability, to be Paid, Year Two"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesFinanceLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r703",
      "r710"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Finance Lease, Principal Payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r702",
      "r707",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r713",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r712",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FinanceLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r412",
      "r413",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r507",
      "r525",
      "r657",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r836",
      "r917",
      "r918",
      "r919",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted-Average Amortization Life in Years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r291",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450",
      "r756",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r115",
      "r760"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r110",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r115",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency [Abstract]",
        "terseLabel": "Foreign Currency [Abstract]"
       }
      }
     },
     "localname": "ForeignCurrencyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesForeignExchangeForwardContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign Currency Contract, Asset, Fair Value Disclosure"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "auth_ref": [
      "r992",
      "r993"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Realized",
        "negatedTerseLabel": "Foreign Currency Transaction Gain (Loss), Realized"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesForeignCurrencyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r992",
      "r993"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "negatedTerseLabel": "Foreign Currency Transaction Loss, before Tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r828",
      "r853",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward [Member]"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading of derivative or nonderivative instruments whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange [Member]",
        "terseLabel": "Foreign Exchange"
       }
      }
     },
     "localname": "ForeignExchangeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r652",
      "r896"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (Loss) on Disposition of Business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r896"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "terseLabel": "Gain (Loss) on Disposition of Other Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Property Plant Equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain reclassified into earnings in the period when cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring",
        "terseLabel": "Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring"
       }
      }
     },
     "localname": "GainOnDiscontinuationOfCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicAreasLongLivedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Areas, Long-Lived Assets [Abstract]",
        "terseLabel": "Geographic Areas, Long-Lived Assets [Abstract]"
       }
      }
     },
     "localname": "GeographicAreasLongLivedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r290",
      "r434",
      "r761",
      "r838",
      "r866",
      "r922",
      "r929"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "GOODWILL",
        "periodStartLabel": "GOODWILL",
        "terseLabel": "GOODWILL"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r436",
      "r838"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Acquired During Period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r445",
      "r446",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Goodwill, Foreign Currency Translation Gain (Loss)"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Goodwill, Other Increase (Decrease)"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Goodwill, Period Increase (Decrease)"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r178",
      "r928"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, Purchase Accounting Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r45",
      "r331",
      "r385",
      "r394",
      "r398",
      "r400",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r675",
      "r835",
      "r940"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r213",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r48",
      "r316"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r332",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r332",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncomeLossfromContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r603",
      "r609",
      "r613",
      "r622",
      "r628",
      "r630",
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r334",
      "r359",
      "r360",
      "r384",
      "r601",
      "r623",
      "r629",
      "r772"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails",
      "http://www.icumed.com/role/IncomeTaxesTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "auth_ref": [
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "terseLabel": "Income Tax Holiday, Aggregate Dollar Amount"
       }
      }
     },
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "terseLabel": "Income Tax Holiday, Income Tax Benefits Per Share"
       }
      }
     },
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeTaxHolidayLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Holiday [Line Items]",
        "terseLabel": "Income Tax Holiday [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxHolidayLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxHolidayTable": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction.",
        "label": "Income Tax Holiday [Table]",
        "terseLabel": "Income Tax Holiday [Table]"
       }
      }
     },
     "localname": "IncomeTaxHolidayTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxHolidayDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r313",
      "r597",
      "r598",
      "r609",
      "r610",
      "r612",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r975"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Income Tax Reconciliation, Foreign Income Tax Rate Differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r975"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r975"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "Income Tax Reconciliation, State and Local Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r975"
     ],
     "calculation": {
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "Income Tax Reconciliation, Tax Credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesEffectivetaxrateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r65",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the year for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Increase (Decrease) in Accounts Receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Increase (Decrease) in Income Taxes Payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesChangeintaxespayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r829"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Increase (Decrease) in Deferred Revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase (Decrease) in Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Increase (Decrease) in Other Operating Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Increase (Decrease) in Prepaid Expense and Other Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "INTANGIBLE ASSETS, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r246",
      "r260",
      "r317",
      "r382",
      "r694"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r51",
      "r502",
      "r512",
      "r843",
      "r844"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r52",
      "r503",
      "r843",
      "r844"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Interest Expense, Debt, Excluding Amortization"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInterestExpenseIncomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r324",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r255",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedTerseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "terseLabel": "Interest Rate Derivative Assets, at Fair Value"
       }
      }
     },
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "terseLabel": "Interest Rate Derivative Liabilities, at Fair Value"
       }
      }
     },
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesInterestRateContractsDetails",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished Goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r299",
      "r826",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r285",
      "r298",
      "r374",
      "r431",
      "r432",
      "r433",
      "r754",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r887"
     ],
     "calculation": {
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw Materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r886"
     ],
     "calculation": {
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in Process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Bond premium amortization"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r415",
      "r1010"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandBuildingsAndImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business.",
        "label": "Land, Buildings and Improvements [Member]",
        "terseLabel": "Land, Buildings and Improvements [Member]"
       }
      }
     },
     "localname": "LandBuildingsAndImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r714",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Lessor, Operating Lease, Payments to be Received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r254",
      "r272",
      "r866",
      "r898",
      "r920",
      "r991"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Liabilities Assumed"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r284",
      "r331",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r648",
      "r653",
      "r654",
      "r675",
      "r866",
      "r940",
      "r1000",
      "r1001"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.",
        "label": "Liabilities, Other than Long-Term Debt, Noncurrent",
        "terseLabel": "OTHER LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of total liabilities, when it serves as a benchmark in a concentration of risk calculation. Sum of all reported liabilities as of the balance sheet date.",
        "label": "Liabilities, Total [Member]",
        "terseLabel": "Liabilities, Total [Member]"
       }
      }
     },
     "localname": "LiabilitiesTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Line of Credit Facility, Commitment Fee Amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Line of Credit Facility, Commitment Fee Percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/ApplicableMarginBasedonLeverageRatioTermLoanADetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Line of Credit Facility, Expiration Date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2017CreditFacilityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2017CreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r2",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Line of Credit, Current"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2017CreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r252",
      "r269",
      "r495",
      "r511",
      "r841",
      "r842"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Long-Term Debt, Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r133",
      "r335",
      "r943"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Long-Term Debt, Maturity, after Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r133",
      "r335",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Long-Term Debt, Maturity, Year One"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r133",
      "r335",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Long-Term Debt, Maturity, Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r133",
      "r335",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Long-Term Debt, Maturity, Year Four"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r133",
      "r335",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Long-Term Debt, Maturity, Year Three"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r133",
      "r335",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Long-Term Debt, Maturity, Year Two"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt, Excluding Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r25",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by labor or machinery, classified as other.",
        "label": "Manufactured Product, Other [Member]",
        "terseLabel": "Manufactured Product, Other"
       }
      }
     },
     "localname": "ManufacturedProductOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueInputsLiabilitiesPursuitQuantitativeInformationDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r43",
      "r69",
      "r258",
      "r276",
      "r282",
      "r308",
      "r311",
      "r316",
      "r331",
      "r349",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r360",
      "r368",
      "r385",
      "r394",
      "r398",
      "r400",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r662",
      "r675",
      "r835",
      "r940"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income",
        "totalLabel": "Net Income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails",
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r281",
      "r347",
      "r348",
      "r351",
      "r352",
      "r361",
      "r362",
      "r363",
      "r408",
      "r409",
      "r418",
      "r419",
      "r619",
      "r620",
      "r621",
      "r659",
      "r663",
      "r664",
      "r665",
      "r676",
      "r677",
      "r678",
      "r697",
      "r698",
      "r717",
      "r719",
      "r757",
      "r758",
      "r759",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.",
        "label": "Nonfinancial Liabilities Fair Value Disclosure",
        "terseLabel": "Nonfinancial Liabilities Fair Value Disclosure"
       }
      }
     },
     "localname": "NonfinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "OTHER INCOME,NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Nonvested Restricted Stock Shares Activity [Table Text Block]"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r385",
      "r394",
      "r398",
      "r400",
      "r835"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r708",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseMaturityDetails",
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails",
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails",
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r705",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r896"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Amortization Expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r713",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r712",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalBalanceSheetLeaseinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Operating Loss Carryforwards, Valuation Allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r255",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r300",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other Assets, Current"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r215",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other Assets, Miscellaneous, Noncurrent"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Assets",
        "totalLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/PrepaidsandOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r203",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment, net of taxes of $0 for all periods"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r31",
      "r36",
      "r679",
      "r680",
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r315",
      "r684",
      "r686",
      "r691",
      "r890"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r104",
      "r319",
      "r684",
      "r689",
      "r691",
      "r763",
      "r769",
      "r890",
      "r891"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesCashFlowHedgeActivityIncludedinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r29",
      "r37",
      "r681",
      "r690"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r136",
      "r309",
      "r312",
      "r319",
      "r684",
      "r689",
      "r691",
      "r763",
      "r769",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement",
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r34",
      "r36"
     ],
     "calculation": {
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Other adjustments, net of taxes of $0 for all periods"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r34",
      "r37",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Other Comprehensive (Income) Loss, Other Adjustments, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StatementofComprehensiveIncomeParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other long-term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r215",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other Income Disclosure, Nonoperating"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherexpenseincomenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r888",
      "r921"
     ],
     "calculation": {
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other Prepaid Expense, Current"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment for Contingent Consideration Liability, Financing Activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r454",
      "r894"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments for Restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "terseLabel": "Payment, Tax Withholding, Share-based Payment Arrangement"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r55",
      "r639"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Business acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Payments to Acquire Equity Method Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Intangible asset additions"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPostretirementandPostemploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r3",
      "r543",
      "r544",
      "r545",
      "r855"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "terseLabel": "Liability, Defined Benefit Plan, Current"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Pension and Other Postretirement Plans, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Convertible preferred stock, authorized shares"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stock, outstanding shares"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r889"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeBalanceSheetLocationDetails",
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r827",
      "r837",
      "r921"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid income taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r893"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from Issuance of Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from Long-term Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from Sale and Maturity of Other Investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesOtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Proceeds from Sale of Other Property, Plant, and Equipment",
        "terseLabel": "Proceeds from Sale of Other Property, Plant, and Equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r160"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash received from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityAccrualComponentAmount": {
     "auth_ref": [
      "r839"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recorded amount of the accrual for a material component of a product liability contingency.",
        "label": "Product Liability Accrual, Component Amount",
        "terseLabel": "Product Liability Accrual, Component Amount"
       }
      }
     },
     "localname": "ProductLiabilityAccrualComponentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails",
      "http://www.icumed.com/role/OtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r22",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Warranties and returns"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments or Charges",
        "terseLabel": "Production Related Impairments or Charges"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r282",
      "r308",
      "r311",
      "r325",
      "r331",
      "r349",
      "r359",
      "r360",
      "r385",
      "r394",
      "r398",
      "r400",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r646",
      "r649",
      "r650",
      "r662",
      "r675",
      "r766",
      "r835",
      "r861",
      "r862",
      "r892",
      "r940"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]",
        "verboseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r123",
      "r288"
     ],
     "calculation": {
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r125",
      "r273",
      "r767",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, net",
        "totalLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r322",
      "r422"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r6",
      "r253",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/CollaborativeandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r315",
      "r684",
      "r688",
      "r691",
      "r890"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481",
      "r900",
      "r999"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Related Party Transaction, Purchases from Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsTextDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayments of Long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "terseLabel": "Repayments of Short-Term Debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r163",
      "r278",
      "r1008"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r452",
      "r454",
      "r457",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r68",
      "r458",
      "r460",
      "r934"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r453",
      "r454",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r454",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring Reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r454",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "negatedTerseLabel": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Restructuring Reserve, Accrual Adjustment"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r884",
      "r935",
      "r936"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Restructuring accrual"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveTranslationAdjustment": {
     "auth_ref": [
      "r935",
      "r936"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.",
        "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)"
       }
      }
     },
     "localname": "RestructuringReserveTranslationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r141",
      "r271",
      "r777",
      "r781",
      "r866"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r279",
      "r344",
      "r345",
      "r346",
      "r350",
      "r358",
      "r360",
      "r417",
      "r591",
      "r592",
      "r593",
      "r617",
      "r618",
      "r660",
      "r774",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "negatedTerseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueRemainingPerformanceObligationRecognitionTimingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r318",
      "r331",
      "r380",
      "r381",
      "r393",
      "r396",
      "r397",
      "r401",
      "r402",
      "r404",
      "r416",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r675",
      "r766",
      "r940"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedicalProFormaDetails",
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenueProductLineDetails",
      "http://www.icumed.com/role/RevenueDisaggregationofRevenuebyGeographyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "REVENUES:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/A2022CreditFacilityTextDetails",
      "http://www.icumed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r711",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r711",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesSupplementalCashFlowLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r404",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AccruedLiabilitiesanOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r39",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesFutureEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsForeignInfusionSystemsSupplierDetails",
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedTableDetails",
      "http://www.icumed.com/role/AcquisitionsTextDetails",
      "http://www.icumed.com/role/CommitmentsandContingenciesContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r25",
      "r137",
      "r138",
      "r139",
      "r140",
      "r244",
      "r245",
      "r247",
      "r263",
      "r841",
      "r843",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r78",
      "r81",
      "r366",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsEquityMethodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r110",
      "r114",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r838",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r14",
      "r15",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/PrepaidsandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment1Details",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPropertyandEquipment2Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/BusinessCombinationandAssetAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Restructuring and Related Costs [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationScheduleofRestructuringandRelatedCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r42",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeographicInformationandSignificantCustomersLongLivedAssetsbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r555",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r153",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Long-Term Debt, Noncurrent"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting, Policy"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ShareBasedAwardStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardOptionsexerciseddataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, Number",
        "periodStartLabel": "Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and Expected to Vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails",
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionPlansDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardShareAwarddataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSURollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardRSUandPRSUDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionsGrantedandValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Forfeited or expired"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price Range, Exercisable Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r709",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term Lease, Cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software Development"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r136",
      "r279",
      "r314",
      "r315",
      "r316",
      "r344",
      "r345",
      "r346",
      "r350",
      "r358",
      "r360",
      "r375",
      "r417",
      "r527",
      "r591",
      "r592",
      "r593",
      "r617",
      "r618",
      "r660",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r718",
      "r774",
      "r775",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/StockholdersEquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r375",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets",
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/StatementofComprehensiveIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r7",
      "r8",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Stock Issued During Period, Shares, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r136",
      "r141",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Issuance of restricted stock and exercise of stock options, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.icumed.com/role/ShareBasedAwardStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r28",
      "r136",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock Issued During Period, Value, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r136",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of restricted stock and exercise of stock options, including excess income tax benefits"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Treasury stock purchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Treasury stock purchase plan remaining available"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r92",
      "r866",
      "r898",
      "r920",
      "r991"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r201",
      "r202",
      "r207",
      "r279",
      "r280",
      "r315",
      "r344",
      "r345",
      "r346",
      "r350",
      "r358",
      "r417",
      "r527",
      "r591",
      "r592",
      "r593",
      "r617",
      "r618",
      "r660",
      "r684",
      "r685",
      "r691",
      "r718",
      "r775",
      "r776",
      "r898",
      "r920",
      "r991"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r330",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r692",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r692",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r692",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r720",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r166",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesIncometaxdisclosureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesTaxCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/AcquisitionsSmithsMedical2020LimitedIntangibleDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesIntangibleAssets1Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingRevenueMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about trading revenue have been included.",
        "label": "Trading Revenue [Member]",
        "terseLabel": "Trading Revenue"
       }
      }
     },
     "localname": "TradingRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/DerivativesandHedgingActivitiesDerivativeInstrumentsandHedgingActivitiesAmountsAffectingConsolidatedStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r412",
      "r413",
      "r507",
      "r525",
      "r657",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r917",
      "r918",
      "r919",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury Stock, Common, Shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r27",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r27",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r8",
      "r136",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r27",
      "r142",
      "r145"
     ],
     "calculation": {
      "http://www.icumed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r136",
      "r141",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r453",
      "r454",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails1",
      "http://www.icumed.com/role/RestructuringStrategicTransactionandIntegrationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "US Government Debt Securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r833",
      "r853",
      "r855",
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementFairValueMeasurementsRecurringBasisDetails",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r264",
      "r277",
      "r595",
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Undistributed Earnings of Foreign Subsidiaries"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUndistributedforeignearningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r596",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r976"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Acquisition"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r976"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/IncomeTaxesUnrecognizedtaxbenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r907"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "terseLabel": "Write-off/ Disposals"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r336",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at\u00a0End of\u00a0Period",
        "periodStartLabel": "Balance\u00a0at Beginning\u00a0of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged\u00a0to Costs\u00a0and Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged\u00a0to Other\u00a0Accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/FairValueMeasurementSmithsMedicalSimulationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantyReservesMember": {
     "auth_ref": [
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for expected cost from warranty provided on specific product or service.",
        "label": "SEC Schedule, 12-09, Reserve, Warranty [Member]",
        "terseLabel": "SEC Schedule, 12-09, Reserve, Warranty"
       }
      }
     },
     "localname": "WarrantyReservesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/SECScheduleArticle1209ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r365",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted Average common and common equivalent shares outstandding (diluted)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r364",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (basic)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.icumed.com/role/ConsolidatedStatementsofIncome",
      "http://www.icumed.com/role/GeneralandSummaryofSignificantAccountingPoliciesNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r871": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r872": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r873": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r874": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r875": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r876": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r877": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r878": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r879": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>154
<FILENAME>0000883984-23-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000883984-23-000009-xbrl.zip
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M9X 'LH(;R[K1#+F(8.U_'LW@1U<E2WN>O0$#=0N>3S,/71B=(L&!%2=FM9+
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M,)NHV=)=KV.0.S)AZ+C[#87E[,'?CE%:?N[8;<[SM,F%797!3I/#^ZDS19[
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M-4HTJ"T;1G(TSUPMM )ETE;AQT0OR:6S5%DB^\!VA ;O0N?AAS;:?=TK$VT
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MV^:2'*3!:<H31P[BQE0NEVU5#\%*DQ%N%0S#=YE8;HRS'5BG[@R]UZSPB+N
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MG+GJE/ITTX#35MA3@Z4^D8H@W9GA;K7VTZ2/@%9U2YGNZ>'R;[TB!*7L\.,
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MY(3]G7R[-6BF9?66V<EDM#4E'DG)+)=5R]+J%)R?%Y?PLT$BQ[A2WY"B!0>
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MOF&4XQ6D0J]?<$TB!:7#PZ%')VB#LQYLZXNS/;*K,MS!WI;M,)8UDSX?WD'
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M8KJX8=:P<=#/<<00/T=\#?S/IMGFW_U_4$L#!!0    ( .F+6U;8&Y/NE@@
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MK039?.H\S)FOXL"IE1R[A$,>=SA$(?!;U(V%U9P<:W6FJ!DN.A^%Q)QCHBQ
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M!D0VGN]\07LE9R:@?K6$3%#2F5B]9%6W:.7GN,5O_G%P]IGR_K]02P,$%
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M(=375)O4KD]N'>&3;[\Y\_IZVU?+[]ODE=2]AD>+'?B?!=]]!'X02LC>[M5
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MZFQL3L #YPW4R8Q<VFZ^AB=;=3I2<Y6LF!;,WI=H8BE4-'$)O#V87OTL[T8
M16<"62G4H@-PJ60L%$-2HTV-W18"NIE9WLU8J[$(#06<[<VU-5'*B)JW"EN#
M,<+V@7N5L[P;@92IJ@8,B:@:J*K5%3] RL0.3&RX?9!N?I9W(T!;"I4ENA!!
M(,94O"070N)F&-SYOIFM OJ*9WDW@JIG#.A<LBD%J&*S6)*^/$Y(P(6N;L_
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MQ&4*?3]")+8>M\RJ[N*T_G@RT3M/GRSTXCO'+^:SEV<GN(S$N"I+E23-U1!
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MIQ!;;8YD62SNRT)PSD^O*>G/G.SE% 9?"GB.! QP%)<,M)(SM=B\::5H-I*
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M<)A)!GS*X7KCXF<?M[KIX>1X,GWRKM]^.ILO#V5^O'YN7$I#P&PL472N80Z
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M(?,[7N3V7!S1TO'[=H>; 5 KC+;X3#ZQ+[*2TVC:6&%K]8+([+LNLYGI=H#
MD6WV>T[4VX#BD/6CZN-4\9C<P[(YQIW(M2W?ZUAVWPLZ/F/<[)A\B\_A.EBS
M*SF<S P<LV^[D>7Z;L1<H'D0NE80='M1-V!K/!]@PTC]*"<VZ(#6])AC,S]P
M0ZO;[SH]R_),IPN$#,--JM]:5XMG]<4<'4Q_N* P QO$LAWT+8^;H>_W+=LS
M^28,-UM7VCY.]K_OV3T6]7C'96[/[_5[73MT^X'#'>:9T2;-KEX_NV?UI]$V
M.QV[WW/MR$&1&_J=C@NN)>MW@]#KN%MX&I_4FGVX<^A'#LZ-=[U^9 )Y?-;O
ML;#3[9J=*/2P)GU[S^$Z6+,K.9RNWX]<)[1=SCTW[)J>$UA!!VS;/B<7=/L.
MY^JMV1\\L;_%7U_DO,@F.7RB^.>0LY#6$\;7K_X)_R539$[@= ,>!MSSW&Z$
MD%]]OP^_Z >^9?7<OY&8]3U%.4V ;*,X;0]Y/!B6+YSNN'QY$X?E\(5EFO^S
M1]>]^F<Q9NFK?_KY;W"W^%D\9.Y1N. V2^)!^@+'"O)\3]RL_AYD29:_^"^3
M_N]E!%_8CM@H3J8O_G$%%"Z,,WYCO,]&+/U'JV!IT09BQI&XL(B_\1>6"PND
M?]Z(%??@.4F<<O4%EHW+_G!V<G5\9%Q>'5P=7QJ7QX<?WI]<G<"/!V='QO'_
M._S]X.SML7%X?GIZ<GEY<G[6_*PG_2#S3A_T%RN&<3HHL[1E'.T?[ALVYJU7
MM^S.S*K=A:O^W_^RNN;+%6YN_TZ;^^;\_:GQ3SA6:9:>34;PD,"0I^\]CQ!.
MSP=!:4:1U^MYKFE[?=:SF,T<'G8P![U001HI0YD8\OC%419,4%Z@3-J3R17G
MSZE_E%V_L]]??W1.)^'GX^M/;[W/YY]/OWW\=FI_M/_\\M'^T#F_^L/^]/FC
M^_';@?OQ\_#SI[_^<#_:)U]/KP+SG7.6?/R6P=6GW\Y&9\FGMV?)^=47\VST
MT3Y_>WIS_O;$Q>><OSV+3Z^.G;,W_:_O[$_3CW\%W8_V^_C\"NX9?8(WOOYR
M]O:#<VK_:_CI[;^&IZ-/R=E?I]-/\+N/?WV\#M_^Z8:__ROY9"?7_N?QYT]O
M3SJG]I^C3Z/3;Z=O_S _707?/H[>?/DX.IY^&GVP/G[[UY=/5^'P4]+_=G;U
MA_DW"SVPZ7FG'?69UW;MT&Q[8!:V \MA(*-\T^?1WBO+;/^;A%M-A5?&MG'X
M2_I-G*+^(_:\^[(/\I@EQH<T#K*0&Z>7=Q4HBQ?^!.Q^D*83EKSGXRPO]XPH
MRT>LA*?#]X-U\,+/LL1GH(I+/_OZZYT*Z^^.ZP0=A_MMV%FS[?+ ;7MFG[6[
M9F!V89O[MF<C@\%1Z;Z</1B*X^[(.W^![@CA/\7/,8UQS]<^J H\.#O[</#.
M>']\<?[^RKCX\/[RP\'9E7%UCOK]"I2X83G&^7O#ZCP+GQOG;XRKWX]UU5^I
M_8/#*_RSY3GN^HB7Q=^\<@5Z-]*\R7*C''(CBHL 9-24L]P WX2'3Z%5+\AL
M/A:N4$/.O CA-^T1O'.(M[5#-FWCVMH\_;4$SO3T*/B[[U@][GH<!$R?@Q8.
M@C;S';O=YWW?ZX'DL<WNWJLC'I"O(SC/L5H&[OV<7L[R;3LZ/Z&9'TBZ/H4%
MBIU_,<UZWZGE16K9_CODMM?M]7KMP#6#-NAHK\TZ73@U@=>Q.YX/VMF4:MF=
M4\LK59!7[P_.+D]($VZIDEQ3+_-^2K*LSJ A(CY&E&<C\1$__]]&F3W8HW:$
M?Q#"'V:C45Q@\-)X$R?<.,OV'],N.J9@)+X)G@Z:_)<3XJ>=OQT;K)VN T(\
M[((0[W7#ML<#JVVY-A@^W U[?1_CTE;;<;LHX;8\[+"BP-K)X0?C]/CHY/#@
M7<LX.3O<7^'&WM$(>W;\E04E'2<CBXSW?! 7*+%+@Q5&,>8X9PK\FC@UXK(P
M@B'+8:W/YSYK';EBQ/)!G+;+;$S/6[3C)?-!0,GK_2P/>=Z&Q2=L7/ 7ZH>7
M85R,$S9]$:>T!KKII7RZGY5E-J(77/.\Q/$J\B7T/O%GF6+PNON>V4?+M\SA
M/Z%ZL4Q [)-1_%L9SO_-[>V;=F_IG\U]:^G?;GNLO=]UW0=_*BW6N]-C?Z.-
M$)L!VXV$_+\]9T_=,&8A^ADO[/%7PUI$PMD]%]O]]'K/?&1_1NBXDS3(<G!C
M**M'0 R'8H3N81;R>=>FP"O&>7:-S]G0$,";V'_[H?OI[:ES]NV+^^GMI]%'
MO.=H\.WTVY>O^)^/H[/AV;=C\_3;FP3TI+SG3WA7)_UT-?[R\5O@G%\-O]#[
M0)>>'YU^.[\ZAO^\B3_:Q\[IU1_?3O_Z,SFS^C?OK@[*TTOSZ[NK+U-XIONW
MXW4[GAWX[9#WO+;K6E&[']I1._1=;K&(.WX08 PA83<LY\N"ENH8W(_#$Q[-
MR91'XN\[L?>,M/VA;UI\:D%";^N1O6)?3V3N/Z!CN\$VZE.?Q9/F6;0]J^?S
M(&AW6!"U7;/;;_M.T&GSON/ZW(\X9^'>*\=IFT"-KC<7PVMP[D,KGJ=@X3DC
MB%CX&2D" YSM#+SMW/@\R>,BC -RN,&BBW6E09?E Y;&W^C?SS=51"W>B\T6
M44OH>[+_?O]RWS@>C9-L"@1NRA/TKI_/L_9O9*1NEH$NB=)&KA(>E_I-+I[9
M7Q<KOM=S?\2*M^U]IV?_D+U]^]\\Z\?N?*3%?L?EZ"S_Z\^X'%[GQUT.;[TE
MPXJ,EX,PS'E1R/]Y!PNP-MAP.;WZ8'Z\@M7 ZLZN3JPS,CZ&7SY^#KZ>??MX
M\^GM'U_//B?QV=5@QG#)OIY=O1_"&C_#W=;IYP]@X)QVSM^^C\$P<<X^O_[R
MZ>C8/O_KQ#I_L\")Z'O,\\(^;UMNE[?=@(=M/[#M=MCQ?<;=H,<Q..=U+..0
M)2#(#H S>(!5F=OA3FR#KO[13_IQ.Y-TWJ\G; [AQ_/\*KO9Y'C%$XF:KW.B
M)NPZELF]L&VZ'=9V>8^U/1 L[1X/+;O3\?P>^DB7P#Z'":%X/G#,8MU49.OA
M9>;V'T%R*,_SBSR[!N=QJP.+3W=09X(902=R>-_RVEW7">"@^KUV/XH8, [O
M.D$86JX)-L$A@AUG>1JS;;$%=J'%ASZM%QD<Q^13/!9)@-U1_.Y1_*-Y%'M1
MZ'?<;M3N.*;==D.[BW7)4=MSP3:W(L?J^0S,<[O;<^X?4EQSQW))R$FR%H8/
MQSGH@'C,$H-_Y<&DC*\Q3QS% 2]VP</UIR3(!0,%PUU"A+N:CQ\IH*@K)O[W
MO_JVU7M9&%<\X>-AEG)#9'M:QDD:)!-D&N,@YXPH\F*EM9//'E$]H0N'G[FQ
M"NFGBK'LOUG/ZWG]CMGNAF:G[?:=/NB2P&N;CM\+^X'I.EX'% JV,S;5R?/'
M+)-[EX% ND"NW. 4Y$_5.M_\;?->%/4<U@XZGMMV;9.UF<_]MM7ON2S *5B.
MO??*Z7;;MM6?T_9;5R7W$RT #RJ,+L&PR.,RAB?F)$UYSD-C/,F+"1:BE9D!
M5U"RR[*?^<_1+,'"XH.@?+$^)/FAKHQF!NS)4UE@).R;PENY;R[+Z>]W'B&1
M8_7WP=)^\,<ZWKYMWZW2;3-*TKY;CTI4O8K+A,HZ.0N&1I"PHG@,^W:EGY@S
MLJLNIR,_2[;MZ\YD62[1CW\-ABP=P"]2XV88PV]J:7F?I(,4*RAT8 .,(DOB
MT%"?HK;'Q,W9NW4GG_0YZU8"NMC?>D3[32K)Z;'D F2-^= L\LC&1V7AGL^?
MCEY_/C_ZX'Z\.G;/CCY:GXZ&P_._CLW3HR_3\ZN/UMFWY//9Y]E0$-J$9U].
MWYZZ9U?#X>G5P#S[C.LZ[GP$^^_\ZJ1S]OF#<_[7J;TP*MO'OM#(C]I1%%AM
M-[1Z;<]V>FW3-UG'[%K,L;L@<L#V.&-%R/YC7)99\,4X9?D77AKOWAT^:<W9
M* [#A&\OIUNV3PILQ\G?X^3I7"*P%X&+T^]WV]QR;/!T_$Z[W^F"NP-<P<)^
MC[F\*SJU,F0=X.*6,6:Y<<V2"3?^&PPB$[OUC&*XH*[9> PUNZW<+ T489_L
M6/D.K'S<9&4SX/U.Z$5M$XM_7:L3M<%=C]K=/FQZKV\SUW6H]>KD*7+9*V73
M9V^3S&<)N,,).,12[VQJ]><FA"/>U^&(B\7AB$$C'"$;B<^RE&]$B]R3[_CB
M59ZD(98S<\.?&L&0@TDU M8V8K&Q>=V3&!<&,VYXDK2_I-D-K).S O8ZA#\4
M$PRTL\((Q;Q9;%E\/P'WUS4[BD0:98%:^T9S=YX6_>)__\ON./=]]X/N^N,W
M9?\%E/HW$NI2TNF$R+216O"G0L]?_[;#,."=B+5=)P+7PHS\MM?C8;MCV]QU
MS:X/N[OWZB,O9I78##;!TS)IME+^/,M6)KA^5>F:9B7\YC^3&%4>:+H( 1QR
MPLXI%D?D'>PIJOY%,"M2VJI(A9"UOR(#PW%>Z?']%73,GUDR24N6$P)(7OQZ
MNF7ZM\6YU>&LTPZLKM]VO2XX^UVWW_9#QW+<CN69'#P6E*;W2FCNQ.O/B->;
M(:=^S%J^OC">6<^-(9BH*%5#@R5))5IUF>MS>0$\L"EF&^)5,V9U28M_1A0K
M(X2_I@.Z=)SS@%.:Q+(-P@<LC&?PO C^4TR"H5$,,\3U4 !-Y9"5NF*X8<6\
M5J ;Y?J?@^6=AL8S6WR?SSF08>)_1B\5KJ=+X29<@7P.%I\7M !:("M*PS.-
MD$V+_9W(?&21>3C)<]A^ 8F'L:F2E9-?3W*>.G_[D<L"UO?:0<<&T]RR^NU^
MG[-VQW*9;7MA/_#XSBK?6>5/KS9F3'.4JB!01W%9@@BF\%^>I1B73*8&O^;Y
MU#C!&!H+J$+WB)5,@*_-*);Z&;HQK\=)WO/!)!&MY9?M*^,9[F;OI>W8^U4@
M)28@J#$"0?VTEIGYSEE-(]9;*1!>/*_4P^.C[53[B=LIA>8O)R7_^/:W;W8\
MS_=[;<9#D)(F=]K]'C?;?M!G5M_OF);572@E?UT=7@6"5ZTB=C+ZR60T!:<3
MEH,=SH( 9'3.4-"BV,+(=+KPMP8<E_:"/X#,9$8QPH;P7%K9*%F#; 3[,!5_
M3PTPH['H;V ,\NRF'*H_*QEYR;D(A\<*#09KU&WXU"6KI#];+]5EW[U@^0+5
MA>@6["U99FNO"M);MM^V%P6.7CS*,7YT^)*>O8)RSFYGW['M'ZKF?!PD0'O?
M\1X>M=""S^P^ H:(M=_U^H^P!ZYY-W26'Z\/>L)6JI774]1PO_DA"*9!ED\W
MTB:378^?P19[^^'KQ]&I=?KV='KV]F3Z\6H(3WB=G'W[8IU>?9S"ZJW3;U]F
MNQZGIY^_W'Q"Y+1O'VX^?CLQ/W[^U_#\+5AU\([SJP]?SSZ??#O[_.';^9\+
M0$F"CLM[GN.WHQX+VF[7M]K,"YUV8 6F&W7MGM/M[;UZ1WKB0%,#M/%K61#T
M\Y83L>[7>WS+'8I;-^G4'LRJ^VVB:S9?)O-@LG9U#9X/T;2Z=GQX[X]Z^'.X
M011M?/P6V1!GBQRC[95(OY2FN1S5R2_-:_Q)ZJ[=9SZZ&4S[^'I2P)N+8AN'
M&SVIE3R=PP:Q0]MS79/F:H1MU^_VVG[HL;;MV7T_# .W8X5+AR,M,C@4!ZKY
MPR)*\%!'?[TNO:,NVAC1MBFVRTI%WO'B4-]6VJF/+M[59KZEO3P46[D3\S\I
MYLTY,6^%?=OO=-QVU[:BMLOL?IN%7J_=BVSN=!TK9/WN/<3\YK1?K$&*);HE
MC]$RXKO6KF*"G-+BX"E@$6N9&9."TU7PH6(XZX))=%E.[TJF^/*;&%Z-9F@*
MWY9A5N,Z+LCS2%D:X#1J\$=PX@I>7)0L#5D>%@8B(<;A,L0*YQE;4A$[/X%N
M0W*%K_[IY[^]6GO.NG>!A2S+DWX)MMEC]HJ5)4?$2Z0F$!;'8,':V(!*V"K,
M)U848(+CKQ2Q>11QJAY()90:WAFC_YD")Z&RR+/$R$"A:0Q6NT03V,"ZL-HU
M70WYY)+E/H/'ML^_)GQ*57_/K([Q8?]R_W"_9W<1)>4Y?G?]D1)2Q4] 46E<
M',7Y2!1BC.'5#"\"QJ=NFI 6S"9A7,IEW;N(FT:XK^V0V),@R@_P\[+\H*;Q
MFX0-ME'%_E2EG/MWM^-8X/_8;<OL(ZB5[;7[/>:U._!OT_*=GAGQ[TYO_Y4%
M#%4'%$.>)%6TX]F";K6EB?#GJZV+??Q0!F[-%INX/W7^K+]-SCSN=N' =2*[
M[;I8C=7MF6W;8ZX3V5:_WU\^IGG7!+/::K!=R>R#[","K[#! (0J2MV10%T1
MB!528%YGTC9'6!80*-1#0156$;8?P&UDB>6-*:?PBW]-4B[VP#%;!@JI%CTO
MP;X$7\97L3NA>7=E_8VR HTD3"\D4^%1</1$0'1E*3H010#&W7\F-#VU156N
M_RTEZANJ,043;Y+&0IY.BG"O*6#-?N1$(0M,UV1NU^TR[GI^O]?KFKS7,?W^
MWR>P9-/L.N8>*)0@'K&D^+\]<U[(7I !^";)6-F0L2_2R:@=9F5;WKUGX((Y
M/>-7DK73\ZOCKW\' ??MOMUK=_J=+M@Z';_M\Z[5#H(N=@3XMMUE>Z^<EF-V
M6IYIMKP:*U)1\]7^[L0_T(E/":X4#QZ!T<!YG93D?.-)7WP<@P:NS7\3F(T"
MMVFI(\]2.(XR,.E8=.H=.IE+#Z9X_\S9Y#;W3-<+NA'ONSYW/(\[ONFZ?2L,
M0MOIT=ET3 MMGOILGIR]6="70\LF3*E+>M5Y_:6[X[K(-#H].K[YF_/(9:%I
MMWN>X[7=7M!O^_W ;(>.R\/ C7QF6GNO;*?E>?V6W;'O>U8W#]AU1:?UZ/SP
MP^GQV=4ESCX_?W]Q_O[@ZOC(>/W1>'_\YOC]\=GA\3;L].K%XB,Z8T=9,*'>
MS'K8- ]?3^'9/.=IP*_@1:\3D%"_F*0YN_K#^9O;H67Z%FOW>BX#2<,=, S,
MJ&V:?L?T[%[/[+E[!@=A/$9FR2=\[]4%QO.RM% FZD6>?9T:-&.'HH51EB]2
M8:2-#E+048EQRGDIE1TIAV&6A#Q7\4ILH=6:AAM]774OE^4>4'P[1M0BT6@+
MKP:'^D8TY<XM0-JL4PZ*4X3/C\"^157<4)E@*(.FTJ;,BK[E7/$+1CPSXP(,
M7^/DY*3J'Q.]I_O?#12MHQ!H5N9W[QJU4BG_+O8*9"(/\2+G2)]K7@,RX_'6
M[I)O,>M;F%]DR:1<?LLR4;IH??I_XR/H3#M.X'0#T)W<\]QNU 5EV@>-RL'X
M]2VKY_[=VU/W#*N*AC$;\+:?<_8%G"UXZ0N6W "3[?W6W#O8.+D1KKW?0WK,
M?L;W%KM2Q;<8,>SD\ ,<4HP&)C3K884&Q1U7_ :,2<,RV__>A)62W/R(@NCX
M%D&T0GC^.W[*U<'K=\?&^1OC\/SL"NVDNZR8YD ^>2N1Y^Z;9N='6HDL<[]G
M>0_>1M/S]D&]/OACN_OV'6<G;T1E[9--6]O&;UH_^/<+T*G?;UOH_C3!'M[0
MNE,%E5A?R .T&]&TH9PW7@5K8FNS%F.8HV?U7]^WBRS7[I'&NF%YV'Z795]H
M-(&R]8M__L9F39J'A-=_6.X0+1 [UG@HUG#MO5?OX^*+\88%90;NV^5D!)IY
M>B^FN#O=[S1Y<*5T7R+S#MY?&2<+-N21%/".P1^(P1&$&^2<8?T00^_(MCJR
MJ0:2IR+<&L6MMY6DRP[A3HBN-^FZ2H@>[*3HRM=R/[KIMMU.DFX-6:WN3I1N
M).T\)4I?[T3IRM=R/[I]2'->9,DU#S%X$D4&5L;<.X"RDZOK3&.GMY.KFT@[
MVY9RU=Z)U96OY7YDN\BS,6XSW\G1[2'J3HYN*.TZ4HXZ.SFZ\K7<CVSO^( E
M6,@7<,([WXG3[:&MT]^)TXVD75^*4W<G3E>^EON1[11N,2Y9Q,NI<10709(5
MDWQGHVX1A>\G5#>[<F%7NK F:[D[BSJNU!V=G>Y8^5KN1S8Q KV:(_=^OH]%
M-%4:Q_^9Q.6T!5<DU*.B-=(8IPCQDQ=BAIT848SCOH,A*T2_N+A9F[BWTTU;
MPT&.MS/X-Y)V/2FTE^5G=V1;5[*]Y_#^:Q[NI.C6D-0U=U)T$VGGFE**+LLB
M[,BVKF0[K4 H_U%0W&12%+'$K#Q(63(M8C)>WU3@DH=9&@KX4[P&I/ D*>F2
M\S$7B]D9MMO#'SN1O*&T4XT4O5T-\.K7<C^Z_8'(&W%)D XD9.$7B?JW%MLV
MF)]-2D-&+[!R>"=XMX8).LO"B#O!N]ZT4\T7R[(5.[*M*]EJ&[=NMB;Y>SD9
MCQ/Z-\NG!LYQWPG:K:%ZYVE:,QYC%N =MND)@#IV(NB!F-'#H"8BFA%#;NHG
M%!N]>@QDG,"]8T[XC#(72',O!.PQSC%6<R_>Q/EHIPFVYO!U=D70&TD[RU:E
M%\NRL#NZK2W=#FDV"<XT(E/[*"[8(.?2^*996E+@,OQ%ENKR%V^HC?8Z,K*3
MR=O#'Y:YJZ7>4.JIV@IO%X)>_5KN2;C#C";+B?@'-:F$NW+J[2+Q3K)N*O4<
M56_A[5 I5K^6>Q+NG.;ZG:1B$@L\:B=3MX>XEKDK!-Y0ZJF"">]P)U-7OI9[
M$JYV_3%@RW*:ZO4FR^%=J?&O21X781R( 2HTIO@BY]<8W3U)B[&8C;RS;+>(
M'>XIA3>\57#7*[@F:[D/EU:X<LOJ*W>$6UO"'<4Y)X#.EG'\E0<3JLL[CZ(X
MP'E:&# Y5&.LC+<9D 0CU+N@]!9QP,[,WU3JN0IXSMHAS*]^+?<D7"UM#[/1
MF*?%+GZR912VEA[+G6!=<^HI)#IK!^FY^K7<DW 2DV)JG-^D8,,.XS'6P1W"
MUK,X-5[SE(-QBS46XN]DX]:=@[(1<"DDQDY ;P^G6$N/]TY KSGU%+:=M<,*
M7?U:[DDX)8I)RF*X&D1TT9"[5SDLDXE8=DN6THDPA5;/O(M";!-3[&3QIE*O
M8RE9O ,:7?U:[DFXBSQ.@W@,UG!=F6R\X5SV"O+\.@YVE7+;1/%["MK-SB?^
MN=,GZ[&6^S"I*K6V=N"CJU_+/0EW_'48^[%L-5_0@VY<!D,>3I*=3MDFJEM+
MW?"=L%UOZG6K\:I/ QJZ7C1[D^58M=+^=SUY_C&1!7:BZ/&9V7KJZ:1/3[@=
M#,8&L:2W]^H2MI:5NXZS[:+J=P3-;R7S$ZY^OY@F.2Y+DN35/_W\MYFG[>[:
MW;6[ZTGNDB+"M?=['1 CXZP@6. 7.>6HKOG+FS@LAU+]ZC<*L?O"K&]A?I$E
MDW+Y+<ND\J(EZO^-CXC#_]N[4_D1>&7RMF%>:Y0!;_LY9U_:+(+WOF#)#9L6
M>[\UEC>*T_;,=LQ^R??6^X,?NU+--1=&M/%KP4.X87EHO,NR+]B'4X/IS2W]
M[M\5$QS3"Z<[+I]>(=-G_<GR.)L4!@)T42=1%AGE,"Z,@S2=L,00T%V(4((N
MDC WT4]J&7$:)!-J2:+KZ\*9:KS,0P%OB\1OF 43@9\"VIGGF/8-C2'\$*<M
M(^1%D,<^-TKX0TBX*]DD-_Q) 5]<B"!41._DLEGJAAOP@H K--H"Z6D4V8CC
MR_%F_A6[J,02Z!*?)S&/%$ M7A)-T)K;-ZZ&O.#B$1)?D2[!L3OB$H/!?W!C
M;"2FX*1$<E)]6XNNL%X20@Q\ MX_XBS%JV!1EZ*I2Q#![AT(6G%M]HYQ$)3X
M6\MS'-@U6,<(,^1A2R9Q]/NMXP7W'W\-"+E&>Y [_R#8NQ&;@@B"1<?1%!\R
M,ORI@;L],&ZR'"A03((AWKB'J+^86"IY:\_8HSV\IA_%_M)/11F/Y 4QG/$T
MQ)_&"4OQ?V_B),'_#3+$QYEP\?,DH8M@'? _1)VI4<1P0AA1#FSLHB+<'&%8
M/ *N&F1,0D'@JPHBH[&<.D1#GQ7 =IF@C0\+!U:K>IX-V$?@OS*9&NR:P5+
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M Z8QB7ZF4<ZA)TY1/1)@G*RK^O(JC#H"&5X8IU)^-&+/]"X08H.\.H'T!)S
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ML.>UL!9 88)AF8N:KIL8TP%8MJM&$T_WJV51.4K*1ES(,MNT^BU9[$(9=7P
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MY^KW1!WAZM1L(*P<\6 %\Z%X0MXP&>L$$<"LL$P@&Q M F^E/>4,41N!$>2
M<K!E!-X(?(CX:S96J(^$("("4L]B6!W.</[>RN07?']A8A58J8Q>%%:4\=3
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M/+88<Q5S%S1C&(#D(PKD(=X%YN$UX5DSZO?,&7&,<%'[4@553VX^KV+: 4*
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M'I6VXXG'X D*ZTFZ@2MVS>,D(<,><PW7$M:W29XJED9!&8)Y6M@\X'.M3T$
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MFQ5;\PD"4MH#A!9;:+S7D(LJ)8-'DQQDF7A0"T$^GV?S"@KA&<8#G\\-I3E
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MK*V:PJRD#D:N2]LM4K?.V<GO=D]BK:&IUPV14]C^L%**%SX&J3OIC<73;K
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M1,.P<28X7]C9VL0P<R U&T=1F_Q=<&S_9=2LS(;(-M@YA30(+K0A\Y2Q;>1
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M,4(Z>P.<FCLC6$C0,=.7D;"^4VCR7$'M"Q)H FPVN&@W7.7P"OA# E;^=-<
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M#&[TBCUFJEW$YK8JWV*]< \N=R-K-*84X+[G6H"-;#/Q +UQ% JW\0"=F:Y
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MI-9K;VHE2QHD C_%Q/4QM=&0;T_.TG__GV^^^/K+)X\?S3:@:V$:V"^I!5N
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M$T4Z4W.'3>CS[VIP13OJB)9[,>*E42!9D4/IJT^^Q%#K"&_ 9"'([8%KFI:
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M<,2;"H>68A-TYR!XVZAL&[(C!VP!09MW!%N#[!E!=$-X-<U[616([BOL<=Q
M#57*DTP;:N*L"J8J'CIUT*'5?J=M"H54NNL'IL=$[/JALZ-FT"D_F>G\1=#@
M\%:\__RTMPT6+4DHPXI;>)^YKOO*(5-F5GQ*P"JJIA<& -9'4* JE99VF),W
MN2",TLCV(1&AW<IU@",>DD",(=ZB.EG:"U4#<6R3AW2 KTFIRS*QIYYB2JA/
M2Y:J$I-+LJ.+5_0G#I_N;(5'-!WPFU#7\<;.Z0(B;^VLB%;9.<:7P9L6!<=;
MS7O*+&KOU!0B-\#5E63/'&?'Z96C9U/'X3:2H8YE$-]8_[5I0U%L3C=7PUO
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MJ<9N;C*3%]9<R -.(=+ .=TH@VAP:&D(),^?K3E%/K(DYB,(/0BPP?9^C?M
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MP0DL0EA?(6=LV>Y>PHX\"DZ&^ 6Y^-S!&2O-$RHP'./\\4J+\,7TUGV3Y<F
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MT)_Q."K5TBGX'SS4 ?IBLE*NHZ22952.HG+5ASZ.)$">*M'?WLJ+>]9RK^A
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M\;7[M06&=848XT'8,!517_(K7LHKBGS>F5=\\:H#7\(/W\<PT8-8'--3(2J
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M98S@B'K9-0*6)G!KA2QFT6229W_&8[@ L4@W*H'OQ_ J(^I?JX=C>ACWDZQ
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MY-.9DP>ED^<<1+-67O6-3K>H57IE##IZI2;IE3DH'BALB+M&L*P&TZ<GHR6
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M7WQ@JBB><OL$D'A+**?3IOEII=N[#?X CMI-J .87J@88?3.P45892]=7E3
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M5XCQ X993F'CRFLWY;<MG#FDM'P0.;Q1)B&FDZ'_Y?&>T=3H4(GYAH'R?-@
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MT]S; ?"(;&'N0== KKA*-XOD(Y>^E[4Q*/N[)<$]<U<DSE7Z!0U3B"\BR@?
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MWQ8!^_PJ1HX@54OWHE@O5JI%JY9.+BI846=7AV/1;5=>>,*3SD7VP7@2!I1
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M62U>%P4,7EQXV>C/4N3+O/@Y1,*ZXMC$4\]W!5@N>%H;@L98Y"NC)D1;VS1
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M]:"Q'CUHFQV[$7K0L#OZNM3@ I4UJP4-:[%NFV5T^D%O@=:LU86XD\7/5UB
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MU^NJ5F_5U.KG+X3?LE8%;9/A%DTMFEJQMV6(VE1^>E:[9M;57U1_N(5-H9,
MO/>)&RH3]Y:7I<31C-W<MH5>O935-%6KW_:T;2Z&VBEW+9I:-+7R;ELPM*F,
MM EVH[F%[:&YM<A3E(/$US!A^?:I0JHOW,=[;:I&?X7N6L_OW6T9@C;5"6_1
MU**I>6AJQ5W#$;2I?+0-MF.3S.6'C1:YC)-I&VS<0M>N15.+IN:AR;#U!TQ]
M:='4<E.+IKH[5<Y.FQ09W@2ST=J^D.,IFQ1!QW58C:U3MXE.78NF%DW-0]/J
M>JY%4<M)+9K6Y7\]/YJVP6ILDJ'\H& CNV&)%XAV=]/8^Z[$$VI(UX8=5X8L
M3NJP6_^[V4AR5*O_P"D1+9*>3.59JN&L.ANWQ=)3F_CV R;>M>AY,O18*MCW
MFX2@3; 8N]L79_Q<*H01_>65D&'?YS;*N#I7]@9M3*3)Z-';Q*L&H\>R6_0T
M&#U]J\5.<[%CVINK>K8B-%=<Y]8,G6HC<FU.S,M$TVNCKUJ;E1*S91AJ&6DC
MT,3YJ,52L[&T@>)N$R)S]O9%YL[=&QKZ=1F'N.>B94UII!*V>$POW80I*9M.
M0R8M3#%ZS[UV$[\-Y#V$BW5U,&C]W09C:*!:U@HM.%H$/3D+F>J@WVLQU%P,
MF:K=';0(:BR"NH ?HTT-? 1SLO<HJ8$$Y3X?6-=DR_*8B5&\64JC.$O3#MWY
MR9-K]/WN^YWH&E\,?%;\.,/1?!(F2T_:>&FMQ=</H&:+/D/M67U5MQZ8S;<^
M.#USM*3EF)9CEK6W>V!OKQYX:EFE995M8Y5NRR8MF[1L<K\-9ENJH[<V6,LQ
M+<<L;8-9VZI<*(KRZ]2%C<-__>#J_;_@#[G6V$TN@JATQK7CR+P/1R;BZ)^%
M_U-RM-V[=PD #9GSK3&0'!M$/HNF;S7\9-WGZW7L)0[X;A*G 19YOJ5KPN"*
MO4.JT2SZ]2P-N"G#!6@:")?R\W]*J#PQ0Q&RE/TLP; 4#G15E6NF ",D\37S
M%=B+>W&1L MW2O6MKXQ.7QD&80A'5S*:>(>3PL]8%,0)_,?+$OC5'OP13)6/
MKA>$%.6B7#P7WDMQ,/R%>&07UN;7J=-8P7;/@1N&MWF)1)PEBNO])PLXL'$'
M9^-@>IDJG^#G &'E=<J8<AS#[@SCK7*$,T;.L8'+/C:-AC7Y"EX\!K#>XAEA
M)\37=+<K(G*P3CJ%#_C%[PA.@G2';X1O@@@^&+OXKS<=Y1SV/I'EOW@C+,;_
MO;+ZG8$R%I"!0Q:C3^Z:#=C99F8P&\D,I0S25Z;9Z>9(A0\FM9-MEN( -_)A
MO8Y9II%[NIQO-7%8C22.0E#JJN("5I6$I5E(U )(^0["( /\)2CL *F>2['_
MX:VR=_+GX;YF.%7Q^LJP]8Z>DP07J"BR@*0B6/HJ#J](:'%R&G%RNN5OGB0,
MUB<IE=PJ8^:F0'HH\X!&$ZPM4\( 1"?\\+:C_,642Q<$7H;B-6$3%RP;$+6*
M.P:[ \BXD/@DL?:9Q\9#V(QEJ'3:K:;%;B-IL=J% H70PDX4RC50F'*%=$(/
M3^"-,:4VB;_A87TIRX#JLC$M(G\N%_9)C%5>!2*1S\7%3],)\X)1X,W_<*OI
MQVXD_12RS""I1#+AE=GK6&4=13>8I5PX0G,E"PX_^9PE:082JJ;FHJ.<\&<J
M2ZOT$9<^L+R'GA<)'_JX9/*AH0:"+TB ?,.,P4XO ^\2-"59<@$(S,*.0TF)
MVQWAP'AX$I9[9?1+YRFLQ<%;4,ZPZ)^X*%B3)#Q)H[]93*HOCC![C23,PTAX
M(J@)V7@2QK<,5@<,)61( \*[?9PMRI,R26'AHV#EC^-(2#Z2<U<L1;*%9Z8@
MIO"O_$N>L8GD)HF(['MN^D_ OK\)P.)GH"I?&7K'*?/#.(B"<38FAR&;QB!1
MR]FC\1! ['+91_S$12H0VI!=NN&HH_##&7<>3E<M6W^*PPVJO/ZS9Q.'T^\Z
M7*^OZEWC23!GKA=S\+^%DJ$L!ZQ>+@;>_VN8_/I^U5\]-;^=S&)@DB7>)1J0
MD]"-I,0%4_,R3F!9;@" #2F? B1F$]0-P"QE<[8&N5PH$Z*NN&&,3WR( :ED
M=@:@"@ U*>)K-[O(TBD0E.%TN% ZOP2QCWL"6S95HAC,BTD@" #U1$?9K;5>
M092@K2MTU<PNW2LW"#&:1C24'PKW"1H!['BDCB+4@:\G<QJ=_S 8!U-N./'\
M</ES.@#&'1*?_#FD-/HY=I?ESB#0+X\QY%PP%Q-9%-PX*=$JO&?U&,>;3IVL
MS^GS3N)];!KMU](H+K,+9\S(OE# ]HUB]+3H.$^^QWH^6@#-AG'[64Y3;Y4/
M;AH0^7T&00O[XJR$U'F6C<?H+F#$#8P&-.I=H,@R"H#"/(QL"*-PKTQT'W.B
M.RL":T"JG]UDJAP>JLHA?*@,Q*BW5-F-H@P>/F63&!Z /7R,DS&'IZ%K_]O9
M'$+=2P(RMFI!A9 ]2*>DHEJJ755'I25"= OH3G+H8H$.T2UI*2 W3N=+4Z@@
M,[!B)A@B(?>(:[#[8L8UTOZWW=W/A/ )^D8N#W&3YLQ"00H)N\A"-]<!%$<\
MV"-G;.Q^!R=;D@K&FN!DPJG&GW[+_ O^ZNFE"^ 8C4!Q2L4,/(3.E CMP,KP
M:S:%5<+ '8J I(KA)1:!\X/+@2)E44HOHGUQ=\\/4B^,T3-*9PKJ^8+T<&E-
MTHM#,@G0_EMF]\#JP/^@\HEG<!M)P!"&^-A"HA2DT35Y%O"\]W,=^--+<5U8
M_J&(,NC%3]PAH#:;+OY)Z8;/@RVSY)DXP#:KX"C_>9D4+NH%TX8)<[]K[@@V
M^]8-K]W;=.?7:LPEB+09&,X>?[%H?69Y%0.1)Q@*)3N1J!]#JN#2 CV3#,#@
M9QRA24<$R3!P0/=7*Q"E*Y@S07H.^ -@MH:WN;4U*WWH1^24@.<"+$*_XQPA
M]D9[I>#9,IL((HS^%C=FI7>BH2JY%V,G(!:G%%,1SZ#EZK'@BJQ:7'68I0#'
M%)VF\1#D%W_?I4N; F$3@YT]B7';*-<","0]TL)+";^.\GO.P>&MNCR8);?*
M>SI/JLXZ\-)FHW@*0@ED'7J2N'XB[@O1980]HPW! _)W7)XT1*/=:=(\PF9H
MQ;?!%$29M\3V3N?IZSEC0@\Q !N&\+]R8/Y@DGU3<*Y9A )LFL#20-BD99,X
MY->-\9BB[A=Q[*<YFX!7'(\9=Y+Q@IX'44FZ)&P4@B' PZC5" G\FCORUXST
MK$<&R1#^ 9PV#;F@83?@OH**)Q$#_CZH<GHWR;%X1/OCMUOBED#C-P<)&R*W
MRRV"X3!-@B%=3A7[58L-R*WAG41 8JJZ68(*B */[".0 ^0[(XBP=":.^+5#
M!QP&_EX4^[&0"_ MJ/E+D,:CX$9>603XU:_YVX1P/A2/>B[9/K"Q#$Y<NO$O
M10>$[ :YQF4JGK/>="'SC[EP4GETA(L4B87$#8/OC&[C\ P"C3RT$*8Q(O\*
M *( 0I(+ACE"!-X<M+GV2UD8T@LPJ)#3!GQ!,$H5GV'0@9(O>!C#Y32&,G[(
MIM<,0)VEQ<U.:9F.LE=Z.P(9GQ 2&(\J?R]>=2VW>P<5R. ';0#V5/R41'P>
M*2GO0X:@$I%\D:;\LH#?B]Y#=H1F 7U)2IP!8!&Z5"#C-C]H;C@C#W!ZR&&X
MD!27)QX5[V?#S)?.12T-%61P[28).@]P;C]#SG8O@/N >GPV(DY'<!+D7*XL
M;_%.;QQ,\[,F;)HE%(WC/T&-*U=3Z9 Y6X+B3:H>087L\5K1#?&<N/:"D][%
M&AU%04<N%W[<6I.7/_Q-U&S!11=) I9?^!#0R'$J6 DWOT""E*ZLA'!2*ZQ$
MGAF'@H!0C<FP2>H%,Y.N7"",L?L- #^]E6%%#DSXQV$T LP!;- 1SL8(- !*
M_NG9+1BN8_SD3^4,?2(TV50E#VCL ;;F']>J"5FJ\J>;>F0X[WK(J#/?$]S_
M1"N$UIO]MJ!R].7CT.=F-1B;D>^&<<1*YKBT@(.TT*L@XB;B%CM7J,)S19V:
M$[K/V%BH/Q24<2 G@ 43M$TWFQ(H5A*/IM<\1.T1'X.\9M<@40BRI:M3#@0)
M+/&)6TA>#"X( *$C0MJ/,RH@)>%M4%#5B?5%0@%=[X(Q$B=L 9Y<8;'@BIW[
M;B&?.>"WHNF\BQ+[0D2&2)]] H\DF(",V@=7\ I$%++>1M,8J%1I"'I!XF5C
M9%%/&%$4)@%R04HJPR*("@Z4YLU8@L8O@6;.U 7% ?(-R'@()@S:JI5UI[<3
M[GQ*_SO/1T%M!7\/I-!*N="BSCW$Z7@S%(,R(S2Y/ H]RSMI)2B6?PMN,D^"
MX H' 'D5>-SCA0-B;E5:O-BKB-P_E50*6*%LIW@_ZDMM3[&T^?#7)A$("B&R
M<LM1VQG?/\\H03NCC% $[^O@C1+@*8+1K31E4-?'8*N"D"';@W*$2Y=A",O7
M ?QPQMS+(PTE18)F,T489 (3B;'ZE=42B7'CQP5C$^\J,2 T1-23"3)FX#.!
MSDIRWX7Y,C"$(980]L[SG80>XS] /T9ZVY5$&TGM)7+-R0_/>A\MUNG&ZJ,\
MHWG.G,7[TM@K;R4G4;&V!A!ADEYO9X5[FDO]^$I>G(J<L\O2K\1:^&LA#VH2
MQ39#YL]'WIX_7++9$J0&I-PLG!)=@NV KD+" $,_Z$ORY3K*;D34>TT\7*(L
M\A:DZT"%.!@J09(/XQ2E?)X$B4&5R UOQ>4H15\O\B3'8CLJ7?S+G,<)&M]^
MQHHH;,6WRD,>I1=SXPNKD*:CC-O&^28\2IJ9EEY'P2( P/<HO@8G"!:,Q_#>
M4B)!OA?* @:4!CXIM)((+OSPL7M+#R&;ES<%AY8[(C<TP2 %%PR8("'2XZ>8
MT8/^8R4B+.((,S'ZF> 'Y>AQN*#R%_DZE*(ZE. %0:"<9>CS"V<<-H_1WZ$\
M/BGL(M-:V*0U\6F1&4('H8@^A5RN B#2$HARY W=D P90IZ "K_@NBV<<O*W
M15(V>+=T1<9W%*#IPP/LL&H!;$X*\5B)4+N$!1AY/@@:&S'YU KE<21!RLF#
MQ^"$)\?!6HVDT%M]^#= V*M$ASK*X4@&Q>>)G=U@\K (A+C"UR,RS<#K(CR
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M?J9'#R\U27FI22WR:-IY-DP#/W!Q?ICR&M?<V>-+[KQ94*!BRH()0RT&P=/
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MC,8N7GKAA<%=32[SF[4MZT^XX52$^&^8)+]'XCUG$\Y*)]WZ3CST2I2ER_0
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M_1*[C4Z5L!#VZ@J</G9OR3T5:")H$W(J_=U1G(1IK%;2MLD[OLW- HZ;J@$
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M4!+\L@70VA(SBS85[<WJ8\B>P_D(A3]PG)%C:IYO&EK7' PT9]@WM#[\X8\
M?7Z?\1;=W=Y/]YYI(Q3-Y>&U962V//SH/#P;DG!8?^0Y0*^#OJMU>YZM.0.L
MY!^93G_8ZWJ>ZV+MEMKO-JET:QLB$KRU2+W]\. :W:7Z"C0.%*\>[_PO1@BO
MMX-**W77)W4_S5E.CN_J@RXS-:>+_8'MD:NY7:>O#;M>K]MS]9%OH=>FVH:M
M]KH_'0K>L,&VK7!KA=NC-HMIA=M:A=N,2:DS%U1.W]8 )5VMRRRP)OW>0.L-
M_9[1MT$[T>0F=3#0U7[-5,.&"K='"%EYX-ZPI%$\>72X^^'PB$I]J(O)V?G)
MWO_^?G*T?W!Z]E__;V :_7?4V>3\Z\*0UA(P*2'+ G3@/-^0+<+6<PFQI>!5
M3ZQK#2]L.SRWP=>3#21+[/?V041U_]DW >7/T-5JPR&V9?.#\EGQ$_<6:ZU^
M)@;UTKR$NB.^&$=@W1.:/W/Z:=M'KMTQF.\39AJV-S3!$_ 9,[6NT>UJP^[
MUT:6[W2'(\?O#^R=]_"4ZN@O\+ZHE4DO5":M>]9T*Y,>42;-!"N,[L %&332
M#&;T02;U>IKCN8[F^JYMVY;MN[WASON!H1J-FM2V90.?@#.2C/E*&+C#(*3R
M^38U]PE,) 3Z40'S5B*M72+-MSECM@\&D6EJ=@\S<PW'U5S G39T!IAN8^@]
MKP]64A?K?II4C=BFYC;7K&CY^ GX>-:R,"Q/'_JF9M)0#-8?:D-3]S3/M3US
M-+(ML^_MO#>,@6HX[23JYXN\BH&1DS@AAHQ'2AA'%]J4)6-@JV%;:_SHAL81
MP/L<P(W]D5K1M';15.EW9G_Z<?#/R'"'=J_'M)Z!79X'EJD-W6%/<X>F[?5&
M(\<:H8GAJ+U!DYR>-F^WH1;&O0P\"FZ8K_U@2=SR[JJ\>UOFW8M_7*/'K*YI
M:&S8 [.BZUO:8-0U-:MK#_M.S_*&QA!OB 8@>-\UB'FW+&+!Z^"4J7NSZ(JJ
M=70>*6"1ER"VCLYC6Q.\>Y+'/&:#(>$PS]2ZONZ"(>%V-=VU^X.!!PBT])WW
M/=74?[K!8ANN:"X7KSE<T7+QD]D5/&O3 38U^CUM9"$7#\P!^ 1]IC&=6:SO
MVEW=[%+S0GN#ZHC;F<C/5[A4D]+6#D9^QB!+&_Y]/'GZHZ9]V]#7N[JC:W;?
M<+2N 0:1Z_5=K3<TF*T##IV^N?.^ZW15V]Z,2:GM;.2-LZ5:IG]DII_M-3]R
MN@X.0G>[?1PDH=O@"NE,,QV]Q_PN&WA]?^<].$)JO__3@VV>A.G;\<CM>.2?
MOV,[.<:YA6@-'NR>'FLG7PJS<'$=T=:'Y]=E^GW(4MA&FN[%XV$0N?C:/7@/
M  X4 OPM#7R:A!9'4E_<MNTW'D-AS+?0Z?5UQN#_M:Z%Z8>^]__9>]>E-I*L
M;?16%.R)O7LBM#QY/KC?( (#]M!?(]F VR_^X\BCD0T2GR1L\-7OS!+86 (;
M02%*D#TQ&%0E*2M7/D^N4ZY%06-LTI]"(^73QB]MVC!XF\M'F!%=H%ZWPE>@
MWARH3^F&%'G&N3= F$IX]\R!4E0#IR808;*Y&!+4VUS590XV*&S7:/7D1\O#
MC<T7>R5.=]_Z2-4#+?C+60.%>NJCGMER,\IIE@Q2"5(C!TPZ"=I1#X9:QCPW
M!B.3??N"T+:034I&+%&ZABH:O\5P2?FY/7RGO4K,(25]L@\LY>D'MF \12"Y
M=5QK[Q@3M:7\-"^3N-&ZPZ3([P\-HJ9HU^,FH5IK_E[R<1<MHCX:>C.K11AF
M"(D1-%,46&Z09EC2)Q1SV$NEC10B'VA@;7SW6N/%6=%<^-9:[K? ][[@>S9=
MK3L!,*D,8%3N3HH"!X5L]CP2Z5BT6#&^LLIP6]'2"'FQV"N]AYK1>^@2%Y7&
M);72T=O9K.$HK;1: B$< =,N*1)$(* \;2O(2(=M;I9,1!NA.X?*BT>BN6B^
MMPY$!<WWB.8IY4)0+&2,"H)3V<.84V"P0H"HI(Y:2NBDYBO333H#\!0<%#]4
MBI)R\9!'D4J8]3Z8:+;('.>,N<@L>)KS*!S%B8FB@2@""UH+R3BNS!RI2]?D
M1XSD^SN.5)!\3TB>+J!B*8XZY/;(0@'S.H#F,0)!BA,5!6%8YV[)[23'!B'Y
M*3@LDDJQO;6WO=G9FU2)_Y[@N9[KQO_1&8Q#"_-_%Q?&?>L9ZX.CH][X*''1
M:*WOOZ=ZN1EO:@G'WI*79@NT44L0$IY#2%8/L$@9:&0"Y/!(T,A*HE43P['%
M<]%0%:. > $@GE(ND@+!:6Y-0Q*:@3&F00D=L_]"81,<<50V$<1/P65Q?<^9
MV_7$^/T4+$.'AP=H*[/D,[9H3=SWOEQ\]OE'0+[_N:C*%3V4JC[H5^/-#8&.
MA^<^\C2(@?O<;OWK5[O=ZS#</3##4(OJBJ8WO=<78]G-0WEMAMWA[MB,@__'
M')Z$']]]OL^ALL_=8)_[/-Y>_VF?^^)?_</\?_\Z?$\.O]A/ ]IY]?)H_^@-
MW?[V5YJQ+=3Y]M?A_KO]L^V-?SYU]OQ!GJ?.N\W3?:R^;7_](+#A@@8).H@(
M+ 0&5E 'WEK'L,(4Y2C=+5;1[72GLHJ6<A7%I&SQW&2:2L-SD7T$2N?S;E2D
M5T1PJ"J%^^R* E$S+[2.S;#U)4OWS];:R?A@,$QDZ"\4M>L6XB@O@]$BUF"U
MX$8_1E8T]8=;>[B[]@&)H%DB,2 ^+3LFDZ*OG:<@)$$R)'6?,?(+!KMRX=S+
M%E@63K,6#N8<$:H)J, (,*L\6"D8<(Z5=\0(D@NX\!MQUF05_=G:&HUR&PO3
M]ZW!R7@T3K\D+?&<O%J-8:_NC[$5!T3S5B=/6RHW(FKO$*0_&3 G%6AE$8CH
M&8X\)AXR#:*ULJ(:OZ(T0S8:RX!&E50S0F@N"H[!8\EEH$G?YW%E-=>R^SWA
M?3?#DTE</,?W&?[Y;MS_C+K.H)]^#>$H5Q[N#G>^_U[M0,/N<1YA92,5.-8%
MQ^GC,C0ZRZD"HUWN_V$0V"AR9S%BM G11\N;Z&$N8:+&AHD*V!L#]JEPD@[.
M,ZDYA&083(P%8Q&&*"E*/)#D*U@3P;[H<%)#7>1'1X/^XGWBY*I \*!?7)EU
M(;6SL?8;+?GX\_N-C[BSL7_Z_MW6V?:WMZCS:1]U-S;Q_KOT^4>;I]OI^=X?
M):WY'W7:7?M )8^&))/+)QL+F&$8-$<D_="4&$PD0W*!#O&RA)9O"6EI)&?8
M  ]I^V5,<3 &68A4!^85MB[BE57T#"^#-_SJ;);S%3CKTBSYLHU<EBC9_Y)J
M;353('P.S4AJ0 ?B@3@;F4':.8$6XU$J:^K1K"F&L$M2S^<[0PZ^*% R_ZD$
M)SX09F52BQ5JHUNXT6_%<K=;D5N=E[]=DI-!E>78T.5(MM]\8)12PW*S]RIS
M5Q@--EH"AF(CO I.5ZV5:5M?T9&UBMHL8DLMBVWY%UN.'SK*O"<,I,V6@G!I
MG4DM@%OEL Q*"YYKP>,V4;/<=TYU+3-N;007CFP8MBANMS(Y50LQ+YQV*]UR
M'-([OH3#L_8U8<5[=TO_>KU6IL>UX9^R9ANS9D^WOWW^H D*VCH/:=&%O&B3
M$JB3>6N]=Q9CI)57YPQ)F\V09<DMP9)+]WW@QH>(#$]KC"?-$%,'VE -GA$:
MM3-<X5IY\@ZQR2=Q</8>;+8K8@\%A7=$X52T,8G*A\ UA,@0,)H4#243>U.>
M#'=L.4FV5ZXNGHS\!IV5+:?>&QMK+."]1_!.10^3#>J\9Q&43;L?T]*#)CQ
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MRL8U\M%L/U;,%<5:6I F:<N,8 ;&>@M&R&@91<A[NK*JJ&QS=.?2QL69VEQ
MUZ4S%$ O&-!3"@:BT0NE"9#@;#X[$< ::2 0*14QD9-(5E8UQFVIFM3,J"9G
MZK*H&I=@T1KDYH/IH8^.A^$@]$>]+Z%U.!C=3OMX&A;.[=6/47K.]-L5O14N
MY%'U@ER_+(U)QX6_DT@Z8=R->^:T<%A]''9%>U?&%-)*0L#4 T,^)@XS%KB)
MSD6F0_JG.JNCY6P62O%A/ J$WUX?*0AO(,*GM!2%M>,A5T'T)L=] @5#;01!
MK>/14*&(7%G%NDW$K,=^F5TAC59*]KI[:W^W+M<\___.JYW?Q1%B!T,?AC >
M'.?ZV:W1X+#G6Q</LX0L]@!>DLH!>S X3/,XVOR_)[WQ62*LPY,\<Z\'PSR*
MM?%XV+,GXUQK9V^0^T*E<0P'AVGX'[?2B(9A5 RO&BEMMHNL"]YR+QD86179
MRI6JA=; L2<2J4@C"3ES%BG=UG?/GIT77$OD:'G"A%&7%Z801@,)8TH'8FEO
MT)(DLT;KI -QCR I/PR<I8IP%JW5H<I]P:*-:%W.UWLGC*?0%F:B*%TTL<V-
MYG+KN9LH3K^;A7/Q3)[N.4TR\(.3W##CXJ'N1HZ-F\E_/> $/9I=HRXU\U*;
M\K6^G]U#RGY0WWXPVRXXF;K("H+ >*>!$:IR:H !@36+.!IC=5Q996V.>5NP
MNOJ,UH>G!_:=%68MS-I8?;PPZT*9=4K3II9)9YR#8$C2M%FN\$"2SDT2T7)'
M<22Y$3MN*X7:DM9UL/7AF;52Q?]3F7@7F<R7SI <F>''7O_BZR]_M O9 %P\
M.DFE6Q^$5I+5X"A]]UF:@59_,,YE-8;IY7ZKET;V<5@=?!V.6X/8&A^$4<B@
MK::OBJ?&7M_T72_=-,HE1ZMNIL]^3NB^- WG7\[()&A\/!A5A\&>#\.AR<G@
M?W[M^?'!!75<>N.Y8-&/MQB;!G$ROOXM39EC@:?RVR_]S,.M6(921X4+W@6M
MF8A".:2L2B^H7']'L@^<KUR\Z6#XXV32QP!V&,QG,#$]X7-S^-6<C5;^\_/:
M2PMO:N*GYVPR,ZO_8X?_F6[B,"W"Q4^KO&):)PA*G#T8FFHY)$H(PWS7RNK6
M^MO6]N;&UOK:W^T)FVQUUI]-K,:W+W:W-K;6=I(9>>TB;?X3KG<[N]V_MS;6
M]C:S)9S^F?1D[[YL=5]O[JSM;:4;&O1\5P/CC[6CQ.3C4>*9Q"R#D_19?M1N
MA5,7$@<?A^'DM$@K$8WY]UQ/4['P#^JHF#\]U:$Y'H7G%[_\Z7NCXT-S]KS7
MK\96O>G/<Z(^YYN,E2G6K[YO<OD<1EH_4YQF))U[8LZ_^!QDSRJ036UDDVL"
M/=-27WL9/</77OO5Q^)TD9-;?>ROKW%ZNT]]7(.E-_K8W[CFFN&!^QT/W:0I
M,>8W>:@)-A?S6/I&C[4?S+ 5$JGZGVJ(S=-*^/$(\9(O8 Y%N=D"SGZXNA[X
M)NVT']/$X3)QMYLX- ]_7&@@N;O:K^=HF>\LD_"D4IIV-O_9[+R]9%_5'2Q]
M;"[AN9__T7A\A?6$H1BUE)HAHI61V!!#@^<X8AL_;.0]'&&$X:8GW+Z$_LE-
MZY \M(NWLWOAXOWXM?/M+=K?V_S:>;?_=7OC#>Z\>\NV]]*WD3>T\VGS;/O;
M&];YML9_N'BW3M_O[1QVWVU]2[#C^]_>G';?;?/M5_MI/#N?W[_ZJ_=^+[WO
MW2::<?%^>GG8>?66[W]*]V\<?NIL;*;W?_[Z_M/F:>?5SN?]H[\.MW,)B+V=
MV#DO';&]B_CV)Y<;V5A&,6+< '.> #/!@Q9*@C$$6\E0NIHK][:)U&VMZSKW
MTIC0V&^2KPK-%9J;HKDHB U*2<>"8H(Y@P3VQ-M@M2=*\(KF\ 7-W>C<7Z&Y
MVFGNVQ3-(>PTCQZ!E%(!\U'FQL@$N'1$.J&4#:(J?HA%FZ*GEF-::*[0W#3-
M(<(LP@(KK1GQ2.G(F*>8>2V9%!-M#EW0'"HT]R TAZ=HCD1)B0LLT9S&P(+$
MH+R-H#$7B";%SE.;:8Y(W$:(+0O-/87,V/7N[EZ.^;WJ=C=V6[O=OS>>V"GF
MAS0UUP>C<3>^&@Q\E644AE]Z+HQV!X=+TIYK*>AJ=\;XI-1Y)8P%)F2N/2@8
M6&(56!LU8A9C+URF*ZZ2 4I%@^KFEV/+33>K"J07 NEI0\LB+K1+>D?T+@)C
M.(#)W9$]#TY@EH\GJY5515A;X28UPBB ;KH!40"]$$!/FQ36>A-<L$#2;ISK
MG!%0)#@@GD>G9&Y/*7))$=WFZ,[NX>:5'9C@4C?<>'BUT]W=;;W>Z;[<VBL5
M!YIA4[P:#D:CU\-!7);";4M!4+T9(P)1%U'D"I*:D8P(*AT821)!4<F0-E8S
MB596A99M*9;F+' I'K#4QD?!_OU@?]K:D,%ZZ0,!DY0/8%HK2+RMP9@D+(H5
M99:NK#*-VTS/-IXMV"_8K]].*=B_'^Q/&R:.$<Z9LJ"3C@;,<@R:^  F:(N-
MY@Q)F[ O,O:7)F_E*40ZSD\U=5ZU-O_W]69G=W/W^4T2E']S6G3NC.-%LM:-
MYN7F6?VW]DJ5Z6SD=/[T!4^L=<1NJ"IGM5L?0S_D\\FY.9GQ1[U^;S0>5@>)
M2S.)A3DMSJ7Q:B*+M;Y?^TD2FZ?'H3]:DD[BRZ#7=*_(R$UF"^<Q0@Q. *.<
M@I4X0!(S\X8X3DSV9R#5IHPWJ Y]:2S1=*]$ ??"P3T3'J5)7%@38$F8P$BD
MH+ U(#3"W D2$-4KJQ21-E>S7>8*N!\/N.MV.Q1P+QS<,QX)K8V.B@#2N39[
ME PL]02B)$E!\]HXF<_2*-K6O$G@?F(=9';"*)BA.Z@L#1^^A,/!<2YU5/(M
M%WBT;R*"1%,;/P10.*INCII-N;2$><F9!*VH 28" ^,C3EH("<Y(@06G*ZN:
MM+6Z<WIX2<]J+J3OX1A;@?1B(#UM4Q"370.,0% YBYI:!49Z"EISEQ01AGG
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M072",TXY"BY1 !6J3>Y>9J50P*.D@+J#?H4"[I4"ILUV$K1VE!F(,8F(<>=
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M25'TJ:4!==&GBI2*E!:_0=;N:BT;Y((WR!GOJC%4Z\@YZ)!KY[F@P0KE(:+
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M\<A65HF8M0%*^NER0GE6G5<XV>W!*Q]4PK$VBE(MD$B*H48^<E<7CG_5*K;
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M\+-WL XC^=89=>)PPPX/7W;[)WLC.XI5S<4&AVZ!0U_G3Q."5T'K@!)F'+B
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M8.SB,';GS(R:8.SI9T:I,Q;LJ( #8"PE'-F<>Y4D4%98$MP+L[(FE&@9)>X
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M8X9*;JV54=4Q.K1Q2ST\?+SJ]\-)I]MMG9W4_<>&+^-A3NB<5-P^AAOW?^\
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MIXRDJ!#D:+)=5OO2I4M_Y72]L?3J1B5*5IGE=9%7/L^56NX"8S?L@+$UF&Y
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M$NJ%?,[%)N(^_CYRLU+F3SC3^*< X+U64EJA&>8!4T<($90D%8+CC#8 \ @
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M><B=HZA#GCB>/5A64II+4\S;T4_9U_M43JRFAQS%Z/R4X[%]O0V2W1');G*
MU5BAB[=")_X#H;B.6'!$N#"(:^-0CI/.;<6MY)Y2JP'QA&Q1S9;3#*W? 1=]
MQ C:23HM ^&%_C@GYTYGHPFQ7=@$U7O_N,7V@8-3++H( R+<<9J+O%FJI+),
M"QU=>1QX"_=RLQ7<A_F[N[_-=O8//J?@B>98(.I41-S1@"PF&O&HL+-,8FY#
MZ4OFID7%O%?B3G&X"]";.^THEVM$S]<D.!_?(]5J^/SS__VJIL+Y^/^ZY$TA
M>@K$DW(4*+^RZ&>\@5N#WB6'[E=54AY#8%4!*-PJ5DJVOE(<#P"F!O!%DTK1
MPUPMQ]ZJCJ$*G#$EC);,<J:#B?FD7@M*C";2D%M7K5R@'WC9"ARV]P]^[)Q\
M=@E(D8X$81$ *Y45R' PJ+UT%HB3<Q9S0,W5>?.Y6J+3(H='T0['@[*"5:X$
MUNF'PIZ)H*K[E6*N/5Z,[/<X/*LV/JFXE%/=JR#[2H6RX0A"'8X[H^)?._3C
MKAVTBNV>7RW+LJ2*=A7^"DZ]>BV6/#OD. _MKU-MIPHY2%ES:YHW 4 Q!&WK
MGDFNTTOC81;T\'0XBD?#8CC.Y>5SL;N3PXX_S-4QQ]U)3>7;8$Q4(0(G-%(3
MSB, C1.6ZT")9EI1+!\A.&#IH.7+^H_=MY^UHTFDF% D.2LJ!"#GAN7F7-P8
M@2.+)AMD>/6Z,/HIMERHA+9$RLUJJ=SOSO?^O:/.Z'!8[,1<4O(\12I7MIQ6
MU)$5XR_^&,98M/LC /H7Q?HYS __7"*!\EK:>>^JXO6Y4.7/]_"Y'3N72+N\
M8]\8Y)=(ZN)1U;BX@1Y7Q3Z[L9*@AR?)_0WRO?(K9S(\'O3#."\4>'/CL-.S
M-ZTY^=.^(O6I<GQ>PKJH:EC78L1/H-PQO>!6N_\:GMOPJ*D#]E_,7<[F"H_O
M9S_($M?W)#O[[S][DZR23"&38RLYX0DY01PR5"<LB,)!\]E6+DQ%ZJ-SD</_
MF++6<F*XU39Q%Z/0<_5 'ZVV_.S?RUIC'JX]^&RY%]1&A3P+*=>8%\A2PY#[
M?^Q]:5,;2;;V7ZG@W;IO*)G<%_<$$;1Q]V6B$6V#VV%_(7(%V4+B2L(8__KW
M9)8DA 0V& '"5$\,EE156;F=Y^PGHS#"1Y:TE/-+-X-T]0EBK5(:M9/5M%$Y
M$:SJQN'PTDE@]CB7,?XZ/@FL-_VAEO> \8,&GN$ 96@(=4'S>9:0-<)!<0O5
M55N'BY55YP^WFV<PS?E@T_/!3',^V+=FK3D?[![.!_ON>5]S3"4"3PD"!\NS
M!RTJ[8CD(@!B,0J/L.M.Z?HN,UJQNLM:L!^IN\S5.I,W*V5\V[K+/];J-^LN
MPT71=+;I+'26WZ;\]AR+9K2FT66<$WY/D00WJIQ]M;_X&V/Z5NWP 4A#<T%[
M*U)'W-QH,MZ5+S&@3>@4R!S5YJR\^%<GQ<)H0-Q[?^FHXSO,&A%/<ZJ^'0]U
M-<U0TM#,$FZ]32S&:F^BEZ"DW22.[B8#?E83MWFATQ9$FL6I9D)_8$+;<705
M@/W4 :Y_P_;IC6["Q7X\#^D&;3R%372[J,PKK8DJ"BY#8#1&PB/+^F:@F"1*
MM*+.Z1M8$_^XUF#\=AC3:3<+*)=\^3 ._R*<#LY!6GF:EL5Q/*;_\OZC/VMO
MO3K?V?_0^;#UIOMA_TUG]]T.>?_NS<?W[^"]6_\<[1R_Y@OQF%__Z+2_;N*=
M_>TO[>/_?&K_^4^W_>>V>/_UGR/H]U$>8_O=J_,/6T=I9['PE#11*(<I"C%[
M_TGP2 >94&#6A4BCP<)D[_^U-K^FOG)37_G^8KNUMQ$+SXQ5E!NL'""+5RYZ
M3JT.1-PTMOMZ9!G^.7@FZ3\/AC%X#F,PUX(0YY#30N2C60C2%C.$I?".8V(I
MQFL;U+2,67*\]_V%<S>0UT#>DX6\&>UJ5K%J0'")($CGZ^!A9U5P <4H).+>
M>V0R"#KX75#AC?,Z5_AL2;*L DH-"#8@N$H#7RT0;,=1 WA+!#P^+_71J!11
M :D2W<220UHPAXC%5&CEF(L6 (^TV!55C5<4\)Y#W>.7IT-X>1P4@LSK\6,&
MM)N6O[C;[#TQ&QF7V&IIG;>2\>"-QI3#]A?"::IEN$G$76,CNV<D6RQA'&&9
M3 H4Z6@QXD9'I)VV2!CGHHF$>9'+7]*EV,B>=]F8VX@(R0J>*-:&,,YE<-G&
MP$S@GAA.<6A,0RM(6O.FH<"2=98D9+Q.B =%D(D1B,P3CX,FB0E?3G'!*W6*
M2T/,3X^8&Z/'_9/WO-%#* 7*&S#-D&A.6R<".*=*H ,X0R6Q!(NPMB%;G%^7
MN-Y0=T/=C3;_\)0\K\U31RW51"*C9:9DK9 3EH(,+!RAPF-%@9)92UQ1P>W)
MG[:VTOIZN]]#$U7]U'8K/]'?Z[2:?F]XU#EY]""8GT>'#TDS&STS)$D>G+3)
M 78I(Q-SG(>K*U<T.OQ#XM<59_]*3"+E5B.62@E*Q9#5$B,OB B!**L2Z/#Z
M(<)<?O(:UK<I-"6BX22)Y(7A2AKCE9=$$.TM2(A2-2K\"E+6O K/6)0R4(>T
MIQSQR T"V=X@9S2)44==#H<17+8,$RMT-$Q#S4^/FAL=_O[I>UZ'5RP$#$2.
M1&(2.">P3VV!<R8>'0'M/B7,LHF.M(2XLXVNH>]G3=^-%K]<6I[7XDGTV'F0
M?37A#K1XBI$CRB$IG=#*!JKRT1.<BQ93=SZ-<_7.H%AI/7Y_8$,\MH-/C;]]
M:;IZ/E"%,0K*.G6PVZWVF"9!F#6&1H=-HZL_/DHM'A=!5*""*(Z\L:"K"TZ1
M$4(A@8W"WDJ?: 2)HW&W/R3WS\7TI8O&::.X<L8P0K!7AEIFK'4WKK+?Z.H/
M2%GSNKJ/TBJB04./(H*NG@]B"4HCJ@WFL)(D%%V]Q>F=-?7&'_>L:;G1U.^?
MNN<U=<E2=KAK8)E89NG>H)QS@##P31FY9$RZAKI7C;KG2W(\!>I>T--3YTL,
MZ&L<]!LBOAT1SZOH2HD8:7"(JL@09T#.VGJ'+/:>8158XC97:-&P@K^M$!D_
M!U=[4=$+E33N]*6YT[D,.$;EF*0<@,KBP$C4P45'$Z6J4=$?'Z6N*!O!'?,!
MI Q'< )%(C%0*1(H$I8P3(P"002#BBX:?_I#RO6<)ZZ"L#PQRI7 FF=F(J6R
MD6%#4J.CKR!IS>OH C1R@G-M:(L-XL2!MNZ30$10$16P:\=5212F@JR0B;XA
MYJ='S(V2?O_D/:^DVT2<<A(C2:5#/(GLC",$Y'LNG$O4>E9,<$:LD@.NH>ZG
M1]V-,WVYE#ROJ7/N(['$(XFC!1D8:^1\)FP?.(4_0<I<T8.VJ*$K1,K/P9>^
M%3_';O\D'X,5_5$/WGIXWGC5EZ6R,VF299PPY2/\Y5I@QD#OX]HIC)5H5/;'
MAZO%+'9)+58Z621TC*!7T(ATX@Y1SY7G'GOBW-(J/?ZLQOKEI\;QG !GI)94
M<,."X]IH4/JDL\8'2AN5?05):UYE5\Y1R8Q$27F0Z:.6R 0J$"8:='G& K!O
MD.DU:Q'5I+$WU-SH[*M-W_,Z.W'8<<P3$@1[Q$WPR 7,D(W46&XH35YFUJE;
M"M^YEE5#W\^:OANM?;FT/*^U&T.=S!*PP@9HV6(+6KM.B,1D%?4I>,O6-KCB
M+2Y7B9:?@W^]3F4_/HFCQL&^O!AXQADV6FBJ#0<E3RN&@W0L1BV,)TV^^N/#
MU.X5^>K<@U!A-(K2@[;.94+:1H<<3\$&1I-A>FV#-?[UAV3_DGDM@4]0+!6W
M6IED90Q,INBY(U(WROH*4M:\LDZ$$5P![W<Q@;+.,U$I3)$!D1X4=B:956L;
MI@6[8X6L]@TM/SU:;E3U^Z?NQ8ISE@DA,<CSBB-.-$%6>X9XPD$(YB(6)0:>
MBH:Z&^IN%/75H>1Y15TP*B-5'@GK">**:62T%\@EX-(ZFN2CSQ7G]$I1\G/P
MKM>SN_AWOS^RW<K6K"Z&JC.EF,H6DEEA%_Q#HMTM)OD^9NQ[SSW;XU9N/?Z?
MAEWBX!2+(!R!!L0=IR88;:F2*N>2Z=@D=Z\>PUQ,[G;8@'!K([*62L1#9,C!
M+XAJAJ4V.DB7#UQIP5*V#+ES[/AMJ>61G5@-ZC6H]_"HUY@ [A\'YTT &I0_
MJBE&WI(<Z,83<I0D9+$P3!AMA#-K&U20EKE[!DV#@@T*-BC8F$H>%/$6CMJ#
M)73,,92(RP<L,X*,#0(QHT747!$6TMJ&$;AEY)V-)0^%>&-+RJ0CD^W-"YX]
M8D1 T\8S:>,YF/*V<RA+SW:[YX#MDYR983^-SNP@_M>JV.ONHXT[!S*NW%K>
M6MCY.>69J(6@"41]X'L\8685I8Q2 Y)_P);:QI:U:A(-]'74?HF_9*EF=W^;
M[>P?'CB73P[3 5F7#P;4PB,K7$#"<JN\3Y+F&J",M#3^F3,J&I!L0+(!R08D
M:Y#<G0-)I4SDGD7D/ ^@]RF*C,<6*:4T%LQA(=D*@F2CV35M_ R:7=G\:EV)
M%>=Y=5S&RD9C/(;@,K9>U<OR@L%:AOYIGIK):C2&\*5-T$\C-"W+4GZEI/3J
MB^^>YDG[L]\/9YUNMQ&=EB<Z[2SHEY$H:G+QK:B#S='!&D0G(Y%44>- /;&$
MEV )QEN*J.4:S9= 54_#C]C@:X.O*^6);.(Q'@)K.Y>QEI"41,@'^"0%:JJV
M&FD<-;)!^!"%EE;=5T!&@[0-TC9(^V"2;#N.&CGV7K%UW@3(#99)<(883@QQ
M82-@*Q,H5]&W+& I.<BQ1M.6DLNR 3X^MA8#SK]&%EX*_X;.YXU_PY])QX_M
MX+#3F^G?PQ,DS01Y\.W_IM,^Z?_C]/*_JF\& 529ABL79_)ZSHYBKQH=Q>ID
MT/\8_6A8Y?MRX8YN',&-O5"NUE:F<FT0;3C/.) O= ;9%A5[ 9HZ'<;U*^:A
MK.QT']:[">:C:T^&\<7DPV^A,SSIVO,7G5X957GHM\N+GTUS<SNI[+3Z\F]G
MG3 Z>F',NA8L(^C8)CA^<7V5K!=PG2..^AI7ZTS2:R_C=?*#UP3[L5:_U5D"
M%T73V::ST%E^HV:O=M0P^@U'S6H$/\T!G[I;AMU-#-6#_ME\ZO6*E! R-YJ,
M=^5+#&@3.F4/8S6K'E>YP,^_W>!?&YU>]3[:P4U\!]^=-2*>YE1M11^/71Q4
MC+0JD)/)I<FXFF8H:6AF";?>1K!<[4WTLC\<W<0!=Y,!/ZN)F['@%42:Q:EF
M0G]@0D%GOPK ?NI"@W_#]NG]H =\B<$)3V$3+:$"(7618^YS-0_,D]':)9D8
M3L80@A5WI0(AF50@)$T%PAG3TO%_NNVO1\?O][=9>^L]WMUZ VV_%W OV?FX
MP]Y_W?ZZ\^?K+SOO7HEYT]+[X[=L]\\/1SL?/6Y_?,W;?[[F'SY^XCO[;\]W
MOH:/\/S9AZU77][O=]/.XA%_QGC-N$M(6!,0)RH@;81"FM,DK',R\;BT\P*^
M0U1+(Z2?S<9]Z_'_-"9L$I*6DB0*^Y0SQ8QTC'GO'0&@L;ZN\$2:"-:5PICY
MDA6<LF -3\@F@Q$7GB"GG$:4BTB)P,YCMK9!58O399V&MC)^OP;R&LA;.<A[
MOO$1#P>"\_4J)!<*)V<132X?^(H5<EP8)$/"5'JNL0L@:,F6DKP!P08$&Q"\
M9Q!\'N4J'@[PYLM56$,43X;7AV1Q)BQR\!."%<26*!6X]5FS;$DIG@K@/8=B
M 2]/A_#R."@$F==C95)(GKZ-3#*M9:2".YLX)=8H#'001'3:64=U8R-[?"1;
M/%/34*F#QQ+YY!3BWE-DA*. :=YSZEPD(9^I29LS-1]21#"42>F!AKP,/&JG
MDU32!@Q+PQR6I#$-K2!IS9N&/"P9T2JA8$+6B@R0%K8<!6U-Q%JPR$P1$CBY
M\^G:*UP HB'F^R?FQNAQ_^0];_2@(AF@X81@-1WB!@=D-*/(Z1"422X0E]8V
M9(N85:I<T%#WTZ/N1IM?+B4O:/,L*)^P0SYHB7A* ADN#8HVU]HURC.JUC9X
MBY)5HN3G$.52'Z=9J^JGMEOYB?X^B-W"X89'G9-'#X+Y>71XXRW#UDJNE.&&
MPS=NC/5&!N]U2KS1X1\=O]J+)VUJ(X+P1B,2 ^CP5($0PAWL4I&P<28&F:V1
MICEI\R'E AHY2XD83FG@@@M+@V7*66/S\<VX4>%7D;(65/@H@H-50QX;4.%A
M#9%5WJ'DC,"2::X87]L0JL7N+AHTA_$]:V)N5/C[)^]Y%3YQBCT%<9\[@A%7
MP#V!729$C*.PN-I'%=8V&&MAO*RXA8:\GR=Y-SK\<DEY7H=GBA ; T7*6R!E
M["-RS"?D>;)":Y+]]6L;E .GOK.QO3EL\W;%&P<VQ&,[^-0XVY>FJ/LD$E7"
M,6(5#U@;Y;!EU+H8HQ.L4=17 *3V%A3U**VSC A$@^8@='B/G)($D2"Y%"(*
M%T&=X(VO_2&9?^ D:2>5PMAP&8+&+(5@-);$><KY\A3UAL/?AGCF=?$4%'-&
M,^2XT8C'!+JXC@X)*2(AR0F+)1 /O7/ 7>-M>];$>JTBWI#O;<AW7M?F1EKA
M%48F\"R@TX ,31(E1;SFA"5G0T.^#?DN7=%.G2\QH*]QT&](^'8D/*]C>PXZ
MMG :.5!_$1?4(ZV  SM.E M486--+K"B*:&_K1 9/P=/>5&R"Y4TWO!E*=E!
M*:]98#+K9=0$YQ-S.DJ<) >N11HE^_%1:K'J ^ 2: 2@56L6*>+*.J1% $%#
M@@9A(DW4@)Y 1.,.?]!ZO4()84#&B\YSDY(FAK!@",5"&QIPXPY?0=):4,%]
MXE;(B$@"JN*6@3*>N$>>86P]5=I3#:2E6_3NAS0W_K)G3<R-._S^R7LAHIT0
M;5TRB*8 \CV.#%F+->($-K73$E.1<ARL8G<^XZ"A[F=-W8TW?+F4/*^I&X43
M:.8*12/SV5 BY:)G%'DG;8H)+M*<>L9:8FE5B1IO^,T(<6M:GWX4_5$/WGIX
MWOC%EZ6R$TL#YSP8V)3<.&.4DA@3Q[#F)*K&+[X"<+68A.ZYU%$'C;2QN9R&
MC\@Z4#.2<ID/I1!8RG#5.,8?4@X0UCB,M?(DQ5S@R08?J/1*:^DQ3[91V5>0
MM.95=ARX%U9Z1 4&F3Y3E37:H9BT#A9PT.NLL@O:TH:MD,V^H>:G1\V-SG[_
M]#VOL^< 94),0A:D\)RAHI!+C"*!M4C&AT #!9W=M#A>I>35AKR?'GDW2OMR
M27E>:0]2$J="0HS(@#B7#FE-/ K8&4H8QH[17"^&M;A>UG'.C7O]-HGHQR=Q
MU/C7EY=MSE+"3B<MG..8.LT PY+T3AJ7K,6-LO[H,+6[F&WN4B#>6(E(=!%Q
MZC!RP6HDJ9%8<V9(+O:['%V]L=G?-+"..&-PY,1JSS61UALMJ658&A,C3HVN
MOH*4-:^KLZ22=RXA!9]0CCA"V5Z// W81)TL8VIMP[1@=ZR0T;ZAY:='RXVF
M?O_4O>!=5PS(FE#D?+*@J4N.+.4*T>! NH>%U8&O;= 6$TTIB8:Z&T5]=2AY
M7E'7E&+IK4-$)9" E1 (F',$<@Z**8M#C"Y7?E1\E:I&+,FY7MZM5EQ=W^^/
M;'?FO/?.E$+&9[JOL,?](='M1I-YXQ-S;SUCWWONVC,/?NJ346XW^)^&,0I+
M% G1!B4"=Y1;)JR.RIM(O#<N-BKLRK'&Q21M3(5T- 442, @Y(J(M-(1)2&%
M#HEAD2LJ425:FBTKT_-FA/+(GJH&ZAJH>TBH:S3\^P>_>0W?\\23PPQIX@WB
M+&'DDJ4H)@&:/X_,)+:V >O:TGI9)SXTX-> WPJ,>K7 KS& +!?H%M(+M)7>
M"(P88P1QS"QR$B>$HV2PCKF:8CXT2M*6$<L**KQ?H!L;1R:]F.QM7F#L$9W\
M31O/I(WGD/JRG:-3>K;;/0=@GV3!#/MI=&8'\;]6Q21W'VW<.39QY=;RUF+.
MSRG,4 6<4# ;")5<8&>-HP'4 (]C]MK3QFBU:N(,]'74?HF_9)%F%]ZULW]X
MP 4)GEF) HN@N$6FD99$(.'R"4X$5#HLUC:H:#&A5RCP<H4 K@')!B0;D/RI
M0')W#B0IA1W*/$,XYV=RG4W[E'MDI')246Y",>VO&D@VFEW3QL^@V=5Q%^M*
MK#C/JT,O5C;@XC$$E['IJEZ6%PS6,O1/\]1,5N-:V];S,H$O8X)^&J%I66;R
M*R6E5U]\]S1/VI_]?CCK=+N-Z+0\T6EG0;]46CJ!/46,Y_H6@8'49+% V&#N
MA& L<;VVP3!ID:4EX2^/IIZ&\[!!UP9=5\H)V41@/ 32=BXC+1$4!TLULJ"4
M(HYSL7*O':(Y.]%Y+KQT]Q2"T2!M@[0-TCZ8'-N.HT:*O5=LG3< :N6X""0A
MXYU!G'.&M#0$J:BL=D$[2FVN_JQ;C-RY0.S*8&LQW_QK9.&E\&_H?-[X-_R9
M=/S8#@X[O9G^/3Q!TDR0!]_^;SKMD_X_3B__J_IF"$"5:;AR<29QY^PH]JK1
M4:Q.!OV/T8^&5;XO5^+HQA'<V OE:FUC*M<& #7G&0?RA<X@6Z)B+T!3I\.X
M?GD>\A;-6-7IG1;1[-+*EEW2@2=[HQ=,/MK"SI'-_/Y;D5[."KA5_'(2>T-8
M33NL_O<M.(5T@7*<DE'*<$R-MHI8:ED,@B3B4BD'0B?E0.@"RQ#S+&.V5[MI
MGH'<C%G(I\DLNO&_WYQ_>!=.@.-*:)OL[H>/'_;]UYUW[4[[S_=G[>,_CG>^
MOC[?V7H%#,"??=C_3V?GZU%J?WQ+=U\?^$B#QS0BD5.4.28$60. SX7CTN@0
ME<R':#"SOICB6,$&Z\*'UJU6/TGJHM;*\ZBYY-YB20(-+CH3J);BRF(PS>HO
M??79SMF!DI1I+3PB+K)<B$+E(U02"DX;;Z. 9G.J.EM?=/1-%K] \ZW6'U/N
M,)%$&\-I/M(V<1X8X<$HKF1-_7BR_KA9_WM:?[ZS>:"B,9$K@3!/''&I+*Q_
MM,@'*82PF(I\5A^L_Z(*/5W_3J_**-W*?TG9#7G96L"?AR? R#O _,_7;\O7
M-O[M!O_:N/:I!6GLMQ7AC]^J@O5#;._R5M_S1S&<=F,_?<,>]<?IZ'009ZGB
M5<VH][-LNP_]^;W;]Y^>V8[?^;@-O7MU$'#B*1B-5(H.("]$! B($8V<RT0]
M=<+6B 728@R;&3@P84%%FD24'K#+&J8E"Z#P,JNQ30 >$7#D)&_GP6D$*6E8
M]5.U%7T\=G%0,=(:DT@<C@!V1B"DVA[(HM/,]5J>RK)L_W2PZ%,M5Z+U1[G9
M+ ;W8!&K!(M?Y?)FPZH#(O$)2,Y?2NL@<__2R=)T_Q3V<AC^^N+:&EW?%X_'
MVYMG=_1)?]C)-[P8Q*[-E/W;62>,CB:V@IFGQI2)+QZQ#E2VT]'UCRR4MWLD
M$E9X;G9F_AY-PTM.[&%$#G203\@FZ.P+VSVSY\.U?UW&*0"I<>,Z&\'FQ_Y-
ML+L1$C[\K*DK9VW[Y=MJY]76]LO-OUK5=OOE>K79WJKVWOZ^M[VUO?EF^]7>
MR@^AO;O_:J_:WZU>[K;W=O_:WMK<?[55_;'=WFR_W-[\J]K;AQ]V7K7W]ZI?
M7D[PX==;+%O]=X[8:A2.D?H@<+ @@7,7E79$<A$$L =*O6'SB.0 A3BE@=G
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MQLP+H3/>#H^J$WM>W@N;_'\_0M[LU3MX\Q#FXQ!(*]NB;L:ZY?/;U[2]M7-
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M?.>8(G+P30Y%+P%_"QM_.3:"^^7O?\"N >6HKLP)_'TF<A $T_)U''+X[ 4
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MNSTV2&0G89W8-&M GR3MMFJC^+AT?\R&\7%40[&_GIZ<=#OYQZ'-%E/X,!K
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MEGV_2@=Q;SP[@N+4OL@GB," ?? S@RW0<4C_$+7"2,,,;Q8A].E?5G</S(8
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MG\MP46GT?\X7EM&.G^S/Y6RR0MK.^D^O>N=INY^CVUTPB/N#+)=RC+,>9[Z
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MZT$RYE]E__EQ;M/R4\7ND)M%OSLWZ_A^_YO.XX(?XUF>V?Y)NSNQ"^/U11G
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M\GW.%R]AZP> ^/#;+ T <H U_2<0>K/1Y4;OXF-%H[$Y^BM,Y(C[0) C4:*
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M'U)$8$D50QK@:X#O"OB2I"YJK<"J ];@WF)) @TN.A.HEE4V)AD#'VF ;]6
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MN-B@UX]#K[EP)08%FEN%" DF'U^(R D641)>!QFP"LJN;4HYWWYO%='K-1S
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M:W5'8.*2M1K%S)RXP@#A@E,DM/).4.DTU?ELX\,A'$:06A)PI#AQRA/8.N6
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MEH:CU<D*%O!6H0,C=#1&HZ[><#B/1T8(D'%T[L@,_5CHA@A]62-35E\&YN,
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M&%$ 3;A!]"*QICE%F.IGJ]J17FC N=G=OKX)_A#!@M<&O=->\=5 [Y.H_XX
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M(M((Z_23B#2:EZG1N%H+$1=YQB+/^'3RC*\KIWOZ2_\JB?8N[UTD^1XNR;<
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M:G_=:_T);_GG^DES;>];<ZVUO[G6W=_>AVOV_Y,5WD_',^BI$A8+CQ36#O%
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MVWHND3_RV";\N:O9.O\YGY*K0''VA[][\Y+YFVV_0Z-1@@+SMH)SQ)TS2).
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M[(P[G-1$(6")05I1A;AQ&MD4"7+:\T!UTMZS7+;IP?60"^P4V'F1_F:!G3G
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M&F\N(H12W"3)#:+!!,0)5D@;KI"/0O 4E8W!K+W6?)UI70/$LP8(;QB7FL3
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MLM_*'F8,?3J(%J;9)8:L-B!7</Z-!XI\H"YJ#U99XFM%!.E] A,,B@% PK6
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M0W441.8M_(WQ]M:0R%[?AX%4ZR+/11=9B@ZR DF\Q[K)"\CC_7 @Q*=W2U0
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M10B$NK772N!,9#.JQJ@&P33-P;78_1ZKI.C-X4(,"3O35EZG(?5DRND-W%?
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MD=6YYK5.&%GX%3&9I'+,T)2SZ/%U?<E!B<<K>5T#40U$UV7C(HY*0KBWG-/
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M8Q"7(2&M#44,8P)+IX+CRPNPJ;&HQJ*'B3K@COJ8&!'$\L"%Y=A+HJT,2N#
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MR8)6V8%+C A&,*KH2J92R21<?,\T7#1[)0"=P-Q%^,T"*'4&K3#$P0CH-L3
M7@2,!0""W@(X O)TNL6)!:4;<*\$*\#=PA:MIG7-5K-_E@$*GBW5]-;95,JP
M_FF,[>+8=K]!0R<9DWT3YJ$/4-<O^W,<;6:LO!%7!,#=C>)BG\^5 W=6V).3
M"CLO)H4Y:L:N[?JC,U!ECYK^* ^RTVWV8:*J03?;)Z"8%(->+$<Q_&:1)K[4
MSJ,[ZD; ^/@]MGJE<I(3PU4M>.C"(;3YLZ*@C.?-2N*,/UX,3H9""+J5)4[9
M4%:YR\]7<PXCLM]MLU4F=\F?R,I(F54&QE]VX4*W)F9G-IG,7+;'T$A"V?M2
M4N)ODZ2)B'XTVLP;Y52.#<:'[\)O%^:&\)P:<.WU7^6JD5=%\=]!)]-=R3%E
MMB!;9OH<4G,OZQH )3"-V;JL>*67F67$&<W8^ZU>E^6N"X5U&7)SI9\!5[6+
MX9I5+&:!LSL.OOP],]EZ$9OE@Z$),-<'@,JKUA[]M5[T!@ 8MC?7:O>:,%C;
MO7RMUZ>:N$@>-[V=OSCZU'@8[4Y_V(WU_'@UXN'P+QEK?@: )$.Z[W2['=?I
MCI!SXJ$A& /8VFI0 Y=MMG[3MC)\9P :@'X,:O-Q!J]\X7+:AK]K\EXN>3,@
M[T%[8K&F%[LW.!F:!;"HL []:M7;G=&REN22I7(6+N>O72=E>M<N\\9B<N?>
M9G3^O!7E,E=I% ^S6A%MMXTZ(($G1G6'E)B/K]5MCVS=01?,RO\.0*T"7(!%
M!'O&E.Z\B?QYV<$R/0%G19EFM=*&RI7W_QTTJW2JN9V_!]W>H-DO?NF!/M0
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MY-NAJ7;C\/\>Z>9?#1YC;R4+-J0+(F"3K^2U,E0*:9CB*LSM+XV66JE,?-2
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MC#IHJVVT04O GLY=)-SJ=6.[:[JN;3H7-J;B<CRJR]&<.1S3!"167"$602+
MDB$+5B#P(4TTPQ"L6%FC?)7+!T>.ZY=S5&#JE<*4,MAJ![G.V8!@U 3A:'#8
MI2=B4',?V=\7IDI6Y/T1:BHH0K$0V.N((K9969ARI*,** 2+#00L*)!7G!99
M(.J50I1@6&O&N>7"0L(H+1F/7A+--7<X/#J3*A!U;XB:.9I2&*@4*J&3S%HK
M$I#Q(B"J$F[1$$-@K[DS>(&H5PI1H)V#A%+4>0+*5\J,WA'!(]<XQ$=G4<79
M>R!.35$I+B+ES#%$O<H5)MXB2ZQ$RG/"?%")'<L:.GO+$)R?Z6CZ0,'&EQ";
M+I_QB"U-7X "P[IS_>/@ST+):4LH0@S7!EYS>TL7@1*3W 7'C(#D&3-#TR]2
M$?- F>3!9%\^+;ORH^[*GV9"L,%(S'3:D 6):5>VC"(#5J=-VDJ)<6);Q.;<
M706R1IMRJ?I<=,@2O!(^&7"0 K1UVF!E33+JJ)Q--.WI#+Q$!NYOV]-Y^<Y2
M'(E&1!.)@'.?-1HPLMP8IL'*"*\Y,E"L>V+=R;4B0EM"-8D0<UZF$I+9Y%0S
M)BD.Q;I?@'5/Q_VT"38&IM-^S2D";!W2T@<4! W!$<V4X,6ZE\"ZM9'6&4.=
MQ0YP<#K2B#F7-#*1W+TGW+L+.7^@B4]MX%)8%@E32$".[\>TBUNM(Y*)E6%B
M$SG3IG[D?*&M'UY )&&DY=CI=;^B8>@?/CBBL!2JLXIPX$QQ+1P%2;C15G&)
M%0G61NKF+OF]'V@57+H#+NW-! T\XY&;&%'P+I>*&((,H0J9: @CX#2#C$OB
MP:A4=*/K:\$^6 J.T,BI@^#!1J]S':0*T>)DW,6I> F6/<4XA(K<1691%O1/
MEIW<"QO (8&YHL9S0?'BG(IBW36V;AT,59CF*" $SK6BS*E !;=$2J.*=;\
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MC$-6QY>*)V<7[JM<>IT9OSI%L2>SX)E3#2>C I%H1 PR63#&2"F+41"22<F
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MP<4SG(_C&4P48N-\_LYDW(I_L$!&,2O)J(P-P6J#,(M9&]I5.B,.R9#^,R$
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MB.<I=SH2B8# @,%C%*7:95(D];UKG8L;Y?[C)VY82%XZGC_" KT85)\57;N
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M90;D1X<I+E.5H#WH7R20LPGX/RS<?O6[,1QU '(OY\SV2Y_?89_?G6T5B0V
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MCYI+[BV6)-#@HC.!:BDJ "0C "0/!H O;FK%(V+?I>92G\6V5"PYD@2"4RT
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M:EK5.2M2BI)>A/(_3LRH\(LGU_23<4V/(F#L,1*,R#QCW2$=F$<Z@LB >GM
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M5*E$U=(*%0T0C0HYF;4B5XR'U8K\V(H\R[VP5S9Y!MR+YQ*MS"*#N428>@Q
M3*W%<FE%-XBY=R&N.EAT9XW\;/M]VQV>T9,Z8O0LV<F-=AU-YWIZJ0; !0+@
MA9./-HZWUO=$Z\,N-E%BZ3!23''$A2;(,@N(J(2QC.'D-4 @80W*7^#>R5KM
MJ['9<%[M:\V^I69_N*#9WXZ;Q[LJ!)Z<XT@ZPQ#GV")KA$"">)^HC<Y[DJ/%
MJD)J_=I"+]MQK)A$LC<'<R?)U=Y:E8A-&36?A;?)!,+\'=1498& 1B]3E6\_
MFA]VA: T.!J0"0!C/":/= 27S1(?L>%:^9265DR#R'J+U@O6XX6L?MU8C^ND
MNWNH\"5.\F/KPZY423CE%**>1L03=T@';9 D),*<V01.2!73[E[O:E?U&ES7
M2+L.1-?V;7\OYFX-&@4,B(>^#>%7/QI HV(_XZB/@\&=RP34WG0UR@3X\XD^
MF^;I)%^8XYJ1+M"<L;EE0,XD%08<;$)%0EPQBIQQ$N'$A !.XJ7$2RO,- 36
M%?*Q:V6O(B&ME;UBRCZS5 A45>!D&8H8.\2=-<CDLV$%(TDJ:UW*-0:I:AA5
MI:VRKRV@]H_MC":[XO+9&A;4HXZJW7H4WU1AO?!L*E>G,UE#W (ACL_Q&>RB
ME9)Q)(0'B&.)(^-20M@SJG4R+&E?9J)>%6";"U[7L;7GJ,T/M@Q8:_-#:_,,
M8>&:,^,"1Y3AO+!O!+)":Z2Q$5)[%:R*0%@:ALT?5/HDRKR@:$TU#MU9^&$6
MO_#&?G5??2CUJSMS&@>G6'3@KV#"':<F&&VI F>%::$G4'[W&%0-WPN$;S%'
MQJ*R3O.0>1@/B">OD77$(@!SJV0^\E=F,D9E0S"ZV%-B*W^0= UV-=C-@)VP
M1)$0;5 B<$>Y9=D1!?\S$N^-B_>,P=5@MUBPF^&JP04M52(H[WA$7'+P/,%@
M(3!A3#)#@_5X:46:!C'S9+6B6/?J#KZ;GG![4J7#[ZXXZOR9']=6C^>C'G_W
MXI($RCW]%TZHON-NWWM2M%? PEXFT5*&,Z:<Y"(*SGG2)"FB6<3<1Y9HO'M!
MF?=3^U%*Z&8IH#M9/FORM3CRM3E?"B\D&1PV!#&C% (!2<AI@Q'VG+KDL>.4
M@Z?9T.0%%I6I<>J%XE0BFA-.;1 @P"(8)Y5@''MG.'=2BKO7R*EQZI%P:L9)
M]-%A3SU'X-V#DTB$1MI0@I1)QA# (4EU7M!0=%$^8ITY7&<.OXZTF?5XU ><
MFF3.=$-A#WO0NM.[G[[QNI?<JT6H+\YNWG1[86YKF[5 FS5?*4@JPKAP&EE)
M5 YL)J0=XR@8S#A0$Z-D IN%34/J>^_#K1-KJJOECT!':RU_-"V?8:;&B6@\
M!HG&3.9S? FR@6$DK,*1AT@I#EG+&_S^AVA4+^'FV9"<Z69[KLD;^_;"L1D%
M*OR^[>[EL&AA?9EB#QTL#N-POQ?JG5(/"8P1TR )LR:"18S266L,!85BF&.K
M?-I=S_0'$TS0+;;G#^V/L^6H\=2VN^<3.Y[7>I_O8O"0S)\J%B7WQ H49=[E
MZR.P'F$-HH(Y0JE3BJ6%[?*M7DRQ5NXSY>8.3)\TV#@"KHUR5(<0I([<!BZ#
M+I6;3)7[IGOV;Z_<->.YKX;/,!YJI5(Q'ZL1D\S'J3*DJ3"(!^"TUE"!,5M:
MX0VMZIK550A85:_!=2RN/NNMRJ;KOF&Y*S;"3#WU=AQL#?=C/Y]TV8_[L3MH
M?Y^L(]5F:X%F:WZ'FTC2$HH]2MJ97+@[(9.X0<%0!=-,N9,N5Y 2^MZU+NM@
M7'5U^[[!N$7H=NUOWD.M9]@H$SQJC0.RGA#$:3)(2X%1<I8+RE1,E#W#JE)W
M=SSKO17UWHKG0H5JRK- ;+QJ'YG$-A*)%#$*<44\<IHE%"76#GQXG6+>!DQ)
M ^MGL[>BQKH:ZYXC-:RQ;K%8-\,#B8U>>2O J7. =88R9'3P2"F= G!$25)>
MA]4 =8NJT?18V\BF#9G(M2AQ[ FV BUX.]'U8_;\&OD8R^GEW^UNB-WA.\3(
M<OY.E9#VTH; -V>K-&^+<A=MH^C&X1-6OQ@/S55[V&I+O[ !JC85N$TMI/L6
MT*BYP&-Q@>;\KB9LL?14*.2M!B[@F$4:9A,1J@CQ+!D>\-**X0TAYLMGW+S^
MT<+UYWFX1#62OGHD?<3B'-<6E;L IZVZ2,>B$77&NXH^&6VX04E8BC@ :3Z(
MQ2/+7%2"LABC6EKAI$'(@@-)3PBK):G_;6CAI?!O:']?F7:M-3H$Q?$K_RH_
M'/?+]7];.>MC^?G9Q0=0S_*)[]I#:+?_N<+2K+"@-<7_Y@&R)X-RC\^:[?=/
M0&6.;3\,YIH];?!%EX/)TEC\I+._N.L10:KL,Z!"T3N*?5OF\W9Z@T'Q9JFU
M]7[I;>$O]C[CU: ]@"^G=T5.#DX1Y,IV"OCNS#=[J?B?6V"?5]RFD*+UB7,N
ME.;&48&UH<XR8M4U)%+,8M_6M!?OH1.79NYFL">?*>Q]_<\^]H?_=.UG,]HZ
M^,9:Z_#L@SW1/-T47P\^'GQ=][QY^/6P^?D#;4%[OAQ\[;0^?SC^S^G&<>O
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M0PR%!4B<.T#DUISL;G'C6YC+NQ;3?WT&]!/>VO&DM;/W Y0+;WW8]9XGD&G
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MW@"$$P8T=DMD3,7@"/0DM7W6VM >-]K"\P_C<+G8F<!F^_ (.C=YW"#^O,5
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M#TE%C[RV#O&4MX0Y9E P4E!I",6LDBO?KV'19Z,;[EM&_Q=1GE_=-ZFF.#D
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M N(TG/J1=EBL1Q\/'= 11DJJ09=?@ $G]S'@25(7M5:>1\TE]Q9+$FAPT9E
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MV)15,$\Z6)MA+D?PWY'ME^X\:-9A]@Z!O)V]I7=)=P;0BF%Y?<P(<V ]_QF
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M%-P!D%R:L6"%2CI7'?-O+PHTULZ'G9O.Y85]?MDVSC]_T&!4^[S7'7[I_37
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M2JCAW! 1HF)9E!B#N9RRG(1FE5!7K8-'R L@9"$6[/&R3%@RXC8Y'I\^18V
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M*&BJ6(F#Y]6:7&!-3%Q84UFV'-8F\SO-6=LQ5KX=2X2-E;^:[V'Y*>;;5VK
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MVH=.1/MDUL#E2/1("<D5"9.QL!?-;F.5!BI[P02:Z19//7$D^IZPVI+IE3(
M0N3-;5\"LO.?$ H)]HIE[8W+2L6%CV?92<Y7 B_.[W;74E-IB99I6+M_^?+>
M9>GD:HYA]4DT'349P-:P@>?77YX>[OM,U]D<YH.RTO3 IU7+LV^46?4!G7FC
MG?DU5\3=E+<A"C@3B2L%F7 ^(&>-(BP3+%Q/"BCNZ+A+0%8EL!3A]T*AD7Y'
M67!Q#^ 4L =T/\G&B"U8OI4UHB!,?*1C=DFFYUAAR:*'4FO64%?M5+3*A"IJ
M3.,WA0LKGP2P^PG!5M&S\[LJ9U[US$T1$*CW?3J&ZY1.&YGPW<!]P_*X*.3"
MMF#[XLH-BRBZ67&RDP!-'2A-9&24?H?=/#X&T#\H@6QNPSC,KCZ89:#&<;H*
M%!R*R8A$F&S_9YJS?N:EY8+AT")\S$Y^ 4WRTNY1P96&&+T%+T/GK:&O%)TJ
MJ]Q0?)I*1:PGXU28$GVTBID78E0#UC#D30:Q".ZT_%B%U)*Y.U4(5LD(AI_6
MHN4M&1]%UY BTRW& I%W\[DYEWI3,X&IHE$[C:E"DY<*3<&5NND0Z*PL=/P.
MRR!S)\1=9*6\V!9L)7J-+=ZQRU*#-\(A<$56>7DX6+P]P7=_(JQ"S7R,!"(Q
MN^"Z[_NL6>ATD1I*AWW>< <DAF$J>LPMU?C96!=8#[IL-\KYV+1EZ@)?Y))D
M89$YJG2Z*Z:'(6)73>5,S(*O=I6$-A_[8S17KAKW'2$#3V@&#A>@7O#E-!Y?
M8Z0$FS:HDNQL0]QDT?Z-->H93NNE1Q5VIV0P$GN"7,$ALM_R"2CX"&BPLV/.
M%?!3]K(@(V'_1ORE62$ L9_ S)3K-!M$URC,\>+R,'&@9]3#LY6[GM!*'?"P
MW/AIG?'7E;]..PN6%2!Y@ KL #=,PY]?3TM^3Y%5]"4L[%ZL8OEK)4OR;Y69
MO5;&W,O&MA-VXZ8AOEA,H-KY,.<'-W,;"B%?G#$*?-,AL!8YF@T\(9?EK"?=
MD&\=[EI%3(G%;8DGHU"TP?C._/L9MW49OI!O2@V_%) 6W:A\-HWJ/)%RRZ^^
M37\(T1&I-<54+.6 R= '+;X#^T!=&1+VVS2-&#L?DDL8)(9?BR:5C/H*9RV\
M"$2FD%RD(#8<S^[1"ID0Q8U72A<$%Q"*\675@#(<L@A]XHTHN7S VATGV$AY
M)NY+W (02"Y&L!X,G!JCDZ91>KFY"^DU7,/Q> "/]E+@^2E;&>MD1:9H,7,3
ML0>7N( $O<EC(0L ^Y\PNV$Q1-5Y!./@%SXEN(ML+1=<6+SJ$R"GD$[X:QA=
M3$.@PJHLRM]:<4MCW[OJMBZ*E_.[.R/9O5*."3S'^SE4S;4(LL()_M=D<,.#
MS*[[ **5+R#]Y.F 8:\PD2Y VFN0S=BU"7'%XH30I[4@['%%@F\P[^;)3=SS
ML(=(-Z38=(Q#6I*%V'<4O7N%FBAT6CYOM^*Q-U\KK0&,069%?+)PPC"!BXP,
MA[P:+5!?.!T?7WY&K\;ER>I+P@7L!M\N,5QUJ[ OS^ U".3XB1"HI\3 -6$V
MB0%N=07%T5Y]<:,&K+<* <3K \<-"PP2X7@S)%=9NL_)+SE-@W0\O_P,_\@N
M2''=;J;7F.]FQ><ZYQ9=)8!/J7(-Z1N7=V?I6]R9:D>'5:]HB [*0#(9T ?G
M@I3I[L4\<AZR6MR<><%'RN5U,66^;2Y+'-ZN;+Y:,O=^)9C/$1EG+7,2^'+;
MIC!:5C;B-A]8)<!\J2WC.(GI;" WHD6SC+P5T;X8%+X@92Q\M[$P.VZEROG,
M\#*.\(]X#SOAW\!# 2^XU^T@;0+XI.&$214LM((Y3) M-@I3@H*=G,<< <(^
M'2(NY 4PP/A-$%N 8]!RAL4@BQ-C)HDI@E2*C(^5=[VVV 4<Z'/S%(T+I-!D
MTN;"RV;MQG,&%A[Y31*$][?HE>)G*N+3,5JM8 OP]B7/">M*7LJ0<](&]Z%:
MZ\]JOS#['%;-/N\&9/(MS2L+GXZ%[X<C GE[A)XM]DBC_$RS7XLP47H%@OF(
M<M%RQGK$8POG9XA]3A-&O4H R@9("UEIGF22%V<$$;W(J!!9/H[@"UF><*&Y
M@RPG3\=$W*%.<[_9:BY[4LBF*ZU',U=J+?M1C@'Z%Z7</LTE$DQHB7..O2MD
MEW&Q-S?VHBH$@P 4M07FO)H9/<O0'5W;N= =*1O<NVS :RYTFK-E%^IKLO-6
MF=PJUKJ5EKI?"0:X&VP/5CHR5_L4A2.C$A'#\[@ PGL-Y<.$# JN>THO"OVK
M%<<@T^0/%%MEK+?GVSQPD!0.Z0\ YSFG*_]CX7.MGHRP%?$'4+]!=8WS;V>)
M?%6\??J"THBS$,SZXKJ?\@[<V+MO=1PZB\O"D[P&AMCGJNK5!-N7+TV?8]_0
M?.5%B&GRK-4>NN'$2O</9SW+/!UM.ETAF\)+AFC&X;%<W*P%1,K-6;"+^X<5
MOUNE 3KK]L>(?D5XUW+*K.PD#C.&,^>C5'>2R7]"+OU/Y379E,")('!F4Q;A
M8Q6CYJPS400>LY2]AO*9#F!S6X/!#7=I%\E^TVRWZC8%%%/D6.]4^(3GZ<W9
MC)E)+D7I2CE#J0B80Q(J_73 ]FQN*K"9:,W$3^;LW7 2\!?*HIF9!W_.\RQV
MHCJYBHRVWSQKMIMM?M:?"6MFS6:$#1ZK\E9%&%LFBTV_^D#19&N"QW:3&9;+
MH>+B/+ 'DSU6M8TTV NGKT&+:L5X/GLQ,LI@AAD_-\H)>WIADFCW6E4>IVY"
M"#>1&OH:$L@J?R%W Y4KY6\1KL"J'7OJ$F> Q"#?L 7BHV;'@V 0PJI?*LAV
M?AC!-_?)#U3/*BG#5>96L%_^5,F8X ;,JLJ:NX8W9CK!*;:6_AA=FW7%D)E@
ME3DFSJ?3F%M1R<B9>I^1,C#LF'Q#GPN@-/"WHP&<<)KD\_NQAN'_#(XR*;@X
M-\_/NFC$J]E>')-AD"MO2<:>.4Y@K\8WWQ/@^-4YK##[3J>UJ>7W=IQZ*'2I
M&93HAH"2U<6('AE,V(Q^ 295KY0N^(,0V0HXF,W+>L\=S-.4+&'V8\:0=UEZ
M#61:9JDNB#^%R[RXX_SCZATO)R1\%&PW^1;.N6B92]9W<7Z=,IRM2$-#?Q-Z
MQCFD%.[P".@=+O_-U/O")!R!'MQ?,T6,BIAK6&506B'?KHP;F(9'G(Q";O@Y
M*X9C=X--M@P86)QE&6]4Q.9QA!E1YOQP&T L"@6>GMY0F%_INE^"657W<;&)
M)6*=)<CY%PM=,"&\G%2Y!M17T?E5#?9(BP]%"*B2ER[6,L)0N#J+X4LQ=/],
MV /9FY8,R.3M_";L\U^%L'HSHDOD5%@29>&<& ;?*=[,-#.QNO?]FQQ]945@
M_[Q9$:\BB=*YV?[2(,Q%X*43JMA]2\NKUU@53\G, ?BU ^[\/N@3@(_1!:V^
MIRCSXG%#OF%48H:6OW+)GAZ- &''<(P+KUOM#BSV8CVND-$!_8YAG[.B+$BE
M3.1<R1\>*MN@EAP",T^7UO.J&7>HQ#_QF(5,S'<N=DP \[N_N\K5(*Q$20 1
MPR>4!85<<&<"MT28W'8!(_/PE2+&K$P2X,YY5&;X*$,1DL5=)*UQ,1@0'<^4
M8X8 I"T!VS%+^!%7 ;C6U60PDY5\*,"U48UK8UX]FH$L1]AD^"--I0W0F_ P
MH(IZC^?(]T-$,)O:U!C2._V,&_$1=.W"^3\98]@;L@S&=LIQQ,Y<][&N07\N
M<4[8-@KW1"G&"A>B&/]6H,*87@QA87M6S=@X XV@7QS#^^.#BJOH5P!3;/^T
M+E/I7VSE"IX6SQ,@08H!R+!Q(59<"*=EA2J91__*66(26R 3VM/P&SZ/'%5H
M!46$'S.-B>I$N"PV^\9"&M/,JIA[@]FO8(Y$.>O#\:')A68P< LY!:,N;DG#
MJ,-\]ON,JHITJ@CX_,4(\1X]9  O0"31!$/68(:LWA/CY=6\*Z#.0<IMMS/O
M#>B(@J248%J DEYSIR7(!?E8L?^G(,=QBB'9Z62<CV%A>)%RG'^9LU"LFFU:
MLTH3R>QPTX2!8@73ULJWQ$>LG8-> X0U9KO*3+7?&O")NW0AK]DL/P,\$40P
M(+R(W=;2VW"0CI@0B/>O/>ZCM$4P@RAD\5AX]08#EL9<!K,URD;?C6K$5"';
M5M,X\'M7P$?"Y KYRGRG\$;EPP67;/7#:7CJU&&;L;RD#'4V>!8#'&!&J-O
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M[!ZVWTKRK?>9K2+?0]&M];D1KZ)KU@;G^Y3JU!^D,!7E/:CM/(]&6 $.T0K
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MUS1F?WT/[T^C^]TJ(7JC6@7/*GDZ2"*E6/-.[>-!'_0"&A7M0=B.':1Y08-
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MDM9/Q\$2('(?$,]AFS#V"7F1,7*=(=9SU$*KV#XJT!8"/)#@543T'4[VOZV
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M':HR0NM7%(>LSC+6KK&Y#:4=;9M,Q\=6ZQ1,S FY1<LI(DVZVUA\ZUH:IF0
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MK;^B%/((W/N8'7H#!%;X64*D;8L-^Q6K#&M'D3&L)0^*/2=GCX/YECB9\0-
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MC G!HTP2LLJU0"8*<#QYL)IKD^JHPN9=1:Z!,^0F/5FRTCT+9)V<*&ON4(%
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M->C$-?WMZ>QKG5ZT#:XQG3=[DICF[&J36'GZ]6_+27NZ#RL\_/-P(G),*JL
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MRO !ZY/@[C\7\]0V6'WCHYL%JF^WB$9!ZE,2\^.UQ%VAM)<%%'%V/0<V,*M
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M/_QS-/Y7_W, ^/?Y?_1\].GKN/_AX_0'P82\^]OQWZ4IP2G-@?E80"6T$)1
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MAZ/AE"R 7P98'4*R4?!#_6(?';_"#V'PRW#:GWY]]J4_Z0EF,":=0 93-_M
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M33E4=X4GHS6Z9!ZJPMX] /"D-;J#\.ZKT.^KPE?]$/N#N;%8,TK34?K7Q]&
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MI7T^Y)B-%TRWKI_<&-QW#FZOHPYZE.Q;!W=5^3FF%V?XX:91>E4<$$/0D>4
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M!,T>R=6>*LNV45<7W='"]&;3'2^"-49"=BZ#0N\@!,M \T2;>\G9YM;%]K<
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MTCMUP)*KH]RA.046;:N*#D+5U]6RCPOD9MG9HH 64>I8"'P2M7%5%!DB[;5
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MDBE:6O?G58NEG $O3TG9#;.D\]=M]>E\?28OQY32.IZ'R<>>2#;P9 0=P%R
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MO3-U?97F%_CM J1:]1_U1[_/+Q98D?9F%Y_?Y?]SM;S\NL+<NS6[F2TQ)LU
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MV.V$;9:BYQHM>=1\->N!Z).8@:%(1I948N@&B;=UB?$LOH;\GS=G7FO#?6V
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MZ)DS2J5NB @=%CMU?1F$J0-@Q+:ZDK^3[5(#.[_,%ZML[1GG/J>$"KPH%0.
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M@YBW-7!]%]Y^U-*'%4W*&PTF>08*"X)/ED'6,?F$F'EN'?_=0<[KLE-:R66
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MEO[4 _62^^A-MI #O?1*2E.;2.B,<F^U]2GI+-X"]8-H1L= ?1\)'27NVH7
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M8 ^<K0W0 =!^"Z^3!#R%_=6$]H?Y> +A6E>D[ 665)8E>0W9!])W.$'TJO:
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M]<Y&#H:B\1XY.-F;>%5T<8\ 6SW)J,!C]!*\*X$,*T] )>? .-VNT01N!BJ
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M!N$^ M3PQA6RP@W=EL@@.$EXE"%D7D@HW@M%)A^JW1+R'D)\O<R/P?/C*3M
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ME@@I'%T0I/Q5D"*A+L*+?L4/SR)/NX]X/)BGW8<\H^5I"[J]%6K:7/#5GQO
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M7U!MQA\UDK[%C0N>>Y%;Y^@\ ND9J"#'LF]7+!K2OJ$>4KU#ZP*J&GZY2=K
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MBC1"1&.<CRDD)DP,:G+*PL?/N;I^_JN]SY\NJVYRN<BWM"B'M>=LS>+U 91
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M"<QRXE1JWMWX 3SCJ]?M.;C;)+05^0>('F_5_>UV-ZB,\5:(0%=Q=):,/>$
M.3HP*(MBI \FFQL+Q7XD9R@.#4@^RMWRKOR42UZ0P'[$/U\MEWFUA2IUM"YC
MABQMK)WW.#@I4RUK88(G*^,(_NR#\,Y09(9B3NL>P_<XNZ9BSNG+?_Y<\]>6
M4]+X?YY=?KENR52]:H_F]/60GKK@\D9\ZM+]DO@:;.$Z5>_$6WO-U5=AN5I@
M;*WS[SR\Q2BQJT?^?3Z+5]/.&B/>O\;X<\#V<F7O *]#!!G@]-XVL*I]IZ\6
M&TAN'ECH]/;VB\N<[B_06O(/KC.Z+#W.M3W]YA\FTK"R=2/+PXO7GK5:G%*W
M5ACB@+K]^*>4I\.<VGM4[:'* ))T-6WL>LC00#)T:)71NH&^JOK]I_7B-0^*
MOOQU=M5(\%UYK#=EZV&:8Z$>7=8?D:7CVX0VX5[?,IK-M^L? 9?Y?_^O_Q]0
M2P,$%     @ Z8M;5IE%NH"@!@$ J4\! !0   !I8W5I+3(P,C(Q,C,Q7V<Q
M+FIP9^R[!UA3W[LFNI&.!5&JE*A414!%FD B^D-$!$2$2!<!:4(HTD,BH* 4
M$1"0&J6(U(@T:0D=I(CT)H2 ="())032!O\SY\XY<^[,<\^=9^Z9,_>W\KS[
M29Z]WYWU[?7M];W?*LQQYBQP_/9-_9L RR$6X.'!!V#^!H[I.,(>.0%.P$%A
M84X!-X!#+'_*G^.A/X6-]<^1G8V-E8V#G8/C'^#DYCH )P<'UV$N;IX_Y>#;
MD<,\1_[\^'.3_TP]Q,[*RL[#R<')\V\NS": C^M0&5L'*\M9X! ?"RL?"[,-
M !W4D?T?U6,!_DMA.<3*QL[!>5"-PP<75!T_J#XKZT&EV0]J?' V]. \P,;'
M?N+,)1V.DR;VG&>]^2^')7S@DKQ>WBQP;X HI?S()YR;1U!(6.24M(RLW+GS
M5U14U=0UKM[X2_>FWBW]VZ;WS<RA#RPL'1R='CN[N+KY/O7S#P@,"HYX_B(R
MZN6KZ,2DM\DIJ>_2TG-R\_(_%GPJ+/I245E57?.UMJZEM:V]H[/K6_?@T/#(
MZ-CXQ"1^;O[7PN+2\LHJ:7-K>X>\2]G;_V,7"\#*\D_E_]8NO@.[#OUI \X_
M=K$<"OAS 1\;^YE+'"=T3#CMO4^>O1S&Q7\]X4-Y,[>D\CVBP".? 1Y!J2MX
M:=(?T_YAV?\SP\+_7UGV?QGV7^V:!(ZPLAPT'BL?  'HM)QH.>!O_-N!/D\O
M@;ACHR!?U)X_G?;M.&5>6NK&.#,\9DA$OX!KNR_AUH3B8G5/.'I=KG^7K28G
M\M@,7&P=%<<X1).F))! +2C!!@\\&Y;$&2Y=F]HR^3S55VG<]BFW/-=(BX:3
M&75U?)*K6>0]+\\/[&S>?O\+\!E*2!.N*FH]:XX)O!#$* X+MK9F2X[ 2C<J
M]SQ1=&OE'FZ0L_^ZL)B/$;_R,1RYDUZU#9DX9L?EL@D_3Y*-4T&?6H4*!LM$
MX%W,K0K3A4=^%IU,Z=@1MLYV;T;.OD>H5-'K&$J![@QN/)&; ^V=1RD:LJ2@
MYF+LLL=:S5,6HA(=Q4+S8_@JQ2)9>"]059B !SH*6PV*/2 S 1XM&%43?F;(
M+P3"3C&^E]YC1[)I;<\9=Q/".)ZXLJ@T4WLK488KPE?P'F^W%\LRB T)LWO)
M!(0PYUPAQ_RPX[+SG,\5_#2D+.!Z<W:\[YX\J6[;9)6?7SAR_S03<'WAAAB
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MKP+.<YK2]2%G5!/K+XP:Q\+]\*"H?0-WQ*4QPKI"AW]E_Y;&MBY(&?60&RU
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M10300TKC$'+@",29"40@]*();9;D>B\E/W4?[FJ;#P[/$H:+?J%N^HN%I1/
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M-(T)$'G_W.^HBO .+S<E?5'@)CM!ZDW#B?B;L9D@-)O_6<P(18ED>H?2.FL
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ML1^8\E$3\01P$UG]!?C =0-2"C,/HVVTY0P3.>@V#WUS^&D'>SMZ?=FH6/K
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M3_."D/!K;Q)2EP*DX!K=DJX96T!^6&^3+4O?1:)D+%S7,>OQ'7K)YN&L_<U
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M%G[T&_\2LCA@)(OJ<]5J>Y1%/94H^)#Z,./.#JE<T?^L*P,@KWA*%G)OJ.!
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M@=O3#P(@ZTLLD >NH2,0!U[G&_4$4)QD>;S_?V'OO8.:C-YUT2 "T@R]"D%
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MPFM"BWNWOJ[O=M?4@NF4M< ]^]HA^,A]TF"<TC$#K^HN\Q;'JN>+1#S[ID.
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M'.UJ)=!.A:)F\@R ^ !"@W/1R''@#6>I)U^ZP<WZZ#/M/4<J%]-L!%_9ZY<
MQAL,'B@U$&D!.)-5>F;EJ@$'TD,5&4TPW^]S7;4G/OA,'-I0W04+\A&UCB2(
M*TA<.M0?!Z)&)P'3E-L-9/NU&"IR9:X\=;"+W[]+EH.L%RW>;0B""\S5_/B*
MD;\V!'.O@GX9$L@XP_7GL>7:VISKJE196NS;'XCL5[/.-;E5@P''#5?DL]P
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M@]G29 =-W3",OJ/)6;X?3YVVGV2'GE8R\-Q*A-3CDKA@%!HH89U>4]' M>.
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M4^[0. P<M@L]+*NRK_5]!V,TZU60S-\>3ZV^@.:ZCB1YX1&9N=@S<A_A["/
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M B?&%;C)\"=,[X.?)*7<'>BXS^_4D'7(TOQR?(_F.<W($X&A1N_B^?I<448
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MBJB3G%KV'H;D0!?_%-O>HHJ,2/U[JGT=Y]/X<&^ST>;-90&1HZT")C^D<Q-
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M3GB8^"2[1%PX#KI9-_CG*:<!+8+T)H_1MGF\(X)1Q?2%2')E $)/;J"7ZE'
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M:Q@K 2DY=,3\G<#O-Q ^"PW@)S.#UU%+'V,6I<!P3&'+\NS7Z[YISU]LZK%
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MTJ8[ GT$^]?U31-N_R"E^O)][%^.7C_U?JQ "X+'7&%GE'VE"=L+,&V&L#-
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MX$J'@)K7I%RM-_6RYXDN#@VE>1(FD=I,<(DAS@(!*4]3*-*(81IBPH71V?#
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M<(/#3T)')@KVW&%TK8.S\_/7=5DK&^SAY7JECTCTR:NBE()WT;>_ENNJ6LB
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ME%$1P91@'4<92IBS/(%)$ C.$$()"ZSB*.WFGQOEM>+#1GZP4Z#K4' #&AU
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M5@WQZPBK^U7Q#\'?<O4Q*&1!MEG2M^SOFT*QS-X.4;?NK2KUW> ?1+U A).
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M X2IB=Q)<J")*@8I3N*8*@4A3!SFU1VBQD9&VVKH/\A*75.8K-KYFTM'-K(
MVFKB' B^WF?+@R+G-#,.A.!@T^&KD'2=!5N <V'JV]7"D/-="TL.)KDV=_BY
M@6_JV?+KQ6J]]3;K=(.2R2Q)10Q@*B! "<?:Z4,2)%F*)$4QE+E3>$J'K+'Q
M:Z-J5.K:FE/YI'3LPMC.LPN$7,_4Z@N:LQMG 4<@SZU+TJ#.FH7)A_Z9S2T>
M+MD?=+G4;MZS;O&37&^6\T_25%23I9A)7&2:'B0$/(=2NV2Y "3',<BS-$&2
M025%;.V2=8H:&V4TRI;/?:5N5.L;<:.P@T_1C;&%-Q8,N9XI8SC0'!RQ8. -
MY(CY@^CF@UGATNF#=;<PG ]F9<F>#V9WAP>=OMEM5]"2FW4GSG:GHM]O<Y;%
M.88D401D" N 4G. &2(*8"%BF,*8$VF5%==)ZMA(]DUKLRVJ-"^?^I;N'OGD
MW#K"@G[[@'<HY^T%D77@Z#X0'HBNVRA&:K&,K* /.IMV1:^3U*T;&X[?7>W;
MHWKGFSUKRD_G5%ORWM2KW]89_DB?S1.X>K.1_R/I\MWTFYQ I&*8J 1 +@I@
M=EP $3 &"56L*-(<,J&<RL1;"AX;]]=Z1Z7BK7K@-]%Z$3$9?:13<1,9[2.C
MOF,M>-O>L)NP]X%QSP- *'C=ZZ\[8A6JI+JMV&&KI#N"<53XW/7^:W>/#S,S
MOYG.-FLI7CV_7GS]NIB_GFD.K9;"B::K#&44$&PJS F1 RH@!CF.(:&PP!FB
M?AO)UCJ,C=(:$\P)K5.9Q6M#;B+V'%6V1*4Q-^:<5UVJX.&O1?5E]*M<?UF(
M:[>B[3O4=5>ZEV[JF15?I(>NV-=VQCCX%K>]!B^TV^T,T?F-;_>F/.,/:P)_
MMUA^DD_ZV?ZBZ?U>55(^KTU9R00E+"]0#! 2"J 48X %HT J5'":*083TN0#
MM>/7RT*MWM/]_)T]$^K'6DWSNJZ7>A#<+)^CE='5,;;P,N!V[!<(Q(&B<6IE
MRUGI3ET#9LUMGSNA= \@M$8G5.#@98'#!@Q: W 4*&A_IQ_GM$L(_DK7FV4Y
M^]6R:L$F[&<ZY],G.KM5VEG:SI!BBI.D2"G@2IK,Q!QK/T_EH,@(1!PK2#.G
M+.Z^BHS-V3LLAEG;HB=8U*CM.W/U[B<[ AL"_9YI[7K@G8GM6M0"T9VW&H.2
MX+5@'5+CU>U=65[]XV(VY<^MTNJ*<5JD"- "0SWQ53$@"'*0Q@3A!"J:0^A5
M6OU T-@(;W=>ZB:J5(W^K/^]OK3Z(<AV;!8"NI[9ZDK4_,NJGX$D=$GU0S$O
M4T[]C+%G2ZF?NSY@ (W)!C/7??7\AR8L[<JIU22!/*64"4!BS1<H0Q#@3!)
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M(J0>(E5. <H+"2B/<T!4GD"1QRP73D>[0B$[R"G24M=H992]B5:ENM%BIV]
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M$#4YBQ^4PGS!.:0Z[W9\*5$^T:E9PY:K"<*<RA1A4"1(^[DF\@$7&0,L9TI
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M[R^)'':BXP#"T=3'Y5Z/+=VR_3IDMFI9MUKZ\4I!0JDL)T12#P=( 9(1"8C
M:6Y2<">%%15UBQDG^?Q0YSG_,9J6RMY$<[EVFB!= +>;8\)!-@BK](Z6P]9O
M$-0&VO[M0"_0#O!%-#IW@<_?/=Q.\$4+]G:#+U_M09&W'V]?U\'HN(!":/\,
MQ!G*09GPB6": AP7A<REU#];Q?T?M#LV$C2:.0;S'R)E07!^]O?,: %,=V K
M/P@&HB>C7" >.K:SDWA:EP_'-,<Z[E'+B9_]YN(_+Q;BK^EL=LO_O9DNI7BS
M,<F//Y8%@2=$Q@669MF9I!P@D\X2"ST=Q!F,19'E,A9.J]!=PL;&.HVN-U&C
M;52I&U7ZNDWU.F&VF^*% J]GRO+&S7DV9P-(H%E<IZA!9V\V1A_.VJSN\:./
M5YO5="Y7J[+IU;0, _ZX7+PS]3X_-:&2,B^84@@PF&DW):&9=E,*!'!"<ICI
MZ1S-G;*J6,@<&YDT*D<MG6\BK714:NV7?,4&>SMJ"8QHSPQS+9C.1., 3R"^
ML9$X*.TX0'#(/BZW^I%06:5RP]<EK>D_Y/*;;'*+*)HJ1C,.&%<)0+$@@,4\
M!Y10*)G"!9-.%=HZ9(V-=/94C2CGRPV=N5%,%[)VU!((KYXI91^J6LT>$K18
MH!&(0;HD#<H<%B8?,H;-+=[YH*JF-0G=S34+/>JG:%7G+8.R*%"24<"SG %$
M-&E@AG.0YP6BO&!,V9T<LA$V-JYHZVH"=AMM+^<]<\?9CCA"H=<S<_@#YY/=
MZ2(BX;(ZG1<U=#:GBT:?R.)T^9[KYCNO%U_9=%XN>9FDV(]S4QKJ3FB&FJHI
M;4)_5\V,ZW8N6H5@]&^;KWH:)I74I"8>Z/?6CY.<9A##+ :"Q":FMR" %I*#
MC#/.)&8Q$\ED+A^IR9[I/FOJ3W.KMY)4;^61_@-,%UJ6E_7I:MNCMO%5D/UJ
MMW9A8I5:-D8U C=1@T&9X[Y]Q0?]8/NDRAO@T7*;#;[PDS+P9'*8IR/\I+3_
M7@H\I^U1X1>9$O?? >=FU -(OB+ KQ*^8\,)DC)E3 ]L*F<2(%DD@&;:R280
MZ[$-LEA1]VBR0REC<ZSK0B>EEA[184<@JB*7!2H04(@1@ 34WH$>50$AHA \
M2U4AI7-8Y%4@#A8'&0Y$NW'P:FAZ'KK:J-S8N!U^\7+G$ @9('<D8_B(N'-F
MG@R!.WNQ'U]6=9/NU=OO_(O)PF)*)MW/30D]\S^3=^4;G9F,*^7*R-3DS3<_
M:$+?_Z)UY=V<SS8F$\N;Z>IIL:*SGY>+S9.^0__-JQ+O4NPJO&]/(Q0QBQ/)
M)8@%5P A_1^&40%DG@K&XYSEJ5,R[/&8-K:1H4+&Q+@VV%2ELA;SJ"R>:'$:
M8NP/DQW/CD?A$9'[A:?CIGI&6B:;24N#1GV)F9T<?+E_QQ:FJ,$I*H$J[VQ#
M%>VPZJ60\/@>@4"CVX@,&W1('9'=9\;Q$6HX<$+7_>*D9K[X85-MA%"6QQP6
M0"EB C88!%0)_:>>O#$)F:#(:2,DN(:C&\IW"@Z4P/1LW]D-N2_:(SV/G"$+
MP+7LU#.LTM(1) &]U DOG<CSK'Y_CV2<E^ -EE#SHB"_ >&-?%I*7M5HU9]G
MLC[/V\[,-$F26,2<"\"Q0 !AI@"A@H"89$F<DP1SXI1XVT;HV&B[K7/I\M*6
MLFY$;H6Y'3>'1K)GNFVK:_8]:H5+/&]M\'3F31>  E&AE<A!V<T%A$/"<KK7
MXXA2':M3AWN0I% %2A#(XSP!B'$$<!P+D&*.N$@$S*%]0MZ]IL?&)T[;OB>0
MZN:'Z^SOF05JTQW#A4Y@X'!<R1N+@4XL!5N./V]MY[FE_3N&.[IT4M.]TTNG
MKPB=J7/5YK/Z&.:MTD1@LE&^TS=,4I%194+\4H4*@" V"773#,"889XJ@O+,
MJ<[[%;J,C<LZDU#JF=%>FL_:H)N(&I/*;)^1,2I4QL_+/6GG6@W4/SUS[87\
MH-M*Y6V3[+LF8.I0:U![SRAZ69.1)!JUALP^_ZA]DWX$_%YJ*7(_*:*I[7"O
MFF(/$YQG/(MA#"12%" >9X"D&088QUB06&3(+GF'O<BQT6FE\4UTE*73J&UV
M>1K%W2C3 GL[9@R+:,\$>#V8SB1GCT\@+K,0."AEV0-PR$P.=_K,->LVJ*$Z
M.A>SIEHOHS-3C'/U8-;5)GE.!$U,>N0,ZDFH0A*03$B@*,MR[>MI-]#J&)B#
MS+%1T+8@=:EVN3ZS53QJ-(_^+'5WFK_9]8#-Y#8XKCT3T0M#ZC)7#@[M0)/H
M,! [3K6=P.J>@]LU->#DW,FV_5F[VZU^WN0MUX_59F8.AW0EFZM>@#11*&9<
MF'SW9FF144!Y4OXGIP6"/%=.?J6+\+'1>TOWZ&)Z13=.\NH;.[^S+\1[)OZP
M8#M[HSZH!?)+G40/ZJ'Z@'+HJWJUX;M+R]:[6HJ_S>N]1UD%"VWFZX]+^76Z
M^6K"A\REJ]7&D*PI-V!2;4X8YC%#F000P@R@+"X 0WIBS13BV 3JQ(RZ;>!>
MI<_8Z-#HV*H$>Q.U+(H:DZ(?:J-^K"(>RWMJP\KZ&:LR#ZWK5O!U'6N[2SQ8
M=_6^@3Q 3WEL,@?!-]C^\W7:#+PU'02ZXUWK,,WZUFC1K"57ZVH0T#*:+^H5
M5:/$;+':+&4Y.#S([^M7&I1_36 FLXP1 @11!* B$X"D(@%9GL6)HHAR[E2B
MR5>1L1%THW;C*YG7>OM=;4NT,\:U$(QG;]F1[Q!]T#/K.L)?^["1,24J;0E:
M@.8Z.(.5J?%48^!B-M>!=5SRYLKV?-.\MXX;OY_.Y=U:?EU-6)P4-(]SD/!<
M>[5QF@"B8@B8+%C,58%%+MW2O)\2,S8NK*:0LU8B@3^-KE&IK'/2\I/ 6BR_
M!H&K9]H: "G7].[7(C9H>G=GY#PRO'<!<CG#^\F[!\[PWF7!<8;WSJL]S_34
MQ;/NE3EB]&ZV^.L7*1ZG\\>= [SZK)^8,KQ\=:_>3>?:UYW2V4>Y5":QHC94
M4_GNZT65>/&]Z3[][X'7(W,E,UK$@"F<FN(:3+,N9T 2+E,HXP*F3FL)PZH_
M-C9OK"]WHLV92P- 5"/0FNGJ*>L.!'/QUMZHA4/IF;5^630)3QLP7%RS,3QL
M=B[V>!^AGD>X$3\][B><7J030QU_&E;Y8<]&O4C''!V<>ADM7C[SWRY";S4A
M/"6Q) A007.SAZD 0Y""/(=%46!2D,1I?:@G/<<VR/:4M^U,;*UCUJ&^GA6[
MH7,$3T#/8^18.O]%D_:=Z)H19NIK:_FW3<]W NH^<_*=$N<V: DYG;S5(M?/
M9EEO^;2H4DZ4@^EKLU>R?'Z]$'(".<$29BG()#6!V5D"*-*?"D@(SQ-.$+$*
MH+&4-[9!I%(YVM.Y=JLUS%&M>614MQL ;''O)O(>T.R9D$, :4VFCO"<(,65
MY#\]+K[]0[=4\:'^L*-!V_8'H3-'8QM:<KW-8Q'_Y\4WN9P;U_SG)9VOZU(>
M]3'.G-*"Y[D *3,U?[#D@$&5@U@A1" J5&Q'+!<EC8U2=KI&I;)NI7TN VNQ
MCA\*KIXYXQQ2/F>(.R%S6- /!=U :_K.#YO;:KX-&IT+^IT-#+>F;V/'WK*^
MU0UNE+E:KNMCS_RYK"*,*:$YS2%(8YH"E.$$8$@8*-(XAC&/8YY8G3T^;'AL
MA-CHYE2!^0BM;MJ[!H.>6<[6?.LW\YRM77,_?4]KWJ?_VCD[1\T-\EJ>,Z)Y
M"\_^[IF/?._P69V":34IC'-"B0!Q3!E *HT!9:H 218CF%&5<>JT[75:S-A>
MR*-3DXVBCIFU3V-JMT1U/5)]QQDX@^2>7+L3@U#9M4\+&3:]=J>A1_FUNZ_V
MF*A\DM5:2YF$[9?%S&3HO%>?UPO^+Q,D*L7MNE6;<,(T!2BE$B 4D0 E, ,$
MYAQ(F7!&"EA0:I49S4/VV*BBT;[*E1C5^D?W*BHMB"H3HMMUNQ2G@]ONV#,6
M<Y_^\.Z9<$8&M<.<J3_(!YI%A87>;8KE!U[GI,NQR>&F87ZV[DW,/)OP+2O[
M5(\^]^K]8OYHDA:8DP63(L,84ZY 010$*$\E8"G.0*946B2Q+.*$>U1H.R?/
MZI49OJ[:3ET3?6(4!NLR_P:;31^K#->NQ6;/X&WG4UX%WU D?P19F;+$J!FR
MR&PW$,$JS)X1,W!YV6YCCVO+7KC>LX++UZ?9XEG*DHJJO+[UZB.36$\C40Z*
M.,Y-014,,(D1* 1,8R@3D69.\1UG)8W->:SR:[/]_-J[I,A-EFW/"K/G ;=C
MBR P]DP7)S.4^R#H7H_C$CJARF.<E3-LM8I+YAX5C[AX@Q^-/"SUI'>S?"[;
M_9W.-G)"92JUNX% #K6?@2A$ %.B %:*IC"+N>+"P]DXEC12-Z-1M'+&;Z)2
M5S>N.(&J'4EX@C0,.[@!XTP!YVT/].Z?$##H2W_>P,.WO>/**^ICGLDM\=%\
M4:;C+J_ZN%BMEW*M)SUE)0$YEVJZ_J@?A-6M^.=FM3;??I#K>_5 OT^2''()
M"0%ID66:*T@!*-.?<BS21/"TD!QZ<$5/ZHZ4<*J#4G2K[NHFFLNR$M>:?I>E
MY_Y?,%(+?<UL%CW)Y70A?*I2]M#_EHOO+]B=0YX2W$_)\T-EY(^1,;,LT#R=
M:[^JMBDR1C5)<C])/J.KU51-ZS,2.V.;2[2]@<ML]M<A(0MU]J#E\*4^^X/Z
M9+'0'L4-7#'L'9TNR_&O#%1MJM=4Z:9_7\QT,R8=G*FD-B&95"@I8D!10@#2
M Q+ :9Z!C,HBSV"BO5JKA)L#ZCRV"?0VD?>J7(9^6DZYC+YM51ZHTIA#G]L-
M/R/KR0'G\)[5R(S=E7<?M2QO)7K?&5_6"!U!A3+WKGKIFF4.&O\]JIBY=T&P
MNF8>HCV3A<YFB[_,*<!WB^6;Q8:MU69VR\MD4"OMQ,GI-W/BHJXV,L&*Y'FJ
M.$@(0P!E- $$4P8R!F6!54HRYE36TDGZV :7K?+E3$;4ZD>TUM\Q,:A3/]@-
M$[VAVS/A-SI&.R5OHGVT7R^ET%..:B+R.E25H*N "Y4=U$GVL.E!?6 YR@_J
MU8BGE[[;U7ZS64[GCQ_+I8:26%OKSDWY2"DF&<\*#J4$1&08((P((-2$%"<(
MQ?K_$>;$R>=VU6!L)+?-$+E0T7)7"+WRI\TQ4%EK;BZHOETTWM5T6QM=?N?F
MK.FT2I2VIM\C5LW.'%G2O4,M'>H^NZEO][@=85-I'U7JUPO:-W403FU#M#4B
MH)?KBU\HG]59_K >J"\\1_ZD=T-^!*J]UJ_FR)MNN?135[>;]9?%TAS(G>0<
M)8E,,A 7D #$F:;*1&6 <)7FDE),D5/H=X>LL9%BI6I%=S?1JM0VHEMUW3BM
M"V,[]@J$7,\\58-6;[55BD:WET%S)B,+. +13I>D00G&PN1#*K&YQ=?KJO/-
MW*MM1LP3"[BW;%65U]+3R")5&0<XE1P@4J2:0Z "#"<JIC1%+(%N/I>3_+&1
MRU;]J@S7B9H(?S:JNV8I<^P86]^I-[A[]YP"(.WA*WGA%<Q3<I,^L)_D!<VQ
ME^37C'>YG>7&9!PQ;3Z8_>UFE2;G,<UC0D&,S/G4'*: JA0#F">*,?V3Y&ZK
M9><DC8W":D6;MZA4]?(RC2.ZEFM@(3#K?[W+ RZ?DC?=4(2K;W-&SM#%;+K-
M/5&YYL(-5QZ=K=.!KR9%G&(JTUQS M=3)Y)E !>2 (&)9HF<2,JRR7JQIC/+
MZ*)#"4Z$L)738Z"=D1$MMB="9:VGYWG9+9"6T3K7P--WG,T6D[>7,/$_'GMH
M=^B3L=OV7^90[*%Y9\_#'EWHGH#B5_I]^G7SM0Z4IRQ.42HX4&G, $HA!CA7
M$. LS0F3HJ")L,U L=?RV$;T6CG'DP;'@'6_L%?!T/.+:HV 4QJ*D]9>D8=B
MO[W!$E&<-*.=B>+T!1XGT3^;QC:S]?2IV22JTEN\67RET_F$8ZJ@P H4R@RO
M*4H CA,*,BYAC#E$3&36)\^[98WM%5V=T3;ZL]+7)1G4!92[W^+ V/7\7@\(
MF\.)\'#P#70"W!]&M]/>=L!TGNZ^T,1PI[GM;-D[O6UYR[4E,YI4K*V3X*M7
MSZV_J@*U129XB@H&(#>Y3TF< A)G#"@*!84IDHHPOZ(7=@J,C8+;A0>V"9;;
M)MR8.,76%WY%A)W[R7(AMT?T^U[)#0[\%84:W- +7FK!4OP+%4MP ^=\N0/'
M=CRWO^GJBUD[UO^\U0U_HS-SF.EV_9HNE\]Z/ED=A%0)CW%*,I"A6 "49SE@
M28Y!$:<Q%C3-$+3*=N0D=6S45]99,?% W'R0.[T=-\.M$+?CL^ X]DQB6PC+
M#RV5;R*ZCAJM0Q]2=4(IU+ZYE<QA=]!=8#C:2W>ZV;=Z[C?=Z&+Y_,=B^:^[
M^<?EPH343=(XPSF+8X"5( #%$NH)KT  $IAP!1.2%4X!BZ?%C(UMC'+1=![5
MZKE6MCV)I!VI7(]/SRRR5? F.D#I)OIYN>@ RZ/H;!<6P4K*GA0R<,'8+D./
MR\%V7NWW^K^1J^GCW!S@OET=E7AJLG1CFA442>-Y4%/Y-0<TSU. 1<*D_K^X
M4$Z!-!8RQT8,.Y4CNCI1\LTS58X-^G;\$1C3GLGD>CB=2<4!H$ ,8R-Q4+IQ
M@."0>UQN]5A]?[=82MU^_<2K(DM1RC* $F3B6U($<,(3 &4,N>)$,XY5_O7C
MIL=&*[5R/G45]B&S6#GW!J)G+@B&@<,RN#<6 ZUZ6V/BMLA]TNS.->W].X9;
MPCZIZ=Z*]>DKKBL@V5KF>;\M.JZ=GY@QK@!&5 %4) H0K/^,4T1B%"N44ZMZ
M.3;"QL9/I]8\/<JZ6^%LY^>$0J]G4O,'SKMP81<B@:L/GA3U(B4$NXP^5P>P
M\QX_ OEYL1!_36>S,EW,W9R;K&3RC:S^G<12(LD0!&F::'^&%AB8&!X0<U)(
M+&7!$Z<339W2QD8AC;(W497ZJ=$W^J'1^$<W$NG&VHY%@B'8,XU< YXSD5B!
M$HA)NF4-2B569A]RB=U-'C,AD_3X_8+.;VNG%L=YHET, LQQ)8",X\'RA(-4
M<2P))=HYL:_6=]#XV*BB3+AM](MN'28!AXA93(6NP*'G%[X%@<^$Z! +ARG1
M%9@,-"FR>3S<YD-G;.Z<$1W>,]R<Z(RV>[.B<]=<D>?BRV*F[UB9#:CU\X?%
M6KZ9KOALL=HLY8/\OGZE]?O71!0Y37&<F/A(K"=)1$^29*+_9+E$-(YE(9Q<
M'&O)8^.PMN+_*ZI4CXSNT4[YZ$^C?E3J[WS4TK9'[!RA7G#NF2/#0>R7C\(%
MKI!Y**SD#I]_P@6.DWDGG!KP">TNDUMH@^;KZ3=9YNW<K3K0-,FD5 7@*A4
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M:<RUUY1IKPEIUXGP- :20:X]*I05RFHAK5/*V'RE/3VC4E&?8[)G0;68@8:
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MJ_,Z,CF*I[K32@O=YA^!.M!N,C%@?PQ#_XU!4<NBFW;&FZ@V*C+O<+1G5I,
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M=C1QN>5!*,+:P(8>[&_P/B5NDNS+-[+Z]VY^R_ERHUMOCJ/*)KO*1"4,%4I
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M*2H(E# A,;<?@G;MCFU,*36+GHQJ#O34PLF"]?VL[YG&KS;<@6C] !B(.6V
M<*/"8W,[N:UU^7!D=:SC'ON<^#EDG%9=JZD5")0@#IFD",0*:8\7*@$P33"
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M%)<<1YRI+3&':40[?8#]-$&G$=BIU.84M56?VAN,[MK"Y\(YTJ"Z+2/C#=7
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MQS(E,DD0Y*5*($9*0BIY"3--:9XGJ$@I"SAB&$O^B1XY'*:*/03@,+THX#_
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M6*YUEJ7$J8II#&&F1GN=+M;=99^(Y:"ZDU4('&MT\PWX3:/I:#V.-$9#\^G
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M1"52EEQ3X971T;7CJ4W7K=Q-?&XC.3@6'32RST K/?AC^]]@CP+G 7);GH>
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M]7ET/CG*LWGC5AJTTN]*>-L9V2@ =AJ 3@5/#O09&4?N&PCOH3DO(M3^)!B
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M4SKU;.[YG8*@T7 &#G5L0WS!L9;;TZ70 .D(H^^V&KS0F Z\)(P_G.%1V_&
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MD8"#Y.9^$V^]*+E$6J1) 566)1!KQ""W<;2XQ)D294$3YIZG]+#EJ4W%UC,
M>YQ#'N'D<(X;JOW 4V^KN*<O[BD"'H>MH4B,=)YZ[5/P.R4]IVSO0>C1"^.=
M=9Z3\^@X\^P#?OQ2FTWH+FG[/IT 6S0+&-9,,99HPS7V<HHJ!4M,.#045))<
MT901)Z[I[65JO',HGY<)T(]E/Q]%0VA@;O(!QWE6.BG?9_.;!@[L??/3WDSH
M;WN4R>RD7C>QW1X..P;XY:FNELIL#_89%;<!RNQ!W>N_K6R&LL[!JGUJK>0\
M5X@JG!JCGV<"8HXDI*S((<.:YDPCFDHG\_\V,:9&$YT6X$"-&=@K8@_86U7
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MV]_.=6'+8B4<4B*9L:)+ CE#9J^?T(1B+DG"O-)0Q1%K:L2["[8X4&L&6L5
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M=W]EUE;PW-BZ?(!W+$+4M\!M1GJIL>UY"GJI8?7OZ=(#_K&ZP,14;=B^,3V
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M+F\-QL:QC0&'KD)MPU$;\JT=$V L =844-OBYXOY#Y:;M];K$/3,V2[HKQ>
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M<P4J,3:".C0#M': VA!P8$FS;>RXQKMIC+J):RCD>Z8R+]!] N?BC8-'DMH
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M?>%,%)"7G,-<88K+@I:8>O:7:I\\-LIJ^Q19U7S;0&VQ<EPTA2#0]T+(P?B
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M1<&85V)O@ YCXXVM"># !ONU;*T 1V9,0K/N0D;+C8%Z'H.>V2D^_-[$=0.
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M+YVPO0[4&]7\UU9OM2V9UNQ/9=;08K:1=M7\IS"K:?,[WK3?7;&YE$JKI:T
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M.:2<4IB) E%>$(QQYNP<7I8S-F^PU12TJH):5] JZ^&@="#KX.S%P:MGCA@
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MY R9N4JE*20BS<V$A7+-M.+<+^>Z4]K89IA]P?M:VPFH]84+#8W&[;+5LYE
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MW0^U9(^J"0WYI-]4LXWY;4U!JT^;]6K-;-'IQRE.RQ0760DS9J.6&>*0R;R
M65)0@C+;.=DK=L]3_NC(H=$3_&2<AE6MK.?9G#?^JB!8VM@8GAC\$YI!RCF#
ME%%4EEF&<E3XA3SU. +#A#-M#0"M!4 LOGTS3J!-,V]_5/_:F.]F9OV^9I3
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M"8>:V#K;6"K(*):VM@\N!--2>A+W>3FC(^-63;#3,[#DX25<'4GR=K3Z)KX
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M-=F?8[1QUI/FJD!_)B^;YV0Y)33/2,$CR 6-];JH#?\BHP7,XJQ0A/ 8":>
M]B["C&UAM/>FK32J+_N,3CO/N_K4=!I,N_W"4$/4\ZH89G3>R,?Y&KX#.C>?
M%65T7LW70/-Q9[[:9C^Q]"8L^>GWQ32C(BZD0) K)B"660P940(J&F.1(HD1
M2T*&T#?]CHUI'6*YM?1A(^?;H; CSQX [IDG V$;/$[^ *F!PN/;7D<5%7\
MA6LP_.'K'J<K?UU*S8/+U5<ZQPBM%A%"381 1#(5932#B4P+B(LT@T6"",SS
MF&5,B!A1*T^_R]V,C9">=P3]2R6I_J?#YOD\GA8'%T%0ZIE53@+D&)QR!2F'
M$X0@B UT..#V:;EM\Z_B<'$'?_[MX3;G5S78VW=??[K+EOI!W?W@7\V]G;$;
M'^:WM/QJ_G_WK_7L.WTQ[%LEHYOQE13F%[4;]\X/=IZ<\CR5&><*(MTXQ!'B
MD(@LA6F1I#CB69XD5B?0/<HX-A:N530'9*V2]09O,0=&\DGU3["CP 1L=6L>
M:<(K=G^X_\;M8KZ:S=>FX,?#-[FL9K_7ICWLY^*REW^SCV"0+?ZHQM_S-*"7
M$0IZ2!!6PC<X.^@%XM-'"OUTY5VZ67^U>C^@9TX5+Z1;_F;,F$]R-<TQ*W(9
MZ^4F2R.]YD04TAPG4$2)I"Q#@I+(L6KSV<[&MGA\_O+P^>[+TS\GX//'FT]/
MX.;3>W#W7[_>?_[E[M-3=?/B7*OY/-!)GA4Q2RB,F0%:H@PRFF50Y+B0*I8,
M*^Q2KS88T ,4K#4E5K\U\E9T*UMA P)LMQR&@JW_"]U*S$E59;$)[6Q%K6K6
M!JU^?162<(6OSW<U=,WKJTJ?*'=]_9UNT9<+]6$VGZWDQ]EW*>[U3G/^/&,O
ML@[H^;!>K9?RYM640OMW984TH9\'07AQ1E+&<@;C),E,?'L,"2LTU40QSXLH
M)X6A&O?0RQ#"C6T-V W8J[6#E7I@JU\3LC<!M8I@5\<VWMHE7*__#\"."M]J
M6'NFSC<84>\ S)#0!XZ^#"+:FX1>A@3U7-QET#X\3N.;?>C\^651EIPNES_5
M8FE\Q+?EU!B*HY@0!)$P09@YQK @*8$I3[ V^@D5N540IF5_8R/VC<3 B SV
M9+8IL>:%N<71?5@D>^;2-P'1X50_+)@#'>]W!=7MP-\>HHLG_Q;-#'<%8*_3
MWEV PVL!?3H^:87J*L:5)XGYP![4A]8=_O.BG-4KQ,K40]?KP\=9J<D[51RG
M7$'!J3)I2"/(4E% F>+8V.]93/+.7A\^DHV-YL_[+FRU:_R[JHB]VBALHDI:
M%<%O6R7!W5R30'W(ZVC#AQO^#IXF?0_JF_FB]#J>87Q7NF#?IW>+EUQO[__2
M!4XK#YE.'?@M$;L>W],<$Y3&'$$I4 )QA!74\R.#F),\ST16Q)E3(L+=QL=&
MU!\W<0U&.C=BW0/-CAM]H>B9WBH4GJZBX$Q'I]0-Q"A[30]*"J>4.IS7)Y\9
M.!6*.0=>_;R?FZJ#E<==5?SYZ2N=-Q';'Q9+)6<K<U+PN<HY,46F8 S5!IV*
M<@$Q4PRR)-9_HHI'N?Y?3KE'>=$!5;":5,-7+*VS-##+; [L5#:'&@NP T93
MI-TX$6US/6P0 ;,YJ#$9*)F'Q_=F>2(\LL_G#Y, I(=/9KCT(/Z#]]:)0SPD
M_V.D%/$?DF#)1CJ(X+?\OJ,OQD)__"KERL3:5'+^F)73A""N:(HA2I72*R0Q
M59]R"CGC0A2H2+!;Z:=S'8W-8F[D!)6@H)44_&9D=3R9.(NMW;H0 K&>2=P/
M+&>2O89$($8\V\V@]'5-V4.NN?J\QT77_5RM2]W.K6:<]:NY/RL?7V>KK^4O
M4LPX?6DB 2B6,L\EATHBJCDBS2$U!9SR/,[S5)!(1%9N; Y]CHTN6JG!CMBP
MEALT@CO<TUCB;G'A%1[-GJG$ DB?,!9+1!UNO\(C.] -6)=/U>WVRPVBBS=@
MEDT-=POFIMO>39CCJWX&7>7/O.:K]7(V?Z[\FZM"Y#<FX+K*_[1-^[1U78JR
M5,0T(Y C:HHW:0ZG"54PYE)RFNB_QTXQ,#Y"C(W9]W1HPA4J+<!6C9U4:. W
M;R\TKR&SLR'['HB>%X5>QL#9_.P"8B#3U$N$0<W6+B =FK2=VO+<!VMFGLNR
MU/MU-IM7*W$=@/2L%V9#V#/17&>>N,>:(J+B+,\3J.F204RX@D4:1U#0).51
M5L2X<,K6TTF:L1'I5G(@Z7(.%^L5>#EUP^RXN^XT8I9;\*'&H>]]>J,'V%&D
MC;"K!F9/ES,.  'W\R%@#;7I[R3+L"<#(6 [.CX(TFC7"B8[)YZ:[_\FQ;-A
M_A-\7W[4TMZOY&LYS:*44I1C*')$(,Z(A$0F^A\J3[49BUE>.'EK=9)F;*2[
M4PUD]W[$F%"-/J=-J!+\9G0"E5+>%55\AM..D0<;I)X9N>?QZ5#AI0.NP>O!
M^,CR1M5C.L!VOM9,ET;]*/F&\_7KNC*WJZLG<W^UE%^-*U:;K^WCHBRKM)E/
M],>4TTQQD420\@)!C(H,$J$BF$<Q+3B3E,1.!: =^Q\;[>Z(#Q;5733?5:#R
M/7<C5=<!L:/1'F'NF3AW$:YO^_=D;Y-(_LF(_^<J9M=XJVH=PG&E)WB!V-&U
M]T'YT!.:0P;T;<;3.U1SYX.Z74HQ6WV@O+)Q-UGR']3-ZV(]7^W4_Y@2F2)A
M*C&).*7:\E3F;CQ+H2*(1)PII?_OY$'J*,#86*^R2/0LJS4 K0J3W:(1^M>U
M'KOE>AP=4EW'R8X+^T2_9S(,#[R[#ZPG>J'\9%V[']:7UA.<(W];WW8\C< J
MH/:V.2I3$HL,DP3F2:;9#J,<%HG",,N)B'!$DJ2(7'*H[+7N1&4#)$UY,GV
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M2"8H2PI(XXA#G,@44H4BB DM\DCB1,1L^ETNV<*Z/F8HV5RH;%?"'IW'Z _
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M-MEJ]*:VN?A.D*2(Q +R#$40)X6 !<DIC#G!6811EA.GW>:U#L?&5K\^@JW
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MMM>Q66);N4$M.%C,@1$=&-D=DD-8PWZ987H#LV>:N8RCBU]9!V@=LF_T ?%
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M[<62V;\5I/;$R8H'2:I85J (%AA+B"F2L%#*Q)*E3/]8&Z]IW*'HQ!^SVD2
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M,[$PU1U6](?>);&4Y#3"".+4A$I%(H<L1H7FUIQ0FA99*@KK??91\V/CR$9
M4$D(*A$=MIC'Z%GLMSMATC,OA8;#8<O="9:!]MPN\+AMNL]J?W'7??S6<-ON
MLQ+O[;O//^7M)#-;R8^S[\<72#>OB^5J]N_J$VA*6_Q3TN4'_>R4HR@1O$!0
M,!/@GB$&J=([\%Q%2L9I06/FM._V$V-LY%=K 2LUCJ]1]9YN1Y6V$,L$&&V
M4<?9K\9GY.SVW?V/1\_$>W$H)A7XO-J5[VAC,Q0^KC@=D SGFN,CQ-"N.AV
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M3>G=,?BH__2__D?[$_T/LWW]7__C_P=02P,$%     @ Z8M;5B).[+=4* $
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M[JQR9M/"PQ0AA0T%3) >5)(1G!4U#=%X%9Q0KGG:>0.RQ^[Q-![J[JCOYX5
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M6.3:-)\;L[7\V"D(30&R+UL[B+Q>-=.]:/I^K5Z5E%Y[LJJ-KB/1.<O@?-2
M3)5BB2$BM-8G#Q(S=O9 4[2T87D'VN0C#H\.?\,Y;6A&JO%%/IW.IW4SZ^D7
MO-C>)/N02\X).-VH9,\'\O]2<&!SQEA<S7!H_<JZ&V7CVC.-8'"GUK&Y3#I
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M)3"1)=,,.6_=V^0A6L;.XFZ*F28,[^ V^GTQ7]R$_Z4WJS-B,,X $[H^1>L
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M?)3^" /]'B*GNY3]0Z#4BNT_5@O?>UHV[_&(]81//V)KW^_M9:RG+*5-B::
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M=.O7ZD<)ZC+"?2RLM1--1R;;AOS7B^7WNA#=P]6)]#XG0^YU+74'Y892 .,
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M?[F8)ZR)D$,]\=7Y%L:[Q+@#9BVQ)%ER%(Q+8$LL6'R*.MCO ?I@*L;5JT<
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MDQ9^77%QE4APT9U[8.[V"8HNF%) &S(T5;4[W>#4U#H/E24WK+4FVY6V;E/
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MA]#5;9QU3S0,AMN>HND:;MN+F8,\>I3)6K(^?2!C5&D(DG1V"5E'1_=#:3X
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MW7DK0WH&ZU@QOCBPOBJT\O56BS ^F5!KFV6L_:-9K8M)X.IH8!^9#,V?W1Q
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MS+[UU)0]R#RX]2())=</7WZ]U1CPE[_3Z3FQO0ZUK>_%SZ_&-]ZGZZ=O#W_
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M]0[ \W <T-LD/6.DID/1H*1D$+VH!7A>,O)NDLJMK[C](Z^3N973 .=PCG<
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MY( A>HR2)6/XOO;  ^O-D]D[GG%P*(OG1LT_PS:=GX;-JT3\N5)X0F9="LO
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M!\!I?SG,?6,]]!BUQJAM%.3D,>MJ!K5 5#*!RR:*R 2G:W>8*;OGX]ZCXN$
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MAZ\Y3ZSA*!?Z1(R?'4_O[I8P?/MS?7I:UIN_PB;7+]]<?+FPM &-&H%NSMJ
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M[,^P.KF,]F01(WJ$*&VM'ZEC?3BQA87L+5/&:=\B^'6]X-Q(:"2^]:&\[ $
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M<<4$D[0TACOPR&MB7<P0I=<0?.1>2DW_[Z:0]S$B3C[W<LI]<1@D>O @#F3
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MEU+;IRE0O"3P'AEQ4DJG7%(Z-Y^^]7<ZY4#,CI=..43\'5C6][.LO,A>**W
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M'"*'#GSS;6Q[/UO]]Z9<6-7X@K4&'+$#%!<"@E89DDZLI%"RSZW[8#VUGEX
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M.T#+';C?I2(1P$6NB8_%.E"BMBYFTH# ))EQ1:@GVT#O YGM*YFF8>3HN&G
M]@[ \V.89>,6>YMLKM.34L8Z(+TD\-ERLAUMT#R$%'3K:[GM*YG64.\TCM5
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MAS9:Y@\+5DY7^Y2]V,]0UJ&Z3Y#<Q K_8[Z8?[W\NB=<2<]4?:.)DJ)G550
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MY_6'O+Z\J%=$;TC0[U?SY8K\Q_FR_MWWR_5\UX\\9Q.DE ID;7RO$MK:C[P
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M>&S=ZOT4.J=]]SDZ1L?67 ?H?(\_M@V)/^2+;3/LY5 ^52I<:6^@*$/B]&C
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M<BYH=&U02P$"% ,4    " #IBUM6<GO?)CL#  !W#0  '@
M@ %:!   97AH:6)I=#$P-&YO;BUE;7!L;WEE961I<F4N:'1M4$L! A0#%
M  @ Z8M;5MX]AS3A3@  =@P" !X              ( !T0<  &5X:&EB:70Q
M,#9A;65N9&5D86YD<F5S=&%T+FAT;5!+ 0(4 Q0    ( .F+6U;8&Y/NE@@
M %FL   >              "  >Y6  !E>&AI8FET,C%S=6)S:61I87)I97-O
M9G)E9RYH=&U02P$"% ,4    " #IBUM6/S)$BQ($  #F$P  '@
M    @ ' 7P  97AH:6)I=#(S,6-O;G-E;G1O9F1E;&]I='0N:'1M4$L! A0#
M%     @ Z8M;5N*X"R@Q"   +RD  !0              ( !#F0  &5X:&EB
M:70S,3$Q,C,Q,C(N:'1M4$L! A0#%     @ Z8M;5K434.I-"   ;BL  !0
M             ( !<6P  &5X:&EB:70S,3(Q,C,Q,C(N:'1M4$L! A0#%
M  @ Z8M;5AMT7DVW!0   2T  !,              ( !\'0  &5X:&EB:70S
M,C$R,S$R,BYH=&U02P$"% ,4    " #IBUM6?*587#(8!0 ((3< $0
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M2P$"% ,4    " #IBUM6(D[LMU0H 0#_BPT %0              @ %@@ D
K:6-U:2TR,#(R,3(S,5]P<F4N>&UL4$L%!@     /  \ #00  .>H"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
